PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Day, L; Fildes, B; Gordon, I; Fitzharris, M; Flamer, H; Lord, S				Day, L; Fildes, B; Gordon, I; Fitzharris, M; Flamer, H; Lord, S			Randomised factorial trial of falls prevention among older people living in their own homes	BRITISH MEDICAL JOURNAL			English	Article							EXERCISE; COMMUNITY; PROGRAM; HAZARDS; WOMEN; RISK	Objective To test the effectiveness of, and explore interactions between, three interventions to prevent falls among older people. Design A randomised controlled trial with a full factorial design. Setting Urban community in Melbourne, Australia. Participants 1090 aged 70 years and over and living at home. Most were Australian born and rated their health as good to excellent; just over half lived alone. Interventions Three interventions (group based exercise, home hazard management, and vision improvement) delivered to eight groups defined by the presence or absence of each intervention. Main outcome measure Time to first fall ascertained by an 18 month falls calendar and analysed with survival analysis techniques. Changes to targeted risk factors were assessed by using measures of quadriceps strength, balance, vision, and number of hazards in the home. Results The rate ratio for exercise was 0.82 (95% confidence interval 0.70 to 0.97, P=0.02), and a significant effect (P < 0.05) was observed for the combinations of interventions that involved exercise. Balance measures improved significantly among the exercise group. Neither home hazard management nor treatment of poor vision showed a significant effect. The strongest effect was observed for all three interventions combined (rate ratio 0.67 (0.51 to 0.88, P=0.004)), producing an estimated 14.0% reduction in the annual fall rate. The number of people needed to be treated to prevent one fall a year ranged from 32 for home hazard management to 7 for all three interventions combined. Conclusions Group based exercise was the most potent single intervention tested, and the reduction in falls among this group seems to have been associated with improved balance. Falls were further reduced by the addition of home hazard management or reduced vision management, or both of these. Cost effectiveness is yet to be examined. These findings are most applicable to Australian born adults aged 70-84 years living at home who rate their health as good.	Monash Univ, Accid Res Ctr, Clayton, Vic 3800, Australia; Univ Melbourne, Ctr Stat Consulting, Melbourne, Vic 3010, Australia; Maimonides Hosp, Div Geriatr Med, Brooklyn, NY 11219 USA; Prince Wales Med Res Inst, Sydney, NSW 3021, Australia	Monash University; University of Melbourne; Maimonides Medical Center; Prince Wales Medical Research Institute	Day, L (corresponding author), Monash Univ, Accid Res Ctr, POB 70A, Clayton, Vic 3800, Australia.		Lord, Stephen R/C-9612-2011	Fitzharris, Michael/0000-0002-3691-6868; Lord, Stephen R/0000-0002-7111-8802				Buchner DM, 1997, J GERONTOL A-BIOL, V52, pM218, DOI 10.1093/gerona/52A.4.M218; Campbell AJ, 1999, J AM GERIATR SOC, V47, P850, DOI 10.1111/j.1532-5415.1999.tb03843.x; Campbell AJ, 1997, BMJ-BRIT MED J, V315, P1065, DOI 10.1136/bmj.315.7115.1065; CASAGRANDE JT, 1978, BIOMETRICS, V34, P483, DOI 10.2307/2530613; Cumming RG, 1999, J AM GERIATR SOC, V47, P1397, DOI 10.1111/j.1532-5415.1999.tb01556.x; DOMATO BE, 1989, EYE, V3, P727; Feder G, 2000, BRIT MED J, V321, P1007, DOI 10.1136/bmj.321.7267.1007; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; HALLETT B, 1999, YOUTH PARTICIPATION; Hill KD, 1996, ARCH PHYS MED REHAB, V77, P1025, DOI 10.1016/S0003-9993(96)90063-5; LAWTON MP, 1982, J GERONTOL, V37, P91, DOI 10.1093/geronj/37.1.91; LORD SR, 1991, AGE AGEING, V20, P175, DOI 10.1093/ageing/20.3.175; Lord SR, 1996, ARCH PHYS MED REHAB, V77, P232, DOI 10.1016/S0003-9993(96)90103-3; Maxwell S.E., 2018, DESIGNING EXPT ANAL, V3rd edition, DOI 10.4324/9781315642956; *MERCK SHARP DOHM, 1989, OKP GLAUC SCREEN TES; PFIEFFER E, 1975, J AM GERIATR SOC, V23, P433; Podsialdo D, 1981, J AM GERIATR SOC, V39, P142; SMITH J, 1996, RANDOM COMPUTER PROG; *STER OPT, 1988, RAND DOT STER BUTT T; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; VERBAKEN J, 1986, DUAL CONTRAST VISUAL	21	343	351	0	25	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 20	2002	325	7356					128	131		10.1136/bmj.325.7356.128	http://dx.doi.org/10.1136/bmj.325.7356.128			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	577PG	12130606	Green Published, Bronze			2022-12-28	WOS:000177069900017
J	Heller, RF; McElduff, P; Edwards, R				Heller, RF; McElduff, P; Edwards, R			Impact of upward social mobility on population mortality: analysis with routine data	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEALTH; NUMBER	Objective To examine the contribution of changes in the distribution of social class to the mortality of the whole population between 1970-2 and 1991-3. Design Examination of routine data at two time points: 1970-2 and 1991-3. Data source Data provided by the Office for National Statistics. Main outcome measures Difference for the total population in the number of deaths between 1971 and 1991. Proportion of difference accounted for by change in population size, change in risk of death within each social class, or change in distribution of population across social classes. Results Reductions in mortality between 1970-2 and 1991-3 among men in England and Wales Were partially (16% of all deaths) attributable to increases in the proportion of men in higher social classes, representing 3943 fewer deaths per year or one less death for every 3056 men in 1991-3 compared with 1970-2. Conclusion Some of the observed reduction in mortality seen between 1970-2 and 1991-3 can be accounted for by improved overall socioeconomic status of the population.	Univ Manchester, Sch Epidemiol & Hlth Sci, Sch Med, Evidence Populat Hlth Unit, Manchester M13 9PT, Lancs, England	University of Manchester	Heller, RF (corresponding author), Univ Manchester, Sch Epidemiol & Hlth Sci, Sch Med, Evidence Populat Hlth Unit, Manchester M13 9PT, Lancs, England.	Dick.Heller@man.ac.uk	Edwards, Richard/O-4771-2017	Edwards, Richard/0000-0003-2264-9823; Heller, Richard/0000-0003-3161-5967				Acheson D., 1998, INDEPENDENT INQUIRY; [Anonymous], 1987, CONDITION WORKING CL; Attia J, 2002, J EPIDEMIOL COMMUN H, V56, P600, DOI 10.1136/jech.56.8.600; Blane D, 1999, J ROY STAT SOC A STA, V162, P59, DOI 10.1111/1467-985X.00121; DREVER F, 1997, DS SERIES, V15; Heller RF, 2000, BRIT MED J, V321, P950, DOI 10.1136/bmj.321.7266.950; MacIntyre S, 1997, SOC SCI MED, V44, P723, DOI 10.1016/S0277-9536(96)00183-9; Mackenbach JP, 1997, SOC SCI MED, V44, P757, DOI 10.1016/S0277-9536(96)00073-1; Oliver A, 2000, J PUBLIC HEALTH MED, V22, P454, DOI 10.1093/pubmed/22.4.454; Raleigh VS, 1997, J EPIDEMIOL COMMUN H, V51, P649, DOI 10.1136/jech.51.6.649; ROSE G, 1990, BRIT MED J, V301, P1031, DOI 10.1136/bmj.301.6759.1031; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; Townsend P., 1988, INEQUALITIES HLTH BL	13	13	13	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 20	2002	325	7356					134	136A		10.1136/bmj.325.7356.134	http://dx.doi.org/10.1136/bmj.325.7356.134			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	577PG	12130608	Bronze, Green Published			2022-12-28	WOS:000177069900019
J	Altewischer, E; van Exter, MP; Woerdman, JP				Altewischer, E; van Exter, MP; Woerdman, JP			Plasmon-assisted transmission of entangled photons	NATURE			English	Article							EXTRAORDINARY OPTICAL-TRANSMISSION; SUBWAVELENGTH HOLE ARRAYS; SURFACE-PLASMONS; FLUORESCENCE	The state of a two-particle system is said to be entangled when its quantum-mechanical wavefunction cannot be factorized into two single-particle wavefunctions. This leads to one of the strongest counter-intuitive features of quantum mechanics, namely non-locality(1,2). Experimental realization of quantum entanglement is relatively easy for photons; a starting photon can spontaneously split into a pair of entangled photons inside a nonlinear crystal. Here we investigate the effects of nanostructured metal optical elements(3) on the properties of entangled photons. To this end, we place optically thick metal films perforated with a periodic array of subwavelength holes in the paths of the two entangled photons. Such arrays convert photons into surface-plasmon waves-optically excited compressive charge density waves-which tunnel through the holes before reradiating as photons at the far side(4-7). We address the question of whether the entanglement survives such a conversion process. Our coincidence counting measurements show that it does, so demonstrating that the surface plasmons have a true quantum nature. Focusing one of the photon beams on its array reduces the quality of the entanglement. The propagation of the surface plasmons makes the array effectively act as a 'which way' detector.	Leiden Univ, Huygens Lab, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Altewischer, E (corresponding author), Leiden Univ, Huygens Lab, POB 9504, NL-2300 RA Leiden, Netherlands.		van+Exter, Martin/AAA-4183-2021					Bethe HA, 1944, PHYS REV, V66, P163, DOI 10.1103/PhysRev.66.163; Bouwmeester D, 1997, NATURE, V390, P575, DOI 10.1038/37539; Ebbesen TW, 1998, NATURE, V391, P667, DOI 10.1038/35570; Ghaemi HF, 1998, PHYS REV B, V58, P6779, DOI 10.1103/PhysRevB.58.6779; GREENBERGER DM, 1993, PHYS TODAY, V46, P22, DOI 10.1063/1.881360; Grupp DE, 2000, APPL PHYS LETT, V77, P1569, DOI 10.1063/1.1308530; Hecht B, 1996, PHYS REV LETT, V77, P1889, DOI 10.1103/PhysRevLett.77.1889; KIMBLE HJ, 1977, PHYS REV LETT, V39, P691, DOI 10.1103/PhysRevLett.39.691; Kurtsiefer C, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.023802; KWIAT PG, 1995, PHYS REV LETT, V75, P4337, DOI 10.1103/PhysRevLett.75.4337; Landau LD., 1984, ELECTRODYNAMICS CONT; Lu YJ, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.023601; Martin-Moreno L, 2001, PHYS REV LETT, V86, P1114, DOI 10.1103/PhysRevLett.86.1114; Raether H., 1988, SURFACE PLASMONS; Sonnichsen C, 2000, APPL PHYS LETT, V76, P140, DOI 10.1063/1.125682	16	418	427	5	140	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 18	2002	418	6895					304	306		10.1038/nature00869	http://dx.doi.org/10.1038/nature00869			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574BF	12124618	Green Submitted			2022-12-28	WOS:000176868000036
J	Li, J; Van Vliet, KJ; Zhu, T; Yip, S; Suresh, S				Li, J; Van Vliet, KJ; Zhu, T; Yip, S; Suresh, S			Atomistic mechanisms governing elastic limit and incipient plasticity in crystals	NATURE			English	Article							DISLOCATION NUCLEATION; COMPUTER-SIMULATION; THIN-FILMS; NANOINDENTATION; INDENTATION; STABILITY; DEFECTS; SOLIDS	Nanometre-scale contact experiments(1-6) and simulations(7-10) demonstrate the potential to probe incipient plasticity-the onset of permanent deformation-in crystals. Such studies also point to the need for an understanding of the mechanisms governing defect nucleation in a broad range of fields and applications. Here we present a fundamental framework for describing incipient plasticity that combines results of atomistic and finite-element modelling, theoretical concepts of structural stability at finite strain, and experimental analysis. We quantify two key features of the nucleation and subsequent evolution of defects. A position-sensitive criterion based on elastic stability determines the location and character of homogeneously nucleated defects. We validate this stability criterion at both the atomistic and the continuum levels. We then propose a detailed interpretation of the experimentally observed sequence of displacement bursts to elucidate the role of secondary defect sources operating locally at stress levels considerably smaller than the ideal strength required for homogeneous nucleation. These findings provide a self-consistent explanation of the discontinuous elastic-plastic response in nanoindentation measurements, and a guide to fundamental studies across many disciplines that seek to quantify and predict the initiation and early stages of plasticity.	MIT, Dept Nucl Engn, Cambridge, MA 02139 USA; MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Yip, S (corresponding author), MIT, Dept Nucl Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		Li, Ju/A-2993-2008; Zhu, Ting/A-2206-2009; Suresh, Subra/B-8289-2008	Li, Ju/0000-0002-7841-8058; Suresh, Subra/0000-0002-6223-6831				Ackland GJ, 1997, PHILOS MAG A, V75, P713, DOI 10.1080/01418619708207198; Brochard S, 2001, MAT SCI ENG A-STRUCT, V309, P456, DOI 10.1016/S0921-5093(00)01701-9; EGAMI T, 1980, PHILOS MAG A, V41, P883, DOI 10.1080/01418618008243894; ERCOLESSI F, 1994, EUROPHYS LETT, V26, P583, DOI 10.1209/0295-5075/26/8/005; Ericksen JL., 1984, PHASE TRANSFORMATION, P61; GERBERICH WW, 1995, ACTA METALL MATER, V43, P1569, DOI 10.1016/0956-7151(94)00351-H; Gouldstone A, 2000, ACTA MATER, V48, P2277, DOI 10.1016/S1359-6454(00)00009-4; Gouldstone A, 2001, NATURE, V411, P656, DOI 10.1038/35079687; *HIBB KARLSS SOR, 2000, ABAQUS THEOR MAN VER; HILL R, 1962, J MECH PHYS SOLIDS, V10, P1, DOI 10.1016/0022-5096(62)90024-8; Hwu C, 1998, INT J SOLIDS STRUCT, V35, P3945, DOI 10.1016/S0020-7683(97)00210-2; Kelchner CL, 1998, PHYS REV B, V58, P11085, DOI 10.1103/PhysRevB.58.11085; Kiely JD, 1999, LANGMUIR, V15, P4513, DOI 10.1021/la9813681; Kramer DE, 2001, PHILOS MAG A, V81, P2033, DOI 10.1080/001418610010028693; Morris JW, 2000, PHILOS MAG A, V80, P2827, DOI 10.1080/01418610008223897; Ray J. R., 1988, Computer Physics Reports, V8, P109, DOI 10.1016/0167-7977(88)90009-3; RICE JR, 1976, 14TH P INT C THEOR A, V1, P207; Shenoy VB, 2000, J MECH PHYS SOLIDS, V48, P649, DOI 10.1016/S0022-5096(99)00055-1; Suresh S, 1999, SCRIPTA MATER, V41, P951, DOI 10.1016/S1359-6462(99)00245-6; Tadmor EB, 1996, PHILOS MAG A, V73, P1529, DOI 10.1080/01418619608243000; Tadmor EB, 1999, J MATER RES, V14, P2233, DOI 10.1557/JMR.1999.0300; WANG JH, 1995, PHYS REV B, V52, P12627, DOI 10.1103/PhysRevB.52.12627; Zhou Z, 1996, PHYS REV B, V54, P3841, DOI 10.1103/PhysRevB.54.3841; Zimmerman JA, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.165507	24	572	586	10	232	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 18	2002	418	6895					307	310		10.1038/nature00865	http://dx.doi.org/10.1038/nature00865			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574BF	12124619				2022-12-28	WOS:000176868000037
J	Yang, HI; Lu, SN; Liaw, YF; You, SL; Sun, CA; Wang, UY; Hsiao, CK; Chen, PJ; Chen, DS; Chen, CJ				Yang, HI; Lu, SN; Liaw, YF; You, SL; Sun, CA; Wang, UY; Hsiao, CK; Chen, PJ; Chen, DS; Chen, CJ		Taiwan Community Based Canc Scree	Hepatitis B e antigen and the risk of hepatocellular carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIRUS-INFECTION; TRANSGENIC MICE; SURFACE-ANTIGEN; TAIWAN; DNA; ANTIBODY; SAMPLE; ALPHA; GENE	Background The presence of hepatitis B e antigen (HBeAg) in serum indicates active viral replication in hepatocytes. HBeAg is thus a surrogate marker for the presence of hepatitis B virus DNA. We conducted a prospective study to determine the relation between positivity for hepatitis B surface antigen (HBsAg) and HBeAg and the development of hepatocellular carcinoma. Methods In 1991 and 1992,We enrolled 11,893 men without evidence of hepatocellular carcinoma (age range, 30 to 65 years) from seven townships in Taiwan. Serum samples obtained at the time of enrollment were tested for HBsAg and HBeAg by radioimmunoassay. The diagnosis of hepatocellular carcinoma was ascertained through data linkage with the computerized National Cancer Registry in Taiwan and with death certificates. We performed a multiple regression analysis to determine the relative risk of hepatocellular carcinoma among Men who were positive for HBsAg alone or for HBsAg and HBeAg, as compared with those who were negative for both. Results There were 111 cases of newly diagnosed hepatocellular carcinoma during 92,359 person-years of follow-up. The incidence rate of hepatocellular carcinoma was 1169 cases per 100,000 person-years among men who were positive for both HBsAg and HBeAg, 324 per 100,000 person-years for those who were positive for HBsAg only, and 39 per 100,000 person-years for those who were negative for both. After adjustment for age, sex, the presence or absence of antibodies against hepatitis C virus, cigarette-smoking status, and use or nonuse of alcohol, the relative risk of hepatocellular carcinoma was 9.6 (95 percent confidence interval, 6.0 to 15.2) among men who were positive for HBsAg alone and 60.2 (95 percent confidence interval, 35.5 to 1021) among those who were positive for both HBsAg and HBeAg, as compared with men who were negative for both. Conclusions Positivity for HBeAg is associated with an increased risk of hepatocellular carcinoma.	Natl Taiwan Univ, Coll Publ Hlth, Grad Inst Epidemiol, Taipei 10018, Taiwan; Kaohsiung Chang Gung Mem Hosp, Dept Gastroenterol, Kaohsiung, Taiwan; Chang Gung Mem Hosp, Tao Yuan, Taiwan; Chang Gung Univ, Tao Yuan, Taiwan; Natl Def Med Ctr, Dept Publ Hlth, Taipei, Taiwan; Tzu Chi Univ, Grad Inst Aboriginal Hlth, Hualien, Taiwan; Natl Taiwan Univ Hosp, Liver Res Unit, Taipei, Taiwan; Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Taipei, Taiwan	National Taiwan University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University; National Defense Medical Center; Tzu Chi University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Chen, CJ (corresponding author), Natl Taiwan Univ, Coll Publ Hlth, Grad Inst Epidemiol, 1 Jen Ai Rd,Sect 1, Taipei 10018, Taiwan.		Chen, Chien-Jen/C-6976-2008; 王, 豊裕/C-1460-2010; Chen, Chien-Jen/N-4723-2019; Yang, Hwai-I/A-9470-2008; Ibrahim, Essam Hassan/G-1960-2018; Liaw, Yun-Fan/B-4305-2009	Yang, Hwai-I/0000-0002-3433-942X; Ibrahim, Essam Hassan/0000-0003-0130-2257; CHEN, DING-SHINN/0000-0001-7791-6154; hsiao, chuhsing kate/0000-0003-4905-8484; Chen, Pei-Jer/0000-0001-8316-3785				AALEN O, 1978, ANN STAT, V6, P701, DOI 10.1214/aos/1176344247; BEASLEY RP, 1981, LANCET, V2, P1129; BRESLOW N, 1974, ANN STAT, V2, P437, DOI 10.1214/aos/1176342705; CHEN CJ, 1991, HEPATOLOGY, V13, P398, DOI 10.1002/hep.1840130303; Chen CJ, 1997, J GASTROEN HEPATOL, V12, pS294, DOI 10.1111/j.1440-1746.1997.tb00513.x; CHEN DS, 1993, SCIENCE, V262, P369, DOI 10.1126/science.8211155; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CHU CM, 1983, HEPATOLOGY, V3, P947; Chu CM, 1997, J GASTROEN HEPATOL, V12, pS218, DOI 10.1111/j.1440-1746.1997.tb00503.x; Farrell G, 2000, J MED VIROL, V61, P374, DOI 10.1002/1096-9071(200007)61:3&lt;374::AID-JMV16&gt;3.0.CO;2-7; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FREEMAN BA, 1982, LAB INVEST, V47, P412; Henkler F, 1996, J VIRAL HEPATITIS, V3, P109, DOI 10.1111/j.1365-2893.1996.tb00001.x; HEYWARD WL, 1982, LANCET, V2, P889; *IARC, 1994, IARC MON EV CARC RIS, V59; Kew MC, 1998, RES VIROLOGY, V149, P257, DOI 10.1016/S0923-2516(99)89003-7; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; LIAW YF, 1984, J MED VIROL, V13, P385, DOI 10.1002/jmv.1890130410; Lin SM, 1999, HEPATOLOGY, V29, P971, DOI 10.1002/hep.510290312; LIN TM, 1991, ANTICANCER RES, V11, P2063; LU SN, 1988, CANCER-AM CANCER SOC, V62, P2051, DOI 10.1002/1097-0142(19881101)62:9<2051::AID-CNCR2820620930>3.0.CO;2-1; MATSUBARA K, 1990, MOL BIOL MED, V7, P243; Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; PENA EA, 1993, J STAT PLAN INFER, V37, P193, DOI 10.1016/0378-3758(93)90088-N; POPPER H, 1987, P NATL ACAD SCI USA, V84, P866, DOI 10.1073/pnas.84.3.866; SHAFRITZ DA, 1981, HEPATOLOGY, V1, P1, DOI 10.1002/hep.1840010102; Tsai JF, 1996, BRIT J CANCER, V73, P1498, DOI 10.1038/bjc.1996.283; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG XW, 1995, CANCER RES, V55, P6012; YU MW, 1991, CANCER RES, V51, P5621	31	925	997	0	35	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 18	2002	347	3					168	174		10.1056/NEJMoa013215	http://dx.doi.org/10.1056/NEJMoa013215			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	574BR	12124405	Green Published			2022-12-28	WOS:000176869000003
J	Ko, DT; Hebert, PR; Coffey, CS; Sedrakyan, A; Curtis, JP; Krumholz, HM				Ko, DT; Hebert, PR; Coffey, CS; Sedrakyan, A; Curtis, JP; Krumholz, HM			beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							MYOCARDIAL-INFARCTION; ANTIHYPERTENSIVE DRUGS; MILD HYPERTENSION; RANDOMIZED-TRIAL; ELDERLY-PATIENTS; PROPRANOLOL; MORTALITY; METOPROLOL; MORBIDITY; LIFE	Context beta-Blocker therapy remains substantially underused in cardiac patients despite its proven mortality benefits. Reluctance to prescribe these agents may derive from concerns about their association with symptoms of depression, fatigue, and sexual dysfunction. Objective To determine the association of beta-blockers with depressive symptoms, fatigue, and sexual dysfunction by performing a quantitative review of randomized trials that tested beta-blockers in myocardial infarction, heart failure, and hypertension. Data Sources Randomized trials of beta-blockers used in the treatment of myocardial infarction, heart failure, or hypertension were identified by searching the MEDLINE database for English-language articles (1966-2001). In addition, we searched the reference lists of previously published trials and reviews of beta-blockers for additional studies. Study Selection Criteria for inclusion of trials in the review were: random allocation of study treatments, placebo control, noncrossover design, enrollment of at least 100 patients, and a minimum of 6 months of follow-up. The initial search produced 475 articles, 42 of which met these criteria. Fifteen of these trials reported on depressive symptoms, fatigue, or sexual dysfunction and were selected for inclusion. Data Extraction For each trial, 1 author abstracted the frequency of adverse events in the beta-blocker and placebo groups and the numbers of patients randomized to the treatment groups. Two other authors verified the counts of events, and all authors adjudicated any discrepancies. Two different types of information on adverse events were abstracted: patient-reported symptoms and withdrawal of therapy due to a specified symptom. We categorized the tested beta-blockers by generation (early vs late) and lipid solubility (high vs low to moderate). Data Synthesis The 15 trials involved more than 35000 subjects. beta-Blocker therapy was not associated with a significant absolute annual increase in risk of reported depressive symptoms (6 per 1000 patients 95% confidence interval [CI], -7 to 19). beta-Blockers were associated with a small significant annual increase in risk of reported fatigue (18 per 1000 patients; 95% Cl, 5-30), equivalent to 1 additional report of fatigue for every 57 patients treated per year with beta-blockers. beta-Blockers were also associated with a small, significant annual increase in risk of reported sexual dysfunction (5 per 1000 patients; 95% Cl, 2-8), equivalent to one additional report for every 199 patients treated per year. None of the risks of adverse effects differed significantly by degree of beta-blocker lipid solubility, The risk associated with reported fatigue was significantly higher for early-generation than for late-generation beta-blockers (P=.04). Conclusion The conventional wisdom that beta-blocker therapy is associated with substantial risks of depressive symptoms, fatigue, and sexual dysfunction is not supported by data from clinical trials. There is no significant increased risk of depressive symptoms and only small increased risks of fatigue and sexual dysfunction. The risks of these adverse effects should be put in the context of the documented benefits of these medications.	Yale Univ, Sch Med, Dept Med, Sect Cardiovasc Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT 06520 USA; Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA; Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA	Yale University; Yale University; Yale University; University of Alabama System; University of Alabama Birmingham	Krumholz, HM (corresponding author), Yale Univ, Sch Med, Dept Med, Sect Cardiovasc Med, POB 208025, New Haven, CT 06520 USA.		, Harlan/AAI-2875-2020	Ko, Dennis/0000-0001-6840-8051				[Anonymous], 1981, LANCET, V2, P539; AVORN J, 1986, JAMA-J AM MED ASSOC, V255, P357, DOI 10.1001/jama.255.3.357; Barksdale JD, 1999, PHARMACOTHERAPY, V19, P573, DOI 10.1592/phco.19.8.573.31526; BATHEN J, 1978, ANN INTERN MED, V88, P716, DOI 10.7326/0003-4819-88-5-716_4; BRAUNWALD E, 2001, HEART DIS TXB CARDIO, P1293; BRIGHT RA, 1992, JAMA-J AM MED ASSOC, V267, P1783; Bristow MR, 2000, CIRCULATION, V101, P558, DOI 10.1161/01.CIR.101.5.558; CARNEY RM, 1987, AM J MED, V83, P223, DOI 10.1016/0002-9343(87)90689-9; COOPE J, 1986, BRIT MED J, V293, P1145, DOI 10.1136/bmj.293.6555.1145; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; Eichhorn E, 2001, NEW ENGL J MED, V344, P1659; Ekbom T, 1993, J HYPERTENS S2, V11, pS19; Freemantle N, 1999, BMJ-BRIT MED J, V318, P1730, DOI 10.1136/bmj.318.7200.1730; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; FRISHMAN WH, 1981, NEW ENGL J MED, V305, P500, DOI 10.1056/NEJM198108273050907; Gheorghiade Mihai, 2001, American Journal of Medicine, V110, p68S; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; GREENBLA.DJ, 1974, DRUGS, V7, P118, DOI 10.2165/00003495-197407010-00008; Grimm RH, 1997, HYPERTENSION, V29, P8, DOI 10.1161/01.HYP.29.1.8; HALL PE, 1984, J CLIN HOSP PHARM, V9, P283, DOI 10.1111/j.1365-2710.1984.tb01089.x; HANSTEEN V, 1982, BRIT MED J, V284, P155, DOI 10.1136/bmj.284.6310.155; Hjalmarson A, 2000, JAMA-J AM MED ASSOC, V283, P1295, DOI 10.1001/jama.283.10.1295; Hjalmarson A, 1999, LANCET, V353, P2001; IOANNIDIS JPA, 1995, ANN INTERN MED, V122, P856, DOI 10.7326/0003-4819-122-11-199506010-00009; JULIAN DG, 1982, LANCET, V1, P1142; Kohn R, 2001, Med Health R I, V84, P92; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; Lue TF, 2000, NEW ENGL J MED, V342, P1802, DOI 10.1056/NEJM200006153422407; MCAINSH J, 1990, PHARMACOL THERAPEUT, V46, P163, DOI 10.1016/0163-7258(90)90092-G; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; *MED EC CO INC, 2002, PHYS DESK REF; MIDDLEMISS DN, 1977, NATURE, V267, P289, DOI 10.1038/267289a0; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; OLSSON G, 1985, J AM COLL CARDIOL, V5, P1428, DOI 10.1016/S0735-1097(85)80360-0; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; Perez-Stable EJ, 2000, AM J MED, V108, P359, DOI 10.1016/S0002-9343(00)00304-1; PEREZSTABLE EJ, 1995, J GEN INTERN MED, V10, P419, DOI 10.1007/BF02599912; Petitti D, 1994, DECISION ANAL COST E; Shadish W. R., 1994, HDB RES SYNTHESIS; TAYLOR SH, 1982, NEW ENGL J MED, V307, P1293, DOI 10.1056/NEJM198211183072101; THIESSEN BQ, 1990, ARCH INTERN MED, V150, P2286, DOI 10.1001/archinte.150.11.2286; WAAL HJ, 1967, BRIT MED J, V2, P50, DOI 10.1136/bmj.2.5543.50; WANG MC, 1999, INTEGRATING RESULTS; WARREN SC, 1977, ANN INTERN MED, V86, P112, DOI 10.7326/0003-4819-86-1-112_1; WEISS RJ, 1991, AM FAM PHYSICIAN, V44, P2075	46	359	375	0	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	2002	288	3					351	357		10.1001/jama.288.3.351	http://dx.doi.org/10.1001/jama.288.3.351			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573AK	12117400				2022-12-28	WOS:000176807000027
J	Gomez, LD; Marshall, T; Tsai, PC; Shao, YS; Guo, YLL				Gomez, LD; Marshall, T; Tsai, PC; Shao, YS; Guo, YLL			Number of boys born to men exposed to polychlorinated byphenyls	LANCET			English	Article							SEX-RATIO; CHLORACNE; TAIWAN; COHORT; DIOXIN	We studied the sex of children born to individuals involved in the Yucheng oil disaster, Taiwan, who were exposed to polychlorinated byphenyls (PCBs) after an oil contamination accident in 1979. Men exposed to PCBs before age 20 years had a lower chance of having a baby boy than did age-matched and neighbourhood-matched controls (odds ratio 0.65, 95% CI 0.45-0.93). The male-to-female sex ratio of children born to men exposed to PCBs after age 20 years, however, approached that seen in controls (0.90, 0.59-1.35). We noted no significant difference in the birth ratio of infants born to exposed and unexposed mothers (0.93, 0.77-1.12). Our findings suggest that paternal exposure to PCBs before age 20 years affects the sex of a subsequently born child.	Natl Cheng Kung Univ, Coll Med, Tainan 70428, Taiwan; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	National Cheng Kung University; University of London; London School of Hygiene & Tropical Medicine	Guo, YLL (corresponding author), Natl Cheng Kung Univ, Coll Med, Tainan 70428, Taiwan.		Guo, Yue-Liang Leon/ABF-2314-2020	Tsai, Pei-Chien/0000-0002-5044-6727; GUO, Yue Leon/0000-0002-8530-4809; Shao, Yu-Hsuan/0000-0002-0757-1901				Crisp TM, 1998, ENVIRON HEALTH PERSP, V106, P11, DOI 10.2307/3433911; Guo YLL, 1999, ENVIRON HEALTH PERSP, V107, P715, DOI 10.2307/3434656; Mocarelli P, 2000, LANCET, V355, P1858, DOI 10.1016/S0140-6736(00)02290-X; Moshammer H, 2000, LANCET, V356, P1271, DOI 10.1016/S0140-6736(05)73872-1; Rogan WJ, 1999, LANCET, V353, P206, DOI 10.1016/S0140-6736(05)77215-9	5	72	77	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 13	2002	360	9327					143	144		10.1016/S0140-6736(02)09386-8	http://dx.doi.org/10.1016/S0140-6736(02)09386-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573PB	12126828				2022-12-28	WOS:000176839100017
J	Jenkins, P				Jenkins, P			Doping in sport	LANCET			English	Editorial Material							GROWTH-HORMONE TREATMENT; ERYTHROPOIETIN; STRENGTH; ADULTS		St Bartholomews Hosp, Dept Endocrinol, London EC1A 7BE, England	University of London; Queen Mary University London	Jenkins, P (corresponding author), St Bartholomews Hosp, Dept Endocrinol, London EC1A 7BE, England.							CATLIN D, 2002, BMJ C DRUGS SPORT LO; CUNEO RC, 1991, J APPL PHYSIOL, V70, P688, DOI 10.1152/jappl.1991.70.2.688; DEYSSIG R, 1993, ACTA ENDOCRINOL-COP, V128, P313, DOI 10.1530/acta.0.1280313; Jenkins P, 1999, LANCET, V353, P1532, DOI 10.1016/S0140-6736(05)67231-5; Jenkins PJ, 1999, CLIN ENDOCRINOL, V50, P683, DOI 10.1046/j.1365-2265.1999.00784.x; Jenkins PJ, 2001, J CLIN ENDOCR METAB, V86, P2935, DOI 10.1210/jc.86.7.2935; Monson JP, 2000, CLIN ENDOCRINOL, V53, P281, DOI 10.1046/j.1365-2265.2000.01104.x; Skibeli V, 2001, BLOOD, V98, P3626, DOI 10.1182/blood.V98.13.3626; WIDE L, 1995, MED SCI SPORT EXER, V27, P1569; Wu Z, 1999, LANCET, V353, P895, DOI 10.1016/S0140-6736(99)00775-8; YARASHESKI KE, 1992, AM J PHYSIOL, V262, P261	11	13	13	1	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 13	2002	360	9327					99	100		10.1016/S0140-6736(02)09432-1	http://dx.doi.org/10.1016/S0140-6736(02)09432-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573PB	12126814				2022-12-28	WOS:000176839100003
J	van Woensel, JBM; van Aalderen, WMC				van Woensel, JBM; van Aalderen, WMC			Treatment for bronchiolitis: the story continues	LANCET			English	Editorial Material							RESPIRATORY SYNCYTIAL VIRUS; HOSPITALIZATIONS; CHILDREN		Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, NL-1105 AZ Amsterdam, Netherlands	Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	van Woensel, JBM (corresponding author), Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	j.b.vanwoensel@amc.uva.nl						Abul-Ainine A, 2002, ARCH DIS CHILD, V86, P276, DOI 10.1136/adc.86.4.276; Flores G, 1997, PEDIATRICS, V100, P233, DOI 10.1542/peds.100.2.233; Garrison MM, 2000, PEDIATRICS, V106, P184; Hall CB, 2001, NEW ENGL J MED, V344, P1917, DOI 10.1056/NEJM200106213442507; KELLNER JD, 1998, COCHRANE LIB; OPENSHAW PJM, 1995, SPRINGER SEMIN IMMUN, V17, P187; Ruuskanen O, 1993, Curr Probl Pediatr, V23, P50, DOI 10.1016/0045-9380(93)90003-U; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; van Woensel JBM, 2002, ARCH DIS CHILD, V86, P370, DOI 10.1136/adc.86.5.370; van Woensel JBM, 1997, THORAX, V52, P634, DOI 10.1136/thx.52.7.634	10	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 13	2002	360	9327					101	102		10.1016/S0140-6736(02)09433-3	http://dx.doi.org/10.1016/S0140-6736(02)09433-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573PB	12126816				2022-12-28	WOS:000176839100005
J	Gahl, WA; Thoene, JG; Schneider, JA				Gahl, WA; Thoene, JG; Schneider, JA			Cystinosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							NEPHROPATHIC CYSTINOSIS; CYSTEAMINE THERAPY; COUNTER-TRANSPORT; CORNEAL CRYSTALS; BINDING-PROTEIN; CTNS MUTATIONS; RENAL-FUNCTION; GENE CTNS; CHILDREN; INSUFFICIENCY		NICHHD, Heritable Disorders Branch, Bethesda, MD 20892 USA; Tulane Hlth Sci Ctr, Hayward Genet Ctr, New Orleans, LA USA; Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Tulane University; University of California System; University of California San Diego	Gahl, WA (corresponding author), NICHHD, Heritable Disorders Branch, 10 Ctr Dr,MSC 1830,Bldg 10,Rm 9S-241, Bethesda, MD 20892 USA.	bgahl@helix.nih.gov	Thoene, Jess/AAF-5305-2020		NCRR NIH HHS [M01 RR00827] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000131] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000827] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000215, ZIAHG000215] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ABDERHALDEN E, 1903, Z PHYSL CHEM, V38, P557; Anikster Y, 1999, MOL GENET METAB, V66, P111, DOI 10.1006/mgme.1998.2790; Anikster Y, 2001, CHEST, V119, P394, DOI 10.1378/chest.119.2.394; Anikster Y, 2000, PEDIATR RES, V47, P17, DOI 10.1203/00006450-200001000-00007; Anikster Y, 1999, HUM MUTAT, V14, P454, DOI 10.1002/(SICI)1098-1004(199912)14:6<454::AID-HUMU2>3.0.CO;2-H; Attard M, 1999, HUM MOL GENET, V8, P2507, DOI 10.1093/hmg/8.13.2507; Aula P., 2001, METABOLIC MOL BASES, P5109; Ballantyne AO, 2000, NEUROPSY NEUROPSY BE, V13, P254; Beckman DA, 1998, TERATOLOGY, V58, P96, DOI 10.1002/(SICI)1096-9926(199809/10)58:3/4<96::AID-TERA5>3.3.CO;2-U; BICKEL H, 1952, ACTA PAEDIATR SC   S, V90, P1; CHARNAS LR, 1994, ANN NEUROL, V35, P181, DOI 10.1002/ana.410350209; CHIK CL, 1993, ANN INTERN MED, V119, P568, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00004; COGAN DG, 1957, JAMA-J AM MED ASSOC, V164, P394, DOI 10.1001/jama.1957.02980040034009; CORDEN BJ, 1981, DEV PHARMACOL THERAP, V3, P25, DOI 10.1159/000457418; DENT CE, 1947, BIOCHEM J, V41, P240, DOI 10.1042/bj0410240; EHRICH JHH, 1979, NEUROPADIATRIE, V10, P128, DOI 10.1055/s-0028-1085319; FINK JK, 1989, ARCH NEUROL-CHICAGO, V46, P543, DOI 10.1001/archneur.1989.00520410077027; FIVUSH B, 1988, J PEDIATR-US, V112, P49, DOI 10.1016/S0022-3476(88)80119-7; FIVUSH B, 1987, AM J DIS CHILD, V141, P1087, DOI 10.1001/archpedi.1987.04460100065027; Forestier L, 1999, AM J HUM GENET, V65, P353, DOI 10.1086/302509; Gahl W A, 1986, Adv Pediatr, V33, P95; Gahl W.A., 2001, METAB MOL BASES INHE, V4, P5085; GAHL WA, 1986, J PEDIATR-US, V109, P605, DOI 10.1016/S0022-3476(86)80221-9; GAHL WA, 1983, BIOCHEM J, V216, P393, DOI 10.1042/bj2160393; GAHL WA, 1987, NEW ENGL J MED, V316, P971, DOI 10.1056/NEJM198704163161602; GAHL WA, 1984, J PEDIATR-US, V104, P904, DOI 10.1016/S0022-3476(84)80494-1; GAHL WA, 1984, AM J HUM GENET, V36, P277; GAHL WA, 1988, NEW ENGL J MED, V319, P1461, DOI 10.1056/NEJM198812013192206; GAHL WA, 1982, SCIENCE, V217, P1263, DOI 10.1126/science.7112129; GAHL WA, 1988, J CLIN INVEST, V81, P549, DOI 10.1172/JCI113353; Gahl WA, 2000, MOL GENET METAB, V71, P100, DOI 10.1006/mgme.2000.3062; GOLDMAN H, 1971, PEDIATRICS, V47, P979; GOODMAN SI, 1972, DHEW PUBLICATION NIH, P225; GRETZ N, 1982, P EUR DIAL TRANS, V19, P582; HAGGE W, 1965, ANN PAEDIATR-BASEL, V205, P442; JONAS AJ, 1982, J BIOL CHEM, V257, P13185; KAISERKUPFER MI, 1987, NEW ENGL J MED, V316, P775, DOI 10.1056/NEJM198703263161304; KAISERKUPFER MI, 1990, ARCH OPHTHALMOL-CHIC, V108, P689, DOI 10.1001/archopht.1990.01070070075038; KAISERKUPFER MI, 1986, ARCH OPHTHALMOL-CHIC, V104, P706, DOI 10.1001/archopht.1986.01050170096030; Kalatzis V, 2001, EMBO J, V20, P5940, DOI 10.1093/emboj/20.21.5940; Kalatzis V, 2001, J AM SOC NEPHROL, V12, P2170, DOI 10.1681/ASN.V12102170; KATZIR Z, 1988, ARCH DIS CHILD, V63, P548, DOI 10.1136/adc.63.5.548; KIMONIS VE, 1995, J CLIN ENDOCR METAB, V80, P3257, DOI 10.1210/jc.80.11.3257; MAHONEY CP, 1970, NEW ENGL J MED, V283, P397, DOI 10.1056/NEJM197008202830804; Mahoney CP, 2000, PEDIATR NEPHROL, V15, P50, DOI 10.1007/PL00013448; MALEKZADEH MH, 1977, AM J MED, V63, P525, DOI 10.1016/0002-9343(77)90197-8; MARKELLO TC, 1993, NEW ENGL J MED, V328, P1157, DOI 10.1056/NEJM199304223281604; MCDOWELL GA, 1995, NAT GENET, V10, P246, DOI 10.1038/ng0695-246; OREGAN S, 1980, ACTA PAEDIATR BELG, V33, P51; OSHIMA RG, 1974, J BIOL CHEM, V249, P6033; Park MA, 2001, AM J HUM GENET, V69, P485; Phornphutkul C, 2001, AM J HUM GENET, V69, P712, DOI 10.1086/323484; PISONI RL, 1985, J BIOL CHEM, V260, P4791; REISS RE, 1988, NEW ENGL J MED, V319, P223, DOI 10.1056/NEJM198807283190406; SCHNEIDER JA, 1967, BIOCHEM BIOPH RES CO, V29, P527, DOI 10.1016/0006-291X(67)90516-5; SCHNEIDER JA, 1967, SCIENCE, V157, P1321, DOI 10.1126/science.157.3794.1321; SCHNEIDER JA, 1974, NEW ENGL J MED, V290, P878, DOI 10.1056/NEJM197404182901604; SCHNEIDER JA, 1990, AKF NEPHROL LETT, V7, P22; SCHULMAN JD, 1969, SCIENCE, V166, P1152, DOI 10.1126/science.166.3909.1152; SEEGMILL.JE, 1968, ANN INTERN MED, V68, P883, DOI 10.7326/0003-4819-68-4-883; Shotelersuk V, 1998, AM J HUM GENET, V63, P1352, DOI 10.1086/302118; SMITH M, 1987, METHOD ENZYMOL, V143, P144; SMITH ML, 1987, PRENATAL DIAG, V7, P23, DOI 10.1002/pd.1970070105; SMITH ML, 1989, NEW ENGL J MED, V321, P397; SMOLIN LA, 1987, AM J HUM GENET, V41, P266; SONIES BC, 1990, NEW ENGL J MED, V323, P565, DOI 10.1056/NEJM199008303230903; THEODOROPOULOS DS, 1995, PEDIATR NEPHROL, V9, P412, DOI 10.1007/BF00866713; THEODOROPOULOS DS, 1993, JAMA-J AM MED ASSOC, V270, P2200, DOI 10.1001/jama.270.18.2200; Thoene J, 1999, MOL GENET METAB, V67, P283, DOI 10.1006/mgme.1999.2876; THOENE JG, 1976, J CLIN INVEST, V58, P180, DOI 10.1172/JCI108448; THOENE JG, 1992, PATHOPHYSIOLOGY LYSO; Touchman JW, 2000, GENOME RES, V10, P165, DOI 10.1101/gr.10.2.165; Town M, 1998, NAT GENET, V18, P319, DOI 10.1038/ng0498-319; Wuhl E, 1998, PEDIATR RES, V43, P484	74	459	477	0	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 11	2002	347	2					111	121		10.1056/NEJMra020552	http://dx.doi.org/10.1056/NEJMra020552			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	572HC	12110740				2022-12-28	WOS:000176767300007
J	Horng, S; Miller, FG				Horng, S; Miller, FG			Is placebo surgery unethical?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CLINICAL RESEARCH; TRIALS; CONSENT		NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Horng, S (corresponding author), NIH, Bldg 10, Bethesda, MD 20892 USA.							APPELBAUM PS, 1987, HASTINGS CENT REP, V17, P20, DOI 10.2307/3562038; Beauchamp T L, 2012, PRINCIPLES BIOMEDICA; BEECHER HK, 1961, JAMA-J AM MED ASSOC, V176, P1102, DOI 10.1001/jama.1961.63040260007008; Clark PA, 2002, J LAW MED ETHICS, V30, P58, DOI 10.1111/j.1748-720X.2002.tb00720.x; COBB LA, 1959, NEW ENGL J MED, V260, P1115, DOI 10.1056/NEJM195905282602204; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701; Freeman TB, 1999, NEW ENGL J MED, V341, P988, DOI 10.1056/NEJM199909233411311; Gillett G R, 2001, IRB, V23, P1, DOI 10.2307/3563896; Hrobjartsson A, 2001, NEW ENGL J MED, V345, P304; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; Joffe S, 2001, LANCET, V358, P1772, DOI 10.1016/S0140-6736(01)06805-2; JOHNSON AG, 1994, LANCET, V344, P1140, DOI 10.1016/S0140-6736(94)90637-8; Kaptchuk TJ, 2000, J CLIN EPIDEMIOL, V53, P786, DOI 10.1016/S0895-4356(00)00206-7; LEVINE RJ, 1986, ETHICS REGULATION CL, P72; Macklin R, 1999, NEW ENGL J MED, V341, P992, DOI 10.1056/NEJM199909233411312; Miller FG, 1998, JAMA-J AM MED ASSOC, V280, P1449, DOI 10.1001/jama.280.16.1449; Moerman DE, 2002, ANN INTERN MED, V136, P471, DOI 10.7326/0003-4819-136-6-200203190-00011; Moseley JB, 2002, NEW ENGL J MED, V347, P81, DOI 10.1056/NEJMoa013259; Moseley JB, 1996, AM J SPORT MED, V24, P28, DOI 10.1177/036354659602400106; Weijer C, 2002, J LAW MED ETHICS, V30, P69, DOI 10.1111/j.1748-720X.2002.tb00721.x; Wendler D, 1996, MILBANK Q, V74, P87, DOI 10.2307/3350434	21	117	119	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 11	2002	347	2					137	139		10.1056/NEJMsb021025	http://dx.doi.org/10.1056/NEJMsb021025			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	572HC	12110744				2022-12-28	WOS:000176767300011
J	Fradin, MS; Day, JF				Fradin, MS; Day, JF			Comparative efficacy of insect repellents against mosquito bites	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN VOLUNTEERS; FORMULATIONS; DISEASE; SAFETY; DEET	Background: The worldwide threat of arthropod-transmitted diseases, with their associated morbidity and mortality, underscores the need for effective insect repellents. Multiple chemical, botanical, and ``alternative'' repellent products are marketed to consumers. We sought to determine which products available in the United States provide reliable and prolonged complete protection from mosquito bites. Methods: We conducted studies involving 15 volunteers to test the relative efficacy of seven botanical insect repellents; four products containing N,N-diethyl-m-toluamide, now called N,N-diethyl-3-methylbenzamide (DEET); a repellent containing IR3535 (ethyl butylacetylaminopropionate); three repellent-impregnated wristbands; and a moisturizer that is commonly claimed to have repellent effects. These products were tested in a controlled laboratory environment in which the species of the mosquitoes, their age, their degree of hunger, the humidity, the temperature, and the light-dark cycle were all kept constant. Results: DEET-based products provided complete protection for the longest duration. Higher concentrations of DEET provided longer-lasting protection. A formulation containing 23.8 percent DEET had a mean complete-protection time of 301.5 minutes. A soybean-oil-based repellent protected against mosquito bites for an average of 94.6 minutes. The IR3535-based repellent protected for an average of 22.9 minutes. All other botanical repellents we tested provided protection for a mean duration of less than 20 minutes. Repellent-impregnated wristbands offered no protection. Conclusions: Currently available non-DEET repellents do not provide protection for durations similar to those of DEET-based repellents and cannot be relied on to provide prolonged protection in environments where mosquito-borne diseases are a substantial threat. (N Engl J Med 2002;347:13-8.)	Chapel Hill Dermatol, Chapel Hill, NC 27514 USA; Univ Florida, Florida Med Entomol Lab, Vero Beach, FL USA	State University System of Florida; University of Florida	Fradin, MS (corresponding author), Chapel Hill Dermatol, 891 Willow Dr,Suite 1, Chapel Hill, NC 27514 USA.	mark_fradin@med.unc.edu						BUESCHER MD, 1983, MOSQ NEWS, V43, P364; Chou JT, 1997, J MED ENTOMOL, V34, P624, DOI 10.1093/jmedent/34.6.624; CORO F, 2000, WING BEATS, V11, P6; Curtis C. F., 1992, Review of Medical and Veterinary Entomology, V80, P543; *ENV PROT AG, 1999, BIOP TECHN DOC 3 N B; *ENV RISK AN PROGR, 2001, WHATS GOING W NILE V; Fradin M. S., 2001, Wilderness medicine, P754; Fradin MS, 1998, ANN INTERN MED, V128, P931, DOI 10.7326/0003-4819-128-11-199806010-00013; Fradlin M. S., 2001, COMPREHENSIVE DERMAT, P717; GODDARD J, 2000, PHYSICIANS GUIDE ART; Golenda CF, 1999, AM J TROP MED HYG, V60, P654, DOI 10.4269/ajtmh.1999.60.654; Goodyer L, 1998, AM J TROP MED HYG, V59, P323, DOI 10.4269/ajtmh.1998.59.323; GUPTA RK, 1991, J AM MOSQUITO CONTR, V7, P490; GUPTA RK, 1989, J AM MOSQUITO CONTR, V5, P52; KHAN A A, 1969, Transactions of the St. John's Hospital Dermatological Society, V55, P99; KING WV, 1954, AGR HDB DEP AGR ENT, V69; MAIBACH HI, 1966, J AMER MED ASSOC, V196, P263, DOI 10.1001/jama.196.3.263; MAIBACH HI, 1974, ARCH DERMATOL, V109, P32, DOI 10.1001/archderm.109.1.32; MAIBACH HI, 1974, CLIN PHARMACOL THER, V16, P970, DOI 10.1002/cpt1974165part2970; MCHUGH CP, 1994, LAB MED, V25, P429, DOI 10.1093/labmed/25.7.429; MUIRHEADTHOMSON RC, 1951, BRIT MED J, V1, P1114, DOI 10.1136/bmj.1.4715.1114; Nash D, 2001, NEW ENGL J MED, V344, P1807, DOI 10.1056/NEJM200106143442401; *OFF PEST PROGR PR, 1998, EPA738R98010 OFF PES; *OFF PEST TOX SUBS, 1980, EPA540RS81004 OFF PE; OSIMITZ TG, 1995, J AM MOSQUITO CONTR, V11, P274; QUARLES W, 1996, COMMON SENSE PEST CO, V12, P12; SCHRECK CE, 1977, ANNU REV ENTOMOL, V22, P101, DOI 10.1146/annurev.en.22.010177.000533; SELIM S, 1995, FUND APPL TOXICOL, V25, P95, DOI 10.1006/faat.1995.1043; Shell E.R., 1997, ATLANTIC MONTHLY, P45; Sokal R. R., 1981, BIOMETRY PRINCIPLES; STRAUSS WG, 1968, AM J TROP MED HYG, V17, P461, DOI 10.4269/ajtmh.1968.17.461; Suarez S, 2000, WING BEATS, V11, P30; Taubes G, 1997, NY TIMES MAG AUG, P40; Tawatsin A, 2001, J VECTOR ECOL, V26, P76; VELTRI JC, 1994, J TOXICOL-CLIN TOXIC, V32, P1, DOI 10.3109/15563659409000426; *WHO, 1999, 94 WHO; 2000, MMWR MORB MORTAL WKL, V49, P25; 2000, MMWR MORB MORTAL WKL, V49, P1044; 2000, CONSUMER REPORTS JUN, P14; 2001, MMWR MORB MORTAL WKL, V50, P265; 1983, FED REG, V48, P26987	41	492	544	1	109	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 4	2002	347	1					13	18		10.1056/NEJMoa011699	http://dx.doi.org/10.1056/NEJMoa011699			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569HA	12097535				2022-12-28	WOS:000176594500003
J	Parkinson, G				Parkinson, G			The many faces of poison ivy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Falmouth Pediat Assoc, Falmouth, MA 02540 USA		Parkinson, G (corresponding author), Falmouth Pediat Assoc, Falmouth, MA 02540 USA.								0	4	4	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 4	2002	347	1					35	35		10.1056/NEJMicm0010418	http://dx.doi.org/10.1056/NEJMicm0010418			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569HA	12097538				2022-12-28	WOS:000176594500006
J	Gold, ER; Caulfield, TA				Gold, ER; Caulfield, TA			The moral tollbooth: a method that makes use of the patent system to address ethical concerns in biotechnology	LANCET			English	Article							POLICY FORUM; DEBATE; GENE	Patents granted for biotechnological innovations continue to cause social and ethical dilemmas. For example, much controversy surrounds the patenting of genes that predispose to breast-cancer, and in the USA the debate continues about whether or not stem-cell technology should be accessible to all. In this report, we argue that some of these concerns can be addressed within national patent systems. In particular, we examine the "order public or morality" clause that exists in most national patent procedures. Furthermore, we propose that patents for inventions that present social and ethical questions should be subject to suspension by an independent, transparent, and responsible tribunal made up of specialists in ethics, research, and economics. This suspension should be reversible so that, when the social or ethical concerns have been addressed in an appropriate manner, the suspension can be lifted. Although controversial, such a flexible mechanism would assist governments and industry in enhancing public support for patents in the biotechnology area.	McGill Univ, Fac Law, Montreal, PQ H3A 1W9, Canada; Univ Alberta, Hlth Law Inst, Edmonton, AB, Canada	McGill University; University of Alberta	Gold, ER (corresponding author), McGill Univ, Fac Law, Montreal, PQ H3A 1W9, Canada.			Gold, E. Richard/0000-0002-3789-9238				Barton JH, 2000, NAT BIOTECHNOL, V18, P805, DOI 10.1038/78319; Barton JH, 2000, NATURE, V406, P455, DOI 10.1038/35020244; Barton JH, 2000, SCIENCE, V287, P1933, DOI 10.1126/science.287.5460.1933; Caulfield T, 2001, Alta Law Rev, V39, P335; Caulfield T, 2000, NAT REV GENET, V1, P227, DOI 10.1038/35042087; CAULFIELD T, 1999, J CONSUM POLICY, V21, P483; CONNOR S, 1992, INDEPENDENT LON 0202, P5; Gold ER, 2000, NAT BIOTECHNOL, V18, P1319, DOI 10.1038/82460; Gold ER, 2000, NAT BIOTECHNOL, V18, P1217, DOI 10.1038/81233; GOLD ER, 2001, EUR LAW J, V7, P328; Heller MA, 1998, SCIENCE, V280, P698, DOI 10.1126/science.280.5364.698; Knoppers B, 1999, COMMERCIALIZATION GE, P1; Knoppers BM, 2000, SCIENCE, V290, P49; Knoppers BM, 1999, SCIENCE, V286, P2277, DOI 10.1126/science.286.5448.2277; Marshall E, 2000, SCIENCE, V290, P1062, DOI 10.1126/science.290.5494.1062; Pollara Research and Earnscliffe Research and Communications, 2000, PUBL OP RES BIOT ISS; Singer PA, 2000, NAT BIOTECHNOL, V18, P1225, DOI 10.1038/82256; Smaglik P, 2000, NATURE, V407, P821, DOI 10.1038/35038209; *STAND COMM HLTH, 2001, ASS REPR BUILD FAM; The Upjohn Company, PCT, Patent No. [WO 90/06367, 9006367]; Vogel G, 2001, SCIENCE, V291, P23; 2000, HUGO ETHICS COMMITTE; 2000, TORONTO STAR    1007	23	12	14	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 29	2002	359	9325					2268	2270		10.1016/S0140-6736(02)09298-X	http://dx.doi.org/10.1016/S0140-6736(02)09298-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567YJ	12103305				2022-12-28	WOS:000176514500027
J	Johnson, KR; Ellis, B				Johnson, KR; Ellis, B			A tropical rainforest in Colorado 1.4 million years after the Cretaceous-Tertiary boundary	SCIENCE			English	Article							EARLY EOCENE; LEAF; PALEOCENE; LARAMIDE; CLIMATE; LEAVES; PLANT	An extremely diverse lower Paleocene (64.1 million years ago) fossil leaf site from Castle Rock, Colorado, contains fossil litter that is similar to the litter of extant equatorial rainforests. The presence of a high-diversity tropical rainforest is unexpected, because other Paleocene floras are species-poor, a feature generally attributed to the Cretaceous-Tertiary (K-T) extinction. The site occurs on the margin of the Denver Basin in synorogenic sedimentary rocks associated with the rise of the Laramide Front Range. Orographic conditions caused by local topography, combined with equable climate, appear to have allowed for the establishment of rainforests within 1.4 million years of the K-T boundary.	Denver Museum Nat & Sci, Dept Earth Sci, Denver, CO 80205 USA		Johnson, KR (corresponding author), Denver Museum Nat & Sci, Dept Earth Sci, Denver, CO 80205 USA.	kjohnson@dmns.org						Archibald J.D., 1987, P24; BARCLAY RS, 2001, GEOL SOC AM ABSTR, V33, pA198; BARCLAY RS, 2002, THESIS U FLORIDA GAI; BROWN RW, 1962, 375 US GEOL SURV, P119; Burnham RJ, 2001, AM J BOT, V88, P1096, DOI 10.2307/2657093; BURNHAM RJ, 1994, REV PALAEOBOT PALYNO, V81, P99, DOI 10.1016/0034-6667(94)90129-5; Burnham Robyn J., 1996, P127; Cherven V. B., 1985, CENOZOIC PALEOGEOGRA, P127; DICKINSON WR, 1988, GEOL SOC AM BULL, V100, P1023, DOI 10.1130/0016-7606(1988)100<1023:PAPSOL>2.3.CO;2; HICKEY LJ, 1980, U MICHIGAN PAPERS PA, V24, P33; HICKS JF, IN PRESS ROCKY MOUNT; HICKS JF, 2002, IN PRESS HELL CREEK, V361; Hopkins Dennis J. Jr., 1997, American Journal of Botany, V84, P135; Johnson K.R., 1989, THESIS YALE U NEW HA; JOHNSON KR, 1992, CRETACEOUS RES, V13, P91, DOI 10.1016/0195-6671(92)90029-P; JOHNSON KR, 1990, GEOLOGICAL SOC AM SP, V247, P433, DOI DOI 10.1130/SPE247-P433; KIRKHAM RM, 1979, RESOURCE SERIES, V5; L.A.W.G. Leaf Architecture Working Group, 1999, MAN LEAF ARCH MORPH; Labandeira CC, 2002, P NATL ACAD SCI USA, V99, P2061, DOI 10.1073/pnas.042492999; Morley R.J., 2000, ORIGIN EVOLUTION TRO; NICHOLS DJ, IN PRESS ROCKY MOUNT; OMAR GI, 1994, GEOL SOC AM BULL, V106, P74, DOI 10.1130/0016-7606(1994)106<0074:AFTEFL>2.3.CO;2; Pearson DA, 2001, GEOLOGY, V29, P39, DOI 10.1130/0091-7613(2001)029<0039:PCVRFN>2.0.CO;2; RAYNOLDS RG, 1997, 7 RMSAAPG, P43; RAYNOLDS RG, 2001, 010185 US GEOL SURV; Richards P.W., 1996, TROPICAL RAINFOREST, P775, DOI 10.1017/S0266467400010944; ROBSON SG, 1993, 93442 US GEOL SURV; Sweet AR, 2001, GEOSCI CAN, V28, P127; WARWICK PD, IN PRESS AM ASS PETR; Wilf P, 1997, PALEOBIOLOGY, V23, P373, DOI 10.1017/S0094837300019746; Wilf P, 2000, GEOL SOC AM BULL, V112, P292, DOI 10.1130/0016-7606(2000)112<0292:LPEECC>2.3.CO;2; Wilf P, 1998, GEOLOGY, V26, P203, DOI 10.1130/0091-7613(1998)026<0203:UFLAPI>2.3.CO;2; WING SL, 1993, PHILOS T ROY SOC B, V341, P243, DOI 10.1098/rstb.1993.0109; Wing SL, 1998, LATE PALEOCENE-EARLY EOCENE CLIMATIC AND BIOTIC EVENTS IN THE MARINE AND TERRESTRIAL RECORDS, P380; WING SL, 1995, PALAEOGEOGR PALAEOCL, V115, P117, DOI 10.1016/0031-0182(94)00109-L; WOLFE J. A., 1979, GEOLOGICAL SURVEY PR; WOLFE JA, 1987, P NATL ACAD SCI USA, V84, P5096, DOI 10.1073/pnas.84.15.5096; WOLFE JA, 1987, PALEOBIOLOGY, V13, P215	38	95	102	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 28	2002	296	5577					2379	2383		10.1126/science.1072102	http://dx.doi.org/10.1126/science.1072102			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	567CE	12089439				2022-12-28	WOS:000176467200037
J	Blaser, MJ				Blaser, MJ			The genetic gymnastics of our indigenous microbes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HELICOBACTER-PYLORI; HOST		NYU, Sch Med, New York, NY 10016 USA	New York University	Blaser, MJ (corresponding author), NYU, Sch Med, New York, NY 10016 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063270] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53707] Funding Source: Medline; NIGMS NIH HHS [R01 GM63270] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alm RA, 1999, NATURE, V397, P719, DOI 10.1038/17837; Aras RA, 2001, MOL MICROBIOL, V42, P369, DOI 10.1046/j.1365-2958.2001.02637.x; Bjorkholm B, 2001, P NATL ACAD SCI USA, V98, P14607, DOI 10.1073/pnas.241517298; Blaser MJ, 1999, P NATL ACAD SCI USA, V96, P8359, DOI 10.1073/pnas.96.15.8359; Israel DA, 2001, P NATL ACAD SCI USA, V98, P14625, DOI 10.1073/pnas.251551698	5	9	10	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 27	2002	346	26					2083	2085		10.1056/NEJMcibr020229	http://dx.doi.org/10.1056/NEJMcibr020229			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566DN	12087147				2022-12-28	WOS:000176411900012
J	Gribble, PL; Scott, SH				Gribble, PL; Scott, SH			Overlap of internal models in motor cortex for mechanical loads during reaching	NATURE			English	Article							NEURAL ACTIVITY; TASK; SHOULDER; ELBOW; MOVEMENTS	A hallmark of the human motor system is its ability to adapt motor patterns for different environmental conditions, such as when a skilled ice-hockey player accurately shoots a puck with or without protective equipment. Each object (stick, shoulder pad, elbow pad) imparts a distinct load upon the limb, and a key problem in motor neuroscience is to understand how the brain controls movement for different mechanical contexts(1,2). We addressed this issue by training non-human primates to make reaching movements with and without viscous loads applied to the shoulder and/or elbow joints, and then examined neural representations in primary motor cortex (MI) for each load condition. Even though the shoulder and elbow loads are mechanically independent, we found that some neurons responded to both of these single-joint loads. Furthermore, changes in activity of individual neurons during multi-joint loads could be predicted from their response to subordinate single-joint loads. These findings suggest that neural representations of different mechanical contexts in MI are organized in a highly structured manner that may provide a neural basis for how complex motor behaviour is learned from simpler motor tasks.	Queens Univ, Ctr Neurosci Studies, CIHR Grp Sensory Motor Syst, Dept Anat & Cell Biol, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Scott, SH (corresponding author), Queens Univ, Ctr Neurosci Studies, CIHR Grp Sensory Motor Syst, Dept Anat & Cell Biol, Kingston, ON K7L 3N6, Canada.			Gribble, Paul/0000-0002-1368-032X				Ashe J, 1997, BEHAV BRAIN RES, V87, P255; Cabel DW, 2001, J NEUROPHYSIOL, V86, P2102, DOI 10.1152/jn.2001.86.4.2102; FITZ EE, 1989, PERIPHERAL CONTROL P, P437; Gandolfo F, 2000, P NATL ACAD SCI USA, V97, P2259, DOI 10.1073/pnas.040567097; Gribble PL, 2002, J NEUROSCI METH, V113, P187, DOI 10.1016/S0165-0270(01)00492-7; Humphrey D R, 1983, Adv Neurol, V39, P347; Imamizu H, 2000, NATURE, V403, P192, DOI 10.1038/35003194; KALASKA JF, 1989, J NEUROSCI, V9, P2080; Kalaska JF, 1997, CURR OPIN NEUROBIOL, V7, P849, DOI 10.1016/S0959-4388(97)80146-8; Loeb G. E., 1986, ELECTROMYOGRAPHY EXP; McKiernan BJ, 1998, J NEUROPHYSIOL, V80, P1961, DOI 10.1152/jn.1998.80.4.1961; Porter R, 1995, CORTICOSPINAL FUNCTI; Sanes JN, 2001, NEUROIMAGE, V13, P968, DOI 10.1006/nimg.2000.0733; Schmidt R.A., 2000, MOTOR LEARNING PERFO, V2nd ed.; Scott SH, 1999, J NEUROSCI METH, V89, P119, DOI 10.1016/S0165-0270(99)00053-9; Scott SH, 1997, J NEUROPHYSIOL, V77, P826, DOI 10.1152/jn.1997.77.2.826; Scott SH, 2001, NATURE, V413, P161, DOI 10.1038/35093102; SHADMEHR R, 1994, J NEUROSCI, V14, P3208; WIGHTMAN DC, 1985, HUM FACTORS, V27, P267, DOI 10.1177/001872088502700304; Wolpert DM, 2000, NAT NEUROSCI, V3, P1212, DOI 10.1038/81497; Wolpert DM, 1998, NEURAL NETWORKS, V11, P1317, DOI 10.1016/S0893-6080(98)00066-5; Wolpert DM, 1998, TRENDS COGN SCI, V2, P338, DOI 10.1016/S1364-6613(98)01221-2	22	99	100	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 27	2002	417	6892					938	941		10.1038/nature00834	http://dx.doi.org/10.1038/nature00834			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	566RC	12087402				2022-12-28	WOS:000176441200036
J	Hammer, SM				Hammer, SM			Perspective - Increasing choices for HIV therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Columbia Presbyterian Med Ctr, New York, NY 10032 USA	Columbia University; NewYork-Presbyterian Hospital	Hammer, SM (corresponding author), Columbia Presbyterian Med Ctr, New York, NY 10032 USA.								0	24	26	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 27	2002	346	26					2022	2023		10.1056/NEJM2p020052	http://dx.doi.org/10.1056/NEJM2p020052			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566DN	12087136	Bronze			2022-12-28	WOS:000176411900001
J	Marchbanks, PA; McDonald, JA; Wilson, HG; Folger, SG; Mandel, MG; Daling, JR; Bernstein, L; Malone, KE; Ursin, G; Strom, BL; Norman, SA; Weiss, LK; Wingo, PA; Burkman, RT; Berlin, JA; Simon, MS; Spirtas, R; Weiss, LK				Marchbanks, PA; McDonald, JA; Wilson, HG; Folger, SG; Mandel, MG; Daling, JR; Bernstein, L; Malone, KE; Ursin, G; Strom, BL; Norman, SA; Weiss, LK; Wingo, PA; Burkman, RT; Berlin, JA; Simon, MS; Spirtas, R; Weiss, LK			Oral contraceptives and the risk of breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WOMEN; PROGNOSIS; WHITE	Background: It is uncertain whether the use of an oral contraceptive increases the risk of breast cancer later in life, when the incidence of breast cancer is increased. We conducted a population-based, case-control study to determine the risk of breast cancer among former and current users of oral contraceptives. Methods: We interviewed women who were 35 to 64 years old. A total of 4575 women with breast cancer and 4682 controls were interviewed. Conditional logistic regression was used to calculate odds ratios as estimates of the relative risk (incidence-density ratios) of breast cancer. Results: The relative risk was 1.0 (95 percent confidence interval, 0.8 to 1.3) for women who were currently using oral contraceptives and 0.9 (95 percent confidence interval, 0.8 to 1.0) for those who had previously used them. The relative risk did not increase consistently with longer periods of use or with higher doses of estrogen. The results were similar among white and black women. Use of oral contraceptives by women with a family history of breast cancer was not associated with an increased risk of breast cancer, nor was the initiation of oral-contraceptive use at a young age. Conclusions: Among women from 35 to 64 years of age, current or former oral-contraceptive use was not associated with a significantly increased risk of breast cancer.	Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30333 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA; Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; Wayne State Univ, Karmanos Canc Inst, Div Epidemiol, Detroit, MI USA; Amer Canc Soc, Dept Epidemiol & Surveillance Res, Atlanta, GA 30329 USA; Bay State Med Ctr, Dept Obstet & Gynecol, Springfield, MA USA; Wayne State Univ, Karmanos Canc Inst, Div Hematol & Oncol, Detroit, MI USA; NICHHD, Contracept & Reprod Hlth Branch, Populat Res Ctr, Bethesda, MD 20892 USA	Centers for Disease Control & Prevention - USA; Fred Hutchinson Cancer Center; University of Southern California; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Barbara Ann Karmanos Cancer Institute; Wayne State University; American Cancer Society; Barbara Ann Karmanos Cancer Institute; Wayne State University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Marchbanks, PA (corresponding author), Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30333 USA.				NCI NIH HHS [N01-CN-0532, N01-PC-67010, N01-PC-67006, N01-CN-65064] Funding Source: Medline; NICHD NIH HHS [N01-HD-3-3168, Y01-HD-7022, N01-HD-3-3176, N01-HD-3-3175, N01-HD-3-3174, N01-HD-2-3166] Funding Source: Medline; DIVISION OF CANCER CONTROL &POPULATION SCIENCE [N01PC067006, N01PC067010] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD007022, N01HD033176, N01HD023166, N01HD033168, N01HD033174, N01HD033175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); DIVISION OF CANCER CONTROL &POPULATION SCIENCE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Control & Population Sciences); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEVERLY LN, 1987, AM J PUBLIC HEALTH, V77, P351, DOI 10.2105/AJPH.77.3.351; Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; Calle EE, 1996, CONTRACEPTION, V54, pS1; CHEN VW, 1994, CANCER EPIDEM BIOMAR, V3, P127; COULTER A, 1986, CONTRACEPTION, V33, P127, DOI 10.1016/0010-7824(86)90079-X; *DEP DRUGS DIV DRU, 1986, DRUG EV; Dickey RP, 2000, MANAGING CONTRACEPTI; DICKEY RP, 1984, MANAGING CONTRACEPTI; Dignam JJ, 2000, CA-CANCER J CLIN, V50, P50, DOI 10.3322/canjclin.50.1.50; ELEY JW, 1994, JAMA-J AM MED ASSOC, V272, P947, DOI 10.1001/jama.272.12.947; ELLEDGE RM, 1994, J NATL CANCER I, V86, P705, DOI 10.1093/jnci/86.9.705; Gabrick DM, 2000, JAMA-J AM MED ASSOC, V284, P1791, DOI 10.1001/jama.284.14.1791; GREENLAND S, 1982, AM J EPIDEMIOL, V116, P547, DOI 10.1093/oxfordjournals.aje.a113439; GREENLAND S, 1990, AM J EPIDEMIOL, V131, P1102; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Hatcher RA, 1998, CONTRACEPTIVE TECHNO, P405; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; Marchbanks PA, 2002, ANN EPIDEMIOL, V12, P213, DOI 10.1016/S1047-2797(01)00274-5; Mosher William D, 1998, FAMILY PLANNING PERS, V30, P46; Piccinino LJ, 1998, FAM PLANN PERSPECT, V30, P4, DOI 10.2307/2991517; Ursin G, 1997, CANCER RES, V57, P3678; Ursin G, 2000, EPIDEMIOLOGY, V11, P615, DOI 10.1097/00001648-200009000-00026; WALLACH M, 2000, MODERN ORAL CONTRACE; West SL, 2000, PHARMACOEPIDEMIOLOGY, V3rd edn, P661; Wingo PA, 1998, CANCER-AM CANCER SOC, V82, P1197, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1197::AID-CNCR26>3.0.CO;2-0; WINGO PA, 1988, AM J EPIDEMIOL, V128, P206, DOI 10.1093/oxfordjournals.aje.a114942; WINGO PA, 1991, OBSTET GYNECOL, V78, P161	27	348	369	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 27	2002	346	26					2025	2032		10.1056/NEJMoa013202	http://dx.doi.org/10.1056/NEJMoa013202			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566DN	12087137				2022-12-28	WOS:000176411900002
J	Wyithe, JSB; Loeb, A				Wyithe, JSB; Loeb, A			Magnification of light from many distant quasars by gravitational lenses	NATURE			English	Article							DIGITAL SKY SURVEY; LUMINOSITY FUNCTION; GALAXIES; DENSITY; DISTRIBUTIONS; REIONIZATION; STATISTICS	Exceptionally bright quasars with redshifts up to z = 6.28 have recently been discovered(1). Quasars are thought to be powered by the accretion of gas onto supermassive black holes at the centres of galaxies. Their maximum (Eddington) luminosity depends on the mass of the black hole, and the brighter quasars are inferred to have black holes with masses of more than a few billion solar masses. The existence of such massive black holes poses a challenge to models for the formation of structures in the early Universe 2,3, as it requires their formation within one billion years of the Big Bang. Here we show that up to one-third of known quasars with z approximate to 6 will have had their observed flux magnified by a factor of ten or more, as a consequence of gravitational lensing by galaxies along the line of sight. The inferred abundance of quasar host galaxies, as well as the luminosity density provided by the quasars, has therefore been substantially overestimated.	Harvard Univ, Dept Astron, Cambridge, MA 02138 USA	Harvard University	Loeb, A (corresponding author), Harvard Univ, Dept Astron, 60 Garden St, Cambridge, MA 02138 USA.	aloeb@cfa.harvard.edu						Barkana R, 2001, PHYS REP, V349, P126, DOI 10.1016/s0370-1573(01)00019-9; Barkana R, 2000, ASTROPHYS J, V531, P613, DOI 10.1086/308503; Becker RH, 2001, ASTRON J, V122, P2850, DOI 10.1086/324231; Blanton MR, 2001, ASTRON J, V121, P2358, DOI 10.1086/320405; DJORGOVSKI S, 1987, ASTROPHYS J, V313, P59, DOI 10.1086/164948; Djorgovski SG, 2001, ASTROPHYS J, V560, pL5, DOI 10.1086/324175; Fan XH, 2001, ASTRON J, V121, P54, DOI 10.1086/318033; Fan XH, 2001, ASTRON J, V122, P2833, DOI 10.1086/324111; FERRARESE L, 2001, ASTROPH0203469; Fukugita M, 1998, ASTROPHYS J, V503, P518, DOI 10.1086/306025; FUKUGITA M, 1995, PUBL ASTRON SOC PAC, V107, P945, DOI 10.1086/133643; GUNN JE, 1965, ASTROPHYS J, V142, P1633, DOI 10.1086/148444; Haiman Z, 1998, ASTROPHYS J, V503, P505, DOI 10.1086/306017; HOGG D, 2001, ASTROPH105280; Kochanek CS, 1996, ASTROPHYS J, V466, P638, DOI 10.1086/177538; Koopmans LVE, 2002, ASTROPHYS J, V568, pL5, DOI 10.1086/340143; Madau P, 1999, ASTROPHYS J, V514, P648, DOI 10.1086/306975; MADGWICK, 2001, ASTROPH0107197; MOLLER P, 1990, ASTRON ASTROPHYS, V228, P299; Nagamine K, 2000, ASTROPHYS J, V541, P25, DOI 10.1086/309391; OSTRIKER JP, 1986, ASTROPHYS J, V300, P68, DOI 10.1086/163783; PEI YC, 1995, ASTROPHYS J, V438, P623, DOI 10.1086/175105; PENTERICCI L, 2001, ASTROPH0112075; PRESS WH, 1974, ASTROPHYS J, V187, P425, DOI 10.1086/152650; SCHWARTZ DA, 2002, ASTROPH0202190; Turnbull GK, 1991, J REAL ESTATE FINANC, V4, P5; TURNER EL, 1984, ASTROPHYS J, V284, P1, DOI 10.1086/162379; WYITHE JSB, 2002, ASTROPH0203214; [No title captured]	29	51	51	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 27	2002	417	6892					923	925		10.1038/nature00794	http://dx.doi.org/10.1038/nature00794			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	566RC	12087397	Green Submitted			2022-12-28	WOS:000176441200031
J	Butler, CC; Robling, M; Prout, H; Hood, K; Kinnersley, P				Butler, CC; Robling, M; Prout, H; Hood, K; Kinnersley, P			Management of suspected acute viral upper respiratory tract infection in children with intranasal sodium cromoglicate: a randomised controlled trial	LANCET			English	Article							ADHESION MOLECULE-1 ICAM-1; COMMON COLD; NEDOCROMIL SODIUM; ASTHMA; CROMOGLYCATE; PATHOGENESIS; SYMPTOMS; THERAPY	Background Upper respiratory tract infection in children is one of the most frequent reasons for visiting a family doctor, and antibiotics are often prescribed inappropriately. Sodium cromoglicate inhibits the ICAM-1 molecule, which is the receptor for human rhinoviruses. We aimed to investigate whether intranasal cromoglicate shortens duration of infection of the upper respiratory tract. Methods We randomly assigned 290 children diagnosed with suspected acute viral upper respiratory tract infection by their family doctor (137 boys, 153 girls; mean age 5.2 years [SD 3.39]) either intranasal 4% sodium cromoglicate spray or intranasal normal saline spray. Follow-up was by daily symptom diary for 2 weeks and by telephone. Canadian Acute Respiratory Illness and Flu Scale (CARIFS) score was the primary outcome measure. Findings 195 patients returned symptom diaries, and 20 of these could not be included in the main analysis. 246 patients completed the telephone interview at week 1. There was no difference in recovery rate over the first week between the two groups, with the estimated difference in slope of log (CARIFS) being -0.01 (95% CI -0.05 to 0.03). There were no differences between the two groups in side-effects or re-consultation rates. 43 (17%) of 246 children with suspected acute viral upper respiratory tract infection went back to see their family doctor, and 220 (89%) of 246 were managed without prescription of antibiotics. Interpretation Intranasal sodium cromoglicate is not a useful additional treatment for this infection. Our results further clarify the role of prescribed drugs for children with these frequent illnesses.	Cardiff Univ, Dept Gen Practice, Cardiff CF4 4XN, S Glam, Wales	Cardiff University	Butler, CC (corresponding author), McMaster Univ, Fac Hlth Sci, Dept Family Med, 1200 Main St W,HSC 2V14, Hamilton, ON L8N 3Z5, Canada.	cbutler@mcmaster.ca	Robling, Michael/B-5516-2009; Hood, Kerenza/C-2528-2008; Butler, Christopher C/B-5048-2009	Robling, Michael/0000-0002-1004-036X; Hood, Kerenza/0000-0002-5268-8631; Butler, Christopher/0000-0002-0102-3453				ABerg N, 1996, CLIN EXP ALLERGY, V26, P1045, DOI 10.1111/j.1365-2222.1996.tb00642.x; Adam P, 1998, ARCH FAM MED, V7, P39, DOI 10.1001/archfami.7.1.39; BALFOURLYNN IM, 1994, CLIN EXP ALLERGY, V24, P121, DOI 10.1111/j.1365-2222.1994.tb00207.x; BARROW GI, 1990, CLIN EXP ALLERGY, V20, P45, DOI 10.1111/j.1365-2222.1990.tb02774.x; BISSONETTE EY, 1993, IMMUNOPHARMACOLOGY G, P95; Butler CC, 1998, BRIT J GEN PRACT, V48, P1865; DUSTIN ML, 1988, J EXP MED, V167, P1323, DOI 10.1084/jem.167.4.1323; FRIEDMAN ND, 2001, UPTODATE ONLINE VERS, P1; GOLDSTEIN H, 1994, STAT MED, V13, P1643, DOI 10.1002/sim.4780131605; Hall Caroline Breese, 1994, P101; HAY CM, 2001, TREATMENT PREVENTION, P1; Hoshino M, 1997, EUR RESPIR J, V10, P858; Jacobs B, 2000, J CLIN EPIDEMIOL, V53, P793, DOI 10.1016/S0895-4356(99)00238-3; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Johnston SL, 1996, CLIN EXP ALLERGY, V26, P989, DOI 10.1046/j.1365-2222.1996.d01-402.x; Johnston SL, 1997, TRENDS MICROBIOL, V5, P58, DOI 10.1016/S0966-842X(96)10082-2; KONIG P, 1995, AM J RESP CRIT CARE, V152, P1879; KUZEMKO JA, 1989, RESP MED, V83, P11, DOI 10.1016/S0954-6111(89)80245-8; Lowenstein S R, 1987, Adv Intern Med, V32, P207; Majeed A, 1999, BRIT J GEN PRACT, V49, P735; Mossad SB, 1998, BMJ-BRIT MED J, V317, P33, DOI 10.1136/bmj.317.7150.33; PENTTINEN K, 1977, BRIT MED J, V1, P82, DOI 10.1136/bmj.1.6053.82; Stanciu LA, 1998, EUR RESPIR J, V11, P949, DOI 10.1183/09031936.98.11040949; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STOTT NCH, 1979, BRIT MED J, V1, P29, DOI 10.1136/bmj.1.6155.29; Tasche MJA, 2000, THORAX, V55, P913, DOI 10.1136/thorax.55.11.913; WALD ER, 1991, PEDIATRICS, V87, P129; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; Yang M, 1999, MLWIN MACROS ADV MUL	29	20	21	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 22	2002	359	9324					2153	2158		10.1016/S0140-6736(02)09091-8	http://dx.doi.org/10.1016/S0140-6736(02)09091-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566RJ	12090980				2022-12-28	WOS:000176441800009
J	Fegan, C				Fegan, C			Chronic lymphocytic leukaemia: one cell, two diseases?	LANCET			English	Editorial Material							LEUKEMIA; EXPRESSION; MUTATION; GENES; IDENTIFICATION; PHENOTYPE; BCL-6; CLL		Birmingham Heartlands & Solihull Natl Hlth Serv T, Dept Haematol, Birmingham B9 5SS, W Midlands, England		Fegan, C (corresponding author), Birmingham Heartlands & Solihull Natl Hlth Serv T, Dept Haematol, Birmingham B9 5SS, W Midlands, England.							Damle RN, 1999, BLOOD, V94, P1840, DOI 10.1182/blood.V94.6.1840; Dighiero G, 1996, LEUKEMIA LYMPHOMA, V22, P13, DOI 10.3109/10428199609102700; Fegan C, 1995, LEUKEMIA, V9, P2003; Gahn B, 1997, BLOOD, V89, P4275, DOI 10.1182/blood.V89.12.4275; Hamblin TJ, 2002, BLOOD, V99, P1023, DOI 10.1182/blood.V99.3.1023; Hamblin TJ, 1999, BLOOD, V94, P1848, DOI 10.1182/blood.V94.6.1848; Jelinek DF, 2001, BRIT J HAEMATOL, V115, P854, DOI 10.1046/j.1365-2141.2001.03149.x; Klein U, 2001, J EXP MED, V194, P1625, DOI 10.1084/jem.194.11.1625; Kroeber A, 2000, BLOOD, V96, p835A; MOREAU EJ, 1997, AM J CLIN PATHOL, V108, P372; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Rosenwald A, 2001, J EXP MED, V194, P1639, DOI 10.1084/jem.194.11.1639; Sahota SS, 2000, BLOOD, V95, P3534, DOI 10.1182/blood.V95.11.3534.011k17_3534_3540; Stankovic T, 2002, BLOOD, V99, P300, DOI 10.1182/blood.V99.1.300; Stilgenbauer S, 2000, Rev Clin Exp Hematol, V4, P48, DOI 10.1046/j.1468-0734.2000.00003.x	16	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 20	2002	360	9328					184	186		10.1016/S0140-6736(02)09501-6	http://dx.doi.org/10.1016/S0140-6736(02)09501-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	576DX	12133650				2022-12-28	WOS:000176988500005
J	Gardon, J; Boussinesq, M; Kamgno, J; Gardon-Wendel, N; Demanga-Ngangue; Duke, BOL				Gardon, J; Boussinesq, M; Kamgno, J; Gardon-Wendel, N; Demanga-Ngangue; Duke, BOL			Effects of standard and high doses of ivermectin on adult worms of Onchocerca volvulus: a randomised controlled trial	LANCET			English	Article							LOA LOA INFECTION; CENTRAL PROVINCE; CAMEROON; CHEMOTHERAPY; TRANSMISSION; MODEL; AREA	Background At present, control of onchocerciasis depends almost entirely on yearly treatments with 150 mug/kg ivermectin. We aimed to compare the effect of higher doses, more frequent doses, or both with the standard regimen on adult Onchocerca volvulus. Methods We randomly allocated 657 patients who had onchocerciasis to 150 mug/kg ivermectin yearly (reference group), 150 mug/kg every 3 months, 400 then 800 mug/kg yearly, or 400 then 800 mug/kg every 3 months. We took skin snip samples from every patient before, and 3 years and 4 years after the first dose, and, at the same time excised one subcutaneous 0 volvulus nodule, which was examined histologically. The primary outcome was the vital status of the female worms. Analysis was done per protocol. Findings We obtained nodules from 511 patients. After 3 years of treatment, more female worms had died in the groups treated every 3 months than in the reference group (odds ratio=1.84 [95% CI 1.23-2.75], p=0.003 for 150 mug/kg; and 2.17 [1.42-3.31], p<0.001 for high doses). Female worms were also less fertile in these groups than in the reference group (0.24 [0.14-0.43], p<0.0001; and 0.14 [0.06-0.29], p<0.0001, respectively). No difference was recorded between groups treated yearly (p=0.83 for the proportion of dead females). Unexpected side-effects consisted of mild, temporary, subjective visual changes in patients on high-dose regimens. Interpretation Treatment with 3-monthly ivermectin could greatly reduce the number of female worms and acute itching and skin lesions; lower transmission of 0 volvulus; and change the duration of control programmes.	Inst Pasteur Guyane, Cayenne, Guyane Francais, French Guiana; Ctr Pasteur Cameroun, Lab Mixte IRD CPC Epidemiol & Sante Publ, Yaounde, Cameroon; Ctr Pasteur Cameroun, Delegat Prov Sante Publ, Douala, Cameroon; River Blindness Fdn, Lancaster, England	Centre Pasteur du Cameroun; Centre Pasteur du Cameroun	Duke, BOL (corresponding author), 2 Hillside, Lancaster LA1 1YH, England.		Gardon, Jacques/J-8022-2016; Boussinesq, Michel/J-7256-2016; Gardon, Jacques/AAQ-8410-2020	Gardon, Jacques/0000-0002-0570-634X; Boussinesq, Michel/0000-0001-6312-0681; Gardon, Jacques/0000-0002-0570-634X				Abiose A, 2000, LANCET, V356, P1523, DOI 10.1016/S0140-6736(05)73271-2; Albiez E J, 1988, Trop Med Parasitol, V39 Suppl 4, P331; Awadzi K, 1999, T ROY SOC TROP MED H, V93, P189, DOI 10.1016/S0035-9203(99)90305-X; AWADZI K, 1995, TROP MED PARASITOL, V46, P131; Boussinesq M, 1997, T ROY SOC TROP MED H, V91, P82, DOI 10.1016/S0035-9203(97)90406-5; Boussinesq M, 2001, ANN TROP MED PARASIT, V95, P495, DOI 10.1080/00034980120073184; Boussinesq M, 2001, ANN TROP MED PARASIT, V95, P379, DOI 10.1080/00034980120064337; Burnham G, 1998, LANCET, V351, P1341, DOI 10.1016/S0140-6736(97)12450-3; DUKE BOL, 1992, AM J TROP MED HYG, V46, P189, DOI 10.4269/ajtmh.1992.46.189; DUKE BOL, 1990, AM J TROP MED HYG, V43, P657, DOI 10.4269/ajtmh.1990.43.657; DUKE BOL, 1991, B WORLD HEALTH ORGAN, V69, P163; DUKE BOL, 1990, TROP MED PARASITOL, V41, P387; Gardon J, 1997, LANCET, V350, P18, DOI 10.1016/S0140-6736(96)11094-1; Hoerauf A, 2000, LANCET, V355, P1242, DOI 10.1016/S0140-6736(00)02095-X; Hoerauf A, 2001, LANCET, V357, P1415, DOI 10.1016/S0140-6736(00)04581-5; PLAISIER AP, 1990, COMPUT METH PROG BIO, V31, P43, DOI 10.1016/0169-2607(90)90030-D; REMME J, 1986, B WORLD HEALTH ORGAN, V64, P667; Richards F, 2000, LANCET, V355, P1663, DOI 10.1016/S0140-6736(00)02235-2; Williams CB, 1937, ANN APPL BIOL, V24, P404, DOI 10.1111/j.1744-7348.1937.tb05042.x	19	104	105	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 20	2002	360	9328					203	210		10.1016/S0140-6736(02)09456-4	http://dx.doi.org/10.1016/S0140-6736(02)09456-4			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	576DX	12133654				2022-12-28	WOS:000176988500009
J	Hu, JP; Aguirre, M; Peto, C; Alonso, J; Ecker, J; Chory, J				Hu, JP; Aguirre, M; Peto, C; Alonso, J; Ecker, J; Chory, J			A role for peroxisomes in photomorphogenesis and development of Arabidopsis	SCIENCE			English	Article							GENE-EXPRESSION; LIGHT; MUTANT; PLANT; BIOGENESIS; DET1; TIME	The nuclear protein DET1 is a central repressor of photomorphogenesis in plants. We have identified the molecular lesion in ted3, a mutation that dominantly suppresses the phenotypes of det1-1. TED3 encodes a peroxisomal protein (AtPex2p) essential for Arabidopsis growth. Developmental defects and the abnormal expression of many genes in det1 are rescued by ted3. ted3 also partially suppresses another pleiotropic de-etiolated mutant cop1. Thus, peroxisomes, whose functions are still largely unexplored, play a key role in a photomorphogenetic pathway negatively regulated by the DET1 and COP proteins.	Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Neuronal Struct & Funct Lab, La Jolla, CA 92037 USA	Salk Institute; Howard Hughes Medical Institute; Salk Institute; Salk Institute	Chory, J (corresponding author), Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA.	chory@salk.edu	Alonso, Jose M/K-6826-2014; Ecker, Joseph R/B-9144-2008	Alonso, Jose M/0000-0001-7087-1571; Ecker, Joseph R/0000-0001-5799-5895				Boudonck K, 1998, J CELL SCI, V111, P3687; CHORY J, 1989, CELL, V58, P991, DOI 10.1016/0092-8674(89)90950-1; Corpas FJ, 2001, TRENDS PLANT SCI, V6, P145, DOI 10.1016/S1360-1385(01)01898-2; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Hayashi M, 1998, PLANT CELL, V10, P183, DOI 10.1105/tpc.10.2.183; Hu J. L., UNPUB; Johnson TL, 2001, PLANT PHYSIOL, V127, P731, DOI 10.1104/pp.010262; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; LI HM, 1995, PLANT CELL, V7, P1599, DOI 10.1105/tpc.7.10.1599; Lopez-Huertas E, 2000, EMBO J, V19, P6770, DOI 10.1093/emboj/19.24.6770; Mullineaux P, 2000, PHILOS T ROY SOC B, V355, P1531, DOI 10.1098/rstb.2000.0713; Neff MM, 2000, GENE DEV, V14, P257; PEPPER A, 1994, CELL, V78, P109, DOI 10.1016/0092-8674(94)90577-0; Pepper AE, 1997, GENETICS, V145, P1125; SCHROEDER D, IN PRESS CURR BIOL; Schwechheimer C, 2000, SEMIN CELL DEV BIOL, V11, P495, DOI 10.1006/scdb.2000.0203; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; Zolman BK, 2001, PLANT PHYSIOL, V127, P1266, DOI 10.1104/pp.010550	18	115	121	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 19	2002	297	5580					405	409		10.1126/science.1073633	http://dx.doi.org/10.1126/science.1073633			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574LV	12130786				2022-12-28	WOS:000176892600053
J	Kellner, AWA; Campos, DD				Kellner, AWA; Campos, DD			The function of the cranial crest and jaws of a unique pterosaur from the Early Cretaceous of Brazil	SCIENCE			English	Article								The discovery of a previously undescribed pterosaur, Thalassodromeus sethi, yields information on the function of cranial crests and the feeding strategy developed by these extinct flying reptiles. The material consists of a large skull ( length: 1420 millimeters, including the crest) with a huge bony crest that was well irrigated by blood vessels and may have been used for regulation of its body temperature. The rostrum consists of two bladelike laminae, the arrangement of which is analogous to the condition found in the bird Rynchops, which skims over the water to catch food, indicating that T. sethi also may have been a skimmer.	Univ Fed Rio de Janeiro, Museu Nacl, Dept Geol & Paleontol, Paleovertebrate Sector, BR-20940040 Rio De Janeiro, Brazil; Dept Nacl Prod Mineral, Museu Ciencias Terra, BR-22290240 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro	Kellner, AWA (corresponding author), Univ Fed Rio de Janeiro, Museu Nacl, Dept Geol & Paleontol, Paleovertebrate Sector, BR-20940040 Rio De Janeiro, Brazil.	kellner@mn.ufrj.br	Kellner, Alexander W/H-1023-2015; Kellner, Alexander/ABE-9591-2020	Kellner, Alexander W/0000-0001-7174-9447; Kellner, Alexander/0000-0001-7174-9447				Bennett S.C., 1992, Journal of Vertebrate Paleontology, V12, P422; Bennett S. C., 2001, PALAEONTOGR ABT A, V260, P1; BEURLEN K, 1971, AN ACAD BRAS CIENC, V43, P411; BRAMWELL CD, 1981, PHILOS T R SOC LON B, V267, P503; Buffetaut E, 2002, NATURWISSENSCHAFTEN, V89, P180, DOI 10.1007/s00114-002-0307-1; CAMPOS DD, 1985, AN ACAD BRAS CIENC, V57, P453; Campos Diogenes De A., 1997, Anais da Academia Brasileira de Ciencias, V69, P83; Eaton G. F., 1910, Memoirs of the Connecticut Academy of Arts and Sciences New Haven, V2; FARLOW JO, 1976, SCIENCE, V192, P1123, DOI 10.1126/science.192.4244.1123; Frey Eberhard, 1994, Neues Jahrbuch fuer Geologie und Palaeontologie Abhandlungen, V194, P379; Kellner A.W.A., 1989, Anais da Academia Brasileira de Ciencias, V61, P439; KELLNER A W A, 1988, Anais da Academia Brasileira de Ciencias, V60, P459; Kellner Alexander W. A., 1993, Journal of Vertebrate Paleontology, V13, p44A; Kellner Alexander Wilhelm Armin, 1994, Anais da Academia Brasileira de Ciencias, V66, P467; Kellner AWA, 1996, J VERTEBR PALEONTOL, V16, P222, DOI 10.1080/02724634.1996.10011310; Kellner AWA., 1994, ACTA GEOLOGICA LEOPO, V39, P175; Kellner AWA, 2000, NATL SCI MUSEUM MONO, V17, P1, DOI 10.1159/000061634; Kellner AWA, 1996, THESIS COLUMBIA U; KRIPP D, 1943, NOVA ACTA LEOPOLDINA, V12, P16; LANGSTON W, 1981, SCI AM, V244, P92; Maisey JG, 1991, SANTANA FOSSILS ILLU; PONS D, 1990, S BAC AR BAC INT NOR, P241; PRICE LI, 1971, AN ACAD BRAS CIENC, V43, P451; Sampson Scott D., 1997, P39; Sayao Juliana M., 2000, Boletim do Museu Nacional Nova Serie Geologia, V54, P1; Wellnhofer P., 1991, Mitteilungen der Bayerischen Staatssammlung fuer Palaeontologie und Historische Geologie, V31, P89; WELLNHOFER P, 1985, Palaeontographica Abteilung A Palaeozoologie-Stratigraphie, V187, P105; Wellnhofer P., 1975, PALAONTOGRAPHICA A, V148, P1; Wellnhofer P, 1991, ILLUSTRATED ENCY PTE; Young CC, 1973, SPECIAL PUBLICATION, V11, P18; Zusi R. L., 1962, PUBL NUTTALL ORNITHO, V3, P1	31	81	88	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 19	2002	297	5580					389	392		10.1126/science.1073186	http://dx.doi.org/10.1126/science.1073186			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574LV	12130783	Green Submitted			2022-12-28	WOS:000176892600048
J	Sudbery, P				Sudbery, P			Cell biology: When wee meets whi	SCIENCE			English	Editorial Material							SACCHAROMYCES-CEREVISIAE; YEAST; DIVISION; CYCLE; GENE; SIZE		Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Sudbery, P (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England.	p.sudbery@sheffield.ac.uk						Binley KM, 1999, YEAST, V15, P1459, DOI 10.1002/(SICI)1097-0061(199910)15:14<1459::AID-YEA472>3.0.CO;2-A; FANTES PA, 1975, J THEOR BIOL, V50, P213, DOI 10.1016/0022-5193(75)90034-X; Futcher B, 1996, YEAST, V12, P1635; Gari E, 2001, GENE DEV, V15, P2803; HARTWELL LH, 1977, J CELL BIOL, V75, P422, DOI 10.1083/jcb.75.2.422; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; Jorgensen P, 2002, SCIENCE, V297, P395, DOI 10.1126/science.1070850; Kozma SC, 2002, BIOESSAYS, V24, P65, DOI 10.1002/bies.10031; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; SUDBERY PE, 1980, NATURE, V288, P401, DOI 10.1038/288401a0; YICHIEH ND, 2002, CELL, V109, P835; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721	13	13	13	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 19	2002	297	5580					351	352		10.1126/science.1073042	http://dx.doi.org/10.1126/science.1073042			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574LV	12130772				2022-12-28	WOS:000176892600037
J	Hurst, WJ; Tarka, SM; Powis, TG; Valdez, F; Hester, TR				Hurst, WJ; Tarka, SM; Powis, TG; Valdez, F; Hester, TR			Archaeology: Cacao usage by the earliest Maya civilization	NATURE			English	Article							RIO-AZUL; VESSELS		Hershey Foods Tech Ctr, Hershey, PA 17033 USA; Univ Texas, Dept Anthropol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Hurst, WJ (corresponding author), Hershey Foods Tech Ctr, POB 805, Hershey, PA 17033 USA.			Hurst, William/0000-0002-7867-3665				[Anonymous], 1941, LANDAS RELACION COSA; Coe Sophie D., 1996, TRUE HIST CHOCOLATE; HALL GD, 1990, AM ANTIQUITY, V55, P138, DOI 10.2307/281499; HESTER TR, 1994, ARCHAEOLOGICAL VIEWS, P48; HURST WJ, 1989, J CHROMATOGR, V466, P279, DOI 10.1016/S0021-9673(01)84623-9; Potter DanielR., 1982, ARCHAEOLOGY COLHA BE, P98; POTTER DR, 1980, COLHA PROJECT 2 SEAS, P173; POWIS TG, 2001, P 66 ANN M SOC AM AR; STUART D, 1988, ANTIQUITY, V62, P153, DOI 10.1017/S0003598X00073634; TURNER BL, 1984, ECON BOT, V38, P179, DOI 10.1007/BF02858831; VALDEZ F, 1987, THESIS HARVARD U	11	105	110	1	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 18	2002	418	6895					289	290		10.1038/418289a	http://dx.doi.org/10.1038/418289a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	574BF	12124611				2022-12-28	WOS:000176868000029
J	Konner, M				Konner, M			Development: Weaving life's pattern	NATURE			English	Article									Emory Univ, Atlanta, GA 30322 USA	Emory University	Konner, M (corresponding author), Emory Univ, Atlanta, GA 30322 USA.							ANASTASI A, 1958, PSYCHOL REV, V65, P197, DOI 10.1037/h0044895; CHANGEUX JP, 1997, NEURONAL MAN BIOL MI; WOLPERT L, 1991, TRIUMP EMBRYO; [No title captured]	4	1	1	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 18	2002	418	6895					279	279		10.1038/418279a	http://dx.doi.org/10.1038/418279a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	574BF	12124603	Bronze			2022-12-28	WOS:000176868000022
J	Agerbo, E; Nordentoft, M; Mortensen, PB				Agerbo, E; Nordentoft, M; Mortensen, PB			Familial, psychiatric, and socioeconomic risk factors for suicide in young people: nested case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENDER DIFFERENCES; YOUTH SUICIDE; ADOLESCENT; ILLNESS; CHILD	Objective To estimate the risk of suicide in young people related to family and individual psychiatric and socioeconomic factors. Design Population based nested case-control study. Setting Data from longitudinal Danish registers. Cases and controls 496 young people aged 10-21 years who had committed suicide during 1981-97 in Denmark and 24 800 controls thatched for sex, age, and time. Main outcome measures All suicides in Denmark compared with controls; parents and siblings identified from population based registers; inpatient information from discharge registers of national hospitals; and socioeconomic data from administrative registers. Results Parental factors associated with an increased risk of suicide in young people were suicide or early death, admission to hospital for a mental illness, unemployment, low income, poor schooling, and divorce, as well as mental illness in siblings and mental illness and short duration of schooling in the young people themselves. The strongest risk factor was mental illness in the young people. The effect of the parents' socioeconomic factors decreased after adjustment for a family history of mental illness and a family history of suicide. Conclusions Recognising mental illness in young people and dealing with it appropriately could help prevent suicides. The high relative risk associated with a low socioeconomic status of the parents may be confounded and overestimated if not adjusted for mental illness and suicide in the family.	Aarhus Univ, Natl Ctr Register Based Res, DK-8000 Aarhus C, Denmark; Bispebjerg Hosp, Psychiat Dept E, DK-2400 Copenhagen NV, Denmark	Aarhus University; University of Copenhagen; Bispebjerg Hospital	Agerbo, E (corresponding author), Aarhus Univ, Natl Ctr Register Based Res, DK-8000 Aarhus C, Denmark.	ea@ncrr.dk	Mortensen, Preben B/D-2358-2015; Agerbo, Esben/A-2645-2012; Nordentoft, Merete/AAH-3253-2019	Mortensen, Preben B/0000-0002-5230-9865; Agerbo, Esben/0000-0002-2849-524X; 				Agerbo E, 2001, BRIT MED J, V322, P334, DOI 10.1136/bmj.322.7282.334; Beautrais AL, 1998, AUST NZ J PSYCHIAT, V32, P349, DOI 10.3109/00048679809065527; Bell CC, 1998, PEDIATR CLIN N AM, V45, P365, DOI 10.1016/S0031-3955(05)70012-2; Brent DA, 1996, ARCH GEN PSYCHIAT, V53, P1145; Cantor C., 2000, INT HDB SUICIDE ATTE, P9; *DAN NAT BOARD HLT, 1992, CAUS DEATH DENM 1990; Gould MS, 1998, J AM ACAD CHILD PSY, V37, P155, DOI 10.1097/00004583-199802000-00007; Gould MS, 1996, ARCH GEN PSYCHIAT, V53, P1155; Hawton K, 2000, BRIT J PSYCHIAT, V177, P484, DOI 10.1192/bjp.177.6.484; Hills, 1993, STAT MODELS EPIDEMIO; Jenkins R., 2000, INT HDB SUICIDE ATTE, P597, DOI 10.1002/9780470698976; Knudsen LB, 1998, DAN MED BULL, V45, P221; MALIG C, 1996, 66 INT I VIT REG STA; MARTTUNEN MJ, 1995, J AM ACAD CHILD PSY, V34, P1297, DOI 10.1097/00004583-199510000-00015; Mortensen PB, 2000, LANCET, V355, P9, DOI 10.1016/S0140-6736(99)06376-X; MunkJorgensen P, 1997, DAN MED BULL, V44, P82; Qin P, 2000, BRIT J PSYCHIAT, V177, P546, DOI 10.1192/bjp.177.6.546; ROY A, 1991, ARCH GEN PSYCHIAT, V48, P29; RUNESON B, 1989, ACTA PSYCHIAT SCAND, V79, P490, DOI 10.1111/j.1600-0447.1989.tb10292.x; Schulsinger F., 1979, ORIGIN PREVENTION TR, P277; Shaffer D, 1999, J CLIN PSYCHIAT, V60, P70; vanderSande R, 1997, ACTA PSYCHIAT SCAND, V96, P43; Weber W, 2000, LANCET, V356, P1092, DOI 10.1016/S0140-6736(05)74544-X	23	278	284	2	34	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 13	2002	325	7355					74	77		10.1136/bmj.325.7355.74	http://dx.doi.org/10.1136/bmj.325.7355.74			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575CU	12114236	Bronze, Green Published			2022-12-28	WOS:000176929400018
J	Dorenbaum, A; Cunningham, CK; Gelber, RD; Culnane, M; Mofenson, L; Britto, P; Rekacewicz, C; Newell, ML; Delfraissy, JF; Cunningham-Schrader, B; Mirochnick, M; Sullivan, JL				Dorenbaum, A; Cunningham, CK; Gelber, RD; Culnane, M; Mofenson, L; Britto, P; Rekacewicz, C; Newell, ML; Delfraissy, JF; Cunningham-Schrader, B; Mirochnick, M; Sullivan, JL		Int PACTG 316 Team	Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MATERNAL-INFANT TRANSMISSION; QUALITY-ASSURANCE PROGRAM; VERTICAL TRANSMISSION; INFECTED WOMEN; ZIDOVUDINE; PREVENTION; TYPE-1; PHARMACOKINETICS; COHORT	Context A 2-dose intrapartum/newborn nevirapine regimen reduced perinatal human immunodeficiency virus (HIV) transmission in Ugandan women not receiving antenatal antiretroviral therapy (ART). However, it is unknown whether the addition of the 2-dose nevirapine regimen to standard ART would further reduce perinatal HIV transmission. Objective To determine whether a 2-dose nevirapine regimen can decrease perinatal transmission of HIV in nonbreastfeeding women receiving standard ART. Design and Setting International, blinded, placebo-controlled, phase 3 trial enrolling women between May 1997 and June 2000 at clinical sites providing care for HIV infection throughout the United States, Europe, Brazil, and the Bahamas. Participants A total of 1270 women received nevirapine (n=642) or placebo (n=628). Infants were followed up for 6 months to determine HIV-infection status, which was available for 1248 deliveries. Intervention A 200-mg dose of oral nevirapine to women after onset of labor and a 2-mg/kg,dose of oral nevirapine to newborns between 48 and 72 hours after birth., Main Outcome Measures Detection of HIV infection in infants and grade 3 and 4 toxic effects in women and newborns. Results After review by the data and safety monitoring board, the trial was stopped early because the overall transmission rates were significantly lower than assumed for the study design. Antenatal ART included zidovudine alone in 23%; combinations without protease inhibitors in 36%; and combinations with protease inhibitors in 41%. Thirty-four percent of women had elective cesarean delivery. No significant safety concerns were identified for women or infants. Detection of HIV infection occurred in 9 (1.4%; 95% confidence interval (01, 0.6%-2.7%) of 631 nevirapine group deliveries and 10 (1.6%; 95% Cl, 0.8%-2.9%) of 617 placebo group deliveries. The 95% Cl for the difference in transmission rate (-0.2) between the 2 study arms ranged from -1.5% in favor of nevirapine to 1.2% in favor of placebo (P=.82, Fisher exact test). The transmission rate was higher in women with lower baseline CD4 cell counts and higher delivery HIV RNA levels, but there was no significant difference between treatment arms in any subgroup. Conclusion Risk of. perinatal HIV transmission was low and no benefit from additional intrapartum/newborn nevirapine was demonstrated when women received prenatal care and antenatal ART, and elective cesarean section was made available.	SUNY Upstate Med Univ, Dept Pediat, Syracuse, NY 13210 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Harvard Univ, Sch Publ Hlth, Stat & Data Anal Ctr, Boston, MA 02115 USA; NIAID, Rockville, MD USA; NICHHD, Bethesda, MD 20892 USA; Agence Natl Rech SIDA, Villejuif, France; INSERM, Villejuif, France; Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London, England; CHU Bicetre, Enquete Perinatale Francaise, Paris, France; Frontier Sci, Buffalo, NY USA; Boston Univ, Sch Med, Dept Pediat, Boston, MA 02118 USA; Univ Massachusetts, Sch Med, Dept Pediat & Mol Med, Worcester, MA USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of California System; University of California San Francisco; Harvard University; Harvard T.H. Chan School of Public Health; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Institut National de la Sante et de la Recherche Medicale (Inserm); University of London; University College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Boston University; University of Massachusetts System; University of Massachusetts Worcester	Cunningham, CK (corresponding author), SUNY Upstate Med Univ, Dept Pediat, 750 E Adams St, Syracuse, NY 13210 USA.	cunningc@upstate.edu	Newell, Marie-Louise/AAE-8222-2019; Mofenson, Lynne/P-9631-2019; SAVASI, VALERIA MARIA/K-8433-2016	Newell, Marie-Louise/0000-0002-1074-7699; Mofenson, Lynne/0000-0002-2818-9808; Culnane, Mary/0000-0003-2070-4454; SAVASI, VALERIA MARIA/0000-0002-1476-7689				Andiman W, 1999, NEW ENGL J MED, V340, P977, DOI 10.1056/NEJM199904013401301; BRYSON YJ, 1992, NEW ENGL J MED, V327, P1246, DOI 10.1056/NEJM199210223271718; CHAIX M, 2001, 8 C RETR OPP INF FEB; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cooper ER, 2000, J ACQ IMMUN DEF SYND, V24, P45; Cooper ER, 1996, J INFECT DIS, V174, P1207, DOI 10.1093/infdis/174.6.1207; CUNNINGHAM CK, 2001, 8 C RETR OPP INF FEB; *CYT SOFTW CORP, 2000, STATX VERS 4 0; Eshleman SH, 2001, J INFECT DIS, V184, P914, DOI 10.1086/323153; Eshleman SH, 2001, AIDS, V15, P1951, DOI 10.1097/00002030-200110190-00006; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; HOLLINGER FB, 1992, J CLIN MICROBIOL, V30, P1787, DOI 10.1128/JCM.30.7.1787-1794.1992; Mandelbrot L, 2001, JAMA-J AM MED ASSOC, V285, P2083, DOI 10.1001/jama.285.16.2083; MAYAUX MJ, 1995, J ACQ IMMUN DEF SYND, V8, P188; Mayaux MJ, 1997, J PEDIATR-US, V131, P857, DOI 10.1016/S0022-3476(97)70033-7; McGowan JP, 2000, J ANTIMICROB CHEMOTH, V46, P657, DOI 10.1093/jac/46.5.657; MCINTYRE J, 2000, 13 INT AIDS C JUL 9; Mirochnick M, 1998, J INFECT DIS, V178, P368, DOI 10.1086/515641; MOODLEY D, 2000, 13 INT AIDS C JUL 9; Morris AB, 2000, J ACQ IMMUN DEF SYND, V25, P306, DOI 10.1097/00126334-200012010-00003; Musoke P, 1999, AIDS, V13, P479, DOI 10.1097/00002030-199903110-00006; *NAT I ALL INF DIS, 1997, US DEP HLTH HUM SERV; Rouzioux C, 1995, AM J EPIDEMIOL, V142, P1330, DOI 10.1093/oxfordjournals.aje.a117601; Stiehm ER, 1999, J INFECT DIS, V179, P567, DOI 10.1086/314637; Thorne C, 2001, AIDS, V15, P761, DOI 10.1097/00002030-200104130-00012; YenLieberman B, 1996, J CLIN MICROBIOL, V34, P2695, DOI 10.1128/JCM.34.11.2695-2701.1996	26	242	253	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	2002	288	2					189	198		10.1001/jama.288.2.189	http://dx.doi.org/10.1001/jama.288.2.189			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	571HC	12095383	Bronze			2022-12-28	WOS:000176711100019
J	Ligoxygakis, P; Pelte, N; Hoffmann, JA; Reichhart, JM				Ligoxygakis, P; Pelte, N; Hoffmann, JA; Reichhart, JM			Activation of Drosophila Toll during fungal infection by a blood serine protease	SCIENCE			English	Article							HOST-DEFENSE; GENE; ANTIFUNGAL; BACTERIA; ENZYME	Drosophila host defense to fungal and Gram-positive bacterial infection is mediated by the Spaetzle/Toll/cactus gene cassette. It has been proposed that Toll does not function as a pattern recognition receptor per se but is activated through a cleaved form of the cytokine Spaetzle. The upstream events linking infection to the cleavage of Spaetzle have long remained elusive. Here we report the identification of a central component of the fungal activation of Toll. We show that ethylmethane sulfonate- induced mutations in the Persephone gene, which encodes a previously unknown serine protease, block induction of the Toll pathway by fungi and resistance to this type of infection.	Inst Biol Mol & Cellulaire, CNRS, UPR 9022, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Reichhart, JM (corresponding author), Inst Biol Mol & Cellulaire, CNRS, UPR 9022, 15 Rue R Descartes, F-67084 Strasbourg, France.	jm.reichhart@ibmc.u-strasbg.fr						Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; BRAND AH, 1993, DEVELOPMENT, V118, P401; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; Georgel P, 2001, DEV CELL, V1, P503, DOI 10.1016/S1534-5807(01)00059-4; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Green C, 2000, GENETICS, V156, P1117; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Krem MM, 2002, TRENDS BIOCHEM SCI, V27, P67, DOI 10.1016/S0968-0004(01)02007-2; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; LEMAITRE B, 1995, P NATL ACAD SCI USA, V92, P9465, DOI 10.1073/pnas.92.21.9465; LeMosy EK, 1999, TRENDS CELL BIOL, V9, P102, DOI 10.1016/S0962-8924(98)01494-9; Levashina EA, 1999, SCIENCE, V285, P1917, DOI 10.1126/science.285.5435.1917; LIGOXYGAKIS P, UNPUB; LIGOXYGAKIS P, 2000, NATURE IMMUNOL, V1, P342; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Rutschmann S, 2000, NAT IMMUNOL, V1, P342, DOI 10.1038/79801; Rutschmann S, 2000, IMMUNITY, V12, P569, DOI 10.1016/S1074-7613(00)80208-3; Satoh D, 1999, J BIOL CHEM, V274, P7441, DOI 10.1074/jbc.274.11.7441; SMITH C, 1994, GENETICS, V136, P1355; Spradling A. C, 1986, DROSOPHILA PRACTICAL; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; Wright HT, 1996, BIOESSAYS, V18, P453, DOI 10.1002/bies.950180607	27	265	293	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 5	2002	297	5578					114	116		10.1126/science.1072391	http://dx.doi.org/10.1126/science.1072391			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571HB	12098703				2022-12-28	WOS:000176711000047
J	Rishbeth, H				Rishbeth, H			Ionosphere - High above the earth	NATURE			English	Editorial Material									Univ Southampton, Dept Phys & Astron, Southampton SO17 1BJ, Hants, England	University of Southampton	Rishbeth, H (corresponding author), Univ Southampton, Dept Phys & Astron, Southampton SO17 1BJ, Hants, England.							GARDINER GW, 1969, NATURE, V224, P1086; Hargreaves J.K., 1992, SOLAR TERRESTRIAL EN; Lodge O, 1902, NATURE, V66, P222, DOI 10.1038/066222c0; Roble RG, 2000, GEOPH MONOG SERIES, V123, P53; SCHUNK R, 2000, IONOSPHERES PHYSICS	5	1	1	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 4	2002	418	6893					23	23		10.1038/418023a	http://dx.doi.org/10.1038/418023a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	569JL	12097888				2022-12-28	WOS:000176599200019
J	Kettle, C; Hills, RK; Jones, P; Darby, L; Gray, R; Johanson, R				Kettle, C; Hills, RK; Jones, P; Darby, L; Gray, R; Johanson, R			Continuous versus interrupted perineal repair with standard or rapidly absorbed sutures after spontaneous vaginal birth: a randomised controlled trial	LANCET			English	Article								Background Trauma to the perineum is a serious and frequent problem after childbirth, with about 350 000 women each year in the UK needing sutures for perineal injury after spontaneous vaginal delivery, and many millions more worldwide. We compared the continuous technique of perineal repair with the interrupted method, and the more rapidly absorbed polyglactin 910 suture material with the standard polyglactin 910 material. Methods 1542 women who had a spontaneous vaginal delivery with a second-degree perineal tear or episiotomy were randomly allocated to either the continuous (n=771) or interrupted (771) suturing method, and to either the more rapidly absorbed polyglactin 910 suture material (772) or standard polyglactin 910 material (770). Primary outcomes were pain 10 days after delivery and superficial dyspareunia 3 months postpartum. Analysis was by intention to treat. Findings At day 10, three women had dropped out of the study. Significantly fewer women reported pain at 10 days with the continuous technique than with the interrupted method (204/770 [26.5%] vs 338/769 [44.0%], odds ratio 0.47, 95% Cl 0.38-0.58, p<0.0001). Occurrence of pain did not differ significantly between groups assigned the more rapidly absorbed material or standard material (256/769 [33.3%] vs 286/770 [37.1%], 0.84, 0.68-1.04, p=0.10). Women reported no difference in superficial dyspareunia at 3 months for the continuous vs the interrupted method (98/581 [16.9%] vs 102/593 [17.2%], 0.98, 0.72-1.33, p=0.88) or the more rapidly absorbed versus standard material (105/586 [17.9%] vs 95/588 [16.2%], 1.13, 0.84-1.54, p=0.42). Suture removal was done less with the more rapidly absorbed material than with standard suture material (22/769 [3%] vs 98/770 [13%], p<0.0001), and with the continuous versus interrupted method (24/770 [3%] vs 96/769 [12%], p<0.0001). Interpretation A simple and widely practicable continuous repair technique can prevent one woman in six from having pain at 10 days. Also, the more rapidly absorbed polyglactin 910 material obviates need for suture removal up to 3 months postpartum for one in ten women sutured.	Acad Dept Obstet & Gynaecol, Womens & Childrens Div, Stoke On Trent ST4 6QG, Staffs, England; Univ Birmingham, Clin Trials Unit, Birmingham B15 2TT, W Midlands, England; Keele Univ, Dept Math, Keele, Staffs, England	University of Birmingham; Keele University	Kettle, C (corresponding author), Acad Dept Obstet & Gynaecol, Womens & Childrens Div, City Gen Site, Stoke On Trent ST4 6QG, Staffs, England.	chris@kogs.freeserve.co.uk		Gray, Richard/0000-0003-4440-574X; Hills, Robert/0000-0003-0166-0062				CHRISTHILF SM, 1962, AM J OBSTET GYNECOL, V84, P812, DOI 10.1016/0002-9378(62)90038-8; DETLEFSEN G U, 1980, Ugeskrift for Laeger, V142, P3117; Donaldson LJ, 1998, QUAL HEALTH CARE, V7, pS37; Early Breast Cancer Trialists' Collaborative Group, 1990, TREATM EARL BREAST C; *ETH, 1991, UN NEW PROD COMPL FA; FLEMING N, 1990, J NURSE-MIDWIFERY, V4, P65; Gemynthe A., 1996, BR J MIDWIFERY, V4, P230; Gordon B, 1998, BRIT J OBSTET GYNAEC, V105, P435, DOI 10.1111/j.1471-0528.1998.tb10130.x; GRANT A, 1989, BRIT J OBSTET GYNAEC, V96, P1281, DOI 10.1111/j.1471-0528.1989.tb03225.x; GRANT A, 1989, EFFECTIVE CARE PREGN, P1170; GRANT A, 1989, GUIDE EFFECTIVE CARE, P240; GUILHEM P, 1960, Gynecol Obstet (Paris), V59, P261; ISAGERSALLY L, 1986, BRIT J OBSTET GYNAEC, V93, P420; Jordan K, 1998, QUESTIONNAIRE DESIGN; KEEN A, 1999, RISING CAESAREAN RAT, P1; KETTLE C, 2001, COCHRANE LIB; LLEWELLYNJONES D, 1990, FUNDAMENTALS OBSTET, V1, P358; MAHOMED K, 1989, BRIT J OBSTET GYNAEC, V96, P1272, DOI 10.1111/j.1471-0528.1989.tb03224.x; MANDY TE, 1951, AM J SURG, V82, P251, DOI 10.1016/0002-9610(51)90352-2; MASSON F, 1988, CLIN GYNECOL OBSTET, P19; McCandlish R, 1998, BRIT J OBSTET GYNAEC, V105, P1262, DOI 10.1111/j.1471-0528.1998.tb10004.x; OLAH K, 1994, BRIT J MIDWIFERY, V2, P67; RUCKER MP, 1930, AM J OBSTET GYNECOL, V38, P707; SLEEP J, 1984, BRIT MED J, V289, P587, DOI 10.1136/bmj.289.6445.587; SLEEP J, 1991, MIDWIVES RES CHILDBI, P200; Wagner M, 2000, LANCET, V356, P1677, DOI 10.1016/S0140-6736(00)03169-X	26	80	81	1	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 29	2002	359	9325					2217	2223		10.1016/S0140-6736(02)09312-1	http://dx.doi.org/10.1016/S0140-6736(02)09312-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567YJ	12103284				2022-12-28	WOS:000176514500006
J	Levy, JA				Levy, JA			HIV-1: hitching a ride on erythrocytes	LANCET			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; FOLLICULAR DENDRITIC CELLS; T-CELLS; IMMUNE-COMPLEXES; TYPE-1; INFECTION; TRANSMIT; BIND; PLASMA		Univ Calif San Francisco, Div Hematol Oncol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Levy, JA (corresponding author), Univ Calif San Francisco, Div Hematol Oncol, San Francisco, CA 94143 USA.							BREWER AW, 1992, VET PATHOL, V29, P356, DOI 10.1177/030098589202900412; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; HEATH SL, 1995, NATURE, V377, P740, DOI 10.1038/377740a0; Jakubik JJ, 2000, J VIROL, V74, P552, DOI 10.1128/JVI.74.1.552-555.2000; Kacani L, 1998, J VIROL, V72, P6671, DOI 10.1128/JVI.72.8.6671-6677.1998; Levy JA, 1998, LANCET, V352, P982, DOI 10.1016/S0140-6736(98)05391-4; Levy JA, 1998, HIV PATHOGENESIS AID; Liao ZH, 2000, AIDS RES HUM RETROV, V16, P355, DOI 10.1089/088922200309232; Moir S, 2000, J EXP MED, V192, P637, DOI 10.1084/jem.192.5.637; MORROW WJW, 1986, CLIN IMMUNOL IMMUNOP, V40, P515, DOI 10.1016/0090-1229(86)90196-0; Olinger GG, 2000, J VIROL, V74, P8550, DOI 10.1128/JVI.74.18.8550-8557.2000; PAN LZ, 1993, J CLIN MICROBIOL, V31, P283, DOI 10.1128/JCM.31.2.283-288.1993; Pohlmann S, 2001, J VIROL, V75, P10523, DOI 10.1128/JVI.75.21.10523-10526.2001; SPEAR GT, 1991, IMMUNOLOGY, V73, P377; SPEAR GT, 1993, AIDS, V7, P1149, DOI 10.1097/00002030-199309000-00001; SPIEGEL H, 1992, AM J PATHOL, V140, P15; TATENO M, 1989, P NATL ACAD SCI USA, V86, P4287, DOI 10.1073/pnas.86.11.4287; Tsunetsugu-Yokota Y, 1997, VIROLOGY, V239, P259, DOI 10.1006/viro.1997.8895	18	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 29	2002	359	9325					2212	2213		10.1016/S0140-6736(02)09314-5	http://dx.doi.org/10.1016/S0140-6736(02)09314-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567YJ	12103280				2022-12-28	WOS:000176514500002
J	Hood, JD; Bednarski, M; Frausto, R; Guccione, S; Reisfeld, RA; Xiang, R; Cheresh, DA				Hood, JD; Bednarski, M; Frausto, R; Guccione, S; Reisfeld, RA; Xiang, R; Cheresh, DA			Tumor regression by targeted gene delivery to the neovasculature	SCIENCE			English	Article							ALPHA(V)BETA(3) ANTAGONISTS; KINASE-ACTIVITY; IN-VIVO; ANGIOGENESIS; GROWTH; INTEGRIN-ALPHA-V-BETA-3; METASTASES; THERAPY; VIRUS	Efforts to influence the biology of blood vessels by gene delivery have been hampered by a lack of targeting vectors specific for endothelial cells in diseased tissues. Here we show that a cationic nanoparticle (NP) coupled to an integrin alphavbeta3-targeting ligand can deliver genes selectively to angiogenic blood vessels in tumor-bearing mice. The therapeutic efficacy of this approach was tested by generating NPs conjugated to a mutant Raf gene, ATP(mu)-Raf, which blocks endothelial signaling and angiogenesis in response to multiple growth factors. Systemic injection of the NP into mice resulted in apoptosis of the tumor-associated endothelium, ultimately leading to tumor cell apoptosis and sustained regression of established primary and metastatic tumors.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Stanford Sch Med, Lucas Magnet Resonance Spect Res Ctr, Stanford, CA 94305 USA	Scripps Research Institute; Stanford University	Cheresh, DA (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	cheresh@scripps.edu	Frausto, Ricardo/AAE-3146-2021		NCI NIH HHS [T32 CA09696, CA50286] Funding Source: Medline; NCRR NIH HHS [P41 RR09784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050286, T32CA009696, R37CA050286] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR009784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; BERINSTEIN A, 1995, J VIROL, V69, P2664, DOI 10.1128/JVI.69.4.2664-2666.1995; Blezinger P, 1999, NAT BIOTECHNOL, V17, P343, DOI 10.1038/7895; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Carron CP, 1998, CANCER RES, V58, P1930; Duggan ME, 2000, J MED CHEM, V43, P3736, DOI 10.1021/jm000133v; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Eliceiri BP, 2001, CURR OPIN CELL BIOL, V13, P563, DOI 10.1016/S0955-0674(00)00252-0; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; Guerrero CA, 2000, P NATL ACAD SCI USA, V97, P14644, DOI 10.1073/pnas.250299897; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800; Sipkins DA, 1998, NAT MED, V4, P623, DOI 10.1038/nm0598-623; Takeshita S, 1996, LAB INVEST, V75, P487; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Xiang R, 1997, CANCER RES, V57, P4948; Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9	19	723	807	0	78	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 28	2002	296	5577					2404	2407		10.1126/science.1070200	http://dx.doi.org/10.1126/science.1070200			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	567CE	12089446				2022-12-28	WOS:000176467200045
J	Melchor, RN; de Valais, S; Genise, JF				Melchor, RN; de Valais, S; Genise, JF			Bird-like fossil footprints from the late triassic	NATURE			English	Article								The study of fossilized footprints and tracks of dinosaurs and other vertebrates has provided insight into the origin, evolution and extinction of several major groups and their behaviour; it has also been an important complement to their body fossil record(1-4). The known history of birds starts in the Late Jurassic epoch (around 150 Myr ago) with the record of Archaeopteryx(5), whereas the coelurosaurian ancestors of the birds date back to the Early Jurassic(6). The hind limbs of Late Triassic epoch theropods lack osteological evidence for an avian reversed hallux and also display other functional differences from birds(7). Previous references to suggested Late Triassic to Early Jurassic bird-like footprints have been reinterpreted as produced by non-avian dinosaurs having a high angle between digits II and IV8,9 and in all cases their avian affinities have been challenged(10). Here we describe well-preserved and abundant footprints with clearly avian characters from a Late Triassic redbed sequence of Argentina(11,12),at least 55 Myr before the first known skeletal record of birds. These footprints document the activities, in an environment interpreted as small ponds associated with ephemeral rivers, of an unknown group of Late Triassic theropods having some avian characters.	Consejo Nacl Invest Cient & Tecn, RA-6300 Santa Rosa, La Pampa, Argentina; Univ Nacl La Pampa, RA-6300 Santa Rosa, La Pampa, Argentina; Museo Paleontol Egidio Feruglio, RA-9100 Trelew, Chubut, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Melchor, RN (corresponding author), Consejo Nacl Invest Cient & Tecn, Av Uruguay 151, RA-6300 Santa Rosa, La Pampa, Argentina.	melchor_r@cpsarg.com	Melchor, Ricardo Nestor/R-8107-2019	Genise, Jorge/0000-0002-0050-1679				Artabe AE, 1999, REV PALAEOBOT PALYNO, V105, P63, DOI 10.1016/S0034-6667(98)00063-3; CAMINOS R, 1995, REV ASOC GEOL ARGENT, V50, P262; CHIAPPE LM, 1995, NATURE, V378, P349, DOI 10.1038/378349a0; COUGHLIN TJ, 2001, THESIS U QUEENSLAND; CURRIE P J, 1981, Journal of Vertebrate Paleontology, V1, P257; Doyle P, 2000, GEOL MAG, V137, P517, DOI 10.1017/S0016756800004490; Ellenburger P., 1972, CONTRIBUTION CLASSIF, P1; Gatesy SM, 1999, NATURE, V399, P141, DOI 10.1038/20167; Gierlinski Gerard, 1996, Zubia, V14, P79; Gierlinski Gerard, 1998, Journal of Vertebrate Paleontology, V18, p46A; GRADSTEIN FM, 1995, SEPM SPEC PUBL, V54, P95; Haubold H., 1984, SAURIERFAHRTEN; Heckert Andrew B., 2000, Gaia (Lisboa), V15, P63; KENT DV, 2000, ZBL GEOL PALAONT, V8, P1463; LOCKLEY M, 1995, DINOSAUR TRACKS OTHE; Lockley M.G., 2000, DINOSAUR TRACKS OTHE; LOCKLEY MG, 1992, PHILOS T ROY SOC B, V336, P113, DOI 10.1098/rstb.1992.0051; Lockley MG, 1998, NATURE, V396, P429, DOI 10.1038/24783; McCrea Richard T., 2001, P453; OSTROM JH, 1979, AM SCI, V67, P46; Padian K, 1998, BIOL REV, V73, P1, DOI 10.1111/j.1469-185X.1997.tb00024.x; Palfy J, 2000, CAN J EARTH SCI, V37, P923, DOI 10.1139/cjes-37-6-923; Rainforth Emma C., 2001, Journal of Vertebrate Paleontology, V21, p91A; Thulborn RA., 1990, DINOSAUR TRACKS; VIDARTE CF, 1996, ESTUD GEOL-MADRID, V52, P63; WEEMS RE, 1993, P BIOL SOC WASH, V106, P390	26	35	36	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 27	2002	417	6892					936	938		10.1038/nature00818	http://dx.doi.org/10.1038/nature00818			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	566RC	12087401	Green Published			2022-12-28	WOS:000176441200035
J	Niikura, H; Legare, F; Hasbani, R; Bandrauk, AD; Ivanov, MY; Villeneuve, DM; Corkum, PB				Niikura, H; Legare, F; Hasbani, R; Bandrauk, AD; Ivanov, MY; Villeneuve, DM; Corkum, PB			Sub-laser-cycle electron pulses for probing molecular dynamics	NATURE			English	Article							ABOVE-THRESHOLD IONIZATION; TUNNEL IONIZATION; LOCALIZATION; EMISSION; ATOMS; IONS	Experience shows that the ability to make measurements in any new time regime opens new areas of science. Currently, experimental probes for the attosecond time regime (10(-18)-10(-15) s) are being established. The leading approach is the generation of attosecond optical pulses by ionizing atoms with intense laser pulses. This nonlinear process leads to the production of high harmonics during collisions between electrons and the ionized atoms. The underlying mechanism implies control of energetic electrons with attosecond precision. We propose that the electrons themselves can be exploited for ultrafast measurements. We use a 'molecular clock', based on a vibrational wave packet in H-2(+) to show that distinct bunches of electrons appear during electron-ion collisions with high current densities, and durations of about 1 femtosecond (10(-15) s). Furthermore, we use the molecular clock to study the dynamics of non-sequential double ionization.	Natl Res Council Canada, Ottawa, ON K1A 0R6, Canada; Univ Sherbrooke, Sherbrooke, PQ J1K 2R1, Canada	National Research Council Canada; University of Sherbrooke	Corkum, PB (corresponding author), Natl Res Council Canada, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.	Paul.Corkum@nrc.ca	NUTER, Rachel/ABC-3536-2020; Ivanov, Mikhail/AAG-1727-2021; NIIKURA, HIROMICHI/C-3838-2012; Villeneuve, David M/I-4140-2012; NUTER, Rachel/L-7818-2017	Villeneuve, David M/0000-0002-2810-3648; NUTER, Rachel/0000-0001-9543-3164; Corkum, Paul/0000-0003-3394-5572				AMMOSOV MV, 1986, ZH EKSP TEOR FIZ+, V91, P2008; AMMOSOV MV, 1989, SOV PHYS JETP, V64, P1191; Antoine P, 1996, PHYS REV LETT, V77, P1234, DOI 10.1103/PhysRevLett.77.1234; Bartels R, 2000, NATURE, V406, P164, DOI 10.1038/35018029; Becker A, 2000, J PHYS B-AT MOL OPT, V33, pL547, DOI 10.1088/0953-4075/33/15/106; Bhardwaj VR, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.253003; Bhardwaj VR, 2001, PHYS REV LETT, V86, P3522, DOI 10.1103/PhysRevLett.86.3522; Constant E, 1996, PHYS REV LETT, V76, P4140, DOI 10.1103/PhysRevLett.76.4140; CORKUM PB, 1994, OPT LETT, V19, P1870, DOI 10.1364/OL.19.001870; CORKUM PB, 1993, PHYS REV LETT, V71, P1994, DOI 10.1103/PhysRevLett.71.1994; DELONE NB, 1991, J OPT SOC AM B, V8, P1207, DOI 10.1364/JOSAB.8.001207; Dietrich P, 1996, PHYS REV LETT, V77, P4150, DOI 10.1103/PhysRevLett.77.4150; DIETRICH P, 1994, PHYS REV A, V50, pR3585, DOI 10.1103/PhysRevA.50.R3585; Drescher M, 2001, SCIENCE, V291, P1923, DOI 10.1126/science.1058561; Ellert C, 1999, PHYS REV A, V59, pR3170, DOI 10.1103/PhysRevA.59.R3170; Feuerstein B, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.043003; FITTINGHOFF DN, 1992, PHYS REV LETT, V69, P2642, DOI 10.1103/PhysRevLett.69.2642; Hankin SM, 2000, PHYS REV LETT, V84, P5082, DOI 10.1103/PhysRevLett.84.5082; Hentschel M, 2001, NATURE, V414, P509, DOI 10.1038/35107000; Ihee H, 2001, SCIENCE, V291, P458, DOI 10.1126/science.291.5503.458; IVANOV M, 1995, PHYS REV LETT, V74, P2933, DOI 10.1103/PhysRevLett.74.2933; Keldysh L.V., 1964, J EXPT THEOR PHYS, V47, P1945; MACKLIN JJ, 1993, PHYS REV LETT, V70, P766, DOI 10.1103/PhysRevLett.70.766; MOHIDEEN U, 1993, PHYS REV LETT, V71, P509, DOI 10.1103/PhysRevLett.71.509; Muth-Bohm J, 2000, PHYS REV LETT, V85, P2280, DOI 10.1103/PhysRevLett.85.2280; Neutze R, 2000, NATURE, V406, P752, DOI 10.1038/35021099; Papadogiannis NA, 1999, PHYS REV LETT, V83, P4289, DOI 10.1103/PhysRevLett.83.4289; Paul PM, 2001, SCIENCE, V292, P1689, DOI 10.1126/science.1059413; PAULUS GG, 1994, PHYS REV LETT, V72, P2851, DOI 10.1103/PhysRevLett.72.2851; PEEK JM, 1964, PHYS REV, V134, pA877, DOI 10.1103/PhysRev.134.A877; Rischel C, 1997, NATURE, V390, P490, DOI 10.1038/37317; SAKAI H, UNPUB PHYS REV LETT; SEIDEMAN T, 1995, PHYS REV LETT, V75, P2819, DOI 10.1103/PhysRevLett.75.2819; Staudte A, 2002, PHYS REV A, V65, DOI 10.1103/PhysRevA.65.020703; Trump C, 1999, PHYS REV A, V60, P3924, DOI 10.1103/PhysRevA.60.3924; WALKER B, 1994, PHYS REV LETT, V73, P1227, DOI 10.1103/PhysRevLett.73.1227; Weber T, 2000, NATURE, V405, P658, DOI 10.1038/35015033; Yudin GL, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.019902; Yudin GL, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.033404; ZAVRIYEV A, 1993, PHYS REV LETT, V70, P1077, DOI 10.1103/PhysRevLett.70.1077; ZAVRIYEV A, 1990, PHYS REV A, V42, P5500, DOI 10.1103/PhysRevA.42.5500; ZUO T, 1995, PHYS REV A, V52, pR2511, DOI 10.1103/PhysRevA.52.R2511	42	557	563	5	148	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 27	2002	417	6892					917	922		10.1038/nature00787	http://dx.doi.org/10.1038/nature00787			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	566RC	12087396				2022-12-28	WOS:000176441200030
J	Eikelboom, J				Eikelboom, J			The up of the iceberg?	LANCET			English	Editorial Material									Royal Perth Hosp, Perth, WA 6847, Australia	Royal Perth Hospital; University of Western Australia	Eikelboom, J (corresponding author), Royal Perth Hosp, Perth, WA 6847, Australia.		Eikelboom, John/AAG-6117-2019	Eikelboom, John/0000-0003-4126-1285					0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 22	2002	359	9324					2194	2194		10.1016/S0140-6736(02)09097-9	http://dx.doi.org/10.1016/S0140-6736(02)09097-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566RJ	12090999				2022-12-28	WOS:000176441800027
J	Cello, J; Paul, AV; Wimmer, E				Cello, J; Paul, AV; Wimmer, E			Chemical synthesis of poliovirus cDNA: Generation of infectious virus in the absence of natural template	SCIENCE			English	Article							NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; RECEPTOR; RNA; TRANSLATION; EXPRESSION	Full-length poliovirus complementary DNA (cDNA) was synthesized by assembling oligonucleotides of plus and minus strand polarity. The synthetic poliovirus cDNA was transcribed by RNA polymerase into viral RNA, which translated and replicated in a cell-free extract, resulting in the de novo synthesis of infectious poliovirus. Experiments in tissue culture using neutralizing antibodies and CD155 receptor specific antibodies and neurovirulence tests in CD155 transgenic mice confirmed that the synthetic virus had biochemical and pathogenic characteristics of poliovirus. Our results show that it is possible to synthesize an infectious agent by in vitro chemical-biochemical means solely by following instructions from a written sequence.	SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Wimmer, E (corresponding author), SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.							CAO X, 1993, J VIROL, V67, P3149; CELLO J, UNPUB; GROMEIER M, 1995, MICROB PATHOGENESIS, V18, P253, DOI 10.1016/S0882-4010(05)80002-6; HOGLE JM, 1985, SCIENCE, V229, P1358, DOI 10.1126/science.2994218; HORIE H, 1994, J VIROL, V68, P681, DOI 10.1128/JVI.68.2.681-688.1994; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; KITAMURA N, 1981, NATURE, V291, P547, DOI 10.1038/291547a0; KOIKE S, 1990, EMBO J, V9, P3217, DOI 10.1002/j.1460-2075.1990.tb07520.x; KOIKE S, 1991, P NATL ACAD SCI USA, V88, P951, DOI 10.1073/pnas.88.3.951; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; MIRZAYAN C, 1992, VIROLOGY, V189, P547, DOI 10.1016/0042-6822(92)90578-D; MOLLA A, 1991, SCIENCE, V254, P1647, DOI 10.1126/science.1661029; NOBIS P, 1985, J GEN VIROL, V66, P2563, DOI 10.1099/0022-1317-66-12-2563; Nomoto A, 2002, NAT IMMUNOL, V3, P205, DOI 10.1038/ni0302-205; Pan WQ, 1999, NUCLEIC ACIDS RES, V27, P1094, DOI 10.1093/nar/27.4.1094; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Pfister T, 1999, ENCY VIROLOGY, P1330; RACANIELLO VR, 1981, P NATL ACAD SCI-BIOL, V78, P4887, DOI 10.1073/pnas.78.8.4887; REED L. J., 1938, AMER JOUR HYG, V27, P493; SCHAFFER FL, 1955, P NATL ACAD SCI USA, V41, P1020, DOI 10.1073/pnas.41.12.1020; VANDERWERF S, 1986, P NATL ACAD SCI USA, V83, P2330; WIMMER E, 1993, ANNU REV GENET, V27, P353, DOI 10.1146/annurev.ge.27.120193.002033; Wohler F., 1828, ANN PHYS CHEM, V88, P253, DOI DOI 10.1002/ANDP.18280880206; XIANG WK, 1995, J VIROL, V69, P3658, DOI 10.1128/JVI.69.6.3658-3667.1995; Xiang WK, 1997, SEMIN VIROL, V8, P256, DOI 10.1006/smvy.1997.0128	25	568	710	10	279	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 9	2002	297	5583					1016	1018		10.1126/science.1072266	http://dx.doi.org/10.1126/science.1072266			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	581ZN	12114528				2022-12-28	WOS:000177325400045
J	Power, C; Manor, O; Li, L				Power, C; Manor, O; Li, L			Are inequalities in height underestimated by adult social position? Effects of changing social structure and height selection in a cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEALTH; MOBILITY; POLICY; MEN	Objectives To investigate whether changing social structure and social mobility related to height generate (inflate) inequalities in height. Design Longitudinal 1958. British birth cohort study. Setting England, Scotland, and Wales. Participants 10 176 people born 3-9 March 1958 for whom data were available at age 33 years. Main outcome measures Adult height and social class at age 33 years; class of origin (father's occupation when participant was 7 years old). Results Adult height showed a social gradient with class at age 7 years and age 33 years. The difference in mean height between extreme groups was greater for class of origin than for adult class, reducing from 2.21 cm to 1.62 cm for men and from 2.18 cm to 1.74 cm for women. This narrowing inequality was due mainly to a decrease in mean height in classes I and H. This was because of the pattern of height related social mobility in which, for example, men moving into classes I and H were taller (mean 177.2 cm) than men remaining in class Ell manual (mean 176.1 cm) yet shorter than men with class I and 11 origins (mean 178.3 cm) and the relatively large number of individuals moving into classes I and H. Changes in the structure of society, seen here with the general trend of upward social mobility, have acted to diminish inequalities in adult height. Conclusions The combination of changing social structure and height related mobility constrains, rather than inflates, inequalities in height and may lead to an underestimation of the role of childhood socioeconomic factors in the development of inequalities in adult disease.	Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London WC1N 1EH, England; Hebrew Univ Jerusalem, Sch Publ Hlth & Community Med, IL-91120 Jerusalem, Israel	University of London; University College London; Hebrew University of Jerusalem	Power, C (corresponding author), Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, 30 Guilford St, London WC1N 1EH, England.	cpower@ich.ucl.ac.uk						Bartley M, 1997, J HEALTH SOC BEHAV, V38, P376, DOI 10.2307/2955432; *CTR LONG STUD I E, 1994, 3148 SN CTR LONG STU; *DEP HLTH, 1995, VAR HLTH WHAT CAN DE; Elstad JI, 2001, EUR J PUBLIC HEALTH, V11, P135, DOI 10.1093/eurpub/11.2.135; FERRI E, 1993, LIFE 33 5 FOLLOW UP; LEON DA, 1995, J EPIDEMIOL COMMUN H, V49, P5, DOI 10.1136/jech.49.1.5; Macintyre S, 2001, BRIT MED J, V322, P222, DOI 10.1136/bmj.322.7280.222; MARMOT MG, 1984, LANCET, V1, P1003; SMITH GD, 1990, BMJ-BRIT MED J, V301, P373, DOI 10.1136/bmj.301.6748.373; Smith GD, 2001, BRIT MED J, V322, P184, DOI 10.1136/bmj.322.7280.184; Sorkin JD, 1999, EPIDEMIOL REV, V21, P247, DOI 10.1093/oxfordjournals.epirev.a018000; Townsend P., 1988, INEQUALITIES HLTH BL; WAALER HT, 1984, ACTA MED SCAND, P1; WALKER M, 1988, J EPIDEMIOL COMMUN H, V42, P299, DOI 10.1136/jech.42.3.299; YARNELL JWG, 1992, EUR HEART J, V13, P1602, DOI 10.1093/oxfordjournals.eurheartj.a060111	15	46	48	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 20	2002	325	7356					131	134		10.1136/bmj.325.7356.131	http://dx.doi.org/10.1136/bmj.325.7356.131			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	577PG	12130607	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000177069900018
J	Lu, TT; Cyster, JG				Lu, TT; Cyster, JG			Integrin-mediated long-term B cell retention in the splenic marginal zone	SCIENCE			English	Article							LYMPHOTOXIN-BETA-RECEPTOR; LYMPHOCYTE MIGRATION; MICE; ADHESION; RESPONSIVENESS; POPULATION; FOLLICLES; TISSUES; SUBSETS; SPLEEN	The mechanisms that control localization of marginal zone (MZ) B cells are poorly understood. Here we show that MZ B cells express elevated levels of the integrins LFA-1 (alphaLbeta2) and alpha4beta1 and that they bind to the ligands ICAM-1 and VCAM-1. These ligands are expressed within the MZ in a lymphotoxin-dependent manner. Combined inhibition of LFA-1 and alpha4beta1 causes a rapid and selective release of B cells from the MZ. Furthermore, lipopolysaccharide-triggered MZ B cell relocalization involves down-regulation of integrin-mediated adhesion. These studies identify key requirements for MZ B cell localization and establish a role for integrins in peripheral lymphoid tissue compartmentalization.	Univ Calif San Francisco, Dept Microbiol & Immunol, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Div Pediat Immunol & Rheumatol, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Cyster, JG (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, Howard Hughes Med Inst, 513 Parnassus Ave, San Francisco, CA 94143 USA.			Lu, Theresa/0000-0002-5707-8744	NIAID NIH HHS [AI-40098] Funding Source: Medline; NICHD NIH HHS [K12-HD00850] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD000850] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040098, R37AI040098] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ansel KM, 2000, NATURE, V406, P309, DOI 10.1038/35018581; Ansel KM, 2002, IMMUNITY, V16, P67, DOI 10.1016/S1074-7613(01)00257-6; Berlin-Rufenach C, 1999, J EXP MED, V189, P1467, DOI 10.1084/jem.189.9.1467; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Cariappa A, 2001, IMMUNITY, V14, P603, DOI 10.1016/S1074-7613(01)00135-2; Cyster JG, 1995, IMMUNITY, V3, P691, DOI 10.1016/1074-7613(95)90059-4; DUNNWALTERS DK, 1995, J EXP MED, V182, P559, DOI 10.1084/jem.182.2.559; Ettinger R, 2001, J EXP MED, V193, P1333, DOI 10.1084/jem.193.11.1333; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; Fukui Y, 2001, NATURE, V412, P826, DOI 10.1038/35090591; Girkontaite I, 2001, NAT IMMUNOL, V2, P855, DOI 10.1038/ni0901-855; Grimaldi CM, 2001, J IMMUNOL, V167, P1886, DOI 10.4049/jimmunol.167.4.1886; Guinamard R, 2000, NAT IMMUNOL, V1, P31, DOI 10.1038/76882; Hargreaves DC, 2001, J EXP MED, V194, P45, DOI 10.1084/jem.194.1.45; KRAAL G, 1992, INT REV CYTOL, V132, P31, DOI 10.1016/S0074-7696(08)62453-5; Li YJ, 2002, J EXP MED, V195, P181, DOI 10.1084/jem.20011453; LU TB, UNPUB; Mackay F, 1997, EUR J IMMUNOL, V27, P2033, DOI 10.1002/eji.1830270830; MACLENNAN ICM, 1982, IMMUNOL TODAY, V3, P305, DOI 10.1016/0167-5699(82)90032-9; Makowska A, 1999, EUR J IMMUNOL, V29, P3285, DOI 10.1002/(SICI)1521-4141(199910)29:10<3285::AID-IMMU3285>3.3.CO;2-G; Martin F, 2000, IMMUNOL REV, V175, P70, DOI 10.1034/j.1600-065X.2000.017515.x; Martin F, 2001, CURR OPIN IMMUNOL, V13, P195, DOI 10.1016/S0952-7915(00)00204-1; McDonald JT, 2000, IMMUNOL INVEST, V29, P71; Mebius RE, 1998, J IMMUNOL, V161, P3836; Murphy M, 1998, CELL DEATH DIFFER, V5, P497, DOI 10.1038/sj.cdd.4400374; Papayannopoulou T, 2001, BLOOD, V97, P1282, DOI 10.1182/blood.V97.5.1282; PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451; Rose DM, 2001, J IMMUNOL, V167, P2824, DOI 10.4049/jimmunol.167.5.2824; Scharffetter-Kochanek K, 1998, J EXP MED, V188, P119, DOI 10.1084/jem.188.1.119; SCHMIDT EE, 1993, SCANNING MICROSCOPY, V7, P613; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Wagner N, 1996, NATURE, V382, P366, DOI 10.1038/382366a0; Wellmann U, 2001, EUR J IMMUNOL, V31, P2800, DOI 10.1002/1521-4141(200109)31:9<2800::AID-IMMU2800>3.0.CO;2-E; XU H, 1994, J EXP MED, V180, P95, DOI 10.1084/jem.180.1.95	34	303	307	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 19	2002	297	5580					409	412		10.1126/science.1071632	http://dx.doi.org/10.1126/science.1071632			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574LV	12130787				2022-12-28	WOS:000176892600054
J	Evers, JLH				Evers, JLH			Female subfertility	LANCET			English	Review							IN-VITRO FERTILIZATION; FOLLICLE-STIMULATING-HORMONE; ASSISTED REPRODUCTIVE TECHNOLOGY; TREATMENT-INDEPENDENT PREGNANCY; HUMAN MENOPAUSAL GONADOTROPINS; INTRAUTERINE INSEMINATION; MILD ENDOMETRIOSIS; SPERM MORPHOLOGY; EMBRYO-TRANSFER; PREIMPLANTATION EMBRYOS	With an average monthly fecundity rate of only 20%, human beings are not fertile mammals. 10-15% of couples have difficulties conceiving, or conceiving the number of children they want, and seek specialist fertility care at least once during their reproductive lifetime. Dependent on the two main factors that determine subfertility, duration of childlessness and age of the woman, three questions need to be addressed before treatment is offered. Is it time to start the routine fertility investigation?-ie, has sufficient exposure to the chance of conception taken place? Are cost-effective, safe, and reliable treatments available for the disorder diagnosed? And, should the couple be referred straightaway for assisted reproduction?	Acad Ziekenhuis, Res Inst GROW, Dept Obstet & Gynaecol, Maastricht, Netherlands; Maastricht Univ, Maastricht, Netherlands	Maastricht University; Maastricht University	Evers, JLH (corresponding author), Acad Ziekenhuis, Res Inst GROW, Dept Obstet & Gynaecol, Maastricht, Netherlands.	jev@sgyn.azm.nl	Evers, Johannes L/F-6000-2012	Evers, Johannes/0000-0001-8079-1436				Adamson D, 2002, REPRODUCTIVE MEDICINE IN THE TWENTY-FIRST CENTURY, P209; ADAMSON GD, 1994, AM J OBSTET GYNECOL, V171, P1488, DOI 10.1016/0002-9378(94)90392-1; ALFREDSSON JH, 1987, ACTA OBSTET GYN SCAN, V66, P43, DOI 10.3109/00016348709092952; BAYER SR, 1988, J REPROD MED, V33, P179; Bayram NV, 2001, HUM REPROD, V16, P60; Beurskens M P, 1995, Ned Tijdschr Geneeskd, V139, P235; BOSTOFTE E, 1993, FERTIL STERIL, V59, P102; COHLEN BJ, 1998, EVIDENCE BASED FERTI, P205; COHLEN BJ, 2000, COCHRANE LIB; COLLINS JA, 1983, NEW ENGL J MED, V309, P1201, DOI 10.1056/NEJM198311173092001; COLLINS JA, 1984, CAN MED ASSOC J, V130, P269; COLLINS JA, 1995, FERTIL STERIL, V64, P22, DOI 10.1016/s0015-0282(16)57650-x; COLLINS JA, 1989, FERTIL STERIL, V52, P15; COLLINS JA, 1998, EVIDENCE BASED FERTI, P378; Corabian P, 1999, INT J TECHNOL ASSESS, V15, P66, DOI 10.1017/S0266462399015172; DABEKAUSEN YAJM, 1994, FERTIL STERIL, V61, P833; Delhanty JDA, 1997, HUM GENET, V99, P755, DOI 10.1007/s004390050443; Delhanty JDA, 2001, ANN HUM GENET, V65, P331, DOI 10.1017/S0003480001008739; DOWNEY J, 1989, FERTIL STERIL, V52, P425; DUNPHY BC, 1989, FERTIL STERIL, V52, P454; EggertKruse W, 1996, HUM REPROD, V11, P139; EIMERS JM, 1994, FERTIL STERIL, V61, P44; Evers JL, 2001, OBSTET GYNAECOLOGIE, P435; Evers JLH, 1998, HUM REPROD, V13, P1206, DOI 10.1093/humrep/13.5.1206; Evers JLH, 1998, FERTIL STERIL, V69, P1010, DOI 10.1016/S0015-0282(98)00080-6; FARQUHAR C, 2000, COCHRANE LIB; FEDELE L, 1992, FERTIL STERIL, V58, P28; FEDELE L, 1992, AM J OBSTET GYNECOL, V166, P1345, DOI 10.1016/0002-9378(92)91602-7; GADIR AA, 1990, CLIN ENDOCRINOL, V33, P585; GIBBONS RA, 1911, LECT STERILITY ITS E; Glazener CMA, 2000, HUM REPROD, V15, P1953, DOI 10.1093/humrep/15.9.1953; Goverde AJ, 2000, LANCET, V355, P13, DOI 10.1016/S0140-6736(99)04002-7; GRIFFITH CS, 1990, AM J OBSTET GYNECOL, V162, P615, DOI 10.1016/0002-9378(90)90969-E; Guzick DS, 2001, NEW ENGL J MED, V345, P1388, DOI 10.1056/NEJMoa003005; Guzick DS, 1999, NEW ENGL J MED, V340, P177, DOI 10.1056/NEJM199901213400302; GUZICK DS, 1994, HUM REPROD, V9, P2306, DOI 10.1093/oxfordjournals.humrep.a138442; HAMILTON CJCM, 1986, GYNECOL OBSTET INVES, V21, P80, DOI 10.1159/000298933; *HFEA, 2000, UK HUM FERT EMBR AUT; HUGHES E, 2000, COCHRANE LIB; HULL MGR, 1985, BRIT MED J, V291, P1693, DOI 10.1136/bmj.291.6510.1693; Hull MGR, 1999, BRIT MED J, V318, P1007, DOI 10.1136/bmj.318.7189.1007a; JANSEN RPS, 1993, FERTIL STERIL, V59, P1041; Johnson NP, 2000, BRIT J OBSTET GYNAEC, V107, P174, DOI 10.1111/j.1471-0528.2000.tb11687.x; JOHNSON NP, 2001, COCHRANE LIB; Kocak M, 2002, FERTIL STERIL, V77, P101, DOI 10.1016/S0015-0282(01)02941-7; KRUGER TF, 1987, UROLOGY, V30, P248, DOI 10.1016/0090-4295(87)90246-9; Land JA, 1997, FERTIL STERIL, V68, P278, DOI 10.1016/S0015-0282(97)81515-4; Land JA, 1998, HUM REPROD, V13, P1094, DOI 10.1093/humrep/13.4.1094; LERIDON H, 1984, FERTIL STERIL, V41, P580; MAHMOOD TA, 1989, HUM REPROD, V4, P782, DOI 10.1093/oxfordjournals.humrep.a136985; Marcoux S, 1997, NEW ENGL J MED, V337, P217, DOI 10.1056/NEJM199707243370401; Martikainen H, 2001, HUM REPROD, V16, P1900, DOI 10.1093/humrep/16.9.1900; MOL BW, 2001, EVIDENCE BASED REPRO, P73; Mol BWJ, 2000, FERTIL STERIL, V73, P748, DOI 10.1016/S0015-0282(99)00610-X; Mol BWJ, 1999, HUM REPROD, V14, P1237, DOI 10.1093/humrep/14.5.1237; Mol BWJ, 1997, FERTIL STERIL, V67, P1031, DOI 10.1016/S0015-0282(97)81435-5; Munne S, 1998, HUM REPROD UPDATE, V4, P842, DOI 10.1093/humupd/4.6.842; Nestler JE, 1998, NEW ENGL J MED, V338, P1876, DOI 10.1056/NEJM199806253382603; NISOLLE M, 1990, FERTIL STERIL, V53, P984; NULSEN JC, 1993, OBSTET GYNECOL, V82, P780; Oei SG, 1996, EUR J OBSTET GYN R B, V64, P217, DOI 10.1016/0301-2115(95)02287-2; Ombelet W, 1997, HUM REPROD, V12, P987; OVERTON CE, 1994, FERTIL STERIL, V62, P701; Parazzini F, 1999, HUM REPROD, V14, P1332; Posaci C, 1999, HUM REPROD, V14, P120, DOI 10.1093/humrep/14.suppl_1.120; ROSENFELD DL, 1976, FERTIL STERIL, V27, P1256; *ROYAL COLL OBST G, 1998, MAN INF SEC CAR EV B, P103; SCHENKER JG, 1994, FERTIL STERIL, V61, P411; SCOTT RT, 1989, FERTIL STERIL, V51, P651; SCOTT RT, 1995, HUM REPROD, V10, P1706, DOI 10.1093/oxfordjournals.humrep.a136159; Snick HKA, 1997, HUM REPROD, V12, P1582, DOI 10.1093/humrep/12.7.1582; STEPTOE PC, 1978, LANCET, V2, P366; Stevens VC, 1997, HUM REPROD UPDATE, V3, P533, DOI 10.1093/humupd/3.6.533; STRANDELL A, 1994, HUM REPROD, V9, P861, DOI 10.1093/oxfordjournals.humrep.a138606; Strandell A, 2001, HUM REPROD, V16, P2403, DOI 10.1093/humrep/16.11.2403; Swan SH, 2000, ENVIRON HEALTH PERSP, V108, P961, DOI 10.2307/3435055; Taylor P, 1992, UNEXPLAINED INFERTIL, P153; TAYLOR PJ, 1992, UNEXPLAINED INFERTIL, P19; TELIMAA S, 1988, FERTIL STERIL, V50, P872; Telimaa S, 1987, Gynecol Endocrinol, V1, P13, DOI 10.3109/09513598709082692; THOMAS EJ, 1987, BRIT MED J, V294, P1117, DOI 10.1136/bmj.294.6580.1117; Tiitinen A, 2001, HUM REPROD, V16, P1140, DOI 10.1093/humrep/16.6.1140; TORKEL G, 1887, MONATSCHR GEBURSH GY, V26, P361; Tummon IS, 1997, FERTIL STERIL, V68, P8, DOI 10.1016/S0015-0282(97)81467-7; *US NAT CTR CHRON, 1999, REPR HLTH INF SOURC; Vandermolen DT, 2001, FERTIL STERIL, V75, P310, DOI 10.1016/S0015-0282(00)01675-7; VANNOORDZAADSTRA BM, 1991, BMJ-BRIT MED J, V302, P1361, DOI 10.1136/bmj.302.6789.1361; ViudesdeCastro MP, 1997, ANIM REPROD SCI, V46, P313, DOI 10.1016/S0378-4320(96)01628-4; Wells D, 2000, MOL HUM REPROD, V6, P1055, DOI 10.1093/molehr/6.11.1055; Whiteford L M, 1995, Soc Sci Med, V40, P27, DOI 10.1016/0277-9536(94)00124-C; WHO, 1987, OVERALL EVALUATION C; Williams RS, 2001, AM J OBSTET GYNECOL, V185, P332, DOI 10.1067/mob.2001.116733	92	454	477	0	55	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 13	2002	360	9327					151	159		10.1016/S0140-6736(02)09417-5	http://dx.doi.org/10.1016/S0140-6736(02)09417-5			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573PB	12126838				2022-12-28	WOS:000176839100026
J	Hughes, P; Turton, P; Hopper, E; Evans, CDH				Hughes, P; Turton, P; Hopper, E; Evans, CDH			Assessment of guidelines for good practice in psychosocial care of mothers after stillbirth: a cohort study	LANCET			English	Article							DISORGANIZED ATTACHMENT; CONFIDENCE-INTERVALS; PREGNANCY; SATISFACTION; DEPRESSION; SUBSEQUENT; MANAGEMENT; CHILDHOOD; BEHAVIOR; GRIEF	Background Most maternity units have good practice protocols, advising that after stillbirth parents should be encouraged to see and hold their dead infant. Our aim was to assess whether adherence to these protocols is associated with measurably beneficial effects on the psychological health of mother and next-born child. This study forms part of a wider case-control study of the psychological effects of stillbirth. Methods We identified 65 women in the pregnancy after stillbirth, and enrolled matched controls for 60 of them. Outcome measures included depression, anxiety, and posttraumatic-stress disorder (PTSD) in pregnancy and 1 year after the next birth, and disorganised attachment behaviour in the next-born infant. Comparison variables included seeing and holding the stillborn infant, having a funeral, and keeping mementoes. Findings Behaviours that promote contact with the stillborn infant were associated with worse outcome. Women who had held their stillborn infant were more depressed than those who only saw the infant, while those who did not see the infant were least likely to be depressed (13 of 33, 39%, vs three of 14, 21%, vs one of 17, 6%; p=0.03). Women who had seen their stillborn infant had greater anxiety (p=0.02) and higher symptoms of PTSD than those who had not (p=0.02), and their next-born infants were more likely to show disorganised attachment behaviour (18 of 43, 42%, vs one of 12, 8%, p=0.04). Having a funeral and keeping mementoes were not associated with further adverse outcomes, but small numbers limited interpretation. Interpretation Our findings do not support good-practice guidelines, which state that failure to see and hold the dead child could have adverse effects on parents' mourning.	St George Hosp, Sch Med, Dept Psychiat, London SW17 0RE, England; Rampton Hosp, London, England; Tavistock Clin, Tavistock & Portman NHS Trust, London, England	St Georges University London	Hughes, P (corresponding author), St George Hosp, Sch Med, Dept Psychiat, London SW17 0RE, England.		Evans, Chris/E-7526-2011	Evans, Chris/0000-0002-4197-4202				Ainsworth M., 1978, PATTERNS ATTACHMENT; Allen NB, 1998, DEV PSYCHOPATHOL, V10, P513, DOI 10.1017/S0954579498001722; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BOURNE S, 1984, BRIT MED J, V289, P147, DOI 10.1136/bmj.289.6438.147; CAIN AC, 1964, J CHILD PSYCHOL PSYC, V3, P443, DOI 10.1016/S0002-7138(09)60158-8; Carter Jemmy, 1986, CHILD BIRTH AGES; COOPER JD, 1980, BRIT J SOC WORK, V10, P55; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; CUISINIER MCJ, 1993, EUR J OBSTET GYN R B, V52, P163, DOI 10.1016/0028-2243(93)90066-L; FORREST CG, 1982, BRIT MED J, V285, P1475; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; Hughes P, 2001, J CHILD PSYCHOL PSYC, V42, P791; Hughes PM, 1999, BRIT MED J, V318, P1721, DOI 10.1136/bmj.318.7200.1721; JOLLY H, 1976, P ROY SOC MED, V69, P835, DOI 10.1177/003591577606901124; LASKER JN, 1994, DEATH STUD, V18, P41, DOI 10.1080/07481189408252642; LEWIS E, 1976, LANCET, V2, P619; LEWIS E, 1979, ARCH DIS CHILD, V54, P303, DOI 10.1136/adc.54.4.303; LEWIS E, 1978, BRIT J MED PSYCHOL, V51, P237, DOI 10.1111/j.2044-8341.1978.tb02468.x; Main M, 1990, ATTACHMENT PRESCHOOL, P121; May WL, 1997, STAT MED, V16, P2127, DOI 10.1002/(SICI)1097-0258(19970930)16:18<2127::AID-SIM633>3.0.CO;2-W; METCALFE M, 1965, BRIT J PSYCHIAT, V111, P240, DOI 10.1192/bjp.111.472.240; Murray D, 1990, J REPROD INFANT PSYC, V8, P99, DOI DOI 10.1080/02646839008403615; Oakley A., 1984, THE CAPTURED WOMB; POZNANSKI EO, 1972, J PEDIATR-US, V81, P1190; Radestad I, 1996, BRIT MED J, V312, P1505, DOI 10.1136/bmj.312.7045.1505; Rand CSW, 1998, J PSYCHOSOM OBST GYN, V19, P44, DOI 10.3109/01674829809044220; *ROYAL COLL OBST G, 1985, REP RCOG WORK PART M; SPIELBERGER CD, 1970, TEST STATE TRAIT ANX; Turton P, 2001, BRIT J PSYCHIAT, V178, P556, DOI 10.1192/bjp.178.6.556; van Ijzendoorn MH, 1999, DEV PSYCHOPATHOL, V11, P225, DOI 10.1017/S0954579499002035; WATSON CG, 1991, J CLIN PSYCHOL, V47, P179, DOI 10.1002/1097-4679(199103)47:2<179::AID-JCLP2270470202>3.0.CO;2-P	32	163	166	0	22	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 13	2002	360	9327					114	118		10.1016/S0140-6736(02)09410-2	http://dx.doi.org/10.1016/S0140-6736(02)09410-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	573PB	12126820				2022-12-28	WOS:000176839100009
J	Nishihata, Y; Mizuki, J; Akao, T; Tanaka, H; Uenishi, M; Kimura, M; Okamoto, T; Hamada, N				Nishihata, Y; Mizuki, J; Akao, T; Tanaka, H; Uenishi, M; Kimura, M; Okamoto, T; Hamada, N			Self-regeneration of a Pd-perovskite catalyst for automotive emissions control	NATURE			English	Article								Catalytic converters are widely used to reduce the amounts of nitrogen oxides, carbon monoxide and unburned hydrocarbons in automotive emissions. The catalysts are finely divided precious-metal particles dispersed on a solid support. During vehicle use, the converter is exposed to heat, which causes the metal particles to agglomerate and grow, and their overall surface area to decrease. As a result, catalyst activity deteriorates. The problem has been exacerbated in recent years by the trend to install catalytic converters closer to the engine, which ensures immediate activation of the catalyst on engine start-up, but also places demanding requirements on the catalyst's heat resistance. Conventional catalyst systems thus incorporate a sufficient excess of precious metal to guarantee continuous catalytic activity for vehicle use over 50,000 miles (80,000 km). Here we use X-ray diffraction and absorption to show that LaFe0.57Co0.38Pd0.05O3, one of the perovskite-based catalysts investigated(1-4) for catalytic converter applications since the early 1970s, retains its high metal dispersion owing to structural responses to the fluctuations in exhaust-gas composition that occur in state-of-the-art petrol engines(5). We find that as the catalyst is cycled between oxidative and reductive atmospheres typically encountered in exhaust gas, palladium (Pd) reversibly moves into and out of the perovskite lattice. This movement appears to suppress the growth of metallic Pd particles, and hence explains the retention of high catalyst activity during long-term use and ageing.	Japan Atom Energy Res Inst, Synchrotron Radiat Res Ctr, Mikazuki, Hyogo 6795148, Japan; Daihatsu Motor Co Ltd, Ctr Tech, Mat R&D Div, Ryuo, Shiga 5202593, Japan; Toyota Cent Res & Dev Labs Inc, Mat Anal & Evaluat Div, Nagakute, Aichi 4801192, Japan; Tokyo Univ Sci, Fac Sci & Technol, Chiba 2788510, Japan	Japan Atomic Energy Agency; Japan Synchrotron Radiation Research Institute; Daihatsu Motor Co., Ltd.; Toyota Central R&D Labs Inc; Tokyo University of Science	Nishihata, Y (corresponding author), Japan Atom Energy Res Inst, Synchrotron Radiat Res Ctr, Mikazuki, Hyogo 6795148, Japan.	yasuon@spring8.or.jp		Tanaka, Hirohisa/0000-0002-8097-175X				Blume, 1994, RESONANT ANOMALOUS X; EMSLEY J, 1994, ELEMENTS; Hansen M., 1958, CONSTITUTION BINARY, V2nd ed., P1175; HECK RM, 1995, CATALYTIC AIR POLLUT, P94; JONKER GH, 1969, PHILIPS RES REP, V24, P1; LIBBY WF, 1971, SCIENCE, V171, P499, DOI 10.1126/science.171.3970.499; MEADOWCROFT DB, 1970, NATURE, V226, P847, DOI 10.1038/226847a0; PAINTER GS, 1981, PHYS REV B, V24, P4264, DOI 10.1103/PhysRevB.24.4264; SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551; Tanaka H, 2001, TOP CATAL, V16, P63, DOI 10.1023/A:1016626713430; Tanaka H, 1995, 950256 SAE; TANAKA H, 1993, 930251 SAE; TANAKA H, 1994, SCI TECHNOLOGY CATAL, P457; TEJUCA LG, 1989, ADV CATAL, V36, P237, DOI 10.1016/S0360-0564(08)60019-X; Teo, 1986, EXAFS BASIC PRINCIPL; VOSKO SH, 1980, CAN J PHYS, V58, P1200, DOI 10.1139/p80-159; WALTNER A, 1998, 980663 SAE; WATANABE H, 1957, J PHYS SOC JPN, V12, P515, DOI 10.1143/JPSJ.12.515	18	883	904	25	570	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 11	2002	418	6894					164	167		10.1038/nature00893	http://dx.doi.org/10.1038/nature00893			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571GV	12110885				2022-12-28	WOS:000176710400035
J	Sullenger, BA; Gilboa, E				Sullenger, BA; Gilboa, E			Emerging clinical applications of RNA	NATURE			English	Review							CYTOTOXIC T-LYMPHOCYTES; RIBOZYME-MEDIATED REPAIR; MHC CLASS-I; DENDRITIC CELLS; MESSENGER-RNA; GROWTH-FACTOR; TUMOR RNA; ANTITUMOR IMMUNITY; TRANSSPLICING RIBOZYMES; HAMMERHEAD RIBOZYMES	RNA is a versatile biological macromolecule that is crucial in mobilizing and interpreting our genetic information. It is not surprising then that researchers have sought to exploit the inherent properties of RNAs so as to interfere with or repair dysfunctional nucleic acids or proteins and to stimulate the production of therapeutic gene products in a variety of pathological situations. The first generation of the resulting RNA therapeutics are now being evaluated in clinical trials, raising significant interest in this emerging area of medical research.	Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA	Duke University	Sullenger, BA (corresponding author), Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA.							Amado RG, 1999, HUM GENE THER, V10, P2255, DOI 10.1089/10430349950017239; Ashley DM, 1997, J EXP MED, V186, P1177, DOI 10.1084/jem.186.7.1177; Ayre BG, 1999, P NATL ACAD SCI USA, V96, P3507, DOI 10.1073/pnas.96.7.3507; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bauer G, 1997, BLOOD, V89, P2259, DOI 10.1182/blood.V89.7.2259; BEIGELMAN L, 1995, J BIOL CHEM, V270, P25702, DOI 10.1074/jbc.270.43.25702; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; Boczkowski D, 2000, CANCER RES, V60, P1028; Boczkowski D, 1996, J EXP MED, V184, P465, DOI 10.1084/jem.184.2.465; CECH TR, 1988, JAMA-J AM MED ASSOC, V260, P3030; COLEMAN J, 1984, CELL, V37, P429, DOI 10.1016/0092-8674(84)90373-8; DEANDA A, 1994, ANN THORAC SURG, V58, P344, DOI 10.1016/0003-4975(94)92206-3; Drolet DW, 2000, PHARMACEUT RES, V17, P1503, DOI 10.1023/A:1007657109012; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Gilboa E, 1999, IMMUNITY, V11, P263, DOI 10.1016/S1074-7613(00)80101-6; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Granstein RD, 2000, J INVEST DERMATOL, V114, P632, DOI 10.1046/j.1523-1747.2000.00929.x; GREEN PJ, 1986, ANNU REV BIOCHEM, V55, P569, DOI 10.1146/annurev.bi.55.070186.003033; GRIFFIN LC, 1993, BLOOD, V81, P3271, DOI 10.1182/blood.V81.12.3271.3271; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; Guo HT, 2000, SCIENCE, V289, P452, DOI 10.1126/science.289.5478.452; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; Heiser A, 2002, J CLIN INVEST, V109, P409, DOI 10.1172/JCI14364; Heiser A, 2000, J IMMUNOL, V164, P5508, DOI 10.4049/jimmunol.164.10.5508; Heiser A, 2001, CANCER RES, V61, P3388; Heiser A, 2001, J IMMUNOL, V166, P2953, DOI 10.4049/jimmunol.166.5.2953; Hicke BJ, 2000, J CLIN INVEST, V106, P923, DOI 10.1172/JCI11324; IZANT JG, 1985, SCIENCE, V229, P345, DOI 10.1126/science.2990048; JELLINEK D, 1995, BIOCHEMISTRY-US, V34, P11363, DOI 10.1021/bi00036a009; Jones JT, 1996, NAT MED, V2, P643, DOI 10.1038/nm0696-643; Kikumori T, 2001, HUM GENE THER, V12, P1429, DOI 10.1089/104303401750298580; Kohler U, 1999, J MOL BIOL, V285, P1935, DOI 10.1006/jmbi.1998.2447; Kohn DB, 1999, BLOOD, V94, P368, DOI 10.1182/blood.V94.1.368.413a47_368_371; Koido S, 2000, J IMMUNOL, V165, P5713, DOI 10.4049/jimmunol.165.10.5713; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; Lan N, 1998, SCIENCE, V280, P1593, DOI 10.1126/science.280.5369.1593; Lee NS, 1999, RNA, V5, P1200, DOI 10.1017/S1355838299990246; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; LEE TC, 1992, NEW BIOL, V4, P66; Liu XM, 2002, NAT BIOTECHNOL, V20, P47, DOI 10.1038/nbt0102-47; Macejak DG, 2000, HEPATOLOGY, V31, P769, DOI 10.1002/hep.510310331; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; Nair SK, 2000, NAT MED, V6, P1011, DOI 10.1038/79519; Nair SK, 1998, NAT BIOTECHNOL, V16, P364, DOI 10.1038/nbt0498-364; Ostendorf T, 2001, J AM SOC NEPHROL, V12, P909, DOI 10.1681/ASN.V125909; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Pavco PA, 2000, CLIN CANCER RES, V6, P2094; PESTKA S, 1984, P NATL ACAD SCI-BIOL, V81, P7525, DOI 10.1073/pnas.81.23.7525; Phylactou LA, 1998, NAT GENET, V18, P378, DOI 10.1038/ng0498-378; Puttaraju M, 1999, NAT BIOTECHNOL, V17, P246, DOI 10.1038/6986; Puttaraju M, 2001, MOL THER, V4, P105, DOI 10.1006/mthe.2001.0426; Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556; Saeboe-Larssen S, 2002, J IMMUNOL METHODS, V259, P191, DOI 10.1016/S0022-1759(01)00506-3; Srivastava P K, 1996, Semin Immunol, V8, P295, DOI 10.1006/smim.1996.0038; Strobel I, 2000, GENE THER, V7, P2028, DOI 10.1038/sj.gt.3301326; Su Z, 2001, EUR J IMMUNOL, V31, P947, DOI 10.1002/1521-4141(200103)31:3<947::AID-IMMU947>3.0.CO;2-M; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N; SULLENGER BA, 1994, NATURE, V371, P619, DOI 10.1038/371619a0; SULLENGER BA, 1990, MOL CELL BIOL, V10, P6512, DOI 10.1128/MCB.10.12.6512; SULLENGER BA, 1993, SCIENCE, V262, P1566, DOI 10.1126/science.8248806; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; Thornburg C, 2000, J IMMUNOTHER, V23, P412, DOI 10.1097/00002371-200007000-00004; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; Usman N, 2000, J CLIN INVEST, V106, P1197, DOI 10.1172/JCI11631; Van Tendeloo VFI, 2001, BLOOD, V98, P49, DOI 10.1182/blood.V98.1.49; VANDERKROL AR, 1988, BIOTECHNIQUES, V6, P958; Watanabe T, 2000, P NATL ACAD SCI USA, V97, P8490, DOI 10.1073/pnas.150104097; Weissman D, 2000, J IMMUNOL, V165, P4710, DOI 10.4049/jimmunol.165.8.4710; White RR, 2000, J CLIN INVEST, V106, P929, DOI 10.1172/JCI11325; WINCOTT F, 1995, NUCLEIC ACIDS RES, V23, P2677, DOI 10.1093/nar/23.14.2677; Wong-Staal F, 1998, HUM GENE THER, V9, P2407, DOI 10.1089/hum.1998.9.16-2407; Yewdell JW, 1999, ADV IMMUNOL, V73, P1, DOI 10.1016/S0065-2776(08)60785-3; Zarrinkar PP, 1999, BIOCHEMISTRY-US, V38, P3426, DOI 10.1021/bi982688m; Zhang WP, 1999, HUM GENE THER, V10, P1151, DOI 10.1089/10430349950018148	77	253	315	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 11	2002	418	6894					252	258		10.1038/418252a	http://dx.doi.org/10.1038/418252a			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571GV	12110902				2022-12-28	WOS:000176710400054
J	Taylor, HR; Tikellis, G; Robman, LD; McCarty, CA; McNeil, JJ				Taylor, HR; Tikellis, G; Robman, LD; McCarty, CA; McNeil, JJ			Vitamin E supplementation and macular degeneration: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							AGE-RELATED MACULOPATHY; VISUAL IMPAIRMENT; 5-YEAR INCIDENCE; RISK-FACTORS; PROGRESSION	Objective To determine whether vitamin E supplementation influences the incidence or rate of progression of age related maculopathy (AMD). Design Prospective randomised placebo controlled clinical trial. Setting An urban study centre in a residential area supervised by university research staff. Participants 1193 healthy volunteers aged between 55 and 80 years; 73% completed the trial on full protocol. Interventions Vitamin E 500 IU or placebo daily for four years. Main outcome measures Primary outcome: development of early age related macular degeneration in retinal photographs. Other pleasures included alternative definitions of age related macular degeneration, progression, changes in component features, Visual acuity, and visual function Results The incidence of early age related macular degeneration (early AMD 3) was 8.6% in those receiving vitamin E versus 8.1% in those on placebo (relative risk 1.05, 95% confidence interval 0.69 to 1.61). For late disease the incidence was 0.8% versus 0.6% (1.36, 0.67 to 2.77). Further analysis showed no consistent differences in secondary outcomes. Conclusion Daily supplement with vitamin E supplement does not prevent the development or progression of early or later stages of age related macular degeneration.	Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 8002, Australia; Monash Univ, Dept Epidemiol & Prevent Med, Alfred Hosp, Caulfield, Vic 3145, Australia	Centre for Eye Research Australia; University of Melbourne; Florey Institute of Neuroscience & Mental Health; Monash University	Taylor, HR (corresponding author), Univ Melbourne, Ctr Eye Res Australia, Locked Bag 8, Melbourne, Vic 8002, Australia.	h.taylor@unimelb.edu.au	McNeil, John/L-6440-2019	McNeil, John/0000-0002-1049-5129; Taylor, Hugh/0000-0002-9437-784X; McCarty, Catherine/0000-0003-1089-0142				Age-Related Eye Disease Study Research Group, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X; BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022; Bressler NM, 2000, BRIT MED J, V321, P1425, DOI 10.1136/bmj.321.7274.1425; Christen WG, 1999, AM J EPIDEMIOL, V149, P476, DOI 10.1093/oxfordjournals.aje.a009836; Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384; Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9; Garrett SKM, 2000, J CLIN EPIDEMIOL, V53, P541, DOI 10.1016/S0895-4356(99)00153-5; HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106; HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629; Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6; McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455; Meagher EA, 2001, JAMA-J AM MED ASSOC, V285, P1178, DOI 10.1001/jama.285.9.1178; Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7; Robman LD, 1999, AUST NZ J OPHTHALMOL, V27, P410; Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7; Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722; TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035; Tikellis G, 2000, CLIN EXP OPHTHALMOL, V28, P367, DOI 10.1046/j.1442-9071.2000.00336.x; VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1; VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648; WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031; WEST S, 1995, ARCH OPHTHALMOL-CHIC, V113, P1377, DOI 10.1001/archopht.1995.01100110037022; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302	25	110	117	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 6	2002	325	7354					11	14		10.1136/bmj.325.7354.11	http://dx.doi.org/10.1136/bmj.325.7354.11			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573BC	12098721	Green Published, Bronze			2022-12-28	WOS:000176808600014
J	Gross, CP; Mallory, R; Heiat, A; Krumholz, HM				Gross, CP; Mallory, R; Heiat, A; Krumholz, HM			Reporting the recruitment process in clinical trials: Who are these patients and how did they get there?	ANNALS OF INTERNAL MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIALS; CONSORT STATEMENT; ANGIOPLASTY; REGISTRY; QUALITY	Background: A common criticism of randomized, controlled trials (RCTs) is that the enrollment process may be highly selective and those who enroll may not represent persons in the general population. The recruitment process reported in published RCTs has not been systematically evaluated. Objective: To determine whether published RCTs report information about how their study sample was assembled and to describe the proportion of potential study participants who were actually enrolled. Design: Cross-sectional explicit review of RCTs published in four high-impact medical journals between 1 April 1999 and 1 April 2000. All RCTs involved interventions in humans. Measurements: The number of persons who were screened for eligibility, the number who were eligible, and the number who were enrolled in each RCT. Results: A total of 172 RCTs were reviewed. Ninety (52%) reported the number of persons who were evaluated by the investigators for eligibility, and 74 (43%) reported the number of persons who were actually eligible for participation. Of the studies that reported quantitative recruitment information, the median proportion of screened persons who were eligible for participation was 65% (interquartile range, 41% to 82%) and the median proportion of eligible persons who enrolled was 93% (interquartile range, 79% to 100%). Some trials reportedly enrolled every person screened for eligibility; others screened as many as 68 people for each person finally enrolled. Conclusions: many RCTs published in major medical journals do not provide information about the patient recruitment process. As a result, it is difficult for readers to gauge the extent to which participants may represent a highly selected subgroup.	Yale Univ, Sch Med, Yale New Haven Hosp, Ctr Outcomes Res & Evaluat, New Haven, CT USA; Louis Stokes Cleveland Dept Vet Affairs Med Ctr, Youngstown, OH USA	Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	Gross, CP (corresponding author), Yale Univ, Sch Med, Primary Care Ctr, 333 Cedar St,POB 208025, New Haven, CT 06520 USA.	cary.gross@yale.edu	, Harlan/AAI-2875-2020		NATIONAL CANCER INSTITUTE [K07CA090402] Funding Source: NIH RePORTER; NCI NIH HHS [1K07CA-90402] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; BAILAR JC, 1988, ANN INTERN MED, V108, P266, DOI 10.7326/0003-4819-108-2-266; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CHARLSON ME, 1984, BRIT MED J, V289, P1281, DOI 10.1136/bmj.289.6454.1281; CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112; DERSIMONIAN R, 1982, NEW ENGL J MED, V306, P1332, DOI 10.1056/NEJM198206033062204; Egger M, 2001, JAMA-J AM MED ASSOC, V285, P1996, DOI 10.1001/jama.285.15.1996; EVANS M, 1984, ARCH SURG-CHICAGO, V119, P109; Feit F, 2000, CIRCULATION, V101, P2795, DOI 10.1161/01.CIR.101.24.2795; Furlan A, 1999, JAMA-J AM MED ASSOC, V282, P2003, DOI 10.1001/jama.282.21.2003; Horton R, 1996, LANCET, V348, P757, DOI 10.1016/S0140-6736(05)65668-1; King SB, 1997, AM J CARDIOL, V79, P1453, DOI 10.1016/S0002-9149(97)00170-7; McNamee D, 1996, LANCET, V348, P562; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; RENNIE D, 1995, JAMA-J AM MED ASSOC, V273, P1054, DOI 10.1001/jama.273.13.1054; Schulz KF, 1996, BRIT MED J, V312, P742; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; WILLIAMS DH, 1994, CONTROL CLIN TRIALS, V15, P294, DOI 10.1016/0197-2456(94)90045-0; WILLIFORD WO, 1993, J CLIN EPIDEMIOL, V46, P1025, DOI 10.1016/0895-4356(93)90170-6	20	171	173	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 2	2002	137	1					10	16		10.7326/0003-4819-137-1-200207020-00007	http://dx.doi.org/10.7326/0003-4819-137-1-200207020-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569VA	12093240				2022-12-28	WOS:000176622000002
J	O'Sullivan, B; Davis, AM; Turcotte, R; Bell, R; Catton, C; Chabot, P; Wunder, J; Kandel, R; Goddard, K; Sadura, A; Pater, J; Zee, B				O'Sullivan, B; Davis, AM; Turcotte, R; Bell, R; Catton, C; Chabot, P; Wunder, J; Kandel, R; Goddard, K; Sadura, A; Pater, J; Zee, B			Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial	LANCET			English	Article							RADIATION-THERAPY; LOCAL-CONTROL; EXTREMITY; SURGERY; IRRADIATION	Background External-beam radiotherapy (delivered either preoperatively or postoperatively) is frequently used in local management of sarcomas in the soft tissue of limbs, but the two approaches differ substantially in their potential toxic effects. We aimed to determine whether the timing of external-beam radiotherapy affected the number of wound healing complications in soft-tissue sarcoma in the limbs of adults. Methods After stratification by tumour size (less than or equal to10 cm or >10 cm), we randomly allocated 94 patients to preoperative radiotherapy (50 Gy in 25 fractions) and 96 to postoperative radiotherapy (66 Gy in 33 fractions). The primary endpoint was rate of wound complications within 120 days of surgery. Analyses were per protocol for primary outcomes and by intention to treat for secondary outcomes. Findings Median follow-up was 3.3 years (range 0.27-5.6). Four patients, all in the preoperative group, did not undergo protocol surgery and were not evaluable for the primary outcome. Of those patients who were eligible and evaluable, wound complications were recorded in 31 (35%) of 88 in the preoperative group and 16 (17%) of 94 in the postoperative group (difference 18% [95% Cl 5-30], p=0.01). Tumour size and anatomical site were also significant risk factors in multivariate analysis. Overall survival was slightly better in patients who had preoperative radiotherapy than in those who had postoperative treatment (0=0.0481). Interpretation Because preoperative radiotherapy is associated with a greater risk of wound complications than postoperative radiotherapy, the choice of regimen for patients with soft-tissue sarcoma should take into account the timing of surgery and radiotherapy, and the size and anatomical site of the tumour.	Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Dept Radiat Oncol, Toronto, ON M5G 2M9, Canada; Toronto Rehabil Inst, Toronto, ON, Canada; Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; Hop Maison Neuve Rosemont, Montreal, PQ H1T 2M4, Canada; Montreal Gen Hosp, Montreal, PQ H3G 1A4, Canada; British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada; Queens Univ Kingston, NCI Canada Clin Trials Grp, Kingston, ON, Canada; Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto Rehabilitation Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Universite de Montreal; McGill University; British Columbia Cancer Agency; Queens University - Canada; Chinese University of Hong Kong	O'Sullivan, B (corresponding author), Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Dept Radiat Oncol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	brian.osullivan@rmp.uhn.on.ca	Kandel, Rita/AAU-9908-2021; Zee, Benny Chung Ying/G-5606-2017; Kandel, Rita/E-2149-2017	Kandel, Rita/0000-0003-4047-3913; Zee, Benny Chung Ying/0000-0002-7238-845X; Kandel, Rita/0000-0003-4047-3913; Davis, Aileen/0000-0002-9903-9399				BELL RS, 1991, J SURG ONCOL, V48, P224, DOI 10.1002/jso.2930480404; BROWN DC, 1995, SURGERY, V117, P96, DOI 10.1016/S0039-6060(05)80235-1; BUJKO K, 1993, SURG GYNECOL OBSTET, V176, P124; Cheng EY, 1996, J SURG ONCOL, V61, P90, DOI 10.1002/(SICI)1096-9098(199602)61:2<90::AID-JSO2>3.0.CO;2-M; Chmell MJ, 1996, J SURG ONCOL, V61, P185, DOI 10.1002/(SICI)1096-9098(199603)61:3<185::AID-JSO4>3.0.CO;2-7; COX JD, 1995, INT J RADIAT ONCOL, V31, P1341, DOI 10.1016/0360-3016(95)00060-C; Davis AM, 1996, QUAL LIFE RES, V5, P508, DOI 10.1007/BF00540024; DAVIS AM, 1999, CLIN ORTHOP RELAT R, V358, P90; DOBROVIC A, 1995, P AACR, V36, P1273; ENNEKING WF, 1987, LIMB SALVAGE MUSCULO, P626; International Commission on Radiation Units and Measurements (ICRU), 1993, 50 ICRU; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KARASEK K, 1992, INT J RADIAT ONCOL, V24, P651, DOI 10.1016/0360-3016(92)90710-Y; NIELSEN OS, 1991, INT J RADIAT ONCOL, V21, P1595, DOI 10.1016/0360-3016(91)90337-4; OSULLIVAN B, 2002, OXFORD TXB ONCOLOGY, P2495; Pahlman L, 1997, NEW ENGL J MED, V336, P980; Paulussen M, 2001, J CLIN ONCOL, V19, P1818, DOI 10.1200/JCO.2001.19.6.1818; PEAT BG, 1994, PLAST RECONSTR SURG, V93, P980, DOI 10.1097/00006534-199404001-00012; Pisters PWT, 1996, J CLIN ONCOL, V14, P859, DOI 10.1200/JCO.1996.14.3.859; Prosnitz LR, 1999, INT J RADIAT ONCOL, V45, P941, DOI 10.1016/S0360-3016(99)00272-2; ROSENBERG SA, 1982, ANN SURG, V196, P305, DOI 10.1097/00000658-198209000-00009; SADDEGH MK, 1993, CLIN ORTHOP RELAT R, P247; SADOSKI C, 1993, J SURG ONCOL, V52, P223, DOI 10.1002/jso.2930520405; SUIT HD, 1985, CANCER-AM CANCER SOC, V55, P2659, DOI 10.1002/1097-0142(19850601)55:11<2659::AID-CNCR2820551122>3.0.CO;2-Q; Ware JE, 1993, SF36 HLTH SURVEY MAN; WILCOXON F, 1945, BIOMETRICS BULL, V1, P80, DOI 10.1093/jee/39.2.269; WILSON AN, 1994, EUR J CANCER, V30A, P746, DOI 10.1016/0959-8049(94)90286-0; Wunder JS, 2000, CANCER, V88, P2721, DOI 10.1002/1097-0142(20000615)88:12<2721::AID-CNCR10>3.0.CO;2-D; Yang JC, 1998, J CLIN ONCOL, V16, P197, DOI 10.1200/JCO.1998.16.1.197; Zoubek A, 1996, EUR J PEDIATR, V155, P373, DOI 10.1007/s004310050420	30	957	980	2	22	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 29	2002	359	9325					2235	2241		10.1016/S0140-6736(02)09292-9	http://dx.doi.org/10.1016/S0140-6736(02)09292-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567YJ	12103287				2022-12-28	WOS:000176514500009
J	Rieger, MA; Lamond, M; Preston, C; Powles, SB; Roush, RT				Rieger, MA; Lamond, M; Preston, C; Powles, SB; Roush, RT			Pollen-mediated movement of herbicide resistance between commercial canola fields	SCIENCE			English	Article							RAPE BRASSICA-NAPUS; GENE FLOW; FREQUENCY; RELATIVES; DISTANCE	There is considerable public and scientific debate for and against genetically modified (GM) crops. One of the first GM crops, Brassica napus (oilseed rape or canola) is now widely grown in North America, with proposed commercial release into Australia and Europe. Among concerns of opponents to these crops are claims that pollen movement will cause unacceptable levels of gene flow from GM to non-GM crops or to related weedy species, resulting in genetic pollution of the environment. Therefore, quantifying pollen-mediated gene flow is vital for assessing the environmental impact of GM crops. This study quantifies at a landscape level the gene flow that occurs from herbicide-resistant canola crops to nearby crops not containing herbicide resistance genes.	Univ Adelaide, Cooperat Res Ctr Australian Weed Management, Glen Osmond, SA 5064, Australia; Univ Adelaide, Dept Appl & Mol Ecol, Glen Osmond, SA 5064, Australia; Univ Western Australia, Western Australian Herbicide Resistance Initiat, Nedlands, WA 6907, Australia	University of Adelaide; University of Adelaide; University of Western Australia	Rieger, MA (corresponding author), Univ Adelaide, Cooperat Res Ctr Australian Weed Management, PMB1, Glen Osmond, SA 5064, Australia.	mary.rieger@adelaide.edu.au	Powles, Stephen/A-2558-2008	Preston, Christopher/0000-0002-7588-124X; powles, stephen/0000-0001-6375-1977				Barton JE, 2000, AGRON J, V92, P797, DOI 10.2134/agronj2000.924797x; Champolivier J, 1999, BCPC SYMP SER, P233; Downey RK, 1999, BCPC SYMP SER, P109; Eckert JE, 1933, J AGRIC RES, V47, P0257; Ellstrand NC, 1999, ANNU REV ECOL SYST, V30, P539, DOI 10.1146/annurev.ecolsys.30.1.539; Hall L, 2000, WEED SCI, V48, P688, DOI 10.1614/0043-1745(2000)048[0688:PFBHRB]2.0.CO;2; PAUL E, 1995, EUPHYTICA, V1, P283; Preston C, 2002, HEREDITY, V88, P8, DOI 10.1038/sj.hdy.6800004; RAKOW G, 1987, CAN J PLANT SCI, V67, P147, DOI 10.4141/cjps87-017; Rieger MA, 1999, AUST J AGR RES, V50, P115, DOI 10.1071/A97138; SCHEFFLER JA, 1993, TRANSGENIC RES, V2, P356, DOI 10.1007/BF01976177; SCHEFFLER JA, 1995, PLANT BREEDING, V114, P317, DOI 10.1111/j.1439-0523.1995.tb01241.x; Simpson EC, 1999, BCPC SYMP SER, P75; Staniland BK, 2000, CAN J PLANT SCI, V80, P521, DOI 10.4141/P99-117; STRINGAM GR, 1978, CAN J PLANT SCI, V58, P427, DOI 10.4141/cjps78-065; Thompson CE, 1999, BCPC SYMP SER, P95	16	247	280	0	116	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 28	2002	296	5577					2386	2388		10.1126/science.1071682	http://dx.doi.org/10.1126/science.1071682			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	567CE	12089441				2022-12-28	WOS:000176467200039
J	Aviles, RJ; Askari, AT; Lindahl, B; Wallentin, L; Jia, G; Ohman, EM; Mahaffey, KW; Newby, LK; Califf, RM; Simoons, ML; Topol, EJ; Lauer, MS; Berger, P				Aviles, RJ; Askari, AT; Lindahl, B; Wallentin, L; Jia, G; Ohman, EM; Mahaffey, KW; Newby, LK; Califf, RM; Simoons, ML; Topol, EJ; Lauer, MS; Berger, P			Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROGNOSTIC VALUE; MYOCARDIAL INJURY; SERUM CREATININE; I LEVELS; FAILURE; DISEASE; INSUFFICIENCY; PREDICTION; ELEVATIONS; OUTCOMES	Background: Among patients with suspected acute coronary syndromes, cardiac troponin T levels have prognostic value. However, there is concern that renal dysfunction may impair the prognostic value, because cardiac troponin T may be cleared by the kidney. Methods: We analyzed the outcomes in 7033 patients enrolled in the Global Use of Strategies to Open Occluded Coronary Arteries IV trial who had complete base-line data on troponin T levels and creatinine clearance rates. The troponin T level was considered abnormal if it was 0.1 ng per milliliter or higher, and creatinine clearance was assessed in quartiles. The primary end point was a composite of death or myocardial infarction within 30 days. Results: Death or myocardial infarction occurred in 581 patients. Among patients with a creatinine clearance above the 25th percentile value of 58.4 ml per minute, an abnormally elevated troponin T level was predictive of an increased risk of myocardial infarction or death (7 percent vs. 5 percent; adjusted odds ratio, 1.7; 95 percent confidence interval, 1.3 to 2.2; P<0.001). Among patients with a creatinine clearance in the lowest quartile, an elevated troponin T level was similarly predictive of increased risk (20 percent vs. 9 percent; adjusted odds ratio, 2.5; 95 percent confidence interval, 1.8 to 3.3; P<0.001). When the creatinine clearance rate was considered as a continuous variable and age, sex, ST-segment depression, heart failure, previous revascularization, diabetes mellitus, and other confounders had been accounted for, elevation of the troponin T level was independently predictive of risk across the entire spectrum of renal function. Conclusions: Cardiac troponin T levels predict short-term prognosis in patients with acute coronary syndromes regardless of their level of creatinine clearance.	Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44951 USA; Uppsala Univ, Dept Cardiol, Uppsala, Sweden; Univ N Carolina, Chapel Hill, NC USA; Duke Clin Res Inst, Durham, NC USA; Univ Rotterdam Hosp, Dept Cardiol, Rotterdam, Netherlands; Mayo Clin, Div Cardiovasc Dis, Rochester, MN USA	Cleveland Clinic Foundation; Uppsala University; University of North Carolina; University of North Carolina Chapel Hill; Duke University; Erasmus University Rotterdam; Erasmus MC; Mayo Clinic	Lauer, MS (corresponding author), Cleveland Clin Fdn, Dept Cardiol, Desk F25,9500 Euclid Ave, Cleveland, OH 44951 USA.		Lauer, Michael S/L-9656-2013	Lauer, Michael S/0000-0002-9217-8177; Topol, Eric/0000-0002-1478-4729				Agresti A., 1990, CATEGORICAL DATA ANA, pXV; Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; Apple FS, 1997, AM J KIDNEY DIS, V29, P399, DOI 10.1016/S0272-6386(97)90201-8; BHAYANA V, 1995, CLIN CHEM, V41, P312; Braunwald E, 2000, J AM COLL CARDIOL, V36, P970, DOI 10.1016/S0735-1097(00)00889-5; Braunwald E, 2001, J AM COLL CARDIOL, V38, P294; Cannon CP, 2001, NEW ENGL J MED, V344, P1879, DOI 10.1056/NEJM200106213442501; *CAPTURE INV, 1997, LANCET, V350, P744; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Collinson PO, 1998, ANN CLIN BIOCHEM, V35, P380, DOI 10.1177/000456329803500306; Coresh J, 1998, J Am Soc Nephrol, V9, pS24; Frankel WL, 1996, AM J CLIN PATHOL, V106, P118; Fuchs S, 2000, AM J CARDIOL, V85, P1077, DOI 10.1016/S0002-9149(00)00699-8; Hallermayer K, 1999, SCAND J CLIN LAB INV, V59, P128; KLOOTWIJK P, 1999, LANCET S2, V353, P10; Levey AS, 1999, NEPHROL DIAL TRANSPL, V14, P828, DOI 10.1093/ndt/14.4.828; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Li D, 1996, CLIN CHEM, V42, P114; LI D, 1995, CLIN BIOCHEM, V28, P474, DOI 10.1016/0009-9120(95)00027-7; Lindahl B, 1997, J AM COLL CARDIOL, V29, P43, DOI 10.1016/S0735-1097(96)00447-0; Martin GS, 1998, NEPHROL DIAL TRANSPL, V13, P1709, DOI 10.1093/ndt/13.7.1709; McLaurin MD, 1998, AM J CARDIOL, V82, P973, DOI 10.1016/S0002-9149(98)00515-3; Mockel M, 1999, NEPHROL DIAL TRANSPL, V14, P1489, DOI 10.1093/ndt/14.6.1489; MullerBardorff M, 1997, CLIN CHEM, V43, P458; Musso P, 1999, CLIN BIOCHEM, V32, P125, DOI 10.1016/S0009-9120(98)00089-7; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; Sarnak MJ, 2000, AM J KIDNEY DIS, V35, pS117, DOI 10.1016/S0272-6386(00)70239-3; Simoons ML, 1997, LANCET, V349, P1429; Simoons ML, 2001, LANCET, V357, P1915; Van Lente F, 1999, J AM COLL CARDIOL, V33, P471, DOI 10.1016/S0735-1097(98)00592-0; [No title captured]	31	244	249	0	10	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 27	2002	346	26					2047	2052		10.1056/NEJMoa013456	http://dx.doi.org/10.1056/NEJMoa013456			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566DN	12087140				2022-12-28	WOS:000176411900005
J	Ravdin, P				Ravdin, P			Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer	LANCET			English	Editorial Material							BOWEL-PROJECT P-1; TAMOXIFEN; PREVENTION; THERAPY		Univ Texas, Hlth Sci Ctr, Dept Med Oncol, San Antonio, TX USA	University of Texas System; University of Texas Health San Antonio	Ravdin, P (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med Oncol, San Antonio, TX USA.							Clarke M, 1998, LANCET, V351, P1451; Day R, 1999, J CLIN ONCOL, V17, P2659, DOI 10.1200/JCO.1999.17.9.2659; DUFFY SR, 2002, P ASCO, V21; Ellis MJ, 2001, J CLIN ONCOL, V19, P3808, DOI 10.1200/JCO.2001.19.18.3808; FALLOWFIELD L, 2002, P AN M AM SOC CLIN, V21, P159; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; RAVDIN PM, 1992, J CLIN ONCOL, V10, P1284, DOI 10.1200/JCO.1992.10.8.1284; WINER E, 2002, AM SOC CLIN ONCOLOGY	9	9	11	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 22	2002	359	9324					2126	2127		10.1016/S0140-6736(02)09111-0	http://dx.doi.org/10.1016/S0140-6736(02)09111-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566RJ	12090973				2022-12-28	WOS:000176441800002
J	Froehlich, AC; Liu, Y; Loros, JJ; Dunlap, JC				Froehlich, AC; Liu, Y; Loros, JJ; Dunlap, JC			White collar-1, a circadian blue light photoreceptor, binding to the frequency promoter	SCIENCE			English	Article							CLOCK GENE-FREQUENCY; NEUROSPORA-CRASSA; SIGNAL-TRANSDUCTION; FEEDBACK LOOP; PROTEIN; PHOTORESPONSES; RHYTHMS; PAS; EXPRESSION; PLANTS	In the fungus Neurospora crassa, the blue light photoreceptor(s) and signaling pathway( s) have not been identified. We examined light signaling by exploiting the light sensitivity of the Neurospora biological clock, specifically the rapid induction by light of the clock component frequency (frq). Light induction of frq is transcriptionally controlled and requires two cis-acting elements (LREs) in the frq promoter. Both LREs are bound by a White Collar-1 (WC-1)/White Collar-2 (WC-2) containing complex (WCC), and light causes decreased mobility of the WCC bound to the LREs. The use of in vitro translated WC-1 and WC-2 confirmed that WC-1, with flavin adenine dinucleotide as a cofactor, is the blue light photoreceptor that mediates light input to the circadian system through direct binding( with WC-2) to the frq promoter.	Dartmouth Coll, Sch Med, Dept Genet, Hanover, NH 03755 USA; Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College	Loros, JJ (corresponding author), Dartmouth Coll, Sch Med, Dept Genet, Hanover, NH 03755 USA.		Dunlap, Jay/L-6232-2013; Loros, Jennifer/B-6293-2014	Dunlap, Jay/0000-0003-1577-0457; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH044651] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37GM34985] Funding Source: Medline; NIMH NIH HHS [MH44651] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; Ballario P, 1998, MOL MICROBIOL, V29, P719, DOI 10.1046/j.1365-2958.1998.00955.x; Ballario P, 1996, EMBO J, V15, P1650, DOI 10.1002/j.1460-2075.1996.tb00510.x; Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262; BILWES AM, UNPUB; Briggs WR, 1999, ANNU REV CELL DEV BI, V15, P33, DOI 10.1146/annurev.cellbio.15.1.33; CARATTOLI A, 1994, MOL MICROBIOL, V13, P787, DOI 10.1111/j.1365-2958.1994.tb00471.x; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; Cheng P, 2001, EMBO J, V20, P101, DOI 10.1093/emboj/20.1.101; Collett MA, 2002, GENETICS, V160, P149; Crosson S, 2001, P NATL ACAD SCI USA, V98, P2995, DOI 10.1073/pnas.051520298; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Denault DL, 2001, EMBO J, V20, P109, DOI 10.1093/emboj/20.1.109; DHARMANANDA S, 1980, THESIS U CALIFORNIA; FRANCIS CD, 1979, PLANT PHYSIOL, V64, P1000, DOI 10.1104/pp.64.6.1000; FROEHLICH AC, UNPUB; Garceau NY, 1997, CELL, V89, P469, DOI 10.1016/S0092-8674(00)80227-5; Harmer SL, 2001, ANNU REV CELL DEV BI, V17, P215, DOI 10.1146/annurev.cellbio.17.1.215; Hattar S, 2002, SCIENCE, V295, P1065, DOI 10.1126/science.1069609; He QY, 2002, SCIENCE, V297, P840, DOI 10.1126/science.1072795; Heintzen C, 2001, CELL, V104, P453, DOI 10.1016/S0092-8674(01)00232-X; Iseki M, 2002, NATURE, V415, P1047, DOI 10.1038/4151047a; Lee K, 2000, SCIENCE, V289, P107, DOI 10.1126/science.289.5476.107; Lee K. T., UNPUB; Linden H, 1997, FUNGAL GENET BIOL, V22, P141, DOI 10.1006/fgbi.1997.1013; Linden H, 1997, EMBO J, V16, P98, DOI 10.1093/emboj/16.1.98; Linden H, 1997, MOL GEN GENET, V254, P111, DOI 10.1007/s004380050398; Liu Y, 1998, SCIENCE, V281, P825, DOI 10.1126/science.281.5378.825; LOROS JJ, 1989, SCIENCE, V243, P385, DOI 10.1126/science.2563175; Loros JJ, 2001, ANNU REV PHYSIOL, V63, P757, DOI 10.1146/annurev.physiol.63.1.757; Luo CH, 1998, EMBO J, V17, P1228, DOI 10.1093/emboj/17.5.1228; Margolin B.S., 1997, FUNGAL GENET REP, V44, P34, DOI [10.4148/1941-4765.1281, DOI 10.4148/1941-4765.1281, DOI 10.1128/EC.00244-07]; MCCLUNG CR, 1989, NATURE, V339, P558, DOI 10.1038/339558a0; Merrow M, 2001, EMBO J, V20, P307, DOI 10.1093/emboj/20.3.307; PAIETTA J, 1981, P NATL ACAD SCI-BIOL, V78, P5573, DOI 10.1073/pnas.78.9.5573; PAIETTA J, 1983, PLANT PHYSIOL, V72, P764, DOI 10.1104/pp.72.3.764; Payen A. de, 1843, ANN CHIM PHYS, V9, P5; Provencio I, 2000, J NEUROSCI, V20, P600, DOI 10.1523/JNEUROSCI.20-02-00600.2000; Roenneberg T, 2000, METHOD ENZYMOL, V305, P104; SARGENT ML, 1967, PLANT PHYSIOL, V42, P1504, DOI 10.1104/pp.42.11.1504; SCHMITZ O, 2000, SCIENCE, V289; Staben C, 1989, FUNGAL GENET NEWSL, V36, P79, DOI DOI 10.4148/1941-4765.1519; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490	44	393	414	2	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 2	2002	297	5582					815	819		10.1126/science.1073681	http://dx.doi.org/10.1126/science.1073681			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	579RZ	12098706				2022-12-28	WOS:000177192800044
J	Baeyens, L; Vermeersch, E; Bourgeois, P				Baeyens, L; Vermeersch, E; Bourgeois, P			Bicyclist's vulva: observational study	BRITISH MEDICAL JOURNAL			English	Article									Free Univ Brussels, Hop Univ Brugmann, Sports Gynaecol Unit, B-1020 Brussels, Belgium; Inst Jules Bordet, Dept Radioisotopes, B-1000 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Institut Jules Bordet	Baeyens, L (corresponding author), Free Univ Brussels, Hop Univ Brugmann, Sports Gynaecol Unit, Pl Van Gehuchten, B-1020 Brussels, Belgium.							Abraham P, 1997, SPORTS MED, V24, P221, DOI 10.2165/00007256-199724040-00001; Bourgeois P., 1997, EUR J LYMPHOL, V6, P10; MELLION MB, 1991, SPORTS MED, V11, P52, DOI 10.2165/00007256-199111010-00004; POWELL B, 1983, JAMA-J AM MED ASSOC, V249, P2457, DOI 10.1001/jama.1983.03330420019014; RUBIN JR, 1993, J VASC SURG, V17, P896, DOI 10.1016/0741-5214(93)90039-O	5	21	21	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 20	2002	325	7356					138	138		10.1136/bmj.325.7356.138	http://dx.doi.org/10.1136/bmj.325.7356.138			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	577PG	12130610	Green Published, Bronze			2022-12-28	WOS:000177069900021
J	Best, JM; O'Shea, S; Tipples, G; Davies, N; Al-Khusaiby, SM; Krause, A; Hesketh, LM; Jin, L; Enders, G				Best, JM; O'Shea, S; Tipples, G; Davies, N; Al-Khusaiby, SM; Krause, A; Hesketh, LM; Jin, L; Enders, G			Lesson of the week - Interpretation of rubella serology in pregnancy - pitfalls and problems	BRITISH MEDICAL JOURNAL			English	Review							VIRUS INFECTION; IGM REACTIVITY; AVIDITY		St Thomas Hosp, Guys Kings & St Thomass Sch Med, London SE1 7EH, England; Guys & St Thomass Hosp Trust, Dept Infect, London SE1 7EH, England; Lab Ctr Dis Control, Bur Microbiol, Winnipeg, MB, Canada; Univ Witwatersrand, ZA-2000 Johannesburg, South Africa; S African Inst Med Res, Dept Child Hlth, ZA-2000 Johannesburg, South Africa; S African Inst Med Res, Dept Human Genet, ZA-2000 Johannesburg, South Africa; Royal Preston Hosp, Publ Hlth Lab, Preston PR2 9HG, Lancs, England; Cent Publ Hlth Lab, London NW9 5HT, England; Inst Virol Infektol & Epidemiol, D-70193 Stuttgart, Germany	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Witwatersrand; Royal Preston Hospital; Public Health England	Best, JM (corresponding author), St Thomas Hosp, Guys Kings & St Thomass Sch Med, London SE1 7EH, England.		Krause, Amanda/AAQ-7038-2020	Krause, Amanda/0000-0002-7157-0807				ALMEIDA JD, 1980, LANCET, V2, P1361; BANATVALA JE, 1985, REV INFECT DIS, V7, pS86; Best JM, 2000, PRINCIPLES PRACTICE, P387; BEST JM, 1989, BRIT MED J, V299, P1773; Bottiger B, 1997, CLIN DIAGN VIROL, V8, P105, DOI 10.1016/S0928-0197(97)00018-4; Enders G, 1997, CLIN LAB, V43, P1019; ENDERS G, 1998, PRENATAL GEBURTSMEDI, P76; Enders G, 2000, VARICELLA ZOSTER VIR; Hudson P, 1996, CLIN DIAGN VIROL, V5, P21, DOI 10.1016/0928-0197(95)00155-7; Pustowoit B, 1998, INTERVIROLOGY, V41, P170, DOI 10.1159/000024932; Revello MG, 1997, J CLIN MICROBIOL, V35, P708, DOI 10.1128/JCM.35.3.708-713.1997; Thomas HIJ, 1999, J CLIN VIROL, V14, P107, DOI 10.1016/S1386-6532(99)00051-7; THOMAS HIJ, 1991, J VIROL METHODS, V31, P219, DOI 10.1016/0166-0934(91)90160-2; THOMAS HIJ, 1992, J MED VIROL, V36, P188, DOI 10.1002/jmv.1890360308; *WHO, 2000, M PREV CONG RUB SYND	15	47	56	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 20	2002	325	7356					147	148		10.1136/bmj.325.7356.147	http://dx.doi.org/10.1136/bmj.325.7356.147			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	577PG	12130613	Green Published			2022-12-28	WOS:000177069900026
J	Waalen, J; Felitti, V; Beutler, E				Waalen, J; Felitti, V; Beutler, E			Haemoglobin and ferritin concentrations in men and women: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article									Scripps Res Inst, Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Kaiser Permanente, Dept Prevent Med, San Diego, CA 92111 USA	Scripps Research Institute; Kaiser Permanente	Waalen, J (corresponding author), Scripps Res Inst, Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA.				NCRR NIH HHS [RR00833, M01 RR000833] Funding Source: Medline; NIDDK NIH HHS [DK 07022-20, R01 DK053505, DK53505-04, T32 DK007022] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053505, T32DK007022] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beutler E, 2002, LANCET, V359, P211, DOI 10.1016/S0140-6736(02)07447-0; BEUTLER E, 1960, ANN INTERN MED, V52, P378, DOI 10.7326/0003-4819-52-2-378; GARDNER FH, 1968, BRIT J HAEMATOL, V14, P611, DOI 10.1111/j.1365-2141.1968.tb00367.x; GIULIETTI M, 1991, LAB ANIM SCI, V41, P606; Rushton DH, 2001, BMJ-BRIT MED J, V322, P1355, DOI 10.1136/bmj.322.7298.1355	5	23	23	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 20	2002	325	7356					137	137		10.1136/bmj.325.7356.137	http://dx.doi.org/10.1136/bmj.325.7356.137			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	577PG	12130609	Green Published, Bronze			2022-12-28	WOS:000177069900020
J	Lin, EK; Soles, CL; Goldfarb, DL; Trinque, BC; Burns, SD; Jones, RL; Lenhart, JL; Angelopoulos, M; Willson, CG; Satija, SK; Wu, WL				Lin, EK; Soles, CL; Goldfarb, DL; Trinque, BC; Burns, SD; Jones, RL; Lenhart, JL; Angelopoulos, M; Willson, CG; Satija, SK; Wu, WL			Direct measurement of the reaction front in chemically amplified photoresists	SCIENCE			English	Article							DEEP-ULTRAVIOLET RESISTS; ACID DIFFUSION; POLYMER-FILMS; SIMULATIONS	The continuing drive by the semiconductor industry to fabricate smaller structures using photolithography will soon require dimensional control at length scales comparable to the size of the polymeric molecules in the materials used to pattern them. The current technology, chemically amplified photoresists, uses a complex reaction-diffusion process to delineate patterned areas with high spatial resolution. However, nanometer-level control of this critical process is limited by the lack of direct measurements of the reaction front. We demonstrate the use of x-ray and neutron reflectometry as a general method to measure the spatial evolution of the reaction-diffusion process with nanometer resolution. Measuring compositional profiles, provided by deuterium-labeled reactant groups for neutron scattering contrast, we show that the reaction front within the material is broad rather than sharply defined and the compositional profile is altered during development. Measuring the density profile, we directly correlate the developed film structure with that of the reaction front.	Natl Inst Stand & Technol, Div Polymers, Gaithersburg, MD 20899 USA; Natl Inst Stand & Technol, Ctr Neutron Res, Gaithersburg, MD 20899 USA; IBM Corp, Thomas J Watson Res Ctr, Yorktown Hts, NY 10598 USA; Univ Texas, Dept Chem, Austin, TX 78712 USA; Univ Texas, Dept Chem Engn, Austin, TX 78712 USA	National Institute of Standards & Technology (NIST) - USA; National Institute of Standards & Technology (NIST) - USA; International Business Machines (IBM); University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Lin, EK (corresponding author), Natl Inst Stand & Technol, Div Polymers, Gaithersburg, MD 20899 USA.		Lin, Eric K/B-4972-2008	Soles, Christopher/0000-0002-1963-6039; Lin, Eric/0000-0002-5866-8471; Jones, Ronald/0000-0003-2884-8321				Burns S., 2001, FOREFRONT LITHOGRAPH, P323; Croffie E, 1999, J VAC SCI TECHNOL B, V17, P3339, DOI 10.1116/1.591008; FEDYNYSHYN TH, 1994, J VAC SCI TECHNOL B, V12, P3888, DOI 10.1116/1.587569; Frank CW, 1996, SCIENCE, V273, P912, DOI 10.1126/science.273.5277.912; Frechet J. M. J., 1982, P MICROCIRCUIT ENG, V82, P260; Fryer DS, 2000, MACROMOLECULES, V33, P6439, DOI 10.1021/ma0003349; Goldfarb DL, 2001, J VAC SCI TECHNOL B, V19, P2699, DOI 10.1116/1.1421559; Higgins J. S., 1994, POLYM NEUTRON SCATTE; Houle FA, 2000, P SOC PHOTO-OPT INS, V3999, P181, DOI 10.1117/12.388301; Houle FA, 2000, J VAC SCI TECHNOL B, V18, P1874, DOI 10.1116/1.1303753; Itani T, 1995, J VAC SCI TECHNOL B, V13, P3026, DOI 10.1116/1.588315; Ito H., 1998, Journal of Photopolymer Science and Technology, V11, P379, DOI 10.2494/photopolymer.11.379; Ito H, 1999, P SOC PHOTO-OPT INS, V3678, P104, DOI 10.1117/12.350176; ITO H, 1982, POLYM ENG SCI, V23, P1021; Kim JB, 1999, POLYMER, V40, P1087, DOI 10.1016/S0032-3861(98)00298-5; KRASNOPEROVA AA, 1994, J VAC SCI TECHNOL B, V12, P3900, DOI 10.1116/1.587571; Lu B, 1999, J VAC SCI TECHNOL B, V17, P3345, DOI 10.1116/1.591009; MCKEAN DR, 1989, J POLYM SCI POL CHEM, V27, P3927, DOI 10.1002/pola.1989.080271205; PARRATT LG, 1954, PHYS REV, V95, P359, DOI 10.1103/PhysRev.95.359; PETERSEN JS, 1995, P SOC PHOTO-OPT INS, V2438, P167, DOI 10.1117/12.210378; POPE BM, 1988, ORG SYNTH, V6, P418; Postnikov SV, 1999, J VAC SCI TECHNOL B, V17, P3335, DOI 10.1116/1.591007; Russell T. P., 1990, Material Science Reports, V5, P171, DOI 10.1016/S0920-2307(05)80002-7; Schmid GM, 2001, P SOC PHOTO-OPT INS, V4345, P1037, DOI 10.1117/12.436829; *SEM IND ASS, 2001, 2001 NAT TECHN ROADM; Soles CL, 2001, J VAC SCI TECHNOL B, V19, P2690, DOI 10.1116/1.1415502; Stewart MD, 2000, P SOC PHOTO-OPT INS, V3999, P665, DOI 10.1117/12.388353; Tsiartas PC, 1997, MACROMOLECULES, V30, P4656, DOI 10.1021/ma9707594; Wallraff GM, 1999, CHEM REV, V99, P1801, DOI 10.1021/cr980003i; Zuniga M, 1995, J VAC SCI TECHNOL B, V13, P2957, DOI 10.1116/1.588287	30	88	91	2	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 19	2002	297	5580					372	375		10.1126/science.1072092	http://dx.doi.org/10.1126/science.1072092			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574LV	12130778				2022-12-28	WOS:000176892600043
J	Millar, CB; Guy, J; Sansom, OJ; Selfridge, J; MacDougall, E; Hendrich, B; Keightley, PD; Bishop, SM; Clarke, AR; Bird, A				Millar, CB; Guy, J; Sansom, OJ; Selfridge, J; MacDougall, E; Hendrich, B; Keightley, PD; Bishop, SM; Clarke, AR; Bird, A			Enhanced CpG mutability and tumorigenesis in MBD4-deficient mice	SCIENCE			English	Article							DNA N-GLYCOSYLASE; GENETIC INSTABILITY; TRANSGENIC MICE; MED1 MBD4; MIN MICE; MUTATIONS; 5-METHYLCYTOSINE; DEAMINATION; CARCINOMAS; SPECTRUM	The mammalian protein MBD4 contains a methyl-CpG binding domain and can enzymatically remove thymine (T) or uracil (U) from a mismatched CpG site in vitro. These properties suggest that MBD4 might function in vivo to minimize the mutability of 5-methylcytosine by removing its deamination product from DNA. We tested this hypothesis by analyzing Mbd4(-/-) mice and found that the frequency of of C 3 T transitions at CpG sites was increased by a factor of three. On a cancer-susceptible Apc(Min/+) background, Mbd4(-/-) mice showed accelerated tumor formation with CpG --> TpG mutations in the Apc gene. Thus MBD4 suppresses CpG mutability and tumorigenesis in vivo.	Univ Edinburgh, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales; Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland	University of Edinburgh; Cardiff University; University of Edinburgh	Bird, A (corresponding author), Univ Edinburgh, Wellcome Trust Ctr Cell Biol, Kings Bldg, Edinburgh EH9 3JR, Midlothian, Scotland.		Hendrich, Brian/AAG-5898-2020; Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Hendrich, Brian/0000-0002-0231-3073; SELFRIDGE, JIM/0000-0003-2473-4386; Clarke, Alan/0000-0002-4281-426X; Sansom, Owen J./0000-0001-9540-3010; Millar, Catherine/0000-0002-8649-5408; Guy, Jacky/0000-0002-8440-5667; Bird, Adrian/0000-0002-8600-0372				Bader S, 2000, BRIT J CANCER, V83, P1646, DOI 10.1054/bjoc.2000.1482; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GUY J, UNPUB; Harbach PR, 1999, ENVIRON MOL MUTAGEN, V33, P132, DOI 10.1002/(SICI)1098-2280(1999)33:2<132::AID-EM5>3.0.CO;2-2; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hendrich B, 1999, MAMM GENOME, V10, P906, DOI 10.1007/s003359901112; Jakubczak JL, 1996, P NATL ACAD SCI USA, V93, P9073, DOI 10.1073/pnas.93.17.9073; KOHLER SW, 1991, P NATL ACAD SCI USA, V88, P7958, DOI 10.1073/pnas.88.18.7958; Krawczak M, 1998, AM J HUM GENET, V63, P474, DOI 10.1086/301965; Kuraguchi M, 2000, ONCOGENE, V19, P5755, DOI 10.1038/sj.onc.1203962; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LEROY JL, 1988, J MOL BIOL, V200, P223, DOI 10.1016/0022-2836(88)90236-7; LUONGO C, 1994, CANCER RES, V54, P5947; MILLAR CH, UNPUB; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; Petronzelli F, 2000, J BIOL CHEM, V275, P32422, DOI 10.1074/jbc.M004535200; Petronzelli F, 2000, J CELL PHYSIOL, V185, P473, DOI 10.1002/1097-4652(200012)185:3<473::AID-JCP19>3.0.CO;2-#; Poole A, 2001, NAT REV MOL CELL BIO, V2, P147, DOI 10.1038/35052091; Riccio A, 1999, NAT GENET, V23, P266, DOI 10.1038/15443; SHEN JC, 1994, NUCLEIC ACIDS RES, V22, P972, DOI 10.1093/nar/22.6.972; Shoemaker AR, 1997, CANCER RES, V57, P1999; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0	25	242	254	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 19	2002	297	5580					403	405		10.1126/science.1073354	http://dx.doi.org/10.1126/science.1073354			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574LV	12130785	Green Submitted			2022-12-28	WOS:000176892600052
J	Lacey, JV; Mink, PJ; Lubin, JH; Sherman, ME; Troisi, R; Hartge, P; Schatzkin, A; Schairer, C				Lacey, JV; Mink, PJ; Lubin, JH; Sherman, ME; Troisi, R; Hartge, P; Schatzkin, A; Schairer, C			Menopausal hormone replacement therapy and risk of ovarian cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NONCONTRACEPTIVE ESTROGEN USE; STATES CASE-CONTROL; BREAST-CANCER; UNITED-STATES; COLLABORATIVE ANALYSIS; EPITHELIAL-CELLS; RECEPTOR-ALPHA; MESSENGER-RNA; FOLLOW-UP; WOMEN	Context The association between menopausal hormone replacement therapy and ovarian cancer is unclear. Objective To determine whether hormone replacement therapy using estrogen only, estrogen-progestin only, or both estrogen only and estrogen-progestin increases ovarian cancer risk. Design A 1979-1998 cohort study of former participants in the Breast Cancer Detection Demonstration Project, a nationwide breast cancer screening program. Setting Twenty-nine US clinical centers. Participants A total of 44241 postmenopausal women (mean age at start of follow-up, 56.6 years). Main Outcome Measure Incident ovarian cancer. Results We identified 329 women who developed ovarian cancer during follow-up. In time-dependent analyses adjusted for age, menopause type, and oral contraceptive use, ever use of estrogen only was significantly associated with ovarian cancer (rate ratio [RR], 1.6; 95% confidence interval [CI], 1.2-2.0). Increasing duration of estrogen-only use was significantly associated with ovarian cancer: RRS for 10 to 19 years and 20 or more years were 1.8 (95% Cl, 1.1-3.0) and 3.2 (95% Cl, 1.7-5.7), respectively (P value for trend <.001), and we observed a 7% (95% Cl, 2%-13%) increase in RR per year of use. We observed significantly elevated RRs with increasing duration of estrogen-only use across all strata of other ovarian cancer risk factors, including women with hysterectomy. The RR for estrogen-progestin use after prior estrogen-only use was 1.5 (95% Cl, 0.91-2.4), but the RR for estrogen-progestin-only use was 1.1 (95% Cl, 0.64-1.7). The RRs for less than 2 years and 2 or more years of estrogen-progestin-only use were 1.6 (95% Cl, 0.78-3.3) and 0.80 (95% Cl, 0.35-1.8), respectively, and there was no evidence of a duration response (P value for trend =30). Conclusion Women who used estrogen-only replacement therapy, particularly for 10 or more years, were at significantly increased risk of ovarian cancer in this study. Women who used short-term estrogen-progestin-only replacement therapy were not at increased risk, but risk associated with short-term and longer-term estrogen-progestin replacement therapy warrants further investigation.	NCI, Div Canc Epidemiol & Genet, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lacey, JV (corresponding author), NCI, Div Canc Epidemiol & Genet, 6120 Execut Blvd,MSC 7234, Rockville, MD 20852 USA.							ADAMI HO, 1989, INT J CANCER, V44, P833, DOI 10.1002/ijc.2910440515; ANNEGERS JF, 1979, CANCER, V43, P723, DOI 10.1002/1097-0142(197902)43:2<723::AID-CNCR2820430248>3.0.CO;2-1; Auersperg N, 1998, SEMIN ONCOL, V25, P281; Bai WL, 2000, IN VITRO CELL DEV-AN, V36, P657; Baldwin WS, 1998, IN VITRO CELL DEV-AN, V34, P649; Beral V, 1999, J Epidemiol Biostat, V4, P191; BOOTH M, 1989, BRIT J CANCER, V60, P592, DOI 10.1038/bjc.1989.320; Brandenberger AW, 1998, J CLIN ENDOCR METAB, V83, P1025, DOI 10.1210/jc.83.3.1025; Breslow NE., 1987, STAT METHODS CANC RE, P81; Brett KM, 1997, AM J EPIDEMIOL, V145, P536; BRINTON LA, 1981, CANCER-AM CANCER SOC, V47, P2517, DOI 10.1002/1097-0142(19810515)47:10<2517::AID-CNCR2820471035>3.0.CO;2-L; Coughlin SS, 2000, J CLIN EPIDEMIOL, V53, P367, DOI 10.1016/S0895-4356(99)00179-1; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P711; Garg PP, 1998, OBSTET GYNECOL, V92, P472, DOI 10.1016/S0029-7844(98)00139-2; HARTGE P, 1988, AM J EPIDEMIOL, V127, P990, DOI 10.1093/oxfordjournals.aje.a114902; Hempling RE, 1997, OBSTET GYNECOL, V89, P1012, DOI 10.1016/S0029-7844(97)00118-X; HILDRETH NG, 1981, AM J EPIDEMIOL, V114, P398, DOI 10.1093/oxfordjournals.aje.a113207; HOOVER R, 1977, LANCET, V2, P533; JOHN EM, 1993, JNCI-J NATL CANCER I, V85, P142, DOI 10.1093/jnci/85.2.142; KAUFMAN DW, 1989, AM J EPIDEMIOL, V130, P1142, DOI 10.1093/oxfordjournals.aje.a115441; Lau KM, 1999, P NATL ACAD SCI USA, V96, P5722, DOI 10.1073/pnas.96.10.5722; LAVECCHIA C, 1982, J NATL CANCER I, V69, P1207; LEE NC, 1986, AGING REPROD CLIMACT, P287; McKinney KA, 1998, DRUGS, V56, P49, DOI 10.2165/00003495-199856010-00005; Mink PJ, 1996, EPIDEMIOLOGY, V7, P38, DOI 10.1097/00001648-199601000-00008; Negri E, 1999, INT J CANCER, V80, P848; PARAZZINI F, 1994, INT J CANCER, V57, P135, DOI 10.1002/ijc.2910570124; Persson I, 1996, INT J CANCER, V67, P327, DOI 10.1002/(SICI)1097-0215(19960729)67:3<327::AID-IJC4>3.0.CO;2-T; Pike MC, 1998, AM J EPIDEMIOL, V147, P718; Pike MC, 2000, STEROIDS, V65, P659, DOI 10.1016/S0039-128X(00)00122-7; POLYCHRONOPOULOU A, 1993, INT J CANCER, V55, P402, DOI 10.1002/ijc.2910550312; PRESTON DL, 1996, EPICURE SOFTWARE REL; PURDIE D, 1995, INT J CANCER, V62, P678, DOI 10.1002/ijc.2910620606; Purdie DM, 1999, BRIT J CANCER, V81, P559, DOI 10.1038/sj.bjc.6690731; Riman T, 2002, JNCI-J NATL CANCER I, V94, P497, DOI 10.1093/jnci/94.7.497; Risch HA, 1996, GYNECOL ONCOL, V63, P254, DOI 10.1006/gyno.1996.0315; Risch HA, 1998, JNCI-J NATL CANCER I, V90, P1774, DOI 10.1093/jnci/90.23.1774; Risch HA, 1996, AM J EPIDEMIOL, V144, P363, DOI 10.1093/oxfordjournals.aje.a008937; Rockhill B, 2000, AM J EPIDEMIOL, V151, P404; RODRIGUEZ C, 1995, AM J EPIDEMIOL, V141, P828, DOI 10.1093/oxfordjournals.aje.a117518; Rodriguez C, 2001, JAMA-J AM MED ASSOC, V285, P1460, DOI 10.1001/jama.285.11.1460; SCHAIRER C, 1994, CANCER CAUSE CONTROL, V5, P491, DOI 10.1007/BF01831376; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; Syed V, 2001, CANCER RES, V61, P6768; TZONOU A, 1984, EUR J CANCER CLIN ON, V20, P1045, DOI 10.1016/0277-5379(84)90107-X; WEISS NS, 1982, J NATL CANCER I, V68, P95; Weiss NS, 2001, LANCET, V358, P438, DOI 10.1016/S0140-6736(01)05669-0; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427	48	411	445	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	2002	288	3					334	341		10.1001/jama.288.3.334	http://dx.doi.org/10.1001/jama.288.3.334			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573AK	12117398	Bronze			2022-12-28	WOS:000176807000025
J	Selker, HP; Beshansky, JR; Griffith, JL				Selker, HP; Beshansky, JR; Griffith, JL		TPI Trial Investigators	Use of the electrocardiograph-based thrombolytic predictive instrument to assist thrombolytic and reperfusion therapy for acute myocardial infarction - A multicenter, randomized, controlled, clinical effectiveness trial	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE CARDIAC ISCHEMIA; PRACTICE GUIDELINES COMMITTEE; TISSUE-PLASMINOGEN ACTIVATOR; PRIMARY CORONARY ANGIOPLASTY; ASSOCIATION TASK-FORCE; PREHOSPITAL ELECTROCARDIOGRAM; EMERGENCY-DEPARTMENT; NATIONAL REGISTRY; INTRAVENOUS THROMBOLYSIS; ACC/AHA GUIDELINES	Background: Deciding which patients should receive thrombolytic therapy or percutaneous transluminal coronary angioplasty (PTCA) for acute myocardial infarction (AMI) can be difficult, especially for less-obvious candidates and when consulting physicians are off site. Objective: To test whether the electrocardiograph-based Thrombolytic Predictive Instrument (TPI) improves use of thrombolytic and overall reperfusion therapy. Design: 22-month randomized, controlled, clinical effectiveness trial. Setting: Emergency departments at 28 urban, suburban, and rural hospitals in the United States. Patients: Persons presenting to the emergency department with AMI and ST-segment elevation on an electrocardiogram (ECG). Intervention: TPI predictions automatically printed on ECG text headers. Measurements: Percentages of patients receiving thrombolytic therapy, thrombolytic therapy within 1 hour of initial ECG, and overall reperfusion (thrombolytic therapy or PTCA). Results: Of 2875 patients with AMI, 1243 (43.2%) had ST-segment elevation. Of these, 1197 were randomly assigned to study groups; 732 (61.2%) had inferior AMI, and 465 (38.8%) had anterior AMI. A total of 60.5% of controls and 62.1% of TPI patients (P = 0.2) received thrombolytic therapy, 52.5% of controls and 53.3% of TPI patients received thrombolytic therapy within 1 hour (P > 0.2), and 67.6% of controls and 70.3% of TPI patients received overall reperfusion (P = 0.2). Of patients with inferior AMI in the control group versus the TPI group, 61.1% versus 67.6% (P = 0.03) received thrombolytic therapy, 53.2% versus 58.6% (P = 0.08) received thrombolytic therapy within 1 hour, and 67.7% versus 74.7% (P = 0.03) received overall reperfusion. Of patients with anterior AMI in the control group versus the TPI group, 59.5% versus 53.9% (P > 0.2) received thrombolytic therapy, 51.4% versus 45.3% (P > 0.2) received thrombolytic therapy within 1 hour, and 67.6% versus 63.8% (P > 0.2) received overall reperfusion. Among women (n = 398) in the control group versus the TPI group, 48.1% versus 58.2% (P = 0.03) received thrombolytic therapy, 40.5% versus 48.4% (P = 0.10) received thrombolytic therapy within I hour, and 55.7% versus 65.7% (P = 0.04) received overall reperfusion. Of patients who required physician consultation by telephone (n = 271) in the control group versus the TPI group, 47.3% versus 63.2% (P= 0.01) received thrombolytic therapy, 41.1 % versus 53.6% (P = 0.04) received thrombolytic therapy within 1 hour, and 50.7% versus 66.4% (P = 0.01) received overall reperfusion. Conclusions: The TPI increased use of thrombolytic therapy, use of thrombolytic therapy within 1 hour, and use of overall coronary reperfusion by 11% to 12% for patients with inferior AMI, 18% to 22% for women, and 30% to 34% for patients with an off-site physician. Although its effect was minimal on patients with high baseline reperfusion rates, the TPI increased use and timeliness of reperfusion in often-missed groups and when involved physicians were off site.	Tufts Univ New England Med Ctr, Div Clin Care Res, Boston, MA 02111 USA	Tufts Medical Center	Selker, HP (corresponding author), Tufts Univ New England Med Ctr, Div Clin Care Res, 750 Washington St,63, Boston, MA 02111 USA.	hselker@lifespan.org			AHRQ HHS [R01 HS 08212] Funding Source: Medline; NCRR NIH HHS [M01 RR00054] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008212] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000054] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Al-Mubarak N, 1999, AM J CARDIOL, V83, P89, DOI 10.1016/S0002-9149(98)00785-1; Amit G, 1999, J THROMB THROMBOLYS, V8, P113, DOI 10.1023/A:1008959017880; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1994, Ann Emerg Med, V23, P311; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; AUFDERHEIDE TP, 1990, ANN EMERG MED, V19, P1280, DOI 10.1016/S0196-0644(05)82288-7; Ayanian JZ, 2000, CIRCULATION, V101, P2224, DOI 10.1161/01.CIR.101.19.2224; Barron H V, 1999, Cardiol Rev, V7, P156, DOI 10.1097/00045415-199905000-00013; Barron HV, 1998, CIRCULATION, V97, P1150, DOI 10.1161/01.CIR.97.12.1150; Bates ER, 1997, J AM COLL CARDIOL, V30, P334, DOI 10.1016/S0735-1097(97)00178-2; Berger AK, 2000, AM HEART J, V139, P985, DOI 10.1067/mhj.2000.105703; Betriu A, 1997, NEW ENGL J MED, V336, P1621; Cannon CP, 1999, CLIN CARDIOL, V22, P10, DOI 10.1002/clc.4960221604; Cannon CP, 1998, CIRCULATION, V98, P2805, DOI 10.1161/01.CIR.98.25.2805; CANNON CP, 1994, J THROMB THROMBOLYS, V1, P27; Canto JG, 1997, J AM COLL CARDIOL, V29, P498, DOI 10.1016/S0735-1097(96)00532-3; CLAWSON JJ, 1995, AM J EMERG MED, V13, P67; Coronado BE, 1997, J AM COLL CARDIOL, V29, P1490, DOI 10.1016/S0735-1097(97)00077-6; Dracup K, 1997, ANN INTERN MED, V126, P645, DOI 10.7326/0003-4819-126-8-199704150-00010; El Gaylani N, 1998, CORONARY ARTERY DIS, V9, P753, DOI 10.1097/00019501-199809110-00008; Every NR, 1996, NEW ENGL J MED, V335, P1253, DOI 10.1056/NEJM199610243351701; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; Goldberg RJ, 1998, AM J CARDIOL, V82, P259, DOI 10.1016/S0002-9149(98)00342-7; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; KARAGOUNIS L, 1990, AM J CARDIOL, V66, P786, DOI 10.1016/0002-9149(90)90352-2; KEREIAKES DJ, 1992, AM HEART J, V123, P835, DOI 10.1016/0002-8703(92)90684-N; Krumholz HM, 1997, JAMA-J AM MED ASSOC, V277, P1683, DOI 10.1001/jama.277.21.1683; Kudenchuk PJ, 1998, J AM COLL CARDIOL, V32, P17, DOI 10.1016/S0735-1097(98)00175-2; Lange RA, 1996, NEW ENGL J MED, V335, P1311; LEIZOROVICZ A, 1993, NEW ENGL J MED, V329, P383; MCCARTHY BD, 1993, ANN EMERG MED, V22, P579, DOI 10.1016/S0196-0644(05)81945-6; Pope JH, 2000, NEW ENGL J MED, V342, P1163, DOI 10.1056/NEJM200004203421603; RAWLES J, 1994, J AM COLL CARDIOL, V23, P1, DOI 10.1016/0735-1097(94)90494-4; ROGERS WJ, 1994, CIRCULATION, V90, P2103, DOI 10.1161/01.CIR.90.4.2103; Rogers WJ, 2000, J AM COLL CARDIOL, V36, P2056, DOI 10.1016/S0735-1097(00)00996-7; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; Ryan TJ, 1999, CIRCULATION, V100, P1016, DOI 10.1161/01.CIR.100.9.1016; SARASIN FP, 1994, J GEN INTERN MED, V9, P187, DOI 10.1007/BF02600122; Schmid CH, 1997, J CLIN EPIDEMIOL, V50, P1219, DOI 10.1016/S0895-4356(97)00125-X; SELKER HP, 1993, ANN INTERN MED, V118, P820, DOI 10.7326/0003-4819-118-10-199305150-00010; SELKER HP, 1991, MED CARE, V29, P1196, DOI 10.1097/00005650-199112000-00003; Selker HP, 1997, ANN EMERG MED, V29, P13, DOI 10.1016/S0196-0644(97)70298-1; Selker HP, 1998, ANN INTERN MED, V129, P845, DOI 10.7326/0003-4819-129-11_Part_1-199812010-00002; Selker HP, 1997, ANN INTERN MED, V127, P538, DOI 10.7326/0003-4819-127-7-199710010-00006; SELKER HP, 1994, CIRCULATION, V90, P1657, DOI 10.1161/01.CIR.90.4.1657; SELKER HP, 1992, THROMBOLYTIC PREDICT, P9; SIMES RJ, 1995, CIRCULATION, V91, P1923, DOI 10.1161/01.CIR.91.7.1923; Stern R, 1998, Eur J Emerg Med, V5, P471; Thiemann DR, 2000, CIRCULATION, V101, P2239, DOI 10.1161/01.CIR.101.19.2239; Tiefenbrunn AJ, 1998, J AM COLL CARDIOL, V31, P1240, DOI 10.1016/S0735-1097(98)00094-1; Van de Werf F, 1999, AM HEART J, V137, P786, DOI 10.1016/S0002-8703(99)70400-X; Wang-Clow F, 2001, AM HEART J, V141, P33, DOI 10.1067/mhj.2001.112092; Weaver WD, 1997, JAMA-J AM MED ASSOC, V278, P2093, DOI 10.1001/jama.278.23.2093; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; Widimsky P, 2000, EUR HEART J, V21, P823, DOI 10.1053/euhj.1999.1993; Zucker DR, 1997, J GEN INTERN MED, V12, P79, DOI 10.1046/j.1525-1497.1997.00011.x; 1998, J THROMB THROMBOLYSI, V6, P47; 1995, AM J EMERG MED, V13, P188; 1986, J THROMB THROMBOLYSI, V6, P19	60	52	52	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 16	2002	137	2					87	95		10.7326/0003-4819-137-2-200207160-00006	http://dx.doi.org/10.7326/0003-4819-137-2-200207160-00006			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575VN	12118963				2022-12-28	WOS:000176969300002
J	Jayne, BC; Voris, HK; Ng, PKL				Jayne, BC; Voris, HK; Ng, PKL			Herpetology: Snake circumvents constraints on prey size	NATURE			English	Article							CONSTRICTION		Univ Cincinnati, Dept Biol Sci, Cincinnati, OH 45221 USA; Field Museum Nat Hist, Div Amphibians & Reptiles, Chicago, IL 60605 USA; Natl Univ Singapore, Dept Biol Sci, Raffles Museum Biodivers Res, Singapore 119260, Singapore	University System of Ohio; University of Cincinnati; Field Museum of Natural History (Chicago); National University of Singapore	Jayne, BC (corresponding author), Univ Cincinnati, Dept Biol Sci, Cincinnati, OH 45221 USA.		Ng, Peter/J-7393-2012	Voris, Harold/0000-0001-6698-8283				Arnold Stevan J., 1993, P87; Cundall David, 2000, P293, DOI 10.1016/B978-012632590-4/50010-1; GREENE HW, 1978, SCIENCE, V200, P74, DOI 10.1126/science.635575; SAVITZKY AH, 1983, AM ZOOL, V23, P397; SHINE R, 1985, COPEIA, P1067; VORIS HK, IN PRESS COPEIA; VORIS HK, IN PRESS J NAT HIST	7	50	53	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 11	2002	418	6894					143	143		10.1038/418143a	http://dx.doi.org/10.1038/418143a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571GV	12110878	Bronze			2022-12-28	WOS:000176710400028
J	Wessels, MW; Willems, PJ				Wessels, MW; Willems, PJ			Chondrodysplasia punctata	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Rotterdam Hosp, NL-3015 GD Rotterdam, Netherlands; Synergene Belgium, B-2800 Mechelen, Belgium	Erasmus University Rotterdam; Erasmus MC	Wessels, MW (corresponding author), Univ Rotterdam Hosp, NL-3015 GD Rotterdam, Netherlands.								0	0	0	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 11	2002	347	2					110	110		10.1056/NEJMicm010895	http://dx.doi.org/10.1056/NEJMicm010895			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	572HC	12110739				2022-12-28	WOS:000176767300006
J	Clack, JA				Clack, JA			An early tetrapod from 'Romer's Gap'	NATURE			English	Article							ACANTHOSTEGA GUNNARI JARVIK; CARBONIFEROUS TETRAPOD; EVOLUTION; SKELETON; ANATOMY	The fossil record of early tetrapods has been increased recently by new finds from the Devonian period(1) and mid-late Early Carboniferous period(2). Despite this, understanding of tetrapod evolution has been hampered by a 20-million-year gap ('Romer's Gap'(3)) that covers the crucial, early period when many key features of terrestrial tetrapods were acquired. Here I describe the only articulated skeleton of a tetrapod, Pederpes, yet found from the Tournaisian epoch (354-344 million years ago (Myr)). The new taxon includes a pes with five robust digits, but a very small, possibly supernumerary digit preserved on the manus suggests the presence of polydactyly. Polydactylous early tetrapods may have survived beyond the end of the Devonian and pentadactyly cannot be assumed for the pes. However, the pes has characteristics that distinguish it from the paddle-like feet of the Devonian forms and resembles the feet of later, more terrestrially adapted Carboniferous forms. Pederpes is the earliest-known tetrapod to show the beginnings of terrestrial locomotion and was at least functionally pentadactyl. With its later American sister-genus, Whatcheeria(4,5), it represents the next most primitive tetrapod clade after those of the Late Devonian, bridging the temporal, morphological and phylogenetic gaps that have hitherto separated Late Devonian and mid-Carboniferous tetrapod faunas.	Univ Cambridge, Museum Zool, Cambridge CB2 3EJ, England	University of Cambridge	Clack, JA (corresponding author), Univ Cambridge, Museum Zool, Downing St, Cambridge CB2 3EJ, England.	j.a.clack@zoo.cam.ac.uk	TATSUTA, HARUKI/F-2997-2010					Anderson JS, 2001, SYST BIOL, V50, P170; Bolt John R., 2000, P1044; CAMERON IB, 1985, BRIT GEOLOGICAL SURV; CARROLL RL, 1995, STUDIES EARLY VERTEB, P389; CLACK JA, 1994, T ROY SOC EDIN-EARTH, V84, P369; Clack JA, 1998, ZOOL J LINN SOC-LOND, V122, P61, DOI 10.1006/zjls.1997.0114; CLACK JA, 1994, NATURE, V369, P392, DOI 10.1038/369392a0; Clack JA, 1998, NATURE, V394, P66, DOI 10.1038/27895; Clack Jennifer A., 2000, Amphibian Biology, V4, P1030; Clack Jennifer A., 2000, Amphibian Biology, V4, P979; Coates MI, 1996, T ROY SOC EDIN-EARTH, V87, P363, DOI 10.1017/S0263593300006787; COATES MI, 1990, NATURE, V347, P66, DOI 10.1038/347066a0; COATES MI, 1995, STUDIES EARLY VERTEB, P373; GODFREY SJ, 1989, PHILOS T ROY SOC B, V323, P75, DOI 10.1098/rstb.1989.0002; HOLMES R, 1984, PHILOS T ROY SOC B, V306, P431, DOI 10.1098/rstb.1984.0103; Laurin Michel, 1997, P9, DOI 10.1016/B978-012676460-4/50003-2; LEBEDEV OA, 1995, ZOOL J LINN SOC-LOND, V114, P307, DOI 10.1006/zjls.1995.0027; LOMBARD RE, 1995, PALAEONTOLOGY, V38, P471; MADDISON WP, 1992, MACCLADE VERSION 3 0; Milner AC, 1998, ZOOL J LINN SOC-LOND, V122, P211, DOI 10.1111/j.1096-3642.1998.tb02530.x; PANCHEN AL, 1985, PHILOS T ROY SOC B, V309, P505, DOI 10.1098/rstb.1985.0095; PATERSON IB, 1990, BRIT GEOLOGICAL SURV; Paton RL, 1999, NATURE, V398, P508, DOI 10.1038/19071; SWOFFORD DL, 1993, PAUP PHYLOGENETIC EN	24	104	109	2	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 4	2002	418	6893					72	76		10.1038/nature00824	http://dx.doi.org/10.1038/nature00824			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	569JL	12097908				2022-12-28	WOS:000176599200040
J	McCune, AR; Fuller, RC; Aquilina, AA; Dawley, RM; Fadool, JM; Houle, D; Travis, J; Kondrashov, AS				McCune, AR; Fuller, RC; Aquilina, AA; Dawley, RM; Fadool, JM; Houle, D; Travis, J; Kondrashov, AS			A low genomic number of recessive lethals in natural populations of bluefin killifish and zebrafish	SCIENCE			English	Article							MUTATIONS; FREQUENCY; MUTANTS	Despite the importance of selection against deleterious mutations in natural populations, reliable estimates of the genomic numbers of mutant alleles in wild populations are scarce. We found that, in wild-caught bluefin killifish Lucania goodei (Fundulidae) and wild-caught zebrafish Danio rerio (Cyprinidae), the average numbers of recessive lethal alleles per individual are 1.9 (95% confidence limits 1.3 to 2.6) and 1.4 (95% confidence limits 1.0 to 2.0), respectively. These results, together with data on several Drosophila species and on Xenopus laevis, show that phylogenetically distant animals with different genome sizes and numbers of genes carry similar numbers of lethal mutations.	Cornell Univ, Dept Ecol & Evolutionary Biol, Ithaca, NY 14853 USA; Florida State Univ, Dept Biol Sci, Tallahassee, FL 32306 USA; Ursinus Coll, Dept Biol, Collegeville, PA 19426 USA; NIH, Natl Ctr Biotechnol Informat, Bethesda, MD 20892 USA	Cornell University; State University System of Florida; Florida State University; National Institutes of Health (NIH) - USA	McCune, AR (corresponding author), Cornell Univ, Dept Ecol & Evolutionary Biol, Ithaca, NY 14853 USA.	arm2@cornell.edu; fuller@neuro.fsu.edu		Fuller, Rebecca/0000-0002-5744-8012				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Berg RL, 1937, GENETICS, V22, P225; Crow JF, 1999, NATURE, V397, P293, DOI 10.1038/16789; Crow JF, 1997, P NATL ACAD SCI USA, V94, P8380, DOI 10.1073/pnas.94.16.8380; DAWLEY RM, 1992, P NATL ACAD SCI USA, V89, P2485, DOI 10.1073/pnas.89.6.2485; DOBZHANSKY T, 1954, GENETICS, V39, P472; Driever W, 1996, DEVELOPMENT, V123, P37; DUBININ NP, 1946, GENETICS, V31, P21; Haffter P, 1996, DEVELOPMENT, V123, P1; Krawczak M, 2000, HUM MUTAT, V15, P45, DOI 10.1002/(SICI)1098-1004(200001)15:1<45::AID-HUMU10>3.0.CO;2-T; KROTOSKI DM, 1985, J EXP ZOOL, V233, P443, DOI 10.1002/jez.1402330313; Kusakabe S, 2000, GENETICS, V154, P679; Lewontin RC, 1974, GENETIC BASIS EVOLUT; McLysaght A, 2000, YEAST, V17, P22, DOI 10.1002/(SICI)1097-0061(200004)17:1<22::AID-YEA5>3.0.CO;2-S; NAKAMURA D, 1990, CYTOGENET CELL GENET, V53, P201, DOI 10.1159/000132930; OHNISHI O, 1982, JPN J GENET, V57, P623, DOI 10.1266/jjg.57.623; Powell J. R., 1997, PROGR PROSPECTS EVOL; Rodriguez M, 1997, BIOCHEM CELL BIOL, V75, P579, DOI 10.1139/bcb-75-5-579; SPENCER WP, 1947, U TEX PUBL, V5721, P186; STURTEVANT A. H., 1937, BIOL BULL, V73, P542, DOI 10.2307/1537613; Timofeeff-Ressovsky H A, 1927, Wilhelm Roux Arch Entwickl Mech Org, V109, P70, DOI 10.1007/BF02079096; VINDELOV LL, 1983, CYTOMETRY, V3, P317, DOI 10.1002/cyto.990030502; Walker C, 1999, METHOD CELL BIOL, V60, P43; WILLIS JH, 1992, HEREDITY, V69, P562, DOI 10.1038/hdy.1992.172	24	44	45	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 28	2002	296	5577					2398	2401		10.1126/science.1071757	http://dx.doi.org/10.1126/science.1071757			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	567CE	12089444				2022-12-28	WOS:000176467200043
J	Horton, R				Horton, R			What the UK government is (not) doing about health inequalities	LANCET			English	Editorial Material							POLICY		Lancet, London NW1 7BY, England		Horton, R (corresponding author), Lancet, London NW1 7BY, England.							Acheson D., 1998, INDEPENDENT INQUIRY; Macintyre S, 2001, BRIT MED J, V322, P222, DOI 10.1136/bmj.322.7280.222; *NHS, 2002, LANCET, V359, P1447; Smith GD, 2001, BRIT MED J, V322, P184, DOI 10.1136/bmj.322.7280.184; Zoritch B, 1998, SOC SCI MED, V47, P317, DOI 10.1016/S0277-9536(98)00037-9; 1999, SAVING LIVES OUR HLT; 1999, REDUCING HLTH INEQUA	7	6	6	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 20	2002	360	9328					186	186		10.1016/S0140-6736(02)09502-8	http://dx.doi.org/10.1016/S0140-6736(02)09502-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	576DX	12133651				2022-12-28	WOS:000176988500006
J	Golding, NL; Staff, NP; Spruston, N				Golding, NL; Staff, NP; Spruston, N			Dendritic spikes as a mechanism for cooperative long-term potentiation	NATURE			English	Article							CA1 PYRAMIDAL NEURONS; HIPPOCAMPAL-NEURONS; SYNAPTIC POTENTIALS; CALCIUM INFLUX; IN-VIVO; PROPAGATION; INITIATION; PLASTICITY; AFFERENTS; INDUCTION	Strengthening of synaptic connections following coincident pre- and postsynaptic activity was proposed by Hebb as a cellular mechanism for learning(1). Contemporary models assume that multiple synapses must act cooperatively to induce the postsynaptic activity required for hebbian synaptic plasticity(2-5). One mechanism for the implementation of this cooperation is action potential firing, which begins in the axon, but which can influence synaptic potentiation following active backpropagation into dendrites(6). Backpropagation is limited, however, and action potentials often fail to invade the most distal dendrites(7-10). Here we show that long-term potentiation of synapses on the distal dendrites of hippocampal CA1 pyramidal neurons does require cooperative synaptic inputs, but does not require axonal action potential firing and backpropagation. Rather, locally generated and spatially restricted regenerative potentials (dendritic spikes) contribute to the postsynaptic depolarization and calcium entry necessary to trigger potentiation of distal synapses. We find that this mechanism can also function at proximal synapses, suggesting that dendritic spikes participate generally in a form of synaptic potentiation that does not require postsynaptic action potential firing in the axon.	Northwestern Univ, Inst Neurosci, Dept Neurobiol & Physiol, Evanston, IL 60208 USA	Northwestern University	Spruston, N (corresponding author), Northwestern Univ, Inst Neurosci, Dept Neurobiol & Physiol, 2153 N Campus Dr, Evanston, IL 60208 USA.		Staff, Nathan/M-2583-2019	Staff, Nathan/0000-0001-6760-3859; Spruston, Nelson/0000-0003-3118-1636				Bi GQ, 1998, J NEUROSCI, V18, P10464, DOI 10.1523/jneurosci.18-24-10464.1998; CALLAWAY JC, 1995, J NEUROPHYSIOL, V74, P1395, DOI 10.1152/jn.1995.74.4.1395; COLBERT CM, 1993, BRAIN RES, V606, P87, DOI 10.1016/0006-8993(93)91573-B; Golding NL, 1999, J NEUROSCI, V19, P8789, DOI 10.1523/JNEUROSCI.19-20-08789.1999; Golding NL, 2001, J NEUROPHYSIOL, V86, P2998, DOI 10.1152/jn.2001.86.6.2998; Golding NL, 1998, NEURON, V21, P1189, DOI 10.1016/S0896-6273(00)80635-2; GUSTAFSSON B, 1987, J NEUROSCI, V7, P774; Hausser M, 2000, SCIENCE, V290, P739, DOI 10.1126/science.290.5492.739; Hebb Donald O., 1949, ORG BEHAV; Helmchen F, 1999, NAT NEUROSCI, V2, P989, DOI 10.1038/14788; Kamondi A, 1998, HIPPOCAMPUS, V8, P244, DOI 10.1002/(SICI)1098-1063(1998)8:3<244::AID-HIPO7>3.0.CO;2-J; Kamondi A, 1998, J NEUROSCI, V18, P3919; Larkum ME, 1999, NATURE, V398, P338, DOI 10.1038/18686; LEE KS, 1983, J NEUROSCI, V3, P1369; Magee JC, 1997, SCIENCE, V275, P209, DOI 10.1126/science.275.5297.209; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; MCNAUGHTON BL, 1978, BRAIN RES, V157, P277, DOI 10.1016/0006-8993(78)90030-6; MEL BW, 1993, J NEUROPHYSIOL, V70, P1086, DOI 10.1152/jn.1993.70.3.1086; Miles R, 1996, NEURON, V16, P815, DOI 10.1016/S0896-6273(00)80101-4; Pike FG, 1999, J PHYSIOL-LONDON, V518, P571, DOI 10.1111/j.1469-7793.1999.0571p.x; Poirazi P, 2001, NEURON, V29, P779, DOI 10.1016/S0896-6273(01)00252-5; Schiller J, 2000, NATURE, V404, P285, DOI 10.1038/35005094; Schiller J, 1998, NAT NEUROSCI, V1, P114, DOI 10.1038/363; Schiller J, 1997, J PHYSIOL-LONDON, V505, P605, DOI 10.1111/j.1469-7793.1997.605ba.x; Segev I, 1998, TRENDS NEUROSCI, V21, P453, DOI 10.1016/S0166-2236(98)01327-7; Sjostrom PJ, 2001, NEURON, V32, P1149, DOI 10.1016/S0896-6273(01)00542-6; SPRUSTON N, 1994, TRENDS NEUROSCI, V17, P161, DOI 10.1016/0166-2236(94)90094-9; SPRUSTON N, 1995, SCIENCE, V268, P297, DOI 10.1126/science.7716524; Stuart G, 1997, J PHYSIOL-LONDON, V505, P617, DOI 10.1111/j.1469-7793.1997.617ba.x; Wei DS, 2001, SCIENCE, V293, P2272, DOI 10.1126/science.1061198	30	451	461	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 18	2002	418	6895					326	331		10.1038/nature00854	http://dx.doi.org/10.1038/nature00854			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574BF	12124625				2022-12-28	WOS:000176868000043
J	Humphries, MM; Thomas, DW; Speakman, JR				Humphries, MM; Thomas, DW; Speakman, JR			Climate-mediated energetic constraints on the distribution of hibernating mammals	NATURE			English	Article							BATS MYOTIS-LUCIFUGUS; LIMITS	To predict the consequences of human-induced global climate change, we need to understand how climate is linked to biogeography(1). Energetic constraints are commonly invoked to explain animal distributions, and physiological parameters are known to vary along distributional gradients(2). But the causal nature of the links between climate and animal biogeography remain largely obscure(2,3). Here we develop a bioenergetic model that predicts the feasibility of mammalian hibernation under different climatic conditions. As an example, we use the well-quantified hibernation energetics of the little brown bat (Myotis lucifugus) to parameterize the model(4). Our model predicts pronounced effects of ambient temperature on total winter energy requirements, and a relatively narrow combination of hibernaculum temperatures and winter lengths permitting successful hibernation. Microhabitat and northern distribution limits of M. lucifugus are consistent with model predictions, suggesting that the thermal dependence of hibernation energetics constrains the biogeography of this species. Integrating projections of climate change into our model predicts a pronounced northward range expansion of hibernating bats within the next 80 years. Bioenergetics can provide the simple link between climate and biogeography needed to predict the consequences of climate change.	Univ Aberdeen, Dept Zool, Aberdeen AB24 3TZ, Scotland; Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada; Univ Sherbrooke, Dept Biol, Sherbrooke, PQ J1K 2R1, Canada; Rowett Res Inst, Aberdeen AB21 9BS, Scotland	University of Aberdeen; University of Alberta; University of Sherbrooke; University of Aberdeen	Humphries, MM (corresponding author), Univ Aberdeen, Dept Zool, Aberdeen AB24 3TZ, Scotland.	murray_humphries@hotmail.com	Speakman, John R./A-9494-2008	Speakman, John R./0000-0002-2457-1823				BELL GP, 1986, J COMP PHYSIOL B, V156, P441, DOI 10.1007/BF01101107; Bennett A.F., 1996, ANIMALS TEMPERATURE; BRACK V, 1985, CAN J ZOOL, V63, P2952, DOI 10.1139/z85-442; Canterbury G, 2002, ECOLOGY, V83, P946, DOI 10.2307/3071904; Chown SL, 1999, BIOL REV, V74, P87, DOI 10.1017/S000632319800526X; Davis W. H., 1964, Journal of Mammalogy, V45, P475, DOI 10.2307/1377426; DWYER P D, 1971, Mammalia, V35, P424, DOI 10.1515/mamm.1971.35.3.424; FENTON MB, 1980, MAMMALIAN SPECIES, V142, P1, DOI DOI 10.2307/3503792; GATES DM, 1993, CLIMATE CHANGE ITS B, P162; HENSHAW RE, 1966, PHYSIOL ZOOL, V39, P223, DOI 10.1086/physzool.39.3.30152849; Johns TC, 1997, CLIM DYNAM, V13, P103, DOI 10.1007/s003820050155; Kunz TH, 1998, ECOSCIENCE, V5, P8, DOI 10.1080/11956860.1998.11682443; MCMANUS JJ, 1974, J MAMMAL, V55, P844, DOI 10.2307/1379416; MENAKER M, 1962, J CELL COMPAR PHYSL, V59, P163, DOI 10.1002/jcp.1030590209; Nagorsen David W., 1994, Northwestern Naturalist, V74, P61, DOI 10.2307/3536599; NAGORSEN DW, 1980, CAN FIELD NAT, V94, P83; Parker DI, 1997, ARCTIC, V50, P256; Pearson E. W., 1962, Journal of Mammalogy, V43, P27, DOI 10.2307/1376877; RAESLY RL, 1987, AM MIDL NAT, V118, P15, DOI 10.2307/2425624; RAINEY RC, 1976, INSECT FLIGHT, P75; ROOT T, 1988, J BIOGEOGR, V15, P489, DOI 10.2307/2845278; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; SCHOWALTER DB, 1980, J MAMMAL, V61, P350, DOI 10.2307/1380065; SPEAKMAN JR, IN PRESS BAT BIOL; Thomas DW, 1995, SYM ZOOL S, P233; Twente J. W., 1960, Proceedings of the Utah Academy, V37, P67; Webb PI, 1996, CAN J ZOOL, V74, P761, DOI 10.1139/z96-087; WEINER J, 1992, TRENDS ECOL EVOL, V7, P384, DOI 10.1016/0169-5347(92)90009-Z; WHITAKER JO, 1992, AM MIDL NAT, V127, P52, DOI 10.2307/2426321; [No title captured]	30	254	267	3	144	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 18	2002	418	6895					313	316		10.1038/nature00828	http://dx.doi.org/10.1038/nature00828			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574BF	12124621				2022-12-28	WOS:000176868000039
J	Halpern, SD; Karlawish, JHT; Berlin, JA				Halpern, SD; Karlawish, JHT; Berlin, JA			The continuing unethical conduct of underpowered clinical trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED CONTROLLED-TRIALS; SAMPLE-SIZE; STATISTICAL POWER; ETHICS; PARTICIPATION; METAANALYSIS; RECRUITMENT; PLACEBO; ENROLL; BIAS	Despite long-standing critiques of the conduct of underpowered clinical trials, the practice not only remains widespread, but also has garnered Increasing support. Patients and healthy volunteers continue to participate in research that may be of limited clinical value, and authors recently have offered 2 related arguments to support the validity and value of underpowered clinical trials: that meta-analysis may "save" small studies by providing a means to combine the results with those of other similar studies to enable estimates of an intervention's efficacy, and that although small studies may not provide a good basis for testing hypotheses, they may provide valuable estimates of treatment effects using confidence intervals. In this article, we examine these arguments in light of the distinctive moral issues associated with the conduct of underpowered trials, the disclosures that are owed to potential participants in underpowered trials so they may make autonomous enrollment decisions, and the circumstances in which the prospects for future meta-analyses may justify individually underpowered trials. We conclude that underpowered trials are ethical in only 2 situations: small trials of interventions for rare diseases in which investigators document explicit plans for including their results with those of similar trials in a prospective meta-analysis, and early-phase trials in the development of drugs or devices, provided they are adequately powered for defined purposes other than randomized treatment comparisons. In both cases, investigators must inform prospective subjects that their participation may only indirectly contribute to future health care benefits.	Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Bioeth, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Halpern, SD (corresponding author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, 108 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	shalpern@mail.med.upenn.edu						ALTMAN DG, 1994, BRIT MED J, V308, P283, DOI 10.1136/bmj.308.6924.283; ALTMAN DG, 1980, BRIT MED J, V281, P1336, DOI 10.1136/bmj.281.6251.1336; ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; Bailar JC, 1997, NEW ENGL J MED, V337, P559, DOI 10.1056/NEJM199708213370810; BEGG CB, 1988, J ROY STAT SOC A STA, V151, P419, DOI 10.2307/2982993; Berlin JA, 1999, JAMA-J AM MED ASSOC, V281, P830, DOI 10.1001/jama.281.9.830; Braunholtz DA, 2001, J CLIN EPIDEMIOL, V54, P217, DOI 10.1016/S0895-4356(00)00305-X; CASSILETH BR, 1982, JAMA-J AM MED ASSOC, V248, P968, DOI 10.1001/jama.248.8.968; Chalmers T C, 1993, Stat Methods Med Res, V2, P161; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; *CURR CONTR TRIAL, 2001, CURR CONTR TRIALS; DERSIMONIAN R, 1982, NEW ENGL J MED, V306, P1332, DOI 10.1056/NEJM198206033062204; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; Edwards SJL, 1997, LANCET, V350, P804, DOI 10.1016/S0140-6736(97)02290-3; Egger M, 1998, BMJ-BRIT MED J, V316, P61, DOI 10.1136/bmj.316.7124.61; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Feagan BG, 2000, NEW ENGL J MED, V342, P1627, DOI 10.1056/NEJM200006013422202; FREEDMAN B, 1992, CONTROL CLIN TRIALS, V13, P1, DOI 10.1016/0197-2456(92)90025-U; Freedman Benjamin, 1987, IRB, V9, P7, DOI 10.2307/3563623; Freedman KB, 1999, J BONE JOINT SURG AM, V81A, P1454, DOI 10.2106/00004623-199910000-00011; FREIMAN JA, 1978, NEW ENGL J MED, V299, P690, DOI 10.1056/NEJM197809282991304; GOODMAN SN, 1994, ANN INTERN MED, V121, P200, DOI 10.7326/0003-4819-121-3-199408010-00008; Halpern SD, 2001, J ACQ IMMUN DEF SYND, V27, P281, DOI 10.1097/00126334-200107010-00011; Horton R, 1999, BRIT MED J, V319, P865, DOI 10.1136/bmj.319.7214.865; HUNNINGHAKE DB, 1987, CONTROL CLIN TRIALS, V8, pS6; Karlawish JHT, 2001, NEUROLOGY, V56, P789, DOI 10.1212/WNL.56.6.789; Knapp TR, 1996, NURS RES, V45, P379, DOI 10.1097/00006199-199611000-00018; Knottnerus JA, 2001, J CLIN EPIDEMIOL, V54, P109, DOI 10.1016/S0895-4356(00)00276-6; Koblin BA, 1998, AIDS, V12, P785, DOI 10.1097/00002030-199807000-00015; MATTHEWS JNS, 1995, STAT MED, V14, P115, DOI 10.1002/sim.4780140204; MATTSON ME, 1985, CONTROL CLIN TRIALS, V6, P156, DOI 10.1016/0197-2456(85)90121-7; Meinert C., 1986, CLIN TRIALS DESIGN C, P149; MOHER D, 1994, JAMA-J AM MED ASSOC, V272, P122, DOI 10.1001/jama.272.2.122; NEWELL DJ, 1978, BRIT MED J, V4, P1789; Nichol MB, 1999, ANN PHARMACOTHER, V33, P531, DOI 10.1345/aph.18233; POCOCK SJ, 1987, NEW ENGL J MED, V317, P426, DOI 10.1056/NEJM198708133170706; RUTSTEIN DD, 1970, EXPT HUMAN SUBJECTS, P383; Schron EB, 1997, J AM GERIATR SOC, V45, P934, DOI 10.1111/j.1532-5415.1997.tb02962.x; Schumm LP, 1999, SURGERY, V125, P41, DOI 10.1016/S0039-6060(99)70286-2; SIMES RJ, 1995, AM J CARDIOL, V76, pC122; Sugarman Jeremy, 1998, IRB, V20, P1, DOI 10.2307/3564262; TAYLOR KM, 1984, NEW ENGL J MED, V310, P1363, DOI 10.1056/NEJM198405243102106; Welton AJ, 1999, BRIT MED J, V318, P1114, DOI 10.1136/bmj.318.7191.1114	44	328	336	0	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	2002	288	3					358	362		10.1001/jama.288.3.358	http://dx.doi.org/10.1001/jama.288.3.358			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573AK	12117401				2022-12-28	WOS:000176807000028
J	Dickinson, A; Cant, A				Dickinson, A; Cant, A			Haemopoietic stem-cell transplantation: improving immune reconstitution, avoiding graft-versus-host disease	LANCET			English	Editorial Material							SEVERE COMBINED IMMUNODEFICIENCY; BONE-MARROW-TRANSPLANTATION; ALLOREACTIVE T-CELLS; DEPLETION; IMMUNOTOXIN; FUTURE; BMT		Newcastle Univ, Royal Victoria Infirm, Dept Haematol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Newcastle Gen Hosp, Immuniodeficiency Bone Marrow Transplant Unit, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England	Newcastle University - UK; Newcastle General Hospital	Dickinson, A (corresponding author), Newcastle Univ, Royal Victoria Infirm, Dept Haematol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.	a.m.dickinson@ncl.ac.uk						Andre-Schmutz I, 2001, BLOOD, V98, p390A; CAVAZZANACALVO M, 1990, TRANSPLANTATION, V50, P1, DOI 10.1097/00007890-199007000-00001; Dickinson AM, 1997, BONE MARROW TRANSPL, V19, P323, DOI 10.1038/sj.bmt.1700669; Gennery AR, 2001, CYTOTHERAPY, V3, P221, DOI 10.1080/146532401753174052; Haddad E, 1998, BLOOD, V91, P3646; Ho VT, 2001, BLOOD, V98, P3192, DOI 10.1182/blood.V98.12.3192; Koh MBC, 1999, BONE MARROW TRANSPL, V23, P1071, DOI 10.1038/sj.bmt.1701749; Lowdell MW, 1997, BONE MARROW TRANSPL, V19, P891, DOI 10.1038/sj.bmt.1700756; Lowdell MW, 2000, J CLIN PATHOL, V53, P49, DOI 10.1136/jcp.53.1.49; Montagna D, 1999, BLOOD, V93, P3550, DOI 10.1182/blood.V93.10.3550.410k24_3550_3557; Schnell R, 1998, LEUKEMIA LYMPHOMA, V30, P525, DOI 10.3109/10428199809057565	11	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 13	2002	360	9327					98	99		10.1016/S0140-6736(02)09431-X	http://dx.doi.org/10.1016/S0140-6736(02)09431-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573PB	12126813				2022-12-28	WOS:000176839100002
J	Frenk, J; Gomez-Dantes, O				Frenk, J; Gomez-Dantes, O			Globalisation and the challenges to health systems	BRITISH MEDICAL JOURNAL			English	Article									Minist Hlth, Mexico City 06600, DF, Mexico		Frenk, J (corresponding author), Minist Hlth, Mexico City 06600, DF, Mexico.							[Anonymous], 2001, MACR HLTH INV HLTH E; *AT KEARN INC, 2001, FOREIGN POLICY   JAN; BERLIN I, 2001, LETRAS LIBRES, V3, P105; Berlin Isaiah, 1992, CROOKED TIMBER HUMAN, P1; *BOARD INT HLTH I, 1997, AM VIT INT GLOB HLTH, P1; Chen L.C., 2003, GLOBAL PUBLIC GOODS, DOI [10.1093/0195130529.003.0014, DOI 10.1093/0195130529.003.0014]; DEBRAY R, 2001, NEW PERSPECTIVES Q, V9; EPSTEIN H, 2001, NEW YORK REV BO 0314; Feachem RGA, 2001, BRIT MED J, V323, P504, DOI 10.1136/bmj.323.7311.504; Frenk J, 1997, BRIT MED J, V314, P1404; HAVEL V, 1995, HARVARD GAZETTE 0615, P9; HAWLEY WA, 1987, SCIENCE, V236, P1114, DOI 10.1126/science.3576225; HOBSBAWM E, 1994, AGE EXTREMES HIST WO, P12; Karlen A., 1995, MAN MICROBES DIS PLA; Kaul I., 1999, GLOBAL PUBLIC GOODS; Keating, 1968, CHAKA KING ZULUS; Prescott-Allen R., 2001, WELLBEING NATIONS CO; United Nations Development Programme, 1999, HUM DEV REP 1999; VALASKAKIS K, 2001, ESTE PAFS, V126, P4; YORK G, 1999, TORONTO GLOBE M 0324, pA1	20	24	25	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 13	2002	325	7355					95	97		10.1136/bmj.325.7355.95	http://dx.doi.org/10.1136/bmj.325.7355.95			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575CU	12114243	Green Published			2022-12-28	WOS:000176929400025
J	Ward, K; Hilton, P				Ward, K; Hilton, P		United Kingdom Ireland Tension Fre	Prospective multicentre randomised trial of tension-free vaginal tape and colposuspension as primary treatment for stress incontinence	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BURCH COLPOSUSPENSION; URINARY-INCONTINENCE; WOMEN; SURGERY; QUESTIONNAIRE	Objective To compare tension-free vaginal tape with colposuspension as primary treatment for stress incontinence. Design Multicentred randomised comparative trial. Setting Gynaecology or urology departments in 14 centres in the United Kingdom and Eire, including university teaching hospitals and district general hospitals. Participants 344 women with urodynamic stress incontinence; 175 randomised to tension-free vaginal tape and 169 to colposuspension Main outcome measures Assessment before treatment and at six months postoperatively with the SF-36, the Bristol female lower urinary tract symptoms questionnaire, the EQ-5D health questionnaire, a one week urinary diary, one hour perineal pad test, cystometry, and, in some centres, urethral profilomeury. Results 23 women in the colposuspension group and 5 in the vaginal tape group withdrew before surgery. No significant difference was found between the groups for cure rates: 115 (66%) women in the vaginal tape group and 97 (57%) in the colposuspension group were objectively cured (95% confidence interval for difference in cure -4.7% to 21.3%). Bladder injury was more common during the vaginal tape procedure; postoperative complications, in particular delayed resumption of micturition, were more common after colposuspension. Operation time, duration of hospital stay, and return to normal activity were all longer after colposuspension than after the vaginal tape procedure. Conclusion Surgery with tension-free vaginal tape is associated with more operative complications than colposuspension, but colposuspension is associated with more postoperative complications and longer recovery. Vaginal tape shows promise for the treatment of urodynamic stress incontinence because of minimal access and rapid recovery times; cure rates at six months were: comparable with colposuspension.	Royal Victoria Infirm, Directorate Womens Serv, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Newcastle Univ, Dept Obstet & Gynaecol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	Hilton, P (corresponding author), Royal Victoria Infirm, Directorate Womens Serv, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.	paul.hilton@ncl.ac.uk	Hilton, Paul/D-9300-2011	Hilton, Paul/0000-0002-2541-5195; Ward, Karen/0000-0002-8626-4810				Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052; Black N, 1997, BRIT MED J, V315, P1493, DOI 10.1136/bmj.315.7121.1493; Black NA, 1996, BRIT J UROL, V78, P497, DOI 10.1046/j.1464-410X.1996.01422.x; Bo K, 1999, BMJ-BRIT MED J, V318, P487, DOI 10.1136/bmj.318.7182.487; BROCKLEHURST JC, 1993, BRIT MED J, V306, P832, DOI 10.1136/bmj.306.6881.832; Carey M., 2000, Neurourology and Urodynamics, V19, P389; ERIKSEN BC, 1990, ACTA OBSTET GYN SCAN, V69, P45, DOI 10.3109/00016349009021038; GALLOWAY NTM, 1987, BRIT J UROL, V60, P122, DOI 10.1111/j.1464-410X.1987.tb04946.x; Haab F, 2001, J UROLOGY, V165, P159, DOI 10.1097/00005392-200101000-00038; HILTON P, 1983, BRIT J OBSTET GYNAEC, V90, P934, DOI 10.1111/j.1471-0528.1983.tb06765.x; HILTON P, 1983, BRIT J OBSTET GYNAEC, V90, P919, DOI 10.1111/j.1471-0528.1983.tb06764.x; Jackson S, 1996, BRIT J UROL, V77, P805, DOI 10.1046/j.1464-410X.1996.00186.x; JARVIS GJ, 1994, BRIT J OBSTET GYNAEC, V101, P371, DOI 10.1111/j.1471-0528.1994.tb11907.x; JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437; Jenkinson C, 1996, UK SF 36 ANAL INTERP; KEANE DP, 1992, BRIT MED J, V305, P808, DOI 10.1136/bmj.305.6857.808; Kobashi KC, 1999, J UROLOGY, V162, P2070, DOI 10.1016/S0022-5347(05)68103-7; LOSE G, 1987, OBSTET GYNECOL, V69, P33; MORAN PA, 2000, BJU INT, V861, P39; Nilsson CG, 1998, ACTA OBSTET GYN SCAN, V77, P34; Ulmsten U, 1998, Int Urogynecol J Pelvic Floor Dysfunct, V9, P210, DOI 10.1007/BF01901606; Ulmsten U, 1996, Int Urogynecol J Pelvic Floor Dysfunct, V7, P81, DOI 10.1007/BF01902378	22	367	371	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 13	2002	325	7355					67	70		10.1136/bmj.325.7355.67	http://dx.doi.org/10.1136/bmj.325.7355.67			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575CU	12114234	Green Published, Bronze			2022-12-28	WOS:000176929400016
J	Gong, YY; Cardwell, K; Hounsa, A; Egal, S; Turner, PC; Hall, AJ; Wild, CP				Gong, YY; Cardwell, K; Hounsa, A; Egal, S; Turner, PC; Hall, AJ; Wild, CP			Dietary aflatoxin exposure and impaired growth in young children from Benin and Togo: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							HEPATOCELLULAR-CARCINOMA		Univ Leeds, Sch Med, Mol Epidemiol Unit, Leeds LS2 9JT, W Yorkshire, England; Int Inst Trop Agr, Cotonou, Benin; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	University of Leeds; University of London; London School of Hygiene & Tropical Medicine	Wild, CP (corresponding author), Univ Leeds, Sch Med, Mol Epidemiol Unit, Leeds LS2 9JT, W Yorkshire, England.		Gong, Yun Yun/L-7094-2016; Turner, Paul C/A-6152-2011; Gong, Yun Yun/C-8412-2018; Wild, Christopher/ABC-6260-2020; Turner, Paul C/B-8131-2013	Gong, Yun Yun/0000-0003-4927-5526; Gong, Yun Yun/0000-0003-4927-5526; Wild, Christopher/0000-0003-0249-8669; 	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES006052] Funding Source: NIH RePORTER; NIEHS NIH HHS [P01 ES006052] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		HALL AJ, 1994, HUMAN HLTH VET AGR S, P233; Montesano R, 1997, JNCI-J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844; Terry MB, 2001, INT J EPIDEMIOL, V30, P95, DOI 10.1093/ije/30.1.95; Turner PC, 2000, TROP MED INT HEALTH, V5, P837, DOI 10.1046/j.1365-3156.2000.00664.x; Wild CP, 2000, MUTAT RES-REV MUTAT, V462, P381, DOI 10.1016/S1383-5742(00)00027-2	5	318	327	1	44	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 6	2002	325	7354					20	21		10.1136/bmj.325.7354.20	http://dx.doi.org/10.1136/bmj.325.7354.20			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573BC	12098724	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000176808600017
J	Kirpichnikov, D; McFarlane, SI; Sowers, JR				Kirpichnikov, D; McFarlane, SI; Sowers, JR			Metformin: An update	ANNALS OF INTERNAL MEDICINE			English	Review							POLYCYSTIC-OVARY-SYNDROME; GLUCOSE-INDUCED ABNORMALITIES; TYPE-2 DIABETES-MELLITUS; TYROSINE KINASE-ACTIVITY; SYSTOLIC BLOOD-PRESSURE; FREE FATTY-ACIDS; INSULIN-RESISTANCE; CARDIOVASCULAR-DISEASE; GLYCEMIC CONTROL; LACTIC-ACIDOSIS	Metformin is an insulin-sensitizing agent with potent antihyperglycemic properties. Its efficacy in reducing hyperglycemia in type 2 diabetes mellitus is similar to that of sulfonylureas, thiazolidinediones, and insulin. Metformin-based combination therapy is often superior to therapy with a single hypoglycemic agent. The anti hyperglycemic properties of metformin are mainly attributed to suppressed hepatic glucose production, especially hepatic gluconeogenesis, and increased peripheral tissue insulin sensitivity. Although the precise mechanism of hypoglycemic action of metformin remains unclear, it probably interrupts mitochondrial oxidative processes in the liver and corrects abnormalities of intracellular calcium metabolism in insulin-sensitive tissues (liver, skeletal muscle, and adipocytes) and cardiovascular tissue.	SUNY Hlth Sci Ctr, Brooklyn, NY 11203 USA; Vet Affairs Med Ctr, Brooklyn, NY USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Sowers, JR (corresponding author), SUNY Hlth Sci Ctr, 450 Clarkson Ave,Box 1205, Brooklyn, NY 11203 USA.	jsowers@netmail.hscbklyn.edu			NHLBI NIH HHS [R01-HL-63904-01] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbasi F, 1997, DIABETES CARE, V20, P1863, DOI 10.2337/diacare.20.12.1863; Adler AI, 2000, BMJ-BRIT MED J, V321, P412, DOI 10.1136/bmj.321.7258.412; [Anonymous], 1998, Diabetes Care, V21, P179; ARGAUD D, 1993, EUR J BIOCHEM, V213, P1341, DOI 10.1111/j.1432-1033.1993.tb17886.x; Bailey CJ, 1996, NEW ENGL J MED, V334, P574, DOI 10.1056/NEJM199602293340906; Bauman WA, 2000, DIABETES CARE, V23, P1227, DOI 10.2337/diacare.23.9.1227; Bhalla RC, 1996, AM J HYPERTENS, V9, P570, DOI 10.1016/0895-7061(95)00356-8; CAMPBELL JD, 1992, J PHYSIOL-LONDON, V447, P67, DOI 10.1113/jphysiol.1992.sp018991; Charles MA, 1998, DIABETES CARE, V21, P1967, DOI 10.2337/diacare.21.11.1967; Chen XL, 1997, J HYPERTENS, V15, P269, DOI 10.1097/00004872-199715030-00008; CLORE JN, 1991, AM J PHYSIOL, V261, pE425, DOI 10.1152/ajpendo.1991.261.4.E425; Cusi K, 1998, DIABETES REV, V6, P89; DAVIDOFF F, 1978, DIABETES, V27, P757, DOI 10.2337/diabetes.27.7.757; DAVIDOFF F, 1972, P NATL ACAD SCI USA, V69, P1957, DOI 10.1073/pnas.69.7.1957; Davidson MB, 1997, AM J MED, V102, P99, DOI 10.1016/S0002-9343(96)00353-1; DeFronzo RA, 1999, ANN INTERN MED, V131, P281, DOI 10.7326/0003-4819-131-4-199908170-00008; DEFRONZO RA, 1995, NEW ENGL J MED, V333, P541, DOI 10.1056/NEJM199508313330902; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; Dominguez LJ, 1996, ENDOCRINOLOGY, V137, P113, DOI 10.1210/en.137.1.113; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; Fiordaliso F, 2000, LAB INVEST, V80, P513, DOI 10.1038/labinvest.3780057; Fonseca V, 2000, JAMA-J AM MED ASSOC, V283, P1695, DOI 10.1001/jama.283.13.1695; Garber AJ, 1997, AM J MED, V103, P491, DOI 10.1016/S0002-9343(97)00254-4; GIUGLIANO D, 1993, EUR J CLIN PHARMACOL, V44, P107, DOI 10.1007/BF00315466; Glueck CJ, 1999, METABOLISM, V48, P511, DOI 10.1016/S0026-0495(99)90113-0; GRANT PJ, 1991, DIABETIC MED, V8, P361, DOI 10.1111/j.1464-5491.1991.tb01610.x; Gress TW, 2000, NEW ENGL J MED, V342, P905, DOI 10.1056/NEJM200003303421301; Haffner SM, 1999, AM J CARDIOL, V84, p11J; HAUPT E, 1991, DIABETES METAB, V17, P224; HERMANN LS, 1994, DIABETES CARE, V17, P1100, DOI 10.2337/diacare.17.10.1100; Howard BV, 1999, AM J CARDIOL, V84, p28J; HUNDAL HS, 1992, ENDOCRINOLOGY, V131, P1165, DOI 10.1210/en.131.3.1165; Hundal RS, 2000, DIABETES, V49, P2063, DOI 10.2337/diabetes.49.12.2063; Ikeda T, 2000, BIOCHEM PHARMACOL, V59, P887, DOI 10.1016/S0006-2952(99)00396-2; Inzucchi SE, 1998, NEW ENGL J MED, V338, P867, DOI 10.1056/NEJM199803263381303; JENG CY, 1994, DIABETES, V43, P1440, DOI 10.2337/diabetes.43.12.1440; Johansen K, 1999, DIABETES CARE, V22, P33, DOI 10.2337/diacare.22.1.33; Katakam PVG, 2000, HYPERTENSION, V35, P108, DOI 10.1161/01.HYP.35.1.108; Kelley DE, 2000, DIABETES, V49, P677, DOI 10.2337/diabetes.49.5.677; Kirpichnikov D, 2001, TRENDS ENDOCRIN MET, V12, P225, DOI 10.1016/S1043-2760(01)00391-5; KLIP A, 1992, ENDOCRINOLOGY, V130, P2535, DOI 10.1210/en.130.5.2535; KOZKA IJ, 1993, DIABETES, V42, P1159, DOI 10.2337/diabetes.42.8.1159; Lalau J. D., 1999, DRUGS S1, V58, P75, DOI DOI 10.2165/00003495-199958001-00013; LALAU JD, 1989, INT J CLIN PHARM TH, V27, P285; Lalau LD, 1999, DRUGS, V58, P55; LANDIN K, 1991, J INTERN MED, V229, P181, DOI 10.1111/j.1365-2796.1991.tb00328.x; Large V, 1999, DIABETES, V48, P1251, DOI 10.2337/diabetes.48.6.1251; Marfella R, 1996, DIABETES CARE, V19, P934, DOI 10.2337/diacare.19.9.934; McFarlane SI, 2001, J CLIN ENDOCR METAB, V86, P713, DOI 10.1210/jc.86.2.713; Misbin RI, 1998, NEW ENGL J MED, V338, P265, DOI 10.1056/NEJM199801223380415; Moghetti P, 2000, J CLIN ENDOCR METAB, V85, P139, DOI 10.1210/jc.85.1.139; Muntzel MS, 1999, HYPERTENSION, V33, P1135, DOI 10.1161/01.HYP.33.5.1135; NAGI DK, 1993, DIABETES CARE, V16, P621, DOI 10.2337/diacare.16.4.621; NESTLER JE, 1991, J CLIN ENDOCR METAB, V72, P83, DOI 10.1210/jcem-72-1-83; Ofenstein JP, 1999, METABOLISM, V48, P1357, DOI 10.1016/S0026-0495(99)90143-9; Olsson J, 2000, DIABETOLOGIA, V43, P558, DOI 10.1007/s001250051343; Pasquali R, 2000, J CLIN ENDOCR METAB, V85, P2767, DOI 10.1210/jc.85.8.2767; Patane G, 2000, DIABETES, V49, P735, DOI 10.2337/diabetes.49.5.735; PERRIELLO G, 1994, DIABETES, V43, P920, DOI 10.2337/diabetes.43.7.920; Petersen JS, 1996, HYPERTENSION, V27, P619, DOI 10.1161/01.HYP.27.3.619; Peuler JD, 1997, METABOLISM, V46, P1199, DOI 10.1016/S0026-0495(97)90217-1; Pugeat M, 1999, DRUGS, V58, P41, DOI 10.2165/00003495-199958001-00010; Radziuk J, 1997, DIABETES, V46, P1406, DOI 10.2337/diabetes.46.9.1406; REAVEN GM, 1992, J CLIN ENDOCR METAB, V74, P1020, DOI 10.1210/jc.74.5.1020; Ren J, 1996, DIABETES, V45, P1822, DOI 10.2337/diabetes.45.12.1822; Ren J, 1997, AM J PHYSIOL-HEART C, V272, pH148, DOI 10.1152/ajpheart.1997.272.1.H148; Ren J, 2000, AM J PHYSIOL-HEART C, V279, pH1708, DOI 10.1152/ajpheart.2000.279.4.H1708; Ren J, 1999, DIABETES, V48, P2059, DOI 10.2337/diabetes.48.10.2059; Riddle Matthew, 2000, American Journal of Medicine, V108, p15S; Robinson AC, 1998, DIABETES CARE, V21, P701, DOI 10.2337/diacare.21.5.701; Ruige JB, 1998, CIRCULATION, V97, P996; Scheen AJ, 1996, CLIN PHARMACOKINET, V30, P359, DOI 10.2165/00003088-199630050-00003; Selby JV, 1999, DIABETES CARE, V22, P38, DOI 10.2337/diacare.22.1.38; SEMPLICINI A, 1993, J HYPERTENS, V11, pS276; Shindler DM, 1996, AM J CARDIOL, V77, P1017, DOI 10.1016/S0002-9149(97)89163-1; Shulman GI, 1999, AM J CARDIOL, V84, p3J; Sindelar DK, 1997, DIABETES, V46, P187, DOI 10.2337/diabetes.46.2.187; SOMOGYI A, 1987, BRIT J CLIN PHARMACO, V23, P545, DOI 10.1111/j.1365-2125.1987.tb03090.x; Sowers James R., 1998, Journal of Basic and Clinical Physiology and Pharmacology, V9, P223; Sowers JR, 2001, HYPERTENSION, V37, P1053, DOI 10.1161/01.HYP.37.4.1053; Sowers JR, 1998, CLIN CHEM, V44, P1821; Steiner G, 2000, DIABETES CARE, V23, pB49; Stith BJ, 1996, ENDOCRINOLOGY, V137, P2990, DOI 10.1210/en.137.7.2990; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; Taskinen MR, 1997, DIABETES METAB REV, V13, P93, DOI 10.1002/(SICI)1099-0895(199706)13:2&lt;93::AID-DMR187&gt;3.0.CO;2-6; Tessier D, 1999, METABOLISM, V48, P897, DOI 10.1016/S0026-0495(99)90226-3; Trovati M, 1998, DIABETOLOGIA, V41, P609, DOI 10.1007/s001250050958; Turner RC, 1999, CARDIOLOGY, V91, P203; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Turner RC, 1999, JAMA-J AM MED ASSOC, V281, P2005, DOI 10.1001/jama.281.21.2005; United Kingdom Prospective Diabetes Study (UKPDS), 1995, BMJ-BRIT MED J, V310, P83, DOI DOI 10.1136/BMJ.310.6972.83; VELAZQUEZ EM, 1994, METABOLISM, V43, P647, DOI 10.1016/0026-0495(94)90209-7; VERMA S, 1994, AM J PHYSIOL, V266, pH714, DOI 10.1152/ajpheart.1994.266.2.H714; Verma S, 2000, J HYPERTENS, V18, P1445, DOI 10.1097/00004872-200018100-00012; Wiernsperger NF, 1999, DRUGS, V58, P31, DOI 10.2165/00003495-199958001-00009; WILCOCK C, 1991, J PHARM PHARMACOL, V43, P120, DOI 10.1111/j.2042-7158.1991.tb06645.x; WILCOCK C, 1994, XENOBIOTICA, V24, P49, DOI 10.3109/00498259409043220; Wright AD, 1998, DIABETES CARE, V21, P87; WU MS, 1990, DIABETES CARE, V13, P1, DOI 10.2337/diacare.13.1.1; Yki-Jarvinen H, 1999, DRUGS, V58, P53, DOI 10.2165/00003495-199958001-00012; Yusuf S, 2000, NEW ENGL J MED, V342, P145	102	763	836	0	103	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 2	2002	137	1					25	33		10.7326/0003-4819-137-1-200207020-00009	http://dx.doi.org/10.7326/0003-4819-137-1-200207020-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569VA	12093242				2022-12-28	WOS:000176622000004
J	Coolen, MJL; Cypionka, H; Sass, AM; Sass, H; Overmann, J				Coolen, MJL; Cypionka, H; Sass, AM; Sass, H; Overmann, J			Ongoing modification of Mediterranean Pleistocene sapropels mediated by prokaryotes	SCIENCE			English	Article							GRADIENT GEL-ELECTROPHORESIS; GREEN NONSULFUR BACTERIA; PURPLE SULFUR BACTERIA; DEEP-SEA SEDIMENTS; 16S RIBOSOMAL-RNA; ORGANIC-MATTER; HYDROLYTIC POTENTIALS; CONTINENTAL-SLOPE; GENE FRAGMENTS; LAKE	Late Pleistocene organic-rich sediments (sapropels) from the eastern Mediterranean Sea harbor unknown, metabolically active chemoorganotrophic prokaryotes. As compared to the carbon-lean intermediate layers, sapropels exhibit elevated cell numbers, increased activities of hydrolytic exoenzymes, and increased anaerobic glucose degradation rates, suggesting that microbial carbon substrates originate from sapropel layers up to 217,000 years old. 16 S ribosomal RNA gene analyses revealed that as-yet-uncultured green nonsulfur bacteria constitute up to 70% of the total microbial biomass. Crenarchaeota constitute a smaller fraction (on average, 16%). A slow but significant turnover of glucose could be detected. Apparently, sapropels are still altered by the metabolic activity of green nonsulfur bacteria and crenarchaeota.	Carl von Ossietzky Univ Oldenburg, Inst Chem Biol & Marine Environm, Paleomicrobiol Grp, D-26111 Oldenburg, Germany; Royal Netherlands Inst Sea Res, Dept Biogeochem & Toxicol, NL-1797 SZ Den Hoorn, Netherlands; Univ Munich, Inst Genet & Microbiol, D-80638 Munich, Germany	Carl von Ossietzky Universitat Oldenburg; Utrecht University; Royal Netherlands Institute for Sea Research (NIOZ); University of Munich	Overmann, J (corresponding author), Carl von Ossietzky Univ Oldenburg, Inst Chem Biol & Marine Environm, Paleomicrobiol Grp, POB 2503, D-26111 Oldenburg, Germany.	j.overmann@LRZ.uni-muenchen.de	Sass, Henrik/B-8817-2009; Coolen, Marco J. L./B-8263-2015; Sass, Andrea Michaela/G-6537-2014	Sass, Henrik/0000-0001-8740-4224; Coolen, Marco J. L./0000-0002-0417-920X; Sass, Andrea Michaela/0000-0001-9396-7648; Overmann, Jorg/0000-0003-3909-7201				Aksu AE, 1999, MAR GEOL, V153, P303, DOI 10.1016/S0025-3227(98)00077-2; [Anonymous], 1978, P OCEAN DRILLING PRO, DOI [DOI 10.2973/DSDP.PROC.42-1.113.1978, DOI 10.2973/DSDP.PROC.42-1.113-1]; Bidle KA, 1999, FEMS MICROBIOL LETT, V177, P101, DOI 10.1016/S0378-1097(99)00297-9; Boetius A, 1998, DEEP-SEA RES PT I, V45, P239, DOI 10.1016/S0967-0637(97)00052-6; Boetius A, 1996, MAR ECOL PROG SER, V140, P239, DOI 10.3354/meps140239; Chandler DP, 1998, MICROBIAL ECOL, V36, P37, DOI 10.1007/s002489900091; CHROST RJ, 1991, BROCK SPR S, P29; Coolen MJL, 1998, APPL ENVIRON MICROB, V64, P4513; Coolen MJL, 2000, APPL ENVIRON MICROB, V66, P2589, DOI 10.1128/AEM.66.6.2589-2598.2000; EMEIS KC, COMMUNICATION; Gich F, 2001, ARCH MICROBIOL, V177, P1, DOI 10.1007/s00203-001-0354-6; Hein I, 2001, APPL ENVIRON MICROB, V67, P3122, DOI 10.1128/AEM.67.7.3122-3126.2001; Hugenholtz P, 1998, J BACTERIOL, V180, P4765, DOI 10.1128/JB.180.18.4765-4774.1998; KEIL RG, 1994, NATURE, V370, P549, DOI 10.1038/370549a0; Lourens LJ, 1996, PALEOCEANOGRAPHY, V11, P391, DOI 10.1029/96PA01125; Maidak BL, 1997, NUCLEIC ACIDS RES, V25, P109, DOI 10.1093/nar/25.1.109; MaymoGatell X, 1997, SCIENCE, V276, P1568, DOI 10.1126/science.276.5318.1568; Norland S., 1993, HDB METHODS AQUATIC, P303, DOI DOI 10.1201/9780203752746-36; Overmann J, 1999, ARCH MICROBIOL, V172, P83, DOI 10.1007/s002030050744; Overmann J, 1996, APPL ENVIRON MICROB, V62, P3251, DOI 10.1128/AEM.62.9.3251-3258.1996; Ovreas L, 1997, APPL ENVIRON MICROB, V63, P3367; Parkes RJ, 2000, HYDROGEOL J, V8, P11, DOI 10.1007/PL00010971; PARKES RJ, 1994, NATURE, V371, P410, DOI 10.1038/371410a0; Petsch ST, 2001, SCIENCE, V292, P1127, DOI 10.1126/science.1058332; POREMBA K, 1995, MAR ECOL PROG SER, V118, P237, DOI 10.3354/meps118237; Ruddy G., 1997, BIOGEOCHEMISTRY INTE, P99; RYAN WBF, 1977, MAR GEOL, V23, P197, DOI 10.1016/0025-3227(77)90089-5; Scholten JCM, 2000, APPL ENVIRON MICROB, V66, P2934, DOI 10.1128/AEM.66.7.2934-2942.2000; Sekiguchi Y, 2001, APPL ENVIRON MICROB, V67, P5740, DOI 10.1128/AEM.67.12.5740-5749.2001; Stahl D.A., 1991, NUCL ACID TECHNIQUES, P205; TENHAVEN HL, 1987, MAR GEOL, V75, P137, DOI 10.1016/0025-3227(87)90100-9; Vetriani C, 1999, APPL ENVIRON MICROB, V65, P4375; Walker NJ, 2002, SCIENCE, V296, P557, DOI 10.1126/science.296.5567.557; WRIGHT RT, 1966, ECOLOGY, V47, P447, DOI 10.2307/1932984; Zengler K, 1999, NATURE, V401, P266, DOI 10.1038/45777	35	120	131	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 28	2002	296	5577					2407	2410		10.1126/science.1071893	http://dx.doi.org/10.1126/science.1071893			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	567CE	12089447				2022-12-28	WOS:000176467200046
J	Nagel, G; Ollig, D; Fuhrmann, M; Kateriya, S; Mustl, AM; Bamberg, E; Hegemann, P				Nagel, G; Ollig, D; Fuhrmann, M; Kateriya, S; Mustl, AM; Bamberg, E; Hegemann, P			Channelrhodopsin-1: A light-gated proton channel in green algae	SCIENCE			English	Article							VOLTAGE-DEPENDENCE; BACTERIORHODOPSIN; RHODOPSIN; CHLAMYDOMONAS; PHOTORECEPTOR; PHOTOTAXIS; PROTEIN	Phototaxis and photophobic responses of green algae are mediated by rhodopsins with microbial-type chromophores. We report a complementary DNA sequence in the green alga Chlamydomonas reinhardtii that encodes a microbial opsin-related protein, which we term Channelopsin-1. The hydrophobic core region of the protein shows homology to the light-activated proton pump bacteriorhodopsin. Expression of Channelopsin-1, or only the hydrophobic core, in Xenopus laevis oocytes in the presence of all-trans retinal produces a light-gated conductance that shows characteristics of a channel selectively permeable for protons. We suggest that Channelrhodopsins are involved in phototaxis of green algae.	Max Planck Inst Biophys, D-60596 Frankfurt, Germany; Univ Regensburg, Inst Biochem, D-93040 Regensburg, Germany; Univ Calabria, Dipartimento Farmacobiol, I-87036 Arcavacata Di Rende, Italy	Max Planck Society; University of Regensburg; University of Calabria	Nagel, G (corresponding author), Max Planck Inst Biophys, Kennedyallee 70, D-60596 Frankfurt, Germany.	nagel@mpibp-frankfurt.mpg.de	Musti, Anna Maria/M-2520-2019	MUSTI, Anna Maria/0000-0003-1443-2739; Kateriya, Suneel/0000-0001-5428-4297; Nagel, Georg/0000-0001-8174-8712				Asamiziu E, 2000, DNA RES, V7, P305, DOI 10.1093/dnares/7.5.305; Bieszke JA, 1999, P NATL ACAD SCI USA, V96, P8034, DOI 10.1073/pnas.96.14.8034; BUTT HJ, 1989, EMBO J, V8, P1657, DOI 10.1002/j.1460-2075.1989.tb03556.x; Ehlenbeck S, 2002, BIOPHYS J, V82, P740, DOI 10.1016/S0006-3495(02)75436-2; FOSTER KW, 1984, NATURE, V311, P756, DOI 10.1038/311756a0; Fuhrmann M, 2001, J CELL SCI, V114, P3857; Geibel S, 2001, BIOPHYS J, V81, P2059, DOI 10.1016/S0006-3495(01)75855-9; HARZ H, 1991, NATURE, V351, P489, DOI 10.1038/351489a0; Holland EM, 1996, BIOPHYS J, V70, P924, DOI 10.1016/S0006-3495(96)79635-2; Kimura Y, 1997, NATURE, V389, P206, DOI 10.1038/38323; Lanyi JK, 2001, CURR OPIN STRUC BIOL, V11, P415, DOI 10.1016/S0959-440X(00)00226-8; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Luecke H, 2001, SCIENCE, V293, P1499, DOI 10.1126/science.1062977; Luecke H, 1998, SCIENCE, V280, P1934, DOI 10.1126/science.280.5371.1934; Nagel G, 1995, FEBS LETT, V377, P263, DOI 10.1016/0014-5793(95)01356-3; Nagel G, 1998, BIOPHYS J, V74, P403, DOI 10.1016/S0006-3495(98)77797-5; Nagel G, 2001, EMBO REP, V2, P249, DOI 10.1093/embo-reports/kve045; Schmies G, 2001, P NATL ACAD SCI USA, V98, P1555, DOI 10.1073/pnas.031562298; SINESHCHEKOV OA, 1990, BIOPHYS J, V57, P33, DOI 10.1016/S0006-3495(90)82504-2; Stewart AK, 2001, AM J PHYSIOL-CELL PH, V281, pC1344, DOI 10.1152/ajpcell.2001.281.4.C1344; UHL R, 1990, BIOPHYS J, V58, P1295, DOI 10.1016/S0006-3495(90)82469-3	22	727	805	8	198	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 28	2002	296	5577					2395	2398		10.1126/science.1072068	http://dx.doi.org/10.1126/science.1072068			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	567CE	12089443				2022-12-28	WOS:000176467200042
J	Haffner, SM				Haffner, SM			Glucose-tolerance testing in acute myocardial infarction	LANCET			English	Editorial Material							CORONARY-HEART-DISEASE; MORTALITY; TRIAL; RISK		Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Haffner, SM (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.							Borch-Johnsen K, 1999, LANCET, V354, P617; FULLER JH, 1980, LANCET, V1, P1373; Gavin JR, 1997, DIABETES CARE, V20, P1183; Haffner SM, 2000, CIRCULATION, V101, P975, DOI 10.1161/01.CIR.101.9.975; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; MALMBERG K, 1995, J AM COLL CARDIOL, V26, P57, DOI 10.1016/0735-1097(95)00126-K; Miettinen H, 1998, DIABETES CARE, V21, P69, DOI 10.2337/diacare.21.1.69; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300	10	11	11	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 22	2002	359	9324					2127	2128		10.1016/S0140-6736(02)09112-2	http://dx.doi.org/10.1016/S0140-6736(02)09112-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566RJ	12090974				2022-12-28	WOS:000176441800003
J	Vulliamy, T; Marrone, A; Dokal, I; Mason, PJ				Vulliamy, T; Marrone, A; Dokal, I; Mason, PJ			Association between aplastic anaemia and mutations in telomerase RNA	LANCET			English	Article								The main cause of aplastic anaemia remains elusive. Germline mutations in the gene encoding the RNA component of telomerase (hTR) have been seen in the autosomal dominant form of dyskeratosis congenita-an Inherited syndrome characterised by aplastic anaemia. By screening the hTR gene, we Identified mutations in two of 17 patients with Idiopathic aplastic anaemia, three of 27 patients with constitutional aplastic anaemia, but In none of 214 normal controls (p<0.0001). Furthermore, patients with hTR mutations had significantly shorter telomeres than age-matched controls (p=0.027). These data indicate that, In a subset of patients with aplastic anaemia, the disorder might be associated with a genetic lesion In the telomere maintenance pathway.	Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Fac Med, Dept Haematol,Div Invest Sci, London W12 0NN, England	Imperial College London	Dokal, I (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Fac Med, Dept Haematol,Div Invest Sci, London W12 0NN, England.		Mason, Philip J/B-1087-2008	Dokal, Inderjeet/0000-0003-4462-4782				Ball SE, 1998, BLOOD, V91, P3582; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; Collins K, 2000, CURR OPIN CELL BIOL, V12, P378, DOI 10.1016/S0955-0674(00)00103-4; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; Young NS., 2000, REV CLIN EXP HEMATOL, V4, P236, DOI [10.1046/j.1468-0734.2000.00017.x, DOI 10.1046/J.1468-0734.2000.00017.X]	5	214	228	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 22	2002	359	9324					2168	2170		10.1016/S0140-6736(02)09087-6	http://dx.doi.org/10.1016/S0140-6736(02)09087-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566RJ	12090986				2022-12-28	WOS:000176441800015
J	Saitou, M; Barton, SC; Surani, MA				Saitou, M; Barton, SC; Surani, MA			A molecular programme for the specification of germ cell fate in mice	NATURE			English	Article							MOUSE EMBRYO; MESODERM FORMATION; GENE-EXPRESSION; STEM-CELLS; HOMOLOG; PROTEIN; GENERATION; FAMILY; TISSUE; LINE	Germ cell fate in mice is induced in proximal epiblast cells by the extra-embryonic ectoderm, and is not acquired through the inheritance of any preformed germ plasm. To determine precisely how germ cells are specified, we performed a genetic screen between single nascent germ cells and their somatic neighbours that share common ancestry. Here we show that fragilis, an interferon-inducible transmembrane protein, marks the onset of germ cell competence, and we propose that through homotypic association, it demarcates germ cells from somatic neighbours. Using single-cell gene expression profiles, we also show that only those cells with the highest expression of fragilis subsequently express stella, a gene that we detected exclusively in lineage-restricted germ cells. The stella positive nascent germ cells exhibit repression of homeobox genes, which may explain their escape from a somatic cell fate and the retention of pluripotency.	Univ Cambridge, Wellcome Trust Canc Res UK Inst Canc & Dev Biol, Cambridge CB2 1QR, England	University of Cambridge	Surani, MA (corresponding author), Univ Cambridge, Wellcome Trust Canc Res UK Inst Canc & Dev Biol, Tennis Court Rd, Cambridge CB2 1QR, England.			Surani, Azim/0000-0002-8640-4318				Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; BARLOW DP, 1984, DIFFERENTIATION, V27, P229, DOI 10.1111/j.1432-0436.1984.tb01433.x; BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; BASTIAN H, 1990, EMBO J, V9, P1839, DOI 10.1002/j.1460-2075.1990.tb08309.x; BRADY G, 1993, METHOD ENZYMOL, V225, P611; CHIQUOINE AD, 1954, ANAT REC, V118, P135, DOI 10.1002/ar.1091180202; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DEBLANDRE GA, 1995, J BIOL CHEM, V270, P23860, DOI 10.1074/jbc.270.40.23860; DOWNS KM, 1993, DEVELOPMENT, V118, P1255; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; EDDY EM, 1975, INT REV CYTOL, V43, P229; EVANS SS, 1993, J IMMUNOL, V150, P736; EVANS SS, 1990, BLOOD, V76, P2583; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; FUJII T, 1994, DEV DYNAM, V199, P73, DOI 10.1002/aja.1001990108; FUJIWARA Y, 1994, P NATL ACAD SCI USA, V91, P12258, DOI 10.1073/pnas.91.25.12258; GINSBURG M, 1990, DEVELOPMENT, V110, P521; GOMPERTS M, 1994, DEVELOPMENT, V120, P135; GURDON JB, 1993, CURR OPIN GENET DEV, V3, P662, DOI 10.1016/0959-437X(93)90104-W; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; HERRMANN BG, 1991, DEVELOPMENT, V113, P913; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; Johnson AD, 2001, DEV BIOL, V234, P402, DOI 10.1006/dbio.2001.0264; JOHNSON AD, 2000, GERM CELLS COLD SPRI, P61; Kita Masakazu, 1994, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V188, P593; Kuramochi-Miyagawa S, 2001, MECH DEVELOP, V108, P121, DOI 10.1016/S0925-4773(01)00499-3; LAWSON KA, 1994, CIBA F SYMP, V182, P68; Lawson KA, 1999, GENE DEV, V13, P424, DOI 10.1101/gad.13.4.424; MACGREGOR GR, 1995, DEVELOPMENT, V121, P1487; McLaren A, 1999, GENE DEV, V13, P373, DOI 10.1101/gad.13.4.373; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Pesce M, 1998, BIOESSAYS, V20, P722, DOI 10.1002/(SICI)1521-1878(199809)20:9&lt;722::AID-BIES5&gt;3.0.CO;2-I; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; Saitou M, 1998, J CELL BIOL, V141, P397, DOI 10.1083/jcb.141.2.397; Sato M, 2002, MECH DEVELOP, V113, P91, DOI 10.1016/S0925-4773(02)00002-3; Seydoux G, 1999, DEVELOPMENT, V126, P3275; Sutasurya L. A., 1979, PRIMORDIAL GERM CELL; Tam PPL, 1996, DEV BIOL, V178, P124, DOI 10.1006/dbio.1996.0203; Tanabe Y, 1998, CELL, V95, P67, DOI 10.1016/S0092-8674(00)81783-3; Toyooka Y, 2000, MECH DEVELOP, V93, P139, DOI 10.1016/S0925-4773(00)00283-5; Weismann A., 1892, KEIMPLASMA THEORIE V; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; Wylie C, 1999, CELL, V96, P165, DOI 10.1016/S0092-8674(00)80557-7; Yeom YI, 1996, DEVELOPMENT, V122, P881; Ying Y, 2000, MOL ENDOCRINOL, V14, P1053, DOI 10.1210/me.14.7.1053; Ying Y, 2001, DEV BIOL, V232, P484, DOI 10.1006/dbio.2001.0173; Ying Y, 2001, P NATL ACAD SCI USA, V98, P7858, DOI 10.1073/pnas.151242798; Yoshimizu T, 2001, DEVELOPMENT, V128, P481	50	645	694	1	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 18	2002	418	6895					293	300		10.1038/nature00927	http://dx.doi.org/10.1038/nature00927			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574BF	12124616				2022-12-28	WOS:000176868000034
J	Lynn, J; Nolan, K; Kabcenell, A; Weissman, D; Milne, C; Berwick, DM				Lynn, J; Nolan, K; Kabcenell, A; Weissman, D; Milne, C; Berwick, DM		End Life Care Consensus Panel	Reforming care for persons near the end of life: The promise of quality improvement	ANNALS OF INTERNAL MEDICINE			English	Article							ADVANCE DIRECTIVES; INSTRUCTIONS; PREFERENCES; MANAGEMENT; SURGERY; TRIAL; DEATH	Most people in developed countries will live with a serious, eventually fatal, chronic condition for months or years before dying; yet, the delivery of health care services has only just recently begun adapting to this reality. Quality improvement methods have been effective in helping clinical services to make substantial changes quickly. Quality improvement requires stating an aim, measuring success, and testing possible improvements. The testing of changes requires a clinical team to Plan, Do, Study, and Act on new insights (the "PDSA cycle"). Repeated PDSA cycles generate deep understanding of complex systems and make sustainable improvements rapidly. This paper discusses a composite case study in a nursing home setting, which builds on experience with multisite collaborative efforts and introduces quality improvement methods in the context of end-of-life care.	Washington Home Ctr Palliat Care Studies, Washington, DC USA; Associates Proc Improvement, Silver Spring, MD USA; Cornell Univ, Ithaca, NY USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA; Inst Healthcare Improvement, Boston, MA USA	Cornell University; Medical College of Wisconsin; Institute for Healthcare Improvement	Lynn, J (corresponding author), Care of Snyder Lois, Amer Soc Internal Med, Ctr Eth & Professionalism, Amer Coll Phys, 190 N Independence Mall W, Philadelphia, PA 19106 USA.							Baer WM, 2000, J AM GERIATR SOC, V48, P879, DOI 10.1111/j.1532-5415.2000.tb06883.x; BAILEY WC, 1990, ARCH INTERN MED, V150, P1664, DOI 10.1001/archinte.150.8.1664; Berwick DM, 1998, ANN INTERN MED, V128, P651, DOI 10.7326/0003-4819-128-8-199804150-00009; *CTR EV CLIN SCI D, 1996, DARTM ATL HLTH CAR; Ditto PH, 2001, ARCH INTERN MED, V161, P421, DOI 10.1001/archinte.161.3.421; EPSTEIN SW, 1979, CAN MED ASSOC J, V120, P813; Hammes BJ, 1998, ARCH INTERN MED, V158, P383, DOI 10.1001/archinte.158.4.383; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; LANGLEY G, 1996, IMPROVEMENT BOOK; LAZOVICH D, 1991, JAMA-J AM MED ASSOC, V266, P3433, DOI 10.1001/jama.266.24.3433; Lynn J, 2000, Jt Comm J Qual Improv, V26, P254; LYNN J, 2000, CTR IMPROVE CARE DYI; OConnor GT, 1996, JAMA-J AM MED ASSOC, V275, P841, DOI 10.1001/jama.275.11.841; Pritchard RS, 1998, J AM GERIATR SOC, V46, P1242, DOI 10.1111/j.1532-5415.1998.tb04540.x; Rich MW, 1999, J CARD FAIL, V5, P64, DOI 10.1016/S1071-9164(99)90026-X; *RW JOHNS FDN, 1998, MON RW JOHNS FDN PUB; SANDMIRE HF, 1994, AM J OBSTET GYNECOL, V170, P1790; SCHNEIDERMAN LJ, 1992, ARCH INTERN MED, V152, P2114, DOI 10.1001/archinte.152.10.2114; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; Teno JM, 1997, J AM GERIATR SOC, V45, P508, DOI 10.1111/j.1532-5415.1997.tb05179.x; 2002, PHYSICIAN ORDERS LIF	21	43	43	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 16	2002	137	2					117	122		10.7326/0003-4819-137-2-200207160-00010	http://dx.doi.org/10.7326/0003-4819-137-2-200207160-00010			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	575VN	12118967				2022-12-28	WOS:000176969300006
J	Pignone, M; Rich, M; Teutsch, SM; Berg, AO; Lohr, KN				Pignone, M; Rich, M; Teutsch, SM; Berg, AO; Lohr, KN			Screening for colorectal cancer in adults at average risk: A summary of the evidence for the US Preventive Services Task Force	ANNALS OF INTERNAL MEDICINE			English	Article							FECAL-OCCULT-BLOOD; BARIUM ENEMA EXAMINATION; FLEXIBLE SIGMOIDOSCOPY; COLONOSCOPIC POLYPECTOMY; DOUBLE-CONTRAST; OUTPATIENT COLONOSCOPY; ASYMPTOMATIC ADULTS; COST-EFFECTIVENESS; COMPLICATIONS; MORTALITY	Purpose: To assess the effectiveness of different colorectal cancer screening tests for adults at average risk. Data Sources: Recent systematic reviews; Guide to Clinical Preventive Services, 2nd edition; and focused searches of MEDLINE from 1966 through September 2001. The authors also conducted hand searches, reviewed bibliographies, and consulted context experts to ensure completeness. Study Selection: When available, the most recent high-quality systematic review was used to identify relevant articles. This review was then supplemented with a MEDLINE search for more recent articles. Data Extraction: One reviewer abstracted information from the final set of studies into evidence tables, and a second reviewer checked the tables for accuracy. Discrepancies were resolved by consensus. Data Synthesis: For average-risk adults older than 50 years of age, evidence from multiple well-conducted randomized trials supported the effectiveness of fecal occult blood testing in reducing colorectal cancer incidence and mortality rates compared with no screening. Data from well-conducted case-control studies supported the effectiveness of sigmoidoscopy and possibly colonoscopy in reducing colon cancer incidence and mortality rates. A nonrandomized, controlled trial examining colorectal cancer mortality rates and randomized trials examining diagnostic yield supported the use of fecal occult blood testing plus sigmoidoscopy. The effectiveness of barium enema is unclear. Data are insufficient to support a definitive determination of the most effective screening strategy. Conclusions: Colorectal cancer screening reduces death from colorectal cancer and can decrease the incidence of disease through removal of adenomatous polyps. Several available screening options seem to be effective, but the single best screening approach cannot be determined because data are insufficient.	Univ N Carolina, Chapel Hill, NC 27515 USA; Res Triangle Inst, Res Triangle Pk, NC 27709 USA; Merck & Co Inc, West Point, PA USA; Univ Washington, Seattle, WA USA	University of North Carolina; University of North Carolina Chapel Hill; Research Triangle Institute; Merck & Company; University of Washington; University of Washington Seattle	Pignone, M (corresponding author), Univ N Carolina, Chapel Hill, NC 27515 USA.		Wilkins, Thad/G-2541-2010	Lohr, Kathleen/0000-0002-3825-0713; Pignone, Michael/0000-0002-6657-7342	PHS HHS [290-97-0011] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Anderson ML, 2000, AM J GASTROENTEROL, V95, P3418, DOI 10.1111/j.1572-0241.2000.03356.x; Atkin WS, 1998, GUT, V42, P560, DOI 10.1136/gut.42.4.560; Balas EA, 2000, ARCH INTERN MED, V160, P301, DOI 10.1001/archinte.160.3.301; Berg AO, 2002, ANN INTERN MED, V137, P129, DOI 10.7326/0003-4819-137-2-200207160-00014; Berry DP, 1997, BRIT J SURG, V84, P1274; Bini EJ, 1999, ARCH INTERN MED, V159, P2022, DOI 10.1001/archinte.159.17.2022; Blakeborough A, 1997, CLIN RADIOL, V52, P142, DOI 10.1016/S0009-9260(97)80108-0; BLOOMFIELD JA, 1981, MED J AUSTRALIA, V1, P631, DOI 10.5694/j.1326-5377.1981.tb135891.x; BRADY AP, 1994, RADIOLOGY, V192, P373, DOI 10.1148/radiology.192.2.8029400; BREKKAN A, 1983, GASTROINTEST RADIOL, V8, P363, DOI 10.1007/BF01948152; BRYNITZ S, 1986, ANN CHIR GYNAECOL FE, V75, P142; DIPRIMA RE, 1988, AM J GASTROENTEROL, V83, P123; Eckardt VF, 1999, GASTROINTEST ENDOSC, V49, P560, DOI 10.1016/S0016-5107(99)70382-2; EISNER MS, 1991, ARCH INTERN MED, V151, P2180, DOI 10.1001/archinte.151.11.2180; Farley DR, 1997, MAYO CLIN PROC, V72, P729, DOI 10.1016/S0025-6196(11)63592-1; Foliente PL, 1996, AM J GASTROENTEROL, V91, P705; Gibbs DH, 1996, DIS COLON RECTUM, V39, P806, DOI 10.1007/BF02054448; Glick S, 1998, AM J ROENTGENOL, V170, P629, DOI 10.2214/ajr.170.3.9490943; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; HERRINTON LJ, 1995, AM J EPIDEMIOL, V142, P961, DOI 10.1093/oxfordjournals.aje.a117744; Imperiale TF, 2000, NEW ENGL J MED, V343, P169, DOI 10.1056/NEJM200007203430302; JOHNSON CD, 1983, AM J ROENTGENOL, V140, P1143, DOI 10.2214/ajr.140.6.1143; Kewenter J, 1996, DIS COLON RECTUM, V39, P676, DOI 10.1007/BF02056949; KRAMER BS, 1993, CANCER, V71, P589; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; Lieberman DA, 2000, NEW ENGL J MED, V343, P162, DOI 10.1056/NEJM200007203430301; LO AY, 1994, J AM COLL SURGEONS, V179, P333; MACRAE FA, 1983, GUT, V24, P376, DOI 10.1136/gut.24.5.376; Mandel JS, 2000, NEW ENGL J MED, V343, P1603, DOI 10.1056/NEJM200011303432203; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; Mandel JS, 1999, J NATL CANCER I, V91, P434, DOI 10.1093/jnci/91.5.434; MULLER AD, 1995, ARCH INTERN MED, V155, P1741, DOI 10.1001/archinte.155.16.1741; MYLLYLA V, 1984, FORTSCHR RONTG NEUEN, V140, P393, DOI 10.1055/s-2008-1052995; NELSON RL, 1982, DIS COLON RECTUM, V25, P305, DOI 10.1007/BF02553602; NEWCOMB PA, 1992, JNCI-J NATL CANCER I, V84, P1572, DOI 10.1093/jnci/84.20.1572; Newcomer MK, 1999, J CLIN GASTROENTEROL, V29, P76, DOI 10.1097/00004836-199907000-00019; NIVATVONGS S, 1988, AM SURGEON, V54, P61; OTT DJ, 1989, SOUTHERN MED J, V82, P197, DOI 10.1097/00007611-198902000-00013; Pignone M, 2002, AHRQ PUBLICATION; Podolsky DK, 2000, NEW ENGL J MED, V343, P207, DOI 10.1056/NEJM200007203430309; Ransohoff DF, 1997, ANN INTERN MED, V126, P811, DOI 10.7326/0003-4819-126-10-199705150-00014; Rasmussen M, 1999, SCAND J GASTROENTERO, V34, P73; Rembacken BJ, 2000, LANCET, V355, P1211, DOI 10.1016/S0140-6736(00)02086-9; Rex DK, 1997, GASTROENTEROLOGY, V112, P17, DOI 10.1016/S0016-5085(97)70213-0; Rex DK, 2000, AM J GASTROENTEROL, V95, P868, DOI 10.1111/j.1572-0241.2000.02059.x; Rex DK, 1997, GASTROENTEROLOGY, V112, P24, DOI 10.1016/S0016-5085(97)70214-2; ROSEN L, 1993, DIS COLON RECTUM, V36, P1126, DOI 10.1007/BF02052261; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; Strom E, 1999, RADIOLOGY, V211, P211, DOI 10.1148/radiology.211.1.r99ap37211; TEEFEY SA, 1983, AM J ROENTGENOL, V141, P1279, DOI 10.2214/ajr.141.6.1279; Thiis-Evensen E, 1999, SCAND J GASTROENTERO, V34, P414; URE T, 1995, SURG ENDOSC-ULTRAS, V9, P505; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; Verne JECW, 1998, BRIT MED J, V317, P182, DOI 10.1136/bmj.317.7152.182; Vernon SW, 1997, JNCI-J NATL CANCER I, V89, P1406, DOI 10.1093/jnci/89.19.1406; Wagner JL, 1996, PREVENTION EARLY DET, P321; WEBB WA, 1985, ANN SURG, V201, P626, DOI 10.1097/00000658-198505000-00012; Wexner SD, 1998, SURG ENDOSC-ULTRAS, V12, P1410, DOI 10.1007/s004649900870; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; WINAWER SJ, 1993, J NATL CANCER I, V85, P1311, DOI 10.1093/jnci/85.16.1311; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; Winawer SJ, 2000, NEW ENGL J MED, V342, P1766, DOI 10.1056/NEJM200006153422401; Woolf SH, 2000, NEW ENGL J MED, V343, P1641, DOI 10.1056/NEJM200011303432211; Yamamoto M, 2000, HEPATO-GASTROENTEROL, V47, P396; Zubarik R, 1999, GASTROINTEST ENDOSC, V50, P322, DOI 10.1053/ge.1999.v50.97111	66	595	612	1	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 16	2002	137	2					132	141		10.7326/0003-4819-137-2-200207160-00015	http://dx.doi.org/10.7326/0003-4819-137-2-200207160-00015			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575VN	12118972				2022-12-28	WOS:000176969300010
J	Boers, M				Boers, M			Seminal pharmaceutical trials: maintaining masking in analysis	LANCET			English	Editorial Material							SELECTIVE COX-2 INHIBITORS; GASTROINTESTINAL TOXICITY; RHEUMATOID-ARTHRITIS; ROFECOXIB; CELECOXIB; EVENTS		VU Univ Med Ctr, Dept Clin Epidemiol & Biostat, NL-1007 MB Amsterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Boers, M (corresponding author), VU Univ Med Ctr, Dept Clin Epidemiol & Biostat, NL-1007 MB Amsterdam, Netherlands.							Boers M, 2001, LANCET, V357, P1222, DOI 10.1016/S0140-6736(00)04451-2; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Davidoff F, 2001, NEW ENGL J MED, V345, P825, DOI 10.1056/NEJMed20010093; Gotzsche PC, 1996, CONTROL CLIN TRIALS, V17, P285, DOI 10.1016/0197-2456(95)00263-4; Horton R, 2001, CONTROL CLIN TRIALS, V22, P593, DOI 10.1016/S0197-2456(01)00175-1; Hrachovec JB, 2001, JAMA-J AM MED ASSOC, V286, P2398, DOI 10.1001/jama.286.19.2398; Juni P, 2002, BRIT MED J, V324, P1287, DOI 10.1136/bmj.324.7349.1287; Konstam MA, 2001, CIRCULATION, V104, P2280, DOI 10.1161/hc4401.100078; MOHER D, 2002, CONSORT STATEMENT RE; Montaner JSG, 2001, LANCET, V358, P1893, DOI 10.1016/S0140-6736(01)06891-X; Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; STRAND V, IN PRESS ARTHRITIS R	13	9	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 13	2002	360	9327					100	101		10.1016/S0140-6736(02)09436-9	http://dx.doi.org/10.1016/S0140-6736(02)09436-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573PB	12126815				2022-12-28	WOS:000176839100004
J	Chodosh, LA				Chodosh, LA			The reciprocal dance between cancer and development	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CYCLIN D1		Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Chodosh, LA (corresponding author), Univ Penn, Sch Med, Philadelphia, PA 19104 USA.							Bowe DB, 2002, ONCOGENE, V21, P291, DOI 10.1038/sj/onc/1205025; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	4	19	19	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 11	2002	347	2					134	136		10.1056/NEJMcibr020712	http://dx.doi.org/10.1056/NEJMcibr020712			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	572HC	12110743				2022-12-28	WOS:000176767300010
J	Drasdo, N; Chiti, Z; Owens, DR; North, RV				Drasdo, N; Chiti, Z; Owens, DR; North, RV			Effect of darkness on inner retinal hypoxia in diabetes	LANCET			English	Article							RETINOPATHY	It has been postulated that diabetic retinopathy might be initiated by hypoxia during the hours of darkness. Oscillatory potentials, which reflect inner retinal function, are reduced in diabetic patients. We tested the effect of oxygen inhalation on the amplitude of these oscillatory potentials after dark adaptation in seven patients with type 2 diabetes and eight controls. We found that the decreased oscillatory potentials induced by dark adaptation in the diabetic patients increased during oxygen inhalation to an amplitude that was not significantly different from that of the controls before oxygen. Oscillatory potentials in the controls were unaffected by oxygen. This finding strengthens support for the suggestion that diabetic patients might benefit from sleeping with night-time illumination.	Cardiff Univ, Dept Optometry & Vis Sci, Cardiff CF10 3NB, S Glam, Wales; Univ Wales Coll Med, Cardiff CF4 4XN, S Glam, Wales	Cardiff University; Cardiff University	Drasdo, N (corresponding author), Cardiff Univ, Dept Optometry & Vis Sci, Redwood Bldg,King Edward VII Ave,Cathays Pk, Cardiff CF10 3NB, S Glam, Wales.			North, Rachel Valerie/0000-0002-6657-5099				AIELLO LP, 1997, INVST OPHTHALMOL VIS, V38, P1847; Arden GB, 2001, BRIT J OPHTHALMOL, V85, P366, DOI 10.1136/bjo.85.3.366; Arden GB, 1998, VISION RES, V38, P1723, DOI 10.1016/S0042-6989(98)00004-2; Drasdo N, 2001, INVEST OPHTH VIS SCI, V42, P1266; RIVA CE, 1983, INVEST OPHTH VIS SCI, V24, P47	5	46	49	1	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 29	2002	359	9325					2251	2253		10.1016/S0140-6736(02)09265-6	http://dx.doi.org/10.1016/S0140-6736(02)09265-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567YJ	12103292				2022-12-28	WOS:000176514500014
J	Norman, G				Norman, G			Research in medical education: three decades of progress	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LEARNING CURRICULA; PERFORMANCE; PHYSICIANS; STUDENT		McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada	McMaster University	Norman, G (corresponding author), McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada.	norman@mcmaster.ca						ALBANESE MA, 1993, ACAD MED, V68, P52, DOI 10.1097/00001888-199301000-00012; BARROWS HS, 1982, CLIN INVEST MED, V5, P49; Colliver JA, 2000, ACAD MED, V75, P259, DOI 10.1097/00001888-200003000-00017; Elstein AS, 1978, MED PROBLEM SOLVING; Enarson C, 2001, MED EDUC, V35, P1050, DOI 10.1046/j.1365-2923.2001.01058.x; EVANS D, 1989, COGNITIVE SCI MED; Fowell S, 2001, MED EDUC, V35, P1006, DOI 10.1046/j.1365-2923.2001.01062.x; HARDEN RM, 1979, MED EDUC, V13, P41; Jolly B, 2001, BRIT MED J, V322, P358; Monette J, 1997, EVAL HEALTH PROF, V20, P115, DOI 10.1177/016327879702000201; Norman GR, 2000, MED EDUC, V34, P721, DOI 10.1046/j.1365-2923.2000.00749.x; Norman GR, 2000, MED TEACH, V22, P141, DOI 10.1080/01421590078553; Norman GR, 1999, COGNITION INSTRUCT, V17, P433, DOI 10.1207/S1532690XCI1704_3; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; PAGE GG, 1995, CMAJ, V15, P1723; RETHANS JJ, 1991, BRIT J GEN PRACT, V41, P97; Reznick RK, 1996, ACAD MED, V71, pS19, DOI 10.1097/00001888-199601000-00031; SCHMIDT HG, 1990, ACAD MED, V65, P611, DOI 10.1097/00001888-199010000-00001; Ten Cate O, 2001, ADV HEALTH SCI EDUC, V6, P81, DOI 10.1023/A:1009874100973; van der Vleuten C.P., 1990, TEACH LEARN MED, V2, P58, DOI [https://doi.org/10.1080/10401339009539432, DOI 10.1080/10401339009539432]; VERNON DTA, 1993, ACAD MED, V68, P550, DOI 10.1097/00001888-199307000-00015; WOODWARD CA, 1985, MED CARE, V23, P1019, DOI 10.1097/00005650-198508000-00009	22	97	104	1	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 29	2002	324	7353					1560	1562		10.1136/bmj.324.7353.1560	http://dx.doi.org/10.1136/bmj.324.7353.1560			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	570WP	12089095	Bronze, Green Published			2022-12-28	WOS:000176683000024
J	Williams, C; Northstone, K; Harrad, RA; Sparrow, JM; Harvey, I				Williams, C; Northstone, K; Harrad, RA; Sparrow, JM; Harvey, I		ALSPAC Study Team	Amblyopia treatment outcomes after screening before or at age 3 years: follow up from randomised trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							VISUAL-ACUITY; CHILDREN; IMPAIRMENT; PREVALENCE; POPULATION; TODDLERS; FUTURE; RISK	Objective To assess the effectiveness of early treatment for amblyopia in children, Design Follow tip of outcomes of treatment for amblyopia in a randomised controlled trial comparing intensive orthoptic screening at 8, 12, 18, 25, 3 1, and 37 months (intensive group) with orthoptic screening at 37 months only (control group). Setting Avon, southwest England, Participants 3490 children who were part of a birth cohort study. Main outcome measures Prevalence of amblyopia and visual acuity of the worse seeing eye at 7.5 years of age. Results Amblyopia at 7.5 years was less prevalent in the intensive group than in the control group (0.6% v 1.8%; P=0.02). Mean Visual acuities in the worse seeing eye were better for children who had been treated for amblyopia in the intensive group than for similar children in the control group (0.15 v 0.26 LogMAR units; P < 0.001). A higher proportion of the children who were treated for amblyopia had been seen in a hospital eye clinic before 3),cars of age in the intensive group than in the control group (48% v 13%; P=0.0002). Conclusions The intensive screening protocol was associated with better acuity in the amblyopic eye and a lower prevalence of amblyopia at 7.5 years of age, in comparison with screening at 37 months only. These data support the hypothesis that early treatment for amblyopia leads to a better outcome than later treatment and may act as a stimulus for research into feasible screening programmes.	Univ Bristol, Div Child Hlth, Bristol BS8 1TQ, Avon, England; Bristol Eye Hosp, Bristol BS1 2LX, Avon, England; Univ E Anglia, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England	University of Bristol; Bristol Eye Hospital; University of East Anglia	Williams, C (corresponding author), Univ Bristol, Div Child Hlth, Bristol BS8 1TQ, Avon, England.	Cathy.Williams@bristol.ac.uk	Northstone, Kate/A-8165-2011	Northstone, Kate/0000-0002-0602-1983	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abrahamsson M, 1999, ACTA OPHTHALMOL SCAN, V77, P653, DOI 10.1034/j.1600-0420.1999.770609.x; ADOH TO, 1994, VISION RES, V34, P555, DOI 10.1016/0042-6989(94)90168-6; ADOH TO, 1992, OPTOMETRY VISION SCI, V69, P427, DOI 10.1097/00006324-199206000-00003; Attebo K, 1998, OPHTHALMOLOGY, V105, P154, DOI 10.1016/S0161-6420(98)91862-0; BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740; Bray LC, 1996, EYE, V10, P714, DOI 10.1038/eye.1996.166; EDWARDS RS, 1993, BR ORTHOPT J, V50, P2; Eibschitz-Tsimhoni M, 2000, J AAPOS, V4, P194, DOI 10.1067/mpa.2000.105274; Fielder AR, 1998, BRIT MED J, V316, P938; Flynn J T, 1999, Trans Am Ophthalmol Soc, V97, P373; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; Harrad R A, 1999, Surv Ophthalmol, V43, P374; Harvey EM, 1999, INVEST OPHTH VIS SCI, V40, P1565; Holmes JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1345; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; INGRAM RM, 1977, BRIT J OPHTHALMOL, V61, P8, DOI 10.1136/bjo.61.1.8; KAY H, 1983, BRIT J OPHTHALMOL, V67, P131, DOI 10.1136/bjo.67.2.131; Kay H, 1984, BRIT ORTHOP J, V41, P77; Kvarnstrom G, 1998, ACTA PAEDIATR, V87, P1173; Moseley MJ, 1997, BRIT J OPHTHALMOL, V81, P956, DOI 10.1136/bjo.81.11.956; Powls A, 1997, ARCH DIS CHILD-FETAL, V76, pF82, DOI 10.1136/fn.76.2.F82; Rahi JS, 2000, INVEST OPHTH VIS SCI, V41, pS296; Rahi JS, 1997, BMJ-BRIT MED J, V315, P1247, DOI 10.1136/bmj.315.7118.1247; SMITH LK, 1995, J PEDIATR OPHTHALMOL, V32, P98; SNOWDON S, 1997, CRD9 U YORK; SNOWDON S, 1997, CRD9; Stager DR, 1990, AM ORTHOPT J, V40, P51, DOI 10.1080/0065955X.1990.11981816; STEWARTBROWN SL, 1988, ARCH DIS CHILD, V63, P356, DOI 10.1136/adc.63.4.356; WIESEL TN, 1982, NATURE, V299, P583, DOI 10.1038/299583a0; Williams C, 2001, Ophthalmic Epidemiol, V8, P279; Williams C, 2000, INVEST OPHTH VIS SCI, V41, P1031; Williams C, 2001, AM J CLIN NUTR, V73, P316; WOODRUFF G, 1994, EYE, V8, P627, DOI 10.1038/eye.1994.157	33	125	132	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 29	2002	324	7353					1549	+		10.1136/bmj.324.7353.1549	http://dx.doi.org/10.1136/bmj.324.7353.1549			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	570WP	12089090	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000176683000016
J	Bewley, S; Cockburn, L				Bewley, S; Cockburn, L			Responding to fear of childbirth	LANCET			English	Editorial Material							REQUEST CESAREAN-SECTION; WOMEN; INTERVENTION; DEPRESSION; PREGNANCY; ANXIETY; RISK		Guys & St Thomas Hosp Trust, Womens Hlth Serv, London SE1 9RT, England; Frimley Pk Hosp, Surrey, England	Guy's & St Thomas' NHS Foundation Trust	Bewley, S (corresponding author), Guys & St Thomas Hosp Trust, Womens Hlth Serv, London SE1 9RT, England.	Susan.Bewley@gstt.sthames.nhs.uk		bewley, susan/0000-0001-8064-652X				Bewley S, 2002, BJOG-INT J OBSTET GY, V109, P593, DOI 10.1111/j.1471-0528.2002.01706.x; Bewley S, 2002, BJOG-INT J OBSTET GY, V109, P597, DOI 10.1016/S1470-0328(02)07106-9; Feinmann J, 2002, LANCET, V359, P774, DOI 10.1016/S0140-6736(02)07918-7; Forman DN, 2000, BRIT J OBSTET GYNAEC, V107, P1210; HODNETT ED, 2000, COCHRANE LIB, V2; Hofberg K, 2000, BRIT J PSYCHIAT, V176, P83, DOI 10.1192/bjp.176.1.83; Hopkins K, 2000, SOC SCI MED, V51, P725, DOI 10.1016/S0277-9536(99)00480-3; KOLDER VEB, 1987, NEW ENGL J MED, V316, P1192, DOI 10.1056/NEJM198705073161905; Kurki T, 2000, OBSTET GYNECOL, V95, P487, DOI 10.1016/S0029-7844(99)00602-X; Paterson-Brown S, 1998, BMJ-BRIT MED J, V317, P462; Roberts CL, 2000, BRIT MED J, V321, P137, DOI 10.1136/bmj.321.7254.137; Ryding EL, 1998, ACTA OBSTET GYN SCAN, V77, P542; Saisto T, 2001, OBSTET GYNECOL, V98, P820, DOI 10.1016/S0029-7844(01)01552-6; Schenker JG, 1999, INT J GYNECOL OBSTET, V64, P317; Sjogren B, 1997, ACTA OBSTET GYN SCAN, V76, P948, DOI 10.3109/00016349709034907; Wagner M, 2000, LANCET, V356, P1677, DOI 10.1016/S0140-6736(00)03169-X; WILLIAMS AS, 1997, WOMEN CHILDBIRTH 20, P198	17	51	53	1	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 22	2002	359	9324					2128	2129		10.1016/S0140-6736(02)09113-4	http://dx.doi.org/10.1016/S0140-6736(02)09113-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566RJ	12090975				2022-12-28	WOS:000176441800004
J	Lu, W; Fadeev, AG; Qi, BH; Smela, E; Mattes, BR; Ding, J; Spinks, GM; Mazurkiewicz, J; Zhou, DZ; Wallace, GG; MacFarlane, DR; Forsyth, SA; Forsyth, M				Lu, W; Fadeev, AG; Qi, BH; Smela, E; Mattes, BR; Ding, J; Spinks, GM; Mazurkiewicz, J; Zhou, DZ; Wallace, GG; MacFarlane, DR; Forsyth, SA; Forsyth, M			Use of ionic liquids for pi-conjugated polymer electrochemical devices	SCIENCE			English	Article							CONDUCTING POLYMERS; POLYANILINE; PERFORMANCE; STABILITY; MECHANISM	pi-Conjugated polymers that are electrochemically cycled in ionic liquids have enhanced lifetimes without failure (up to 1 million cycles) and fast cycle switching speeds (100 ms). We report results for electrochemical mechanical actuators, electrochromic windows, and numeric displays made from three types of pi-conjugated polymers: polyaniline, polypyrrole, and polythiophene. Experiments were performed under ambient conditions, yet the polymers showed negligible loss in electroactivity. These performance advantages were obtained by using environmentally stable, room-temperature ionic liquids composed of 1-butyl-3-methyl imidazolium cations together with anions such as tetrafluoroborate or hexafluorophosphate.	Santa Fe Sci & Technol, Santa Fe, NM 87507 USA; Univ Wollongong, IPRI, Wollongong, NSW, Australia; Monash Univ, Dept Chem, Clayton, Vic 3168, Australia	University of Wollongong; Monash University	Mattes, BR (corresponding author), Santa Fe Sci & Technol, 3216 Richards Lane, Santa Fe, NM 87507 USA.	mattes@sfst.net	Fadeev, Andrei/AAR-3992-2020; Spinks, Geoffrey/T-6363-2019; QI, BAOHUA/AAC-4008-2020; Spinks, Geoffrey/E-5612-2011; MacFarlane, Douglas R/A-9642-2008; Forsyth, Maria/D-8342-2012; Forsyth, Maria/ABH-8102-2020; Smela, Elisabeth/B-9911-2011; Macfarlane, Douglas/AAY-7545-2020; Wallace, Gordon G/H-1123-2011	Spinks, Geoffrey/0000-0003-4656-9473; Spinks, Geoffrey/0000-0003-4656-9473; MacFarlane, Douglas R/0000-0001-5963-9659; Smela, Elisabeth/0000-0003-3921-2265; Wallace, Gordon G/0000-0002-0381-7273; Ding, Jie/0000-0001-5425-555X; Forsyth, Maria/0000-0002-4273-8105				Baughman RH, 1996, SYNTHETIC MET, V78, P339, DOI 10.1016/0379-6779(96)80158-5; Bay L, 2001, J PHYS CHEM B, V105, P8492, DOI 10.1021/jp003872w; BECK F, 1993, J ELECTROANAL CHEM, V351, P169, DOI 10.1016/0022-0728(93)80232-7; Bonhote P, 1996, INORG CHEM, V35, P1168, DOI 10.1021/ic951325x; CARLIN RT, 1994, J ELECTROCHEM SOC, V141, pL73, DOI 10.1149/1.2055041; Chandrasekhar P, 2002, ADV FUNCT MATER, V12, P95, DOI 10.1002/1616-3028(20020201)12:2<95::AID-ADFM95>3.0.CO;2-N; DellaSanta A, 1997, SYNTHETIC MET, V90, P93, DOI 10.1016/S0379-6779(97)81256-8; DeLongchamp D, 2001, ADV MATER, V13, P1455, DOI 10.1002/1521-4095(200110)13:19<1455::AID-ADMA1455>3.0.CO;2-7; Freemantle M, 2000, CHEM ENG NEWS, V78, P37, DOI 10.1021/cen-v078n020.p037; GANDHI MR, 1995, SYNTHETIC MET, V73, P247, DOI 10.1016/0379-6779(95)80022-0; GENIES EM, 1986, J ELECTROANAL CHEM, V200, P127, DOI 10.1016/0022-0728(86)90051-3; Gratzel M, 2001, NATURE, V409, P575, DOI 10.1038/35054655; Huber JE, 1997, P ROY SOC A-MATH PHY, V453, P2185, DOI 10.1098/rspa.1997.0117; KOBAYASHI T, 1984, J ELECTROANAL CHEM, V161, P419, DOI 10.1016/S0022-0728(84)80201-6; KOCH VR, 1995, J ELECTROCHEM SOC, V142, pL116, DOI 10.1149/1.2044332; Lewis T.W., 1997, POLYM PREP-ACS, V38, P520; Lewis TW, 1997, SYNTHETIC MET, V85, P1419, DOI 10.1016/S0379-6779(97)80301-3; LI YF, 1993, SYNTHETIC MET, V53, P149, DOI 10.1016/0379-6779(93)90886-2; LU W, UNPUB; MacFarlane DR, 2001, ADV MATER, V13, P957, DOI 10.1002/1521-4095(200107)13:12/13<957::AID-ADMA957>3.0.CO;2-#; Madden JD, 2000, SYNTHETIC MET, V113, P185, DOI 10.1016/S0379-6779(00)00195-8; Mazzoldi A, 1998, MAT SCI ENG C-BIOMIM, V6, P65, DOI 10.1016/S0928-4931(98)00036-8; Otero TF, 1997, BIOELECTROCH BIOENER, V42, P117, DOI 10.1016/S0302-4598(96)05112-4; Papageorgiou N, 1996, J ELECTROCHEM SOC, V143, P3099, DOI 10.1149/1.1837171; PEI QB, 1993, SOLID STATE IONICS, V60, P161, DOI 10.1016/0167-2738(93)90291-A; Sapp SA, 1998, CHEM MATER, V10, P2101, DOI 10.1021/cm9801237; SCHLENOFF JB, 1992, J ELECTROCHEM SOC, V139, P2397, DOI 10.1149/1.2221238; SKOTHEIM TA, 1998, HDB CONDUCTING POLY; SMELA E, 1995, SCIENCE, V268, P1735, DOI 10.1126/science.268.5218.1735; Suarez PAZ, 1998, J CHIM PHYS PCB, V95, P1626, DOI 10.1051/jcp:1998103; TAKASHIMA W, 1995, SYNTHETIC MET, V71, P2265, DOI 10.1016/0379-6779(94)03252-2; TANG JS, 1991, SYNTHETIC MET, V44, P307, DOI 10.1016/0379-6779(91)91818-U; TANG JS, 1991, SYNTHETIC MET, V45, P1, DOI 10.1016/0379-6779(91)91842-X; TIYAPIBOONCHAIY.C, IN PRESS MACROMOL CH; Walden P, 1914, B ACAD IMPER SCI ST, P405; WILKES JS, 1982, INORG CHEM, V21, P1263, DOI 10.1021/ic00133a078; WILKES JS, 1992, J CHEM SOC CHEM COMM, P965, DOI 10.1039/c39920000965	37	1066	1109	8	610	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	2002	297	5583					983	987		10.1126/science.1072651	http://dx.doi.org/10.1126/science.1072651			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	581ZN	12098704				2022-12-28	WOS:000177325400036
J	Jorgensen, P; Nishikawa, JL; Breitkreutz, BJ; Tyers, M				Jorgensen, P; Nishikawa, JL; Breitkreutz, BJ; Tyers, M			Systematic identification of pathways that couple cell growth and division in yeast	SCIENCE			English	Article							LHERMITTE-DUCLOS-DISEASE; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-CHARACTERIZATION; RETINOBLASTOMA PROTEIN; DELETION MUTANTS; GENETIC-ANALYSIS; RNA-POLYMERASE; SIZE-CONTROL; SOMA SIZE; CYCLE	Size homeostasis in budding yeast requires that cells grow to a critical size before commitment to division in the late prereplicative growth phase of the cell cycle, an event termed Start. We determined cell size distributions for the complete set of similar to6000 Saccharomyces cerevisiae gene deletion strains and identified similar to500 abnormally small (whi) or large (lge) mutants. Genetic analysis revealed a complex network of newly found factors that govern critical cell size at Start, the most potent of which were Sfp1, Sch9, Cdh1, Prs3, and Whi5. Ribosome biogenesis is intimately linked to cell size through Sfp1, a transcription factor that controls the expression of at least 60 genes implicated in ribosome assembly. Cell growth and division appear to be coupled by multiple conserved mechanisms.	Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, Toronto, ON M5G 1X5, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Tyers, M (corresponding author), Univ Toronto, Dept Med Genet & Microbiol, 100 Coll St, Toronto, ON M5S 1A8, Canada.		Tyers, Michael/ABE-3194-2021					Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Bassler J, 2001, MOL CELL, V8, P517, DOI 10.1016/S1097-2765(01)00342-2; Binley KM, 1999, YEAST, V15, P1459, DOI 10.1002/(SICI)1097-0061(199910)15:14<1459::AID-YEA472>3.0.CO;2-A; Breitkreutz BJ, 2001, GENOME BIOL, V2; Conlon IJ, 2001, NAT CELL BIOL, V3, P918, DOI 10.1038/ncb1001-918; CROSS FR, 1995, CURR OPIN CELL BIOL, V7, P790, DOI 10.1016/0955-0674(95)80062-X; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DICOMO CJ, 1995, MOL CELL BIOL, V15, P1835; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fabrizio P, 2001, SCIENCE, V292, P288, DOI 10.1126/science.1059497; Fatica A, 2002, MOL CELL, V9, P341, DOI 10.1016/S1097-2765(02)00458-6; Gari E, 2001, GENE DEV, V15, P2803; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Harnpicharnchai P, 2001, MOL CELL, V8, P505, DOI 10.1016/S1097-2765(01)00344-6; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hughes JD, 2000, J MOL BIOL, V296, P1205, DOI 10.1006/jmbi.2000.3519; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; JOHNSTON GC, 1979, J BACTERIOL, V137, P1; KILLANDER D, 1965, EXP CELL RES, V40, P12, DOI 10.1016/0014-4827(65)90285-5; Kozma SC, 2002, BIOESSAYS, V24, P65, DOI 10.1002/bies.10031; Kwon CH, 2001, NAT GENET, V29, P404, DOI 10.1038/ng781; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; MELESE T, 1995, CURR OPIN CELL BIOL, V7, P319, DOI 10.1016/0955-0674(95)80085-9; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; MORTIMER RK, 1958, RADIAT RES, V9, P312, DOI 10.2307/3570795; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; Nash RS, 2001, GENETICS, V157, P1469; Neufeld TP, 1998, CURR OPIN CELL BIOL, V10, P784, DOI 10.1016/S0955-0674(98)80122-1; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; Peters JM, 1998, CURR OPIN CELL BIOL, V10, P759, DOI 10.1016/S0955-0674(98)80119-1; Polymenis M, 1999, CURR OPIN GENET DEV, V9, P76, DOI 10.1016/S0959-437X(99)80011-2; Sasaki T, 2000, MOL CELL BIOL, V20, P7971, DOI 10.1128/MCB.20.21.7971-7979.2000; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; SMID A, 1995, J BIOL CHEM, V270, P13534, DOI 10.1074/jbc.270.22.13534; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; SUDBERY PE, 1980, NATURE, V288, P401, DOI 10.1038/288401a0; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; TYSON CB, 1979, J BACTERIOL, V138, P92, DOI 10.1128/JB.138.1.92-98.1979; Umen JG, 2001, GENE DEV, V15, P1652, DOI 10.1101/gad.892101; Wade C, 2001, MOL CELL BIOL, V21, P8638, DOI 10.1128/MCB.21.24.8638-8650.2001; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; White RJ, 1997, TRENDS BIOCHEM SCI, V22, P77, DOI 10.1016/S0968-0004(96)10067-0; Wijnen H, 1999, GENETICS, V153, P1131; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Xu ZH, 1998, GENETICS, V150, P1419; YEN A, 1975, EXP CELL RES, V95, P295, DOI 10.1016/0014-4827(75)90554-6	49	588	596	0	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 19	2002	297	5580					395	400		10.1126/science.1070850	http://dx.doi.org/10.1126/science.1070850			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574LV	12089449				2022-12-28	WOS:000176892600050
J	Lin, SJ; Kaeberlein, M; Andalis, AA; Sturtz, LA; Defossez, PA; Culotta, VC; Fink, GR; Guarente, L				Lin, SJ; Kaeberlein, M; Andalis, AA; Sturtz, LA; Defossez, PA; Culotta, VC; Fink, GR; Guarente, L			Calorie restriction extends Saccharomyces cerevisiae lifespan by increasing respiration	NATURE			English	Article							SUPEROXIDE-DISMUTASE; PROTEIN SIR2; METABOLISM; EXTENSION; LONGEVITY; OVEREXPRESSION; CATALASE; STRESS; NAD	Calorie restriction (CR) extends lifespan in a wide spectrum of organisms and is the only regimen known to lengthen the lifespan of mammals(1-4). We established a model of CR in budding yeast Saccharomyces cerevisiae. In this system, lifespan can be extended by limiting glucose or by reducing the activity of the glucose-sensing cyclic-AMP-dependent kinase (PKA)(5). Lifespan extension in a mutant with reduced PKA activity requires Sir2 and NAD (nicotinamide adenine dinucleotide)(5). In this study we explore how CR activates Sir2 to extend lifespan. Here we show that the shunting of carbon metabolism toward the mitochondrial tricarboxylic acid cycle and the concomitant increase in respiration play a central part in this process. We discuss how this metabolic strategy may apply to CR in animals.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute; Johns Hopkins University	Guarente, L (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	leng@mit.edu		Defossez, Pierre-Antoine/0000-0002-6463-9263; Kaeberlein, Matt/0000-0002-1311-3421				Bakker BM, 2001, FEMS MICROBIOL REV, V25, P15, DOI 10.1016/S0168-6445(00)00039-5; Blom J, 2000, APPL ENVIRON MICROB, V66, P1970, DOI 10.1128/AEM.66.5.1970-1973.2000; DEWINDE JH, 1993, PROG NUCLEIC ACID RE, V46, P51, DOI 10.1016/S0079-6603(08)61018-1; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fabrizio P, 2001, SCIENCE, V292, P288, DOI 10.1126/science.1059497; Feng JL, 2001, DEV CELL, V1, P633, DOI 10.1016/S1534-5807(01)00071-5; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; Guarente L, 2000, GENE DEV, V14, P1021; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hegde P, 2000, BIOTECHNIQUES, V29, P548, DOI 10.2144/00293bi01; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Pronk JT, 1996, YEAST, V12, P1607, DOI 10.1002/(SICI)1097-0061(199612)12:16<1607::AID-YEA70>3.0.CO;2-4; Roth GS, 1999, J AM GERIATR SOC, V47, P896, DOI 10.1111/j.1532-5415.1999.tb03851.x; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; STRYER I, 1995, BIOCHEMISTRY; Taub J, 1999, NATURE, V399, P162, DOI 10.1038/20208; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; WEINDRUCH W, 1998, RETARDATION AGING DI; YU BP, 1994, MODULATION AGING PRO	28	811	847	4	103	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 18	2002	418	6895					344	348		10.1038/nature00829	http://dx.doi.org/10.1038/nature00829			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574BF	12124627				2022-12-28	WOS:000176868000047
J	Maisel, AS; Krishnaswamy, P; Nowak, RM; McCord, J; Hollander, JE; Duc, P; Omland, T; Storrow, AB; Abraham, WT; Wu, AHB; Clopton, P; Steg, PG; Westheim, A; Knudsen, CW; Perez, A; Kazanegra, R; Herrmann, HC; McCullough, PA				Maisel, AS; Krishnaswamy, P; Nowak, RM; McCord, J; Hollander, JE; Duc, P; Omland, T; Storrow, AB; Abraham, WT; Wu, AHB; Clopton, P; Steg, PG; Westheim, A; Knudsen, CW; Perez, A; Kazanegra, R; Herrmann, HC; McCullough, PA		Breathing Not Properly Multination	Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	51st Annual Scientific Session of the American-College-of-Cardiology	MAR 17-20, 2002	ATLANTA, GEORGIA	Amer Coll Cardiol			LEFT-VENTRICULAR DYSFUNCTION; SEQUENCE-ANALYSIS; UNITED-STATES; CARE; ECHOCARDIOGRAPHY; UTILITY; PROGNOSIS; COMMUNITY; PRECURSOR; INDICATOR	Background B-type natriuretic peptide is released from the cardiac ventricles in response to increased wall tension. Methods We conducted a prospective study of 1586 patients who came to the emergency department with acute dyspnea and whose B-type natriuretic peptide was measured with a bedside assay. The clinical diagnosis of congestive heart failure was adjudicated by two independent cardiologists, who were blinded to the results of the B-type natriuretic peptide assay. Results The final diagnosis was dyspnea due to congestive heart failure in 744 patients (47 percent), dyspnea due to noncardiac causes in 72 patients with a history of left ventricular dysfunction (5 percent), and no finding of congestive heart failure in 770 patients (49 percent). B-type natriuretic peptide levels by themselves were more accurate than any historical or physical findings or laboratory values in identifying congestive heart failure as the cause of dyspnea. The diagnostic accuracy of B-type natriuretic peptide at a cutoff of 100 pg per milliliter was 83.4 percent. The negative predictive value of B-type natriuretic peptide at levels of less than 50 pg per milliliter was 96 percent. In multiple logistic-regression analysis, measurements of B-type natriuretic peptide added significant independent predictive power to other clinical variables in models predicting which patients had congestive heart failure. Conclusions Used in conjunction with other clinical information, rapid measurement of B-type natriuretic peptide is useful in establishing or excluding the diagnosis of congestive heart failure in patients with acute dyspnea.	Univ Calif San Diego, Vet Affairs Med Ctr, La Jolla, CA 92161 USA; Henry Ford Hosp, Detroit, MI 48202 USA; Univ Penn, Philadelphia, PA 19104 USA; Hop Bichat, F-75877 Paris, France; Ulleval Univ Hosp, Oslo, Norway; Univ Cincinnati, Coll Med, Cincinnati, OH USA; Univ Kentucky, Coll Med, Lexington, KY USA; Hartford Hosp, Hartford, CT 06115 USA; Univ Missouri, Truman Med Ctr, Sch Med, Kansas City, MO 64108 USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Henry Ford Health System; Henry Ford Hospital; University of Pennsylvania; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; University of Oslo; University System of Ohio; University of Cincinnati; University of Kentucky; Hartford Hospital; University of Missouri System; University of Missouri Kansas City	Maisel, AS (corresponding author), Univ Calif San Diego, Vet Affairs Med Ctr, 3350 La Jolla Village Dr, La Jolla, CA 92161 USA.		STEG, Philippe Gabriel/Z-1567-2019; Ulatan, Jeffrey/AAM-5560-2020	Ulatan, Jeffrey/0000-0002-3756-0568; Hollander, Judd/0000-0002-1318-2785; STEG, Philippe Gabriel/0000-0001-6896-2941				Bales AC, 1997, POSTGRAD MED, V101, P44, DOI 10.3810/pgm.1997.01.141; Cheng V, 2001, J AM COLL CARDIOL, V37, P386, DOI 10.1016/S0735-1097(00)01157-8; Clerico A, 1998, J ENDOCRINOL INVEST, V21, P170, DOI 10.1007/BF03347297; COHN JN, 1993, CIRCULATION, V87, P5; Cowie MR, 1997, LANCET, V350, P1349, DOI 10.1016/S0140-6736(97)06031-5; Dao Q, 2001, J AM COLL CARDIOL, V37, P379, DOI 10.1016/S0735-1097(00)01156-6; Davie AP, 1996, BRIT MED J, V312, P222; DAVIS M, 1994, LANCET, V343, P440, DOI 10.1016/S0140-6736(94)92690-5; de Lemos JA, 2001, NEW ENGL J MED, V345, P1014, DOI 10.1056/NEJMoa011053; DEVEREUX RB, 1987, HYPERTENSION, V9, P97; FAHEY MT, 1995, AM J EPIDEMIOL, V141, P680, DOI 10.1093/oxfordjournals.aje.a117485; Harrison A, 2002, ANN EMERG MED, V39, P131, DOI 10.1067/mem.2002.121483; Jacobsen SJ, 1996, ARCH INTERN MED, V156, P2462, DOI 10.1001/archinte.156.21.2462; KOJIMA M, 1989, BIOCHEM BIOPH RES CO, V159, P1420, DOI 10.1016/0006-291X(89)92268-7; Krishnaswamy P, 2001, AM J MED, V111, P274, DOI 10.1016/S0002-9343(01)00841-5; Luchner A, 1998, AM J PHYSIOL-HEART C, V274, pH1684, DOI 10.1152/ajpheart.1998.274.5.H1684; Maeda K, 1998, AM HEART J, V135, P825, DOI 10.1016/S0002-8703(98)70041-9; Mair J, 2001, CLIN CHEM LAB MED, V39, P571, DOI 10.1515/CCLM.2001.093; Maisel AS, 2001, AM HEART J, V141, P367, DOI 10.1067/mhj.2001.113215; Morrison LK, 2002, J AM COLL CARDIOL, V39, P202, DOI 10.1016/S0735-1097(01)01744-2; NAKAGAWA O, 1995, J CLIN INVEST, V96, P1280, DOI 10.1172/JCI118162; OCONNELL JB, 1994, J HEART LUNG TRANSPL, V13, pS107; Omland T, 1996, CIRCULATION, V93, P1963, DOI 10.1161/01.CIR.93.11.1963; Packer M, 1999, AM J CARDIOL, V83, p1A; Rame JE, 2001, AM HEART J, V142, P714, DOI 10.1067/mhj.2001.118473; REMES J, 1991, EUR HEART J, V12, P315, DOI 10.1093/oxfordjournals.eurheartj.a059896; Remme WJ, 2001, EUR HEART J, V22, P1527, DOI 10.1053/euhj.2001.2783; Remme WJ, 2001, EUR HEART J, V22, P2217; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4; Sodian R, 2001, J AM COLL CARDIOL, V38, P1942, DOI 10.1016/S0735-1097(01)01677-1; STEVENSON LW, 1989, JAMA-J AM MED ASSOC, V261, P884, DOI 10.1001/jama.261.6.884; SUDOH T, 1989, BIOCHEM BIOPH RES CO, V159, P1427, DOI 10.1016/0006-291X(89)92269-9; SWETS JA, 1991, MED DECIS MAKING, V11, P9, DOI 10.1177/0272989X9101100102; Tsutamoto T, 1997, CIRCULATION, V96, P509; WHEELDON NM, 1993, Q J MED, V86, P17; YASUE H, 1994, CIRCULATION, V90, P195, DOI 10.1161/01.CIR.90.1.195	36	2359	2556	5	86	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 18	2002	347	3					161	167		10.1056/NEJMoa020233	http://dx.doi.org/10.1056/NEJMoa020233			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	574BR	12124404	Bronze			2022-12-28	WOS:000176869000002
J	Berg, AO; Allan, JD; Frame, PS; Homer, CJ; Johnson, MS; Klein, JD; Lieu, TA; Mulrow, CD; Orleans, CT; Peipert, JF; Pender, NJ; Siu, AL; Teutsch, SM; Westhoff, C; Woolf, SH				Berg, AO; Allan, JD; Frame, PS; Homer, CJ; Johnson, MS; Klein, JD; Lieu, TA; Mulrow, CD; Orleans, CT; Peipert, JF; Pender, NJ; Siu, AL; Teutsch, SM; Westhoff, C; Woolf, SH		US Preventive Serv Task Force	Screening for colorectal cancer: Recommendation and rationale	ANNALS OF INTERNAL MEDICINE			English	Article								This statement summarizes the current U.S. Preventive Services Task Force (USPSTF) recommendation on screening for colorectal cancer and the supporting scientific evidence and updates the 1995 recommendations contained in the Guide to Clinical Preventive Services, 2nd edition. At that time, the USPSTF recommended screening for colorectal cancer with annual fecal occult blood testing, periodic sigmoidoscopy, or the combination of fecal occult blood testing and sigmoidoscopy but concluded that the evidence was insufficient to recommend for or against colonoscopy or barium enema. The complete USPSTF recommendation and rationale statement on this topic, which includes a brief review of the supporting evidence, is available through the USPSTF Web site (www.preventiveservices.ahrq.gov), the National Guideline Clearing-house (www.guideline.gov), and in print through the Agency for Healthcare Research and Quality Publications Clearinghouse (telephone, 800-358-9295; e-mail, ahrqpubs@ahrq.gov). The complete information on which this statement is based, including tables and references, is available in the accompanying article in this issue and in the summary of the evidence and systematic evidence review on the Web sites already mentioned.			Berg, AO (corresponding author), US Prevent Serv Task Force, Agcy Healthcare Res & Qual, Rockville, MD USA.							*AM AC FAM PHYS, 2001, SUMM POL REC PER HLT; *AM COLL OBST GYN, 2000, ACOG COMM OP, V246; Byers T, 1997, CA-CANCER J CLIN, V47, P154, DOI 10.3322/canjclin.47.3.154; Colorectal Cancer Screening, 2001, CMAJ, V165, P206; Goldstein MM, 1998, J AM COLL SURGEONS, V186, P63, DOI 10.1016/S1072-7515(97)00150-6; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594	6	484	489	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 16	2002	137	2					129	131		10.7326/0003-4819-137-2-200207160-00014	http://dx.doi.org/10.7326/0003-4819-137-2-200207160-00014			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575VN	12118971				2022-12-28	WOS:000176969300009
J	Ashfield-Watt, PAL; Moat, SJ; Newcombe, RG; McDowell, IFW				Ashfield-Watt, PAL; Moat, SJ; Newcombe, RG; McDowell, IFW			Effect of supplementation with folic-acid on relation between plasma homocysteine, folate, and vitamin B12	LANCET			English	Letter							REDUCTASE		Univ Cambridge, Strangeways Res Lab, EPIC, Cambridge CB1 8RN, England; Univ Wales Coll Med, Cardiovasc Sci Res Grp, Cardiff CF4 4XN, S Glam, Wales; Univ Wales Coll Med, Dept Epidemiol Stat & Publ Hlth, Cardiff CF4 4XN, S Glam, Wales	University of Cambridge; Cardiff University; Cardiff University	Ashfield-Watt, PAL (corresponding author), Univ Cambridge, Strangeways Res Lab, EPIC, Cambridge CB1 8RN, England.		Quinlivan, Eoin/AAJ-1979-2021; Newcombe, Robert G/B-4897-2009	Quinlivan, Eoin/0000-0002-0908-1762; McNulty, Helene/0000-0002-4366-6457; Ashfield-Watt, Pauline/0000-0003-4063-991X; Ward, Mary/0000-0001-6470-1728				ASHFIELDWATT PAL, IN PRESS AM J CLIN N; Harmon DL, 1996, QJM-MON J ASSOC PHYS, V89, P571; Pullin CH, 2001, J AM COLL CARDIOL, V38, P1799, DOI 10.1016/S0735-1097(01)01668-0; Quinlivan EP, 2002, LANCET, V359, P227, DOI 10.1016/S0140-6736(02)07439-1	4	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 13	2002	360	9327					171	172		10.1016/S0140-6736(02)09393-5	http://dx.doi.org/10.1016/S0140-6736(02)09393-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573PB	12126848				2022-12-28	WOS:000176839100036
J	Johnston, S				Johnston, S			All that glitters is not gold	LANCET			English	Editorial Material									Belfast City Hosp, Dept Gastroenterol, Belfast BT9 7AB, Antrim, North Ireland	Belfast City Hospital	Johnston, S (corresponding author), Belfast City Hosp, Dept Gastroenterol, Lisburn Rd, Belfast BT9 7AB, Antrim, North Ireland.								0	0	0	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 13	2002	360	9327					137	137		10.1016/S0140-6736(02)09414-X	http://dx.doi.org/10.1016/S0140-6736(02)09414-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573PB	12126824				2022-12-28	WOS:000176839100013
J	Davison, PA; Hunter, CN; Horton, P				Davison, PA; Hunter, CN; Horton, P			Overexpression of beta-carotene hydroxylase enhances stress tolerance in Arabidopsis	NATURE			English	Article							CHLOROPHYLL FLUORESCENCE; TRANSGENIC PLANTS; BIOSYNTHESIS; PHOTOPROTECTION; ACCUMULATION; ZEAXANTHIN; THALIANA; MUTANTS; PHOTOINHIBITION; METABOLISM	Plant stress caused by extreme environmental conditions is already a principal reason for yield reduction in crops(1). The threat of global environment change makes it increasingly important to generate crop plants that will withstand such conditions. Stress, particularly stress caused by increased sunlight, leads to the production of reactive oxygen species that cause photo-oxidative cell damage(2). Carotenoids, which are present in the membranes of all photosynthetic organisms, help protect against such light-dependent oxidative damage(3). In plants, the xanthophyll cycle (the reversible interconversion of two carotenoids, violaxanthin and zeaxanthin(4)) has a key photoprotective role(5) and is therefore a promising target for genetic engineering to enhance stress tolerance. Here we show that in Arabidopsis thaliana overexpression of the chyB gene that encodes beta-carotene hydroxylase-an enzyme in the zeaxanthin biosynthetic pathway(6)-causes a specific twofold increase in the size of the xanthophyll cycle pool. The plants are more tolerant to conditions of high light and high temperature, as shown by reduced leaf necrosis, reduced production of the stress indicator anthocyanin and reduced lipid peroxidation. Stress protection is probably due to the function of zeaxanthin in preventing oxidative damage of membranes.	Univ Sheffield, Dept Mol Biol & Biotechnol, Robert Hill Inst, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Horton, P (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Robert Hill Inst, Sheffield S10 2TN, S Yorkshire, England.		Horton, Peter/A-3958-2012	Horton, Peter/0000-0002-6095-1460				COGDELL RJ, 1987, BIOCHIM BIOPHYS ACTA, V895, P63, DOI 10.1016/S0304-4173(87)80008-3; Cunningham FX, 1998, ANNU REV PLANT PHYS, V49, P557, DOI 10.1146/annurev.arplant.49.1.557; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; DIXON RA, 1995, PLANT CELL, V7, P1085, DOI 10.1105/tpc.7.7.1085; Havaux M, 1999, P NATL ACAD SCI USA, V96, P8762, DOI 10.1073/pnas.96.15.8762; Havaux M, 1996, PLANT CELL ENVIRON, V19, P1359, DOI 10.1111/j.1365-3040.1996.tb00014.x; Hodges DM, 1999, PLANTA, V207, P604, DOI 10.1007/s004250050524; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; Hurry V, 1997, PLANT PHYSIOL, V113, P639, DOI 10.1104/pp.113.2.639; Khush G., 2001, NOVART FDN SYMP, V236, P11; Laby RJ, 2000, PLANT J, V23, P587, DOI 10.1046/j.1365-313x.2000.00833.x; Li XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131; MISAWA N, 1994, PLANT J, V6, P481, DOI 10.1046/j.1365-313X.1994.6040481.x; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; NOCTOR G, 1991, BIOCHIM BIOPHYS ACTA, V1057, P320, DOI 10.1016/S0005-2728(05)80143-4; Pogson BJ, 1998, P NATL ACAD SCI USA, V95, P13324, DOI 10.1073/pnas.95.22.13324; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Rissler HM, 2001, PHOTOSYNTH RES, V67, P127, DOI 10.1023/A:1010669404183; ROCK CD, 1991, P NATL ACAD SCI USA, V88, P7496, DOI 10.1073/pnas.88.17.7496; Romer S, 2000, NAT BIOTECHNOL, V18, P666, DOI 10.1038/76523; Ruban AV, 1999, J BIOL CHEM, V274, P10458, DOI 10.1074/jbc.274.15.10458; Sandmann G, 2001, TRENDS PLANT SCI, V6, P14, DOI 10.1016/S1360-1385(00)01817-3; Sun ZR, 1996, J BIOL CHEM, V271, P24349, DOI 10.1074/jbc.271.40.24349; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; Verhoeven AS, 2001, PHOTOSYNTH RES, V67, P27, DOI 10.1023/A:1010684327864; Winkel-Shirley B, 2001, PLANT PHYSIOL, V126, P485, DOI 10.1104/pp.126.2.485; Xiang CB, 2001, PLANT PHYSIOL, V126, P564, DOI 10.1104/pp.126.2.564; YAMAMOTO HY, 1962, ARCH BIOCHEM BIOPHYS, V97, P168, DOI 10.1016/0003-9861(62)90060-7; Ye XD, 2000, SCIENCE, V287, P303, DOI 10.1126/science.287.5451.303; Young AJ, 2001, ARCH BIOCHEM BIOPHYS, V385, P20, DOI 10.1006/abbi.2000.2149	30	278	310	4	102	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 11	2002	418	6894					203	206		10.1038/nature00861	http://dx.doi.org/10.1038/nature00861			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571GV	12110893				2022-12-28	WOS:000176710400045
J	Maniatis, T; Tasic, B				Maniatis, T; Tasic, B			Alternative pre-mRNA splicing and proteome expansion in metazoans	NATURE			English	Review							FULL-LENGTH CDNAS; SR PROTEINS; CODING SEQUENCES; MAMMALIAN-CELLS; HUMAN GENOME; HEAVY-CHAIN; RAT-LIVER; EXON; ENHANCER; RECOGNITION	The protein coding sequences of most eukaryotic messenger RNA precursors (pre mRNAs) are interrupted by non-coding sequences called introns. Pre-mRNA splicing is the process by which introns are removed and the protein coding elements assembled into mature mRNAs. Alternative pre-mRNA splicing selectively joins different protein coding elements to form mRNAs that encode proteins with distinct functions, and is therefore an important source of protein diversity. The elaboration of this mechanism may have had a significant role in the expansion of metazoan proteomes during evolution.	Harvard Univ, Dept Cellular & Mol Biol, Cambridge, MA 02138 USA	Harvard University	Maniatis, T (corresponding author), Harvard Univ, Dept Cellular & Mol Biol, Cambridge, MA 02138 USA.							Akopian AN, 1999, FEBS LETT, V445, P177, DOI 10.1016/S0014-5793(99)00126-X; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; Banks RE, 2000, LANCET, V356, P1749, DOI 10.1016/S0140-6736(00)03214-1; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Berke JD, 2001, NEURON, V32, P277, DOI 10.1016/S0896-6273(01)00465-2; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Black DL, 1998, NEURON, V20, P165, DOI 10.1016/S0896-6273(00)80444-4; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; BLUMENTHAL T, 1995, TRENDS GENET, V11, P132, DOI 10.1016/S0168-9525(00)89026-5; Bono H, 2002, NUCLEIC ACIDS RES, V30, P116, DOI 10.1093/nar/30.1.116; Brett D, 2002, NAT GENET, V30, P29, DOI 10.1038/ng803; Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Caudevilla C, 1998, P NATL ACAD SCI USA, V95, P12185, DOI 10.1073/pnas.95.21.12185; Caudevilla C, 2001, FEBS LETT, V507, P269, DOI 10.1016/S0014-5793(01)02957-X; Caudevilla C, 2001, NUCLEIC ACIDS RES, V29, P3108, DOI 10.1093/nar/29.14.3108; Chatterjee TK, 2000, J BIOL CHEM, V275, P29660, DOI 10.1074/jbc.M000330200; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; Cowper AE, 2001, J BIOL CHEM, V276, P48908, DOI 10.1074/jbc.M103967200; Cramer P, 1999, MOL CELL, V4, P251, DOI 10.1016/S1097-2765(00)80372-X; Daly MJ, 2002, CELL, V109, P283, DOI 10.1016/S0092-8674(02)00742-0; Daoud R, 1999, EUR J NEUROSCI, V11, P788, DOI 10.1046/j.1460-9568.1999.00486.x; Davidson E. H., 2001, DEV EVOLUTION; Deutsch M, 1999, NUCLEIC ACIDS RES, V27, P3219, DOI 10.1093/nar/27.15.3219; Dorn R, 2001, P NATL ACAD SCI USA, V98, P9724, DOI 10.1073/pnas.151268698; Dredge BK, 2001, NAT REV NEUROSCI, V2, P43, DOI 10.1038/35049061; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; EUL J, 1995, EMBO J, V14, P3226, DOI 10.1002/j.1460-2075.1995.tb07325.x; Finta C, 2002, J BIOL CHEM, V277, P5882, DOI 10.1074/jbc.M109175200; Frantz SA, 1999, P NATL ACAD SCI USA, V96, P5400, DOI 10.1073/pnas.96.10.5400; Fujieda S, 1996, J IMMUNOL, V157, P3450; Gautheret D, 1998, GENOME RES, V8, P524, DOI 10.1101/gr.8.5.524; Goldstrohm AC, 2001, GENE, V277, P31, DOI 10.1016/S0378-1119(01)00695-3; Grabowski PJ, 2001, PROG NEUROBIOL, V65, P289, DOI 10.1016/S0301-0082(01)00007-7; Graveley BR, 1999, CURR BIOL, V9, pR6, DOI 10.1016/S0960-9822(99)80032-3; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Hastings ML, 2001, CURR OPIN CELL BIOL, V13, P302, DOI 10.1016/S0955-0674(00)00212-X; Hertel KJ, 1998, MOL CELL, V1, P449, DOI 10.1016/S1097-2765(00)80045-3; Hirayama T, 2001, GENES CELLS, V6, P151, DOI 10.1046/j.1365-2443.2001.00403.x; Hofmann Y, 2000, P NATL ACAD SCI USA, V97, P9618, DOI 10.1073/pnas.160181697; Hu GK, 2001, GENOME RES, V11, P1237, DOI 10.1101/gr.165501; Keegan LP, 2001, NAT REV GENET, V2, P869, DOI 10.1038/35098584; KRAWCZAK M, 1992, HUM GENET, V90, P41; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Kristiansen TZ, 2002, TRENDS BIOCHEM SCI, V27, P266, DOI 10.1016/S0968-0004(02)02081-9; Labourier E, 2001, MOL CELL, V8, P363, DOI 10.1016/S1097-2765(01)00311-2; Labrador M, 2001, NATURE, V409, P1000, DOI 10.1038/35059000; Lallena MJ, 2002, CELL, V109, P285, DOI 10.1016/S0092-8674(02)00730-4; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li BL, 1999, J BIOL CHEM, V274, P11060, DOI 10.1074/jbc.274.16.11060; Lisbin MJ, 2001, GENE DEV, V15, P2546, DOI 10.1101/gad.903101; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; Lynch KW, 2000, MOL CELL BIOL, V20, P70, DOI 10.1128/MCB.20.1.70-80.2000; Lynch KW, 1996, GENE DEV, V10, P2089, DOI 10.1101/gad.10.16.2089; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Mayeda A, 1999, MOL CELL BIOL, V19, P1853; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; Missler M, 1998, TRENDS GENET, V14, P20, DOI 10.1016/S0168-9525(97)01324-3; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; Nilsen TW, 2001, TRENDS GENET, V17, P678, DOI 10.1016/S0168-9525(01)02499-4; Page-McCaw PS, 1999, RNA, V5, P1548, DOI 10.1017/S1355838299991938; Perez-Canadillas JM, 2001, CURR OPIN STRUC BIOL, V11, P53, DOI 10.1016/S0959-440X(00)00164-0; Poleev A, 2000, EUR J BIOCHEM, V267, P4002, DOI 10.1046/j.1432-1327.2000.01431.x; PTASHNE M, 2002, GENES SIGNALS; QUELLE DE, 1995, CELL, V83, P993; Reed R, 2000, CURR OPIN CELL BIOL, V12, P340, DOI 10.1016/S0955-0674(00)00097-1; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; Rowen L, 2002, GENOMICS, V79, P587, DOI 10.1006/geno.2002.6734; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Schaal TD, 1999, MOL CELL BIOL, V19, P261; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; Schutt C, 2000, DEVELOPMENT, V127, P667; SHIMIZU A, 1993, FASEB J, V7, P149, DOI 10.1096/fasebj.7.1.7916698; Shoemaker DD, 2001, NATURE, V409, P922, DOI 10.1038/35057141; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Sorek R, 2001, NAT BIOTECHNOL, V19, P196, DOI 10.1038/85613; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Stevens SW, 2002, MOL CELL, V9, P31, DOI 10.1016/S1097-2765(02)00436-7; SULLIVAN PM, 1991, J BIOL CHEM, V266, P143; Sun HZ, 2000, MOL CELL BIOL, V20, P6414, DOI 10.1128/MCB.20.17.6414-6425.2000; Suzuki Y, 2002, NUCLEIC ACIDS RES, V30, P328, DOI 10.1093/nar/30.1.328; Takahara T, 2000, J BIOL CHEM, V275, P38067, DOI 10.1074/jbc.M002010200; ten Dam GB, 2000, J IMMUNOL, V164, P5287, DOI 10.4049/jimmunol.164.10.5287; Toba G, 2002, J CELL SCI, V115, P2413; Valentine CR, 1998, MUTAT RES-REV MUTAT, V411, P87, DOI 10.1016/S1383-5742(98)00010-6; Van Buskirk C, 2002, DEV CELL, V2, P343, DOI 10.1016/S1534-5807(02)00128-4; VELLARD M, 1991, ONCOGENE, V6, P505; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; Wang HY, 2001, MOL CELL, V7, P331, DOI 10.1016/S1097-2765(01)00181-2; Xie JY, 2001, NATURE, V410, P936, DOI 10.1038/35073593; YEAKLY JM, 2002, NAT BIOTECHNOL, V20, P1; ZHOU Z, UNPUB NATURE; Zhu J, 2001, MOL CELL, V8, P1351, DOI 10.1016/S1097-2765(01)00409-9	96	584	614	2	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 11	2002	418	6894					236	243		10.1038/418236a	http://dx.doi.org/10.1038/418236a			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571GV	12110900				2022-12-28	WOS:000176710400052
J	Gaschen, B; Taylor, J; Yusim, K; Foley, B; Gao, F; Lang, D; Novitsky, V; Haynes, B; Hahn, BH; Bhattacharya, T; Korber, B				Gaschen, B; Taylor, J; Yusim, K; Foley, B; Gao, F; Lang, D; Novitsky, V; Haynes, B; Hahn, BH; Bhattacharya, T; Korber, B			AIDS - Diversity considerations in HIV-1 vaccine selection	SCIENCE			English	Review							HUMAN MONOCLONAL-ANTIBODIES; AMINO-ACID SUBSTITUTION; T-LYMPHOCYTE RESPONSES; SUBTYPE-C SEQUENCES; ENVELOPE GLYCOPROTEIN; TYPE-1; NEUTRALIZATION; EVOLUTION; GAG; IDENTIFICATION		Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Duke Univ, AIDS Ctr, Durham, NC 27710 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Univ Alabama Birmingham, Birmingham, AL 35294 USA; Santa Fe Inst, Santa Fe, NM 87501 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; Duke University; Harvard University; Harvard T.H. Chan School of Public Health; University of Alabama System; University of Alabama Birmingham; The Santa Fe Institute	Korber, B (corresponding author), Los Alamos Natl Lab, POB 1663, Los Alamos, NM 87545 USA.	btk@t10.lanl.gov	Foley, Brian T/N-4527-2018; Bhattacharya, Tanmoy/J-8956-2013	Foley, Brian T/0000-0002-1086-0296; Bhattacharya, Tanmoy/0000-0002-1060-652X; Korber, Bette/0000-0002-2026-5757; Hahn, Beatrice/0000-0002-9400-9887	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI085338, R01AI040951, P30AI027767] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 35351, R01 AI 40951, R01 AI 05397, P20 AI 27767, YI AI 1500-01, N01 AI 85338] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agwale SM, 2002, VACCINE, V20, P2131, DOI 10.1016/S0264-410X(02)00059-2; Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124; Barnet SW, 2001, J VIROL, V75, P5526, DOI 10.1128/JVI.75.12.5526-5540.2001; Beekman NJ, 2000, J IMMUNOL, V164, P1898, DOI 10.4049/jimmunol.164.4.1898; Binley JM, 2000, J VIROL, V74, P627, DOI 10.1128/JVI.74.2.627-643.2000; Cao HY, 2000, J INFECT DIS, V182, P1350, DOI 10.1086/315868; Dorrell L, 2001, EUR J IMMUNOL, V31, P1747, DOI 10.1002/1521-4141(200106)31:6<1747::AID-IMMU1747>3.3.CO;2-C; FELSENSTEIN J, 1984, PHYLIP V3 5; Ferrari G, 2001, IMMUNOL LETT, V79, P37, DOI 10.1016/S0165-2478(01)00264-4; Foley B, 2000, AIDS RES HUM RETROV, V16, P1463, DOI 10.1089/088922200750005985; Francis DP, 1998, AIDS RES HUM RETROV, V14, pS325; GAO F, 2002, UNPUB; GOUDSMIT J, 2001, IAVI REP DEC 2000 JA; Goulder PJR, 2000, J VIROL, V74, P5679, DOI 10.1128/JVI.74.12.5679-5690.2000; Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576; GRAHAM BS, 2000, HIV MOL IMMUNOLOGY 2, P20; GROENINK M, 1993, SCIENCE, V260, P1513, DOI 10.1126/science.8502996; GUPTA KS, COMMUNICATION; HAYNES BF, 1995, AIDS RES HUM RETROV, V11, P211, DOI 10.1089/aid.1995.11.211; Kesmir C, 2002, PROTEIN ENG, V15, P287, DOI 10.1093/protein/15.4.287; Korber B, 2000, SCIENCE, V288, P1789, DOI 10.1126/science.288.5472.1789; Korber B, 2001, BRIT MED BULL, V58, P19, DOI 10.1093/bmb/58.1.19; KORBER B, 2000, HIV IMMUNOLOGY SEQUE; Korber BT, 2001, INFEC DIS S, P1; Kuiken C.L., 1999, MOL EVOLUTION HIV; LANGEDIJK JPM, 1995, AIDS RES HUM RETROV, V11, P1153, DOI 10.1089/aid.1995.11.1153; Lee SA, 2001, VACCINE, V20, P563, DOI 10.1016/S0264-410X(01)00334-6; Li A, 1998, J VIROL, V72, P3235, DOI 10.1128/JVI.72.4.3235-3240.1998; Liao HX, 2000, J VIROL, V74, P254, DOI 10.1128/JVI.74.1.254-263.2000; Liitsola K, 1998, AIDS, V12, P1907, DOI 10.1097/00002030-199814000-00023; Mascola JR, 1999, J VIROL, V73, P4009, DOI 10.1128/JVI.73.5.4009-4018.1999; McCutchan FE, 1996, J VIROL, V70, P3331, DOI 10.1128/JVI.70.6.3331-3338.1996; Mokili JLK, 1999, AIDS RES HUM RETROV, V15, P655, DOI 10.1089/088922299310953; Novitsky V, 2001, J VIROL, V75, P9210, DOI 10.1128/JVI.75.19.9210-9228.2001; Novitsky V, 2002, J VIROL, V76, P5435, DOI 10.1128/JVI.76.11.5435-5451.2002; OLSEN GJ, 1994, COMPUT APPL BIOSCI, V10, P41; Rodenburg CM, 2001, AIDS RES HUM RETROV, V17, P161, DOI 10.1089/08892220150217247; Rowland-Jones SL, 1998, J CLIN INVEST, V102, P1758, DOI 10.1172/JCI4314; Saphire EO, 2001, SCIENCE, V293, P1155, DOI 10.1126/science.1061692; Schultz AM, 2001, AIDS, V15, pS147, DOI 10.1097/00002030-200100005-00018; Shankarappa R, 2001, J VIROL, V75, P10479, DOI 10.1128/JVI.75.21.10479-10487.2001; Sharp PM, 1999, BIOL BULL-US, V196, P338, DOI 10.2307/1542965; Stephens EB, 1996, J MED PRIMATOL, V25, P175, DOI 10.1111/j.1600-0684.1996.tb00014.x; van Harmelen J, 2001, AIDS RES HUM RETROV, V17, P1527, DOI 10.1089/08892220152644232; Vidal N, 2000, J VIROL, V74, P10498, DOI 10.1128/JVI.74.22.10498-10507.2000; Walker BD, 2001, NAT IMMUNOL, V2, P473, DOI 10.1038/88656; Xu WD, 2001, J HUMAN VIROL, V4, P55; Yang ZH, 2000, GENETICS, V155, P431; YUSIM K, IN PRESS J VIROL; Zolla-Pazner S, 1999, J VIROL, V73, P4042, DOI 10.1128/JVI.73.5.4042-4051.1999; Zwick MB, 2001, J VIROL, V75, P12198, DOI 10.1128/JVI.75.24.12198-12208.2001	51	636	700	0	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 28	2002	296	5577					2354	2360		10.1126/science.1070441	http://dx.doi.org/10.1126/science.1070441			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	567CE	12089434				2022-12-28	WOS:000176467200030
J	Heber, U				Heber, U			Astronomy: White dwarf mergers and the rebirth of luminous stars	SCIENCE			English	Editorial Material							CORONAE-BOREALIS STARS		Univ Erlangen Nurnberg, Dr REmeis Sternwarte, D-96049 Bamberg, Germany	University of Erlangen Nuremberg	Heber, U (corresponding author), Univ Erlangen Nurnberg, Dr REmeis Sternwarte, Sternwartstr 7, D-96049 Bamberg, Germany.		Heber, Ulrich/W-3956-2019	Heber, Ulrich/0000-0001-7798-6769				Asplund M, 2000, ASTRON ASTROPHYS, V353, P287; Jeffery CS, 2001, MON NOT R ASTRON SOC, V321, P111, DOI 10.1046/j.1365-8711.2001.03992.x; Landau L. D., 1962, CLASSICAL THEORY FIE; Marsh TR, 2000, NEW ASTRON REV, V44, P119, DOI 10.1016/S1387-6473(00)00024-5; Napiwotzki R, 2002, ASTRON ASTROPHYS, V386, P957, DOI 10.1051/0004-6361:20020361; Nelemans G, 2001, ASTRON ASTROPHYS, V365, P491, DOI 10.1051/0004-6361:20000147; SAFFER RA, 1988, ASTROPHYS J, V334, P947, DOI 10.1086/166888; Saio H, 2000, MON NOT R ASTRON SOC, V313, P671, DOI 10.1046/j.1365-8711.2000.03221.x; Saio H, 2002, MON NOT R ASTRON SOC, V333, P121, DOI 10.1046/j.1365-8711.2002.05384.x; Schutz BF, 1999, CLASSICAL QUANT GRAV, V16, pA131, DOI 10.1088/0264-9381/16/12A/307; WEBBINK RF, 1984, ASTROPHYS J, V277, P355, DOI 10.1086/161701	11	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 28	2002	296	5577					2344	2345		10.1126/science.1073695	http://dx.doi.org/10.1126/science.1073695			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	567CE	12089429				2022-12-28	WOS:000176467200025
J	Cooper, JM; Katcher, MS; Orlov, MV				Cooper, JM; Katcher, MS; Orlov, MV			Current concepts - Implantable devices for the treatment of atrial fibrillation	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							QUALITY-OF-LIFE; TERM-FOLLOW-UP; ATRIOVENTRICULAR JUNCTION ABLATION; SICK SINUS SYNDROME; DUAL-SITE; CLINICAL-EXPERIENCE; CATHETER ABLATION; RANDOMIZED-TRIAL; VVIR PACEMAKER; DRUG-THERAPY		VA Boston Healthcare Syst, Div Cardiol, Vet Affairs Med Ctr, W Roxbury, MA 02132 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University; Brigham & Women's Hospital	Katcher, MS (corresponding author), VA Boston Healthcare Syst, Div Cardiol, Vet Affairs Med Ctr, 111A,1400 VFW Pkwy, W Roxbury, MA 02132 USA.							Adler SW, 2001, CIRCULATION, V104, P887, DOI 10.1161/hc3301.094739; ANDERSEN HR, 1994, LANCET, V344, P1523, DOI 10.1016/S0140-6736(94)90347-6; Andersen HR, 1997, LANCET, V350, P1210, DOI 10.1016/S0140-6736(97)03425-9; [Anonymous], 2001, CIRCULATION, V104, P2118; Bailin SJ, 2001, J CARDIOVASC ELECTR, V12, P912, DOI 10.1046/j.1540-8167.2001.00912.x; Benjamin EJ, 1998, CIRCULATION, V98, P946, DOI 10.1161/01.CIR.98.10.946; Best PJM, 1999, PACE, V22, P79, DOI 10.1111/j.1540-8159.1999.tb00303.x; Blommaert D, 2000, J AM COLL CARDIOL, V35, P1411, DOI 10.1016/S0735-1097(00)00608-2; Brignole M, 1998, CIRCULATION, V98, P953, DOI 10.1161/01.CIR.98.10.953; CARLSON MD, 2001, 22 ANN SCI M N AM SO; Clark DM, 1997, J AM COLL CARDIOL, V30, P1039, DOI 10.1016/S0735-1097(97)00254-4; CONNELLY DT, 1993, BRIT HEART J, V69, P250; Connolly SJ, 2000, NEW ENGL J MED, V342, P1385, DOI 10.1056/NEJM200005113421902; COSIO FG, 1983, AM J CARDIOL, V51, P122, DOI 10.1016/S0002-9149(83)80022-8; COUMEL P, 1983, PACE, V6, P552, DOI 10.1111/j.1540-8159.1983.tb05295.x; Daoud EG, 2000, CIRCULATION, V102, P761, DOI 10.1161/01.CIR.102.7.761; Daoud EG, 2000, CIRCULATION, V102, P1407, DOI 10.1161/01.CIR.102.12.1407; Daoud EG, 1996, AM J CARDIOL, V78, P1433, DOI 10.1016/S0002-9149(97)89297-1; Defaye P, 1998, PACE, V21, P250, DOI 10.1111/j.1540-8159.1998.tb01098.x; Delfaut P, 1998, J AM COLL CARDIOL, V32, P1900, DOI 10.1016/S0735-1097(98)00489-6; Dijkman B, 2000, J CARDIOVASC ELECTR, V11, P1196, DOI 10.1046/j.1540-8167.2000.01196.x; Fan K, 2000, CIRCULATION, V102, P755, DOI 10.1161/01.CIR.102.7.755; Fitzpatrick AP, 1996, AM HEART J, V131, P499, DOI 10.1016/S0002-8703(96)90528-1; Friedman PA, 2001, CIRCULATION, V104, P1023, DOI 10.1161/hc3401.095039; FROMER M, 1990, PACE, V13, P890, DOI 10.1111/j.1540-8159.1990.tb02126.x; Funck RC, 2001, PACE, V24, pVIII; Funck RC, 2000, PACE, V23, P1891; Ganz LI, 1997, J CARDIOVASC ELECTR, V8, P1175, DOI 10.1111/j.1540-8167.1997.tb01005.x; Garrigue S, 1998, PACE, V21, P1751, DOI 10.1111/j.1540-8159.1998.tb00275.x; Gerstenfeld EP, 1999, J AM COLL CARDIOL, V33, P1981, DOI 10.1016/S0735-1097(99)00115-1; Gillis AM, 1999, CIRCULATION, V99, P2553, DOI 10.1161/01.CIR.99.19.2553; Gillis AM, 2000, CIRCULATION, V102, P736, DOI 10.1161/01.CIR.102.7.736; Goette A, 1996, CIRCULATION, V94, P2968, DOI 10.1161/01.CIR.94.11.2968; HESSELSON AB, 1992, J AM COLL CARDIOL, V19, P1542, DOI 10.1016/0735-1097(92)90616-U; Israel CW, 2001, J AM COLL CARDIOL, V38, P355, DOI 10.1016/S0735-1097(01)01351-1; Israel CW, 2000, PACE, V23, P1888, DOI 10.1046/j.1460-9592.2000.01581.x; JENSEN SM, 1995, PACE, V18, P1609, DOI 10.1111/j.1540-8159.1995.tb06982.x; Katsivas A, 1998, PACE, V21, P2220, DOI 10.1111/j.1540-8159.1998.tb01156.x; Lamas GA, 1998, NEW ENGL J MED, V338, P1097, DOI 10.1056/NEJM199804163381602; Leclercq JF, 2000, PACE, V23, P2101, DOI 10.1111/j.1540-8159.2000.tb00783.x; Levy T, 2000, INT J CARDIOL, V75, P91, DOI 10.1016/S0167-5273(00)00303-X; Levy T, 2000, CIRCULATION, V102, P1382, DOI 10.1161/01.CIR.102.12.1382; MIDDLEKAUFF HR, 1995, ARCH INTERN MED, V155, P913; MISIER ARR, 1992, J AM COLL CARDIOL, V19, P1531; MURGATROYD FD, 1994, PACE, V17, P1966, DOI 10.1111/j.1540-8159.1994.tb03782.x; *N AM SOC PAC EL, 2001, DUAL CHAMB PAC IND P; NATTEL S, 1994, DRUGS, V48, P345, DOI 10.2165/00003495-199448030-00003; Newman D, 2000, CIRCULATION, V102, P715; Padeletti L, 2001, AM HEART J, V142, P1047, DOI 10.1067/mhj.2001.119373; Papageorgiou P, 1997, CIRCULATION, V96, P1893, DOI 10.1161/01.CIR.96.6.1893; Prakash A, 1998, AM J CARDIOL, V82, P1197, DOI 10.1016/S0002-9149(98)00604-3; Prakash A, 1997, J AM COLL CARDIOL, V29, P1007, DOI 10.1016/S0735-1097(97)00043-0; Prystowsky E N, 1996, Am J Cardiol, V78, P35, DOI 10.1016/S0002-9149(96)00564-4; Roithinger FX, 2001, PACE, V24, P316, DOI 10.1046/j.1460-9592.2001.00316.x; SAKSENA S, 2001, J AM COLL CARDIOL, V38, P598; Satoh T, 1996, J CARDIOVASC ELECTR, V7, P833, DOI 10.1111/j.1540-8167.1996.tb00596.x; Schoels W, 2001, J CARDIOVASC ELECTR, V12, P521, DOI 10.1046/j.1540-8167.2001.00521.x; SGARBOSSA EB, 1993, CIRCULATION, V88, P1045, DOI 10.1161/01.CIR.88.3.1045; Skanes AC, 2001, J AM COLL CARDIOL, V38, P167, DOI 10.1016/S0735-1097(01)01326-2; Spencer WH, 1997, PACE, V20, P2739, DOI 10.1111/j.1540-8159.1997.tb05431.x; STANGL K, 1988, PACE, V11, P1176, DOI 10.1111/j.1540-8159.1988.tb03969.x; STANGL K, 1990, PACE, V13, P2080, DOI 10.1111/j.1540-8159.1990.tb06946.x; Ueng KC, 2001, J CARDIOVASC ELECTR, V12, P303, DOI 10.1046/j.1540-8167.2001.00303.x; Waktare JEP, 2001, EUR HEART J, V22, P333, DOI 10.1053/euhj.2000.2517; Wellens HJJ, 1998, CIRCULATION, V98, P1651, DOI 10.1161/01.CIR.98.16.1651; Wharton JM, 1998, CIRCULATION, V98, P494; WIJFFELS MCEF, 1995, CIRCULATION, V92, P1954, DOI 10.1161/01.CIR.92.7.1954; Wolf PA, 1998, ARCH INTERN MED, V158, P229, DOI 10.1001/archinte.158.3.229; WOOD DL, 1983, MAYO CLIN PROC, V58, P791	69	41	44	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 27	2002	346	26					2062	2068		10.1056/NEJMra012144	http://dx.doi.org/10.1056/NEJMra012144			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566DN	12087143				2022-12-28	WOS:000176411900008
J	Lorincz, AT; Castle, PE; Sherman, ME; Scott, DR; Glass, AG; Wacholder, S; Rush, BB; Gravitt, PE; Schussler, JE; Schiffman, M				Lorincz, AT; Castle, PE; Sherman, ME; Scott, DR; Glass, AG; Wacholder, S; Rush, BB; Gravitt, PE; Schussler, JE; Schiffman, M			Viral load of human papillomavirus and risk of CIN3 or cervical cancer	LANCET			English	Article							INTRAEPITHELIAL NEOPLASIA	Carcinogenic human papillomaviruses (HPV) are thought to be necessary for development of cervical cancer. We assessed whether higher viral loads of such viruses predicted future risk of CIN3 or cancer (CIN3+) in a cohort of 20 810 women followed up for 10 years with cytological screening. We measured the viral load for 13 types of carcinogenic HPV (relative light units normalised to 1 pg/mL HPV 16 positive controls [RLU/PC]) using Hybrid Capture 2 testing of cervicovaginal lavages obtained at enrolment. Results were stratified into four groups (RLU/PC 1 to <10, 10 to <100, 100 to <1000, &GE;1000). Although presence of HPV strongly Increased risk of CIN3+, high viral load did not further predict risk of CIN3+.	Digene Corp, Gaithersburg, MD 20878 USA; NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; Kaiser Permanente, Portland, OR USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA; Informat Management Serv Inc, Silver Spring, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kaiser Permanente; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Information Management Services, Inc.	Lorincz, AT (corresponding author), Digene Corp, 1201 Clopper Rd, Gaithersburg, MD 20878 USA.		Schiffman, Mark/B-9766-2015; Castle, Philip/AAP-6395-2020	Castle, Philip/0000-0003-1082-6554				OSTOR AG, 1993, INT J GYNECOL PATHOL, V12, P186; Schiffman M, 2000, JAMA-J AM MED ASSOC, V283, P87, DOI 10.1001/jama.283.1.87; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958; Scott DR, 2002, CANCER CYTOPATHOL, V96, P14, DOI 10.1002/cncr.10317; Ylitalo N, 2000, LANCET, V355, P2194, DOI 10.1016/S0140-6736(00)02402-8	5	174	212	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 20	2002	360	9328					228	229		10.1016/S0140-6736(02)09463-1	http://dx.doi.org/10.1016/S0140-6736(02)09463-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	576DX	12133661				2022-12-28	WOS:000176988500016
J	Mu, JB; Duan, JH; Makova, KD; Joy, DA; Huynh, CQ; Branch, OH; Li, WH; Su, XZ				Mu, JB; Duan, JH; Makova, KD; Joy, DA; Huynh, CQ; Branch, OH; Li, WH; Su, XZ			Chromosome-wide SNPs reveal an ancient origin for Plasmodium falciparum	NATURE			English	Article							SEQUENCE; PROTEIN; POLYMORPHISMS; POPULATIONS; COMPLEXITY; REGIONS; BOTTLENECK; SELECTION; EVOLUTION; MALARIAS	The Malaria's Eve hypothesis, proposing a severe recent population bottleneck (about 3,000-5,000 years ago) of the human malaria parasite Plasmodium falciparum, has prompted a debate about the origin and evolution of the parasite(1-6). The hypothesis implies that the parasite population is relatively homogeneous, favouring malaria control measures. Other studies, however, suggested an ancient origin and large effective population size(5,7-10). To test the hypothesis, we analysed single nucleotide polymorphisms (SNPs) from 204 genes on chromosome 3 of P. falciparum. We have identified 403 polymorphic sites, including 238 SNPs and 165 microsatellites, from five parasite clones, establishing chromosome-wide haplotypes and a dense map with one polymorphic marker per similar to2.3 kilobases. On the basis of synonymous SNPs and non-coding SNPs, we estimate the time to the most recent common ancestor to be similar to100,000-180,000 years, significantly older than the proposed bottleneck. Our estimated divergence time coincides approximately with the start of human population expansion(11), and is consistent with a genetically complex organism able to evade host immunity and other antimalarial efforts.	NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA; Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA; NIH, Informat Engn Branch, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA; NIH, Computat Biol Branch, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Chicago; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Su, XZ (corresponding author), NIAID, Lab Malaria & Vector Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.			Li, Wen-Hsiung/0000-0003-1086-1456; Su, Xinzhuan/0000-0003-3246-3248				Anderson TJC, 2000, MOL BIOL EVOL, V17, P1467, DOI 10.1093/oxfordjournals.molbev.a026247; Bowman S, 1999, NATURE, V400, P532, DOI 10.1038/22964; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Conway DJ, 1999, P NATL ACAD SCI USA, V96, P4506, DOI 10.1073/pnas.96.8.4506; ESCALANTE AA, 1995, MOL BIOL EVOL, V12, P616; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; GRAUR D, 2000, FUNDAMENTALS MOL EVO; Hey J, 1999, CURR BIOL, V9, pR565, DOI 10.1016/S0960-9822(99)80356-X; Hughes AL, 2001, P ROY SOC B-BIOL SCI, V268, P1855, DOI 10.1098/rspb.2001.1759; Hughes AL, 1998, GENETICS, V150, P511; HUGHES AL, 1991, GENETICS, V127, P345; Louis A, 2001, GENOME RES, V11, P1296, DOI 10.1101/gr.GR-1776R; Musto H, 1999, J MOL EVOL, V49, P27, DOI 10.1007/PL00006531; Pizzi E, 2001, GENOME RES, V11, P218, DOI 10.1101/gr.GR-1522R; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Rich SM, 1998, P NATL ACAD SCI USA, V95, P4425, DOI 10.1073/pnas.95.8.4425; Rozas J, 1999, BIOINFORMATICS, V15, P174, DOI 10.1093/bioinformatics/15.2.174; Saul A, 1999, PARASITOL TODAY, V15, P38, DOI 10.1016/S0169-4758(98)01364-7; Su XZ, 1999, SCIENCE, V286, P1351, DOI 10.1126/science.286.5443.1351; Su XZ, 1997, CELL, V91, P593, DOI 10.1016/S0092-8674(00)80447-X; SWOFFORD DL, 2000, PAUPSTAR PHYLOGENETI; Templeton AR, 2002, NATURE, V416, P45, DOI 10.1038/416045a; Volkman SK, 2001, SCIENCE, V293, P482, DOI 10.1126/science.1059878; Walliker David, 1998, P235; WOOTTON JC, 1994, COMPUT CHEM, V18, P269, DOI 10.1016/0097-8485(94)85023-2; WOOTTON JC, 1993, COMPUT CHEM, V17, P149, DOI 10.1016/0097-8485(93)85006-X; WOOTTON JC, NATURE, V418, P320; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555; Yu A, 2001, NATURE, V409, P951, DOI 10.1038/35057185	29	115	118	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 18	2002	418	6895					323	326		10.1038/nature00836	http://dx.doi.org/10.1038/nature00836			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574BF	12124624				2022-12-28	WOS:000176868000042
J	Chiarugi, A; Moskowitz, MA				Chiarugi, A; Moskowitz, MA			Cell biology: PARP-1 - A perpetrator of apoptotic cell death?	SCIENCE			English	Editorial Material							POLY(ADP-RIBOSE) POLYMERASE-1; NERVOUS-SYSTEM; MITOCHONDRIA; PROTEINS; NAD(+)		Univ Florence, Dept Preclin & Clin Pharmacol, I-50139 Florence, Italy; Univ Massachusetts, Dept Cellular & Mol Physiol, Worcester, MA 01655 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02029 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurosurg, Charlestown, MA 02029 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol,Neurosci Ctr, Charlestown, MA 02029 USA	University of Florence; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Chiarugi, A (corresponding author), Univ Florence, Dept Preclin & Clin Pharmacol, I-50139 Florence, Italy.		Moskowitz, Michael A/D-9916-2011					Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Chiarugi A, 2002, TRENDS PHARMACOL SCI, V23, P122, DOI 10.1016/S0165-6147(00)01902-7; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; Di Lisa F, 2001, FEBS LETT, V492, P4, DOI 10.1016/S0014-5793(01)02198-6; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324; HERCEG Z, 2001, BIOCHEM J, V477, P97; James ER, 2002, CELL DEATH DIFFER, V9, P355, DOI 10.1038/sj.cdd.4400986; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Nicotera P, 2000, BRAIN PATHOL, V10, P276, DOI 10.1111/j.1750-3639.2000.tb00261.x; Reed JC, 2001, TRENDS MOL MED, V7, P314, DOI 10.1016/S1471-4914(01)02026-3; Scovassi AI, 1999, MOL CELL BIOCHEM, V199, P125; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	17	121	132	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 12	2002	297	5579					200	201		10.1126/science.1074592	http://dx.doi.org/10.1126/science.1074592			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571UT	12114611				2022-12-28	WOS:000176738100024
J	Galindo, MI; Bishop, SA; Greig, S; Couso, JP				Galindo, MI; Bishop, SA; Greig, S; Couso, JP			Leg patterning driven by proximal-distal interactions and EGFR signaling	SCIENCE			English	Article							DROSOPHILA LEG; DPP EXPRESSION; WINGLESS; AXIS; SPECIFICATION; APPENDAGE; PATHWAY; GENES; LIMBS; MUTATIONS	wingless and decapentaplegic signaling establishes the proximal-distal axis of Drosophila legs by activating the expression of genes such as Distalless and dachshund in broad proximal-distal domains during early leg development. However, here we show that wingless and decapentaplegic are not required throughout all of proximal-distal development. The tarsus, which has been proposed to be an ancestral structure, is instead defined by the activity of Distalless, dachshund, and a distal gradient of epidermal growth factor receptor ( EGFR) Ras signaling. Our results uncover a mechanism for appendage patterning directed by genes expressed in proximal-distal domains and possibly conserved in other arthropods and vertebrates.	Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England	University of Sussex	Couso, JP (corresponding author), Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England.		Galindo, Máximo Ibo/A-5299-2010; Couso, Juan Pablo/ABH-5860-2020	Galindo, Máximo Ibo/0000-0001-8448-9760; 				Abu-Shaar M, 1998, DEVELOPMENT, V125, P3821; Abzhanov A, 2000, DEV BIOL, V227, P673, DOI 10.1006/dbio.2000.9904; ASHBURNER M, 1989, DROSOPHILA LAB HDB, P140; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; Bodenstein D, 1994, BIOL DROSOPHILA, P275; BRYANT SV, 1981, SCIENCE, V212, P993, DOI 10.1126/science.212.4498.993; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; Casares F, 2001, SCIENCE, V293, P1477, DOI 10.1126/science.1062542; CASTELLIGAIR J, 1995, DEVELOPMENT, V121, P2973; Chu J, 2002, DEVELOPMENT, V129, P695; Couso JP, 1998, INT J DEV BIOL, V42, P345; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; COUSO JP, 1994, DEVELOPMENT, V120, P621; COUSO JP, UNPUB; Davis RJ, 1999, DEV GENES EVOL, V209, P526, DOI 10.1007/s004270050285; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; Gelbart WM, 1999, NUCLEIC ACIDS RES, V27, P85, DOI 10.1093/nar/27.1.85; GODT D, 1993, DEVELOPMENT, V119, P799; Gonzalez-Crespo S, 1998, NATURE, V394, P196, DOI 10.1038/28197; Goto S, 1999, DEVELOPMENT, V126, P3407; Jiang J, 1996, CELL, V86, P401, DOI 10.1016/S0092-8674(00)80113-0; Jockusch EL, 2000, DEVELOPMENT, V127, P1617; Kojima T, 2000, DEVELOPMENT, V127, P769; Lecuit T, 1997, NATURE, V388, P139, DOI 10.1038/40563; Mercader N, 1999, NATURE, V402, P425, DOI 10.1038/46580; Niwa N, 2000, DEVELOPMENT, V127, P4373; Pueyo JI, 2000, DEVELOPMENT, V127, P5391; Qu SM, 1998, DEVELOPMENT, V125, P2711; Robledo RF, 2002, GENE DEV, V16, P1089, DOI 10.1101/gad.988402; Schnepp B, 1996, GENE DEV, V10, P2302, DOI 10.1101/gad.10.18.2302; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; St Pierre SE, 2002, DEVELOPMENT, V129, P1273; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x	33	132	134	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 12	2002	297	5579					256	259		10.1126/science.1072311	http://dx.doi.org/10.1126/science.1072311			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571UT	12114628				2022-12-28	WOS:000176738100043
J	Grulich, AE; Kaldor, JM				Grulich, AE; Kaldor, JM			Evidence of success in HIV prevention in Africa	LANCET			English	Editorial Material							PREVALENCE; SURVEILLANCE; BEHAVIOR; WOMEN		Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW 2010, Australia	University of New South Wales Sydney; Kirby Institute	Grulich, AE (corresponding author), Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW 2010, Australia.	agrulich@nchecr.unsw.edu.au	Kaldor, John M/D-4545-2011					Fylkesnes K, 2001, AIDS, V15, P907, DOI 10.1097/00002030-200105040-00011; Janssen RS, 1998, JAMA-J AM MED ASSOC, V280, P42, DOI 10.1001/jama.280.1.42; Kamali A, 2000, AIDS, V14, P427, DOI 10.1097/00002030-200003100-00017; Kilian AHD, 1999, AIDS, V13, P391, DOI 10.1097/00002030-199902250-00012; Walker N, 2001, AIDS, V15, P1545, DOI 10.1097/00002030-200108170-00012; *WHO UNAIDS, 2000, GUID 2 GEN SURV HIV; Zaba B, 2000, AIDS, V14, P1633, DOI 10.1097/00002030-200007280-00020; Zaba BW, 2000, AIDS, V14, P2741, DOI 10.1097/00002030-200012010-00014	8	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 6	2002	360	9326					3	4		10.1016/S0140-6736(02)09359-5	http://dx.doi.org/10.1016/S0140-6736(02)09359-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569JR	12114032				2022-12-28	WOS:000176599700003
J	Shepherd, J				Shepherd, J			Resource management in prevention of coronary heart disease: optimising prescription of lipid-lowering drugs	LANCET			English	Editorial Material							CLINICAL-PRACTICE; TASK-FORCE; RISK; RECOMMENDATIONS; CHOLESTEROL; PRAVASTATIN; STATIN; LEVEL		Glasgow Royal Infirm, Inst Biochem, Glasgow G4 0SF, Lanark, Scotland	University of Glasgow	Shepherd, J (corresponding author), Glasgow Royal Infirm, Inst Biochem, Glasgow G4 0SF, Lanark, Scotland.	JShepherd@gri-biochem.org.uk						Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Gaw A, 2000, CURR OPIN LIPIDOL, V11, P363, DOI 10.1097/00041433-200008000-00004; Grundy SM, 1999, CIRCULATION, V100, P988, DOI 10.1161/01.CIR.100.9.988; Jackson PR, 2000, CURR OPIN LIPIDOL, V11, P357, DOI 10.1097/00041433-200008000-00003; Jones P, 1998, AM J CARDIOL, V81, P582, DOI 10.1016/S0002-9149(97)00965-X; LaRosa JC, 1999, EUR HEART J SUPPL, V1, pJ18; Meade T, 1999, EUR HEART J, V20, P725; Packard CJ, 1998, CIRCULATION, V97, P1440; PYORALA K, 1994, ATHEROSCLEROSIS, V110, P121, DOI 10.1016/0021-9150(94)90200-3; ROSE G, 1991, J ROY COLL PHYS LOND, V25, P48; *ROYAL COLL PHYS, SIGN PUBL, V40; Sacks FM, 1998, CIRCULATION, V97, P1446; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; Wood D, 1998, ATHEROSCLEROSIS, V140, P199, DOI 10.1016/S0021-9150(98)90209-X	14	40	40	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 29	2002	359	9325					2271	2273		10.1016/S0140-6736(02)09299-1	http://dx.doi.org/10.1016/S0140-6736(02)09299-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567YJ	12103306				2022-12-28	WOS:000176514500028
J	Liu, BP; Fournier, A; GrandPre, T; Strittmatter, SM				Liu, BP; Fournier, A; GrandPre, T; Strittmatter, SM			Myelin-associated glycoprotein as a functional ligand for the Nogo-66 receptor	SCIENCE			English	Article							AXON REGENERATION; NEURITE OUTGROWTH; INHIBITION; BINDING; GANGLIOSIDES; SIALOADHESIN; INTERACTS; PROTEIN; ANALOGS; FAMILY	Axonal regeneration in the adult central nervous system (CNS) is limited by two proteins in myelin, Nogo and myelin-associated glycoprotein (MAG). The receptor for Nogo (NgR) has been identified as an axonal glycosyl-phosphatidylinositol (GPI) anchored protein, whereas the MAG receptor has remained elusive. Here, we show that MAG binds directly, with high affinity, to NgR. Cleavage of GPI-linked proteins from axons protects growth cones from MAG-induced collapse, and dominant-negative NgR eliminates MAG inhibition of neurite outgrowth. MAG-resistant embryonic neurons are rendered MAG-sensitive by expression of NgR. MAG and Nogo-66 activate NgR independently and serve as redundant NgR ligands that may limit axonal regeneration after CNS injury.	Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06510 USA	Yale University; Yale University	Strittmatter, SM (corresponding author), Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA.		Strittmatter, Stephen/F-5739-2011	Strittmatter, Stephen/0000-0001-8188-3092				Brittis PA, 2001, NEURON, V30, P11, DOI 10.1016/S0896-6273(01)00258-6; Cai D, 2001, J NEUROSCI, V21, P4731, DOI 10.1523/JNEUROSCI.21-13-04731.2001; Collins BE, 1999, J BIOL CHEM, V274, P37637, DOI 10.1074/jbc.274.53.37637; Collins BE, 1997, J BIOL CHEM, V272, P16889, DOI 10.1074/jbc.272.27.16889; Filbin MT, 2000, CURR BIOL, V10, pR100, DOI 10.1016/S0960-9822(00)00302-X; FOURNIER A, UNPUB; Fournier AE, 2001, CURR OPIN NEUROBIOL, V11, P89, DOI 10.1016/S0959-4388(00)00178-1; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; Fransen E, 1998, HUM MOL GENET, V7, P999, DOI 10.1093/hmg/7.6.999; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Huber AB, 2000, BIOL CHEM, V381, P407, DOI 10.1515/BC.2000.053; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; KIM J, UNPUB; Li M, 1996, J NEUROSCI RES, V46, P404, DOI 10.1002/(SICI)1097-4547(19961115)46:4<404::AID-JNR2>3.3.CO;2-W; Liu B. J., UNPUB; McKerracher L, 2001, NEUROBIOL DIS, V8, P11, DOI 10.1006/nbdi.2000.0359; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; Qiu J, 2000, GLIA, V29, P166, DOI 10.1002/(SICI)1098-1136(20000115)29:2<166::AID-GLIA10>3.0.CO;2-G; Sawada N, 1999, CARBOHYD RES, V316, P1, DOI 10.1016/S0008-6215(99)00081-6; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tang S, 1997, J CELL BIOL, V138, P1355, DOI 10.1083/jcb.138.6.1355; Vinson M, 2001, J BIOL CHEM, V276, P20280, DOI 10.1074/jbc.M100345200; Wang XX, 2002, J NEUROSCI, V22, P5505; Yang LJS, 1996, P NATL ACAD SCI USA, V93, P814, DOI 10.1073/pnas.93.2.814	24	462	513	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 16	2002	297	5584					1190	1193		10.1126/science.1073031	http://dx.doi.org/10.1126/science.1073031			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	584BP	12089450				2022-12-28	WOS:000177447600053
J	Rolain, JM; Foucault, C; Guieu, R; La Scola, B; Brouqui, P; Raoult, D				Rolain, JM; Foucault, C; Guieu, R; La Scola, B; Brouqui, P; Raoult, D			Bartonella quintana in human erythrocytes	LANCET			English	Article								Bartonella quintana Is transmitted by body lice among homeless people. Infection with this organism leads to chronic bacteraemia with few symptoms. We looked for B quintana In erythrocytes In a population of homeless people In Marseille, France. In this report we show the Intraerythrocytic presence of B quintana In people with symptomless bacteraemia, by use of a specific monoclonal antibody and laser confocal microscopy. Presence of at least 5x10(4) colony-forming units per mL was predictive of Intracelluar Infection. However, such Infection was not associated with evidence of haemolysis. Colonisation of erythrocytes could allow efficient transmission of B quintana by body lice.	Hop CHU Nord, Serv Malad Infect & Trop, Marseille, France; Univ Mediterranee, Fac Med, Unite Rickettsies, CNRS,UPRESA 6020, F-13385 Marseille 05, France; Hop La Timone, Lab Biochim Pr Rochat, Marseille, France	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Raoult, D (corresponding author), Hop CHU Nord, Serv Malad Infect & Trop, Marseille, France.		Brouqui, Philippe/P-5771-2016; Rolain, Jean-Marc/Y-3788-2019; RAOULT, Didier/A-8434-2008; LA SCOLA, Bernard/P-6477-2016	Rolain, Jean-Marc/0000-0002-2402-4467; RAOULT, Didier/0000-0002-0633-5974; LA SCOLA, Bernard/0000-0001-8006-7704				Jacomo V, 2002, CLIN DIAGN LAB IMMUN, V9, P8, DOI 10.1128/CDLI.9.1.8-18.2002; KORDICK DL, 1995, J CLIN MICROBIOL, V33, P1655, DOI 10.1128/JCM.33.6.1655-1656.1995; Liang ZX, 2001, CLIN DIAGN LAB IMMUN, V8, P847, DOI 10.1128/CDLI.8.4.847-849.2001; Raoult D, 2001, Lancet Infect Dis, V1, P77, DOI 10.1016/S1473-3099(01)00062-7; ROUX V, 1995, GENE, V156, P107, DOI 10.1016/0378-1119(94)00919-J	5	60	62	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 20	2002	360	9328					226	228		10.1016/S0140-6736(02)09462-X	http://dx.doi.org/10.1016/S0140-6736(02)09462-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	576DX	12133660				2022-12-28	WOS:000176988500015
J	Perez-Orive, J; Mazor, O; Turner, GC; Cassenaer, S; Wilson, RI; Laurent, G				Perez-Orive, J; Mazor, O; Turner, GC; Cassenaer, S; Wilson, RI; Laurent, G			Oscillations and sparsening of odor representations in the mushroom body	SCIENCE			English	Article							VISUAL-CORTEX; PATTERN-RECOGNITION; CORTICAL NEURON; ANTENNAL LOBE; SYNCHRONIZATION; RESPONSES; BRAIN; INFORMATION; INTEGRATOR; CELLS	In the insect olfactory system, oscillatory synchronization is functionally relevant and reflects the coherent activation of dynamic neural assemblies. We examined the role of such oscillatory synchronization in information transfer between networks in this system. The antennal lobe is the obligatory relay for olfactory afferent signals and generates oscillatory output. The mushroom body is responsible for formation and retrieval of olfactory and other memories. The format of odor representations differs significantly across these structures. Whereas representations are dense, dynamic, and seemingly redundant in the antennal lobe, they are sparse and carried by more selective neurons in the mushroom body. This transformation relies on a combination of oscillatory dynamics and intrinsic and circuit properties that act together to selectively filter and synthesize the output from the antennal lobe. These results provide direct support for the functional relevance of correlation codes and shed some light on the role of oscillatory synchronization in sensory networks.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Laurent, G (corresponding author), CALTECH, Div Biol, 139-74, Pasadena, CA 91125 USA.	laurentg@caltech.edu	Wilson, Rachel/E-2227-2012; Laurent, Gilles/A-4583-2012	Laurent, Gilles/0000-0002-2296-114X; Perez-Orive, Javier/0000-0002-4799-0326; Wilson, Rachel/0000-0001-8573-9266; Mazor, Ofer/0000-0002-6860-7242; Turner, Glenn/0000-0002-5341-2784	NCRR NIH HHS [P41-RR09754] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR009754] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Abbott LF, 1999, NEURAL COMPUT, V11, P91, DOI 10.1162/089976699300016827; ABELES M, 1982, ISRAEL J MED SCI, V18, P83; ABELES M, 1993, J NEUROPHYSIOL, V70, P1629, DOI 10.1152/jn.1993.70.4.1629; Adrian ED, 1942, J PHYSIOL-LONDON, V100, P459, DOI 10.1113/jphysiol.1942.sp003955; BARLOW HB, 1969, ANN NY ACAD SCI, V156, P872, DOI 10.1111/j.1749-6632.1969.tb14019.x; BRAGIN A, 1995, J NEUROSCI, V15, P47; Cain WS, 1996, CHEM SENSES, V21, P35, DOI 10.1093/chemse/21.1.35; Clyne PJ, 1999, NEURON, V22, P327, DOI 10.1016/S0896-6273(00)81093-4; Contreras D, 1997, J NEUROPHYSIOL, V78, P335, DOI 10.1152/jn.1997.78.1.335; Csibra G, 2000, SCIENCE, V290, P1582, DOI 10.1126/science.290.5496.1582; Diesmann M, 1999, NATURE, V402, P529, DOI 10.1038/990101; Dubnau J, 2001, NATURE, V411, P476, DOI 10.1038/35078077; DuchampViret P, 1996, NEUROSCIENCE, V74, P885, DOI 10.1016/0306-4522(96)00194-7; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; Engel AK, 2001, NAT REV NEUROSCI, V2, P704, DOI 10.1038/35094565; Fricker D, 2000, NEURON, V28, P559, DOI 10.1016/S0896-6273(00)00133-1; Fries P, 2001, SCIENCE, V291, P1560, DOI 10.1126/science.1055465; Galarreta M, 2001, SCIENCE, V292, P2295, DOI 10.1126/science.1061395; Gao Q, 2000, NAT NEUROSCI, V3, P780, DOI 10.1038/77680; GELPERIN A, 1990, NATURE, V345, P437, DOI 10.1038/345437a0; Gray C M, 1994, J Comput Neurosci, V1, P11, DOI 10.1007/BF00962716; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; Haberly L.B., 1990, Cerebral Cortex, V8B, P137; Hansson BS, 2000, ANNU REV ENTOMOL, V45, P203, DOI 10.1146/annurev.ento.45.1.203; HEISENBERG M, 1985, J NEUROGENET, V2, P1, DOI 10.3109/01677068509100140; HOPFIELD JJ, 1995, NATURE, V376, P33, DOI 10.1038/376033a0; Kenyon F., 1896, J COMP NEUROL, V6, P133, DOI DOI 10.1002/CNE.910060302; Konig P, 1996, TRENDS NEUROSCI, V19, P130, DOI 10.1016/S0166-2236(96)80019-1; Lam YW, 2000, J NEUROSCI, V20, P749, DOI 10.1523/JNEUROSCI.20-02-00749.2000; LAURENT G, 1994, J NEUROSCI, V14, P2993; LAURENT G, 1994, SCIENCE, V265, P1872, DOI 10.1126/science.265.5180.1872; Laurent G, 1996, J NEUROSCI, V16, P3837; Leitch B, 1996, J COMP NEUROL, V372, P487; Linster C, 1999, PHYSIOL BEHAV, V66, P701, DOI 10.1016/S0031-9384(99)00007-4; Livermore A, 1996, J EXP PSYCHOL HUMAN, V22, P267, DOI 10.1037/0096-1523.22.2.267; MacLeod K, 1996, SCIENCE, V274, P976, DOI 10.1126/science.274.5289.976; MacLeod K, 1998, NATURE, V395, P693, DOI 10.1038/27201; McGuire SE, 2001, SCIENCE, V293, P1330, DOI 10.1126/science.1062622; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; NEMITZ JW, 1983, J NEUROPHYSIOL, V49, P188, DOI 10.1152/jn.1983.49.1.188; Patel AD, 2000, NATURE, V404, P80, DOI 10.1038/35003577; Pouille F, 2001, SCIENCE, V293, P1159, DOI 10.1126/science.1060342; POUZAT C, IN PRESS MODEL BASED; POWER DV, 1997, NEUROTRANSMITTER MET; Rodriguez E, 1999, NATURE, V397, P430, DOI 10.1038/17120; ROLLS ET, 1995, J NEUROPHYSIOL, V73, P713, DOI 10.1152/jn.1995.73.2.713; RUEHLE A, 1997, SCIENCE, V281, P34; SCHAFER S, 1994, J NEUROSCI, V14, P4600; Shadlen MN, 1999, NEURON, V24, P67, DOI 10.1016/S0896-6273(00)80822-3; Steriade M, 1996, J NEUROSCI, V16, P392, DOI 10.1523/jneurosci.16-01-00392.1996; Stopfer M, 1997, NATURE, V390, P70, DOI 10.1038/36335; TANABE T, 1975, J NEUROPHYSIOL, V38, P1284, DOI 10.1152/jn.1975.38.5.1284; Vinje WE, 2000, SCIENCE, V287, P1273, DOI 10.1126/science.287.5456.1273; VONDERMALSBURG C, 1986, BIOL CYBERN, V54, P29, DOI 10.1007/BF00337113; Vosshall LB, 2000, CELL, V102, P147, DOI 10.1016/S0092-8674(00)00021-0; Wehr M, 1996, NATURE, V384, P162, DOI 10.1038/384162a0; Wicklein M, 2000, J COMP NEUROL, V424, P356; Willmore B, 2001, NETWORK-COMP NEURAL, V12, P255, DOI 10.1088/0954-898X/12/3/302; Zars T, 2000, SCIENCE, V288, P672, DOI 10.1126/science.288.5466.672; Zou ZH, 2001, NATURE, V414, P173, DOI 10.1038/35102506	60	560	565	2	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 19	2002	297	5580					359	365		10.1126/science.1070502	http://dx.doi.org/10.1126/science.1070502			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574LV	12130775				2022-12-28	WOS:000176892600040
J	Rikkinen, J; Oksanen, I; Lohtander, K				Rikkinen, J; Oksanen, I; Lohtander, K			Lichen guilds share related cyanobacterial symbionts	SCIENCE			English	Article							SPECIFICITY		Univ Helsinki, Dept Appl Biol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Appl Chem & Microbiol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Systemat & Ecol, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki	Rikkinen, J (corresponding author), Univ Helsinki, Dept Appl Biol, POB 27, FIN-00014 Helsinki, Finland.		Rikkinen, Jouko/AAM-8732-2021					Lohtander K, 2000, MYCOLOGIA, V92, P728, DOI 10.2307/3761429; Paulsrud P, 1998, APPL ENVIRON MICROB, V64, P310; Paulsrud P, 2001, NEW PHYTOL, V152, P117, DOI 10.1046/j.0028-646x.2001.00234.x; Paulsrud P, 2001, THESIS UPPSALA U UPP; RIKKINEN J, IN PRESS CYANOBACTER; RIKKINEN J, 1995, BRYOBROTHERA, V4, P170; SWOFFORD DL, 2000, PHYLOGENET ANAL US P; WILMOTTE A, 1993, FEBS LETT, V317, P96, DOI 10.1016/0014-5793(93)81499-P	8	140	142	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 19	2002	297	5580					357	357		10.1126/science.1072961	http://dx.doi.org/10.1126/science.1072961			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574LV	12130774				2022-12-28	WOS:000176892600039
J	Lashuel, HA; Hartley, D; Petre, BM; Walz, T; Lansbury, PT				Lashuel, HA; Hartley, D; Petre, BM; Walz, T; Lansbury, PT			Neurodegenerative disease - Amyloid pores from pathogenic mutations	NATURE			English	Article							ALZHEIMERS-DISEASE; TOXICITY		Brigham & Womens Hosp, Ctr Neurol Dis, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Dept Neurol, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University; Harvard Medical School	Lansbury, PT (corresponding author), Brigham & Womens Hosp, Ctr Neurol Dis, 65 Landsdowne St, Cambridge, MA 02139 USA.		Lashuel, Hilal/M-3500-2017	Walz, Thomas/0000-0003-2606-2835				Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hotze EM, 2002, J BIOL CHEM, V277, P11597, DOI 10.1074/jbc.M111039200; Janson J, 1999, DIABETES, V48, P491, DOI 10.2337/diabetes.48.3.491; Kagan BL, 2001, BRAIN RES BULL, V56, P281, DOI 10.1016/S0361-9230(01)00654-2; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; Lin H, 2001, FASEB J, V15, P2433, DOI 10.1096/fj.01-0377com; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; Sousa MM, 2001, AM J PATHOL, V159, P1993; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a	13	1071	1108	4	107	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 18	2002	418	6895					291	291		10.1038/418291a	http://dx.doi.org/10.1038/418291a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574BF	12124613	Bronze, Green Published			2022-12-28	WOS:000176868000031
J	Sagy, A; Reches, Z; Fineberg, J				Sagy, A; Reches, Z; Fineberg, J			Dynamic fracture by large extraterrestrial impacts as the origin of shatter cones	NATURE			English	Article							CRACK FRONT WAVES; VREDEFORT STRUCTURE; BRITTLE MATERIALS; CONSTRAINTS; SPALLATION; SIZE	A large impact by a comet or meteorite releases an enormous amount of energy, which evaporates, melts and fractures the surrounding rocks(1-4). Distinctive features of such impacts are 'shatter cones', deformed rocks characterized by hierarchical striated features(5,6). Although such features have been used for decades as unequivocal fingerprints of large-body impacts, the process by which shatter cones form has remained enigmatic. Here we show that the distinctive shatter-cone striations naturally result from nonlinear waves (front waves) that propagate along a fracture front(7-10). This explains the observed systematic increase of striation angles with the distance from the impact. Shatter-cone networks, typically spanning many scales, can be understood as hierarchical bifurcations of the fracture front, which is generated by the immense energy flux carried by the initial, impact-generated, shock waves. Our quantitative predictions based on this theory are supported by field measurements at the Kentland and Vredefort impact sites. These measurements indicate that shatter cones near to the impact site were formed by fractures propagating at nearly the Rayleigh wave speed of the host rocks, whereas the furthest shatter cones observed (about 40 km from the impact site) were formed by fronts moving more slowly. These results provide insight into impact dynamics as well as dissipative mechanisms in solids subjected to sudden, extremely intense fluxes of energy.	Hebrew Univ Jerusalem, Racah Inst Phys, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Inst Earth Sci, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Fineberg, J (corresponding author), Hebrew Univ Jerusalem, Racah Inst Phys, IL-91904 Jerusalem, Israel.			Fineberg, Jay/0000-0002-8381-6675				AHRENS TJ, 1993, J GEOPHYS RES-PLANET, V98, P1185, DOI 10.1029/92JE02679; ALBAT HM, 1989, TECTONOPHYSICS, V162, P265, DOI 10.1016/0040-1951(89)90248-5; Arakawa M, 2000, GEOPHYS RES LETT, V27, P305, DOI 10.1029/1999GL010841; Asphaug E, 1996, ICARUS, V120, P158, DOI 10.1006/icar.1996.0043; Camacho GT, 1996, INT J SOLIDS STRUCT, V33, P2899, DOI 10.1016/0020-7683(95)00255-3; DALLY JW, 1979, EXP MECH, V19, P349, DOI 10.1007/BF02324250; DIETZ RS, 1969, SHOCK METAMORPHISM N, P267; FIELD JE, 1971, CONTEMP PHYS, V12, P1, DOI 10.1080/00107517108205103; FRENCH BM, 1998, HDB SHOCK METAMORPHI; Freund LB, 1990, DYNAMIC FRACTURE MEC, DOI [10.1017/oretCBO9780511546761-en, DOI 10.1017/ORETCBO9780511546761-EN]; Gash P. J. S., 1971, Nature (Physical Science), V230, P32; Henkel H, 1998, TECTONOPHYSICS, V287, P1, DOI 10.1016/S0040-1951(98)80058-9; JOHNSON GP, THESIS AIR FORCE I T; Melosh H.J., 1989, OXFORD MONOGRAPHS GE; MELOSH HJ, 1984, ICARUS, V59, P234, DOI 10.1016/0019-1035(84)90026-5; MELOSH HJ, 1992, J GEOPHYS RES-PLANET, V97, P14735, DOI 10.1029/92JE01632; Milton D. J., 1977, IMPACT EXPLOSION CRA, P703; Morrissey JW, 1998, J MECH PHYS SOLIDS, V46, P467, DOI 10.1016/S0022-5096(97)00072-0; Morrissey JW, 2000, J MECH PHYS SOLIDS, V48, P1229, DOI 10.1016/S0022-5096(99)00069-1; Nicolaysen LO, 1999, J GEOPHYS RES-SOL EA, V104, P4911, DOI 10.1029/1998JB900068; POLANSKEY CA, 1990, ICARUS, V87, P140, DOI 10.1016/0019-1035(90)90025-5; Ramanathan S, 1997, PHYS REV LETT, V79, P877, DOI 10.1103/PhysRevLett.79.877; ROY DW, 1979, TECTONOPHYSICS, V60, pT37, DOI 10.1016/0040-1951(79)90128-8; Sagy A, 2001, J STRUCT GEOL, V23, P1223, DOI 10.1016/S0191-8141(00)00190-5; Sharon E, 1996, PHYS REV B, V54, P7128, DOI 10.1103/PhysRevB.54.7128; Sharon E, 2001, NATURE, V410, P68, DOI 10.1038/35065051; Sharpton VL, 1996, GEOLOGY, V24, P851, DOI 10.1130/0091-7613(1996)024<0851:NCOTSI>2.3.CO;2; Shibuya T., 1968, Bulletin of the Japan Society of Mechanical Engineers, V11, P983, DOI 10.1299/jsme1958.11.983; Therriault AM, 1997, METEORIT PLANET SCI, V32, P71, DOI 10.1111/j.1945-5100.1997.tb01242.x; Turtle EP, 1998, METEORIT PLANET SCI, V33, P483, DOI 10.1111/j.1945-5100.1998.tb01652.x	30	53	56	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 18	2002	418	6895					310	313		10.1038/nature00903	http://dx.doi.org/10.1038/nature00903			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574BF	12124620				2022-12-28	WOS:000176868000038
J	Calman, KC				Calman, KC			Communication of risk: choice, consent, and trust	LANCET			English	Editorial Material							MMR; INFORMATION		Univ Durham, Durham DH1 3HP, England	Durham University	Calman, KC (corresponding author), Univ Durham, Old Elvet, Durham DH1 3HP, England.	Kenneth.calman@durham.ac.uk						Bennett P., 1999, RISK COMMUNICATION P; Berry CL, 2000, J ROY COLL PHYS LOND, V34, P486; Calman K, 2001, PUBLIC ADMIN, V79, P185, DOI 10.1111/1467-9299.00252; Calman KC, 1996, BRIT MED J, V313, P799; Calman KC, 2001, TRANSFUSION, V41, P1326, DOI 10.1046/j.1537-2995.2001.41111326.x; Calman KC, 2001, BRIT J GEN PRACT, V51, P47; Edwards A, 2001, BRIT J GEN PRACT, V51, P259; Elliman DAC, 2001, ARCH DIS CHILD, V85, P271, DOI 10.1136/adc.85.4.271; GUTTELING JM, 1996, EXPLORING RISK COMMU; Heller D, 2001, BMJ-BRIT MED J, V323, P839; Heller T, 2001, BRIT MED J, V323, P838, DOI 10.1136/bmj.323.7317.838; Hupcey JE, 2001, J ADV NURS, V36, P282, DOI 10.1046/j.1365-2648.2001.01970.x; Jewell D, 2001, BRIT J GEN PRACT, V51, P875; Misselbrook D, 2001, BRIT J GEN PRACT, V51, P276; Richard MA, 1999, BRIT J DERMATOL, V140, P909, DOI 10.1046/j.1365-2133.1999.02824.x	15	60	60	1	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 13	2002	360	9327					166	168		10.1016/S0140-6736(02)09421-7	http://dx.doi.org/10.1016/S0140-6736(02)09421-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573PB	12126841				2022-12-28	WOS:000176839100029
J	Moore, PB; Steitz, TA				Moore, PB; Steitz, TA			The involvement of RNA in ribosome function	NATURE			English	Review							PEPTIDYL TRANSFERASE CENTER; ELONGATION-FACTOR G; CONFORMATIONAL-CHANGE; ANGSTROM-RESOLUTION; CRYSTAL-STRUCTURES; STRUCTURAL BASIS; 70S RIBOSOME; SUBUNIT; PROTEIN; VISUALIZATION	The ribosome is a particle made of RNA and protein that is found in abundance in all cells that are actively making protein. It catalyses the messenger RNA-directed synthesis of proteins. Recent structural work has demonstrated a profound involvement of the ribosome's RNA component in all aspects of its function, supporting the hypothesis that proteins were added to the ribosome late in its evolution.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Yale University; Howard Hughes Medical Institute	Moore, PB (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 208107, New Haven, CT 06520 USA.	peter.moore@yale.edu	Steitz, Thomas A./C-6559-2009					Agrawal RK, 2000, J CELL BIOL, V150, P447, DOI 10.1083/jcb.150.3.447; Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; Agrawal RK, 1999, NAT STRUCT BIOL, V6, P643, DOI 10.1038/10695; Agrawal RK, 2001, J MOL BIOL, V311, P777, DOI 10.1006/jmbi.2001.4907; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Ban N, 1999, NATURE, V400, P841, DOI 10.1038/23641; Bayfield MA, 2001, P NATL ACAD SCI USA, V98, P10096, DOI 10.1073/pnas.171319598; Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; BERNABEU C, 1982, P NATL ACAD SCI-BIOL, V79, P3111, DOI 10.1073/pnas.79.10.3111; BERNABEU C, 1983, J CELL BIOL, V96, P1471, DOI 10.1083/jcb.96.5.1471; Carter AP, 2001, SCIENCE, V291, P498, DOI 10.1126/science.1057766; Carter AP, 2000, NATURE, V407, P340, DOI 10.1038/35030019; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; Chambliss G., 1980, RIBOSOMES STRUCTURE, P357; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; Czworkowski J, 1996, PROG NUCLEIC ACID RE, V54, P293, DOI 10.1016/S0079-6603(08)60366-9; Dallas A, 2001, MOL CELL, V8, P855, DOI 10.1016/S1097-2765(01)00356-2; Frank J, 2000, NATURE, V406, P318, DOI 10.1038/35018597; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; Garrett R. A., 1996, RIBOSOMAL RNA STRUCT, P327; GAVRILOVA LP, 1976, J MOL BIOL, V101, P537, DOI 10.1016/0022-2836(76)90243-6; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HANSEN JL, IN PRESS MOL CELL; KATUNIN VL, IN PRESS MOL CELL; Kim DF, 1999, MOL CELL, V4, P859, DOI 10.1016/S1097-2765(00)80395-0; KOSHLAND D E JR, 1971, Pure and Applied Chemistry, V25, P119, DOI 10.1351/pac197125010119; KOSHLAND DE, 1971, COLD SPRING HARB SYM, V36, P13; McCutcheon JP, 1999, P NATL ACAD SCI USA, V96, P4301, DOI 10.1073/pnas.96.8.4301; MILLER KD, 1993, J AM HIST, V80, P319, DOI 10.2307/2079816; Moore PB, 1993, RNA WORLD, P119; Muth GW, 2000, SCIENCE, V289, P947, DOI 10.1126/science.289.5481.947; Muth GW, 2001, RNA, V7, P1403; NIERHAUS KH, 1980, BIOCHEM INT, V1, P185; Nissen P, 2001, P NATL ACAD SCI USA, V98, P4899, DOI 10.1073/pnas.081082398; NOLLER HF, 1984, ANNU REV BIOCHEM, V53, P119, DOI 10.1146/annurev.bi.53.070184.001003; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; Ogle JM, 2001, SCIENCE, V292, P897, DOI 10.1126/science.1060612; PAGE MI, 1971, FED PROC, V30, P1240; Peske F, 2000, MOL CELL, V6, P501, DOI 10.1016/S1097-2765(00)00049-6; Pioletti M, 2001, EMBO J, V20, P1829, DOI 10.1093/emboj/20.8.1829; Polacek N, 2001, NATURE, V411, P498, DOI 10.1038/35078113; RHEINBERGER HJ, 1990, RIBOSOME, P318; SAMAHA RR, 1995, NATURE, V377, P309, DOI 10.1038/377309a0; SANTER M, 1995, RIBOSOMAL RNA STRUCT, P3; Schmeing TM, 2002, NAT STRUCT BIOL, V9, P225, DOI 10.1038/nsb758; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; Stark H, 2000, CELL, V100, P301, DOI 10.1016/S0092-8674(00)80666-2; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; STEITZ JA, 1975, P NATL ACAD SCI USA, V72, P4734, DOI 10.1073/pnas.72.12.4734; Su┬ll D., 1995, TRNA STRUCTURE BIOSY; Thompson J, 2001, P NATL ACAD SCI USA, V98, P9002, DOI 10.1073/pnas.151257098; Tissieres A., 1974, RIBOSOME RES HIST BA, P3; Wool IG, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P461; Xiong LQ, 2001, RNA, V7, P1365; YONATH A, 1987, SCIENCE, V236, P813, DOI 10.1126/science.3576200; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Yusupova GZ, 2001, CELL, V106, P233, DOI 10.1016/S0092-8674(01)00435-4	63	126	132	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 11	2002	418	6894					229	235		10.1038/418229a	http://dx.doi.org/10.1038/418229a			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571GV	12110899				2022-12-28	WOS:000176710400051
J	Vicsek, T				Vicsek, T			Complexity - The bigger picture	NATURE			English	Editorial Material									Eotvos Lorand Univ, Dept Biol Phys, H-1117 Budapest, Hungary	Eotvos Lorand University	Vicsek, T (corresponding author), Eotvos Lorand Univ, Dept Biol Phys, Pazmany Stny 1A, H-1117 Budapest, Hungary.		Vicsek, Tamas/A-3305-2009					Gell-Mann M., 2002, EUROPHYS NEWS, V33, P17; WALDROP MM, 1993, COMPLEXITY; 2001, NATURE, V410, P241	3	114	119	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 11	2002	418	6894					131	131		10.1038/418131a	http://dx.doi.org/10.1038/418131a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571GV	12110869	Bronze, Green Submitted			2022-12-28	WOS:000176710400020
J	Wellesley, D; Boyle, T; Barber, J; Howe, DT				Wellesley, D; Boyle, T; Barber, J; Howe, DT			Retrospective audit of different antenatal screening policies for Down's syndrome in eight district general hospitals in one health region	BRITISH MEDICAL JOURNAL			English	Article							UNCONJUGATED ESTRIOL; ALPHA-FETOPROTEIN	Objective To compare the effectiveness of different screening policies for the antenatal detection of Down's syndrome. Design Retrospective six year survey. Setting Maternity units of eight districts. Participants Women who completed their pregnancies between 1 January 1994 and 31 December 1999 (155 501 deliveries). Main outcome measures Cases of Down's syndrome identified before 24 weeks' gestation. Results 335 cases of Down's syndrome were identified, 323 in continuing pregnancies or liveborn children. Of these, 171 were identified antenatally. Seven different screening policies were used, in three principal groups: serum screening offered to all mothers, maternal age with serum screening or nuchal translucency available to limited groups, and maternal age combined with anomaly scans. The districts that used serum screening detected 57%, those using maternal age plus serum or nuchal translucency screening 52%, and those using a maternal age of greater than or equal to35 and anomaly scans detected 54%. The least successful district, which offered amniocentesis only to women aged over 37 years, detected only 31%. If amniocentesis had been offered from 35 years, as in all other districts, the detection rate would have risen to 54%. Across the region 15% (range 12-20%) of pregnant women were 35 years or more at delivery, and 58% (33-69%) of infants with Down's syndrome were born to women in this age range. Conclusions Current additional serum or nuchal translucency screening techniques for antenatal detection of Down's syndrome are less advantageous than previously supposed. More pregnant women were aged over 35 than has been presumed in statistical models used in demonstration projects of serum screening and, as a result; the proportion of affected fetuses in this age group is much greater than predicted.	Princess Anne Hosp, Wessex Clin Genet Serv, Southampton SO16 5YA, Hants, England; Salisbury Dist Hosp, Wessex Reg Genet Lab, Salisbury SP2 8BJ, Wilts, England; Southampton Gen Hosp, Human Genet Res Div, Southampton SO16 6YD, Hants, England; Princess Anne Hosp, Wessex Fetal Med Unit, Southampton SO16 5YA, Hants, England	Salisbury District Hospital; University of Southampton	Wellesley, D (corresponding author), Princess Anne Hosp, Wessex Clin Genet Serv, Southampton SO16 5YA, Hants, England.							ADAMS MM, 1981, JAMA-J AM MED ASSOC, V246, P758, DOI 10.1001/jama.246.7.758; CHENG EY, 1993, OBSTET GYNECOL, V81, P72; GOODBURN SF, 1994, PRENATAL DIAG, V14, P391, DOI 10.1002/pd.1970140509; Howe DT, 2000, BRIT MED J, V320, P606, DOI 10.1136/bmj.320.7235.606; MUTTON DE, 1991, BRIT MED J, V303, P1295, DOI 10.1136/bmj.303.6813.1295; MUTTON DE, 1989, BRIT MED J, V303, P1295; Wald NJ, 1998, HEALTH TECHNOL ASSES, V2, P1, DOI DOI 10.3310/HTA2010	7	25	26	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 6	2002	325	7354					15	17		10.1136/bmj.325.7354.15	http://dx.doi.org/10.1136/bmj.325.7354.15			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573BC	12098722	Green Published, Bronze			2022-12-28	WOS:000176808600015
J	Stechmann, A; Cavalier-Smith, T				Stechmann, A; Cavalier-Smith, T			Rooting the eukaryote tree by using a derived gene fusion	SCIENCE			English	Article							ORIGINS; DICTYOSTELIUM; GLUCOKINASE; PHYLOGENY; SALVAGE; PROTEIN	Single-gene trees have failed to locate the root of the eukaryote tree because of systematic biases in sequence evolution. Structural genetic data should yield more reliable insights into deep phylogenetic relationships. We searched major protist groups for the presence or absence of a gene fusion in order to locate the root of the eukaryote tree. In striking contrast to previous molecular studies, we show that all eukaryote groups ancestrally with two cilia (bikonts) are evolutionarily derived. The root lies between bikonts and opisthokonts ( animals, Fungi, Choanozoa). Amoebozoa either diverged even earlier or are sister of bikonts or ( less likely) opisthokonts.	Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Oxford	Stechmann, A (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.	alexandra.stechmann@zoo.ox.ac.uk						ALDRITT SM, 1985, J EXP MED, V161, P437, DOI 10.1084/jem.161.3.437; Andersson JO, 2002, CURR BIOL, V12, P115, DOI 10.1016/S0960-9822(01)00649-2; Baldauf SL, 2000, SCIENCE, V290, P972, DOI 10.1126/science.290.5493.972; Baldauf SL, 1999, AM NAT, V154, pS178, DOI 10.1086/303292; Bapteste E, 2002, P NATL ACAD SCI USA, V99, P1414, DOI 10.1073/pnas.032662799; Cavalier-Smith T, 2002, INT J SYST EVOL MICR, V52, P297, DOI 10.1099/00207713-52-2-297; Cavalier-Smith T, 1999, J EUKARYOT MICROBIOL, V46, P347, DOI 10.1111/j.1550-7408.1999.tb04614.x; Cavalier-Smith T, 1998, SYST ASSOC SPEC VOL, V56, P375; CAVALIERSMITH T, 1982, BIOL J LINN SOC, V17, P289, DOI 10.1111/j.1095-8312.1982.tb02023.x; CAVALIERSMITH T, 2000, FLAGELLATES, P361; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; Embley TM, 1998, CURR OPIN GENET DEV, V8, P624, DOI 10.1016/S0959-437X(98)80029-4; GARRETT CE, 1984, MOL BIOCHEM PARASIT, V11, P257, DOI 10.1016/0166-6851(84)90070-7; Henze K, 2001, GENE, V281, P123, DOI 10.1016/S0378-1119(01)00773-9; Keeling PJ, 2000, NATURE, V405, P635, DOI 10.1038/35015167; Lang BF, 1997, NATURE, V387, P493, DOI 10.1038/387493a0; Philippe H, 2000, P ROY SOC B-BIOL SCI, V267, P1213, DOI 10.1098/rspb.2000.1130; Roger AJ, 1999, AM NAT, V154, pS146, DOI 10.1086/303290; Silberman JD, 2002, MOL BIOL EVOL, V19, P777, DOI 10.1093/oxfordjournals.molbev.a004135; WANG CC, 1984, MOL BIOCHEM PARASIT, V10, P171, DOI 10.1016/0166-6851(84)90005-7; WANG CC, 1983, P NATL ACAD SCI-BIOL, V80, P2564, DOI 10.1073/pnas.80.9.2564; Wu G, 2001, GENE, V264, P265, DOI 10.1016/S0378-1119(01)00329-8	22	270	283	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 5	2002	297	5578					89	91		10.1126/science.1071196	http://dx.doi.org/10.1126/science.1071196			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571HB	12098695				2022-12-28	WOS:000176711000038
J	Antin, JH				Antin, JH			Long-term care after hematopoietic-cell transplantation in adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; VERSUS-HOST DISEASE; CHRONIC GRAFT; RISK-FACTORS; STEM-CELL; THYROID-DYSFUNCTION; AVASCULAR NECROSIS; RECIPIENTS; SURVIVORS; LEUKEMIA		Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Adult Oncol, Adult Oncol Stem Cell Transplantat Program, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute	Antin, JH (corresponding author), Brigham & Womens Hosp, Dept Med, 44 Binney St, Boston, MA 02115 USA.							*AM SOC BLOOD MARR, 2000, MMWR-MORBID MORTAL W, V49, P1; Arvin AM, 2000, BIOL BLOOD MARROW TR, V6, P219, DOI 10.1016/S1083-8791(00)70004-8; BOULAD F, 1995, BONE MARROW TRANSPL, V15, P71; Chatterjee R, 1996, BONE MARROW TRANSPL, V17, P5; Curtis RE, 1997, NEW ENGL J MED, V336, P897, DOI 10.1056/NEJM199703273361301; Cutler C, 2001, J CLIN ONCOL, V19, P3685, DOI 10.1200/JCO.2001.19.16.3685; Deeg HJ, 1996, BLOOD, V87, P386, DOI 10.1182/blood.V87.1.386.bloodjournal871386; Dimeo F, 1996, BONE MARROW TRANSPL, V18, P1157; Dykewicz CA, 2000, BIOL BLOOD MARROW TR, V6, P659; Fink JC, 1998, BONE, V22, P67, DOI 10.1016/S8756-3282(97)00219-6; GALE RP, 1987, BRIT J HAEMATOL, V67, P397, DOI 10.1111/j.1365-2141.1987.tb06160.x; Hata A, 2002, NEW ENGL J MED, V347, P26, DOI 10.1056/NEJMoa013441; HOROWITZ MM, 1999, HEMATOPOIETIC CELL T, P12; KEEFE KA, 2000, CLIN ONCOLOGY, P318; Kolb HJ, 1999, ANN INTERN MED, V131, P738, DOI 10.7326/0003-4819-131-10-199911160-00004; Kollman C, 2001, BLOOD, V98, P2043, DOI 10.1182/blood.V98.7.2043; Kulkarni S, 2000, BLOOD, V95, P3683; Lee SJ, 2001, J CLIN ONCOL, V19, P242, DOI 10.1200/JCO.2001.19.1.242; Ljungman P, 1998, TRANSPLANTATION, V66, P1330, DOI 10.1097/00007890-199811270-00012; Mookerjee B, 1999, BONE MARROW TRANSPL, V24, P517, DOI 10.1038/sj.bmt.1701936; Nordoy T, 1999, BONE MARROW TRANSPL, V24, P873, DOI 10.1038/sj.bmt.1702006; NORDOY T, 2001, BLOOD, V97, P3380; Osarogiagbon RU, 2000, BIOL BLOOD MARROW TR, V6, P280, DOI 10.1016/S1083-8791(00)70010-3; SALOOJA N, 1994, BONE MARROW TRANSPL, V13, P431; Sanders JE, 1996, BLOOD, V87, P3045, DOI 10.1182/blood.V87.7.3045.bloodjournal8773045; SANDERS JE, 1986, BLOOD, V68, P1129; SHULMAN HM, 1980, AM J MED, V69, P204, DOI 10.1016/0002-9343(80)90380-0; SKLAR CA, 1984, CANCER, V53, P1498, DOI 10.1002/1097-0142(19840401)53:7<1498::AID-CNCR2820530712>3.0.CO;2-A; SKLAR CA, 1982, AM J MED, V73, P688, DOI 10.1016/0002-9343(82)90411-9; Smith RA, 2002, CA-CANCER J CLIN, V52, P8, DOI 10.3322/canjclin.52.1.8; Socie G, 2000, J CLIN ONCOL, V18, P348, DOI 10.1200/JCO.2000.18.2.348; Socie G, 1997, BRIT J HAEMATOL, V97, P865, DOI 10.1046/j.1365-2141.1997.1262940.x; Sokos DR, 2002, BIOL BLOOD MARROW TR, V8, P117, DOI 10.1053/bbmt.2002.v8.pm11939601; Storek J, 1997, AM J HEMATOL, V54, P131, DOI 10.1002/(SICI)1096-8652(199702)54:2<131::AID-AJH6>3.0.CO;2-Y; Storek J, 2001, BLOOD, V98, P3505, DOI 10.1182/blood.V98.13.3505; SULLIVAN KM, 1981, BLOOD, V57, P267, DOI 10.1182/blood.V57.2.267.267; Weilbaecher KN, 2000, BIOL BLOOD MARROW TR, V6, P165, DOI 10.1016/S1083-8791(00)70039-5; 2000, BIOL BLOOD MARROW TR, V6, P715; 2000, BIOL BLOOD MARROW TR, V6, P717	39	55	60	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 4	2002	347	1					36	42		10.1056/NEJMcp010518	http://dx.doi.org/10.1056/NEJMcp010518			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569HA	12097539				2022-12-28	WOS:000176594500008
J	Infante-Rivard, C; Rivard, GE; Yotov, WV; Genin, E; Guiguet, M; Weinberg, C; Gauthier, R; Feoli-Fonseca, JC				Infante-Rivard, C; Rivard, GE; Yotov, WV; Genin, E; Guiguet, M; Weinberg, C; Gauthier, R; Feoli-Fonseca, JC			Absence of association of thrombophilia polymorphisms with intrauterine growth restriction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							METHYLENETETRAHYDROFOLATE REDUCTASE GENE; BIRTH-WEIGHT; VASCULAR-DISEASE; PROTHROMBIN GENE; COMMON MUTATION; RISK FACTOR; FETAL LOSS; HOMOCYSTEINE; THROMBOSIS; PREGNANCY	Background: Previous data have demonstrated associations between thrombophilia polymorphisms in pregnant women and an increased risk of intrauterine growth restriction in their offspring, but this finding remains uncertain. Methods: We performed a hospital-based case-control study and a family-based study including 493 newborns with intrauterine growth restriction (defined by birth weight below the 10th percentile for gestational age and sex according to Canadian norms) and 472 controls (with birth weight at or above the 10th percentile). We determined the presence or absence in newborns and their parents of the following polymorphisms: methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C, factor V Leiden G1691A, and prothrombin G20210A. Mothers were interviewed to obtain information on other risk factors for intrauterine growth restriction. Results: The risk of intrauterine growth restriction was not increased among mothers carrying a polymorphism associated with thrombophilia. In the case-control study, the odds ratios associated with two copies of the variant, after adjustment for newborn genotype and other risk factors, were 1.55 for MTHFR C677T (95 percent confidence interval, 0.83 to 2.90) and 0.49 for MTHFR A1298C (95 percent confidence interval, 0.25 to 0.93); heterozygotes for factor V Leiden had an odds ratio of 1.18 (95 percent confidence interval, 0.54 to 2.55), and heterozygotes for prothrombin G20210A had an odds ratio of 0.92 (95 percent confidence interval, 0.36 to 2.35). These polymorphisms in the newborn were not associated with an increased risk. Newborns who were homozygous for the MTHFR C677T variant had a decreased risk of intrauterine growth restriction (odds ratio after adjustment for mother's genotype and other confounders, 0.52 [95 percent confidence interval, 0.29 to 0.94]). The results of the family-based study supported those of the case-control study. Conclusions: Our findings do not indicate that there are associations between maternal or newborn polymorphisms associated with thrombophilia and an increased risk of intrauterine growth restriction.	McGill Univ, Fac Med, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ H3A 1A3, Canada; Univ Montreal, Hop St Justine, Ctr Hosp Univ Mere Enfant, Res Ctr, Montreal, PQ H3T 1C5, Canada; Univ Montreal, Hop St Justine, Ctr Hosp Univ Mere Enfant, Div Hematol & Oncol, Montreal, PQ H3T 1C5, Canada; Univ Montreal, Hop St Justine, Ctr Hosp Univ Mere Enfant, Dept Obstet, Montreal, PQ H3T 1C5, Canada; INSERM, U535, Paris, France; NIEHS, Res Triangle Pk, NC 27709 USA	McGill University; Universite de Montreal; Universite de Montreal; Universite de Montreal; Institut National de la Sante et de la Recherche Medicale (Inserm); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Infante-Rivard, C (corresponding author), McGill Univ, Fac Med, Dept Epidemiol Biostat & Occupat Hlth, 1130 Pine Ave W, Montreal, PQ H3A 1A3, Canada.		Genin, Emmanuelle/C-4974-2013; Guiguet, Marguerite/L-8480-2018	Genin, Emmanuelle/0000-0003-4117-2813; Weinberg, Clarice/0000-0002-7713-8556	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES100490, ZIAES040007, Z01ES040007] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		*ACOG, 2000, ACOG PRACT B, V12, P1; ARBUCKLE TE, 1993, OBSTET GYNECOL, V81, P39; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Brenner B, 2000, CURR OPIN HEMATOL, V7, P290, DOI 10.1097/00062752-200009000-00006; Cardon LR, 2001, NAT REV GENET, V2, P91, DOI 10.1038/35052543; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; Hankey GJ, 1999, LANCET, V354, P407, DOI 10.1016/S0140-6736(98)11058-9; Helewa ME, 1997, CAN MED ASSOC J, V157, P715; INFANTERIVARD C, 1991, NEW ENGL J MED, V325, P1063, DOI 10.1056/NEJM199110103251503; Kupferminc MJ, 2000, ACTA OBSTET GYN SCAN, V79, P963, DOI 10.1034/j.1600-0412.2000.079011963.x; Kupferminc MJ, 1999, NEW ENGL J MED, V340, P9, DOI 10.1056/NEJM199901073400102; Lane DA, 2000, BLOOD, V95, P1517, DOI 10.1182/blood.V95.5.1517.005k48_1517_1532; Lensing AWA, 1999, LANCET, V353, P479, DOI 10.1016/S0140-6736(98)04298-6; Martinelli P, 2001, HAEMATOLOGICA, V86, P428; Matte TD, 2001, BRIT MED J, V323, P310, DOI 10.1136/bmj.323.7308.310; McIntire DD, 1999, NEW ENGL J MED, V340, P1234, DOI 10.1056/NEJM199904223401603; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; Rozen R, 2000, SEMIN THROMB HEMOST, V26, P255, DOI 10.1055/s-2000-8470; Schaid DJ, 1999, AM J EPIDEMIOL, V149, P706; Seeds JW, 1998, AM J OBSTET GYNECOL, V178, P658, DOI 10.1016/S0002-9378(98)70475-2; Skibola CF, 1999, P NATL ACAD SCI USA, V96, P12810, DOI 10.1073/pnas.96.22.12810; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Szczeklik A, 2001, AM J MED GENET, V101, P36, DOI 10.1002/ajmg.1315; Ueland PM, 2000, AM J CLIN NUTR, V72, P324; USHER R, 1969, J PEDIATR-US, V74, P901, DOI 10.1016/S0022-3476(69)80224-6; van der Put NMJ, 1998, AM J HUM GENET, V62, P1044, DOI 10.1086/301825; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1019, DOI 10.1093/oxfordjournals.aje.a116396; Weinberg CR, 1998, AM J HUM GENET, V62, P969, DOI 10.1086/301802; Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507; Zietkiewicz E, 1997, GENE, V205, P161	30	186	194	0	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 4	2002	347	1					19	25		10.1056/NEJM200207043470105	http://dx.doi.org/10.1056/NEJM200207043470105			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569HA	12097536	Bronze			2022-12-28	WOS:000176594500004
J	Kinsinger, LS; Harris, R; Woolf, SH; Sox, HC; Lohr, KN				Kinsinger, LS; Harris, R; Woolf, SH; Sox, HC; Lohr, KN			Chemoprevention of breast cancer: A summary of the evidence for the US Preventive Services Task Force	ANNALS OF INTERNAL MEDICINE			English	Article							SURGICAL ADJUVANT BREAST; BOWEL PROJECT P-1; QUALITY-OF-LIFE; POSTMENOPAUSAL WOMEN; RANDOMIZED-TRIAL; TAMOXIFEN THERAPY; HYSTERECTOMIZED WOMEN; CARDIOVASCULAR HEALTH; ESTROGEN-RECEPTORS; SERUM ESTRADIOL	Purpose: Chemoprevention offers promise as a strategy for reducing morbidity and mortality from breast cancer in women. This review examined the evidence for the effectiveness of chemoprevention in women without a history of breast cancer. Data Sources: MEDLINE (1966 to December 2001). Study Selection: English-language, randomized, controlled trials (RCTs) of chemoprevention of breast cancer in women without a previous diagnosis of breast cancer were examined, and 4 relevant trials, 3 involving tamoxifen and 1 involving raloxifene, were selected. Trials that provided data on the harms of tamoxifen or raloxifene, studies of the costs of chemoprevention, and studies of risk assessment were also reviewed. Data Extraction: Four reviewers independently abstracted data on key variables, including study population, sample size, randomization, treatment, and outcomes. Data Synthesis: The largest of the RCTs of tamoxifen reported a 49% reduction in relative risk (0.51 [95% Cl, 0.39 to 0.66]) for invasive cancer among women with an estimated 5-year breast cancer risk of at least 1.66%. The other tamoxifen trials did not observe a statistically significant benefit, but only a few women in each trial took tamoxifen during the entire study period. The raloxifene study of postmenopausal women with osteoporosis found a 76% reduction in relative risk (0.24 [Cl, 0.13 to 0.44]) for invasive breast cancer. Tamoxifen and raloxifene were effective only against estrogen receptor-positive tumors. Both drugs increased risk for venous thromboembolic disease and hot flashes; tamoxifen increased risk for endometrial cancer and stroke. Conclusions: Tamoxifen and raloxifene reduce the incidence of estrogen receptor-positive breast cancer in women. The relative risk reduction seems similar across all breast cancer risk groups. The absolute risk reduction varies by risk factors for breast cancer, however, and must be balanced against the potential harms to judge the appropriateness of treatment for individual women.	Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27514 USA; Virginia Commonwealth Univ, Fairfax, VA USA; Amer Coll Physicians, Amer Soc Internal Med, Philadelphia, PA USA; Res Triangle Inst, Res Triangle Pk, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill; Virginia Commonwealth University; American College of Physicians; Research Triangle Institute	Kinsinger, LS (corresponding author), Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27514 USA.			Lohr, Kathleen/0000-0002-3825-0713	PHS HHS [290-97-0011] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1992, Lancet, V339, P1; [Anonymous], 1998, LANCET, V351, P1451; Armstrong K, 2000, NEW ENGL J MED, V342, P564, DOI 10.1056/NEJM200002243420807; Barrett-Connor E, 2002, JAMA-J AM MED ASSOC, V287, P847, DOI 10.1001/jama.287.7.847; Barrett-Connor E, 1998, MATURITAS, V31, P1; Benichou J, 1996, J CLIN ONCOL, V14, P103, DOI 10.1200/JCO.1996.14.1.103; BONDY ML, 1994, J NATL CANCER I, V86, P620, DOI 10.1093/jnci/86.8.620; BRODERICK JP, 1989, STROKE, V20, P577, DOI 10.1161/01.STR.20.5.577; Bruzzi P, 1998, BRIT MED J, V316, P1181, DOI 10.1136/bmj.316.7139.1181; Cauley JA, 2001, BREAST CANCER RES TR, V65, P125, DOI 10.1023/A:1006478317173; Cauley JA, 1999, ANN INTERN MED, V130, P270, DOI 10.7326/0003-4819-130-4_Part_1-199902160-00004; Chu KC, 1996, JNCI-J NATL CANCER I, V88, P1571, DOI 10.1093/jnci/88.21.1571; Costantino JP, 1999, J NATL CANCER I, V91, P1541, DOI 10.1093/jnci/91.18.1541; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; Cummings SR, 2002, JAMA-J AM MED ASSOC, V287, P216, DOI 10.1001/jama.287.2.216; Cuzick J, 2001, ANN NY ACAD SCI, V949, P123; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; Day R, 1999, J CLIN ONCOL, V17, P2659, DOI 10.1200/JCO.1999.17.9.2659; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; Fisher B, 1992, J Natl Cancer Inst Monogr, P105; Fisher B, 1999, LANCET, V353, P1993, DOI 10.1016/S0140-6736(99)05036-9; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fisher B, 1996, JNCI-J NATL CANCER I, V88, P1529, DOI 10.1093/jnci/88.21.1529; Fisher D, 1997, ARACHNE, V4, P78; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; Gail MH, 1999, J NATL CANCER I, V91, P1829, DOI 10.1093/jnci/91.21.1829; Gail MH, 2001, J NATL CANCER I, V93, P334, DOI 10.1093/jnci/93.5.334; Ganz PA, 2002, JNCI-J NATL CANCER I, V94, P39; Grann VR, 2000, CANCER J, V6, P169; HABEL LA, 1993, EPIDEMIOL REV, V15, P209, DOI 10.1093/oxfordjournals.epirev.a036107; Hankinson SE, 1998, JNCI-J NATL CANCER I, V90, P1292, DOI 10.1093/jnci/90.17.1292; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; HULKA BS, 1995, LANCET, V346, P883, DOI 10.1016/S0140-6736(95)92713-1; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115; Kelsey JL, 1996, ANNU REV PUBL HEALTH, V17, P47, DOI 10.1146/annurev.pu.17.050196.000403; King MC, 2001, JAMA-J AM MED ASSOC, V286, P2251, DOI 10.1001/jama.286.18.2251; KINSINGER L, 2001, IN PRESS CHEMOPROPHY; Kinsinger L S, 2001, Breast Dis, V13, P21; Kuller L, 1998, ARTERIOSCL THROM VAS, V18, P283, DOI 10.1161/01.ATV.18.2.283; LeBlanc ES, 1999, J GEN INTERN MED, V14, P625, DOI 10.1046/j.1525-1497.1999.08108.x; Lippman SM, 1999, JNCI-J NATL CANCER I, V91, P1809, DOI 10.1093/jnci/91.21.1809; LOVE RR, 1990, JNCI-J NATL CANCER I, V82, P1327, DOI 10.1093/jnci/82.16.1327; MacGregor JI, 1998, PHARMACOL REV, V50, P151; Manolio TA, 1996, STROKE, V27, P1479, DOI 10.1161/01.STR.27.9.1479; *NCI NSABP, 2002, PREV STUD TAM RAL ST; *NCI NSABP, 2002, BREAST CANC RISK ASS; Noe LL, 1999, AM J MANAG CARE, V5, pS389; POTTER JD, 1995, CANCER EPIDEM BIOMAR, V4, P319; Powles T, 1998, LANCET, V352, P98; Radmacher MD, 2000, J NATL CANCER I, V92, P48, DOI 10.1093/jnci/92.1.48; Rockhill B, 2001, J NATL CANCER I, V93, P358, DOI 10.1093/jnci/93.5.358; Rockhill B, 2000, J NATL CANCER I, V92, P657, DOI 10.1093/jnci/92.8.657A; Rosamond WD, 1999, STROKE, V30, P736, DOI 10.1161/01.STR.30.4.736; RUTQVIST LE, 1991, J NATL CANCER I, V83, P1299, DOI 10.1093/jnci/83.18.1299; SACCO RL, 1991, STROKE, V22, P1491, DOI 10.1161/01.STR.22.12.1491; Silverstein MD, 1998, ARCH INTERN MED, V158, P585, DOI 10.1001/archinte.158.6.585; SPIEGELMAN D, 1994, J NATL CANCER I, V86, P600, DOI 10.1093/jnci/86.8.600; STANFORD JL, 1986, EPIDEMIOL REV, V8, P42, DOI 10.1093/oxfordjournals.epirev.a036295; Stewart H J, 1992, J Natl Cancer Inst Monogr, P117; Stewart HJ, 2001, JNCI-J NATL CANCER I, V93, P456, DOI 10.1093/jnci/93.6.456; Taylor AL, 1999, J NATL CANCER I, V91, P1792, DOI 10.1093/jnci/91.21.1792; TONIOLO PG, 1995, JNCI-J NATL CANCER I, V87, P190, DOI 10.1093/jnci/87.3.190; Verloop J, 2000, J NATL CANCER I, V92, P128, DOI 10.1093/jnci/92.2.128; Veronesi U, 1998, LANCET, V352, P93; Veronesi U, 2002, LANCET, V359, P1122, DOI 10.1016/S0140-6736(02)08159-X; Veronesi U, 1999, J NATL CANCER I, V91, P1847, DOI 10.1093/jnci/91.21.1847; Walsh BW, 1998, JAMA-J AM MED ASSOC, V279, P1445, DOI 10.1001/jama.279.18.1445; Whisnant JP, 1996, NEUROLOGY, V47, P1420, DOI 10.1212/WNL.47.6.1420; Zhang YQ, 1997, NEW ENGL J MED, V336, P611, DOI 10.1056/NEJM199702273360903; Zmuda JM, 2001, J NATL CANCER I, V93, P930, DOI 10.1093/jnci/93.12.930; 2002, MMWR MORB MORTAL WKL, V51, P49; 1999, J NATL CANC I MONOGR, V25, P1	73	81	84	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 2	2002	137	1					59	67		10.7326/0003-4819-137-1-200207020-00017	http://dx.doi.org/10.7326/0003-4819-137-1-200207020-00017			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569VA	12093250				2022-12-28	WOS:000176622000011
J	Arendt, AA; Echelmeyer, KA; Harrison, WD; Lingle, CS; Valentine, VB				Arendt, AA; Echelmeyer, KA; Harrison, WD; Lingle, CS; Valentine, VB			Rapid wastage of Alaska glaciers and their contribution to rising sea level	SCIENCE			English	Article							MASS-BALANCE; CLIMATE-CHANGE; ELEVATION; RISE; ICEFIELD; VOLUME; MELT	We have used airborne laser altimetry to estimate volume changes of 67 glaciers in Alaska from the mid-1950s to the mid-1990s. The average rate of thickness change of these glaciers was -0.52 m/year. Extrapolation to all glaciers in Alaska yields an estimated total annual volume change of -52 +/- 15 km(3)/year (water equivalent), equivalent to a rise in sea level (SLE) of 0.14 +/- 0.04 mm/year. Repeat measurements of 28 glaciers from the mid-1990s to 2000 2001 suggest an increased average rate of thinning, -1.8 m/year. This leads to an extrapolated annual volume loss from Alaska glaciers equal to 96 +/- 35 km(3)/year, or 0.27 +/- mm/ year SLE, during the past decade. These recent losses are nearly double the estimated annual loss from the entire Greenland Ice Sheet during the same time period and are much higher than previously published loss estimates for Alaska glaciers. They form the largest glaciological contribution to rising sea level yet measured.	Univ Alaska, Inst Geophys, Fairbanks, AK 99775 USA	University of Alaska System; University of Alaska Fairbanks	Arendt, AA (corresponding author), Univ Alaska, Inst Geophys, 903 Koyukuk Dr,POB 757320, Fairbanks, AK 99775 USA.	arendta@gi.alaska.edu		Arendt, Anthony/0000-0003-0429-6905				Adalgeirsdottir G, 1998, J GLACIOL, V44, P570, DOI 10.3189/S0022143000002082; Cabanes C, 2001, SCIENCE, V294, P840, DOI 10.1126/science.1063556; Cubasch U., 2001, CLIMATE CHANGE 2001, P525; Dyurgerov MB, 2000, P NATL ACAD SCI USA, V97, P1406, DOI 10.1073/pnas.97.4.1406; Dyurgerov MB, 1997, ARCTIC ALPINE RES, V29, P392, DOI 10.2307/1551987; Dyurgerov MB, 1997, ARCTIC ALPINE RES, V29, P379, DOI 10.2307/1551986; Echelmeyer KA, 1996, J GLACIOL, V42, P538, DOI 10.3189/S002214300000352X; Fountain AG, 1999, GEOGR ANN A, V81A, P563; Gregory JM, 1998, NATURE, V391, P474, DOI 10.1038/35119; Haeberli W., 1989, WORLD GLACIER INVENT; Harrison WD, 2001, J GLACIOL, V47, P659, DOI 10.3189/172756501781831837; Hodge SM, 1998, J CLIMATE, V11, P2161, DOI 10.1175/1520-0442(1998)011<2161:CVACIM>2.0.CO;2; JOHANNESSON T, 1989, J GLACIOL, V35, P355, DOI 10.3189/S002214300000928X; Krabill W, 2000, SCIENCE, V289, P428, DOI 10.1126/science.289.5478.428; MEIER MF, 1984, SCIENCE, V226, P1418, DOI 10.1126/science.226.4681.1418; MEIER MF, 1993, ICE CLIMATE SYSTEM, P141; Miller MM, 1999, GEOGR ANN A, V81A, P671, DOI 10.1111/1468-0459.00095; PATERSON W, 1994, PHYSICS GLACIERS, P14; PELTO MS, 1990, NORTHWEST SCI, V64, P121; Rabus BT, 1998, J GLACIOL, V44, P333, DOI 10.3189/S0022143000002665; Sapiano JJ, 1998, J GLACIOL, V44, P119, DOI 10.3189/S0022143000002410; Zuo Z, 1997, CLIM DYNAM, V13, P835, DOI 10.1007/s003820050200	22	469	481	2	123	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 19	2002	297	5580					382	386		10.1126/science.1072497	http://dx.doi.org/10.1126/science.1072497			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574LV	12130781				2022-12-28	WOS:000176892600046
J	Moulik, PK; Hadcroft, J				Moulik, PK; Hadcroft, J			An unusual case of orthopnea	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Hosp Aintree, Liverpool L9 7AL, Merseyside, England		Moulik, PK (corresponding author), Univ Hosp Aintree, Liverpool L9 7AL, Merseyside, England.								0	0	0	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 18	2002	347	3					193	193		10.1056/NEJMicm020378	http://dx.doi.org/10.1056/NEJMicm020378			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	574BR	12124408				2022-12-28	WOS:000176869000006
J	Turner, J; King, JC; Lachlan-Cope, TA; Jones, PD				Turner, J; King, JC; Lachlan-Cope, TA; Jones, PD			Climate change - Recent temperature trends in the Antarctic	NATURE			English	Article									British Antarctic Survey, NERC, Cambridge CB3 0ET, England; Univ E Anglia, Climat Res Unit, Norwich NR4 7TJ, Norfolk, England	UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Antarctic Survey; University of East Anglia	Turner, J (corresponding author), British Antarctic Survey, NERC, Cambridge CB3 0ET, England.		Jones, Philip Douglas/C-8718-2009	Jones, Philip Douglas/0000-0001-5032-5493; MCKNIGHT, DIANE/0000-0002-4171-1533; Walsh, John/0000-0001-9541-5927				Comiso JC, 2000, J CLIMATE, V13, P1674, DOI 10.1175/1520-0442(2000)013<1674:VATIAS>2.0.CO;2; Doran PT, 2002, NATURE, V415, P517, DOI 10.1038/nature710; Jones PD, 1999, REV GEOPHYS, V37, P173, DOI 10.1029/1999RG900002; Shuman CA, 2001, J CLIMATE, V14, P1977, DOI 10.1175/1520-0442(2001)014<1977:DLCIWA>2.0.CO;2; Vaughan DG, 2001, SCIENCE, V293, P1777, DOI 10.1126/science.1065116	5	41	43	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 18	2002	418	6895					291	292		10.1038/418291b	http://dx.doi.org/10.1038/418291b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574BF	12124614				2022-12-28	WOS:000176868000032
J	Egger, M; May, M; Chene, G; Phillips, AN; Ledergerber, B; Dabis, F; Costagliola, D; Monforte, AD; de Wolf, F; Reiss, P; Lundgren, JD; Justice, AC; Staszewski, S; Leport, C; Hogg, RS; Sabin, CA; Gill, MJ; Salzberger, B; Sterne, JAC				Egger, M; May, M; Chene, G; Phillips, AN; Ledergerber, B; Dabis, F; Costagliola, D; Monforte, AD; de Wolf, F; Reiss, P; Lundgren, JD; Justice, AC; Staszewski, S; Leport, C; Hogg, RS; Sabin, CA; Gill, MJ; Salzberger, B; Sterne, JAC		ART Cohort Collaboration	Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies	LANCET			English	Article							CD4 CELL COUNT; IMMUNODEFICIENCY-VIRUS-INFECTION; VIROLOGICAL RESPONSE; VIRAL LOAD; CLINICAL PROGRESSION; CONTROLLED-TRIAL; HIV-1 INFECTION; AIDS; MORTALITY; SURVIVAL	Background Insufficient data are available from single cohort studies to allow estimation of the prognosis of HIV-1 infected, treatment-naive patients who start highly active antiretroviral therapy (HAART). The ART Cohort Collaboration, which includes 13 cohort studies from Europe and North America, was established to fill this knowledge gap. Methods We analysed data on 12 574 adult patients starting HAART with a combination of at least three drugs. Data were analysed by intention-to-continue-treatment, ignoring treatment changes and interruptions. We considered progression to a combined endpoint of a new AIDS-defining disease or death, and to death alone. The prognostic model that generalised best was a Weibull model, stratified by baseline CD4 cell count and transmission group. Findings During 24 310 person-years of follow up, 1094 patients developed AIDS or died and 344 patients died. Baseline CD4 cell count was strongly associated with the probability of progression to AIDS or death: compared with patients starting HAART with less than 50 CD4 cells/muL, adjusted hazard ratios were 0.74 (95% CI 0.62-0.89) for 50-99 cells/muL, 0.52 (0.44-0.63) for 100-199 cells/muL, 0.24 (0.20-0.30) for 200-349 cells/muL, and 0.18 (0.14-0.22) for 350 or more CD4 cells/muL. Baseline HIV-1 viral load was associated with a higher probability of progression only if 100000 copies/mL or above. Other independent predictors of poorer outcome were advanced age, infection through injection-drug use, and a previous diagnosis of AIDS. The probability of progression to AIDS or death at 3 years ranged from 3.4% (2.8-4.1) in patients in the lowest-risk stratum for each prognostic variable, to 50% (43-58) in patients in the highest-risk strata. Interpretation The CD4 cell count at initiation was the dominant prognostic factor in patients starting HAART. Our findings have important implications for clinical management and should be taken into account in future treatment guidelines.	Univ Bern, Dept Social & Prevent Med, CH-3012 Bern, Switzerland; Univ Bristol, Dept Social Med, Bristol, Avon, England; Univ Victor Seglen, INSERM, U330, Bordeaux, France; UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London, England; Univ Zurich, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland; Ctr Hosp Univ Pitie Salpetriere, INSERM, EMI 0214, Paris, France; Univ Milan, Inst Infect & Trop Dis, Milan, Italy; Univ Amsterdam, Acad Med Ctr, HIV Monitoring Fdn, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Natl AIDS Therpay Evaluat Ctr, NL-1105 AZ Amsterdam, Netherlands; Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Infect Dis Epidemiol, London, England; Hvidovre Univ Hosp, Dept Infect Dis, DK-2650 Hvidovre, Denmark; VA Pittsburgh Healthcare Syst, Gen Internal Med Sect, Pittsburgh, PA USA; Goethe Univ Frankfurt, Zentrum Inneren Med, Frankfurt, Germany; Hop Bichat Claude Bernard, Serv Malad Infect & Trop, F-75877 Paris 18, France; BC Ctr Excellence HIV AIDS, Div Epidemiol & Populat Hlth, Vancouver, BC, Canada; Univ Calgary, Div Infect Dis, Calgary, AB, Canada; Klinikum Univ Regensburg, Innere Med Klin 1, Regensburg, Germany	University of Bern; University of Bristol; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; University of London; University College London; UCL Medical School; University of Zurich; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Milan; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Imperial College London; University of Copenhagen; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; Goethe University Frankfurt; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; B.C. Centre for Excellence in HIV/AIDS; University of Calgary; University of Regensburg	Egger, M (corresponding author), Univ Bern, Dept Social & Prevent Med, CH-3012 Bern, Switzerland.	egger@ispm.unibe.ch	May, Margaret T/E-8099-2013; Lundgren, Jens/AAE-6876-2019; Sabin, Caroline/C-2464-2008; Sterne, Jonathan/Z-3106-2019; Costagliola, Dominique/H-5849-2011; DABIS, FRANCOIS/S-9298-2019; Ledergerber, Bruno/B-5656-2009; VALLET, Yannick/F-9979-2011; Hogg, Robert S/B-2783-2012; Dodsley, Maria/G-7083-2016; chene, genevieve/H-8665-2014; Phillips, Andrew N/B-4427-2008; Gill, Michael John/G-7083-2016	May, Margaret T/0000-0002-9733-1003; Sabin, Caroline/0000-0001-5173-2760; Sterne, Jonathan/0000-0001-8496-6053; Costagliola, Dominique/0000-0003-0765-0869; DABIS, FRANCOIS/0000-0002-1614-8857; Ledergerber, Bruno/0000-0002-6881-4401; Hogg, Robert S/0000-0003-3463-5488; Dodsley, Maria/0000-0001-7587-558X; chene, genevieve/0000-0002-8368-6460; Phillips, Andrew N/0000-0003-2384-4807; Lundgren, Jens/0000-0001-8901-7850; Egger, Matthias/0000-0001-7462-5132; Gill, Michael John/0000-0002-8546-8790	MRC [G0100221] Funding Source: UKRI; Medical Research Council [G0100221] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Babiker A, 2000, AIDS RES HUM RETROV, V16, P1123; Becker SL, 2001, J ACQ IMMUN DEF SYND, V26, P72, DOI 10.1097/00126334-200101010-00011; Binquet C, 2001, AM J EPIDEMIOL, V153, P386, DOI 10.1093/aje/153.4.386; Brodt HR, 1997, AIDS, V11, P1731, DOI 10.1097/00002030-199714000-00010; Cameron DW, 1998, LANCET, V351, P543, DOI 10.1016/S0140-6736(97)04161-5; Chaisson RE, 1998, AIDS, V12, P29, DOI 10.1097/00002030-199801000-00004; Egger M, 2001, AIDS, V15, pS193, DOI 10.1097/00002030-200100005-00023; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; ESKILD A, 1993, INT J EPIDEMIOL, V22, P315, DOI 10.1093/ije/22.2.315; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; Fatkenheuer G, 1997, AIDS, V11, pF113, DOI 10.1097/00002030-199714000-00001; Fellay J, 2002, LANCET, V359, P30, DOI 10.1016/S0140-6736(02)07276-8; Frisch M, 2001, JAMA-J AM MED ASSOC, V285, P1736, DOI 10.1001/jama.285.13.1736; Grabar S, 2000, ANN INTERN MED, V133, P401, DOI 10.7326/0003-4819-133-6-200009190-00007; Greub G, 2000, LANCET, V356, P1800, DOI 10.1016/S0140-6736(00)03232-3; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Harrington M, 2000, LANCET, V355, P2147, DOI 10.1016/S0140-6736(00)02388-6; Hogg RS, 1999, CAN MED ASSOC J, V160, P659; Hogg RS, 2001, JAMA-J AM MED ASSOC, V286, P2568, DOI 10.1001/jama.286.20.2568; Hughes MD, 1998, AIDS, V12, P1823, DOI 10.1097/00002030-199814000-00014; Justice AC, 1999, ANN INTERN MED, V130, P515, DOI 10.7326/0003-4819-130-6-199903160-00016; Le Moing V, 2002, J INFECT DIS, V185, P471, DOI 10.1086/338929; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Lederman MM, 2000, JAMA-J AM MED ASSOC, V284, P223, DOI 10.1001/jama.284.2.223; Lundgren JD, 1997, J ACQ IMMUN DEF SYND, V16, P153, DOI 10.1097/00042560-199711010-00003; Lundgren JD, 2002, J INFECT DIS, V185, P178, DOI 10.1086/338267; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Miettinen O S, 1983, Stat Med, V2, P267, DOI 10.1002/sim.4780020222; Mocroft A, 1999, AIDS, V13, P1255, DOI 10.1097/00002030-199907090-00016; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Mocroft A, 1998, AIDS, V12, P2161, DOI 10.1097/00002030-199816000-00011; Monforte AD, 2000, AIDS, V14, P499, DOI 10.1097/00002030-200003310-00005; Moore AL, 2001, J ACQ IMMUN DEF SYND, V26, P159, DOI 10.1097/00126334-200102010-00008; Nieuwkerk PT, 2001, ARCH INTERN MED, V161, P1962, DOI 10.1001/archinte.161.16.1962; PHILLIPS A N, 1991, Journal of Acquired Immune Deficiency Syndromes, V4, P970; Phillips AN, 2001, JAMA-J AM MED ASSOC, V286, P2560, DOI 10.1001/jama.286.20.2560; Royston P, 2001, STATA J, V1, P1, DOI 10.1177/1536867X0100100101; Saves M, 1999, AIDS, V13, pF115, DOI 10.1097/00002030-199912030-00002; Schuurman R, 1996, J CLIN MICROBIOL, V34, P3016, DOI 10.1128/JCM.34.12.3016-3022.1996; SELWYN PA, 1989, AM J PUBLIC HEALTH, V79, P1358, DOI 10.2105/AJPH.79.10.1358; Spiegelhalter DJ, 2002, J R STAT SOC B, V64, P583, DOI 10.1111/1467-9868.00353; Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: A collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action, 2000, RAP ADV ANT THER HIV, V355, P1131; Valdez H, 1999, JAMA-J AM MED ASSOC, V282, P734, DOI 10.1001/jama.282.8.734; Viard JP, 2001, J INFECT DIS, V183, P1290, DOI 10.1086/319678; Yamashita TE, 2001, AIDS, V15, P735, DOI 10.1097/00002030-200104130-00009	49	1187	1234	4	106	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 13	2002	360	9327					119	129		10.1016/S0140-6736(02)09411-4	http://dx.doi.org/10.1016/S0140-6736(02)09411-4			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573PB	12126821				2022-12-28	WOS:000176839100010
J	Metzger, TH				Metzger, TH			Applied physics: Squeezing x-ray photons	SCIENCE			English	Editorial Material							PROPAGATION; RESOLUTION		European Synchrotron Radiat Facil, F-38043 Grenoble, France	European Synchrotron Radiation Facility (ESRF)	Metzger, TH (corresponding author), European Synchrotron Radiat Facil, BP 220, F-38043 Grenoble, France.							Di Fonzo S, 2000, NATURE, V403, P638, DOI 10.1038/35001035; FENG YP, 1993, PHYS REV LETT, V71, P537, DOI 10.1103/PhysRevLett.71.537; Lagomarsino S, 1997, APPL PHYS LETT, V71, P2557, DOI 10.1063/1.119324; Pfeiffer F, 2002, SCIENCE, V297, P230, DOI 10.1126/science.1071994; SPILLER E, 1974, APPL PHYS LETT, V24, P60, DOI 10.1063/1.1655093; Zwanenburg MJ, 2000, PHYS REV LETT, V85, P5154, DOI 10.1103/PhysRevLett.85.5154; Zwanenburg MJ, 1999, PHYS REV LETT, V82, P1696, DOI 10.1103/PhysRevLett.82.1696	7	5	5	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 12	2002	297	5579					205	206		10.1126/science.1073847	http://dx.doi.org/10.1126/science.1073847			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571UT	12114615				2022-12-28	WOS:000176738100028
J	Nowlan, W				Nowlan, W			Human genetics: A rational view of insurance and genetic discrimination	SCIENCE			English	Editorial Material							INFORMATION; LAWS		Natl Life Insurance Co, Montpelier, VT 05604 USA		Nowlan, W (corresponding author), Natl Life Insurance Co, Montpelier, VT 05604 USA.							*AM COUNC LIF INS, 2000, LIF INS FACT BOOK 20; Annas GJ, 2001, NEW ENGL J MED, V345, P385, DOI 10.1056/NEJM200108023450523; ENGMAN M, 1998, AM AC INS MED ANN M; Greely HT, 2001, U PENN LAW REV, V149, P1483, DOI 10.2307/3312966; Hall MA, 2000, AM J HUM GENET, V66, P293, DOI 10.1086/302714; HALL MA, 2000, NY TIMES        0219, pD7; Holtzman NA, 2000, NEW ENGL J MED, V343, P141, DOI 10.1056/NEJM200007133430213; HUDSON KL, 1995, SCIENCE, V270, P391, DOI 10.1126/science.270.5235.391; Lapham EV, 1996, SCIENCE, V274, P621, DOI 10.1126/science.274.5287.621; LEE AM, 1939, FINE ART PROPAGANDA; NOWLAN WJ, 1999, NATL UNDERWRITER, V15, P39; Stephenson J, 1999, JAMA-J AM MED ASSOC, V282, P2197, DOI 10.1001/jama.282.23.2197; Welch HG, 1998, JAMA-J AM MED ASSOC, V280, P1525, DOI 10.1001/jama.280.17.1525	13	35	35	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 12	2002	297	5579					195	196		10.1126/science.1070987	http://dx.doi.org/10.1126/science.1070987			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571UT	12114609				2022-12-28	WOS:000176738100020
J	Mbulaiteye, SM; Mahe, C; Whitworth, JAG; Ruberantwari, A; Nakiyingi, JS; Ojwiya, A; Kamali, A				Mbulaiteye, SM; Mahe, C; Whitworth, JAG; Ruberantwari, A; Nakiyingi, JS; Ojwiya, A; Kamali, A			Declining HIV-1 incidence and associated prevalence over 10 years in a rural population in south-west Uganda: a cohort study	LANCET			English	Article							SEXUALLY-TRANSMITTED DISEASES; CONDOM PROMOTION; INFECTION-RATES; TANZANIA; BEHAVIOR; TRENDS; SEROPREVALENCE; PROSTITUTES; MORTALITY; EPIDEMIC	Background In Uganda, there have been encouraging reports of reductions in HIV-1 prevalence but not in incidence, which is the most reliable measure of epidemic trends. We describe HIV-1 incidence and prevalence trends in a rural population-based cohort between 1989 and 1999. Methods We surveyed the adult population of 15 neighbouring villages for HIV-1 infection using annual censuses, questionnaires, and serological surveys. We report crude annual incidence rates by calendar year and prevalence by survey round. Findings 6566 HIV-1 seronegative adults were bled two or more times between January, 1990, and December, 1999, contributing 31984 person years at risk (PYAR) and 190 seroconversions. HIV-1 incidence fell from 8.0 to 5.2 per 1000 PYAR between 1990 and 1999 (p=0.002, chi(2) for trend). Significant sex-specific and age-group-specific reductions in incidence were evident. Incidence was 37% lower for 1995-99 than for 1990-94 (p=0.002, t-test). On average, 4642 adult residents had a definite HIV-1 serostatus at each yearly survey round. HIV-1 prevalence fell significantly between the first and tenth annual survey rounds (p=0.03, chi(2) for trend), especially among men aged 20-24 years (6.5% to 2.2%) and 25-29 years (15.2% to 10.9%) and women aged 13-19 years (2.8% to 0.9%) and 20-24 years (19.3% to 10.1%) (all p<0-001, &chi;(2) for trend). Interpretation Our findings of a significant drop in adult HIV-1 incidence in rural Ugandans give hope to AIDS control programmes elsewhere in sub-Saharan Africa where rates of HIV-1 infection remain high.	Uganda Virus Res Inst, MRC, Program AIDS Uganda, Entebbe, Uganda	Uganda Virus Research Institute	Whitworth, JAG (corresponding author), Uganda Virus Res Inst, MRC, Program AIDS Uganda, POB 49, Entebbe, Uganda.		Mbulaiteye, Sam/O-3056-2019	Mbulaiteye, Sam/0000-0002-8273-9831				ALLEN S, 1992, JAMA-J AM MED ASSOC, V268, P3338, DOI 10.1001/jama.268.23.3338; ASIMWEOKIROR G, 1997, AIDS, V11, P1757; Baeten JM, 2000, J ACQ IMMUN DEF SYND, V24, P458, DOI 10.1097/00126334-200008150-00011; Fylkesnes K, 2001, AIDS, V15, P907, DOI 10.1097/00002030-200105040-00011; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; Joint Select Committee on Victims Compensation, 2000, REP GLOB HIV AIDS EP, P9; *JOINT UN PROGR HI, 1998, MEAS SUCC UG; Kamali A, 2000, AIDS, V14, P427, DOI 10.1097/00002030-200003100-00017; Kamali A, 1999, SEX TRANSM INFECT, V75, P98, DOI 10.1136/sti.75.2.98; KAMENGA M, 1991, AIDS, V5, P61, DOI 10.1097/00002030-199101000-00009; Kilian AHD, 1999, AIDS, V13, P391, DOI 10.1097/00002030-199902250-00012; LAGA M, 1994, LANCET, V344, P246, DOI 10.1016/S0140-6736(94)93005-8; Meda N, 1999, AIDS, V13, P1397, DOI 10.1097/00002030-199907300-00018; MULDER D, 1995, BRIT MED J, V311, P833, DOI 10.1136/bmj.311.7009.833; Ngweshemi JZL, 1996, AIDS, V10, P1415, DOI 10.1097/00002030-199610000-00015; Nunn AJ, 1997, BRIT MED J, V315, P767, DOI 10.1136/bmj.315.7111.767; NUNN AJ, 1993, AIDS, V7, P1057, DOI 10.1097/00002030-199308000-00005; Nunn AJ, 1996, LANCET, V348, P833, DOI 10.1016/S0140-6736(05)65261-0; NUNN AJ, 1995, AIDS, V9, P503, DOI 10.1097/00002030-199509050-00013; NUNN AJ, 1994, METHOD INFORM MED, V33, P253; Orroth KK, 2000, AIDS, V14, P1429, DOI 10.1097/00002030-200007070-00017; PIOT P, 2000, REPORT GLOBAL HIV AI; SEELEY J, 1991, AIDS Care, V3, P207, DOI 10.1080/09540129108253064; Senkoro KP, 2000, J ACQ IMMUN DEF SYND, V23, P194; Strickler Howard, 1995, Annals of Epidemiology, V5, P447, DOI 10.1016/1047-2797(95)00070-4; Tarantola D, 1997, AIDS, V11 Suppl B, pS5; Wawer MJ, 1997, AIDS, V11, P1023, DOI 10.1097/00002030-199708000-00011; WILLERFORD DM, 1993, J INFECT DIS, V167, P1414, DOI 10.1093/infdis/167.6.1414	28	113	114	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 6	2002	360	9326					41	46		10.1016/S0140-6736(02)09331-5	http://dx.doi.org/10.1016/S0140-6736(02)09331-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569JR	12114040				2022-12-28	WOS:000176599700010
J	Wienholds, E; Schulte-Merker, S; Walderich, B; Plasterk, RHA				Wienholds, E; Schulte-Merker, S; Walderich, B; Plasterk, RHA			Target-selected inactivation of the zebrafish rag1 gene	SCIENCE			English	Article							RADIATION HYBRID MAP; CAENORHABDITIS-ELEGANS; RECOMBINATION; MUTAGENESIS; EXPRESSION; MUTATIONS; REGION; GENOME	The zebrafish has become a favorite organism for genetic analysis of vertebrate development, but methods for generating mutants by reverse genetic approaches have been lacking. We report a method to obtain stable mutants of a gene based on knowledge of the gene sequence only. Parental fish were mutagenized with N-ethyl-N-nitrosourea; in 2679 F-1 fish, the rag1 gene was analyzed for heterozygous mutations by resequencing. In total, we found 15 mutations: 9 resulted in amino acid substitutions and 1 resulted in a premature stop codon. This truncation mutant was found to be homozygous viable and defective in V( D) J joining. Although presumably immune deficient, these homozygous rag1 mutant fish are able to reach adulthood and are fertile. As sperm samples from all 2679 F-1 fish were collected and cryopreserved, we have in principle generated a mutant library from which mutants of most zebrafish genes can be isolated.	Netherlands Inst Dev Biol, Hubrecht Lab, Ctr Biomed Genet, NL-3584 CT Utrecht, Netherlands; ARTEMIS Pharmaceut GmbH, Exelixis Deutschland, D-72076 Tubingen, Germany	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Plasterk, RHA (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Ctr Biomed Genet, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	plasterk@niob.knaw.nl						BALLINGER DG, 1989, P NATL ACAD SCI USA, V86, P9402, DOI 10.1073/pnas.86.23.9402; Beier DR, 2000, MAMM GENOME, V11, P594, DOI 10.1007/s003350010113; Bentley A, 2000, GENETICS, V156, P1169; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; COGHILL EL, 2002, NAT GENET, V19, P19; Danilova N, 2000, IMMUNOGENETICS, V52, P81, DOI 10.1007/s002510000255; DANILOVA N, COMMUNICATION; Driever W, 1996, DEVELOPMENT, V123, P37; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Geisler R, 1999, NAT GENET, V23, P86, DOI 10.1038/12692; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Gordon D, 2001, GENOME RES, V11, P614, DOI 10.1101/gr.171401; Haffter P, 1996, DEVELOPMENT, V123, P1; Hukriede N, 2001, GENOME RES, V11, P2127, DOI 10.1101/gr.210601; Jansen G, 1997, NAT GENET, V17, P119, DOI 10.1038/ng0997-119; Jansen G, 1999, NAT GENET, V21, P414, DOI 10.1038/7753; KAISER K, 1990, P NATL ACAD SCI USA, V87, P1686, DOI 10.1073/pnas.87.5.1686; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; Liu LX, 1999, GENOME RES, V9, P859, DOI 10.1101/gr.9.9.859; Ma CG, 2001, P NATL ACAD SCI USA, V98, P2461, DOI 10.1073/pnas.041449398; McCallum CM, 2000, NAT BIOTECHNOL, V18, P455, DOI 10.1038/74542; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745; Notarangelo LD, 1999, CURR OPIN IMMUNOL, V11, P435, DOI 10.1016/S0952-7915(99)80073-9; Parinov S, 2000, CURR OPIN BIOTECH, V11, P157, DOI 10.1016/S0958-1669(00)00075-6; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; van Eeden FJM, 1999, METHOD CELL BIOL, V60, P21; Willett CE, 1997, DEV BIOL, V182, P331, DOI 10.1006/dbio.1996.8446; Willett CE, 1997, IMMUNOGENETICS, V45, P394, DOI 10.1007/s002510050221; Woods IG, 2000, GENOME RES, V10, P1903, DOI 10.1101/gr.10.12.1903; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431	32	316	346	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 5	2002	297	5578					99	102		10.1126/science.1071762	http://dx.doi.org/10.1126/science.1071762			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571HB	12098699				2022-12-28	WOS:000176711000042
J	Boctor, FN; Uehlinger, J				Boctor, FN; Uehlinger, J			Malaria and sickle cell disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Yeshiva Univ Albert Einstein Coll Med, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Boctor, FN (corresponding author), Yeshiva Univ Albert Einstein Coll Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.								0	0	0	0	5	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 4	2002	347	1					E1	E1		10.1056/ENEJMicm010253	http://dx.doi.org/10.1056/ENEJMicm010253			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569HA	12097532				2022-12-28	WOS:000176594500007
J	Glockner, G; Eichinger, L; Szafranski, K; Pachebat, JA; Bankier, AT; Dear, PH; Lehmann, D; Baumgart, C; Parra, G; Abril, JF; Guigo, R; Kumpf, K; Tunggal, B; Cox, E; Quail, MA; Platzer, M; Rosenthal, A; Noegel, AA				Glockner, G; Eichinger, L; Szafranski, K; Pachebat, JA; Bankier, AT; Dear, PH; Lehmann, D; Baumgart, C; Parra, G; Abril, JF; Guigo, R; Kumpf, K; Tunggal, B; Cox, E; Quail, MA; Platzer, M; Rosenthal, A; Noegel, AA		Dictyostelium Genome Sequencing	Sequence and analysis of chromosome 2 of Dictyostelium discoideum	NATURE			English	Article							GENOME SEQUENCE; MODEL	The genome of the lower eukaryote Dictyostelium discoideum comprises six chromosomes. Here we report the sequence of the largest, chromosome 2, which at 8 megabases (Mb) represents about 25% of the genome. Despite an A+T content of nearly 80%, the chromosome codes for 2,799 predicted protein coding genes and 73 transfer RNA genes. This gene density, about 1 gene per 2.6 kilobases (kb), is surpassed only by Saccharomyces cerevisiae (one per 2 kb) and is similar to that of Schizosaccharomyces pombe (one per 2.5 kb)(1,2). If we assume that the other chromosomes have a similar gene density, we can expect around 11,000 genes in the D. discoideum genome. A significant number of the genes show higher similarities to genes of vertebrates than to those of other fully sequenced eukaryotes(1-6). This analysis strengthens the view that the evolutionary position of D. discoideum is located before the branching of metazoa and fungi but after the divergence of the plant kingdom(7), placing it close to the base of metazoan evolution.	Univ Cologne, Fac Med, Ctr Biochem, D-50931 Cologne, Germany; IMB Jena, Dept Genome Anal, D-07745 Jena, Germany; Univ Cambridge, MRC Ctr, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Pompeu Fabra, Inst Municipal Invest Med, Grp Recerca Informat Biomed, Ctr Regulacio Genom, Barcelona 08003, Spain; Princeton Univ, Princeton, NJ 08544 USA; Sanger Inst, Hinxton CB10 1SA, Cambs, England; Univ Jena, D-07743 Jena, Germany	University of Cologne; MRC Laboratory Molecular Biology; University of Cambridge; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Princeton University; Wellcome Trust Sanger Institute; Friedrich Schiller University of Jena	Glockner, G (corresponding author), Univ Cologne, Fac Med, Ctr Biochem, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.	gernot@imb-jena.de; noegel@uni-koeln.de	Glöckner, Gernot/A-7800-2010; Quail, michael/ABE-6131-2020; Guigo, Roderic/D-1303-2010; Ferrando, Josep F Abril/B-3877-2014; Dear, Paul H/A-1162-2012; Eichinger, Ludwig/AAJ-8895-2021; Gasull, Martina/J-4076-2019	Glöckner, Gernot/0000-0002-9061-1061; Guigo, Roderic/0000-0002-5738-4477; Ferrando, Josep F Abril/0000-0001-7793-589X; Eichinger, Ludwig/0000-0003-1594-6117; Pachebat, Justin/0000-0003-3369-3205; Parra, Genis/0000-0002-0575-2936				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Apweiler R, 2000, BIOINFORMATICS, V16, P1145, DOI 10.1093/bioinformatics/16.12.1145; Arabidopsis Genome Initiative, 2000, Nature (London), V408, P796, DOI 10.1038/35048692; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Baldauf SL, 2000, SCIENCE, V290, P972, DOI 10.1126/science.290.5493.972; Bowman S, 1999, NATURE, V400, P532, DOI 10.1038/22964; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; COX EC, 1990, P NATL ACAD SCI USA, V87, P8247, DOI 10.1073/pnas.87.21.8247; Dear P.H., 1997, GENOME MAPPING PRACT, P95; Eichinger L, 1999, MICROSC RES TECHNIQ, V47, P124, DOI 10.1002/(SICI)1097-0029(19991015)47:2<124::AID-JEMT5>3.0.CO;2-8; Firtel RA, 2000, CURR OPIN GENET DEV, V10, P421, DOI 10.1016/S0959-437X(00)00107-6; Fortini ME, 2000, J CELL BIOL, V150, pF23, DOI 10.1083/jcb.150.2.F23; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; Glockner G, 2001, GENOME RES, V11, P585, DOI 10.1101/gr.GR-1622RR; GLOCKNER G, 2000, CURR GENOMICS, V1, P289; GOEBL MG, 1986, CELL, V46, P983, DOI 10.1016/0092-8674(86)90697-5; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Kay RR, 1999, TRENDS GENET, V15, P294, DOI 10.1016/S0168-9525(99)01770-9; Konfortov BA, 2000, GENOME RES, V10, P1737, DOI 10.1101/gr.141700; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lim LP, 2001, P NATL ACAD SCI USA, V98, P11193, DOI 10.1073/pnas.201407298; Loomis WF, 1996, MICROBIOL REV, V60, P135, DOI 10.1128/MMBR.60.1.135-150.1996; LOOMIS WF, 1997, DICTYOSTELIUM MODEL, P15; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Morio T, 1998, DNA Res, V5, P335, DOI 10.1093/dnares/5.6.335; Noegel AA, 2000, J CELL SCI, V113, P759; PAN WC, 1981, CELL, V23, P459, DOI 10.1016/0092-8674(81)90141-0; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Parra G, 2000, GENOME RES, V10, P511, DOI 10.1101/gr.10.4.511; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724	30	143	1053	2	18	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 4	2002	418	6893					79	85		10.1038/nature00847	http://dx.doi.org/10.1038/nature00847			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	569JL	12097910				2022-12-28	WOS:000176599200042
J	Debiec, H; Guigonis, V; Mougenot, B; Decobert, F; Haymann, J; Bensman, A; Deschenes, G; Ronco, PM				Debiec, H; Guigonis, V; Mougenot, B; Decobert, F; Haymann, J; Bensman, A; Deschenes, G; Ronco, PM			Brief report - Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LYMPHOBLASTIC-LEUKEMIA ANTIGEN; HEYMANN NEPHRITIS; ENKEPHALINASE; GP330; LOCALIZATION; MODULATION; INDUCTION; MECHANISM; PEPTIDE; RATS		Hop Tenon, INSERM, U489, F-75020 Paris, France; Armand Trousseau Hosp, Dept Pediat Neurol, Paris, France; Assistance Publ Hop Paris, Paris, France; Univ Paris 06, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Sorbonne Universite	Ronco, PM (corresponding author), Hop Tenon, INSERM, U489, 4 Rue Chine, F-75020 Paris, France.		Guigonis, Vincent/O-8863-2016; Debiec, Hanna/AAL-8144-2021; Ronco, Pierre/AAC-8390-2022	Guigonis, Vincent/0000-0002-2529-0919; Debiec, Hanna/0000-0002-8946-8245; deschenes, georges/0000-0002-5158-2915				ARDAILLOU N, 1992, J CELL PHYSIOL, V152, P599, DOI 10.1002/jcp.1041520320; AVIV R, 1995, KIDNEY INT, V47, P855, DOI 10.1038/ki.1995.128; Brandslund I, 1981, Methods Enzymol, V74 Pt C, P551; Debiec H, 1998, J CELL BIOL, V143, P2067, DOI 10.1083/jcb.143.7.2067; DESCHODTLANCKMAN M, 1989, LIFE SCI, V45, P133, DOI 10.1016/0024-3205(89)90287-7; DOUGLAS MFS, 1981, NEW ENGL J MED, V305, P1326, DOI 10.1056/NEJM198111263052206; DUSSAULE JC, 1993, AM J PHYSIOL, V264, P45; ERDOS EG, 1989, FASEB J, V3, P145, DOI 10.1096/fasebj.3.2.2521610; HEYMANN W, 1959, P SOC EXP BIOL MED, V100, P660; Horl WH, 2000, J NEPHROL, V13, P291; JONGENEEL CV, 1989, J CLIN INVEST, V83, P713, DOI 10.1172/JCI113936; JORDAN SC, 1981, NEW ENGL J MED, V304, P1212, DOI 10.1056/NEJM198105143042006; KERJASCHKI D, 1983, J EXP MED, V157, P667, DOI 10.1084/jem.157.2.667; KERJASCHKI D, 1987, AM J PATHOL, V129, P183; LEHMAN DH, 1974, TRANSPLANTATION, V17, P429, DOI 10.1097/00007890-197404000-00017; LETARTE M, 1988, J EXP MED, V168, P1247, DOI 10.1084/jem.168.4.1247; LU B, 1995, J EXP MED, V181, P2271, DOI 10.1084/jem.181.6.2271; MALATHI P, 1979, BIOCHIM BIOPHYS ACTA, V554, P259, DOI 10.1016/0005-2736(79)90023-3; MATSUO S, 1985, J CLIN INVEST, V75, P1369, DOI 10.1172/JCI111838; METZGAR RS, 1981, J EXP MED, V154, P1249, DOI 10.1084/jem.154.4.1249; NARUSE T, 1973, Journal of Immunology, V110, P1163; NAUTA J, 1990, PEDIATR NEPHROL, V4, P111, DOI 10.1007/BF00858820; Papandreou CN, 1998, NAT MED, V4, P50, DOI 10.1038/nm0198-050; RONCO P, 1988, LAB INVEST, V58, P210; RONCO P, 1989, Applied Pathology, V7, P85; Ronco P M, 1994, Adv Nephrol Necker Hosp, V23, P91; Ronco PM, 1999, KIDNEY INT, V56, P355, DOI 10.1046/j.1523-1755.1999.00548.x; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; TAUC M, 1988, J HISTOCHEM CYTOCHEM, V36, P523, DOI 10.1177/36.5.2895788; Turner AJ, 1997, FASEB J, V11, P355, DOI 10.1096/fasebj.11.5.9141502; ZANETTI M, 1981, CLIN NEPHROL, V15, P272	31	349	389	0	18	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 27	2002	346	26					2053	2060		10.1056/NEJMoa012895	http://dx.doi.org/10.1056/NEJMoa012895			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566DN	12087141				2022-12-28	WOS:000176411900006
J	Zhang, RG; Pappas, T; Brace, JL; Miller, PC; Oulmassov, T; Molyneauz, JM; Anderson, JC; Bashkin, JK; Winans, SC; Joachimiak, A				Zhang, RG; Pappas, T; Brace, JL; Miller, PC; Oulmassov, T; Molyneauz, JM; Anderson, JC; Bashkin, JK; Winans, SC; Joachimiak, A			Structure of a bacterial quorum-sensing transcription factor complexed with pheromone and DNA	NATURE			English	Article							C-TERMINAL REGION; VIBRIO-FISCHERI; AUTOINDUCER-BINDING; TI PLASMID; IN-VITRO; PROTEIN; LUXR; TRAR; ACTIVATOR; DIMERIZATION	Many proteobacteria are able to monitor their population densities through the release of pheromones known as N-acylhomoserine lactones. At high population densities, these pheromones elicit diverse responses that include bioluminescence, biofilm formation, production of antimicrobials, DNA exchange, pathogenesis and symbiosis(1). Many of these regulatory systems require a pheromone-dependent transcription factor similar to the LuxR protein of Vibrio fischeri. Here we present the structure of a LuxR-type protein. TraR of Agrobacterium tumefaciens was solved at 1.66 Angstrom as a complex with the pheromone N-3-oxooctanoyl-L-homoserine lactone (OOHL) and its TraR DNA-binding site. The amino-terminal domain of TraR is an alpha/beta/alpha sandwich that binds OOHL, whereas the carboxy-terminal domain contains a helix-turn-helix DNA-binding motif. The TraR dimer displays a two-fold symmetry axis in each domain; however, these two axes of symmetry are at an approximately 90degrees angle, resulting in a pronounced overall asymmetry of the complex. The pheromone lies fully embedded within the protein with virtually no solvent contact, and makes numerous hydrophobic contacts with the protein as well as four hydrogen bonds: three direct and one water-mediated.	Argonne Natl Lab, Biosci Div, Struct Biol Ctr, Argonne, IL 60439 USA; Cornell Univ, Dept Microbiol, Ithaca, NY 14853 USA; Monsanto Co, St Louis, MO 63167 USA	United States Department of Energy (DOE); Argonne National Laboratory; Cornell University; Monsanto	Joachimiak, A (corresponding author), Argonne Natl Lab, Biosci Div, Struct Biol Ctr, 9700 S Cass Ave, Argonne, IL 60439 USA.		Bashkin, James K./F-5327-2010	Bashkin, James K./0000-0001-6735-4733; Brace, Jennifer/0000-0002-7734-2450				Baikalov I, 1998, BIOCHEMISTRY-US, V37, P3665, DOI 10.1021/bi972365a; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chai Y, 2001, MOL MICROBIOL, V40, P414, DOI 10.1046/j.1365-2958.2001.02385.x; Choi S. H., 1992, Molecular Marine Biology and Biotechnology, V1, P408; CHOI SH, 1991, P NATL ACAD SCI USA, V88, P11115, DOI 10.1073/pnas.88.24.11115; Egland KA, 2000, J BACTERIOL, V182, P805, DOI 10.1128/JB.182.3.805-811.2000; Egland KA, 2001, J BACTERIOL, V183, P382, DOI 10.1128/JB.183.1.382-386.2001; Fuqua C, 2001, ANNU REV GENET, V35, P439, DOI 10.1146/annurev.genet.35.102401.090913; FUQUA WC, 1994, J BACTERIOL, V176, P2796, DOI 10.1128/JB.176.10.2796-2806.1994; HANZELKA BL, 1995, J BACTERIOL, V177, P815, DOI 10.1128/jb.177.3.815-817.1995; JOACHIMIAK A, 1991, METHOD ENZYMOL, V208, P82; Luo ZQ, 2000, J BIOL CHEM, V275, P7713, DOI 10.1074/jbc.275.11.7713; Luo ZQ, 1999, P NATL ACAD SCI USA, V96, P9009, DOI 10.1073/pnas.96.16.9009; *MOL SIM INC, 2000, QUANTA; NELSON HCM, 1995, CURR OPIN GENET DEV, V5, P180, DOI 10.1016/0959-437X(95)80006-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Qin YP, 2000, EMBO J, V19, P5212, DOI 10.1093/emboj/19.19.5212; Sandler BH, 2000, CHEM BIOL, V7, P143, DOI 10.1016/S1074-5521(00)00078-8; STEVENS AM, 1994, P NATL ACAD SCI USA, V91, P12619, DOI 10.1073/pnas.91.26.12619; TEMPE J, 1977, P NATL ACAD SCI USA, V74, P2848, DOI 10.1073/pnas.74.7.2848; von Bodman SB, 1998, P NATL ACAD SCI USA, V95, P7687, DOI 10.1073/pnas.95.13.7687; Walsh MA, 1999, ACTA CRYSTALLOGR D, V55, P1168, DOI 10.1107/S0907444999003698; Walsh MA, 1999, ACTA CRYSTALLOGR D, V55, P1726, DOI 10.1107/S0907444999008392; Welch M, 2000, EMBO J, V19, P631, DOI 10.1093/emboj/19.4.631; Whitehead NA, 2001, FEMS MICROBIOL REV, V25, P365, DOI 10.1111/j.1574-6976.2001.tb00583.x; Zhu J, 1999, P NATL ACAD SCI USA, V96, P4832, DOI 10.1073/pnas.96.9.4832; Zhu J, 2001, P NATL ACAD SCI USA, V98, P1507, DOI 10.1073/pnas.98.4.1507	28	349	377	3	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 27	2002	417	6892					971	974		10.1038/nature00833	http://dx.doi.org/10.1038/nature00833			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	566RC	12087407				2022-12-28	WOS:000176441200044
J	Polo, JM; de Arcaya, AA; Cid, C; Berciano, J				Polo, JM; de Arcaya, AA; Cid, C; Berciano, J			Aphasia in a farmer following viper bite	LANCET			English	Editorial Material							INFARCTION		Univ Hosp Marques de Valdecilla, Serv Neurol, Santander 39008, Spain	Hospital Universitario Marques de Valdecilla (HUMV)	Polo, JM (corresponding author), Univ Hosp Marques de Valdecilla, Serv Neurol, Santander 39008, Spain.	polojm@unican.es						BRACHLOW J, 1992, ANAESTHESIST, V41, P361; Lee BC, 2001, NEUROLOGY, V56, P1244, DOI 10.1212/WNL.56.9.1244; LEIPZIG TJ, 1986, SURG NEUROL, V25, P478, DOI 10.1016/0090-3019(86)90087-X; Murthy JMK, 1997, J COMPUT ASSIST TOMO, V21, P35, DOI 10.1097/00004728-199701000-00007; Panicker J N, 2000, J Assoc Physicians India, V48, P744	5	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 22	2002	359	9324					2164	2164		10.1016/S0140-6736(02)09094-3	http://dx.doi.org/10.1016/S0140-6736(02)09094-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566RJ	12090983				2022-12-28	WOS:000176441800012
J	Beyrer, C; Kass, NE				Beyrer, C; Kass, NE			Human rights, politics, and reviews of research ethics	LANCET			English	Article							HEALTH	Although the human rights movement and the sphere of research ethics have overlapping principles and goals, there has been little attempt to incorporate external political and human rights contexts Into research ethics codes or ethics reviews. Every element of a research ethics review-the balance of risks and benefits, the assurance of rights for Individual participants, and the fair selection of research populations-can be affected by the political and human rights background in which a study Is done. Research that at first seems to be low In risk may become high In risk If implemented in a country where the government might breach the confidentiality of study results or where results might be used to deport a refugee group. Researchers should determine whether research could or should be done by consulting human rights organisations and, when possible, a trusted colleague, to learn the background political context and human rights conditions of the settings In which they propose to do research.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; Johns Hopkins Univ, Phoebe R Berman Bioeth Inst, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University	Kass, NE (corresponding author), 624 N Broadway,Hampton House,Room 348, Baltimore, MD 21205 USA.							Benatar SR, 2000, BMJ-BRIT MED J, V321, P824, DOI 10.1136/bmj.321.7264.824; Beyrer C, 2001, SOC SCI MED, V53, P543, DOI 10.1016/S0277-9536(00)00358-0; BEYRER C, 1998, MED ETHICS HUMAN RIG; BEYRER C, 1998, MED ETHICS HUMAN RIG, P145; BEYRER C, 1993, 10 INT AIDS C YOK JA; *BRIT MED ASS, 2001, MED PROF HUM RIGHTS; CHAPMAN C, 1999, 5 INT C AIDS AS PAC; Cook Rebecca J, 1995, Health Hum Rights, V1, P350, DOI 10.2307/4065247; ESTEBANEZ P, 1993, B WORLD HEALTH ORGAN, V71, P397; Farmer P, 1999, AM J PUBLIC HEALTH, V89, P1486, DOI 10.2105/AJPH.89.10.1486; *GLOB FOR HLTH RES, 1999, 1090 GLOB FOR HLTH R; Gostin LO, 1997, HUMAN RIGHTS PUBLIC; Gourevitch P., 1999, WE WISH INFORM YOU T; *IOMS, 1992, 26 CIOMS C GEN SWITZ; Klouda, 1994, Health Hum Rights, V1, P101, DOI 10.2307/4065264; Leaning J, 2001, LANCET, V357, P1432, DOI 10.1016/S0140-6736(00)04572-4; Leaning J, 1999, HUMANITARIAN CRISIS; MACKINNON C, 1993, HUMAN RIGHTS OXFORD, P210; MACKLIN R, 1999, RELATIVISM CULTURAL, P219; Mann J., 1999, HLTH HUMAN RIGHTS; Mann JM, 1997, HASTINGS CENT REP, V27, P6, DOI 10.2307/3528660; Neugebauer R, 1999, AM J PUBLIC HEALTH, V89, P1473, DOI 10.2105/AJPH.89.10.1473; Rasekh Z, 1998, JAMA-J AM MED ASSOC, V280, P449, DOI 10.1001/jama.280.5.449; *ROYAL THAI MIN PU, 1999, ANN REP; Thomasma DC, 1997, J LAW MED ETHICS, V25, P295, DOI 10.1111/j.1748-720X.1997.tb01412.x; *UN, 1992, INT CONV RIGHTS CHIL; *US DEP STAT BUR D, 2000, COUNTR REP HUM RIGHT; Weijer C, 1999, NAT GENET, V23, P275, DOI 10.1038/15455; World Medical Association General Assembly, 1964, DECL HELS	29	36	37	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 20	2002	360	9328					246	251		10.1016/S0140-6736(02)09465-5	http://dx.doi.org/10.1016/S0140-6736(02)09465-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	576DX	12133674				2022-12-28	WOS:000176988500029
J	Lin, SH; Chau, T				Lin, SH; Chau, T			A puzzling cause of hypokalaemia	LANCET			English	Article							HYPERTENSION; HYPOKALEMIA		Natl Def Med Ctr, Tri Serv Gen Hosp, Dept Med, Div Nephrol, Taipei, Taiwan	National Defense Medical Center; Tri-Service General Hospital	Lin, SH (corresponding author), Natl Def Med Ctr, Tri Serv Gen Hosp, Dept Med, Div Nephrol, Neihu 114, Taipei, Taiwan.							deKlerk GJ, 1997, BRIT MED J, V314, P731, DOI 10.1136/bmj.314.7082.731; EDWARDS CRW, 1991, NEW ENGL J MED, V325, P1242, DOI 10.1056/NEJM199110243251709; Frey FJ, 2001, NEPHROL DIAL TRANSPL, V16, P1112, DOI 10.1093/ndt/16.6.1112; GROSS EG, 1966, NEW ENGL J MED, V274, P602, DOI 10.1056/NEJM196603172741104; WALKER BR, 1994, ENDOCRIN METAB CLIN, V23, P359, DOI 10.1016/S0889-8529(18)30102-6	5	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 20	2002	360	9328					224	224		10.1016/S0140-6736(02)09460-6	http://dx.doi.org/10.1016/S0140-6736(02)09460-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	576DX	12133658				2022-12-28	WOS:000176988500013
J	Robinson, IM; Ranjan, R; Schwarz, TL				Robinson, IM; Ranjan, R; Schwarz, TL			Synaptotagmins I and IV promote transmitter release independently of Ca2+ binding in the C(2)A domain	NATURE			English	Article							NEUROTRANSMITTER RELEASE; SYNAPTIC TRANSMISSION; REGULATED EXOCYTOSIS; CALCIUM-DEPENDENCE; MUTANTS; DROSOPHILA; VESICLES; ABSENCE; SENSORS; ELEGANS	At nerve terminals, a focal and transient increase in intracellular Ca2+ triggers the fusion of neurotransmitter-filled vesicles with the plasma membrane. The most extensively studied candidate for the Ca2+-sensing trigger is synaptotagmin I, whose Ca2+-dependent interactions with acidic phospholipids and syntaxin(1) have largely been ascribed to its C(2)A domain(2-6), although the C2B domain also binds Ca2+ (refs 7, 8). Genetic tests of synaptotagmin I have been equivocal as to whether it is the Ca2+-sensing trigger of fusion(6,9-15). Synaptotagmin IV, a related isoform that does not bind Ca2+ in the C(2)A domain, might be an inhibitor of release(16,17). We mutated an essential aspartate of the Ca2+ binding site of the synaptotagmin I C(2)A domain and expressed it in Drosophila lacking synaptotagmin I. Here we show that, despite the disruption of the binding site, the Ca2+-dependent properties of transmission were not altered. Similarly, we found that synaptotagmin IV could substitute for synaptotagmin I. We conclude that the C(2)A domain of synaptotagmin is not required for Ca2+-dependent synaptic transmission, and that synaptotagmin IV promotes rather than inhibits transmission.	Childrens Hosp, Div Neurosci, Boston, MA 02115 USA; Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; University of Cambridge; Harvard University; Harvard Medical School	Schwarz, TL (corresponding author), Childrens Hosp, Div Neurosci, 300 Longwood Ave, Boston, MA 02115 USA.							BROADIE K, 1994, P NATL ACAD SCI USA, V91, P10727, DOI 10.1073/pnas.91.22.10727; Burgoyne RD, 1998, CELL CALCIUM, V24, P367, DOI 10.1016/S0143-4160(98)90060-4; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; DAMER CK, 1994, J BIOL CHEM, V269, P31115; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Desai RC, 2000, J CELL BIOL, V150, P1125, DOI 10.1083/jcb.150.5.1125; DIANTONIO A, 1994, NEURON, V12, P909, DOI 10.1016/0896-6273(94)90342-5; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Haucke V, 1999, SCIENCE, V285, P1268, DOI 10.1126/science.285.5431.1268; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; Kee Y, 1996, J NEUROSCI, V16, P1975; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LI C, 1995, J BIOL CHEM, V270, P24898, DOI 10.1074/jbc.270.42.24898; LITTLETON JT, 1994, P NATL ACAD SCI USA, V91, P10888, DOI 10.1073/pnas.91.23.10888; Littleton JT, 1999, NATURE, V400, P757, DOI 10.1038/23462; Loewen CA, 2001, GENESIS, V31, P30, DOI 10.1002/gene.10002; MACKLER JM, 2002, NATURE          0707; MARTIN AR, 1955, J PHYSIOL-LONDON, V130, P114, DOI 10.1113/jphysiol.1955.sp005397; NEHER E, 1994, NATURE, V372, P316, DOI 10.1038/372316a0; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; Reist NE, 1998, J NEUROSCI, V18, P7662; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Ubach J, 1998, EMBO J, V17, P3921, DOI 10.1093/emboj/17.14.3921; Voets T, 2001, P NATL ACAD SCI USA, V98, P11680, DOI 10.1073/pnas.201398798; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314; Wang CT, 2001, SCIENCE, V294, P1111, DOI 10.1126/science.1064002; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; Zhang XY, 1998, BIOCHEMISTRY-US, V37, P12395, DOI 10.1021/bi9807512	31	179	188	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 18	2002	418	6895					336	340		10.1038/nature00915	http://dx.doi.org/10.1038/nature00915			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574BF	12110845				2022-12-28	WOS:000176868000045
J	Lea, DW				Lea, DW			Paleoclimate - The glacial tropical Pacific - Not just a west side story	SCIENCE			English	Editorial Material							SOUTH CHINA SEA; CLIMATE; MAXIMUM; OCEAN		Univ Calif Santa Barbara, Dept Geol Sci, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Lea, DW (corresponding author), Univ Calif Santa Barbara, Dept Geol Sci, Santa Barbara, CA 93106 USA.							Andreasen DH, 2001, J GEOPHYS RES-OCEANS, V106, P879, DOI 10.1029/1999JC000087; Cane M, 1999, GEOPH MONOG SERIES, V112, P373; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; Huang C.-H., UNPUB; Kienast M, 2001, SCIENCE, V291, P2132, DOI 10.1126/science.1057131; Koutavas A, 2002, SCIENCE, V297, P226, DOI 10.1126/science.1072376; Lea DW, 2000, SCIENCE, V289, P1719, DOI 10.1126/science.289.5485.1719; Martinez JI, 1997, MAR MICROPALEONTOL, V32, P311; Pelejero C, 1999, PALEOCEANOGRAPHY, V14, P224, DOI 10.1029/1998PA900015; ROSENTHAL Y, 2001, EOS T AGU S, P128; Stott L, 2002, SCIENCE, V297, P222, DOI 10.1126/science.1071627; Wang L, 1999, MAR GEOL, V156, P245, DOI 10.1016/S0025-3227(98)00182-0; 1998, NOAA NODC WORLD OCEA	13	16	26	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 12	2002	297	5579					202	203		10.1126/science.1073841	http://dx.doi.org/10.1126/science.1073841			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571UT	12114613				2022-12-28	WOS:000176738100026
J	Doudna, JA; Cech, TR				Doudna, JA; Cech, TR			The chemical repertoire of natural ribozymes	NATURE			English	Review							GROUP-II INTRON; RIBOSOMAL PEPTIDYL TRANSFERASE; METAL-ION COORDINATION; SELF-SPLICING INTRON; DELTA VIRUS RIBOZYME; HAMMERHEAD RIBOZYME; HAIRPIN RIBOZYME; RIBONUCLEASE-P; CRYSTAL-STRUCTURE; ACTIVE-SITE	Although RNA is generally thought to be passive genetic blueprint, some RNA molecules, called ribozymes, have intrinsic enzyme-like activity-they can catalyse chemical reactions in the complete absence of protein cofactors. In addition to the well-known small ribozymes that cleave phosphoclester bonds, we now know that RNA catalysts probably effect a number of key cellular reactions. This versatility has lent credence to the idea that RNA molecules may have been central to the early stages of life on Earth.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley; Howard Hughes Medical Institute	Doudna, JA (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.							Andersen AA, 2000, MOL CELL, V5, P469, DOI 10.1016/S1097-2765(00)80441-4; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Boudvillain M, 2000, NATURE, V406, P315, DOI 10.1038/35018589; Caprara MG, 1996, J MOL BIOL, V257, P512, DOI 10.1006/jmbi.1996.0182; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CECH TR, 1996, GROUP 1 RIBOZYMES SU; Chanfreau G, 1996, EMBO J, V15, P3466, DOI 10.1002/j.1460-2075.1996.tb00713.x; Chu VT, 2001, EMBO J, V20, P6866, DOI 10.1093/emboj/20.23.6866; Cohen SB, 1997, J AM CHEM SOC, V119, P6259, DOI 10.1021/ja9707421; Collins CA, 2000, NAT STRUCT BIOL, V7, P850; CONNELL GJ, 1994, SCIENCE, V264, P1137, DOI 10.1126/science.7513905; Costa M, 2000, EMBO J, V19, P5007, DOI 10.1093/emboj/19.18.5007; Curtis EA, 2001, RNA, V7, P546, DOI 10.1017/S1355838201002357; Drum CL, 2002, NATURE, V415, P396, DOI 10.1038/415396a; Ferre-D'Amare AR, 1998, NATURE, V395, P567, DOI 10.1038/26912; Frank DN, 1998, ANNU REV BIOCHEM, V67, P153, DOI 10.1146/annurev.biochem.67.1.153; Frank DN, 2000, RNA, V6, P1895, DOI 10.1017/S1355838200001461; Golden BL, 1998, SCIENCE, V282, P259, DOI 10.1126/science.282.5387.259; Gordon PM, 2000, BIOCHEMISTRY-US, V39, P12939, DOI 10.1021/bi001089o; Gordon PM, 2001, NAT STRUCT BIOL, V8, P893, DOI 10.1038/nsb1001-893; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; Hampel A, 1997, CHEM BIOL, V4, P513, DOI 10.1016/S1074-5521(97)90323-9; HAN S, 2001, BIOCHEMISTRY-US, V40, P5161; Harris ME, 1997, RNA, V3, P561; Illangasekare M, 1999, RNA, V5, P1482, DOI 10.1017/S1355838299991264; Illangasekare M, 1999, P NATL ACAD SCI USA, V96, P5470, DOI 10.1073/pnas.96.10.5470; INPTAK A, 2001, J AM CHEM SOC, V123, P8447; Jadhav VR, 2002, BIOCHEMISTRY-US, V41, P723, DOI 10.1021/bi011803h; Jestin JL, 1997, EMBO J, V16, P2945, DOI 10.1093/emboj/16.10.2945; Juneau K, 2001, STRUCTURE, V9, P221, DOI 10.1016/S0969-2126(01)00579-2; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; Kumar RK, 2001, BIOCHEMISTRY-US, V40, P6998, DOI 10.1021/bi010710x; LEGAULT P, 1994, J AM CHEM SOC, V116, P8390, DOI 10.1021/ja00097a066; Li Y, 2001, P NATL ACAD SCI USA, V98, P441, DOI 10.1073/pnas.021555498; Liphardt J, 2001, SCIENCE, V292, P733, DOI 10.1126/science.1058498; Lohse PA, 1996, NATURE, V381, P442, DOI 10.1038/381442a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; Morl M, 2001, EMBO REP, V2, P17, DOI 10.1093/embo-reports/kve006; Murchie AIH, 1998, MOL CELL, V1, P873, DOI 10.1016/S1097-2765(00)80086-6; Murray JB, 1998, CHEM BIOL, V5, P587, DOI 10.1016/S1074-5521(98)90116-8; Murray JB, 2000, J MOL BIOL, V296, P33, DOI 10.1006/jmbi.1999.3428; Murray JB, 2002, J MOL BIOL, V315, P121, DOI 10.1006/jmbi.2001.5145; Murray JB, 1998, CELL, V92, P665, DOI 10.1016/S0092-8674(00)81134-4; MURRAY JM, 1987, J ELECTRON MICR TECH, V5, P279, DOI 10.1002/jemt.1060050308; Murray JM, 2001, TRENDS BIOCHEM SCI, V26, P699, DOI 10.1016/S0968-0004(01)02019-9; Nakano S, 2000, SCIENCE, V287, P1493, DOI 10.1126/science.287.5457.1493; Nakano S, 2001, J AM CHEM SOC, V123, P11333, DOI 10.1021/ja0166850; Nakano S, 2001, BIOCHEMISTRY-US, V40, P12022, DOI 10.1021/bi011253n; Narlikar GJ, 1997, ANNU REV BIOCHEM, V66, P19, DOI 10.1146/annurev.biochem.66.1.19; Nesbitt S, 1997, CHEM BIOL, V4, P619, DOI 10.1016/S1074-5521(97)90247-7; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; O'Rear JL, 2001, RNA, V7, P537, DOI 10.1017/S1355838201002461; Peracchi A, 1997, J BIOL CHEM, V272, P26822, DOI 10.1074/jbc.272.43.26822; Perrotta AT, 1999, SCIENCE, V286, P123, DOI 10.1126/science.286.5437.123; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; Polacek N, 2001, NATURE, V411, P498, DOI 10.1038/35078113; Profenno LA, 1997, BIOCHEMISTRY-US, V36, P12477, DOI 10.1021/bi9708895; RAJAGOPAL P, 1989, NATURE, V339, P637, DOI 10.1038/339637a0; Ravindranathan S, 2000, BIOCHEMISTRY-US, V39, P16026, DOI 10.1021/bi001976r; Rupert PB, 2001, NATURE, V410, P780, DOI 10.1038/35071009; Russell R, 2002, P NATL ACAD SCI USA, V99, P155, DOI 10.1073/pnas.221593598; Ryder SP, 2001, RNA, V7, P1454; Salehi-Ashtiani K, 2001, NATURE, V414, P82, DOI 10.1038/35102081; Santoro SW, 2000, J AM CHEM SOC, V122, P2433, DOI 10.1021/ja993688s; Scott EC, 1999, NUCLEIC ACIDS RES, V27, P479, DOI 10.1093/nar/27.2.479; Scott WG, 1996, SCIENCE, V274, P2065, DOI 10.1126/science.274.5295.2065; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; Sengle G, 2001, CHEM BIOL, V8, P459, DOI 10.1016/S1074-5521(01)00026-6; Shih I, 2001, P NATL ACAD SCI USA, V98, P1489, DOI 10.1073/pnas.98.4.1489; Sigel RKO, 2000, NAT STRUCT BIOL, V7, P1111; SKLENAR V, 1990, NATURE, V345, P836, DOI 10.1038/345836a0; Swisher J, 2001, EMBO J, V20, P2051, DOI 10.1093/emboj/20.8.2051; Szewczak AA, 1999, P NATL ACAD SCI USA, V96, P11183, DOI 10.1073/pnas.96.20.11183; Tang J, 1997, CHEM BIOL, V4, P453, DOI 10.1016/S1074-5521(97)90197-6; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Thirumalai D, 2000, RNA, V6, P790, DOI 10.1017/S1355838200000522; Thirumalai D, 2001, ANNU REV PHYS CHEM, V52, P751, DOI 10.1146/annurev.physchem.52.1.751; Thompson J, 2001, P NATL ACAD SCI USA, V98, P9002, DOI 10.1073/pnas.151257098; Treiber DK, 2001, CURR OPIN STRUC BIOL, V11, P309, DOI 10.1016/S0959-440X(00)00206-2; Treiber DK, 1999, CURR OPIN STRUC BIOL, V9, P339, DOI 10.1016/S0959-440X(99)80045-1; Unrau PJ, 1998, NATURE, V395, P260, DOI 10.1038/26193; Valadkhan S, 2001, NATURE, V413, P701, DOI 10.1038/35099500; Walter NG, 1998, CURR OPIN CHEM BIOL, V2, P303, DOI 10.1016/S1367-5931(98)80073-2; Wang SL, 1999, BIOCHEMISTRY-US, V38, P14363, DOI 10.1021/bi9913202; Warnecke JM, 1999, J MOL BIOL, V290, P433, DOI 10.1006/jmbi.1999.2890; Warnecke JM, 2000, NUCLEIC ACIDS RES, V28, P720, DOI 10.1093/nar/28.3.720; Weeks KM, 1996, SCIENCE, V271, P345, DOI 10.1126/science.271.5247.345; WELCH M, 1995, BIOCHEMISTRY-US, V34, P385, DOI 10.1021/bi00002a001; WESTHOF E, 1994, P NATL ACAD SCI USA, V91, P5133, DOI 10.1073/pnas.91.11.5133; Wiegand TW, 1997, CHEM BIOL, V4, P675, DOI 10.1016/S1074-5521(97)90223-4; Wilson DS, 1999, ANNU REV BIOCHEM, V68, P611, DOI 10.1146/annurev.biochem.68.1.611; WYCKOFF HW, 1970, J BIOL CHEM, V245, P305; Xiao SH, 2001, J CELL PHYSIOL, V187, P11, DOI 10.1002/1097-4652(200104)187:1<11::AID-JCP1055>3.0.CO;2-K; Yang J, 1996, NATURE, V381, P332, DOI 10.1038/381332a0; Yean SL, 2000, NATURE, V408, P881, DOI 10.1038/35048617; Zhang L, 2002, SCIENCE, V295, P2084, DOI 10.1126/science.1069268; Zhuang XW, 2000, SCIENCE, V288, P2048, DOI 10.1126/science.288.5473.2048	98	512	543	2	139	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 11	2002	418	6894					222	228		10.1038/418222a	http://dx.doi.org/10.1038/418222a			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571GV	12110898				2022-12-28	WOS:000176710400050
J	Moreno, JC; Bikker, H; Kempers, MJE; van Trotsenburg, P; Baas, F; de Vijlder, JJM; Vulsma, T; Ris-Stalpers, C				Moreno, JC; Bikker, H; Kempers, MJE; van Trotsenburg, P; Baas, F; de Vijlder, JJM; Vulsma, T; Ris-Stalpers, C			Inactivating mutations in the gene for thyroid oxidase 2 (THOX2) and congenital hypothyroidism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FACTOR-I TTF-1; NADPH OXIDASE; TRANSIENT HYPOTHYROIDISM; FREE-THYROXINE; GOITER; INFANTS; NEWBORN; CLONING; THYROGLOBULIN; CHILDHOOD	Background Several genetic defects are associated with permanent congenital hypothyroidism. Immunologic, environmental, and iatrogenic (but not genetic) factors are known to induce transient congenital hypothyroidism, which spontaneously resolves within the first months of life. We hypothesized that molecular defects in the thyroid oxidase system, which is composed of at least two proteins, might be involved in the pathogenesis of permanent or transient congenital hypothyroidism in babies with defects in iodide organification, for which the oxidase system is required. Methods Nine patients were recruited who had idiopathic congenital hypothyroidism (one with permanent and eight With transient hypothyroidism) and an iodide-organification defect and who had been identified by the screening program for congenital hypothyroidism. The DNA of the patients and their relatives was analyzed for mutations in the genes for thyroid oxidase 1 (THOX1) and 2 (THOX2). Results The one patient with permanent and severe thyroid hormone deficiency and a complete iodide-organification defect had a homozygous nonsense mutation in the THOX2 gene that eliminates all functional domains of the protein. Three of the eight patients with mild transient congenital hypothyroidism and a partial iodide-organification defect had heterozygous mutations in the THOX2 gene that prematurely truncate the protein, thus abolishing its functional domains. Conclusions Biallelic inactivating mutations in the THOX2 gene result in complete disruption of thyroid-hormone synthesis and are associated with severe and permanent congenital hypothyroidism. Monoallelic mutations are associated with milder, transient hypothyroidism caused by insufficient thyroidal production of hydrogen peroxide, which prevents the synthesis of sufficient quantities of thyroid hormones to meet the large requirement for thyroid hormones at the beginning of life.	Emma Childrens Hosp, Dept Pediat Endocrinol, Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Neurozintuigen Lab, NL-1105 AZ Amsterdam, Netherlands	Emma Children's Hospital; University of Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Moreno, JC (corresponding author), POB 22700, NL-1100 DE Amsterdam, Netherlands.	j.c.moreno@amc.uva.nl	van Trotsenburg, Paul/ABC-2379-2020; Baas, Frank/F-9574-2010	van Trotsenburg, Paul/0000-0002-9677-7441; Baas, Frank/0000-0003-3912-5428				Bakker B, 2000, J CLIN ENDOCR METAB, V85, P3708, DOI 10.1210/jc.85.10.3708; Bakker B, 1999, J ENDOCRINOL, V161, P115, DOI 10.1677/joe.0.1610115; CALACIURA F, 1995, CLIN ENDOCRINOL, V43, P473, DOI 10.1111/j.1365-2265.1995.tb02620.x; Clifton-Bligh RJ, 1998, NAT GENET, V19, P399, DOI 10.1038/1294; COAKLEY JC, 1989, AUST PAEDIATR J, V25, P25; CORVILAIN B, 1991, ENDOCRINOLOGY, V128, P779, DOI 10.1210/endo-128-2-779; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; De Deken X, 2002, EXP CELL RES, V273, P187, DOI 10.1006/excr.2001.5444; DELANGE F, 1978, J PEDIATR-US, V92, P974, DOI 10.1016/S0022-3476(78)80380-1; DEVIJLDER JJM, 2000, WERNER INGBARS THYRO, P733; Devriendt K, 1998, NEW ENGL J MED, V338, P1317, DOI 10.1056/NEJM199804303381817; Dupuy C, 1999, J BIOL CHEM, V274, P37265, DOI 10.1074/jbc.274.52.37265; Everett LA, 1997, NAT GENET, V17, P411, DOI 10.1038/ng1297-411; Figueiredo MDL, 2001, J CLIN ENDOCR METAB, V86, P4843, DOI 10.1210/jc.86.10.4843; FISHER DA, 1981, NEW ENGL J MED, V304, P702, DOI 10.1056/NEJM198103193041205; FISHER DA, 1979, J PEDIATR-US, V94, P700, DOI 10.1016/S0022-3476(79)80133-X; FISHER DA, 1991, J CLIN ENDOCR METAB, V72, P523, DOI 10.1210/jcem-72-3-523; Frank JE, 1996, J PEDIATR-US, V128, P548, DOI 10.1016/S0022-3476(96)70368-2; Haddow JE, 1999, NEW ENGL J MED, V341, P549, DOI 10.1056/NEJM199908193410801; Hishinuma A, 1999, J CLIN ENDOCR METAB, V84, P1438, DOI 10.1210/jc.84.4.1438; Jones AC, 1999, CLIN CHEM, V45, P1133; Keller T, 1998, PLANT CELL, V10, P255, DOI 10.1105/tpc.10.2.255; KUSAKABE T, 1975, METABOLISM, V24, P1103, DOI 10.1016/0026-0495(75)90147-X; LALLEMAND D, 1983, J PEDIATR-US, V102, P935, DOI 10.1016/S0022-3476(83)80028-6; Lapi P, 1997, THYROID, V7, P383, DOI 10.1089/thy.1997.7.383; LEGER J, 1988, ARCH FR PEDIATR, V45, P783; Macchia PE, 1998, NAT GENET, V19, P83, DOI 10.1038/ng0598-83; MATSUURA N, 1980, NEW ENGL J MED, V303, P738, DOI 10.1056/NEJM198009253031306; MCDOUGALL IR, 2000, WERNER INGBARS THYRO, P355; Moreno JC, 2001, GENOMICS, V75, P70, DOI 10.1006/geno.2001.6586; NELSON JC, 1993, J PEDIATR-US, V123, P899, DOI 10.1016/S0022-3476(05)80385-3; *NEW ENGL CONG HYP, 1981, LANCET, V14, P1095; NIEPOMNISZCZE H, 1987, J CLIN ENDOCR METAB, V65, P344, DOI 10.1210/jcem-65-2-344; NOSE O, 1986, J PEDIATR-US, V108, P573, DOI 10.1016/S0022-3476(86)80838-1; Perna MG, 1997, THYROID, V7, P377, DOI 10.1089/thy.1997.7.377; Pop VJ, 1999, CLIN ENDOCRINOL, V50, P149, DOI 10.1046/j.1365-2265.1999.00639.x; SAVA L, 1984, J CLIN ENDOCR METAB, V59, P90, DOI 10.1210/jcem-59-1-90; STUBBE P, 1980, EUR J PEDIATR, V135, P97, DOI 10.1007/BF00445902; TRIMARCHI F, 1983, ACTA PAEDIATR SCAND, V72, P145, DOI 10.1111/j.1651-2227.1983.tb09684.x; van de Graaf SAR, 1999, BIOCHIMIE, V81, P425, DOI 10.1016/S0300-9084(99)80091-1; Van Hauwe P, 1998, HUM MOL GENET, V7, P1099, DOI 10.1093/hmg/7.7.1099; vanWassenaer AG, 1997, NEW ENGL J MED, V336, P21, DOI 10.1056/NEJM199701023360104; VULSMA T, 1989, NEW ENGL J MED, V321, P13, DOI 10.1056/NEJM198907063210103; VULSMA T, 1991, THESIS U AMSTERDAM A; Xiao WZ, 2001, HUM MUTAT, V17, P439, DOI 10.1002/humu.1130.abs; Yu LX, 1999, BLOOD, V94, P2497, DOI 10.1182/blood.V94.7.2497.419k11_2497_2504	46	345	371	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 11	2002	347	2					95	102		10.1056/NEJMoa012752	http://dx.doi.org/10.1056/NEJMoa012752			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	572HC	12110737	Green Published			2022-12-28	WOS:000176767300004
J	Moseley, JB; O'Malley, K; Petersen, NJ; Menke, TJ; Brody, BA; Kuykendall, DH; Hollingsworth, JC; Ashton, CM; Wray, NP				Moseley, JB; O'Malley, K; Petersen, NJ; Menke, TJ; Brody, BA; Kuykendall, DH; Hollingsworth, JC; Ashton, CM; Wray, NP			A controlled trial of arthroscopic surgery for osteoarthritis of the knee	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-LIFE; CLINICAL-TRIALS; HEALTH-STATUS; INSTRUMENTS; IRRIGATION; ARTHRITIS; DISEASE; LAVAGE; SF-36	Background Many patients report symptomatic relief after undergoing arthroscopy of the knee for osteoarthritis, but it is unclear how the procedure achieves this result. We conducted a randomized, placebo-controlled trial to evaluate the efficacy of arthroscopy for osteoarthritis of the knee. Methods A total of 180 patients with osteoarthritis of the knee were randomly assigned to receive arthroscopic debridement, arthroscopic lavage, or placebo surgery. Patients in the placebo group received skin incisions and underwent a simulated debridement without insertion of the arthroscope. Patients and assessors of outcome were blinded to the treatment-group assignment. Outcomes were assessed at multiple points over a 24-month period with the use of five self-reported scores - three on scales for pain and two on scales for function - and one objective test of walking and stair climbing. A total of 165 patients completed the trial. Results At no point did either of the intervention groups report less pain or better function than the placebo group. For example, mean (+/-SD) scores on the Knee-Specific Pain Scale (range, 0 to 100, with higher scores indicating more severe pain) were similar in the placebo, lavage, and debridement groups: 48.9+/-21.9, 54.8+/-19.8, and 51.7+/-22.4, respectively, at one year (P=0.14 for the comparison between placebo and lavage; P=0.51 for the comparison between placebo and debridement) and 51.6+/-23.7, 53.7+/-23.7, and 51.4+/- 23.2, respectively, at two years (P=0.64 and P=0.96, respectively). Furthermore, the 95 percent confidence intervals for the differences between the placebo group and the intervention groups exclude any clinically meaningful difference. Conclusions In this controlled trial involving patients with osteoarthritis of the knee, the outcomes after arthroscopic lavage or arthroscopic debridement were no better than those after a placebo procedure.	Baylor Coll Med, Sect Hlth Serv Res, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Orthoped Surg, Houston, TX 77030 USA; Baylor Coll Med, Ctr Med Eth & Hlth Policy, Houston, TX 77030 USA; Vet Adm Med Ctr, Houston, TX USA; Int Survey Res, Houston, TX USA; Laguna Honda Hosp, San Francisco, CA USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Wray, NP (corresponding author), Baylor Coll Med, Sect Hlth Serv Res, Dept Med, 2002 Holcombe Blvd,MR 152, Houston, TX 77030 USA.	nwray@bcm.tmc.edu						ALTMAN DG, 1995, BRIT MED J, V311, P485, DOI 10.1136/bmj.311.7003.485; Angst F, 2001, ARTHRIT RHEUM-ARTHR, V45, P384, DOI 10.1002/1529-0131(200108)45:4<384::AID-ART352>3.0.CO;2-0; BAUMGAERTNER MR, 1990, CLIN ORTHOP RELAT R, P197; BERT J M, 1989, Arthroscopy, V5, P25, DOI 10.1016/0749-8063(89)90086-8; BRANDT KD, 1986, J RHEUMATOL, V13, P1126; CHANG RW, 1993, ARTHRITIS RHEUM, V36, P289, DOI 10.1002/art.1780360302; Greene WL, 2000, ANN INTERN MED, V132, P715, DOI 10.7326/0003-4819-132-9-200005020-00006; GROSS DE, 1991, ORTHOPEDICS, V14, P1317; HAYBITTLE JL, 1971, BRIT J RADIOL, V44, P793, DOI 10.1259/0007-1285-44-526-793; Hrobjartsson A, 2001, NEW ENGL J MED, V345, P304; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; IKE RW, 1992, J RHEUMATOL, V19, P772; JACKSON RW, 1982, J BONE JOINT SURG BR, V64, P481, DOI 10.1302/0301-620X.64B4.6896516; JACKSON RW, 1986, ARTHROSCOPY, V2, P114; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; JENNINGS JE, 1986, ARTHROSCOPY, V2, P123; Jones, 1996, BRIT MED J, V313, P550; Kalunian KC, 2000, OSTEOARTHR CARTILAGE, V8, P412, DOI 10.1053/joca.1999.0316; KANTZ ME, 1992, MED CARE, V30, pMS240, DOI 10.1097/00005650-199205001-00024; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; Kosinski M, 2000, ARTHRITIS RHEUM-US, V43, P1478, DOI 10.1002/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M; LIANG MH, 1990, MED CARE, V28, P632, DOI 10.1097/00005650-199007000-00008; LIVESLEY PJ, 1991, J BONE JOINT SURG BR, V73, P922, DOI 10.1302/0301-620X.73B6.1720118; MCLAREN AC, 1991, CAN J SURG, V34, P595; MEENAN RF, 1992, ARTHRITIS RHEUM, V35, P1, DOI 10.1002/art.1780350102; OGILVIE-HARRIS D J, 1991, Arthroscopy, V7, P151, DOI 10.1016/0749-8063(91)90101-3; Owings M. F., 1996, VITAL HLTH STAT, V13; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; RAND J A, 1991, Arthroscopy, V7, P358; Rand J A, 1985, Arthroscopy, V1, P253, DOI 10.1016/S0749-8063(85)80093-1; RICHARDS RN, 1984, ORTHOPEDICS, V7, P1705, DOI 10.3928/0147-7447-19841101-08; SALISBURY RB, 1985, CLIN ORTHOP RELAT R, V198, P268; SPRAGUE NF, 1981, CLIN ORTHOP RELAT R, V160, P118; Timoney J M, 1990, Orthop Rev, V19, P371; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wyrwich KW, 1999, J CLIN EPIDEMIOL, V52, P861, DOI 10.1016/S0895-4356(99)00071-2	36	1301	1350	0	86	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 11	2002	347	2					81	88		10.1056/NEJMoa013259	http://dx.doi.org/10.1056/NEJMoa013259			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	572HC	12110735				2022-12-28	WOS:000176767300002
J	Hettiaratchy, S; Butler, PEM				Hettiaratchy, S; Butler, PEM			Face transplantation - fantasy or the future?	LANCET			English	Editorial Material							INDUCTION; TOLERANCE		Royal Free Hosp, Dept Plast Surg, London NW3 20G, England; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr, Boston, MA USA	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital	Butler, PEM (corresponding author), Royal Free Hosp, Dept Plast Surg, London NW3 20G, England.			Butler, Peter/0000-0001-7419-1493				Boyd JG, 2002, EUR J NEUROSCI, V15, P613, DOI 10.1046/j.1460-9568.2002.01891.x; Doolabh VB, 1999, PLAST RECONSTR SURG, V103, P1928, DOI 10.1097/00006534-199906000-00018; Francois CG, 2000, MICROSURG, V20, P360, DOI 10.1002/1098-2752(2000)20:8<360::AID-MICR4>3.3.CO;2-5; LEE WPA, 1991, PLAS RECONSTR SURG, V87, P400; Rossini AA, 1999, PHYSIOL REV, V79, P99, DOI 10.1152/physrev.1999.79.1.99; Spitzer TR, 1999, TRANSPLANTATION, V68, P480, DOI 10.1097/00007890-199908270-00006	6	58	62	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 6	2002	360	9326					5	6		10.1016/S0140-6736(02)09361-3	http://dx.doi.org/10.1016/S0140-6736(02)09361-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569JR	12114034				2022-12-28	WOS:000176599700005
J	Parkhurst, JO				Parkhurst, JO			The Ugandan success story? Evidence and claims of HIV-1 prevention	LANCET			English	Editorial Material							PREVALENCE; INFECTION; BEHAVIOR; WOMEN		Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Parkhurst, JO (corresponding author), Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, Keppel St, London WC1E 7HT, England.	justin.parkhurst@lshtm.ac.uk	Parkhurst, Justin/AAP-3615-2021					AsiimweOkiror G, 1997, AIDS, V11, P1757, DOI 10.1097/00002030-199714000-00013; Browne S., 1999, AID PATRONAGE PARTNE; BURNELL PJ, 1991, AID FATIGUE CONCEPT; FISHER I, 2001, NY TIMES        0303; Garnett GP, 1998, AIDS PATIENT CARE ST, V12, P435, DOI 10.1089/apc.1998.12.435; *GOV UG, NAT STRAT FRAM HIV A; Gray RH, 1998, LANCET, V351, P98, DOI 10.1016/S0140-6736(97)09381-1; Karim QA, 1997, AIDS SB, V11, P143; Kilian AHD, 1999, AIDS, V13, P391, DOI 10.1097/00002030-199902250-00012; Macintyre K, 2001, AIDS EDUC PREV, V13, P160, DOI 10.1521/aeap.13.2.160.19736; MBULAITEYE S, 2000, 13 INT AIDS C JUL 9; Parkhurst Justin O., 2001, INT RELAT, V15, P69, DOI DOI 10.1177/004711701015006006; Stoneburner RL, 1996, AM J EPIDEMIOL, V144, P682, DOI 10.1093/oxfordjournals.aje.a008981; *UG AIDS COMM, 1994, ANN REP 1993; *UG MIN HLTH AIDS, 1999, HIV AIDS SURV REP; *UG MIN HLTH COND, 1999, DRAFT OV COND SIT UG; *UNAIDS, 2000, UG EP FACT SHEET HIV; *UNAIDS, 1998, REACH REG CONS IMPR; Williams B, 2001, STAT MED, V20, P2003, DOI 10.1002/sim.840; Zaba BW, 2000, AIDS, V14, P2741, DOI 10.1097/00002030-200012010-00014	20	66	67	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 6	2002	360	9326					78	80		10.1016/S0140-6736(02)09340-6	http://dx.doi.org/10.1016/S0140-6736(02)09340-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569JR	12114061				2022-12-28	WOS:000176599700030
J	Prati, D; Taioli, E; Zanella, A; Della Torre, E; Butelli, S; Del Vecchio, E; Vianello, L; Zanuso, F; Mozzi, F; Milani, S; Conte, D; Colombo, M; Sirchia, G				Prati, D; Taioli, E; Zanella, A; Della Torre, E; Butelli, S; Del Vecchio, E; Vianello, L; Zanuso, F; Mozzi, F; Milani, S; Conte, D; Colombo, M; Sirchia, G			Updated definitions of healthy ranges for serum alanine aminotransferase levels	ANNALS OF INTERNAL MEDICINE			English	Article							CHRONIC HEPATITIS-C; FATTY LIVER-DISEASE; BODY-MASS INDEX; BLOOD-DONORS; RISK-FACTORS; VIRUS-INFECTION; NONALCOHOLIC STEATOHEPATITIS; GENERAL-POPULATION; CRYPTOGENIC CIRRHOSIS; PREVALENCE	Background: Serum alanine aminotransferase (ALT) activity, the variable most commonly measured to assess hepatic disease, fails to identify many patients with hepatic injury. Current standards for "normal" ALT level were defined by using populations that included persons with subclinical liver disease. Objective: To update definitions of healthy ranges for serum ALT level. Design: Retrospective cohort study. Setting: A university hospital in Milan, Italy. Participants: 6835 persons who were first-time blood donors from 1995 through 1999, were negative for anti-hepatitis C virus (HCV), and had no contraindications to donation and 209 persons who attempted to donate blood from 1990 through 1999 but were found to have anti-HCV antibodies. Of the latter group, 131 had HCV viremia. Measurements: Univariate and multivariate analyses examined associations between clinical and laboratory factors and ALT levels. Healthy ranges for ALT were computed from the population at lowest risk for liver disease. Sensitivity and specificity of healthy ALT ranges were evaluated in the donors with HCV antibodies, of whom 133 had liver biopsy. Results: Serum ALT activity was independently related to body mass index and to laboratory indicators of abnormal lipid or carbohydrate metabolism. Updated upper limits (for men, 500 nkat/L [30 U/L]; for women, 317 nkat/L [19 U/L]) were lower than current limits (for men, 667 nkat/L [40 U/L]; for women, 500 nkat/L [30 U/L]) and, during 6-month follow-up, showed superior sensitivity in identifying participants with HCV viremia (sensitivity, 76.3% [95 % Cl, 69.1% to 83.6%] vs. 55% [Cl, 46.4% to 63.5%]). The related tradeoff in specificity was acceptable (88.5% [Cl, 79.2% to 94.6%] vs. 97.4% [91% to 99.7%]). The increased sensitivity targeted patients with minimal to mild histologic lesions. Conclusion: In patients with chronic HCV infection or nonalcoholic fatty liver disease, revision of normal limits for ALT level is advisable.	Osped Maggiore, Ctr Trasfus & Immunol Trapianti, IRCCS, Lab Epidemiol,Div Ematol, I-20122 Milan, Italy; Osped Maggiore, Ist Stat Med & Biometria, IRCCS, Cattedra Gastroenterol, I-20122 Milan, Italy; Osped Maggiore, Ist Med Interna, IRCCS, I-20122 Milan, Italy; Univ Milan, I-20122 Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	Prati, D (corresponding author), Osped Maggiore, Ctr Trasfus & Immunol Trapianti, IRCCS, Lab Epidemiol,Div Ematol, Via F Sforza 35, I-20122 Milan, Italy.	dprati@yahoo.com	milani, silvano/I-7889-2012; Prati, Daniele/P-8215-2019	milani, silvano/0000-0002-5677-1758; Prati, Daniele/0000-0002-2281-7498				ALBERTI A, 1992, LANCET, V340, P697, DOI 10.1016/0140-6736(92)92234-7; Angulo P, 1999, HEPATOLOGY, V30, P1356, DOI 10.1002/hep.510300604; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; BELLENTANI S, 1994, HEPATOLOGY, V20, P1442, DOI 10.1002/hep.1840200611; Bellentani S, 1999, GUT, V44, P874, DOI 10.1136/gut.44.6.874; Bellentani S, 2000, ANN INTERN MED, V132, P112, DOI 10.7326/0003-4819-132-2-200001180-00004; BLAJCHMAN MA, 1995, LANCET, V345, P21, DOI 10.1016/S0140-6736(95)91153-7; Caldwell SH, 1999, HEPATOLOGY, V29, P664, DOI 10.1002/hep.510290347; Calle EE, 1999, NEW ENGL J MED, V341, P1097, DOI 10.1056/NEJM199910073411501; ConryCantilena C, 1996, NEW ENGL J MED, V334, P1691, DOI 10.1056/NEJM199606273342602; Craxi A, 1996, J HEPATOL, V25, P47; Daniel S, 1999, AM J GASTROENTEROL, V94, P3010, DOI 10.1111/j.1572-0241.1999.01451.x; Darling GM, 1997, NEW ENGL J MED, V337, P595, DOI 10.1056/NEJM199708283370903; DEBAC C, 1994, HEPATOLOGY, V20, P1225; DESFORGES JF, 1995, JAMA-J AM MED ASSOC, V274, P1374; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; Dixon JB, 2001, GASTROENTEROLOGY, V121, P91, DOI 10.1053/gast.2001.25540; Falck-Ytter Y, 2001, SEMIN LIVER DIS, V21, P17, DOI 10.1055/s-2001-12926; Guadagnino V, 1997, HEPATOLOGY, V26, P1006, DOI 10.1053/jhep.1997.v26.pm0009328327; GUAZZOTTI L, 1983, SISTEMA SANGUE, P95; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hourigan LF, 1999, HEPATOLOGY, V29, P1215, DOI 10.1002/hep.510290401; LONARDO A, 1995, AM J GASTROENTEROL, V90, P2072; Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8; McCullough AJ, 1999, HEPATOLOGY, V29, P1328, DOI 10.1002/hep.510290451; Piton A, 1998, HEPATOLOGY, V27, P1213, DOI 10.1002/hep.510270505; Poonawala A, 2000, HEPATOLOGY, V32, P689, DOI 10.1053/jhep.2000.17894; Prati D, 1997, TRANSFUSION, V37, P1200, DOI 10.1046/j.1537-2995.1997.37111298088052.x; Prati D, 2000, J VIRAL HEPATITIS, V7, P352; Prati D, 1997, HEPATOLOGY, V25, P702, DOI 10.1002/hep.510250335; Prati D, 1996, GASTROENTEROLOGY, V110, P178, DOI 10.1053/gast.1996.v110.pm8536854; Pratt DS, 2000, NEW ENGL J MED, V342, P1266, DOI 10.1056/NEJM200004273421707; Puoti C, 1997, HEPATOLOGY, V26, P1393; Ratziu V, 2000, GASTROENTEROLOGY, V118, P1117, DOI 10.1016/S0016-5085(00)70364-7; Sheth SG, 1997, ANN INTERN MED, V126, P137, DOI 10.7326/0003-4819-126-2-199701150-00008; Silvani C, 2000, HAEMATOLOGICA, V85, P1055; WEJSTAL R, 1988, VOX SANG, V55, P152, DOI 10.1111/j.1423-0410.1988.tb05083.x; Willett WC, 1999, NEW ENGL J MED, V341, P427, DOI 10.1056/NEJM199908053410607; ZANELLA A, 1995, HEPATOLOGY, V21, P913, DOI 10.1016/0270-9139(95)90233-3	39	1044	1087	1	33	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 2	2002	137	1					1	9		10.7326/0003-4819-137-1-200207020-00006	http://dx.doi.org/10.7326/0003-4819-137-1-200207020-00006			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569VA	12093239				2022-12-28	WOS:000176622000001
J	Ducharme, FM				Ducharme, FM			Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence	BMJ-BRITISH MEDICAL JOURNAL			English	Article							METAANALYSIS; MONTELUKAST; CORTICOSTEROIDS; ANTAGONIST; BIAS	Objectives To examine the evidence for the efficacy and glucocorticoid sparing effect of oral anti-leukotrienes Liken daily as add-on therapy to inhaled glucocorticoids in patients with asthma. Design Systematic review of randomised controlled trials of children and adults with. asthma comparing tire addition of anti-leukotrienes or placebo to inhaled glucocorticoids. Main outcome measures The rate of exacerbations of asthma requiring rescue systemic glucocorticoids when the intervention was compared to the same or double dose of inhaled glucocorticoids, and the glucocorticoid sparing effect when the intervention was aimed at tapering the glucocorticoid. Results Of 376 citations, 13 were included: 12 in adult patients and one in children. The addition of licensed doses of anti-leukotrienes to inhaled glucocorticoids resulted in a non-significant reduction in the risk of exacerbations requiring systemic steroids (two trials; relative risk 0.61, 95% confidence interval 0.36 to 1.05). No trials comparing the use of anti-leukotrienes with. double the dose of inhaled glucocorticoids could be pooled. The use of anti-leukotrienes resulted in no overall group difference in the lowest achieved dose of inhaled glucocorticoids (three trials; weighted mean difference -44.43 mug/day, -147.87 to 59.02: random effect model) but was associated with a reduction in withdrawals owing to poor asthma control (four trials; relative risk 0.56, 0.35 to 0.89). Conclusions The addition of anti-leukotrienes to inhaled glucocorticoids may modestly improve asthma control compared with. inhaled glucocorticoids alone but this strategy cannot be recommended as a substitute for increasing the dose of inhaled glucocorticoids. The addition of anti-leukotrienes is possibly associated with superior asthma control after tapering of glucocorticoids, but the glucocorticoid sparing effect cannot be quantified at present.	McGill Univ, Ctr Hlth, Dept Paediat, Montreal, PQ H3H 1P3, Canada; McGill Univ, Ctr Hlth, Dept Epidemiol & Biostat, Montreal, PQ H3H 1P3, Canada	McGill University; McGill University	Ducharme, FM (corresponding author), McGill Univ, Ctr Hlth, Dept Paediat, Montreal, PQ H3H 1P3, Canada.	Francine.ducharme@muhc.mcgill.ca	Ducharme, Francine/N-8332-2013	Ducharme, Francine/0000-0001-5096-0614	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Baba K, 1999, AM J RESP CRIT CARE, V159, pA626; Bateman ED, 1995, ALLERGY S26, V50, P320; Boulet LP, 1999, CAN MED ASSOC J, V161, pS1; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DUCHARME FM, 2001, COCHRANE LIB; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; Holt PG, 1997, THORAX, V52, P1, DOI 10.1136/thx.52.1.1; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Laitinen LA, 1995, ALLERGY S26, V50, P320; Laviolette M, 1999, AM J RESP CRIT CARE, V160, P1862, DOI 10.1164/ajrccm.160.6.9803042; Lofdahl CG, 1999, BMJ-BRIT MED J, V319, P87, DOI 10.1136/bmj.319.7202.87; MURPHY S, 1997, NIH PUBLICATION; Nayak AS, 1998, J ALLERGY CLIN IMMUN, V101, pS233; Pearson MG, 1997, THORAX, V52, pS1; PIPER PJ, 1989, EUR J ANAESTH, V6, P241; Ringdal N, 1999, AM J RESP CRIT CARE, V159, pA639; SHINGO S, 2001, COMMUNICATION; Simons FER, 2001, J PEDIATR-US, V138, P694, DOI 10.1067/mpd.2001.112899; Spahn JD, 1996, ALLERGY ASTHMA PROC, V17, P341, DOI 10.2500/108854196778606365; Tamaoki J, 1997, AM J RESP CRIT CARE, V155, P1235, DOI 10.1164/ajrccm.155.4.9105060; Thornton A, 2000, J CLIN EPIDEMIOL, V53, P207, DOI 10.1016/S0895-4356(99)00161-4; TOMITA T, 1999, ARERUGI, V48, P459; VIRCHOW JC, 1997, AM J RESP CRIT CARE, V156, P578; Wada Kiyoko, 2000, Allergology International, V49, P63, DOI 10.1046/j.1440-1592.2000.00160.x	25	48	50	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 29	2002	324	7353					1545	1548A		10.1136/bmj.324.7353.1545	http://dx.doi.org/10.1136/bmj.324.7353.1545			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	570WP	12089089	Green Published, Bronze			2022-12-28	WOS:000176683000015
J	Gask, L; Usherwood, T				Gask, L; Usherwood, T			ABC of psychological medicine - The consultation	BRITISH MEDICAL JOURNAL			English	Review									Univ Manchester, Manchester M13 9PL, Lancs, England; Univ Sydney, Sydney, NSW 2006, Australia	University of Manchester; University of Sydney	Gask, L (corresponding author), Univ Manchester, Manchester M13 9PL, Lancs, England.							Cole Steven A., 2000, MED INTERVIEW 3 FUNC; GASK L, 2000, REATTRIBUTION MANAGI; Usherwood T., 1999, UNDERSTANDING CONSUL	3	40	41	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 29	2002	324	7353					1567	1569		10.1136/bmj.324.7353.1567	http://dx.doi.org/10.1136/bmj.324.7353.1567			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	570WP	12089097	Green Published			2022-12-28	WOS:000176683000026
J	Senn, DB; Hemond, HF				Senn, DB; Hemond, HF			Nitrate controls on iron and arsenic in an urban lake	SCIENCE			English	Article							OXIDATION; SPECIATION; REDUCTION; MANGANESE; GENERATION; ADSORPTION; WATERS; PH	Aquatic ecosystems are often contaminated by multiple substances. Nitrate, a common aquatic pollutant, strongly influenced the cycling of arsenic (As) under anoxic conditions in urban Upper Mystic Lake (Massachusetts, USA) by oxidizing ferrous iron [Fe(II)] to produce As-sorbing particulate hydrous ferric oxides and causing the more oxidized As(V), which is more particle-reactive than As(III) under these conditions, to dominate. This process is likely to be important in many natural waters.	MIT, Dept Civil & Environm Engn, Parsons Lab, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Senn, DB (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Environm Sci & Engn, Bldg 1,Room G21,665 Huntington Ave, Boston, MA 02115 USA.	dbsenn@alum.mit.edu	张, 楠/B-1010-2010; Senn, David B/E-7813-2010	Senn, David/0000-0002-4869-3550	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004675] Funding Source: NIH RePORTER; NIEHS NIH HHS [5P42ES04675-06] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AGGETT J, 1988, WATER RES, V22, P407, DOI 10.1016/0043-1354(88)90034-6; Ahmann D, 1997, ENVIRON SCI TECHNOL, V31, P2923, DOI 10.1021/es970124k; AURILLO AC, 1994, ENVIRON SCI TECHNOL, V28, P577, DOI 10.1021/es00053a008; BALISTRIERI LS, 1992, LIMNOL OCEANOGR, V37, P510, DOI 10.4319/lo.1992.37.3.0510; Benz M, 1998, ARCH MICROBIOL, V169, P159, DOI 10.1007/s002030050555; CULLEN WR, 1989, CHEM REV, V89, P713, DOI 10.1021/cr00094a002; Cummings DE, 1999, ENVIRON SCI TECHNOL, V33, P723, DOI 10.1021/es980541c; DAVISON W, 1993, EARTH-SCI REV, V34, P119, DOI 10.1016/0012-8252(93)90029-7; DEVITRE RR, 1988, GEOCHIM COSMOCHIM AC, V52, P1601, DOI 10.1016/0016-7037(88)90229-3; Dzombak D.A., 1990, SURFACE COMPLEXATION, P416; Gelda RK, 2000, WATER RES, V34, P1107, DOI 10.1016/S0043-1354(99)00265-1; Harrington JM, 1998, ENVIRON SCI TECHNOL, V32, P2425, DOI 10.1021/es971129k; Hoeft SE, 2002, GEOMICROBIOL J, V19, P23, DOI 10.1080/014904502317246147; LEWIS BL, 1991, DEEP-SEA RES, V38, pS773, DOI 10.1016/S0198-0149(10)80009-3; LOVLEY DR, 1986, APPL ENVIRON MICROB, V52, P751, DOI 10.1128/AEM.52.4.751-757.1986; MASSCHELEYN PH, 1991, ENVIRON SCI TECHNOL, V25, P1414, DOI 10.1021/es00020a008; Mengis M, 1997, LIMNOL OCEANOGR, V42, P1530, DOI 10.4319/lo.1997.42.7.1530; MOORE JN, 1988, ENVIRON SCI TECHNOL, V22, P432, DOI 10.1021/es00169a011; MURRAY JW, 1995, ADV CHEM SER, V244, P157, DOI 10.1021/ba-1995-0244.ch007; Naqvi SWA, 2000, NATURE, V408, P346, DOI 10.1038/35042551; Nickson RT, 2000, APPL GEOCHEM, V15, P403, DOI 10.1016/S0883-2927(99)00086-4; Nolan BT, 2000, ENVIRON SCI TECHNOL, V34, P1156, DOI 10.1021/es9907663; Ottley CJ, 1997, GEOCHIM COSMOCHIM AC, V61, P1819, DOI 10.1016/S0016-7037(97)00058-6; PIERCE ML, 1982, WATER RES, V16, P1247, DOI 10.1016/0043-1354(82)90143-9; POSTMA D, 1991, WATER RESOUR RES, V27, P2027, DOI 10.1029/91WR00989; Ratering S, 2001, ENVIRON MICROBIOL, V3, P100, DOI 10.1046/j.1462-2920.2001.00163.x; Raven KP, 1998, ENVIRON SCI TECHNOL, V32, P344, DOI 10.1021/es970421p; SCOTT MJ, 1995, ENVIRON SCI TECHNOL, V29, P1898, DOI 10.1021/es00008a006; SENN DB, 2001, THESIS MIT; SIGG L, 1991, MAR CHEM, V36, P9, DOI 10.1016/S0304-4203(09)90051-2; SOLORZANO L, 1969, LIMNOL OCEANOGR, V14, P799, DOI 10.4319/lo.1969.14.5.0799; Spliethoff HM, 1996, ENVIRON SCI TECHNOL, V30, P121, DOI 10.1021/es950169q; SPLIETHOFF HM, 1995, ENVIRON SCI TECHNOL, V29, P2157, DOI 10.1021/es00008a041; STOOKEY LL, 1970, ANAL CHEM, V42, P779, DOI 10.1021/ac60289a016; Straub KL, 1996, APPL ENVIRON MICROB, V62, P1458, DOI 10.1128/AEM.62.4.1458-1460.1996; TROWBRIDGE PR, 1995, THESIS MIT; Vitousek PM, 1997, ECOL APPL, V7, P737, DOI 10.2307/2269431; Weber KA, 2001, ENVIRON SCI TECHNOL, V35, P1644, DOI 10.1021/es0016598; Wetzel RG, 2001, LIMNOLOGY, Vthird, P331; Wilkie JA, 1998, ENVIRON SCI TECHNOL, V32, P657, DOI 10.1021/es970637r	40	152	169	8	182	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 28	2002	296	5577					2373	2376		10.1126/science.1072402	http://dx.doi.org/10.1126/science.1072402			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	567CE	12089437				2022-12-28	WOS:000176467200035
J	Moore, AC; Ryan, ET; Waldron, MA				Moore, AC; Ryan, ET; Waldron, MA			A 37-year-old man with fever, hepatosplenomegaly, and a cutaneous foot lesion after a trip to Africa - East African trypanosomiasis (Trypanosom brucei rhodesiense infection)	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SLEEPING-SICKNESS; GAMBIENSE TRYPANOSOMIASIS; RISK-FACTORS; MELARSOPROL; DIAGNOSIS; TRAVELERS; ENCEPHALOPATHY; FIELD		Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Parasit Dis Drug Serv, Atlanta, GA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Moore, AC (corresponding author), Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA 30333 USA.			Moore, Anne/0000-0003-3656-4230				AERTS D, 1992, T ROY SOC TROP MED H, V86, P394, DOI 10.1016/0035-9203(92)90234-4; BAILEY JW, 1992, T ROY SOC TROP MED H, V86, P630, DOI 10.1016/0035-9203(92)90160-E; BARRETTCONNOR E, 1973, ARCH INTERN MED, V131, P574, DOI 10.1001/archinte.131.4.574; BIA FJ, 1994, TRAVEL MED ADVISOR P, P27; BRYAN RT, 1989, TRAVEL MED, P384; Burri C, 2000, LANCET, V355, P1419, DOI 10.1016/S0140-6736(00)02141-3; DOHERTY JF, 1995, QJM-INT J MED, V88, P277; Donelson JE, 1998, MOL BIOCHEM PARASIT, V91, P51, DOI 10.1016/S0166-6851(97)00209-0; Ekwanzala M, 1996, LANCET, V348, P1427, DOI 10.1016/S0140-6736(96)06088-6; FOULKES JR, 1981, BRIT MED J, V283, P1172, DOI 10.1136/bmj.283.6300.1172; Hide G, 1999, CLIN MICROBIOL REV, V12, P112, DOI 10.1128/CMR.12.1.112; Jelinek T, 2002, EMERG INFECT DIS, V8, P634, DOI 10.3201/eid0806.010432; Kanmogne GD, 1996, ANN TROP MED PARASIT, V90, P475, DOI 10.1080/00034983.1996.11813072; Kirchhoff L. V., 1998, Central African Journal of Medicine, V44, P134; Legros D, 1999, T ROY SOC TROP MED H, V93, P439, DOI 10.1016/S0035-9203(99)90151-7; LUMSDEN WHR, 1979, T ROY SOC TROP MED H, V73, P312, DOI 10.1016/0035-9203(79)90092-0; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P169; Malesker MA, 1999, AM J TROP MED HYG, V61, P428, DOI 10.4269/ajtmh.1999.61.428; Matovu E, 2001, TROP MED INT HEALTH, V6, P407, DOI 10.1046/j.1365-3156.2001.00712.x; MCGOVERN TW, 1995, ARCH DERMATOL, V131, P1178, DOI 10.1001/archderm.131.10.1178; Miezan TW, 1998, TROP MED INT HEALTH, V3, P571, DOI 10.1046/j.1365-3156.1998.00267.x; Moore A, 2001, TROP MED INT HEALTH, V6, P342, DOI 10.1046/j.1365-3156.2001.00714.x; Moore DAJ, 2002, EMERG INFECT DIS, V8, P74, DOI 10.3201/eid0801.010130; Nantulya VM, 1997, T ROY SOC TROP MED H, V91, P551, DOI 10.1016/S0035-9203(97)90023-7; Pecoul B, 1999, JAMA-J AM MED ASSOC, V281, P361, DOI 10.1001/jama.281.4.361; PEPIN J, 1989, LANCET, V1, P1246, DOI 10.1016/S0140-6736(89)92340-4; PEPIN J, 1994, ADV PARASIT, V33, P1, DOI 10.1016/S0065-308X(08)60410-8; PEPIN J, 1995, T ROY SOC TROP MED H, V89, P92, DOI 10.1016/0035-9203(95)90673-8; PETRU AM, 1988, AM J DIS CHILD, V142, P224, DOI 10.1001/archpedi.1988.02150020126047; ROBINSON B, 1980, SOUTHERN MED J, V73, P516, DOI 10.1097/00007611-198004000-00032; Sinha A, 1999, CLIN INFECT DIS, V29, P840, DOI 10.1086/520446; SPENCER HC, 1975, ANN INTERN MED, V82, P633, DOI 10.7326/0003-4819-82-5-633; Stanghellini A, 2001, TROP MED INT HEALTH, V6, P330, DOI 10.1046/j.1365-3156.2001.00724.x; STEFFEN R, 1999, TROPICLA INFECT DIS, V1, P106; Van Nieuwenhove S, 2001, TROP MED INT HEALTH, V6, P335, DOI 10.1046/j.1365-3156.2001.00731.x; VANNIEUWENHOVE S, 1992, ANN SOC BELG MED TR, V72, P39; *WHO, 2002, AFR TRYP CONTR	37	19	20	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 27	2002	346	26					2069	2076		10.1056/NEJMcpc010056	http://dx.doi.org/10.1056/NEJMcpc010056			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566DN	12087144				2022-12-28	WOS:000176411900009
J	Vadhan-Raj, S; Kavanagh, JJ; Freedman, RS; Folloder, J; Currie, LM; Bueso-Ramos, C; Verschraegen, CF; Narvios, AB; Connor, J; Hoots, WK; Broemeling, LD; Lichtiger, B				Vadhan-Raj, S; Kavanagh, JJ; Freedman, RS; Folloder, J; Currie, LM; Bueso-Ramos, C; Verschraegen, CF; Narvios, AB; Connor, J; Hoots, WK; Broemeling, LD; Lichtiger, B			Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study	LANCET			English	Article							VITRO FUNCTIONAL-ACTIVITY; PROGENITOR-CELL TRANSPLANTATION; HIGH-DOSE CHEMOTHERAPY; 2ND-MESSENGER EFFECTORS; DIMETHYL-SULFOXIDE; ENHANCED RETENTION; BREAST-CANCER; STORAGE; REFRACTORINESS; DONORS	Background The increasing demand for platelet products, and concern over the transfusion-associated risks of alloimmunisation and infections, have motivated a search for improved methods aimed at keeping exposure to donor antigens to a minimum. Transfusion of thrombopoietin-derived autofogous platelets might provide an alternative strategy. We aimed to compare the safety and efficacy of this strategy with that of transfusion with fresh allogeneic platelets in patients with severe chemotherapy-induced thrombocytopenia. Methods 20 patients with gynaecological malignancies were treated with two doses of 1.2 wg/kg recombinant human thrombopoietin. From day 12, we aimed to collect 50 units of platelets from these patients by plateletpheresis. Harvested platelets were cryopreserved in ThromboSol and 2% dimethyl sulfoxide (DMSO) for use in subsequent autologous transfusions. Patients then received carboplatin for up to six cycles. Patients were randomly assigned to group A (n=10), which received allogeneic fresh platelets at the first instance of severe thrombocytopenia (platelet count <15 000/&mu;L) and then autologous cryopreserved platelets at the next, or to group B (n=10), which received first autologous and then allogeneic platelets. In subsequent cycles, all patients received autologous platelets while available. The primary endpoint was platelet count increment corrected for the number of platelets transfused and the patients' body-surface area. Analysis was by intention to treat. Findings Treatment with recombinant human thrombopoietin significantly increased platelet count (median 2.3-fold [range 1.5-3.3], p<0.0001) in all but one patient in group A. The median number of platelets collected per patient was 53 units (14-66) in two collections (one to three). There was no significant difference in the corrected platelet count increments (CCIs) between the 19 paired transfusions of cryopreserved autologous platelets and fresh allogeneic platelets (median 1-h CC] 15.7 vs 19.8, p=0.398; median 24-h CCI 13.0 vs 18.1, p=0398). 14 of the 19 patients had a good response (1-h CCI >7.5) to their first transfusion of allogeneic platelets. By contrast, all patients had a good response to their first transfusion of autologous platelets (p=0.063). Moreover, no significant decrease in the CCIs (p=0.405) was seen over six cycles after autologous platelet transfusions (n=63). No transfusion reactions or any serious adverse event was recorded during autologous platelet transfusions. Interpretation Recombinant human thrombopoietin facilitated collection of multiple units of platelets, which could be cryopreserved and reinfused to counteract severe thrombocytopenia during multicycle chemotherapy. Transfusion of autologous cryopreserved platelets derived from recombinant human thrombopoietin can provide a viable strategy to minimise the risks of allogeneic platelet transfusions and provide along-lasting supply of platelet support.	Univ Texas, MD Anderson Canc Ctr, Dept Immunotherapy, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Med Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Lab Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pediat, Houston, TX 77030 USA; Life Cell Corp, Dept Med Hematol Oncol, Branchburg, TX USA; Life Cell Corp, Dept GYN Med Therapeut, Branchburg, TX USA; Life Cell Corp, Dept Lab Med, Branchburg, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Vadhan-Raj, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunotherapy, Box 422,1515 Holcombe Blvd, Houston, TX 77030 USA.		Verschraegen, Claire/AAE-7620-2020	Verschraegen, Claire/0000-0001-6544-3089				BAYTHOON H, 1982, J CLIN PATHOL, V35, P870, DOI 10.1136/jcp.35.8.870; BISHOP JF, 1992, TRANSFUSION MED, V2, P35, DOI 10.1111/j.1365-3148.1992.tb00132.x; Bock M, 1995, TRANSFUSION, V35, P921, DOI 10.1046/j.1537-2995.1995.351196110896.x; CALVERT AH, 1989, J CLIN ONCOL, V7, P1748, DOI 10.1200/JCO.1989.7.11.1748; *COMM STAND, 2000, STAND BLOOD BANKS TR; Connor J, 1996, TRANSFUSION, V36, P691, DOI 10.1046/j.1537-2995.1996.36896374372.x; Currie LM, 1999, BRIT J HAEMATOL, V105, P826, DOI 10.1046/j.1365-2141.1999.01411.x; Currie LM, 1998, TRANSFUSION, V38, P160, DOI 10.1046/j.1537-2995.1998.38298193098.x; Goodnough LT, 2001, BLOOD, V98, P1346, DOI 10.1182/blood.V98.5.1346; HOGGE DE, 1995, TRANSFUSION, V35, P645, DOI 10.1046/j.1537-2995.1995.35895357895.x; Holme S, 1998, VOX SANG, V74, P207, DOI 10.1111/j.1423-0410.1998.tb05422.x; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; Kruskall MS, 1997, NEW ENGL J MED, V337, P1914, DOI 10.1056/NEJM199712253372609; Kuter DJ, 2001, BLOOD, V98, P1339, DOI 10.1182/blood.V98.5.1339; LAZARUS HM, 1982, TRANSFUSION, V22, P39, DOI 10.1046/j.1537-2995.1982.22182154213.x; Lill M., 1997, Transfusion (Bethesda), V37, p26S; McCullough J, 2000, SEMIN HEMATOL, V37, P3, DOI 10.1016/S0037-1963(00)90047-7; McFarland J, 1997, NEW ENGL J MED, V337, P1861; MURPHY S, 1985, SEMIN HEMATOL, V22, P165; Novotny VMJ, 1999, VOX SANG, V76, P1, DOI 10.1046/j.1423-0410.1999.7610001.x; Pedrazzoli P, 1998, HAEMATOLOGICA, V83, P718; RODAK BF, 1995, DIAGNOSTIC HEMATOL, P554; SCHIFFER CA, 1976, BRIT J HAEMATOL, V34, P377, DOI 10.1111/j.1365-2141.1976.tb03584.x; SCHIFFER CA, 1978, NEW ENGL J MED, V299, P7, DOI 10.1056/NEJM197807062990102; SINTNICOLAAS K, 1995, BLOOD, V85, P824, DOI 10.1182/blood.V85.3.824.bloodjournal853824; Slichter SJ, 1991, HEMATOLOGY BASIC PRI, P1610; Torretta L, 1998, VOX SANG, V75, P224, DOI 10.1046/j.1423-0410.1998.7530224.x; Vadhan-Raj S, 1999, BRIT J HAEMATOL, V104, P403, DOI 10.1046/j.1365-2141.1999.01178.x; Vadhan-Raj S, 2000, ANN INTERN MED, V132, P364, DOI 10.7326/0003-4819-132-5-200003070-00005; VadhanRaj S, 1997, ANN INTERN MED, V126, P673, DOI 10.7326/0003-4819-126-9-199705010-00001; VANKOOIJ M, 1991, BLOOD, V77, P201; Vostal J. G., 2000, Transfusion (Bethesda), V40, P742, DOI 10.1046/j.1537-2995.2000.40060742.x; Wallace EL, 1998, TRANSFUSION, V38, P625, DOI 10.1046/j.1537-2995.1998.38798346630.x; WALLACE EL, 1995, TRANSFUSION, V35, P802, DOI 10.1046/j.1537-2995.1995.351096026360.x	34	46	51	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 22	2002	359	9324					2145	2152		10.1016/S0140-6736(02)09090-6	http://dx.doi.org/10.1016/S0140-6736(02)09090-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566RJ	12090979				2022-12-28	WOS:000176441800008
J	Van Eerdewegh, P; Little, RD; Dupuis, J; Del Mastro, RG; Falls, K; Simon, J; Torrey, D; Pandit, S; McKenny, J; Braunschweiger, K; Walsh, A; Liu, ZY; Hayward, B; Folz, C; Manning, SP; Bawa, A; Saracino, L; Thackston, M; Benchekroun, Y; Capparell, N; Wang, M; Adair, R; Feng, Y; Dubois, J; FitzGerald, MG; Huang, H; Gibson, R; Allen, KM; Pedan, A; Danzig, MR; Umland, SP; Egan, RW; Cuss, FM; Rorke, S; Clough, JB; Holloway, JW; Holgate, ST; Keith, TP				Van Eerdewegh, P; Little, RD; Dupuis, J; Del Mastro, RG; Falls, K; Simon, J; Torrey, D; Pandit, S; McKenny, J; Braunschweiger, K; Walsh, A; Liu, ZY; Hayward, B; Folz, C; Manning, SP; Bawa, A; Saracino, L; Thackston, M; Benchekroun, Y; Capparell, N; Wang, M; Adair, R; Feng, Y; Dubois, J; FitzGerald, MG; Huang, H; Gibson, R; Allen, KM; Pedan, A; Danzig, MR; Umland, SP; Egan, RW; Cuss, FM; Rorke, S; Clough, JB; Holloway, JW; Holgate, ST; Keith, TP			Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness	NATURE			English	Article							LINKAGE DISEQUILIBRIUM; PROTEASE; PROTEINS; MARKERS; MUTATION; DOMAIN; FAMILY	Asthma is a common respiratory disorder characterized by recurrent episodes of coughing, wheezing and breathlessness. Although environmental factors such as allergen exposure are risk factors in the development of asthma, both twin and family studies point to a strong genetic component(1,2). To date, linkage studies have identified more than a dozen genomic regions linked to asthma(3). In this study, we performed a genome-wide scan on 460 Caucasian families and identified a locus on chromosome 20p13 that was linked to asthma (log(10) of the likelihood ratio (LOD), 2.94) and bronchial hyperresponsiveness (LOD, 3.93). A survey of 135 polymorphisms in 23 genes identified the ADAM33 gene 4 as being significantly associated with asthma using case-control, transmission disequilibrium and haplotype analyses (P=0.04-0.000003). ADAM proteins are membrane-anchored metalloproteases with diverse functions, which include the shedding of cell-surface proteins such as cytokines and cytokine receptors(5). The identification and characterization of ADAM33, a putative asthma susceptibility gene identified by positional cloning in an outbred population, should provide insights into the pathogenesis and natural history of this common disease.	Genome Therapeut Corp, Waltham, MA 02453 USA; Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA; Univ Southampton, Sch Med, Resp Cell & Mol Biol Infect Inflammat & Repair Re, Southampton Gen Hosp, Southampton, Hants, England	Merck & Company; Schering Plough Corporation; University of Southampton	Keith, TP (corresponding author), Genome Therapeut Corp, 100 Beaver St, Waltham, MA 02453 USA.		Little, Randall/O-7172-2014; Holloway, John W/B-5424-2009	Holloway, John W/0000-0001-9998-0464; Dupuis, Josee/0000-0003-2871-3603; Hayward, Brooke/0000-0002-1234-7445				Abecasis GR, 2000, BIOINFORMATICS, V16, P182, DOI 10.1093/bioinformatics/16.2.182; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; BOEHNKE M, 1991, AM J HUM GENET, V48, P22; Burney P, 1997, AM J RESP CRIT CARE, V156, P1773; Das M, 2001, PHYSIOL GENOMICS, V6, P57, DOI 10.1152/physiolgenomics.2001.6.2.57; Del Mastro R G, 1997, Methods Mol Biol, V68, P183; DESANCTIS GT, 1995, NAT GENET, V11, P150, DOI 10.1038/ng1095-150; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; Dupuis J, 1999, GENETICS, V151, P373; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; Ghosh S, 1997, GENOME RES, V7, P165, DOI 10.1101/gr.7.2.165; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Howard L, 2000, BIOCHEM J, V348, P21, DOI 10.1042/0264-6021:3480021; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; KRUGLYAK L, 1995, AM J HUM GENET, V57, P439; LANGE K, 1988, GENET EPIDEMIOL, V5, P471, DOI 10.1002/gepi.1370050611; Loechel F, 1999, J BIOL CHEM, V274, P13427, DOI 10.1074/jbc.274.19.13427; Los H, 2001, Twin Res, V4, P81, DOI 10.1375/1369052012191; Maquat LE, 2001, NAT GENET, V27, P5, DOI 10.1038/83759; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; Mullberg J, 2000, EUR CYTOKINE NETW, V11, P27; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Richter A, 2001, AM J RESP CELL MOL, V25, P385, DOI 10.1165/ajrcmb.25.3.4437; Soares M. B., 1994, AUTOMATED DNA SEQUEN, P110; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Stone AL, 1999, J PROTEIN CHEM, V18, P447, DOI 10.1023/A:1020692710029; Wilkinson J, 1998, GENOMICS, V53, P251, DOI 10.1006/geno.1998.5485; Wjst M, 1998, BIOINFORMATICS, V14, P827, DOI 10.1093/bioinformatics/14.9.827; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Yoshinaka T, 2002, GENE, V282, P227, DOI 10.1016/S0378-1119(01)00818-6	30	816	855	0	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 25	2002	418	6896					426	430		10.1038/nature00878	http://dx.doi.org/10.1038/nature00878			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	576MU	12110844				2022-12-28	WOS:000177009700040
J	Follath, F; Cleland, JGF; Just, H; Papp, JGY; Scholz, H; Peuhkurinen, K; Harjola, VP; Mitrovic, V; Abdalla, M; Sandell, EP; Lehtonen, L				Follath, F; Cleland, JGF; Just, H; Papp, JGY; Scholz, H; Peuhkurinen, K; Harjola, VP; Mitrovic, V; Abdalla, M; Sandell, EP; Lehtonen, L		Steering Comm Investigators Levosi	Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial	LANCET			English	Article							CARDIAC TROPONIN-C; CA2+ SENSITIZER; INFUSION; MILRINONE	Background Levosimendan, a novel calcium sensitiser, improves myocardial contractility without causing an increase in myocardial oxygen demand. We compared the effects of levosimendan and dobutamine on haemodynamic performance and clinical outcome in patients with low-output heart failure. Methods Patients were recruited into a multicentre, randomised, double-blind, double-dummy, parallel-group trial. Under continuous haemodynamic monitoring, an initial loading dose of levosimendan of 24 mug/kg was infused over 10 min, followed by a continuous infusion of 0.1 mug kg(-1) min(-1) for 24 h. Dobutamine was infused for 24 h at an initial dose of 5 mug kg(-1) min(-1) without a loading dose. The infusion rate was doubled if the response was inadequate at 2 h. The primary endpoint was the proportion of patients with haemodynamic improvement (defined as an increase of 30% or more in cardiac output and a decrease of 25% or more in pulmonary-capillary wedge pressure) at 24 h. Analyses were by intention to treat. Findings 103 patients were assigned levosimendan and 100 dobutamine. The primary haemodynamic endpoint was achieved in 29 (28%) levosimendan-group patients and 15 (15%) in the dobutamine group (hazard ratio 1.9 [95% Cl 1.1-3.3]; p=0.022). At 180 days, 27 (26%) levosimendan-group patients had died, compared with 38 (38%) in the dobutamine group (0.57 [0.34-0.95]; p=0.029). Interpretation In patients with severe, low-output heart failure, levosimendan improved haemodynamic performance more effectively than dobutamine. This benefit was accompanied by lower mortality in the levosimendan group than in the dobutamine group for up to 180 days.	Univ Zurich Hosp, Dept Internal Med, CH-8091 Zurich, Switzerland; Univ Hull, Kingston Upon Hull, Yorks, England; Univ Freiburg Klinikum, Freiburg, Germany; Albert Szent Gyorgyi Med Univ, H-6701 Szeged, Hungary; Univ Hamburg, Krankenhaus Eppendorf, D-2000 Hamburg, Germany; Kuopio Univ Hosp, SF-70210 Kuopio, Finland; Univ Helsinki Hosp, Helsinki, Finland; Max Planck Inst, Kerkhoff Clin, D-6350 Bad Nauheim, Germany; London Sch Hyg & Trop Med, London WC1, England; Orion Pharma, Espoo, Finland	University of Zurich; University Zurich Hospital; University of Hull; University of Freiburg; Szeged University; University of Hamburg; Kuopio University Hospital; University of Eastern Finland; University of Helsinki; Helsinki University Central Hospital; Max Planck Society; University of London; London School of Hygiene & Tropical Medicine; Orion Corporation	Follath, F (corresponding author), Univ Zurich Hosp, Dept Internal Med, Ramistr 100, CH-8091 Zurich, Switzerland.	dimffo@usz.unizh.ch	Harjola, Veli-Pekka/G-9229-2015; Cleland, John G./AAZ-4185-2020	Cleland, John G./0000-0002-1471-7016				Brown AM, 1998, EUR HEART J, V19, P1063, DOI 10.1053/euhj.1997.0859; Cleland JGF, 1999, EUR J HEART FAIL, V1, P229, DOI 10.1016/S1388-9842(99)00032-X; Cotter G, 1998, LANCET, V351, P389, DOI 10.1016/S0140-6736(97)08417-1; DIES F, 1986, CIRCULATION, V74, P38; Figgitt DP, 2001, DRUGS, V61, P613, DOI 10.2165/00003495-200161050-00006; HAIKALA H, 1995, J CARDIOVASC PHARM, V25, P794, DOI 10.1097/00005344-199505000-00016; HAIKALA H, 1995, J MOL CELL CARDIOL, V27, P1859, DOI 10.1016/0022-2828(95)90009-8; Hampton JR, 1997, LANCET, V349, P971, DOI 10.1016/S0140-6736(96)10488-8; Hasenfuss G, 1995, J CARDIOVASC PHARM, V26, pS45; Hasenfuss G, 1998, CIRCULATION, V98, P2141, DOI 10.1161/01.CIR.98.20.2141; Heyndrickx G, 1996, HEART, V76, P223, DOI 10.1136/hrt.76.3.223; Jaagosild P, 1998, ARCH INTERN MED, V158, P1081, DOI 10.1001/archinte.158.10.1081; Jamali IN, 1997, ANESTH ANALG, V85, P23, DOI 10.1097/00000539-199707000-00005; Lancaster MK, 1997, EUR J PHARMACOL, V339, P97, DOI 10.1016/S0014-2999(97)01362-9; LIANG CS, 1984, CIRCULATION, V69, P113, DOI 10.1161/01.CIR.69.1.113; Lilleberg J, 1998, EUR HEART J, V19, P660, DOI 10.1053/euhj.1997.0806; MOISEYEV VS, 1999, J CARDIAC FAIL S1, V5, P42; Nieminen MS, 2000, J AM COLL CARDIOL, V36, P1903, DOI 10.1016/S0735-1097(00)00961-X; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; Pagel PS, 1996, BRIT J PHARMACOL, V119, P609, DOI 10.1111/j.1476-5381.1996.tb15716.x; POLLESELLO P, 1994, J BIOL CHEM, V269, P28584; SHARPE N, 1998, LANCET S1, V352, P37; Singh BN, 1999, AM J CARDIOL, V83, p16I; Slawsky MT, 2000, CIRCULATION, V102, P2222; Thackray S, 2000, EUR J HEART FAIL, V2, P209, DOI 10.1016/S1388-9842(00)00080-5; THACKRAY S, IN PRESS EUR J HEART; Ukkonen H, 2000, CLIN PHARMACOL THER, V68, P522, DOI 10.1067/mcp.2000.110972; Yokoshiki H, 1997, EUR J PHARMACOL, V333, P249, DOI 10.1016/S0014-2999(97)01108-4	28	780	878	0	27	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 20	2002	360	9328					196	202		10.1016/S0140-6736(02)09455-2	http://dx.doi.org/10.1016/S0140-6736(02)09455-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	576DX	12133653				2022-12-28	WOS:000176988500008
J	Huby, G; Gerry, M; McKinstry, B; Porter, M; Shaw, J; Wrate, R				Huby, G; Gerry, M; McKinstry, B; Porter, M; Shaw, J; Wrate, R			Morale among general practitioners: qualitative study exploring relations between partnership arrangements, personal style, and workload	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MENTAL-HEALTH; STRESS; SATISFACTION	Objectives To explore general practitioners' experiences of wellbeing and distress at work, to identify their perceptions of the causes of and solutions to distress, and to draw out implications for improving morale in general practice. Design Three stage qualitative study consisting of one to one unstructured interviews, one to one guided interviews, and focus groups. Setting Fife, Lothian, and the Borders, South East Scotland. Participants 63 general practitioner principals. Results Morale of general practitioners was explained by the complex interrelations between factors. Three key factors were identified: workload, personal style, and practice arrangements. Workload was commonly identified as a cause of low morale, but partnership arrangements were also a key mediating variable between increasing workload and external changes in general practice on the one hand and individual responses to these changes on the other. Integrated interventions at personal, partnership, and practice levels were seen to make considerable contributions to improving morale. Effective partnerships helped individuals to manage workload, but increasing Workload was also seen to take away time and Opportunities for practices to manage change and to build Supportive and effective working environments. Conclusions Solutions to the problem of low morale need integrated initiatives at individual, partnership, practice, and policy levels. Improving partnership arrangements is a key intervention, and rigorous action research is needed to evaluate different approaches.	Univ Edinburgh, Primary Care Res Grp, Dept Community Hlth Sci, Edinburgh EH8 9DX, Midlothian, Scotland; Family Business Facilitat, Kirkwall KW15 1PR, Orkney, Scotland; Lister Inst, Edinburgh EH8 9DR, Midlothian, Scotland; Univ Edinburgh, Royal Edinburgh Hosp, Dept Psychiat, Young Peoples Unit, Edinburgh EH10 5HF, Midlothian, Scotland	University of Edinburgh; University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh	Huby, G (corresponding author), Univ Edinburgh, Primary Care Res Grp, Dept Community Hlth Sci, 20 W Richmond St, Edinburgh EH8 9DX, Midlothian, Scotland.	guro.huby@ed.ac.uk		McKinstry, Brian/0000-0001-9581-0468				Calnan M, 2001, SOC SCI MED, V52, P499, DOI 10.1016/S0277-9536(00)00155-6; Firth-Cozens J, 1998, BRIT J GEN PRACT, V48, P1647; Firth-Cozens J, 1998, BRIT MED J, V317, P1335, DOI 10.1136/bmj.317.7169.1335; Fletcher J, 2000, BRIT J GEN PRACT, V50, P815; Heaney D, 1998, BRIT J GEN PRACT, V48, P1077; HOWIE JGR, 1999, STRESS HLTH PROFESSI; Kmietowicz Z, 2001, BRIT MED J, V323, P887, DOI 10.1136/bmj.323.7318.887; Malterud K, 2001, LANCET, V358, P483, DOI 10.1016/S0140-6736(01)05627-6; *SCOTT GEN PRACT C, 2001, REAL RHET SURV VIEWS; Sibbald B, 2000, FAM PRACT, V17, P364, DOI 10.1093/fampra/17.5.364; SUTHERLAND VJ, 1992, BMJ-BRIT MED J, V304, P1545, DOI 10.1136/bmj.304.6841.1545	11	42	44	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 20	2002	325	7356					140	142B		10.1136/bmj.325.7356.140	http://dx.doi.org/10.1136/bmj.325.7356.140			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	577PG	12130611	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000177069900023
J	Peveler, R; Carson, A; Rodin, G				Peveler, R; Carson, A; Rodin, G			ABC of psychological medicine - Depression in medical patients	BRITISH MEDICAL JOURNAL			English	Review									Univ Southampton, Southampton SO9 5NH, Hants, England; Univ Edinburgh, Edinburgh EH8 9YL, Midlothian, Scotland; Univ Toronto, Toronto, ON, Canada	University of Southampton; University of Edinburgh; University of Toronto	Peveler, R (corresponding author), Univ Southampton, Southampton SO9 5NH, Hants, England.			Rodin, Gary/0000-0002-6626-6974	ODCDC CDC HHS [U58 CD001312] Funding Source: Medline	ODCDC CDC HHS		Jenkins R, 1997, PSYCHOL MED, V27, P765, DOI 10.1017/S003329179700531X; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Rodin G., 1991, DEPRESSION MED ILL I; *ROYAL COLL PHYS R, 1995, PSYCH CAR MED PAT RE; SMITH NF, 1993, JAMA-J AM MED ASSOC, V270, P1819	5	101	105	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 20	2002	325	7356					149	152		10.1136/bmj.325.7356.149	http://dx.doi.org/10.1136/bmj.325.7356.149			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	577PG	12130614	Green Published			2022-12-28	WOS:000177069900027
J	Geiderman, JM; Larkin, GL				Geiderman, JM; Larkin, GL			Commercial filming of patient care activities in hospitals	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFORMED CONSENT; CARDIOPULMONARY-RESUSCITATION; DOMESTIC VIOLENCE; NEWS MEDIA; EMERGENCY; TELEVISION; HEALTH; MEDICINE; CONFIDENTIALITY; PUBLICATION	Commercial filming of patient care activities is common in hospital settings. This article reviews common circumstances in which patients are commercially filmed, explores the potential positive and negative aspects of filming, and considers the ethical and legal issues associated with commercial filming of patients in hospital settings. We examine the competing goals of commercial filming and the duties of journalists vs the rights of patients to privacy. Current standards and recommendations for commercial filming of patient care activities are reviewed and additional recommendations are offered.	Cedars Sinai Med Ctr, Burns & Allen Res Inst, Ruth & Harry Roman Emergency Dept, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Burns & Allen Res Inst, Dept Emergency Med, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Burns & Allen Res Inst, Cedars Sinai Ctr Hlth Care Eth, Los Angeles, CA 90048 USA; Univ Texas SW, Parkland Mem Hosp, Dept Surg Emergency Med, Dallas, TX USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center; University of Texas System; University of Texas Southwestern Medical Center Dallas	Geiderman, JM (corresponding author), Cedars Sinai Med Ctr, Burns & Allen Res Inst, Ruth & Harry Roman Emergency Dept, 8700 Beverly Blvd,Room 1110, Los Angeles, CA 90048 USA.			LARKIN, GREGORY LUKE/0000-0002-8655-7824				Adomat R, 1999, Nurs Stand, V14, P37; ALBERTS MJ, 1992, STROKE, V23, P352, DOI 10.1161/01.STR.23.3.352; ALDERMAN E, 1995, RIGHT PRIVACY, pR13; *AM MED ASS COUNC, 3101 CEJA AM MED ASS; [Anonymous], THEORY JUSTICE; Bauer HM, 1999, WESTERN J MED, V171, P118; Beauchamp T., 1994, PRINCIPLES BIOMEDICA, P120; BLOCK MR, 1985, J FAM PRACTICE, V21, P467; BOROW W, 1993, JAMA-J AM MED ASSOC, V270, P1601, DOI 10.1001/jama.270.13.1601; Clever LH, 1997, JAMA-J AM MED ASSOC, V278, P628, DOI 10.1001/jama.278.8.628; Cohn V, 1996, JAMA-J AM MED ASSOC, V276, P1917; Cohn V, 2001, STAT MED, V20, P1341, DOI 10.1002/sim.671; Collins S, 2001, WESTERN J MED, V175, P384, DOI 10.1136/ewjm.175.6.384; DANIELS N, 1985, JUST HLTH CARE, P36; De Amici D, 2000, ANESTH ANALG, V90, P739, DOI 10.1097/00000539-200003000-00042; DEJONG W, 1990, HEALTH AFFAIR, V9, P30, DOI 10.1377/hlthaff.9.2.30; deSemir V, 1996, LANCET, V347, P1163, DOI 10.1016/S0140-6736(96)90614-5; Diem SJ, 1996, NEW ENGL J MED, V334, P1578, DOI 10.1056/NEJM199606133342406; DIKEMA DS, 1996, AM J EMERG MED, V14, P226; Eitel DR, 1998, J FAM PRACTICE, V46, P251; EPPLER E, 1994, ANN EMERG MED, V24, P202, DOI 10.1016/S0196-0644(94)70131-8; Fontanarosa PB, 1997, JAMA-J AM MED ASSOC, V278, P682, DOI 10.1001/jama.278.8.682; FOUBISTER V, 2000, AM MED NEWS     0327, P43; FRANKEL DH, 1995, LANCET, V345, P1105, DOI 10.1016/S0140-6736(95)90836-6; Frankena W. K., 1973, ETHICS, P47; Freed GL, 1996, JAMA-J AM MED ASSOC, V276, P1869, DOI 10.1001/jama.276.23.1869; Geiderman J, 2000, ANN EMERG MED, V35, P403, DOI 10.1016/S0196-0644(00)70063-1; Geiderman JM, 2001, ANN EMERG MED, V37, P217, DOI 10.1067/mem.2001.113559; GERBNER G, 1981, NEW ENGL J MED, V305, P901, DOI 10.1056/NEJM198110083051530; Holden JD, 2001, J EVAL CLIN PRACT, V7, P65, DOI 10.1046/j.1365-2753.2001.00280.x; Hood CA, 1998, BRIT MED J, V316, P1009, DOI 10.1136/bmj.316.7136.1009; HOYT DB, 1988, J TRAUMA, V28, P435, DOI 10.1097/00005373-198804000-00003; HYMAN A, 1995, JAMA-J AM MED ASSOC, V273, P1781, DOI 10.1001/jama.273.22.1781; ISERSON KI, 1995, ETHICS EMERGENCY MED, P427; Iserson KV, 2001, ANN EMERG MED, V37, P220, DOI 10.1067/mem.2001.113560; JENCKS SF, 1994, JOINT COMM J QUAL IM, V20, P359; Jones RB, 1999, J MED ETHICS, V25, P379, DOI 10.1136/jme.25.5.379; KASSIRER JP, 2000, BOSTON GLOBE    0911, pA17; Knopp RK, 1999, EMERG MED CLIN N AM, V17, P385, DOI 10.1016/S0733-8627(05)70066-3; MANN FA, 1994, J TRAUMA, V36, P226, DOI 10.1097/00005373-199402000-00015; MARTIN H, 2002, LOS ANGELES TIM 0115, pA1; MASON MS, 2000, CHRISTIAN SCI M 0602; McArthur DL, 2001, WESTERN J MED, V175, P380, DOI 10.1136/ewjm.175.6.380; MEAD GE, 1995, J MED ETHICS, V21, P39, DOI 10.1136/jme.21.1.39; Mlinek EJ, 1997, ACAD EMERG MED, V4, P1142, DOI 10.1111/j.1553-2712.1997.tb03697.x; Moreno J, 1998, JAMA-J AM MED ASSOC, V280, P1951, DOI 10.1001/jama.280.22.1951; Moynihan R, 2000, NEW ENGL J MED, V342, P1645, DOI 10.1056/NEJM200006013422206; Nelkin D, 1996, LANCET, V347, P1600, DOI 10.1016/S0140-6736(96)91081-8; Nelkin D, 2001, PERSPECT BIOL MED, V44, P199, DOI 10.1353/pbm.2001.0032; NELKIN D, 1991, MILBANK Q, V69, P293, DOI 10.2307/3350206; PARSONS HM, 1974, SCIENCE, V183, P922, DOI 10.1126/science.183.4128.922; POMPLIO N, 2001, AM J REV         JUL, P14; PROSSER WL, 1960, CALIF LAW REV, V48, P383, DOI 10.2307/3478805; Protection of Human Subjects, 1996, FED REGISTER, V61, P51497; Rodriguez MA, 1998, WESTERN J MED, V169, P337; Rodriguez RM, 2001, ACAD EMERG MED, V8, P740, DOI 10.1111/j.1553-2712.2001.tb00195.x; Rogers G, 1999, INT J QUAL HEALTH C, V11, P251, DOI 10.1093/intqhc/11.3.251; *ROYAL SOC MED, 1985, PUBL UND SCI REP ROY; Santora TA, 1996, AM J EMERG MED, V14, P564, DOI 10.1016/S0735-6757(96)90100-X; SCHUMACHER WC, 2000, EMERGENCY PHYSIC DEC, P7; SHUCHMAN M, 1997, ANN INTERN MED, V126, P967; Simon RI, 1997, J FORENSIC SCI, V42, P884; SMITH MS, 1988, NEW ENGL J MED, V319, P1421, DOI 10.1056/NEJM198811243192119; Smithline HA, 1999, ACAD EMERG MED, V6, P776, DOI 10.1111/j.1553-2712.1999.tb01205.x; Snider DE, 1997, JAMA-J AM MED ASSOC, V278, P624, DOI 10.1001/jama.278.8.624; Turney J, 1996, LANCET, V347, P1087, DOI 10.1016/S0140-6736(96)90283-4; TUROW J, 1985, J COMMUN, V35, P36, DOI 10.1111/j.1460-2466.1985.tb02971.x; TUROW J, 1996, LANCET, V347, P1382; Warren Samuel D., 1890, HARVARD LAW REV, V4, P193, DOI DOI 10.2307/1321160; Weil TP, 2001, AM J MED QUAL, V16, P23, DOI 10.1177/106286060101600105; WEISS BD, 1982, JAMA-J AM MED ASSOC, V247, P2695, DOI 10.1001/jama.247.19.2695; WINSTEN JA, 1985, HLTH AFF MILLWOOD, V5, P5; Wolfe S, 1999, Clin Perform Qual Health Care, V7, P38; 2000, HLTH CARE PR MA 0914, P18; 2000, HLTH CARE PR MA 0914, P19	75	16	16	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	2002	288	3					373	379		10.1001/jama.288.3.373	http://dx.doi.org/10.1001/jama.288.3.373			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	573AK	12117405	Bronze			2022-12-28	WOS:000176807000032
J	Johnson, PC; Wheat, LJ; Cloud, GA; Goldman, M; Lancaster, D; Bamberger, DM; Powderly, WG; Hafner, R; Kauffman, CA; Dismukes, WE				Johnson, PC; Wheat, LJ; Cloud, GA; Goldman, M; Lancaster, D; Bamberger, DM; Powderly, WG; Hafner, R; Kauffman, CA; Dismukes, WE		US Natl Inst Allergy & Infect Dis	Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS	ANNALS OF INTERNAL MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; CENTRAL-NERVOUS-SYSTEM; CAPSULATUM ANTIGEN; FLUCONAZOLE; DIAGNOSIS	Background: In patients with moderate to severe histoplasmosis associated with AIDS, the preferred treatment has been the deoxycholate formulation of amphotericin B. However, serious side effects are associated with use of amphotericin B. Objective: To compare amphotericin B with liposomal amphotericin B for induction therapy of moderate to severe disseminated histoplasmosis in patients with AIDS. Design: Randomized, double-blind, multicenter clinical trial. Setting: 21 sites of the U.S. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Patients: 81 patients with AIDS and moderate to severe disseminated histoplasmosis. Measurements: Clinical success, conversion of baseline blood cultures to negative, and acute toxicities that necessitated discontinuation of treatment. Results: Clinical success was achieved in 14 of 22 patients (64%) treated with amphotericin B compared with 45 of 51 patients (88%) receiving liposomal amphotericin B (difference, 24 percentage points [95% Cl, 1 to 52 percentage points]). Culture conversion rates were similar. Three patients treated with amphotericin B and one treated with liposomal amphotericin 8 died during induction (P = 0.04). Infusion-related side effects were greater with amphotericin B (63%) than with liposomal amphotericin B (25%) (P = 0.002). Nephrotoxicity occurred in 37% of patients treated with amphotericin B and 9% of patients treated with liposomal amphotericin B (P = 0.003). Conclusion: Liposomal amphotericin B seems to be a less toxic alternative to amphotericin B and is associated with improved survival.	Univ Texas, Sch Med, Div Gen Med, Houston, TX 77030 USA; Indiana Univ, Sch Med, Indianapolis, IN 46204 USA; Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA; Univ Alabama Birmingham, Birmingham, AL USA; Methodist Hosp, Memphis, TN USA; Univ Missouri, Kansas City, MO 64110 USA; Washington Univ, Sch Med, St Louis, MO USA; NIAID, Mycoses Study Grp, NIH, Bethesda, MD 20892 USA; Vet Affairs Med Ctr, Ann Arbor, MI USA; Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA	University of Texas System; Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; University of Alabama System; University of Alabama Birmingham; University of Missouri System; University of Missouri Kansas City; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Michigan System; University of Michigan	Johnson, PC (corresponding author), Univ Texas, Sch Med, Div Gen Med, 6431 Fannin,MSB 1-122, Houston, TX 77030 USA.	Philip.C.Johnson@uth.tmc.edu	Bamberger, David/GYV-3403-2022	Powderly, William/0000-0001-7808-3086	NCRR NIH HHS [MO1-RR02558] Funding Source: Medline; PHS HHS [N01-A1-15802] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002558] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Agresti A., 1966, INTRO CATEGORICAL DA; Boswell GW, 1998, J CLIN PHARMACOL, V38, P583, DOI 10.1002/j.1552-4604.1998.tb04464.x; CONOVER W. J, 1980, PRACTICAL NONPARAMET; Durkin MM, 1997, J CLIN MICROBIOL, V35, P2252, DOI 10.1128/JCM.35.9.2252-2255.1997; GRAYBILL JR, 1995, ANTIMICROB AGENTS CH, V39, P1885, DOI 10.1128/AAC.39.8.1885; Groll AH, 2000, J INFECT DIS, V182, P274, DOI 10.1086/315643; JOHNSON PC, 1988, AM J MED, V85, P152, DOI 10.1016/S0002-9343(88)80334-6; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; McKinsey DS, 1996, CLIN INFECT DIS, V23, P996, DOI 10.1093/clinids/23.5.996; SNEDECOR TW, 1967, STAT METHODS; Walsh TJ, 1999, NEW ENGL J MED, V340, P764, DOI 10.1056/NEJM199903113401004; Wheat J, 1996, Curr Top Med Mycol, V7, P7; WHEAT J, 1993, ANN INTERN MED, V118, P610, DOI 10.7326/0003-4819-118-8-199304150-00006; Wheat J, 1997, AM J MED, V103, P223, DOI 10.1016/S0002-9343(97)00151-4; WHEAT LJ, 1990, MEDICINE, V69, P244, DOI 10.1097/00005792-199007000-00006; WHEAT LJ, 1986, NEW ENGL J MED, V314, P83, DOI 10.1056/NEJM198601093140205; WHEAT LJ, 1990, MEDICINE, V69, P361, DOI 10.1097/00005792-199011000-00004	17	192	204	1	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 16	2002	137	2					105	109		10.7326/0003-4819-137-2-200207160-00008	http://dx.doi.org/10.7326/0003-4819-137-2-200207160-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575VN	12118965				2022-12-28	WOS:000176969300004
J	Yu, SW; Wang, HM; Poitras, MF; Coombs, C; Bowers, WJ; Federoff, HJ; Poirier, GG; Dawson, TM; Dawson, VL				Yu, SW; Wang, HM; Poitras, MF; Coombs, C; Bowers, WJ; Federoff, HJ; Poirier, GG; Dawson, TM; Dawson, VL			Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor	SCIENCE			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; GENOMIC STABILITY; GENE DISRUPTION; POLYMERASE; ACTIVATION; PARP; SYNTHETASE; NEUROTOXICITY; REPERFUSION; INHIBITION	Poly(ADP-ribose) polymerase-1 (PARP-1) protects the genome by functioning in the DNA damage surveillance network. PARP-1 is also a mediator of cell death after ischemia-reperfusion injury, glutamate excitotoxicity, and various inflammatory processes. We show that PARP-1 activation is required for translocation of apoptosis-inducing factor (AIF) from the mitochondria to the nucleus and that AIF is necessary for PARP-1 dependent cell death. N-methyl-N'-nitro-N-nitrosoguanidine, H2O2, and N-methyl-D-aspartate induce AIF translocation and cell death, which is prevented by PARP inhibitors or genetic knockout of PARP-1, but is caspase independent. Microinjection of an antibody to AIF protects against PARP-1 dependent cytotoxicity. These data support a model in which PARP-1 activation signals AIF release from mitochondria, resulting in a caspase-independent pathway of programmed cell death.	Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD 21287 USA; Univ Rochester, Ctr Aging & Dev Biol, Dept Neurol, Rochester, NY 14642 USA; Univ Laval, Med Res Ctr, CHUQ, Hlth & Environm Unit, Ste Foy, PQ G1V 4G2, Canada	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Rochester; Laval University	Dawson, VL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21287 USA.	vdawson@jhmi.edu	Dawson, Valina/Y-9757-2019	Poirier, Guy/0000-0002-4869-1424; Dawson, Valina/0000-0002-2915-3970				Cosi C, 1999, ANN NY ACAD SCI, V890, P227, DOI 10.1111/j.1749-6632.1999.tb07998.x; DEMURCIA G, 1994, MOL CELL BIOCHEM, V138, P15, DOI 10.1007/BF00928438; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; ENDRES M, 1997, BLOOD FLOW METAB, V17, P1143; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Filipovic DM, 1999, AM J PHYSIOL-RENAL, V277, pF428, DOI 10.1152/ajprenal.1999.277.3.F428; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Herceg Z, 1999, MOL CELL BIOL, V19, P5124; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LAUTIER D, 1993, MOL CELL BIOCHEM, V122, P171, DOI 10.1007/BF01076101; Lee Y, 1999, J BIOL CHEM, V274, P19792, DOI 10.1074/jbc.274.28.19792; Mandir AS, 2000, J NEUROSCI, V20, P8005; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; Pieper AA, 2000, MOL MED, V6, P271, DOI 10.1007/BF03401936; Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; Smulson ME, 2000, ADV ENZYME REGUL, V40, P183, DOI 10.1016/S0065-2571(99)00024-2; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Virag L, 1998, J IMMUNOL, V161, P3753; Walisser JA, 1999, EXP CELL RES, V251, P401, DOI 10.1006/excr.1999.4589; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	28	1473	1528	3	103	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 12	2002	297	5579					259	263		10.1126/science.1072221	http://dx.doi.org/10.1126/science.1072221			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571UT	12114629				2022-12-28	WOS:000176738100044
J	Hannon, GJ				Hannon, GJ			RNA interference	NATURE			English	Review							DOUBLE-STRANDED-RNA; GERM-LINE DEVELOPMENT; C-ELEGANS; GENE-EXPRESSION; TRYPANOSOMA-BRUCEI; MESSENGER-RNA; ANTISENSE RNA; CAENORHABDITIS-ELEGANS; NEUROSPORA-CRASSA; TRANSGENIC PLANTS	A conserved biological response to double-stranded RNA, known variously as RNA interference (RNA) or post-transcriptional gene silencing, mediated resistance to both endogenous parasitic and exogenous pathogenic nucleic acids, and regulates the expression of protein-coding genes. RNAi has been cultivated as a means to manipulate gene expression experimentally and to probe gene function on a whole-genome scale.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Hannon, GJ (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	hannon@cshl.org	Hannon, Gregory/AAB-3568-2019					Angell SM, 1997, EMBO J, V16, P3675, DOI 10.1093/emboj/16.12.3675; Baulcombe D, 1999, ARCH VIROL, P189; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Bernstein E, 2001, RNA, V7, P1509; Blaszczyk J, 2001, STRUCTURE, V9, P1225, DOI 10.1016/S0969-2126(01)00685-2; Bohmert K, 1998, EMBO J, V17, P170, DOI 10.1093/emboj/17.1.170; BRUMMELKAMP TR, 2002, SCIENCE, V21, P21; Catalanotto C, 2002, GENE DEV, V16, P790, DOI 10.1101/gad.222402; CLARKE PA, 1995, RNA, V1, P7; Cogoni C, 1999, SCIENCE, V286, P2342, DOI 10.1126/science.286.5448.2342; Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; Cox DN, 1998, GENE DEV, V12, P3715, DOI 10.1101/gad.12.23.3715; Dalmay T, 2000, CELL, V101, P543, DOI 10.1016/S0092-8674(00)80864-8; DECARVALHO F, 1992, EMBO J, V11, P2595, DOI 10.1002/j.1460-2075.1992.tb05324.x; Dernburg AF, 2000, GENE DEV, V14, P1578; Domeier ME, 2000, SCIENCE, V289, P1928, DOI 10.1126/science.289.5486.1928; DOUGHERTY WG, 1994, MOL PLANT MICROBE IN, V7, P544, DOI 10.1094/MPMI-7-0554; Dudley NR, 2002, P NATL ACAD SCI USA, V99, P4191, DOI 10.1073/pnas.062605199; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Elmayan T, 1996, PLANT J, V9, P787, DOI 10.1046/j.1365-313X.1996.9060787.x; Fagard M, 2000, P NATL ACAD SCI USA, V97, P11650, DOI 10.1073/pnas.200217597; Filippov V, 2000, GENE, V245, P213, DOI 10.1016/S0378-1119(99)00571-5; FIRE A, 1991, DEVELOPMENT, V113, P503; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Furner IJ, 1998, GENETICS, V149, P651; Gil J, 2000, APOPTOSIS, V5, P107, DOI 10.1023/A:1009664109241; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Grishok A, 2000, SCIENCE, V287, P2494, DOI 10.1126/science.287.5462.2494; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Ha I, 1996, GENE DEV, V10, P3041, DOI 10.1101/gad.10.23.3041; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Jacobsen SE, 1999, DEVELOPMENT, V126, P5231; Jones L, 2001, CURR BIOL, V11, P747, DOI 10.1016/S0960-9822(01)00226-3; JORGENSEN R, 1990, TRENDS BIOTECHNOL, V8, P340, DOI 10.1016/0167-7799(90)90220-R; Jorgensen RA, 1996, PLANT MOL BIOL, V31, P957, DOI 10.1007/BF00040715; Kataoka Y, 2001, GENES CELLS, V6, P313, DOI 10.1046/j.1365-2443.2001.00427.x; Kennerdell JR, 2000, NAT BIOTECHNOL, V18, P896, DOI 10.1038/78531; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; KUMAGAI MH, 1995, P NATL ACAD SCI USA, V92, P1679, DOI 10.1073/pnas.92.5.1679; LaCount DJ, 2000, MOL BIOCHEM PARASIT, V111, P67, DOI 10.1016/S0166-6851(00)00300-5; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lipardi C, 2001, CELL, V107, P297, DOI 10.1016/S0092-8674(01)00537-2; Mallory AC, 2001, PLANT CELL, V13, P571, DOI 10.1105/tpc.13.3.571; Martienssen RA, 2001, SCIENCE, V293, P1070, DOI 10.1126/science.293.5532.1070; Meissner W, 2001, NUCLEIC ACIDS RES, V29, P1672, DOI 10.1093/nar/29.8.1672; Mette MF, 2000, EMBO J, V19, P5194, DOI 10.1093/emboj/19.19.5194; Morel JB, 2002, PLANT CELL, V14, P629, DOI 10.1105/tpc.010358; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Mourrain P, 2000, CELL, V101, P533, DOI 10.1016/S0092-8674(00)80863-6; Moussian B, 1998, EMBO J, V17, P1799, DOI 10.1093/emboj/17.6.1799; NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Ohkawa J, 2000, HUM GENE THER, V11, P577, DOI 10.1089/10430340050015761; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Pal-Bhadra M, 2002, MOL CELL, V9, P315, DOI 10.1016/S1097-2765(02)00440-9; Palauqui JC, 1997, EMBO J, V16, P4738, DOI 10.1093/emboj/16.15.4738; PalBhadra M, 1997, CELL, V90, P479, DOI 10.1016/S0092-8674(00)80508-5; Parrish S, 2001, RNA, V7, P1397; Que QD, 1997, PLANT CELL, V9, P1357, DOI 10.1105/tpc.9.8.1357; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; ROMANO N, 1992, MOL MICROBIOL, V6, P3343, DOI 10.1111/j.1365-2958.1992.tb02202.x; Ruiz MT, 1998, PLANT CELL, V10, P937, DOI 10.1105/tpc.10.6.937; Schiebel W, 1998, PLANT CELL, V10, P2087, DOI 10.1105/tpc.10.12.2087; Shi HF, 2000, RNA, V6, P1069, DOI 10.1017/S1355838200000297; Sijen T, 2001, CELL, V107, P465, DOI 10.1016/S0092-8674(01)00576-1; Slack FJ, 2000, MOL CELL, V5, P659, DOI 10.1016/S1097-2765(00)80245-2; Smardon A, 2000, CURR BIOL, V10, P169, DOI 10.1016/S0960-9822(00)00323-7; Smith NA, 2000, NATURE, V407, P319, DOI 10.1038/35030305; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Svoboda P, 2000, DEVELOPMENT, V127, P4147; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Tavernarakis N, 2000, NAT GENET, V24, P180, DOI 10.1038/72850; Tijsterman M, 2002, SCIENCE, V295, P694, DOI 10.1126/science.1067534; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; Vaistij FE, 2002, PLANT CELL, V14, P857, DOI 10.1105/tpc.010480; VANDERKROL AR, 1990, PLANT MOL BIOL, V14, P457, DOI 10.1007/BF00027492; Voinnet O, 1998, CELL, V95, P177, DOI 10.1016/S0092-8674(00)81749-3; Voinnet O, 2000, CELL, V103, P157, DOI 10.1016/S0092-8674(00)00095-7; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; WASSENEGGER M, 1994, CELL, V76, P567, DOI 10.1016/0092-8674(94)90119-8; Wianny F, 2000, NAT CELL BIOL, V2, P70, DOI 10.1038/35000016; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Winston WM, 2002, SCIENCE, V295, P2456, DOI 10.1126/science.1068836; Wu-Scharf D, 2000, SCIENCE, V290, P1159, DOI 10.1126/science.290.5494.1159; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	100	3183	4026	29	1199	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 11	2002	418	6894					244	251		10.1038/418244a	http://dx.doi.org/10.1038/418244a			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571GV	12110901				2022-12-28	WOS:000176710400053
J	Maguire, JD; Sumawinata, IW; Masbar, S; Laksana, B; Prodjodipuro, P; Susanti, I; Sismadi, P; Mahmud, N; Bangs, MJ; Baird, JK				Maguire, JD; Sumawinata, IW; Masbar, S; Laksana, B; Prodjodipuro, P; Susanti, I; Sismadi, P; Mahmud, N; Bangs, MJ; Baird, JK			Chloroquine-resistant Plasmodium malariae in south Sumatra, Indonesia	LANCET			English	Article								Oral chloroquine is the treatment of choice for uncomplicated Plasmodium malariae Infections worldwide. We did a prospective 28-day In-vivo assessment of the efficacy of chloroquine for treatment of P malariae on Legundl Island In Lampung Bay, Sumatra, Indonesia. Of 28 patients, one had recurrent parasitaemia an day 28, and two had persistent parasitaemia to day 8. Whole-blood chloroquine and desethylchloroquine concentrations were at ordinarily effective levels (greater than or equal to100 mug/L) on day 8 In both cases of persistent parasitaemia. These findings suggest that clinical resistance to chloroquine by P malariae occurs In the Indonesian archipelago of southeast Asia.	USN, Med Res Unit 2, Jakarta, Indonesia; Indonesian Minist Hlth, Inst Hlth Res & Dev, Jakarta, Indonesia; Dist Hlth Serv, Lampung Selatan, Sumatra, Indonesia	University of 19 November Kolaka; Ministry of Health - Indonesia	Maguire, JD (corresponding author), US Embassy Jakarta, Unit 8132, NAMRU TWO, FPO, AP 96520 USA.							COLLINS WE, 1973, AM J TROP MED HYG, V22, P685, DOI 10.4269/ajtmh.1973.22.685; Kimura Masatsugu, 1997, Parasitology International, V46, P91, DOI 10.1016/S1383-5769(97)00013-5; Mason DP, 1999, J THEOR BIOL, V198, P549, DOI 10.1006/jtbi.1999.0932; ROMBO L, 1986, T ROY SOC TROP MED H, V80, P763, DOI 10.1016/0035-9203(86)90380-9; Tan-Ariya Peerapan, 1994, Southeast Asian Journal of Tropical Medicine and Public Health, V25, P784	5	67	69	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 6	2002	360	9326					58	60		10.1016/S0140-6736(02)09336-4	http://dx.doi.org/10.1016/S0140-6736(02)09336-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569JR	12114045	Green Submitted			2022-12-28	WOS:000176599700015
J	McCaffrey, AP; Meuse, L; Pham, TTT; Conklin, DS; Hannon, GJ; Kay, MA				McCaffrey, AP; Meuse, L; Pham, TTT; Conklin, DS; Hannon, GJ; Kay, MA			Gene expression - RNA interference in adult mice	NATURE			English	Article							PLASMID DNA; HEPATOCYTES		Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Stanford University; Stanford University; Cold Spring Harbor Laboratory	McCaffrey, AP (corresponding author), Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA.		Eckhardt, Erik/G-1567-2010; Hannon, Gregory/AAB-3568-2019	Conklin, Douglas/0000-0003-4922-4307; Kay, Mark/0000-0002-2799-2615				Bitko V, 2001, BMC Microbiol, V1, P34, DOI 10.1186/1471-2180-1-34; Chang JH, 2001, J VIROL, V75, P3469, DOI 10.1128/JVI.75.7.3469-3473.2001; Contag CH, 1997, PHOTOCHEM PHOTOBIOL, V66, P523, DOI 10.1111/j.1751-1097.1997.tb03184.x; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Tuschl T, 2002, NAT BIOTECHNOL, V20, P446, DOI 10.1038/nbt0502-446; Yant SR, 2000, NAT GENET, V25, P35, DOI 10.1038/75568; Zhang GF, 1999, HUM GENE THER, V10, P1735, DOI 10.1089/10430349950017734	9	854	1143	0	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 4	2002	418	6893					38	39		10.1038/418038a	http://dx.doi.org/10.1038/418038a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	569JL	12097900				2022-12-28	WOS:000176599200030
J	Salters, VJM; Dick, HJB				Salters, VJM; Dick, HJB			Mineralogy of the mid-ocean-ridge basalt source from neodymium isotopic composition of abyssal peridotites	NATURE			English	Article							SOUTHWEST INDIAN RIDGE; UPPER-MANTLE; GEOCHEMISTRY; DISEQUILIBRIUM; PETROGENESIS; BENEATH; GARNET; ORIGIN; LAVAS; MORB	Inferring the melting process at mid-ocean ridges, and the physical conditions under which melting takes place, usually relies on the assumption of compositional similarity between all mid-ocean-ridge basalt sources(1-4). Models of mantle melting therefore tend to be restricted to those that consider the presence of only one lithology in the mantle, peridotite. Evidence from xenoliths and peridotite massifs show that after peridotite, pyroxenite and eclogite are the most abundant rock types in the mantle. But at mid-ocean ridges, where most of the melting takes place, and in ophiolites, pyroxenite is rarely found. Here we present neodymium isotopic compositions of abyssal peridotites to investigate whether peridotite can indeed be the sole source for mid-ocean-ridge basalts. By comparing the isotopic compositions of basalts and peridotites at two segments of the southwest Indian ridge, we show that a component other than peridotite is required to explain the low end of the Nd-143/Nd-144 variations of the basalts. This component is likely to have a lower melting temperature than peridotite, such as pyroxenite or eclogite, which could explain why it is not observed at midocean ridges.	Florida State Univ, Natl High Magnet Field Lab, Tallahassee, FL 32306 USA; Florida State Univ, Dept Geol Sci, Tallahassee, FL 32306 USA; Woods Hole Oceanog Inst, Dept Marine Geol & Geophys, Woods Hole, MA 02543 USA	State University System of Florida; Florida State University; State University System of Florida; Florida State University; Woods Hole Oceanographic Institution	Salters, VJM (corresponding author), Florida State Univ, Natl High Magnet Field Lab, Tallahassee, FL 32306 USA.	salters@magnet.fsu.edu	Facility, NENIMF/B-8811-2015; Salters, Vincent J/F-9792-2014	Salters, Vincent J/0000-0002-5669-7869				ALLEGRE CJ, 1986, NATURE, V323, P123, DOI 10.1038/323123a0; Bourdon B, 1996, NATURE, V384, P231, DOI 10.1038/384231a0; DICK HJB, 1984, EARTH PLANET SC LETT, V69, P88, DOI 10.1016/0012-821X(84)90076-1; DICK HJB, 1998, EOS, V79, pF919; DICK HJB, 2001, EOS, V82, pS407; Hanan B. B., 2000, J C ABSTR, V5, P478; HANSON GN, 1977, J GEOL SOC LONDON, V134, P1; Hellebrand E, 2001, NATURE, V410, P677, DOI 10.1038/35070546; Hirschmann MM, 1996, CONTRIB MINERAL PETR, V124, P185, DOI 10.1007/s004100050184; JOHNSON KTM, 1990, J GEOPHYS RES-SOLID, V95, P2661, DOI 10.1029/JB095iB03p02661; JOHNSON KTM, 1992, J GEOPHYS RES-SOL EA, V97, P9219, DOI 10.1029/92JB00701; Keshav S, 2001, GEOPHYS RES LETT, V28, P3509, DOI 10.1029/2001GL012950; KLEIN EM, 1987, J GEOPHYS RES-SOLID, V92, P8089, DOI 10.1029/JB092iB08p08089; LANGMUIR CH, 1992, GEOPH MONOG SERIES, V71, P183; LEROEX AP, 1989, J PETROL, V30, P947, DOI 10.1093/petrology/30.4.947; LEROEX AP, 1992, CONTRIB MINERAL PETR, V110, P253, DOI 10.1007/BF00310742; LEROEX AP, 1983, J PETROL, V24, P267, DOI 10.1093/petrology/24.3.267; MAHONEY J, 1992, J GEOPHYS RES-SOL EA, V97, P19771, DOI 10.1029/92JB01424; MAHONEY JJ, 1989, J GEOPHYS RES-SOLID, V94, P4033, DOI 10.1029/JB094iB04p04033; MCKENZIE D, 1991, J PETROL, V32, P1021, DOI 10.1093/petrology/32.5.1021; Salters VJM, 1996, EARTH PLANET SC LETT, V141, P109, DOI 10.1016/0012-821X(96)00070-2; SALTERS VJM, 1989, NATURE, V342, P420, DOI 10.1038/342420a0; Salters VJM, 1999, EARTH PLANET SC LETT, V166, P15, DOI 10.1016/S0012-821X(98)00271-4; SLEEP NH, 1984, J GEOPHYS RES, V89, P29, DOI 10.1029/JB089iB12p10029; SNOW JE, 1994, NATURE, V371, P57, DOI 10.1038/371057a0; SPIEGELMAN M, 1993, EARTH PLANET SC LETT, V118, P1, DOI 10.1016/0012-821X(93)90155-3; Stracke A, 1999, GEOCHEM GEOPHY GEOSY, V1, DOI 10.1029/1999GC000013; Sun S.-S., 1989, GEOLOGICAL SOC LONDO, V42, P323, DOI [10.1144/GSL.SP.1989.042.01.19, DOI 10.1144/GSL.SP.1989.042.01.19]; Wendt JI, 1999, EARTH PLANET SC LETT, V173, P271, DOI 10.1016/S0012-821X(99)00236-8; ZINDLER A, 1984, EARTH PLANET SC LETT, V70, P175, DOI 10.1016/0012-821X(84)90004-9	30	151	152	5	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 4	2002	418	6893					68	72		10.1038/nature00798	http://dx.doi.org/10.1038/nature00798			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	569JL	12097907				2022-12-28	WOS:000176599200039
J	Wright, N; Tanner, MS				Wright, N; Tanner, MS			Medical students' compliance with simple administrative tasks and success in final examinations: retrospective cohort study	BRITISH MEDICAL JOURNAL			English	Article									Sheffield Childrens Hosp, Sheffield S10 2TH, S Yorkshire, England	Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital	Wright, N (corresponding author), Sheffield Childrens Hosp, Sheffield S10 2TH, S Yorkshire, England.							NEWBLE DI, 1986, MED EDUC, V20, P162, DOI 10.1111/j.1365-2923.1986.tb01163.x; NEWBLE DI, 1992, MED EDUC, V26, P504; NEWBLE DI, 1988, MED EDUC, V22, P518, DOI 10.1111/j.1365-2923.1988.tb00797.x	3	20	20	2	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 29	2002	324	7353					1554	1555		10.1136/bmj.324.7353.1554	http://dx.doi.org/10.1136/bmj.324.7353.1554			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	570WP	12089092	Bronze, Green Published			2022-12-28	WOS:000176683000018
J	Zhang, YX; Yu, ZL; Fu, XR; Liang, C				Zhang, YX; Yu, ZL; Fu, XR; Liang, C			Noc3p, a bHLH protein, plays an integral role in the initiation of DNA replication in budding yeast	CELL			English	Article							ORIGIN RECOGNITION COMPLEX; CYCLIN-DEPENDENT KINASES; LOOP-HELIX PROTEINS; SACCHAROMYCES-CEREVISIAE; MCM PROTEINS; S-PHASE; CELL-CYCLE; CHROMOSOMAL REPLICATION; LICENSING SYSTEM; RE-REPLICATION	Initiation of eukaryotic DNA replication requires many proteins that interact with one another and with replicators. Using a yeast genetic screen, we have identified Noc3p (nucleolar complex-associated protein) as a novel replication-initiation protein. Noc3p interacts with MCM proteins and ORC and binds to chromatin and replicators throughout the cell cycle. It functions as a critical link between ORC and other initiation proteins to effect chromatin association of Cdc6p and MCM proteins for the establishment and maintenance of prereplication complexes. Noc3p is highly conserved in eukaryotes and is the first identified bHLH (basic helix-loop-helix) protein required for replication initiation. As Noc3p is also required for pre-rRNA processing, Noc3p is a multifunctional protein that plays essential roles in two vital cellular processes.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Liang, C (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.			Zhang, Yuexuan/0000-0002-5227-0809				Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; Calzada A, 2001, NATURE, V412, P355, DOI 10.1038/35085610; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Dalton S, 1997, MOL CELL BIOL, V17, P5867, DOI 10.1128/MCB.17.10.5867; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Drury LS, 2000, CURR BIOL, V10, P231, DOI 10.1016/S0960-9822(00)00355-9; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; Gopalakrishnan V, 2001, P NATL ACAD SCI USA, V98, P13114, DOI 10.1073/pnas.221467598; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; Homesley L, 2000, GENE DEV, V14, P913; Jallepalli PV, 1996, GENE DEV, V10, P541, DOI 10.1101/gad.10.5.541; Lei M, 1996, MOL CELL BIOL, V16, P5081; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Merchant AM, 1997, MOL CELL BIOL, V17, P3261, DOI 10.1128/MCB.17.6.3261; Milkereit P, 2001, CELL, V105, P499, DOI 10.1016/S0092-8674(01)00358-0; MuziFalconi M, 1995, P NATL ACAD SCI USA, V92, P12475, DOI 10.1073/pnas.92.26.12475; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Owens JC, 1997, P NATL ACAD SCI USA, V94, P12521, DOI 10.1073/pnas.94.23.12521; Robinson KA, 2000, NUCLEIC ACIDS RES, V28, P1499, DOI 10.1093/nar/28.7.1499; Saha P, 1998, J BIOL CHEM, V273, P18205, DOI 10.1074/jbc.273.29.18205; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Tanaka S, 2002, NAT CELL BIOL, V4, P198, DOI 10.1038/ncb757; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Thommes P, 1997, EMBO J, V16, P3312, DOI 10.1093/emboj/16.11.3312; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; Weinreich M, 1999, P NATL ACAD SCI USA, V96, P441, DOI 10.1073/pnas.96.2.441; Weinreich M, 2001, P NATL ACAD SCI USA, V98, P11211, DOI 10.1073/pnas.201387198; Whittaker AJ, 2000, GENE DEV, V14, P1765; Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Yankulov K, 1999, MOL CELL BIOL, V19, P6154; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593; Zou L, 1997, MOL CELL BIOL, V17, P553, DOI 10.1128/MCB.17.2.553	55	90	91	0	10	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 28	2002	109	7					849	860		10.1016/S0092-8674(02)00805-X	http://dx.doi.org/10.1016/S0092-8674(02)00805-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	570KJ	12110182	Bronze			2022-12-28	WOS:000176657200008
J	Zhu, CM; Mills, KD; Ferguson, DO; Lee, C; Manins, J; Fleming, J; Gao, YJ; Morton, CC; Alt, FW				Zhu, CM; Mills, KD; Ferguson, DO; Lee, C; Manins, J; Fleming, J; Gao, YJ; Morton, CC; Alt, FW			Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations	CELL			English	Article							DIHYDROFOLATE-REDUCTASE GENE; WILD-TYPE P53; V(D)J RECOMBINATION; FRAGILE SITES; EMBRYONIC LETHALITY; CHROMOSOME BREAKAGE; MAMMALIAN-CELLS; HAMSTER CELLS; LIGASE-IV; REPAIR	Amplification of large genomic regions associated with complex translocations (complicons) is a basis for tumor progression and drug resistance. We show that pro-B lymphomas in mice deficient for both p53 and nonhomologous end-joining (NHEJ) contain complicons that coamplify c-myc (chromosome 15) and IgH (chromosome 12) sequences. While all carry a translocated (12;15) chromosome, coamplified sequences are located within a separate complicon that often involves a third chromosome. Complicon formation is initiated by recombination of RAGI1/2-catalyzed IgH locus double-strand breaks with sequences downstream of c-myc, generating a dicentric (15;12) chromosome as an amplification intermediate. This recombination event employs a microhomology-based end-joining repair pathway, as opposed to classic NHEJ or homologous recombination. These findings suggest a general model for oncogenic complicon formation.	Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Alt, FW (corresponding author), Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [P01CA092625] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL067580] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035714] Funding Source: NIH RePORTER; NCI NIH HHS [CA92625] Funding Source: Medline; NHLBI NIH HHS [K08 HL67580-02] Funding Source: Medline; NIAID NIH HHS [AI35714] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT FW, 1978, J BIOL CHEM, V253, P1357; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Bogue MA, 1997, IMMUNITY, V7, P37, DOI 10.1016/S1074-7613(00)80508-7; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Carson DR, 2001, P NATL ACAD SCI USA, V98, P8270, DOI 10.1073/pnas.131022798; Coene ED, 1997, VIRCHOWS ARCH, V430, P365, DOI 10.1007/s004280050045; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; CORY S, 1985, EMBO J, V4, P675, DOI 10.1002/j.1460-2075.1985.tb03682.x; Debatisse M, 1998, RECENT RES CANCER, V154, P216; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; DJALALI M, 1987, HUM GENET, V77, P157, DOI 10.1007/BF00272384; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; FEDERSPIEL NA, 1984, J BIOL CHEM, V259, P9127; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Frank KM, 2000, MOL CELL, V5, P993, DOI 10.1016/S1097-2765(00)80264-6; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Kabotyanski EB, 1998, NUCLEIC ACIDS RES, V26, P5333, DOI 10.1093/nar/26.23.5333; Kline GH, 2001, J IMMUNOL, V167, P5136, DOI 10.4049/jimmunol.167.9.5136; Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746; KUO MT, 1994, MOL CELL BIOL, V14, P5202, DOI 10.1128/MCB.14.8.5202; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lee J, 1999, IMMUNITY, V11, P771, DOI 10.1016/S1074-7613(00)80151-X; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; Lim DS, 2000, MOL CELL BIOL, V20, P3772, DOI 10.1128/MCB.20.11.3772-3780.2000; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; Manis JP, 2002, TRENDS IMMUNOL, V23, P31, DOI 10.1016/S1471-4906(01)02111-1; McClintock B, 1941, GENETICS, V26, P234; Megonigal MD, 1998, P NATL ACAD SCI USA, V95, P6413, DOI 10.1073/pnas.95.11.6413; Padilla-Nash HM, 2001, GENE CHROMOSOME CANC, V30, P349, DOI 10.1002/gcc.1101; Paulson TG, 1998, MOL CELL BIOL, V18, P3089, DOI 10.1128/MCB.18.5.3089; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pipiras E, 1998, EMBO J, V17, P325, DOI 10.1093/emboj/17.1.325; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; Sambrook J., 2002, MOL CLONING LAB MANU; Schwab M, 1999, SEMIN CANCER BIOL, V9, P319, DOI 10.1006/scbi.1999.0126; Sharpless NE, 2001, MOL CELL, V8, P1187, DOI 10.1016/S1097-2765(01)00425-7; Skok JA, 2001, NAT IMMUNOL, V2, P848, DOI 10.1038/ni0901-848; SMITH KA, 1990, CELL, V63, P1219, DOI 10.1016/0092-8674(90)90417-D; STARK GR, 1993, ADV CANCER RES, V61, P87, DOI 10.1016/S0065-230X(08)60956-2; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TOLEDO F, 1992, EMBO J, V11, P2665, DOI 10.1002/j.1460-2075.1992.tb05332.x; Vanasse GJ, 1999, J CLIN INVEST, V103, P1669, DOI 10.1172/JCI6658; Verkaik NS, 2002, EUR J IMMUNOL, V32, P701, DOI 10.1002/1521-4141(200203)32:3<701::AID-IMMU701>3.0.CO;2-T; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZIMMERMAN K, 1990, Critical Reviews in Oncogenesis, V2, P75	60	344	351	1	7	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 28	2002	109	7					811	821		10.1016/S0092-8674(02)00770-5	http://dx.doi.org/10.1016/S0092-8674(02)00770-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	570KJ	12110179	Bronze			2022-12-28	WOS:000176657200005
J	Field, MJ; Grigsby, J				Field, MJ; Grigsby, J			Telemedicine and remote patient monitoring	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CARE; PROGRAM		Natl Acad Sci, Inst Med, Washington, DC 20418 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Geriatr, Denver, CO 80262 USA	National Academies of Sciences, Engineering & Medicine; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Field, MJ (corresponding author), Natl Acad Sci, Inst Med, 2101 Constitut Ave NW, Washington, DC 20418 USA.							*3 US USSR JOINT W, 1989, US USSR TEL CONS SPA; Angood PB, 2000, TELEMED J E-HEALTH, V6, P315, DOI 10.1089/153056200750040174; BENSCHOTER RA, 1967, ANN NY ACAD SCI, V142, P471, DOI 10.1111/j.1749-6632.1967.tb14360.x; BERTERA EM, 1981, AM J PUBLIC HEALTH, V71, P626, DOI 10.2105/AJPH.71.6.626; CONRATH DW, 1977, BEHAV SCI, V22, P12, DOI 10.1002/bs.3830220103; COUCH JB, 1997, PHYSICIANS GUIDE DIS; Dimmick S L, 2000, Home Healthc Nurse, V18, P124, DOI 10.1097/00004045-200002000-00013; Finkelstein J, 2000, CHEST, V117, P148, DOI 10.1378/chest.117.1.148; Gray JE, 2000, PEDIATRICS, V106, P1318, DOI 10.1542/peds.106.6.1318; GRIGSBY B, 1998, 2 ASS TEL SERV PROV; GRIGSBY B, 2000, 1999 REPORT US TELEM; *HLTH CAR FIN ADM, 2001, HOM HLTH POL PPS POL; *HLTH CAR FIN ADM, 2001, AB0169 HLTH CAR FIN; Institute of Medicine, 1996, TEL GUID ASS TEL HLT; JOHNSON BE, 1990, J GEN INTERN MED, V5, P234, DOI 10.1007/BF02600541; Johnston B, 2000, ARCH FAM MED, V9, P40, DOI 10.1001/archfami.9.1.40; MOORE GT, 1975, NEW ENGL J MED, V292, P729, DOI 10.1056/NEJM197504032921406; Nicogossian AE, 2001, TELEMED J E-HEALTH, V7, P1, DOI 10.1089/153056201300093813; *OFF ADV TEL, 2001, 2001 REP C TEL PAYM; Perednia DA, 1998, TELEMED J, V4, P145; Rosenfeld BA, 2000, CRIT CARE MED, V28, P3925, DOI 10.1097/00003246-200012000-00034; Shah NB, 1998, AM HEART J, V135, P373, DOI 10.1016/S0002-8703(98)70310-2; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Starren J, 2002, J AM MED INFORM ASSN, V9, P25, DOI 10.1136/jamia.2002.0090025; Strode SW, 1999, JAMA-J AM MED ASSOC, V281, P1066, DOI 10.1001/jama.281.12.1066; WASSON J, 1992, JAMA-J AM MED ASSOC, V267, P1788, DOI 10.1001/jama.267.13.1788; WEINBERGER M, 1989, ARTHRITIS RHEUM, V32, P1577, DOI 10.1002/anr.1780321212; 2002, EHEALTHCARE WEEK	28	104	105	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 24	2002	288	4					423	425		10.1001/jama.288.4.423	http://dx.doi.org/10.1001/jama.288.4.423			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575NZ	12132953				2022-12-28	WOS:000176955400002
J	Koenig, HG				Koenig, HG			An 83-year-old woman with chronic illness and strong religious beliefs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; OLDER ADULTS; TRANSPLANT RECIPIENTS; CARDIAC-SURGERY; BLOOD-PRESSURE; AMERICAN WOMEN; OF-LIFE; SPIRITUALITY; INVOLVEMENT; DEPRESSION		Duke Univ, Med Ctr, Ctr Geriatr Res Educ & Clin, VA Med Ctr, Durham, NC 27710 USA	Duke University; Geriatric Research Education & Clinical Center	Koenig, HG (corresponding author), Duke Univ, Med Ctr, Ctr Geriatr Res Educ & Clin, VA Med Ctr, Box 3400, Durham, NC 27710 USA.		Koenig, Harold G/F-7379-2011					Ai AL, 1998, GERONTOLOGIST, V38, P591, DOI 10.1093/geront/38.5.591; Astrow AB, 2001, AM J MED, V110, P283; Avants SK, 2001, J PSYCHOACTIVE DRUGS, V33, P39, DOI 10.1080/02791072.2001.10400467; Ayele H, 1999, J AM GERIATR SOC, V47, P453, DOI 10.1111/j.1532-5415.1999.tb07238.x; Bartlett SJ, 2001, ARTHRITIS RHEUM, V44, pS382; BECKER D, 2000, PRAYER BLACK WOMEN B; Benson H., 1975, RELAXATION RESPONSE; BLALOCK SJ, 1995, ANN BEHAV MED, V17, P107, DOI 10.1007/BF02895059; Braam AW, 1997, SOC PSYCH PSYCH EPID, V32, P284, DOI 10.1007/BF00789041; Braam AW, 2001, PSYCHOL MED, V31, P803, DOI 10.1017/S0033291701003956; Braam AW, 1997, ACTA PSYCHIAT SCAND, V96, P199, DOI 10.1111/j.1600-0447.1997.tb10152.x; CEDERBLAD M, 1995, ACTA PSYCHIAT SCAND, V91, P322, DOI 10.1111/j.1600-0447.1995.tb09789.x; Chibnall JT, 2001, SOUTHERN MED J, V94, P374; Cooper-Effa M, 2001, J Am Board Fam Pract, V14, P116; CRONAN TA, 1989, ARTHRITIS RHEUM, V32, P1604, DOI 10.1002/anr.1780321217; Ehman JW, 1999, ARCH INTERN MED, V159, P1803, DOI 10.1001/archinte.159.15.1803; Fitchett G, 1997, J NERV MENT DIS, V185, P320, DOI 10.1097/00005053-199705000-00006; Fox SA, 1998, HEALTH EDUC BEHAV, V25, P742, DOI 10.1177/109019819802500605; Fry PS, 2000, AGING MENT HEALTH, V4, P375, DOI 10.1080/713649965; GOLDBOURT U, 1993, CARDIOLOGY, V82, P100, DOI 10.1159/000175862; HARRIS RC, 1995, J RELIG HEALTH, V34, P17, DOI 10.1007/BF02248635; Hebert RS, 2001, J GEN INTERN MED, V16, P685, DOI 10.1046/j.1525-1497.2001.01034.x; HOGE DR, 1972, J SCI STUD RELIG, V11, P369; Hummer RA, 1999, DEMOGRAPHY, V36, P273, DOI 10.2307/2648114; IDLER EL, 1987, SOC FORCES, V66, P226, DOI 10.2307/2578909; Idler EL, 1997, J GERONTOL B-PSYCHOL, V52, pS306, DOI 10.1093/geronb/52B.6.S306; Idler EL, 1995, SOC FORCES, V74, P683, DOI 10.2307/2580497; Ironson G, 2002, ANN BEHAV MED, V24, P34, DOI 10.1207/S15324796ABM2401_05; JENKINS RA, 1995, J PSYCHOSOC ONCOL, V13, P51, DOI 10.1300/J077V13N01_04; KABATZINN J, 1985, J BEHAV MED, V8, P163, DOI 10.1007/BF00845519; Kaldjian LC, 1998, AIDS, V12, P103, DOI 10.1097/00002030-199801000-00012; Keefe FJ, 2001, J PAIN, V2, P101, DOI 10.1054/jpai.2001.19296; KING DE, 1994, J FAM PRACTICE, V39, P349; Koenig, 2002, SPIRITUALITY PATIENT; Koenig HG, 1998, J NERV MENT DIS, V186, P513, DOI 10.1097/00005053-199809000-00001; KOENIG HG, 1989, J FAM PRACTICE, V28, P441; Koenig HG, 1998, INT J PSYCHIAT MED, V28, P189, DOI 10.2190/75JM-J234-5JKN-4DQD; Koenig HG, 1997, INT J PSYCHIAT MED, V27, P233, DOI 10.2190/40NF-Q9Y2-0GG7-4WH6; Koenig HG, 1998, AM J PSYCHIAT, V155, P536, DOI 10.1176/ajp.155.4.536; KOENIG HG, 1988, J AM GERIATR SOC, V36, P362, DOI 10.1111/j.1532-5415.1988.tb02365.x; KOENIG HG, 1992, AM J PSYCHIAT, V149, P1693; KOENIG HG, 1995, J RELIGIOUS GERONTOL, V9, P1; Koening H, 2001, HDB RELIG HLTH; Lo B, 1999, ANN INTERN MED, V130, P744, DOI 10.7326/0003-4819-130-9-199905040-00015; Matthees BJ, 2001, HEART LUNG, V30, P258, DOI 10.1067/mhl.2001.116135; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; Melkus G, 2001, DIABETES, V50, pA394; Meredith KL, 2001, HEALTH EDUC BEHAV, V28, P40, DOI 10.1177/109019810102800105; Morris EL, 2001, ALTERN THER HEALTH M, V7, P96; Mueller PS, 2001, MAYO CLIN PROC, V76, P1225, DOI 10.4065/76.12.1225; Murphy PL, 2000, NEUROLOGY, V55, P1581, DOI 10.1212/WNL.55.10.1581; OXMAN TE, 1995, PSYCHOSOM MED, V57, P5, DOI 10.1097/00006842-199501000-00002; Pargament KI, 2001, ARCH INTERN MED, V161, P1881, DOI 10.1001/archinte.161.15.1881; PETTERSSON T, 1991, J SCI STUD RELIG, V30, P279, DOI 10.2307/1386973; Post SG, 2000, ANN INTERN MED, V132, P578, DOI 10.7326/0003-4819-132-7-200004040-00010; PRESSMAN P, 1990, AM J PSYCHIAT, V147, P758; *PRINC REL RES CTR, 1982, REL AM, P120; PULCHALSKI CM, 1998, ACAD MED, V73, P970; Rabin B.S., 1999, STRESS IMMUNE FUNCTI; RINGDAL G, 1995, BRIT J CANCER, V73, P1594; Samuel-Hodge CD, 2000, DIABETES CARE, V23, P928, DOI 10.2337/diacare.23.7.928; Schnoll RA, 2000, CANCER PRACT, V8, P298, DOI 10.1046/j.1523-5394.2000.86006.x; Schuster MA, 2001, NEW ENGL J MED, V345, P1507, DOI 10.1056/NEJM200111153452024; Sephton S E, 2001, Breast J, V7, P345, DOI 10.1046/j.1524-4741.2001.20014.x; SILBER TJ, 1985, ADOLESCENCE, V20, P217; Sloan RP, 2000, NEW ENGL J MED, V342, P1913, DOI 10.1056/NEJM200006223422513; Steffen PR, 2001, PSYCHOSOM MED, V63, P523, DOI 10.1097/00006842-200107000-00002; STERN RC, 1992, J ADOLESCENT HEALTH, V13, P612, DOI 10.1016/1054-139X(92)90376-M; Strawbridge WJ, 1997, AM J PUBLIC HEALTH, V87, P957, DOI 10.2105/AJPH.87.6.957; Subach RA, 1999, RENAL FAILURE, V21, P223, DOI 10.3109/08860229909066987; Tix AP, 1998, J CONSULT CLIN PSYCH, V66, P411, DOI 10.1037/0022-006X.66.2.411; Tull ES, 2001, DIABETES, V50, pA397; TURNER JA, 1986, PAIN, V24, P355, DOI 10.1016/0304-3959(86)90121-1; Woods TE, 1999, J PSYCHOSOM RES, V46, P165, DOI 10.1016/S0022-3999(98)00078-6	74	85	88	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 24	2002	288	4					487	493		10.1001/jama.288.4.487	http://dx.doi.org/10.1001/jama.288.4.487			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	575NZ	12132980				2022-12-28	WOS:000176955400032
J	McCracken, GH				McCracken, GH			Rich nations, poor nations, and bacterial meningitis	LANCET			English	Editorial Material							DEXAMETHASONE; INFLAMMATION; RELEASE		Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	McCracken, GH (corresponding author), Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA.							FISCHER H, 1984, J BACTERIOL, V157, P507, DOI 10.1128/JB.157.2.507-513.1984; FRIEDLAND IR, 1993, J INFECT DIS, V168, P657, DOI 10.1093/infdis/168.3.657; LUTSAR I, 1997, 35 ANN M INF DIS SOC; McIntyre PB, 1997, JAMA-J AM MED ASSOC, V278, P925, DOI 10.1001/jama.278.11.925; MUSTAFA MM, 1989, J INFECT DIS, V160, P818, DOI 10.1093/infdis/160.5.818; Nau R, 1999, J INFECT DIS, V179, P1557, DOI 10.1086/314760; Nau R, 1997, J ANTIMICROB CHEMOTH, V39, P781, DOI 10.1093/jac/39.6.781; ODIO CM, 1991, NEW ENGL J MED, V324, P1525, DOI 10.1056/NEJM199105303242201; SAEZLLORENS X, 1990, J PEDIATR-US, V116, P671, DOI 10.1016/S0022-3476(05)82647-2	9	17	19	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 20	2002	360	9328					183	183		10.1016/S0140-6736(02)09499-0	http://dx.doi.org/10.1016/S0140-6736(02)09499-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	576DX	12133648				2022-12-28	WOS:000176988500003
J	Jacobs, SS; Giulivi, CF; Mele, PA				Jacobs, SS; Giulivi, CF; Mele, PA			Freshening of the Ross Sea during the late 20th century	SCIENCE			English	Article							ICE SHELF; PACK-ICE; VARIABILITY; OCEAN; AMUNDSEN; PACIFIC; GLACIER; CLIMATE	Ocean measurements in the Ross Sea over the past four decades, one of the longest records near Antarctica, reveal marked decreases in shelf water salinity and the surface salinity within the Ross Gyre. These changes have been accompanied by atmospheric warming on Ross Island, ocean warming at depths of similar to300 meters north of the continental shelf, a more negative Southern Oscillation Index, and thinning of southeast Pacific ice shelves. The freshening appears to have resulted from a combination of factors, including increased precipitation, reduced sea ice production, and increased melting of the West Antarctic Ice Sheet.	Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA	Columbia University	Jacobs, SS (corresponding author), Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA.	sjacobs@ldeo.columbia.edu						BIRNBAUM G, 2001, REPORTS POLAR MARINE, V380, P64; Bromwich D, 1998, ANTARCT RES SER, V75, P101; Cullather RI, 1998, J CLIMATE, V11, P334, DOI 10.1175/1520-0442(1998)011<0334:SATVOA>2.0.CO;2; GORDON A, 1983, P CARB DIOX RES C CO; Gouretski VV, 1999, J ATMOS OCEAN TECH, V16, P1791, DOI 10.1175/1520-0426(1999)016<1791:ADAQAO>2.0.CO;2; Grosfeld K, 1998, ANTARCT RES SER, V75, P319; HELLMER HH, 1995, J GEOPHYS RES-OCEANS, V100, P10873, DOI 10.1029/95JC00753; Hellmer HH, 1998, ANTARCT RES SER, V75, P83; Huybrechts P, 1999, J CLIMATE, V12, P2169, DOI 10.1175/1520-0442(1999)012<2169:TDROTG>2.0.CO;2; Jacobs SS, 1996, GEOPHYS RES LETT, V23, P957, DOI 10.1029/96GL00723; Jacobs SS, 1998, ANTARCT RES SER, V75, P135; Jacobs SS, 1997, J CLIMATE, V10, P697, DOI 10.1175/1520-0442(1997)010<0697:CVITAA>2.0.CO;2; Jacobs SS, 1985, OCEANOLOGY ANTARCTIC, V43, P59, DOI DOI 10.1029/AR043P0059; Jeffries MO, 1997, ANTARCT SCI, V9, P188, DOI 10.1017/S0954102097000242; JEFFRIES MO, 1994, ANN GLACIOL, V20, P33, DOI 10.3189/172756494794587546; KARL DM, 2001, OCEANOGRAPHY, V14, P16; Kwok R, 2002, J CLIMATE, V15, P487, DOI 10.1175/1520-0442(2002)015<0487:SOCASI>2.0.CO;2; Levitus S, 2000, SCIENCE, V287, P2225, DOI 10.1126/science.287.5461.2225; MANABE S, 1991, J CLIMATE, V4, P785, DOI 10.1175/1520-0442(1991)004<0785:TROACO>2.0.CO;2; Parkinson CL, 2002, ANN GLACIOL, V34, P435, DOI 10.3189/172756402781817482; Rignot E, 2002, SCIENCE, V296, P2020, DOI 10.1126/science.1070942; ROBERTSON R, IN PRESS DEEP SEA RE; Shepherd A, 2001, SCIENCE, V291, P862, DOI 10.1126/science.291.5505.862; SHEPHERD A, 2001, EOS, V82, pF537; Van Woert ML, 1999, J GEOPHYS RES-OCEANS, V104, P7753, DOI 10.1029/1999JC900003; Whitworth T, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014282; Wong APS, 1999, NATURE, V400, P440, DOI 10.1038/22733; Yuan XJ, 2000, J CLIMATE, V13, P1697, DOI 10.1175/1520-0442(2000)013<1697:ASIEVA>2.0.CO;2; Zwally HJ, 2002, J GEOPHYS RES-OCEANS, V107, DOI 10.1029/2000JC000733	29	255	266	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 19	2002	297	5580					386	389		10.1126/science.1069574	http://dx.doi.org/10.1126/science.1069574			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574LV	12130782				2022-12-28	WOS:000176892600047
J	Reichmanis, E; Nalamasu, O				Reichmanis, E; Nalamasu, O			Applied physics: Testing the limits for resists	SCIENCE			English	Editorial Material							ETCH RESISTANCE		Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA	Alcatel-Lucent; Lucent Technologies; AT&T	Reichmanis, E (corresponding author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.							ALLEN RD, 1995, P SOC PHOTO-OPT INS, V2438, P474, DOI 10.1117/12.210396; BARDEEN J, 1948, PHYS REV, V74, P230, DOI 10.1103/PhysRev.74.230; Kunz RR, 1996, P SOC PHOTO-OPT INS, V2724, P365, DOI 10.1117/12.241835; Lin EK, 2002, SCIENCE, V297, P372, DOI 10.1126/science.1072092; Reichmanis E, 1999, ACCOUNTS CHEM RES, V32, P659, DOI 10.1021/ar970150n; Schmid GM, 2001, P SOC PHOTO-OPT INS, V4345, P1037, DOI 10.1117/12.436829; THOMPSON LF, 1994, INTRO MICROLITHOGRAP; WILSON CG, 1982, 1982 S VLSI TECHN SE, P86	8	3	3	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 19	2002	297	5580					349	350		10.1126/science.1073842	http://dx.doi.org/10.1126/science.1073842			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574LV	12130770				2022-12-28	WOS:000176892600035
J	Sulkowski, MS; Moore, RD; Mehta, SH; Chaisson, RE; Thomas, DL				Sulkowski, MS; Moore, RD; Mehta, SH; Chaisson, RE; Thomas, DL			Hepatitis C and progression of HIV disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; INJECTING DRUG-USERS; NATURAL-HISTORY; LIVER-DISEASE; INFECTION; COINFECTION; MORTALITY; PREVALENCE; HEPATOTOXICITY	Context Conflicting reports exist regarding the effect of hepatitis C virus (HCV) on the progression of human immunodeficiency virus (HIV) disease. Objective To assess the effect of HCV infection on clinical and immunologic progression of HIV disease and immunologic response to highly active antiretroviral therapy (HAART). Design Prospective cohort study. Setting University-based, urban HIV clinic in the United States. Patients There were 1955 patients enrolled between January 1995 and January 2001 who were eligible for analysis because of having at least 1 return visit to the clinic and being free of acquired immunodeficiency syndrome (AIDS) at enrollment. Median (interquartile range) length,of follow-up was 2.19 (1.00-3.50) years for HCV-infected and 2.00 (1.00-3.00) years for HCV-uninfected patients. Main Outcome Measures Progression to an AIDS-defining illness, survival, and progression to a CD4 cell count below 200/muL; CD4 cell count change following initiation of effective HAART (resulting in a viral load of <400 copies/mL recorded at >= 75% of measurements). Results No difference was detected in the risk of acquiring an AIDS-defining illness (HCV-infected patients, 231,events [26.4%] and HCV-uninfected patients, 264 events [24.4%]; relative hazard [RH], 1.03; 95% confidence interval [CI], 0.86-1.23) or in the risk of death (HCV-infected patients, 153 deaths [17.5%] and HCV-uninfected patients, 168 deaths [15.5%]; RH, 1.05; 95% Cl, 0.85-1.30). Although an increased risk of death was detected in the subgroup of 429 HCV-infected patients with a baseline CD4 cell count of 50/mu L through 200/mu L (RH, 1.51; 95% Cl, 1.01-2.27), after adjustment for exposure to HAART and its effectiveness in a multivariate Cox regression analysis, death was not independently associated with HCV infection in this subgroup (RH, 1.01; 5% Cl, 0.65-1.56). Similarly, in those receiving effective HAART (n=208), there was no difference in the increase in CD4 cell count or CD4 percentage during HAART in HCV-infected compared with HCV-uninfected patients. Conclusions Among patients in this urban US cohort, we did not detect evidence that HCV infection substantially alters the risk of dying, developing AIDS, or responding immunologically to HAART, especially after accounting for differences in its administration and effectiveness.	Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Gen Internal Med, Baltimore, MD 21287 USA; Johns Hopkins Univ, Bloomberg Sch PUbl Hlth, Dept Epidemiol, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Sulkowski, MS (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, 1830 E Monument St,Room 448, Baltimore, MD 21287 USA.	msulkows@jhmi.edu			NIAID NIH HHS [K24 AI-01637] Funding Source: Medline; NIDA NIH HHS [K24 DA-00342, R01 DA-13806, R01 DA-11602] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI001637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011602, R01DA013806] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802; [Anonymous], 1997, HEPATOLOGY, V26, pS2; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Broers B, 1998, AIDS, V12, P2059, DOI 10.1097/00002030-199815000-00018; Celentano DD, 1998, JAMA-J AM MED ASSOC, V280, P544, DOI 10.1001/jama.280.6.544; Christensen JK, 2000, J INFECT DIS, V181, P1796, DOI 10.1086/315440; Darby SC, 1997, LANCET, V350, P1425, DOI 10.1016/S0140-6736(97)05413-5; den Brinker M, 2000, AIDS, V14, P2895, DOI 10.1097/00002030-200012220-00011; Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497; DORRUCCI M, 1995, J INFECT DIS, V172, P1503, DOI 10.1093/infdis/172.6.1503; Escaffre N, 2000, AIDS CARE, V12, P723, DOI 10.1080/09540120020014264; EYSTER ME, 1993, J ACQ IMMUN DEF SYND, V6, P602; Goedert JI, 2001, AIDS, V15, P1295, DOI 10.1097/00002030-200107060-00012; Greub G, 2000, LANCET, V356, P1800, DOI 10.1016/S0140-6736(00)03232-3; Haydon GH, 1998, EUR J GASTROEN HEPAT, V10, P485, DOI 10.1097/00042737-199806000-00009; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; HUGHES MD, 1994, J INFECT DIS, V169, P28, DOI 10.1093/infdis/169.1.28; Lesens O, 1999, J INFECT DIS, V179, P1254, DOI 10.1086/314720; Lok ASF, 1997, HEPATOLOGY, V26, pS48, DOI 10.1002/hep.510260709; Lucas GM, 2001, J ACQ IMMUN DEF SYND, V27, P251, DOI 10.1097/00126334-200107010-00006; Macias J, 1998, EUR J CLIN MICROBIOL, V17, P167, DOI 10.1007/BF01691112; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Martinez E, 2001, AIDS, V15, P1261, DOI 10.1097/00002030-200107060-00007; Mocroft A, 1999, J ACQ IMMUN DEF SYND, V22, P369; Monga HK, 2001, CLIN INFECT DIS, V33, P240, DOI 10.1086/321819; MOORE RD, 1994, NEW ENGL J MED, V330, P763, DOI 10.1056/NEJM199403173301107; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Piroth L, 1998, AIDS, V12, P381, DOI 10.1097/00002030-199804000-00006; Prins M, 1997, AIDS, V11, P1747, DOI 10.1097/00002030-199714000-00012; QUAN CM, 1993, CLIN INFECT DIS, V17, P117, DOI 10.1093/clinids/17.1.117; Sabin CA, 1997, J INFECT DIS, V175, P164, DOI 10.1093/infdis/175.1.164; Sehdev AES, 2001, ARCH INTERN MED, V161, P277, DOI 10.1001/archinte.161.2.277; SHERMAN KE, 1993, J CLIN MICROBIOL, V31, P2679, DOI 10.1128/JCM.31.10.2679-2682.1993; Staples CT, 1999, CLIN INFECT DIS, V29, P150, DOI 10.1086/520144; Strathdee SA, 1998, JAMA-J AM MED ASSOC, V280, P547, DOI 10.1001/jama.280.6.547; Sulkowski MS, 2000, CLIN INFECT DIS, V30, pS77, DOI 10.1086/313842; Sulkowski MS, 2000, JAMA-J AM MED ASSOC, V283, P74, DOI 10.1001/jama.283.1.74; Thio CL, 2000, J CLIN MICROBIOL, V38, P575, DOI 10.1128/JCM.38.2.575-577.2000; Thomas DL, 2000, J INFECT DIS, V181, P844, DOI 10.1086/315314; Thomas DL, 2000, JAMA-J AM MED ASSOC, V284, P450, DOI 10.1001/jama.284.4.450; Thomas DL, 1998, J INFECT DIS, V177, P539, DOI 10.1086/514245; Tillmann HL, 2001, NEW ENGL J MED, V345, P715, DOI 10.1056/NEJMoa010398; WRIGHT TL, 1994, HEPATOLOGY, V20, P1152; Xiang JH, 2001, NEW ENGL J MED, V345, P707, DOI 10.1056/NEJMoa003364; Yeo AET, 2000, ANN INTERN MED, V132, P959, DOI 10.7326/0003-4819-132-12-200006200-00006; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	46	332	352	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	2002	288	2					199	206		10.1001/jama.288.2.199	http://dx.doi.org/10.1001/jama.288.2.199			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	571HC	12095384	Bronze			2022-12-28	WOS:000176711100020
J	Harraf, F; Sharma, AK; Brown, MM; Lees, KR; Vass, RI; Kalra, L				Harraf, F; Sharma, AK; Brown, MM; Lees, KR; Vass, RI; Kalra, L		Acute Stroke Intervention Study Gr	A multicentre observational study of presentation and early assessment of acute stroke	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IN-HOSPITAL DELAYS; HEALTH-CARE DASH; EMERGENCY-DEPARTMENT; ADMISSION; SYMPTOMS; DISEASE	Objective To investigate delays in the presentation to hospital and evaluation of patients with suspected stroke. Design Multicentre prospective observational study. Setting 22 hospitals in the United Kingdom and Dublin. Participants 739 patients with suspected stroke presenting to hospital. Main outcome measures Time from onset of stroke symptoms to arrival at hospital, and time from arrival to evaluation by a senior doctor. Results The median age of patients was 75 years, and 400 were women. The median delay between onset of symptoms and arrival at hospital was 6 hours (interquartile range 1 hour 48 minutes to 19 hours 12 minutes). 37% of patients arrived within 3 hours, 50% within 6 hours. The median delay for patients using the emergency service was 2 hours 3 minutes (47 minutes to 7 hours 12 minutes) compared with 7 hours 12 minutes (2 hours 5 minutes to 20 hours 37 minutes) for referrals from general practitioners (P < 0.0001). Use of emergency services reduced delays to hospital (odds ratio 0.45, 95% confidence interval 0.23 to 0.61). The median titre to evaluation by a senior doctor was 1 hour 9 minutes (interquartile range 33 minutes to 1 flour 50 minutes) but was undertaken in only 477 (65%) patients within 3 hours of arrival. This was not influenced by age, sex, time of presentation, mode of referral, hospital type, or the presence of a stroke unit. Computed tomography was requested within 3 hours of arrival in 166 (22%) patients but undertaken in only 60 (8%). Conclusion Delays in patients arriving at hospital with suspected stroke can be reduced by the increased use of emergency services. Over a third of patients arrive at hospital within three hours of stroke; their management can be improved by expediting medical evaluation and performing computed tomography early.	Guys Kings & St Thomass Med Sch, Dept Med, London SE5 9PJ, England; Univ Hosp, Dept Med, Liverpool L9 7AL, Merseyside, England; UCL Natl Hosp Neurol & Neurosurg, Inst Neurol, Dept Vasc Neurol, London WC1N 3BG, England; Univ Glasgow, Western Infirm, Dept Med & Therapeut, Gardiner Inst, Glasgow G11 6NT, Lanark, Scotland; Boehringer Ingelheim GmbH & Co KG, Bracknell RG12 8YS, Berks, England	University of London; King's College London; University of Liverpool; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of Glasgow; Boehringer Ingelheim	Kalra, L (corresponding author), Guys Kings & St Thomass Med Sch, Dept Med, London SE5 9PJ, England.	lalit.kalra@kcl.ac.uk	Brown, Martin M/B-3288-2009	Brown, Martin M/0000-0002-3273-1356				Alberts MJ, 2000, JAMA-J AM MED ASSOC, V283, P3102, DOI 10.1001/jama.283.23.3102; American Heart Association, 1999, HEART STROK STAT UPD; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BARER D, 1992, LANCET, V339, P1540, DOI 10.1016/0140-6736(92)91306-S; Bath PHW, 2000, BMJ-BRIT MED J, V320, P920, DOI 10.1136/bmj.320.7239.920; BRATINA P, 1995, STROKE, V26, P409, DOI 10.1161/01.STR.26.3.409; BRITO E, 1995, REV THEOL LOUVAIN, V26, P109; Evenson KR, 2001, NEUROEPIDEMIOLOGY, V20, P65, DOI 10.1159/000054763; Grotta JC, 1999, STROKE, V30, P1722, DOI 10.1161/01.STR.30.8.1722; Hacke W, 2000, LANCET, V356, P869, DOI 10.1016/S0140-6736(00)02671-4; Hankey GJ, 1999, LANCET, V354, P1457, DOI 10.1016/S0140-6736(99)04407-4; HARPER GD, 1992, STROKE, V23, P835, DOI 10.1161/01.STR.23.6.835; *INT WORK PART STR, 2000, NAT CLIN GUID STROK; Katzan IL, 1999, STROKE, V30, P266; Kothari R, 1999, ANN EMERG MED, V33, P3, DOI 10.1016/S0196-0644(99)70431-2; Lacy CR, 2001, STROKE, V32, P63, DOI 10.1161/01.STR.32.1.63; Lees KR, 2000, BRIT MED BULL, V56, P389, DOI 10.1258/0007142001903030; Menon SC, 1998, NEUROLOGY, V51, P427, DOI 10.1212/WNL.51.2.427; Morris DL, 2000, STROKE, V31, P2585, DOI 10.1161/01.STR.31.11.2585; Morris DL, 1999, ACAD EMERG MED, V6, P218, DOI 10.1111/j.1553-2712.1999.tb00159.x; Rosamond WD, 1998, ACAD EMERG MED, V5, P45, DOI 10.1111/j.1553-2712.1998.tb02574.x; Salisbury HR, 1998, QJM-MON J ASSOC PHYS, V91, P635, DOI 10.1093/qjmed/91.9.635; Schroeder EB, 2000, STROKE, V31, P2591, DOI 10.1161/01.STR.31.11.2591; *SCOTT EX, 2001, COR HEART DIS STROK; Smith MA, 1998, ANN INTERN MED, V129, P190, DOI 10.7326/0003-4819-129-3-199808010-00005; WARDLAW JM, 2000, COCHRANE LIB; Wester P, 1999, STROKE, V30, P40, DOI 10.1161/01.STR.30.1.40	27	152	155	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 6	2002	325	7354					17	20		10.1136/bmj.325.7354.17	http://dx.doi.org/10.1136/bmj.325.7354.17			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573BC	12098723	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000176808600016
J	Martin, BR				Martin, BR			Medical marijuana - moving beyond the smoke	LANCET			English	Editorial Material							SYMPTOMS		Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	Virginia Commonwealth University	Martin, BR (corresponding author), Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Med Coll Virginia Campus, Richmond, VA 23298 USA.							*AM MED ASS, 1998, SUBJ MED MAR; Benson J.A., 1999, MARIJUANA MED; British Medical Association, 1997, THER US CANN; Cabral GA, 1998, J NEUROIMMUNOL, V83, P116, DOI 10.1016/S0165-5728(97)00227-0; Haney M, 1999, PSYCHOPHARMACOLOGY, V141, P395, DOI 10.1007/s002130050849; *HLTH COUNC NETH S, 1996, MAR MED; Martin BR, 1998, NEUROBIOL DIS, V5, P447, DOI 10.1006/nbdi.1998.0218; MARTIN BR, 2002, NEUROPSYCHOPHARMACOL, P1519; *NIH, 1997, WORKSH MED UT MAR BE; Solowij N, 2002, JAMA-J AM MED ASSOC, V287, P1123, DOI 10.1001/jama.287.9.1123; TASHKIN DP, 1987, AM REV RESPIR DIS, V135, P209; World Health Organization, 1997, CANN HLTH PERSP RES	12	6	6	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 6	2002	360	9326					4	5		10.1016/S0140-6736(02)09360-1	http://dx.doi.org/10.1016/S0140-6736(02)09360-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569JR	12114033				2022-12-28	WOS:000176599700004
J	Park, S; Clark, BL; Keszler, DA; Bender, JP; Wager, JF; Reynolds, TA; Herman, GS				Park, S; Clark, BL; Keszler, DA; Bender, JP; Wager, JF; Reynolds, TA; Herman, GS			Low-temperature thin-film deposition and crystallization	SCIENCE			English	Article									Oregon State Univ, Dept Chem, Corvallis, OR 97331 USA; Oregon State Univ, Dept Elect & Comp Engn, Corvallis, OR 97331 USA; ReyTech Corp, Bend, OR 97702 USA; Hewlett Packard Corp, Corvallis, OR 97330 USA	Oregon State University; Oregon State University; Hewlett-Packard	Keszler, DA (corresponding author), Oregon State Univ, Dept Chem, Gilbert Hall 153, Corvallis, OR 97331 USA.			Keszler, Douglas/0000-0002-7112-1171				BAUR WH, 1976, ACTA CRYSTALLOGR B, V32, P2200, DOI 10.1107/S0567740876007371; Clark BL, 2001, INORG CHEM, V40, P1724, DOI 10.1021/ic000842z; GELLER S, 1971, ACTA CRYSTALL B-STRU, VB 27, P821, DOI 10.1107/S0567740871002966; MARTIN U, 1993, ACTA CRYSTALLOGR B, V49, P403, DOI 10.1107/S0108768192011297; NICOLAU YF, 1985, APPL SURF SC, V22-3, P1061, DOI 10.1016/0378-5963(85)90241-7; Ritala M, 2000, SCIENCE, V288, P319, DOI 10.1126/science.288.5464.319	6	93	97	5	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 5	2002	297	5578					65	65		10.1126/science.1072009	http://dx.doi.org/10.1126/science.1072009			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571HB	12098690				2022-12-28	WOS:000176711000030
J	Weinstein, IB				Weinstein, IB			Cancer: Addiction to oncogenes - The Achilles heal of cancer	SCIENCE			English	Editorial Material							MYC; AMPLIFICATION; TUMORIGENESIS; MUTATION; RAS		Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University	Weinstein, IB (corresponding author), Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA.		Califano, Andrea/F-7239-2012; ravegnini, gloria/K-1330-2016	ravegnini, gloria/0000-0002-7774-402X				Aoki K, 1997, MOL CARCINOGEN, V20, P251, DOI 10.1002/(SICI)1098-2744(199710)20:2<251::AID-MC12>3.0.CO;2-9; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; COLOMER R, 1994, BRIT J CANCER, V70, P819, DOI 10.1038/bjc.1994.405; CRUZ CC, 2001, NAT MED, V7, P235; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; McCormick F, 2001, NAT REV CANCER, V1, P130, DOI 10.1038/35101008; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Vogelstein B., 1998, GENETIC BASIS HUMAN; Weinstein IB, 2000, CARCINOGENESIS, V21, P857, DOI 10.1093/carcin/21.5.857	20	1352	1424	0	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 5	2002	297	5578					63	64		10.1126/science.1073096	http://dx.doi.org/10.1126/science.1073096			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571HB	12098689				2022-12-28	WOS:000176711000029
J	Berg, AO; Allan, JD; Frame, P; Homer, CJ; Johnson, MS; Klein, JD; Lieu, TA; Mulrow, CD; Orleans, TC; Peipert, JF; Pender, NJ; Siu, AL; Teutsch, SM; Westhoff, C; Woolf, SH				Berg, AO; Allan, JD; Frame, P; Homer, CJ; Johnson, MS; Klein, JD; Lieu, TA; Mulrow, CD; Orleans, TC; Peipert, JF; Pender, NJ; Siu, AL; Teutsch, SM; Westhoff, C; Woolf, SH		US Preventive Services Task Force	Chemoprevention of breast cancer: Recommendations and rationale	ANNALS OF INTERNAL MEDICINE			English	Article							TAMOXIFEN	This statement summarizes the current recommendations of the U.S. Preventive Services Task Force (USPSTF) for chemoprevention of breast cancer. The complete USPSTF recommendation and rationale statement on this topic, including a summary of the supporting evidence, is available through the USPSTF Web site (www.preventiveservices.ahrq.gov), the National Guideline Clearinghouse (www.guideline.gov), and in print through the Agency for Healthcare Research and Quality Publications Clearinghouse (telephone, 800-358-9295; e-mail, ahrqpubs@ahrq.gov). The complete information on which this statement is based, including evidence tables and references, is available in the accompanying article in this issue and in the summary of the evidence and systematic evidence review on the Web sites already mentioned.	Univ Washington, Seattle, WA 98195 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; Univ Rochester, Rochester, NY USA; Natl Initiat Childrens Healthcare Qual, Boston, MA USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; Univ Rochester, Sch Med, Rochester, NY USA; Harvard Pilgrim Hlth Care, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; Robert Wood Johnson Generalist Phys Fac Scholars, Natl Program Off, San Antonio, TX USA; Robert Wood Johnson Fdn, Princeton, NJ 08540 USA; Brown Univ, Women & Infants Hosp, Providence, RI USA; Univ Michigan, Ann Arbor, MI 48109 USA; Mt Sinai Sch Med, New York, NY USA; Merck & Co Inc, West Point, PA USA; Columbia Univ, New York, NY USA; Virginia Commonwealth Univ, Fairfax, VA USA	University of Washington; University of Washington Seattle; University of Texas System; University of Texas Health San Antonio; University of Rochester; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Rochester; Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; University of Texas System; University of Texas Health San Antonio; Robert Wood Johnson Foundation (RWJF); Brown University; Women & Infants Hospital Rhode Island; University of Michigan System; University of Michigan; Icahn School of Medicine at Mount Sinai; Merck & Company; Columbia University; Virginia Commonwealth University	Berg, AO (corresponding author), Univ Washington, Seattle, WA 98195 USA.							*AM COLL OBST GYN, 1999, TAM PREV BREAST CANC; Chlebowski RT, 1999, J CLIN ONCOL, V17, P1939, DOI 10.1200/JCO.1999.17.6.1939; Gail MH, 1999, J NATL CANCER I, V91, P1829, DOI 10.1093/jnci/91.21.1829; Levine M, 2001, CAN MED ASSOC J, V164, P1681	4	55	56	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 2	2002	137	1					56	58		10.7326/0003-4819-137-1-200207020-00016	http://dx.doi.org/10.7326/0003-4819-137-1-200207020-00016			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569VA	12093249				2022-12-28	WOS:000176622000010
J	Law, MR; Wald, NJ				Law, MR; Wald, NJ			Risk factor thresholds: their existence under scrutiny	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; SERUM-CHOLESTEROL CONCENTRATION; BLOOD-PRESSURE; HYPERTENSION MANAGEMENT; PALEOLITHIC NUTRITION; CLINICAL-PRACTICE; BONE-DENSITY; TASK-FORCE; PREVENTION; STROKE		Barts & London Queen Marys Sch Med & Dent, Dept Environm & Prevent Med, Wolfson Inst Prevent Med, London EC1M 6BQ, England	University of London; Queen Mary University London	Law, MR (corresponding author), Barts & London Queen Marys Sch Med & Dent, Dept Environm & Prevent Med, Wolfson Inst Prevent Med, London EC1M 6BQ, England.	m.r.law@qmul.ac.uk	Wald, Nicholas/AAY-8924-2021; Wald, Nicholas/AAY-2814-2021					[Anonymous], 1991, Lancet, V338, P131, DOI 10.1016/0140-6736(91)90133-A; [Anonymous], 1991, JAMA, V265, P3255; Britton A, 1998, HLTH TECHNOLOGY ASSE, V2, P1; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DALY LE, 1995, JAMA-J AM MED ASSOC, V274, P1698, DOI 10.1001/jama.274.21.1698; *DEP HLTH, 1993, HLTH SURVEY ENGLAND; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Eaton SB, 1997, EUR J CLIN NUTR, V51, P207, DOI 10.1038/sj.ejcn.1600389; EATON SB, 1985, NEW ENGL J MED, V312, P283, DOI 10.1056/NEJM198501313120505; FAN WX, 1990, AM J CLIN NUTR, V52, P1027, DOI 10.1093/ajcn/52.6.1027; GLUECK CJ, 1976, J LAB CLIN MED, V88, P941; Gueyffier F, 1997, STROKE, V28, P2557, DOI 10.1161/01.STR.28.12.2557; KNOWLER WC, 1981, AM J EPIDEMIOL, V113, P144, DOI 10.1093/oxfordjournals.aje.a113079; LAW MR, 1994, EUR J CLIN NUTR, V48, P305; LAW MR, 1991, BMJ-BRIT MED J, V303, P453, DOI 10.1136/bmj.303.6800.453; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LAW MR, 1991, BMJ-BRIT MED J, V302, P811, DOI 10.1136/bmj.302.6780.811; LAW MR, IN PRESS ARCH INTERN; LAW MR, IN PRESS HLTH TECHNO; LEES B, 1993, LANCET, V341, P673, DOI 10.1016/0140-6736(93)90433-H; LINTON MF, 1993, J LIPID RES, V34, P521; LIU LS, 1995, CHINESE MED J-PEKING, V108, P710; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MEISSNER I, 1988, STROKE, V19, P459, DOI 10.1161/01.STR.19.4.459; NEATON JD, 1992, ARCH INTERN MED, V152, P56, DOI 10.1001/archinte.152.1.56; *OFF POP CENS SURV, 1990, DIET NUTR SURV BRIT; OLIVER M, 1995, BMJ-BRIT MED J, V310, P1280, DOI 10.1136/bmj.310.6990.1280; PAGE LB, 1974, CIRCULATION, V49, P1132, DOI 10.1161/01.CIR.49.6.1132; PEDERSEN TR, 1995, LANCET, V345, P1274; PEDERSEN TR, 1994, LANCET, V344, P1383; PROGRESS Collaborat Grp, 2001, LANCET, V358, P1556; PYORALA K, 1994, EUR HEART J, V15, P1300; Ramsay LE, 1999, BMJ-BRIT MED J, V319, P630, DOI 10.1136/bmj.319.7210.630; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; WALD NJ, 1994, LANCET, V343, P75, DOI 10.1016/S0140-6736(94)90814-1; Wald NJ, 1999, BMJ-BRIT MED J, V319, P1562, DOI 10.1136/bmj.319.7224.1562; Wald NJ, 2001, LANCET, V358, P2069, DOI 10.1016/S0140-6736(01)07104-5; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; Wood D, 1998, EUR HEART J, V19, P1434; 1998, N ENGL J MED, V339, P1349	48	180	186	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 29	2002	324	7353					1570	1576		10.1136/bmj.324.7353.1570	http://dx.doi.org/10.1136/bmj.324.7353.1570			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	570WP	12089098	Green Published			2022-12-28	WOS:000176683000027
J	Eiserich, JP; Baldus, S; Brennan, ML; Ma, WX; Zhang, CX; Tousson, A; Castro, L; Lusis, AJ; Nauseef, WM; White, CR; Freeman, BA				Eiserich, JP; Baldus, S; Brennan, ML; Ma, WX; Zhang, CX; Tousson, A; Castro, L; Lusis, AJ; Nauseef, WM; White, CR; Freeman, BA			Myeloperoxidase, a leukocyte-derived vascular NO oxidase	SCIENCE			English	Article							NITRIC-OXIDE; MISSENSE MUTATION; COMPOUNDS I; OXIDATION; TYROSINE; ATHEROSCLEROSIS; KINETICS; INJURY	Myeloperoxidase (MPO) is an abundant mammalian phagocyte hemoprotein thought to primarily mediate host defense reactions. Although its microbicidal functions are well established in vitro, humans deficient in MPO are not at unusual risk of infection. MPO was observed herein to modulate the vascular signaling and vasodilatory functions of nitric oxide (NO) during acute inflammation. After leukocyte degranulation, MPO localized in and around vascular endothelial cells in a rodent model of acute endotoxemia and impaired endothelium-dependent relaxant responses, to which MPO-deficient mice were resistant. Altered vascular responsiveness was due to catalytic consumption of NO by substrate radicals generated by MPO. Thus MPO can directly modulate vascular inflammatory responses by regulating NO bioavailability.	Univ Calif Davis, Dept Internal Med, Div Nephrol, Davis, CA 95616 USA; Univ Calif Davis, Dept Human Physiol, Div Nephrol, Davis, CA 95616 USA; Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Imaging Facil, Birmingham, AL 35233 USA; Univ Calif Los Angeles, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Iowa, Iowa City, IA 52242 USA; Vet Adm Med Ctr, Dept Med, Iowa City, IA 52242 USA; Vet Adm Med Ctr, Inflammat Program, Iowa City, IA 52242 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)	Eiserich, JP (corresponding author), Univ Calif Davis, Dept Internal Med, Div Nephrol, Davis, CA 95616 USA.	jpeiserich@ucdavis.edu; bruce.freeman@ccc.uab.edu	Freeman, Bruce A/H-9342-2012; zhang, xiang chun/HCH-7063-2022	zhang, xiang chun/0000-0001-8303-6495; Nauseef, William/0000-0003-4032-757X	FIC NIH HHS [R03 TW005682] Funding Source: Medline; NHLBI NIH HHS [R01 HL067930] Funding Source: Medline; BLRD VA [I01 BX000513] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW005682] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067930] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000513] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); BLRD VA; FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Veterans Affairs(US Department of Veterans Affairs)		Abu-Soud HM, 2000, J BIOL CHEM, V275, P37524, DOI 10.1074/jbc.275.48.37524; Abu-Soud HM, 2000, J BIOL CHEM, V275, P5425, DOI 10.1074/jbc.275.8.5425; Baldus S, 2001, J CLIN INVEST, V108, P1759; Brennan ML, 2001, J CLIN INVEST, V107, P419, DOI 10.1172/JCI8797; Deby-Dupont G., 1999, Intensivmedizin und Notfallmedizin, V36, P500, DOI 10.1007/s003900050270; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; EISERICH JP, 1995, BIOCHEM J, V310, P745, DOI 10.1042/bj3100745; EISERICH JP, UNPUB; Glover RE, 1999, NITRIC OXIDE-BIOL CH, V3, P439, DOI 10.1006/niox.1999.0256; Heinecke JW, 1999, J LAB CLIN MED, V133, P321, DOI 10.1016/S0022-2143(99)90061-6; Houston M, 1999, J BIOL CHEM, V274, P4985, DOI 10.1074/jbc.274.8.4985; Hsuanyu Y, 1999, ARCH BIOCHEM BIOPHYS, V368, P413, DOI 10.1006/abbi.1999.1328; Klebanoff S. J, 1991, PEROXIDASES CHEM BIO, V1, P1; Lanza F, 1998, J MOL MED-JMM, V76, P676, DOI 10.1007/s001090050267; Lefer DJ, 1996, AM J PHYSIOL-HEART C, V271, pH2421, DOI 10.1152/ajpheart.1996.271.6.H2421; Lentsch AB, 2000, J PATHOL, V190, P343; Marquez LA, 1995, J BIOL CHEM, V270, P30434, DOI 10.1074/jbc.270.51.30434; Murray PT, 2000, ANESTH ANALG, V90, P89, DOI 10.1097/00000539-200001000-00021; Nauseef WM, 1996, J BIOL CHEM, V271, P9546, DOI 10.1074/jbc.271.16.9546; NAUSEEF WM, 1994, J BIOL CHEM, V269, P1212; Pendergraft WF, 2000, KIDNEY INT, V57, P1981, DOI 10.1046/j.1523-1755.2000.00048.x; Rubbo H, 2000, J BIOL CHEM, V275, P10812, DOI 10.1074/jbc.275.15.10812; SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0; SUN WM, 1993, BIOCHEM BIOPH RES CO, V194, P306, DOI 10.1006/bbrc.1993.1820; Tyrrell DJ, 1999, ADV PHARMACOL, V46, P151, DOI 10.1016/S1054-3589(08)60471-8; Winterbourn CC, 2000, CURR OPIN HEMATOL, V7, P53, DOI 10.1097/00062752-200001000-00010	26	535	572	3	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 28	2002	296	5577					2391	2394		10.1126/science.1106830	http://dx.doi.org/10.1126/science.1106830			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	567CE	12089442				2022-12-28	WOS:000176467200041
J	Terman, JR; Mao, TY; Pasterkamp, RJ; Yu, HH; Kolodkin, AL				Terman, JR; Mao, TY; Pasterkamp, RJ; Yu, HH; Kolodkin, AL			MICALs, a family of conserved flavoprotein oxidoreductases, function in plexin-mediated axonal repulsion	CELL			English	Article							FAD-BINDING; ESCHERICHIA-COLI; SEMAPHORIN-III; GUIDANCE; TRANSMEMBRANE; PROJECTIONS; DROSOPHILA; MECHANISM; PROTEINS; DOMAIN	Members of the semaphorin family of secreted and transmembrane proteins utilize plexins as neuronal receptors to signal repulsive axon guidance. It remains unknown how plexin proteins are directly linked to the regulation of cytoskeletal dynamics. Here, we show that Drosophila MICAL, a large, multidomain, cytosolic protein expressed in axons, interacts with the neuronal plexin A (PlexA) receptor and is required for Semaphorin 1a (Sema-1a)-PlexA-mediated repulsive axon guidance. In addition to containing several domains known to interact with cytoskeletal components, MICAL has a flavoprotein monooxygenase domain, the integrity of which is required for Sema-1a-PlexA repulsive axon guidance. Vertebrate orthologs of Drosophila MICAL are neuronally expressed and also interact with vertebrate plexins, and monooxygenase inhibitors abrogate semaphorin-mediated axonal repulsion. These results suggest a novel role for oxidoreductases in repulsive neuronal guidance.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University	Kolodkin, AL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.		Yu, Hung-Hsiang/AGP-0497-2022	Yu, Hung-Hsiang/0000-0002-2430-9251; Mao, Tianyi/0000-0002-3532-8319; Pasterkamp, Jeroen/0000-0003-1631-6440				Abe I, 2000, BIOCHEM BIOPH RES CO, V268, P767, DOI 10.1006/bbrc.2000.2217; Abe I, 2000, FEBS LETT, V483, P131, DOI 10.1016/S0014-5793(00)02100-1; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; BRAND AH, 1993, DEVELOPMENT, V118, P401; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Cheng HJ, 2001, NEURON, V32, P249, DOI 10.1016/S0896-6273(01)00478-0; Dalle-Donne I, 2001, FREE RADICAL BIO MED, V31, P1624, DOI 10.1016/S0891-5849(01)00749-3; Dalle-Donne I, 2001, FREE RADICAL BIO MED, V31, P1075, DOI 10.1016/S0891-5849(01)00690-6; Dym O, 2001, PROTEIN SCI, V10, P1712, DOI 10.1110/ps.12801; EGGINK G, 1990, J MOL BIOL, V212, P135, DOI 10.1016/0022-2836(90)90310-I; Eppink MHM, 1997, PROTEIN SCI, V6, P2454; FAN JH, 1993, J CELL BIOL, V121, P867, DOI 10.1083/jcb.121.4.867; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Gimona M, 2002, FEBS LETT, V513, P98, DOI 10.1016/S0014-5793(01)03240-9; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; Goodman CS, 1999, CELL, V97, P551, DOI 10.1016/S0092-8674(00)80766-7; Harris BZ, 2001, J CELL SCI, V114, P3219; HE Z, 2002, SCI STKE, V119; HOSOKAWA K, 1966, J BIOL CHEM, V241, P2453; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Kim SO, 2002, CELL, V109, P383, DOI 10.1016/S0092-8674(02)00723-7; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kubo A, 1997, ARCH BIOCHEM BIOPHYS, V345, P271, DOI 10.1006/abbi.1997.0242; Landgraf M, 1997, J NEUROSCI, V17, P9642; LAWTON MP, 1993, J BIOL CHEM, V268, P5728; Lindsay H, 2000, J BIOL CHEM, V275, P36665, DOI 10.1074/jbc.M004777200; Liu BP, 2001, CURR OPIN CELL BIOL, V13, P619, DOI 10.1016/S0955-0674(00)00260-X; Macheroux P, 1999, METH MOL B, V131, P1; MASSEY V, 1994, J BIOL CHEM, V269, P22459; MASSEY V, 1995, FASEB J, V9, P473, DOI 10.1096/fasebj.9.7.7737454; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; Milzani A, 1997, ARCH BIOCHEM BIOPHYS, V339, P267, DOI 10.1006/abbi.1996.9847; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Pasterkamp RJ, 1998, J NEUROSCI, V18, P9962; Raper JA, 2000, CURR OPIN NEUROBIOL, V10, P88, DOI 10.1016/S0959-4388(99)00057-4; Rhee S. G., 2000, SCI STKE, V53; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Suzuki T, 2002, J BIOL CHEM, V277, P14933, DOI 10.1074/jbc.M111842200; Takahashi T, 2001, NEURON, V29, P429, DOI 10.1016/S0896-6273(01)00216-1; Tamagnone L, 2000, TRENDS CELL BIOL, V10, P377, DOI 10.1016/S0962-8924(00)01816-X; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Vallon O, 2000, PROTEINS, V38, P95, DOI 10.1002/(SICI)1097-0134(20000101)38:1<95::AID-PROT10>3.0.CO;2-A; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; White DJ, 2001, MOL MICROBIOL, V42, P503, DOI 10.1046/j.1365-2958.2001.02659.x; Whitford KL, 2001, NEURON, V32, P1, DOI 10.1016/S0896-6273(01)00459-7; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; Winberg ML, 1998, CELL, V93, P581, DOI 10.1016/S0092-8674(00)81187-3; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; Xu XM, 2000, J NEUROSCI, V20, P2638; Yu HH, 1998, NEURON, V20, P207, DOI 10.1016/S0896-6273(00)80450-X	53	273	285	1	14	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 28	2002	109	7					887	900		10.1016/S0092-8674(02)00794-8	http://dx.doi.org/10.1016/S0092-8674(02)00794-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	570KJ	12110185	Bronze			2022-12-28	WOS:000176657200011
J	Baughman, KL				Baughman, KL			B-type natriuretic peptide - A window to the heart	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine	Baughman, KL (corresponding author), Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.								0	98	104	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 18	2002	347	3					158	159		10.1056/NEJMp020057	http://dx.doi.org/10.1056/NEJMp020057			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	574BR	12124403				2022-12-28	WOS:000176869000001
J	Zhang, Y; Ma, C; Delohery, T; Nasipak, B; Foat, BC; Bounoutas, A; Bussemaker, HJ; Kim, SK; Chalfie, M				Zhang, Y; Ma, C; Delohery, T; Nasipak, B; Foat, BC; Bounoutas, A; Bussemaker, HJ; Kim, SK; Chalfie, M			Identification of genes expressed in C-elegans touch receptor neurons	NATURE			English	Article							CAENORHABDITIS-ELEGANS; HOMEOPROTEINS UNC-86; MEC-3; DIFFERENTIATION; MICROTUBULES; SENSITIVITY; SEQUENCES; GENOMICS; ENCODES	The extent of gene regulation in cell differentiation is poorly understood. We previously used saturation mutagenesis to identify 18 genes that are needed for the development and function of a single type of sensory neuron-the touch receptor neuron for gentle touch in Caenorhabditis elegans(1,2). One of these genes, mec-3, encodes a transcription factor that controls touch receptor differentiation(3,4). By culturing and isolating wild-type and mec-3 mutant cells from embryos and applying their amplified RNA to DNA microarrays, here we have identified genes that are known to be expressed in touch receptors, a previously uncloned gene (mec-17) that is needed for maintaining touch receptor differentiation(2,5), and more than 50 previously unknown mec-3-dependent genes. These genes are randomly distributed in the genome and under-represented both for genes that are co-expressed in operons and for multiple members of gene families. Using regions 5' of the start codon of the first 20 genes, we have also identified an over-represented heptanucleotide, AATGCAT, that is needed for the expression of touch receptor genes(6).	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Stanford Univ, Med Ctr, Dept Genet & Dev Biol, Stanford, CA 94305 USA	Columbia University; Memorial Sloan Kettering Cancer Center; Stanford University	Chalfie, M (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030997] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM030997] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY TL, 1994, ISMB, V2, P28; Barnes TM, 1996, J NEUROCHEM, V67, P46; Blumenthal T, 2002, NATURE, V417, P851, DOI 10.1038/nature00831; CHALFIE M, 1982, J CELL BIOL, V93, P15, DOI 10.1083/jcb.93.1.15; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; CHALFIE M, 1989, SCIENCE, V243, P1027, DOI 10.1126/science.2646709; Duggan A, 1998, DEVELOPMENT, V125, P4107; EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010; Fukushige T, 1999, J CELL SCI, V112, P395; Gu GQ, 1996, P NATL ACAD SCI USA, V93, P6577, DOI 10.1073/pnas.93.13.6577; HAN M, 1991, GENE DEV, V5, P2188, DOI 10.1101/gad.5.12a.2188; Hill AA, 2000, SCIENCE, V290, P809, DOI 10.1126/science.290.5492.809; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; Jiang M, 2001, P NATL ACAD SCI USA, V98, P218, DOI 10.1073/pnas.011520898; Liang P, 1997, J CELL SCI, V110, P1431; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MITANI S, 1993, DEVELOPMENT, V119, P773; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Reinke V, 2000, MOL CELL, V6, P605, DOI 10.1016/S1097-2765(00)00059-9; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; SAVAGE C, 1989, GENE DEV, V3, P870, DOI 10.1101/gad.3.6.870; Treinin M, 1998, P NATL ACAD SCI USA, V95, P15492, DOI 10.1073/pnas.95.26.15492; TREININ M, 1995, NEURON, V14, P871, DOI 10.1016/0896-6273(95)90231-7; Van Helden J, 2000, YEAST, V16, P177, DOI 10.1002/(SICI)1097-0061(20000130)16:2<177::AID-YEA516>3.0.CO;2-9; WAY JC, 1989, GENE DEV, V3, P1823, DOI 10.1101/gad.3.12a.1823; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; XUE D, 1992, EMBO J, V11, P4969, DOI 10.1002/j.1460-2075.1992.tb05604.x; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	30	173	208	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 18	2002	418	6895					331	335		10.1038/nature00891	http://dx.doi.org/10.1038/nature00891			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574BF	12124626				2022-12-28	WOS:000176868000044
J	Reilly, BM; Evans, AT; Schaider, JJ; Das, K; Calvin, JE; Moran, LA; Roberts, RR; Martinez, E				Reilly, BM; Evans, AT; Schaider, JJ; Das, K; Calvin, JE; Moran, LA; Roberts, RR; Martinez, E			Impact of a clinical decision rule on hospital triage of patients with suspected acute cardiac ischemia in the emergency department	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE CORONARY SYNDROMES; ACUTE CHEST PAIN; ELEVATION MYOCARDIAL-INFARCTION; RISK STRATIFICATION; UNSTABLE ANGINA; PREDICTIVE INSTRUMENT; MISSED DIAGNOSES; POTENTIAL IMPACT; OBSERVATION UNIT; TROPONIN-I	Context Emergency department (ED) physicians often are uncertain about wherein the hospital to triage patients with suspected acute cardiac ischemia, Many patients are triaged unnecessarily to intensive or intermediate cardiac care units. Objective To determine whether use of a clinical decision rule improves physicians' hospital triage decisions for patients with suspected acute cardiac ischemia. Design and Setting Prospective before-after impact analysis conducted at a large, urban, US public hospital. Participants Consecutive patients admitted from the ED with suspected acute cardiac ischemia during 2 periods: preintervention group (n=207 patients enrolled in March 1997) and intervention group (n = 1008 patients enrolled in August-November 1999). Intervention An adaptation of a previously validated clinical decision rule was adopted as the standard of care in the ED after a 3-month period of pilot testing and training. The rule predicts major cardiac complications within 72 hours after evaluation in the ED and stratifies patients' risk of major complications into 4 groups-high, moderate, low, and very low-according to electrocardiographic findings and presence or absence of 3 clinical predictors in the ED, Main Outcome Measures Safety of physicians' triage decisions, defined as the proportion of patients with major cardiac complications who were admitted to inpatient cardiac care beds (coronary care unit or inpatient telemetry unit); efficiency of decisions, defined as the proportion of patients without major complications who were triaged to an ED observation unit or an unmonitored ward. Results By intention-to-treat analysis, efficiency was higher in the intervention group (36%) than the preintervention group (21%) (difference, 15%; 95% confidence interval [CI], 8%-21%; P<.001). Safety was not significantly different (94% in the intervention group vs 89%; difference, 5%; 95% Cl, -11 % to 39%; P=.57). Subgroup analysis of intervention-group patients showed higher efficiency when physicians actually used the decision rule (38% vs 27%; difference, 11 %; 95% Cl, 3%-18%; P=.01). Improved efficiency was explained solely by different triage decisions for very low-risk patients. Most surveyed physicians (16/19 [84%]) believed that the decision rule improved patient care. Conclusions Use of the clinical decision rule had a favorable impact on physicians' hospital triage decisions. Efficiency improved without compromising safety.	Cook Cty Hosp, Dept Med, Chicago, IL 60612 USA; Cook Cty Hosp, Dept Emergency Med, Chicago, IL 60612 USA; Rush Med Coll, Chicago, IL 60612 USA	John H Stroger Junior Hospital Cook County; John H Stroger Junior Hospital Cook County; Rush University	Reilly, BM (corresponding author), Cook Cty Hosp, Dept Med, Room 2129,1835 W Harrison St, Chicago, IL 60612 USA.							Antman EM, 2000, JAMA-J AM MED ASSOC, V284, P835, DOI 10.1001/jama.284.7.835; Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; Bayes-Genis A, 2001, NEW ENGL J MED, V345, P1022, DOI 10.1056/NEJMoa003147; Braunwald E, 2000, CIRCULATION, V102, P1193, DOI 10.1161/01.CIR.102.10.1193; CALVIN JE, 1995, JAMA-J AM MED ASSOC, V273, P136; Canto JG, 2000, JAMA-J AM MED ASSOC, V283, P3223, DOI 10.1001/jama.283.24.3223; de Lemos JA, 2001, NEW ENGL J MED, V345, P1014, DOI 10.1056/NEJMoa011053; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; Durairaj L, 2001, AM J MED, V110, P7, DOI 10.1016/S0002-9343(00)00640-9; Farkouh ME, 1998, NEW ENGL J MED, V339, P1882, DOI 10.1056/NEJM199812243392603; Goldman L, 2001, AM J MED, V110, P67, DOI 10.1016/S0002-9343(00)00679-3; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; Goldman L, 1996, NEW ENGL J MED, V334, P1498, DOI 10.1056/NEJM199606063342303; Goodacre SW, 2000, J ACCID EMERG MED, V17, P1; Hamm CW, 1997, NEW ENGL J MED, V337, P1648, DOI 10.1056/NEJM199712043372302; LEE TH, 1995, ANN INTERN MED, V122, P434, DOI 10.7326/0003-4819-122-6-199503150-00006; LEE TH, 1987, AM J CARDIOL, V60, P219, DOI 10.1016/0002-9149(87)90217-7; Mace SE, 2002, ACAD EMERG MED, V9, P169, DOI 10.1197/aemj.9.2.169; Martinez E, 2001, AM J MED, V110, P274, DOI 10.1016/S0002-9343(00)00710-5; MCCARTHY BD, 1993, ANN EMERG MED, V22, P579, DOI 10.1016/S0196-0644(05)81945-6; McGinn TG, 2000, JAMA-J AM MED ASSOC, V284, P79, DOI 10.1001/jama.284.1.79; Mehta RH, 2000, NEW ENGL J MED, V342, P1207, DOI 10.1056/NEJM200004203421610; MIETTINEN O, 1985, STAT MED, V4, P213, DOI 10.1002/sim.4780040211; Nichol G, 1997, ANN INTERN MED, V127, P996, DOI 10.7326/0003-4819-127-11-199712010-00009; O'Rourke RA, 2001, ARCH INTERN MED, V161, P674, DOI 10.1001/archinte.161.5.674; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; Ohman EM, 2000, JAMA-J AM MED ASSOC, V284, P876, DOI 10.1001/jama.284.7.876; Panju AA, 1998, JAMA-J AM MED ASSOC, V280, P1256, DOI 10.1001/jama.280.14.1256; Pope JH, 2000, NEW ENGL J MED, V342, P1163, DOI 10.1056/NEJM200004203421603; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; Reilly B, 1999, AM J MED, V106, P285, DOI 10.1016/S0002-9343(99)00024-8; Reilly BM, 2002, AM J MED, V112, P95, DOI 10.1016/S0002-9343(01)01054-3; RUSNAK RA, 1989, ANN EMERG MED, V18, P1021; SCHOR S, 1976, JAMA-J AM MED ASSOC, V236, P941; Selker HP, 1997, ANN EMERG MED, V29, P1, DOI 10.1016/S0196-0644(97)70297-X; Selker HP, 1998, ANN INTERN MED, V129, P845, DOI 10.7326/0003-4819-129-11_Part_1-199812010-00002; Selker HP, 1997, ANN INTERN MED, V127, P538, DOI 10.7326/0003-4819-127-7-199710010-00006; Tatum JL, 1997, ANN EMERG MED, V29, P116, DOI 10.1016/S0196-0644(97)70317-2; Zalenski RJ, 1998, AM J CARDIOL, V81, P1305, DOI 10.1016/S0002-9149(98)00159-3; Zalenski RJ, 1997, ARCH INTERN MED, V157, P1085, DOI 10.1001/archinte.157.10.1085	40	82	84	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	2002	288	3					342	350		10.1001/jama.288.3.342	http://dx.doi.org/10.1001/jama.288.3.342			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573AK	12117399	Bronze			2022-12-28	WOS:000176807000026
J	Burton, MJ; Burton, KJ; Chuka-Okosa, CM; Bailey, RL				Burton, MJ; Burton, KJ; Chuka-Okosa, CM; Bailey, RL			Plummeting lenses in the TB clinic	LANCET			English	Editorial Material									MRC Labs, Fajara, Gambia; Royal Victoria Hosp, Banjul, Gambia	MRC Laboratory Molecular Biology	Burton, MJ (corresponding author), MRC Labs, Fajara, Gambia.			burton, kathryn/0000-0002-5991-8612; Burton, Matthew/0000-0003-1872-9169				AICARDI J, 1998, DIS NERVOUS SYSTEM C, P274; Franco RF, 1998, HUM HERED, V48, P338, DOI 10.1159/000022826; HANDMAN J, 1996, GOODMAN GILMANS PHAR, P1561; McKusick V. A., 2002, ONLINE MENDELIAN INH; SHULMAN D, 1977, S AFR MED J, V52, P127	5	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 13	2002	360	9327					138	138		10.1016/S0140-6736(02)09415-1	http://dx.doi.org/10.1016/S0140-6736(02)09415-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573PB	12126825				2022-12-28	WOS:000176839100014
J	Ficker, JH				Ficker, JH			Unilateral anhidrosis of the leg	LANCET			English	Editorial Material									Univ Erlangen Nurnberg, Dept Med 1, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Ficker, JH (corresponding author), Univ Erlangen Nurnberg, Dept Med 1, D-91054 Erlangen, Germany.		Ficker, Joachim H./A-1153-2015	Ficker, Joachim H./0000-0002-7175-5852					0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 13	2002	360	9327					129	129		10.1016/S0140-6736(02)09412-6	http://dx.doi.org/10.1016/S0140-6736(02)09412-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573PB	12126822	Bronze			2022-12-28	WOS:000176839100011
J	Levy, YY; Mesnage, S; Mylne, JS; Gendall, AR; Dean, C				Levy, YY; Mesnage, S; Mylne, JS; Gendall, AR; Dean, C			Multiple roles of Arabidopsis VRN1 in vernalization and flowering time control	SCIENCE			English	Article							MADS DOMAIN PROTEIN; EXPRESSION; THALIANA; GENES; REPRESSOR; ENCODES; VECTORS; GENOME	Arabidopsis VRN genes mediate vernalization, the process by which a long period of cold induces a mitotically stable state that leads to accelerated flowering during later development. VRN1 encodes a protein that binds DNA in vitro in a non sequence-specific manner and functions in stable repression of the major target of the vernalization pathway, the oral repressor FLC. Overexpression of VRN1 reveals a vernalization-independent function for VRN1, mediated predominantly through the oral pathway integrator FT, and demonstrates that VRN1 requires vernalization-specific factors to target FLC.	John Innes Ctr Plant Sci Res, Dept Cell & Dev Biol, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Dean, C (corresponding author), John Innes Ctr Plant Sci Res, Dept Cell & Dev Biol, Colney Lane, Norwich NR4 7UH, Norfolk, England.		Mylne, Josh/GMX-4544-2022; Mylne, Joshua S/A-5581-2009; MESNAGE, Stephane/H-7156-2019	Mylne, Josh/0000-0003-4957-6388; Mylne, Joshua S/0000-0003-4957-6388; MESNAGE, Stephane/0000-0003-1648-4890; Gendall, Anthony/0000-0002-2255-3939				Bent E, 1998, PLANT J, V13, P849, DOI 10.1046/j.1365-313X.1998.00082.x; Blazquez M, 2001, EMBO REP, V2, P1078, DOI 10.1093/embo-reports/kve254; Chandler J, 1996, PLANT J, V10, P637, DOI 10.1046/j.1365-313X.1996.10040637.x; CLARKE JH, 1995, MOL GEN GENET, V248, P278, DOI 10.1007/BF02191594; Gendall AR, 2001, CELL, V107, P525, DOI 10.1016/S0092-8674(01)00573-6; Kanaya E, 2002, J BIOL CHEM, V277, P11957, DOI 10.1074/jbc.M108889200; Kardailsky I, 1999, SCIENCE, V286, P1962, DOI 10.1126/science.286.5446.1962; Kobayashi Y, 1999, SCIENCE, V286, P1960, DOI 10.1126/science.286.5446.1960; Lee H, 2000, GENE DEV, V14, P2366, DOI 10.1101/gad.813600; Macknight R, 1997, CELL, V89, P737, DOI 10.1016/S0092-8674(00)80256-1; Michaels SD, 1999, PLANT CELL, V11, P949, DOI 10.1105/tpc.11.5.949; Mozo T, 1998, PLANT J, V16, P377, DOI 10.1046/j.1365-313x.1998.00299.x; Mylne J, 1998, PLANT MOL BIOL REP, V16, P257, DOI 10.1023/A:1007520410190; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Samach A, 2000, SCIENCE, V288, P1613, DOI 10.1126/science.288.5471.1613; Sheldon CC, 2000, P NATL ACAD SCI USA, V97, P3753, DOI 10.1073/pnas.060023597; Sheldon CC, 1999, PLANT CELL, V11, P445, DOI 10.1105/tpc.11.3.445; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; Simpson GG, 2002, SCIENCE, V296, P285, DOI 10.1126/science.296.5566.285; Suzuki M, 1997, PLANT CELL, V9, P799, DOI 10.1105/tpc.9.5.799; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Ulmasov T, 1997, PLANT CELL, V9, P1963, DOI 10.1105/tpc.9.11.1963; VARAGONA MJ, 1992, PLANT CELL, V4, P1213, DOI 10.1105/tpc.4.10.1213; von Arnim AG, 1998, GENE, V221, P35, DOI 10.1016/S0378-1119(98)00433-8	25	318	368	6	117	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 12	2002	297	5579					243	246		10.1126/science.1072147	http://dx.doi.org/10.1126/science.1072147			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571UT	12114624				2022-12-28	WOS:000176738100039
J	Dai, ZR; Bradley, JP; Joswiak, DJ; Brownlee, DE; Hill, HGM; Genge, MJ				Dai, ZR; Bradley, JP; Joswiak, DJ; Brownlee, DE; Hill, HGM; Genge, MJ			Possible in situ formation of meteoritic nanodiamonds in the early Solar System	NATURE			English	Article							INTERPLANETARY DUST PARTICLES; PRESOLAR DIAMONDS; GRAINS; COMETS; CARBON	Grains of dust that pre-date the Sun provide insights into their formation around other stars and into the early evolution of the Solar System(1-4). Nanodiamonds recovered from meteorites, which originate in asteroids, have been thought to be the most abundant type of presolar grain(3,4). If that is true, then nanodiamonds should be at least as abundant in comets, because they are thought to have formed further out in the early Solar System than the asteroid parent bodies, and because they should be more pristine(5-7). Here we report that nanodiamonds are absent or very depleted in fragile, carbon-rich interplanetary dust particles, some of which enter the atmosphere at speeds within the range of cometary meteors(8,9). One interpretation of the results is that some (perhaps most) nanodiamonds formed within the inner Solar System and are not presolar at all, consistent with the recent detection of nanodiamonds within the accretion discs of other young stars(10). An alternative explanation is that all meteoritic nanodiamonds are indeed presolar, but that their abundance decreases with heliocentric distance, in which case our understanding of large-scale transport and circulation within the early Solar System is incomplete(11).	Georgia Inst Technol, Sch Mat Sci & Engn, Atlanta, GA 30332 USA; Univ Washington, Dept Astron, Seattle, WA 98195 USA; NASA, Goddard Space Flight Ctr, Extraterr Phys Lab, Greenbelt, MD 20771 USA; Nat Hist Museum, Dept Mineral, London SW7 5BD, England	University System of Georgia; Georgia Institute of Technology; University of Washington; University of Washington Seattle; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Natural History Museum London	Bradley, JP (corresponding author), Lawrence Livermore Natl Lab, Inst Geophys & Planetary Phys, Mail Stop L-413,7000 East Ave, Livermore, CA 94550 USA.	jbradley@igpp.ucllnl.org	Dai, Zurong/E-6732-2010	Dai, Zurong/0000-0002-4209-8718				ANDERS E, 1993, METEORITICS, V28, P490, DOI 10.1111/j.1945-5100.1993.tb00274.x; BERNATOWICZ TJ, 1990, ASTROPHYS J, V359, P246, DOI 10.1086/169056; Bernatowicz TJ, 1997, PHYS TODAY, V50, P26, DOI 10.1063/1.882049; BRADLEY JP, 1994, SCIENCE, V265, P925, DOI 10.1126/science.265.5174.925; BRADLEY JP, 1986, SCIENCE, V231, P1542, DOI 10.1126/science.231.4745.1542; BRADLEY JP, 1992, SCIENCE, V251, P489; Brownlee D.E., 1995, LUNAR PLANET SCI, P183; BROWNLEE DE, 2000, LUNAR PLANET SCI, V31, P1921; Daulton TL, 1996, GEOCHIM COSMOCHIM AC, V60, P4853, DOI 10.1016/S0016-7037(96)00223-2; FARINELLA P, 1993, ICARUS, V101, P174, DOI 10.1006/icar.1993.1016; Greenberg J., 1982, COMETS, P131; Guillois O, 1999, ASTROPHYS J, V521, pL133, DOI 10.1086/312199; Hill HGM, 2001, P NATL ACAD SCI USA, V98, P2182, DOI 10.1073/pnas.051530998; Hill HGM, 1998, ASTRON ASTROPHYS, V336, pL41; Hoppe P, 2000, J GEOPHYS RES-SPACE, V105, P10371, DOI 10.1029/1999JA900194; HOWARD W, 1990, J APPL PHYS, V68, P1247, DOI 10.1063/1.346725; HUSS GR, 1994, METEORITICS, V29, P791, DOI 10.1111/j.1945-5100.1994.tb01094.x; Huss GR, 1997, AIP CONF PROC, P721, DOI 10.1063/1.53338; Liou JC, 1996, ICARUS, V124, P429, DOI 10.1006/icar.1996.0220; LODDERS K, 2000, PROTOSTARS PLANETS, V4, P1019; LUU JX, 1993, ICARUS, V104, P138, DOI 10.1006/icar.1993.1088; Messenger S, 2000, NATURE, V404, P968, DOI 10.1038/35010053; Russell SS, 1996, METORIT PLANET SCI, V31, P343, DOI 10.1111/j.1945-5100.1996.tb02071.x; SCHRAMM LS, 1989, METEORITICS, V24, P99, DOI 10.1111/j.1945-5100.1989.tb00950.x; Sylvester R. J., 1999, Solid interstellar matter: the ISO revolution, P263; THOMAS KL, 1995, GEOCHIM COSMOCHIM AC, V59, P2797, DOI 10.1016/0016-7037(95)00174-X; THOMAS KL, 1993, GEOCHIM COSMOCHIM AC, V57, P1551, DOI 10.1016/0016-7037(93)90012-L; Van Kerckhoven C, 2002, ASTRON ASTROPHYS, V384, P568, DOI 10.1051/0004-6361:20011814	28	133	136	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 11	2002	418	6894					157	159		10.1038/nature00897	http://dx.doi.org/10.1038/nature00897			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571GV	12110882				2022-12-28	WOS:000176710400032
J	Furmanski, L				Furmanski, L			Waiting	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	2002	288	2					142	142		10.1001/jama.288.2.142	http://dx.doi.org/10.1001/jama.288.2.142			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	571HC	12095365				2022-12-28	WOS:000176711100001
J	Patel, MG; Wright, DJ; Gill, PS; Jerwood, D; Silcock, J; Chrystyn, H				Patel, MG; Wright, DJ; Gill, PS; Jerwood, D; Silcock, J; Chrystyn, H			Prescribing of lipid lowering drugs to South Asian patients: ecological study	BRITISH MEDICAL JOURNAL			English	Article							ORIGIN		Univ Bradford, Sch Pharm, Bradford BD7 1DP, W Yorkshire, England; Univ Bradford, Sch Comp & Math, Bradford BD7 1DP, W Yorkshire, England; Univ Birmingham, Dept Primary Care & Gen Practice, Hlth Inequalities Res Grp, Birmingham B15 2TT, W Midlands, England	University of Bradford; University of Bradford; University of Birmingham	Patel, MG (corresponding author), Univ Bradford, Sch Pharm, Bradford BD7 1DP, W Yorkshire, England.		Silcock, Jonathan/AAB-1856-2020; Silcock, Jonathan/AAZ-2124-2021	Silcock, Jonathan/0000-0002-4920-9249; Patel, Mahendra/0000-0001-6703-3542				Bhopal R, 1999, BRIT MED J, V319, P215, DOI 10.1136/bmj.319.7204.215; Cummins C, 1999, J PUBLIC HEALTH MED, V21, P401, DOI 10.1093/pubmed/21.4.401; *DEP HLTH, 2000, NAT SERV FRAM COR HE; Primatesta P, 2000, BMJ-BRIT MED J, V321, P1322, DOI 10.1136/bmj.321.7272.1322; Wild S, 1997, BRIT MED J, V314, P705, DOI 10.1136/bmj.314.7082.705	5	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 6	2002	325	7354					25	26		10.1136/bmj.325.7354.25	http://dx.doi.org/10.1136/bmj.325.7354.25			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573BC	12098726	Bronze, Green Published			2022-12-28	WOS:000176808600020
J	Zimhony, O				Zimhony, O			Photographic negative shadow of pulmonary oedema	LANCET			English	Editorial Material									Kaplan Med Ctr, Infect Dis Unit, IL-76100 Rehovot, Israel	Hebrew University of Jerusalem; Kaplan Medical Center	Zimhony, O (corresponding author), Kaplan Med Ctr, Infect Dis Unit, IL-76100 Rehovot, Israel.								0	8	8	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 6	2002	360	9326					33	33		10.1016/S0140-6736(02)09329-7	http://dx.doi.org/10.1016/S0140-6736(02)09329-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569JR	12114038				2022-12-28	WOS:000176599700008
J	Kulheim, C; Agren, J; Jansson, S				Kulheim, C; Agren, J; Jansson, S			Rapid regulation of light harvesting and plant fitness in the field	SCIENCE			English	Article							CHLOROPHYLL FLUORESCENCE; ARABIDOPSIS-THALIANA; XANTHOPHYLL CYCLE; GREEN PLANTS; MUTANTS; ENERGY	We used Arabidopsis thaliana mutants to examine how a photosynthetic regulatory process, the qE-type or DeltapH-dependent nonphotochemical quenching, hereafter named feedback de-excitation, influences plant fitness in different light environments. We show that the feedback de-excitation is important for plant fitness in the field and in fluctuating light in a controlled environment but that it does not affect plant performance under constant light conditions. Our findings demonstrate that the feedback de-excitation confers a strong fitness advantage under field conditions and suggest that this advantage is due to the increase in plant tolerance to variation in light intensity rather than tolerance to high-intensity light itself.	Umea Univ, Dept Plant Physiol, Umea Plant Sci Ctr, SE-90187 Umea, Sweden; Uppsala Univ, Dept Plant Ecol, Evolutionary Biol Ctr, SE-75236 Uppsala, Sweden	Umea University; Uppsala University	Jansson, S (corresponding author), Umea Univ, Dept Plant Physiol, Umea Plant Sci Ctr, SE-90187 Umea, Sweden.	stefan.jansson@plantphys.umu.se	Ågren, Jon/E-6093-2011; Jansson, Stefan/A-1119-2009; Kulheim, Carsten/F-4720-2010	Ågren, Jon/0000-0001-9573-2463; Jansson, Stefan/0000-0002-7906-6891; Kulheim, Carsten/0000-0002-0798-3324				DemmigAdams B, 1996, TRENDS PLANT SCI, V1, P21, DOI 10.1016/S1360-1385(96)80019-7; Havaux M, 1999, P NATL ACAD SCI USA, V96, P8762, DOI 10.1073/pnas.96.15.8762; Havaux M, 2001, PLANTA, V213, P953, DOI 10.1007/s004250100572; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; HORTON P, 1994, PLANT PHYSIOL, V106, P415, DOI 10.1104/pp.106.2.415; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Li XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131; Mitchell-Olds T, 2001, TRENDS ECOL EVOL, V16, P693, DOI 10.1016/S0169-5347(01)02291-1; Muller P, 2001, PLANT PHYSIOL, V125, P1558, DOI 10.1104/pp.125.4.1558; Niyogi KK, 1998, PLANT CELL, V10, P1121, DOI 10.1105/tpc.10.7.1121; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; OQUIST G, 1988, PHYSIOL PLANTARUM, V73, P211, DOI 10.1111/j.1399-3054.1988.tb00588.x; SCHMITT J, 1995, AM NAT, V146, P9347	13	433	454	1	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 5	2002	297	5578					91	93		10.1126/science.1072359	http://dx.doi.org/10.1126/science.1072359			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571HB	12098696				2022-12-28	WOS:000176711000039
J	Sigel, R; Fytas, G; Vainos, N; Pispas, S; Hadjichristidis, N				Sigel, R; Fytas, G; Vainos, N; Pispas, S; Hadjichristidis, N			Pattern formation in homogeneous polymer solutions induced by a continuous-wave visible laser	SCIENCE			English	Article							MANIPULATION; TRANSITIONS; DEPENDENCE; PARTICLES; DIFFUSION; LIGHT	We report an unexpected nonphotothermal material organization induced by continuous-wave visible laser light at low power levels. This effect is observed along the laser beam propagation direction in fully transparent entangled solutions of common homopolymers featuring sufficiently high molecular mass and optical anisotropy along the chain backbone. The resulting formation of long-lived stringlike or dotlike patterns on the micrometer scale, probed by dark-field coherent imaging, depends on the molecular mass, architecture, solvent nature, and polymer concentration. Electrostrictive and alignment forces as well as chain cooperativity are responsible for the osmotic compression of the polymer solute. Subsequent waveguiding effects induce autoamplification and pattern writing upon prolonged illumination. This wave-medium coupling could potentially lead to photorefractive, microoptics, and nanotechnology applications.	FORTH, Inst Elect Struct & Laser, Iraklion 71110, Crete, Greece; Max Planck Inst Polymer Res, D-55021 Mainz, Germany; Univ Athens, Dept Chem, Athens 15701, Greece	Foundation for Research & Technology - Hellas (FORTH); Max Planck Society; National & Kapodistrian University of Athens	Fytas, G (corresponding author), FORTH, Inst Elect Struct & Laser, POB 1527, Iraklion 71110, Crete, Greece.			Sigel, Reinhard/0000-0002-8074-1268; VAINOS, NIKOLAOS/0000-0001-8868-0888				Ashkin A, 1997, P NATL ACAD SCI USA, V94, P4853, DOI 10.1073/pnas.94.10.4853; ASHKIN A, 1987, NATURE, V330, P769, DOI 10.1038/330769a0; ASHKIN A, 1982, OPT LETT, V7, P276, DOI 10.1364/OL.7.000276; Chiu DT, 1996, J AM CHEM SOC, V118, P6512, DOI 10.1021/ja960978p; CHU S, 1991, SCIENCE, V253, P861, DOI 10.1126/science.253.5022.861; De Gennes P.-G., 1979, SCALING CONCEPTS POL; Delville JP, 1999, PHYS REV E, V59, P5804, DOI 10.1103/PhysRevE.59.5804; FYTAS G, 1988, POLYM COMMUN, V29, P322; Hirano K, 2002, APPL PHYS LETT, V80, P515, DOI 10.1063/1.1435803; Hofkens J, 1997, LANGMUIR, V13, P414, DOI 10.1021/la9606308; Ichimura K, 2000, SCIENCE, V288, P1624, DOI 10.1126/science.288.5471.1624; Juodkazis S, 2000, NATURE, V408, P178, DOI 10.1038/35041522; KELLER A, 1985, COLLOID POLYM SCI, V263, P187; McCann LI, 1999, NATURE, V402, P785, DOI 10.1038/45492; ROOVERS J, 1994, MACROMOLECULES, V27, P5359, DOI 10.1021/ma00097a015; SCHIMPF ME, 1989, J POLYM SCI POL PHYS, V27, P1317, DOI 10.1002/polb.1989.090270610	16	38	38	2	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 5	2002	297	5578					67	69		10.1126/science.1071930	http://dx.doi.org/10.1126/science.1071930			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571HB	12098691				2022-12-28	WOS:000176711000031
J	Vekua, A; Lordkipanidze, D; Rightmire, GP; Agusti, J; Ferring, R; Maisuradze, G; Mouskhelishvili, A; Nioradze, M; de Leon, MP; Tappen, M; Tvalchrelidze, M; Zollikofer, C				Vekua, A; Lordkipanidze, D; Rightmire, GP; Agusti, J; Ferring, R; Maisuradze, G; Mouskhelishvili, A; Nioradze, M; de Leon, MP; Tappen, M; Tvalchrelidze, M; Zollikofer, C			A new skull of early homo from Dmanisi, Georgia	SCIENCE			English	Article							TAXONOMY; REMAINS; ERECTUS	Another hominid skull has been recovered at Dmanisi ( Republic of Georgia) from the same strata in which hominid remains have been reported previously. The Dmanisi site dated to similar to1.75 million years ago has now produced craniofacial portions of several hominid individuals, along with many well-preserved animal fossils and quantities of stone artifacts. Although there are certain anatomical differences among the Dmanisi specimens, the hominids do not clearly represent more than one taxon. We assign the new skull provisionally to Homo erectus (=ergaster). The Dmanisi specimens are the most primitive and small-brained fossils to be grouped with this species or any taxon linked unequivocally with genus Homo and also the ones most similar to the presumed habilis-like stem. We suggest that the ancestors of the Dmanisi population dispersed from Africa before the emergence of humans identified broadly with the H. erectus grade.	Georgian Acad Sci, Georgian State Museum, GE-380007 Tbilisi, Georgia; Georgian Acad Sci, Inst Paleobiol, GE-380004 Tbilisi, Georgia; SUNY Binghamton, Dept Anthropol, Binghamton, NY 13902 USA; Inst Paleontol M Crusafont, Sabadell 08201, Spain; Univ N Texas, Dept Geog, Denton, TX 76203 USA; Georgian Acad Sci, Inst Geog, GE-380093 Tbilisi, Georgia; Georgian Acad Sci, Archeol Ctr, GE-380002 Tbilisi, Georgia; Univ Zurich Irchel, Inst Anthropol, CH-8057 Zurich, Switzerland; Univ Zurich Irchel, MultiMedia Lab, CH-8057 Zurich, Switzerland; Univ Minnesota, Dept Anthropol, Minneapolis, MN 55455 USA; Georgian Acad Sci, Inst Geol, GE-380093 Tbilisi, Georgia	National Academy of Sciences of Georgia; National Academy of Sciences of Georgia; State University of New York (SUNY) System; State University of New York (SUNY) Binghamton; University of North Texas System; University of North Texas Denton; National Academy of Sciences of Georgia; National Academy of Sciences of Georgia; University of Zurich; University of Zurich; University of Minnesota System; University of Minnesota Twin Cities; National Academy of Sciences of Georgia	Lordkipanidze, D (corresponding author), Georgian Acad Sci, Georgian State Museum, 3 Purtseladze St, GE-380007 Tbilisi, Georgia.	geonathist@ip.osgf.ge	Lordkipanidze, David/AAH-6472-2020					Asfaw B, 2002, NATURE, V416, P317, DOI 10.1038/416317a; BEHRENSMEYER AK, 1978, PALEOBIOLOGY, V4, P150, DOI 10.1017/S0094837300005820; Dean C, 2001, NATURE, V414, P628, DOI 10.1038/414628a; GABOUNIA L, 1995, ANTHROPOLOGIE, V99, P29; Gabunia L, 2000, SCIENCE, V288, P1019, DOI 10.1126/science.288.5468.1019; Gabunia L, 2000, SCIENCE, V289, P55; Gabunia L, 2001, EVOL ANTHROPOL, V10, P158, DOI 10.1002/evan.1030; Gabunia L, 2000, J HUM EVOL, V38, P785, DOI 10.1006/jhev.1999.0383; GABUNIA L, 2001, EURASIA, V2, P128; GABUNIA L, 1992, JAHR RGZM, V39, P185; Gabunia L., 2000, ERAUL, V92, P13; GABUNIA L, 1993, DMANISI MAN ACCOMPAN, P1; Gabunia L.K., 1999, ARCHAOL KORRESPONDEN, V29, P451; GABUNIA LL, UNPUB C R ACAD SCI; JUSTUS A, 2001, MITT BERL GESEL ANTH, V21, P61; Kimbel WH, 1996, J HUM EVOL, V31, P549, DOI 10.1006/jhev.1996.0079; Lordkipanidze D, 2002, J HUM EVOL, V42, pA20; MCCOLLUM MA, 1993, J HUM EVOL, V24, P87, DOI 10.1006/jhev.1993.1009; Rightmire GP, 1998, AM J PHYS ANTHROPOL, V106, P61, DOI 10.1002/(SICI)1096-8644(199805)106:1<61::AID-AJPA5>3.3.CO;2-U; RIGHTMIRE GP, 1990, COMP ANATOMICAL STUD, P1; ROBINSON JT, 1965, NATURE, V205, P121, DOI 10.1038/205121a0; Tappen Martha, 2002, P161; TESAKOV AS, 1998, TNO, V60, P71; Tobias P.V, 1991, OLDUVAI GORGE, V4, P1; Walker A, 1993, NARIOKOTOME HOMO ERE, P1; WALKER A, 1976, EARLIEST MAN ENV LAK, P484; Weidenreich F., 1943, Palaeontologia Sinica, VD 10, P1; Wolpoff M. H., 1999, PALEOANTHROPOLOGY; Wood B, 1999, SCIENCE, V284, P65, DOI 10.1126/science.284.5411.65; WOOD B, 1992, NATURE, V355, P783, DOI 10.1038/355783a0; Wood B., 1991, HOMINID CRANIAL REMA, V4; ZAGWIJN WH, 1998, TNO, V60, P19	32	255	267	2	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 5	2002	297	5578					85	89		10.1126/science.1072953	http://dx.doi.org/10.1126/science.1072953			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571HB	12098694				2022-12-28	WOS:000176711000037
J	Nonaka, S; Shiratori, H; Saijoh, Y; Hamada, H				Nonaka, S; Shiratori, H; Saijoh, Y; Hamada, H			Determination of left-right patterning of the mouse embryo by artificial nodal flow	NATURE			English	Article							LEFT-RIGHT ASYMMETRY; SITUS-INVERSUS; EXPRESSION; MICE; CILIA	Substantial insight has recently been achieved into the mechanisms responsible for the generation of left-right (L-R) asymmetry in the vertebrate body plan(1-4). However, the mechanism that underlies the initial breaking of symmetry has remained unclear. In the mouse, a leftward fluid flow on the ventral side of the node caused by the vortical motion of cilia (referred to as nodal flow) is implicated in symmetry breaking(5), but direct evidence for the role of this flow has been lacking. Here we describe the development of a system in which mouse embryos are cultured under an artificial fluid flow and with which we have examined how flow affects L-R patterning. An artificial rightward flow that was sufficiently rapid to reverse the intrinsic leftward nodal flow resulted in reversal of situs in wild-type embryos. The artificial flow was also able to direct the situs of mutant mouse embryos with immotile cilia. These results provide the first direct evidence for the role of mechanical fluid flow in L-R patterning.	Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Tokyo, Japan	Osaka University; Japan Science & Technology Agency (JST)	Nonaka, S (corresponding author), Osaka Univ, Grad Sch Frontier Biosci, 1-3 Yamada Oka, Suita, Osaka 5650871, Japan.		Hamada, Hiroshi/N-6374-2015; Nonaka, Shigenori/I-2132-2013	Hamada, Hiroshi/0000-0002-7196-5948; Nonaka, Shigenori/0000-0002-8093-0325; Saijoh, Yukio/0000-0002-7548-4789				Beddington RSP, 1999, CELL, V96, P195, DOI 10.1016/S0092-8674(00)80560-7; Capdevila J, 2000, CELL, V101, P9, DOI 10.1016/S0092-8674(00)80619-4; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; DOWNS KM, 1993, DEVELOPMENT, V118, P1255; FUJINAGA M, 1991, TERATOLOGY, V44, P453, DOI 10.1002/tera.1420440411; Hamada H, 2002, NAT REV GENET, V3, P103, DOI 10.1038/nrg732; Hogan B, 1994, MANIPULATING MOUSE E; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Okada Y, 1999, MOL CELL, V4, P459, DOI 10.1016/S1097-2765(00)80197-5; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; Shiratori H, 2001, MOL CELL, V7, P137, DOI 10.1016/S1097-2765(01)00162-9; SULIK K, 1994, DEV DYNAM, V201, P260, DOI 10.1002/aja.1002010309; Supp DM, 1999, DEVELOPMENT, V126, P5495; Takeda S, 1999, J CELL BIOL, V145, P825, DOI 10.1083/jcb.145.4.825; Wright C V, 2001, Dev Cell, V1, P179, DOI 10.1016/S1534-5807(01)00036-3	18	481	504	2	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 4	2002	418	6893					96	99		10.1038/nature00849	http://dx.doi.org/10.1038/nature00849			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	569JL	12097914				2022-12-28	WOS:000176599200046
J	Crawford, LM				Crawford, LM			Meetings on drug applications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Crawford, LM (corresponding author), US FDA, Rockville, MD 20857 USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	2002	288	1					36	36		10.1001/jama.288.1.36	http://dx.doi.org/10.1001/jama.288.1.36			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	568YW	12090852				2022-12-28	WOS:000176573400008
J	Wong, TY; Klein, R; Sharrett, AR; Couper, DJ; Klein, BEK; Liao, DP; Hubbard, LD; Mosley, TH				Wong, TY; Klein, R; Sharrett, AR; Couper, DJ; Klein, BEK; Liao, DP; Hubbard, LD; Mosley, TH		ARIC Investigators	Cerebral white matter lesions, retinopathy, and incident clinical stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RETINAL MICROVASCULAR ABNORMALITIES; ATHEROSCLEROSIS RISK; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; SUBCORTICAL LESIONS; ELDERLY-PEOPLE; HYPERINTENSITIES; LEUKOARAIOSIS; MRI; HYPERTENSION	Context White matter lesions (WMLs) detected on cerebral imaging scans have been hypothesized to have a microvascular etiology and to precede the development of clinical stroke. However, few clinical data are available to support these hypotheses. Objective To examine the relationship of WMLs, retinal microvascular abnormalities, and incident clinical stroke in healthy, middle-aged men and women. Design and Setting The Atherosclerosis Risk in Communities Study (ARIC), a prospective, population-based cohort study conducted in 4 US communities and initiated in 1987-1989. Participants A total of 1684 persons aged 51 to 72 years who had cerebral magnetic resonance imaging (MRI) and retinal photography at the third examination (1993-1995). Main Outcome Measures Odds of WMLs, defined by standardized methods from MRI, by presence or absence of specific retinal microvascular abnormality (eg, microaneurysm, retinal hemorrhage) on retinal photograph; incident clinical stroke, ascertained after a median follow-up of 47 years, according to presence or absence of WMLs and retinopathy. Results Persons with retinopathy were more likely to have WMLs than those without retinopathy (22.9% vs 9.9%; odds ratio, 2.5; 95% confidence interval [CI], 1.5-4.0, adjusted for age, sex, race, and vascular risk factors). The 5-year cumulative incidence of clinical stroke was higher in persons with vs without WMLs (6,8% vs 1.4%; adjusted relative risk [RR], 3.4; 95% CI, 1.5-7.7) and in persons with vs without retinopathy (8.0% vs 1.4%; adjusted RR, 4.9; 95% CI, 2.0-11.9). Persons with both WMLS and retinopathy had a significantly higher 5-year cumulative incidence of stroke than those without either WMLs or retinopathy (20.0% vs 1.4%; adjusted RR, 18.1; 95% CI, 5.9-55.4). Conclusions In this cohort, middle-aged persons with cerebral WMLs detected on MRI were more likely to have retinal microvascular abnormalities and to have an increased risk of clinical stroke than people without WMLs. The risk of stroke was higher when retinopathy was simultaneously present in persons with WMLs.	Natl Univ Singapore, Dept Ophthalmol, Singapore 119260, Singapore; Natl Univ Singapore, Singapore Natl Eye Ctr, Singapore 119260, Singapore; Univ Wisconsin, Dept Ophthalmol, Madison, WI USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; NHLBI, Bethesda, MD 20892 USA; Univ N Carolina, Chapel Hill, NC USA; Penn State Univ, Coll Med, Dept Hlth Evaluat Sci, Hershey, PA USA; Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA	National University of Singapore; National University of Singapore; Singapore National Eye Center; University of Wisconsin System; University of Wisconsin Madison; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of North Carolina; University of North Carolina Chapel Hill; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Mississippi; University of Mississippi Medical Center	Wong, TY (corresponding author), Natl Univ Singapore, Dept Ophthalmol, 10 Kent Ridge Crescent, Singapore 119260, Singapore.	ophwty@nus.edu.sg	Wong, Tien Yin/AAC-9724-2020	Wong, Tien Yin/0000-0002-8448-1264; Couper, David/0000-0002-4313-9235; Klein, Ronald/0000-0002-4428-6237	NEI NIH HHS [EY013939] Funding Source: Medline; NHLBI NIH HHS [N01-HC-35125, N01-HC-55019, N01-HC-55022, N01-HC-35126, N01-HC-55020, N01-HC-55015, N01-HC-55021, N01-HC-55016, N01-HC-55018] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055019, N01HC055015, N01HC055021, N01HC055022, N01HC035125, N01HC055016, N01HC055018, N01HC035126, N01HC055020] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R03EY013939] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AWAD IA, 1986, STROKE, V17, P1084, DOI 10.1161/01.STR.17.6.1084; BOTS ML, 1993, LANCET, V341, P1232, DOI 10.1016/0140-6736(93)91144-B; BRETELER MMB, 1994, NEUROLOGY, V44, P1246, DOI 10.1212/WNL.44.7.1246; Dufouil C, 2001, NEUROLOGY, V56, P921, DOI 10.1212/WNL.56.7.921; FAZEKAS F, 1993, NEUROLOGY, V43, P1683, DOI 10.1212/WNL.43.9.1683; FAZEKAS F, 1988, STROKE, V19, P1285, DOI 10.1161/01.STR.19.10.1285; Goldstein IB, 1998, STROKE, V29, P765, DOI 10.1161/01.STR.29.4.765; GOTO I, 1975, STROKE, V6, P263, DOI 10.1161/01.STR.6.3.263; HOSMER DW, 1989, APPL LOGISTIC REGRES; Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0; Klein R, 2000, ARTERIOSCL THROM VAS, V20, P1644, DOI 10.1161/01.ATV.20.6.1644; Kobayashi S, 1997, STROKE, V28, P1932, DOI 10.1161/01.STR.28.10.1932; KORBER N, 1986, J NEUROL, V233, P30, DOI 10.1007/BF00313988; Liao DP, 1997, NEUROEPIDEMIOLOGY, V16, P149, DOI 10.1159/000368814; Liao DP, 1996, STROKE, V27, P2262, DOI 10.1161/01.STR.27.12.2262; Longstreth WT, 1996, STROKE, V27, P1274, DOI 10.1161/01.STR.27.8.1274; Longstreth WT, 2001, ARCH NEUROL-CHICAGO, V58, P2074, DOI 10.1001/archneur.58.12.2074; Manolio TA, 1999, ARTERIOSCL THROM VAS, V19, P356, DOI 10.1161/01.ATV.19.2.356; MIYAO S, 1992, STROKE, V23, P1434, DOI 10.1161/01.STR.23.10.1434; Moody DM, 1997, ANN NY ACAD SCI, V826, P103, DOI 10.1111/j.1749-6632.1997.tb48464.x; *NAT HEART LUNG BL, 1988, ARIC MAN OP; Pantoni L, 1997, STROKE, V28, P652, DOI 10.1161/01.STR.28.3.652; PANTONI L, 1995, STROKE, V26, P1293, DOI 10.1161/01.STR.26.7.1293; Pantoni L, 1998, STROKE, V29, P543, DOI 10.1161/01.STR.29.2.543; Perros P, 1997, DIABETES CARE, V20, P1013, DOI 10.2337/diacare.20.6.1013; Rao VM, 1997, RADIOLOGY, V204, P443, DOI 10.1148/radiology.204.2.9240533; Rosamond WD, 1999, STROKE, V30, P736, DOI 10.1161/01.STR.30.4.736; SCHMIDT R, 1992, ARCH NEUROL-CHICAGO, V49, P825, DOI 10.1001/archneur.1992.00530320049011; SCHNEIDER R, 1993, STROKE, V24, P1874, DOI 10.1161/01.STR.24.12.1874; Sharrett AR, 1999, AM J EPIDEMIOL, V150, P263; STREIFLER JY, 1995, ARCH NEUROL-CHICAGO, V52, P21, DOI 10.1001/archneur.1995.00540250025008; TSO MOM, 1982, OPHTHALMOLOGY, V89, P1132; VANSWIETEN JC, 1991, ANN NEUROL, V30, P825, DOI 10.1002/ana.410300612; VANSWIETEN JC, 1992, ANN NEUROL, V32, P177, DOI 10.1002/ana.410320209; VANSWIETEN JC, 1991, BRAIN, V114, P761; WAHLUND LO, 1994, MAGN RESON IMAGING, V12, P387, DOI 10.1016/0730-725X(94)92531-3; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184; Wong TY, 2001, SURV OPHTHALMOL, V46, P59, DOI 10.1016/S0039-6257(01)00234-X; Wong TY, 2001, LANCET, V358, P1134, DOI 10.1016/S0140-6736(01)06253-5; YLIKOSKI A, 1995, STROKE, V26, P1171, DOI 10.1161/01.STR.26.7.1171	40	391	410	1	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	2002	288	1					67	74		10.1001/jama.288.1.67	http://dx.doi.org/10.1001/jama.288.1.67			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	568YW	12090864	Bronze			2022-12-28	WOS:000176573400021
J	Aiuti, A; Slavin, S; Aker, M; Ficara, F; Deola, S; Mortellaro, A; Morecki, S; Andolfi, G; Tabucchi, A; Carlucci, F; Marinello, E; Cattaneo, F; Vai, S; Servida, P; Miniero, R; Roncarolo, MG; Bordignon, C				Aiuti, A; Slavin, S; Aker, M; Ficara, F; Deola, S; Mortellaro, A; Morecki, S; Andolfi, G; Tabucchi, A; Carlucci, F; Marinello, E; Cattaneo, F; Vai, S; Servida, P; Miniero, R; Roncarolo, MG; Bordignon, C			Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning	SCIENCE			English	Article							ADENOSINE-DEAMINASE DEFICIENCY; SEVERE COMBINED IMMUNODEFICIENCY; PERIPHERAL-BLOOD LYMPHOCYTES; HUMAN CD34(+) CELLS; BONE-MARROW; TRANSPLANTATION; DISEASE	Hematopoietic stem cell (HSC) gene therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID) has shown limited clinical efficacy because of the small proportion of engrafted genetically corrected HSCs. We describe an improved protocol for gene transfer into HSCs associated with nonmyeloablative conditioning. This protocol was used in two patients for whom enzyme replacement therapy was not available, which allowed the effect of gene therapy alone to be evaluated. Sustained engraftment of engineered HSCs with differentiation into multiple lineages resulted in increased lymphocyte counts, improved immune functions (including antigen-specific responses), and lower toxic metabolites. Both patients are currently at home and clinically well, with normal growth and development. These results indicate the safety and efficacy of HSC gene therapy combined with nonmyeloablative conditioning for the treatment of SCID.	San Raffaele Telethon Inst Gene Therapy HSR TIGET, Milan, Italy; Hadassah Univ Hosp, Dept Bone Marrow Transplantat, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Pediat, IL-91120 Jerusalem, Israel; Univ Siena, Inst Biochem & Enzymol, I-53100 Siena, Italy; Univ Turin, Dept Biol & Clin Sci, Turin, Italy; Univ Vita Salute San Raffaele, Milan, Italy	Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Hebrew University of Jerusalem; Hebrew University of Jerusalem; University of Siena; University of Turin; Vita-Salute San Raffaele University	Bordignon, C (corresponding author), San Raffaele Telethon Inst Gene Therapy HSR TIGET, Milan, Italy.		Ficara, Francesca/M-4624-2016; Mortellaro, Alessandra/AAN-4678-2020; Deola, Sara/AAQ-7059-2020; Deola, Sara/AFT-5954-2022; AIUTI, ALESSANDRO/K-3918-2016	Ficara, Francesca/0000-0003-1873-1189; Mortellaro, Alessandra/0000-0003-1744-2430; Deola, Sara/0000-0002-3178-1271; Deola, Sara/0000-0002-3178-1271; AIUTI, ALESSANDRO/0000-0002-5398-1717; RONCAROLO, Maria Grazia/0000-0002-2193-9186	Telethon [TGT06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		Aiuti A, 2002, NAT MED, V8, P423, DOI 10.1038/nm0502-423; Aiuti A, 1999, BLOOD, V94, P62, DOI 10.1182/blood.V94.1.62.413k04_62_73; AIUTI A, UNPUB; BACCHETTA R, 1994, J EXP MED, V179, P493, DOI 10.1084/jem.179.2.493; Bauer TR, 2000, CURR OPIN MOL THER, V2, P383; BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; Bollinger ME, 1996, NEW ENGL J MED, V334, P1367, DOI 10.1056/NEJM199605233342104; BORDIGNON C, 1993, HUM GENE THER, V4, P513, DOI 10.1089/hum.1993.4.4-513; BORDIGNON C, 1995, SCIENCE, V270, P470, DOI 10.1126/science.270.5235.470; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Carlucci F, 2000, ELECTROPHORESIS, V21, P1552, DOI 10.1002/(SICI)1522-2683(20000501)21:8<1552::AID-ELPS1552>3.0.CO;2-M; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Dando JS, 2001, J GENE MED, V3, P219, DOI 10.1002/1521-2254(200105/06)3:3<219::AID-JGM184>3.0.CO;2-E; FICARA F, UNPUB; Hirschhorn R, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P121; HIRSCHHORN R, 1981, J CLIN INVEST, V68, P1387, DOI 10.1172/JCI110389; Hoogerbrugge PM, 1996, GENE THER, V3, P179; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; Kohn DB, 1998, NAT MED, V4, P775, DOI 10.1038/nm0798-775; Malech HL, 1997, P NATL ACAD SCI USA, V94, P12133, DOI 10.1073/pnas.94.22.12133; OCHS HD, 1992, BLOOD, V80, P1163; Rogers MH, 2001, J PEDIATR-US, V139, P44, DOI 10.1067/mpd.2001.115023; Roncarolo M G, 1996, Semin Immunol, V8, P207, DOI 10.1006/smim.1996.0026; Wack A, 1996, J IMMUNOL METHODS, V196, P181, DOI 10.1016/0022-1759(96)00114-7; Zhang LQ, 1999, J EXP MED, V190, P725, DOI 10.1084/jem.190.5.725	25	871	918	1	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 28	2002	296	5577					2410	2413		10.1126/science.1070104	http://dx.doi.org/10.1126/science.1070104			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	567CE	12089448				2022-12-28	WOS:000176467200047
J	Tikhonov, VI; Volkov, AA				Tikhonov, VI; Volkov, AA			Separation of water into its ortho and para isomers	SCIENCE			English	Article									Russian Acad Sci, Inst Gen Phys, Moscow, Russia	Russian Academy of Sciences; Prokhorov General Physics Institute of the Russian Academy of Sciences	Tikhonov, VI (corresponding author), Russian Acad Sci, Inst Gen Phys, Moscow, Russia.		Volkov, Alexander/H-9133-2018					BERG TGO, 1990, J CHIM PHYS PCB, V87, P497, DOI 10.1051/jcp/1990870497; Crovisier J, 1997, SCIENCE, V275, P1904, DOI 10.1126/science.275.5308.1904; MEIBOOM S, 1961, J CHEM PHYS, V34, P375, DOI 10.1063/1.1700960; VOLKOV AA, 1985, INFRARED PHYS, V25, P369, DOI 10.1016/0020-0891(85)90109-5; [No title captured]	5	147	169	1	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 28	2002	296	5577					2363	2363		10.1126/science.1069513	http://dx.doi.org/10.1126/science.1069513			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	567CE	12089435				2022-12-28	WOS:000176467200031
J	Baum, M; Buzdar, AU; Cuzick, J; Forbes, J; Houghton, J; Klijn, JGM; Sahmoud, T				Baum, M; Buzdar, AU; Cuzick, J; Forbes, J; Houghton, J; Klijn, JGM; Sahmoud, T		ATAC Trialists' Grp	Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial	LANCET			English	Article							FIRST-LINE THERAPY; ENDOMETRIAL CANCER; RISK; CARCINOMA; SUPERIOR; ARIMIDEX	Background In the adjuvant setting, tamoxifen is the established treatment for postmenopausal women with hormone-sensitive breast cancer. However, it is associated with several side-effects including endometrial cancer and thromboembolic disorders. We aimed to compare the safety and efficacy outcomes of tamoxifen with those of anastrozole alone and the combination of anastrozole plus tamoxifen for 5 years. Methods Participants were postmenopausal patients with invasive operable breast cancer who had completed primary therapy and were eligible to receive adjuvant hormonal therapy. The primary endpoints were disease-free survival and occurrence of adverse events. Analysis for efficacy was by intention to treat. Findings 9386 patients were recruited, of whom 3125 were randomly assigned anastrozole, 3116 tamoxifen, and 3125 combination. Median follow-up was 33.3 months. 7839 (84%) patients were known to be hormone-receptor-positive. Disease-free survival at 3 years was 89.4% on anastrozole and 87.4% on tamoxifen (hazard ratio 0.83 [95% CI 0.71-0.96], p=0.013). Results with the combination were not significantly different from those with tamoxifen alone (87.2%, 1.02 [0.89-1.18], p=0.8). The improvement in disease-free survival with anastrozole was seen in the subgroup of hormone-receptor-positive patients, but not the receptor-negative patients. Incidence of contralateral breast cancer was significantly lower with anastrozole than with tamoxifen (odds ratio 0.42 [0.22-0.79], p=0.007). Anastrozole was significantly better tolerated than tamoxifen with respect to endometrial cancer (p=0.02), vaginal bleeding and discharge (p<0.0001 for both), cerebrovascular events (p=0.0006), venous thromboembolic events (p=0.0006), and hot flushes (p<0.0001). Tamoxifen was significantly better tolerated than anastrozole with respect to musculoskeletal disorders and fractures (p<0.0001 for both). Interpretation Anastrozole is an effective and well tolerated endocrine option for the treatment of postmenopausal patients with hormone-sensitive early breast cancer. Longer follow-up is required before a final benefit:risk assessment can be made.	Canc Res UK, ATAC Secretariat, London NW1 2ND, England; UCL Canc Trials Ctr, London NW1 2ND, England	Cancer Research UK; University of London; University College London; University of London; University College London	Baum, M (corresponding author), Canc Res UK, ATAC Secretariat, Stephenson House,158-160 N Gower St, London NW1 2ND, England.		WILLIAMS, Norman/C-2002-2008	WILLIAMS, Norman/0000-0001-6496-312X				*AM COLL OBST GYN, 2000, OBSTET GYNECOL, V95, pC1; Andrykowski MA, 1999, J PAIN SYMPTOM MANAG, V18, P85, DOI 10.1016/S0885-3924(99)00053-6; BAUM M, 1983, LANCET, V1, P257; Baum M, 2001, BRIT J CANCER, V85, P317, DOI 10.1054/bjoc.2001.1925; Bergman L, 2000, LANCET, V356, P881, DOI 10.1016/S0140-6736(00)02677-5; Bernstein L, 1999, J NATL CANCER I, V91, P1654, DOI 10.1093/jnci/91.19.1654; BISSETT D, 1994, LANCET, V344, P1244, DOI 10.1016/S0140-6736(94)90747-1; Bonneterre J, 2000, J CLIN ONCOL, V18, P3748, DOI 10.1200/JCO.2000.18.22.3748; Bonneterre J, 2001, CANCER, V92, P2247, DOI 10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y; Buzdar AU, 1998, CANCER-AM CANCER SOC, V83, P1142, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1142::AID-CNCR13>3.3.CO;2-7; Clarke M, 1998, LANCET, V351, P1451; CUTULI BF, 1994, ONCOL REP, V1, P59; Cuzick J, 2000, BREAST CANCER RES, V2, P258, DOI 10.1186/bcr66; CUZICK J, 1985, LANCET, V2, P282; DEWAR J, 2001, EUR J CANC S5, V37, P5; Donnellan PP, 2001, J CLIN ONCOL, V19, P2767; *EARL BREAST CANC, 1992, LANCET, V339, P1; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; Geisler J, 1996, BRIT J CANCER, V74, P1286, DOI 10.1038/bjc.1996.531; Howell A, 1997, BRIT MED J, V315, P863, DOI 10.1136/bmj.315.7112.863; LOPRINZI CL, 1993, J CLIN ONCOL, V11, P768, DOI 10.1200/JCO.1993.11.4.768; LOVE RR, 1994, ARCH INTERN MED, V154, P2585, DOI 10.1001/archinte.154.22.2585; Meier CR, 1998, BRIT J CLIN PHARMACO, V45, P608, DOI 10.1046/j.1365-2125.1998.00733.x; Nabholtz JM, 2000, J CLIN ONCOL, V18, P3758, DOI 10.1200/JCO.2000.18.22.3758; Rutqvist LE, 1996, J NATL CANCER I, V88, P1543; SANTEN RJ, 1990, ENDOCR REV, V11, P221, DOI 10.1210/edrv-11-2-221; Van Poznak C, 2001, SEMIN ONCOL, V28, P69, DOI 10.1053/sonc.2001.25445; Wluka A, 2000, MATURITAS, V35, P183, DOI 10.1016/S0378-5122(00)00118-3	28	1505	1553	1	59	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 22	2002	359	9324					2131	2139						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566RJ	12090977				2022-12-28	WOS:000176441800006
J	Li, X; Perissi, V; Liu, F; Rose, DW; Rosenfeld, MG				Li, X; Perissi, V; Liu, F; Rose, DW; Rosenfeld, MG			Tissue-specific regulation of retinal and pituitary precursor cell proliferation	SCIENCE			English	Article							HISTONE DEACETYLASE COMPLEX; TUMOR-SUPPRESSOR; HOMEOBOX GENE; MICE LACKING; EYES; PROTEINS; DIFFERENTIATION; HYPERPLASIA; COMPONENT; HOMOLOGS	Mammalian organogenesis requires the expansion of pluripotent precursor cells before the subsequent determination of specific cell types, but the tissue-specific molecular mechanisms that regulate the initial expansion of primordial cells remain poorly defined. We have genetically established that Six6 homeodomain factor, acting as a strong tissue-specific repressor, regulates early progenitor cell proliferation during mammalian retinogenesis and pituitary development. Six6, in association with Dach corepressors, regulates proliferation by directly repressing cyclin-dependent kinase inhibitors, including the p27Kip1 promoter. These data reveal a molecular mechanism by which a tissue-specific transcriptional repressor-corepressor complex can provide an organ-specific strategy for physiological expansion of precursor populations.	Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, Dept Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Endocrinol & Metab, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Rosenfeld, MG (corresponding author), Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, Dept Mol Med, 9500 Gilman Dr,Room 345, La Jolla, CA 92093 USA.	mrosenfeld@ucsd.edu		Perissi, Valentina/0000-0002-3716-0003	NIDDK NIH HHS [5F32DK09814] Funding Source: Medline; Telethon [484/B] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009814] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; Cepko CL, 1999, CURR OPIN NEUROBIOL, V9, P37, DOI 10.1016/S0959-4388(99)80005-1; Chen R, 1997, CELL, V91, P893, DOI 10.1016/S0092-8674(00)80481-X; CHEYETTE BNR, 1994, NEURON, V12, P977, DOI 10.1016/0896-6273(94)90308-5; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Gallardo ME, 1999, GENOMICS, V61, P82, DOI 10.1006/geno.1999.5916; Hazbun TR, 1997, BIOCHEMISTRY-US, V36, P3680, DOI 10.1021/bi9625206; Heanue TA, 1999, GENE DEV, V13, P3231, DOI 10.1101/gad.13.24.3231; Jean D, 1999, MECH DEVELOP, V84, P31, DOI 10.1016/S0925-4773(99)00068-4; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; Levine EM, 2000, DEV BIOL, V219, P299, DOI 10.1006/dbio.2000.9622; Marquardt T, 2001, CELL, V105, P43, DOI 10.1016/S0092-8674(01)00295-1; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Oliver G, 1995, DEVELOPMENT, V121, P4045; Perron M, 2000, CELL MOL LIFE SCI, V57, P215, DOI 10.1007/PL00000685; Pignoni F, 1997, CELL, V91, P881, DOI 10.1016/S0092-8674(00)80480-8; QUELLE DE, 1995, CELL, V83, P993; Shinagawa T, 2000, EMBO J, V19, P2280, DOI 10.1093/emboj/19.10.2280; Sidman RL, 1961, STRUCTURE EYE, P487; Xu PX, 1997, P NATL ACAD SCI USA, V94, P11974, DOI 10.1073/pnas.94.22.11974; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215; Zimmerman JE, 1997, GENOME RES, V7, P128, DOI 10.1101/gr.7.2.128; Zuber ME, 1999, CELL, V98, P341, DOI 10.1016/S0092-8674(00)81963-7	25	219	230	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 16	2002	297	5584					1180	1183						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	584BP	12130660				2022-12-28	WOS:000177447600050
J	Beral, V; Bull, D; Doll, R; Peto, R; Reeves, G; La Vecchia, C; Magnusson, C; Miller, T; Peterson, B; Pike, M; Thomas, D; van Leeuwen, F				Beral, V; Bull, D; Doll, R; Peto, R; Reeves, G; La Vecchia, C; Magnusson, C; Miller, T; Peterson, B; Pike, M; Thomas, D; van Leeuwen, F		Collaborative Group on Hormonal Factors in Breast Cancer	Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50 302 women with breast cancer and 96 973 women without the disease	LANCET			English	Article							ORAL-CONTRACEPTIVE USE; FULL-TERM PREGNANCY; RISK-FACTORS; REPRODUCTIVE FACTORS; LACTATION HISTORY; REDUCED RISK; AGE; ASSOCIATION; EXPERIENCE; FERTILITY	Background Although childbearing is known to protect against breast cancer, whether or not breastfeeding contributes to this protective effect is unclear. Methods Individual data from 47 epidemiological studies in 30 countries that included information on breastfeeding patterns and other aspects of childbearing were collected, checked, and analysed centrally, for 50 302 women with invasive breast cancer and 96 973 controls. Estimates of the relative risk for breast cancer associated with breastfeeding in parous women were obtained after stratification by fine divisions of age, parity, and women's ages when their first child was born, as well as by study and menopausal status. Findings Women with breast cancer had, on average, fewer births than did controls (2.2 vs 2.6). Furthermore, fewer parous women with cancer than parous controls had ever breastfed (71% vs 79%), and their average lifetime duration of breastfeeding was shorter (9.8 vs 15.6 months). The relative risk of breast cancer decreased by 4.3% (95% Cl 2.9-5.8; p<0.0001) for every 12 months of breastfeeding in addition to a decrease of 7.0% (5.0-9.0; p<0.0001) for each birth. The size of the decline in the relative risk of breast cancer associated with breastfeeding did not differ significantly for women in developed and developing countries, and did not vary significantly by age, menopausal status, ethnic origin, the number of births a woman had, her age when her first child was born, or any of nine other personal characteristics examined. It is estimated that the cumulative incidence of breast cancer in developed countries would be reduced by more than half, from 6.3 to 2.7 per 100 women by age 70, if women had the average number of births and lifetime duration of breastfeeding that had been prevalent in developing countries until recently. Breastfeeding could account for almost two-thirds of this estimated reduction in breast cancer incidence. Interpretation The longer women breast feed the more they are protected against breast cancer. The lack of or short lifetime duration of breastfeeding typical of women in developed countries makes a major contribution to the high incidence of breast cancer in these countries.	Radcliffe Infirm, Epidemiol Unit, Oxford OX2 6HE, England	Radcliffe Infirmary	Beral, V (corresponding author), Radcliffe Infirm, Epidemiol Unit, Gibson Bldg, Oxford OX2 6HE, England.		Zheng, Wei/O-3351-2013	Zheng, Wei/0000-0003-1226-070X; Bishop, Tim/0000-0002-8752-8785; Magnusson, Cecilia/0000-0002-8567-6725; Olsson, Hakan/0000-0002-8794-9635; Rosero-Bixby, Luis/0000-0002-3063-3111	Medical Research Council [MC_U137686851] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Beral V, 2001, LANCET, V358, P1389, DOI 10.1016/S0140-6736(01)06524-2; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; BRINTON LA, 1995, J NATL CANCER I, V87, P827, DOI 10.1093/jnci/87.11.827; Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; Calle EE, 1996, CONTRACEPTION, V54, pS1; Chang-Claude J, 2000, CANCER CAUSE CONTROL, V11, P687, DOI 10.1023/A:1008907901087; CHILVERS C, 1989, LANCET, V1, P973; CHO LJ, 1964, DEMOGRAPHY, V1, P359, DOI 10.2307/2060058; CLAVEL F, 1991, INT J EPIDEMIOL, V20, P32, DOI 10.1093/ije/20.1.32; Coogan PF, 1999, CANCER-AM CANCER SOC, V86, P982, DOI 10.1002/(SICI)1097-0142(19990915)86:6&lt;982::AID-CNCR13&gt;3.0.CO;2-B; EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703; Enger SM, 1998, CANCER EPIDEM BIOMAR, V7, P365; Enger SM, 1997, BRIT J CANCER, V76, P118, DOI 10.1038/bjc.1997.346; EWERTZ M, 1988, BRIT J CANCER, V58, P99, DOI 10.1038/bjc.1988.172; FERRARONI M, 1993, INT J EPIDEMIOL, V22, P772, DOI 10.1093/ije/22.5.772; Freudenheim JL, 1997, AM J EPIDEMIOL, V146, P932, DOI 10.1093/oxfordjournals.aje.a009219; Furberg H, 1999, INT J EPIDEMIOL, V28, P396, DOI 10.1093/ije/28.3.396; GAJALAKSHMI V, 2000, ASIAN PACIFIC J CA S, V1, P39; Gao YT, 2000, INT J CANCER, V87, P295, DOI 10.1002/1097-0215(20000715)87:2<295::AID-IJC23>3.0.CO;2-7; Gilliland FD, 1998, AM J EPIDEMIOL, V148, P683, DOI 10.1093/aje/148.7.683; Hirose K, 1999, JPN J CANCER RES, V90, P255, DOI 10.1111/j.1349-7006.1999.tb00741.x; HOPPER JL, 1999, MONOGR NATL CANC I, V26, P95; HUTTLY SRA, 1990, AM J EPIDEMIOL, V132, P572, DOI 10.1093/oxfordjournals.aje.a115693; KALACHE A, 1993, LANCET, V341, P33, DOI 10.1016/0140-6736(93)92497-H; LAND CE, 1994, CANCER CAUSE CONTROL, V5, P167, DOI 10.1007/BF01830263; LANECLAYPON JE, 1926, 32 MIN HLTH PUBL HLT; LAVECCHIA C, 1995, INT J CANCER, V60, P163, DOI 10.1002/ijc.2910600205; LAYDE PM, 1989, J CLIN EPIDEMIOL, V42, P963, DOI 10.1016/0895-4356(89)90161-3; LE MG, 1984, HORMONES SEXUAL FACT; LEE HP, 1992, CANCER CAUSE CONTROL, V3, P313, DOI 10.1007/BF00146884; Levi F, 1996, EUR J CANCER, V32A, P2108, DOI 10.1016/S0959-8049(96)00229-8; LIPWORTH L, 1995, INT J CANCER, V62, P548, DOI 10.1002/ijc.2910620510; LUBIN F, 1986, JNCI-J NATL CANCER I, V77, P605, DOI 10.1093/jnci/77.3.605; Magnusson C, 1999, INT J CANCER, V81, P339, DOI 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.3.CO;2-Y; McCredie MRE, 1998, CANCER CAUSE CONTROL, V9, P189, DOI 10.1023/A:1008886328352; MCPHERSON K, 1987, BRIT J CANCER, V56, P653, DOI 10.1038/bjc.1987.261; MEIRIK O, 1986, LANCET, V2, P650; Michels KB, 1996, LANCET, V347, P431, DOI 10.1016/S0140-6736(96)90010-0; MORABIA A, 1993, PREV MED, V22, P178, DOI 10.1006/pmed.1993.1015; NEWCOMB PA, 1994, NEW ENGL J MED, V330, P81, DOI 10.1056/NEJM199401133300201; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Parkin DM, 1997, CANC INCIDENCE 5 CON, VVII; PAUL C, 1990, INT J CANCER, V46, P366, DOI 10.1002/ijc.2910460305; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; ROHAN TE, 1988, MED J AUSTRALIA, V149, P520, DOI 10.5694/j.1326-5377.1988.tb120759.x; Romieu I, 1996, AM J EPIDEMIOL, V143, P543, DOI 10.1093/oxfordjournals.aje.a008784; ROOKUS MA, 1994, LANCET, V344, P844, DOI 10.1016/S0140-6736(94)92826-6; ROSEROBIXBY L, 1989, J BIOSOC SCI, V21, P419, DOI 10.1017/S0021932000018150; Rossing MA, 1996, AM J EPIDEMIOL, V144, P161, DOI 10.1093/oxfordjournals.aje.a008903; SISKIND V, 1989, AM J EPIDEMIOL, V130, P229; Stuver SO, 1997, INT J CANCER, V71, P166, DOI 10.1002/(SICI)1097-0215(19970410)71:2<166::AID-IJC7>3.0.CO;2-Z; The Million Women Study Collaborative Group, 1999, BREAST CANCER RES, V1, P73, DOI DOI 10.1186/BCR16; THOMAS DB, 1993, INT J EPIDEMIOL, V22, P619, DOI 10.1093/ije/22.4.619; Thomas DB, 1997, JNCI-J NATL CANCER I, V89, P355, DOI 10.1093/jnci/89.5.355; Thomas HV, 1997, J NATL CANCER I, V89, P396, DOI 10.1093/jnci/89.5.396; Tryggvadottir L, 2001, AM J EPIDEMIOL, V154, P37, DOI 10.1093/aje/154.1.37; VESSEY M, 1983, BRIT J CANCER, V47, P455, DOI 10.1038/bjc.1983.74; Victora CG, 2000, LANCET, V355, P451, DOI 10.1016/S0140-6736(00)82011-5; Viladiu P, 1996, EUR J CANCER PREV, V5, P329, DOI 10.1097/00008469-199610000-00004; Wainwright JM, 1931, AM J CANCER, V15, P10; WANG QS, 1992, CANCER EPIDEM BIOMAR, V1, P435; WEINSTEIN AL, 1991, EPIDEMIOLOGY, V2, P353, DOI 10.1097/00001648-199109000-00007; WHITE E, 1994, JNCI-J NATL CANCER I, V86, P505, DOI 10.1093/jnci/86.7.505; YANG CP, 1992, CANCER CAUSE CONTROL, V3, P475, DOI 10.1007/BF00051360; YUAN JM, 1988, CANCER RES, V48, P1949; Zheng TZ, 2000, AM J EPIDEMIOL, V152, P1129, DOI 10.1093/aje/152.12.1129; 1999, DEMOGRAPHIC HLTH SUR; 1998, 28 MACR INT	68	874	902	1	68	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 20	2002	360	9328					187	195		10.1016/S0140-6736(02)09454-0	http://dx.doi.org/10.1016/S0140-6736(02)09454-0			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	576DX	12133652				2022-12-28	WOS:000176988500007
J	Yayanos, AA				Yayanos, AA			Are cells viable at gigapascal pressures?	SCIENCE			English	Editorial Material							FORMATE DEHYDROGENASE; BAROPHILIC BACTERIA; DEEP		Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography	Yayanos, AA (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA.		Fogel, Marilyn L/M-2395-2015	Fogel, Marilyn L/0000-0002-1176-3818				BROCK TD, 1994, BIOL MICROORGANISMS, P325; HEDEN CG, 1964, BACTERIOL REV, V28, P14; Hill M.N., 1957, PHYS CHEM EARTH, V2, P129, DOI [10.1016/0079-1946(57)90008-3, DOI 10.1016/0079-1946(57)90008-3]; Hite B. H., 1914, B W VIRGINIA U AGR E, V146, P1; Kato C, 1998, APPL ENVIRON MICROB, V64, P1510; KROGER A, 1980, BIOCHIM BIOPHYS ACTA, V589, P118, DOI 10.1016/0005-2728(80)90136-X; LUDWIG H, 1999, ADV HIGH PRESSURE BI; Quirk DJ, 2001, BIOCHEMISTRY-US, V40, P847, DOI 10.1021/bi001991w; Ritz M, 2001, APPL ENVIRON MICROB, V67, P2240, DOI 10.1128/AEM.67.5.2240-2247.2001; Sharma A, 2002, SCIENCE, V295, P1514, DOI 10.1126/science.1068018; YAYANOS AA, 1986, P NATL ACAD SCI USA, V83, P9542, DOI 10.1073/pnas.83.24.9542; YAYANOS AA, 2000, ENCY MICROBIOLOGY, V2, P664	12	15	16	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 19	2002	297	5580												1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574LV	12130751				2022-12-28	WOS:000176892600001
J	Stracker, TH; Carson, CT; Weitzman, MD				Stracker, TH; Carson, CT; Weitzman, MD			Adenovirus oncoproteins inactivate the Mre11-Rad50-NBS1 DNA repair complex	NATURE			English	Article							NIJMEGEN BREAKAGE SYNDROME; LATE GENE-EXPRESSION; EARLY REGION-4; PROTEIN COMPLEX; DAMAGE RESPONSE; REPLICATION; MRE11; TELOMERES; PHOSPHORYLATION; DELETION	In mammalian cells, a conserved multiprotein complex of Mre11, Rad50 and NBS1 (also known as nibrin and p95) is important for double-strand break repair, meiotic recombination and telomere maintenance(1-4). This complex forms nuclear foci and may be a sensor of double-strand breaks. In the absence of the early region E4, the double-stranded DNA genome of adenovirus is joined into concatemers too large to be packaged(5,6). We have investigated the cellular proteins involved in this concatemer formation and how they are inactivated by E4 products during a wild-type infection. Here we show that concatemerization requires functional Mre11 and NBS1, and that these proteins are found at foci adjacent to viral replication centres. Infection with wild-type virus results in both reorganization and degradation of members of the Mre11-Rad50-NBS1 complex. These activities are mediated by three viral oncoproteins that prevent concatemerization. This targeting of cellular proteins involved in genomic stability suggests a mechanism for 'hit-and-run' transformation observed for these viral oncoproteins(7).	Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Biol, Grad Program, San Diego, CA 92093 USA	Salk Institute; University of California System; University of California San Diego	Weitzman, MD (corresponding author), Salk Inst Biol Studies, Genet Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Stracker, Travis H/I-2815-2015	Stracker, Travis H/0000-0002-8650-2081				Boyer J, 1999, VIROLOGY, V263, P307, DOI 10.1006/viro.1999.9866; Bressan DA, 1998, GENETICS, V150, P591; BRIDGE E, 1989, J VIROL, V63, P631, DOI 10.1128/JVI.63.2.631-638.1989; BRIDGE E, 1990, VIROLOGY, V174; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Cathomen T, 2000, J VIROL, V74, P11407, DOI 10.1128/JVI.74.23.11407-11412.2000; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Haber JE, 1997, CELL, V89, P163, DOI 10.1016/S0092-8674(00)80194-4; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; Lombard DB, 2000, CANCER RES, V60, P2331; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; Moreau S, 1999, MOL CELL BIOL, V19, P556; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Nevels M, 2001, J VIROL, V75, P3089, DOI 10.1128/JVI.75.7.3089-3094.2001; Petrini JHJ, 1999, AM J HUM GENET, V64, P1264, DOI 10.1086/302391; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; WEIDEN MD, 1994, P NATL ACAD SCI USA, V91, P153, DOI 10.1073/pnas.91.1.153; WEINBERG DH, 1986, J VIROL, V57, P833, DOI 10.1128/JVI.57.3.833-838.1986; WEINBERG DH, 1983, P NATL ACAD SCI-BIOL, V80, P5383, DOI 10.1073/pnas.80.17.5383; Weitzman MD, 1996, J VIROL, V70, P1845, DOI 10.1128/JVI.70.3.1845-1854.1996; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	29	416	422	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 18	2002	418	6895					348	352		10.1038/nature00863	http://dx.doi.org/10.1038/nature00863			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574BF	12124628				2022-12-28	WOS:000176868000048
J	Rossouw, JE; Anderson, GL; Prentice, RL; LaCroix, AZ; Kooperberg, C; Stefanick, ML; Jackson, RD; Beresford, SAA; Howard, BV; Johnson, KC; Kotchen, JM; Ockene, J				Rossouw, JE; Anderson, GL; Prentice, RL; LaCroix, AZ; Kooperberg, C; Stefanick, ML; Jackson, RD; Beresford, SAA; Howard, BV; Johnson, KC; Kotchen, JM; Ockene, J			Risks and benefits of estrogen plus progestin in healthy postmenopausal women - Principal results from the Women's Health Initiative randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE REPLACEMENT THERAPY; BREAST-CANCER RISK; CORONARY-ARTERY ATHEROSCLEROSIS; CARDIOVASCULAR-DISEASE; SECONDARY PREVENTION; HEART-DISEASE; METAANALYSIS; EVENTS; ASSOCIATION; FRACTURES	Context Despite decades of accumulated observational evidence, the balance of risks and benefits for hormone use in healthy postmenopausal women remains uncertain. Objective To assess the major health benefits and risks of the most commonly used combined hormone preparation in the United States. Design Estrogen plus progestin component of the Women's Health Initiative, a randomized controlled primary prevention trial (planned duration, 8.5 years) in which 16608 postmenopausal women aged 50-79 years with an intact uterus at baseline were recruited by 40 US clinical centers in 1993-1998. Interventions Participants received conjugated equine estrogens, 0.625 mg/d, plus medroxylprogesterone acetate, 2.5 mg/d, in 1 tablet (n = 8506) or placebo (n = 8102). Main Outcomes Measures The primary outcome was coronary heart disease (CHD) (nonfatal myocardial infarction and CHD death), with invasive breast cancer as the primary adverse outcome. A global index summarizing the balance of risks and benefits included the 2 primary outcomes plus stroke, pulmonary embolism (PE), endometrial cancer, colorectal cancer, hip fracture, and death due to other causes. Results On May 31, 2002, after a mean of 5.2 years of follow-up, the data and safety monitoring board recommended stopping the trial of estrogen plus progestin vs placebo because the test statistic for invasive breast cancer exceeded the stopping boundary for this adverse effect and the global index statistic supported risks exceeding benefits. This report includes data on the major clinical outcomes through April 30, 2002. Estimated hazard ratios (HRs) (nominal 95% confidence intervals [Cis]) were as follows: CHD, 1.29 (1.02-1.63) with 286 cases; breast cancer, 1.26 (1.00-1.59) with 290 cases; stroke, 1.41 (1.07-1.85) with 212 cases; PE, 2.13 (1.39-3.25) with 101 cases; colorectal cancer, 0.63 (0.43-0.92) with 112 cases; endometrial cancer, 0.83 (0.47-1.47) with 47 cases; hip fracture, 0.66 (0.45-0.98) with 106 cases; and death due to other causes, 0.92 (0.74-1.14) with 331 cases, Corresponding HRs (nominal 95% Cis) for composite outcomes were 1.22 (1.09-1.36) for total cardiovascular disease (arterial and venous disease), 1,03 (0.90-1.17) for total cancer, 0.76 (0.69-0.85) for combined fractures, 0.98 (0.82-1.18) for total mortality, and 1.15 (1.03-1.28) for the global index. Absolute excess risks per 10000 person-years attributable to estrogen plus progestin were 7 more CHD events, 8 more strokes, 8 more PEs, and 8 more invasive breast cancers, while absolute risk reductions per 10000 1 person-years were 6 fewer colorectal cancers and 5 fewer hip fractures. The absolute excess risk of events included in the global index was 19 per 10000 person-years. Conclusions Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women. All-cause mortality was not affected during the trial. The risk-benefit profile found in this trial is not consistent with the requirements for a viable intervention for primary prevention of chronic diseases, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.	NHLBI, Div Womens Hlth Initiat, Bethesda, MD 20817 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Stanford Univ, Ctr Clin, Stanford, CA 94305 USA; Ohio State Univ, Ctr Clin, Columbus, OH 43210 USA; MedStar Res Inst, Washington, DC USA; Univ Tennessee, Memphis, TN USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA; Univ Massachusetts, Sch Med, Worcester, MA USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Fred Hutchinson Cancer Center; Stanford University; University System of Ohio; Ohio State University; University of Tennessee System; University of Tennessee Health Science Center; Medical College of Wisconsin; University of Massachusetts System; University of Massachusetts Worcester	Rossouw, JE (corresponding author), NHLBI, Div Womens Hlth Initiat, 6705 Rockledge Dr,1 Rockledge Ctr,Suite 300,MS-79, Bethesda, MD 20817 USA.	rossouw@nih.gov						ADAMS MR, 1990, ARTERIOSCLEROSIS, V10, P1051, DOI 10.1161/01.ATV.10.6.1051; Alexander KP, 2001, J AM COLL CARDIOL, V38, P1, DOI 10.1016/S0735-1097(01)01329-8; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Angerer P, 2001, ARTERIOSCL THROM VAS, V21, P262, DOI 10.1161/01.ATV.21.2.262; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Castellsague J, 1998, DRUG SAFETY, V18, P117, DOI 10.2165/00002018-199818020-00003; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; COX DR, 1972, J R STAT SOC B, V34, P187; DEGERHARDSSON VM, 1992, CANCER CAUSE CONTROL, V3, P355; Freedman L, 1996, CONTROL CLIN TRIALS, V17, P509, DOI 10.1016/S0197-2456(96)00016-5; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; GENANT HK, 1990, OBSTET GYNECOL, V76, P579; Grady D, 2000, ANN INTERN MED, V132, P689, DOI 10.7326/0003-4819-132-9-200005020-00002; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Greendale GA, 1999, ANN INTERN MED, V130, P262, DOI 10.7326/0003-4819-130-4_Part_1-199902160-00003; Grodstein F, 1999, AM J MED, V106, P574, DOI 10.1016/S0002-9343(99)00063-7; Grodstein F, 2001, ANN INTERN MED, V135, P1, DOI 10.7326/0003-4819-135-1-200107030-00003; Grodstein F, 2000, ANN INTERN MED, V133, P933, DOI 10.7326/0003-4819-133-12-200012190-00008; Heckbert SR, 2001, ARCH INTERN MED, V161, P1709, DOI 10.1001/archinte.161.14.1709; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Hodis HN, 2001, ANN INTERN MED, V135, P939, DOI 10.7326/0003-4819-135-11-200112040-00005; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; IVES DG, 1995, ANN EPIDEMIOL, V5, P275; Judd HL, 1996, JAMA-J AM MED ASSOC, V275, P370, DOI 10.1001/jama.1996.03530290040035; Magnusson C, 1999, INT J CANCER, V81, P339, DOI 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.3.CO;2-Y; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Mosca L, 2001, CIRCULATION, V104, P499, DOI 10.1161/hc2901.092200; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Pilon D, 2001, OBSTET GYNECOL, V97, P97, DOI 10.1016/S0029-7844(00)01104-2; RIJPKEMA AHM, 1990, MATURITAS, V12, P259, DOI 10.1016/0378-5122(90)90007-S; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; Schulman SP, 2002, J AM COLL CARDIOL, V39, P231, DOI 10.1016/S0735-1097(01)01724-7; Simon JA, 2001, CIRCULATION, V103, P638, DOI 10.1161/01.cir.103.5.638; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; Stephenson J, 1996, JAMA-J AM MED ASSOC, V275, P1389, DOI 10.1001/jama.275.18.1389; Torgerson DJ, 2001, JAMA-J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891; Vickers MR, 1995, CIBA F SYMP, V191, P150; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102	43	11433	11914	20	1225	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	2002	288	3					321	333		10.1001/jama.288.3.321	http://dx.doi.org/10.1001/jama.288.3.321			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573AK	12117397	Bronze, Green Published			2022-12-28	WOS:000176807000024
J	Jensen, T; van de Bildt, M; Dietz, HH; Andersen, TH; Hammer, AS; Kuiken, T; Osterhaus, A				Jensen, T; van de Bildt, M; Dietz, HH; Andersen, TH; Hammer, AS; Kuiken, T; Osterhaus, A			Another phocine distemper outbreak in Europe	SCIENCE			English	Article							VIRUS		Seal Rehabil & Res Ctr, NL-9968 AG Pieterburen, Netherlands; Danish Vet Inst, DK-8200 Aarhus N, Denmark; Erasmus MC, Inst Virol, NL-3015 GE Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Jensen, T (corresponding author), Seal Rehabil & Res Ctr, Hoofdstr 94A, NL-9968 AG Pieterburen, Netherlands.			Osterhaus, Albert/0000-0002-6074-1172				BARRETT T, 1993, VIROLOGY, V193, P1010, DOI 10.1006/viro.1993.1217; COSBY SL, 1988, NATURE, V336, P115, DOI 10.1038/336115b0; DIETZ R, 1989, AMBIO, V18, P258; GRENFELL BT, 1992, SCI TOTAL ENVIRON, V115, P15, DOI 10.1016/0048-9697(92)90029-R; OSTERHAUS ADME, 1988, NATURE, V335, P20, DOI 10.1038/335020a0; OSTERHAUS ADME, 1989, NATURE, V337, P21, DOI 10.1038/337021a0; REINEKING B, 2002, COMMON WADDEN S 0619; TOUGAARD S, 2000, WADDEN SEA NEWSL, P29	8	119	126	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 12	2002	297	5579					209	209		10.1126/science.1075343	http://dx.doi.org/10.1126/science.1075343			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571UT	12114617	Green Submitted			2022-12-28	WOS:000176738100030
J	Koutavas, A; Lynch-Stieglitz, J; Marchitto, TM; Sachs, JP				Koutavas, A; Lynch-Stieglitz, J; Marchitto, TM; Sachs, JP			El Nino-like pattern in ice age tropical Pacific sea surface temperature	SCIENCE			English	Article							LAST GLACIAL MAXIMUM; OXYGEN ISOTOPIC COMPOSITION; SOUTH CHINA SEA; PLANKTONIC-FORAMINIFERA; EQUATORIAL PACIFIC; LATE PLEISTOCENE; CLIMATE-CHANGE; RAPID CHANGES; GREENLAND; VARIABILITY	Sea surface temperatures (SSTs) in the cold tongue of the eastern equatorial Pacific exert powerful controls on global atmospheric circulation patterns. We examined climate variability in this region from the Last Glacial Maximum (LGM) to the present, using a SST record reconstructed from magnesium/calcium ratios in foraminifera from sea-floor sediments near the Galapagos Islands. Cold-tongue SST varied coherently with precession-induced changes in seasonality during the past 30,000 years. Observed LGM cooling of just 1.2degrees C implies a relaxation of tropical temperature gradients, weakened Hadley and Walker circulation, southward shift of the Intertropical Convergence Zone, and a persistent El Nino like pattern in the tropical Pacific. This is contrasted with mid-Holocene cooling suggestive of a La Nina like pattern with enhanced SST gradients and strengthened trade winds. Our results support a potent role for altered tropical Pacific SST gradients in global climate variations.	Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; Columbia Univ, Dept Earth & Environm Sci, Palisades, NY 10964 USA; MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA	Columbia University; Columbia University; Massachusetts Institute of Technology (MIT)	Koutavas, A (corresponding author), Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA.		Lynch-Stieglitz, Jean/J-2277-2018	Lynch-Stieglitz, Jean/0000-0002-9353-1972				Andrus CFT, 2002, SCIENCE, V295, P1508, DOI 10.1126/science.1062004; Baker PA, 2001, NATURE, V409, P698, DOI 10.1038/35055524; Beaufort L, 2001, SCIENCE, V293, P2440, DOI 10.1126/science.293.5539.2440; Bemis BE, 1998, PALEOCEANOGRAPHY, V13, P150, DOI 10.1029/98PA00070; Blunier T, 2001, SCIENCE, V291, P109, DOI 10.1126/science.291.5501.109; Brook EJ, 2000, GLOBAL BIOGEOCHEM CY, V14, P559, DOI 10.1029/1999GB001182; Chappellaz J, 1997, J GEOPHYS RES-ATMOS, V102, P15987, DOI 10.1029/97JD01017; CLAPPERTON CM, 1993, PALAEOGEOGR PALAEOCL, V101, P189, DOI 10.1016/0031-0182(93)90012-8; Clement AC, 1999, PALEOCEANOGRAPHY, V14, P441, DOI 10.1029/1999PA900013; Clement AC, 2000, PALEOCEANOGRAPHY, V15, P731, DOI 10.1029/1999PA000466; Elderfield H, 2000, NATURE, V405, P442, DOI 10.1038/35013033; FAIRBANKS RG, 1982, NATURE, V298, P841, DOI 10.1038/298841a0; Fedorov AV, 2000, SCIENCE, V288, P1997, DOI 10.1126/science.288.5473.1997; Grootes PM, 1997, J GEOPHYS RES-OCEANS, V102, P26455, DOI 10.1029/97JC00880; Harrison S.P, 1984, GEOPHYS MONOGR SER, V29, P118; Joussaume S, 1999, GEOPHYS RES LETT, V26, P859, DOI 10.1029/1999GL900126; Kienast M, 2001, SCIENCE, V291, P2132, DOI 10.1126/science.1057131; Kitagawa H, 1998, RADIOCARBON, V40, P505; KUTZBACH JE, 1988, SCIENCE, V241, P1043, DOI 10.1126/science.241.4869.1043; Lea DW, 2000, SCIENCE, V289, P1719, DOI 10.1126/science.289.5485.1719; Levitus S., 1994, WORLD OCEAN ATLAS 19, V4; Mayle FE, 2000, SCIENCE, V290, P2291, DOI 10.1126/science.290.5500.2291; Mix AC, 1999, PALEOCEANOGRAPHY, V14, P350, DOI 10.1029/1999PA900012; Nurnberg D, 1996, GEOCHIM COSMOCHIM AC, V60, P803, DOI 10.1016/0016-7037(95)00446-7; Pelejero C, 1999, PALEOCEANOGRAPHY, V14, P224, DOI 10.1029/1998PA900015; Peterson LC, 2000, SCIENCE, V290, P1947, DOI 10.1126/science.290.5498.1947; Pisias NG, 1997, PALEOCEANOGRAPHY, V12, P381, DOI 10.1029/97PA00583; Rind D, 1998, J GEOPHYS RES-ATMOS, V103, P5943, DOI 10.1029/97JD03649; Rodbell DT, 1999, SCIENCE, V283, P516, DOI 10.1126/science.283.5401.516; Rosenthal Y, 2000, PALEOCEANOGRAPHY, V15, P135, DOI 10.1029/1999PA000415; Sandweiss DH, 1996, SCIENCE, V273, P1531, DOI 10.1126/science.273.5281.1531; Schrag DP, 1996, SCIENCE, V272, P1930, DOI 10.1126/science.272.5270.1930; SHULMEISTER J, 1995, HOLOCENE, V5, P10, DOI 10.1177/095968369500500102; Stuiver M, 1998, RADIOCARBON, V40, P1041, DOI 10.1017/S0033822200019123; Thompson LG, 1998, SCIENCE, V282, P1858, DOI 10.1126/science.282.5395.1858; TOGGWEILER JR, 1991, J GEOPHYS RES-OCEANS, V96, P20467, DOI 10.1029/91JC02063; Trenberth KE, 1998, J GEOPHYS RES-OCEANS, V103, P14291, DOI 10.1029/97JC01444; Tudhope AW, 2001, SCIENCE, V291, P1511, DOI 10.1126/science.1057969; Vink A, 2001, PALEOCEANOGRAPHY, V16, P479, DOI 10.1029/2000PA000582; White WB, 1996, NATURE, V380, P699, DOI 10.1038/380699a0; Yin JH, 2001, J CLIMATE, V14, P565, DOI 10.1175/1520-0442(2001)014<0565:TIOTSS>2.0.CO;2; Yokoyama Y, 2000, NATURE, V406, P713, DOI 10.1038/35021035	42	433	489	1	110	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 12	2002	297	5579					226	230		10.1126/science.1072376	http://dx.doi.org/10.1126/science.1072376			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571UT	12114619				2022-12-28	WOS:000176738100034
J	Stott, L; Poulsen, C; Lund, S; Thunell, R				Stott, L; Poulsen, C; Lund, S; Thunell, R			Super ENSO and global climate oscillations at millennial time scales	SCIENCE			English	Article							LAST GLACIAL MAXIMUM; AGE CALIBRATION; PACIFIC; TEMPERATURE; VARIABILITY; CORALS; OXYGEN	The late Pleistocene history of seawater temperature and salinity variability in the western tropical Pacific warm pool is reconstructed from oxygen isotope (delta(18)O) and magnesium/calcium composition of planktonic foraminifera. Differentiating the calcite delta(18)O record into components of temperature and local water delta(18)O reveals a dominant salinity signal that varied in accord with Dansgaard/ Oeschger cycles over Greenland. Salinities were higher at times of high-latitude cooling and were lower during interstadials. The pattern and magnitude of the salinity variations imply shifts in the tropical Pacific ocean/atmosphere system analogous to modern El Nino Southern Oscillation (ENSO). El Nino conditions correlate with stadials at high latitudes, whereas La Nina conditions correlate with interstadials. Millennial-scale shifts in atmospheric convection away from the western tropical Pacific may explain many paleo-observations, including lower atmospheric CO2, N2O, and CH4 during stadials and patterns of extratropical ocean variability that have tropical source functions that are negatively correlated with El Nino.	Univ So Calif, Dept Earth Sci, Los Angeles, CA 90089 USA; Univ S Carolina, Dept Geol Sci, Columbia, SC 29208 USA	University of Southern California; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Stott, L (corresponding author), Univ So Calif, Dept Earth Sci, 3651 Trousdale Pkwy, Los Angeles, CA 90089 USA.	stott@usc.edu	Poulsen, Christopher J/C-6213-2009	Poulsen, Christopher J/0000-0001-5104-4271				Altabet MA, 2002, NATURE, V415, P159, DOI 10.1038/415159a; Andreasen DH, 2001, J GEOPHYS RES-OCEANS, V106, P879, DOI 10.1029/1999JC000087; Bard E, 1998, RADIOCARBON, V40, P1085, DOI 10.1017/S0033822200019135; Baumgartner S, 1998, SCIENCE, V279, P1330, DOI 10.1126/science.279.5355.1330; Behl RJ, 1996, NATURE, V379, P243, DOI 10.1038/379243a0; BENDER M, 1994, GLOBAL BIOGEOCHEM CY, V8, P363, DOI 10.1029/94GB00724; Blunier T, 1998, NATURE, V394, P739, DOI 10.1038/29447; Bush ABG, 1998, SCIENCE, V279, P1341, DOI 10.1126/science.279.5355.1341; Cane M, 1999, GEOPH MONOG SERIES, V112, P373; Cane MA, 1998, SCIENCE, V282, P59, DOI 10.1126/science.282.5386.59; CANE MA, 2002, SCIENCE, V282, P5386; CARON D, COMMUNICATION; CLEMENT AC, 1999, GEOPHYSICAL MONOGRAP, V112; Emmer E, 2000, PALEOCEANOGRAPHY, V15, P377, DOI 10.1029/1999PA000417; EREZ J, 1983, GEOCHIM COSMOCHIM AC, V47, P1025, DOI 10.1016/0016-7037(83)90232-6; Fairbanks RG, 1997, CORAL REEFS, V16, pS93, DOI 10.1007/s003380050245; Fluckiger J, 1999, SCIENCE, V285, P227, DOI 10.1126/science.285.5425.227; Gagan MK, 2000, QUATERNARY SCI REV, V19, P45, DOI 10.1016/S0277-3791(99)00054-2; Ganeshram RS, 2002, NATURE, V415, P156, DOI 10.1038/415156a; Lea DW, 2000, SCIENCE, V289, P1719, DOI 10.1126/science.289.5485.1719; LINDSLEY BK, 1996, NATURE, V380, P243; Lund S., 1999, QUATERNARY CLIMATES, P323; Martinez JI, 1997, MAR MICROPALEONTOL, V32, P311; McPhaden MJ, 1999, SCIENCE, V283, P950, DOI 10.1126/science.283.5404.950; Nurnberg D, 1996, GEOCHIM COSMOCHIM AC, V60, P803, DOI 10.1016/0016-7037(95)00446-7; Peterson LC, 2000, SCIENCE, V290, P1947, DOI 10.1126/science.290.5498.1947; Philander S, 1990, EL NINO LA NINA SO O; Pride C, 1999, PALEOCEANOGRAPHY, V14, P397, DOI 10.1029/1999PA900004; ROELSTRA SR, 1989, NETH J SEA RES, V24, P459; Schrag DP, 1999, PALEOCEANOGRAPHY, V14, P97, DOI 10.1029/1998PA900025; Schwartz M, 1998, J GEOPHYS RES-SOL EA, V103, P30407, DOI 10.1029/1998JB900003; SCHWING FB, 1999, EOS, V80, P262; Shackleton NJ, 2000, SCIENCE, V289, P1897, DOI 10.1126/science.289.5486.1897; SOWERS T, 1993, PALEOCEANOGRAPHY, V8, P737, DOI 10.1029/93PA02328; Stauffer B, 1998, NATURE, V392, P59, DOI 10.1038/32133; Stott LD, 2000, NATURE, V407, P367, DOI 10.1038/35030084; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; Stuiver M, 1998, RADIOCARBON, V40, P1041, DOI 10.1017/S0033822200019123; Tudhope AW, 2001, SCIENCE, V291, P1511, DOI 10.1126/science.1057969; Urban FE, 2000, NATURE, V407, P989, DOI 10.1038/35039597; Wang YJ, 2001, SCIENCE, V294, P2345, DOI 10.1126/science.1064618	41	442	509	2	131	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 12	2002	297	5579					222	226		10.1126/science.1071627	http://dx.doi.org/10.1126/science.1071627			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571UT	12114618				2022-12-28	WOS:000176738100033
J	Kerr, B; Riley, MA; Feldman, MW; Bohannan, BJM				Kerr, B; Riley, MA; Feldman, MW; Bohannan, BJM			Local dispersal promotes biodiversity in a real-life game of rock-paper-scissors	NATURE			English	Article							ESCHERICHIA-COLI; BACTERIA; ALLELOPATHY; POPULATIONS; COMPETITION; EVOLUTION; DYNAMICS; RESISTANCE; DIVERSITY; PLANKTON	One of the central aims of ecology is to identify mechanisms that maintain biodiversity(1,2). Numerous theoretical models have shown that competing species can coexist if ecological processes such as dispersal, movement, and interaction occur over small spatial scales(1-10). In particular, this may be the case for nontransitive communities, that is, those without strict competitive hierarchies(3,6,8,11). The classic non-transitive system involves a community of three competing species satisfying a relationship similar to the children's game rock-paper-scissors, where rock crushes scissors, scissors cuts paper, and paper covers rock. Such relationships have been demonstrated in several natural systems(12-14). Some models predict that local interaction and dispersal are sufficient to ensure coexistence of all three species in such a community, whereas diversity is lost when ecological processes occur over larger scales(6,8). Here, we test these predictions empirically using a non-transitive model community containing three populations of Escherichia coli. We find that diversity is rapidly lost in our experimental community when dispersal and interaction occur over relatively large spatial scales, whereas all populations coexist when ecological processes are localized.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06511 USA	Stanford University; Yale University	Kerr, B (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.		Bohannan, Brendan J. M./R-1582-2017; Riley, Margaret Ann/AAB-9743-2022	Bohannan, Brendan J. M./0000-0003-2907-1016; 				ADAMS J, 1979, GENETICS, V91, P627; Bohannan BJM, 2000, ECOL LETT, V3, P362, DOI 10.1046/j.1461-0248.2000.00161.x; BUSS LW, 1979, AM NAT, V113, P223, DOI 10.1086/283381; CHAO L, 1981, P NATL ACAD SCI-BIOL, V78, P6324, DOI 10.1073/pnas.78.10.6324; Chesson P, 2000, ANNU REV ECOL SYST, V31, P343, DOI 10.1146/annurev.ecolsys.31.1.343; Czaran TL, 2002, P NATL ACAD SCI USA, V99, P786, DOI 10.1073/pnas.012399899; Dieckmann U., 2000, GEOMETRY ECOLOGICAL; DURRETT R, 1994, THEOR POPUL BIOL, V46, P363, DOI 10.1006/tpbi.1994.1032; Durrett R, 1997, J THEOR BIOL, V185, P165, DOI 10.1006/jtbi.1996.0292; Feldgarden M, 1998, EVOLUTION, V52, P1270, DOI 10.1111/j.1558-5646.1998.tb02008.x; Feldgarden M, 1999, EVOLUTION, V53, P1019, DOI 10.1111/j.1558-5646.1999.tb04517.x; FRANK SA, 1994, EVOL ECOL, V8, P369, DOI 10.1007/BF01238189; Frean M, 2001, P ROY SOC B-BIOL SCI, V268, P1323, DOI 10.1098/rspb.2001.1670; Gordon DM, 1999, MICROBIOL-SGM, V145, P655, DOI 10.1099/13500872-145-3-655; HASSELL MP, 1994, NATURE, V370, P290, DOI 10.1038/370290a0; Huisman J, 1999, NATURE, V402, P407, DOI 10.1038/46540; Huisman J, 2001, ECOL LETT, V4, P408, DOI 10.1046/j.1461-0248.2001.00256.x; Iwasa Y, 1998, EVOL ECOL, V12, P785, DOI 10.1023/A:1006590431483; James R, 1996, MICROBIOL-SGM, V142, P1569, DOI 10.1099/13500872-142-7-1569; KORONA R, 1994, P NATL ACAD SCI USA, V91, P9037, DOI 10.1073/pnas.91.19.9037; Nakamaru M, 2000, THEOR POPUL BIOL, V57, P131, DOI 10.1006/tpbi.1999.1448; Pagie L, 1999, J THEOR BIOL, V196, P251, DOI 10.1006/jtbi.1998.0838; PAQUIN CE, 1983, NATURE, V306, P368, DOI 10.1038/306368a0; Rainey PB, 1998, NATURE, V394, P69, DOI 10.1038/27900; Rice EL, 1984, ALLELOPATHY; Riley MA, 1999, TRENDS MICROBIOL, V7, P129, DOI 10.1016/S0966-842X(99)01459-6; Rohani P, 1997, TRENDS ECOL EVOL, V12, P70, DOI 10.1016/S0169-5347(96)20103-X; Sinervo B, 1996, NATURE, V380, P240, DOI 10.1038/380240a0; Tilman D, 1997, SPATIAL ECOLOGY ROLE; Tilman David, 1993, P13	30	1075	1092	5	297	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 11	2002	418	6894					171	174		10.1038/nature00823	http://dx.doi.org/10.1038/nature00823			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571GV	12110887				2022-12-28	WOS:000176710400037
J	Grady, D; Herrington, D; Bittner, V; Blumenthal, R; Davidson, M; Hlatky, M; Hsia, J; Hulley, S; Herd, A; Khan, S; Newby, LK; Waters, D; Vittinghoff, E; Wenger, N				Grady, D; Herrington, D; Bittner, V; Blumenthal, R; Davidson, M; Hlatky, M; Hsia, J; Hulley, S; Herd, A; Khan, S; Newby, LK; Waters, D; Vittinghoff, E; Wenger, N		HERS Res Grp	Cardiovascular disease outcomes during 6.8 years of hormone therapy - Heart and Estrogen/progestin Replacement Study follow-up (HERS II)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MYOCARDIAL-INFARCTION; ESTROGEN-REPLACEMENT; RANDOMIZED-TRIAL; RISK; PROGESTIN; EVENTS; INITIATION; WOMEN	Context The Heart and Estrogen/progestin Replacement Study (HERS) found no overall reduction in risk of coronary heart disease (CHD) events among postmenopausal women with CHD. However, in the hormone group, findings did suggest a higher risk of CHD events during the first year, and a decreased risk during years 3 to 5. Objective To determine if the risk reduction observed in the later years of HERS persisted and resulted in an overall reduced risk of CHD events with additional years of follow-up. Design and Setting Randomized, blinded, placebo-controlled trial of 4.1 years' duration (HERS) and subsequent unblinded follow-up for 2.7 years (HERS II) conducted at outpatient and community settings at 20 US clinical centers. Participants A total of 2763 postmenopausal women with CHD and average age of 67 years at enrollment in HERS; 2321 women (93% of those surviving) consented to follow-up in HERS II. Intervention Participants were randomly assigned to receive 0.625 mg/d of conjugated estrogens and 2.5 mg of medroxyprogesterone acetate (n=1380), or placebo (n=1383) during HERS; open-label hormone therapy was prescribed at personal physicians' discretion during HERS II, The proportions with at least 80% adherence to hormones declined from 81 % (year 1) to 45% (year 6) in the hormone group, and increased from 0% (year 1) to 8% (year 6) in the placebo group. Main Outcome Measures The primary outcome was nonfatal myocardial infarction and CHD death. Secondary cardiovascular events were coronary revascularization, hospitalization for unstable angina or congestive heart failure, nonfatal ventricular arrhythmia, sudden death, stroke or transient ischemic attack, and peripheral arterial disease. Results There were no significant decreases in rates of primary CHD events or secondary cardiovascular events among women assigned to the hormone group compared with the placebo group in HERS, HERS 11, or overall, The unadjusted relative hazard (RH) for CHD events in HERS was 0.99 (95% confidence interval [CI], 0.81-1.22); HERS II, 1.00 (95% CI, 0.77-1.29); and overall, 0.99 (0.84-1.17). The overall RHs were similar after adjustment for potential confounders and differential use of statins between treatment groups (RH, 0.97; 95 % CI, 0.82-1.14), and in analyses restricted to women who were adherent to randomized treatment assignment (RH, 0.96; 95% CI, 0.77-1.19). Conclusions Lower rates of CHD events among women in the hormone group in the final years of HERS did not persist during additional years of follow-up. After 6.8 years, hormone therapy did not reduce risk of cardiovascular events in women with CHD. Postmenopausal hormone therapy should not be used to reduce risk for CHD events in women with CHD.	Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94105 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94105 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Winston Salem, NC 27103 USA; Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA; Johns Hopkins Univ, Sch Med, Div Cardiol, Baltimore, MD USA; Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA; Stanford Univ, Sch Med, Dept Hlth Res & Policy, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Dept Med, Palo Alto, CA 94304 USA; George Washington Univ, Dept Med, Washington, DC USA; Univ Calif Los Angeles, Sch Med, Div Cardiol, Los Angeles, CA USA; Cedars Sinai, Div Cardiol, Los Angeles, CA USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA; Emory Univ, Sch Med, Dept Med, Atlanta, GA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Wake Forest University; Wake Forest Baptist Medical Center; University of Alabama System; University of Alabama Birmingham; Johns Hopkins University; Rush University; Stanford University; Stanford University; George Washington University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; Baylor College of Medicine; Duke University; Emory University	Grady, D (corresponding author), Univ Calif San Francisco, Dept Epidemiol & Biostat, 74 New Montgomery St,Suite 600, San Francisco, CA 94105 USA.	dgrady@itsa.ucsf.edu	Blumenthal, Roger S/H-3223-2018	Blumenthal, Roger S/0000-0003-1910-3168; Bittner, Vera/0000-0001-9456-850X; Hlatky, Mark/0000-0003-4686-9441				Alexander KP, 2001, J AM COLL CARDIOL, V38, P1, DOI 10.1016/S0735-1097(01)01329-8; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; Furberg CD, 2002, CIRCULATION, V105, P917, DOI 10.1161/hc0802.104280; Grady D, 2000, ANN INTERN MED, V132, P689, DOI 10.7326/0003-4819-132-9-200005020-00002; Grady D, 1998, CONTROL CLIN TRIALS, V19, P314, DOI 10.1016/S0197-2456(98)00010-5; Heckbert SR, 2001, ARCH INTERN MED, V161, P1709, DOI 10.1001/archinte.161.14.1709; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Hsia J, 2000, CIRCULATION, V102, P2228; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Hulley SB, 2002, EUR HEART J, V23, P89, DOI 10.1053/euhj.2001.2840; KJELSBERG MO, 1990, JAMA-J AM MED ASSOC, V263, P1795; Mosca L, 2001, CIRCULATION, V104, P499, DOI 10.1161/hc2901.092200; Pedersen TR, 2000, AM J CARDIOL, V86, P257, DOI 10.1016/S0002-9149(00)00910-3; Psaty BM, 2001, JAMA-J AM MED ASSOC, V285, P906, DOI 10.1001/jama.285.7.906; Ridker PM, 1997, HAEMOSTASIS, V27, P2; Rossouw JE, 2001, CURR OPIN LIPIDOL, V12, P371, DOI 10.1097/00041433-200108000-00001; Shlipak MG, 2001, ANN INTERN MED, V134, P1043, DOI 10.7326/0003-4819-134-11-200106050-00010; Simon JA, 2001, CIRCULATION, V103, P638, DOI 10.1161/01.cir.103.5.638; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Wenger NK, 2000, JAMA-J AM MED ASSOC, V284, P41, DOI 10.1001/jama.284.1.41-a; 2002, WHI HRT UPD	22	1248	1313	0	31	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	2002	288	1					49	57		10.1001/jama.288.1.49	http://dx.doi.org/10.1001/jama.288.1.49			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	568YW	12090862	Bronze			2022-12-28	WOS:000176573400019
J	Huth, EJ; Case, K				Huth, EJ; Case, K			Annals of Internal Medicine at age 75: Reflections on the past 25 years	ANNALS OF INTERNAL MEDICINE			English	Article							INFORMATION; AUTHORSHIP; ABSTRACTS; PROPOSAL; QUALITY; TRIALS; BLIND		Amer Coll Physicians, Amer Soc Internal Med, Philadelphia, PA 19106 USA	American College of Physicians	Huth, EJ (corresponding author), Amer Coll Physicians, Amer Soc Internal Med, 190 N Independence Mall W, Philadelphia, PA 19106 USA.							ALLYN R, 1973, ANN INTERN MED, V79, P293, DOI 10.7326/0003-4819-79-2-293; Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; *AM COLL PHYS, 1998, AM COLL PHYS ETH MAN; [Anonymous], COMMON SCREENING TES; Aronoff GR, 1999, DRUG PRESCRIBING REN; Badgett RG, 2002, ANN INTERN MED, V136, P553, DOI 10.7326/0003-4819-136-7-200204020-00015; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; BRAITMAN LE, 1988, ANN INTERN MED, V108, P296, DOI 10.7326/0003-4819-108-2-296; BURMAN KD, 1982, ANN INTERN MED, V97, P602, DOI 10.7326/0003-4819-97-4-602; CASE K, 1982, SCI EDITOR ELECT AGE, P47; Cassell EJ, 1984, PLACE HUMANITIES MED; CHALMERS I, 1991, FUTURE MED J COMMEMO; Clever LH, 1997, ANN INTERN MED, V126, P36, DOI 10.7326/0003-4819-126-1-199701010-00006; CLOUGH PW, 1957, ANN INTERN MED, V46, P187, DOI 10.7326/0003-4819-46-1-187; *COUNC SCI ED, 2000, SCI EDITOR, V23, P111; COVELL DG, 1985, ANN INTERN MED, V103, P596, DOI 10.7326/0003-4819-103-4-596; DARSEE JR, 1978, ANN INTERN MED, V89, P867, DOI 10.7326/0003-4819-89-6-867; DARSEE JR, 1980, ANN INTERN MED, V92, P735, DOI 10.7326/0003-4819-92-6-735; Davidoff F, 1999, ANN INTERN MED, V130, P1019, DOI 10.7326/0003-4819-130-12-199906150-00022; Davidoff F, 1998, ANN INTERN MED, V128, P66, DOI 10.7326/0003-4819-128-1-199801010-00011; Davidoff F, 1997, ANN INTERN MED, V126, P986, DOI 10.7326/0003-4819-126-12-199706150-00011; Davidoff F, 2000, ANN INTERN MED, V132, P92, DOI 10.7326/0003-4819-132-1-200001040-00016; Davidoff F, 2000, ANN INTERN MED, V133, P229, DOI 10.7326/0003-4819-133-3-200008010-00017; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; ERTL N, 1969, KARGER GAZETTE  1127, P1; Fackler ML, 1996, ANN INTERN MED, V124, P741, DOI 10.7326/0003-4819-124-8-199604150-00007; FACKLER ML, 1994, ANN INTERN MED, V121, P894, DOI 10.7326/0003-4819-121-11-199412010-00015; FOTION N, 1984, ANN INTERN MED, V100, P592, DOI 10.7326/0003-4819-100-4-592; Garber AM, 1996, ANN INTERN MED, V124, P518, DOI 10.7326/0003-4819-124-5-199603010-00013; GOODMAN SN, 1994, ANN INTERN MED, V121, P11, DOI 10.7326/0003-4819-121-1-199407010-00003; GREENBERGER NJ, 1990, ANN INTERN MED, V112, P637, DOI 10.7326/0003-4819-112-9-637; GUYATT GH, 1991, ACP J CLUB, V1, pA16; HAYNES RB, 1987, ANN INTERN MED, V106, P598; HEWITT RM, 1957, PHYSICIAN WRITERS BO, P312; HUTH E, 1981, ANN INTERN MED, V94, P130, DOI 10.7326/0003-4819-94-1-130; HUTH E, 1979, BRIT MED J, V1, P1697, DOI 10.1136/bmj.1.6179.1697; HUTH EJ, 1989, B NEW YORK ACAD MED, V65, P647; HUTH EJ, 1977, ANN INTERN MED, V87, P103, DOI 10.7326/0003-4819-87-1-103; HUTH EJ, 1985, ANN INTERN MED, V103, P797, DOI 10.7326/0003-4819-103-5-797; HUTH EJ, 1982, ANN INTERN MED, V97, P613, DOI 10.7326/0003-4819-97-4-613; HUTH EJ, 1986, ANN INTERN MED, V104, P269, DOI 10.7326/0003-4819-104-2-269; HUTH EJ, 1987, ANN INTERN MED, V106, P626, DOI 10.7326/0003-4819-106-4-626; HUTH EJ, 1995, CBE VIEWS, V18, P11; HUTH EJ, 1987, MED STYLE FORMAT, P17; Kass EH, 1981, COPING BIOMEDICAL LI, P79; LACOMBE MA, 2000, BEING DOCTOR, V2; Moher D, 2001, ANN INTERN MED, V134, P657, DOI 10.7326/0003-4819-134-8-200104170-00011; Mossad SB, 1996, ANN INTERN MED, V125, P81, DOI 10.7326/0003-4819-125-2-199607150-00001; MULROW CD, 1988, ANN INTERN MED, V108, P613, DOI 10.7326/0003-4819-108-4-613; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; Mulrow CD, 1998, SYSTEMATIC REV SYNTH; Physicians for the Twenty-First Century, 1984, J MED EDUC, V59, P1; PINCOFFS MC, 1933, ANN INTERN MED, V6, P1115; RELMAN AS, 1983, NEW ENGL J MED, V308, P1415, DOI 10.1056/NEJM198306093082311; Rennie D, 1997, JAMA-J AM MED ASSOC, V278, P579, DOI 10.1001/jama.278.7.579; ROBERTS JC, 1994, JAMA-J AM MED ASSOC, V272, P119, DOI 10.1001/jama.272.2.119; SNYDER L, 2001, PHYSICIANS GUIDE END; Sox HC, 1987, COMMON DIAGNOSTIC TE; VANSTEENBURGH J, 2002, ACP ASIM OBSERVE MAR, P1; WARREN KS, 1984, ANN INTERN MED, V101, P697, DOI 10.7326/0003-4819-101-5-697; WILKES MS, 1992, ANN INTERN MED, V116, P912, DOI 10.7326/0003-4819-116-11-912; 1967, ANN INTERN MED S7, V67, P3; 1979, ANN INTERN MED, V90, P95; 1985, LANCET, V2, P595; 1985, BR MED J, V291, P722; 1979, ANN INTERN MED, V90, P985; 1979, ANN INTERN MED, V91, P312; 1983, ANN INTERN MED, V99, P275; 1979, BR MED J, V1, P532	69	12	12	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 2	2002	137	1					34	45		10.7326/0003-4819-137-1-200207020-00010	http://dx.doi.org/10.7326/0003-4819-137-1-200207020-00010			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569VA	12093243				2022-12-28	WOS:000176622000005
J	Gibbons, RV; Vaughn, DW				Gibbons, RV; Vaughn, DW			Dengue: an escalating problem	BMJ-BRITISH MEDICAL JOURNAL			English	Review							HEMORRHAGIC-FEVER; AEDES-AEGYPTI; INFECTIONS; TRAVELERS; IMPACT; RISK		Walter Reed Army Inst Res, Dept Virus Dis, Silver Spring, MD 20910 USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	Gibbons, RV (corresponding author), Walter Reed Army Inst Res, Dept Virus Dis, Silver Spring, MD 20910 USA.	robert.gibbons@na.amedd.anny.mil		Lai, Shengjie/0000-0001-9781-8148				BURKE DS, 1988, AM J TROP MED HYG, V38, P172, DOI 10.4269/ajtmh.1988.38.172; Cam BV, 2001, AM J TROP MED HYG, V65, P848, DOI 10.4269/ajtmh.2001.65.848; *CDCP, 2002, DENG FEV HOM PAG; *CDCP, 2000, JAMA-J AM MED ASSOC, V283, P1953; Gaultier C, 2000, REV NEUROL, V156, P169; Gubler DJ, 1999, ADV VIRUS RES, V53, P35, DOI 10.1016/S0065-3527(08)60342-5; GUBLER DJ, 1989, AM J TROP MED HYG, V40, P571, DOI 10.4269/ajtmh.1989.40.571; Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480; Halstead SB, 2001, AM J TROP MED HYG, V65, P180, DOI 10.4269/ajtmh.2001.65.180; Harrington LC, 2001, J MED ENTOMOL, V38, P411, DOI 10.1603/0022-2585-38.3.411; Innis Bruce L., 1995, P103; Isturiz RE, 2000, INFECT DIS CLIN N AM, V14, P121, DOI 10.1016/S0891-5520(05)70221-X; Jelinek T, 2000, CLIN INFECT DIS, V31, P144, DOI 10.1086/313889; Krishnamurti C, 2001, AM J TROP MED HYG, V65, P840, DOI 10.4269/ajtmh.2001.65.840; Kurane I, 2000, EMERG INFECT DIS, V6, P569, DOI 10.3201/eid0606.000603; Kurane I, 2001, REV MED VIROL, V11, P301, DOI 10.1002/rmv.324; Lei HY, 2001, J BIOMED SCI, V8, P377, DOI 10.1007/BF02255946; Lum LCS, 1996, AM J TROP MED HYG, V54, P256, DOI 10.4269/ajtmh.1996.54.256; Magill AJ, 1998, INFECT DIS CLIN N AM, V12, P445, DOI 10.1016/S0891-5520(05)70013-1; McBride WJH, 2000, MICROBES INFECT, V2, P1041, DOI 10.1016/S1286-4579(00)01258-2; MONATH TP, 1994, P NATL ACAD SCI USA, V91, P2395, DOI 10.1073/pnas.91.7.2395; Nam VS, 2000, AM J TROP MED HYG, V62, P5, DOI 10.4269/ajtmh.2000.62.5; Nhan NT, 2001, CLIN INFECT DIS, V32, P204, DOI 10.1086/318479; O'Brien D, 2001, CLIN INFECT DIS, V33, P603, DOI 10.1086/322602; Platt KB, 1997, AM J TROP MED HYG, V57, P119, DOI 10.4269/ajtmh.1997.57.119; Potasman I, 1999, EMERG INFECT DIS, V5, P824, DOI 10.3201/eid0506.990615; RICOHESSE R, 1990, VIROLOGY, V174, P479, DOI 10.1016/0042-6822(90)90102-W; Rigau-Perez, 1997, J Travel Med, V4, P65, DOI 10.1111/j.1708-8305.1997.tb00782.x; Rigau-Perez JG, 1998, LANCET, V352, P971, DOI 10.1016/S0140-6736(97)12483-7; ROSEN L, 1999, MED TROP, V59, P193; SHARP TW, 1995, AM J TROP MED HYG, V53, P89, DOI 10.4269/ajtmh.1995.53.89; Solomon T, 2000, LANCET, V355, P1053, DOI 10.1016/S0140-6736(00)02036-5; Sullivan NJ, 2001, CURR TOP MICROBIOL, V260, P145; Thein S, 1997, AM J TROP MED HYG, V56, P566, DOI 10.4269/ajtmh.1997.56.566; Vaughn DW, 2000, J INFECT DIS, V181, P2, DOI 10.1086/315215; WATERMAN SH, 1989, CLIN DERMATOL, V7, P117, DOI 10.1016/0738-081X(89)90034-5; WHO, 2002, DENG DENG HAEM FEV F; WHO, 1997, DENG HAEM FEV DIAGN; Wu SJL, 2000, NAT MED, V6, P816, DOI 10.1038/77553	39	494	541	0	40	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 29	2002	324	7353					1563	1566		10.1136/bmj.324.7353.1563	http://dx.doi.org/10.1136/bmj.324.7353.1563			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	570WP	12089096	Green Published			2022-12-28	WOS:000176683000025
J	Bannister, AJ; Schneider, R; Kouzarides, T				Bannister, AJ; Schneider, R; Kouzarides, T			Histone methylation: Dynamic or static?	CELL			English	Review							LYSINE 9; H3; TETRAHYMENA; HP1; OXIDASE	Methylation of histones mediates transcriptional silencing at heterochromatin sites and affects regulated transcription at euchromatic loci. So is the methyl group a permanent mark on histones, or can it be removed by an active process necessary for regulated gene expression?	Univ Cambridge, Dept Pathol, Wellcome Trust Canc Res UK Inst, Cambridge CB2 1QR, England	University of Cambridge	Kouzarides, T (corresponding author), Univ Cambridge, Dept Pathol, Wellcome Trust Canc Res UK Inst, Tennis Court Rd, Cambridge CB2 1QR, England.			Bannister, Andrew/0000-0002-6312-4436; Kouzarides, Tony/0000-0002-8918-4162				ALLIS CD, 1980, CELL, V20, P55; ANNUNZIATO AT, 1995, BIOCHEMISTRY-US, V34, P2916, DOI 10.1021/bi00009a023; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bauer UM, 2002, EMBO REP, V3, P39, DOI 10.1093/embo-reports/kvf013; BORUN TW, 1972, J BIOL CHEM, V247, P4288; BYVOET P, 1972, ARCH BIOCHEM BIOPHYS, V148, P558, DOI 10.1016/0003-9861(72)90174-9; BYVOET P, 1972, ARCH BIOCHEM BIOPHYS, V152, P887, DOI 10.1016/0003-9861(72)90286-X; Chinenov Y, 2002, TRENDS BIOCHEM SCI, V27, P115, DOI 10.1016/S0968-0004(02)02058-3; de Montellano PR Ortiz, 1995, CYTOCHROME P450 STRU; DUERRE JA, 1974, J NEUROCHEM, V23, P541, DOI 10.1111/j.1471-4159.1974.tb06057.x; Hagiwara T, 2002, BIOCHEM BIOPH RES CO, V290, P979, DOI 10.1006/bbrc.2001.6303; Khanna P, 2001, BIOCHEMISTRY-US, V40, P1441, DOI 10.1021/bi0024411; KIM S, 1964, J BIOL CHEM, V239, P3790; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; OGAWA T, 1989, J BIOL CHEM, V264, P10205; PAIK WK, 1974, ARCH BIOCHEM BIOPHYS, V165, P369, DOI 10.1016/0003-9861(74)90175-1; PAIK WK, 1973, BIOCHEM BIOPH RES CO, V51, P781, DOI 10.1016/0006-291X(73)91383-1; PINA B, 1987, DEV BIOL, V123, P51, DOI 10.1016/0012-1606(87)90426-X; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; THATCHER TH, 1994, NUCLEIC ACIDS RES, V22, P180, DOI 10.1093/nar/22.2.180; Tyihak E, 1998, ANN NY ACAD SCI, V851, P259, DOI 10.1111/j.1749-6632.1998.tb09001.x; Wagner MA, 2000, BIOCHEMISTRY-US, V39, P8825, DOI 10.1021/bi000350y; WATERBOURG JH, 1993, J BIOL CHEM, V168, P4912; Wolffe A., 1998, CHROMATIN STRUCTURE; WUNSCH AM, 1990, CELL DIFFER DEV, V30, P19, DOI 10.1016/0922-3371(90)90070-D; Yu LL, 1997, MOL CELL BIOL, V17, P6303, DOI 10.1128/MCB.17.11.6303; Zegerman P, 2002, J BIOL CHEM, V277, P11621, DOI 10.1074/jbc.C200045200; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	32	398	419	1	29	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 28	2002	109	7					801	806		10.1016/S0092-8674(02)00798-5	http://dx.doi.org/10.1016/S0092-8674(02)00798-5			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	570KJ	12110177	Bronze			2022-12-28	WOS:000176657200003
J	Du, YCN; Stillman, B				Du, YCN; Stillman, B			Yph1p, an ORC-interacting protein: Potential links between cell proliferation control, DNA replication, and ribosome biogenesis	CELL			English	Article							ORIGIN RECOGNITION COMPLEX; SACCHAROMYCES-CEREVISIAE; PHOSPHATASE YVH1P; GENE-EXPRESSION; YEAST GENE; INITIATION; CYCLE; TRANSLATION; PESCADILLO; GROWTH	Immunoprecipitation of the origin recognition complex (ORC) from yeast extracts identified Yph1p, an essential protein containing a BRCT domain. Two Yph1p complexes were characterized. Besides ORC, MCM proteins, cell-cycle regulatory proteins, checkpoint proteins, 60S ribosomal proteins, and preribosome particle proteins were found to be associated with Yph1p. Yph1p is predominantly nucleolar and is required for 60S ribosomal subunit biogenesis and possibly for translation on polysomes. Proliferating cells depleted of Yph1p arrest in G(1) or G(2), with no cells in S phase, or significantly delay S phase progression after release from a hydroxyurea arrest. Yph1p levels decline as cells commit to exit the cell cycle, and levels vary depending on energy source. Yph1p may link cell proliferation control to DNA replication, ribosome biogenesis, and translation on polysomes.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Stillman, B (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	stiliman@cshl.org		Stillman, Bruce/0000-0002-9453-4091	NIGMS NIH HHS [R01 GM045436, GM45436] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045436] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams CC, 2002, RNA, V8, P150, DOI 10.1017/S1355838202010026; Allende ML, 1996, GENE DEV, V10, P3141, DOI 10.1101/gad.10.24.3141; AMBERG DC, 1995, YEAST, V11, P1275, DOI 10.1002/yea.320111307; BAIM SB, 1985, MOL CELL BIOL, V5, P1839, DOI 10.1128/MCB.5.8.1839; Bassler J, 2001, MOL CELL, V8, P517, DOI 10.1016/S1097-2765(01)00342-2; Basu U, 2001, MOL CELL BIOL, V21, P1453, DOI 10.1128/MCB.21.5.1453-1462.2001; Beeser AE, 2000, J BACTERIOL, V182, P3517, DOI 10.1128/JB.182.12.3517-3528.2000; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; Charpentier AH, 2000, CANCER RES, V60, P5977; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dillin A, 1998, SCIENCE, V279, P1733, DOI 10.1126/science.279.5357.1733; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; ENGBERG J, 1985, EUR J CELL BIOL, V36, P133; Haber JE, 1998, ANNU REV GENET, V32, P561, DOI 10.1146/annurev.genet.32.1.561; Harnpicharnchai P, 2001, MOL CELL, V8, P505, DOI 10.1016/S1097-2765(01)00344-6; Hodges PE, 1999, NUCLEIC ACIDS RES, V27, P69, DOI 10.1093/nar/27.1.69; Jager S, 2001, EMBO J, V20, P4423, DOI 10.1093/emboj/20.16.4423; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; KEM SE, 1991, SCIENCE, V252, P1708; Kennedy BK, 2000, GENE DEV, V14, P2855, DOI 10.1101/gad.842600; Kinoshita Y, 2001, J BIOL CHEM, V276, P6656, DOI 10.1074/jbc.M008536200; Kobayashi T, 1996, GENES CELLS, V1, P465, DOI 10.1046/j.1365-2443.1996.d01-256.x; Kondoh H, 2000, GENES CELLS, V5, P525, DOI 10.1046/j.1365-2443.2000.00344.x; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MILLER SD, 1995, MOL CELL BIOL, V15, P6554; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Pestov DG, 2001, NUCLEIC ACIDS RES, V29, P3621, DOI 10.1093/nar/29.17.3621; Racevskis J, 1996, CELL GROWTH DIFFER, V7, P271; RIVIN CJ, 1980, J CELL BIOL, V85, P96, DOI 10.1083/jcb.85.1.96; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; SAFFER LD, 1986, MOL CELL BIOL, V6, P1148, DOI 10.1128/MCB.6.4.1148; Sakumoto N, 2001, BIOCHEM BIOPH RES CO, V289, P608, DOI 10.1006/bbrc.2001.6021; Saveanu C, 2001, EMBO J, V20, P6475, DOI 10.1093/emboj/20.22.6475; Schwikowski B, 2000, NAT BIOTECHNOL, V18, P1257, DOI 10.1038/82360; Senger B, 2001, MOL CELL, V8, P1363, DOI 10.1016/S1097-2765(01)00403-8; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; Strezoska Z, 2000, MOL CELL BIOL, V20, P5516, DOI 10.1128/MCB.20.15.5516-5528.2000; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Wade C, 2001, MOL CELL BIOL, V21, P8638, DOI 10.1128/MCB.21.24.8638-8650.2001; WARD MP, 1994, MOL CELL BIOL, V14, P5619, DOI 10.1128/MCB.14.9.5619; Warner JR, 2001, CELL, V107, P133, DOI 10.1016/S0092-8674(01)00531-1; Weinberger M, 1999, J BIOL CHEM, V274, P35975, DOI 10.1074/jbc.274.50.35975; Wood LC, 1999, J BIOL CHEM, V274, P11653, DOI 10.1074/jbc.274.17.11653	53	151	155	1	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	2002	109	7					835	848		10.1016/S0092-8674(02)00773-0	http://dx.doi.org/10.1016/S0092-8674(02)00773-0			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	570KJ	12110181	Bronze			2022-12-28	WOS:000176657200007
J	Selan, L; Passariello, C; Rizzo, L; Varesi, P; Speziale, F; Renzini, G; Thaller, MC; Fiorani, P; Rossolini, GM				Selan, L; Passariello, C; Rizzo, L; Varesi, P; Speziale, F; Renzini, G; Thaller, MC; Fiorani, P; Rossolini, GM			Diagnosis of vascular graft infections with antibodies against staphylococcal slime antigens	LANCET			English	Article							EPIDERMIDIS	Late-onset Infections of synthetic vascular grafts (LO-SVGIs) are generally caused by staphylococcl that produce a slime polysaccharide and grow as a biofilm on the graft surface. We developed an ELISA to detect serum antibodies against staphylococcal slime polysaccharide antigens (SSPA). Patients with an ongoing staphylococcal LO-SVGI had greater titres of IgM antibodies against SSPA than did patients In other groups. Antibody titres of 0.40 ELISA units (EU) or more, or 0.35 EU or more detected 97% and 100% of staphylococcal LO-SVGIs, respectively, 0% and 2% titre/unit false-positive results. Our findings suggest that such an ELISA represents a sensitive, specific, and non-invasive diagnostic test for staphylococcal LO-SVGIs.	Univ Siena, Dipartimento Biol Mol, Sez Microbiol, Siena, Italy; Univ Roma Tor Vergata, Dipartimento Biol, I-00173 Rome, Italy; Univ Roma La Sapienza, Dipartimento Sci Sanita Pubbl, Rome, Italy; Univ Roma La Sapienza, Dipartimento Chirurg Vasc, Rome, Italy	University of Siena; University of Rome Tor Vergata; Sapienza University Rome; Sapienza University Rome	Rossolini, GM (corresponding author), Univ Siena, Dipartimento Biol Mol, Sez Microbiol, Siena, Italy.			THALLER, MARIA CRISTINA/0000-0003-2788-3563; ROSSOLINI, Gian Maria/0000-0002-9386-0434; SPEZIALE, Francesco/0000-0001-8106-2083				CALLIGARO KD, 1991, SURGERY, V110, P805; Henke PK, 1998, AM SURGEON, V64, P39; HUSSAIN M, 1991, J MED MICROBIOL, V34, P143, DOI 10.1099/00222615-34-3-143; Karamanos NK, 1997, ARCH BIOCHEM BIOPHYS, V342, P389, DOI 10.1006/abbi.1997.0107; Lambert PA, 2000, FEMS IMMUNOL MED MIC, V29, P195, DOI 10.1111/j.1574-695X.2000.tb01523.x	5	25	31	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 22	2002	359	9324					2166	2168		10.1016/S0140-6736(02)09086-4	http://dx.doi.org/10.1016/S0140-6736(02)09086-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566RJ	12090985				2022-12-28	WOS:000176441800014
J	Burns, RB; Hartman, EE				Burns, RB; Hartman, EE			A 28-year-old woman with panic disorder, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Gorman JM, 2001, JAMA-J AM MED ASSOC, V286, P450, DOI 10.1001/jama.286.4.450	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 24	2002	288	4					494	494		10.1001/jama.288.4.494	http://dx.doi.org/10.1001/jama.288.4.494			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575NZ	12132981				2022-12-28	WOS:000176955400033
J	Chi, TH; Wan, M; Zhao, KJ; Taniuchi, I; Chen, L; Littman, DR; Crabtree, GR				Chi, TH; Wan, M; Zhao, KJ; Taniuchi, I; Chen, L; Littman, DR; Crabtree, GR			Reciprocal regulation of CD4/CD8 expression by SWI/SNF-like BAF complexes	NATURE			English	Article							CD4 GENE-EXPRESSION; T-CELL DEVELOPMENT; STOCHASTIC MECHANISM; CHROMATIN; LINEAGE; PROMOTER; SUBSETS; BRAHMA; YEAST	Thymic development produces two sub-lineages of T cells expressing either CD4 or CD8 co-receptors that assist antibody production and mediate cell killing, respectively. The mechanisms for mutually exclusive co-receptor expression remain poorly defined(1,2). We find that mutations in the high mobility group (HMG) domain of BAF57-a DNA-binding subunit of the mammalian SWI/SNF-like chromatin-remodelling BAF complexesor in the BAF complex ATPase subunit Brg, impair both CD4 silencing and CD8 activation. Brg is haploinsufficient for CD8 activation, but not for CD4 silencing, whereas BAF57 mutations preferentially impair CD4 silencing, pointing to target- and subunit-specific mechanisms of chromatin remodelling. BAF complexes directly bind the CD4 silencer, but the BAF57 HMG domain is dispensable for tethering BAF complexes to the CD4 silencer or other chromatin loci in vivo, or for remodelling reconstituted templates in vitro(3,4), suggesting that chromatin remodelling in vivo requires HMG-dependent DNA bending. These results indicate that BAF complexes contribute to lineage bifurcation by reciprocally regulating lineage-specific genes, reminiscent of the role of the yeast SWI/SNF complex in mediating mating-type switching(5,6)	Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Pathol & Dev Biol, Stanford, CA 94305 USA; NHLBI, Mol Immunol Lab, NIH, Bethesda, MD 20892 USA; NYU, Sch Med, Skirball Inst Biomol Med, Mol Pathogenesis Program, New York, NY 10016 USA; NYU, Sch Med, Howard Hughes Med Inst, New York, NY 10016 USA	Howard Hughes Medical Institute; Stanford University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); New York University; Howard Hughes Medical Institute; New York University	Crabtree, GR (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Pathol & Dev Biol, Stanford, CA 94305 USA.		Taniuchi, Ichiro/N-6399-2015	Taniuchi, Ichiro/0000-0002-9853-9068				Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; DAVIS CB, 1993, CELL, V73, P237, DOI 10.1016/0092-8674(93)90226-G; Ellmeier W, 1999, ANNU REV IMMUNOL, V17, P523, DOI 10.1146/annurev.immunol.17.1.523; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GODFREY DI, 1993, J IMMUNOL, V150, P4244; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Leung RKM, 2001, NAT IMMUNOL, V2, P1167, DOI 10.1038/ni733; Liu R, 2001, CELL, V106, P309, DOI 10.1016/S0092-8674(01)00446-9; NAKAYAMA T, 1990, SCIENCE, V249, P1558, DOI 10.1126/science.2120773; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Robertson HG, 1997, AFR ENTOMOL, V5, P1; Sarafova SD, 1999, BRAZ J MED BIOL RES, V32, P785, DOI 10.1590/S0100-879X1999000700001; SAWADA S, 1994, CELL, V77, P917, DOI 10.1016/0092-8674(94)90140-6; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TEH HS, 1991, NATURE, V349, P241, DOI 10.1038/349241a0; Wang WD, 1998, P NATL ACAD SCI USA, V95, P492, DOI 10.1073/pnas.95.2.492; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5; Zou YR, 2001, NAT GENET, V29, P332, DOI 10.1038/ng750	23	199	205	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 11	2002	418	6894					195	199		10.1038/nature00876	http://dx.doi.org/10.1038/nature00876			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571GV	12110891				2022-12-28	WOS:000176710400043
J	Yeni, PG; Hammer, SM; Carpenter, CCJ; Cooper, DA; Fischl, MA; Gatell, JM; Gazzard, BG; Hirsch, MS; Jacobsen, DM; Katzenstein, DA; Montaner, JSG; Richman, DD; Saag, MS; Schechter, M; Schooley, RT; Thompson, MA; Vella, S; Volberding, PA				Yeni, PG; Hammer, SM; Carpenter, CCJ; Cooper, DA; Fischl, MA; Gatell, JM; Gazzard, BG; Hirsch, MS; Jacobsen, DM; Katzenstein, DA; Montaner, JSG; Richman, DD; Saag, MS; Schechter, M; Schooley, RT; Thompson, MA; Vella, S; Volberding, PA			Antiretroviral treatment for adult HIV infection in 2002 - Updated recommendations of the international AIDS Society-USA panel	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEASE INHIBITOR THERAPY; STRUCTURED TREATMENT INTERRUPTIONS; CD4 CELL COUNT; PLASMA VIRAL LOAD; VIROLOGICAL RESPONSE; DRUG SUSCEPTIBILITY; HIV-1-INFECTED PATIENTS; RANDOMIZED-TRIAL; LACTIC-ACIDOSIS	Objective New information warrants updated recommendations for the 4 central issues in antiretroviral therapy: when to start, what drugs to start with, when to change, and what to change to. These updated recommendations are intended to guide practicing physicians actively involved in human immunodeficiency virus (HIV)- and acquired immunodeficiency syndrome (AIDS)-related care. Participants In 1995, physicians with specific expertise in HIV-related basic science and clinical research, antiretroviral therapy, and HIV patient care were invited by the International AIDS Society-USA to serve on a volunteer panel. In 1999, others were invited to broaden international representation. The 17-member panel met regularly in closed meetings between its last report in 2000 and April 2002 to review current data. The effort was sponsored and funded by the International AIDS Society-USA, a not-for-profit physician education organization. Evidence and Consensus Process The full panel was convened in late 2000 and assigned 7 section committees. A section writer and 3 to 5 section committee members (each panel member served on numerous sections) identified relevant evidence and prepared draft recommendations. Basic science, clinical research, and epidemiologic data from the published literature and abstracts from recent (within 2 years) scientific conferences were considered by strength of evidence. Extrapolations from basic science data and expert opinion of the panel members were included as evidence. Draft sections were combined and circulated to the entire panel and discussed in a series of full-panel conference calls until consensus was reached. Final recommendations represent full consensus agreement of the panel. Conclusions Because of increased awareness of the activity and toxicity of current drugs, the threshold for initiation of therapy has shifted to a later time in the course of HIV disease. However, the optimal time to initiate therapy remains imprecisely defined. Availability of new drugs has broadened options for therapy initiation and management of treatment failure, which remains a difficult challenge.	Int AIDS Soc USA, San Francisco, CA 94129 USA; Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Brown Univ, Sch Med, Providence, RI 02912 USA; Univ New S Wales, Sydney, NSW, Australia; Univ Miami, Sch Med, Miami, FL USA; Univ Barcelona, Hosp Clin, Barcelona, Spain; Chelsea & Westminster Hosp, London, England; Harvard Univ, Sch Med, Boston, MA USA; Hop Bichat Claude Bernard, Dept Infect Dis, X Bichat Med Sch, F-75877 Paris 18, France; Stanford Univ, Med Ctr, Stanford, CA 94305 USA; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; Univ Calif San Diego, La Jolla, CA 92093 USA; San Diego VA Healthcare Syst, San Diego, CA USA; Univ Alabama Birmingham, Birmingham, AL USA; Univ Fed Rio de Janeiro, BR-21941 Rio De Janeiro, Brazil; Univ Colorado, Sch Med, Denver, CO USA; AIDS Res Consortium Atlanta, Atlanta, GA USA; Ist Super Sanita, I-00161 Rome, Italy; Univ Calif San Francisco, San Francisco, CA 94143 USA; San Francisco VA Med Ctr, San Francisco, CA USA	Columbia University; Brown University; University of New South Wales Sydney; University of Miami; University of Barcelona; Hospital Clinic de Barcelona; Imperial College London; Harvard University; Harvard Medical School; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Stanford University; University of British Columbia; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of Alabama System; University of Alabama Birmingham; Universidade Federal do Rio de Janeiro; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Istituto Superiore di Sanita (ISS); University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Yeni, PG (corresponding author), Int AIDS Soc USA, 1001 B OReilly Ave, San Francisco, CA 94129 USA.	patrick.yeni@bch.ap-hop-paris.fr	VELLA, STEFANO/V-8440-2019; VELLA, STEFANO/ABI-3368-2020; Vella, Stefano/GZM-0519-2022	VELLA, STEFANO/0000-0003-2347-5984; katzenstein, david/0000-0002-8593-4560				*ABB LAB, 2000, NORV; *AG PHARM CO, 2001, VIR; *AG PHARM CO, 2001, RESCR DEL; Arpadi SM, 2002, J ACQ IMMUN DEF SYND, V29, P450, DOI 10.1097/00126334-200204150-00004; Bangsberg DR, 2000, AIDS, V14, P357, DOI 10.1097/00002030-200003100-00008; Barouch DH, 2000, P NATL ACAD SCI USA, V97, P4192, DOI 10.1073/pnas.050417697; Baxter JD, 2000, AIDS, V14, pF83, DOI 10.1097/00002030-200006160-00001; Behrens G, 1999, AIDS, V13, pF63, DOI 10.1097/00002030-199907090-00001; Benson CA, 2002, J INFECT DIS, V185, P599, DOI 10.1086/339014; BERNSTEIN B, 2001, 8 C RETR OPP INF FEB; Bossi P, 2000, CLIN INFECT DIS, V30, P227, DOI 10.1086/313629; Bourezane Y, 1998, CLIN INFECT DIS, V27, P1321, DOI 10.1086/517713; Brambilla D, 1999, AIDS, V13, P2269, DOI 10.1097/00002030-199911120-00009; Brivet FG, 2000, J HEPATOL, V32, P364, DOI 10.1016/S0168-8278(00)80088-4; BRUNVEZINET F, 2000, ANTIVIR THER S, V5, P78; BURGER DM, 2001, 2 INT WORKSH CLIN PH; CAHN P, 2001, 1 INT AIDS SOC C HIV; Call SA, 2001, J INFECT DIS, V183, P401, DOI 10.1086/318078; Cameron DW, 1999, AIDS, V13, P213, DOI 10.1097/00002030-199902040-00009; Carcelain G., 1999, Journal de la Societe de Biologie, V193, P5; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Carr A, 2000, LANCET, V356, P1423, DOI 10.1016/S0140-6736(00)02854-3; *CDCP, 2001, MMWR-MORBID MORTAL W, V49, P1153, DOI DOI 10.1097/01.INF.0000035031.50613.44; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; Chaisson RE, 2000, JAMA-J AM MED ASSOC, V284, P3128, DOI 10.1001/jama.284.24.3128; CHEN R, 2001, 8 C RETR OPP INF FEB; CHEN RY, 2001, 41 INT C ANT AG CHEM; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Clements-Mann ML, 1998, J INFECT DIS, V177, P1230, DOI 10.1086/515288; Coghlan ME, 2001, CLIN INFECT DIS, V33, P1914, DOI 10.1086/323783; Cohen CJ, 2002, AIDS, V16, P579, DOI 10.1097/00002030-200203080-00009; CROWE SM, 1991, J ACQ IMMUN DEF SYND, V4, P770; DAQUILA RT, 2002, TOPICS HIV MED, V10, P11; Davey RT, 2000, JAMA-J AM MED ASSOC, V284, P183, DOI 10.1001/jama.284.2.183; Davey RT, 1999, J INFECT DIS, V179, P849, DOI 10.1086/314678; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; Deeks SG, 2000, J INFECT DIS, V181, P946, DOI 10.1086/315334; Deeks SG, 2002, J INFECT DIS, V185, P315, DOI 10.1086/338467; Deeks SG, 2000, CLIN INFECT DIS, V30, pS177, DOI 10.1086/313855; DeGruttola V, 2000, ANTIVIR THER, V5, P41; DeHovitz JA, 2000, J INFECT DIS, V182, P1527, DOI 10.1086/315875; Demeter LM, 2001, ANN INTERN MED, V135, P954, DOI 10.7326/0003-4819-135-11-200112040-00007; DeSimone JA, 2000, ANN INTERN MED, V133, P447, DOI 10.7326/0003-4819-133-6-200009190-00013; DUBE MP, 2000, ANTIVIR THER S5, V5, P26; *DUP PHARM CO, 2000, SUST; Dybul M, 2001, P NATL ACAD SCI USA, V98, P15161, DOI 10.1073/pnas.261568398; EASTERBROOK PJ, 2001, 8 C RETR OPP INF FEB; Echevarria KL, 1999, ANN PHARMACOTHER, V33, P859, DOI 10.1345/aph.18174; EGGER M, 2001, 41 INT C ANT AG CHEM; Farzadegan H, 1998, LANCET, V352, P1510, DOI 10.1016/S0140-6736(98)02372-1; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; FISCHL M, 2000, 7 C RETR OPP INF JAN; FISCHL M, 2001, 8 C RETR OPP INF FEB; Fletcher CV, 2000, AIDS, V14, P2495, DOI 10.1097/00002030-200011100-00011; Flexner C, 2000, ANNU REV PHARMACOL, V40, P649, DOI 10.1146/annurev.pharmtox.40.1.649; FORTGANG IS, 1995, AM J GASTROENTEROL, V90, P1433; Garcia F, 2001, AIDS, V15, pF29, DOI 10.1097/00002030-200106150-00002; GERBER JG, 2002, TOP HIV MED, V10, P27; *GLAX, 2001, ZIAG AB; *GLAX SMITH KLIN, 2001, AG AMPR; Glesby MJ, 2001, J INFECT DIS, V184, P519, DOI 10.1086/322779; GRANT RM, 2001, 8 C RETR OPP INF FEB; GREENBERG BH, 1977, ANN INTERN MED, V87, P526, DOI 10.7326/0003-4819-87-5-526; GULICK R, 2001, 1 INT AIDS SOC C HIV; Gulick RM, 2000, J INFECT DIS, V182, P1375, DOI 10.1086/315867; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hance AJ, 2001, J VIROL, V75, P6410, DOI 10.1128/JVI.75.14.6410-6417.2001; Haubrich RH, 2001, CLIN INFECT DIS, V33, P1060, DOI 10.1086/322636; HAUBRICH RH, 2000, TOP HIV MED, V8, P9; Havlir DV, 2001, JAMA-J AM MED ASSOC, V286, P171, DOI 10.1001/jama.286.2.171; Havlir DV, 1998, NEW ENGL J MED, V339, P1261, DOI 10.1056/NEJM199810293391801; Havlir DV, 2001, AIDS, V15, P1379, DOI 10.1097/00002030-200107270-00007; Hirsch MS, 2000, JAMA-J AM MED ASSOC, V283, P2417, DOI 10.1001/jama.283.18.2417; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; HIRSCHTICK RE, 1995, NEW ENGL J MED, V333, P845, DOI 10.1056/NEJM199509283331305; Hockett RD, 1999, J EXP MED, V189, P1545, DOI 10.1084/jem.189.10.1545; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; Hogg RS, 2001, JAMA-J AM MED ASSOC, V286, P2568, DOI 10.1001/jama.286.20.2568; Hughes MD, 1997, ANN INTERN MED, V126, P929, DOI 10.7326/0003-4819-126-12-199706150-00001; *INT AIDS SOC US R, 2002, UPD DRUG RES MUT HIV; Junghans C, 1999, LANCET, V353, P589, DOI 10.1016/S0140-6736(05)75645-2; KAHN SE, 1989, DIABETES, V38, P562, DOI 10.2337/diabetes.38.5.562; KAPLAN J, 2001, 8 C RETR OPP INF FEB; Kaufmann GR, 2000, AIDS, V14, P959, DOI 10.1097/00002030-200005260-00007; Kemper CA, 2001, AIDS, V15, P609, DOI 10.1097/00002030-200103300-00010; Kempf DJ, 1998, AIDS, V12, pF9, DOI 10.1097/00002030-199805000-00001; KERULY JC, 2001, 8 C RETR OPP INF FEB; Kessler HA, 2002, CLIN INFECT DIS, V34, P535, DOI 10.1086/338638; Kilby JM, 1997, AIDS RES HUM RETROV, V13, P1533, DOI 10.1089/aid.1997.13.1533; Kim S, 2000, AIDS RES HUM RETROV, V16, P645, DOI 10.1089/088922200308873; KING M, 2001, 8 C RETR OPP INF FEB; KNOBEL H, 2001, 8 C RETR OPP INF FEB; KOVACS JA, 1995, NEW ENGL J MED, V332, P567, DOI 10.1056/NEJM199503023320904; KUROWSKI M, 2000, 40 INT C ANT AG CHEM; KUROWSKI M, 2001, 1 INT AIDS SOC C HIV; LANIER ER, 2001, 8 C RETR OPP INF FEB; LAWAL A, 2001, 8 C RETR OPP INF FEB; Le Moing V, 2002, J INFECT DIS, V185, P471, DOI 10.1086/338929; Lenzo NP, 1997, AIDS, V11, P1294, DOI 10.1097/00002030-199710001-00003; Lepri AC, 2001, AIDS, V15, P47, DOI 10.1097/00002030-200101050-00008; Leri F, 1999, AIDS, V13, P1433, DOI 10.1097/00002030-199908200-00001; Levy Y, 1999, LANCET, V353, P1923, DOI 10.1016/S0140-6736(98)07345-0; LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417; Li TS, 1998, LANCET, V351, P1682, DOI 10.1016/S0140-6736(97)10291-4; Little SJ, 1999, JAMA-J AM MED ASSOC, V282, P1142, DOI 10.1001/jama.282.12.1142; Lo JC, 1998, LANCET, V351, P867, DOI 10.1016/S0140-6736(97)11443-X; Lonergan JT, 2000, CLIN INFECT DIS, V31, P162, DOI 10.1086/313912; Lori F, 2001, JAMA-J AM MED ASSOC, V286, P2981, DOI 10.1001/jama.286.23.2981; LOUIE M, 2002, 9 C RETR OPP INF FEB; Lyles RH, 2000, J INFECT DIS, V181, P872, DOI 10.1086/315339; MacGregor RR, 1998, J INFECT DIS, V178, P92, DOI 10.1086/515613; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Marschner IC, 1998, J INFECT DIS, V177, P40, DOI 10.1086/513823; MCGOWAN I, 2001, 8 C RETR OPP INF FEB; Melby T, 2001, 8 C RETR OPP INF FEB; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; MEYER D, 2000, ANTIVIR THER, V5, P54; Miller MD, 2001, NUCLEOS NUCLEOT NUCL, V20, P1025, DOI 10.1081/NCN-100002483; Miller V, 2000, ANTIVIR THER, V5, P49; Miller V, 2000, AIDS, V14, P2857, DOI 10.1097/00002030-200012220-00007; MILLER V, 2002, 9 C RETR OPP INF FEB; Mocroft A, 2000, AIDS, V14, P1545, DOI 10.1097/00002030-200007280-00010; MONTANER J, 2000, 13 INT C AIDS JUL 9; MONTANER JSG, 2001, 41 INT C ANT AG CHEM; MOYLE GJ, 2001, ANTIVIR THER S4, V6, P66; MOYLE GJ, 2001, 3 INT WORKSH ADV DRU; Mulligan K, 2000, J ACQ IMMUN DEF SYND, V23, P35, DOI 10.1097/00042560-200001010-00005; Murphy RL, 1999, J INFECT DIS, V179, P808, DOI 10.1086/314668; Murphy RL, 2001, AIDS, V15, pF1, DOI 10.1097/00002030-200101050-00002; MURPHY RL, 1999, 39 INT C ANT AG CHEM; *NAT CHOL ED PROGR, 1994, CIRCULATION, V89, P1333; Neuvonen PJ, 1998, CLIN PHARMACOL THER, V63, P332, DOI 10.1016/S0009-9236(98)90165-5; Neuvonen PJ, 1996, CLIN PHARMACOL THER, V60, P54, DOI 10.1016/S0009-9236(96)90167-8; Noor MA, 2001, AIDS, V15, pF11, DOI 10.1097/00002030-200105040-00001; OPRAVIL M, 2001, 8 C RETR OPP INF FEB; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Palmer S, 2001, AIDS RES HUM RETROV, V17, P1167, DOI 10.1089/088922201316912772; Parkin NT, 2000, AIDS, V14, P2877, DOI 10.1097/00002030-200012220-00009; Perilla JL, 1999, HISPANIC J BEHAV SCI, V21, P107, DOI 10.1177/0739986399212001; Petit JM, 2000, HORM METAB RES, V32, P367, DOI 10.1055/s-2007-978655; Phillips AN, 2001, JAMA-J AM MED ASSOC, V286, P2560, DOI 10.1001/jama.286.20.2560; Pialoux G, 1998, NEW ENGL J MED, V339, P1269, DOI 10.1056/NEJM199810293391802; Pirmohamed M, 2001, CURR OPIN ALLERGY CL, V1, P311, DOI 10.1097/00130832-200108000-00006; PODZAMCZER D, 2001, 1 INT AIDS SOC C HIV; Polis MA, 2001, LANCET, V358, P1760, DOI 10.1016/S0140-6736(01)06802-7; Powderly WG, 1999, AIDS, V13, P1873, DOI 10.1097/00002030-199910010-00009; Purnell JQ, 2000, AIDS, V14, P51, DOI 10.1097/00002030-200001070-00006; Raboud JM, 1998, AIDS, V12, P1619, DOI 10.1097/00002030-199813000-00008; Rizzardi GP, 2000, J CLIN INVEST, V105, P777, DOI 10.1172/JCI9079; Roberts AD, 1999, CLIN INFECT DIS, V29, P441, DOI 10.1086/520231; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; *ROX LAB INC, 2000, VIR; Ruiz L, 2001, AIDS, V15, pF19, DOI 10.1097/00002030-200106150-00001; Saag MS, 2002, TOPICS HIV MED, V10, P47; Saint-Marc T, 1999, AIDS, V13, P1659, DOI 10.1097/00002030-199909100-00009; Schapiro JM, 1996, ANN INTERN MED, V124, P1039, DOI 10.7326/0003-4819-124-12-199606150-00003; SCHOOLEY R, 2001, 41 INT C ANT AG CHEM; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; Scribner AN, 2000, J ACQ IMMUN DEF SYND, V25, P19, DOI 10.1097/00126334-200009010-00003; Sereti I, 2001, CLIN INFECT DIS, V32, P1738, DOI 10.1086/320758; Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999; Smith S C Jr, 2000, Circulation, V101, P111; SPRITZLER J, 2002, 9 C RETR OPP INF FEB; SQUIRES K, 2001, 41 INT C ANT AG CHEM; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; Staszewski S, 2001, JAMA-J AM MED ASSOC, V285, P1155, DOI 10.1001/jama.285.9.1155; Staszewski S, 1999, INT J CLIN PRACT, P10; Stenzel M S, 2001, AIDS Read, V11, P317; STERLING TR, 2001, 8 C RETR OPP INF FEB; Stone VE, 2001, J ACQ IMMUN DEF SYND, V28, P124, DOI 10.1097/00042560-200110010-00003; Sulkowski MS, 2000, JAMA-J AM MED ASSOC, V283, P74, DOI 10.1001/jama.283.1.74; Tarwater PM, 2001, J ACQ IMMUN DEF SYND, V27, P168, DOI 10.1097/00126334-200106010-00012; Tashima KT, 2001, CLIN INFECT DIS, V33, P2055, DOI 10.1086/323978; Tebas P, 2000, AIDS, V14, pF63, DOI 10.1097/00002030-200003100-00005; Tortajada C, 2000, J ACQ IMMUN DEF SYND, V25, P296, DOI 10.1097/00126334-200012010-00002; Tuldra A, 2000, J ACQ IMMUN DEF SYND, V25, P221, DOI 10.1097/00126334-200011010-00003; Tural C, 2002, AIDS, V16, P209, DOI 10.1097/00002030-200201250-00010; *US FDA, 2001, FDA BRIST MYERS SQUI; *US PHS, 2002, GUID US ANT AG HIV I; *USPHS IDSA PREV O, 2001, USPHS IDSA GUID PREV; van der Valk M, 2001, AIDS, V15, P2407, DOI 10.1097/00002030-200112070-00008; VANGEMEN B, 2001, 3 INT WORKSH ADV DRU; Yamashita TE, 2001, AIDS, V15, P735, DOI 10.1097/00002030-200104130-00009; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101; Zolopa AR, 1999, ANN INTERN MED, V131, P813, DOI 10.7326/0003-4819-131-11-199912070-00003	186	594	610	0	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	2002	288	2					222	235		10.1001/jama.288.2.222	http://dx.doi.org/10.1001/jama.288.2.222			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	571HC	12095387				2022-12-28	WOS:000176711100023
J	Joffe, BI				Joffe, BI			Uses of error - Always something new from Africa	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 6	2002	360	9326					72	72		10.1016/S0140-6736(02)09338-8	http://dx.doi.org/10.1016/S0140-6736(02)09338-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569JR	12114059				2022-12-28	WOS:000176599700028
J	Moore, DAJ; Girdwood, RWA; Chiodini, PL				Moore, DAJ; Girdwood, RWA; Chiodini, PL			Treatment of anisakiasis with albendazole	LANCET			English	Article									Hosp Trop Dis, London, England; UCL Hosp, London, England; Scottish Parasit Diagnost Lab, Glasgow, Lanark, Scotland	University College London Hospitals NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine; University College London Hospitals NHS Foundation Trust; University of London; University College London	Chiodini, PL (corresponding author), Hosp Trop Dis, London, England.	peter.chiodini@uclh.org						HUBERT B, 1989, AM J TROP MED HYG, V40, P301, DOI 10.4269/ajtmh.1989.40.301; KLIKS MM, 1983, AM J TROP MED HYG, V32, P526, DOI 10.4269/ajtmh.1983.32.526; OSHIMA T, 1987, PARASITOL TODAY, V3, P44, DOI 10.1016/0169-4758(87)90212-2; SAKANARI JA, 1989, CLIN MICROBIOL REV, V2, P278, DOI 10.1128/CMR.2.3.278-284.1989; WATT IA, 1979, LANCET, V2, P893	5	40	41	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 6	2002	360	9326					54	54		10.1016/S0140-6736(02)09333-9	http://dx.doi.org/10.1016/S0140-6736(02)09333-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569JR	12114042				2022-12-28	WOS:000176599700012
J	Gruninger, M; Ruckamp, R; Windt, M; Reutler, P; Zobel, C; Lorenz, T; Freimuth, A; Revcolevschi, A				Gruninger, M; Ruckamp, R; Windt, M; Reutler, P; Zobel, C; Lorenz, T; Freimuth, A; Revcolevschi, A			Orbital physics - Experimental quest for orbital waves	NATURE			English	Article							LAMNO3; SCATTERING		Univ Cologne, Inst Phys 2, D-50937 Cologne, Germany; Rhein Westfal TH Aachen, D-52056 Aachen, Germany; Univ Paris 11, Lab Physicochim Etat Solide, F-91405 Orsay, France	University of Cologne; RWTH Aachen University; UDICE-French Research Universities; Universite Paris Saclay	Gruninger, M (corresponding author), Univ Cologne, Inst Phys 2, D-50937 Cologne, Germany.		Lorenz, Thomas/AAC-3331-2020; Lorenz, Thomas/J-2955-2017	Lorenz, Thomas/0000-0003-4832-5157; Lorenz, Thomas/0000-0003-4832-5157; Gruninger, Markus/0000-0002-6550-8054				Ahn KH, 2000, PHYS REV B, V61, P13545, DOI 10.1103/PhysRevB.61.13545; Allen PB, 1999, PHYS REV LETT, V83, P4828, DOI 10.1103/PhysRevLett.83.4828; Bala J, 2000, PHYS REV B, V62, pR6085, DOI 10.1103/PhysRevB.62.R6085; Ballhausen C.J., 1962, ADV CHEM SER; Elfimov IS, 1999, PHYS REV LETT, V82, P4264, DOI 10.1103/PhysRevLett.82.4264; Paolone A, 2000, PHYS REV B, V61, P11255, DOI 10.1103/PhysRevB.61.11255; Perebeinos V, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.085118; Pickett WE, 1996, PHYS REV B, V53, P1146, DOI 10.1103/PhysRevB.53.1146; Saitoh E, 2001, NATURE, V410, P180, DOI 10.1038/35065547; Solovyev I, 1996, PHYS REV B, V53, P7158, DOI 10.1103/PhysRevB.53.7158	11	53	54	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 4	2002	418	6893					39	40		10.1038/418039a	http://dx.doi.org/10.1038/418039a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	569JL	12097901				2022-12-28	WOS:000176599200031
J	Pollack, RJ; Kiszewski, AE; Spielman, A				Pollack, RJ; Kiszewski, AE; Spielman, A			Perspective - Repelling mosquitoes	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Pollack, RJ (corresponding author), Harvard Univ, Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA.								0	15	18	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 4	2002	347	1					2	3		10.1056/NEJM200207043470102	http://dx.doi.org/10.1056/NEJM200207043470102			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569HA	12097533				2022-12-28	WOS:000176594500001
J	Allan, D; Jones, B				Allan, D; Jones, B			Compartment syndrome: a forgotten diagnosis	LANCET			English	Editorial Material							VENOUS THROMBOEMBOLISM; THROMBOSIS; TRAVEL; RISK		So Gen Hosp, S Glasgow Univ Hosp NHS Trust, Glasgow G51 4TF, Lanark, Scotland	University of Glasgow	Allan, D (corresponding author), So Gen Hosp, S Glasgow Univ Hosp NHS Trust, Glasgow G51 4TF, Lanark, Scotland.	davidballan@aol.com						Arfvidsson B, 2000, HEMATOL ONCOL CLIN N, V14, P391, DOI 10.1016/S0889-8588(05)70140-4; Hansson PO, 1997, ARCH INTERN MED, V157, P1665, DOI 10.1001/archinte.157.15.1665; Hirsh J, 2001, LANCET, V357, P1461, DOI 10.1016/S0140-6736(00)04669-9; Kraaijenhagen RA, 2000, LANCET, V356, P1492, DOI 10.1016/S0140-6736(00)02878-6; McQueen MM, 1996, J BONE JOINT SURG BR, V78B, P99, DOI 10.1302/0301-620X.78B1.0780099	5	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 29	2002	359	9325					2248	2248		10.1016/S0140-6736(02)09296-6	http://dx.doi.org/10.1016/S0140-6736(02)09296-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567YJ	12103290				2022-12-28	WOS:000176514500012
J	Goldmeier, D; Lamba, H				Goldmeier, D; Lamba, H			Prolonged erections produced by dihydrocodeine and sildenafil	BRITISH MEDICAL JOURNAL			English	Editorial Material									St Marys Hosp, London W2 1NY, England	Imperial College London	Goldmeier, D (corresponding author), St Marys Hosp, Praed St, London W2 1NY, England.							Gulliford S., 1998, J PHARM CARE PAIN SY, V6, P67, DOI [10.1300/J088v06n02_05, DOI 10.1300/J088V06N02_05]; Kassim AA, 2000, BLOOD, V95, P1878, DOI 10.1182/blood.V95.5.1878; MIRIN SM, 1980, AM J PSYCHIAT, V137, P909; Sur R L, 2000, Urology, V55, P950, DOI 10.1016/S0090-4295(99)00610-X	4	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 29	2002	324	7353					1555	1555		10.1136/bmj.324.7353.1555	http://dx.doi.org/10.1136/bmj.324.7353.1555			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	570WP	12089093	Bronze, Green Published			2022-12-28	WOS:000176683000019
J	Kaufman, J; Jing, J				Kaufman, J; Jing, J			AIDS - China and AIDS - The time to act is now	SCIENCE			English	Editorial Material									Harvard Univ, Radcliffe Inst Adv Studies, Cambridge, MA 02138 USA; Tsinghua Univ, Beijing 100084, Peoples R China	Harvard University; Tsinghua University	Kaufman, J (corresponding author), 50 Woodridge Rd, Wellesley, MA 02482 USA.	joankaufman@levineonline.com						[Anonymous], 1997, NIH Consens Statement, V15, P1; Beyrer C, 2000, AIDS, V14, P75, DOI 10.1097/00002030-200001070-00009; CHAN E, 2001, REUTERS         1115; *CHIN UN THEM GROU, 2001, HIV AIDS CHIN TIT PE; *CHIN UN THEM GROU, 1997, CHIN RESP AIDS HIV A; CHUAN Q, 2001, CHINA DAILY     1114; Cowhig D., 2000, LIANHE ZAOBAO   1002; HE A, 2000, REVEALING BLOOD WOUN; JING J, 2002, WORKSH CHANG HLTH NE; Kaufman J, 1999, STUD FAMILY PLANN, V30, P112, DOI 10.1111/j.1728-4465.1999.00112.x; LIU W, 2002, 12 INT AIDS C DURB S; *MIN HLTH BRAZ, HIV AIDS CONTR BRAZ; NANTULYA V, 2002, SEM HARV U CTR POP D; PAN S, 2001, UNPUB 1 CHIN C AIDS; Rosenthal E, 2008, NY TIMES        0820, pA1; Saich T, 2000, CHINA QUART, P124; *SHANGH I PLANN PA, 2000, P INT S REPR HLTH RE; *UNAIDS, 2001, UNAIDS0115E; *UNAIDS CHIN, 2000, WE CARE DO YOU; XIN Y, 2002, HIV AIDS RELATED MEN; ZHANG B, 2001, FRIENDS EXCHANGE APR; ZHANG B, 2000, UNPUB SURVEY HIV AID; 2000, CHINA HLTH NEWS 0726; 2002, CHINA DAILY     0412; 2000, CHINA HLTH NEWS 0828; 2000, SO WEEKEND      1130	26	97	109	2	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 28	2002	296	5577					2339	2340		10.1126/science.1074479	http://dx.doi.org/10.1126/science.1074479			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	567CE	12089428				2022-12-28	WOS:000176467200022
J	Lee, SK; Yu, SL; Prakash, L; Prakash, S				Lee, SK; Yu, SL; Prakash, L; Prakash, S			Requirement of yeast RAD2, a homolog of human XPG gene, for efficient RNA polymerase II transcription: Implications for Cockayne syndrome	CELL			English	Article							NUCLEOTIDE EXCISION-REPAIR; XERODERMA-PIGMENTOSUM PATIENTS; SACCHAROMYCES-CEREVISIAE; DNA-REPAIR; COUPLED REPAIR; 6-AZAURACIL SENSITIVITY; NUCLEASE ACTIVITY; ABASIC SITES; IN-VITRO; B GENE	In addition to xeroderma pigmentosum, mutations in the human XPG gene cause early onset Cockayne syndrome (CS). Here, we provide evidence for the involvement of RAD2, the S. cerevisiae counterpart of XPG, in promoting efficient RNA polymerase II transcription. Inactivation of RAD26, the S. cerevisiae counterpart of the human CSB gene, also causes a deficiency in transcription, and a synergistic decline in transcription occurs in the absence of both the RAD2 and RAD26 genes. Growth is also retarded in the rad2Delta and rad26Delta single mutant strains, and a very severe growth inhibition is seen in the rad2Delta rad26Delta double mutant. From these and other observations presented here, we suggest that transcriptional defects are the underlying cause of CS.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Prakash, S (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6-104 Blocker Med Res Bldg,11th & Mech St, Galveston, TX 77555 USA.		Prakash, Satya/C-6420-2013	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NATIONAL CANCER INSTITUTE [R01CA041261, R01CA035035, R37CA041261, R37CA035035] Funding Source: NIH RePORTER; NCI NIH HHS [CA35035, CA41261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; CHRISTIE KR, 1994, J BIOL CHEM, V269, P936; Coin F, 1999, EMBO J, V18, P1357, DOI 10.1093/emboj/18.5.1357; Constantinou A, 1999, J BIOL CHEM, V274, P5637, DOI 10.1074/jbc.274.9.5637; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; Guzder SN, 1996, J BIOL CHEM, V271, P18314, DOI 10.1074/jbc.271.31.18314; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; HABRAKEN Y, 1995, J BIOL CHEM, V270, P30194; Hanawalt PC, 2000, NATURE, V405, P415, DOI 10.1038/35013197; Harada YN, 1999, MOL CELL BIOL, V19, P2366, DOI 10.1128/mcb.19.3.2366; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; HIGGINS DR, 1984, GENE, V30, P121, DOI 10.1016/0378-1119(84)90112-4; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Lee SK, 2001, MOL CELL BIOL, V21, P8651, DOI 10.1128/MCB.21.24.8651-8656.2001; Lennon JC, 1998, MOL CELL BIOL, V18, P5771, DOI 10.1128/MCB.18.10.5771; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; NAKANISHI T, 1995, J BIOL CHEM, V270, P8991, DOI 10.1074/jbc.270.15.8991; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; Nouspikel T, 1997, P NATL ACAD SCI USA, V94, P3116, DOI 10.1073/pnas.94.7.3116; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; Powell W, 1996, J BIOL CHEM, V271, P6866, DOI 10.1074/jbc.271.12.6866; Prakash S, 2000, MUTAT RES-FUND MOL M, V451, P13, DOI 10.1016/S0027-5107(00)00037-3; QIU HF, 1993, GENE DEV, V7, P2161, DOI 10.1101/gad.7.11.2161; Reardon JT, 1997, P NATL ACAD SCI USA, V94, P9463, DOI 10.1073/pnas.94.17.9463; REINES D, 1994, TRANSCRIPTION MECHAN, P263; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; Shaw RJ, 2000, MOL CELL BIOL, V20, P7427, DOI 10.1128/MCB.20.20.7427-7437.2000; Torres-Ramos CA, 2000, MOL CELL BIOL, V20, P3522, DOI 10.1128/MCB.20.10.3522-3528.2000; TRECO DA, 1993, CURRENT PROTOCOLS MO, V2; vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8; VANGOOL AJ, 1994, EMBO J, V13, P5361, DOI 10.1002/j.1460-2075.1994.tb06871.x; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707	43	70	71	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 28	2002	109	7					823	834		10.1016/S0092-8674(02)00795-X	http://dx.doi.org/10.1016/S0092-8674(02)00795-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	570KJ	12110180	Bronze			2022-12-28	WOS:000176657200006
J	Wardle, M; Yusef-Zadeh, F				Wardle, M; Yusef-Zadeh, F			Astronomy - Supernova remnant OH masers: signposts of cosmic collision	SCIENCE			English	Review							MAGNETOHYDRODYNAMIC SHOCK-WAVES; FORMED DENSE SHELL; 1720 MHZ MASERS; GALACTIC-CENTER; MOLECULAR CLOUDS; INTERSTELLAR-MEDIUM; MAGNETIC-FIELD; RESOLUTION OBSERVATIONS; CIRCULAR-POLARIZATION; ASTROPHYSICAL MASERS		Univ Sydney, Sch Phys, Res Ctr Theoret Astrophys A28, Sydney, NSW 2006, Australia; Northwestern Univ, Dept Phys & Astron, Evanston, IL 60208 USA	University of Sydney; Northwestern University	Wardle, M (corresponding author), Univ Sydney, Sch Phys, Res Ctr Theoret Astrophys A28, Sydney, NSW 2006, Australia.	wardle@physics.usyd.edu.au		Wardle, Mark/0000-0002-1737-0871				Arikawa Y, 1999, PUBL ASTRON SOC JPN, V51, pL7, DOI 10.1093/pasj/51.4.L7; Borkowski KJ, 2001, ASTROPHYS J, V550, P334, DOI 10.1086/319716; Bourke TL, 2001, ASTROPHYS J, V554, P916, DOI 10.1086/321405; BRAND PWJL, 1988, ASTROPHYS J, V334, pL103, DOI 10.1086/185322; Brogan CL, 2000, ASTROPHYS J, V537, P875, DOI 10.1086/309068; BURTON MG, 1990, ASTROPHYS J, V355, P158; CAMERON AGW, 1957, PUBL ASTRON SOC PAC, V69, P201, DOI 10.1086/127051; CHERNOFF DF, 1982, ASTROPHYS J, V259, pL97, DOI 10.1086/183855; Chevalier RA, 1999, ASTROPHYS J, V511, P798, DOI 10.1086/306710; Claussen MJ, 1997, ASTROPHYS J, V489, P143, DOI 10.1086/304784; Cox DP, 1999, ASTROPHYS J, V524, P179, DOI 10.1086/307781; DENOYER LK, 1979, ASTROPHYS J, V228, pL41, DOI 10.1086/182899; DESFORETS GP, 1986, MON NOT R ASTRON SOC, V223, P743; DRAINE BT, 1982, ASTROPHYS J, V259, pL91, DOI 10.1086/183854; DRAINE BT, 1993, ANNU REV ASTRON ASTR, V31, P373, DOI 10.1146/annurev.aa.31.090193.002105; DRAINE BT, 1983, ASTROPHYS J, V264, P485, DOI 10.1086/160617; Dubner GM, 2000, ASTRON J, V120, P1933, DOI 10.1086/301583; Elitzur M, 1996, ASTROPHYS J, V457, P415, DOI 10.1086/176741; ELITZUR M, 1992, ANNU REV ASTRON ASTR, V30, P75; ELITZUR M, 1976, ASTROPHYS J, V203, P124, DOI 10.1086/154054; Elitzur M, 1998, ASTROPHYS J, V504, P390, DOI 10.1086/306076; FRAIL DA, 1994, ASTROPHYS J, V424, pL111, DOI 10.1086/187287; Frail DA, 1996, ASTRON J, V111, P1651, DOI 10.1086/117904; Frail DA, 1998, ASTROPHYS J, V508, P690, DOI 10.1086/306452; GOSS WM, 1968, ASTROPHYS LETT COMM, V2, P81; GRAY AD, 1995, ASTROPHYS J, V448, P164, DOI 10.1086/175949; Gray M, 1999, PHILOS T R SOC A, V357, P3277, DOI 10.1098/rsta.1999.0494; Green AJ, 1997, ASTRON J, V114, P2058, DOI 10.1086/118626; GREEN AJ, 2000, 24 M IAU JOINT DISC; HARTQUIST TW, 1995, MON NOT R ASTRON SOC, V272, P184, DOI 10.1093/mnras/272.1.184; HARTQUIST TW, 1994, ASTROPHYS SPACE SCI, V216, P185, DOI 10.1007/BF00982493; HARTQUIST TW, 1991, MON NOT R ASTRON SOC, V248, P48, DOI 10.1093/mnras/248.1.48; Kaufman MJ, 1996, ASTROPHYS J, V456, P611, DOI 10.1086/176683; Koralesky B, 1998, ASTRON J, V116, P1323, DOI 10.1086/300508; Lazendic JS, 2002, MON NOT R ASTRON SOC, V331, P537, DOI 10.1046/j.1365-8711.2002.05227.x; LAZENDIC JS, UNPUB; Lockett P, 1999, ASTROPHYS J, V511, P235, DOI 10.1086/306667; MCKEE CF, 1977, ASTROPHYS J, V218, P148, DOI 10.1086/155667; MCKEE CF, 1978, ASTROPHYS J, V219, pL23, DOI 10.1086/182599; MIYOSHI M, 1995, NATURE, V373, P127, DOI 10.1038/373127a0; MULLAN DJ, 1971, MON NOT R ASTRON SOC, V153, P145, DOI 10.1093/mnras/153.2.145; PASTCHENKO MI, 1974, ASTRON ASTROPHYS, V35, P153; PRASAD SS, 1983, ASTROPHYS J, V267, P603, DOI 10.1086/160896; REID MJ, 1981, ANNU REV ASTRON ASTR, V19, P231, DOI 10.1146/annurev.aa.19.090181.001311; Rho J, 1998, ASTROPHYS J, V503, pL167, DOI 10.1086/311538; RICHTER MJ, 1995, ASTROPHYS J, V449, pL83, DOI 10.1086/309624; SHAVER PA, 1985, ASTRON ASTROPHYS, V147, pL23; Shelton RL, 1999, ASTROPHYS J, V524, P192, DOI 10.1086/307799; STEWART RT, 1994, ASTROPHYS J, V432, pLO9; Wardle M, 1999, ASTROPHYS J, V525, pL101, DOI 10.1086/312351; Wardle M, 1999, ASTR SOC P, V186, P432; Watson WD, 2001, ASTROPHYS J, V558, pL55, DOI 10.1086/323513; WEAVER H, 1965, NATURE, V208, P29, DOI 10.1038/208029a0; WEILER KW, 1988, ANNU REV ASTRON ASTR, V26, P295; WEINREB S, 1963, NATURE, V208, P29; Yusef-Zadeh F, 1999, ASTROPHYS J, V527, P172, DOI 10.1086/308087; Yusef-Zadeh F, 1999, ASTROPHYS J, V512, P230, DOI 10.1086/306769; Yusef-Zadeh F, 2001, ASTROPHYS J, V560, P749, DOI 10.1086/322496; Yusef-Zadeh F, 2000, SCIENCE, V287, P85, DOI 10.1126/science.287.5450.85; YUSEFZADEH F, 1995, SCIENCE, V270, P1801, DOI 10.1126/science.270.5243.1801; Zweibel EG, 1999, PHYS PLASMAS, V6, P1725, DOI 10.1063/1.873431	61	70	71	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 28	2002	296	5577					2350	2354		10.1126/science.1068168	http://dx.doi.org/10.1126/science.1068168			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	567CE	12089433	Green Submitted			2022-12-28	WOS:000176467200029
J	Brown, DA; Breit, SN; Buring, J; Fairlie, WD; Bauskin, AR; Liu, T; Ridker, PM				Brown, DA; Breit, SN; Buring, J; Fairlie, WD; Bauskin, AR; Liu, T; Ridker, PM			Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study	LANCET			English	Article							TGF-BETA SUPERFAMILY; GROWTH-FACTOR-BETA; C-REACTIVE PROTEIN; ATHEROSCLEROSIS; DISEASE; MEMBER; MIC-1; P53; INFLAMMATION; EXPRESSION	Background Macrophage inhibitory cytokine-1 (MIC-1) is part of the TGF-beta superfamily. Raised concentrations of MIC-1 in serum arise in several disease states, can be detected in normal individuals, and can partly be genetically determined. We aimed to investigate whether MIC-1 has a role in atherothrombosis. Methods We did a prospective, nested, case-control study in 27 628 initially healthy women. Of these women, we established baseline concentrations of MIC-1 in 257 who subsequently had myocardial infarction, stroke, or died from a cardiovascular event (cases) and in 257 matched for age and smoking status, who did not report cardiovascular disease during 4-year follow-up (controls). We also assessed polymorphisms in the MIC-1 gene (MIC-1 H and MIC-1 D) in all 514 women. Findings MIC-1 concentrations were higher at baseline in women who subsequently had cardiovascular events than in those who did not (618 vs 538 pg/mL, p=0.0002). Concentrations above the 90th percentile (>856 pg/mL) were associated with a 2.7-fold increase in risk (95% CI 1.6-4.9, p=0.001). This effect was independent of traditional cardiovascular risk factors and at least additive to that of C-reactive protein. There was no significant association between MIC-1 polymorphism and vascular events. Interpretation MIC-1 could be a novel target for cardiovascular disease prevention.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Leducq Ctr Cardiovasc Res, Boston, MA 02115 USA; St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia; Univ New S Wales, Sydney, NSW, Australia	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; St Vincents Hospital Sydney; University of New South Wales Sydney	Ridker, PM (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, 900 Commonwealth Ave E, Boston, MA 02115 USA.	pridker@partners.org	Fairlie, Walter/M-8401-2015; Liu, Tao/A-3922-2015	Fairlie, Walter/0000-0002-2498-1160; Brown, David/0000-0003-1382-9419; Liu, Tao/0000-0001-6244-7316	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063293, R01HL058755] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-63293, HL-58755] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baoutina A, 2001, TRENDS CARDIOVAS MED, V11, P1, DOI 10.1016/S1050-1738(01)00075-5; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Bottner M, 1999, CELL TISSUE RES, V297, P103, DOI 10.1007/s004410051337; BROWN DA, 2001, J LEUKOCYTE BIOL   S, V90, P311; BROWN DA, IN PRESS BIOTECHNIQU; Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P27; Fairlie WD, 1999, J LEUKOCYTE BIOL, V65, P2, DOI 10.1002/jlb.65.1.2; Fairlie WD, 2001, BIOCHEMISTRY-US, V40, P65, DOI 10.1021/bi001064p; Kannan K, 2000, FEBS LETT, V470, P77, DOI 10.1016/S0014-5793(00)01291-6; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Mayr M, 2001, EXP GERONTOL, V36, P969, DOI 10.1016/S0531-5565(01)00090-0; Moore AG, 2000, J CLIN ENDOCR METAB, V85, P4781, DOI 10.1210/jc.85.12.4781; Ridker PM, 2000, CIRCULATION, V101, P1767, DOI 10.1161/01.CIR.101.15.1767; Ridker PM, 2001, NEW ENGL J MED, V344, P1959, DOI 10.1056/NEJM200106283442601; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; STARY HC, 1994, ARTERIOSCLER THROMB, V14, P840, DOI 10.1161/01.ATV.14.5.840; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Tegos TJ, 2001, ANGIOLOGY, V52, P89, DOI 10.1177/000331970105200201; VONDERTHUSEN TH, 2000, J SUBMICR CYTOL PATH, V32, P328	21	200	237	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 22	2002	359	9324					2159	2163		10.1016/S0140-6736(02)09093-1	http://dx.doi.org/10.1016/S0140-6736(02)09093-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566RJ	12090982				2022-12-28	WOS:000176441800011
J	Carrese, JA; Mullaney, JL; Faden, RR; Finucane, TE				Carrese, JA; Mullaney, JL; Faden, RR; Finucane, TE			Planning for death but not serious future illness: qualitative study of housebound elderly patients	BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	Annual Meeting of the American-Society-for-Bioethics-and-Humanities	OCT, 2000	SALT LAKE CITY, UTAH	Amer Soc Bioethics & Humanities			LIFE DECISION-MAKING; END; CARE; CANCER	Objective To understand how elderly patients think about and approach future illness and the end of life. Design Qualitative study conducted 1997-9. Setting Physician housecall programme affiliated to US university Participants 20 chronically ill housebound patients aged over 75 years who could participate in an interview. Participants identified through purposive and random sampling. Main outcome measures In-depth semistructured interviews lasting one to two hours. Results Sixteen people said that they did not think about the future or did not in general plan for the future. Nineteen were particularly reluctant to think about, discuss, or plan for serious future illness. Instead they described a "one day at a time," "what is to be will be" approach to life, preferring to "cross that bridge" when they got to it. Participants considered end of life matters to be in the hands of God, though 13 participants had made wills and 19 had funeral plans. Although some had completed advance directives, these were not well understood and were intended for use only when death was near and certain. Conclusions The elderly people inter-viewed for this study were resistant to planning in advance for the hypothetical future, particularly for serious illness when death is possible but not certain.	Johns Hopkins Univ, Phoebe R Berman Bioeth Inst, Baltimore, MD 21224 USA; Johns Hopkins Bayview Med Ctr, Div Gen Internal Med, Baltimore, MD 21224 USA; Goucher Coll, Dept Sociol & Anthropol, Baltimore, MD 21204 USA; Johns Hopkins Bayview Med Ctr, Div Geriatr, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Carrese, JA (corresponding author), Johns Hopkins Univ, Phoebe R Berman Bioeth Inst, 4940 Eastern Ave, Baltimore, MD 21224 USA.							BERNARD H, 1994, RES METHODS ANTHR QU, P95; Carrese JA, 2000, J GEN INTERN MED, V15, P92, DOI 10.1046/j.1525-1497.2000.03399.x; CARRESE JA, 1995, JAMA-J AM MED ASSOC, V274, P826, DOI 10.1001/jama.274.10.826; CASSEL CK, 1997, APPROACHING DEATH IM, P139; CRABTREE BF, 1992, DOING QUALITATIVE RE, P18; Curtis JR, 1997, J GEN INTERN MED, V12, P736, DOI 10.1046/j.1525-1497.1997.07158.x; Finucane TE, 1999, JAMA-J AM MED ASSOC, V282, P1670, DOI 10.1001/jama.282.17.1670; Hern HE, 1998, CAMB Q HEALTHC ETHIC, V7, P27, DOI 10.1017/S0963180198701045; Lynn J, 1997, J AM GERIATR SOC, V45, P526; Lynn J, 2001, J GEN INTERN MED, V16, P315, DOI 10.1046/j.1525-1497.2001.90901.x; Martin DK, 1999, ARCH INTERN MED, V159, P86, DOI 10.1001/archinte.159.1.86; McKinley ED, 1996, J GEN INTERN MED, V11, P651, DOI 10.1007/BF02600155; MUECKE MA, 1993, CRITICAL ISSUES QUAL, P198; PEREZSTABLE EJ, 1992, JAMA-J AM MED ASSOC, V268, P3219, DOI 10.1001/jama.268.22.3219; PERKINS HS, 1993, J CLIN ETHIC, V4, P145; PFEIFER MP, 1994, J GEN INTERN MED, V9, P82, DOI 10.1007/BF02600206; Rosenfeld KE, 2000, J GEN INTERN MED, V15, P620, DOI 10.1046/j.1525-1497.2000.06289.x; SEHGAL A, 1992, JAMA-J AM MED ASSOC, V267, P59, DOI 10.1001/jama.267.1.59; Terry PB, 1999, J CLIN ETHIC, V10, P286; TSUJI I, 1995, J AM GERIATR SOC, V43, P761, DOI 10.1111/j.1532-5415.1995.tb07046.x	20	60	61	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 20	2002	325	7356					125	127		10.1136/bmj.325.7356.125	http://dx.doi.org/10.1136/bmj.325.7356.125			5	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	577PG	12130597	Bronze, Green Published			2022-12-28	WOS:000177069900016
J	Bolla, M; Collette, L; Blank, L; Warde, P; Dubois, JB; Mirimanoff, RO; Storme, G; Bernier, J; Kuten, A; Sternberg, C; Mattelaer, J; Torecilla, JL; Pfeffer, JR; Cutajar, CL; Zurlo, A; Pierart, M				Bolla, M; Collette, L; Blank, L; Warde, P; Dubois, JB; Mirimanoff, RO; Storme, G; Bernier, J; Kuten, A; Sternberg, C; Mattelaer, J; Torecilla, JL; Pfeffer, JR; Cutajar, CL; Zurlo, A; Pierart, M			Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial	LANCET			English	Article							THERAPY ONCOLOGY GROUP; RADIATION-THERAPY; RADICAL PROSTATECTOMY; HORMONAL-THERAPY; IN-VIVO; RADIOTHERAPY; DEPRIVATION; GOSERELIN; CARCINOMA; TUMORS	Background We did a randomised phase III trial comparing external irradiation alone and external irradiation combined with an analogue of luteinising-hormone releasing hormone (LHRH) to investigate the added value of long-term androgen suppression in locally advanced prostate cancer. Methods Between 1987 and 1995, 415 patients were randomly assigned radiotherapy alone or radiotherapy plus immediate androgen suppression. Eligible patients had T1-2 tumours of WHO grade 3 or T3-4 N0-1 MO tumours; the median age of participants was 71 years (range 51-80). In both treatment groups, 50 Gy radiation was delivered to the pelvis over 5 weeks, and 20 Gy over 2 weeks as a prostatic boost. Goserelin (3.6 mg subcutaneously every 4 weeks) was started on the first day of irradiation and continued for 3 years; cyproterone acetate (150 mg orally) was given for 1 month starting 1 week before the first goserelin injection. The primary endpoint was clinical disease-free survival. Analyses were by intention to treat. Findings 412 patients had evaluable data, with median follow-up of 66 months (range 1-126). 5-year clinical disease-free survival was 40% (95% CI 32-48) in the radiotherapy-alone group and 74% (67-81) in the combined-treatment group (p=0.0001). 5-year overall survival was 62% (52-72) and 78% (72-84), respectively (p=0.0002) and 5-year specific survival 79% (72-86) and 94% (90-98). Interpretation Immediate androgen suppression with an LHRH analogue given during and for 3 years after external irradiation improves disease-free and overall survival of patients with locally advanced prostate cancer.	Univ Hosp, Dept Radiotherapy, F-38043 Grenoble 9, France; European Org Res & Treatment Canc Data Ctr, Brussels, Belgium; Akad Med Ctr, Amsterdam, Netherlands; Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada; CRLC Val Aurelle, Montpellier, France; CHU Vaudois, CH-1011 Lausanne, Switzerland; Ctr Oncol, Brussels, Belgium; Osped San Giovanni Bellinzona, Bellinzona, Switzerland; Rambam Med Ctr, Haifa, Israel; Ufficio Sternberg & Pansadoro, Rome, Italy; St Maarten Ziekenhuis, Kortrijk, Belgium; Inst Valenciano Oncol, Valencia, Spain; Hadassah Univ, Jerusalem, Israel; St Luc Hosp, Guardamangia, Malta	CHU Grenoble Alpes; European Organisation for Research & Treatment of Cancer; University of Amsterdam; Academic Medical Center Amsterdam; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Regional Hospital of Bellinzona & Valleys, San Giovanni; Rambam Health Care Campus; Technion Israel Institute of Technology; Instituto Valenciano De Oncologia; Hebrew University of Jerusalem; Hadassah University Medical Center	Bolla, M (corresponding author), Univ Hosp, Dept Radiotherapy, BP 217, F-38043 Grenoble 9, France.		Bernier, Jacques/AAE-7248-2020	Bernier, Jacques/0000-0002-0138-9906; Collette, Laurence/0000-0003-2518-7281; Warde, Padraig/0000-0002-4236-0026				AKAKURA K, 1993, CANCER, V71, P2782, DOI 10.1002/1097-0142(19930501)71:9<2782::AID-CNCR2820710916>3.0.CO;2-Z; Bagshaw M A, 1988, NCI Monogr, P47; Bolla M, 1997, NEW ENGL J MED, V337, P295, DOI 10.1056/NEJM199707313370502; BOLLA M, 1996, P AN M AM SOC CLIN, V15, P238; Clarke M, 1998, LANCET, V351, P1451; DUSSERRE A, 1995, RADIOTHER ONCOL, V36, P229, DOI 10.1016/0167-8140(95)01612-K; Freedman L S, 1982, Stat Med, V1, P121, DOI 10.1002/sim.4780010204; Goldenberg S. Larry, 1995, Journal of Urology, V153, p254A; HANKS GE, 1995, CANCER, V75, P1972, DOI 10.1002/1097-0142(19950401)75:7+<1972::AID-CNCR2820751636>3.0.CO;2-P; HANKS GE, 2000, P AN M AM SOC CLIN, V19, pA327; International Commission of Radiation Units and Measurements, 1978, 29 ICRU; Joon DL, 1997, INT J RADIAT ONCOL, V38, P1071, DOI 10.1016/S0360-3016(97)00303-9; Messing EM, 1999, NEW ENGL J MED, V341, P1781, DOI 10.1056/NEJM199912093412401; Overgaard M, 1999, LANCET, V353, P1641, DOI 10.1016/S0140-6736(98)09201-0; Pilepich MV, 1997, J CLIN ONCOL, V15, P1013, DOI 10.1200/JCO.1997.15.3.1013; PILEPICH MV, 1995, UROLOGY, V45, P616, DOI 10.1016/S0090-4295(99)80053-3; PILEPICH MV, 1998, P AN M AM SOC CLIN, V17, pA308; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Pollack A., 1999, International Journal of Radiation Oncology Biology Physics, V45, P146, DOI 10.1016/S0360-3016(99)90022-6; Raghavan D, 1999, J CLIN ONCOL, V17, P3371, DOI 10.1200/JCO.1999.17.11.3371; SOLOWAY MS, 1995, J UROLOGY, V154, P424, DOI 10.1016/S0022-5347(01)67067-8; VANPOPPEL H, 1995, J UROLOGY, V154, P429, DOI 10.1016/S0022-5347(01)67068-X; WHO, 1979, WHO HDB REP RES CANC; WOLMARK N, 2000, P AN M AM SOC CLIN, V19, pA70; Zelefsky MJ, 1998, INT J RADIAT ONCOL, V41, P491, DOI 10.1016/S0360-3016(98)00091-1; Zietman AL, 1997, INT J RADIAT ONCOL, V38, P1067, DOI 10.1016/S0360-3016(97)00309-X; Zietman AL, 1997, CANCER J SCI AM, V3, P31	27	1334	1382	2	52	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 13	2002	360	9327					103	108		10.1016/S0140-6736(02)09408-4	http://dx.doi.org/10.1016/S0140-6736(02)09408-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573PB	12126818				2022-12-28	WOS:000176839100007
J	Scaffidi, P; Misteli, T; Bianchi, ME				Scaffidi, P; Misteli, T; Bianchi, ME			Release of chromatin protein HMGB1 by necrotic cells triggers inflammation	NATURE			English	Article							LINKER HISTONES B4; HIGH-MOBILITY; DNA; BINDING; H1; APOPTOSIS; MEDIATOR; HMG-1	High mobility group 1 (HMGB1) protein is both a nuclear factor and a secreted protein. In the cell nucleus it acts as an architectural chromatin-binding factor that bends DNA and promotes protein assembly on specific DNA targets(1,2). Outside the cell, it binds with high affinity to RAGE (the receptor for advanced glycation end products) 3 and is a potent mediator of inflammation(4-6). HMGB1 is secreted by activated monocytes and macrophages(4), and is passively released by necrotic or damaged cells(7-9). Here we report that Hmgb1(-/-) necrotic cells have a greatly reduced ability to promote inflammation, which proves that the release of HMGB1 can signal the demise of a cell to its neighbours. Apoptotic cells do not release HMGB1 even after undergoing secondary necrosis and partial autolysis, and thus fail to promote inflammation even if not cleared promptly by phagocytic cells. In apoptotic cells, HMGB1 is bound firmly to chromatin because of generalized underacetylation of histone and is released in the extracellular medium (promoting inflammation) if chromatin deacetylation is prevented. Thus, cells undergoing apoptosis are programmed to withhold the signal that is broadcast by cells that have been damaged or killed by trauma.	Univ Vita Salute San Raffaele, I-20132 Milan, Italy; Ist Sci San Raffaele, DIBIT, I-20132 Milan, Italy; NCI, NIH, Bethesda, MD 20892 USA	Vita-Salute San Raffaele University; Vita-Salute San Raffaele University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bianchi, ME (corresponding author), Univ Vita Salute San Raffaele, I-20132 Milan, Italy.	bianchi.marco@hsr.it	Bianchi, Marco Emilio/K-3417-2018; Scaffidi, Paola/GRS-9019-2022	Bianchi, Marco Emilio/0000-0002-5329-6445; Scaffidi, Paola/0000-0002-3642-4193				Abraham E, 2000, J IMMUNOL, V165, P2950, DOI 10.4049/jimmunol.165.6.2950; Andersson L1992A, SCRIPTA BOT BELG, V1, P1; Bianchi ME, 2000, EMBO REP, V1, P109, DOI 10.1093/embo-reports/kvd030; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P152, DOI 10.1016/S0968-0004(00)01777-1; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Calogero S, 1999, NAT GENET, V22, P276, DOI 10.1038/10338; Degryse B, 2001, J CELL BIOL, V152, P1197, DOI 10.1083/jcb.152.6.1197; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fadok VA, 2001, J IMMUNOL, V166, P6847, DOI 10.4049/jimmunol.166.11.6847; Falciola L, 1997, J CELL BIOL, V137, P19, DOI 10.1083/jcb.137.1.19; Herrmann M, 1998, ARTHRITIS RHEUM-US, V41, P1241, DOI 10.1002/1529-0131(199807)41:7<1241::AID-ART15>3.0.CO;2-H; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Kato A, 2000, AM J PATHOL, V157, P297, DOI 10.1016/S0002-9440(10)64540-3; Lawson JA, 2000, TOXICOL SCI, V54, P509, DOI 10.1093/toxsci/54.2.509; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; Muller S, 2001, EMBO J, V20, P4337, DOI 10.1093/emboj/20.16.4337; Nightingale K, 1996, EMBO J, V15, P548, DOI 10.1002/j.1460-2075.1996.tb00387.x; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Ren Y, 1998, CELL DEATH DIFFER, V5, P563, DOI 10.1038/sj.cdd.4400407; Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603; THOMAS SHL, 1993, PHARMACOL THERAPEUT, V60, P91, DOI 10.1016/0163-7258(93)90023-7; Ura K, 1996, EMBO J, V15, P4959, DOI 10.1002/j.1460-2075.1996.tb00876.x; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Zappavigna V, 1996, EMBO J, V15, P4981, DOI 10.1002/j.1460-2075.1996.tb00878.x	24	3169	3366	11	215	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 11	2002	418	6894					191	195		10.1038/nature00858	http://dx.doi.org/10.1038/nature00858			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571GV	12110890				2022-12-28	WOS:000176710400042
J	Reller, LB; Archibald, LK; Jarvis, WR				Reller, LB; Archibald, LK; Jarvis, WR		CDC	Disseminated infection with Simiae-Avium group mycobacteria in persons with AIDS - Thailand and Malawi, 1997 (Reprinted from MMWR, vol 51, pg 501-502, 2002)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Reprint							BLOOD-STREAM INFECTIONS; PATIENT; TRIPLEX		Duke Univ, Med Ctr, Clin Microbiol Lab, Durham, NC 27710 USA; Natl Ctr Infect Dis, Div Healthcare Qual Promot, Atlanta, GA 30333 USA; Natl Ctr Infect Dis, Div AIDS STD & TB Lab Res, Atlanta, GA 30333 USA; CDC, Atlanta, GA 30333 USA	Duke University; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Reller, LB (corresponding author), Duke Univ, Med Ctr, Clin Microbiol Lab, Durham, NC 27710 USA.							Archibald LK, 1999, J INFECT DIS, V180, P87, DOI 10.1086/314836; Archibald LK, 2000, J INFECT DIS, V181, P1414, DOI 10.1086/315367; Cingolani A, 2000, CLIN INFECT DIS, V31, P177, DOI 10.1086/313903; Floyd MM, 1996, J CLIN MICROBIOL, V34, P2963, DOI 10.1128/JCM.34.12.2963-2967.1996; Hoff E, 2001, J CLIN MICROBIOL, V39, P2033, DOI 10.1128/JCM.39.5.2033-2034.2001; Koeck JL, 1996, CLIN INFECT DIS, V23, P832, DOI 10.1093/clinids/23.4.832; LEVYFREBAULT V, 1987, J CLIN MICROBIOL, V25, P154; MUNIER D, 1993, CLIN INFECT DIS, V17, P508; RELLER LB, 2002, MMWR-MORBID MORTAL W, V51, P501; TORRES RA, 1991, J INFECT DIS, V164, P432, DOI 10.1093/infdis/164.2.432; Tortoli E, 1997, J CLIN MICROBIOL, V35, P697, DOI 10.1128/JCM.35.3.697-702.1997	11	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	2002	288	2					157	158						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	571HC	12113261				2022-12-28	WOS:000176711100009
J	De Cock, KM; Mbori-Ngacha, D; Marum, E				De Cock, KM; Mbori-Ngacha, D; Marum, E			Shadow on the continent: public health and HIV/AIDS in Africa in the 21st century	LANCET			English	Article							HIV; TRANSMISSION; EPIDEMIC; AIDS; PREVENTION; POLICY	Approaches to the prevention and control of the HIV/AIDS epidemic in Africa have been heavily based on early experiences and policies from industrialised countries, where the disease affects specific risk groups. HIV/AIDS has been dealt with differently from other sexually transmitted or lethal infectious diseases, despite being Africa's leading cause of death. In this review, we discuss the evolution of the global response to the epidemic, and the importance of redefining HIV/AIDS In Africa as a public health and infectious disease emergency. We discuss reconsideration of policies and practice around HIV testing and partner notification, and emphasise the need for an increased focus on treatment. Human-rights based approaches to HIV/AIDS prevention might have reduced the role of public health and social justice, which offer a more applied and practical framework for HIV/AIDS prevention and care in Africa's devastating epidemic.	Ctr Dis Control & Prevent Kenya, Nairobi, Kenya; Univ Nairobi, Nairobi, Kenya	University of Nairobi	De Cock, KM (corresponding author), POB 30137, Nairobi, Kenya.	kdecock@nairobi.mimcom.net						[Anonymous], 1998, MMWR Recomm Rep, V47, P1; Attaran A, 2001, LANCET, V357, P57, DOI 10.1016/S0140-6736(00)03576-5; BAYER R, 1991, NEW ENGL J MED, V324, P1500, DOI 10.1056/NEJM199105233242111; BRANDT AM, 1980, SOCIAL HIST VENEREAL, P140; Buve A, 2002, LANCET, V359, P2011, DOI 10.1016/S0140-6736(02)08823-2; CDC, 1999, MMWR-MORBID MORTAL W, V48, P1; *CDC, 2000, MMWR-MORBID MORTAL W, V50, P430; Coates TJ, 2000, LANCET, V356, P103, DOI 10.1016/S0140-6736(00)02446-6; De Cock KM, 2000, JAMA-J AM MED ASSOC, V283, P1175, DOI 10.1001/jama.283.9.1175; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; Gostin LO, 1997, HUMAN RIGHTS PUBLIC; Grant AD, 2001, AM J TROP MED HYG, V65, P810, DOI 10.4269/ajtmh.2001.65.810; *I MED, 1999, RED ODDS PREV PER TR; Institute of Medicine Committee for the Study of the Future of Public Health, 1988, FUT PUBL HLTH; Janssen RS, 2001, AM J PUBLIC HEALTH, V91, P1019, DOI 10.2105/AJPH.91.7.1019; Karon JM, 2001, AM J PUBLIC HEALTH, V91, P1060, DOI 10.2105/AJPH.91.7.1060; Lindegren ML, 1999, JAMA-J AM MED ASSOC, V282, P531, DOI 10.1001/jama.282.6.531; *OFF UN HIGH COMM, 1998, HIV AIDS HUM RIGHTS; PARRAN T, 1937, SHADOW LAND; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Schwartlander B, 2001, SCIENCE, V292, P2434, DOI 10.1126/science.1062876; TEMMERMAN M, 1995, LANCET, V345, P969, DOI 10.1016/S0140-6736(95)90707-6; *UNAIDS, 2000, REP GLOB HIV AIDS EP; *UNAIDS, 2001, AIDS EP UPD DEC 2001; *UNAIDS INT PARL U, 1999, HDB LEG HIV AIDS LAW; *US BUR CENS, 2001, REC HIV SER LEV COUN; *WHO, 1985, WEEKL EP REC, V60, P342; 2002, GLOBAL FUND FIGHT AI; 2001, ECONOMIST       0818, P18	29	200	202	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 6	2002	360	9326					67	72		10.1016/S0140-6736(02)09337-6	http://dx.doi.org/10.1016/S0140-6736(02)09337-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569JR	12114058				2022-12-28	WOS:000176599700027
J	Raguram, R; Venkateswaran, A; Ramakrishna, J; Weiss, MG				Raguram, R; Venkateswaran, A; Ramakrishna, J; Weiss, MG			Traditional community resources for mental health: a report of temple healing from India	BRITISH MEDICAL JOURNAL			English	Article							ALTERNATIVE MEDICINE; COMPLEMENTARY	The use of complementary medicine and the traditional medicine of other cultures has been increasing in Europe and North America.(3) Although less well documented, the use of complementary medicines and consultations with traditional healers is widely acknowledged in low income countries, such as India. Here too the limited availability of health services motivates the use of a wide range of alternative systems of care for various ailments, including mental illnesses(4).	Natl Inst Mental Hlth & Neurosci, Bangalore 560029, Karnataka, India; Swiss Trop Inst, Dept Epidemiol & Publ Hlth, CH-4002 Basel, Switzerland	National Institute of Mental Health & Neurosciences - India; University of Basel; Swiss Tropical & Public Health Institute	Raguram, R (corresponding author), Natl Inst Mental Hlth & Neurosci, Bangalore 560029, Karnataka, India.							[Anonymous], 1982, NAT MENT HLTH PROGR; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ernst E, 2000, BMJ-BRIT MED J, V321, P1133, DOI 10.1136/bmj.321.7269.1133; FISHER P, 1994, BRIT MED J, V309, P107, DOI 10.1136/bmj.309.6947.107; Jablensky A, 2000, EUR ARCH PSY CLIN N, V250, P274, DOI 10.1007/s004060070002; KAPUR RL, 1975, BRIT J PSYCHIAT, V127, P286, DOI 10.1192/bjp.127.3.286; KAPUR RL, 1979, SOC SCI MED-MED ANTH, V13, P27, DOI 10.1016/0160-7987(79)90015-2; OVERALL JE, 1962, PSYCHOL REP, V10, P799; PAKASLAHTI A, 1998, CHANGING PATTERNS FA; RAGHU TM, 1999, CULTURAL ASPECTS SCH; Umbricht D, 1995, SCHIZOPHRENIA BULL, V21, P593, DOI 10.1093/schbul/21.4.593; VENKATESWARAN V, 2001, THESIS NATL I MENTAL; Weiss M.G., 2001, ANTHROPOL MED, V8, P5, DOI [10.1080/13648470120070980, DOI 10.1080/13648470120070980]; WHO, 2012, ICD 10 CLASS MENT BE	14	95	97	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 6	2002	325	7354					38	40		10.1136/bmj.325.7354.38	http://dx.doi.org/10.1136/bmj.325.7354.38			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	573BC	12098731	Green Published, Green Submitted			2022-12-28	WOS:000176808600025
J	Laffey, JG; Kavanagh, BP				Laffey, JG; Kavanagh, BP			Medical progress - Hypocapnia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CEREBRAL-BLOOD-FLOW; CENTRAL SLEEP-APNEA; CARBON-DIOXIDE; AIRWAY PRESSURE; NEWBORN PIGLETS; CRITICALLY-ILL; RISK-FACTORS; HYPERVENTILATION; MANAGEMENT; BRAIN		Hosp Sick Children, Dept Crit Care Med, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Lung Biol Program, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Program Crit Care Med, Toronto, ON, Canada; Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dept Physiol, Dublin 2, Ireland; St Vincents Univ Hosp, Dept Anaesthesia & Intens Care, Dublin, Ireland	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University College Dublin; University College Dublin; Saint Vincent's University Hospital	Kavanagh, BP (corresponding author), Hosp Sick Children, Dept Crit Care Med, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	bpk@sickkids.ca	Laffey, John/G-4204-2010	Laffey, John/0000-0002-1246-9573				Adrogue HJ, 1998, NEW ENGL J MED, V338, P107, DOI 10.1056/NEJM199801083380207; Allen CH, 1998, CRIT CARE CLIN, V14, P485, DOI 10.1016/S0749-0704(05)70012-9; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; ANDREYCAK B, 1999, PHASE SHIFTED ZERO V, P3; ATKINSON RS, 1987, SYNOPSIS ANAESTHESIA, P75; Bayindir O, 2000, PERFUSION-UK, V15, P27, DOI 10.1177/026765910001500105; BLACK JA, 1991, NEONATAL EMERGENCIES, P166; BLAIR E, 1970, AM J SURG, V119, P433, DOI 10.1016/0002-9610(70)90146-7; BOIX JH, 1994, REV ESP FISIOL, V50, P19; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; *BRAIN TRAUM FDN, 1996, J NEUROTRAUM, V13, P699; BROWN M, 1989, CLIN ANESTH, P1455; Bullock RM, 2000, J NEUROTRAUM, V17, P449; COHEN EN, 1962, ANESTH ANALG, V41, P122; COOK PT, 1984, ANAESTH INTENS CARE, V12, P296, DOI 10.1177/0310057X8401200402; Coplan JD, 1998, ARCH GEN PSYCHIAT, V55, P130, DOI 10.1001/archpsyc.55.2.130; CUTILLO A, 1974, AM REV RESPIR DIS, V110, P25; DARBY JM, 1988, NEUROSURGERY, V23, P84, DOI 10.1227/00006123-198807000-00014; DEREUCK JL, 1984, ACTA NEUROL SCAND, V70, P391; DOMINO KB, 1993, ANESTHESIOLOGY, V78, P91, DOI 10.1097/00000542-199301000-00014; DRUMMOND WH, 1981, J PEDIATR-US, V98, P603, DOI 10.1016/S0022-3476(81)80775-5; DZIUKAS LJ, 1991, MED J AUSTRALIA, V154, P344, DOI 10.5694/j.1326-5377.1991.tb112889.x; Edge JA, 1996, BRIT J HOSP MED, V55, P508; FENCL V, 1993, RESP PHYSIOL, V91, P1, DOI 10.1016/0034-5687(93)90085-O; FENCL V, 1968, SCAND J CLIN LAB INV, VS 22, pB8; FORTUNE JB, 1995, J TRAUMA, V39, P463; GARLAND JS, 1995, ARCH PEDIAT ADOL MED, V149, P617, DOI 10.1001/archpedi.1995.02170190027005; GILLES FH, 1976, J NEUROL SCI, V27, P183, DOI 10.1016/0022-510X(76)90060-5; Glaser N, 2001, NEW ENGL J MED, V344, P264, DOI 10.1056/NEJM200101253440404; GLEASON CA, 1989, J PEDIATR-US, V115, P309, DOI 10.1016/S0022-3476(89)80091-5; Gluck SL, 1998, LANCET, V352, P474, DOI 10.1016/S0140-6736(98)03087-6; Graham EM, 1996, NEUROSCI LETT, V218, P29, DOI 10.1016/0304-3940(96)13114-1; Graziani LJ, 1997, CLIN PERINATOL, V24, P655, DOI 10.1016/S0095-5108(18)30163-5; GREISEN G, 1987, ACTA PAEDIATR SCAND, V76, P401, DOI 10.1111/j.1651-2227.1987.tb10489.x; Guzman JA, 1999, CRIT CARE MED, V27, P2760, DOI 10.1097/00003246-199912000-00026; Hackett PH, 2001, NEW ENGL J MED, V345, P107, DOI 10.1056/NEJM200107123450206; HANASHIRO PK, 1990, POSTGRAD MED, V88, P191, DOI 10.1080/00325481.1990.11716371; HARPER RG, 1987, HDB NEONATOLOGY, P167; HAYEK DA, 1992, CRITICAL CARE, P1449; HEFFNER JE, 1983, ARCH INTERN MED, V143, P765, DOI 10.1001/archinte.143.4.765; Himmelseher S, 2000, ANAESTHESIST, V49, P412, DOI 10.1007/s001010070109; Hood VL, 1998, NEW ENGL J MED, V339, P819, DOI 10.1056/NEJM199809173391207; HORNBEIN TF, 1989, NEW ENGL J MED, V321, P1714, DOI 10.1056/NEJM198912213212505; Horrobin D F, 1972, East Afr Med J, V49, P327; HOVORKA J, 1982, ACTA ANAESTH SCAND, V26, P498, DOI 10.1111/j.1399-6576.1982.tb01806.x; Huizenga, 2000, Acad Emerg Med, V7, P1171; Huttunen J, 1999, EXP BRAIN RES, V125, P248, DOI 10.1007/s002210050680; JAMISON JP, 1987, THORAX, V42, P809, DOI 10.1136/thx.42.10.809; Javaheri S, 1999, NEW ENGL J MED, V341, P949, DOI 10.1056/NEJM199909233411304; KAZEMI H, 1986, PHYSIOL REV, V66, P953, DOI 10.1152/physrev.1986.66.4.953; Kazmaier S, 1998, ANESTHESIOLOGY, V89, P831, DOI 10.1097/00000542-199810000-00006; KOLOBOW T, 1987, AM REV RESPIR DIS, V135, P312; Laffey JG, 2000, AM J RESP CRIT CARE, V162, P399, DOI 10.1164/ajrccm.162.2.9911026; Laffey JG, 1999, LANCET, V354, P1283, DOI 10.1016/S0140-6736(99)02388-0; Lehrer PM, 1998, APPL PSYCHOPHYS BIOF, V23, P13, DOI 10.1023/A:1022170028979; Marion D W, 1995, New Horiz, V3, P439; Marion DW, 2000, CRIT CARE MED, V28, P16, DOI 10.1097/00003246-200001000-00003; MAZZARA JT, 1974, AM J MED, V56, P450, DOI 10.1016/0002-9343(74)90475-6; MILLER JD, 1991, CLIN NEUROLOGY, P694; MOTOYAMA EK, 1967, ANESTHESIOLOGY, V28, P891, DOI 10.1097/00000542-196709000-00026; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NAGAI A, 1987, AM REV RESPIR DIS, V135, P130; NAUGHTON MT, 1994, AM J RESP CRIT CARE, V150, P1598, DOI 10.1164/ajrccm.150.6.7952621; NEVIN M, 1987, LANCET, V2, P1493; NORBERG K, 1975, BRAIN RES, V86, P31, DOI 10.1016/0006-8993(75)90635-6; NUNN JF, 1987, APPL RESP PHYSL; OCAIN CF, 1979, J APPL PHYSIOL, V47, P8, DOI 10.1152/jappl.1979.47.1.8; OKA A, 1993, J NEUROSCI, V13, P1441; Pastuszko P, 1997, ADV EXP MED BIOL, V411, P65; PECKHAM GJ, 1993, TXB PEDIAT CRITICAL, P61; PENG ATC, 1972, BRIT J ANAESTH, V44, P1173, DOI 10.1093/bja/44.11.1173; PHILLIPSON EA, 1994, HARRISONS PRINCIPLES, P1234; PLUM F, 1972, ANN INTERN MED, V76, P328, DOI 10.7326/0003-4819-76-2-328; Porter JM, 2000, BRIT J ANAESTH, V84, P92, DOI 10.1093/oxfordjournals.bja.a013389; RAICHLE ME, 1970, ARCH NEUROL-CHICAGO, V23, P394, DOI 10.1001/archneur.1970.00480290014002; REYNOLDS AM, 1989, J APPL PHYSIOL, V67, P2454, DOI 10.1152/jappl.1989.67.6.2454; RICHARDSON DW, 1972, AM J PHYSIOL, V223, P1308, DOI 10.1152/ajplegacy.1972.223.6.1308; Riphagen S, 1999, INTENS CARE MED, V25, P1459, DOI 10.1007/s001340051099; ROSENBAUM BJ, 1969, ANN INTERN MED, V71, P1105, DOI 10.7326/0003-4819-71-6-1105; ROSMAN PN, 1999, GELLIS KAGANS CURREN, V16, P431; ROWIN ME, 1999, HDB PEDIAT INTENSIVE, P445; RUBEN BH, 1992, CRITICAL CARE, P725; RUTA TS, 1993, ANESTHESIOLOGY, V78, P134, DOI 10.1097/00000542-199301000-00019; Safar P, 1996, STROKE, V27, P105, DOI 10.1161/01.STR.27.1.105; SCHREIBER MD, 1986, PEDIATR RES, V20, P113, DOI 10.1203/00006450-198602000-00003; SHEPARD JW, 1982, J APPL PHYSIOL, V53, P555, DOI 10.1152/jappl.1982.53.3.555; SHEPARD JW, 1980, J CLIN INVEST, V66, P36, DOI 10.1172/JCI109832; Sin DD, 1999, AM J RESP CRIT CARE, V160, P1101, DOI 10.1164/ajrccm.160.4.9903020; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; STAUBLI M, 1994, EUR J APPL PHYSIOL O, V69, P402, DOI 10.1007/BF00865403; TRIMBLE C, 1971, AM J SURG, V122, P633, DOI 10.1016/0002-9610(71)90291-1; VANDENELSHOUT FJJ, 1991, THORAX, V46, P28, DOI 10.1136/thx.46.1.28; Vannucci RC, 1997, PEDIATR RES, V42, P24, DOI 10.1203/00006450-199707000-00005; Weckesser M, 1999, MAGN RESON MED, V41, P213, DOI 10.1002/(SICI)1522-2594(199901)41:1<213::AID-MRM31>3.0.CO;2-S; WILLIAMS H, 1987, POSTGRAD MED J, V63, P377, DOI 10.1136/pgmj.63.739.377; WOLLMAN SB, 1968, BRIT J ANAESTH, V40, P920, DOI 10.1093/bja/40.12.920; WUNG JT, 1985, PEDIATRICS, V76, P488; Yoon BH, 1997, AM J OBSTET GYNECOL, V177, P406, DOI 10.1016/S0002-9378(97)70206-0; Yundt KD, 1997, CRIT CARE CLIN, V13, P163, DOI 10.1016/S0749-0704(05)70300-6; 1968, N ENGL J MED, V278, P1068	100	234	243	1	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 4	2002	347	1					43	53		10.1056/NEJMra012457	http://dx.doi.org/10.1056/NEJMra012457			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569HA	12097540				2022-12-28	WOS:000176594500009
J	Phillips, BL				Phillips, BL			Skydiving	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	2002	288	1					16	16		10.1001/jama.288.1.16	http://dx.doi.org/10.1001/jama.288.1.16			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	568YW	12090848				2022-12-28	WOS:000176573400001
J	Grant, C; Nicholas, R; Moore, L; Salisbury, C				Grant, C; Nicholas, R; Moore, L; Salisbury, C			An observational study comparing quality of care in walk-in centres with general practice and NUS Direct using standardised patients	BRITISH MEDICAL JOURNAL			English	Article							UNANNOUNCED SIMULATED PATIENTS; PERFORMANCE; PRACTITIONERS; PHYSICIANS	Objectives To compare the quality of clinical care in walk-in centres with that provided in general practice and by NHS Direct. Design Observational study involving assessment of clinicians by standardised patients, Setting 20 walk-in centres, 20 general practices, and 11 NHS Direct sites. Participants 297 consultations with standardised patients, 99 in each setting, carried out by professional role players trained to play five clinical scenarios (postcoital contraception, chest pain, sinusitis, headache, and asthma). Main outcome measures Primary outcomes were mean scores on consensus derived checklists of essential items for the management of the clinical scenarios. Data were also collected on access to and referral by walk-in centres, general practices, and NHS Direct Results Walk-in centres achieved a significantly greater mean score for all scenarios combined than general practices (difference between groups 8.2, 95% confidence interval 1.7 to 14.6) and NHS Direct (10.8, 5.5 to 16.1). There was considerable between scenario variation, with walk-in centres performing particularly well on postcoital contraception and asthma scenarios. In contrast to general practices, walk-in centres and NHS Direct referred a higher proportion of patients (26% and 82%, respectively). Conclusion Walk-in centres perform adequately and safely compared with general practices and NHS Direct for the range of conditions under study, but the impact of referrals on workload of other healthcare providers requires further research.	Univ Bristol, Div Primary Hlth Care, Bristol BS6 6JL, Avon, England; Univ Cardiff, Cardiff Sch Social Sci, Cardiff CF10 3WT, S Glam, Wales	University of Bristol; Cardiff University	Salisbury, C (corresponding author), Univ Bristol, Div Primary Hlth Care, Bristol BS6 6JL, Avon, England.		Salisbury, Chris/C-6724-2008	Salisbury, Chris/0000-0002-4378-3960; Moore, Laurence/0000-0003-2182-823X				BADGER LW, 1994, PSYCHOSOM MED, V56, P128, DOI 10.1097/00006842-199403000-00008; Beullens J, 1997, FAM PRACT, V14, P58, DOI 10.1093/fampra/14.1.58; CARNEY PA, 1993, ANN INTERN MED, V119, P129, DOI 10.7326/0003-4819-119-2-199307150-00007; COLLIVER JA, 1993, ACAD MED, V68, P454, DOI 10.1097/00001888-199306000-00003; George S, 2001, BRIT MED J, V322, P931, DOI 10.1136/bmj.322.7291.931; Gorter S, 2000, ACAD MED, V75, P1130, DOI 10.1097/00001888-200011000-00022; JONES J, 1995, BRIT MED J, V311, P376, DOI 10.1136/bmj.311.7001.376; JONES J, 1997, FAM PRACT, V14, P58; Munro J, 2001, EVALUATION NHS DIREC; *NAT EV WALK CTR R, 2001, NAT EV NHS WALK CTR; OHAGAN JJ, 1986, NEW ZEAL MED J, V99, P948; OHAGAN JJ, 1989, NEW ZEAL MED J, V102, P252; RETHANS JJ, 1991, BRIT J GEN PRACT, V41, P94; RETHANS JJ, 1991, BRIT J GEN PRACT, V41, P97; RETHANS JJ, 1994, BRIT J GEN PRACT, V44, P153; RETHANS JJE, 1987, BRIT MED J, V294, P809, DOI 10.1136/bmj.294.6575.809; RUSSELL NK, 1991, ACAD MED, V66, pS37, DOI 10.1097/00001888-199109000-00034; RUSSELL NK, 1992, AM J PREV MED, V8, P235, DOI 10.1016/S0749-3797(18)30811-0; Salisbury C, 2002, BRIT MED J, V324, P399, DOI 10.1136/bmj.324.7334.399; SHAHABUDIN SH, 1994, MED EDUC, V28, P432, DOI 10.1111/j.1365-2923.1994.tb02554.x; *STAT OFF, 2000, CM4243; Statacorp, 2001, STAT STAT SOFTW REL; TAMBLYN RM, 1991, MED EDUC, V25, P100, DOI 10.1111/j.1365-2923.1991.tb00035.x; van der Vleuten C.P., 1990, TEACH LEARN MED, V2, P58, DOI [https://doi.org/10.1080/10401339009539432, DOI 10.1080/10401339009539432]; WOODWARD CA, 1985, MED CARE, V23, P1019, DOI 10.1097/00005650-198508000-00009; 2001, HLTH WHICH       JAN, P7; CM4243	27	34	34	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 29	2002	324	7353					1556	1559		10.1136/bmj.324.7353.1556	http://dx.doi.org/10.1136/bmj.324.7353.1556			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	570WP	12089094	Bronze, Green Published			2022-12-28	WOS:000176683000023
J	Hon, C; Shek, TW; Liang, R				Hon, C; Shek, TW; Liang, R			Conjunctival chloroma (granulocytic sarcoma)	LANCET			English	Editorial Material									Queen Mary Hosp, Dept Ophthalmol, Hong Kong, Hong Kong, Peoples R China; Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong	Hon, C (corresponding author), Queen Mary Hosp, Dept Ophthalmol, Hong Kong, Hong Kong, Peoples R China.		Liang, Raymond Hin Suen/C-4346-2009						0	8	9	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 29	2002	359	9325					2247	2247		10.1016/S0140-6736(02)09294-2	http://dx.doi.org/10.1016/S0140-6736(02)09294-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567YJ	12103289				2022-12-28	WOS:000176514500011
J	Seivewright, H; Tyrer, P; Johnson, T				Seivewright, H; Tyrer, P; Johnson, T			Change in personality status in neurotic disorders	LANCET			English	Article								Personality disorders are generally thought not to change by much over time. We assessed the personality status of 202 patients who had a defined diagnostic and statistical manual (DSM)-III neurotic disorder, dysthymia, panic disorder, or generalised anxiety. All patients had had drug and psychological treatment in a randomised controlled trial. 12 years after entry to the study, we reassessed the personality status of 178 (88%) of these patients using the same test (personality assessment schedule). The personality traits of patients in the cluster B flamboyant group (antisocial, histrionic) became significantly less pronounced over 12 years, but those in the cluster A odd, eccentric group (schizoid, schizotypal, paranoid), and the cluster C anxious, fearful group (obsessional, avoidant) became more pronounced. The measure of agreement between baseline and 12-year personality clusters was poor or slight (kappa=0.14, 95% Cl 0.04-0.23). Our results suggest that the assumption that personality characteristics do not change with time is incorrect.	MRC, Biostat Unit, Cambridge CB2 2BW, England; Imperial Coll Sch Med, Dept Publ Mental Hlth, Div Neurosci & Psychol Med, Paterson Ctr, London W2 1PD, England	MRC Biostatistics Unit; Imperial College London	Tyrer, P (corresponding author), Imperial Coll Sch Med, Dept Publ Mental Hlth, Div Neurosci & Psychol Med, Paterson Ctr, St Marys Campus,20 S Wharf Rd, London W2 1PD, England.							SPITZER RL, 1983, STRUCTURED CLIN INTE; Stone MH, 2001, HANDBOOK OF PERSONALITY DISORDERS: THEORY, RESEARCH, AND TREATMENT, P259; TYRER P, 1988, LANCET, V2, P235; TYRER P, 1983, PSYCHOL MED, V13, P393, DOI 10.1017/S0033291700051023; Tyrer P., 2000, PERSONALITY DISORDER, P132	5	84	85	3	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 29	2002	359	9325					2253	2254		10.1016/S0140-6736(02)09266-8	http://dx.doi.org/10.1016/S0140-6736(02)09266-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567YJ	12103293				2022-12-28	WOS:000176514500015
J	Martin, SJ				Martin, SJ			Destabilizing influences in apoptosis: sowing the seeds of IAP destruction	CELL			English	Review							CELL-DEATH; DROSOPHILA; REAPER; HID	Inhibitor of apoptosis proteins (IAPs) can block apoptosis through interactions with members of the caspase family of cysteine proteases. Recent developments suggest that ubiquitin-proteasome mediated destruction of the Drosophila IAP, DIAP1, is a key event during the initiation of programmed cell death in the fly.	Univ Dublin Trinity Coll, Dept Genet, Mol Cell Biol Lab, Dublin 2, Ireland	Trinity College Dublin	Martin, SJ (corresponding author), Univ Dublin Trinity Coll, Dept Genet, Mol Cell Biol Lab, Dublin 2, Ireland.			Martin, Seamus/0000-0002-8539-3143				Dorstyn L, 2002, J CELL BIOL, V156, P1089, DOI 10.1083/jcb.200111107; Evans EK, 1997, EMBO J, V16, P7372, DOI 10.1093/emboj/16.24.7372; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Hays R, 2002, NAT CELL BIOL, V4, P425, DOI 10.1038/ncb794; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Lisi S, 2000, GENETICS, V154, P669; Rodriguez A, 2002, EMBO J, V21, P2189, DOI 10.1093/emboj/21.9.2189; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Varkey J, 1999, J CELL BIOL, V144, P701, DOI 10.1083/jcb.144.4.701; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799; Wing JP, 2002, NAT CELL BIOL, V4, P451, DOI 10.1038/ncb800; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793; Zimmermann KC, 2002, J CELL BIOL, V156, P1077, DOI 10.1083/jcb.20112068	18	96	98	2	9	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 28	2002	109	7					793	796		10.1016/S0092-8674(02)00802-4	http://dx.doi.org/10.1016/S0092-8674(02)00802-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	570KJ	12110175	Bronze			2022-12-28	WOS:000176657200001
J	Tabara, H; Yigit, E; Siomi, H; Mello, CC				Tabara, H; Yigit, E; Siomi, H; Mello, CC			The dsRNA binding protein RDE-4 interacts with RDE-1, DCR-1, and a DExX-box helicase to direct RNAi in C-elegans	CELL			English	Article							GERM-LINE DEVELOPMENT; DOUBLE-STRANDED-RNA; GENE; INTERFERENCE; TRANSGENE; ENCODES; DEFENSE; IDENTIFICATION; TRANSCRIPTION; REQUIREMENTS	Double-stranded(ds) RNA induces potent gene silencing, termed RNA interference (RNAi). At an early step in RNAi, an RNaseIII-related enzyme, Dicer (DCR-1), processes long-trigger dsRNA into small interfering RNAs (siRNAs). DCR-1 is also required for processing endogenous regulatory RNAs called miRNAs, but how DCR-1 recognizes its endogenous and foreign substrates is not yet understood. Here we show that the C. elegans RNAi pathway gene, rde-4, encodes a dsRNA binding protein that interacts during RNAi with RNA identical to the trigger dsRNA. RDE-4 protein also interacts in vivo with DCR-1, RDE-1, and a conserved DExH-box helicase. Our findings suggest a model in which RDE-4 and RDE-1 function together to detect and retain foreign dsRNA and to present this dsRNA to DCR-1 for processing.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Tokushima, Inst Genome Res, Tokushima 7708503, Japan; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; Tokushima University; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Mello, CC (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA.	craig.mello@umassmed.edu	Siomi, Haruhiko/A-7020-2015	Siomi, Haruhiko/0000-0001-8690-3822	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058800] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58800] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baulcombe D, 2002, CURR BIOL, V12, pR82, DOI 10.1016/S0960-9822(02)00665-6; Benfey PN, 1999, CURR BIOL, V9, pR171, DOI 10.1016/S0960-9822(99)80105-5; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; BLUMENTHAL T, 1995, TRENDS GENET, V11, P132, DOI 10.1016/S0168-9525(00)89026-5; Catalanotto C, 2000, NATURE, V404, P245, DOI 10.1038/35005169; Catalanotto C, 2002, GENE DEV, V16, P790, DOI 10.1101/gad.222402; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; Cogoni C, 2000, CURR OPIN GENET DEV, V10, P638, DOI 10.1016/S0959-437X(00)00134-9; Dalmay T, 2000, CELL, V101, P543, DOI 10.1016/S0092-8674(00)80864-8; Dalmay T, 2001, EMBO J, V20, P2069, DOI 10.1093/emboj/20.8.2069; Dernburg AF, 2000, GENE DEV, V14, P1578; Fagard M, 2000, P NATL ACAD SCI USA, V97, P11650, DOI 10.1073/pnas.200217597; Fierro-Monti I, 2000, TRENDS BIOCHEM SCI, V25, P241, DOI 10.1016/S0968-0004(00)01580-2; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Grishok A, 2000, SCIENCE, V287, P2494, DOI 10.1126/science.287.5462.2494; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Ketting RF, 2000, NATURE, V404, P296, DOI 10.1038/35005113; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lipardi C, 2001, CELL, V107, P297, DOI 10.1016/S0092-8674(01)00537-2; Mello C, 1995, METHOD CELL BIOL, V48, P451; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Mourrain P, 2000, CELL, V101, P533, DOI 10.1016/S0092-8674(00)80863-6; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Plasterk RHA, 2000, CURR OPIN GENET DEV, V10, P562, DOI 10.1016/S0959-437X(00)00128-3; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558; Reinscheid RK, 2000, PEPTIDES, V21, P901, DOI 10.1016/S0196-9781(00)00226-6; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Ryter JM, 1998, EMBO J, V17, P7505, DOI 10.1093/emboj/17.24.7505; Sijen T, 2001, CELL, V107, P465, DOI 10.1016/S0092-8674(01)00576-1; Smardon A, 2000, CURR BIOL, V10, P169, DOI 10.1016/S0960-9822(00)00323-7; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Tabara H, 1999, DEVELOPMENT, V126, P1; Tijsterman M, 2002, SCIENCE, V295, P694, DOI 10.1126/science.1067534; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Vance V, 2001, SCIENCE, V292, P2277, DOI 10.1126/science.1061334; Waterhouse PM, 2001, NATURE, V411, P834, DOI 10.1038/35081168; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Wu-Scharf D, 2000, SCIENCE, V290, P1159, DOI 10.1126/science.290.5494.1159; Zhang XX, 2000, MICROB PATHOGENESIS, V28, P267, DOI 10.1006/mpat.1999.0349	49	369	439	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	2002	109	7					861	871		10.1016/S0092-8674(02)00793-6	http://dx.doi.org/10.1016/S0092-8674(02)00793-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	570KJ	12110183	Bronze			2022-12-28	WOS:000176657200009
J	Wood, RA; Grotzinger, JP; Dickson, JAD				Wood, RA; Grotzinger, JP; Dickson, JAD			Proterozoic modular biomineralized metazoan from the Nama Group, Namibia	SCIENCE			English	Article							SHELLY FOSSILS; EVOLUTION; ORIGINS; CORALS; SPONGES; AFRICA; FAUNA	We describe a Proterozoic, fully biomineralized metazoan from the Omkyk Member (similar to million years before the present) of the northern Nama Group, Namibia. Namapoikia rietoogensis gen. et sp. nov. is up to 1 meter in diameter and bears a complex and robust biomineralized skeleton; it probably represents a cnidarian or poriferan. Namapoikia encrusts perpendicular to the walls of vertical synsedimentary fissures in microbial reefs. This finding implies that large, modular metazoans with biologically controlled mineralization appeared some 15 million years earlier than previously documented.	Schlumberger Cambridge Res Ltd, Cambridge CB2 OEL, England; Univ Cambridge, Dept Earth Sci, Cambridge CB2 3EQ, England; MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA	Schlumberger; University of Cambridge; Massachusetts Institute of Technology (MIT)	Wood, RA (corresponding author), Schlumberger Cambridge Res Ltd, High Cross,Madingley Rd, Cambridge CB2 OEL, England.							Bengtson S., 1992, TOP GEOBIOL, V20, P447; BOWRING SA, 1993, SCIENCE, V261, P1293, DOI 10.1126/science.11539488; Brasier M, 1997, GEOLOGY, V25, P303, DOI 10.1130/0091-7613(1997)025<0303:ESSCFS>2.3.CO;2; BRASIER MD, 1989, PRECAMBRIAN CAMBRIAN, P117; BRIDGE D, 1995, MOL BIOL EVOL, V12, P679; CONWAY MS, 1993, PALAEONTOLOGY, V36, P593; Gehling JG, 1996, J PALEONTOL, V70, P185, DOI 10.1017/S0022336000023283; GERMS GJB, 1972, AM J SCI, V272, P752, DOI 10.2475/ajs.272.8.752; GRANT SWF, 1990, AM J SCI, V290A, P261; GROTZINGER JP, 1995, SCIENCE, V270, P598, DOI 10.1126/science.270.5236.598; GROTZINGER JP, IN PRESS COMMUN GEOL; Hofmann HJ, 2001, GEOLOGY, V29, P1091, DOI 10.1130/0091-7613(2001)029<1091:NCAINM>2.0.CO;2; Jensen S, 2000, GEOLOGY, V28, P143, DOI 10.1130/0091-7613(2000)028<0143:CTFFTT>2.3.CO;2; KOBLUK DR, 1984, J PALEONTOL, V58, P703; KOBLUK DR, 1979, CAN J EARTH SCI, V16, P2040, DOI 10.1139/e79-189; Narbonne GM, 1997, J PALEONTOL, V71, P953, DOI 10.1017/S0022336000035940; Reitner Joachim, 1992, Berliner Geowissenschaftliche Abhandlungen Reihe E Palaeobiologie, V1, P1; Romano SL, 2000, B MAR SCI, V67, P1043; Saylor BZ, 1998, J SEDIMENT RES, V68, P1223, DOI 10.2110/jsr.68.1223; Scrutton C.T., 1979, ORIGIN MAJOR INVERTE, V12, P161; Scrutton CT, 1997, P YORKS GEOL SOC, V51, P177, DOI 10.1144/pygs.51.3.177; Stanley GD, 2001, SCIENCE, V291, P1913, DOI 10.1126/science.1056632; Watters WA, 2001, PALEOBIOLOGY, V27, P159, DOI 10.1666/0094-8373(2001)027<0159:DROCEM>2.0.CO;2; WOOD R, 1990, AM SCI, V78, P224; Wood R., 1999, REEF EVOLUTION; Xiao SH, 2000, P NATL ACAD SCI USA, V97, P13684, DOI 10.1073/pnas.250491697; ZHURAVLEV AY, 1999, PALEONTOL J, V33, P502	27	138	142	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 28	2002	296	5577					2383	2386		10.1126/science.1071599	http://dx.doi.org/10.1126/science.1071599			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	567CE	12089440				2022-12-28	WOS:000176467200038
J	Dominguez, JM; Serri, K				Dominguez, JM; Serri, K			Disseminated histoplasmosis in a patient with human immunodeficiency virus infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Hop Maison Neuve Rosemont, Montreal, PQ H1T 2M4, Canada	Universite de Montreal	Dominguez, JM (corresponding author), Hop Maison Neuve Rosemont, Montreal, PQ H1T 2M4, Canada.								0	2	2	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 27	2002	346	26					2061	2061		10.1056/NEJMicm010380	http://dx.doi.org/10.1056/NEJMicm010380			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566DN	12087142				2022-12-28	WOS:000176411900007
J	Matthews, FE; Dening, T				Matthews, FE; Dening, T		UK Med Res Council Cognitive Funct	Prevalence of dementia in institutional care	LANCET			English	Article								Information about dementia prevalence In residential and nursing care homes helps these institutions to meet residents' needs. We combined residential characteristics ascertained at a screening Interview in 1991-93 with dementia diagnoses from assessment interviews In the UK Medical Research Council Cognitive Function and Ageing Study, a population-based study of 13 004 elderly people. Almost 5% of people aged 65 years or older lived in institution-34% (95% Cl 30-39) of individuals with dementia. Within institutions, dementia prevalence was 62% (52-71), and was slightly higher in women than in men, with no increase by age. That most residents have dementia has Implications for the type of care that institutions provide.	Univ Forvie Site, Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England; Fulbourne Hosp, Addenbrooks NHS Trust, Cambridge CB1 5EF, England	MRC Biostatistics Unit; University of Cambridge	Matthews, FE (corresponding author), Univ Forvie Site, Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England.		Matthews, Fiona/O-6932-2015; Dening, Tom/E-1335-2013	Matthews, Fiona/0000-0002-1728-2388; Dening, Tom/0000-0003-3387-4241				Brayne C, 1998, PSYCHOL MED, V28, P319; COPELAND JRM, 1986, PSYCHOL MED, V16, P89, DOI 10.1017/S0033291700057779; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Macdonald AJD, 2002, AGE AGEING, V31, P58, DOI 10.1093/ageing/31.1.58; *OFF POP CENS SURV, 1994, REV 1991 POP EST SUP	5	126	126	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 20	2002	360	9328					225	226		10.1016/S0140-6736(02)09461-8	http://dx.doi.org/10.1016/S0140-6736(02)09461-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	576DX	12133659				2022-12-28	WOS:000176988500014
J	Regan, F; Taylor, C				Regan, F; Taylor, C			Recent developments - Blood transfusion medicine	BRITISH MEDICAL JOURNAL			English	Review							BSE; HAEMOVIGILANCE; TRANSMISSION; SYSTEM; PLASMA		Hammersmith Hosp NHS Trust, London W12 0HS, England; Royal Free Hampstead NHS Trust, London NW3 2QG, England	Imperial College London; University of London; University College London	Regan, F (corresponding author), Hammersmith Hosp NHS Trust, London W12 0HS, England.							*ASS AN GREAT BRIT, 2001, BLOOD TRANSFUSION AN; BARBARA J, 2001, SEMIN HEMATOL S11, V38; Blajchman Morris A., 2001, Transfusion Medicine Reviews, V15, P108, DOI 10.1053/tm.2001.22614; Bonetta L, 2001, NAT MED, V7, P261, DOI 10.1038/85359; Bopp MKF, 2001, TRANSFUSION MED, V11, P149; Brown P, 2001, EMERG INFECT DIS, V7, P6, DOI 10.3201/eid0701.010102; Brown P, 2000, LANCET, V356, P955, DOI 10.1016/S0140-6736(00)02706-9; Busch M, 1999, VOX SANG, V77, P67, DOI 10.1159/000031079; Clark P, 2001, BMJ-BRIT MED J, V323, P1118, DOI 10.1136/bmj.323.7321.1118; Debeir J, 1999, VOX SANG, V77, P77, DOI 10.1046/j.1423-0410.1999.7720077.x; Dumont LJ, 2001, BLOOD, V97, P3640, DOI 10.1182/blood.V97.11.3640; Houston F, 2000, LANCET, V356, P999, DOI 10.1016/S0140-6736(00)02719-7; Jensen NJ, 1996, TRANSFUSION, V36, P216, DOI 10.1046/j.1537-2995.1996.36396182138.x; Kelsey P, 1999, TRANSFUSION MED, V9, P227; Koenigbauer UF, 2000, TRANSFUSION, V40, P1203, DOI 10.1046/j.1537-2995.2000.40101203.x; Krombach J, 2002, ANESTH ANALG, V94, P154, DOI 10.1097/00000539-200201000-00029; Linden JV, 2000, TRANSFUSION, V40, P1207, DOI 10.1046/j.1537-2995.2000.40101207.x; McClelland B, 1998, VOX SANG, V74, P431, DOI 10.1111/j.1423-0410.1998.tb05453.x; Murphy MF, 2001, BRIT J HAEMATOL, V113, P24; *NHS EX, 1998, 1998224 DEP HLTH NHS; Pamphilon D, 2000, BRIT J HAEMATOL, V109, P680, DOI 10.1046/j.1365-2141.2000.02019.x; Prowse CV, 1999, TRANSFUSION MED, V9, P287; Roth WK, 1999, LANCET, V353, P359, DOI 10.1016/S0140-6736(98)06318-1; *SER HAZ TRANSF ST, 2001, ANN REP 1999 2000; SIRCHIA G, 1994, TRANSFUSION MED, V4, P251; Watson N., 2000, Hospital Pharmacist, V7, P124	26	68	76	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 20	2002	325	7356					143	147		10.1136/bmj.325.7356.143	http://dx.doi.org/10.1136/bmj.325.7356.143			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	577PG	12130612	Green Published			2022-12-28	WOS:000177069900025
J	Tirlapur, UK; Konig, K				Tirlapur, UK; Konig, K			Cell biology - Targeted transfection by femtosecond laser	NATURE			English	Article							MICROSCOPY; MEMBRANE		Univ Jena, Inst Anat 2, Laser Microscopy Div, D-07743 Jena, Germany	Friedrich Schiller University of Jena	Tirlapur, UK (corresponding author), Univ Jena, Inst Anat 2, Laser Microscopy Div, Teichgraben 7, D-07743 Jena, Germany.							Bildirici L, 2000, NATURE, V405, P298, DOI 10.1038/35012701; Knoblauch M, 1999, NAT BIOTECHNOL, V17, P906, DOI 10.1038/12902; Konig K, 2000, J MICROSC-OXFORD, V200, P83, DOI 10.1046/j.1365-2818.2000.00738.x; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; Luo D, 2000, NAT BIOTECHNOL, V18, P33, DOI 10.1038/71889; Pepperkok R, 1999, CURR BIOL, V9, P269, DOI 10.1016/S0960-9822(99)80117-1; SO PTC, 1995, BIOIMAGING, V3, P1; Squirrell JM, 1999, NAT BIOTECHNOL, V17, P763, DOI 10.1038/11698; Stephens DJ, 2001, P NATL ACAD SCI USA, V98, P4295, DOI 10.1073/pnas.081065198; TAO W, 1987, P NATL ACAD SCI USA, V84, P4180, DOI 10.1073/pnas.84.12.4180	10	520	572	2	82	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 18	2002	418	6895					290	291		10.1038/418290a	http://dx.doi.org/10.1038/418290a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574BF	12124612				2022-12-28	WOS:000176868000030
J	Whyte, MP; Obrecht, SE; Finnegan, PM; Jones, JL; Podgornik, MN; McAlister, WH; Mumm, S				Whyte, MP; Obrecht, SE; Finnegan, PM; Jones, JL; Podgornik, MN; McAlister, WH; Mumm, S			Osteoprotegerin deficiency and juvenile Paget's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EXPANSILE SKELETAL HYPERPHOSPHATASIA; KAPPA-B LIGAND; ARTERIAL CALCIFICATION; RECEPTOR ACTIVATOR; INHIBITORY FACTOR; BONE; RANK; OSTEOPOROSIS; OSTEOLYSIS; TNFRSF11A	Background Juvenile Paget's disease, an autosomal recessive osteopathy, is characterized by rapidly remodeling woven bone, osteopenia, fractures, and progressive skeletal deformity. The molecular basis is not known. Osteoprotegerin deficiency could explain juvenile Paget's disease because osteoprotegerin suppresses bone turnover by functioning as a decoy receptor for osteoclast differentiation factor (also called RANK ligand). Methods We evaluated two apparently unrelated Navajo patients with juvenile Paget's disease for defects in the gene encoding osteoprotegerin (TNFRSF11B) using polymerase-chain-reaction (PCR) amplification followed by direct sequencing and Southern blotting of genomic DNA. Genetic markers near TNFRSF11B were evaluated by both a PCR method that involved sequence-tagged site-content mapping of a deletion of TNFRSF11B and PCR spanning the DNA break points. Results Both patients had a homozygous deletion of TNFRSF11B, with identical break points, on chromosome 8q24.2. The defect spans approximately 100 kb, but neighboring genes are intact. We found that serum levels of osteoprotegerin and soluble osteoclast differentiation factor were undetectable and markedly increased, respectively. Conclusions Juvenile Paget's disease can result from osteoprotegerin deficiency caused by homozygous deletion of TNFRSF11B.	Shriners Hosp Children, Ctr Metab Bone Dis & Mol Res, St Louis, MO 63131 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, Div Bone & Mineral Dis, St Louis, MO USA; Washington Univ, Sch Med, Edward Mallinckrodt Inst Radiol, St Louis Childrens Hosp, St Louis, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)	Whyte, MP (corresponding author), Shriners Hosp Children, Ctr Metab Bone Dis & Mol Res, 2001 S Lindbergh Blvd, St Louis, MO 63131 USA.	mwhyte@shrinenet.org			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033013] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045968] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR45968] Funding Source: Medline; NICHD NIH HHS [HD33013] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bekker PJ, 2001, J BONE MINER RES, V16, P348, DOI 10.1359/jbmr.2001.16.2.348; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; *BUR CENS, 1994, 1990 CENS POP HOUS C; CAFFEY J, 1972, Bulletin of the Hospital for Joint Diseases, V33, P81; CASSINELLI HR, 1992, BONE MINER, V19, P175, DOI 10.1016/0169-6009(92)90924-3; CHINES A, 1991, J PEDIATR-US, V119, P51, DOI 10.1016/S0022-3476(05)81038-8; Cole D.E.C., 1996, STUDIES STOMATOLOGY, P245; DUNN V, 1979, AM J ROENTGENOL, V132, P541, DOI 10.2214/ajr.132.4.541; ENG AM, 1975, ARCH DERMATOL, V111, P271; GILPIN L, 1968, ENDURING NAVAHO, P255; Golob DS, 1996, J BONE MINER RES, V11, P132; Good DA, 2002, AM J HUM GENET, V70, P517, DOI 10.1086/338658; Hilton MJ, 2001, GENOMICS, V71, P192, DOI 10.1006/geno.2000.6438; Hofbauer LC, 2001, CANCER-AM CANCER SOC, V92, P460, DOI 10.1002/1097-0142(20010801)92:3<460::AID-CNCR1344>3.0.CO;2-D; Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226; Hughes AE, 2000, NAT GENET, V24, P45, DOI 10.1038/71667; Kanis J., 1998, PATHOPHYSIOLOGY TREA, VSecond; Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lories RJU, 2001, CLIN RHEUMATOL, V20, P3, DOI 10.1007/s100670170095; McKusick V.A., 1998, MENDELIAN INHERITANC; MITSUDO SM, 1971, J BONE JOINT SURG AM, VA 53, P303, DOI 10.2106/00004623-197153020-00010; Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697; Morinaga T, 1998, EUR J BIOCHEM, V254, P685, DOI 10.1046/j.1432-1327.1998.2540685.x; *NAV NAT, 1995, NAV NAT COD, P111; SILVE C, 1986, J CLIN ENDOCR METAB, V62, P583, DOI 10.1210/jcem-62-3-583; SINGER F, 1994, J BONE MINER RES, V9, P733; Singer F.R., 2001, PRINCIPLES BONE BIOL, P1249; THOMPSON RC, 1969, AM J MED, V47, P209, DOI 10.1016/0002-9343(69)90147-8; Tintut Y, 2001, CURR OPIN LIPIDOL, V12, P555, DOI 10.1097/00041433-200110000-00012; Wallin R, 2001, MED RES REV, V21, P274, DOI 10.1002/med.1010.abs; Whyte MP, 2002, J BONE MINER RES, V17, P26, DOI 10.1359/jbmr.2002.17.1.26; Whyte MP, 2000, J BONE MINER RES, V15, P2330, DOI 10.1359/jbmr.2000.15.12.2330; Wuyts W, 2001, BONE, V28, P104, DOI 10.1016/S8756-3282(00)00411-7	34	323	346	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 18	2002	347	3					175	184		10.1056/NEJMoa013096	http://dx.doi.org/10.1056/NEJMoa013096			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	574BR	12124406				2022-12-28	WOS:000176869000004
J	James, A; McNamee, D; Horton, R				James, A; McNamee, D; Horton, R			Rapid reviews in The Lancet - and beyond	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		James, A (corresponding author), The Lancet, London NW1 7BY, England.							Horton R, 2000, LANCET, V356, P2, DOI 10.1016/S0140-6736(00)02420-X	1	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 13	2002	360	9327					102	102		10.1016/S0140-6736(02)09435-7	http://dx.doi.org/10.1016/S0140-6736(02)09435-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573PB	12126817				2022-12-28	WOS:000176839100006
J	Yin, JAL; Grimwade, D				Yin, JAL; Grimwade, D			Minimal residual disease evaluation in acute myeloid leukaemia	LANCET			English	Review							POLYMERASE-CHAIN-REACTION; BONE-MARROW-TRANSPLANTATION; TIME RT-PCR; FUSION TRANSCRIPT; REMISSION; QUANTIFICATION; THERAPY; RELAPSE; T(8/21); GENE		Univ Manchester, Manchester Royal Infirm, Dept Haematol, Manchester M13 9WL, Lancs, England; UCL Hosp, Guys Kings & St Thomas Sch Med, Dept Haematol, Div Med & Mol Genet, London, England	University of Manchester; University College London Hospitals NHS Foundation Trust; University of London; King's College London; University College London	Yin, JAL (corresponding author), Univ Manchester, Manchester Royal Infirm, Dept Haematol, Manchester M13 9WL, Lancs, England.	jyin@labmed.cmht.nwest.nhs.uk						Bounamici S, 2002, BLOOD, V99, P443, DOI 10.1182/blood.V99.2.443; Burnett AK, 1999, BLOOD, V93, P4131, DOI 10.1182/blood.V93.12.4131.412k12_4131_4143; Burnett AK, 1998, LANCET, V351, P700, DOI 10.1016/S0140-6736(97)09214-3; Burnett AK, 2002, BRIT J HAEMATOL, V118, P385, DOI 10.1046/j.1365-2141.2002.03724.x; Cassinat B, 2000, LEUKEMIA, V14, P324, DOI 10.1038/sj.leu.2401652; Diverio D, 1998, BLOOD, V92, P784; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Grimwade D, 2002, LEUKEMIA, V16, P964, DOI 10.1038/sj.leu.2402421; Grimwade D, 2002, BEST PRACT RES CL HA, V15, P137, DOI 10.1053/beha.2002.0189; Guerrasio A, 2002, LEUKEMIA, V16, P1176, DOI 10.1038/sj.leu.2402478; Jurlander J, 1996, BLOOD, V88, P2183, DOI 10.1182/blood.V88.6.2183.bloodjournal8862183; KOTTARIDIS PD, 2001, BLOOD S1, V98; Krauter J, 1999, BRIT J HAEMATOL, V107, P80, DOI 10.1046/j.1365-2141.1999.01674.x; Lo Coco F, 1999, BLOOD, V94, P2225, DOI 10.1182/blood.V94.7.2225.419k03_2225_2229; Marcucci G, 2001, LEUKEMIA, V15, P1072, DOI 10.1038/sj.leu.2402159; MIWA H, 1992, LEUKEMIA, V6, P405; Morschhauser F, 2000, J CLIN ONCOL, V18, P788, DOI 10.1200/JCO.2000.18.4.788; NUCIFORA G, 1993, BLOOD, V82, P712; Pallisgaard N, 1998, BLOOD, V92, P574, DOI 10.1182/blood.V92.2.574; San Miguel JF, 2001, BLOOD, V98, P1746, DOI 10.1182/blood.V98.6.1746; SanMiguel JF, 1997, BLOOD, V90, P2465, DOI 10.1182/blood.V90.6.2465.2465_2465_2470; Tobal K, 2000, BLOOD, V95, P815, DOI 10.1182/blood.V95.3.815.003k30_815_819; Venditti A, 2000, BLOOD, V96, P3948, DOI 10.1182/blood.V96.12.3948.h8003948_3948_3952; Visani G, 2001, LEUKEMIA, V15, P1696, DOI 10.1038/sj.leu.2402266; Yin JAL, 1999, BRIT J HAEMATOL, V106, P578; Yin JAL, 2002, BEST PRACT RES CL HA, V15, P119, DOI 10.1053/beha.2002.0188	26	44	44	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 13	2002	360	9327					160	162		10.1016/S0140-6736(02)09419-9	http://dx.doi.org/10.1016/S0140-6736(02)09419-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573PB	12126839				2022-12-28	WOS:000176839100027
J	Abouheif, E; Wray, GA				Abouheif, E; Wray, GA			Evolution of the gene network underlying wing polyphenism in ants	SCIENCE			English	Article							ULTRABITHORAX; HYMENOPTERA; LOCALIZATION; FORMICIDAE; EXPRESSION; PATTERN; CASTE	Wing polyphenism in ants evolved once, 125 million years ago, and has been a key to their amazing evolutionary success. We characterized the expression of several genes within the network underlying the wing primordia of reproductive ( winged) and sterile ( wingless) ant castes. We show that the expression of several genes within the network is conserved in the winged castes of four ant species, whereas points of interruption within the network in the wingless castes are evolutionarily labile. The simultaneous evolutionary lability and conservation of the network underlying wing development in ants may have played an important role in the morphological diversification of this group and may be a general feature of polyphenic development and evolution in plants and animals.	Duke Univ, Dept Biol, Durham, NC 27708 USA	Duke University	Abouheif, E (corresponding author), Duke Univ, Dept Biol, POB 90338, Durham, NC 27708 USA.	abouheif@duke.edu	Abouheif, Ehab/H-2507-2011	Abouheif, Ehab/0000-0001-7651-1737				Aspland SE, 1997, DEVELOPMENT, V124, P741; Brakefield PM, 1996, NATURE, V384, P236, DOI 10.1038/384236a0; Brook WJ, 1996, ANNU REV CELL DEV BI, V12, P161, DOI 10.1146/annurev.cellbio.12.1.161; Carroll S. B., 2001, DNA DIVERSITY MOL GE; CARROLL SB, 1994, SCIENCE, V265, P109, DOI 10.1126/science.7912449; COHEN B, 1993, DEVELOPMENT, V117, P597; Cohen S. M., 1993, DEV DROSOPHILA MELAN, P747; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Grimaldi D, 2000, P NATL ACAD SCI USA, V97, P13678, DOI 10.1073/pnas.240452097; Holldobler B., 1990, pi; Holldobler B, 1994, JOURNEY ANTS; KELSH R, 1994, DEV GENET, V15, P19, DOI 10.1002/dvg.1020150104; Labandeira CC, 1998, ANNU REV EARTH PL SC, V26, P329, DOI 10.1146/annurev.earth.26.1.329; Nijhout H.F., 1994, INSECT HORMONES; Nijhout HF, 1999, BIOSCIENCE, V49, P181, DOI 10.2307/1313508; PANGANIBAN G, 1995, SCIENCE, V270, P1363, DOI 10.1126/science.270.5240.1363; PASSERA L, 1979, INSECT SOC, V26, P343, DOI 10.1007/BF02223553; PATEL NH, 1994, METHOD CELL BIOL, V44, P445, DOI 10.1016/S0091-679X(08)60927-9; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Schlichting CD, 1998, PHENOTYPIC EVOLUTION; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Weatherbee SD, 1998, GENE DEV, V12, P1474, DOI 10.1101/gad.12.10.1474; Weatherbee SD, 1999, CURR BIOL, V9, P109, DOI 10.1016/S0960-9822(99)80064-5; WHEELER DE, 1983, J INSECT PHYSIOL, V29, P847, DOI 10.1016/0022-1910(83)90151-8; WHEELER DE, 1981, INT J INSECT MORPHOL, V10, P131, DOI 10.1016/S0020-7322(81)80018-9; WHEELER GEORGE C., 1938, PSYCHE, V45, P139, DOI 10.1155/1938/53417; WILSON EO, 1953, Q REV BIOL, V28, P136, DOI 10.1086/399512; WILSON EO, 1987, PALEOBIOLOGY, V13, P44	31	314	320	1	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 12	2002	297	5579					249	252		10.1126/science.1071468	http://dx.doi.org/10.1126/science.1071468			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571UT	12114626				2022-12-28	WOS:000176738100041
J	Clutton-Brock, TH; Russell, AF; Sharpe, LL; Young, AJ; Balmforth, Z; McIlrath, GM				Clutton-Brock, TH; Russell, AF; Sharpe, LL; Young, AJ; Balmforth, Z; McIlrath, GM			Evolution and development of sex differences in cooperative behavior in meerkats	SCIENCE			English	Article							SURICATA-SURICATTA; HELPING-BEHAVIOR; MONGOOSE; HELPERS; BIRDS	In cooperatively breeding birds, where helpers of both sexes assist with the provisioning and upbringing of offspring who are not their own, males tend to contribute more than females to rearing young. This sex difference has been attributed to paternity uncertainty, but could also occur because males contribute more where they are likely to remain and breed in their group of origin. In contrast to most birds, female meerkats (Suricata suricatta) are more likely to breed in their natal group than males. We show that female meerkat helpers contribute more to rearing young than males and that female helpers feed female pups more frequently than males. Our results suggest that sex differences in cooperative behavior are generated by sex differences in philopatry and occur because females derive greater direct benefits than males from raising recruits to their natal group. These findings support the view that direct, mutualistic benefits are important in the evolution of specialized cooperative behavior.	Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Univ Stellenbosch, Dept Zool, ZA-7602 Matieland, South Africa; Univ Pretoria, Mammal Res Inst, ZA-0002 Pretoria, South Africa	University of Cambridge; Stellenbosch University; University of Pretoria	Clutton-Brock, TH (corresponding author), Univ Cambridge, Dept Zool, Downing St, Cambridge CB2 3EJ, England.							BARNARD JA, 2000, THESIS CAMBRIDGE U; Brotherton PNM, 2001, BEHAV ECOL, V12, P590, DOI 10.1093/beheco/12.5.590; CLARKE MF, 1984, BEHAV ECOL SOCIOBIOL, V14, P137, DOI 10.1007/BF00291904; Clutton-Brock T, 2002, SCIENCE, V296, P69, DOI 10.1126/science.296.5565.69; Clutton-Brock TH, 2000, P ROY SOC B-BIOL SCI, V267, P301, DOI 10.1098/rspb.2000.1000; Clutton-Brock TH, 1998, P ROY SOC B-BIOL SCI, V265, P2291, DOI 10.1098/rspb.1998.0573; Clutton-Brock TH, 2001, SCIENCE, V291, P478, DOI 10.1126/science.291.5503.478; Clutton-Brock TH, 2001, ANIM BEHAV, V61, P705, DOI 10.1006/anbe.2000.1631; Clutton-Brock TH, 1999, J ANIM ECOL, V68, P672, DOI 10.1046/j.1365-2656.1999.00317.x; Clutton-Brock TH, 2001, SCIENCE, V293, P2446, DOI 10.1126/science.1061274; Cockburn A, 1998, ANNU REV ECOL SYST, V29, P141, DOI 10.1146/annurev.ecolsys.29.1.141; GREENWOOD PJ, 1980, ANIM BEHAV, V28, P1140, DOI 10.1016/S0003-3472(80)80103-5; GRIFFIN AS, 1999, THESIS EDINBURGH U; KOMDEUR J, 1994, P ROY SOC B-BIOL SCI, V256, P47, DOI 10.1098/rspb.1994.0047; LACEY EA, 1990, ECOLOGY NAKED MOLE R, P275; MALCOLM JR, 1982, BEHAV ECOL SOCIOBIOL, V10, P1, DOI 10.1007/BF00296390; MCGOWAN KJ, 1989, ANIM BEHAV, V37, P1000, DOI 10.1016/0003-3472(89)90144-9; O'Riain MJ, 2000, BEHAV ECOL SOCIOBIOL, V48, P471, DOI 10.1007/s002650000249; OWENS DD, 1984, NATURE, V308, P843, DOI 10.1038/308843a0; ROOD JP, 1983, ADV STUDY MAMMALIAN, P454; Stacey P.B., 1990, COOPERATIVE BREEDING; Strahl S.D., 1990, P131, DOI 10.1017/CBO9780511752452.006; Zahavi A., 1990, P103, DOI 10.1017/CBO9780511752452.005	23	182	184	2	108	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 12	2002	297	5579					253	256		10.1126/science.1071412	http://dx.doi.org/10.1126/science.1071412			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571UT	12114627				2022-12-28	WOS:000176738100042
J	Hillenbrand, R; Taubner, T; Keilmann, F				Hillenbrand, R; Taubner, T; Keilmann, F			Phonon-enhanced light-matter interaction at the nanometre scale	NATURE			English	Article							SUBWAVELENGTH SCALE; SPECTROSCOPY; MICROSCOPY; RESONANCES	Optical near fields exist close to any illuminated object. They account for interesting effects such as enhanced pinhole transmission 1 or enhanced Raman scattering enabling single-molecule spectroscopy(2). Also, they enable high-resolution (below 10 nm) optical microscopy(3-6). The plasmon-enhanced near-field coupling between metallic nanostructures(7-9) opens new ways of designing optical properties(10-12) and of controlling light on the nanometre scale(13,14). Here we study the strong enhancement of optical near-field coupling in the infrared by lattice vibrations (phonons) of polar dielectrics. We combine infrared spectroscopy with a near-field microscope that provides a confined field to probe the local interaction with a SiC sample. The phonon resonance occurs at 920 cm(-1). Within 20 cm(-1) of the resonance, the near-field signal increases 200-fold; on resonance, the signal exceeds by 20 times the value obtained with a gold sample. We find that phonon-enhanced near-field coupling is extremely sensitive to chemical and structural composition of polar samples, permitting nanometre-scale analysis of semiconductors and minerals. The excellent physical and chemical stability of SiC in particular may allow the design of nanometre-scale optical circuits for high-temperature and high-power operation.	Max Planck Inst Biochem, Abt Mol Strukturbiol, D-82152 Martinsried, Germany; Univ Munich, Ctr Nanosci, D-80799 Munich, Germany	Max Planck Society; University of Munich	Keilmann, F (corresponding author), Max Planck Inst Biochem, Abt Mol Strukturbiol, D-82152 Martinsried, Germany.		Hillenbrand, Rainer/N-3428-2016; Taubner, Thomas/E-8779-2012	Hillenbrand, Rainer/0000-0002-1904-4551; Taubner, Thomas/0000-0002-0628-3043				Aigouy L, 2000, APPL PHYS LETT, V76, P397, DOI 10.1063/1.125766; ARAVIND PK, 1983, SURF SCI, V124, P506, DOI 10.1016/0039-6028(83)90806-3; Barnes WL, 1998, J MOD OPTIC, V45, P661, DOI 10.1080/09500349808230614; Beck M, 2002, SCIENCE, V295, P301, DOI 10.1126/science.1066408; des Francs GC, 2001, PHYS REV LETT, V86, P4950, DOI 10.1103/PhysRevLett.86.4950; Ebbesen TW, 1998, NATURE, V391, P667, DOI 10.1038/35570; ENGELBRECHT F, 1993, PHYS REV B, V48, P15698, DOI 10.1103/PhysRevB.48.15698; FAIST J, 1994, SCIENCE, V264, P553, DOI 10.1126/science.264.5158.553; Frohlich H, 1949, THEORY DIELECTRICS; HARTMANN T, 1998, PROCEDURES SCANNING, P12; Hillenbrand R, 2000, PHYS REV LETT, V85, P3029, DOI 10.1103/PhysRevLett.85.3029; Hillenbrand R, 2002, APPL PHYS LETT, V80, P25, DOI 10.1063/1.1428767; Hillenbrand R, 2001, APPL PHYS B-LASERS O, V73, P239, DOI 10.1007/s003400100656; Jackson J., 1975, CLASSICAL ELECTRODYN; Joannopoulos JD, 1997, NATURE, V386, P143, DOI 10.1038/386143a0; Knoll B, 2000, APPL PHYS LETT, V77, P3980, DOI 10.1063/1.1330756; Knoll B, 1999, NATURE, V399, P134, DOI 10.1038/20154; Kreibig U, 1997, BER BUNSEN PHYS CHEM, V101, P1593, DOI 10.1002/bbpc.19971011107; Krenn JR, 1999, PHYS REV LETT, V82, P2590, DOI 10.1103/PhysRevLett.82.2590; Palik E D, 1985, HDB OPTICAL CONSTANT; PALIK ED, HDB OPTICAL CONSTANT, P85; Pendry JB, 2000, PHYS REV LETT, V85, P3966, DOI 10.1103/PhysRevLett.85.3966; Ruppin R, 1982, ELECTROMAGNETIC SURF, P345; Shchegrov AV, 2000, PHYS REV LETT, V85, P1548, DOI 10.1103/PhysRevLett.85.1548; Smith DR, 2000, PHYS REV LETT, V84, P4184, DOI 10.1103/PhysRevLett.84.4184; SPECHT M, 1992, PHYS REV LETT, V68, P476, DOI 10.1103/PhysRevLett.68.476; Weeber JC, 2000, PHYS REV E, V62, P7381, DOI 10.1103/PhysRevE.62.7381; Xu HX, 1999, PHYS REV LETT, V83, P4357, DOI 10.1103/PhysRevLett.83.4357; ZENHAUSERN F, 1995, SCIENCE, V269, P1083, DOI 10.1126/science.269.5227.1083	29	646	656	8	287	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 11	2002	418	6894					159	162		10.1038/nature00899	http://dx.doi.org/10.1038/nature00899			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571GV	12110883				2022-12-28	WOS:000176710400033
J	Ludwig, M; Sabatier, N; Bull, PM; Landgraf, R; Dayanithi, G; Leng, G				Ludwig, M; Sabatier, N; Bull, PM; Landgraf, R; Dayanithi, G; Leng, G			Intracellular calcium stores regulate activity-dependent neuropeptide release from dendrites	NATURE			English	Article							MILK-EJECTION REFLEX; RAT SUPRAOPTIC NEURONS; IN-VITRO; SUBSTANTIA-NIGRA; OXYTOCIN NEURONS; SUCKLED RATS; GABA RELEASE; CELLS; VASOPRESSIN; NUCLEUS	Information in neurons flows from synapses, through the dendrites and cell body (soma), and, finally, along the axon as spikes of electrical activity that will ultimately release neurotransmitters from the nerve terminals. However, the dendrites of many neurons also have a secretory role, transmitting information back to afferent nerve terminals(1-4). In some central nervous system neurons, spikes that originate at the soma can travel along dendrites as well as axons, and may thus elicit secretion from both compartments(1). Here, we show that in hypothalamic oxytocin neurons, agents that mobilize intracellular Ca2+ induce oxytocin release from dendrites without increasing the electrical activity of the cell body, and without inducing secretion from the nerve terminals. Conversely, electrical activity in the cell bodies can cause the secretion of oxytocin from nerve terminals with little or no release from the dendrites. Finally, mobilization of intracellular Ca2+ can also prime the releasable pool of oxytocin in the dendrites. This priming action makes dendritic oxytocin available for release in response to subsequent spike activity. Priming persists for a prolonged period, changing the nature of interactions between oxytocin neurons and their neighbours.	Univ Edinburgh, Sch Med, Dept Biomed Sci, Edinburgh EH8 9XD, Midlothian, Scotland; Max Planck Inst Psychiat, Inst Clin, D-80804 Munich, Germany; Univ Montpellier 2, INSERM 432, Dept Neurobiol, F-34094 Montpellier, France	University of Edinburgh; Max Planck Society; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Ludwig, M (corresponding author), Univ Edinburgh, Sch Med, Dept Biomed Sci, George Sq, Edinburgh EH8 9XD, Midlothian, Scotland.		Dayanithi, Govindan/F-6068-2016; Leng, Gareth/C-6688-2011; Dayanithi, Govindan/H-3131-2014	Dayanithi, Govindan/0000-0002-1009-7809; Leng, Gareth/0000-0002-2388-8466; Dayanithi, Govindan/0000-0002-1009-7809				BELIN V, 1986, J PHYSIOL-LONDON, V377, P369, DOI 10.1113/jphysiol.1986.sp016192; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Blochl A, 1996, MOL CELL NEUROSCI, V7, P173, DOI 10.1006/mcne.1996.0014; Brown D, 1997, J PHYSIOL-LONDON, V503, P625, DOI 10.1111/j.1469-7793.1997.625bg.x; CHERAMY A, 1981, NATURE, V289, P537, DOI 10.1038/289537a0; Chevaleyre V, 2000, J NEUROSCI, V20, P5813, DOI 10.1523/JNEUROSCI.20-15-05813.2000; DYBALL REJ, 1986, J PHYSIOL-LONDON, V380, P239, DOI 10.1113/jphysiol.1986.sp016283; HAUSSER M, 1995, NEURON, V15, P637, DOI 10.1016/0896-6273(95)90152-3; Isaacson JS, 2001, P NATL ACAD SCI USA, V98, P337, DOI 10.1073/pnas.021445798; Isaacson JS, 1998, NEURON, V20, P749, DOI 10.1016/S0896-6273(00)81013-2; Jourdain P, 1998, J NEUROSCI, V18, P6641; Kirkpatrick K, 1996, J PHYSIOL-LONDON, V494, P389, DOI 10.1113/jphysiol.1996.sp021500; Kombian SB, 1997, NEURON, V19, P903, DOI 10.1016/S0896-6273(00)80971-X; LAMBERT RC, 1994, J PHYSIOL-LONDON, V478, P275, DOI 10.1113/jphysiol.1994.sp020249; LAMBERT RC, 1993, NEUROSCIENCE, V57, P1027, DOI 10.1016/0306-4522(93)90046-I; LENG G, 1981, EXP BRAIN RES, V41, P135; Leng G, 1999, PROG NEUROBIOL, V57, P625, DOI 10.1016/S0301-0082(98)00072-0; LENG G, 1991, NEUROENDOCRINE RES M, P769; LINCOLN DW, 1974, J PHYSIOL-LONDON, V242, P533, DOI 10.1113/jphysiol.1974.sp010722; LINCOLN DW, 1972, J ANAT, V111, P327; Ludwig M, 1998, J NEUROENDOCRINOL, V10, P881; Ludwig M, 1997, EUR J NEUROSCI, V9, P2532, DOI 10.1111/j.1460-9568.1997.tb01682.x; MOOS F, 1989, EXP BRAIN RES, V76, P593, DOI 10.1007/BF00248916; MOOS F, 1984, J ENDOCRINOL, V102, P63, DOI 10.1677/joe.0.1020063; POW DV, 1989, NEUROSCIENCE, V32, P435, DOI 10.1016/0306-4522(89)90091-2; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; Zilberter Y, 1999, NEURON, V24, P979, DOI 10.1016/S0896-6273(00)81044-2	27	252	256	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 4	2002	418	6893					85	89		10.1038/nature00822	http://dx.doi.org/10.1038/nature00822			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	569JL	12097911	Green Published			2022-12-28	WOS:000176599200043
J	Dyer, C				Dyer, C			BMA has to pay 815 pound 000 in damages for indirect racial discrimination	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 29	2002	324	7353					1541	1541						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	570WP	12089083				2022-12-28	WOS:000176683000011
J	Stracke, S; Kistner, C; Yoshida, S; Mulder, L; Sato, S; Kaneko, T; Tabata, S; Sandal, N; Stougaard, J; Szczyglowski, K; Parniske, M				Stracke, S; Kistner, C; Yoshida, S; Mulder, L; Sato, S; Kaneko, T; Tabata, S; Sandal, N; Stougaard, J; Szczyglowski, K; Parniske, M			A plant receptor-like kinase required for both bacterial and fungal symbiosis	NATURE			English	Article							PEA PISUM-SATIVUM; LOTUS-JAPONICUS; CALCIUM SPIKING; MEDICAGO-TRUNCATULA; NITROGEN-FIXATION; NOD FACTORS; NODULATION; MUTANTS; CELLS; GENE	Most higher plant species can enter a root symbiosis with arbuscular mycorrhizal fungi, in which plant carbon is traded for fungal phosphate(1,2). This is an ancient symbiosis, which has been detected in fossils of early land plants(3). In contrast, the nitrogen-fixing root nodule symbioses of plants with bacteria evolved more recently, and are phylogenetically restricted to the rosid I clade of plants(4). Both symbioses rely on partially overlapping genetic programmes(5,6). We have identified the molecular basis for this convergence by cloning orthologous SYMRK ('symbiosis receptor-like kinase') genes from Lotus and pea, which are required for both fungal and bacterial recognition. SYMRK is predicted to have a signal peptide, an extracellular domain comprising leucine-rich repeats, a transmembrane and an intracellular protein kinase domain. Lotus SYMRK is required for a symbiotic signal transduction pathway leading from the perception of microbial signal molecules to rapid symbiosis-related gene activation. The perception of symbiotic fungi and bacteria is mediated by at least one common signalling component, which could have been recruited during the evolution of root nodule symbioses from the already existing arbuscular mycorrhiza symbiosis.	John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England; Kazusa DNA Res Inst, Chiba 2920812, Japan; Aarhus Univ, IMSB, Gene Express Lab, DK-8000 Aarhus, Denmark; Agr & Agri Food Canada, So Crop Protect & Food Res Ctr, London, ON N5V 4T3, Canada	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Kazusa DNA Research Institute; Aarhus University; Agriculture & Agri Food Canada	Parniske, M (corresponding author), John Innes Ctr Plant Sci Res, Sainsbury Lab, Colney Lane, Norwich NR4 7UH, Norfolk, England.		Parniske, Martin/F-2202-2011; Parniske, Martin/M-3781-2019; yoshida, satoko/AAO-4892-2020; Sato, Shusei/A-3616-2015; Yoshida, Satoko/G-5003-2010; Yoshida, Satoko/AAZ-4757-2021; poinssot, benoit/B-2569-2009	Parniske, Martin/0000-0001-8561-747X; Parniske, Martin/0000-0001-8561-747X; yoshida, satoko/0000-0002-9999-7861; Sato, Shusei/0000-0002-0293-5366; Yoshida, Satoko/0000-0002-9999-7861; poinssot, benoit/0000-0001-5890-4318; Stougaard, Jens/0000-0002-9312-2685				Bonfante P, 2000, MOL PLANT MICROBE IN, V13, P1109, DOI 10.1094/MPMI.2000.13.10.1109; Catoira R, 2000, PLANT CELL, V12, P1647, DOI 10.1105/tpc.12.9.1647; Cullimore JV, 2001, TRENDS PLANT SCI, V6, P24, DOI 10.1016/S1360-1385(00)01810-0; Downie JA, 1999, CURR OPIN PLANT BIOL, V2, P483, DOI 10.1016/S1369-5266(99)00018-7; DUC G, 1989, PLANT SCI, V60, P215, DOI 10.1016/0168-9452(89)90169-6; DUC G, 1989, PLANT SCI, V60, P207, DOI 10.1016/0168-9452(89)90168-4; Ehrhardt DW, 1996, CELL, V85, P673, DOI 10.1016/S0092-8674(00)81234-9; FIRMIN JL, 1993, MOL MICROBIOL, V10, P351, DOI 10.1111/j.1365-2958.1993.tb01961.x; Harrison MJ, 1999, ANNU REV PLANT PHYS, V50, P361, DOI 10.1146/annurev.arplant.50.1.361; Heidstra R, 1997, MOL PLANT MICROBE IN, V10, P215, DOI 10.1094/MPMI.1997.10.2.215; Jones DA, 1997, ADV BOT RES, V24, P89; Rausch C, 2001, NATURE, V414, P462, DOI 10.1038/35106601; REMY W, 1994, P NATL ACAD SCI USA, V91, P11841, DOI 10.1073/pnas.91.25.11841; Sato S, 2001, DNA RES, V8, P311, DOI 10.1093/dnares/8.6.311; Schauser L, 1998, MOL GEN GENET, V259, P414, DOI 10.1007/s004380050831; Schauser L, 1999, NATURE, V402, P191, DOI 10.1038/46058; Schneider A, 1999, MOL GEN GENET, V262, P1, DOI 10.1007/s004380051053; Shiu SH, 2001, P NATL ACAD SCI USA, V98, P10763, DOI 10.1073/pnas.181141598; SOLTIS DE, 1995, P NATL ACAD SCI USA, V92, P2647, DOI 10.1073/pnas.92.7.2647; Szczyglowski K, 1998, MOL PLANT MICROBE IN, V11, P684, DOI 10.1094/MPMI.1998.11.7.684; TURNER SR, 1993, MOL GEN GENET, V236, P402, DOI 10.1007/BF00277140; van Spronsen PC, 2001, MOL PLANT MICROBE IN, V14, P839, DOI 10.1094/MPMI.2001.14.7.839; Wais RJ, 2000, P NATL ACAD SCI USA, V97, P13407, DOI 10.1073/pnas.230439797; Walker SA, 2000, P NATL ACAD SCI USA, V97, P13413, DOI 10.1073/pnas.230440097; Wegel E, 1998, MOL PLANT MICROBE IN, V11, P933, DOI 10.1094/MPMI.1998.11.9.933	25	617	667	24	215	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 27	2002	417	6892					959	962		10.1038/nature00841	http://dx.doi.org/10.1038/nature00841			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	566RC	12087405				2022-12-28	WOS:000176441200041
J	Carlson, GA				Carlson, GA			Postexposure prophylaxis against transmissible spongiform encephalopathies: CpG oligodeoxynucleotides in mice	LANCET			English	Editorial Material							INCUBATION PERIOD; SCRAPIE; PATHOGENESIS; SPLEEN		McKaughlin Res Inst, Great Falls, MT 59405 USA	McLaughlin Research Institute for Biomedical Sciences, Inc.	Carlson, GA (corresponding author), McKaughlin Res Inst, Great Falls, MT 59405 USA.	gac@mri8.mri.montana.edu						BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; DICKINSON AG, 1972, HEREDITY, V29, P91, DOI 10.1038/hdy.1972.67; Farquhar C, 1999, LANCET, V353, P117, DOI 10.1016/S0140-6736(98)05395-1; FARQUHAR CF, 1986, J GEN VIROL, V67, P463, DOI 10.1099/0022-1317-67-3-463; FRASER H, 1978, J COMP PATHOL, V88, P563, DOI 10.1016/0021-9975(78)90010-5; KIMBERLIN RH, 1979, J COMP PATHOL, V89, P551, DOI 10.1016/0021-9975(79)90046-X; KIMBERLIN RH, 1988, CIBA F SYMP, V135, P37; Mabbott NA, 2001, J GEN VIROL, V82, P2307, DOI 10.1099/0022-1317-82-10-2307; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; Safar J, 2000, ARCH VIROL, P227	10	2	4	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 20	2002	360	9328					184	184		10.1016/S0140-6736(02)09500-4	http://dx.doi.org/10.1016/S0140-6736(02)09500-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	576DX	12133649				2022-12-28	WOS:000176988500004
J	Hariri, AR; Mattay, VS; Tessitore, A; Kolachana, B; Fera, F; Goldman, D; Egan, MF; Weinberger, DR				Hariri, AR; Mattay, VS; Tessitore, A; Kolachana, B; Fera, F; Goldman, D; Egan, MF; Weinberger, DR			Serotonin transporter genetic variation and the response of the human amygdala	SCIENCE			English	Article							ANXIETY-RELATED TRAITS; PERSONALITY-TRAITS; POLYMORPHISM; NEUROTICISM; ASSOCIATION; DISORDERS; GENOTYPE; EXPRESSION; CORTEX; BRAIN	A functional polymorphism in the promoter region of the human serotonin transporter gene (SLC6A4) has been associated with several dimensions of neuroticism and psychopathology, especially anxiety traits, but the predictive value of this genotype against these complex behaviors has been inconsistent. Serotonin [5-hydroxytryptamine, (5-HT)] function influences normal fear as well as pathological anxiety, behaviors critically dependent on the amygdala in animal models and in clinical studies. We now report that individuals with one or two copies of the short allele of the serotonin transporter (5-HTT) promoter polymorphism, which has been associated with reduced 5-HTT expression and function and increased fear and anxiety-related behaviors, exhibit greater amygdala neuronal activity, as assessed by BOLD functional magnetic resonance imaging, in response to fearful stimuli compared with individuals homozygous for the long allele. These results demonstrate genetically driven variation in the response of brain regions underlying human emotional behavior and suggest that differential excitability of the amygdala to emotional stimuli may contribute to the increased fear and anxiety typically associated with the short SLC6A4 allele.	NIMH, Clin Brain Disorders Branch, Intramural Res Program, NIH, Bethesda, MD 20892 USA; NIAAA, Neurogenet Lab, Intramural Res Program, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Weinberger, DR (corresponding author), NIMH, Clin Brain Disorders Branch, Intramural Res Program, NIH, 10 Ctr Dr,Room 4S235, Bethesda, MD 20892 USA.		Hariri, Ahmad/D-5761-2011; Goldman, David/F-9772-2010; Majid, Salma/AAT-2616-2020; Tessitore, Alessandro/K-3124-2018	Goldman, David/0000-0002-1724-5405; Majid, Salma/0000-0002-1724-5405; Tessitore, Alessandro/0000-0003-1740-8566	NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002716, Z01MH002734, ZIAMH002734, Z01MH002716] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000302, Z01AA000303, Z01AA000290] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Armony JL, 1998, J NEUROSCI, V18, P2592; Ball D, 1997, NEUROREPORT, V8, P1301, DOI 10.1097/00001756-199703240-00048; Callicott JH, 1999, CEREB CORTEX, V9, P20, DOI 10.1093/cercor/9.1.20; Canli T, 2001, BEHAV NEUROSCI, V115, P33, DOI 10.1037//0735-7044.115.1.33; Cloninger C.R., 1986, PSYCHIATRIC DEV, V3, P167; Davis M, 2001, MOL PSYCHIATR, V6, P13, DOI 10.1038/sj.mp.4000812; Deary IJ, 1999, PSYCHOL MED, V29, P735, DOI 10.1017/S0033291798007557; Du LS, 2000, PSYCHIATR GENET, V10, P159, DOI 10.1097/00041444-200010040-00002; Ebstein RP, 1997, AM J MED GENET, V74, P65, DOI 10.1002/(SICI)1096-8628(19970221)74:1<65::AID-AJMG15>3.0.CO;2-P; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Ekman P., 1976, PICTURES FACIAL AFFE; Flory JD, 1999, MOL PSYCHIATR, V4, P93, DOI 10.1038/sj.mp.4000466; Garpenstrand H, 2001, BEHAV NEUROSCI, V115, P358, DOI 10.1037//0735-7044.115.2.358; Gross C, 2002, NATURE, V416, P396, DOI 10.1038/416396a; Hariri AR, 2000, NEUROREPORT, V11, P43, DOI 10.1097/00001756-200001170-00009; HARIRI AR, IN PRESS NEUROIMAGE; HARIRI AR, IN PRESS NEUROPSYCHO; Haxby JV, 2002, BIOL PSYCHIAT, V51, P59, DOI 10.1016/S0006-3223(01)01330-0; Heils A, 1996, J NEUROCHEM, V66, P2621; Heinz A, 2000, BIOL PSYCHIAT, V47, P643, DOI 10.1016/S0006-3223(99)00171-7; Hidalgo RB, 2000, J CLIN PSYCHIAT, V61, P5; HOLMES A, 2001, ACNP ABSTR, P235; HRDINA PD, 1993, BRAIN RES, V614, P37, DOI 10.1016/0006-8993(93)91015-K; Julius D, 1998, P NATL ACAD SCI USA, V95, P15153, DOI 10.1073/pnas.95.26.15153; Katsuragi S, 1999, BIOL PSYCHIAT, V45, P368, DOI 10.1016/S0006-3223(98)00090-0; LeDoux J. E., 1996, EMOTIONAL BRAIN; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; Lesch KP, 1998, BIOL PSYCHIAT, V44, P179, DOI 10.1016/S0006-3223(98)00121-8; Little KY, 1998, AM J PSYCHIAT, V155, P207; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Melke J, 2001, AM J MED GENET, V105, P458, DOI 10.1002/ajmg.1434; Morris JS, 1998, BRAIN, V121, P47, DOI 10.1093/brain/121.1.47; Murphy DL, 2001, BRAIN RES BULL, V56, P487, DOI 10.1016/S0361-9230(01)00622-0; Ohara K, 1998, BIOL PSYCHIAT, V44, P550, DOI 10.1016/S0006-3223(98)00112-7; Rainnie DG, 1999, J NEUROPHYSIOL, V82, P69, DOI 10.1152/jn.1999.82.1.69; Ressler KJ, 2000, DEPRESS ANXIETY, V12, P2, DOI 10.1002/1520-6394(2000)12:1+<2::AID-DA2>3.3.CO;2-W; Zald DH, 2002, P NATL ACAD SCI USA, V99, P2450, DOI 10.1073/pnas.042457199	37	1734	1769	2	204	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 19	2002	297	5580					400	403		10.1126/science.1071829	http://dx.doi.org/10.1126/science.1071829			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574LV	12130784				2022-12-28	WOS:000176892600051
J	Hunt, KK; Vorburger, SA				Hunt, KK; Vorburger, SA			Hurdles and hopes for cancer treatment	SCIENCE			English	Editorial Material							DIRECTED GENE-THERAPY		Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Hunt, KK (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.							BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; Hacein-Bey-Abina S, 2002, NEW ENGL J MED, V346, P1185, DOI 10.1056/NEJMoa012616; Haviv YS, 2001, ADV DRUG DELIVER REV, V53, P135, DOI 10.1016/S0169-409X(01)00225-3; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; Rainov NG, 2000, HUM GENE THER, V11, P2389, DOI 10.1089/104303400750038499; SINKOVICS J, 1993, INTERVIROLOGY, V36, P193, DOI 10.1159/000150339; SMITH RR, 1956, CANCER, V9, P1211, DOI 10.1002/1097-0142(195611/12)9:6<1211::AID-CNCR2820090624>3.0.CO;2-7; Swisher SG, 1999, J NATL CANCER I, V91, P763, DOI 10.1093/jnci/91.9.763; VANIN EF, 1994, J VIROL, V68, P4241, DOI 10.1128/JVI.68.7.4241-4250.1994; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995	10	75	85	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 19	2002	297	5580					415	416		10.1126/science.297.5580.415	http://dx.doi.org/10.1126/science.297.5580.415			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574LV	12130788				2022-12-28	WOS:000176892600055
J	Meier, MF; Dyurgerov, MB				Meier, MF; Dyurgerov, MB			Sea level changes: How Alaska affects the world	SCIENCE			English	Editorial Material							GLACIER MELT; RISE		Univ Colorado, Inst Arctic & Alpine Res, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Meier, MF (corresponding author), Univ Colorado, Inst Arctic & Alpine Res, Boulder, CO 80309 USA.							Arendt AA, 2002, SCIENCE, V297, P382, DOI 10.1126/science.1072497; Cabanes C, 2001, SCIENCE, V294, P840, DOI 10.1126/science.1063556; DOUGLAS BC, 2001, LEVEL RISE HIST CONS; DYURGEROV M, 2002, 55 INSTAAR U COL; Dyurgerov MB, 2000, P NATL ACAD SCI USA, V97, P1406, DOI 10.1073/pnas.97.4.1406; Gregory JM, 1998, NATURE, V391, P474, DOI 10.1038/35119; HOUGHTON JT, 2001, 3 INT PAN CLIM CHANG; MEIER MF, 1984, SCIENCE, V226, P1419; Munk W, 2002, P NATL ACAD SCI USA, V99, P6550, DOI 10.1073/pnas.092704599; Ostrem G., 1993, ARCT ANTARCT ALP RES, V25, P77, DOI [10.2307/1551489, DOI 10.2307/1551489]; Van de Wal RSW, 2001, CLIM DYNAM, V18, P359, DOI 10.1007/s003820100184; Zuo Z, 1997, CLIM DYNAM, V13, P835, DOI 10.1007/s003820050200	12	48	54	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 19	2002	297	5580					350	351		10.1126/science.1073591	http://dx.doi.org/10.1126/science.1073591			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574LV	12130771				2022-12-28	WOS:000176892600036
J	Noble, JT; Mark, EJ; Hurtado, R; Arena, JF				Noble, JT; Mark, EJ; Hurtado, R; Arena, JF			A 37-year-old man with unexplained fever after a long trip through South America - Brucella melitensis infection.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ABDOMINAL TUBERCULOSIS; IMMUNOLOGIC CONTROL; TYPHOID FEVER; PATHOGENESIS; PERSISTENCE		Concord Hosp, Infect Dis Sect, Concord, NH 03301 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA	Concord Hospital; Tufts University	Noble, JT (corresponding author), Concord Hosp, Infect Dis Sect, Concord, NH 03301 USA.							Alt HL, 1930, J AMER MED ASSOC, V94, P1457, DOI 10.1001/jama.1930.02710450001001; ARIZA J, 1993, CLIN INFECT DIS, V16, P761, DOI 10.1093/clind/16.6.761; BLACK PH, 1960, NEW ENGL J MED, V262, P921, DOI 10.1056/NEJM196005052621806; BLACK PH, 1960, NEW ENGL J MED, V262, P811, DOI 10.1056/NEJM196004212621606; *BLAST COOP STUD V, 1964, AM REV RESPIR DIS, V89, P659; BUCHANAN TM, 1974, MEDICINE, V53, P403, DOI 10.1097/00005792-197411000-00001; CHEVILLE NF, 1995, LAB INVEST, V73, P96; Cheville NF, 1996, INFECT IMMUN, V64, P2431, DOI 10.1128/IAI.64.7.2431-2439.1996; CHO HJ, 1972, CAN J MICROBIOL, V18, P449, DOI 10.1139/m72-070; COX SK, 1981, MO MED, V78, P70; Durack D T, 1991, Curr Clin Top Infect Dis, V11, P35; Franco M, 1987, Rev Soc Bras Med Trop, V20, P129, DOI 10.1590/S0037-86821987000200012; GOODWIN RA, 1980, MEDICINE, V59, P1, DOI 10.1097/00005792-198001000-00001; GRIFFITTS JJ, 1947, PUBLIC HEALTH REP, V62, P865, DOI 10.2307/4586164; HALL WH, 1953, J CLIN INVEST, V32, P96, DOI 10.1172/JCI102716; HALL WH, 1982, BACTERIAL INFECTIONS, P119; Haslhofer L, 1933, VIRCHOWS ARCH A, V291, P912, DOI 10.1007/BF01891744; HORNICK RB, 1970, NEW ENGL J MED, V283, P739, DOI 10.1056/NEJM197010012831406; HORNICK RB, 1970, NEW ENGL J MED, V283, P686, DOI 10.1056/NEJM197009242831306; HULNICK DH, 1985, RADIOLOGY, V157, P199, DOI 10.1148/radiology.157.1.4034967; JAKUBOWSKI A, 1988, J INFECT DIS, V158, P687, DOI 10.1093/infdis/158.4.687; KAZANJIAN PH, 1992, CLIN INFECT DIS, V15, P968, DOI 10.1093/clind/15.6.968; KIMBROUGH RC, 1979, ANN INTERN MED, V91, P400, DOI 10.7326/0003-4819-91-3-400; Kirkland TN, 1996, EMERG INFECT DIS, V2, P192, DOI 10.3201/eid0203.960305; Mahmoud A. A. F., 1990, Tropical and Geographical Medicine., P458; Mahmoud AAF, 1996, CLIN INFECT DIS, V23, P949, DOI 10.1093/clinids/23.5.949; Pearson RD, 1996, CLIN INFECT DIS, V22, P1, DOI 10.1093/clinids/22.1.1; PETERS PAS, 1987, BAILLIERE CLIN TROP, V2, P419; PETERSDORF R, 1961, MEDICINE, V40, P1, DOI 10.1097/00005792-196102000-00001; SCHULZE K, 1977, AM J MED, V63, P735, DOI 10.1016/0002-9343(77)90160-7; TURCK WPG, 1976, Q J MED, V45, P193; YOUNG EJ, 1995, CLIN INFECT DIS, V21, P283, DOI 10.1093/clinids/21.2.283; YOUNG EJ, 1991, REV INFECT DIS, V13, P359	33	6	6	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 18	2002	347	3					200	206		10.1056/NEJMcpc020102	http://dx.doi.org/10.1056/NEJMcpc020102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	574BR	12124410				2022-12-28	WOS:000176869000008
J	Wisner, KL; Parry, BL; Piontek, CM				Wisner, KL; Parry, BL; Piontek, CM			Postpartum depression	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Seminar on Women and Depression	OCT 05-07, 2000	QUEENSTOWN, MD				MOTHER-INFANT PAIRS; BREAST-FED INFANTS; POSTNATAL DEPRESSION; NURSING INFANTS; HUMAN-MILK; SERUM; WOMEN; SERTRALINE; ANTIDEPRESSANTS; FLUOXETINE	A woman visits the doctor for her six-week postpartum evaluation. She reports that she cannot sleep even if her baby sleeps. She cries daily and worries constantly. She does not feel hungry and is not eating regularly. Making decisions is overwhelming. She says she is not herself. How should this new mother be evaluated and treated?	Univ Louisville, Sch Med, Dept Psychiat & Behav Sci, Louisville, KY 40202 USA; Univ Calif San Diego, San Diego, CA 92103 USA; Thomas Jefferson Med Coll, Philadelphia, PA USA	University of Louisville; University of California System; University of California San Diego; Jefferson University	Wisner, KL (corresponding author), Univ Louisville, Sch Med, Dept Psychiat & Behav Sci, 608 S Jackson St, Louisville, KY 40202 USA.			Wisner, Katherine/0000-0003-3458-5986	PHS HHS [R01 60335, R01 57102] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Altshuler L L, 2001, Postgrad Med, P1; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; [Anonymous], 2000, Am J Psychiatry, V157, P1; Appleby L, 1997, BRIT MED J, V314, P932, DOI 10.1136/bmj.314.7085.932; Bloch M, 2000, AM J PSYCHIAT, V157, P924, DOI 10.1176/appi.ajp.157.6.924; Brosen K, 1998, INT CLIN PSYCHOPHARM, V13, pS45, DOI 10.1097/00004850-199809005-00009; Chambers CD, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.5.e61; Cohen LS, 2001, J CLIN PSYCHIAT, V62, P592, DOI 10.4088/JCP.v62n0803; COX J, 1994, PERINATAL PSYCHIATRY, P115; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; Epperson N, 2001, AM J PSYCHIAT, V158, P1631, DOI 10.1176/appi.ajp.158.10.1631; Gregoire AJP, 1996, LANCET, V347, P930, DOI 10.1016/S0140-6736(96)91414-2; Hendrick V, 2001, AM J PSYCHIAT, V158, P2089, DOI 10.1176/appi.ajp.158.12.2089-a; Hendrick V, 2001, BRIT J PSYCHIAT, V179, P163, DOI 10.1192/bjp.179.2.163; Ilett KF, 2002, BRIT J CLIN PHARMACO, V53, P17, DOI 10.1046/j.0306-5251.2001.01518.x; Jensen PN, 1997, THER DRUG MONIT, V19, P236, DOI 10.1097/00007691-199704000-00021; KENDELL RE, 1987, BRIT J PSYCHIAT, V150, P662, DOI 10.1192/bjp.150.5.662; KENDELL RE, 1987, BRIT J PSYCHIAT, V151, P135; Kristensen JH, 1999, BRIT J CLIN PHARMACO, V48, P521, DOI 10.1046/j.1365-2125.1999.00040.x; Lawrie TA, 1998, BRIT J OBSTET GYNAEC, V105, P1082, DOI 10.1111/j.1471-0528.1998.tb09940.x; LESTER BM, 1993, J AM ACAD CHILD PSY, V32, P1253, DOI 10.1097/00004583-199311000-00020; Llett KF, 1998, BRIT J CLIN PHARMACO, V45, P459, DOI 10.1046/j.1365-2125.1998.00710.x; *MED EC, 2001, PHYS DESK REF; Misri S, 2000, J CLIN PSYCHIAT, V61, P828, DOI 10.4088/JCP.v61n1104; Nemeroff CB, 1996, AM J PSYCHIAT, V153, P311; O'Hara MW, 2000, ARCH GEN PSYCHIAT, V57, P1039, DOI 10.1001/archpsyc.57.11.1039; OHara MW, 1996, INT REV PSYCHIATR, V8, P37, DOI 10.3109/09540269609037816; Osmond M., 2001, SMILE MY JOURNEY OUT; PARRY BL, 1992, ART PSYCHOPHARMACOLO; Piontek CM, 2001, J CLIN PSYCHIAT, V62, P111, DOI 10.4088/JCP.v62n0207; PRESKORN SH, 1996, CLIN PHARM SELECTIVE, P75; Rampono J, 2000, BRIT J CLIN PHARMACO, V50, P263, DOI 10.1046/j.1365-2125.2000.00253.x; RICHELSON E, 1994, MAYO CLIN PROC, V69, P1069, DOI 10.1016/S0025-6196(12)61375-5; Schmidt K, 2000, BIOL PSYCHIAT, V47, P164, DOI 10.1016/S0006-3223(99)00155-9; Stowe Z, 1995, DEPRESSION, V3, P49, DOI [DOI 10.1002/DEPR.3050030109, 10.1002/depr.3050030109]; Stowe ZN, 2000, AM J PSYCHIAT, V157, P185, DOI 10.1176/appi.ajp.157.2.185; Stowe ZN, 1997, AM J PSYCHIAT, V154, P1255; Swendsen JD, 2000, CLIN PSYCHOL-SCI PR, V7, P17, DOI 10.1093/clipsy/7.1.17; Wisner KL, 2001, J CLIN PSYCHIAT, V62, P82, DOI 10.4088/JCP.v62n0202; WISNER KL, 1994, J AFFECT DISORDERS, V30, P77, DOI 10.1016/0165-0327(94)90034-5; Wisner KL, 1997, PSYCHOPHARMACOL BULL, V33, P243; Wisner KL, 1996, AM J PSYCHIAT, V153, P1132; Wisner KL, 1998, AM J PSYCHIAT, V155, P690, DOI 10.1176/ajp.155.5.690; WISNER KL, 1995, J AFFECT DISORDERS, V34, P1, DOI 10.1016/0165-0327(94)00097-S; Wisner KL, 1997, SEMIN REPROD ENDOCR, V15, P77, DOI 10.1055/s-2008-1067970; WISNER KL, 1999, ARCH WOMEN MENT HLTH, V1, P189; Yapp P, 2000, ANN PHARMACOTHER, V34, P1269, DOI 10.1345/aph.10120; Yoshida K, 1997, J AFFECT DISORDERS, V43, P225, DOI 10.1016/S0165-0327(97)01433-X; Zlotnick C, 2001, AM J PSYCHIAT, V158, P638, DOI 10.1176/appi.ajp.158.4.638	49	383	404	1	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 18	2002	347	3					194	199		10.1056/NEJMcp011542	http://dx.doi.org/10.1056/NEJMcp011542			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	574BR	12124409				2022-12-28	WOS:000176869000007
J	Von Korff, M; Glasgow, RE; Sharpe, M				Von Korff, M; Glasgow, RE; Sharpe, M			ABC of psychological medicine - Organising care for chronic illness	BRITISH MEDICAL JOURNAL			English	Review							MANAGEMENT		Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; AMC Canc Res Ctr, Denver, CO USA; Univ Edinburgh, Edinburgh EH8 9YL, Midlothian, Scotland	Group Health Cooperative; AMC Cancer Research Center; University of Edinburgh	Von Korff, M (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA.			VonKorff, Michael/0000-0001-5386-8477; sharpe, michael/0000-0002-6474-9980	NIDCR NIH HHS [P01 DE008773, P01 DE08773] Funding Source: Medline; NIMH NIH HHS [R01 MH051338, MH41739, R01 MH041739, MH51338] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE008773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH041739, R01MH051338] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Department of Health, EXP PAT NEW APPR CHR; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; Von Korff M, 1997, ANN INTERN MED, V127, P1097, DOI 10.7326/0003-4819-127-12-199712150-00008; Wagner E H, 2001, Jt Comm J Qual Improv, V27, P63; Wolpert HA, 2001, BMJ-BRIT MED J, V323, P994, DOI 10.1136/bmj.323.7319.994	5	78	79	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 13	2002	325	7355					92	94		10.1136/bmj.325.7355.92	http://dx.doi.org/10.1136/bmj.325.7355.92			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575CU	12114242	Green Published			2022-12-28	WOS:000176929400024
J	Hermine, O; Lefrere, F; Bronowicki, JP; Mariette, X; Jondeau, K; Eclache-Saudreau, V; Delmas, B; Valensi, F; Cacoub, P; Brechot, C; Varet, B; Troussard, X				Hermine, O; Lefrere, F; Bronowicki, JP; Mariette, X; Jondeau, K; Eclache-Saudreau, V; Delmas, B; Valensi, F; Cacoub, P; Brechot, C; Varet, B; Troussard, X			Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-HODGKINS-LYMPHOMA; CORE PROTEIN; B-CELLS; GENE; RECEPTOR	Background Some epidemiologic studies suggest a link between hepatitis C virus (HCV) infection and some B-cell non-Hodgkin's lymphomas. We undertook this study after a patient with splenic lymphoma with villous lymphocytes had a hematologic response after antiviral treatment of HCV infection. Methods Nine patients who had splenic lymphoma with villous lymphocytes and HCV infection were treated with interferon alfa-2b (3 million IU three times per week) alone or in combination with ribavirin (1000 to 1200 mg per day). The outcomes were compared with those of six similarly treated patients with splenic lymphoma with villous lymphocytes who tested negative for HCV infection. Results Of the nine patients with HCV infection who received interferon alfa, seven had a complete remission after the loss of detectable HCV RNA. The other two patients had a partial and a complete remission after the addition of ribavirin and the loss of detectable HCV RNA. One patient had a relapse when the HCV RNA load again became detectable in blood. In contrast, none of the six HCV-negative patients had a response to interferon therapy. Conclusions In patients with splenic lymphoma with villous lymphocytes who are infected with HCV, treatment with interferon can lead to regression of the lymphoma.	Hop Necker Enfants Malad, Serv Hematol, Dept Hematol, F-75743 Paris 15, France; Hop Necker Enfants Malad, CNRS, Unite Mixte Rech 8603, F-75743 Paris 15, France; Ctr Hosp Univ Nancy, Dept Hepatol, Nancy, France; Hop Kremlin Bicetre, Dept Rheumatol, Le Kremlin Bicetre, France; Hop Cochin, Dept Hematol, F-75674 Paris, France; Hop Jean Verdier, Dept Hematol, Bondy, France; Hop Paul Brousse, Dept Hematol, Villejuif, France; Hop La Pitie Salpetriere, Dept Internal Med, Paris, France; Ctr Hosp Univ Cote de Narce, Dept Hematol, Caen, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; CHU de Nancy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU de Caen NORMANDIE; Universite de Caen Normandie	Hermine, O (corresponding author), Hop Necker Enfants Malad, Serv Hematol, Dept Hematol, 149-161 Rue Sevres, F-75743 Paris 15, France.	hermine@necker.fr	Hermine, Olivier/Q-7072-2018	Hermine, Olivier/0000-0003-2574-3874; Cacoub, Patrice/0000-0002-6727-4992				Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766; Brind AM, 1996, LEUKEMIA LYMPHOMA, V21, P127, DOI 10.3109/10428199609067589; Chan CH, 2001, BLOOD, V97, P1023, DOI 10.1182/blood.V97.4.1023; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Collier JD, 1999, HEPATOLOGY, V29, P1259, DOI 10.1002/hep.510290422; De Re V, 2000, BLOOD, V96, P3578; Ellenrieder V, 1998, J HEPATOL, V28, P34, DOI 10.1016/S0168-8278(98)80199-2; Germanidis G, 1999, BLOOD, V93, P1778, DOI 10.1182/blood.V93.5.1778.405a39a_1778_1779; Harris NL, 1999, J CLIN ONCOL, V17, P3835, DOI 10.1200/JCO.1999.17.12.3835; Ivanovski M, 1998, BLOOD, V91, P2433, DOI 10.1182/blood.V91.7.2433.2433_2433_2442; Izumi Tohru, 1997, Leukemia (Basingstoke), V11, P516; King PD, 1998, CLIN LAB HAEMATOL, V20, P107, DOI 10.1046/j.1365-2257.1998.00110.x; Kuppers R, 1999, NEW ENGL J MED, V341, P1520; Lefrere F, 2000, LEUKEMIA, V14, P573, DOI 10.1038/sj.leu.2401710; Luppi M, 1998, ANN ONCOL, V9, P495, DOI 10.1023/A:1008255830453; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; MUSSET L, 1992, CLIN CHEM, V38, P798; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; POZZATO G, 1994, BLOOD, V84, P3047; Quinn ER, 2001, BLOOD, V98, P3745, DOI 10.1182/blood.V98.13.3745; Rasul I, 1999, HEPATOLOGY, V29, P543, DOI 10.1002/hep.510290224; Ray RB, 1996, J VIROL, V70, P4438, DOI 10.1128/JVI.70.7.4438-4443.1996; SAKAMURO D, 1995, J VIROL, V69, P3893, DOI 10.1128/JVI.69.6.3893-3896.1995; Silvestri F, 1996, BLOOD, V87, P4296, DOI 10.1182/blood.V87.10.4296.bloodjournal87104296; Tierens A, 1999, BLOOD, V93, P226, DOI 10.1182/blood.V93.1.226.401a30_226_234; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; Zuckerman E, 2001, BLOOD, V97, P1555, DOI 10.1182/blood.V97.6.1555; Zuckerman E, 1997, ANN INTERN MED, V127, P423, DOI 10.7326/0003-4819-127-6-199709150-00002	29	584	606	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 11	2002	347	2					89	94		10.1056/NEJMoa013376	http://dx.doi.org/10.1056/NEJMoa013376			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	572HC	12110736				2022-12-28	WOS:000176767300003
J	Liu, CY; Bard, AJ				Liu, CY; Bard, AJ			Pressure-induced insulator-conductor transition in a photoconducting organic liquid-crystal film	NATURE			English	Article							MONOLAYERS; PORPHYRIN; CELLS	Intermolecular separation determines the extent of orbital overlap and thus the rate of electron transfer between neighbouring molecules in an organic crystal. If such a crystal is compressed, the resistivity decreases owing to a diminishing intermolecular distance(1). Metal-insulator transitions have been observed by applying hydrostatic pressure to, for example, Langmuir films of metal nanoparticles(2,3). But previous attempts to observe a clear transition point in organic crystals, such as anthracene and tetracene, were not successful owing to difficulties with electrically insulating the high-pressure cell(4). Here we report a different approach by using a sample that is photoconductive and forms an organized film. A cylindrical tip (similar to100 mum in diameter) was used to compress the sample instead of a piston/cylinder structure, entirely eliminating the problem of electrical insulation. Furthermore, by illuminating the sample with a laser, the conductivity of the sample is increased by several orders of magnitude. By monitoring the photocurrent with sensitivity at the 10(-13) A level, changes in resistivity at very low pressure could be monitored. We observe a sharp increase in current that could indicate a transition from hopping to delocalized conduction.	Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Bard, AJ (corresponding author), Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA.							AUST RB, 1964, J CHEM PHYS, V41, P1856, DOI 10.1063/1.1726167; Collier CP, 1997, SCIENCE, V277, P1978, DOI 10.1126/science.277.5334.1978; DRICKAMER HG, 1972, ANNU REV PHYS CHEM, V23, P39, DOI 10.1146/annurev.pc.23.100172.000351; GREGG BA, 1990, J PHYS CHEM-US, V94, P1586, DOI 10.1021/j100367a068; Henrichs S, 2000, J AM CHEM SOC, V122, P4077, DOI 10.1021/ja991543f; LIU CY, 1995, J PHYS CHEM-US, V99, P7632, DOI 10.1021/j100019a050; Liu CY, 1998, CHEM MATER, V10, P840, DOI 10.1021/cm970583k; Liu CY, 1999, ACCOUNTS CHEM RES, V32, P235, DOI 10.1021/ar980031n; Liu CY, 1997, CHEM MATER, V9, P1422, DOI 10.1021/cm970039b; LIU CY, 1999, CONJUGATED OLIGOMERS, P85; SAMARA GA, 1962, J CHEM PHYS, V37, P474, DOI 10.1063/1.1701360; SCHOUTEN PG, 1991, NATURE, V353, P736, DOI 10.1038/353736a0	12	61	67	2	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 11	2002	418	6894					162	164		10.1038/nature00875	http://dx.doi.org/10.1038/nature00875			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571GV	12110884				2022-12-28	WOS:000176710400034
J	Collins, R; Armitage, J; Parish, S; Sleight, P; Peto, R				Collins, R; Armitage, J; Parish, S; Sleight, P; Peto, R		Heart Protection Study Collaborati	MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial	LANCET			English	Article							LOW-DENSITY-LIPOPROTEIN; LONG-TERM SUPPLEMENTATION; SERUM ASCORBIC-ACID; BETA-CAROTENE; ALPHA-TOCOPHEROL; CARDIOVASCULAR-DISEASE; PLASMA-CONCENTRATION; LIPID-PEROXIDATION; PULMONARY-FUNCTION; CLINICAL-TRIAL	Background It has been suggested that increased intake of various antioxidant vitamins reduces the incidence rates of vascular disease, cancer, and other adverse outcomes. Methods 20 536 UK adults (aged 40-80) with coronary disease, other occlusive arterial disease, or diabetes were randomly allocated to receive antioxidant vitamin supplementation (600 mg vitamin E, 250 mg vitamin C, and 20 mg beta-carotene daily) or matching placebo. Intention-to-treat comparisons of outcome were conducted between all vitamin-allocated and all placebo-allocated participants. An average of 83% of participants in each treatment group remained compliant during the scheduled 5-year treatment period. Allocation to this vitamin regimen approximately doubled the plasma concentration of alpha-tocopherol, increased that of vitamin C by one-third, and quadrupled that of beta-carotene. Primary outcomes were major coronary events (for overall analyses) and fatal or non-fatal vascular events (for subcategory analyses), with subsidiary assessments of cancer and of other major morbidity. Findings There were no significant differences in all-cause mortality (1446 [14.1%] vitamin-a] located vs 1389 [13.5%] placebo-a I located), or in deaths due to vascular (878 [8.6%] vs 840 [8.2%]) or non-vascular (568 [5.5%] vs 549 [5.3%]) causes. Nor were there any significant differences in the numbers of participants having non-fatal myocardial infarction or coronary death (1063 [10.4%] vs 1047 [10.2%]), non-fatal or fatal stroke (511 [5.0%] vs 518 15.0%]), or coronary or noncoronary revascularisation (1058 [10.3%] vs 1086 [10.6%]). For the first occurrence of any of these "major vascular events", there were no material differences either overall (2306 [22.5%] vs 2312 [22.5%]; event rate ratio 1.00 [95% Cl 0.94-1.06]) or in any of the various subcategories considered. There were no significant effects on cancer incidence or on hospitalisation for any other non-vascular cause. Interpretation Among the high-risk individuals that were studied, these antioxidant vitamins appeared to be safe. But, although this regimen increased blood vitamin concentrations substantially, it did not produce any significant reductions in the 5-year mortality from, or incidence of, any type of vascular disease, cancer, or other major outcome.	Radcliffe Infirm, Clin Trial Serv Unit, Heart Protect Study, Oxford OX2 6HE, England; Radcliffe Infirm, Epidemiol Studies Unit, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford	Collins, R (corresponding author), Radcliffe Infirm, Clin Trial Serv Unit, Heart Protect Study, Oxford OX2 6HE, England.	hps@ctsu.ox.ac.uk	Lindley, Richard/B-8148-2013	Lindley, Richard/0000-0002-0104-5679; Mihaylova, Borislava/0000-0002-0951-1304				Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; BENZIE IFF, 1995, CLIN CHIM ACTA, V239, P185, DOI 10.1016/0009-8981(95)06116-U; BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201; BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; Boaz M, 2000, LANCET, V356, P1213, DOI 10.1016/S0140-6736(00)02783-5; Brigelius-Flohe R, 1999, FASEB J, V13, P1145, DOI 10.1096/fasebj.13.10.1145; Chen J., 1990, DIET LIFE STYLE MORT; Christen WG, 2001, INVEST OPHTH VIS SCI, V42, pS518; Chylack LT, 2002, OPHTHAL EPIDEMIOL, V9, P49; *COLL GROUP PRIM P, 1990, LANCET, V357, P89; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; DIEBERROTHENEDER M, 1991, J LIPID RES, V32, P1325; Fang JC, 2002, LANCET, V359, P1108, DOI 10.1016/S0140-6736(02)08154-0; FLAGG EW, 1995, J AM COLL NUTR, V14, P419; FOLEY DJ, 2002, JAMA-J AM MED ASSOC, V287, P2361; FREI B, 1990, ADV EXP MED BIOL, V264, P155; Gaziano J. Michael, 1995, Annals of Epidemiology, V5, P255, DOI 10.1016/1047-2797(94)00090-G; Greenberg ER, 1996, JAMA-J AM MED ASSOC, V275, P699, DOI 10.1001/jama.275.9.699; Greenwald P, 2002, BMJ-BRIT MED J, V324, P714, DOI 10.1136/bmj.324.7339.714; Grievink L, 1998, THORAX, V53, P166, DOI 10.1136/thx.53.3.166; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; Hoppe PP, 2000, EUR J NUTR, V39, P183, DOI 10.1007/s003940070010; Hu GZ, 2000, AM J EPIDEMIOL, V151, P975, DOI 10.1093/oxfordjournals.aje.a010141; IOM, 2000, DIET REF INT VIT C V; JHA P, 1995, ANN INTERN MED, V123, P860, DOI 10.7326/0003-4819-123-11-199512010-00009; JIALAL I, 1991, J CLIN INVEST, V87, P597, DOI 10.1172/JCI115035; JIALAL I, 1995, ARTERIOSCL THROM VAS, V15, P190, DOI 10.1161/01.ATV.15.2.190; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439; KEECH A, 1992, 11 INT S DRUGS LIP M, P59; Khaw KT, 2001, LANCET, V357, P657, DOI 10.1016/S0140-6736(00)04128-3; Klipstein-Grobusch K, 1999, AM J CLIN NUTR, V69, P261; KNEKT P, 1992, BMJ-BRIT MED J, V305, P1392, DOI 10.1136/bmj.305.6866.1392; Kushi LH, 1996, NEW ENGL J MED, V334, P1156, DOI 10.1056/NEJM199605023341803; Levine M, 2001, P NATL ACAD SCI USA, V98, P9842, DOI 10.1073/pnas.171318198; MacMahon S, 2001, LANCET, V357, P455, DOI 10.1016/S0140-6736(00)04017-4; Meade T, 1999, EUR HEART J, V20, P725; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; OMENN GS, 1994, CANCER EPIDEM BIOMAR, V3, P711; PEDERSEN TR, 1994, LANCET, V344, P1383; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1981, NATURE, V290, P201, DOI 10.1038/290201a0; Prince MJ., 1999, INT J METH PSYCH RES, V8, P49, DOI DOI 10.1002/MPR.56; PRINCEN HMG, 1995, ARTERIOSCL THROM VAS, V15, P325, DOI 10.1161/01.ATV.15.3.325; REGNSTROM J, 1992, LANCET, V339, P1183, DOI 10.1016/0140-6736(92)91129-V; Robman LD, 2001, INVEST OPHTH VIS SCI, V42, pS508; Sacks FM, 2000, CIRCULATION, V102, P1893, DOI 10.1161/01.CIR.102.16.1893; Salonen JT, 2000, J INTERN MED, V248, P377, DOI 10.1046/j.1365-2796.2000.00752.x; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; Simon JA, 1999, J CLIN EPIDEMIOL, V52, P1207, DOI 10.1016/S0895-4356(99)00110-9; Simon JA, 2001, J AM COLL NUTR, V20, P255, DOI 10.1080/07315724.2001.10719040; Simon JA, 2001, AM J EPIDEMIOL, V154, P427, DOI 10.1093/aje/154.5.427; SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1246, DOI 10.1001/archopht.1993.01090090098027; STEINBERG D, 1992, CIRCULATION, V85, P2338, DOI 10.1161/01.CIR.85.6.2337; Steinberg D, 2002, CIRCULATION, V105, P2107, DOI 10.1161/01.CIR.0000014762.06201.06; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Sundaram RK, 1996, CLIN SCI, V90, P255, DOI 10.1042/cs0900255; Teikari JM, 1997, ACTA OPHTHALMOL SCAN, V75, P634; TROISI RJ, 1995, AM J RESP CRIT CARE, V151, P1401, DOI 10.1164/ajrccm.151.5.7735592; Upston JM, 1999, FASEB J, V13, P977, DOI 10.1096/fasebj.13.9.977; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Weber P, 1997, NUTRITION, V13, P450, DOI 10.1016/S0899-9007(97)00110-X; WHITE SJ, 1978, BRIT J CANCER, V37, P849, DOI 10.1038/bjc.1978.124; Willett WC, 2001, NEW ENGL J MED, V345, P1819, DOI 10.1056/NEJMcp010710; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302	66	1099	1137	0	69	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 6	2002	360	9326					23	33						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569JR	12114037				2022-12-28	WOS:000176599700007
J	Walter, JH; White, FJ; Hall, SK; MacDonald, A; Rylance, G; Boneh, A; Francis, DE; Shortland, GJ; Schmidt, M; Vail, A				Walter, JH; White, FJ; Hall, SK; MacDonald, A; Rylance, G; Boneh, A; Francis, DE; Shortland, GJ; Schmidt, M; Vail, A			How practical are recommendations for dietary control in phenylketonuria?	LANCET			English	Article								In patients with phenylketonuria, blood phenylalanine concentration during childhood is the major determinant of cognitive outcome. Guidelines provide age-related recommendations for treatment. To ascertain the extent to which these alms are achievable, we audited results from four centres for the years 1994-2000. The median proportion of samples with phenylalanine concentrations above those recommended was less than 30% for those younger than age 10 years but almost 80% for those aged 15 years and older. Similarly, the median frequency of blood sampling, expressed as a proportion of that recommended, was more than 80% for patients younger than 10 years but less than 50% by age 15 years. Our results indicate the difficulty of maintaining control In phenylketonuria, especially in older rather than younger children.	Royal Manchester Childrens Hosp, Willink Biochem Genet Unit, Manchester M27 4HA, Lancs, England; Birmingham Childrens Hosp, Birmingham, W Midlands, England; Royal Melbourne Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; Univ Wales Hosp, Dept Child Hlth, Cardiff CF4 4XW, S Glam, Wales; Univ Manchester, Biostat Grp, Manchester, Lancs, England	Royal Manchester Children's Hospital; University of Birmingham; Murdoch Children's Research Institute; Cardiff University; University of Manchester	Walter, JH (corresponding author), Royal Manchester Childrens Hosp, Willink Biochem Genet Unit, Manchester M27 4HA, Lancs, England.		White, Fiona/F-5251-2018; White, Fiona/P-5220-2019	White, Fiona/0000-0003-4936-1029; White, Fiona/0000-0003-4936-1029; Vail, Andy/0000-0001-8274-2726				ASPLIN D, 1999, MANAGEMENT PKU; BEASLEY MG, 1994, Q J MED, V87, P155; Schweitzer-Krantz S, 2000, EUR J PEDIATR, V159, pS70, DOI 10.1007/PL00014385; SMITH I, 1993, ARCH DIS CHILD, V68, P426; WAISBREN SE, 1987, PEDIATRICS, V79, P351	5	234	241	0	22	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 6	2002	360	9326					55	57		10.1016/S0140-6736(02)09334-0	http://dx.doi.org/10.1016/S0140-6736(02)09334-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569JR	12114043				2022-12-28	WOS:000176599700013
J	Keren, K; Krueger, M; Gilad, R; Ben-Yoseph, G; Sivan, U; Braun, E				Keren, K; Krueger, M; Gilad, R; Ben-Yoseph, G; Sivan, U; Braun, E			Sequence-specific molecular lithography on single DNA molecules	SCIENCE			English	Article							RECA PROTEIN; CIRCUITS; CLEAVAGE	Recent advances in the realization of individual molecular-scale electronic devices emphasize the need for novel tools and concepts capable of assembling such devices into large-scale functional circuits. We demonstrated sequence-specific molecular lithography on substrate DNA molecules by harnessing homologous recombination by RecA protein. In a sequence-specific manner, we patterned the coating of DNA with metal, localized labeled molecular objects and grew metal islands on specific sites along the DNA substrate, and generated molecularly accurate stable DNA junctions for patterning the DNA substrate connectivity. In our molecular lithography, the information encoded in the DNA molecules replaces the masks used in conventional microelectronics, and the RecA protein serves as the resist. The molecular lithography works with high resolution over a broad range of length scales from nanometers to many micrometers.	Technion Israel Inst Technol, Dept Phys, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Inst Solid State, IL-32000 Haifa, Israel	Technion Israel Institute of Technology; Technion Israel Institute of Technology	Braun, E (corresponding author), Technion Israel Inst Technol, Dept Phys, IL-32000 Haifa, Israel.	erez@physics.technion.ac.il	Krueger, Michael/A-4099-2011	Krueger, Michael/0000-0002-2476-5505; Keren, Kinneret/0000-0002-2962-6977				Bachtold A, 2001, SCIENCE, V294, P1317, DOI 10.1126/science.1065824; BENSIMON D, 1995, PHYS REV LETT, V74, P4754, DOI 10.1103/PhysRevLett.74.4754; Braun E, 1998, NATURE, V391, P775, DOI 10.1038/35826; Cox MM, 2000, PROG NUCLEIC ACID RE, V63, P311, DOI 10.1016/S0079-6603(08)60726-6; Eichen Y, 1998, ACTA POLYM, V49, P663, DOI 10.1002/(SICI)1521-4044(199810)49:10/11<663::AID-APOL663>3.0.CO;2-4; EICHEN Y, 1999, Patent No. 0025136; FERRIN LJ, 1991, SCIENCE, V254, P1494, DOI 10.1126/science.1962209; HONIGBERG SM, 1986, P NATL ACAD SCI USA, V83, P9586, DOI 10.1073/pnas.83.24.9586; Huang Y, 2001, SCIENCE, V294, P1313, DOI 10.1126/science.1066192; Joachim C, 2000, NATURE, V408, P541, DOI 10.1038/35046000; Lieber CM, 2001, SCI AM, V285, P58, DOI 10.1038/scientificamerican0901-58; Mao CD, 1999, J AM CHEM SOC, V121, P5437, DOI 10.1021/ja9900398; MULLER B, 1992, EMBO J, V11, P2685, DOI 10.1002/j.1460-2075.1992.tb05334.x; Niemeyer CM, 2000, CURR OPIN CHEM BIOL, V4, P609, DOI 10.1016/S1367-5931(00)00140-X; Richter J, 2000, ADV MATER, V12, P507, DOI 10.1002/(SICI)1521-4095(200004)12:7<507::AID-ADMA507>3.0.CO;2-G; Sato T, 1997, J APPL PHYS, V82, P696, DOI 10.1063/1.365600; Storhoff JJ, 1999, CHEM REV, V99, P1849, DOI 10.1021/cr970071p; Szybalski W, 1997, CURR OPIN BIOTECH, V8, P75, DOI 10.1016/S0958-1669(97)80161-9; Winfree E, 1998, NATURE, V394, P539, DOI 10.1038/28998	19	532	545	0	119	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 5	2002	297	5578					72	75		10.1126/science.1071247	http://dx.doi.org/10.1126/science.1071247			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571HB	12098693				2022-12-28	WOS:000176711000033
J	Klyachko, VA; Jackson, MB				Klyachko, VA; Jackson, MB			Capacitance steps and fusion pores of small and large-dense-core vesicles in nerve terminals	NATURE			English	Article							MEMBRANE CAPACITANCE; EXOCYTOSIS; RELEASE; NEUROTRANSMITTER; ENDOCYTOSIS; RECORDINGS; DIFFUSION; DISCHARGE; GRANULES; EVENTS	The vesicles that package neurotransmitters fall into two distinct classes, large dense-core vesicles (LDCVs) and small synaptic vesicles, the coexistence of which is widespread in nerve terminals(1). High resolution capacitance recording reveals unitary steps proportional to vesicle size. Measurements of capacitance steps during LDCV and secretory granule fusion in endocrine and immune cells have provided important insights into exocytosis(2-4); however, extending these measurements to small synaptic vesicles has proven difficult. Here we report single vesicle capacitance steps in posterior pituitary nerve terminals. These nerve terminals contain neuropeptide-laden LDCVs, as well as microvesicles. Microvesicles are similar to synaptic vesicles in size, morphology 5 and molecular composition(6-8), but their contents are unknown. Capacitance steps of two characteristic sizes, corresponding with microvesicles and LDCVs, were detected in patches of nerve terminal membrane. Both types of vesicles fuse in response to depolarization-induced Ca2+ entry. Both undergo a reversible fusion process commonly referred to as 'kiss-and-run', but only rarely. Fusion pores seen during microvesicle kiss-and-run have a conductance of 19 pS, 11 times smaller than LDCV fusion pores. Thus, LDCVs and microvesicles use structurally different intermediates during exocytosis.	Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA; Univ Wisconsin, Biophys Grad Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Jackson, MB (corresponding author), Univ Wisconsin, Dept Physiol, 1300 Univ Ave, Madison, WI 53706 USA.	mjackson@physiology.wisc.edu	Klyachko, Vitaly/E-9431-2012					Ales E, 1999, NAT CELL BIOL, V1, P40, DOI 10.1038/9012; ALMERS W, 1991, ANN NY ACAD SCI, V635, P318, DOI 10.1111/j.1749-6632.1991.tb36502.x; BRECKENRIDGE LJ, 1987, NATURE, V328, P814, DOI 10.1038/328814a0; BRUNS D, 1995, NATURE, V377, P62, DOI 10.1038/377062a0; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; Debus K, 2000, BIOPHYS J, V78, P2983, DOI 10.1016/S0006-3495(00)76837-8; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; Fesce Riccardo, 1994, Trends in Cell Biology, V4, P1, DOI 10.1016/0962-8924(94)90025-6; Gentet LJ, 2000, BIOPHYS J, V79, P314, DOI 10.1016/S0006-3495(00)76293-X; Hsu SF, 1996, J PHYSIOL-LONDON, V494, P539, DOI 10.1113/jphysiol.1996.sp021512; Khanin R, 1997, BIOPHYS J, V72, P507, DOI 10.1016/S0006-3495(97)78691-0; KHANIN R, 1994, BIOPHYS J, V67, P966, DOI 10.1016/S0006-3495(94)80562-4; LINDAU M, 1995, CURR OPIN CELL BIOL, V7, P509, DOI 10.1016/0955-0674(95)80007-7; LOLLIKE K, 1995, J CELL BIOL, V129, P99, DOI 10.1083/jcb.129.1.99; MORRIS JF, 1980, NEUROSCIENCE, V5, P639, DOI 10.1016/0306-4522(80)90061-5; MORRISON DL, 1995, INT J REHABIL RES, V18, P1, DOI 10.1097/00004356-199501000-00001; NAGASAWA J, 1971, NATURE, V232, P341, DOI 10.1038/232341a0; NANAVATI C, 1993, SCIENCE, V259, P963, DOI 10.1126/science.8438154; NAVONE F, 1989, J CELL BIOL, V109, P3425, DOI 10.1083/jcb.109.6.3425; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; Pupier S, 1997, J NEUROSCI, V17, P2722; RAE JL, 1992, PFLUG ARCH EUR J PHY, V420, P618, DOI 10.1007/BF00374642; ROSENBOOM H, 1994, P NATL ACAD SCI USA, V91, P5267, DOI 10.1073/pnas.91.12.5267; SPRUCE AE, 1990, NEURON, V4, P643, DOI 10.1016/0896-6273(90)90192-I; Stiles JR, 1996, P NATL ACAD SCI USA, V93, P5747, DOI 10.1073/pnas.93.12.5747; TSE FW, 1993, J CELL BIOL, V121, P543, DOI 10.1083/jcb.121.3.543; VERHAGE M, 1991, NEURON, V6, P517, DOI 10.1016/0896-6273(91)90054-4; WALCHSOLIMENA C, 1993, J NEUROSCI, V13, P3895; ZIMMERBERG J, 1994, J CELL BIOL, V127, P1885, DOI 10.1083/jcb.127.6.1885	30	227	235	0	21	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 4	2002	418	6893					89	92		10.1038/nature00852	http://dx.doi.org/10.1038/nature00852			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	569JL	12097912				2022-12-28	WOS:000176599200044
J	Bascom, PB; Tolle, SW				Bascom, PB; Tolle, SW			Responding to requests for physician-assisted suicide - "These are uncharted waters for both of us. ... "	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; TERMINALLY-ILL PATIENTS; OF-LIFE CARE; PATIENT REQUESTS; OREGON DEATH; LAST RESORT; EUTHANASIA; END; DEPRESSION; ATTITUDES	Studies of dying patients have shown that about half would like the option of physician-assisted suicide (PAS) to be available for possible future use. Those percentages decrease significantly with each step patients take toward action. Studies show that although about 10% of patients seriously consider PAS, only 1% of dying patients specifically request it, and 1 in 10 of those patients actually receive and take a lethal prescription. However, most patients' desires for PAS diminish as their underlying concerns are identified and addressed directly. To help identify concerns motivating a patient's request for PAS, physicians should talk with patients about their expectations and fears, options for end-of-life care, goals, family concerns and burdens, suffering or physical symptoms, sense of meaning and quality of life, and symptoms of depression. A patient with advanced amyotrophic lateral sclerosis (ALS) who requested PAS illustrates how a hasty response may adversely affect patient care and the health care team. Although physicians should remain mindful of their personal, moral, and legal concerns, these concerns should not override their willingness to explore what motivates a patient to make this request. When this approach is taken, suffering can be optimally alleviated and, in almost all cases, the patient's wishes can be met without PAS.	Oregon Hlth & Sci Univ, Div Gen Internal Med & Geriatr, Ctr Eth Hlth Care, Portland, OR 97201 USA	Oregon Health & Science University	Bascom, PB (corresponding author), Oregon Hlth & Sci Univ, Div Gen Internal Med & Geriatr, Ctr Eth Hlth Care, L475, Portland, OR 97201 USA.	bascomp@ohsu.edu						Angell M, 1997, NEW ENGL J MED, V336, P50, DOI 10.1056/NEJM199701023360108; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BLOCH SD, 1994, ARCH INTERN MED, V154, P2039, DOI 10.1001/archinte.154.18.2039; Block SD, 2000, ANN INTERN MED, V132, P209, DOI 10.7326/0003-4819-132-3-200002010-00007; Block SD, 2001, JAMA-J AM MED ASSOC, V285, P2898, DOI 10.1001/jama.285.22.2898; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; Breitbart W, 2000, JAMA-J AM MED ASSOC, V284, P2907, DOI 10.1001/jama.284.22.2907; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; Byock I R, 1994, J Palliat Care, V10, P8; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; Chochinov HM, 1997, AM J PSYCHIAT, V154, P674; COHAN SR, 1996, CANCER, V77, P576; COLBURN D, 2003, OREGONIAN       0527, pA1; *COUNC ETH JUD AFF, 1997, COD MED ETH CURR OP; Emanuel EJ, 2000, ANN INTERN MED, V133, P527, DOI 10.7326/0003-4819-133-7-200010030-00011; EMANUEL EJ, 1994, ANN INTERN MED, V121, P793, DOI 10.7326/0003-4819-121-10-199411150-00010; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V284, P2460, DOI 10.1001/jama.284.19.2460; Field MJ, 1997, APPROACHING DEATH IM; Foley KM, 1997, NEW ENGL J MED, V336, P54, DOI 10.1056/NEJM199701023360109; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; Ganzini L, 1998, NEW ENGL J MED, V339, P967, DOI 10.1056/NEJM199810013391406; Ganzini L, 2001, JAMA-J AM MED ASSOC, V285, P2363, DOI 10.1001/jama.285.18.2363; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; HALEY K, 1998, TASK FORCE IMPROVE C; Hedberg K, 2002, NEW ENGL J MED, V346, P450, DOI 10.1056/NEJM200202073460614; JACOBSON JA, 1995, J CLIN ETHIC, V6, P149; Jansen LA, 2002, ANN INTERN MED, V136, P845, DOI 10.7326/0003-4819-136-11-200206040-00014; Kitchens LW, 1998, ANN INTERN MED, V128, P576, DOI 10.7326/0003-4819-128-7-199804010-00012; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; Lynn J, 2001, JAMA-J AM MED ASSOC, V285, P925, DOI 10.1001/jama.285.7.925; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; Meier DE, 2001, JAMA-J AM MED ASSOC, V286, P3007, DOI 10.1001/jama.286.23.3007; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; Moyers B.D., 2000, OUR OWN TERMS MOYERS; Muskin PR, 1998, JAMA-J AM MED ASSOC, V279, P323, DOI 10.1001/jama.279.4.323; Orentlicher D, 1996, NEW ENGL J MED, V335, P663, DOI 10.1056/NEJM199608293350912; Passik SD, 1998, J CLIN ONCOL, V16, P1594, DOI 10.1200/JCO.1998.16.4.1594; PELLEGRINO ED, 1993, JAMA-J AM MED ASSOC, V270, P874, DOI 10.1001/jama.270.7.874; Prigerson HG, 2001, JAMA-J AM MED ASSOC, V286, P1369, DOI 10.1001/jama.286.11.1369; Quill TE, 2000, ANN INTERN MED, V132, P488, DOI 10.7326/0003-4819-132-6-200003210-00011; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; Quill TE, 2000, ANN INTERN MED, V132, P408, DOI 10.7326/0003-4819-132-5-200003070-00012; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; Quill TE, 1997, JAMA-J AM MED ASSOC, V278, P2099, DOI 10.1001/jama.278.23.2099; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; Reagan P, 1999, LANCET, V353, P1265, DOI 10.1016/S0140-6736(98)12219-5; RIMER S, 2002, NY TIMES        0112, pA9; Silveira MJ, 2000, JAMA-J AM MED ASSOC, V284, P2483, DOI 10.1001/jama.284.19.2483; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Slome LR, 1997, NEW ENGL J MED, V336, P417, DOI 10.1056/NEJM199702063360606; Snyder L, 2001, ANN INTERN MED, V135, P209, DOI 10.7326/0003-4819-135-3-200108070-00015; Sullivan AD, 2000, NEW ENGL J MED, V342, P598, DOI 10.1056/NEJM200002243420822; Sulmasy DP, 1999, ARCH INTERN MED, V159, P545, DOI 10.1001/archinte.159.6.545; Sulmasy DP, 1998, J LAW MED ETHICS, V26, P55, DOI 10.1111/j.1748-720X.1998.tb01906.x; Tolle S, 1994, SUNDAY OREGONIA 1113, pC1; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; Veldink JH, 2002, NEW ENGL J MED, V346, P1638, DOI 10.1056/NEJMsa012739; 2002, NY TIMES        0401, pA9; 2001, FED REG         1109, V66, P56607	62	62	62	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	2002	288	1					91	98		10.1001/jama.288.1.91	http://dx.doi.org/10.1001/jama.288.1.91			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	568YW	12090867				2022-12-28	WOS:000176573400024
J	Ha, JW; Kim, SK; Chang, BC				Ha, JW; Kim, SK; Chang, BC			Pulmonary tumour embolism	LANCET			English	Editorial Material									Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Yonsei Univ, Coll Med, Dept Cardiothorac Surg, Seoul, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Ha, JW (corresponding author), Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea.		Chang, Byung/AAP-9674-2020						0	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 22	2002	359	9324					2158	2158						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566RJ	12090981				2022-12-28	WOS:000176441800010
J	Trouiller, P; Olliaro, P; Torreele, E; Orbinski, J; Laing, R; Ford, N				Trouiller, P; Olliaro, P; Torreele, E; Orbinski, J; Laing, R; Ford, N			Drug development for neglected diseases: a deficient market and a public-health policy failure	LANCET			English	Article							PRIVATE PARTNERSHIPS; COUNTRIES	There is a lack of effective, safe, and affordable pharmaceuticals to control Infectious diseases that cause high mortality and morbidity among poor people in the developing world. We analysed outcomes of pharmaceutical research and development over the past 25 years, and reviewed current public and private Initiatives aimed at correcting the Imbalance in research and development that leaves diseases that occur predominantly In the developing world largely unaddressed. We compiled data by searches of Medline and databases of the US Food and Drug Administration and the European Agency for the Evaluation of Medicinal Products, and reviewed current public and private Initiatives through an analysis of recently published studies. We found that, of 1393 new chemical entities marketed between 1975 and 1999, only 16 were for tropical diseases and tuberculosis. There Is a 13-fold greater chance of a drug being brought to market for central-nervous-system disorders or cancer than for a neglected disease. The pharmaceutical Industry argues that research and development is too costly and risky to invest in low-return neglected diseases, and public and private initiatives have tried to overcome this market limitation through incentive packages and public-private partnerships. The lack of drug research and development for "non-profitable" infectious diseases will require new strategies. No sustainable solution will result for diseases that predominantly affect poor people in the South without the establishment of an International pharmaceutical policy for all neglected diseases. Private-sector research obligations should be explored, and a public-sector not-for-profit research and development capacity promoted.	CHU Grenoble, F-38043 Grenoble 9, France; WHO, World Bank, Special Programme Res & Training Trop Dis, Geneva, Switzerland; Free Univ Brussels VIB, Dept Immunol Parasitol & Ultrastruct, Rhode St Genese, Belgium; Univ Toronto, Munk Ctr Int Studies, Toronto, ON, Canada; Boston Univ, Sch Publ Hlth, Boston, MA USA; Med Sans Frontieres, London, England; Med Sans Frontieres, Drugs Neglected Dis Working Grp, Geneva, Switzerland	CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); The World Bank; World Health Organization; Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; University of Toronto; Boston University; Doctors Without Borders; Doctors Without Borders	Trouiller, P (corresponding author), CHU Grenoble, BP 217, F-38043 Grenoble 9, France.	PTrouiller@chu-grenoble.fr						ANDERSON J, 1996, 7 WELLC TRUST; Buse K, 2000, B WORLD HEALTH ORGAN, V78, P699; Buse K, 2000, B WORLD HEALTH ORGAN, V78, P549; CORREA C, 2000, INTELLECTUAL PROPERT, P42; Dimasi J. A., 1995, INT J ECON BUS, V2, P201, DOI DOI 10.1080/758519309; DiMasi JA, 2001, CLIN PHARMACOL THER, V69, P297, DOI 10.1067/mcp.2001.115446; DiMasi JA, 2001, CLIN PHARMACOL THER, V69, P286, DOI 10.1067/mcp.2001.115132; Drews J, 1998, DRUG DISCOV TODAY, V3, P491, DOI 10.1016/S1359-6446(98)01252-5; *EUR FED PHARM IND, 2000, PHARM IND FIG; Folkers GK, 2001, JAMA-J AM MED ASSOC, V286, P458, DOI 10.1001/jama.286.4.458; Goldman D P, 1992, Int J Technol Assess Health Care, V8, P583; Haffner ME, 1998, DRUG INF J, V32, P93, DOI 10.1177/009286159803200113; *HLTH IMS, 1999, MARK REP; JENSSENS PG, 1992, MED HYGIENE AFRIQUE, P590; KADAR M, 1995, REV PRESCRIRE, V15, P844; Kaitin KI, 2000, DRUG INF J, V34, P1; KANAVOS P, 1999, PHARM PRICING REIMBU; Lee J.W., 2000, FRAMEWORK R D EVALUA; Makinen M, 2000, B WORLD HEALTH ORGAN, V78, P55; MURRAY HW, 2001, RECENT ADV TROPICAL, P490; Pecoul B, 1999, JAMA-J AM MED ASSOC, V281, P361, DOI 10.1001/jama.281.4.361; Pecoul B, 2001, FATAL IMBALANCE CRIS; Stephenson I, 2000, DRUGS, V60, P985, DOI 10.2165/00003495-200060050-00002; Trouiller P, 1999, TROP MED INT HEALTH, V4, P412, DOI 10.1046/j.1365-3156.1999.00420.x; Trouiller P, 1998, Int J Infect Dis, V3, P61, DOI 10.1016/S1201-9712(99)90010-3; *UN DEV PROGR, 2001, HUM DEV REP 2001 MAK; *UN POL RES SCI ME, 1996, MAL RES AUD INT ACT; Vial HJ, 1999, PARASITOL TODAY, V15, P393, DOI 10.1016/S0169-4758(99)01524-0; Webber D, 2001, B WORLD HEALTH ORGAN, V79, P735; Wheeler C, 2001, B WORLD HEALTH ORGAN, V79, P728; WHO, 1996, INV HLTH RES DEV; *WHO, 1997, HLTH REF DRUG FIN OV, P9; WIRTH D, 2001, HARVEST NOTYET REAPE; YOUNG B, 2001, R D MYTHS CASE DRUG	34	510	522	1	78	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 22	2002	359	9324					2188	2194		10.1016/S0140-6736(02)09096-7	http://dx.doi.org/10.1016/S0140-6736(02)09096-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566RJ	12090998				2022-12-28	WOS:000176441800026
J	Molyneux, EM; Walsh, AL; Forsyth, H; Tembo, M; Mwenechanya, J; Kayira, K; Bwanaisa, L; Njobvu, A; Rogerson, S; Malenga, G				Molyneux, EM; Walsh, AL; Forsyth, H; Tembo, M; Mwenechanya, J; Kayira, K; Bwanaisa, L; Njobvu, A; Rogerson, S; Malenga, G			Dexamethasone treatment in childhood bacterial meningitis in Malawi: a randomised controlled trial	LANCET			English	Article							PNEUMOCOCCAL MENINGITIS; CHILDREN; THERAPY; METAANALYSIS; MORTALITY; STEROIDS	Background Steroids are used as adjuvant treatment in childhood pyogenic meningitis to attenuate host inflammatory responses to bacterial invasion. We aimed to assess the effectiveness of dexamethasone in management of acute bacterial meningitis in a developing country. Methods In a double-blind, placebo controlled trial, we included 598 children with pyogenic meningitis who had been admitted to the children's wards of the Queen Elizabeth Central Hospital, Blantyre, Malawi. We did physical, neurological, developmental, and hearing assessments at 1 and 6 months after discharge. The primary outcome was overall death. Secondary outcomes included sequelae, inhospital deaths, and death after discharge. Analysis was done by intention to treat. Findings Of the 598 included children, 307 (51%) were assigned to dexamethasone and 295 (49%) to placebo. 338 (40%) of 598 patients had Streptococcus pneumoniae, 170 (28%) Haemophilus influenzae type b, 66 (11%) Neisseria meningitidis, and 29 (5%) Salmonella spp. 78 (13%) patients had no growth on culture. The number of overall deaths was the same in the two treatment groups (relative risk 1.00 [95% CI 0.8-1.25], p=0.93). At final outcome, sequelae were identified in 84 (28%) of children on steroids and in 81 (28%) on placebo (relative risk 0.99 [95% Cl 0.78-1.27], p=0.97). The number of children dying in hospital did not differ between groups. Interpretation Steroids are not an effective adjuvant treatment in children with acute bacterial meningitis in developing countries.	Coll Med, Dept Paediat, Blantyre, Malawi; Wellcome Trust Res Labs, Blantyre, Malawi; Royal Liverpool Childrens Hosp, Dept Audiol, Liverpool L7 7DG, Merseyside, England	University of Malawi; University of Malawi; Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital	Molyneux, EM (corresponding author), Coll Med, Dept Paediat, POB 360, Blantyre, Malawi.							ALEXANDER HE, J PEDIAT, V25, P517; Barrow G. I., 1993, COWAN STEEL MANUAL I; BORGSTEIN A, 1984, MALAWI MED J, P26; Campagne G, 1999, B WORLD HEALTH ORGAN, V77, P499; CIANA G, 1995, J TROP PEDIATRICS, V41, P164, DOI 10.1093/tropej/41.3.164; Coyle PK, 1999, ARCH NEUROL-CHICAGO, V56, P796, DOI 10.1001/archneur.56.7.796; Daoud AS, 1995, J TROP PEDIATRICS, V41, P308, DOI 10.1093/tropej/41.5.308; Fothergill LD, 1937, NEW ENGL J MED, V216, P587, DOI 10.1056/NEJM193704082161401; GEIMAN BJ, 1992, WESTERN J MED, V157, P27; GIRGIS NI, 1993, AM J TROP MED HYG, V48, P97, DOI 10.4269/ajtmh.1993.48.97; *GOV MAL, 2000, MAL FIG; HAVENS PL, 1992, WESTERN J MED, V157, P84; KANRA GY, 1995, PEDIATR INFECT DIS J, V14, P490, DOI 10.1097/00006454-199506000-00005; KENNEDY WA, 1991, AM J DIS CHILD, V145, P1374, DOI 10.1001/archpedi.1991.02160120042016; LEBEL MH, 1989, AM J DIS CHILD, V143, P301, DOI 10.1001/archpedi.1989.02150150055017; Macaluso A, 1996, ANN TROP PAEDIATR, V16, P193, DOI 10.1080/02724936.1996.11747825; MCCORMICK B, 1993, PAEDIAT AUDIOLOGY 0; MCDERMOTT W, 1982, JOHNS HOPKINS MED J, V151, P302; Molyneux E, 1998, TROP MED INT HEALTH, V3, P610, DOI 10.1046/j.1365-3156.1998.00278.x; Murray JL, 1996, GLOBAL BURDEN DIS IN, VII, P285; MUSTAFA MM, 1990, AM J DIS CHILD, V144, P883, DOI 10.1001/archpedi.1990.02150320047024; *NAT COMM CLIN LAB, 1993, PERF STAND ANT DISK; PETER G, 1994, RED BOOK REPORT COMM, P558; PRASAD K, 1995, J NEUROL NEUROSUR PS, V59, P31, DOI 10.1136/jnnp.59.1.31; Qazi SA, 1996, ARCH DIS CHILD, V75, P482, DOI 10.1136/adc.75.6.482; Quagliarello VJ, 1997, NEW ENGL J MED, V336, P708, DOI 10.1056/NEJM199703063361007; SCHAAD UB, 1993, LANCET, V342, P457, DOI 10.1016/0140-6736(93)91592-A; Schuchat A, 1997, NEW ENGL J MED, V337, P970, DOI 10.1056/NEJM199710023371404; SYRIANNOPOULOS GA, 1994, J INFECT DIS, V169, P853; *WHO, 1997, M REP WHO JUN 18 20	30	205	213	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 20	2002	360	9328					211	218		10.1016/S0140-6736(02)09458-8	http://dx.doi.org/10.1016/S0140-6736(02)09458-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	576DX	12133656				2022-12-28	WOS:000176988500011
J	Brill, TM; Ryu, S; Gaylor, R; Jundt, J; Griffin, DD; Song, YQ; Sen, PN; Hurlimann, MD				Brill, TM; Ryu, S; Gaylor, R; Jundt, J; Griffin, DD; Song, YQ; Sen, PN; Hurlimann, MD			Nonresonant multiple spin echoes	SCIENCE			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; SEQUENCES; DYNAMICS; PULSES; PHASE	Nonresonant manipulation of nuclear spins can probe large volumes of sample situated in inhomogeneous fields outside a magnet, a geometry suitable for mobile sensors for the inspection of roads, buildings, and geological formations. However, the interference by Earths magnetic field causes rapid decay of the signal within a few milliseconds for protons and is detrimental to this method. Here we describe a technique to suppress the effects of Earths field by using adiabatic rotations and sudden switching of the applied fields. We observed hundreds of spin echo signals lasting for more than 600 milliseconds and accurately measured the relaxation times of a liquid sample.	Schlumberger Doll Res Ctr, Ridgefield, CT 06877 USA	Schlumberger	Brill, TM (corresponding author), Schlumberger Doll Res Ctr, 36 Old Quarry Rd, Ridgefield, CT 06877 USA.			Song, Yiqiao/0000-0002-3416-4279; Brill, Thilo/0000-0002-3937-9826; Hurlimann, Martin/0000-0002-0737-6911				Abragam A., 1978, PRINCIPLES NUCL MAGN; BERRY MV, 1984, PROC R SOC LON SER-A, V392, P45, DOI 10.1098/rspa.1984.0023; CHANDLER RN, 1987, T 28 ANN SPWLA LOGG, V1, pC1; Eidmann G, 1996, J MAGN RESON SER A, V122, P104, DOI 10.1006/jmra.1996.0185; Garwood M, 2001, J MAGN RESON, V153, P155, DOI 10.1006/jmre.2001.2340; HAHN EL, 1950, PHYS REV, V80, P580, DOI 10.1103/PhysRev.80.580; Halperin W.P., 1989, MOL DYNAMICS RESTRIC, P311; Hurlimann MD, 2000, J MAGN RESON, V143, P120, DOI 10.1006/jmre.1999.1967; Hurlimann MD, 2001, J MAGN RESON, V152, P109, DOI 10.1006/jmre.2001.2370; HURLIMANN MD, 2000, Patent No. 6133735; JENNER CF, 1988, NATURE, V336, P399, DOI 10.1038/336399a0; KLEINBERG RL, 1996, ENCY NUCL MAGNETIC R, V8, P4960; Levitt M. H., 1996, ENCY NUCL MAGNETIC R, V2, P1396; LEVITT MH, 1983, ADV MAGN RESON, V11, P47; McCarthy M.J., 1994, MAGNETIC RESONANCE I; McDermott R, 2002, SCIENCE, V295, P2247, DOI 10.1126/science.1069280; MELTON BF, 1971, REV SCI INSTRUM, V42, P769, DOI 10.1063/1.1685227; Meriles CA, 2001, SCIENCE, V293, P82, DOI 10.1126/science.1061498; MUTHUPILLAI R, 1995, SCIENCE, V269, P1854, DOI 10.1126/science.7569924; PACKARD M, 1954, PHYS REV, V93, P941; Sloop DJ, 1999, J MAGN RESON, V139, P60, DOI 10.1006/jmre.1999.1745; SOLOMON I, 1959, PHYS REV LETT, V2, P301, DOI 10.1103/PhysRevLett.2.301; Song YQ, 2000, NATURE, V406, P178, DOI 10.1038/35018057; STEBBINS JF, 1989, SCIENCE, V245, P257, DOI 10.1126/science.245.4915.257; TYCKO R, 1983, PHYS REV LETT, V51, P775, DOI 10.1103/PhysRevLett.51.775; ZWANZIGER JW, 1990, ANNU REV PHYS CHEM, V41, P601	26	9	10	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 19	2002	297	5580					369	372		10.1126/science.1072245	http://dx.doi.org/10.1126/science.1072245			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574LV	12130777				2022-12-28	WOS:000176892600042
J	Wootton, JC; Feng, XR; Ferdig, MT; Cooper, RA; Mu, JB; Baruch, DI; Magill, AJ; Su, XZ				Wootton, JC; Feng, XR; Ferdig, MT; Cooper, RA; Mu, JB; Baruch, DI; Magill, AJ; Su, XZ			Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum	NATURE			English	Article							HUMAN MALARIA; PARASITE POPULATIONS; RECENT ORIGIN; RESISTANCE; PROTEIN; POLYMORPHISMS; PFCRT	Widespread use of antimalarial agents can profoundly influence the evolution of the human malaria parasite Plasmodium falciparum. Recent selective sweeps for drug-resistant genotypes may have restricted the genetic diversity of this parasite, resembling effects attributed in current debates(1-4) to a historic population bottleneck. Chloroquine-resistant (CQR) parasites were initially reported about 45 years ago from two foci in southeast Asia and South America(5), but the number of CQR founder mutations and the impact of chlorquine on parasite genomes worldwide have been difficult to evaluate. Using 342 highly polymorphic microsatellite markers from a genetic map(6), here we show that the level of genetic diversity varies substantially among different regions of the parasite genome, revealing extensive linkage disequilibrium surrounding the key CQR gene pfcrt(7) and at least four CQR founder events. This disequilibrium and its decay rate in the pfcrt-flanking region are consistent with strong directional selective sweeps occurring over only similar to20-80 sexual generations, especially a single resistant pfcrt haplotype spreading to very high frequencies throughout most of Asia and Africa. The presence of linkage disequilibrium provides a basis for mapping genes under drug selection in P. falciparum.	NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA; NIH, Computat Biol Branch, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA; Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA; Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Div Communicable Dis & Immunol, Washington, DC 20307 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); University of Notre Dame; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center	Su, XZ (corresponding author), NIAID, Lab Malaria & Vector Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.		feng, xiaorong/G-4811-2010; Ferdig, Michael/C-6627-2016	feng, xiaorong/0000-0001-8410-3020; Su, Xinzhuan/0000-0003-3246-3248	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000892, Z01AI000892] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [ZIALM000026, Z01LM000026] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Anderson TJC, 2000, MOL BIOL EVOL, V17, P1467, DOI 10.1093/oxfordjournals.molbev.a026247; Conway DJ, 1999, P NATL ACAD SCI USA, V96, P4506, DOI 10.1073/pnas.96.8.4506; Conway DJ, 2000, MOL BIOCHEM PARASIT, V111, P163, DOI 10.1016/S0166-6851(00)00313-3; Djimde A, 2001, NEW ENGL J MED, V344, P257, DOI 10.1056/NEJM200101253440403; Dorsey G, 2001, J INFECT DIS, V183, P1417, DOI 10.1086/319865; Dye C, 1997, P ROY SOC B-BIOL SCI, V264, P61, DOI 10.1098/rspb.1997.0009; ESCALANTE AA, 1995, MOL BIOL EVOL, V12, P616; Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(05)00077-8; Hey J, 1999, CURR BIOL, V9, pR565, DOI 10.1016/S0960-9822(99)80356-X; HILL WG, 1995, GENET RES, V65, P53, DOI 10.1017/S0016672300033000; Hughes AL, 2001, P ROY SOC B-BIOL SCI, V268, P1855, DOI 10.1098/rspb.2001.1759; Nomura T, 2001, J INFECT DIS, V183, P1653, DOI 10.1086/320707; PAUL REL, 1995, SCIENCE, V269, P1709, DOI 10.1126/science.7569897; PAYNE D, 1987, PARASITOL TODAY, V3, P241, DOI 10.1016/0169-4758(87)90147-5; Rich SM, 1998, GENETICS, V150, P515; Su XZ, 1999, SCIENCE, V286, P1351, DOI 10.1126/science.286.5443.1351; Su XZ, 1997, CELL, V91, P593, DOI 10.1016/S0092-8674(00)80447-X; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Volkman SK, 2001, SCIENCE, V293, P482, DOI 10.1126/science.1059878; Walliker David, 1998, P235	20	566	579	0	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 18	2002	418	6895					320	323		10.1038/nature00813	http://dx.doi.org/10.1038/nature00813			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574BF	12124623				2022-12-28	WOS:000176868000041
J	Briganti, EM; Russ, GR; McNeil, JJ; Atkins, C; Chadban, SJ				Briganti, EM; Russ, GR; McNeil, JJ; Atkins, C; Chadban, SJ			Risk of renal allograft loss from recurrent glomerulonephritis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOCAL GLOMERULOSCLEROSIS; DISEASE REGISTRY; CYCLOSPORINE ERA; GRAFT-SURVIVAL; TRANSPLANTATION; NEPHRITIS; NEPHROPATHY	Background Recurrent glomerulonephritis is' a known cause of renal allograft loss; however, the incidence of this complication is poorly defined. We determined the incidence, timing, and relative importance of allograft loss due to the recurrence of glomerulonephritis. Methods A total of 1505 patients with biopsy-proved glomerulonephritis received a primary renal transplant in Australia from 1988 through 1997. Recurrence was confirmed by renal biopsy. The Kaplan-Meier method was used to estimate the 10-year incidence of allograft failure due to recurrent glomerulonephritis, and this incidence was compared with the incidence of acute rejection, chronic rejection, and death with a functioning allograft. Characteristics of the recipients and donors were examined as potential predictors of recurrence. Results Allograft loss due to the recurrence of glomerulonephritis occurred in 52 recipients, with a 10-year incidence of 8.4 percent (95 percent confidence interval, 5.9 to 12.0). The type of glomerulonephritis, the sex of the recipient, and the peak level of panel-reactive antibodies were independent predictors of the risk of recurrence. Recurrence was the third most frequent cause of allograft loss at 10 years, after chronic rejection and death with a functioning allograft. Despite the effect of recurrence, the overall 10-year incidence of allograft loss was similar among transplant recipients with biopsy-proved glomerulonephritis and among those with other causes of renal failure (45.4 percent [95 percent confidence interval, 40.9 to 50.2] vs. 45.8 percent [95 percent confidence interval,. 42.3 to 49.3], P=0.09). Conclusions Recurrence is an important cause of allograft loss for those with renal failure due to glomerulonephritis. No risk factors for recurrence were identified that warrant altering the approach to transplantation. However, accurate estimates of risk can now be provided to potential recipients of renal allografts.	Monash Med Ctr, Dept Nephrol, Clayton, Vic 3168, Australia; Monash Univ, Dept Epidemiol & Prevent Med, Clayton, Vic 3168, Australia; Queen Elizabeth Hosp, Renal Unit, Woodville, SA, Australia	Monash University; Monash University	Chadban, SJ (corresponding author), Monash Med Ctr, Dept Nephrol, 265 Clayton Rd, Clayton, Vic 3168, Australia.		McNeil, John/L-6440-2019	McNeil, John/0000-0002-1049-5129; Briganti, Esther/0000-0002-6280-8043				Andresdottir MB, 1997, TRANSPLANTATION, V63, P1628, DOI 10.1097/00007890-199706150-00016; Andresdottir MB, 1999, NEPHROL DIAL TRANSPL, V14, P2650, DOI 10.1093/ndt/14.11.2650; Andresdottir MB, 1999, NEPHROL DIAL TRANSPL, V14, P1723, DOI 10.1093/ndt/14.7.1723; ARTERO M, 1992, AM J MED, V92, P375, DOI 10.1016/0002-9343(92)90267-F; Baum MA, 2001, KIDNEY INT, V59, P328, DOI 10.1046/j.1523-1755.2001.00494.x; Briggs JD, 1999, NEPHROL DIAL TRANSPL, V14, P564; Bumgardner GL, 1998, TRANSPLANTATION, V65, P1053, DOI 10.1097/00007890-199804270-00008; Chadban SJ, 2001, J AM SOC NEPHROL, V12, P394, DOI 10.1681/ASN.V122394; Chang YJ, 1999, MEDICINE, V78, P382, DOI 10.1097/00005792-199911000-00003; Cosyns JP, 1998, CLIN NEPHROL, V50, P144; DISNEY APS, 2000, ANZDATA REGISTRY REP; Hariharan S, 2000, NEW ENGL J MED, V342, P605, DOI 10.1056/NEJM200003023420901; Hariharan S, 1999, TRANSPLANTATION, V68, P635, DOI 10.1097/00007890-199909150-00007; Hariharan S, 1998, AM J KIDNEY DIS, V31, P928, DOI 10.1053/ajkd.1998.v31.pm9631835; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MEULDERS Q, 1994, TRANSPLANTATION, V58, P1179, DOI 10.1097/00007890-199412270-00007; Nachman PH, 1999, KIDNEY INT, V56, P1544, DOI 10.1046/j.1523-1755.1999.00666.x; Odorico JS, 1996, TRANSPLANTATION, V61, P228, DOI 10.1097/00007890-199601270-00012; ODUM J, 1994, NEPHROL DIAL TRANSPL, V9, P309; Pronovost PH, 1996, NEPHROL DIAL TRANSPL, V11, P837, DOI 10.1093/oxfordjournals.ndt.a027409; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; Stone JH, 1998, ARTHRITIS RHEUM, V41, P678, DOI 10.1002/1529-0131(199804)41:4<678::AID-ART15>3.0.CO;2-7; Valente JF, 1997, CLIN TRANSPLANT, V11, P231	23	368	386	0	6	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 11	2002	347	2					103	109		10.1056/NEJMoa013036	http://dx.doi.org/10.1056/NEJMoa013036			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	572HC	12110738				2022-12-28	WOS:000176767300005
J	Pritchard, ME; Simons, M				Pritchard, ME; Simons, M			A satellite geodetic survey of large-scale deformation of volcanic centres in the central Andes	NATURE			English	Article							LASCAR-VOLCANO; RADAR INTERFEROMETRY; MAGMA CHAMBER; MT-ETNA; CHILE	Surface deformation in volcanic areas usually indicates movement of magma or hydrothermal fluids at depth. Stratovolcanoes tend to exhibit a complex relationship between deformation and eruptive behaviour(1). The characteristically long time spans between such eruptions requires a long time series of observations to determine whether deformation without an eruption is common at a given edifice. Such studies, however, are logistically difficult to carry out in most volcanic arcs, as these tend to be remote regions with large numbers of volcanoes (hundreds to even thousands). Here we present a satellite-based interferometric synthetic aperture radar (InSAR) survey of the remote central Andes volcanic arc, a region formed by subduction of the Nazca oceanic plate beneath continental South America. Spanning the years 1992 to 2000, our survey reveals the background level of activity of about 900 volcanoes, 50 of which have been classified as potentially active(2,3). We find four centres of broad (tens of kilometres wide), roughly axisymmetric surface deformation. None of these centres are at volcanoes currently classified as potentially active, although two lie within about 10 km of volcanoes with known activity. Source depths inferred from the patterns of deformation lie between 5 and 17 km. In contrast to the four new sources found, we do not observe any deformation associated with recent eruptions of Lascar, Chile(4,5).	CALTECH, Div Geol & Planetary Sci, Seismol Lab, Pasadena, CA 91125 USA	California Institute of Technology	Pritchard, ME (corresponding author), CALTECH, Div Geol & Planetary Sci, Seismol Lab, Pasadena, CA 91125 USA.		Pritchard, Matthew/L-5892-2015; Simons, Mark/N-4397-2015	Pritchard, Matthew/0000-0003-3616-3373; Simons, Mark/0000-0003-1412-6395				Amelung F, 2000, NATURE, V407, P993, DOI 10.1038/35039604; Chmielowski J, 1999, GEOPHYS RES LETT, V26, P783, DOI 10.1029/1999GL900078; Curtis G.H., 1968, GEOL SOC AM MEM, V116, P153, DOI DOI 10.1130/MEM116-P153; DESILVA SL, 1989, GEOLOGY, V17, P1102, DOI 10.1130/0091-7613(1989)017<1102:APVCOT>2.3.CO;2; DESILVA SL, 1991, VOLCANOES CENTRAL AN; Dvorak JJ, 1997, REV GEOPHYS, V35, P343, DOI 10.1029/97RG00070; Fernandez J, 2001, GEOPHYS RES LETT, V28, P2349, DOI 10.1029/2000GL012656; Gonzalez-Ferran O., 1995, VOLCANES CHILE, V1st ed.; Hanssen R., 2001, RADAR INTERFEROMETRY; JOHNSTON MJS, 1995, B SEISMOL SOC AM, V85, P787; LAZO M, 1991, P 7 C PER GEOL SOC G, P19; MATTHEWS SJ, 1994, J PETROL, V35, P401, DOI 10.1093/petrology/35.2.401; Matthews SJ, 1999, J PETROL, V40, P1891, DOI 10.1093/petrology/40.12.1891; MATTHEWS SJ, 1997, B VOLCANOL, V59, P77; RYMER H, 1993, NATURE, V361, P439, DOI 10.1038/361439a0; Sambridge M, 1998, INVERSE PROBL, V14, P427, DOI 10.1088/0266-5611/14/3/005; Simkin T., 1994, VOLCANOES WORLD; Thouret JC, 1995, Z GEOMORPHOL, V39, P515; Watanabe H, 1998, GEOPHYS RES LETT, V25, P2865, DOI 10.1029/98GL02216; Wigger P.J., 1994, TECTONICS SO CENTRAL, P23, DOI DOI 10.1007/978-3-642-77353-2_2; Williams CA, 1998, GEOPHYS RES LETT, V25, P1549, DOI 10.1029/98GL01136; Wooster MJ, 1997, B VOLCANOL, V58, P566, DOI 10.1007/s004450050163; Wooster MJ, 2001, GEOPHYS RES LETT, V28, P847, DOI 10.1029/2000GL011904; Yuan X, 2000, NATURE, V408, P958, DOI 10.1038/35050073	24	214	218	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 11	2002	418	6894					167	171		10.1038/nature00872	http://dx.doi.org/10.1038/nature00872			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571GV	12110886				2022-12-28	WOS:000176710400036
J	Vignaud, P; Duringer, P; Mackaye, HT; Likius, A; Blondel, C; Boisserie, JR; de Bonis, L; Eisenmann, V; Etienne, ME; Geraads, D; Guy, F; Lehmann, T; Lihoreau, F; Lopez-Martinez, N; Mourer-Chauvire, C; Otero, O; Rage, JC; Schuster, M; Viriot, L; Zazzo, A; Brunet, M				Vignaud, P; Duringer, P; Mackaye, HT; Likius, A; Blondel, C; Boisserie, JR; de Bonis, L; Eisenmann, V; Etienne, ME; Geraads, D; Guy, F; Lehmann, T; Lihoreau, F; Lopez-Martinez, N; Mourer-Chauvire, C; Otero, O; Rage, JC; Schuster, M; Viriot, L; Zazzo, A; Brunet, M			Geology and palaeontology of the Upper Miocene Toros-Menalla hominid locality, Chad	NATURE			English	Article							MANONGA VALLEY; EARLY PLIOCENE; DISCOVERY; RIFT; TANZANIA; LOTHAGAM; ETHIOPIA; FAUNA	All six known specimens of the early hominid Sahelanthropus tchadensis come from Toros-Menalla site 266 (TM 266), a single locality in the Djurab Desert, northern Chad, central Africa. Here we present a preliminary analysis of the palaeontological and palaeoecological context of these finds. The rich fauna from TM 266 includes a significant aquatic component such as fish, crocodiles and amphibious mammals, alongside animals associated with gallery forest and savannah, such as primates, rodents, elephants, equids and bovids. The fauna suggests a biochronological age between 6 and 7 million years. Taken together with the sedimentological evidence, the fauna suggests that S. tchadensis lived close to a lake, but not far from a sandy desert, perhaps the oldest record of desert conditions in the Neogene of northern central Africa.	Univ Poitiers, Fac Sci, F-86022 Poitiers, France; Univ Poitiers, CNRS, UMR 6046, F-86022 Poitiers, France; Univ Strasbourg 1, Ctr Geochim Surface, CNRS, UMR 7517, F-67084 Strasbourg, France; Univ NDjamena, Ndjamena, Chad; Museum Natl Hist Nat, F-75005 Paris, France; CNRS, UMR 8569, F-75005 Paris, France; CNRS, UPR 2147, F-75014 Paris, France; Harvard Univ, Peabody Museum, Cambridge, MA 02138 USA; Univ Complutense, Dept Paleontol, E-28040 Madrid, Spain; Univ Lyon 1, Ctr Sci Terre, CNRS, UMR 5125, F-69622 Villeurbanne, France; Univ Paris 06, CNRS, UMR 162, F-75252 Paris 05, France; Univ Paris 06, Inst Natl Rech Agron, F-75252 Paris 05, France	Universite de Poitiers; Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Harvard University; Complutense University of Madrid; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; INRAE; UDICE-French Research Universities; Sorbonne Universite	Vignaud, P (corresponding author), Univ Poitiers, Fac Sci, 40 Ave Recteur Pineau, F-86022 Poitiers, France.		Lihoreau, Fabrice/C-6671-2015; Lopez-Martinez, Nieves/A-6718-2008; Blondel, cecile/AAH-2618-2022; Lund, Laura/H-7335-2012; GERAADS, Denis/AAC-7241-2021; Geraads, Denis/AAY-6051-2020; zazzo, Antoine/H-1697-2011; Blondel, cecile/AEY-9166-2022; Otero, Olga/T-5467-2018	Lihoreau, Fabrice/0000-0002-4327-5341; GERAADS, Denis/0000-0003-2475-8011; zazzo, Antoine/0000-0001-7608-2207; Blondel, cecile/0000-0002-7022-6959; Otero, Olga/0000-0002-8129-2054; Viriot, Laurent/0000-0003-2092-588X; GUY, Franck/0000-0001-7032-7963; Schuster, Mathieu/0000-0002-4412-8685				Brunet M, 1998, CR ACAD SCI II A, V326, P153, DOI 10.1016/S1251-8050(97)87460-5; Brunet M, 2002, NATURE, V418, P145, DOI 10.1038/nature00879; Brunet M, 1996, CR ACAD SCI II A, V322, P907; Brunet M, 2000, J VERTEBR PALEONTOL, V20, P205, DOI 10.1671/0272-4634(2000)020[0205:CDOAVF]2.0.CO;2; CORYDON SC, 1977, P K NED AKAD B PHYS, V80, P61; de Bonis Louis, 1994, Neues Jahrbuch fuer Geologie und Palaeontologie Abhandlungen, V194, P343; Deino AL, 2002, J HUM EVOL, V42, P117, DOI 10.1006/jhev.2001.0521; Duringer P, 2000, LETHAIA, V33, P277; Eisenmann V, 1999, FOSSIL VERTEBRATES OF ARABIA, P234; Gaziry Abdel Wahid, 1987, P287; GENTRY A W, 1980, Annals of the South African Museum, V79, P213; Gentry Alan W., 1997, Topics in Geobiology, V14, P107; GERAADS D, 1989, GEOBIOS-LYON, V22, P777, DOI 10.1016/S0016-6995(89)80072-5; Ghienne JF, 2002, QUATERN INT, V87, P81, DOI 10.1016/S1040-6182(01)00063-5; Harris J.M., 1979, Transactions of the American Philosophical Society, V69, P1, DOI 10.2307/1006288; HUNTER RE, 1986, J SEDIMENT PETROL, V56, P387, DOI 10.1306/212F8922-2B24-11D7-8648000102C1865D; HUNTER RE, 1977, SEDIMENTOLOGY, V24, P361, DOI 10.1111/j.1365-3091.1977.tb00128.x; LEAKEY MD, 1987, LAETOLI PLIOCENE SIT, P524; Leakey MG, 1996, J VERTEBR PALEONTOL, V16, P556, DOI 10.1080/02724634.1996.10011339; Lehmann Ulrich, 1987, P323; McDougall I, 1999, J GEOL SOC LONDON, V156, P731, DOI 10.1144/gsjgs.156.4.0731; Pickford M, 2001, CR ACAD SCI II A, V332, P145, DOI 10.1016/S1251-8050(01)01528-2; Schuster M, 2000, CR ACAD SCI II A, V331, P15, DOI 10.1016/S1251-8050(00)01377-X; SEIGNOBOS C, 1993, SERIE C SEMINAIRES O, P165; Stewart Kathlyn M., 1997, Topics in Geobiology, V14, P333; TASSY P, 1994, CIFEB OCCAS PUBL, P217; Tassy P., 1994, GEOLOGY PALAEOBIOLOG, VII, P217; Tassy P., 1986, CAHIERS PALEONTOLOGI; Thomas H, 1977, P 8 PAN C PREH, P82; WOLDEGABRIEL G, 1994, NATURE, V371, P330, DOI 10.1038/371330a0; WoldeGabriel G, 2001, NATURE, V412, P175, DOI 10.1038/35084058	32	271	282	1	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 11	2002	418	6894					152	155		10.1038/nature00880	http://dx.doi.org/10.1038/nature00880			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571GV	12110881				2022-12-28	WOS:000176710400031
J	Aung, T; Mulley, GP				Aung, T; Mulley, GP			10-minute consultation - Removal of ear wax	BRITISH MEDICAL JOURNAL			English	Article									St James Hosp, Elderly Serv, Leeds LS9 7TF, W Yorkshire, England; Hull Royal Infirm, Dept Med Elderly, Kingston Upon Hull HU3 2JZ, N Humberside, England	Saint James's University Hospital; University of Hull	Mulley, GP (corresponding author), St James Hosp, Elderly Serv, Beckett St, Leeds LS9 7TF, W Yorkshire, England.							BROWNING G, 2001, CLIN EVID, V6, P420; Cook R, 1998, Nurs Stand, V13, P56; Grossan M, 1998, Ear Nose Throat J, V77, P541; KEMP B, 1999, HEARING J, V52, P58; PRICE J, 1997, PRACTICE NURSE, V14, P126; SHARP JF, 1990, BRIT MED J, V301, P1251, DOI 10.1136/bmj.301.6763.1251	6	7	8	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 6	2002	325	7354					27	27		10.1136/bmj.325.7354.27	http://dx.doi.org/10.1136/bmj.325.7354.27			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573BC	12098727	Green Published, Bronze			2022-12-28	WOS:000176808600021
J	Carr, A				Carr, A			Improvement of the study, analysis, and reporting of adverse events associated with antiretroviral therapy	LANCET			English	Editorial Material							COHORT		St Vincents Hosp, HIV Immunol & Infect Dis Clin Serv Unit, Sydney, NSW 2010, Australia	St Vincents Hospital Sydney	Carr, A (corresponding author), St Vincents Hosp, HIV Immunol & Infect Dis Clin Serv Unit, Sydney, NSW 2010, Australia.							Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; [Anonymous], 1979, HOUSE GOD; Bonfanti P, 2001, BIOMED PHARMACOTHER, V55, P321, DOI 10.1016/S0753-3322(01)00070-1; Carr A, 2000, LANCET, V356, P1423, DOI 10.1016/S0140-6736(00)02854-3; Carrieri P, 2001, J ACQ IMMUN DEF SYND, V28, P232, DOI 10.1097/00042560-200111010-00005; Clever L, 1997, NEW ENGL J MED, V336, P309; de Olalla PG, 2002, J ACQ IMMUN DEF SYND, V30, P105, DOI 10.1097/00042560-200205010-00014; *EUR AG EV MED PRO, 2001, CPMPICH36396 EUR AG; *EUR AG EV MED PRO, 2001, CPMPICH37595 EUR AG; *EUR AG EV MED PRO, 2000, CPMPICH13795 EUR AG; *EUR AG EV MED PRO, 2001, CPMPICH2887 EUR AG E; Fellay J, 2001, LANCET, V358, P1322, DOI 10.1016/S0140-6736(01)06413-3; IOANNIDIS JPA, 2001, JAMA-J AM MED ASSOC, V285, P4437; Kirk O, 2001, HIV Med, V2, P43, DOI 10.1046/j.1468-1293.2001.00045.x; Martinez E, 2001, AIDS, V15, P1261, DOI 10.1097/00002030-200107060-00007; *US FDA, 2001, GUID IND CLIN CONS A; *US FDA, 2001, ADV EV REP SYST; *US FDA, 2000, CDER REP NAT; *US FDA, 2002, MAN RISK MED PROD US; *US FDA, 2001, GUID IND FAST TRACK; US Food and Drug Administration, 2001, GUID IND S7A SAF PHA; Wu AW, 2000, AIDS, V14, P1449, DOI 10.1097/00002030-200007070-00019	22	22	23	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 6	2002	360	9326					81	85		10.1016/S0140-6736(02)09341-8	http://dx.doi.org/10.1016/S0140-6736(02)09341-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569JR	12114062				2022-12-28	WOS:000176599700031
J	Collins, R; Armitage, J; Parish, S; Sleight, P; Peto, R				Collins, R; Armitage, J; Parish, S; Sleight, P; Peto, R		Heart Protection Study Collaborati	MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial	LANCET			English	Article							CORONARY EVENTS; MYOCARDIAL-INFARCTION; PRIMARY PREVENTION; LDL-CHOLESTEROL; MORTALITY; PRAVASTATIN; DISEASE; FRACTURE; DENSITY; MEN	Background Throughout the usual LDL cholesterol range in Western populations, lower blood concentrations are associated with lower cardiovascular disease risk. In such populations, therefore, reducing LDL cholesterol may reduce the development of vascular disease, largely irrespective of initial cholesterol concentrations. Methods 20 536 UK adults (aged 40-80 years) with coronary disease, other occlusive arterial disease, or diabetes were randomly allocated to receive 40 mg simvastatin daily (average compliance: 85%) or matching placebo (average non-study statin use: 17%). Analyses are of the first occurrence of particular events, and compare all simvastatin-allocated versus all placebo-allocated participants. These "Intention-to-treat"comparisons assess the effects of about two-thirds (85% minus 17%) taking a statin during the scheduled 5-year treatment period, which yielded an average difference in LDL cholesterol of 1.0 mmol/L (about two-thirds of the effect of actual use of 40 mg simvastatin daily). Primary outcomes were mortality (for overall analyses) and fatal or non-fatal vascular events (for subcategory analyses), with subsidiary assessments of cancer and of other major morbidity. Findings All-cause mortality was significantly reduced (1328 [12.9%] deaths among 10 269 allocated simvastatin versus 1507 [14.7%] among 10 267 allocated placebo; p=0.0003), due to a highly significant 18% (SE 5) proportional reduction in the coronary death rate (587 [5.7%] vs 707 [6.9%]; p=0.0005), a marginally significant reduction in other vascular deaths (194 [1.9%] vs 230 [2.2%]; p=0.07), and a non-significant reduction in non-vascular deaths (547 [5.3%] vs 570 [5.6%]; p=0-4). There were highly significant reductions of about one-quarter in the first event rate for non-fatal myocardial infarction or coronary death (898 [8.7%] vs 1212 [11.8%]; p<0.0001), for non-fatal or fatal stroke (444 [4.3%] vs 585 [5.7%]; p<0.0001), and for coronary or non-coronary revascularisation (939 [9.1%] vs 1205 [11.7%]; p<0.0001). For the first occurrence of any of these major vascular events, there was a definite 24% (SE 3; 95% Cl 19-28) reduction in the event rate (2033 [19.8%] vs 2585 [25.2%] affected individuals; p<0.0001). During the first year the reduction in major vascular events was not significant, but subsequently it was highly significant during each separate year. The proportional reduction in the event rate was similar (and significant) in each subcategory of participant studied, including: those without diagnosed coronary disease who had cerebrovascular disease, or had peripheral artery disease, or had diabetes; men and, separately, women; those aged either under or over 70 years at entry; and-most notably-even those who presented with LDL cholesterol below 3.0 mmol/L (116 mg/dL), or total cholesterol below 5.0 mmol/L (193 mg/dL). The benefits of simvastatin were additional to those of other cardioprotective treatments. The annual excess risk of myopathy with this regimen was about 0.01%. There were no significant adverse effects on cancer incidence or on hospitalisation for any other non-vascular cause. Interpretation Adding simvastatin to existing treatments safely produces substantial additional benefits for a wide range of high-risk patients, irrespective of their initial cholesterol concentrations. Allocation to 40 mg simvastatin daily reduced the rates of myocardial infarction, of stroke, and of revascularisation by about one-quarter. After making allowance for non-compliance, actual use of this regimen would probably reduce these rates by about one-third. Hence, among the many types of high-risk individual studied, 5 years of simvastatin would prevent about 70-100 people per 1000 from suffering at least one of these major vascular events (and longer treatment should produce further benefit). The size of the 5-year benefit depends chiefly on such individuals' overall risk of major vascular events, rather than on their blood lipid concentrations alone.	Radcliffe Infirm, Clin Trial Serv Unit, Heart Protect Study, Oxford OX2 6HE, England; Radcliffe Infirm, Epidemiol Studies Unit, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford	Collins, R (corresponding author), Radcliffe Infirm, Clin Trial Serv Unit, Heart Protect Study, Oxford OX2 6HE, England.	hps@ctsu.ox.ac.uk	Lindley, Richard/B-8148-2013	Lindley, Richard/0000-0002-0104-5679; Mihaylova, Borislava/0000-0002-0951-1304	Medical Research Council [MC_U137686853] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Armitage J, 2000, HEART, V84, P357, DOI 10.1136/heart.84.4.357; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Bandyopadhyay S, 2001, QJM-INT J MED, V94, P127, DOI 10.1093/qjmed/94.3.127; Brown BG, 2001, NEW ENGL J MED, V345, P1583, DOI 10.1056/NEJMoa011090; Byington RP, 2001, CIRCULATION, V103, P387; Campeau L, 1997, NEW ENGL J MED, V336, P153; Chan KA, 2000, LANCET, V355, P2185, DOI 10.1016/S0140-6736(00)02400-4; Chen J., 1990, DIET LIFE STYLE MORT; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Collins R, 2001, LANCET, V357, P373, DOI 10.1016/S0140-6736(00)03651-5; Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5; COLLINS R, 1992, BRIT MED J, V304, P1689, DOI 10.1136/bmj.304.6843.1689; DOWNS JR, 1995, AM J CARDIOL, V75, P1130; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; JIALAL I, 1995, AM J CLIN PATHOL, V104, P76, DOI 10.1093/ajcp/104.1.76; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Kivipelto M, 2001, BMJ-BRIT MED J, V322, P1447, DOI 10.1136/bmj.322.7300.1447; Kotseva K, 2001, LANCET, V357, P995, DOI 10.1016/S0140-6736(00)04235-5; LANG JM, 1991, STAT MED, V10, P1585, DOI 10.1002/sim.4780101010; MCNAMARA JR, 1995, CLIN CHEM, V41, P232; Meade T, 1999, EUR HEART J, V20, P725; Muldoon MF, 2001, BRIT MED J, V322, P11, DOI 10.1136/bmj.322.7277.11; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; Neal B, 2000, LANCET, V356, P1955; Newman TB, 1996, JAMA-J AM MED ASSOC, V275, P55, DOI 10.1001/jama.275.1.55; OLIVER MF, 1991, LANCET, V337, P1529, DOI 10.1016/0140-6736(91)93208-Q; Packard CJ, 1998, CIRCULATION, V97, P1440; Pasco JA, 2002, ARCH INTERN MED, V162, P537, DOI 10.1001/archinte.162.5.537; PEDERSEN TR, 1994, LANCET, V344, P1383; Pedersen TR, 1998, CIRCULATION, V97, P1453, DOI 10.1161/01.CIR.97.15.1453; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Prince MJ., 1999, INT J METH PSYCH RES, V8, P49, DOI DOI 10.1002/MPR.56; Prior M J, 1993, Ann Epidemiol, V3, P9; Reid IR, 2001, LANCET, V357, P509, DOI 10.1016/S0140-6736(00)04042-3; Rockwood K, 2002, ARCH NEUROL-CHICAGO, V59, P223, DOI 10.1001/archneur.59.2.223; Sacks FM, 1998, CIRCULATION, V97, P1446; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Sacks FM, 2000, CIRCULATION, V102, P1893, DOI 10.1161/01.CIR.102.16.1893; Sandercock P, 2001, LANCET, V357, P1548, DOI 10.1016/S0140-6736(00)04779-6; Schatz IJ, 2001, LANCET, V358, P351, DOI 10.1016/S0140-6736(01)05553-2; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; Staffa JA, 2002, NEW ENGL J MED, V346, P539, DOI 10.1056/NEJM200202143460721; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; SZATROWSKI TP, 1984, J CHRON DIS, V37, P569, DOI 10.1016/0021-9681(84)90007-9; THORVALDSEN P, 1995, STROKE, V26, P361, DOI 10.1161/01.STR.26.3.361; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Waters DD, 2001, CIRCULATION, V104, P2635, DOI 10.1161/circ.104.22.2635; WeverlingRijnsburger AWE, 1997, LANCET, V350, P1119, DOI 10.1016/S0140-6736(97)04430-9; WHITE SJ, 1978, BRIT J CANCER, V37, P849, DOI 10.1038/bjc.1978.124; Wood D, 1998, EUR HEART J, V19, P1434; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; Yusuf S, 2000, NEW ENGL J MED, V342, P145	56	6087	6320	3	437	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 6	2002	360	9326					7	22		10.1016/s0140-6736(02)09327-3	http://dx.doi.org/10.1016/s0140-6736(02)09327-3			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569JR	12114036				2022-12-28	WOS:000176599700006
J	Holleitner, AW; Blick, RH; Huttel, AK; Eberl, K; Kotthaus, JP				Holleitner, AW; Blick, RH; Huttel, AK; Eberl, K; Kotthaus, JP			Probing and controlling the bonds of an artificial molecule	SCIENCE			English	Article							SINGLE-ELECTRON TRANSISTOR; COUPLED QUANTUM DOTS; COULOMB-BLOCKADE	We demonstrate how molecular quantum states of coupled semiconductor quantum dots are coherently probed and manipulated in transport experiments. The applied method probes quantum states by the virtual cotunneling of two electrons and hence resolves the sequences of molecular states simultaneously. This result is achieved by weakly probing the quantum system through parallel contacts to its constituting quantum dots. The overlap of the dots wave functions and, in turn, the splitting of molecular states are adjusted by the direct influence of coupling electrodes.	Univ Munich, Ctr NanoSci, D-80539 Munich, Germany; Univ Munich, Sekt Phys, D-80539 Munich, Germany; Max Planck Inst Festkorperforsch, D-70569 Stuttgart, Germany	University of Munich; University of Munich; Max Planck Society	Holleitner, AW (corresponding author), Univ Munich, Ctr NanoSci, Geschwister Scholl Pl 1, D-80539 Munich, Germany.		Hüttel, Andreas K/C-2400-2008; Blick, Robert H/M-8298-2014; Kotthaus, Jorg P/A-7674-2010	Hüttel, Andreas K/0000-0001-5794-5919; Blick, Robert H/0000-0002-3602-7702; 				AVERIN DV, 1992, NATO ADV SCI I B-PHY, V294, P217; Bayer M, 2001, SCIENCE, V291, P451, DOI 10.1126/science.291.5503.451; BEENAKKER CWJ, 1991, PHYS REV B, V44, P1646, DOI 10.1103/PhysRevB.44.1646; Blick RH, 1998, PHYS REV LETT, V80, P4032, DOI 10.1103/PhysRevLett.80.4032; Busser CA, 2000, PHYS REV B, V62, P9907, DOI 10.1103/PhysRevB.62.9907; Cronenwett SM, 1998, SCIENCE, V281, P540, DOI 10.1126/science.281.5376.540; Fujisawa T, 1998, SCIENCE, V282, P932, DOI 10.1126/science.282.5390.932; Goldhaber-Gordon D, 1998, NATURE, V391, P156, DOI 10.1038/34373; Goldhaber-Gordon D, 1998, PHYS REV LETT, V81, P5225, DOI 10.1103/PhysRevLett.81.5225; Holleitner AW, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.256802; Jeong H, 2001, SCIENCE, V293, P2221, DOI 10.1126/science.1063182; KASTNER MA, 1993, PHYS TODAY, V46, P24, DOI 10.1063/1.881393; Leuenberger MN, 2001, NATURE, V410, P789, DOI 10.1038/35071024; Livermore C, 1996, SCIENCE, V274, P1332, DOI 10.1126/science.274.5291.1332; Oosterkamp TH, 1998, NATURE, V395, P873, DOI 10.1038/27617; Qin H, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.241302; Schmid J, 2000, PHYS REV LETT, V84, P5824, DOI 10.1103/PhysRevLett.84.5824; Simmel F, 1999, PHYS REV LETT, V83, P804, DOI 10.1103/PhysRevLett.83.804	20	224	226	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 5	2002	297	5578					70	72		10.1126/science.1071215	http://dx.doi.org/10.1126/science.1071215			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571HB	12098692				2022-12-28	WOS:000176711000032
J	Kwon, YT; Kashina, AS; Davydov, IV; Hu, RG; An, JY; Seo, JW; Du, F; Varshavsky, A				Kwon, YT; Kashina, AS; Davydov, IV; Hu, RG; An, JY; Seo, JW; Du, F; Varshavsky, A			An essential role of N-terminal arginylation in cardiovascular development	SCIENCE			English	Article							END RULE PATHWAY; RNA-PROTEIN TRANSFERASE; METHIONINE AMINOPEPTIDASE; UBIQUITIN; DEGRADATION; COMPONENT; ASPARTATE; LACKING; CELLS; MOUSE	The enzymatic conjugation of arginine to the N-termini of proteins is a part of the ubiquitin-dependent N-end rule pathway of protein degradation. In mammals, three N-terminal residues aspartate, glutamate, and cysteine are substrates for arginylation. The mouse ATE1 gene encodes a family of Arg-tRNA-protein transferases (R-transferases) that mediate N-terminal arginylation. We constructed ATE1-lacking mouse strains and found that ATE1(-/-) embryos die with defects in heart development and in angiogenic remodeling of the early vascular plexus. Through biochemical analyses, we show that N-terminal cysteine, in contrast to N-terminal aspartate and glutamate, is oxidized before its arginylation by R-transferase, suggesting that the arginylation branch of the N-end rule pathway functions as an oxygen sensor.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Varshavsky, A (corresponding author), CALTECH, Div Biol, 147-75,1200 E Calif Blvd, Pasadena, CA 91125 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031530] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31530] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 2001, CURRENT PROTOCOLS MO; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Creazzo TL, 1998, ANNU REV PHYSIOL, V60, P267, DOI 10.1146/annurev.physiol.60.1.267; Davydov IV, 2000, J BIOL CHEM, V275, P22931, DOI 10.1074/jbc.M001605200; GONDA DK, 1989, J BIOL CHEM, V264, P16700; Griffith EC, 1997, CHEM BIOL, V4, P461, DOI 10.1016/S1074-5521(97)90198-8; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; KAIJI H, 1963, BIOCHIM BIOPHYS ACTA, V76, P474; Kwon YT, 1998, P NATL ACAD SCI USA, V95, P7898, DOI 10.1073/pnas.95.14.7898; Kwon YT, 2000, MOL CELL BIOL, V20, P4135, DOI 10.1128/MCB.20.11.4135-4148.2000; Kwon YT, 1999, MOL CELL BIOL, V19, P182; Kwon YT, 2001, MOL CELL BIOL, V21, P8007, DOI 10.1128/MCB.21.23.8007-8021.2001; Levy F, 1996, P NATL ACAD SCI USA, V93, P4907, DOI 10.1073/pnas.93.10.4907; LI J, 1995, BIOCHEMISTRY-US, V34, P15829, DOI 10.1021/bi00048a028; Rao H, 2001, NATURE, V410, P955, DOI 10.1038/35073627; Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099; Srivastava D, 2001, ANNU REV PHYSIOL, V63, P451, DOI 10.1146/annurev.physiol.63.1.451; Suzuki T, 1999, EMBO J, V18, P6017, DOI 10.1093/emboj/18.21.6017; Takao K, 1999, BIOL PHARM BULL, V22, P1007; TETAZ T, 1990, BIOCHEM INT, V22, P561; Turner GC, 2000, SCIENCE, V289, P2117, DOI 10.1126/science.289.5487.2117; Turner GC, 2000, NATURE, V405, P579, DOI 10.1038/35014629; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Varshavsky A, 2000, METHOD ENZYMOL, V327, P578, DOI 10.1016/S0076-6879(00)27303-5; YAGI T, 1979, BIOCHEM BIOPH RES CO, V90, P447, DOI 10.1016/0006-291X(79)91255-5	28	246	260	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 5	2002	297	5578					96	99		10.1126/science.1069531	http://dx.doi.org/10.1126/science.1069531			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571HB	12098698				2022-12-28	WOS:000176711000041
J	Buffon, A; Biasucci, LM; Liuzzo, G; D'Onofrio, G; Crea, F; Maseri, A				Buffon, A; Biasucci, LM; Liuzzo, G; D'Onofrio, G; Crea, F; Maseri, A			Widespread coronary inflammation in unstable angina	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; ISCHEMIC-HEART-DISEASE; C-REACTIVE PROTEIN; ATHEROSCLEROTIC PLAQUES; IN-VIVO; ADHESION MOLECULES; ELEVATED LEVELS; BLOOD-FLOW; NEUTROPHIL; RUPTURE	Background: Inflammation within vulnerable coronary plaques may cause unstable angina by promoting rupture and erosion. In unstable angina, activated leukocytes may be found in peripheral and coronary-sinus blood, but it is unclear whether they are selectively activated in the vascular bed of the culprit stenosis. Methods: We measured the content neutrophil myeloperoxidase content in the cardiac and femoral circulations in five groups of patients: two groups with unstable angina and stenosis in either the left anterior descending coronary artery (24 patients) or the right coronary artery (9 patients); 13 with chronic stable angina; 13 with variant angina and recurrent ischemia; and 6 controls. Blood samples were taken from the aorta, the femoral vein, and the great cardiac vein, which selectively drains blood from the left but not the right coronary artery. Results: The neutrophil myeloperoxidase content of aortic blood was similar in both groups of patients with unstable angina (-3.9 and -5.5, with negative values representing depletion of the enzyme due to neutrophil activation) and significantly lower than in the other three groups (P<0.05). Independently of the site of the stenosis, the neutrophil myeloperoxidase content in blood from the great cardiac vein was significantly decreased in both groups of patients with unstable angina (-6.4 in those with a left coronary lesion and -6.6 in those with a right coronary lesion), but not in patients with stable angina and multiple stenoses, patients with variant angina and recurrent ischemia, or controls. There was also a significant transcoronary reduction in myeloperoxidase content in both groups with unstable angina. Conclusions: The widespread activation of neutrophils across the coronary vascular bed in patients with unstable angina, regardless of the location of the culprit stenosis, challenges the concept of a single vulnerable plaque in unstable coronary syndromes.	Univ Vita & Salute, Cardiothorac & Vasc Dept, I-20132 Milan, Italy; Catholic Univ, Inst Cardiol, Rome, Italy; Catholic Univ, Inst Hematol, Rome, Italy	Vita-Salute San Raffaele University; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Maseri, A (corresponding author), Univ Vita & Salute, Hosp San Raffaele, Cardiothorac & Vasc Dept, Via Olgettina 60, I-20132 Milan, Italy.	maseri.attilio@hsr.it	LIUZZO, GIOVANNA/J-8090-2018	LIUZZO, GIOVANNA/0000-0002-5714-0907; biasucci, luigi m/0000-0002-6921-6497; Buffon, Antonino/0000-0001-8144-6597				ARAUJO L I, 1988, Cardiovascular Drugs and Therapy, V2, P41; ARBUSTINI E, 1991, AM J CARDIOL, V68, pB36, DOI 10.1016/0002-9149(91)90383-V; Biasucci LM, 1999, CIRCULATION, V99, P855, DOI 10.1161/01.CIR.99.7.855; Biasucci LM, 1996, CIRCULATION, V94, P874, DOI 10.1161/01.CIR.94.5.874; Biasucci LM, 1996, J AM COLL CARDIOL, V27, P611, DOI 10.1016/0735-1097(95)00524-2; BOGATY P, 1993, CIRCULATION, V87, P1938, DOI 10.1161/01.CIR.87.6.1938; Casscells W, 1996, LANCET, V347, P1447, DOI 10.1016/S0140-6736(96)91684-0; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; deServi S, 1996, AM J CARDIOL, V78, P564, DOI 10.1016/S0002-9149(96)00367-0; DINERMAN JL, 1990, J AM COLL CARDIOL, V15, P1559, DOI 10.1016/0735-1097(90)92826-N; DISCIASCIO G, 1994, AM HEART J, V128, P419, DOI 10.1016/0002-8703(94)90612-2; FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657; Fayad ZA, 2000, CIRCULATION, V102, P506; GANZ W, 1971, CIRCULATION, V44, P181, DOI 10.1161/01.CIR.44.2.181; Gibson CM, 1999, J AM COLL CARDIOL, V34, P974, DOI 10.1016/S0735-1097(99)00335-6; GLANTZ SA, 1987, PRIMER BIOSTATISTICS, P287; Goldstein JA, 2000, NEW ENGL J MED, V343, P915, DOI 10.1056/NEJM200009283431303; Hazen SL, 1998, J BIOL CHEM, V273, P4997, DOI 10.1074/jbc.273.9.4997; Jordan JE, 1999, CARDIOVASC RES, V43, P860, DOI 10.1016/S0008-6363(99)00187-X; Libby P, 2000, AM J CARDIOL, V86, p3J; Libby P, 2001, CIRCULATION, V104, P365, DOI 10.1161/01.CIR.104.3.365; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; Liuzzo G, 1999, J AM COLL CARDIOL, V34, P1696, DOI 10.1016/S0735-1097(99)00432-5; MAZZONE A, 1993, CIRCULATION, V88, P358, DOI 10.1161/01.CIR.88.2.358; MEHTA J, 1989, CIRCULATION, V79, P549, DOI 10.1161/01.CIR.79.3.549; MORENO PR, 1994, CIRCULATION, V90, P775, DOI 10.1161/01.CIR.90.2.775; Rabbani R, 1999, CARDIOVASC RES, V41, P402, DOI 10.1016/S0008-6363(98)00279-X; SHAH PK, 1995, CIRCULATION, V92, P1565; Stefanadis C, 1999, CIRCULATION, V99, P1965, DOI 10.1161/01.CIR.99.15.1965; UREN NG, 1994, NEW ENGL J MED, V331, P222, DOI 10.1056/NEJM199407283310402; VANDERWAL AC, 1994, CIRCULATION, V89, P36, DOI 10.1161/01.CIR.89.1.36; WALLSH E, 1986, TEX HEART I J, V13, P105	33	708	763	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 4	2002	347	1					5	12		10.1056/NEJMoa012295	http://dx.doi.org/10.1056/NEJMoa012295			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569HA	12097534				2022-12-28	WOS:000176594500002
J	Hata, A; Asanuma, H; Rinki, M; Sharp, M; Wong, RM; Blume, K; Arvin, AM				Hata, A; Asanuma, H; Rinki, M; Sharp, M; Wong, RM; Blume, K; Arvin, AM			Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; REFRACTORY HODGKINS-DISEASE; HUMAN TRIGEMINAL GANGLIA; ZOSTER VIRUS-INFECTIONS; HERPES-ZOSTER; RISK-FACTORS; T-CELLS; IMMUNITY; IMMUNIZATION; CYTOMEGALOVIRUS	Background: The reactivation of varicella-zoster virus from latency causes zoster and is common among recipients of hematopoietic-cell transplants. Methods: We randomly assigned patients who were scheduled to undergo autologous hematopoietic-cell transplantation for non-Hodgkin's or Hodgkin's lymphoma to receive varicella vaccine or no vaccine. Heat-inactivated, live attenuated varicella vaccine was given within 30 days before transplantation and 30, 60, and 90 days after transplantation. The patients were monitored for zoster and for immunity against varicella-zoster virus for 12 months. Results: Of the 119 patients enrolled, 111 received a transplant. Zoster developed in 7 of 53 vaccinated patients (13 percent) and in 19 of 58 unvaccinated patients (33 percent) (P=0.01). After two patients in whom zoster developed before transplantation were excluded, the respective rates were 13 percent and 30 percent (P=0.02). In vitro CD4 T-cell proliferation in response to varicella-zoster virus (expressed as the mean stimulation index) was greater in patients who received the vaccine than in those who did not at 90 days, after three doses (P=0.04); at 120 days, after all four doses (P<0.001); at 6 months (P=0.004); and at 12 months (P=0.02). The risk of zoster was reduced for each unit increase in the stimulation index above 1.6; a stimulation index above 5.0 correlated with greater than 93 percent protection. Induration, erythema, or local pain at the injection site was observed in association with 10 percent of the doses. Conclusions: Inactivated varicella vaccine given before hematopoietic-cell transplantation and during the first 90 days thereafter reduces the risk of zoster. The protection correlates with reconstitution of CD4 T-cell immunity against varicella-zoster virus.	Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Arvin, AM (corresponding author), Stanford Univ, Sch Med, Dept Pediat, 300 Pasteur Dr,Rm G312, Stanford, CA 94305 USA.				NCI NIH HHS [P01-CA49605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049605] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; ALLISON PD, 1995, SURVIVAL ANAL USING, P111; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Altman JD, 1998, SCIENCE, V280, P1821; AMBROSINO DM, 1993, HEMATOL ONCOL CLIN N, V7, P1027, DOI 10.1016/S0889-8588(18)30216-8; Arvin A. M, 1999, PERSISTENT VIRAL INF, P183; Arvin AM, 2000, BIOL BLOOD MARROW TR, V6, P219, DOI 10.1016/S1083-8791(00)70004-8; Arvin AM, 1999, HEMATOPOIETIC CELL T, P591; DEGAST GC, 1985, BLOOD, V66, P428; Doherty PC, 1998, SCIENCE, V280, P227, DOI 10.1126/science.280.5361.227; Gershon AA, 2001, INFECT DIS CLIN N AM, V15, P65, DOI 10.1016/S0891-5520(05)70268-3; Greenberg PD, 1999, SCIENCE, V285, P546, DOI 10.1126/science.285.5427.546; GUINAN EC, 1994, TRANSPLANTATION, V57, P677, DOI 10.1097/00007890-199403150-00009; HAN CS, 1994, BONE MARROW TRANSPL, V13, P277; HOLLAND HK, 1990, CANCER INVEST, V8, P509, DOI 10.3109/07357909009012076; Horning SJ, 1997, BLOOD, V89, P801, DOI 10.1182/blood.V89.3.801; Johnston LJ, 2000, BIOL BLOOD MARROW TR, V6, P555, DOI 10.1016/S1083-8791(00)70065-6; Kennedy PGE, 1998, P NATL ACAD SCI USA, V95, P4658, DOI 10.1073/pnas.95.8.4658; Koc Y, 2000, BIOL BLOOD MARROW TR, V6, P44, DOI 10.1016/S1083-8791(00)70051-6; Levin MJ, 2001, ARCH VIR S, V17, P151; LJUNGMAN P, 1989, BONE MARROW TRANSPL, V4, P613; LJUNGMAN P, 1990, J INFECT DIS, V162, P496, DOI 10.1093/infdis/162.2.496; LUNGU O, 1995, P NATL ACAD SCI USA, V92, P10980, DOI 10.1073/pnas.92.24.10980; Mahalingam R, 1996, P NATL ACAD SCI USA, V93, P2122, DOI 10.1073/pnas.93.5.2122; MEYERS JD, 1980, J INFECT DIS, V141, P479, DOI 10.1093/infdis/141.4.479; Molrine DC, 1996, BLOOD, V87, P3012, DOI 10.1182/blood.V87.7.3012.bloodjournal8773012; NEGRIN RS, 1995, BLOOD, V85, P3334, DOI 10.1182/blood.V85.11.3334.bloodjournal85113334; Pevenstein SR, 1999, J VIROL, V73, P10514, DOI 10.1128/JVI.73.12.10514-10518.1999; Redman RL, 1997, J INFECT DIS, V176, P578, DOI 10.1086/514077; SAXON A, 1987, PROGR BONE MARROW TR, P623; SCHUCHTER LM, 1989, BLOOD, V74, P1424; Sharma MP, 2000, BIOL AGRIC HORTIC, V18, P1; Silverstein S, 2000, VARICELLA ZOSTER VIR, P123; Smith JG, 2001, CLIN DIAGN LAB IMMUN, V8, P871, DOI 10.1128/CDLI.8.5.871-879.2001; SPERBER SJ, 1992, ANTIVIR RES, V17, P213, DOI 10.1016/0166-3542(92)90042-4; Stockerl-Goldstein K E, 1996, Biol Blood Marrow Transplant, V2, P76; Stuart MJ, 2001, BIOL BLOOD MARROW TR, V7, P552, DOI 10.1016/S1083-8791(01)70015-8; WACKER P, 1989, BONE MARROW TRANSPL, V4, P191; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; WEBSTER A, 1989, J MED VIROL, V27, P117, DOI 10.1002/jmv.1890270209; Whitley RJ, 1990, ANTIVIR AGENTS VIR, P235; WILSON A, 1992, J INFECT DIS, V165, P119, DOI 10.1093/infdis/165.1.119; WIMPERIS JZ, 1986, LANCET, V1, P339; Wingard J R, 1990, Oncology (Williston Park), V4, P69; ZAIA JA, 1995, INFECT DIS CLIN N AM, V9, P879; ZAIA JA, 1990, HEMATOL ONCOL CLIN N, V4, P603, DOI 10.1016/S0889-8588(18)30481-7; ZHANG Y, 1994, CLIN EXP IMMUNOL, V98, P128	47	218	226	1	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 4	2002	347	1					26	34		10.1056/NEJMoa013441	http://dx.doi.org/10.1056/NEJMoa013441			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569HA	12097537	Bronze			2022-12-28	WOS:000176594500005
J	Maddox, J				Maddox, J			Maxwell's demon: Slamming the door	NATURE			English	Article											Maddox, J (corresponding author), 9 Pitt St, London W8 4NX, England.							Harman Peter M., 1998, NATURAL PHILOS JC MA	1	6	6	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 27	2002	417	6892					903	903		10.1038/417903a	http://dx.doi.org/10.1038/417903a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	566RC	12087385	Bronze			2022-12-28	WOS:000176441200021
J	Cleemput, I; Kesteloot, K				Cleemput, I; Kesteloot, K			Economic implications of non-compliance in health care	LANCET			English	Editorial Material							AFRICA		Katholieke Univ Leuven, Ctr Hlth Serv & Nursing Res, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Univ Hosp, B-3000 Louvain, Belgium	KU Leuven; KU Leuven	Cleemput, I (corresponding author), Katholieke Univ Leuven, Ctr Hlth Serv & Nursing Res, B-3000 Louvain, Belgium.			Cleemput, Irina/0000-0003-4479-8950				Ackermann S P, 1994, J Cancer Educ, V9, P96; Cleemput I, 2002, HEALTH POLICY, V59, P65, DOI 10.1016/S0168-8510(01)00178-6; LEADERBACHHOFMA.K, 2000, GEN HOSP PSYCHIAT, V22, P412; Mhlongo SWP, 2001, BRIT J GEN PRACT, V51, P848; MUSHLIN AI, 1977, ARCH INTERN MED, V137, P318, DOI 10.1001/archinte.137.3.318; Neto ACD, 2002, MED J AUSTRALIA, V176, P401; Roter DL, 1998, MED CARE, V36, P1138, DOI 10.1097/00005650-199808000-00004; Shelton JD, 2001, BRIT MED J, V323, P139, DOI 10.1136/bmj.323.7305.139; Spiritus E, 2000, AM J MANAG CARE, V6, pS1216; Stone EG, 2002, ANN INTERN MED, V136, P641, DOI 10.7326/0003-4819-136-9-200205070-00006	10	45	48	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 22	2002	359	9324					2129	2130		10.1016/S0140-6736(02)09114-6	http://dx.doi.org/10.1016/S0140-6736(02)09114-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	566RJ	12090976				2022-12-28	WOS:000176441800005
J	Kasahara, J				Kasahara, J			Geophysics: Tides, earthquakes, and volcanoes	SCIENCE			English	Editorial Material							DE-FUCA RIDGE; SOLID EARTH; ERUPTION		Univ Tokyo, Earthquake Res Inst, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo	Kasahara, J (corresponding author), Univ Tokyo, Earthquake Res Inst, Bunkyo Ku, 1 1 1 Yayoi, Tokyo 1130032, Japan.							AOKI Y, 2000, 14 INT S EARTH TID E; Dziak RP, 1999, GEOPHYS RES LETT, V26, P3641, DOI 10.1029/1999GL002326; DZURISIN D, 1980, GEOPHYS RES LETT, V7, P925, DOI 10.1029/GL007i011p00925; Glasby GP, 2001, EARTH-SCI REV, V52, P261, DOI 10.1016/S0012-8252(00)00031-3; JENTZSCH G, 1997, CAHIER CTR EUROPEEN, V14, P95; Kasahara J, 2001, P JPN ACAD B-PHYS, V77, P98, DOI 10.2183/pjab.77.98; MCNUTT SR, 1984, J GEOPHYS RES, V89, P3075, DOI 10.1029/JB089iB05p03075; MCNUTT SR, 1981, NATURE, V294, P615, DOI 10.1038/294615a0; Nasu N., 1931, B EARTHQ RES I TOKYO, V9, P22; Schultz A, 1997, PHILOS T R SOC A, V355, P387, DOI 10.1098/rsta.1997.0014; Tolstoy M, 2002, GEOLOGY, V30, P503, DOI 10.1130/0091-7613(2002)030<0503:BOTSTC>2.0.CO;2; TSURUOKA H, 1995, GEOPHYS J INT, V122, P183, DOI 10.1111/j.1365-246X.1995.tb03546.x; Wilcock WSD, 2001, GEOPHYS RES LETT, V28, P3999, DOI 10.1029/2001GL013370	13	45	52	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 19	2002	297	5580					348	349		10.1126/science.1074601	http://dx.doi.org/10.1126/science.1074601			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574LV	12130769				2022-12-28	WOS:000176892600034
J	Freedman, R				Freedman, R			Long-term effects of early genetic influences on behavior	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ANXIETY		Dept Vet Affairs Med Ctr, Denver, CO 80220 USA		Freedman, R (corresponding author), Dept Vet Affairs Med Ctr, Denver, CO 80220 USA.							Biederman J, 2001, AM J PSYCHIAT, V158, P1673, DOI 10.1176/appi.ajp.158.10.1673; Flint J, 2001, BEHAV PHARMACOL, V12, P461, DOI 10.1097/00008877-200111000-00006; Gross C, 2002, NATURE, V416, P396, DOI 10.1038/416396a; WEISSMAN MM, 1989, NEW ENGL J MED, V321, P1209, DOI 10.1056/NEJM198911023211801	4	6	6	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 18	2002	347	3					213	215		10.1056/NEJMcibr021046	http://dx.doi.org/10.1056/NEJMcibr021046			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	574BR	12124413				2022-12-28	WOS:000176869000011
J	Yuasa, S; Nagahama, T; Suzuki, Y				Yuasa, S; Nagahama, T; Suzuki, Y			Spin-polarized resonant tunneling in magnetic tunnel junctions	SCIENCE			English	Article							QUANTUM-WELL STATES; MAGNETORESISTANCE; SINGLE; SUPERLATTICES; INTERFACE; LAYER	Insertion of a thin nonmagnetic copper Cu(001) layer between the tunnel barrier and the ferromagnetic electrode of a magnetic tunnel junction is shown to result in the oscillation of the tunnel magnetoresistance as a function of the Cu layer thickness. The effect is interpreted in terms of the formation of spin-polarized resonant tunneling. The amplitude of the oscillation is so large that even the sign of the tunnel magnetoresistance alternates. The oscillation period depends on the applied bias voltage, reflecting the energy band structure of Cu. The results are encouraging for the development of spin-dependent resonant tunneling devices.	Natl Inst Adv Ind Sci & Technol, Nanoelect Res Inst, Tsukuba, Ibaraki 3058568, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kawaguchi 3320012, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Japan Science & Technology Agency (JST)	Yuasa, S (corresponding author), Natl Inst Adv Ind Sci & Technol, Nanoelect Res Inst, Tsukuba, Ibaraki 3058568, Japan.		Nagahama, Taro/A-1777-2013; Yuasa, Shinji/H-2804-2016; SUZUKI, Yoshishige/D-2652-2013; Nagahama, Taro/A-8660-2010	Nagahama, Taro/0000-0002-3787-775X; Yuasa, Shinji/0000-0003-1093-9057; SUZUKI, Yoshishige/0000-0001-9423-8594; 				BRUNO P, 1991, PHYS REV LETT, V67, P1602, DOI 10.1103/PhysRevLett.67.1602; CEBOLLADA A, 1989, PHYS REV B, V39, P9726, DOI 10.1103/PhysRevB.39.9726; De Teresa JM, 1999, SCIENCE, V286, P507, DOI 10.1126/science.286.5439.507; DUKE CB, 1969, TUNNELING SOLIDS, pCH4; ESAKI L, 1986, IEEE J QUANTUM ELECT, V22, P1611, DOI 10.1109/JQE.1986.1073162; JULLIERE M, 1975, PHYS LETT A, V54, P225, DOI 10.1016/0375-9601(75)90174-7; LeClair P, 2000, PHYS REV LETT, V84, P2933, DOI 10.1103/PhysRevLett.84.2933; LeClair P, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.100406; LeClair P, 2001, PHYS REV LETT, V86, P1066, DOI 10.1103/PhysRevLett.86,1066; Mathon J, 1999, PHYS REV B, V60, P1117, DOI 10.1103/PhysRevB.60.1117; MESERVEY R, 1994, PHYS REP, V238, P173, DOI 10.1016/0370-1573(94)90105-8; MIYAZAKI T, 1995, J MAGN MAGN MATER, V139, pL231, DOI 10.1016/0304-8853(94)01648-8; Moodera JS, 1999, PHYS REV LETT, V83, P3029, DOI 10.1103/PhysRevLett.83.3029; MOODERA JS, 1995, PHYS REV LETT, V74, P3273, DOI 10.1103/PhysRevLett.74.3273; Moodera JS, 2000, PHILOS MAG B, V80, P195, DOI 10.1080/13642810008208608; Nagahama T, 2001, APPL PHYS LETT, V79, P4381, DOI 10.1063/1.1424068; ORTEGA JE, 1993, PHYS REV B, V47, P1540, DOI 10.1103/PhysRevB.47.1540; Prinz GA, 1998, SCIENCE, V282, P1660, DOI 10.1126/science.282.5394.1660; SEGALL B, 1962, PHYS REV, V125, P109, DOI 10.1103/PhysRev.125.109; Sun JJ, 1999, J APPL PHYS, V85, P5264, DOI 10.1063/1.369849; Suzuki Y, 1998, PHYS REV LETT, V80, P5200, DOI 10.1103/PhysRevLett.80.5200; Vedyayev A, 1997, EUROPHYS LETT, V39, P219, DOI 10.1209/epl/i1997-00337-8; WEBER W, 1995, EUROPHYS LETT, V31, P491, DOI 10.1209/0295-5075/31/8/012; Wolf SA, 2001, SCIENCE, V294, P1488, DOI 10.1126/science.1065389; Yuasa S, 2000, EUROPHYS LETT, V52, P344, DOI 10.1209/epl/i2000-00445-5; Zhang XD, 1997, PHYS REV B, V56, P5484, DOI 10.1103/PhysRevB.56.5484	26	219	238	5	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 12	2002	297	5579					234	237		10.1126/science.1071300	http://dx.doi.org/10.1126/science.1071300			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571UT	12114621				2022-12-28	WOS:000176738100036
J	Lohmann, C; Myhr, KL; Wong, ROL				Lohmann, C; Myhr, KL; Wong, ROL			Transmitter-evoked local calcium release stabilizes developing dendrites	NATURE			English	Article							DEVELOPING CHICK RETINA; HIPPOCAMPAL-NEURONS; NERVOUS-SYSTEM; SYNAPTIC CA2+; STORES; SYNAPTOGENESIS; SPINES; CELLS; SPECIFICITY; TRANSIENTS	In the central nervous system, dendritic arborizations of neurons undergo dynamic structural remodelling during development. Processes are elaborated, maintained or eliminated to attain the adult pattern of synaptic connections(1-3). Although neuronal activity influences this remodelling(4-6), it is not known how activity exerts its effects. Here we show that neurotransmission- evoked calcium (Ca2+) release from intracellular stores stabilizes dendrites during the period of synapse formation. Using a ballistic labelling method to load cells with Ca2+ indicator dyes 7, we simultaneously monitored dendritic activity and structure in the intact retina. Two distinct patterns of spontaneous Ca2+ increases occurred in developing retinal ganglion cells-global increases throughout the arborization, and local 'flashes' of activity restricted to small dendritic segments. Blockade of local, but not global, activity caused rapid retraction of dendrites. This retraction was prevented locally by focal uncaging of caged Ca2+ that triggered Ca2+ release from internal stores. Thus, local Ca2+ release is a mechanism by which afferent activity can selectively and differentially regulate dendritic structure across the developing arborization.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Wong, ROL (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, 660 S Euclid, St Louis, MO 63110 USA.		Lohmann, Christian/B-8003-2012	Lohmann, Christian/0000-0002-1780-2419				Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Catsicas M, 1998, CURR BIOL, V8, P283, DOI 10.1016/S0960-9822(98)70110-1; Chang KT, 2001, NEURON, V32, P855, DOI 10.1016/S0896-6273(01)00516-5; Cline HT, 2001, CURR OPIN NEUROBIOL, V11, P118, DOI 10.1016/S0959-4388(00)00182-3; EILERS J, 1995, NATURE, V373, P155, DOI 10.1038/373155a0; Gan WB, 2000, NEURON, V27, P219, DOI 10.1016/S0896-6273(00)00031-3; Hering H, 1996, J COMP NEUROL, V375, P393, DOI 10.1002/(SICI)1096-9861(19961118)375:3<393::AID-CNE4>3.0.CO;2-Y; HUGHES WF, 1974, ANAT REC, V179, P297, DOI 10.1002/ar.1091790302; KETTUNEN P, IN PRESS J NEUROSCI; Koizumi S, 1999, NEURON, V22, P125, DOI 10.1016/S0896-6273(00)80684-4; Korkotian E, 1999, P NATL ACAD SCI USA, V96, P12068, DOI 10.1073/pnas.96.21.12068; Li Z, 2000, NAT NEUROSCI, V3, P217, DOI 10.1038/72920; McAllister AK, 2000, CEREB CORTEX, V10, P963, DOI 10.1093/cercor/10.10.963; MILLAR TJ, 1987, NEUROSCIENCE, V21, P725, DOI 10.1016/0306-4522(87)90033-9; Myhr KL, 2001, J NEUROSCI, V21, P8664, DOI 10.1523/JNEUROSCI.21-21-08664.2001; Nishiyama M, 2000, NATURE, V408, P584, DOI 10.1038/35046067; Rose CR, 2001, NEURON, V31, P519, DOI 10.1016/S0896-6273(01)00402-0; Sernagor E, 2000, J NEUROSCI, V20, part. no.; Spitzer NC, 2000, BIOESSAYS, V22, P811; Svoboda K, 1999, NEURON, V22, P427, DOI 10.1016/S0896-6273(00)80698-4; VAUGHN JE, 1989, SYNAPSE, V3, P255, DOI 10.1002/syn.890030312; WONG ROL, 1991, J NEUROBIOL, V22, P685, DOI 10.1002/neu.480220704; Wong WT, 2001, NAT NEUROSCI, V4, P351, DOI 10.1038/85987; Wong WT, 2000, J NEUROSCI, V20, P5024; Wong WT, 2000, CURR OPIN NEUROBIOL, V10, P118, DOI 10.1016/S0959-4388(99)00059-8; Yuste R, 2000, NAT NEUROSCI, V3, P653, DOI 10.1038/76609; Yuste R, 1996, NEURON, V16, P701, DOI 10.1016/S0896-6273(00)80091-4	28	181	182	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 11	2002	418	6894					177	181		10.1038/nature00850	http://dx.doi.org/10.1038/nature00850			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571GV	12110889				2022-12-28	WOS:000176710400039
J	Essner, JJ; Vogan, KJ; Wagner, MK; Tabin, CJ; Yost, HJ; Brueckner, M				Essner, JJ; Vogan, KJ; Wagner, MK; Tabin, CJ; Yost, HJ; Brueckner, M			Conserved function for embryonic nodal cilia	NATURE			English	Article							LEFT-RIGHT ASYMMETRY; MICE; INVERSUS; FLOW		Univ Utah, Ctr Children, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pediat & Cardiol, New Haven, CT 06520 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Harvard University; Harvard Medical School; Yale University	Essner, JJ (corresponding author), Univ Utah, Ctr Children, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.			Vogan, Kyle/0000-0001-9565-9665; Essner, Jeffrey/0000-0001-8816-3848				Capdevila J, 2000, CELL, V101, P9, DOI 10.1016/S0092-8674(00)80619-4; Cooper MS, 1996, DEV BIOL, V180, P184, DOI 10.1006/dbio.1996.0294; Manner J, 2001, ANAT EMBRYOL, V203, P481, DOI 10.1007/s004290100183; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Okada Y, 1999, MOL CELL, V4, P459, DOI 10.1016/S1097-2765(00)80197-5; Olbrich H, 2002, NAT GENET, V30, P143, DOI 10.1038/ng817; Supp DM, 1999, DEVELOPMENT, V126, P5495; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; Wright C V, 2001, Dev Cell, V1, P179, DOI 10.1016/S1534-5807(01)00036-3	9	280	291	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 4	2002	418	6893					37	38		10.1038/418037a	http://dx.doi.org/10.1038/418037a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	569JL	12097899				2022-12-28	WOS:000176599200029
J	Johnson, JR; Manges, AR; O'Bryan, TT; Riley, LW				Johnson, JR; Manges, AR; O'Bryan, TT; Riley, LW			A disseminated multidrug-resistant clonal group of uropathogenic Escherichia coli in pyelonephritis	LANCET			English	Article							URINARY-TRACT INFECTIONS	In acute pyelonephritis, bacterial resistance to cotrimoxazole predicts treatment failure, but the clonal basis of such resistance is undefined. We did molecular and serological analyses of 170 Escherichia coli urine isolates obtained in 1994-96 from women with acute pyelonephritis. 12 (7%) of the pyelonephritis isolates were in clonal group A (CGA; responsible for 38-51% of co-trimoxazole resistance in acute cystitis), including ten (34%) of 29 isolates that were resistant to co-trimoxazole. CGA isolates were obtained from diverse locations across the USA and were related to the 015:K52:H1 clone of the 1986-87 outbreak in London, UK. Thus, CGA is broadly disseminated and contributes to cotrimoxazole resistance in pyelonephritis as well as in cystitis.	Vet Affairs Med Ctr, Med Serv, Minneapolis, MN 55417 USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol & Publ Hlth Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Immun, Berkeley, CA 94720 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Johnson, JR (corresponding author), Vet Affairs Med Ctr, Med Serv, Minneapolis, MN 55417 USA.				NIDDK NIH HHS [DK-47504] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047504] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Gupta K, 2001, ANN INTERN MED, V135, P41, DOI 10.7326/0003-4819-135-1-200107030-00012; JOHNSON JR, 1999, 99 GEN M AM SOC MICR, P31; Manges AR, 2001, NEW ENGL J MED, V345, P1007, DOI 10.1056/NEJMoa011265; ONEILL PM, 1990, J MED MICROBIOL, V33, P23, DOI 10.1099/00222615-33-1-23; Talan DA, 2000, JAMA-J AM MED ASSOC, V283, P1583, DOI 10.1001/jama.283.12.1583	5	89	90	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 29	2002	359	9325					2249	2251		10.1016/S0140-6736(02)09264-4	http://dx.doi.org/10.1016/S0140-6736(02)09264-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567YJ	12103291				2022-12-28	WOS:000176514500013
J	Tuckerman, ME; Marx, D; Parrinello, M				Tuckerman, ME; Marx, D; Parrinello, M			The nature and transport mechanism of hydrated hydroxide ions in aqueous solution	NATURE			English	Article							MOLECULAR-DYNAMICS SIMULATION; LIQUID WATER; PROTON; SOLVATION; MODEL; CLUSTERS; NAOH; H3O+	Compared to other ions, protons (H+) and hydroxide ions (OH-) exhibit anomalously high mobilities in aqueous solutions(1). On a qualitative level, this behaviour has long been explained by 'structural diffusion'-the continuous interconversion between hydration complexes driven by fluctuations in the solvation shell of the hydrated ions. Detailed investigations have led to a clear understanding of the proton transport mechanism at the molecular level(2-8). In contrast, hydroxide ion mobility in basic solutions has received far less attention(2,3,9,10), even though bases and base catalysis play important roles in many organic and biochemical reactions and in the chemical industry. The reason for this may be attributed to the century-old notion(11) that a hydrated OH- can be regarded as a water molecule missing a proton, and that the transport mechanism of such a 'proton hole' can be inferred from that of an excess proton by simply reversing hydrogen bond polarities(11-18). However, recent studies(2,3) have identified OH- hydration complexes that bear little structural similarity to proton hydration complexes. Here we report the solution structures and transport mechanisms of hydrated hydroxide, which we obtained from first-principles computer simulations that explicitly treat quantum and thermal fluctuations of all nuclei(19-21). We find that the transport mechanism, which differs significantly from the proton hole picture, involves an interplay between the previously identified hydration complexes(2,3) and is strongly influenced by nuclear quantum effects.	NYU, Dept Chem, New York, NY 10003 USA; NYU, Courant Inst Math Sci, New York, NY 10003 USA; Ruhr Univ Bochum, Lehrstuhl Theoret Chem, D-44780 Bochum, Germany; Max Planck Inst Festkorperforsch, D-70569 Stuttgart, Germany	New York University; New York University; Ruhr University Bochum; Max Planck Society	Tuckerman, ME (corresponding author), NYU, Dept Chem, 4 Washington Pl, New York, NY 10003 USA.		Lima, Thaísa/AAG-6483-2021					Agmon N, 2000, CHEM PHYS LETT, V319, P247, DOI 10.1016/S0009-2614(00)00136-6; AGMON N, 1995, CHEM PHYS LETT, V244, P456, DOI 10.1016/0009-2614(95)00905-J; Atkins P. W., 1998, PHYS CHEM, P740; BECKE AD, 1990, J CHEM PHYS, V92, P5397, DOI 10.1063/1.458517; Bruni F, 2001, J CHEM PHYS, V114, P8056, DOI 10.1063/1.1362177; Buchner R, 1999, J PHYS CHEM B, V103, P11186, DOI 10.1021/jp992551l; Chaudhuri C, 2001, MOL PHYS, V99, P1161, DOI 10.1080/00268970110046312; Day TJF, 2000, J AM CHEM SOC, V122, P12027, DOI 10.1021/ja002506n; EIGEN M, 1964, ANGEW CHEM INT EDIT, V3, P1, DOI 10.1002/anie.196400011; Geissler PL, 2001, SCIENCE, V291, P2121, DOI 10.1126/science.1056991; Huckel E, 1928, Z ELKTROCHEM ANGEW P, V34, P546; KHOSHTARIYA DE, 1992, CHEM PHYS LETT, V196, P607, DOI 10.1016/0009-2614(92)86002-Y; LIBROVICH NB, 1979, CHEM PHYS, V39, P351, DOI 10.1016/0301-0104(79)80155-X; Liu Y, 2001, J PHYS CHEM B, V105, P6598, DOI 10.1021/jp010008a; Marx D, 1999, NATURE, V397, P601, DOI 10.1038/17579; MARX D, 1994, Z PHYS B CON MAT, V95, P143, DOI 10.1007/BF01312185; Marx D, 2000, J PHYS-CONDENS MAT, V12, pA153, DOI 10.1088/0953-8984/12/8A/317; Marx D., 2000, MODERN METHODS ALGOR, P301; MULLER RP, 1995, J PHYS CHEM-US, V99, P17516, DOI 10.1021/j100049a009; Novoa JJ, 1997, J PHYS CHEM A, V101, P7842, DOI 10.1021/jp970857r; SCHIOBERG D, 1973, J CHEM SOC FARAD T 2, V69, P771, DOI 10.1039/f29736900771; Stillinger F.H., 1978, THEORETICAL CHEM ADV, V3, P177, DOI 10.1016/b978-0-12-681903-8.50011-4; Trout BL, 1999, J PHYS CHEM B, V103, P7340, DOI 10.1021/jp990548w; TRUHLAR DG, 1971, J AM CHEM SOC, V93, P1840; TUCKERMAN M, 1995, J CHEM PHYS, V103, P150, DOI 10.1063/1.469654; TUCKERMAN M, 1995, J PHYS CHEM-US, V99, P5749, DOI 10.1021/j100016a003; Tuckerman ME, 1996, J CHEM PHYS, V104, P5579, DOI 10.1063/1.471771; Tuckerman ME, 1997, SCIENCE, V275, P817, DOI 10.1126/science.275.5301.817; TUNON I, 1995, J PHYS CHEM-US, V99, P3798, DOI 10.1021/j100011a056; Vuilleumier R, 1999, J CHEM PHYS, V111, P4251, DOI 10.1063/1.479723; ZATSEPINA GN, 1971, J STRUCT CHEM, V12, P894	32	742	752	20	303	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 27	2002	417	6892					925	929		10.1038/nature00797	http://dx.doi.org/10.1038/nature00797			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	566RC	12087398				2022-12-28	WOS:000176441200032
J	Sebire, NJ; Foskett, M; Paradinas, FJ; Fisher, RA; Francis, RJ; Short, D; Newlands, ES; Seckl, MJ				Sebire, NJ; Foskett, M; Paradinas, FJ; Fisher, RA; Francis, RJ; Short, D; Newlands, ES; Seckl, MJ			Outcome of twin pregnancies with complete hydatidiform mole and healthy co-twin	LANCET			English	Article								We assessed 77 twin pregnancies, comprising complete hydatidiform mole (CHM) and healthy co-twin, to ascertain the risks to the mother and baby of continuing the pregnancy, versus termination. 24 women with histologically confirmed CHM and healthy co-twin pregnancies decided to have a termination. 53 women continued with their pregnancies, though two had to have terminations because of severe pre-eclampsia, and 23 spontaneously aborted (<24 weeks' gestation). 28 pregnancies lasted 24 weeks or more, resulting in 20 livebirths. Chemotherapy to eliminate persistent gestational trophoblastic disease (pGTD) was required in three of 19 women (16%; 95% CI 3-39) who terminated their pregnancies in the first trimester, and in 12 of 58 (21%; 95% CI 11-33%) who continued their pregnancies. CHM and healthy co-twin pregnancies have a high risk of spontaneous abortion, but about 40% result in livebirths, without significantly increasing the risk of pGTD.	Charing Cross Hosp, Imperial Coll Sch Med, Dept Histopathol, Trophoblast Dis Unit, London W6 8RF, England; Charing Cross Hosp, Imperial Coll Sch Med, Dept Canc Med, London W6 8RF, England	Imperial College London; Imperial College London	Seckl, MJ (corresponding author), Charing Cross Hosp, Imperial Coll Sch Med, Dept Histopathol, Trophoblast Dis Unit, London W6 8RF, England.		sebire, neil J/C-4960-2008	Sebire, Neil/0000-0001-5348-9063; Fisher, Rosemary/0000-0002-2721-8726				GOLDSTEIN DP, 1994, J REPROD MED, V39, P139; Matsui H, 2000, HUM REPROD, V15, P608, DOI 10.1093/humrep/15.3.608; Newlands E.S., 1997, GESTATIONAL TROPHOBL; Paradinas FJ, 1994, CURR DIAGN PATHOL, V1, P24; Seckl MJ, 2000, LANCET, V356, P36, DOI 10.1016/S0140-6736(00)02432-6	5	152	179	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 22	2002	359	9324					2165	2166		10.1016/S0140-6736(02)09085-2	http://dx.doi.org/10.1016/S0140-6736(02)09085-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566RJ	12090984				2022-12-28	WOS:000176441800013
J	Gitlin, L; Karelsky, S; Andino, R				Gitlin, L; Karelsky, S; Andino, R			Short interfering RNA confers intracellular antiviral immunity in human cells	NATURE			English	Article							DOUBLE-STRANDED-RNA; CAENORHABDITIS-ELEGANS; GENETIC INTERFERENCE; MESSENGER-RNA; POLIOVIRUS; PLANTS; COSUPPRESSION; IMMUNIZATION; INHIBITION; EXPRESSION	Gene silencing mediated by double-stranded RNA (dsRNA) is a sequence-specific, highly conserved mechanism in eukaryotes. In plants, it serves as an antiviral defence mechanism(1-3). Animal cells also possess this machinery but its specific function is unclear(4-10). Here we demonstrate that dsRNA can effectively protect human cells against infection by a rapidly replicating and highly cytolytic RNA virus. Pre-treatment of human and mouse cells with double-stranded, short interfering RNAs (siRNAs) to the poliovirus genome markedly reduces the titre of virus progeny and promotes clearance of the virus from most of the infected cells. The antiviral effect is sequence-specific and is not attributable to either classical antisense mechanisms or to interferon and the interferon response effectors protein kinase R (PKR) and RNaseL. Protection is the result of direct targeting of the viral genome by siRNA, as sequence analysis of escape virus (resistant to siRNAs) reveals one nucleotide substitution in the middle of the targeted sequence. Thus, siRNAs elicit specific intracellular antiviral resistance that may provide a therapeutic strategy against human viruses.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Neurosci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Andino, R (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, Box 0414, San Francisco, CA 94143 USA.							Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bahramian MB, 1999, MOL CELL BIOL, V19, P274; BALTIMORE D, 1988, NATURE, V335, P395, DOI 10.1038/335395a0; Bitko V, 2001, BMC Microbiol, V1, P34, DOI 10.1186/1471-2180-1-34; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Crotty S, 1999, J VIROL, V73, P9485, DOI 10.1128/JVI.73.11.9485-9495.1999; DEBENEDETTI A, 1984, NATURE, V311, P79, DOI 10.1038/311079a0; Dernburg AF, 2000, GENE DEV, V14, P1578; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Guidotti LG, 1999, SCIENCE, V284, P825, DOI 10.1126/science.284.5415.825; Herold J, 2000, J VIROL, V74, P6394, DOI 10.1128/JVI.74.14.6394-6400.2000; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Kumar M, 1998, MICROBIOL MOL BIOL R, V62, P1415, DOI 10.1128/MMBR.62.4.1415-1434.1998; LEVINE B, 1991, SCIENCE, V254, P856, DOI 10.1126/science.1658936; LINDBO JA, 1993, PLANT CELL, V5, P1749, DOI 10.1105/tpc.5.12.1749; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; PalBhadra M, 1997, CELL, V90, P479, DOI 10.1016/S0092-8674(00)80508-5; Svoboda P, 2000, DEVELOPMENT, V127, P4147; TOLSKAYA EA, 1995, J VIROL, V69, P1181, DOI 10.1128/JVI.69.2.1181-1189.1995; TORRENCE PF, 1993, P NATL ACAD SCI USA, V90, P1300, DOI 10.1073/pnas.90.4.1300; Vance V, 2001, SCIENCE, V292, P2277, DOI 10.1126/science.1061334; Voinnet O, 1999, P NATL ACAD SCI USA, V96, P14147, DOI 10.1073/pnas.96.24.14147; Wianny F, 2000, NAT CELL BIOL, V2, P70, DOI 10.1038/35000016; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zhou AM, 1999, VIROLOGY, V258, P435, DOI 10.1006/viro.1999.9738	26	466	561	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 25	2002	418	6896					430	434		10.1038/nature00873	http://dx.doi.org/10.1038/nature00873			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	576MU	12087357				2022-12-28	WOS:000177009700041
J	Ahluwalia, JS; Harris, KJ; Catley, D; Okuyemi, KS; Mayo, MS				Ahluwalia, JS; Harris, KJ; Catley, D; Okuyemi, KS; Mayo, MS			Sustained-release bupropion smoking cessation in African Americans - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NICOTINE CHEWING GUM; CIGARETTE-SMOKING; MEDICAL-PRACTICE; NATIONAL-HEALTH; FAGERSTROM TEST; FOLLOW-UP; PATCH; SMOKERS; PLACEBO; PREVALENCE	Context African Americans disproportionately experience greater smoking attributable morbidity and mortality. Few clinical trials for smoking cessation in African Americans have been conducted, despite a different profile of both smoking and quitting patterns. Objective To compare a sustained-release form of bupropion hydrochloride (bupropion SR) with placebo for smoking cessation among African Americans. Design, Setting, and Participants Randomized, double-blind, placebo-controlled trial conducted from February 11, 1999, to December 8, 2000, of 600 African American adults treated at a community-based health care center. Volunteers, who smoked 10 or more cigarettes per day were recruited by targeted media and health care professionals. Intervention Participants were randomly assigned to receive 150 mg of bupropion SR (n=300) or placebo (n=300) twice daily for 7 weeks. Brief motivational counseling was provided in-person at baseline, quit day, weeks I and 3, end of treatment (week 6), and by telephone at day 3 and weeks 5 and 7. Main Outcome Measures Biochemically confirmed 7-day point prevalence abstinence at weeks 6 and 26 following quit day. Results Using intention-to-treat procedures, confirmed abstinence rates at the end of 7 weeks of treatment were 36.0% in the bupropion SR group and 19.0% in the placebo group (17.0 percentage point difference; 95% confidence interval, 9.7-24.4; P<.001). At 26 weeks the quit rates were 21.0% in the treatment and 13.7% in the placebo groups (7.3 percentage point difference; 95% confidence interval, 1.0-13.7; P=.02). Those taking bupropion SR experienced a greater mean reduction in depression symptoms at week 6 (2.96 [9.45] vs 1.13 [8.84]) than those taking placebo, and after controlling for continuous abstinence, those taking bupropion SR also gained less weight than those taking placebo. Conclusions Bupropion SR was effective for smoking cessation among African Americans and may be useful in reducing the health disparities associated with smoking.	Univ Kansas, Sch Med, Dept Prevent Med & Publ Hlth, Kansas City, KS USA; Univ Kansas, Sch Med, Dept Internal Med, Kansas City, KS USA; Univ Kansas, Sch Med, Dept Family Med, Kansas City, KS USA; Univ Kansas, Sch Med, Kansas Canc Inst, Kansas City, KS USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Ahluwalia, JS (corresponding author), Univ Kansas, Sch Med, Dept Prevent Med, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.		Mayo, Matthew S/E-3774-2015		NATIONAL CANCER INSTITUTE [R01CA077856] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA77856] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahluwalia CS, 1998, J GEN INTERN MED, V13, P1, DOI 10.1046/j.1525-1497.1998.00001.x; AHLUWALIA JS, 1993, CLIN RES, V41, pA752; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Caraballo RS, 1998, JAMA-J AM MED ASSOC, V280, P135, DOI 10.1001/jama.280.2.135; Dale LC, 2001, CHEST, V119, P1357, DOI 10.1378/chest.119.5.1357; Etter JF, 1999, ADDICTION, V94, P269, DOI 10.1046/j.1360-0443.1999.94226910.x; FAGERSTROM KO, 1984, PREV MED, V13, P517, DOI 10.1016/0091-7435(84)90020-3; FEE WM, 1982, PRACTITIONER, V226, P148; FIORE MC, 1989, JAMA-J AM MED ASSOC, V261, P49, DOI 10.1001/jama.261.1.49; Giovino Gary A., 1994, Morbidity and Mortality Weekly Report, V43, P1; HAHN LP, 1990, PUBLIC HEALTH REP, V105, P290; Hall S M, 2001, Nicotine Tob Res, V3, P193, DOI 10.1080/14622200110050411; Harris KJ, 2001, J COMMUNITY PSYCHOL, V29, P447, DOI 10.1002/jcop.1028.abs; HARRIS KJ, IN PRESS NICOTINE TO; HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119; HJALMARSON AIM, 1984, JAMA-J AM MED ASSOC, V252, P2835, DOI 10.1001/jama.252.20.2835; HUGHES JR, 1989, JAMA-J AM MED ASSOC, V261, P1300, DOI 10.1001/jama.261.9.1300; HUGHES JR, 1986, ARCH GEN PSYCHIAT, V43, P289; HURT RD, 1994, JAMA-J AM MED ASSOC, V271, P595, DOI 10.1001/jama.271.8.595; Hurt RD, 1997, NEW ENGL J MED, V337, P1195, DOI 10.1056/NEJM199710233371703; Jorenby DE, 1999, NEW ENGL J MED, V340, P685, DOI 10.1056/NEJM199903043400903; KABAT GC, 1991, AM J PUBLIC HEALTH, V81, P1483, DOI 10.2105/AJPH.81.11.1483; KEIL JE, 1993, NEW ENGL J MED, V329, P73, DOI 10.1056/NEJM199307083290201; KORNITZER M, 1995, PREV MED, V24, P41, DOI 10.1006/pmed.1995.1006; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; Lipsitz SR, 2000, BIOMETRICS, V56, P528, DOI 10.1111/j.0006-341X.2000.00528.x; Littell RC, 2000, STAT MED, V19, P1793, DOI 10.1002/1097-0258(20000715)19:13<1793::AID-SIM482>3.3.CO;2-H; Miller W, 2002, MOTIVATIONAL INTERVI, V2nd; OKUYEMI KS, 2002, 8 ANN M SOC RES NIC; Perez-Stable EJ, 1998, JAMA-J AM MED ASSOC, V280, P152, DOI 10.1001/jama.280.2.152; Resnicow K, 1996, AM J HEALTH PROMOT, V10, P343, DOI 10.4278/0890-1171-10.5.343; ROBINSON RG, 1992, PATHWAYS FREEDOM WIN; ROMANO PS, 1991, AM J PUBLIC HEALTH, V81, P1415, DOI 10.2105/AJPH.81.11.1415; ROYCE JM, 1993, AM J PUBLIC HEALTH, V83, P220, DOI 10.2105/AJPH.83.2.220; RUSSELL MAH, 1993, BRIT MED J, V306, P1308, DOI 10.1136/bmj.306.6888.1308; SACHS DPL, 1993, ARCH INTERN MED, V153, P1881, DOI 10.1001/archinte.153.16.1881; SAS Institute Inc, 1999, SAS STAT US GUID VER; Shiffman S, 2000, PSYCHOPHARMACOLOGY, V148, P33, DOI 10.1007/s002130050022; TONNESEN P, 1991, NEW ENGL J MED, V325, P311, DOI 10.1056/NEJM199108013250503; TURNER J, 2000, 6 ANN M SOC RES NIC; US Department of Health and Human Services, 2010, HLTH PEOPL 2010, V2; WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455	42	196	199	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 24	2002	288	4					468	474		10.1001/jama.288.4.468	http://dx.doi.org/10.1001/jama.288.4.468			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575NZ	12132977	Bronze			2022-12-28	WOS:000176955400029
J	Bates, DW				Bates, DW			Unexpected hypoglycemia in a critically ill patient	ANNALS OF INTERNAL MEDICINE			English	Article							ADVERSE DRUG EVENTS; MEDICATION ERRORS; DISPENSING ERROR; ADRENAL CRISIS; COMA; CHLORPROPAMIDE; ANESTHESIA; PREVENTION; SECONDARY; MEDICINE	Administration of the wrong medication is a serious and understudied problem. Because physicians are not directly involved in the drug administration process, they tend to overlook the possibility of adverse drug events and medication errors in their differential diagnoses of patient illnesses or acute deterioration. This article analyzes the case of a patient with iatrogenic hypoglycemia due to administration of the wrong medication: Insulin instead of heparin was used to flush the patient's arterial line. In addition to assessing the results of the institution's "root-cause analysis" of the factors contributing to this particular adverse event and the institution's response, this article reviews the literature on preventing medication errors. Key strategies that might have been helpful in this case include using checklists for common emergency conditions (such as altered level of consciousness) and automated paging for "panic laboratory values," as well as instituting protocols for medication administration. Changing the system of administering medications by bar coding drugs, with checks of the medication, patient, and provider, could have prevented this accident. Finally, organizations need to strive for a "culture of safety" by providing opportunities to discuss errors and adverse events in constructive, supportive environments and by resisting pressure to find a scapegoat.	Brigham & Womens Hosp, Div Gen Internal Med & Primary Care, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Bates, DW (corresponding author), Brigham & Womens Hosp, Div Gen Internal Med & Primary Care, 75 Francis St,PBB-A3, Boston, MA 02115 USA.	dbates@partners.org	Bates, David/AAE-7283-2019					ALLAN EL, 1990, AM J HOSP PHARM, V47, P555, DOI 10.1093/ajhp/47.3.555; [Anonymous], 1999, ERR IS HUMAN BUILDIN; BARKER KN, 1995, AM J HEALTH-SYST PH, V52, P400, DOI 10.1093/ajhp/52.4.400; BATES DW, 1995, J GEN INTERN MED, V10, P199, DOI 10.1007/BF02600255; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; BOUCHARD P, 1982, DIABETES, V31, P40, DOI 10.2337/diabetes.31.1.40; Brient K, 1995, Healthc Inform, V12, P42; BRIENT K, 1995, HEALTHC INFORM, V12, P42; BRIENT K, 1995, HEALTHC INFORM, V12, P40; BROWNING RG, 1990, ANN EMERG MED, V19, P683, DOI 10.1016/S0196-0644(05)82479-5; CATELLIER CR, 1992, CAN MED ASSOC J, V146, P1525; COHEN M, 1999, MED ERRORS; Cohen M R, 1998, J Healthc Risk Manag, V18, P16; Cryer P., 1992, HOSP PRACT OFF ED, V27, P129; Cryer P., 1992, HOSP PRACT OFF ED, V27, P125; CRYER PE, 1992, HOSP PRACT, V27, P119; CULLEN DJ, 1990, ANESTHESIOLOGY, V73, P593; CURRIE M, 1993, ANAESTH INTENS CARE, V21, P596, DOI 10.1177/0310057X9302100517; DAVIES JM, 1994, CAN J ANAESTH, V41, P83, DOI 10.1007/BF03009795; Fischer JE, 2000, INTENS CARE MED, V26, P105, DOI 10.1007/s001340050021; FISCHER KF, 1986, NEW ENGL J MED, V315, P1245, DOI 10.1056/NEJM198611133152002; Flynn EA, 2002, AM J HEALTH-SYST PH, V59, P436, DOI 10.1093/ajhp/59.5.436; GORDON MR, 1988, AM J MED, V85, P271; HEIFETZ S, 1987, NEW ENGL J MED, V316, P223; HILFIKER D, 1984, NEW ENGL J MED, V310, P118, DOI 10.1056/NEJM198401123100211; HOLLIMAN CJ, 1992, ANN EMERG MED, V21, P347, DOI 10.1016/S0196-0644(05)82648-4; HUMINER D, 1989, ARCH INTERN MED, V149, P1890, DOI 10.1001/archinte.149.8.1890; *JOINT COMM ACCR H, 2001, REV JOINT COMM STAND; Kraman SS, 1999, ANN INTERN MED, V131, P963, DOI 10.7326/0003-4819-131-12-199912210-00010; Kuperman GJ, 1999, J AM MED INFORM ASSN, V6, P512, DOI 10.1136/jamia.1999.0060512; Kuperman GJ, 1998, J AM MED INFORM ASSN, V5, P112, DOI 10.1136/jamia.1998.0050112; Laing I, 1998, ANN CLIN BIOCHEM, V35, P545, DOI 10.1177/000456329803500411; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; Lee AJ, 1997, ANN PHARMACOTHER, V31, P727, DOI 10.1177/106002809703100611; LEVINSON W, 1989, JAMA-J AM MED ASSOC, V261, P2252, DOI 10.1001/jama.261.15.2252; Marks V, 1999, ENDOCRIN METAB CLIN, V28, P555, DOI 10.1016/S0889-8529(05)70088-8; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MILLER DR, 1977, NEW ENGL J MED, V297, P339; Perlitz Y, 1999, Obstet Gynecol Surv, V54, P717, DOI 10.1097/00006254-199911000-00023; Randolph AG, 1998, BRIT MED J, V316, P969, DOI 10.1136/bmj.316.7136.969; Reason J., 1991, HUMAN ERROR, DOI 10.1017/cbo9781139062367; Rex J H, 2000, Jt Comm J Qual Improv, V26, P563; ROBINSON I, 1994, J FAM PRACTICE, V38, P78; SELTZER HS, 1989, ENDOCRIN METAB CLIN, V18, P163, DOI 10.1016/S0889-8529(18)30395-5; SERVICE FJ, 1995, NEW ENGL J MED, V332, P1144, DOI 10.1056/NEJM199504273321707; Sexton JB, 2000, BMJ-BRIT MED J, V320, P745, DOI 10.1136/bmj.320.7237.745; Shojania K, 1999, J RHEUMATOL, V26, P195; SHOJANIA K, 2001, AHRQ PUBLICATION; SHUMAK SL, 1991, ARCH INTERN MED, V151, P1877; SLEDGE ED, 1993, SOUTHERN MED J, V86, P1272, DOI 10.1097/00007611-199311000-00020; SOUMERAI SB, 1984, MILBANK FUND Q, V62, P447, DOI 10.2307/3349860; SPADAFORA MP, 1986, AM J EMERG MED, V4, P384, DOI 10.1016/0735-6757(86)90323-2; Studdert DM, 2001, JAMA-J AM MED ASSOC, V286, P217, DOI 10.1001/jama.286.2.217; Tissot E, 1999, INTENS CARE MED, V25, P353, DOI 10.1007/s001340050857; Turnbull J E, 1998, Jt Comm Perspect, V18, P34; VESELY DL, 1982, GERIATRICS, V37, P71; WALD H, 2001, AHRQ PUBLICATION; Wass CT, 1996, MAYO CLIN PROC, V71, P801; WOFE R, 1998, EMERGENCY MED CONCEP; WU AW, 1991, JAMA-J AM MED ASSOC, V265, P2089, DOI 10.1001/jama.265.16.2089; YAMADA KA, 2001, WASHINGTON MANUAL ME; 1998, SWEET REWARD REDUCIN	63	33	34	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 16	2002	137	2					110	116		10.7326/0003-4819-137-2-200207160-00009	http://dx.doi.org/10.7326/0003-4819-137-2-200207160-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575VN	12118966				2022-12-28	WOS:000176969300005
J	Devaraj, A; O'Beirne, JP; Veasey, R; Dunk, AA				Devaraj, A; O'Beirne, JP; Veasey, R; Dunk, AA			Interaction between warfarin and topical miconazole cream	BRITISH MEDICAL JOURNAL			English	Letter									Eastbourne Dist Gen Hosp, Eastbourne BN21 2UD, England		Devaraj, A (corresponding author), Eastbourne Dist Gen Hosp, Eastbourne BN21 2UD, England.		O'Beirne, James/I-8251-2019; o'beirne, james p/C-5701-2009	O'Beirne, James/0000-0003-3400-2816; o'beirne, james p/0000-0001-8590-396X				ARIYARATNAM S, 1997, BRIT MED J, V314, P49; BRUGMANS J, 1972, EUR J CLIN PHARMACOL, V5, P93, DOI 10.1007/BF00561752; OREILLY RA, 1992, CLIN PHARMACOL THER, V51, P656, DOI 10.1038/clpt.1992.78; Silingardi M, 2000, THROMB HAEMOSTASIS, V83, P794; Thirion DJG, 2000, PHARMACOTHERAPY, V20, P98, DOI 10.1592/phco.20.1.98.34665	5	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 13	2002	325	7355					77	77		10.1136/bmj.325.7355.77	http://dx.doi.org/10.1136/bmj.325.7355.77			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575CU	12114237	Bronze, Green Published			2022-12-28	WOS:000176929400019
J	Glatzel, M; Rogivue, C; Ghani, A; Streffer, JR; Amsler, L; Aguzzi, A				Glatzel, M; Rogivue, C; Ghani, A; Streffer, JR; Amsler, L; Aguzzi, A			Incidence of Creutzfeldt-Jakob disease in Switzerland	LANCET			English	Article							PRION	The incidence of Creutzfeldt-Jakob disease (CJD) in Switzerland increased two-fold in 2001, and figures from the first quarter of 2002 indicate that it continues to rise. Neither age at onset nor duration of disease were different from previous years. Genetic analysis of the 27 reported cases revealed only one disease-associated mutation in the prion gene. None of the recognised risk factors for acquired CJD were reported on the offical notification forms. Glycotype profiling, histopathology, and immunohistochemistry indicate that none of the cases fulfilled the definition of variant CJD, which is thought to be caused by bovine prions. Several scenarios could account for the increase in CJD, including improved reporting, iatrogenic transmission, and transmission of a prion zoonosis.	Inst Neuropathol, CH-8091 Zurich, Switzerland; Natl Reference Ctr Prion Dis, CH-8091 Zurich, Switzerland; Fed Off Publ Hlth, Div Epidemiol & Infect Dis, Bern, Switzerland; Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Infect Dis Epidemiol, London, England; Univ Zurich, Div Psychiat Res, Zurich, Switzerland	Imperial College London; University of Zurich	Aguzzi, A (corresponding author), Inst Neuropathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.		Glatzel, Markus/V-8844-2019; Glatzel, Markus/G-3356-2011; Ghani, Azra/B-8560-2009; Aguzzi, Adriano/A-3351-2008	Glatzel, Markus/0000-0002-7720-8817; Glatzel, Markus/0000-0002-7720-8817; Rolf Streffer, Johannes/0000-0002-9387-5951; Ghani, Azra/0000-0002-0007-4910; Aguzzi, Adriano/0000-0002-0344-6708				Aguzzi A, 1997, NATURE, V389, P795, DOI 10.1038/39758; Collins S, 1999, LANCET, V353, P693, DOI 10.1016/S0140-6736(98)08138-0; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Will RG, 2000, ANN NEUROL, V47, P575; Windl O, 1999, HUM GENET, V105, P244, DOI 10.1007/s004390051096	5	71	73	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 13	2002	360	9327					139	141		10.1016/S0140-6736(02)09384-4	http://dx.doi.org/10.1016/S0140-6736(02)09384-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573PB	12126826				2022-12-28	WOS:000176839100015
J	Moya, MP; Gow, AJ; Califf, RM; Goldberg, RN; Stamler, JS				Moya, MP; Gow, AJ; Califf, RM; Goldberg, RN; Stamler, JS			Inhaled ethyl nitrite gas for persistent pulmonary hypertension of the newborn	LANCET			English	Article							OXIDE	Inhaled nitric oxide is used to alleviate pulmonary hypertension and hypoxaemia, but generates toxic free radicals and oxides of nitrogen (NOx), which can cause rebound-hypoxia and additional pulmonary and other morbidity. To address these problems, we assessed the efficacy of inhaled O-nitrosoethanol gas (ENO) as a novel alternative means of providing nitric oxide bioactivity in the treatment of persistent pulmonary hypertension of newborns. We administered ENO over 4 h to seven neonates who required assisted ventilation, and who had an oxygenation index of 25 or more. ENO was then shut off for 15 min before start of treatment with inhaled nitric oxide. Our results show that ENO produced sustained improvements in postductal arterial oxygenation and systemic haemodynamics, which were maintained during the off-drug observation period. Increases in methaemoglobinaemia were modest and toxic NOx, were not detected. Thus, ENO can improve oxygenation and systemic haemodynamics in neonates, and seems to reduce rebound hypoxaemia and production of toxic byproducts.	Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pediat, Neonatal Perinatal Res Inst, Durham, NC 27710 USA; Duke Clin Res Inst, Durham, NC USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Duke University; Duke University	Stamler, JS (corresponding author), Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA.		Gow, Andrew/AAR-2309-2020; Gow, Andrew/N-8566-2013	Gow, Andrew/0000-0003-0876-5158; Gow, Andrew/0000-0003-0876-5158; Stamler, Jonathan/0000-0002-6866-1572				GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Lundin S, 1999, INTENS CARE MED, V25, P911, DOI 10.1007/s001340050982; Moya MP, 2001, P NATL ACAD SCI USA, V98, P5792, DOI 10.1073/pnas.091109498; Ponka A, 1996, AM J PUBLIC HEALTH, V86, P1273, DOI 10.2105/AJPH.86.9.1273; Wedgwood S, 2001, CIRC RES, V89, P357, DOI 10.1161/hh1601.094983	5	91	96	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 13	2002	360	9327					141	143		10.1016/S0140-6736(02)09385-6	http://dx.doi.org/10.1016/S0140-6736(02)09385-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573PB	12126827				2022-12-28	WOS:000176839100016
J	Wilson, P; McConnachie, A; Stirling, M				Wilson, P; McConnachie, A; Stirling, M			Evolving general practice consultation in Britain - Increasing consultation time may not be straightforward	BRITISH MEDICAL JOURNAL			English	Letter									Univ Glasgow, Dept Gen Practice, Glasgow G12 0RR, Lanark, Scotland; Broxburn Hlth Ctr, Ferguson Med Practice, Broxburn EH52 1JZ, England	University of Glasgow	Wilson, P (corresponding author), Univ Glasgow, Dept Gen Practice, Glasgow G12 0RR, Lanark, Scotland.		Wilson, Philip/V-6519-2019	Wilson, Philip/0000-0002-4123-8248				Freeman GK, 2002, BRIT MED J, V324, P880, DOI 10.1136/bmj.324.7342.880; Stirling AM, 2001, BRIT J GEN PRACT, V51, P456	2	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 13	2002	325	7355					104	105		10.1136/bmj.325.7355.104	http://dx.doi.org/10.1136/bmj.325.7355.104			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575CU	12114250	Green Published			2022-12-28	WOS:000176929400044
J	Moore, H; Dvorakova, K; Jenkins, N; Breed, W				Moore, H; Dvorakova, K; Jenkins, N; Breed, W			Exceptional sperm cooperation in the wood mouse	NATURE			English	Article							EXPRESSION; MICE; CELLS	Spermatozoa from a single male will compete for fertilization of ova with spermatozoa from another male when present in the female reproductive tract at the same time(1). Close genetic relatedness predisposes individuals towards altruism, and as haploid germ cells of an ejaculate will have genotypic similarity of 50%, it is predicted that spermatozoa may display cooperation and altruism to gain an advantage when intermale sperm competition is intense(2). We report here the probable altruistic behaviour of spermatozoa in an eutherian mammal. Spermatozoa of the common wood mouse, Apodemus sylvaticus, displayed a unique morphological transformation resulting in cooperation in distinctive aggregations or 'trains' of hundreds or thousands of cells, which significantly increased sperm progressive motility. Eventual dispersal of sperm trains was associated with most of the spermatozoa undergoing a premature acrosome reaction. Cells undergoing an acrosome reaction in aggregations remote from the egg are altruistic in that they help sperm transport to the egg but compromise their own fertilizing ability.	Univ Sheffield, Sect Reprod & Dev Med, Sheffield S10 2UH, S Yorkshire, England; Charles Univ, Dept Dev Biol, CR-12844 Prague, Czech Republic; Univ Adelaide, Dept Anat Sci, Adelaide, SA 5005, Australia	University of Sheffield; Charles University Prague; University of Adelaide	Moore, H (corresponding author), Univ Sheffield, Sect Reprod & Dev Med, Sheffield S10 2UH, S Yorkshire, England.		Komrsková, Kateřina/P-7920-2019; Dvorakova-Hortova, Katerina/A-8705-2010	Komrsková, Kateřina/0000-0002-6837-2148; Dvorakova-Hortova, Katerina/0000-0002-6837-2148; Breed, William/0000-0003-1739-6593				Baker R.R., 1995, HUMAN SPERM COMPETIT; BAKER RR, 1988, ANIM BEHAV, V36, P936, DOI 10.1016/S0003-3472(88)80178-7; Bedford J. M., 1979, The spermatozoon. Maturation, motility, surface properties and comparative aspects. Proceedings of the Third International Symposium on the Spermatozoon, held at the American Academy of Arts and Sciences, Boston, and the Swope Conference Center, Marine Biological Laboratories, Woods Hole, Massachusetts, May 2-5, 1978., P7; BIRKHEAD TR, 1996, SPERM COMPETITION SE; BIRKHEAD TR, 1999, P R SOC LOND B, V266, P1; Breed WG, 2000, J MAMMAL, V81, P758, DOI 10.1644/1545-1542(2000)081&lt;0758:BMTMAS&gt;2.3.CO;2; Dawkins Richard, 1976, SELFISH GENE; De Kretser D. M., 1994, P1177; FRASER LR, 1975, BIOL REPROD, V13, P513, DOI 10.1095/biolreprod13.5.513; Friend GF, 1936, Q J MICROSC SCI, V78, P419; Haig D, 1996, P NATL ACAD SCI USA, V93, P6547, DOI 10.1073/pnas.93.13.6547; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; HANAK V, 1979, MAMMALS; HARCOURT AH, 1981, NATURE, V293, P55, DOI 10.1038/293055a0; Hayashi F, 1996, J INSECT PHYSIOL, V42, P859, DOI 10.1016/0022-1910(96)00037-6; Holt C, 1997, J ANDROL, V18, P312; KIM E, 1989, MOL CELL BIOL, V9, P1875, DOI 10.1128/MCB.9.5.1875; Kleene KC, 2001, MECH DEVELOP, V106, P3, DOI 10.1016/S0925-4773(01)00413-0; MOORE HD, 1999, P R SOC LOND B, V266, P2243; Moore HDM, 1996, J ANDROL, V17, P50; Moore HDM, 1996, REPROD FERT DEVELOP, V8, P605, DOI 10.1071/RD9960605; MOORE HDM, 1985, EXP CLIN IMMUNOGENET, V2, P84; SHEPHERD BA, 1979, ARCH ANDROLOGY, V2, P53, DOI 10.3109/01485017908987292; SIVINSKI J, 1984, SPERM COMPETITION EV, P223; TEW TE, 1994, BEHAV ECOL SOCIOBIOL, V34, P337, DOI 10.1007/BF01209780; Trivers R. L., 1985, SOCIAL EVOLUTION; Wassarman PM, 2001, NAT CELL BIOL, V3, pE59, DOI 10.1038/35055178; Xu X, 1999, NAT GENET, V23, P118, DOI 10.1038/12729; Yanagimachi R., 1994, P189	29	183	187	3	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 11	2002	418	6894					174	177		10.1038/nature00832	http://dx.doi.org/10.1038/nature00832			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571GV	12110888	Green Accepted			2022-12-28	WOS:000176710400038
J	Oldfield, WLG; Larche, M; Kay, AB				Oldfield, WLG; Larche, M; Kay, AB			Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial	LANCET			English	Article							GRASS-POLLEN IMMUNOTHERAPY; LATE ASTHMATIC REACTIONS; GROWTH-FACTOR-BETA; FEL-D-1 PEPTIDES; MAST-CELLS; ACTIVATION; INHIBITION; DECREASES; RESPONSES; EFFICACY	Background Some patients with asthma who are allergic to cats and are injected intradermally with short, overlapping, T-cell peptides derived from Fel d 1 develop late asthmatic reactions to the peptides, which are associated with a reduction in late-phase skin reactions induced by whole allergens and bronchial hyporesponsiveness to the peptides on the second injection. We aimed to ascertain the effect of multiple injections on the magnitude of the early and late phase skin reactions to intact allergens. Methods After a 9-week run-in period, we randomly assigned patients with asthma and allergies to cats to receive either Fel d 1 peptides (90 mug in increasing divided doses) or placebo. The primary outcome was late-phase cutaneous reactions to whole cat dander. Outcomes were measured at baseline, 4-8 weeks, and 3-9 months. Analysis was by intention to treat. Findings 16 patients were randomly assigned to the peptides, and eight to placebo. All patients completed the course of injections. Four of the 16 patients on Fel d 1 peptides had initial late asthmatic reactions, but could be desensitised to the higher dose of peptide. Patients in the peptide group but not the placebo group had a significant reduction in the size of their late reaction to whole cat dander between baseline and both follow-ups, but the difference between groups was not significant (first follow-up, difference -422.8 mm(2) [95% Cl -1115.0 to 269.4], p=0.43; second follow-up -1180.8 mm(2) [-2216.8 to -144-8], p=0.058). The size of the late reaction to Fel d 1 significantly differed between treatment groups at both follow-ups. At second follow-up, the size of the early reaction to Fel D 1, but not to whole cat dander was significantly reduced in those on peptides compared with those on placebo. The concentration of interferon gamma and of interleukin 4 and 13, and the amount of proliferation, significantly decreased between baseline and second follow-up, and the concentration of interleukin 10 was significantly higher in patients on peptides, however, none of these values differed significantly between groups. Patients on peptides had a significantly greater decrease in the concentration of interferon gamma and interleukin 13, and in the amount of proliferation between baseline and first follow-up than did those on placebo. Interpretation Several, short, overlapping Fel d I T-cell peptides have potential in treatment of cat allergy.	Natl Heart & Lung Inst, Imperial Coll, Fac Med, Dept Allergy & Clin Immunol, London SW3 6LY, England	Imperial College London	Kay, AB (corresponding author), Natl Heart & Lung Inst, Imperial Coll, Fac Med, Dept Allergy & Clin Immunol, Dovehouse St, London SW3 6LY, England.	a.b.kay@ic.ac.uk	Larche, Mark/B-4326-2010	Larche, Mark/0000-0002-1439-7593				Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Alexander C, 2001, J ALLERGY CLIN IMMUN, V107, pS217; Bridoux F, 1997, J EXP MED, V185, P1769, DOI 10.1084/jem.185.10.1769; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; Durham SR, 1999, CLIN EXP ALLERGY, V29, P1490; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; KABELITZ D, 1993, IMMUNOL TODAY, V14, P338, DOI 10.1016/0167-5699(93)90231-9; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; Maguire P, 1999, CLIN IMMUNOL, V93, P222, DOI 10.1006/clim.1999.4795; MUELLER DL, 1990, J IMMUNOL, V144, P3701; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; Oldfield WLG, 2001, J IMMUNOL, V167, P1734, DOI 10.4049/jimmunol.167.3.1734; Pene J, 1998, J ALLERGY CLIN IMMUN, V102, P571, DOI 10.1016/S0091-6749(98)70294-5; Powrie F, 1996, J EXP MED, V183, P2669, DOI 10.1084/jem.183.6.2669; Royer B, 2001, CLIN EXP ALLERGY, V31, P694, DOI 10.1046/j.1365-2222.2001.01069.x; Simons FER, 1996, INT IMMUNOL, V8, P1937, DOI 10.1093/intimm/8.12.1937; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633	21	282	313	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 6	2002	360	9326					47	53		10.1016/S0140-6736(02)09332-7	http://dx.doi.org/10.1016/S0140-6736(02)09332-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569JR	12114041				2022-12-28	WOS:000176599700011
J	Wang, J; Hamilton, JI; Carter, MS; Li, S; Wilkinson, MF				Wang, J; Hamilton, JI; Carter, MS; Li, S; Wilkinson, MF			Alternatively spliced TCR mRNA induced by disruption of reading frame	SCIENCE			English	Article							PREMATURE TERMINATION CODON; MESSENGER-RNA LEVELS; NONSENSE CODONS; REGULATORY MECHANISM; PROTEIN-SYNTHESIS; DEPENDENT MANNER; SITE SELECTION; IN-VITRO; TRANSLATION; MUTATIONS	Nonsense codons that prematurely terminate translation generate potentially deleterious truncated proteins. Here, we show that the T cell receptor-beta (TCRbeta) gene, which acquires in-frame nonsense codons at high frequency during normal lymphocyte development, gives rise to an alternatively spliced transcript [ alternative messenger RNA (alt-mRNA)] that skips the offending mutations that generate such nonsense codons. This alt-mRNA is up-regulated by a transfer RNA dependent scanning mechanism that responds specifically to mutations that disrupt the reading frame. The finding that translation signals regulate the levels of alternatively spliced mRNAs generated in the nucleus may alter the current view of how gene expression is controlled in eukaryotic cells.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Wilkinson, MF (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Box 180,1515 Holcombe Blvd, Houston, TX 77030 USA.		Li, Shulin/D-6478-2011					Aoufouchi S, 1996, CELL, V85, P415, DOI 10.1016/S0092-8674(00)81119-8; BEEMON K, COMMUNICATION; BELGRADER P, 1993, P NATL ACAD SCI USA, V90, P482, DOI 10.1073/pnas.90.2.482; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Carter MS, 1996, EMBO J, V15, P5965, DOI 10.1002/j.1460-2075.1996.tb00983.x; CARTER MS, 1995, J BIOL CHEM, V270, P28995, DOI 10.1074/jbc.270.48.28995; CHELLY J, 1990, CELL, V63, P1239, DOI 10.1016/0092-8674(90)90419-F; CHOU HS, 1987, P NATL ACAD SCI USA, V84, P1992, DOI 10.1073/pnas.84.7.1992; Clement JQ, 2001, J BIOL CHEM, V276, P16919, DOI 10.1074/jbc.M005104200; Cooper TA, 1997, AM J HUM GENET, V61, P259, DOI 10.1086/514856; DIETZ HC, 1994, NAT GENET, V8, P183, DOI 10.1038/ng1094-183; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; Dostie J, 2000, EMBO J, V19, P3142, DOI 10.1093/emboj/19.12.3142; Gersappe A, 1999, MOL CELL BIOL, V19, P1640; Gersappe A, 1999, J BIOL CHEM, V274, P22452, DOI 10.1074/jbc.274.32.22452; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Iborra FJ, 2001, SCIENCE, V293, P1139, DOI 10.1126/science.1061216; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; Li BH, 2002, P NATL ACAD SCI USA, V99, P5277, DOI 10.1073/pnas.082095299; Li SL, 1997, J EXP MED, V185, P985, DOI 10.1084/jem.185.6.985; Li SL, 1998, IMMUNITY, V8, P135, DOI 10.1016/S1074-7613(00)80466-5; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; LOZANO F, 1994, EMBO J, V13, P4617, DOI 10.1002/j.1460-2075.1994.tb06783.x; Maquat LE, 1996, AM J HUM GENET, V59, P279; Mendell JT, 2001, CELL, V107, P411, DOI 10.1016/S0092-8674(01)00583-9; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; Muhlemann O, 2001, MOL CELL, V8, P33, DOI 10.1016/S1097-2765(01)00288-X; QIAN L, 1993, J IMMUNOL, V151, P6801; Valentine CR, 1998, MUTAT RES-REV MUTAT, V411, P87, DOI 10.1016/S1383-5742(98)00010-6; Wang J, 2000, BIOTECHNIQUES, V29, P976, DOI 10.2144/00295bm09; Wang J, 2002, J BIOL CHEM, V277, P18489, DOI 10.1074/jbc.M111781200; WANG JC, UNPUB; Wilkinson MF, 2001, BIOESSAYS, V23, P775, DOI 10.1002/bies.1113; Wilkinson MF, 2002, NAT CELL BIOL, V4, pE144, DOI 10.1038/ncb0602-e144	34	61	64	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 5	2002	297	5578					108	110		10.1126/science.1069757	http://dx.doi.org/10.1126/science.1069757			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571HB	12098701				2022-12-28	WOS:000176711000045
J	Starr, DJ; Cline, TW				Starr, DJ; Cline, TW			A host-parasite interaction rescues Drosophila oogenesis defects	NATURE			English	Article							SEX-LETHAL GENE; WOLBACHIA INFECTION; GERM-CELLS; MELANOGASTER; EXPRESSION; INCOMPATIBILITY; LOCUS; SXL	The cytoplasmically inherited bacterium Wolbachia pipientis is a widespread parasite of arthropods that manipulates the reproductive biology of its hosts, often to their detriment, in order to foster its own transmission through egg cytoplasm(1,2). Here we report that infection by Wolbachia restores fertility to Drosophila melanogaster mutant females prevented from making eggs by protein-coding lesions in Sex-lethal (Sxl), the master regulator of sex determination. Suppression of sterility by Wolbachia discriminates markedly among similar germline-specific Sxl alleles, and is not observed for mutations in other genes that produce similar 'tumorous ovary' phenotypes, including one that blocks Sxl germline expression. This allele and gene specificity indicates that suppression probably results from a specific interaction with Sxl protein, rather than from a bypass of the normal germline requirement for this developmental regulator or from an effect on Sxl expression. The Sxl-Wolbachia interaction provides a rare opportunity to explore host-parasite relationships at the molecular level in a model insect. Furthermore, demonstration that a parasite infection can counteract the deleterious effects of mutations in host genes illustrates how hosts might become dependent on parasites.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Cline, TW (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 401 Barker Hall, Berkeley, CA 94720 USA.							BOPP D, 1993, DEVELOPMENT, V118, P797; Bopp D, 1999, DEVELOPMENT, V126, P5785; Bordenstein SR, 2001, NATURE, V409, P707, DOI 10.1038/35055543; Bouchon D, 1998, P ROY SOC B-BIOL SCI, V265, P1081, DOI 10.1098/rspb.1998.0402; Bourtzis K, 1996, GENETICS, V144, P1063; BOYLE L, 1993, SCIENCE, V260, P1796, DOI 10.1126/science.8511587; CLINE TW, 1988, GENETICS, V119, P829; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; CLINE TW, 1979, DEV BIOL, V72, P266, DOI 10.1016/0012-1606(79)90117-9; COOK KR, 1993, THESIS U IOWA; Dedeine F, 2001, P NATL ACAD SCI USA, V98, P6247, DOI 10.1073/pnas.101304298; DINES J, 1998, ANN DROS RES C PROGR, V39, pA245; DINES JL, 2001, THESIS U CALIFORNIA; Hager JH, 1997, DEVELOPMENT, V124, P5033; Huigens ME, 2000, NATURE, V405, P178, DOI 10.1038/35012066; Hurst GDD, 2000, GENETICS, V156, P699; Knight J, 2001, NATURE, V412, P12, DOI 10.1038/35083744; Min KT, 1997, P NATL ACAD SCI USA, V94, P10792, DOI 10.1073/pnas.94.20.10792; OLIVER B, 1988, GENETICS, V120, P159; ONEILL SL, 1992, P NATL ACAD SCI USA, V89, P2699, DOI 10.1073/pnas.89.7.2699; Page SL, 2000, GENETICS, V155, P1757; PAULI D, 1993, DEVELOPMENT, V119, P123; PERRIMON N, 1986, GENETICS, V113, P695; SALZ HK, 1989, GENE DEV, V3, P708, DOI 10.1101/gad.3.5.708; SALZ HK, 1987, GENETICS, V117, P221; SCHUPBACH T, 1985, GENETICS, V109, P529; STEINMANNZWICKY M, 1988, EMBO J, V7, P3889, DOI 10.1002/j.1460-2075.1988.tb03275.x; Werren JH, 1997, ANNU REV ENTOMOL, V42, P587, DOI 10.1146/annurev.ento.42.1.587; Werren JH, 1997, INFLUENTIAL PASSENGERS, P1	29	92	102	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 4	2002	418	6893					76	79		10.1038/nature00843	http://dx.doi.org/10.1038/nature00843			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	569JL	12097909				2022-12-28	WOS:000176599200041
J	Hess, C; Klimkait, T; Schlapbach, L; Del Zenero, V; Sadallah, S; Horakova, E; Balestra, G; Werder, V; Schaefer, C; Battegay, M; Schifferli, JA				Hess, C; Klimkait, T; Schlapbach, L; Del Zenero, V; Sadallah, S; Horakova, E; Balestra, G; Werder, V; Schaefer, C; Battegay, M; Schifferli, JA			Association of a pool of HIV-1 with erythrocytes in vivo: a cohort study	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; COMPLEMENT RECEPTOR-TYPE-1 CR-1; ACTIVE ANTIRETROVIRAL THERAPY; T-CELLS; IMMUNE-COMPLEXES; INFECTION; CD35; PERSISTENCE; EXPRESSION; ANTIBODIES	Background Treatment of HIV-1-infected individuals with antiretrovirals can result in sustained suppression of plasma viral RNA at concentrations below the detection limit of available assays. However, continuing virus replication has been detected in patients with viral RNA in plasma suppressed for months to years, and many cell types are known to act as reservoirs or carriers for the virus. In vitro, erythrocytes bind HIV-1 immune complexes, so we tested for a circulating pool of HIV-1 associated with erythrocytes in people with HIV-1 infection. Methods We investigated 82 chronically HIV-1-infected individuals. Plasma, white cells, and erythrocytes were tested for HIV-1 RNA by RT-PCR. Findings Erythrocyte-associated HIV-1 RNA was detected in 80 of 82 individuals. In 23, plasma HIV-1 RNA had been undetectable (<20 copies/mL) for up to 32 months; in corresponding erythrocyte samples, there were up to 82 878 HIV-1 RNA copies per mL whole blood. HIV-1 associated with erythrocytes in vivo was shown to be infectious. Within the subgroup of patients with undetectable plasma viral load, higher numbers of HIV-1 associated with erythrocytes were correlated with a history of advanced clinical stages of HIV-1 infection (p=0.014). Interpretation A pool of HIV-1 is associated with erythrocytes even after long-term suppression of viral RNA in plasma. This finding is direct evidence for continuing virus replication or release in these individuals. Quantification of this viral pool may help to judge suppression of HIV-1 replication in individuals with undetectable plasma HIV-1 RNA.	Univ Basel Hosp, Dept Res, Immunonephrol Lab, CH-4031 Basel, Switzerland; Univ Basel Hosp, Outpatient Dept Internal Med, Basel Ctr HIV Res, CH-4031 Basel, Switzerland; Univ Basel, Inst Med Microbiol, Basel Ctr HIV Res, Basel, Switzerland; Inst Dr Viollier, Dept Mol Diagnost, Basel, Switzerland	University of Basel; University of Basel; University of Basel	Hess, C (corresponding author), Hebelstr 20, CH-4051 Basel, Switzerland.		Klimkait, Thomas/A-1057-2008; Schlapbach, Luregn J/F-7465-2017; Schlapbach, Luregn/D-8402-2014	Schlapbach, Luregn J/0000-0003-2281-2598; Potlukova, Eliska/0000-0003-4790-8860; Klimkait, Thomas/0000-0003-4945-6511				[Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; Burton GF, 1997, IMMUNOL REV, V156, P185, DOI 10.1111/j.1600-065X.1997.tb00968.x; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1999, P NATL ACAD SCI USA, V96, P10958, DOI 10.1073/pnas.96.20.10958; Davey RT, 1999, P NATL ACAD SCI USA, V96, P15109, DOI 10.1073/pnas.96.26.15109; DAVIES KA, 1990, J IMMUNOL, V144, P4613; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Haase AT, 1999, ANNU REV IMMUNOL, V17, P625, DOI 10.1146/annurev.immunol.17.1.625; JOUVIN MH, 1987, AIDS, V1, P89; Kacani L, 2000, J VIROL, V74, P7997, DOI 10.1128/JVI.74.17.7997-8002.2000; Klickstein LB, 1997, IMMUNITY, V7, P345, DOI 10.1016/S1074-7613(00)80356-8; Klimkait T, 1998, ARCH VIROL, V143, P2109, DOI 10.1007/s007050050447; Lach-Trifilieff E, 1999, J IMMUNOL, V162, P7549; MADI N, 1991, J IMMUNOL, V147, P495; Moir S, 2000, J EXP MED, V192, P637, DOI 10.1084/jem.192.5.637; MONTEFIORI DC, 1994, J INFECT DIS, V170, P429, DOI 10.1093/infdis/170.2.429; Morandi PA, 1998, J CLIN MICROBIOL, V36, P1534, DOI 10.1128/JCM.36.6.1534-1538.1998; Moulds JM, 1998, EXP CLIN IMMUNOGENET, V15, P291, DOI 10.1159/000019084; PASCUAL M, 1993, J IMMUNOL, V151, P397; Ramratnam B, 2000, NAT MED, V6, P82, DOI 10.1038/71577; SCHIFFERLI JA, 1986, NEW ENGL J MED, V315, P488; SCHIFFERLI JA, 1988, J IMMUNOL, V140, P899; Sharkey ME, 2000, NAT MED, V6, P76, DOI 10.1038/71569; TAUSK FA, 1986, J CLIN INVEST, V78, P977, DOI 10.1172/JCI112688; Winston JA, 2001, NEW ENGL J MED, V344, P1979, DOI 10.1056/NEJM200106283442604; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101; Zhou JT, 1996, VIROLOGY, V226, P13, DOI 10.1006/viro.1996.0623	30	64	67	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 29	2002	359	9325					2230	2234		10.1016/S0140-6736(02)09291-7	http://dx.doi.org/10.1016/S0140-6736(02)09291-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567YJ	12103286				2022-12-28	WOS:000176514500008
J	Lacy, AM; Garcia-Valdecasas, JC; Delgado, S; Castells, A; Taura, P; Pique, JM; Visa, J				Lacy, AM; Garcia-Valdecasas, JC; Delgado, S; Castells, A; Taura, P; Pique, JM; Visa, J			Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial	LANCET			English	Article							VS. OPEN COLECTOMY; COLORECTAL-CANCER; SURGERY; RECURRENCE; CARCINOMA; SURVIVAL; IMMUNOSUPPRESSION; RESECTION; HELPER	Background Although early reports on laparoscopy-assisted colectomy (LAC) in patients with colon cancer suggested that it reduces perioperative morbidity, its influence on long-term results is unknown. Our study aimed to compare efficacy of LAC and open colectomy (OC) for treatment of non-metastatic colon cancer in terms of turnout recurrence and survival. Methods From November, 1993, to July, 1998, all patients with adenocarcinoma of the colon were assessed for entry in this randomised trial. Adjuvant therapy and postoperative follow-up were the same in both groups. The main endpoint was cancer-related survival. Data were analysed according to the intention-to-treat principle. Findings 219 patients took part in the study (111 LAC group, 108 OC group). Patients in the LAC group recovered faster than those in the OC group, with shorter peristalsis-detection (p=0.001) and oral-intake times (p=0.001), and shorter hospital stays (p=0.005). Morbidity was lower in the LAC group (p=0.001), although LAC did not influence perioperative mortality. Probability of cancer-related survival was higher in the LAC group (p=0.02). The Cox model showed that LAC was independently associated with reduced risk of tumour relapse (hazard ratio 0.39, 95% Cl 0.19-0.82), death from any cause (0.48, 0.23-1.01), and death from a cancer-related cause (0.38, 0.16-0.91) compared with OC. This superiority of LAC was due to differences in patients with stage III tumours (p=0.04, p=0.02, and p=0.006, respectively). Interpretation LAC is more effective than OC for treatment of colon cancer in terms of morbidity. hospital stay, tumour recurrence, and cancer-related survival.	Univ Barcelona, IDIBAPS, Hosp Clin, Inst Malalties Digest,Dept Surg, E-08036 Barcelona, Spain; Univ Barcelona, IDIBAPS, Hosp Clin, Inst Malalties Digest,Dept Gastroenterol, E-08036 Barcelona, Spain; Univ Barcelona, IDIBAPS, Hosp Clin, Inst Malalties Digest,Dept Anaesthesia, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Lacy, AM (corresponding author), Univ Barcelona, IDIBAPS, Hosp Clin, Inst Malalties Digest,Dept Surg, E-08036 Barcelona, Spain.		Castells, Antoni/ABC-1002-2021	Castells, Antoni/0000-0001-8431-2033				BEAHRS OH, 1993, MANUAL STAGING CANC; BERENDS FJ, 1994, LANCET, V344, P58, DOI 10.1016/S0140-6736(94)91079-0; Bessa X, 2001, J GASTROINTEST SURG, V5, P66, DOI 10.1016/S1091-255X(01)80015-9; Boland CR, 2000, GASTROENTEROLOGY, V118, pS115, DOI 10.1016/S0016-5085(00)70010-2; Bouvy ND, 1997, BRIT J SURG, V84, P358; COLE WH, 1985, J SURG ONCOL, V30, P139; COX DR, 1972, J R STAT SOC B, V34, P187; Da Costa ML, 1998, BRIT J SURG, V85, P1439; Decker D, 1996, SURGERY, V119, P316, DOI 10.1016/S0039-6060(96)80118-8; Delgado S, 2001, DIS COLON RECTUM, V44, P638, DOI 10.1007/BF02234558; FLESHMAN JW, 1996, DIS COLON RECTUM S, V39, P53; Franklin ME, 2000, SURG ENDOSC-ULTRAS, V14, P612, DOI 10.1007/s004640000169; HANSBROUGH JF, 1984, AM J SURG, V148, P303, DOI 10.1016/0002-9610(84)90459-8; Hartley JE, 2000, ANN SURG, V232, P181, DOI 10.1097/00000658-200008000-00005; HUGHES ESR, 1983, DIS COLON RECTUM, V26, P571, DOI 10.1007/BF02552962; Jacobs M, 1991, Surg Laparosc Endosc, V1, P144; Johnson A, 1997, LANCET, V349, P631, DOI 10.1016/S0140-6736(96)10032-5; LACY AM, 1995, SURG ENDOSC-ULTRAS, V9, P1101; Lacy AM, 1998, SURG ENDOSC-ULTRAS, V12, P1039, DOI 10.1007/s004649900776; Lacy AM, 1997, SURG ENDOSC, V11, P119, DOI 10.1007/s004649900311; Leung KL, 1999, DIS COLON RECTUM, V42, P327, DOI 10.1007/BF02236347; Milsom JW, 1998, J AM COLL SURGEONS, V187, P46, DOI 10.1016/S1072-7515(98)00132-X; NEWLAND RC, 1981, CANCER, V47, P1424, DOI 10.1002/1097-0142(19810315)47:6<1424::AID-CNCR2820470630>3.0.CO;2-O; Pearlstone DB, 1999, SURGERY, V125, P67, DOI 10.1016/S0039-6060(99)70290-4; Poulin EC, 1999, ANN SURG, V229, P487, DOI 10.1097/00000658-199904000-00006; Reilly WT, 1996, DIS COLON RECTUM, V39, P200; Schiedeck THK, 2000, DIS COLON RECTUM, V43, P1, DOI 10.1007/BF02237235; Stocchi L, 2000, DIS COLON RECTUM, V43, P326, DOI 10.1007/BF02258297; Vittimberga FJ, 1998, ANN SURG, V227, P326, DOI 10.1097/00000658-199803000-00003; VUKASIN P, 1996, DIS COLON RECTUM, V39, P20	30	1835	1967	0	43	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 29	2002	359	9325					2224	2229		10.1016/S0140-6736(02)09290-5	http://dx.doi.org/10.1016/S0140-6736(02)09290-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567YJ	12103285				2022-12-28	WOS:000176514500007
J	Fukata, M; Watanabe, T; Noritake, J; Nakagawa, M; Yamaga, M; Kuroda, S; Matsuura, Y; Iwamatsu, A; Perez, F; Kaibuchi, K				Fukata, M; Watanabe, T; Noritake, J; Nakagawa, M; Yamaga, M; Kuroda, S; Matsuura, Y; Iwamatsu, A; Perez, F; Kaibuchi, K			Rac1 and Cdc42 capture microtubules through IQGAP1 and CLIP-170	CELL			English	Article							RHO-FAMILY GTPASES; CELL-CELL ADHESION; BINDING PROTEIN; ACTIN CYTOSKELETON; PLASMA-MEMBRANE; DISTAL ENDS; C-ELEGANS; DYNAMICS; POLARITY; TARGET	Linkage of microtubules to special cortical regions is essential for cell polarization. CLIP-170 binds to the growing ends of microtubules and plays pivotal roles in orientation. We have found that IQGAP1, an effector of Rac1 and Cdc42, interacts with CLIP-170. In Vero fibroblasts, IQGAP1 localizes at the polarized leading edge. Expression of carboxy-terminal fragment of 1Q-GAP1, which includes the CLIP-170 binding region, delocalizes GFP-CLIP-170 from the tips of microtubules and alters the microtubule array. Activated Rac1/Cdc42, IQGAP1, and CLIP-170 form a tripartite complex. Furthermore, expression of an IQGAP1 mutant defective in Rac1/Cdc42 binding induces multiple leading edges. These results indicate that Rac1/Cdc42 marks special cortical spots where the IQGAP1 and CLIP-170 complex is targeted, leading to a polarized microtubule array and cell polarization.	Nagoya Univ, Grad Sch Med, Dept Cell Pharmacol, Showa Ku, Aichi 4668550, Japan; Nara Inst Sci & Technol, Div Signal Transduct, Nara 6300101, Japan; Osaka Univ, Res Ctr Emerging Infect Dis, Suita, Osaka 5650871, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanagawa 2360004, Japan; Inst Curie, CNRS, UMR 144, Paris 05, France	Nagoya University; Nara Institute of Science & Technology; Osaka University; Kirin Brewery Company Limited; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Kaibuchi, K (corresponding author), Nagoya Univ, Grad Sch Med, Dept Cell Pharmacol, Showa Ku, 65 Tsurumai, Aichi 4668550, Japan.		Fukata, Masaki/AAZ-2476-2021; Perez, Franck/A-1558-2014	Fukata, Masaki/0000-0001-5200-9806; Perez, Franck/0000-0002-9129-9401; Watanabe, Takashi/0000-0002-9015-5246				Akhmanova A, 2001, CELL, V104, P923, DOI 10.1016/S0092-8674(01)00288-4; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; Brunner D, 2000, CELL, V102, P695, DOI 10.1016/S0092-8674(00)00091-X; Cook TA, 1998, J CELL BIOL, V141, P175, DOI 10.1083/jcb.141.1.175; Daub H, 2001, J BIOL CHEM, V276, P1677, DOI 10.1074/jbc.C000635200; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Fukata M, 2001, MOL CELL BIOL, V21, P2165, DOI 10.1128/MCB.21.6.2165-2183.2001; Fukata M, 1997, J BIOL CHEM, V272, P29579, DOI 10.1074/jbc.272.47.29579; Goode BL, 2000, CURR OPIN CELL BIOL, V12, P63, DOI 10.1016/S0955-0674(99)00058-7; Gotta M, 2001, CURR BIOL, V11, P482, DOI 10.1016/S0960-9822(01)00142-7; Gradin HM, 1997, MOL CELL BIOL, V17, P3459, DOI 10.1128/MCB.17.6.3459; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Ishizaki T, 2001, NAT CELL BIOL, V3, P8; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Kay AJ, 2001, CURR BIOL, V11, P474, DOI 10.1016/S0960-9822(01)00141-5; Kobayashi K, 1998, J BIOL CHEM, V273, P291, DOI 10.1074/jbc.273.1.291; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Mimori-Kiyosue Y, 2000, CURR BIOL, V10, P865, DOI 10.1016/S0960-9822(00)00600-X; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Palazzo AF, 2001, CURR BIOL, V11, P1536, DOI 10.1016/S0960-9822(01)00475-4; Perez F, 1999, CELL, V96, P517, DOI 10.1016/S0092-8674(00)80656-X; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; RICKARD JE, 1990, J CELL BIOL, V110, P1623, DOI 10.1083/jcb.110.5.1623; Rusan NM, 2001, MOL BIOL CELL, V12, P971, DOI 10.1091/mbc.12.4.971; SCHULZE E, 1987, J CELL BIOL, V105, P2167, DOI 10.1083/jcb.105.5.2167; SHISHIDO Y, 1995, J BIOL CHEM, V270, P29578, DOI 10.1074/jbc.270.49.29578; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; SU LK, 1995, CANCER RES, V55, P2972; TIMAUER JS, 2000, J CELL BIOL, V149, P761; VAN AL, 1997, GENE DEV, V11, P2295; Vaughan KT, 1999, J CELL SCI, V112, P1437; WEBSTER DR, 1987, P NATL ACAD SCI USA, V84, P9040, DOI 10.1073/pnas.84.24.9040; Wittmann T, 2001, J CELL SCI, V114, P3795	46	468	480	0	20	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 28	2002	109	7					873	885		10.1016/S0092-8674(02)00800-0	http://dx.doi.org/10.1016/S0092-8674(02)00800-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	570KJ	12110184	Bronze			2022-12-28	WOS:000176657200010
J	Jacque, JM; Triques, K; Stevenson, M				Jacque, JM; Triques, K; Stevenson, M			Modulation of HIV-1 replication by RNA interference	NATURE			English	Article							DOUBLE-STRANDED-RNA; HUMAN-IMMUNODEFICIENCY-VIRUS; GENE-EXPRESSION; DROSOPHILA; CELLS; COMPETENT; TISSUE	RNA interference (RNAi) is the process by which double-stranded RNA (dsRNA) directs sequence-specific degradation of messenger RNA in animal and plant cells(1,2). In mammalian cells, RNAi can be triggered by 21-nucleotide duplexes of small interfering RNA (siRNA)(3). Here we describe inhibition of early and late steps of HIV-1 replication in human cell lines and primary lymphocytes by siRNAs targeted to various regions of the HIV-1 genome. We demonstrate that synthetic siRNA duplexes or plasmid-derived siRNAs inhibit HIV-1 infection by specifically degrading genomic HIV-1 RNA, thereby preventing formation of viral complementary-DNA intermediates. These results demonstrate the utility of RNAi for modulating the HIV replication cycle and provide evidence that genomic HIV-1 RNA, as it exists within a nucleoprotein reverse-transcription complex, is amenable to siRNA-mediated degradation.	Univ Massachusetts, Sch Med, Dept Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Stevenson, M (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Med, 373 Plantat St, Worcester, MA 01605 USA.	mario.stevenson@umassmed.edu	Jacque, Jean-Marc/B-6875-2008		NIAID NIH HHS [R01 AI032890, R33 AI088595, R01 AI037475] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Billy E, 2001, P NATL ACAD SCI USA, V98, P14428, DOI 10.1073/pnas.261562698; Bitko V, 2001, BMC Microbiol, V1, P34, DOI 10.1186/1471-2180-1-34; Bitko V, 2001, J CELL BIOCHEM, V80, P441, DOI 10.1002/1097-4644(20010301)80:3<441::AID-JCB170>3.0.CO;2-C; Brichacek B, 1997, METHODS, V12, P294, DOI 10.1006/meth.1997.0482; Caplen NJ, 2000, GENE, V252, P95, DOI 10.1016/S0378-1119(00)00224-9; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Dornburg R, 2000, Adv Pharmacol, V49, P229; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hutvagner G, 2002, CURR OPIN GENET DEV, V12, P225, DOI 10.1016/S0959-437X(02)00290-3; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; LI YX, 1991, J VIROL, V65, P3973, DOI 10.1128/JVI.65.8.3973-3985.1991; Moore JP, 2000, NAT REV MOL CELL BIO, V1, P40, DOI 10.1038/35036060; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Sharkey ME, 2000, NAT MED, V6, P76, DOI 10.1038/71569; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Tabara H, 1999, DEVELOPMENT, V126, P1; Ui-Tei K, 2000, FEBS LETT, V479, P79, DOI 10.1016/S0014-5793(00)01883-4; Wang MB, 2000, PLANT MOL BIOL, V43, P67, DOI 10.1023/A:1006490331303; Welker R, 1998, J VIROL, V72, P8833, DOI 10.1128/JVI.72.11.8833-8840.1998; Wesley SV, 2001, PLANT J, V27, P581, DOI 10.1046/j.1365-313X.2001.01105.x; Yang SC, 2001, MOL CELL BIOL, V21, P7807, DOI 10.1128/MCB.21.22.7807-7816.2001; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	28	680	883	0	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 25	2002	418	6896					435	438		10.1038/nature00896	http://dx.doi.org/10.1038/nature00896			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	576MU	12087358	Green Accepted			2022-12-28	WOS:000177009700042
J	Braun-Falco, M; Abeck, D				Braun-Falco, M; Abeck, D			Acute infantile haemorrhagic oedema	LANCET			English	Editorial Material									Tech Univ Munich, Dept Dermatol, D-80802 Munich, Germany	Technical University of Munich	Braun-Falco, M (corresponding author), Tech Univ Munich, Dept Dermatol, D-80802 Munich, Germany.								0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 20	2002	360	9328					210	210		10.1016/S0140-6736(02)09457-6	http://dx.doi.org/10.1016/S0140-6736(02)09457-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	576DX	12133655	Bronze			2022-12-28	WOS:000176988500010
J	Doherty, L; Fenton, KA; Jones, J; Paine, TC; Higgins, SP; Williams, D; Palfreeman, A				Doherty, L; Fenton, KA; Jones, J; Paine, TC; Higgins, SP; Williams, D; Palfreeman, A			Syphilis: old problem, new strategy	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TRANSMISSION		Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, HIV STI Div, London NW9 5EQ, England; N Manchester Grp Hosp, Dept Genitourinary Med, Manchester M8 5RB, Lancs, England; Royal Sussex Cty Hosp, Dept Genitourinary Med, Claude Nicol Clin, Brighton BN2 5BE, E Sussex, England; Peterborough Dist Gen Hosp, Dept Genitourinary Med, Peterborough PE3 6DA, England	Public Health England; University of Brighton	Doherty, L (corresponding author), Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, HIV STI Div, London NW9 5EQ, England.	Lorraine.Doherty@dhsspsni.gov.uk						[Anonymous], 2000, Commun Dis Rep CDR Wkly, V10, P89; *CDCP NAT CTR HIV, 1999, NAT PLAN EL SYPH US; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P773; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P117; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P1070; *CLIN EFF GROUP, 2002, NAT GUID MAN EARL SY; *COMM DIS SURV CTR, 2000, COMMUN DIS REP CDR W, V10, P386; *COMM DIS SURV CTR, 2000, COMMUN DIS REP CDR W, V10, P177; *COMM DIS SURV CTR, 2000, COMMUN DIS REP CDR W, V10, P370; *COMM DIS SURV CTR, 2000, COMMUN DIS REP CDR W, V10, P401; *COMM DIS SURV CTR, 2000, COMMUN DIS REP CDR W, V10, P180; *COMM DIS SURV CTR, 2000, COMMUN DIS REP CDR W, V10, P367; *COMM DIS SURV CTR, 1998, COMMUN DIS REP CDR W, V8, P413; *COMM DIS SURV CTR, 1998, COMMUN DIS REP CDR W, V8, P416; *COMM DIS SURV CTR, 2000, COMMUN DIS REP CDR W, V10, P383; Dodds JP, 2000, BRIT MED J, V320, P1510, DOI 10.1136/bmj.320.7248.1510; DOHERTY I, 2000, EUROSURVEILLANCE WEE; Edwards S, 1998, SEX TRANSM INFECT, V74, P95, DOI 10.1136/sti.74.2.95; Egglestone S I, 2000, Commun Dis Public Health, V3, P158; Fleming DT, 1999, SEX TRANSM INFECT, V75, P3, DOI 10.1136/sti.75.1.3; Garnett GP, 1997, SEX TRANSM DIS, V24, P185, DOI 10.1097/00007435-199704000-00002; Higgins SP, 2000, LANCET, V355, P1466, DOI 10.1016/S0140-6736(05)74666-3; JOHNSON AM, 1996, SEX TRANSM INFECT, V72, P107; Klausner JD, 2000, JAMA-J AM MED ASSOC, V284, P447, DOI 10.1001/jama.284.4.447; Kohl KS, 1999, SEX TRANSM DIS, V26, P201, DOI 10.1097/00007435-199904000-00003; Page-Shafer KA, 1999, JAMA-J AM MED ASSOC, V281, P696; *PHLS DHSS PS SCOT, 2001, SEX TRANSM INF UK NE; *PUBL HLTH LAB SER, 2002, EP STIS UK; Rubins A, 2000, SEX TRANSM INFECT, V76, P214, DOI 10.1136/sti.76.3.214; Wasserheit JN, 1996, J INFECT DIS, V174, pS201, DOI 10.1093/infdis/174.Supplement_2.S201; *WORK GROUP UK CHI, 2000, REV EV RISK HIV TRAN	31	88	91	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 20	2002	325	7356					153	156		10.1136/bmj.325.7356.153	http://dx.doi.org/10.1136/bmj.325.7356.153			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	577PG	12130615	Green Published			2022-12-28	WOS:000177069900028
J	Unnasch, TR				Unnasch, TR			River blindness	LANCET			English	Editorial Material							ONCHOCERCA-VOLVULUS; IVERMECTIN TREATMENT		Univ Alabama, Div Geog Med, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Unnasch, TR (corresponding author), Univ Alabama, Div Geog Med, Birmingham, AL 35294 USA.							CUPP EW, 1992, AM J TROP MED HYG, V47, P170, DOI 10.4269/ajtmh.1992.47.170; GREENE BM, 1992, J INFECT DIS, V166, P15, DOI 10.1093/infdis/166.1.15; Hoerauf A, 2001, LANCET, V357, P1415, DOI 10.1016/S0140-6736(00)04581-5; NEWLAND HS, 1988, BRIT J OPHTHALMOL, V72, P561, DOI 10.1136/bjo.72.8.561; Richards FO, 2001, TRENDS PARASITOL, V17, P558, DOI 10.1016/S1471-4922(01)02112-2	5	4	5	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 20	2002	360	9328					182	183		10.1016/S0140-6736(02)09498-9	http://dx.doi.org/10.1016/S0140-6736(02)09498-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	576DX	12133647				2022-12-28	WOS:000176988500002
J	Hardy, J; Selkoe, DJ				Hardy, J; Selkoe, DJ			Medicine - The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics	SCIENCE			English	Review							BETA-PROTEIN-PRECURSOR; HEREDITARY CEREBRAL-HEMORRHAGE; TRANSGENIC MOUSE MODEL; CENTRAL-NERVOUS-SYSTEM; SPASTIC PARAPARESIS; IN-VIVO; FRONTOTEMPORAL DEMENTIA; PRESENILIN-1 MUTATIONS; PLAQUE-FORMATION; GENETIC-LINKAGE		Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; NIA, Neurogenet Lab, Bethesda, MD 20892 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Selkoe, DJ (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA.	selkoe@cnd.bwh.harvard.edu	Hardy, John/C-2451-2009	Hardy, John/0000-0002-3122-0423	NATIONAL INSTITUTE ON AGING [ZIAAG000950, Z01AG000950] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bertram L, 2000, SCIENCE, V290, P2302, DOI 10.1126/science.290.5500.2302; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crook R, 1998, NAT MED, V4, P452, DOI 10.1038/nm0498-452; Davies P, 2000, ANN NY ACAD SCI, V924, P8, DOI 10.1111/j.1749-6632.2000.tb05553.x; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Ertekin-Taner N, 2000, SCIENCE, V290, P2303, DOI 10.1126/science.290.5500.2303; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HARDY J, 1992, NAT GENET, V1, P233, DOI 10.1038/ng0792-233; Hardy J, 1998, NAT NEUROSCI, V1, P355, DOI 10.1038/1565; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; Houlden H, 2000, ANN NEUROL, V48, P806, DOI 10.1002/1531-8249(200011)48:5<806::AID-ANA18>3.0.CO;2-F; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Irizarry MC, 1997, J NEUROPATH EXP NEUR, V56, P965, DOI 10.1097/00005072-199709000-00002; Irizarry MC, 1997, J NEUROSCI, V17, P7053; Jantzen PT, 2002, J NEUROSCI, V22, P2246, DOI 10.1523/JNEUROSCI.22-06-02246.2002; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kwok JBJ, 1997, NEUROREPORT, V8, P1537, DOI 10.1097/00001756-199704140-00043; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lemere CA, 1996, NEUROBIOL DIS, V3, P16, DOI 10.1006/nbdi.1996.0003; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; Lim GP, 2001, NEUROBIOL AGING, V22, P983, DOI 10.1016/S0197-4580(01)00299-8; MANN DMA, 1986, NEUROPATH APPL NEURO, V12, P447, DOI 10.1111/j.1365-2990.1986.tb00053.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Mehta ND, 1998, ANN NEUROL, V43, P256, DOI 10.1002/ana.410430217; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Myers A, 2000, SCIENCE, V290, P2304, DOI 10.1126/science.290.5500.2304; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Neve RL, 1998, TRENDS NEUROSCI, V21, P15, DOI 10.1016/S0166-2236(97)01168-5; Olson JM, 2001, AM J HUM GENET, V69, P895, DOI 10.1086/323472; OLSON MI, 1969, BRAIN, V92, P147, DOI 10.1093/brain/92.1.147; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Price JL, 1999, ANN NEUROL, V45, P358, DOI 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X; Rapoport M, 2002, P NATL ACAD SCI USA, V99, P6364, DOI 10.1073/pnas.092136199; Refolo LM, 2001, NEUROBIOL DIS, V8, P890, DOI 10.1006/nbdi.2001.0422; Refolo LM, 2000, NEUROBIOL DIS, V7, P321, DOI 10.1006/nbdi.2000.0304; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; Rogers J, 1996, NEUROBIOL AGING, V17, P681, DOI 10.1016/0197-4580(96)00115-7; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; Sambamurti K, 2002, NEUROMOL MED, V1, P1, DOI 10.1385/NMM:1:1:1; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Smith MJ, 2001, ANN NEUROL, V49, P125, DOI 10.1002/1531-8249(200101)49:1<125::AID-ANA21>3.0.CO;2-1; Sparks DL, 2000, ANN NY ACAD SCI, V903, P335, DOI 10.1111/j.1749-6632.2000.tb06384.x; Spillantini MG, 1998, BRAIN PATHOL, V8, P387; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; VAN BROECKHOVEN C, 1994, NEUROSCI LETT, V169, P179, DOI 10.1016/0304-3940(94)90385-9; VAN BROECKHOVEN C, 1990, SCIENCE, V248, P1120, DOI 10.1126/science.1971458; Verkkoniemi A, 2001, J NEUROPATH EXP NEUR, V60, P483, DOI 10.1093/jnen/60.5.483; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wavrant-DeVrieze F, 1999, HUM GENET, V104, P432, DOI 10.1007/s004390050980; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; WISNIEWSKI T, 1991, BIOCHEM BIOPH RES CO, V179, P1247, DOI 10.1016/0006-291X(91)91706-I; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439	91	10292	10902	87	3674	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 19	2002	297	5580					353	356		10.1126/science.1072994	http://dx.doi.org/10.1126/science.1072994			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574LV	12130773				2022-12-28	WOS:000176892600038
J	Petersen-Mahrt, SK; Harris, RS; Neuberger, MS				Petersen-Mahrt, SK; Harris, RS; Neuberger, MS			AID mutates E-coli suggesting a DNA deamination mechanism for antibody diversification	NATURE			English	Article							CLASS-SWITCH RECOMBINATION; SOMATIC HYPERMUTATION; ESCHERICHIA-COLI; ENDONUCLEASE-V; MUTAGENESIS; DEFICIENCY; CONVERSION; SEQUENCES; MUTATIONS; REGION	After gene rearrangement, immunoglobulin variable genes are diversified by somatic hypermutation or gene conversion, whereas the constant region is altered by class-switch recombination. All three processes depend on activation-induced cytidine deaminase (AID)(1-7), a B-cell-specific protein that has been proposed (because of sequence homology 1) to function by RNA editing. But indications that the three gene diversification processes might be initiated by a common type of DNA lesion(8-11), together with the proposal that there is a first phase of hypermutation that targets dC/dG(12), suggested to us that AID may function directly at dC/dG pairs. Here we show that expression of AID in Escherichia coli gives a mutator phenotype that yields nucleotide transitions at dC/dG in a context-dependent manner. Mutation triggered by AID is enhanced by a deficiency of uracil-DNA glycosylase, which indicates that AID functions by deaminating dC residues in DNA. We propose that diversification of functional immunoglobulin genes is triggered by AID-mediated deamination of dC residues in the immunoglobulin locus with the outcome-that is, hypermutation phases 1 and 2, gene conversion or switch recombination-dependent on the way in which the initiating dU/dG lesion is resolved.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Neuberger, MS (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.							Arakawa H, 2002, SCIENCE, V295, P1301, DOI 10.1126/science.1067308; BETZ AG, 1994, CELL, V77, P239, DOI 10.1016/0092-8674(94)90316-6; Chen XC, 2001, P NATL ACAD SCI USA, V98, P13860, DOI 10.1073/pnas.241524898; Ehrenstein MR, 1999, EMBO J, V18, P3484, DOI 10.1093/emboj/18.12.3484; Harris RS, 2002, CURR BIOL, V12, P435, DOI 10.1016/S0960-9822(02)00717-0; He B, 2000, MUTAT RES-DNA REPAIR, V459, P109, DOI 10.1016/S0921-8777(99)00063-4; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Jin DJ, 1996, METHOD ENZYMOL, V273, P300; Lindahl T, 2000, MUTAT RES-REV MUTAT, V462, P129, DOI 10.1016/S1383-5742(00)00024-7; MAIZELS N, 1995, CELL, V83, P9, DOI 10.1016/0092-8674(95)90227-9; Manis JP, 2002, TRENDS IMMUNOL, V23, P31, DOI 10.1016/S1471-4906(01)02111-1; Martin A, 2002, NATURE, V415, P802, DOI 10.1038/nature714; Miller J.H., 1972, EXPT MOL GENETICS; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Navaratnam N, 1998, J MOL BIOL, V275, P695, DOI 10.1006/jmbi.1997.1506; Okazaki IM, 2002, NATURE, V416, P340, DOI 10.1038/nature727; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Rada C, 1998, IMMUNITY, V9, P135, DOI 10.1016/S1074-7613(00)80595-6; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Rogozin IB, 2001, NAT IMMUNOL, V2, P530, DOI 10.1038/88732; Sale JE, 1998, IMMUNITY, V9, P859, DOI 10.1016/S1074-7613(00)80651-2; Sale JE, 2001, NATURE, V412, P921, DOI 10.1038/35091100; Schouten KA, 1999, MUTAT RES-DNA REPAIR, V435, P245, DOI 10.1016/S0921-8777(99)00049-X; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; SHEN JC, 1992, CELL, V71, P1073, DOI 10.1016/S0092-8674(05)80057-1; Weill JC, 1996, IMMUNOL TODAY, V17, P92, DOI 10.1016/0167-5699(96)80586-X; Wiesendanger M, 2000, J EXP MED, V191, P579, DOI 10.1084/jem.191.3.579; Zeng XM, 2001, NAT IMMUNOL, V2, P537, DOI 10.1038/88740	29	701	717	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 4	2002	418	6893					99	103		10.1038/nature00862	http://dx.doi.org/10.1038/nature00862			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	569JL	12097915				2022-12-28	WOS:000176599200047
J	Cathebras, P				Cathebras, P			Cure	LANCET			English	Editorial Material									Hop Nord St Etienne, F-42055 St Etienne 2, France	CHU de St Etienne	Cathebras, P (corresponding author), Hop Nord St Etienne, F-42055 St Etienne 2, France.								0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 29	2002	359	9325					2273	2273		10.1016/S0140-6736(02)09300-5	http://dx.doi.org/10.1016/S0140-6736(02)09300-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567YJ	12103307				2022-12-28	WOS:000176514500029
J	Thomas, WE; Trintchina, E; Forero, M; Vogel, V; Sokurenko, EV				Thomas, WE; Trintchina, E; Forero, M; Vogel, V; Sokurenko, EV			Bacterial adhesion to target cells enhanced by shear force	CELL			English	Article							STAPHYLOCOCCUS-AUREUS ADHESION; RECEPTOR-LIGAND BONDS; COLI TYPE-1 FIMBRIAE; ESCHERICHIA-COLI; MOLECULAR-DYNAMICS; FIMH ADHESIN; PROTEINS; GENES; SPECTROSCOPY; KINETICS	Surface adhesion of bacteria generally occurs in the presence of shear stress, and the lifetime of receptor bonds is expected to be shortened in the presence of external force. However, by using Escherichia coli expressing the lectin-like adhesin FimH and guinea pig erythrocytes in flow chamber experiments, we show that bacterial attachment to target cells switches from loose to firm upon a 10-fold increase in shear stress applied. Steered molecular dynamics simulations of tertiary structure of the FimH receptor binding domain and subsequent site-directed mutagenesis studies indicate that shear-enhancement of the FimH-receptor interactions involves extention of the interdomain linker chain under mechanical force. The ability of FimH to function as a force sensor provides a molecular mechanism for discrimination between surface-exposed and soluble receptor molecules.	Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; Univ Washington, Dept Phys, Seattle, WA 98195 USA; Univ Washington, Ctr Nanotechnol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Sokurenko, EV (corresponding author), Univ Washington, Dept Microbiol, Seattle, WA 98195 USA.	evs@u.washington.edu	MLSC, Colletion/B-3912-2013; Vogel, Viola/O-8025-2015	Vogel, Viola/0000-0003-2898-7671; Thomas, Wendy/0000-0001-8602-0819; Forero-Shelton, Manu/0000-0002-7989-0311	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG002360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045820] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK053369] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049063] Funding Source: NIH RePORTER; NHGRI NIH HHS [1 P50 HG02360-01] Funding Source: Medline; NIAID NIH HHS [R01 AI45820] Funding Source: Medline; NIDDK NIH HHS [P01 DK53369] Funding Source: Medline; NIGMS NIH HHS [5R01 GM49063] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM SN, 1987, J BACTERIOL, V169, P5530, DOI 10.1128/jb.169.12.5530-5536.1987; Alon R, 1997, J CELL BIOL, V138, P1169, DOI 10.1083/jcb.138.5.1169; BEACHEY EH, 1981, J INFECT DIS, V143, P325, DOI 10.1093/infdis/143.3.325; BECK R, 1994, NUCLEIC ACIDS RES, V22, P886, DOI 10.1093/nar/22.5.886; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; BLOCH CA, 1992, MOL MICROBIOL, V6, P697, DOI 10.1111/j.1365-2958.1992.tb01518.x; BRINTON CC, 1965, T NEW YORK ACAD SCI, V27, P1003, DOI 10.1111/j.2164-0947.1965.tb02342.x; BROOKS DE, 1983, J GEN MICROBIOL, V129, P3661; BROOKS DE, 1983, ANN NY ACAD SCI, V416, P319, DOI 10.1111/j.1749-6632.1983.tb35196.x; BROOKS DE, 1989, INFECT IMMUN, V57, P377, DOI 10.1128/IAI.57.2.377-383.1989; Celikel R, 2000, NAT STRUCT BIOL, V7, P881; Chen SQ, 2001, P NATL ACAD SCI USA, V98, P950, DOI 10.1073/pnas.98.3.950; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; CHRISTERSSON CE, 1988, SCAND J DENT RES, V96, P91; Dickinson RB, 1997, J BIOMED MATER RES, V36, P152, DOI 10.1002/(SICI)1097-4636(199708)36:2<152::AID-JBM3>3.0.CO;2-J; DICKINSON RB, 1995, INFECT IMMUN, V63, P3143, DOI 10.1128/IAI.63.8.3143-3150.1995; Evans EB, 1999, BIOPHYS CHEM, V82, P83, DOI 10.1016/S0301-4622(99)00108-8; GIBBONS RJ, 1984, J DENT RES, V63, P378, DOI 10.1177/00220345840630030401; HANSON MS, 1988, J BACTERIOL, V170, P3350, DOI 10.1128/jb.170.8.3350-3358.1988; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Isralewitz B, 2001, CURR OPIN STRUC BIOL, V11, P224, DOI 10.1016/S0959-440X(00)00194-9; Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201; KLEMM P, 1987, MOL GEN GENET, V208, P439, DOI 10.1007/BF00328136; Krammer A, 2002, MATRIX BIOL, V21, P139, DOI 10.1016/S0945-053X(01)00197-4; Li ZJ, 2000, BIOTECHNOL PROGR, V16, P1086, DOI 10.1021/bp000117r; Marchese P, 1999, P NATL ACAD SCI USA, V96, P7837, DOI 10.1073/pnas.96.14.7837; Mohamed N, 2000, BIOTECHNOL BIOENG, V68, P628, DOI 10.1002/(SICI)1097-0290(20000620)68:6<628::AID-BIT5>3.0.CO;2-D; Pratt LA, 1998, MOL MICROBIOL, V30, P285, DOI 10.1046/j.1365-2958.1998.01061.x; PRATTTERPSTRA IH, 1987, J GEN MICROBIOL, V133, P3199; Schembri MA, 2000, INFECT IMMUN, V68, P2638, DOI 10.1128/IAI.68.5.2638-2646.2000; Shive MS, 1999, J BIOMED MATER RES, V46, P511, DOI 10.1002/(SICI)1097-4636(19990915)46:4<511::AID-JBM9>3.0.CO;2-M; Sokurenko EV, 1997, J BIOL CHEM, V272, P17880, DOI 10.1074/jbc.272.28.17880; SOKURENKO EV, 1995, J BACTERIOL, V177, P3680, DOI 10.1128/jb.177.13.3680-3686.1995; Sokurenko EV, 1998, P NATL ACAD SCI USA, V95, P8922, DOI 10.1073/pnas.95.15.8922; Sokurenko EV, 2001, MOL MICROBIOL, V41, P675, DOI 10.1046/j.1365-2958.2001.02545.x; SOWDHAMINI R, 1989, PROTEIN ENG, V3, P95, DOI 10.1093/protein/3.2.95; Vogel V, 2001, TRENDS BIOTECHNOL, V19, P416, DOI 10.1016/S0167-7799(01)01737-1; WANG IW, 1995, J BIOMED MATER RES, V29, P485, DOI 10.1002/jbm.820290408; Wang K, 2001, PROG BIOPHYS MOL BIO, V77, P1, DOI 10.1016/S0079-6107(01)00009-8	40	432	444	1	108	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	2002	109	7					913	923		10.1016/S0092-8674(02)00796-1	http://dx.doi.org/10.1016/S0092-8674(02)00796-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	570KJ	12110187	Bronze			2022-12-28	WOS:000176657200013
J	Weston, CR; Lambright, DG; Davis, RJ				Weston, CR; Lambright, DG; Davis, RJ			Signal transduction: MAP kinase signaling specificity	SCIENCE			English	Editorial Material							ANTHRAX LETHAL FACTOR		Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Weston, CR (corresponding author), Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA.							Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Enslen H, 2001, BIOL CELL, V93, P5, DOI 10.1016/S0248-4900(01)01156-X; Pannifer AD, 2001, NATURE, V414, P229, DOI 10.1038/n35101998; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740	10	105	117	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 28	2002	296	5577					2345	2347		10.1126/science.1073344	http://dx.doi.org/10.1126/science.1073344			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	567CE	12089430				2022-12-28	WOS:000176467200026
J	Smith, GCS; Stenhouse, EJ; Crossley, JA; Aitken, DA; Cameron, AD; Connor, JM				Smith, GCS; Stenhouse, EJ; Crossley, JA; Aitken, DA; Cameron, AD; Connor, JM			Development - Early-pregnancy origins of low birth weight	NATURE			English	Article							PLASMA PROTEIN-A; FIRST-TRIMESTER; BETA-HCG; PAPP-A; GROWTH; IGF		Univ Cambridge, Rosie Hosp, Dept Obstet & Gynaecol, Cambridge CB2 2QQ, England; Queen Mothers Hosp, Dept Fetal Med, Glasgow G3 8SJ, Lanark, Scotland; Yorkhill NHS Trust, Inst Med Genet, Glasgow G3 8SJ, Lanark, Scotland	University of Cambridge; University of Glasgow	Smith, GCS (corresponding author), Univ Cambridge, Rosie Hosp, Dept Obstet & Gynaecol, Robinson Way, Cambridge CB2 2QQ, England.	gcss2@cam.ac.uk	Smith, Gordon/A-8070-2008	Smith, Gordon/0000-0003-2124-0997				Hosmer D. W., 1999, APPL SURVIVAL ANAL; Laursen LS, 2001, FEBS LETT, V504, P36, DOI 10.1016/S0014-5793(01)02760-0; Lawrence JB, 1999, P NATL ACAD SCI USA, V96, P3149, DOI 10.1073/pnas.96.6.3149; Neveux LM, 1996, PRENATAL DIAG, V16, P1115, DOI 10.1002/(SICI)1097-0223(199612)16:12<1115::AID-PD3>3.0.CO;2-6; Overgaard MT, 1999, BIOL REPROD, V61, P1083, DOI 10.1095/biolreprod61.4.1083; OZTURK M, 1987, ENDOCRINOLOGY, V120, P549, DOI 10.1210/endo-120-2-549; Rutanen EM, 2000, CURR OPIN OBSTET GYN, V12, P163, DOI 10.1097/00001703-200006000-00001; Smith GCS, 1998, NEW ENGL J MED, V339, P1817, DOI 10.1056/NEJM199812173392504; Smith GCS, 2001, HUM REPROD, V16, P1497, DOI 10.1093/humrep/16.7.1497; Spencer K, 1999, PRENATAL DIAG, V19, P1065, DOI 10.1002/(SICI)1097-0223(199911)19:11<1065::AID-PD695>3.0.CO;2-R	10	94	96	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 27	2002	417	6892					916	916		10.1038/417916a	http://dx.doi.org/10.1038/417916a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	566RC	12087395	Bronze			2022-12-28	WOS:000176441200029
J	Corbett, EL; Steketee, RW; ter Kuile, FO; Latif, AS; Kamali, A; Hayes, RJ				Corbett, EL; Steketee, RW; ter Kuile, FO; Latif, AS; Kamali, A; Hayes, RJ			HIV-1/AIDS and the control of other infectious diseases in Africa	LANCET			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; SEXUALLY-TRANSMITTED-DISEASES; HIV-ASSOCIATED TUBERCULOSIS; PLASMODIUM-FALCIPARUM; MYCOBACTERIUM-TUBERCULOSIS; PLACENTAL MALARIA; RISK-FACTORS; GOLD MINERS; TRIMETHOPRIM-SULFAMETHOXAZOLE; MOLECULAR EPIDEMIOLOGY	The effect of HIV-1 on other infectious diseases in Africa is an increasing public health concern. In this review, we describe the role that three major infectious diseases-malaria, sexually transmitted diseases (STDs), and tuberculosis-have had In the HIV-1 epidemic. The high prevalence of untreated STD infections has been a major factor facilitating the spread of HIV-1 in Africa; with the synergistic interaction between HIV-1 transmission and genital herpes being of especial concern for control of both diseases. Increased susceptibility to tuberculosis after infection with HIV-1 has led to a rising incidence and threat of increased transmission of tuberculosis. Clinical malaria occurs with an increased frequency and severity in HIV-1-infected individuals, especially during pregnancy. As with tuberculosis, STDs, and other communicable HIV-1-associated diseases, the net effect of HIV-1 might include increased rates of malaria transmission across communities. In addition to enhancing access to HIV-1 prevention and care, public health surveillance and control programmes should be greatly intensified to cope with the new realities of infectious disease control in Africa.	Univ Zimbabwe, Biomed Res & Training Inst, Harare, Zimbabwe; London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England; Ctr Dis Control & Prevent, Malaria Epidemiol Branch, Div Parasit Dis, Natl Ctr Infect Dis, Atlanta, GA USA; Univ Zimbabwe, Sch Med, Fac Med, Harare, Zimbabwe; MRC, AIDS Program, Uganda Virus Res Inst, Entebbe, Uganda	Biomedical Research Training Institute; University of Zimbabwe; University of London; London School of Hygiene & Tropical Medicine; Centers for Disease Control & Prevention - USA; University of Zimbabwe; Uganda Virus Research Institute	Corbett, EL (corresponding author), Univ Zimbabwe, Biomed Res & Training Inst, Main Campus,POB CY1753, Harare, Zimbabwe.	Elizabeth.Corbett@lshtm.ac.uk	Kuile, Feiko ter/ABD-6681-2020; Unemo, Magnus/ABD-6653-2021	Kuile, Feiko ter/0000-0003-3663-5617; Hayes, Richard/0000-0002-1729-9892; Corbett, Elizabeth/0000-0002-3552-3181				Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1; AUGENBRAUN M, 1995, ANN INTERN MED, V123, P845, DOI 10.7326/0003-4819-123-11-199512010-00006; AYISI JG, IN PRESS AIDS; Bentwich Z, 2000, AIDS, V14, P2071, DOI 10.1097/00002030-200009290-00002; BLOLAND PB, 1995, AIDS, V9, P721, DOI 10.1097/00002030-199507000-00009; Boelaert JR, 2001, AIDS, V15, P2205, DOI 10.1097/00002030-200111090-00024; Boily MC, 2000, AIDS, V14, P2583, DOI 10.1097/00002030-200011100-00022; Bucher HC, 1999, AIDS, V13, P501, DOI 10.1097/00002030-199903110-00009; BUTCHER GA, 1992, PARASITOL TODAY, V8, P307, DOI 10.1016/0169-4758(92)90104-A; Buve A, 2001, TROP MED INT HEALTH, V6, P971, DOI 10.1046/j.1365-3156.2001.00809.x; Buve A, 2001, AIDS, V15, pS127, DOI 10.1097/00002030-200108004-00014; Buve A, 2001, AIDS, V15, pS5, DOI 10.1097/00002030-200108004-00002; CAMERON DW, 1989, LANCET, V2, P403; Carpenter LM, 1999, AIDS, V13, P1083, DOI 10.1097/00002030-199906180-00012; Chandramohan D, 1998, INT J EPIDEMIOL, V27, P296, DOI 10.1093/ije/27.2.296; Churchyard CJ, 1999, INT J TUBERC LUNG D, V3, P791; Churchyard GJ, 2000, INT J TUBERC LUNG D, V4, P433; Classen CN, 1999, THORAX, V54, P136, DOI 10.1136/thx.54.2.136; Cohen MS, 1997, LANCET, V349, P1868, DOI 10.1016/S0140-6736(97)02190-9; Corbett EL, 2002, CLIN INFECT DIS, V34, P1251, DOI 10.1086/339540; CORBETT EL, IN PRESS ARCH INTERN; Cruciani M, 2001, CLIN INFECT DIS, V33, P1922, DOI 10.1086/324352; De Cock KM, 1999, INT J TUBERC LUNG D, V3, P457; Del Amo J, 1999, AIDS, V13, P1151, DOI 10.1097/00002030-199907090-00002; Espinal MA, 2001, NEW ENGL J MED, V344, P1294, DOI 10.1056/NEJM200104263441706; Feikin DR, 2000, J INFECT DIS, V181, P1501, DOI 10.1086/315382; FENNEMA JSA, 1995, AIDS, V9, P1071, DOI 10.1097/00002030-199509000-00014; FEREBEE SH, 1970, ADV TUBERC RES, V17, P28; Fleming DT, 1999, SEX TRANSM INFECT, V75, P3, DOI 10.1136/sti.75.1.3; Francesconi P, 2001, AIDS, V15, P2445, DOI 10.1097/00002030-200112070-00013; French N, 2001, AIDS, V15, P899, DOI 10.1097/00002030-200105040-00010; French N, 2000, LANCET, V355, P2106, DOI 10.1016/S0140-6736(00)02377-1; French N, 2000, T ROY SOC TROP MED H, V94, P233, DOI 10.1016/S0035-9203(00)90301-8; Ghys PD, 1997, AIDS, V11, pF85, DOI 10.1097/00002030-199712000-00001; Girardi E, 2001, J ACQ IMMUN DEF SYND, V26, P326, DOI 10.1097/00126334-200104010-00006; Girardi E, 2000, AIDS, V14, pS47; Girardi E, 2000, AIDS, V14, P1985, DOI 10.1097/00002030-200009080-00015; Glynn JR, 2001, AIDS, V15, pS51, DOI 10.1097/00002030-200108004-00006; Godfrey-Faussett P, 2000, LANCET, V356, P1066, DOI 10.1016/S0140-6736(00)02730-6; Grant AD, 1997, AIDS, V11, P1357, DOI 10.1097/00002030-199711000-00010; Gray RH, 1999, AIDS, V13, P2113, DOI 10.1097/00002030-199910220-00015; Greenberg A. E., 1992, AIDS WORLD, P143; Grosskurth H, 2000, LANCET, V355, P1981, DOI 10.1016/S0140-6736(00)02336-9; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; Gwanzura L, 1998, J INFECT DIS, V177, P481, DOI 10.1086/517381; HAYES RJ, 1995, J TROP MED HYG, V98, P1; Hoffman IF, 1999, AIDS, V13, P487, DOI 10.1097/00002030-199903110-00007; Iyer JK, 2001, LANCET, V358, P1066, DOI 10.1016/S0140-6736(01)06201-8; Jones JL, 2000, INT J TUBERC LUNG D, V4, P1026; Kamali A, 1999, SEX TRANSM INFECT, V75, P98, DOI 10.1136/sti.75.2.98; Kamya MR, 2001, AIDS, V15, P1187, DOI 10.1097/00002030-200106150-00019; Keou FXM, 1998, INT J STD AIDS, V9, P400, DOI 10.1258/0956462981922485; KORENROMP EL, IN PRESS SEX TRANSM; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; Lalvani A, 2001, AM J RESP CRIT CARE, V163, P824, DOI 10.1164/ajrccm.163.4.2009100; Lockman S, 2001, J CLIN MICROBIOL, V39, P1042, DOI 10.1128/JCM.39.3.1042-1047.2001; MADICO G, 1995, LANCET, V345, P416, DOI 10.1016/S0140-6736(95)90401-8; Mayaud P, 1997, AIDS, V11, P1873, DOI 10.1097/00002030-199715000-00013; Mazurek GH, 2001, JAMA-J AM MED ASSOC, V286, P1740, DOI 10.1001/jama.286.14.1740; Meda N, 1998, REV EPIDEMIOL SANTE, V46, P14; Moore A, 2001, LANCET, V358, P657, DOI 10.1016/S0140-6736(01)05783-X; Moore JM, 2000, J INFECT DIS, V182, P960, DOI 10.1086/315755; Moses S, 1998, SEX TRANSM INFECT, V74, P368, DOI 10.1136/sti.74.5.368; MOSS GB, 1995, J INFECT DIS, V172, P1469, DOI 10.1093/infdis/172.6.1469; Mukadi YD, 2001, AIDS, V15, P143, DOI 10.1097/00002030-200101260-00002; NUNN P, 1994, TUBERCLE LUNG DIS, V75, P25, DOI 10.1016/0962-8479(94)90098-1; Obasi A, 1999, J INFECT DIS, V179, P16, DOI 10.1086/314555; Odhiambo JA, 1999, AM J PUBLIC HEALTH, V89, P1078, DOI 10.2105/AJPH.89.7.1078; Orroth KK, 2000, AIDS, V14, P1429, DOI 10.1097/00002030-200007070-00017; Parise ME, 1998, AM J TROP MED HYG, V59, P813, DOI 10.4269/ajtmh.1998.59.813; Pavlou AK, 2000, CLIN CHEM LAB MED, V38, P99, DOI 10.1515/CCLM.2000.016; PhamKanter GBT, 1996, GENITOURIN MED, V72, P160; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Rana FS, 2000, J ACQ IMMUN DEF SYND, V24, P23; Rodriguez MDM, 2002, AIDS, V16, P451; Sachs JD, 2001, NAT MED, V7, P521, DOI 10.1038/87830; Samba E, 2001, AM J TROP MED HYG, V64, pII, DOI 10.4269/ajtmh.2001.64.ii; Savarino A, 2001, J CLIN VIROL, V20, P131, DOI 10.1016/S1386-6532(00)00139-6; Schellenberg D, 2001, LANCET, V357, P1471, DOI 10.1016/S0140-6736(00)04643-2; Shulman CE, 1999, ANN TROP MED PARASIT, V93, pS59, DOI 10.1080/00034989957745; Snow RW, 2001, TRENDS PARASITOL, V17, P593, DOI 10.1016/S1471-4922(01)02031-1; Sonnenberg P, 2001, LANCET, V358, P1687, DOI 10.1016/S0140-6736(01)06712-5; Steketee RW, 1996, AM J TROP MED HYG, V55, P42, DOI 10.4269/ajtmh.1996.55.42; Steketee RW, 2001, AM J TROP MED HYG, V64, P28, DOI 10.4269/ajtmh.2001.64.28; Stover CK, 2000, NATURE, V405, P962, DOI 10.1038/35016103; Styblo K, 2001, INT J TUBERC LUNG D, V5, P103; Styblo K, 1991, EPIDEMIOLOGY TUBERCU; Van Eijk AM, 2001, AM J TROP MED HYG, V65, P623, DOI 10.4269/ajtmh.2001.65.623; Van Rie A, 1999, NEW ENGL J MED, V341, P1174, DOI 10.1056/NEJM199910143411602; Verhoeff FH, 1999, TROP MED INT HEALTH, V4, P5, DOI 10.1046/j.1365-3156.1999.00349.x; Vynnycky E, 1997, EPIDEMIOL INFECT, V119, P183, DOI 10.1017/S0950268897007917; Wald A, 2002, J INFECT DIS, V185, P45, DOI 10.1086/338231; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; Watson-Jones D, 2000, SEX TRANSM INFECT, V76, P355, DOI 10.1136/sti.76.5.355; Wawer MJ, 1999, LANCET, V353, P525, DOI 10.1016/S0140-6736(98)06439-3; Weiss HA, 2001, AIDS, V15, pS97, DOI 10.1097/00002030-200108004-00011; Whitty CJM, 2002, LANCET, V359, P80, DOI 10.1016/S0140-6736(02)07300-2; Whitworth J, 2000, LANCET, V356, P1051, DOI 10.1016/S0140-6736(00)02727-6; WHO, 2001, REP M GROUND LARV BL; *WHO, 2001, AIDS200105 WHOHIV; WHO/UNAIDS, 1999, WEEKLY EPIDEMIOLOGIC, V74, P385; WHO World Health Organisation STD Statistics, 2001, GLOB PREV INC SEL CU; Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0; Wilkinson D, 1997, TROP MED INT HEALTH, V2, P747, DOI 10.1046/j.1365-3156.1997.d01-386.x; Xiao LH, 1998, J INFECT DIS, V177, P437, DOI 10.1086/514212	106	134	139	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 22	2002	359	9324					2177	2187		10.1016/S0140-6736(02)09095-5	http://dx.doi.org/10.1016/S0140-6736(02)09095-5			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566RJ	12090997				2022-12-28	WOS:000176441800025
J	Ichihara, K; Satoh, K				Ichihara, K; Satoh, K			Disparity between angiographic regression and clinical event rates with hydrophobic statins	LANCET			English	Editorial Material							COA REDUCTASE INHIBITORS; CORONARY-ARTERY-DISEASE; CHOLESTEROL LEVELS; PRAVASTATIN; ATHEROSCLEROSIS; MEN; LIPOPROTEIN; PROGRESSION; PREVENTION; LOVASTATIN		Hokkaido Coll Pharm, Dept Pharmacol, Otaru, Hokkaido 0470264, Japan		Ichihara, K (corresponding author), Hokkaido Coll Pharm, Dept Pharmacol, 7-1 Katsuraoka, Otaru, Hokkaido 0470264, Japan.	ichihara1@hokuyakudai.ac.jp						ALAM SS, 1975, ARCH BIOCHEM BIOPHYS, V171, P183, DOI 10.1016/0003-9861(75)90022-3; Arntz HR, 2000, AM J CARDIOL, V86, P1293, DOI 10.1016/S0002-9149(00)01230-3; BLANKENHORN DH, 1993, ANN INTERN MED, V119, P969, DOI 10.7326/0003-4819-119-10-199311150-00002; CROUSE JR, 1995, AM J CARDIOL, V75, P455, DOI 10.1016/S0002-9149(99)80580-3; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; ELMBERGER PG, 1987, EUR J BIOCHEM, V168, P1, DOI 10.1111/j.1432-1033.1987.tb13379.x; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Herd JA, 1997, AM J CARDIOL, V80, P278, DOI 10.1016/S0002-9149(97)00346-9; ICHIHARA K, 1993, J CARDIOVASC PHARM, V22, P852, DOI 10.1097/00005344-199312000-00012; JUKEMA JW, 1995, CIRCULATION, V91, P2528, DOI 10.1161/01.CIR.91.10.2528; Libby Peter, 1998, American Journal of Medicine, V104, p14S, DOI 10.1016/S0002-9343(98)00041-2; LIEM A, 2000, CIRCULATION, V102, P2672; *LONG TERM INT PRA, 1996, NEW ENGL J MED, V339, P1349; Martin G, 2001, J CLIN INVEST, V107, P1423, DOI 10.1172/JCI10852; OLIVER MF, 1994, LANCET, V344, P633; PEDERSEN TR, 1994, LANCET, V344, P1383; PITT B, 1995, J AM COLL CARDIOL, V26, P1133, DOI 10.1016/0735-1097(95)00301-0; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SATOH K, 1995, BRIT J PHARMACOL, V116, P1894, DOI 10.1111/j.1476-5381.1995.tb16679.x; Satoh K, 2000, J CARDIOVASC PHARM, V35, P256, DOI 10.1097/00005344-200002000-00012; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SHIMIZU S, 1991, ARCH BIOCHEM BIOPHYS, V284, P35, DOI 10.1016/0003-9861(91)90259-L; Staels B, 1998, CIRCULATION, V98, P2088, DOI 10.1161/01.CIR.98.19.2088; WATERS D, 1994, CIRCULATION, V89, P959, DOI 10.1161/01.CIR.89.3.959	25	50	51	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 22	2002	359	9324					2195	2198		10.1016/S0140-6736(02)09098-0	http://dx.doi.org/10.1016/S0140-6736(02)09098-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566RJ	12091000				2022-12-28	WOS:000176441800028
J	Sethi, S; Lipford, G; Wagner, H; Kretzschmar, H				Sethi, S; Lipford, G; Wagner, H; Kretzschmar, H			Postexposure prophylaxis against prion disease with a stimulator of innate immunity	LANCET			English	Article							SCRAPIE	The absence of an immune response to prions-the infectious agents of scrapie, bovine spongiform encephalopathy (BSE), and Creutzfeldt-Jakob disease-might be related to the fact that these agents do not contain nucleic acids. We aimed to use CpG oligodeoxynucleotides, which have been shown to stimulate innate immunity, as a form of postexposure prophylaxis in mice. We inoculated healthy mice with brain homogenates from mice infected with the RML scrapie prion, and then injected CpG oligodeoxynucleotides. This postexposure prophylaxis with CpG oligodeoxynucleotides resulted in 38% longer survival times than treatment with saline (p<0.0001), or even longer after repeated application. The explanation for this finding remains to be elucidated, but the most likely is stimulation of TLR9-expressing cells of the innate immune system such as macrophages, monocytes, and dendritic cells. CpG oligodeoxynucleotides have not been shown to have adverse effects to human health and could therefore be considered as a therapeutic choice in postexposure prophylaxis.	Univ Munich, Inst Neuropathol, D-81377 Munich, Germany; Coley Pharmaceut, Langenfeld, Germany; Tech Univ Munich, Inst Med Mikrobiol Immunol & Hyg, D-8000 Munich, Germany	University of Munich; Coley Pharmaceutical Group; Technical University of Munich	Kretzschmar, H (corresponding author), Univ Munich, Inst Neuropathol, Marchioninistr 15, D-81377 Munich, Germany.		Sethi, Shneh/F-1796-2013					BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Lipford GB, 1998, TRENDS MICROBIOL, V6, P496, DOI 10.1016/S0966-842X(98)01408-5; Wagner H, 2002, CURR OPIN MICROBIOL, V5, P62, DOI 10.1016/S1369-5274(02)00287-4; Zimmermann S, 1998, J IMMUNOL, V160, P3627	5	110	127	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 20	2002	360	9328					229	230		10.1016/S0140-6736(02)09513-2	http://dx.doi.org/10.1016/S0140-6736(02)09513-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	576DX	12133662				2022-12-28	WOS:000176988500017
J	Kiechl, S; Lorenz, E; Reindl, M; Wiedermann, CJ; Oberhollenzer, F; Bonora, E; Willeit, J; Schwartz, DA				Kiechl, S; Lorenz, E; Reindl, M; Wiedermann, CJ; Oberhollenzer, F; Bonora, E; Willeit, J; Schwartz, DA			Toll-like receptor 4 polymorphisms and atherogenesis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CAROTID-ARTERY ATHEROSCLEROSIS; APPARENTLY HEALTHY-MEN; MYOCARDIAL-INFARCTION; CHLAMYDIA-PNEUMONIAE; CARDIOVASCULAR-DISEASE; PATTERN-RECOGNITION; NATURAL COURSE; RISK; TLR4; IMMUNITY	Background The ability to mount a prominent inflammatory response to bacterial pathogens confers an advantage in innate immune defense but may signal an increased risk of atherosclerosis. We determined whether recently discovered genetic variants of toll-like receptor 4 (TLR4) that confer differences in the inflammatory response elicited by bacterial lipopolysaccharide are related to the development of atherosclerosis. Methods As part of the five-year follow-up in the Bruneck (Italy) Study, we screened 810 persons in the study cohort for the TLR4 polymorphisms Asp299Gly and Thr399Ile. The extent and progression of carotid atherosclerosis were assessed by high-resolution duplex ultrasonography. Results As compared with subjects with wild-type TLR4, the 55 subjects with the Asp299Gly TLR4 allele had lower levels of certain proinflammatory cytokines, acute-phase reactants, and soluble adhesion molecules, such as interleukin-6 and fibrinogen. Although these subjects were found to be more susceptible to severe bacterial infections, they had a lower risk of carotid atherosclerosis (odds ratio, 0.54; 95 percent confidence interval, 0.32 to 0.98; P=0.05) and a smaller intima-media thickness in the common carotid artery (regression coefficient, -0.07; 95 percent confidence interval, -0.12 to -0.02; P=0.01). Conclusions The Asp299Gly TLR4 polymorphism, which attenuates receptor signaling and diminishes the inflammatory response to gram-negative pathogens, is associated with a decreased risk of atherosclerosis. This finding is consistent with the hypothesis that innate immunity may play a part in atherogenesis.	Innsbruck Univ Clin, Dept Neurol, A-6020 Innsbruck, Austria; Innsbruck Univ Clin, Dept Internal Med, A-6020 Innsbruck, Austria; Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA; Bruneck Hosp, Dept Internal Med, Brunico, Italy; Univ Verona, Dept Endocrinol & Metab, I-37100 Verona, Italy; Duke Univ, Med Ctr, Dept Med & Genet, Durham, NC USA; Vet Affairs Med Ctr, Durham, NC USA	Medical University of Innsbruck; Medical University of Innsbruck; Wake Forest University; University of Verona; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Kiechl, S (corresponding author), Innsbruck Univ Clin, Dept Neurol, Anichstr 35, A-6020 Innsbruck, Austria.	stefan.kiechl@uibk.ac.at	Bonora, Enzo/AAA-5300-2022; Wiedermann, Christian J./ABG-9521-2020; Reindl, Markus/ABE-5880-2020	BONORA, Enzo/0000-0003-1074-5164; Reindl, Markus/0000-0003-2817-1402	NHLBI NIH HHS [HL66604, HL62628, HL66611] Funding Source: Medline; NIEHS NIH HHS [ES09607, ES11375, ES07498] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062628, U01HL066604] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007498, P01ES009607] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Cox D. R., 1984, ANAL SURVIVAL DATA; Faure E, 2001, J IMMUNOL, V166, P2018, DOI 10.4049/jimmunol.166.3.2018; HOSMER DW, 1989, APPL LOGISTIC REGRES; Hubacek JA, 1999, CIRCULATION, V100, P2550; Kiechl S, 2001, CIRCULATION, V103, P1064, DOI 10.1161/01.CIR.103.8.1064; Kiechl S, 1999, ARTERIOSCL THROM VAS, V19, P1491, DOI 10.1161/01.ATV.19.6.1491; Kiechl S, 1997, CIRCULATION, V96, P3300; Kiechl S, 1999, ARTERIOSCL THROM VAS, V19, P1484, DOI 10.1161/01.ATV.19.6.1484; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Liao W, 1996, J LAB CLIN MED, V128, P452, DOI 10.1016/S0022-2143(96)90042-6; Lorenz E, 2002, ARCH INTERN MED, V162, P1028, DOI 10.1001/archinte.162.9.1028; Lorenz E, 2001, BIOTECHNIQUES, V31, P22, DOI 10.2144/01311bm01; Mayr M, 2000, CIRCULATION, V102, P833; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Muhlestein JB, 1998, CIRCULATION, V97, P633, DOI 10.1161/01.CIR.97.7.633; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Rauramaa R, 2000, ARTERIOSCL THROM VAS, V20, P2657, DOI 10.1161/01.ATV.20.12.2657; Ridker PM, 2000, CIRCULATION, V101, P2149, DOI 10.1161/01.CIR.101.18.2149; Ridker PM, 1997, NEW ENGL J MED, V337, P356; Ridker PM, 2000, CIRCULATION, V101, P1767, DOI 10.1161/01.CIR.101.15.1767; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Sasu S, 2001, CIRC RES, V89, P244, DOI 10.1161/hh1501.094184; Smiley ST, 2001, J IMMUNOL, V167, P2887, DOI 10.4049/jimmunol.167.5.2887; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Unkelbach K, 1999, ARTERIOSCL THROM VAS, V19, P932, DOI 10.1161/01.ATV.19.4.932; Walker AE, 1981, STROKE S1, V12, P13; *WHO REG OFF EUR, 1971, IHD REG REP 5 WORK G; Wiedermann CJ, 1999, J AM COLL CARDIOL, V34, P1975, DOI 10.1016/S0735-1097(99)00448-9; WILLEIT J, 1993, ARTERIOSCLER THROMB, V13, P661, DOI 10.1161/01.ATV.13.5.661; Willeit J, 2000, ARTERIOSCL THROM VAS, V20, P529, DOI 10.1161/01.ATV.20.2.529; Wright SD, 2000, J EXP MED, V191, P1437, DOI 10.1084/jem.191.8.1437; Xu XH, 2001, CIRCULATION, V104, P3103, DOI 10.1161/hc5001.100631; Zarember KA, 2002, J IMMUNOL, V168, P554, DOI 10.4049/jimmunol.168.2.554; Zheng F, 2001, CLIN GENET, V59, P58, DOI 10.1034/j.1399-0004.2001.590110.x	40	852	923	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 18	2002	347	3					185	192		10.1056/NEJMoa012673	http://dx.doi.org/10.1056/NEJMoa012673			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	574BR	12124407				2022-12-28	WOS:000176869000005
J	Torgerson, DJ; Byford, S				Torgerson, DJ; Byford, S			Economics notes - Economic modelling before clinical trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COST		Univ York, Dept Hlth Sci, York YO1 5DD, N Yorkshire, England; Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England	University of York - UK; University of York - UK	Torgerson, DJ (corresponding author), Univ York, Dept Hlth Sci, York YO1 5DD, N Yorkshire, England.	djt6@york.ac.uk	Byford, Sarah/D-1699-2010; Torgerson, David/L-4566-2019	Byford, Sarah/0000-0001-7084-1495; Torgerson, David/0000-0002-1667-4275				Byford S, 2000, BRIT MED J, V320, P1335, DOI 10.1136/bmj.320.7245.1335; GILLESPIE WJ, 1995, J BONE JOINT SURG BR, V77B, P528, DOI 10.1302/0301-620X.77B4.7615594; Jefferson T, 1996, LANCET, V348, P141, DOI 10.1016/S0140-6736(05)66104-1; Mooney G, 1992, EC MED HLTH CARE, V2nd; Parsonnet J, 1996, LANCET, V348, P150, DOI 10.1016/S0140-6736(96)01501-2; Torgerson DJ, 1997, PHARMACOECONOMICS, V11, P126, DOI 10.2165/00019053-199711020-00003; Townsend J, 1997, HEALTH POLICY, V39, P181, DOI 10.1016/S0168-8510(96)00870-6	8	10	10	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 13	2002	325	7355					98	98		10.1136/bmj.325.7355.98	http://dx.doi.org/10.1136/bmj.325.7355.98			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575CU	12114244	Green Published			2022-12-28	WOS:000176929400026
J	Beltrami, H				Beltrami, H			Paleoclimate: Earth's long-term memory	SCIENCE			English	Editorial Material							SURFACE-TEMPERATURE HISTORY; GEOTHERMAL DATA; RECONSTRUCTION		St Francis Xavier Univ, Dept Earth Sci, Antigonish, NS B2G 2W5, Canada	Saint Francis Xavier University - Canada	Beltrami, H (corresponding author), St Francis Xavier Univ, Dept Earth Sci, Antigonish, NS B2G 2W5, Canada.							Beltrami H, 1997, GEOPHYS J INT, V129, P311, DOI 10.1111/j.1365-246X.1997.tb01584.x; Beltrami H, 1995, GLOBAL PLANET CHANGE, V11, P127, DOI 10.1016/0921-8181(95)00006-2; Beltrami H, 1995, EARTH PLANET SC LETT, V136, P437, DOI 10.1016/0012-821X(95)00172-9; Beltrami H, 2002, GEOPHYS RES LETT, V29; BELTRAMI H, 2001, GLOBAL PLANET CHANGE, V29; Bradley R. S., 1999, QUATERNARY PALEOCLIM; Briffa KR, 2001, J GEOPHYS RES-ATMOS, V106, P2929, DOI 10.1029/2000JD900617; Briffa KR, 2002, SCIENCE, V295, P2227, DOI 10.1126/science.1069486; CLOW GD, 1992, GLOBAL PLANET CHANGE, V98, P81; Esper J, 2002, SCIENCE, V295, P2250, DOI 10.1126/science.1066208; Harris RN, 2001, GEOPHYS RES LETT, V28, P747, DOI 10.1029/2000GL012348; Huang SP, 2000, NATURE, V403, P756, DOI 10.1038/35001556; Levitus S, 2001, SCIENCE, V292, P267, DOI 10.1126/science.1058154; Lewis TJ, 1998, GEOPHYS RES LETT, V25, P535, DOI 10.1029/98GL00181; Mann ME, 1999, GEOPHYS RES LETT, V26, P759, DOI 10.1029/1999GL900070; MARESCHAL JC, COMMUNICATION; Pollack HN, 1996, PURE APPL GEOPHYS, V147, P537, DOI 10.1007/BF00878843; Pollack HN, 2000, ANNU REV EARTH PL SC, V28, P339, DOI 10.1146/annurev.earth.28.1.339	18	40	42	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 12	2002	297	5579					206	207		10.1126/science.1074027	http://dx.doi.org/10.1126/science.1074027			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571UT	12114616				2022-12-28	WOS:000176738100029
J	Tang, ZY; Kotov, NA; Giersig, M				Tang, ZY; Kotov, NA; Giersig, M			Spontaneous organization of single CdTe nanoparticles into luminescent nanowires	SCIENCE			English	Article							CDSE NANOCRYSTALS; QUANTUM DOTS; SEMICONDUCTOR; ARRAYS; SE	Nanoparticles of CdTe were found to spontaneously reorganize into crystalline nanowires upon controlled removal of the protective shell of organic stabilizer. The intermediate step in the nanowire formation was found to be pearl-necklace aggregates. Strong dipole-dipole interaction is believed to be the driving force of nanoparticle self-organization. The linear aggregates subsequently recrystallized into nanowires whose diameter was determined by the diameter of the nanoparticles. The produced nanowires have high aspect ratio, uniformity, and optical activity. These findings demonstrate the collective behavior of nanoparticles as well as a convenient, simple technique for production of one-dimensional semiconductor colloids suitable for subsequent processing into quantum-confined superstructures, materials, and devices.	Oklahoma State Univ, Dept Chem, Stillwater, OK 74078 USA; Hahn Meitner Inst Berlin GmbH, Phys Chem Abt, D-15109 Berlin, Germany	Oklahoma State University System; Oklahoma State University - Stillwater; Helmholtz Association; Helmholtz-Zentrum fuer Materialien und Energie GmbH (HZB)	Kotov, NA (corresponding author), Oklahoma State Univ, Dept Chem, Stillwater, OK 74078 USA.		Kotov, Nicholas/AAZ-4204-2021; li, zhiyuan/HGD-9581-2022; tang, zhiyong/A-8563-2008	Kotov, Nicholas/0000-0002-6864-5804; tang, zhiyong/0000-0003-0610-0064; Giersig, Michael/0000-0002-5394-0413				DAI HJ, 1995, NATURE, V375, P769, DOI 10.1038/375769a0; Duan XF, 2001, NATURE, V409, P66, DOI 10.1038/35051047; Gates B, 2001, J AM CHEM SOC, V123, P11500, DOI 10.1021/ja0166895; Holmes JD, 2000, SCIENCE, V287, P1471, DOI 10.1126/science.287.5457.1471; Iakovenko SA, 1999, ADV MATER, V11, P388, DOI 10.1002/(SICI)1521-4095(199903)11:5<388::AID-ADMA388>3.0.CO;2-6; Korgel BA, 1998, ADV MATER, V10, P661, DOI 10.1002/(SICI)1521-4095(199806)10:9<661::AID-ADMA661>3.0.CO;2-L; Li LS, 2001, NANO LETT, V1, P349, DOI 10.1021/nl015559r; Li YD, 1999, INORG CHEM, V38, P1382, DOI 10.1021/ic980878f; Li YD, 2001, J AM CHEM SOC, V123, P9904, DOI 10.1021/ja016435j; Mamedov AA, 2001, J AM CHEM SOC, V123, P7738, DOI 10.1021/ja015857q; MARTIN CR, 1994, SCIENCE, V266, P1961, DOI 10.1126/science.266.5193.1961; Ni T, 2002, J AM CHEM SOC, V124, P3980, DOI 10.1021/ja017149a; Nicewarner-Pena SR, 2001, SCIENCE, V294, P137, DOI 10.1126/science.294.5540.137; Peng XG, 2000, NATURE, V404, P59, DOI 10.1038/35003535; Peshkovsky A, 2000, J MAGN RESON, V147, P104, DOI 10.1006/jmre.2000.2167; Rabani E, 1999, J CHEM PHYS, V110, P5355, DOI 10.1063/1.478431; Rogach AL, 1996, BER BUNSEN PHYS CHEM, V100, P1772, DOI 10.1002/bbpc.19961001104; Rogach AL, 2000, CHEM MATER, V12, P2676, DOI 10.1021/cm000244i; Shim M, 1999, J CHEM PHYS, V111, P6955, DOI 10.1063/1.479988; TAKEUCHI S, 1984, PHILOS MAG A, V50, P171, DOI 10.1080/01418618408244220; Wickham JN, 2000, PHYS REV LETT, V84, P923, DOI 10.1103/PhysRevLett.84.923; Yu JS, 2000, CHEM COMMUN, P2445, DOI 10.1039/b007999p	22	1730	1774	23	754	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 12	2002	297	5579					237	240		10.1126/science.1072086	http://dx.doi.org/10.1126/science.1072086			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571UT	12114622				2022-12-28	WOS:000176738100037
J	Grant, RM; Hecht, FM; Warmerdam, M; Liu, L; Liegler, T; Petropoulos, CJ; Hellmann, NS; Chesney, M; Busch, MP; Kahn, JO				Grant, RM; Hecht, FM; Warmerdam, M; Liu, L; Liegler, T; Petropoulos, CJ; Hellmann, NS; Chesney, M; Busch, MP; Kahn, JO			Time trends in primary HIV-1 drug resistance among recently infected persons	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ANTIRETROVIRAL THERAPY; REVERSE-TRANSCRIPTASE; HETEROSEXUAL TRANSMISSION; VIROLOGICAL FAILURE; PROTEASE INHIBITORS; ZIDOVUDINE; VARIANTS; SUSCEPTIBILITY; INDIVIDUALS	Context Transmission of multiclass drug-resistant human immunodeficiency virus type 1 (HIV-1) may increase with wider use of antiretroviral therapy. Objective To determine trends in prevalence of HIV-1 drug resistance among recently infected individuals in a geographic area with a high penetration of antiviral treatment. Design, Setting, and Patients Consecutive case series of 225 patients referred to a San Francisco, Calif, hospital with recent HIV-1 infection from June 1996 through June 2001. Main Outcome Measure Time trends in the prevalence of genotypic and phenotypic primary drug resistance. Results Mutations associated with resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) steadily increased from 0% in 1996-1997 to 12 (13.2%) in 20002001 (P=.01). There was 1 mutation associated with protease inhibitor resistance in 19961997 (2.5%) and there were 7 (7.7%) in 2000-2001 (P=.25). Genotypic resistance to nucleoside reverse transcriptase inhibitors (NRTIs) initially decreased and then returned to prior levels (P=.007 for test of homogeneity). Genotypic resistance to 2 or more classes of drugs increased from 1 (2.5%) to 12 (13.2%) (P=.004), but only 1 infection (1.2%) in the latter period was resistant to all 3 classes of agents (P=.58). Primary phenotypic resistance decreased for NRTIs from 21% to 6.2% (P=.03) and increased for NNRTIs from 0 to 8 (9.9%) (P=.02). Phenotypic resistance increased for protease inhibitors from 2.6% to 6.2% (P=32). Median time to virologic suppression (<500 copies/mL) during therapy was 12 weeks for patients with genotypic evidence of resistance compared with 5 weeks for patients with drug-sensitive infections (P=.02). Conclusions The frequency of primary resistance to NNRTIs is increasing, although resistance to all available classes of antiretroviral therapy remains rare. Genotypic resistance testing in recently infected persons predicts time to viral suppression during therapy.	Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA; San Francisco Gen Hosp, Posit Hlth Program, San Francisco, CA 94110 USA; Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Blood Ctr Pacific, San Francisco, CA USA; ViroLogic, San Francisco, CA USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Grant, RM (corresponding author), Gladstone Inst Virol & Immunol, POB 914100, San Francisco, CA 94141 USA.		Liu, Li/K-1936-2012	Liu, Li/0000-0002-5054-2372; Hecht, Frederick/0000-0002-5782-1171; Grant, Robert/0000-0002-0851-7085	NIAID NIH HHS [AI 41531] Funding Source: Medline; NIMH NIH HHS [MH64384-01, P30 MH59037] Funding Source: Medline; ODCDC CDC HHS [U64/CCU913941] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI041531] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K24MH064384, P30MH059037] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); ODCDC CDC HHS; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANGARANO G, 1994, AIDS, V8, P1013, DOI 10.1097/00002030-199407000-00023; BACHELER L, 2000, 4 INT WORKSH HIV DRU; Blower SM, 2000, SCIENCE, V287, P650, DOI 10.1126/science.287.5453.650; Blower SM, 2001, NAT MED, V7, P1016, DOI 10.1038/nm0901-1016; Boden D, 1999, JAMA-J AM MED ASSOC, V282, P1135, DOI 10.1001/jama.282.12.1135; BODEN D, 1999, ANTIVIR THER S, V4, P85; CONLON CP, 1994, J INFECT DIS, V169, P411, DOI 10.1093/infdis/169.2.411; DAQUILA RT, 2001, HIV MED, V9, P31; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; Deeks SG, 2002, AIDS, V16, P201, DOI 10.1097/00002030-200201250-00009; Deeks SG, 2000, J INFECT DIS, V181, P946, DOI 10.1086/315334; Deeks SG, 2002, J INFECT DIS, V185, P315, DOI 10.1086/338467; Deeks SG, 1999, AIDS, V13, pF35, DOI 10.1097/00002030-199904160-00001; FAUCI AS, 2002, GUIDELINES USE ANTIR; Goudsmit J, 2001, AIDS, V15, P2293, DOI 10.1097/00002030-200111230-00011; Harrigan PR, 2001, AIDS, V15, P1671, DOI 10.1097/00002030-200109070-00010; HARRIGAN PR, 2000, 4 INT WORKSH HIV DRU; HAUBRICH R, 2001, 5 INT WORKSH HIV DRU; Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504; Hirsch M, 1999, J INFECT DIS, V180, P659, DOI 10.1086/314948; Hirsch MS, 2000, JAMA-J AM MED ASSOC, V283, P2417, DOI 10.1001/jama.283.18.2417; Imrie A, 1997, J INFECT DIS, V175, P1502, DOI 10.1086/516487; IPPOLITO G, 1994, JAMA-J AM MED ASSOC, V272, P433, DOI 10.1001/jama.272.6.433; Janssen RS, 1998, JAMA-J AM MED ASSOC, V280, P42, DOI 10.1001/jama.280.1.42; KEMPF D, 2000, 4 INT WORKSH HIV DRU; LANIER ER, 2001, 8 C RETR OPP INF FEB; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Little SJ, 1999, JAMA-J AM MED ASSOC, V282, P1142, DOI 10.1001/jama.282.12.1142; Mammano F, 1998, J VIROL, V72, P7632, DOI 10.1128/JVI.72.9.7632-7637.1998; MCFARLAND W, 1998, SAN FRANCISCO HIV EP; Miller V, 2001, AIDS, V15, P309, DOI 10.1097/00002030-200102160-00003; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; Petropoulos CJ, 2000, ANTIMICROB AGENTS CH, V44, P920, DOI 10.1128/AAC.44.4.920-928.2000; Porter K, 2001, BRIT MED J, V322, P1087, DOI 10.1136/bmj.322.7294.1087; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Roland ME, 2001, J INFECT DIS, V184, P1608, DOI 10.1086/324580; SAAG MS, 1993, NEW ENGL J MED, V329, P1065, DOI 10.1056/NEJM199310073291502; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; Stoddart CA, 2001, NAT MED, V7, P712, DOI 10.1038/89090; VEENSTRA J, 1995, CLIN INFECT DIS, V21, P556, DOI 10.1093/clinids/21.3.556; Winters MA, 1998, J VIROL, V72, P5303, DOI 10.1128/JVI.72.6.5303-5306.1998; Yerly S, 2001, AIDS, V15, P2287, DOI 10.1097/00002030-200111230-00010; Yerly S, 1999, LANCET, V354, P729, DOI 10.1016/S0140-6736(98)12262-6; Yerly S, 1998, J VIROL, V72, P3520, DOI 10.1128/JVI.72.5.3520-3523.1998	44	381	392	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	2002	288	2					181	188		10.1001/jama.288.2.181	http://dx.doi.org/10.1001/jama.288.2.181			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	571HC	12095382	Bronze			2022-12-28	WOS:000176711100018
J	Lindsay, RS; Funahashi, T; Hanson, RL; Matsuzawa, Y; Tanaka, S; Tataranni, PA; Knowler, WC; Krakoff, J				Lindsay, RS; Funahashi, T; Hanson, RL; Matsuzawa, Y; Tanaka, S; Tataranni, PA; Knowler, WC; Krakoff, J			Adiponectin and development of type 2 diabetes in the Pima Indian population	LANCET			English	Article							INSULIN-RESISTANCE; OBESITY; PROTEIN	Adiponectin Is a collagen-like circulating protein secreted by adipocytes that Is proposed to mediate obesity-related resistance to Insulin. In a case-control series, we assessed the role of adiponectin in later development of type 2 diabetes In 70 patients who later developed type 2 diabetes and 70 controls, matched for body-mass index, age, and sex. Cases and controls were taken from the longitudinal study of health In the Pima Indian population. At baseline, the concentration of adiponectin was lower In cases than in controls (p=0.01) and Individuals with high concentrations of this protein were less likely to develop type 2 diabetes than those with low concentrations (incidence rate ratio 0.63 [95% CI 0.43-0.92]; p=0.02).	NIDDKD, NIH, Phoenix, AZ 85014 USA; Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, Osaka, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Osaka University	Lindsay, RS (corresponding author), NIDDKD, NIH, 1550 E Indian Sch Rd, Phoenix, AZ 85014 USA.		Hanson, Robert L/O-3238-2015	Hanson, Robert L/0000-0002-4252-7068; Lindsay, Robert/0000-0002-9868-5217	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK069000, Z01DK069015, ZIADK069015, ZIADK069000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Maeda N, 2001, DIABETES, V50, P2094, DOI 10.2337/diabetes.50.9.2094; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984	5	848	926	0	15	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 6	2002	360	9326					57	58		10.1016/S0140-6736(02)09335-2	http://dx.doi.org/10.1016/S0140-6736(02)09335-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569JR	12114044				2022-12-28	WOS:000176599700014
J	Niemeyer, CM				Niemeyer, CM			Nanotechnology: Tools for the biomolecular engineer	SCIENCE			English	Editorial Material							DNA; NANOSTRUCTURES		Univ Dortmund, Dept Chem, D-44227 Dortmund, Germany	Dortmund University of Technology	Niemeyer, CM (corresponding author), Univ Dortmund, Dept Chem, D-44227 Dortmund, Germany.		Niemeyer, Christof M/L-3568-2013	Niemeyer, Christof M/0000-0002-8837-081X				Braun E, 1998, NATURE, V391, P775, DOI 10.1038/35826; Keren K, 2002, SCIENCE, V297, P72, DOI 10.1126/science.1071247; Lee SW, 2002, SCIENCE, V296, P892, DOI 10.1126/science.1068054; Moore G. E., 1965, ELECTRONICS, V38, P1, DOI DOI 10.1109/JPROC.1998.658762; Niemeyer CM, 2001, ANGEW CHEM INT EDIT, V40, P4128, DOI 10.1002/1521-3773(20011119)40:22<4128::AID-ANIE4128>3.0.CO;2-S; Niemeyer CM, 1998, ANGEW CHEM INT EDIT, V37, P2265, DOI 10.1002/(SICI)1521-3773(19980904)37:16<2265::AID-ANIE2265>3.0.CO;2-F; Seeman NC, 2001, NANO LETT, V1, P22, DOI 10.1021/nl000182v; Storhoff JJ, 1999, CHEM REV, V99, P1849, DOI 10.1021/cr970071p; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191; Willner I, 2001, TRENDS BIOTECHNOL, V19, P222, DOI 10.1016/S0167-7799(01)01634-1	10	42	46	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 5	2002	297	5578					62	63		10.1126/science.1073843	http://dx.doi.org/10.1126/science.1073843			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571HB	12098688				2022-12-28	WOS:000176711000028
J	Prokopenko, AA; Williams, DF; Kuzmin, MI; Karabanov, EB; Khursevich, GK; Peck, JA				Prokopenko, AA; Williams, DF; Kuzmin, MI; Karabanov, EB; Khursevich, GK; Peck, JA			Muted climate variations in continental Siberia during the mid-Pleistocene epoch	NATURE			English	Article							LAKE BAIKAL; RECORD; INSOLATION; GLACIATION; CYCLES; ORIGIN; AGE	The large difference in carbon and oxygen isotope data from the marine record between marine oxygen isotope stage 12 (MIS 12) and MIS 11, spanning the interval between about 480 and 380 kyr ago, has been interpreted as a transition between an extremely cold glacial period and an unusually warm interglacial period, with consequences for global ice volume, sea level and the global carbon cycle(1-4). The extent of the change is intriguing, because orbital forcing is predicted to have been relatively weak at that time(5). Here we analyse a continuous sediment record from Lake Baikal, Siberia, which reveals a virtually continuous interglacial diatom assemblage, a stable littoral benthic diatom assemblage and lithogenic sediments with 'interglacial' characteristics for the period from MIS 15a to MIS 11 (from about 580 to 380 kyr ago). From these data, we infer significantly weaker climate contrasts between MIS 12 and 11 than during more recent glacial-interglacial transitions in the late Pleistocene epoch (about 130 to 10 kyr ago). For the period from MIS 15a to MIS 11, we also infer an apparent lack of extensive mountain glaciation.	Univ S Carolina, Dept Geol Sci, Columbia, SC 29208 USA; Russian Acad Sci, Siberian Branch, United Inst Geol Geophys & Mineral, Novosibirsk 630090, Russia; Russian Acad Sci, Siberian Branch, Inst Geochem, Irkutsk 664033, Russia; Inst Geol Sci, Minsk 220141, BELARUS; Univ Akron, Dept Geol, Akron, OH 44325 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Russian Academy of Sciences; Sobolev Institute of Geology & Mineralogy of the Russian Academy of Sciences; Trofimuk Institute of Petroleum Geology & Geophysics; Irkutsk Science Centre of the Russian Academy of Sciences; A.P. Vinogradov Institute of Geochemistry of the Siberian Branch of the RAS; Russian Academy of Sciences; University System of Ohio; University of Akron	Prokopenko, AA (corresponding author), Univ S Carolina, Dept Geol Sci, Columbia, SC 29208 USA.	sasha@geol.sc.edu	Kuzmin, Mikhail/O-9118-2015					Antipin V, 2001, QUATERN INT, V80-1, P19, DOI 10.1016/S1040-6182(01)00016-7; *BDP MEMB, 1997, EOS AM GEOPHYS UNION, V78, P597; BERGER AL, 1999, EOS T AM GEOPHYS UN, V80, pF555; COLMAN SM, 1995, NATURE, V378, P769, DOI 10.1038/378769a0; EHLERS J, 1989, J QUATERNARY SCI, V4, P255, DOI 10.1002/jqs.3390040306; Hearty PJ, 1999, GEOLOGY, V27, P375, DOI 10.1130/0091-7613(1999)027<0375:AMMPSL>2.3.CO;2; Howard WR, 1997, NATURE, V388, P418, DOI 10.1038/41201; IMBRIE J, 1993, PALEOCEANOGRAPHY, V8, P699, DOI 10.1029/93PA02751; Karabanov EB, 1998, QUATERNARY RES, V50, P46, DOI 10.1006/qres.1998.1980; Karabanov EB, 2000, J PALEOLIMNOL, V23, P365, DOI 10.1023/A:1008188100542; Khursevich GK, 2001, QUATERN INT, V80-1, P47, DOI 10.1016/S1040-6182(01)00018-0; Kukla G, 1996, PALAEOGEOGR PALAEOCL, V120, P171, DOI 10.1016/0031-0182(95)00040-2; KUKLA G, 1991, START GLACIAL, P307; Kuzmin MI, 2000, INT J EARTH SCI, V89, P183, DOI 10.1007/s005310000090; LASKAR J, 1993, ASTRON ASTROPHYS, V270, P522; MORTLOCK RA, 1989, DEEP-SEA RES, V36, P1415, DOI 10.1016/0198-0149(89)90092-7; Oppo DW, 1990, PALEOCEANOGRAPHY, V5, P43, DOI 10.1029/PA005i001p00043; PECK JA, 1994, EARTH PLANET SC LETT, V122, P221, DOI 10.1016/0012-821X(94)90062-0; Prokopenko AA, 1999, EARTH PLANET SC LETT, V172, P239, DOI 10.1016/S0012-821X(99)00203-4; Prokopenko AA, 2001, QUATERN INT, V80-1, P37, DOI 10.1016/S1040-6182(01)00017-9; Prokopenko AA, 2001, QUATERNARY RES, V55, P123, DOI 10.1006/qres.2000.2212; RASSKAZOV SV, 2000, GEOCHRONOLOGY GEODYN; Rohling EJ, 1998, NATURE, V394, P162, DOI 10.1038/28134; RUDDIMAN WF, 1980, QUATERNARY RES, V13, P33, DOI 10.1016/0033-5894(80)90081-2; Shackleton NJ, 2000, SCIENCE, V289, P1897, DOI 10.1126/science.289.5486.1897; SHORT DA, 1991, QUATERNARY RES, V35, P157, DOI 10.1016/0033-5894(91)90064-C; Thompson R., 1986, ENV MAGNETISM, DOI 10.1007/978-94-011-8036-8; URBAN B, 1991, START GLACIAL, P37; Williams DF, 1997, SCIENCE, V278, P1114, DOI 10.1126/science.278.5340.1114	29	72	76	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 4	2002	418	6893					65	68		10.1038/nature00886	http://dx.doi.org/10.1038/nature00886			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	569JL	12097906				2022-12-28	WOS:000176599200038
J	Davis, RL; Shrimpton, AE; Carrell, RW; Lomas, DA; Gerhard, L; Baumann, B; Lawrence, DA; Yepes, M; Kim, TS; Ghetti, B; Piccardo, P; Takao, M; Lacbawan, F; Muenke, M; Sifers, RN; Bradshaw, CB; Kent, PF; Collins, GH; Larocca, D; Holohan, PD				Davis, RL; Shrimpton, AE; Carrell, RW; Lomas, DA; Gerhard, L; Baumann, B; Lawrence, DA; Yepes, M; Kim, TS; Ghetti, B; Piccardo, P; Takao, M; Lacbawan, F; Muenke, M; Sifers, RN; Bradshaw, CB; Kent, PF; Collins, GH; Larocca, D; Holohan, PD			Association between conformational mutations in neuroserpin and onset and severity of dementia	LANCET			English	Article							SERINE-PROTEASE INHIBITOR; NEURODEGENERATIVE DISEASE; CRYSTAL-STRUCTURE; INCLUSION-BODIES; SERPINS; ALPHA(1)-ANTITRYPSIN; ENCEPHALOPATHY; ACCUMULATION; MECHANISM; MYOCLONUS	Background The aggregation of specific proteins is a common feature of the familial dementias, but whether the formation of neuronal inclusion bodies is a causative or incidental factor in the disease is not known. To clarify this issue, we investigated five families with typical neuroserpin inclusion bodies but with various neurological manifestations. Methods Five families with neurodegenerative disease and typical neuronal inclusions had biopsy or autopsy material available for further examination. Immunostaining confirmed that the inclusions were formed of neuroserpin aggregates, and the responsible mutations in neuroserpin were identified by sequencing of the neuroserpin gene (SERPINI1) in DNA from blood samples or from extraction of histology specimens. Molecular modelling techniques were used to predict the effect of the gene mutations on three-dimensional protein structure. Brain sections were stained and the topographic distribution of the neuroserpin inclusions plotted. Findings Each of the families was heterozygous for an aminoacid substitution that affected the conformational stability of neuroserpin. The least disruptive of these mutations (S49P), as predicted by molecular modelling, resulted in dementia after age 45 years, and presence of neuroserpin inclusions in only a few neurons. By contrast, the most severely disruptive mutation (G392E) resulted, at age 13 years, in progressive myoclonus epilepsy, with many inclusions present in almost all neurons. Interpretation The findings provide evidence that inclusion-body formation is in itself a sufficient cause of neurodegeneration, and that the onset and severity of the disease is associated with the rate and magnitude of neuronal protein aggregation.	Univ Cambridge, Dept Haematol, Cambridge Inst Med Res, Cambridge, England; Univ Cambridge, Dept Med, Cambridge Inst Med Res, Cambridge CB2 2QQ, England; Upstate Med Univ, Dept Pathol, Syracuse, NY USA; Univ Witten Herdecke, Inst Clin Neurosurg, Witten, Germany; Univ Magdeburg, Dept Psychiat, D-39106 Magdeburg, Germany; Amer Red Cross, Holland Lab, Dept Vasc Biol, Rockville, MD USA; Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20007 USA; Yonsei Univ, Coll Med, Dept Pathol, Seoul, South Korea; Indiana Univ, Sch Med, Div Neuropathol, Alzheimer Dis Ctr, Indianapolis, IN USA; Childrens Natl Med Ctr, Dept Med Genet, Washington, DC 20010 USA; NHGRI, Med Genet Branch, NIH, Bethesda, MD 20892 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Upstate Med Univ, Dept Neurol, Syracuse, NY USA; Upstate Med Univ, Dept Pharmacol, Syracuse, NY USA	University of Cambridge; University of Cambridge; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Witten Herdecke University; Otto von Guericke University; American Red Cross; Georgetown University; Yonsei University; Yonsei University Health System; Indiana University System; Indiana University-Purdue University Indianapolis; Children's National Health System; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Baylor College of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Carrell, RW (corresponding author), Univ Cambridge, Dept Haematol, Cambridge Inst Med Res, Cambridge, England.	rwc1000@cam.ac.uk	Sifers, Richard Norman/AGQ-7262-2022; Yepes, Manuel/C-3576-2011	Lawrence, Daniel/0000-0003-3126-1935; Muenke, Maximilian/0000-0002-7719-6545	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014426, R21NS040722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG010133] Funding Source: NIH RePORTER; NIA NIH HHS [AG10133] Funding Source: Medline; NINDS NIH HHS [NS14426, NS40722] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Belorgey D, 2002, J BIOL CHEM, V277, P17367, DOI 10.1074/jbc.M200680200; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; BENISHAY Z, 1968, ISRAEL J MED SCI, V4, P987; Bergener M, 1970, Nervenarzt, V41, P166; Bradshaw CB, 2001, ARCH NEUROL-CHICAGO, V58, P1429, DOI 10.1001/archneur.58.9.1429; Briand C, 2001, FEBS LETT, V505, P18, DOI 10.1016/S0014-5793(01)02764-8; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Carrell RW, 2002, NEW ENGL J MED, V346, P45, DOI 10.1056/NEJMra010772; Davis RL, 1999, AM J PATHOL, V155, P1901, DOI 10.1016/S0002-9440(10)65510-1; Davis RL, 1999, NATURE, V401, P376, DOI 10.1038/43897; GERHARD L, 1990, AKTUELLE NEUROPADIAT, P56; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Hastings GA, 1997, J BIOL CHEM, V272, P33062, DOI 10.1074/jbc.272.52.33062; JOCHMANS K, 1994, BLOOD, V83, P146; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; Murrell JR, 1999, J NEUROPATH EXP NEUR, V58, P1207, DOI 10.1097/00005072-199912000-00002; Osterwalder T, 1996, EMBO J, V15, P2944, DOI 10.1002/j.1460-2075.1996.tb00657.x; Rapin I, 1986, Adv Neurol, V43, P65; Ryu SE, 1996, STRUCTURE, V4, P1181, DOI 10.1016/S0969-2126(96)00126-8; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; Takao M, 2000, J NEUROPATH EXP NEUR, V59, P1070, DOI 10.1093/jnen/59.12.1070; Tran PB, 1999, TRENDS NEUROSCI, V22, P194, DOI 10.1016/S0166-2236(99)01409-5; Verghese J, 2000, ARCH NEUROL-CHICAGO, V57, P389, DOI 10.1001/archneur.57.3.389; Walker LC, 2000, NEUROBIOL AGING, V21, P559, DOI 10.1016/S0197-4580(00)00160-3; WHISSTOCK J, 1996, THESIS CAMBRIDGE U C; Whisstock JC, 2000, J MOL BIOL, V296, P685, DOI 10.1006/jmbi.1999.3520; Wilson CA, 1999, J NEUROPATH EXP NEUR, V58, P787, DOI 10.1097/00005072-199908000-00001; Yazaki M, 2001, AM J PATHOL, V158, P227, DOI 10.1016/S0002-9440(10)63961-2; YERBY MS, 1986, NEUROLOGY, V36, P68, DOI 10.1212/WNL.36.1.68	33	127	130	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 29	2002	359	9325					2242	2247		10.1016/S0140-6736(02)09293-0	http://dx.doi.org/10.1016/S0140-6736(02)09293-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567YJ	12103288				2022-12-28	WOS:000176514500010
J	Vervoort, VS; Beachem, MA; Edwards, PS; Ladd, S; Miller, KE; de Mollerat, X; Clarkson, K; DuPont, B; Schwartz, CE; Stevenson, RE; Boyd, E; Srivastava, AK				Vervoort, VS; Beachem, MA; Edwards, PS; Ladd, S; Miller, KE; de Mollerat, X; Clarkson, K; DuPont, B; Schwartz, CE; Stevenson, RE; Boyd, E; Srivastava, AK			AGTR2 mutations in X-linked mental retardation	SCIENCE			English	Article							TYPE-2 RECEPTOR GENE; MICE LACKING; ANGIOTENSIN; TRANSCRIPTION; BEHAVIOR; AT2; MB	Two angiotensin II (Ang II) specific receptors, AGTR1 and AGTR2, are expressed in the mammalian brain. Ang II actions on blood pressure regulation, water electrolyte balance, and hormone secretion are primarily mediated by AGTR1. The function of AGTR2 remains unclear. Here, we show that expression of the AGTR2 gene was absent in a female patient with mental retardation (MR) who had a balanced X;7 chromosomal translocation. Additionally, 8 of 590 unrelated male patients with MR were found to have sequence changes in the AGTR2 gene, including one frameshift and three missense mutations. These findings indicate a role for AGTR2 in brain development and cognitive function.	Greenwood Genet Ctr, JC Self Res Inst Human Genet, Greenwood, SC 29646 USA; Clemson Univ, Dept Biochem & Genet, Clemson, SC 29634 USA; Fullerton Genet Ctr, Asheville, NC 28803 USA	Greenwood Genetic Center; Clemson University	Srivastava, AK (corresponding author), Greenwood Genet Ctr, JC Self Res Inst Human Genet, 1 Gregor Mendel Circle, Greenwood, SC 29646 USA.	anand@ggc.org			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD039331] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R24MH057840] Funding Source: NIH RePORTER; NICHD NIH HHS [R01-HD39331] Funding Source: Medline; NIMH NIH HHS [R24 MH57840] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Chelly J, 2001, NAT REV GENET, V2, P669, DOI 10.1038/35088558; Chung O, 1996, Blood Press Suppl, V2, P47; Crisponi L, 2001, NAT GENET, V27, P159, DOI 10.1038/84781; GALLINAT S, 2001, AM J PHYSIOL-ENDOC M, V278, P357; Ge JA, 1996, EUR J PHARMACOL, V297, P299, DOI 10.1016/0014-2999(95)00762-8; GIACALONE J, 1992, NAT GENET, V1, P137, DOI 10.1038/ng0592-137; HEIN L, 1995, NATURE, V377, P744, DOI 10.1038/377744a0; ICHIKI T, 1995, NATURE, V377, P748, DOI 10.1038/377748a0; Kleinjan DJ, 1998, HUM MOL GENET, V7, P1611, DOI 10.1093/hmg/7.10.1611; Knowle D, 2000, REGUL PEPTIDES, V87, P73, DOI 10.1016/S0167-0115(99)00111-1; LAZARD D, 1994, RECEPTOR CHANNEL, V2, P271; MACGREGOR DP, 1995, BRAIN RES, V675, P231, DOI 10.1016/0006-8993(95)00076-3; Nagaraja R, 1998, GENOMICS, V52, P247, DOI 10.1006/geno.1998.5438; Nishimura H, 1999, MOL CELL, V3, P1, DOI 10.1016/S1097-2765(00)80169-0; Nuyt AM, 1999, J COMP NEUROL, V407, P193; Okuyama S, 1999, BRAIN RES, V821, P150, DOI 10.1016/S0006-8993(99)01098-7; Pfeifer D, 1999, AM J HUM GENET, V65, P111, DOI 10.1086/302455; Saavedra JM, 1999, REGUL PEPTIDES, V85, P31, DOI 10.1016/S0167-0115(99)00081-6; Sossey-Alaoui K, 1999, GENOMICS, V60, P330, DOI 10.1006/geno.1999.5924; Steingruber HE, 1999, GENOME RES, V9, P751; STEVENSON RE, 2000, XLINKED MENTAL RETAR; Warnecke C, 1999, BIOCHEM J, V340, P17, DOI 10.1042/0264-6021:3400017; Zhu MY, 2000, J NEUROPHYSIOL, V84, P2494, DOI 10.1152/jn.2000.84.5.2494	23	116	123	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 28	2002	296	5577					2401	2403						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	567CE	12089445				2022-12-28	WOS:000176467200044
J	Gerber, HP; Malik, AK; Solar, GP; Sherman, D; Liang, XH; Meng, G; Hong, K; Marsters, JC; Ferrara, N				Gerber, HP; Malik, AK; Solar, GP; Sherman, D; Liang, XH; Meng, G; Hong, K; Marsters, JC; Ferrara, N			VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism	NATURE			English	Article							ENDOTHELIAL GROWTH-FACTOR; HEMATOPOIETIC PROGENITOR CELLS; ACUTE MYELOID-LEUKEMIA; KINASE INHIBITORS; EXPRESSION; GENE; MICE; PROLIFERATION; INACTIVATION; PRECURSORS	Vascular endothelial growth factor (VEGF) is a principal regulator of blood vessel formation and haematopoiesis(1,2), but the mechanisms by which VEGF differentially regulates these processes have been elusive. Here we describe a regulatory loop by which VEGF controls survival of haematopoietic stem cells (HSCs). We observed a reduction in survival, colony formation and in vivo repopulation rates of HSCs after ablation of the VEGF gene in mice. Intracellularly acting small-molecule inhibitors of VEGF receptor (VEGFR) tyrosine kinase dramatically reduced colony formation of HSCs, thus mimicking deletion of the VEGF gene. However, blocking VEGF by administering a soluble VEGFR-1, which acts extracellularly, induced only minor effects. These findings support the involvement in HSC survival of a VEGF-dependent internal autocrine loop mechanism (that is, the mechanism is resistant to inhibitors that fail to penetrate the intracellular compartment). Not only ligands selective for VEGF and VEGFR-2 but also VEGFR-1 agonists rescued survival and repopulation of VEGF-deficient HSCs, revealing a function for VEGFR-1 signalling during haematopoiesis.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Chem, San Francisco, CA 94080 USA; Genentech Inc, Dept Assay Dev, San Francisco, CA 94080 USA; Genentech Inc, Dept Organ Chem, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Gerber, HP (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.			MALIK, AJAY/0000-0002-4831-3597				Austin TW, 1997, BLOOD, V89, P3624, DOI 10.1182/blood.V89.10.3624.3624_3624_3635; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bautz F, 2000, EXP HEMATOL, V28, P700, DOI 10.1016/S0301-472X(00)00168-5; Behringer D, 1997, BRIT J HAEMATOL, V97, P9, DOI 10.1046/j.1365-2141.1997.d01-2143.x; Bellamy WT, 2001, BLOOD, V97, P1427, DOI 10.1182/blood.V97.5.1427; BROWDER TM, 1989, MOL CELL BIOL, V9, P204, DOI 10.1128/MCB.9.1.204; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Dias S, 2001, P NATL ACAD SCI USA, V98, P10857, DOI 10.1073/pnas.191117498; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Fiedler W, 1997, BLOOD, V89, P1870, DOI 10.1182/blood.V89.6.1870; Gerber HP, 2000, CANCER RES, V60, P6253; Gerber HP, 1999, DEVELOPMENT, V126, P1149; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GILLE H, 2000, J BIOL CHEM, V10, P3222; Hennequin LF, 1999, J MED CHEM, V42, P5369, DOI 10.1021/jm990345w; Janowska-Wieczorek A, 2001, STEM CELLS, V19, P99, DOI 10.1634/stemcells.19-2-99; Kabrun N, 1997, DEVELOPMENT, V124, P2039; Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; PARK JE, 1994, J BIOL CHEM, V269, P25646; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Ryan AM, 1999, TOXICOL PATHOL, V27, P78, DOI 10.1177/019262339902700115; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Smolich BD, 2001, BLOOD, V97, P1413, DOI 10.1182/blood.V97.5.1413; Solar GP, 1998, BLOOD, V92, P4, DOI 10.1182/blood.V92.1.4.413k38_4_10; Sun L, 1999, J MED CHEM, V42, P5120, DOI 10.1021/jm9904295; Taraseviciene-Stewart L, 2001, FASEB J, V15, P427, DOI 10.1096/fj.00-0343com; Wedge SR, 2000, CANCER RES, V60, P970; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200	30	540	578	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 27	2002	417	6892					954	958		10.1038/nature00821	http://dx.doi.org/10.1038/nature00821			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	566RC	12087404				2022-12-28	WOS:000176441200040
J	Benner, JS; Glynn, RJ; Mogun, H; Neumann, PJ; Weinstein, MC; Avorn, J				Benner, JS; Glynn, RJ; Mogun, H; Neumann, PJ; Weinstein, MC; Avorn, J			Long-term persistence in use of statin therapy in elderly patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; LIPID-LOWERING MEDICATIONS; CORONARY-HEART-DISEASE; ANTIHYPERTENSIVE THERAPY; DISCONTINUATION RATES; PRIMARY PREVENTION; PRAVASTATIN; EVENTS; INTERVENTIONS; COMORBIDITY	Context Knowledge of long-term persistence with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy is limited because previous studies have observed patients for short periods of time, in closely monitored clinical trials, or in other unrepresentative settings. Objective To describe the patterns and predictors of long-term persistence with statin therapy in an elderly US population. Design, Setting, and Patients Retrospective cohort study including 34501 enrollees in the New Jersey Medicaid and Pharmaceutical Assistance to the Aged and Disabled programs who were 65 years of age and older, initiated statin treatment between 1990 and 1998, and who were followed up until death, disenrollment, or December 31, 1999. Main Outcome Measures Proportion of days covered (PDC) by a statin in each quarter during the first year of therapy and every 6 months thereafter; predictors of suboptimal persistence during each interval (PDC <80%) were identified using generalized linear models for repeated measures. Results The mean PDC was 79% in the first 3 months of treatment, 56% in the second quarter, and 42% after 120 months. Only 1 patient in 4 maintained a PDC of at least 80% after 5 years. The proportion of patients with a PDC less than 80% increased in a log-linear manner, comprising 40%, 61%, and 68% of the cohort after 3, 12, and 120 months, respectively. Independent predictors of poor long-term persistence included nonwhite race, lower income, older age, less cardiovascular morbidity at initiation of therapy, depression, dementia, and occurrence of coronary heart disease events after starting treatment. Patients who initiated therapy between 1996-1998 were 21% to 25% more likely to have a PDC of at least 80% than those who started in 1990. Conclusions Persistence with statin therapy in older patients declines substantially over time, with the greatest drop occurring in the first 6 months of treatment. Despite slightly better persistence among patients who began treatment in recent years, long-term use remains low. Interventions are needed early in treatment and among high-risk groups, including those who experience coronary heart disease events after initiating treatment.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Ctr Risk Anal, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Benner, JS (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Pharmacoepidemiol & Pharmacoecon, 221 Longwood Ave,Suite 341, Boston, MA 02115 USA.	jbenner@post.harvard.edu			NIA NIH HHS [AG-18935, AG-18833] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R56AG018833, R01AG018833] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		American Heart Association, 2000, 2001 HEART STROK STA; ANDRADE SE, 1995, NEW ENGL J MED, V332, P1125, DOI 10.1056/NEJM199504273321703; Avorn J, 1998, JAMA-J AM MED ASSOC, V279, P1458, DOI 10.1001/jama.279.18.1458; Brier KL, 1999, ARCH INTERN MED, V159, P569, DOI 10.1001/archinte.159.6.569; Burke LE, 1997, ANN BEHAV MED, V19, P239, DOI 10.1007/BF02892289; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Choo PW, 1999, MED CARE, V37, P846, DOI 10.1097/00005650-199909000-00002; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Eriksson M, 1998, J INTERN MED, V243, P373; Fedder DO, 2002, CIRCULATION, V105, P152, DOI 10.1161/hc0202.101971; GURWITZ JH, 1993, AM J PUBLIC HEALTH, V83, P711, DOI 10.2105/AJPH.83.5.711; Haynes RB, 1996, LANCET, V348, P383; Hiatt JG, 1999, AM J MANAG CARE, V5, P437; Hunt D, 2001, ANN INTERN MED, V134, P931, DOI 10.7326/0003-4819-134-10-200105150-00007; Insull W, 1997, J INTERN MED, V241, P317, DOI 10.1046/j.1365-2796.1997.112133000.x; Jackevicius CA, 2001, ARCH INTERN MED, V161, P183, DOI 10.1001/archinte.161.2.183; LaRosa JC, 1999, JAMA-J AM MED ASSOC, V282, P2340, DOI 10.1001/jama.282.24.2340; Lemaitre RN, 1998, ARCH INTERN MED, V158, P1761, DOI 10.1001/archinte.158.16.1761; Lewis SJ, 1998, ANN INTERN MED, V129, P681, DOI 10.7326/0003-4819-129-9-199811010-00002; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Majumdar SR, 1999, J GEN INTERN MED, V14, P711, DOI 10.1046/j.1525-1497.1999.02229.x; McCormick D, 1999, ARCH INTERN MED, V159, P561, DOI 10.1001/archinte.159.6.561; Miettinen TA, 1997, CIRCULATION, V96, P4211; Monane M, 1996, AM J PUBLIC HEALTH, V86, P1805, DOI 10.2105/AJPH.86.12.1805; MONANE M, 1994, ARCH INTERN MED, V154, P433, DOI 10.1001/archinte.154.4.433; Monane M, 1997, AM J HYPERTENS, V10, P697, DOI 10.1016/S0895-7061(97)00056-3; *MRC BHF HEART PRO, 2001, PREL RES; PEDERSEN TR, 1994, LANCET, V344, P1383; Redelmeier DA, 1998, NEW ENGL J MED, V338, P1516, DOI 10.1056/NEJM199805213382106; Roter DL, 1998, MED CARE, V36, P1138, DOI 10.1097/00005650-199808000-00004; Rudd P., 1994, CARDIOL REV, V2, P230; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SAS Institute Inc., 2000, SAS VERS 8 2; Schwed A, 1999, J CLIN PHARMACOL, V39, P402, DOI 10.1177/00912709922007976; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Simons LA, 1996, MED J AUSTRALIA, V164, P208, DOI 10.5694/j.1326-5377.1996.tb94138.x; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; WANG PJ, IN PRESS J GEN INTER	40	908	923	2	38	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 24	2002	288	4					455	461		10.1001/jama.288.4.455	http://dx.doi.org/10.1001/jama.288.4.455			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575NZ	12132975	Bronze			2022-12-28	WOS:000176955400027
J	Long, CA; Hoffman, SL				Long, CA; Hoffman, SL			Parasitology: Malaria - from infants to genomics to vaccines	SCIENCE			English	Editorial Material									NIH, Malaria Vaccine Dev Unit, Rockville, MD 20852 USA; Celera Genom, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA	Long, CA (corresponding author), NIH, Malaria Vaccine Dev Unit, Rockville, MD 20852 USA.							*WHO, 2002, REP COMM MACR HLTH W; 2002, KEYST S 3 8 MARCH 20	2	15	20	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 19	2002	297	5580					345	347		10.1126/science.1074484	http://dx.doi.org/10.1126/science.1074484			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574LV	12130768				2022-12-28	WOS:000176892600033
J	Maeda, N; Chen, NH; Tirrell, M; Israelachvili, JN				Maeda, N; Chen, NH; Tirrell, M; Israelachvili, JN			Adhesion and friction mechanisms of polymer-on-polymer surfaces	SCIENCE			English	Article							ELASTIC SOLIDS; THIN-FILM; TRIBOLOGY; INTERFACES; CONTACT; ENERGY; PNBMA; MICA	The adhesion and friction of smooth polymer surfaces were studied below the glass transition temperature by use of a surface forces apparatus. The friction force of a crosslinked polymer was orders of magnitude less than that of an uncrosslinked polymer. In contrast, after chain scission of the outermost layers, the adhesion hysteresis and friction forces increase substantially. These results show that polymer-polymer adhesion hysteresis and friction depend on the dynamic rearrangement of the outermost polymer segments at shearing interfaces, and that both increase as a transition is made from crosslinked surfaces to surfaces with long chains to surfaces with quasi-free ends. The results suggest new ways for manipulating the adhesion and friction of polymer surfaces by adjusting the state of the surface chains.	Univ Calif Santa Barbara, Coll Engn, Dept Chem Engn, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Coll Engn, Dept Mat, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Coll Engn, Mat Res Lab, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Israelachvili, JN (corresponding author), Univ Calif Santa Barbara, Coll Engn, Dept Chem Engn, Santa Barbara, CA 93106 USA.	jacob@engineering.ucsb.edu	Maeda, Nobuo/J-8961-2018; Maeda, Nobuo/C-4234-2011	Maeda, Nobuo/0000-0002-0481-9852; Maeda, Nobuo/0000-0002-0481-9852				Agrawal G, 1996, J POLYM SCI POL PHYS, V34, P2919, DOI 10.1002/(SICI)1099-0488(199612)34:17<2919::AID-POLB6>3.0.CO;2-L; Berman A.D., 2000, MODERN TRIBOLOGY HDB, V1, P567; Brown HR, 1996, MACROMOLECULES, V29, P798, DOI 10.1021/ma951123k; Chen N, UNPUB; CHEN YL, 1991, J PHYS CHEM-US, V95, P10736, DOI 10.1021/j100179a041; Flory PJ., 1953, PRINCIPLES POLYM CHE, V672; HENKEE CS, 1985, THESIS CORNELL U; Heuberger M, 1999, J PHYS CHEM B, V103, P10127, DOI 10.1021/jp991098a; ISRAELAC.JN, 1973, J COLLOID INTERF SCI, V44, P259, DOI 10.1016/0021-9797(73)90218-X; ISRAELACHVILI J, 1995, ORIGIN ENERGY DISSIP; JOHNSON KL, 1971, PROC R SOC LON SER-A, V324, P301, DOI 10.1098/rspa.1971.0141; Li LH, 2001, NATO SCI SER II-MATH, V10, P305; Luengo G, 1997, MACROMOLECULES, V30, P2482, DOI 10.1021/ma9519122; Luengo G, 2000, J PHYS CHEM B, V104, P7944, DOI 10.1021/jp0005773; Persson B. N. J., 1998, SLIDING FRICTION PHY; Persson BNJ, 2001, J CHEM PHYS, V115, P5597, DOI 10.1063/1.1398300; ROBERTS AD, 1975, WEAR, V33, P45, DOI 10.1016/0043-1648(75)90223-9; ROBERTS AD, 1979, RUBBER CHEM TECHNOL, V52, P23, DOI 10.5254/1.3535206; Tirrell M, 1996, LANGMUIR, V12, P4548, DOI 10.1021/la950894e; YOSHIZAWA H, 1993, J PHYS CHEM-US, V97, P4128, DOI 10.1021/j100118a033	20	231	240	13	267	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 19	2002	297	5580					379	382		10.1126/science.1072378	http://dx.doi.org/10.1126/science.1072378			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574LV	12130780				2022-12-28	WOS:000176892600045
J	Bruggen, M; Kaiser, CR				Bruggen, M; Kaiser, CR			Hot bubbles from active galactic nuclei as a heat source in cooling-flow clusters	NATURE			English	Article							RAY; GALAXIES	Hot, X-ray-emitting plasma permeates clusters of galaxies. The X-ray surface brightness often shows a peak near the centre of the cluster that is coincident with a drop in the entropy of the gas. This has been taken as evidence for a 'cooling flow', where the gas cools by radiating away its energy, and then falls to the centre(1). Searches for this cool gas have revealed significantly less than predicted(2), indicating that the mass deposition rate is much lower than expected. Most clusters with cooling flows, however, also host an active galactic nucleus at their centres(3). These active galactic nuclei can inflate large bubbles of hot plasma that subsequently rise through the cluster 'atmosphere', thus stirring the cooling gas(4,5) and adding energy. Here we report highly resolved hydrodynamic simulations which show that buoyant bubbles increase the cooling time in the inner regions of clusters and significantly reduce the deposition of cold gas.	Int Jacobs Univ Bremen, D-28759 Bremen, Germany; Univ Southampton, Dept Phys & Astron, Southampton SO17 1BJ, Hants, England	University of Southampton	Bruggen, M (corresponding author), Int Jacobs Univ Bremen, Campus Ring 1, D-28759 Bremen, Germany.	m.brueggen@iu-bremen.de						BINNEY J, 1995, MON NOT R ASTRON SOC, V276, P663, DOI 10.1093/mnras/276.2.663; BOHRINGER H, UNPUB ASTRON ASTROPH; BOHRINGER H, ASTROPH0111112; Bruggen M, 2001, MON NOT R ASTRON SOC, V325, P676, DOI 10.1046/j.1365-8711.2001.04494.x; BRUGGEN M, IN PRESS MON NOT R A; BURNS JO, 1990, ASTRON J, V99, P14, DOI 10.1086/115307; Churazov E, 2000, ASTRON ASTROPHYS, V356, P788; Churazov E, 2001, ASTROPHYS J, V554, P261, DOI 10.1086/321357; FABIAN AC, 1994, ANNU REV ASTRON ASTR, V32, P277, DOI 10.1146/annurev.aa.32.090194.001425; Fryxell B, 2000, ASTROPHYS J SUPPL S, V131, P273, DOI 10.1086/317361; Kaiser CR, 1999, MON NOT R ASTRON SOC, V305, P707, DOI 10.1046/j.1365-8711.1999.02498.x; MCNAMARA BR, 2001, ASTROPH0110554; MCNAMARA BR, UNPUB ASTROPHYS J; Quilis V, 2001, MON NOT R ASTRON SOC, V328, P1091, DOI 10.1046/j.1365-8711.2001.04927.x; REYNOLDS CS, IN PRESS MON NOT R A; Soker M, 2001, ASTROPHYS J, V549, P832, DOI 10.1086/319433; Voit GM, 2001, NATURE, V414, P425, DOI 10.1038/35106523; Wu KKS, 2000, MON NOT R ASTRON SOC, V318, P889, DOI 10.1046/j.1365-8711.2000.03828.x	21	206	206	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 18	2002	418	6895					301	303		10.1038/nature00857	http://dx.doi.org/10.1038/nature00857			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574BF	12124617	Green Submitted			2022-12-28	WOS:000176868000035
J	Sunda, W; Kieber, DJ; Kiene, RP; Huntsman, S				Sunda, W; Kieber, DJ; Kiene, RP; Huntsman, S			An antioxidant function for DMSP and DMS in marine algae	NATURE			English	Article							DIMETHYLSULFOXIDE DMSO; HYDROXYL RADICALS; RATE CONSTANTS; SEAWATER; SULFUR; IRON; DIMETHYLSULFONIOPROPIONATE; PHYTOPLANKTON; CONVERSION; OXYGEN	The algal osmolyte dimethylsulphoniopropionate (DMSP) and its enzymatic cleavage product dimethylsulphide (DMS) contribute significantly to the global sulphur cycle(1-3), yet their physiological functions are uncertain(4). Here we report results that, together with those in the literature(5,6), show that DMSP and its breakdown products (DMS, acrylate, dimethylsulphoxide, and methane sulphinic acid) readily scavenge hydroxyl radicals and other reactive oxygen species, and thus may serve as an antioxidant system, regulated in part by enzymatic cleavage of DMSP. In support of this hypothesis, we found that oxidative stressors, solar ultraviolet radiation(7), CO2 limitation(8), Fe limitation, high Cu2+ (ref. 9) and H2O2 substantially increased cellular DMSP and/or its lysis to DMS in marine algal cultures. Our results indicate direct links between such stressors and the dynamics of DMSP and DMS in marine phytoplankton, which probably influence the production of DMS and its release to the atmosphere. As oxidation of DMS to sulphuric acid in the atmosphere provides a major source of sulphate aerosols and cloud condensation nuclei(3), oxidative stressors-including solar radiation and Fe limitation-may be involved in complex ocean-atmosphere feedback loops that influence global climate and hydrological cycles(1,2).	NOAA, Beaufort Lab, Beaufort, NC 28516 USA; SUNY Coll Environm Sci & Forestry, Dept Chem, Syracuse, NY 13210 USA; Univ S Alabama, Dept Marine Sci, Mobile, AL 36688 USA	National Oceanic Atmospheric Admin (NOAA) - USA; State University of New York (SUNY) System; State University of New York (SUNY) College of Environmental Science & Forestry; University of South Alabama	Sunda, W (corresponding author), NOAA, Beaufort Lab, Beaufort, NC 28516 USA.	bill.sunda@noaa.gov						Ahner BA, 2002, MAR ECOL PROG SER, V232, P93, DOI 10.3354/meps232093; Andreae MO, 1997, SCIENCE, V276, P1052, DOI 10.1126/science.276.5315.1052; BATES TS, 1987, NATURE, V329, P319, DOI 10.1038/329319a0; BELVISO S, 1993, MAR CHEM, V44, P55, DOI 10.1016/0304-4203(93)90006-A; Butow B, 1998, J PLANKTON RES, V20, P355, DOI 10.1093/plankt/20.2.355; BUXTON GV, 1988, J PHYS CHEM REF DATA, V17, P513, DOI 10.1063/1.555805; CHARLSON RJ, 1987, NATURE, V326, P655, DOI 10.1038/326655a0; DABROWSKI K, 2001, ASCORBATE AQUATIC OR; Dacey JWH, 1998, DEEP-SEA RES PT I, V45, P2085, DOI 10.1016/S0967-0637(98)00048-X; GREENE RM, 1992, PLANT PHYSIOL, V100, P565, DOI 10.1104/pp.100.2.565; Jakob B, 1996, PLANT CELL PHYSIOL, V37, P629, DOI 10.1093/oxfordjournals.pcp.a028991; KARSTEN U, 1990, PLANT CELL ENVIRON, V13, P989, DOI 10.1111/j.1365-3040.1990.tb01991.x; Kieber DJ, 1996, J GEOPHYS RES-OCEANS, V101, P3715, DOI 10.1029/95JC03624; KIENE RP, 1994, MAR CHEM, V47, P1, DOI 10.1016/0304-4203(94)90009-4; Lee PA, 1999, J PHYCOL, V35, P8, DOI 10.1046/j.1529-8817.1999.3510008.x; LESSER MP, 1989, MAR BIOL, V102, P243, DOI 10.1007/BF00428286; NAKANO Y, 1981, PLANT CELL PHYSIOL, V22, P867; Nanninga HJ, 1996, MAR ECOL PROG SER, V136, P195, DOI 10.3354/meps136195; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; Okamoto OK, 2001, ARCH ENVIRON CON TOX, V40, P18; SCADUTO RC, 1995, FREE RADICAL BIO MED, V18, P271, DOI 10.1016/0891-5849(94)E0139-A; Simo R, 2000, MAR ECOL PROG SER, V203, P1, DOI 10.3354/meps203001; Simo R, 1999, NATURE, V402, P396, DOI 10.1038/46516; Simo R, 1998, MAR ECOL PROG SER, V167, P291, DOI 10.3354/meps167291; SIMO R, 1995, MAR ECOL PROG SER, V127, P291, DOI 10.3354/meps127291; Stefels J, 2000, J SEA RES, V43, P183, DOI 10.1016/S1385-1101(00)00030-7; Stefels J, 1998, J PHYCOL, V34, P486, DOI 10.1046/j.1529-8817.1998.340486.x; Steinke M, 1996, BIOLOGICAL AND ENVIRONMENTAL CHEMISTRY OF DMSP AND RELATED SULFONIUM COMPOUNDS, P317; SUNDA WG, 1995, MAR CHEM, V50, P189, DOI 10.1016/0304-4203(95)00035-P; WILKINSON F, 1995, J PHYS CHEM REF DATA, V24, P663, DOI 10.1063/1.555965	30	790	827	13	249	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 18	2002	418	6895					317	320		10.1038/nature00851	http://dx.doi.org/10.1038/nature00851			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574BF	12124622				2022-12-28	WOS:000176868000040
J	Aboff, BM; Collier, VU; Farber, NJ; Ehrenthal, DB				Aboff, BM; Collier, VU; Farber, NJ; Ehrenthal, DB			Residents' prescription writing for nonpatients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	21st Annual Meeting of the Society-of-General-Internal-Medicine	APR 23-25, 1998	CHICAGO, IL	Soc Gen Internal Med			PHYSICIANS	Context Writing prescriptions is one of the most tangible new responsibilities that residents acquire after graduating from medical school, During their regular duties, house officers' prescription writing is carefully monitored. Little is known, however, about residents' patterns of prescription writing outside of supervision or about residents' knowledge of the ethical and legal guidelines that regulate prescription writing. Objective To study what factors influence residents' decision to write prescriptions for nonpatients. Design, Setting, and Participants Survey distributed in December 1997 to 92 internal medicine and family practice residents at a US community-based teaching hospital. Eighty percent responded. Main Outcome Measures Self-reported prescribing activities for nonpatients and for individuals in 12 hypothetical vignettes. Results Eighty-five percent of respondents reported having written prescriptions for nonpatients, Based on their responses to the vignettes, under certain circumstances, up to 95% of residents would write a prescription for an individual who is not their patient (eg, a sibling). Thirteen percent of residents believed that some ethical guidelines on prescription-writing activity existed. Only 4% of residents reported being aware of federal or state laws addressing the appropriateness of physician prescription writing for nonpatients. None of the residents were able to describe the circumstances that make prescription writing for nonpatients illegal or unethical based on legal statutes or ethical guidelines, respectively, Conclusions In a sample of community-based internal medicine and family practice residents, unsupervised prescription writing by residents for individuals who are not their patients is a common occurrence. Since residency training is a time when practice habits are established, it is important that all residents learn about the ethical, legal, and liability implications of writing prescriptions for nonpatients.	Christiana Care Hlth Syst, Dept Med, Wilmington, DE 19899 USA	Christiana Care Health System	Aboff, BM (corresponding author), Christiana Care Hlth Syst, Dept Med, 501 W 14th St, Wilmington, DE 19899 USA.	baboff@christianacare.org						AACH RD, 1992, ANN INTERN MED, V116, P245, DOI 10.7326/0003-4819-116-3-245; AJZEN I, 1977, PSYCHOL BULL, V84, P888, DOI 10.1037/0033-2909.84.5.888; *AM COLL PHYS AM S, 1999, ACP ASIM OBSERVER, V19, P1; *AM MED ASS, 1997, AMA CURR OP COUNC ET; Christie JD, 1998, JAMA-J AM MED ASSOC, V280, P1253, DOI 10.1001/jama.280.14.1253; CLARK AW, 1988, J MED EDUC, V63, P44; Desalvo KB, 2000, J INVEST MED, V48, p226A; DUSDIEKER LB, 1993, AM J DIS CHILD, V147, P146, DOI 10.1001/archpedi.1993.02160260036018; FINKEL SK, 1996, VITAL SIGNS      JUN; HOWARD ML, 1995, LEGAL MED, P265; HUGHES PH, 1991, JAMA-J AM MED ASSOC, V265, P2069, DOI 10.1001/jama.265.16.2069; LAPUMA J, 1991, NEW ENGL J MED, V325, P1290, DOI 10.1056/NEJM199110313251806; LAPUMA J, 1992, JAMA-J AM MED ASSOC, V257, P1810	13	13	13	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	2002	288	3					381	385		10.1001/jama.288.3.381	http://dx.doi.org/10.1001/jama.288.3.381			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	573AK	12117406	Bronze			2022-12-28	WOS:000176807000033
J	Bartlett, C; Sterne, J; Egger, M				Bartlett, C; Sterne, J; Egger, M			What is newsworthy? Longitudinal study of the reporting of medical research in two British newspapers	BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	4th Peer Review Congress	2001	BARCELONS, SPAIN				RANDOM ALLOCATION; CLINICAL-TRIAL; ARTICLES; LEUKEMIA; HEALTH; PARTICIPATION; JOURNALS; COVERAGE; PARENTS; BABIES	Objective To assess the Characteristics of medical research that is press released by general medical journals and reported in newspapers. Design Longitudinal study. Data sources All original research articles published in Lancet and BAY during 1999 and 2000. Main outcome measures Inclusion of articles in Lancet or BAY press releases, and reporting of articles in Times or Sun newspapers. Results Of 1193 original research articles, 517 (43%) were highlighted in a press release and 81 (7%) were reported in one or both newspapers. All articles covered in newspapers had been press released. The probability of inclusion in press releases was similar for observational studies and randomised controlled trials, but trials were less likely to be covered in the newspapers (odds ratio 0.15 (95% confidence interval 0.06 to 0.37)). Good news and bad news were equally likely to be press released, but bad news was snore likely to be reported in newspapers (1.74 (1.07 to 2.83)). Studies of women's health, reproduction, and cancer were more likely to be press released acid covered in newspapers. Studies from industrialised countries other than Britain were less likely to be reported in newspapers (0.51 (0.31 to 0.82)), and no studies from developing countries were covered. Conclusions Characteristics of articles were more strongly associated with selection for reporting in newspapers than with selection for inclusion in press releases, although each stage influenced the reporting process. Newspapers underreported randomised trials, emphasised bad news from observational studies, and ignored research from developing countries.	Univ Bristol, Dept Social Med, MRC Hlth Serv Res Collaborat, Bristol BS8 2PR, Avon, England	University of Bristol	Egger, M (corresponding author), Univ Bern, Dept Social & Prevent Med, Finkenhubelweg 11, CH-3012 Bern, Switzerland.		Sterne, Jonathan/Z-3106-2019	Sterne, Jonathan/0000-0001-8496-6053; Egger, Matthias/0000-0001-7462-5132				Blair PS, 1999, BRIT MED J, V319, P1457, DOI 10.1136/bmj.319.7223.1457; de Semir V, 1998, JAMA-J AM MED ASSOC, V280, P294, DOI 10.1001/jama.280.3.294; Deary IJ, 1998, LANCET, V351, P1726, DOI 10.1016/S0140-6736(97)10317-8; ENTWISTLE V, 1995, BRIT MED J, V310, P920, DOI 10.1136/bmj.310.6984.920; Entwistle VA, 2000, LANCET, V355, P1633, DOI 10.1016/S0140-6736(00)02226-1; Featherstone K, 1998, BRIT MED J, V317, P1177, DOI 10.1136/bmj.317.7167.1177; Girardi E, 1998, JAMA-J AM MED ASSOC, V280, P292, DOI 10.1001/jama.280.3.292; GRILLI R, 2000, COCHRANE DATABASE SY; Gundestrup M, 1999, LANCET, V354, P2029, DOI 10.1016/S0140-6736(99)05093-X; Hansen D, 1999, BRIT MED J, V319, P548, DOI 10.1136/bmj.319.7209.548; Laurance J, 1998, LANCET, V351, P1727, DOI 10.1016/S0140-6736(98)02390-3; Moynihan R, 2000, NEW ENGL J MED, V342, P1645, DOI 10.1056/NEJM200006013422206; Naumburg E, 2000, BMJ-BRIT MED J, V320, P282, DOI 10.1136/bmj.320.7230.282; OXMAN AD, 1993, J CLIN EPIDEMIOL, V46, P987, DOI 10.1016/0895-4356(93)90166-X; ROBERSON NL, 1994, CANCER, V74, P2687, DOI 10.1002/1097-0142(19941101)74:9+<2687::AID-CNCR2820741817>3.0.CO;2-B; Schnohr P, 2000, BRIT MED J, V321, P602, DOI 10.1136/bmj.321.7261.602; Snowdon C, 1997, SOC SCI MED, V45, P1337, DOI 10.1016/S0277-9536(97)00063-4; Steinbrook R, 2000, NEW ENGL J MED, V342, P1668, DOI 10.1056/NEJM200006013422212; VANTRIGT AM, 1995, SOC SCI MED, V41, P893, DOI 10.1016/0277-9536(94)00389-B; Wiemels JL, 1999, LANCET, V354, P1499, DOI 10.1016/S0140-6736(99)09403-9	20	137	141	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 13	2002	325	7355					81	84		10.1136/bmj.325.7355.81	http://dx.doi.org/10.1136/bmj.325.7355.81			4	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575CU	12114239	Green Published, Bronze			2022-12-28	WOS:000176929400021
J	Rothenberg, KH; Terry, SF				Rothenberg, KH; Terry, SF			Human genetics: Before it's too late - Addressing fear of genetic information	SCIENCE			English	Editorial Material									Univ Maryland, Sch Law, Baltimore, MD 21201 USA; Genet Alliance, Washington, DC 20008 USA	University System of Maryland; University of Maryland Baltimore	Rothenberg, KH (corresponding author), Univ Maryland, Sch Law, Baltimore, MD 21201 USA.							ANDREWS L, 1987, MED GENETICS LEGAL F; BRIERLEY K, 1999, AM J HUM GENET, V65, P60; Collins FS, 2001, JAMA-J AM MED ASSOC, V285, P540, DOI 10.1001/jama.285.5.540; Geer K P, 2001, J Genet Couns, V10, P25, DOI 10.1023/A:1009451213035; Greely HT, 2001, U PENN LAW REV, V149, P1483, DOI 10.2307/3312966; HADLEY D, IN PRESS ARCH INTERN; KEVLES D, 1995, GENETICS USES HUMAN, P117; PROCTOR R, 1992, GENE MAPPING USING L, P61; Rothenberg K, 1997, SCIENCE, V275, P1755, DOI 10.1126/science.275.5307.1755; THOMPSON D, 2000, TIME            0703, P23; 2001, VCU NEWS        1004	11	32	32	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 12	2002	297	5579					196	197		10.1126/science.1075221	http://dx.doi.org/10.1126/science.1075221			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	571UT	12114610	Green Submitted			2022-12-28	WOS:000176738100021
J	Brown, S; Heinisch, I; Ross, E; Shaw, K; Buckley, CD; Savill, J				Brown, S; Heinisch, I; Ross, E; Shaw, K; Buckley, CD; Savill, J			Apoptosis disables CD31-mediated cell detachment from phagocytes promoting binding and engulfment	NATURE			English	Article							RECEPTOR-MEDIATED PHAGOCYTOSIS; VITRONECTIN RECEPTOR; NEUTROPHILS; MIGRATION; CLEARANCE; PECAM-1; DEATH; RECOGNITION; PLATELETS; BLOOD	Macrophage recognition and ingestion of 'self' cells undergoing apoptosis in vivo protects tissues from the toxic contents of dying cells and modulates macrophage regulation of inflammatory and immune responses(1,2). However, the complex molecular mechanisms mediating macrophage discrimination between viable and apoptotic cells are poorly understood(2,3). In particular, little is known of why viable nucleated cells are not engulfed by macrophages. To reveal active repulsion of viable cells and to seek specific capture or 'tethering' of apoptotic cells, we studied macrophage binding of viable and apoptotic leukocytes under conditions of flow. We found that homophilic ligation of CD31 (ref. 4) on viable leukocytes promoted their active, temperature-dependent detachment under low shear, whereas such CD31-mediated detachment was disabled in apoptotic leukocytes, promoting tight binding and macrophage ingestion of dying cells. Here we propose that CD31 (also known as platelet-endothelial cell adhesion molecule-1, PECAM-1) is an example of a cell-surface molecule that prevents phagocyte ingestion of closely apposed viable cells by transmitting 'detachment' signals, and which changes function on apoptosis, promoting tethering of dying cells to phagocytes.	Univ Edinburgh, MRC, Ctr Inflammat Res, Inflammat Repair Grp, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Birmingham, MRC, Ctr Immune Regulat, Div Immun & Infect, Birmingham B15 2TT, W Midlands, England	University of Edinburgh; University of Birmingham	Brown, S (corresponding author), Univ Edinburgh, MRC, Ctr Inflammat Res, Inflammat Repair Grp, Edinburgh EH8 9AG, Midlothian, Scotland.		Buckley, Christopher/AAN-6378-2021; Brown, Simon/B-3006-2009	Buckley, Christopher/0000-0001-6924-6402; Ross, Ewan/0000-0001-5733-9361				Bird IN, 1999, J CELL SCI, V112, P1989; Brown SB, 2000, J BIOL CHEM, V275, P5987, DOI 10.1074/jbc.275.8.5987; Brown SB, 1997, BIOCHEM J, V323, P233, DOI 10.1042/bj3230233; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Green DR, 2001, NATURE, V412, P133, DOI 10.1038/35084313; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; MANSFIELD PJ, 1990, J CELL BIOL, V111, P3077, DOI 10.1083/jcb.111.6.3077; METZELAAR MJ, 1991, THROMB HAEMOSTASIS, V66, P700; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129; Newton JP, 1997, J BIOL CHEM, V272, P20555, DOI 10.1074/jbc.272.33.20555; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Pumphrey NJ, 1999, FEBS LETT, V450, P77, DOI 10.1016/S0014-5793(99)00446-9; Rainger GE, 1997, CURR BIOL, V7, P316, DOI 10.1016/S0960-9822(06)00155-2; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; SAKARIASSEN KS, 1983, J LAB CLIN MED, V102, P522; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970	21	265	288	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 11	2002	418	6894					200	203		10.1038/nature00811	http://dx.doi.org/10.1038/nature00811			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571GV	12110892				2022-12-28	WOS:000176710400044
J	Fiaux, J; Bertelsen, EB; Horwich, AL; Wuthrich, K				Fiaux, J; Bertelsen, EB; Horwich, AL; Wuthrich, K			NMR analysis of a 900K GroEL-GroES complex	NATURE			English	Article							TRIPLE-RESONANCE EXPERIMENTS; NUCLEAR-MAGNETIC-RESONANCE; BACTERIAL CHAPERONIN GROEL; CRYSTAL-STRUCTURE; BIOLOGICAL MACROMOLECULES; POLARIZATION TRANSFER; LARGE MOLECULES; LARGE PROTEINS; TROSY; RELAXATION	Biomacromolecular structures with a relative molecular mass (M-r) of 50, 000 to 100,000 (50K-100K) have been generally considered to be inaccessible to analysis by solution NMR spectroscopy. Here we report spectra recorded from bacterial chaperonin complexes ten times this size limit (up to M-r 900K) using the techniques of transverse relaxation-optimized spectroscopy and cross-correlated relaxation-enhanced polarization transfer(1-5). These techniques prevent deterioration of the NMR spectra by the rapid transverse relaxation of the magnetization to which large, slowly tumbling molecules are otherwise subject. We tested the resolving power of these techniques by examining the isotope-labelled homoheptameric co-chaperonin GroES (M-r 72K), either free in solution or in complex with the homotetradecameric chaperonin GroEL (M-r 800K) or with the single-ring GroEL variant SR1 (M-r 400K). Most amino acids of GroES show the same resonances whether free in solution or in complex with chaperonin; however, residues 17-32 show large chemical shift changes on binding. These amino acids belong to a mobile loop region of GroES that forms contacts with GroEL(6-10). This establishes the utility of these techniques for solution NMR studies that should permit the exploration of structure, dynamics and interactions in large macromolecular complexes.	ETH Zurich, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; Howard Hughes Medical Institute; Yale University; Yale University	Wuthrich, K (corresponding author), ETH Zurich, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland.			Wuthrich, Kurt/0000-0001-8739-6965				ARATA Y, 1994, METHOD ENZYMOL, V239, P440; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Brinker A, 2001, CELL, V107, P223, DOI 10.1016/S0092-8674(01)00517-7; DEMARCO A, 1976, J MAGN RESON, V24, P201, DOI 10.1016/0022-2364(76)90028-7; GOLDMAN M, 1984, J MAGN RESON, V60, P437, DOI 10.1016/0022-2364(84)90055-6; GUNTERT P, 1992, J BIOMOL NMR, V2, P619, DOI 10.1007/BF02192850; Horwich AL, 1998, METHOD ENZYMOL, V290, P141, DOI 10.1016/S0076-6879(98)90013-1; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; Landry SJ, 1996, P NATL ACAD SCI USA, V93, P11622, DOI 10.1073/pnas.93.21.11622; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; McEvoy MM, 1997, NAT STRUCT BIOL, V4, P9, DOI 10.1038/nsb0197-9; MORRIS GA, 1979, J AM CHEM SOC, V101, P760, DOI 10.1021/ja00497a058; Pellecchia M, 1999, NAT STRUCT BIOL, V6, P336; PERHAM RN, 1981, NATURE, V292, P474, DOI 10.1038/292474a0; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Riek R, 2000, TRENDS BIOCHEM SCI, V25, P462, DOI 10.1016/S0968-0004(00)01665-0; Riek R, 1999, P NATL ACAD SCI USA, V96, P4918, DOI 10.1073/pnas.96.9.4918; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Salzmann M, 2000, J AM CHEM SOC, V122, P7543, DOI 10.1021/ja0003268; Salzmann M, 1999, J AM CHEM SOC, V121, P844, DOI 10.1021/ja9834226; Salzmann M, 1998, P NATL ACAD SCI USA, V95, P13585, DOI 10.1073/pnas.95.23.13585; Shewmaker F, 2001, J BIOL CHEM, V276, P31257, DOI 10.1074/jbc.M102765200; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Wider G, 1999, CURR OPIN STRUC BIOL, V9, P594, DOI 10.1016/S0959-440X(99)00011-1; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944	30	323	340	0	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 11	2002	418	6894					207	211		10.1038/nature00860	http://dx.doi.org/10.1038/nature00860			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571GV	12110894				2022-12-28	WOS:000176710400046
J	Joyce, GF				Joyce, GF			The antiquity of RNA-based evolution	NATURE			English	Review							NUCLEIC-ACID STRUCTURE; IN-VITRO EVOLUTION; PROTEIN-SYNTHESIS; CATALYTIC RNA; ANGSTROM RESOLUTION; PREBIOTIC SYNTHESIS; RIBOSOMAL-SUBUNIT; CHEMICAL ETIOLOGY; LIGASE RIBOZYME; BOND FORMATION	All life that is known to exist on Earth today and all life for which there is evidence in the geological record seems to be of the same form-one based on DNA genomes and proteins enzymes. Yet there are strong reasons to conclude that DNA- and protein-based life was preceded by a simpler life form based primarily on RNA. This earlier era is referred to as the 'RNA world', during which the genetic information resided in the sequence of RNA molecules and the phenotype derived from the catalytic properties of RNA.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Joyce, GF (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gjoyce@scripps.edu						Admiraal SJ, 1999, J AM CHEM SOC, V121, P5837, DOI 10.1021/ja990903w; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Barta A., 2001, SCIENCE, V291, p203a, DOI [10.1126/science.291.5502.203a, DOI 10.1126/SCIENCE.291.5502.203A]; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; BRACK A, 1975, NATURE, V256, P383, DOI 10.1038/256383a0; Cairns-Smith AG, 1977, ENCY IGNORANCE, P391; CAIRNSSMITH AG, 1966, J THEOR BIOL, V10, P53, DOI 10.1016/0022-5193(66)90178-0; Chaput JC, 2000, J MOL EVOL, V51, P464, DOI 10.1007/s002390010109; Dobson CM, 2000, P NATL ACAD SCI USA, V97, P11864, DOI 10.1073/pnas.200366897; EIGEN M, 1971, NATURWISSENSCHAFTEN, V58, P465, DOI 10.1007/BF00623322; EKLAND EH, 1995, SCIENCE, V269, P364, DOI 10.1126/science.7618102; Ekland EH, 1996, NATURE, V382, P373, DOI 10.1038/382373a0; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Eriksson M, 1998, NEW J CHEM, V22, P1055, DOI 10.1039/a803214i; Eschenmoser A, 1999, SCIENCE, V284, P2118, DOI 10.1126/science.284.5423.2118; FERRIS JP, 1968, J MOL BIOL, V33, P693, DOI 10.1016/0022-2836(68)90314-8; FERRIS JP, 1992, SCIENCE, V257, P1387, DOI 10.1126/science.1529338; Fontana W, 1998, SCIENCE, V280, P1451, DOI 10.1126/science.280.5368.1451; Freeland SJ, 1999, SCIENCE, V286, P690, DOI 10.1126/science.286.5440.690; FULLER WD, 1972, J MOL BIOL, V67, P25, DOI 10.1016/0022-2836(72)90383-X; GIBSON TJ, 1990, J MOL EVOL, V30, P7, DOI 10.1007/BF02102448; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; Hager AJ, 1997, CHEM BIOL, V4, P607, DOI 10.1016/S1074-5521(97)90246-5; Huang FQ, 1997, P NATL ACAD SCI USA, V94, P8965, DOI 10.1073/pnas.94.17.8965; ILLANGASEKARE M, 1995, SCIENCE, V267, P643, DOI 10.1126/science.7530860; Illangasekare M, 1997, J MOL BIOL, V268, P631, DOI 10.1006/jmbi.1997.0988; IZATT RM, 1965, J AM CHEM SOC, V87, P2760, DOI 10.1021/ja01090a044; Jaeger L, 1999, P NATL ACAD SCI USA, V96, P14712, DOI 10.1073/pnas.96.26.14712; James KD, 1999, ORIGINS LIFE EVOL B, V29, P375, DOI 10.1023/A:1006544611320; Jenne A, 1998, CHEM BIOL, V5, P23, DOI 10.1016/S1074-5521(98)90084-9; Johnston WK, 2001, SCIENCE, V292, P1319, DOI 10.1126/science.1060786; JOYCE GF, 1984, NATURE, V310, P602, DOI 10.1038/310602a0; JOYCE GF, 1991, NEW BIOL, V3, P399; Joyce GF, 1998, P NATL ACAD SCI USA, V95, P5845, DOI 10.1073/pnas.95.11.5845; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; JOYCE GF, 1987, P NATL ACAD SCI USA, V84, P4398, DOI 10.1073/pnas.84.13.4398; KINNAR RK, 2001, BIOCHEMISTRY-US, V40, P6998; KIRBY AJ, 1970, J CHEM SOC B, P510, DOI 10.1039/j29700000510; Krishnamurthy R, 1999, ORIGINS LIFE EVOL B, V29, P139, DOI 10.1023/A:1006540518676; Landweber LF, 1999, P NATL ACAD SCI USA, V96, P173, DOI 10.1073/pnas.96.1.173; Lee DH, 1996, NATURE, V382, P525, DOI 10.1038/382525a0; Lee N, 2000, NAT STRUCT BIOL, V7, P28; Li YF, 1999, J AM CHEM SOC, V121, P5364, DOI 10.1021/ja990592p; LOHRMANN R, 1968, SCIENCE, V161, P64, DOI 10.1126/science.161.3836.64; Lohse PA, 1996, NATURE, V381, P442, DOI 10.1038/381442a0; LORSCH JR, 1994, NATURE, V371, P31, DOI 10.1038/371031a0; Luisi PL, 1998, ORIGINS LIFE EVOL B, V28, P613, DOI 10.1023/A:1006517315105; McGinness KE, 2002, CHEM BIOL, V9, P297, DOI 10.1016/S1074-5521(02)00110-2; MERLE Y, 1995, INT J BIOL MACROMOL, V17, P239, DOI 10.1016/0141-8130(95)98150-W; MULLER D, 1990, HELV CHIM ACTA, V73, P1410, DOI 10.1002/hlca.19900730526; Nelson KE, 2000, P NATL ACAD SCI USA, V97, P3868, DOI 10.1073/pnas.97.8.3868; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; ORGEL LE, 1989, J MOL EVOL, V29, P465, DOI 10.1007/BF02602917; ORGEL LE, 1974, ACCOUNTS CHEM RES, V7, P368, DOI 10.1021/ar50083a002; Ourisson G, 1994, CHEM BIOL, V1, P11, DOI 10.1016/1074-5521(94)90036-1; PITSCH S, 1995, HELV CHIM ACTA, V78, P1621, DOI 10.1002/hlca.19950780702; PITSCH S, 1993, HELV CHIM ACTA, V76, P2161, DOI 10.1002/hlca.19930760602; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; Robertson MP, 1999, NAT BIOTECHNOL, V17, P62, DOI 10.1038/5236; ROBERTSON MP, 1995, NATURE, V375, P772, DOI 10.1038/375772a0; Rogers J, 2001, RNA, V7, P395, DOI 10.1017/S135583820100228X; Rohatgi R, 1996, J AM CHEM SOC, V118, P3332, DOI 10.1021/ja953712b; Roth A, 1998, P NATL ACAD SCI USA, V95, P6027, DOI 10.1073/pnas.95.11.6027; Saito H, 2001, EMBO J, V20, P1797, DOI 10.1093/emboj/20.7.1797; SCHIMMEL P, 1994, P NATL ACAD SCI USA, V91, P11283, DOI 10.1073/pnas.91.24.11283; SCHIMMEL P, 1995, CELL, V81, P983, DOI 10.1016/S0092-8674(05)80002-9; Schmidt JG, 1997, J AM CHEM SOC, V119, P1494, DOI 10.1021/ja963563c; SCHNEIDER KC, 1990, J AM CHEM SOC, V112, P453, DOI 10.1021/ja00157a073; SCHON A, 1986, NATURE, V322, P281, DOI 10.1038/322281a0; Schoning KU, 2000, SCIENCE, V290, P1347, DOI 10.1126/science.290.5495.1347; Schultes EA, 2000, SCIENCE, V289, P448, DOI 10.1126/science.289.5478.448; Seelig B, 1999, CHEM BIOL, V6, P167, DOI 10.1016/S1074-5521(99)89008-5; Sengle G, 2001, CHEM BIOL, V8, P459, DOI 10.1016/S1074-5521(01)00026-6; SPACH G, 1984, ORIGINS LIFE EVOL B, V14, P433, DOI 10.1007/BF00933688; Stubbe J, 2001, TRENDS BIOCHEM SCI, V26, P93, DOI 10.1016/S0968-0004(00)01764-3; SUGIMOTO N, 1989, NUCLEIC ACIDS RES, V17, P355, DOI 10.1093/nar/17.1.355; Szostak JW, 2001, NATURE, V409, P387, DOI 10.1038/35053176; Tarasow TM, 1997, NATURE, V389, P54, DOI 10.1038/37950; TJIVIKUA T, 1990, J AM CHEM SOC, V112, P1249, DOI 10.1021/ja00159a057; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Unrau PJ, 1998, NATURE, V395, P260, DOI 10.1038/26193; VONKIEDROWSKI G, 1986, ANGEW CHEM INT EDIT, V25, P932, DOI 10.1002/anie.198609322; WEBER AL, 1980, J MOL EVOL, V16, P1, DOI 10.1007/BF01732065; Wecker M, 1996, RNA, V2, P982; WEINER AM, 1987, P NATL ACAD SCI USA, V84, P7383, DOI 10.1073/pnas.84.21.7383; WHITE HB, 1976, J MOL EVOL, V7, P101, DOI 10.1007/BF01732468; Wiegand TW, 1997, CHEM BIOL, V4, P675, DOI 10.1016/S1074-5521(97)90223-4; WILSON C, 1995, NATURE, V374, P777, DOI 10.1038/374777a0; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; WONG JTF, 1991, ORIGINS LIFE EVOL B, V21, P165, DOI 10.1007/BF01809445; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Zhang BL, 1997, NATURE, V390, P96, DOI 10.1038/36375; Zhang BL, 1998, CHEM BIOL, V5, P539, DOI 10.1016/S1074-5521(98)90113-2	95	668	709	6	248	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 11	2002	418	6894					214	221		10.1038/418214a	http://dx.doi.org/10.1038/418214a			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571GV	12110897				2022-12-28	WOS:000176710400049
J	Pagano, JS				Pagano, JS			Viruses and lymphomas	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ N Carolina, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Pagano, JS (corresponding author), Univ N Carolina, Chapel Hill, NC 27599 USA.								0	42	43	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 11	2002	347	2					78	79		10.1056/NEJMp020056	http://dx.doi.org/10.1056/NEJMp020056			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	572HC	12110734				2022-12-28	WOS:000176767300001
J	De Cock, KM; Janssen, RS				De Cock, KM; Janssen, RS			An unequal epidemic in an unequal world	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MATERNAL MORTALITY; HIV; TUBERCULOSIS; HIV/AIDS; SPREAD; AIDS; MEN; SEX		CDC Kenya, Nairobi, Kenya; CDCP, Div HIV AIDS Prevent Surveillance & Epidemiol, Nat Ctr HIV STD & TB Prevent, Atlanta, GA USA	Centers for Disease Control & Prevention - USA	De Cock, KM (corresponding author), Unit 64112, APO, AE 09831 USA.	kdecock@nairobi.mimcom.net						Ahmed Y, 1999, INT J TUBERC LUNG D, V3, P675; [Anonymous], 1999, MMWR Recomm Rep, V48, P1; Bicego G, 2002, AIDS, V16, P1078, DOI 10.1097/00002030-200205030-00019; Buve A, 2001, AIDS, V15, pS127, DOI 10.1097/00002030-200108004-00014; *CDCP, 2001, HIV AIDS SURVEILLANC, V13, P1; *CENTR BUR STAT OF, 1999, KEN DEM HLTH SURV 19; *CENTR INT AG, 2002, GLOB INF DIS THREAT; Corbett EL, 2002, LANCET, V359, P2177, DOI 10.1016/S0140-6736(02)09095-5; De Cock KM, 1999, INT J TUBERC LUNG D, V3, P457; De Cock KM, 2002, LANCET, V360, P67, DOI 10.1016/S0140-6736(02)09337-6; *EUR, 2001, HIV AIDS SURV EUR, V65, P1; *GLOB FUND FIGHT A, 2002, TUB MAL; Hill K, 2001, B WORLD HEALTH ORGAN, V79, P182; International Rescue Committee, 2001, MORT E DEM REP CONG; Janssen RS, 2001, AM J PUBLIC HEALTH, V91, P1019, DOI 10.2105/AJPH.91.7.1019; Karon JM, 2001, AM J PUBLIC HEALTH, V91, P1060, DOI 10.2105/AJPH.91.7.1060; Katz MH, 2002, AM J PUBLIC HEALTH, V92, P388, DOI 10.2105/AJPH.92.3.388; Kilmarx PH, 2000, AIDS, V14, P2731, DOI 10.1097/00002030-200012010-00013; McElroy PD, 2001, AM J TROP MED HYG, V64, P18, DOI 10.4269/ajtmh.2001.64.18; Ronn AM, 1996, T ROY SOC TROP MED H, V90, P179, DOI 10.1016/S0035-9203(96)90129-7; Rosenberg PS, 1998, JAMA-J AM MED ASSOC, V279, P1894, DOI 10.1001/jama.279.23.1894; Schwartlander B, 2001, SCIENCE, V292, P2434, DOI 10.1126/science.1062876; Stall RD, 2000, AIDS, V14, pS101; *UNAIDS, 2002, EP FACT SHEETS COUNT; *UNAIDS WHO, 2001, AIDS EP UPD DEC 2001; *US BUR CENS, 2001, REC HIV SER LEV COUN; Van Nieuwenhove S, 2001, TROP MED INT HEALTH, V6, P335, DOI 10.1046/j.1365-3156.2001.00731.x; Weidle PJ, 2002, LANCET, V359, P2261, DOI 10.1016/S0140-6736(02)09297-8; White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X; *WORLD BANK, 1993, WORLD DEV REP 1993 I; World Health Organization, 2001, MACR HLTH INV HLTH E; ZABA B, 2000, REP GLOB HIV AIDS EP, P26	32	9	9	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	2002	288	2					236	238		10.1001/jama.288.2.236	http://dx.doi.org/10.1001/jama.288.2.236			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	571HC	12095388	Green Accepted			2022-12-28	WOS:000176711100024
J	Conover, DO; Munch, SB				Conover, DO; Munch, SB			Sustaining fisheries yields over evolutionary time scales	SCIENCE			English	Article							COD GADUS-MORHUA; COUNTERGRADIENT VARIATION; DIFFERENT LATITUDES; ATLANTIC SALMON; MARINE FISHES; LIFE-HISTORY; GROWTH; HERITABILITIES; SELECTION; COLLAPSE	Fishery management plans ignore the potential for evolutionary change in harvestable biomass. We subjected populations of an exploited fish (Menidia menidia) to large, small, or random size-selective harvest of adults over four generations. Harvested biomass evolved rapidly in directions counter to the size-dependent force of fishing mortality. Large-harvested populations initially produced the highest catch but quickly evolved a lower yield than controls. Small-harvested populations did the reverse. These shifts were caused by selection of genotypes with slower or faster rates of growth. Management tools that preserve natural genetic variation are necessary for long-term sustainable yield.	SUNY Stony Brook, Marine Sci Res Ctr, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Conover, DO (corresponding author), SUNY Stony Brook, Marine Sci Res Ctr, Stony Brook, NY 11794 USA.	dconover@notes.cc.sunysb.edu						BAILEY KM, 1989, ADV MAR BIOL, V25, P1; Chen Y, 1999, FISH RES, V42, P87, DOI 10.1016/S0165-7836(99)00036-3; Conover DO, 1997, CAN J FISH AQUAT SCI, V54, P2401, DOI 10.1139/cjfas-54-10-2401; CONOVER DO, 1981, SCIENCE, V213, P577, DOI 10.1126/science.213.4507.577; CONOVER DO, 1990, OECOLOGIA, V83, P316, DOI 10.1007/BF00317554; Falconer D. S., 1981, INTRO QUANTITATIVE G; Harris PJ, 1997, FISH B-NOAA, V95, P732; Haugen TO, 2001, GENETICA, V112, P475, DOI 10.1023/A:1013315116795; Hendry AP, 2001, GENETICA, V112, P515, DOI 10.1023/A:1013367100865; HILL WG, 1972, BIOMETRICS, V28, P747, DOI 10.2307/2528760; HOUDE ED, 1989, J FISH BIOL, V35, P29, DOI 10.1111/j.1095-8649.1989.tb03043.x; Hutchings JA, 2001, J FISH BIOL, V59, P306, DOI 10.1006/jfbi.2001.1756; Hutchings JA, 2000, NATURE, V406, P882, DOI 10.1038/35022565; Imsland AK, 2001, REV FISH BIOL FISHER, V11, P71, DOI 10.1023/A:1014240430779; Jackson JBC, 2001, SCIENCE, V293, P629, DOI 10.1126/science.1059199; Jonasson J, 1997, AQUACULTURE, V154, P219, DOI 10.1016/S0044-8486(97)00059-8; Law R, 2000, ICES J MAR SCI, V57, P659, DOI 10.1006/jmsc.2000.0731; National Research Council, 2001, MAR PROT AR TOOLS SU; NICIEZA AG, 1994, CAN J ZOOL, V72, P1603, DOI 10.1139/z94-213; Palumbi SR, 2001, SCIENCE, V293, P1786, DOI 10.1126/science.293.5536.1786; Purchase CF, 2000, CAN J FISH AQUAT SCI, V57, P2223, DOI 10.1139/cjfas-57-11-2223; Quinn TP, 2001, GENETICA, V112, P493, DOI 10.1023/A:1013348024063; REZNICK DA, 1990, NATURE, V346, P357, DOI 10.1038/346357a0; RICKER WE, 1981, CAN J FISH AQUAT SCI, V38, P1636, DOI 10.1139/f81-213; Roff Derek, 2002, pi; Stergiou KI, 2002, FISH RES, V55, P1; Stokes K, 2000, MAR ECOL PROG SER, V208, P307; STOKES TK, 1993, EXPLOITATION EVOLVIN; Trexler JC, 2000, B MAR SCI, V66, P853; Weigensberg I, 1996, EVOLUTION, V50, P2149, DOI 10.1111/j.1558-5646.1996.tb03605.x	30	682	715	3	280	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 5	2002	297	5578					94	96		10.1126/science.1074085	http://dx.doi.org/10.1126/science.1074085			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571HB	12098697				2022-12-28	WOS:000176711000040
J	Jain, M; Arvanitis, C; Chu, K; Dewey, W; Leonhardt, E; Trinh, M; Sundberg, CD; Bishop, JM; Felsher, DW				Jain, M; Arvanitis, C; Chu, K; Dewey, W; Leonhardt, E; Trinh, M; Sundberg, CD; Bishop, JM; Felsher, DW			Sustained loss of a neoplastic phenotype by brief inactivation of MYC	SCIENCE			English	Article							C-MYC; HUMAN OSTEOSARCOMA; OSTEO-SARCOMA; CELL-LINES; AMPLIFICATION; CANCER; DIFFERENTIATION; TUMORIGENESIS; ONCOGENES; GENE	Pharmacological inactivation of oncogenes is being investigated as a possible therapeutic strategy for cancer. One potential drawback is that cessation of such therapy may allow reactivation of the oncogene and tumor regrowth. We used a conditional transgenic mouse model for MYC-induced tumorigenesis to demonstrate that brief inactivation of MYC results in the sustained regression of tumors and the differentiation of osteogenic sarcoma cells into mature osteocytes. Subsequent reactivation of MYC did not restore the cells malignant properties but instead induced apoptosis. Thus, brief MYC inactivation appears to cause epigenetic changes in tumor cells that render them insensitive to MYC-induced tumorigenesis. These results raise the possibility that transient inactivation of MYC may be an effective therapy for certain cancers.	Stanford Univ, Dept Med, Div Oncol, Stanford, CA 94305 USA; Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA; Univ Calif San Francisco, GW Hooper Fdn, San Francisco, CA 94143 USA	Stanford University; Stanford University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Felsher, DW (corresponding author), Stanford Univ, Dept Med, Div Oncol, Stanford, CA 94305 USA.		Arvanitis, Constadina/C-5975-2013		NATIONAL CANCER INSTITUTE [R01CA089305, K08CA075967, R01CA085610] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA89305-01, R01-CA85610, K08-CA75967-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756-3282(95)00183-E; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Forrester HB, 1999, CANCER RES, V59, P931; Gamberi G, 1998, ONCOLOGY-BASEL, V55, P556, DOI 10.1159/000011912; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; Himelstein Bruce P., 1998, Current Opinion in Oncology, V10, P326, DOI 10.1097/00001622-199807000-00009; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; IKEDA S, 1989, JPN J CANCER RES, V80, P6, DOI 10.1111/j.1349-7006.1989.tb02236.x; ISFORT RJ, 1992, PROG CLIN BIOL RES, V376, P321; ISFORT RJ, 1995, MOL CARCINOGEN, V14, P170, DOI 10.1002/mc.2940140306; LADANYI M, 1993, DIAGN MOL PATHOL, V2, P163, DOI 10.1097/00019606-199303000-00024; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Longhi A, 2001, ONCOL REP, V8, P131; Papagelopoulos PJ, 2000, ORTHOPEDICS, V23, P858; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Philip T, 2001, BRIT J CANCER, V84, P78, DOI 10.1054/bjoc.2000.1770; Pompetti F, 1996, J CELL BIOCHEM, V63, P37; SCHMIDT J, 1988, DIFFERENTIATION, V39, P151, DOI 10.1111/j.1432-0436.1988.tb00090.x; Stock C, 2000, GENE CHROMOSOME CANC, V28, P329, DOI 10.1002/1098-2264(200007)28:3<329::AID-GCC11>3.0.CO;2-F; STURM SA, 1990, CANCER RES, V50, P4146	25	513	550	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 5	2002	297	5578					102	104		10.1126/science.1071489	http://dx.doi.org/10.1126/science.1071489			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571HB	12098700				2022-12-28	WOS:000176711000043
J	Hoen, B; Alla, F; Selton-Suty, C; Beguinot, I; Bouvet, A; Briancon, S; Casalta, JP; Danchin, N; Delahaye, F; Etienne, J; Le Moing, V; Leport, C; Mainardi, JL; Ruimy, R; Vandenesch, F				Hoen, B; Alla, F; Selton-Suty, C; Beguinot, I; Bouvet, A; Briancon, S; Casalta, JP; Danchin, N; Delahaye, F; Etienne, J; Le Moing, V; Leport, C; Mainardi, JL; Ruimy, R; Vandenesch, F		Assoc Etud Prevention Endocardite	Changing profile of infective endocarditis - Results of a 1-year survey in France	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL SPECTRUM	Context Since the first modern clinical description of infective endocarditis (IE) at the end of the 19th century, the profile of the disease has evolved continuously, as highlighted in epidemiological studies including a French survey performed in 1991. Objective To update information gained from the 1991 study on the epidemiology of IE in France. Design and Setting Population-based survey conducted from January through December 1999 in all hospitals in 6 French regions representing 26% of the population (16 million inhabitants). Patients Three hundred ninety adult inpatients diagnosed with IE according to Duke criteria. Main Outcome Measures Incidence of IE; proportion of patients with underlying heart disease; clinical characteristics; causative microorganisms; surgical and mortality outcomes. Results The annual age- and sex-standardized incidence was 31 (95% confidence interval [Cl], 28-35) cases per million, not including the region of New Caledonia, which had 161 (95% Cl, 117-216) cases per million. There was no previously known heart disease in 47% of the cases. The proportion of prosthetic-valve IE was 16%. Causative microorganisms were: streptococci, 48% (group D streptococci, 25%; oral streptococci, 17%, pyogenic streptococci, 6%); enterococci, 8%; Abiotrophia species, 2%; staphylococci, 29%; and other or multiple pathogens, 8%. Blood cultures were negative in 9% and no microorganism was identified in 5% of the cases. Early valve surgery was performed in 49% of the patients. In-hospital mortality was 16%. Compared with 1991, this study showed a decreased incidence of IE in patients with previously known underlying heart disease (20.6 cases per million vs 15.1 cases per million; P<.001); a smaller incidence of oral streptococcal IE (7.8 cases per million vs 5.1 cases per million; P<001), compensated by a larger proportion of IE due to group D streptococci (5.3 cases per million vs 6.2 cases per million; P=.67) and staphylococci (4.9 cases per million vs 5.7 cases per million; P=.97); an increased rate of early valve surgery (31.2% vs 49.7%; P<.001); and a decreased in-hospital mortality rate (21.6% vs 16.6%; P=.08). Conclusion Although the incidence of IE has not changed, important changes in disease characteristics, treatment, and outcomes were noted.	CHU Besancon, F-25030 Besancon, France; CHU Nancy, Nancy, France; CHU Reims, Reims, France; Univ Paris 07, Hotel Dieu, Ctr Natl Reference Streptocoques, F-75221 Paris 05, France; Ctr Natl Reference Rickettsies, Marseille, France; Hop Europeen Georges Pompidou, Paris, France; Hop Louis Pradel, Lyon, France; Ctr Natl Reference Staphylocoques, Lyon, France; CHU Bichat Claude Bernard, Paris, France	Universite de Franche-Comte; CHU Besancon; CHU de Nancy; CHU de Reims; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite	Hoen, B (corresponding author), Univ Besancon, Med Ctr, Serv Malad Infect & Trop, F-25030 Besancon, France.		ETIENNE, Jerome/C-5471-2014; MAINARDI, Jean-Luc/E-2714-2014; Vandenesch, Francois/C-7209-2014; alla, francois/D-2295-2014; Ruimy, Raymond/P-6068-2016; Danchin, Nicolas/AAN-8291-2020	ETIENNE, Jerome/0000-0002-3348-3315; MAINARDI, Jean-Luc/0000-0002-4159-0129; Vandenesch, Francois/0000-0001-9412-7106; alla, francois/0000-0002-5793-7190; Le Moing, Vincent/0000-0002-9529-2792; Selton-Suty, Christine/0000-0003-4129-5784				AHMEDMICHAUX P, 1997, IMAGES POPULATION NO; BAYER AS, 1993, CLIN INFECT DIS, V17, P313, DOI 10.1093/clinids/17.3.313; BERLIN JA, 1995, AM J CARDIOL, V76, P933, DOI 10.1016/S0002-9149(99)80264-1; BOUVET A, 1994, IN VITRO SUSCEPTIBIL, P72; DELAHAYE F, 1995, EUR HEART J, V16, P394, DOI 10.1093/oxfordjournals.eurheartj.a060923; DURACK DT, 1994, AM J MED, V96, P200, DOI 10.1016/0002-9343(94)90143-0; Esteve J., 1994, IARC SCI PUBLICATION, V128; Fay MP, 1997, STAT MED, V16, P791; FERNANDEZGUERRERO ML, 1995, CLIN INFECT DIS, V20, P16, DOI 10.1093/clinids/20.1.16; GARRAUD O, 1986, PRESSE MED, V15, P2047; GARVEY GJ, 1978, MEDICINE, V57, P105, DOI 10.1097/00005792-197803000-00001; GOULET V, 1986, PRESSE MED, V15, P1855; HOGEVIK H, 1995, MEDICINE, V74, P324, DOI 10.1097/00005792-199511000-00003; *INSEE, 1994, POP FRANC REC GEN PO; KING JW, 1988, AM J MED SCI, V295, P517, DOI 10.1097/00000441-198806000-00005; Kupferwasser I, 1998, HEART, V80, P276, DOI 10.1136/hrt.80.3.276; Kurland S, 1999, SCAND J INFECT DIS, V31, P87, DOI 10.1080/00365549950161952; Lamas CC, 1998, HEART, V79, P442, DOI 10.1136/hrt.79.5.442; MAINARDI JL, 1995, B SOC FR MICROBIOL, V10, P12; Mondejar PL, 1997, REV CLIN ESP, V197, P814; Nair B, 1996, AUST NZ J MED, V26, P363, DOI 10.1111/j.1445-5994.1996.tb01923.x; NUNLEY DL, 1993, POSTGRAD MED, V93, P235; Olaison L, 1996, QJM-MON J ASSOC PHYS, V89, P267; Osler W, 1885, Br Med J, V1, P577; Osler W., 1885, BMJ-BRIT MED J, P577; Osler W, 1885, BRIT MED J, V1, P577; Roder BL, 1999, ARCH INTERN MED, V159, P462, DOI 10.1001/archinte.159.5.462; STECKELBERG JM, 1990, AM J MED, V88, P582, DOI 10.1016/0002-9343(90)90521-E; Tornos MP, 1995, EUR HEART J, V16, P1686, DOI 10.1093/oxfordjournals.eurheartj.a060795; VANDERMEER JT, 1868, ARCH INTERN MED, V152, P1863; 2002, RECENSEMENT POPULATI; 2002, 1999 FRENCH NATL DAT	32	660	705	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	2002	288	1					75	81		10.1001/jama.288.1.75	http://dx.doi.org/10.1001/jama.288.1.75			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	568YW	12090865	Bronze			2022-12-28	WOS:000176573400022
J	Winocour, PH				Winocour, PH			Effective diabetes care: a need for realistic targets	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; RISK; HYPERTENSION; SIMVASTATIN; CHOLESTEROL; MELLITUS; ASPIRIN; EVENTS		Queen Elizabeth II Hosp, Dept Endocrinol & Diabet, Welwyn Garden City AL7 4HQ, Herts, England		Winocour, PH (corresponding author), Queen Elizabeth II Hosp, Dept Endocrinol & Diabet, Welwyn Garden City AL7 4HQ, Herts, England.	peter.winocour@qeii.enherts-tr.nhs.uk						ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Amer Diabet Assoc, 2000, DIABETES CARE, V23, pS32; Amos A F, 1997, Diabet Med, V14 Suppl 5, pS1; [Anonymous], 1999, Diabet Med, V16, P716; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; *BRIT DIAB ASS, 1998, UK PROSP DIAB STUD U; Britton A, 1998, HLTH TECHNOLOGY ASSE, V2, P1; Colhoun HM, 1999, DIABETIC MED, V16, P35, DOI 10.1046/j.1464-5491.1999.00017.x; EVANS JMM, BMJ, V324, P939; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Goldberg RB, 1998, CIRCULATION, V98, P2513, DOI 10.1161/01.CIR.98.23.2513; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; Haffner SM, 2000, DIABETES CARE, V23, pS57; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Jeck T, 1997, DIABETIC MED, V14, P564, DOI 10.1002/(SICI)1096-9136(199707)14:7<564::AID-DIA357>3.0.CO;2-K; Kanters SDJM, 1999, DIABETIC MED, V16, P500, DOI 10.1046/j.1464-5491.1999.00080.x; MACLEOD JM, 1995, DIABETOLOGIA, V38, P610, DOI 10.1007/BF00400732; Pyorala K, 1997, DIABETES CARE, V20, P614, DOI 10.2337/diacare.20.4.614; Ramsay LE, 1999, J HUM HYPERTENS, V13, P569, DOI 10.1038/sj.jhh.1000917; *RES DEP, 2001, UKDIABS ANN REP 2001; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Stevens RJ, 2001, CLIN SCI, V101, P671, DOI 10.1042/CS20000335; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; Thomas A, 2000, DIABETIC MED, V17, P2; Turner RC, 1999, JAMA-J AM MED ASSOC, V281, P2005, DOI 10.1001/jama.281.21.2005; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; UK Prospective Diabetes Study (UKPDS) Group, 1998, BMJ-BRIT MED J, V317, P705	27	62	64	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 29	2002	324	7353					1577	1580		10.1136/bmj.324.7353.1577	http://dx.doi.org/10.1136/bmj.324.7353.1577			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	570WP	12089099	Green Published			2022-12-28	WOS:000176683000028
J	Capone, M; Fabrizio, M; Castellani, C; Tosatti, E				Capone, M; Fabrizio, M; Castellani, C; Tosatti, E			Strongly correlated superconductivity	SCIENCE			English	Article							TRANSITION; INSULATOR; SYSTEMS; C-60	High-temperature superconductivity in doped Mott insulators such as the cuprates contradicts the conventional wisdom that electron repulsion is detrimental to superconductivity. Because doped fullerene conductors are also strongly correlated, the recent discovery of high-critical-temperature, presumably s-wave, superconductivity in C-60 field effect devices is even more puzzling. We examine a dynamical mean-field solution of a model for electron-doped fullerenes that shows how strong correlations can indeed enhance superconductivity close to the Mott transition. We argue that the mechanism responsible for this enhancement could be common to a wider class of strongly correlated models, including those for cuprate superconductors.	Univ Roma La Sapienza, Ctr Stat Mech & Complex, INFM, I-00185 Rome, Italy; Univ Roma La Sapienza, Dept Phys, I-00185 Rome, Italy; Scuola Int Super Studi Avanzati, SISSA, I-34014 Trieste, Italy; INFM, Trieste SISSA, I-34014 Trieste, Italy; Abdus Salaam Int Ctr Theoret Phys, I-34014 Trieste, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); Sapienza University Rome; Sapienza University Rome; International School for Advanced Studies (SISSA); Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); International School for Advanced Studies (SISSA); Abdus Salam International Centre for Theoretical Physics (ICTP)	Capone, M (corresponding author), Univ Roma La Sapienza, Ctr Stat Mech & Complex, INFM, Piazzale A Moro 2, I-00185 Rome, Italy.	massimo.capone@roma1.infn.it	fabrizio, michele/N-3762-2014; Capone, Massimo/A-7762-2008; Capone, Massimo/U-6924-2019	fabrizio, michele/0000-0002-2943-3278; Capone, Massimo/0000-0002-9811-5089; CASTELLANI, Claudio/0000-0002-4648-1693				ANDERSON PW, 1987, SCIENCE, V235, P1196, DOI 10.1126/science.235.4793.1196; Brouet V, 2001, PHYS REV LETT, V86, P4680, DOI 10.1103/PhysRevLett.86.4680; Capone M, 2000, PHYS REV B, V62, P7619, DOI 10.1103/PhysRevB.62.7619; Capone M, 2001, PHYS REV LETT, V86, P5361, DOI 10.1103/PhysRevLett.86.5361; Dinnebier RE, 2002, SCIENCE, V296, P109, DOI 10.1126/science.1068344; Fabrizio M, 1997, PHYS REV B, V55, P13465, DOI 10.1103/PhysRevB.55.13465; Georges A, 1996, REV MOD PHYS, V68, P13, DOI 10.1103/RevModPhys.68.13; Gunnarsson O, 1997, REV MOD PHYS, V69, P575, DOI 10.1103/RevModPhys.69.575; Han JE, 2000, PHYS REV LETT, V84, P1276, DOI 10.1103/PhysRevLett.84.1276; HAN JE, COMMUNICATION; KOTLIAR G, 1988, PHYS REV B, V38, P5142, DOI 10.1103/PhysRevB.38.5142; Kotliar G, 1999, EUR PHYS J B, V11, P27, DOI 10.1007/s100510050914; LUKYANCHUK I, 1995, PHYS REV B, V51, P3978, DOI 10.1103/PhysRevB.51.3978; Manini N, 2001, PHILOS MAG B, V81, P793, DOI 10.1080/13642810110062663; Margadonna S, 2001, EUROPHYS LETT, V56, P61, DOI 10.1209/epl/i2001-00481-1; MARTIN RL, 1993, PHYS REV B, V48, P4845, DOI 10.1103/PhysRevB.48.4845; MICNAS R, 1990, REV MOD PHYS, V62, P113, DOI 10.1103/RevModPhys.62.113; Schon JH, 2001, SCIENCE, V293, P2432, DOI 10.1126/science.1064773; Sorella S, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.117002; Tou H, 2000, PHYS REV B, V62, pR775, DOI 10.1103/PhysRevB.62.R775; YILDIRIM T, 1995, SOLID STATE COMMUN, V93, P269, DOI 10.1016/0038-1098(94)00779-9	21	209	210	3	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 28	2002	296	5577					2364	2366		10.1126/science.1071122	http://dx.doi.org/10.1126/science.1071122			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	567CE	12089436				2022-12-28	WOS:000176467200032
J	Walmsley, S; Bernstein, B; King, M; Arribas, J; Beall, G; Ruane, P; Johnson, M; Johnson, D; Lalonde, R; Japour, A; Brun, S; Sun, E				Walmsley, S; Bernstein, B; King, M; Arribas, J; Beall, G; Ruane, P; Johnson, M; Johnson, D; Lalonde, R; Japour, A; Brun, S; Sun, E		M98-863 Study Team	Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS PROTEASE; ANTIRETROVIRAL THERAPY; INHIBITOR THERAPY; DRUG-RESISTANCE; INDINAVIR; LAMIVUDINE; ZIDOVUDINE; ADULTS; ADHERENCE; MORTALITY	Background: Lopinavir is a newly developed inhibitor of human immunodeficiency virus (HIV) protease that, when formulated with ritonavir, yields mean trough plasma lopinavir concentrations that are at least 75 times as high as that needed to inhibit replication of wild-type HIV by 50 percent. Methods: We conducted a double-blind trial in which 653 HIV-infected adults who had not received antiretroviral therapy for more than 14 days were randomly assigned to receive either lopinavir-ritonavir (400 mg of lopinavir plus 100 mg of ritonavir twice daily) with nelfinavir placebo or nelfinavir (750 mg three times daily) with lopinavir-ritonavir placebo. All patients also received open-label stavudine and lamivudine. The primary efficacy end points were the presence of fewer than 400 HIV RNA copies per milliliter of plasma at week 24 and the time to the loss of virologic response through week 48. Results: At week 48, greater proportions of patients treated with lopinavir-ritonavir than of patients treated with nelfinavir had fewer than 400 copies of HIV RNA per milliliter (75 percent vs. 63 percent, P<0.001) and fewer than 50 copies per milliliter (67 percent vs. 52 percent, P<0.001). The time to the loss of virologic response was greater in the lopinavir-ritonavir group than in the nelfinavir group (hazard ratio, 2.0; 95 percent confidence interval, 1.5 to 2.7; P<0.001). The estimated proportion of patients with a persistent virologic response through week 48 was 84 percent for patients receiving lopinavir-ritonavir and 66 percent for those receiving nelfinavir. Both regimens were well tolerated, with the rate of discontinuation related to the study drugs at 3.4 percent among patients receiving lopinavir-ritonavir and 3.7 percent among patients receiving nelfinavir. Among patients with more than 400 copies of HIV RNA per milliliter at some point from week 24 through week 48, resistance mutations in HIV protease were demonstrated in viral isolates from 25 of 76 nelfinavir-treated patients (33 percent) and none of 37 patients treated with lopinavir-ritonavir (P<0.001). Conclusions: For the initial treatment of HIV-infected adults, a combination regimen that includes lopinavir-ritonavir is well tolerated and has antiviral activity superior to that of a nelfinavir-containing regimen.	Univ Toronto, Toronto Hosp, Univ Hlth Network, Toronto, ON, Canada; Hop Univ La Paz, Serv VIH Med Interna 2, Madrid, Spain; Abbott Labs, Abbott Pk, IL 60064 USA; Harbor UCLA Med Ctr, Torrance, CA 90509 USA; Tower Infect Dis, Los Angeles, CA USA; Royal Free Hosp, London NW3 2QG, England; Royal Victoria Hosp, Montreal Chest Inst, Montreal, PQ H3A 1A1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Abbott Laboratories; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; McGill University; Royal Victoria Hospital	Walmsley, S (corresponding author), Toronto Gen Hosp, Div Infect Dis, Rm EN G-219,200 Elizabeth St, Toronto, ON M5G 2C4, Canada.		Arribas, Jose/A-1595-2015	Arribas, Jose/0000-0002-7410-9450; Walmsley, Sharon/0000-0002-3959-5692				Acosta EP, 1999, PHARMACOTHERAPY, V19, P708, DOI 10.1592/phco.19.9.708.31544; Andrews L, 2000, INFECT DIS CLIN N AM, V14, P901, DOI 10.1016/S0891-5520(05)70139-2; [Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; Atkinson B, 2000, J INFECT DIS, V182, P420, DOI 10.1086/315726; Bardsley-Elliot A, 2000, DRUGS, V59, P581, DOI 10.2165/00003495-200059030-00014; Barry M, 1997, CLIN PHARMACOKINET, V32, P194, DOI 10.2165/00003088-199732030-00003; Bertz R, 2001, P 2 INT WORKSH CLIN; Condra JH, 2000, J INFECT DIS, V182, P758, DOI 10.1086/315782; CONDRA JH, 1999, ANTIVIR THER S, V4, P44; Durant J, 2000, AIDS, V14, P1333, DOI 10.1097/00002030-200007070-00005; FATKENHEUER G, 1997, AIDS, V11, P113; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; Hirsch MS, 2000, JAMA-J AM MED ASSOC, V283, P2417, DOI 10.1001/jama.283.18.2417; Hogg RS, 1997, LANCET, V349, P1294, DOI 10.1016/S0140-6736(05)62505-6; Hsu A, 1998, ANTIMICROB AGENTS CH, V42, P2784, DOI 10.1128/AAC.42.11.2784; Hsu A, 1998, CLIN PHARMACOL THER, V63, P453, DOI 10.1016/S0009-9236(98)90041-8; Kempf DJ, 1997, ANTIMICROB AGENTS CH, V41, P654, DOI 10.1128/AAC.41.3.654; Langmann P, 2000, Eur J Med Res, V5, P59; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; Murphy RL, 2001, AIDS, V15, pF1, DOI 10.1097/00002030-200101050-00002; MURPHY SL, 2000, DHHS PHS PUBLICATION, P1; *NELF, 2001, AGR PHARM PACK INS; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Paterson DL, 2002, ANN INTERN MED, V136, P253, DOI 10.7326/0003-4819-136-3-200202050-00020; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; PODZAMCZEER D, 2000, 40 INT C ANT AG CHEM, P293; Saag MS, 2001, AIDS, V15, P1971, DOI 10.1097/00002030-200110190-00009; Selik RM, 1997, J INFECT DIS, V176, P632, DOI 10.1086/514083; Sham HL, 1998, ANTIMICROB AGENTS CH, V42, P3218, DOI 10.1128/AAC.42.12.3218; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; Staszewski S, 2001, JAMA-J AM MED ASSOC, V285, P1155, DOI 10.1001/jama.285.9.1155; STASZEWSKI S, 2001, JAMA-J AM MED ASSOC, V285, P2858; SUIRES K, 2000, 13 INT AIDS C DURB, P43; van Heeswijk RPG, 1999, AIDS, V13, pF95, DOI 10.1097/00002030-199910010-00001; Wit FWNM, 1999, J INFECT DIS, V179, P790, DOI 10.1086/314675	36	515	540	0	15	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 27	2002	346	26					2039	2046		10.1056/NEJMoa012354	http://dx.doi.org/10.1056/NEJMoa012354			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566DN	12087139				2022-12-28	WOS:000176411900004
J	Kim, N; Grey, CP				Kim, N; Grey, CP			Probing oxygen motion in disordered anionic conductors with O-17 and V-51 MAS NMR spectroscopy	SCIENCE			English	Article							MAGNETIC-RESONANCE; ION CONDUCTORS; DYNAMICS	Identification of the local environments of the ions in a solid-state electrolyte that contribute to the ionic conductivity or remain trapped in the lattice represents a challenge for many experimental probes of structure. We show that high-resolution O-17 magic angle spinning nuclear magnetic resonance (MAS NMR) spectra may be obtained even from the highly disordered, layered materials alpha-Bi4V2O11 and beta-Bi4V1.7Ti0.3O10.85, in which the different oxide sites in the lattice may be distinguished. The sites responsible for anionic conduction were determined directly from the variable-temperature O-17 NMR spectra, and correlation times for motion were estimated. Double-resonance O-17/V-51 NMR methods were used as confirmation of the assignments of the resonances and as a second experimental probe of motion that is sensitive to mobility involving oxide ion hops between the same crystallographic sites.	SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Grey, CP (corresponding author), SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA.		Grey, Clare P/Q-8860-2017	Grey, Clare P/0000-0001-5572-192X				ABRAHAM F, 1988, SOLID STATE IONICS, V28, P529, DOI 10.1016/S0167-2738(88)80096-1; Abrahams I, 1998, J MATER CHEM, V8, P1213, DOI 10.1039/a801614c; ADLER S, 1994, SOLID STATE IONICS, V68, P193, DOI 10.1016/0167-2738(94)90177-5; ADLER SB, 1994, J AM CHEM SOC, V116, P675, DOI 10.1021/ja00081a031; AURIVILLIUS B, 1949, ARK KEMI, V0001; Boivin JC, 2001, INT J INORG MATER, V3, P1261, DOI 10.1016/S1466-6049(01)00118-0; Boivin JC, 1998, SOLID STATE IONICS, V113, P639, DOI 10.1016/S0167-2738(98)00330-0; Delmaire F, 2000, PHYS CHEM CHEM PHYS, V2, P4477, DOI 10.1039/b003644g; GOODENOUGH JB, 1992, SOLID STATE IONICS, V81, P225; GREY CP, 1995, J AM CHEM SOC, V117, P8232, DOI 10.1021/ja00136a022; GREY CP, 1993, J CHEM PHYS, V98, P7711, DOI 10.1063/1.464579; HARDCASTLE FD, 1991, J SOLID STATE CHEM, V90, P194, DOI 10.1016/0022-4596(91)90135-5; Harris R. K., 1983, NUCL MAGNETIC RESONA; HARRISON AT, 1985, J CHEM SOC DALTON, P1953, DOI 10.1039/dt9850001953; Kendall KR, 1996, CHEM MATER, V8, P642, DOI 10.1021/cm9503083; KIM NC, UNPUB; Medek A, 1995, J AM CHEM SOC, V117, P12779, DOI 10.1021/ja00156a015; TULLER HL, 1988, MAT SCI ENG B-SOLID, V1, P171, DOI 10.1016/0921-5107(88)90018-9; VANNIER RN, IN PRESS SOLID STATE; WAGNER GW, 1991, INORG CHEM, V30, P1960, DOI 10.1021/ic00008a054; Wang F, 1998, J AM CHEM SOC, V120, P970, DOI 10.1021/ja972312g; WANG F, 1997, CHEM MATER, V9, P1069; XU Z, 1995, SCIENCE, V270, P1332, DOI 10.1126/science.270.5240.1332; YAN J, 1995, SOLID STATE IONICS, V81, P225, DOI 10.1016/0167-2738(95)00187-B; YANG S, 1989, J AM CHEM SOC, V111, P7278, DOI 10.1021/ja00200a067; YANG Y, 1997, LASERS LIFE SCI, V7, P249	26	59	61	3	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 23	2002	297	5585					1317	1320		10.1126/science.1074130	http://dx.doi.org/10.1126/science.1074130			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	586FL	12130662				2022-12-28	WOS:000177573900037
J	Jackevicius, CA; Mamdami, M; Tu, JV				Jackevicius, CA; Mamdami, M; Tu, JV			Adherence with statin therapy in elderly patients with and without acute coronary syndromes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; DISCONTINUATION RATES; LOWERING MEDICATIONS; HEART-DISEASE; PRAVASTATIN; EVENTS; HYPERCHOLESTEROLEMIA; RECOMMENDATIONS; ATORVASTATIN; PREVENTION	Context Landmark clinical trials have demonstrated the survival benefits of statins, with benefits usually starting after 1 to 2 years of treatment. Research prior to these trials of older lipid-lowering agents demonstrated low levels of 1-year adherence. Objective To compare 2-year adherence following statin initiation in 3 cohorts of patients: those with recent acute coronary syndrome (ACS), those with chronic coronary artery disease (CAD), and those without coronary disease (primary prevention). Design and Setting Cohort study using linked population-based administrative data from Ontario. Patients All patients aged 66 years or older who received at least 1 statin prescription between January 1994 and December 1998 and who did not have a statin prescription in the prior year were followed up for 2 years from their first statin prescription. There were 22379 patients in the ACS, 36106 in the chronic CAD, and 85020 in the primary prevention cohorts. Main Outcome Measures Adherence to statins, defined as a statin being dispensed at least every 120 days after the index prescription for 2 years. Results Two-year adherence rates in the cohorts were only 40.1% for ACS, 36.1% for chronic CAD, and 25.4% for primary prevention. Relative to the ACS cohort, nonadherence was more likely among patients receiving statins in the chronic CAD (relative risk ERR], 1.14; 95% Cl, 1,11-1.16) and primary prevention cohorts (RR, 1,92; 95% Cl, 1.87-1.96). Conclusions Elderly patients with and without recent ACS have low rates of adherence to statins. This suggests that many patients initiating statin therapy may receive no or limited benefit from statins because of premature discontinuation.	Toronto Gen Hosp, Univ Hlth Network, Dept Pharm, Toronto, ON M5G 2C4, Canada; Toronto Gen Hosp, Univ Hlth Network, Dept Hlth Policy Management & Evolut, Toronto, ON, Canada; Toronto Gen Hosp, Univ Hlth Network, Dept Med, Toronto, ON, Canada; Toronto Gen Hosp, Univ Hlth Network, Womens Hlth Program, Toronto, ON, Canada; Univ Toronto, Inst Clin Evaluat Sci, Toronto, ON, Canada; Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Gen Internal Med, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Jackevicius, CA (corresponding author), Toronto Gen Hosp, Univ Hlth Network, Dept Pharm, 200 Elizabeth St, Toronto, ON M5G 2C4, Canada.	Cynthia.Jackevicius@uhn.on.ca		Tu, Jack/0000-0003-0111-722X				ANDRADE SE, 1995, NEW ENGL J MED, V332, P1125, DOI 10.1056/NEJM199504273321703; Aronow HD, 2001, LANCET, V357, P1063, DOI 10.1016/S0140-6736(00)04257-4; Avorn J, 1998, JAMA-J AM MED ASSOC, V279, P1458, DOI 10.1001/jama.279.18.1458; Bybee KA, 2001, AM J CARDIOL, V87, P771, DOI 10.1016/S0002-9149(00)01501-0; *CTR DRUG EV RES, 2002, BAYC INF; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; ERAKER SA, 1984, ANN INTERN MED, V100, P258, DOI 10.7326/0003-4819-100-2-258; Eriksson M, 1998, J INTERN MED, V243, P373; Feely J, 1999, PHARMACOECONOMICS, V16, P175, DOI 10.2165/00019053-199916020-00006; Fodor JG, 2000, CAN MED ASSOC J, V162, P1441; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Heeschen C, 2002, CIRCULATION, V105, P1446, DOI 10.1161/01.CIR.0000012530.68333.C8; Hiatt JG, 1999, AM J MANAG CARE, V5, P437; *HLTH SERV UT RES, 1995, CHOL TEST TREATM AD; Insull W, 1997, J INTERN MED, V241, P317, DOI 10.1046/j.1365-2796.1997.112133000.x; Jackevicius CA, 2001, ARCH INTERN MED, V161, P183, DOI 10.1001/archinte.161.2.183; Jones P, 1998, AM J CARDIOL, V81, P582, DOI 10.1016/S0002-9149(97)00965-X; KRAVITZ RL, 1993, ARCH INTERN MED, V153, P1869, DOI 10.1001/archinte.153.16.1869; McDermott MM, 1997, ARCH INTERN MED, V157, P1921, DOI 10.1001/archinte.157.17.1921; Muhlestein JB, 2001, AM J CARDIOL, V87, P257, DOI 10.1016/S0002-9149(00)01354-0; PEDERSEN TR, 1994, LANCET, V344, P1383; Rochon PA, 2000, LANCET, V356, P639, DOI 10.1016/S0140-6736(00)02606-4; Rudd P., 1994, CARDIOL REV, V2, P230; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Shepherd J, 1997, EUR HEART J, V18, P1718; Simons LA, 1996, MED J AUSTRALIA, V164, P208, DOI 10.5694/j.1326-5377.1996.tb94138.x; Steiner JF, 1997, J CLIN EPIDEMIOL, V50, P105, DOI 10.1016/S0895-4356(96)00268-5; Stenestrand U, 2001, JAMA-J AM MED ASSOC, V285, P430, DOI 10.1001/jama.285.4.430; Tonkin A, 1998, NEW ENGL J MED, V339, P1349	32	810	842	0	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 24	2002	288	4					462	467		10.1001/jama.288.4.462	http://dx.doi.org/10.1001/jama.288.4.462			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575NZ	12132976	Bronze			2022-12-28	WOS:000176955400028
J	Malhotra, A; White, DP				Malhotra, A; White, DP			Obstructive sleep apnoea	LANCET			English	Review							POSITIVE AIRWAY PRESSURE; GENIOGLOSSAL ELECTROMYOGRAM RESPONSES; COST-EFFECTIVENESS ANALYSIS; PLACEBO-CONTROLLED TRIAL; SOFT PALATAL MUCOSA; MUSCLE ACTIVATION; NEGATIVE-PRESSURE; DAYTIME FUNCTION; BLOOD-PRESSURE; CPAP THERAPY	Obstructive sleep apnoea is a disease of increasing importance because of Its neurocognitive and cardiovascular sequelae. Abnormalities in the anatomy of the pharynx, the physiology of the upper airway muscle dilator, and the stability of ventilatory control are important causes of repetitive pharyngeal collapse during sleep. Obstructive sleep apnoea can be diagnosed on the basis of characteristic history (snoring, daytime sleepiness) and physical examination (increased neck circumference), but overnight polysomnography is needed to confirm presence of the disorder. Repetitive pharyngeal collapse causes recurrent arousals from sleep, leading to sleepiness and increased risk of motor vehicle and occupational accidents. The surges in hypoxaemia, hypercapnia, and catecholamine associated with this disorder have now been implicated in development of hypertension, but the association between obstructive sleep apnoea and myocardial infarction, stroke, and congestive heart failure is not proven. Continuous positive airway pressure, the treatment of choice for obstructive sleep apnoea, reduces sleepiness and Improves hypertension.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital	Malhotra, A (corresponding author), RF 486,221 Longwood Bldg, Boston, MA 02115 USA.	Amalhotra1@partners.org						Akahoshi T, 2001, J PHYSIOL-LONDON, V531, P677, DOI 10.1111/j.1469-7793.2001.0677h.x; Ayappa I, 2000, SLEEP, V23, P763, DOI 10.1093/sleep/23.6.763; Barnes M, 2002, AM J RESP CRIT CARE, V165, P773, DOI 10.1164/ajrccm.165.6.2003166; Berry RB, 1997, AM J RESP CRIT CARE, V156, P127, DOI 10.1164/ajrccm.156.1.9608037; Berry RB, 1997, SLEEP, V20, P654, DOI 10.1093/sleep/20.8.654; BERTHONJONES M, 1993, SLEEP, V16, pS120, DOI 10.1093/sleep/16.suppl_8.S120; Bixler EO, 1998, AM J RESP CRIT CARE, V157, P144, DOI 10.1164/ajrccm.157.1.9706079; Brooks D, 1997, J CLIN INVEST, V99, P106, DOI 10.1172/JCI119120; Broughton R, 1996, J CLIN NEUROPHYSIOL, V13, P272, DOI 10.1097/00004691-199607000-00002; BURGER CD, 1992, AM REV RESPIR DIS, V145, P846, DOI 10.1164/ajrccm/145.4_Pt_1.846; Chesson AL, 1997, SLEEP, V20, P406; DAVIES RJO, 1992, THORAX, V47, P101, DOI 10.1136/thx.47.2.101; Dixon JB, 2001, ARCH INTERN MED, V161, P102, DOI 10.1001/archinte.161.1.102; Douglas NJ, 2001, AM J RESP CRIT CARE, V163, P1310, DOI 10.1164/ajrccm.163.6.2007021; DOUGLAS NJ, 1992, LANCET, V339, P347, DOI 10.1016/0140-6736(92)91660-Z; Engleman HM, 1997, THORAX, V52, P114, DOI 10.1136/thx.52.2.114; Engleman HM, 1999, AM J RESP CRIT CARE, V159, P461, DOI 10.1164/ajrccm.159.2.9803121; Engleman HM, 1998, THORAX, V53, P341, DOI 10.1136/thx.53.5.341; Epstein L, 2000, AM J RESP CRITICAL S, V161, pA358; Epstein LJE, 1998, CHEST, V113, P97, DOI 10.1378/chest.113.1.97; Faccenda JF, 2001, AM J RESP CRIT CARE, V163, P344, DOI 10.1164/ajrccm.163.2.2005037; Ferguson KA, 1997, AM J RESP CRIT CARE, V155, P1748, DOI 10.1164/ajrccm.155.5.9154887; Ferguson KA, 1996, CHEST, V109, P1269, DOI 10.1378/chest.109.5.1269; Field AE, 2001, INT J OBESITY, V25, P1113, DOI 10.1038/sj.ijo.0801643; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; Fogel RB, 2001, AM J RESP CRIT CARE, V164, P2025, DOI 10.1164/ajrccm.164.11.2102048; Friberg D, 1997, REGUL PEPTIDES, V71, P29, DOI 10.1016/S0167-0115(97)01016-1; Friberg D, 1998, LARYNGOSCOPE, V108, P431, DOI 10.1097/00005537-199803000-00022; Friberg D, 1998, AM J RESP CRIT CARE, V157, P586, DOI 10.1164/ajrccm.157.2.96-06049; GLEESON K, 1990, AM REV RESPIR DIS, V142, P295, DOI 10.1164/ajrccm/142.2.295; Gottlieb DJ, 1999, AM J RESP CRIT CARE, V159, P502, DOI 10.1164/ajrccm.159.2.9804051; Gozal D, 1998, PEDIATRICS, V102, P616, DOI 10.1542/peds.102.3.616; Gugger M, 1997, EUR RESPIR J, V10, P587; Hack M, 2000, THORAX, V55, P224, DOI 10.1136/thorax.55.3.224; HAPONIK EF, 1983, AM REV RESPIR DIS, V127, P221; Hilton MF, 2001, EUR RESPIR J, V17, P1258, DOI 10.1183/09031936.01.00009301; HORNER RL, 1994, J PHYSIOL-LONDON, V476, P141; HORNER RL, 1991, J PHYSIOL-LONDON, V436, P15, DOI 10.1113/jphysiol.1991.sp018536; HORNER RL, 1991, J PHYSIOL-LONDON, V436, P31, DOI 10.1113/jphysiol.1991.sp018537; Horner RL, 1996, SLEEP, V19, P827, DOI 10.1093/sleep/19.10.827; Hosselet JJ, 1998, AM J RESP CRIT CARE, V157, P1461, DOI 10.1164/ajrccm.157.5.9708008; Hoy CJ, 1999, AM J RESP CRIT CARE, V159, P1096, DOI 10.1164/ajrccm.159.4.9808008; Hoy CJ, 1997, AM J RESP CRIT CARE, V155, p304A; Hudgel DW, 2000, SLEEP, V23, P645; HUDGEL DW, 1990, J APPL PHYSIOL, V69, P443, DOI 10.1152/jappl.1990.69.2.443; Hudgel DW, 1997, CHEST, V111, P265, DOI 10.1378/chest.111.2.265; HUNG J, 1990, LANCET, V336, P261, DOI 10.1016/0140-6736(90)91799-G; Isono S, 1997, J APPL PHYSIOL, V82, P1319, DOI 10.1152/jappl.1997.82.4.1319; Jenkinson C, 1999, LANCET, V353, P2100, DOI 10.1016/S0140-6736(98)10532-9; Jenkinson C, 1997, J SLEEP RES, V6, P199, DOI 10.1046/j.1365-2869.1997.00043.x; Karason K, 2000, ARCH INTERN MED, V160, P1797, DOI 10.1001/archinte.160.12.1797; Kimoff J, 2001, AM J RESP CRIT CARE, V164, P250; Kingshott RN, 2000, SLEEP, V23, P1109, DOI 10.1093/sleep/23.8.1j; Kline LR, 1999, AM J RESP CRIT CARE, V159, pA427; Kobayashi I, 1996, J APPL PHYSIOL, V80, P1595, DOI 10.1152/jappl.1996.80.5.1595; Kubin L, 1996, SLEEP, V19, P187; KUBIN L, 1994, BRAIN RES, V645, P291, DOI 10.1016/0006-8993(94)91663-2; Lavie P, 2000, BRIT MED J, V320, P479, DOI 10.1136/bmj.320.7233.479; LAVIE P, 1995, SLEEP, V18, P149, DOI 10.1093/sleep/18.3.149; Lindberg E, 2001, AM J RESP CRIT CARE, V164, P2031, DOI 10.1164/ajrccm.164.11.2102028; Loube DI, 1999, CHEST, V115, P1333, DOI 10.1378/chest.115.5.1333; Malhotra A, 2000, AM J RESP CRIT CARE, V161, P1746, DOI 10.1164/ajrccm.161.5.9907109; Malhotra A, 2002, AM J RESP CRIT CARE, V165, P71, DOI 10.1164/ajrccm.165.1.2011065; Malhotra A, 2000, AM J RESP CRIT CARE, V162, P1058, DOI 10.1164/ajrccm.162.3.9912067; MATHEW OP, 1982, J APPL PHYSIOL, V52, P438, DOI 10.1152/jappl.1982.52.2.438; MATHEW OP, 1982, J APPL PHYSIOL, V52, P445, DOI 10.1152/jappl.1982.52.2.445; MATHEW OP, 1984, J APPL PHYSIOL, V56, P500, DOI 10.1152/jappl.1984.56.2.500; Meza S, 1998, J APPL PHYSIOL, V84, P3, DOI 10.1152/jappl.1998.84.1.3; Mezzanotte WS, 1996, AM J RESP CRIT CARE, V153, P1880, DOI 10.1164/ajrccm.153.6.8665050; MEZZANOTTE WS, 1992, J CLIN INVEST, V89, P1571, DOI 10.1172/JCI115751; Millman RP, 1998, CHEST, V113, P992, DOI 10.1378/chest.113.4.992; Montserrat JM, 2001, AM J RESP CRIT CARE, V164, P608, DOI 10.1164/ajrccm.164.4.2006034; Montserrat JM, 1997, AM J RESP CRIT CARE, V155, P211, DOI 10.1164/ajrccm.155.1.9001314; Nieto FJ, 2000, JAMA-J AM MED ASSOC, V283, P1829, DOI 10.1001/jama.283.14.1829; ONAL E, 1981, AM REV RESPIR DIS, V124, P215; ONAL E, 1981, J APPL PHYSIOL, V50, P1052, DOI 10.1152/jappl.1981.50.5.1052; Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901; Pepperell JCT, 2002, LANCET, V359, P204, DOI 10.1016/S0140-6736(02)07445-7; Phillips B, 1996, HOSP PRACT, V31, P193; Phillips BG, 1999, J HYPERTENS, V17, P61, DOI 10.1097/00004872-199917010-00010; Pillar F, 2000, AM J RESP CRIT CARE, V162, P1627, DOI 10.1164/ajrccm.162.5.2003131; PILLAR G, 1994, CHEST, V106, P1702, DOI 10.1378/chest.106.6.1702; Pittman SD, 2000, COMPUT CARDIOL, V27, P485, DOI 10.1109/CIC.2000.898563; Powell NB, 1998, CLIN CHEST MED, V19, P77, DOI 10.1016/S0272-5231(05)70433-0; Powell NB, 1997, CHEST, V111, P1348, DOI 10.1378/chest.111.5.1348; Powell NB, 1998, CHEST, V113, P1163, DOI 10.1378/chest.113.5.1163; Rechtschaffen A., 1968, BRAIN INFORM SERVICE; Redline S, 1997, AM J RESP CRIT CARE, V155, P186, DOI 10.1164/ajrccm.155.1.9001310; Redline S, 1998, AM J RESP CRIT CARE, V157, P858, DOI 10.1164/ajrccm.157.3.9709042; REEVESHOCHE MK, 1995, AM J RESP CRIT CARE, V151, P443, DOI 10.1164/ajrccm.151.2.7842204; REMMERS JE, 1978, J APPL PHYSIOL, V44, P931, DOI 10.1152/jappl.1978.44.6.931; Reuveni H, 2001, MED DECIS MAKING, V21, P451, DOI 10.1177/02729890122062802; RILEY RW, 1993, J ORAL MAXIL SURG, V51, P742, DOI 10.1016/S0278-2391(10)80412-4; RILEY RW, 1994, OTOLARYNG HEAD NECK, V111, P717, DOI 10.1016/S0194-5998(94)70557-7; RILEY RW, 1993, OTOLARYNG HEAD NECK, V108, P117, DOI 10.1177/019459989310800203; Scheuller M, 2001, OTOLARYNG HEAD NECK, V125, P299, DOI 10.1067/mhn.2001.119139; SCHWAB RJ, 1995, AM J RESP CRIT CARE, V152, P1673, DOI 10.1164/ajrccm.152.5.7582313; SERIES F, 1993, ANN INTERN MED, V119, P449, DOI 10.7326/0003-4819-119-6-199309150-00001; Shahar E, 2001, AM J RESP CRIT CARE, V163, P19, DOI 10.1164/ajrccm.163.1.2001008; SOMERS VK, 1988, CLIN EXP HYPERTENS A, V10, P413, DOI 10.3109/10641968809075998; SOMERS VK, 1995, J CLIN INVEST, V96, P1897, DOI 10.1172/JCI118235; STRADLING JR, 1991, THORAX, V46, P85, DOI 10.1136/thx.46.2.85; Stradling JR, 1997, THORAX, V52, P72, DOI 10.1136/thx.52.1.72; Strollo PJ, 1996, SLEEP, V19, pS255, DOI 10.1093/sleep/19.suppl_10.S255; SUGERMAN HJ, 1992, AM J CLIN NUTR, V55, P597, DOI 10.1093/ajcn/55.2.597s; SURATT PM, 1983, AM REV RESPIR DIS, V127, P487, DOI 10.1164/arrd.1983.127.4.487; Teran-Santos J, 1999, NEW ENGL J MED, V340, P847, DOI 10.1056/NEJM199903183401104; VANDEGRAAFF WB, 1988, J APPL PHYSIOL, V65, P2124, DOI 10.1152/jappl.1988.65.5.2124; VANDEGRAAFF WB, 1991, J APPL PHYSIOL, V70, P1328, DOI 10.1152/jappl.1991.70.3.1328; Walker-Engstrom ML, 2002, CHEST, V121, P739, DOI 10.1378/chest.121.3.739; Weiss JW, 1996, SLEEP, V19, P388, DOI 10.1093/sleep/19.5.388; WEISS JW, 1993, SLEEP, V16, pS39; WETTER DW, 1994, ARCH INTERN MED, V154, P2219, DOI 10.1001/archinte.154.19.2219; WHEATLEY JR, 1993, J APPL PHYSIOL, V75, P2117, DOI 10.1152/jappl.1993.75.5.2117; WHEATLEY JR, 1993, AM REV RESPIR DIS, V148, P597, DOI 10.1164/ajrccm/148.3.597; WHEATLEY JR, 1993, SLEEP, V16, pS87, DOI 10.1093/sleep/16.suppl_8.S87; White DP, 1998, SLEEP, V21, P188; White DP, 1998, SLEEP, V21, P198, DOI 10.1093/sleep/21.2.198; Whittle AT, 1997, THORAX, V52, P1068, DOI 10.1136/thx.52.12.1068; Younes M, 2001, AM J RESP CRIT CARE, V163, P1181, DOI 10.1164/ajrccm.163.5.2007013; Young T, 2002, AM J RESP CRIT CARE, V165, P1217, DOI 10.1164/rccm.2109080; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Young T, 2001, AM J RESP CRIT CARE, V163, P597, DOI 10.1164/ajrccm.163.3.ed09-01a	123	745	773	9	147	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 20	2002	360	9328					237	245		10.1016/S0140-6736(02)09464-3	http://dx.doi.org/10.1016/S0140-6736(02)09464-3			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	576DX	12133673				2022-12-28	WOS:000176988500028
J	Gelb, MH; Hol, WGJ				Gelb, MH; Hol, WGJ			Parasitology - Drugs to combat tropical protozoan parasites	SCIENCE			English	Editorial Material									Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Gelb, MH (corresponding author), Univ Washington, Dept Chem, Seattle, WA 98195 USA.			gelb, michael/0000-0001-7000-5219				Bahl A, 2002, NUCLEIC ACIDS RES, V30, P87, DOI 10.1093/nar/30.1.87; Croft SL, 1996, J ANTIMICROB CHEMOTH, V38, P1041, DOI 10.1093/jac/38.6.1041; Jha TK, 1999, NEW ENGL J MED, V341, P1795, DOI 10.1056/NEJM199912093412403; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; PORTILLO HA, 2001, J INFECT DIS, V183, P1653; Roos DS, 2002, PHILOS T R SOC B, V357, P35, DOI 10.1098/rstb.2001.1047; Sibley CH, 2001, TRENDS PARASITOL, V17, P582, DOI 10.1016/S1471-4922(01)02085-2; *TARG SEL STRUCT B, 2002, KEYST S 3 8 MARCH 20; Urbina JA, 2001, CURR OPIN INFECT DIS, V14, P733, DOI 10.1097/00001432-200112000-00012; Wengelnik K, 2002, SCIENCE, V295, P1311, DOI 10.1126/science.1067236	10	74	79	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 19	2002	297	5580					343	344		10.1126/science.1073126	http://dx.doi.org/10.1126/science.1073126			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574LV	12130767				2022-12-28	WOS:000176892600032
J	Mackler, JM; Drummond, JA; Loewen, CA; Robinson, IM; Reist, NE				Mackler, JM; Drummond, JA; Loewen, CA; Robinson, IM; Reist, NE			The C2BCa2+-binding motif of synaptotagmin is required for synaptic transmission in vivo	NATURE			English	Article							C2B DOMAIN; NEUROTRANSMITTER RELEASE; DROSOPHILA REVEALS; MUTANTS; EXOCYTOSIS; VESICLES; BINDING; LOCALIZATION	Synaptotagmin is a synaptic vesicle protein that is postulated to be the Ca2+ sensor for fast, evoked neurotransmitter release(1). Deleting the gene for synaptotagmin (syt(null)) strongly suppresses synaptic transmission in every species examined(2), showing that synaptotagmin is central in the synaptic vesicle cycle. The cytoplasmic region of synaptotagmin contains two C-2 domains, C(2)A and C2B. Five, highly conserved, acidic residues in both the C(2)A and C2B domains of synaptotagmin coordinate the binding of Ca2+ ions(3-5), and biochemical studies have characterized several in vitro Ca2+-dependent interactions between synaptotagmin and other nerve terminal molecules(6). But there has been no direct evidence that any of the Ca2+-binding sites within synaptotagmin are required in vivo. Here we show that mutating two of the Ca2+-binding aspartate residues in the C2B domain (D-416,N-418 in Drosophila) decreased evoked transmitter release by >95%, and decreased the apparent Ca2+ affinity of evoked transmitter release. These studies show that the Ca2+-binding motif of the C2B domain of synaptotagmin is essential for synaptic transmission.	Colorado State Univ, Dept Anat & Neurobiol, Program Mol Cellular & Integrat Neurosci, Ft Collins, CO 80523 USA; Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England	Colorado State University; University of Cambridge	Reist, NE (corresponding author), Colorado State Univ, Dept Anat & Neurobiol, Program Mol Cellular & Integrat Neurosci, Ft Collins, CO 80523 USA.			Reist, Noreen/0000-0002-1647-3166				Augustine GJ, 2001, CURR OPIN NEUROBIOL, V11, P320, DOI 10.1016/S0959-4388(00)00214-2; Bai JH, 2002, P NATL ACAD SCI USA, V99, P1665, DOI 10.1073/pnas.032541099; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; Desai RC, 2000, J CELL BIOL, V150, P1125, DOI 10.1083/jcb.150.5.1125; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; Earles CA, 2001, J CELL BIOL, V154, P1117, DOI 10.1083/jcb.200105020; Fernandez I, 2001, NEURON, V32, P1057, DOI 10.1016/S0896-6273(01)00548-7; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; Garcia RA, 2000, P NATL ACAD SCI USA, V97, P5883, DOI 10.1073/pnas.100127197; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; Kee Y, 1996, J NEUROSCI, V16, P1975; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Littleton JT, 2001, J NEUROSCI, V21, P1421, DOI 10.1523/JNEUROSCI.21-05-01421.2001; LITTLETON JT, 1993, DEVELOPMENT, V118, P1077; Loewen CA, 2001, GENESIS, V31, P30, DOI 10.1002/gene.10002; Mackler JM, 2001, J COMP NEUROL, V436, P4, DOI 10.1002/cne.1049; Petersen SA, 1997, NEURON, V19, P1237, DOI 10.1016/S0896-6273(00)80415-8; Reist NE, 1998, J NEUROSCI, V18, P7662; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; ROBINSON IM, 2002, NATURE          0707; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; STEWART BA, 1994, J COMP PHYSIOL A, V175, P179, DOI 10.1007/BF00215114; Sutton RB, 1999, J CELL BIOL, V147, P589, DOI 10.1083/jcb.147.3.589; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	28	258	262	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 18	2002	418	6895					340	344		10.1038/nature00846	http://dx.doi.org/10.1038/nature00846			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574BF	12110842				2022-12-28	WOS:000176868000046
J	Durso, SC				Durso, SC			A survivor's way	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	2002	288	3					287	288		10.1001/jama.288.3.287	http://dx.doi.org/10.1001/jama.288.3.287			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573AK	12117373				2022-12-28	WOS:000176807000001
J	Peacock, JE; Herrington, DA; Wade, JC; Lazarus, HM; Reed, MD; Sinclair, JW; Haverstock, DC; Kowalsky, SF; Hurd, DD; Cushing, DA; Harman, CP; Donowitz, GR				Peacock, JE; Herrington, DA; Wade, JC; Lazarus, HM; Reed, MD; Sinclair, JW; Haverstock, DC; Kowalsky, SF; Hurd, DD; Cushing, DA; Harman, CP; Donowitz, GR			Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients - A randomized, double-blind trial	ANNALS OF INTERNAL MEDICINE			English	Article							CANCER-PATIENTS; INTRAVENOUS CIPROFLOXACIN; ANTIBIOTIC-THERAPY; PSEUDOMONAS-AERUGINOSA; ESCHERICHIA-COLI; FEVER; RESISTANCE; CEFTAZIDIME; COMBINATION; EPISODES	Background: Therapy with an aminoglycoside and a beta-lactam remains common empirical therapy for febrile neutropenic patients. Concerns of aminoglycoside-induced ototoxicity and nephrotoxicity have led to studies of alternate regimens. Objective: To determine whether ciprofloxacin-piperacillin is equivalent to tobramycin-piperacillin as empirical therapy for neutropenic fever. Design: Randomized, double-blind multicenter trial. Setting: Seven U.S. university-affiliated hospitals and one private research center. Patients: Febrile (temperature greater than or equal to 38 degreesC), neutropenic (neutrophil level < 1 x 10(9) cells/L) hospitalized patients who had leukemia, lymphoma, or solid tumors, or were undergoing bone marrow transplantation. Interventions: Patients received piperacillin, 50 mg/kg of body weight intravenously every 4 hours, and ciprofloxacin, 400 mg intravenously every 8 hours, or tobramycin, 2 mg/kg intravenously every 8 hours. Measurements: Success was defined as resolution of infection and previously positive cultures without the need to give additional antimicrobial agents. Results: 543 febrile episodes were evaluated, of which 471 were clinically evaluable (234 in the ciprofloxacin-piperacillin group and 237 in the tobramycin-piperacillin group). Success rates in the ciprofloxacin-piperacillin group (63 of 234 febrile episodes) and tobramycin-piperacillin group (52 of 237 episodes) were similar (27% vs. 22%, respectively; difference, 5.0 percentage points [95% Cl, -2.3 to 12.8 percentage points]), as was survival (96.2% of patients receiving ciprofloxacin-piperacillin versus 94.1% of patients receiving tobramycin-piperacillin; difference, 2.1 percentage points [Cl, -2.2 to 6.4 percentage points]). Additions to the initial antimicrobial regimen were the most common reason for treatment failure in both groups (accounting for 67% of failures in the ciprofloxacin-piperacillin group and 72% in the tobramycin-piperacillin group; difference, 5.0 percentage points [Cl, -13.8 to 3.7 percentage points]). Fevers resolved faster in patients receiving ciprofloxacin-piperacillin than in patients receiving tobramycin-piperacillin (mean, 5 vs. 6 days) (P = 0.005). No significant differences in adverse events or toxicity were noted (P = 0.083). Conclusion: Ciprofloxacin-piperacillin is as safe and effective as tobramycin-piperacillin for empirical therapy of neutropenic fever.	Univ Virginia Hlth Syst, Div Infect Dis, Charlottesville, VA 22908 USA; Univ Maryland, Ctr Canc, Baltimore, MD 21201 USA; Univ Hosp Cleveland, Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Bayer Corp, West Haven, CT USA; Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA	University of Virginia; University System of Maryland; University of Maryland Baltimore; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Case Western Reserve University; Bayer AG; Wake Forest University	Donowitz, GR (corresponding author), Univ Virginia Hlth Syst, Div Infect Dis, POB 801343, Charlottesville, VA 22908 USA.							Archibald L, 1997, CLIN INFECT DIS, V24, P211, DOI 10.1093/clinids/24.2.211; BAYSTON KF, 1989, AM J MED, V87, pS269, DOI 10.1016/0002-9343(89)90078-8; BERNSTEIN JM, 1986, ARCH INTERN MED, V146, P2329, DOI 10.1001/archinte.146.12.2329; BODEY GP, 1993, CLIN INFECT DIS, V17, pS378, DOI 10.1093/clinids/17.Supplement_2.S378; BROWN AE, 1989, AM J MED, V87, pS266, DOI 10.1016/0002-9343(89)90077-6; BRUMMETT RE, 1989, ANTIMICROB AGENTS CH, V33, P797, DOI 10.1128/AAC.33.6.797; BUSTAMANTE CI, 1990, ANTIMICROB AGENTS CH, V34, P1814, DOI 10.1128/AAC.34.9.1814; Carmeli Y, 1999, ANTIMICROB AGENTS CH, V43, P1379, DOI 10.1128/AAC.43.6.1379; CHALKLEY LJ, 1985, ANTIMICROB AGENTS CH, V28, P331, DOI 10.1128/AAC.28.2.331; CHAN CC, 1989, ANTIMICROB AGENTS CH, V33, P87, DOI 10.1128/AAC.33.1.87; Cordonnier C, 1997, CLIN INFECT DIS, V24, P41, DOI 10.1093/clinids/24.1.41; deLalla F, 1997, DRUGS, V53, P789, DOI 10.2165/00003495-199753050-00005; Edson RS, 1999, MAYO CLIN PROC, V74, P519, DOI 10.4065/74.5.519; Elting LS, 2000, J CLIN ONCOL, V18, P3699, DOI 10.1200/JCO.2000.18.21.3699; FERNANDES CJ, 1990, DIAGN MICR INFEC DIS, V13, P79, DOI 10.1016/0732-8893(90)90090-I; Finberg RW, 1999, NEW ENGL J MED, V341, P362, DOI 10.1056/NEJM199907293410509; FLAHERTY JP, 1989, AM J MED, V87, pS278, DOI 10.1016/0002-9343(89)90080-6; Freifeld A, 1999, NEW ENGL J MED, V341, P305, DOI 10.1056/NEJM199907293410501; Ghazal HH, 1997, CLIN THER, V19, P520, DOI 10.1016/S0149-2918(97)80136-1; Giamarellou H, 2000, ANTIMICROB AGENTS CH, V44, P3264, DOI 10.1128/AAC.44.12.3264-3271.2000; Griggs JJ, 1998, AM J HEMATOL, V58, P293, DOI 10.1002/(SICI)1096-8652(199808)58:4<293::AID-AJH7>3.0.CO;2-L; Hathorn JW, 1997, CLIN INFECT DIS, V24, pS256, DOI 10.1093/clinids/24.Supplement_2.S256; Hughes WT, 1997, CLIN INFECT DIS, V25, P551, DOI 10.1086/513764; Jones RN, 1999, CLIN INFECT DIS, V29, P495, DOI 10.1086/598621; KAHLMETER G, 1984, J ANTIMICROB CHEMOTH, V13, P9, DOI 10.1093/jac/13.suppl_A.9; KELSEY SM, 1989, AM J MED, V87, pS274, DOI 10.1016/0002-9343(89)90079-X; Kern WV, 1999, NEW ENGL J MED, V341, P312, DOI 10.1056/NEJM199907293410502; Marie JP, 1998, J ANTIMICROB CHEMOTH, V41, P57, DOI 10.1093/jac/41.suppl_4.57; MEUNIER F, 1991, ANTIMICROB AGENTS CH, V35, P873, DOI 10.1128/AAC.35.5.873; ORLANDO PL, 1990, DIAGN MICR INFEC DIS, V13, P93, DOI 10.1016/0732-8893(90)90091-9; Pizzo PA, 1999, NEW ENGL J MED, V341, P893, DOI 10.1056/NEJM199909163411207; PIZZO PA, 1993, NEW ENGL J MED, V328, P1323; ROLSTON KVI, 1989, AM J MED, V87, pS261, DOI 10.1016/0002-9343(89)90076-4; SANDERS CC, 1988, REV INFECT DIS, V10, P516; SCHIMPFF S, 1971, NEW ENGL J MED, V284, P1061, DOI 10.1056/NEJM197105132841904; SMITH GM, 1988, J ANTIMICROB CHEMOTH, V21, P647, DOI 10.1093/jac/21.5.647; Thomson CJ, 1999, J ANTIMICROB CHEMOTH, V43, P31, DOI 10.1093/jac/43.suppl_1.31; van Kraaij MGJ, 1998, EUR J CLIN MICROBIOL, V17, P591, DOI 10.1007/BF01708627; Viscoli C, 1998, J ANTIMICROB CHEMOTH, V41, P65, DOI 10.1093/jac/41.suppl_4.65; 1991, MED LETT DRUGS THER, V33, P75	40	37	39	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 16	2002	137	2					77	86		10.7326/0003-4819-137-2-200207160-00005	http://dx.doi.org/10.7326/0003-4819-137-2-200207160-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575VN	12118962				2022-12-28	WOS:000176969300001
J	Carel, JC; Ecosse, E; Nicolino, M; Tauber, M; Leger, J; Cabrol, S; Bastie-Sigeac, IN; Chaussain, JL; Coste, J				Carel, JC; Ecosse, E; Nicolino, M; Tauber, M; Leger, J; Cabrol, S; Bastie-Sigeac, IN; Chaussain, JL; Coste, J			Adult height after long term treatment with recombinant growth hormone for idiopathic isolated growth hormone deficiency: observational follow up study of the French population based registry	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SHORT STATURE; FINAL HEIGHT; CHILDREN; DIAGNOSIS; VELOCITY; EXPERIENCE; CHILDHOOD; PUBERTY; THERAPY; BOYS	Objective To evaluate the efficacy of recombinant growth hormone for increasing adult height in children treated for idiopathic isolated growth hormone deficiency. Design Observational follow up study. Setting Population based registry. Participants All 2852 French children diagnosed as having isolated idiopathic growth hormone deficiency whose treatment started between 1987 and 1992 and ended before 1996. Main outcome measures Change in height between the start of treatment and adulthood; classification of patients according to whether treatment was completed as scheduled or stopped early. Results Adult height was obtained for 2165 (76%) patients. The mean dose of growth hormone at start of treatment was 0.42 IU/kg/week. Height gain was 1.1 (SD 0.9) standard deviation (SD) scores, resulting in an adult height of -1.6 (0.9) SD score (girls, 154 (5) cm; boys, 167 (6) cm). Patients who completed the treatment gained 1.0 (0.7) SD score of height in 3.6 (1.4) years. Patients with treatments stopped early gained 0.6 (0.6) SD score in 2.7 (1.4) years while receiving treatment and a further 0.4 (0.9) SD score after the end of treatment. Most of the variation in height gain was explained by regression towards the mean, patients' characteristics, and delay in starting puberty. Severe growth hormone deficiency was associated with better outcome. Each year of treatment was associated with a gain of 0.2 SD score (1.3 cm). Conclusion The effect of growth hormone is unclear in many patients treated for so called idiopathic isolated growth hormone deficiency: Most of the patients have pubertal delay and a spontaneous growth potential, which must be taken into account when measuring the effect and cost effectiveness of treatments. Growth hormone deficiency should be clearly distinguished froth pubertal delay, and criteria should restrict the definition to patients with severely and permanently altered growth hormone secretion as our results support the use of growth hormone in such patients. Long term trials are required for most patients currently treated.	Univ Paris 05, Grp Hosp Cochin St Vincent de Paul, F-75014 Paris, France; Univ Paris 05, Fac Cochin, F-75014 Paris, France; Hop Robert Debre, Dept Paediat Endocrinol, F-75019 Paris, France; Hop Robert Debre, INSERM, U561, F-75019 Paris, France; Hop Robert Debre, Dept Biostat, F-75019 Paris, France; Hop Trousseau, Paediat Endocrinol Unit, F-75571 Paris, France; Hop Debrousse, Dept Paediat Endocrinol, F-69322 Lyon, France; Hop Enfants, Dept Paediat Endocrinol, F-31026 Toulouse, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Lyon; CHU de Toulouse	Carel, JC (corresponding author), Univ Paris 05, Grp Hosp Cochin St Vincent de Paul, F-75014 Paris, France.	carel@cochin.inserm.fr	Carel, Jean-Claude/AAZ-7691-2020	Carel, Jean-Claude/0000-0002-0424-6767				August GP, 1998, PEDIATRICS, V102, P512; August GP, 1998, PEDIATRICS, V102, P517; Bayley N, 1952, J PEDIATR, V14, P432; BLAND JM, 1994, BRIT MED J, V308, P1499, DOI 10.1136/bmj.308.6942.1499; Blethen SL, 1997, J CLIN ENDOCR METAB, V82, P418, DOI 10.1210/jc.82.2.418; BOURGUIGNON JP, 1988, ENDOCR REV, V9, P467, DOI 10.1210/edrv-9-4-467; Brook CGD, 1997, BMJ-BRIT MED J, V315, P692, DOI 10.1136/bmj.315.7110.692; Brook CGD, 2000, ARCH DIS CHILD, V83, P176, DOI 10.1136/adc.83.2.176; Carel JC, 1997, J CLIN ENDOCR METAB, V82, P2117, DOI 10.1210/jc.82.7.2117; Chatelain P., 1999, GROWTH HORMONE THERA, V10, P11; COLE T, 1993, KIGS REPORT, V10, P37; *COMM L WILK PED E, 1995, J PEDIATR, V127, P857; Coste J, 1997, BRIT MED J, V315, P708, DOI 10.1136/bmj.315.7110.708; Cutfield W, 1999, ACTA PAEDIATR, V88, P72, DOI 10.1111/j.1651-2227.1999.tb14356.x; FURLANETTO RW, 1995, J PEDIATR-US, V127, P857; Greulich WW., 1959, CALIF MED, V91, P53; Guyda HJ, 2000, PEDIATR RES, V48, P579, DOI 10.1203/00006450-200011000-00003; Guyda HJ, 1999, J CLIN ENDOCR METAB, V84, P4307, DOI 10.1210/jc.84.12.4307; Israel E, 2000, J CLIN ENDOCR METAB, V85, P3990; MARIN G, 1994, J CLIN ENDOCR METAB, V79, P537, DOI 10.1210/jc.79.2.537; MARSHALL WA, 1969, ARCH DIS CHILD, V44, P291, DOI 10.1136/adc.44.235.291; MARSHALL WA, 1970, ARCH DIS CHILD, V45, P13, DOI 10.1136/adc.45.239.13; Price DA, 1999, GROWTH HORMONE THERA, P73; Ranke M. B., 2000, Hormone Research (Basel), V53, P47; Ranke MB, 1997, HORM RES, V48, P62, DOI 10.1159/000185487; ROSENFELD RG, 1995, J CLIN ENDOCR METAB, V80, P1532, DOI 10.1210/jc.80.5.1532; Rosenfeld RG, 1997, J CLIN ENDOCR METAB, V82, P349, DOI 10.1210/jc.82.2.349; Saggese G., 1998, Hormone Research (Basel), V50, P320; THAKRAR A, 1994, J PUBLIC HEALTH MED, V16, P200, DOI 10.1093/oxfordjournals.pubmed.a042957; Van den Broeck J, 1999, HORM RES, V51, P68, DOI 10.1159/000023317; Vance ML, 1999, NEW ENGL J MED, V341, P1206, DOI 10.1056/NEJM199910143411607; VOSS LD, 1991, ARCH DIS CHILD, V66, P833, DOI 10.1136/adc.66.7.833; Weiss NS, 1986, CLIN EPIDEMIOLOGY ST	33	96	100	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 13	2002	325	7355					70	73		10.1136/bmj.325.7355.70	http://dx.doi.org/10.1136/bmj.325.7355.70			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575CU	12114235	Green Published, Bronze			2022-12-28	WOS:000176929400017
J	Marteau, TM; Kinmonth, AL				Marteau, TM; Kinmonth, AL			Screening for cardiovascular risk: public health imperative or matter for individual informed choice?	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE	The National Screening Committee has recommended a paradigm of informed choice for participants in all screening programmes. Theresa Marteau and Ann Louise Kinmonth examine the potential consequences of applying such a policy to screening for risk of coronary heart disease in	Kings Coll London, Psychol & Genet Res Grp, London SE1 9RT, England; Univ Cambridge, Inst Publ Hlth, GP & Primary Care Res Unit, Cambridge CB2 2SR, England	University of London; King's College London; University of Cambridge	Marteau, TM (corresponding author), Kings Coll London, Psychol & Genet Res Grp, London SE1 9RT, England.	theresa.marteau@kcl.ac.uk		Marteau, Theresa/0000-0003-3025-1129	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Armitage CJ, 2001, BRIT J SOC PSYCHOL, V40, P471, DOI 10.1348/014466601164939; Austoker J, 1999, BMJ-BRIT MED J, V319, P722, DOI 10.1136/bmj.319.7212.722; Bernstein T, 1994, RADON RENTAL HOUSING; *BRIT CARD SOC BRI, 2000, BRIT MED J, V320, P795; *DEP HLTH, 2000, NAT SERV FRAM COR HE; EBRAHIM S, 2000, COCHRANE DATABASE SY; Edwards A, 2001, J HEALTH COMMUN, V6, P61, DOI 10.1080/10810730150501413; FLOOD AB, 1996, J GEN INTERN MED, V11, P341; General Medical Council, 1999, SEEK PAT CONS ETH CO; Jackson R, 2000, BMJ-BRIT MED J, V320, P709, DOI 10.1136/bmj.320.7236.709; JEPSON R, 2000, HEALTH TECHNOL ASSES, V4, P1, DOI DOI 10.3310/HTA4140; Marteau TM, 2001, BRIT MED J, V322, P526, DOI 10.1136/bmj.322.7285.526; MARTEAU TM, 2001, HLTH EXPERT, V4, P9; Misselbrook D, 2001, BRIT J GEN PRACT, V51, P276; *NAT SCREEN COMM, 2002, 2ND REP UK NAT SCREE; Petticrew M P, 2000, Health Technol Assess, V4, P1; RAFFLE AE, 1998, TRENDS UROL GYNAECOL, V3, P14; Rouse A, 2001, BRIT J GEN PRACT, V51, P834; Shaw C, 1999, SOC SCI MED, V49, P1571, DOI 10.1016/S0277-9536(99)00244-0; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Smith R, 2002, BRIT MED J, V324, P497, DOI 10.1136/bmj.324.7336.497; STOTT NCH, 1990, FAM PRACT, V7, P125, DOI 10.1093/fampra/7.2.125; Toop L, 2001, BRIT MED J, V323, P246, DOI 10.1136/bmj.323.7307.246; Witte K, 2000, HEALTH EDUC BEHAV, V27, P591, DOI 10.1177/109019810002700506	24	56	56	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 13	2002	325	7355					78	80		10.1136/bmj.325.7355.78	http://dx.doi.org/10.1136/bmj.325.7355.78			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575CU	12114238	Green Published, Bronze			2022-12-28	WOS:000176929400020
J	Nasrallah, ME; Liu, P; Nasrallah, JB				Nasrallah, ME; Liu, P; Nasrallah, JB			Generation of self-incompatible Arabidopsis thaliana by transfer of two S locus genes from A-lyrata	SCIENCE			English	Article							RECEPTOR KINASE; BRASSICA; TRANSFORMATION; EVOLUTION; STIGMA	Transitions from cross-fertilizing to self-fertilizing mating systems have occurred frequently in natural and domesticated plant populations, but the underlying genetic causes are unknown. We show that gene transfer of the stigma receptor kinase SRK and its pollen-borne ligand SCR from one S-locus haplotype of the self-incompatible and cross-fertilizing Arabidopsis lyrata is sufficient to impart self-incompatibility phenotype in self-fertile Arabidopsis thaliana, which lacks functional orthologs of these genes. This successful complementation demonstrates that the signaling cascade leading to inhibition of self-related pollen was maintained in A. thaliana. Analysis of self-incompatibility will be facilitated by the tools available in this species.	Cornell Univ, Dept Plant Biol, Ithaca, NY 14853 USA	Cornell University	Nasrallah, ME (corresponding author), Cornell Univ, Dept Plant Biol, Ithaca, NY 14853 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057527] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57527] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bi YM, 2000, MOL GEN GENET, V263, P648, DOI 10.1007/s004380051213; Charlesworth D, 2001, CURR OPIN GENET DEV, V11, P685, DOI 10.1016/S0959-437X(00)00254-9; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Frary A, 2000, SCIENCE, V289, P85, DOI 10.1126/science.289.5476.85; HODGKIN T, 1978, THEOR APPL GENET, V53, P81, DOI 10.1007/BF00274334; Kachroo A, 2001, SCIENCE, V293, P1824, DOI 10.1126/science.1062509; KHO YO, 1968, EUPHYTICA, V17, P298; Koch MA, 2000, MOL BIOL EVOL, V17, P1483, DOI 10.1093/oxfordjournals.molbev.a026248; Kusaba M, 2001, PLANT CELL, V13, P627, DOI 10.1105/tpc.13.3.627; Nasrallah JB, 2000, CURR OPIN PLANT BIOL, V3, P368, DOI 10.1016/S1369-5266(00)00098-4; NASRALLAH JB, 1994, PLANT J, V5, P373, DOI 10.1111/j.1365-313X.1994.00373.x; Schopfer CR, 1999, SCIENCE, V286, P1697, DOI 10.1126/science.286.5445.1697; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; Stein JC, 1996, PLANT CELL, V8, P429, DOI 10.1105/tpc.8.3.429; Takasaki T, 2000, NATURE, V403, P913, DOI 10.1038/35002628; Takayama S, 2001, NATURE, V413, P534, DOI 10.1038/35097104; VANENGELEN FA, 1995, TRANSGENIC RES, V4, P288, DOI 10.1007/BF01969123; White S, 1998, TRENDS GENET, V14, P327, DOI 10.1016/S0168-9525(98)01524-8	18	153	168	3	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 12	2002	297	5579					247	249		10.1126/science.1072205	http://dx.doi.org/10.1126/science.1072205			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571UT	12114625				2022-12-28	WOS:000176738100040
J	Pfeiffer, F; David, C; Burghammer, M; Riekel, C; Salditt, T				Pfeiffer, F; David, C; Burghammer, M; Riekel, C; Salditt, T			Two-dimensional x-ray waveguides and point sources	SCIENCE			English	Article							SPATIAL-RESOLUTION; DIFFRACTION	We show that resonant coupling of synchrotron beams into suitable nanostructures can be used for the generation of coherent x-ray point sources. A two-dimensionally con ning x-ray waveguide structure has been fabricated by e-beam lithography. By shining a parallel undulator beam onto the structure, a discrete set of resonant modes can be excited in the dielectric cavity, depending on the two orthogonal coupling angles between the beam and the waveguide interfaces. The resonant excitation of the modes is evidenced from the characteristic set of coupling angles as well as the observed far-field pattern. The x-ray nanostructure may be used as coherent x-ray point sources with a beam cross section in the nanometer range.	Univ Saarland, D-66041 Saarbrucken, Germany; Paul Scherrer Inst, Lab Micro & Nanotechnol, CH-5232 Villigen, Switzerland; European Synchrotron Radiat Facil, F-38043 Grenoble, France	Saarland University; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; European Synchrotron Radiation Facility (ESRF)	Salditt, T (corresponding author), Univ Saarland, Stadtwald 38,Postfach 15 11 50, D-66041 Saarbrucken, Germany.							BILDERBACK DH, 1994, SCIENCE, V263, P201, DOI 10.1126/science.8284671; Di Fonzo S, 2000, NATURE, V403, P638, DOI 10.1038/35001035; FENG YP, 1993, PHYS REV LETT, V71, P537, DOI 10.1103/PhysRevLett.71.537; Ghatak A., 1998, INTRO FIBER OPTICS; Lagomarsino S, 1997, APPL PHYS LETT, V71, P2557, DOI 10.1063/1.119324; Marcuse D., 1974, THEORY DIELECTRIC OP; PARRATT LG, 1954, PHYS REV, V95, P359, DOI 10.1103/PhysRev.95.359; Pfeiffer F, 2001, PROC SPIE, V4145, P193, DOI 10.1117/12.411637; Pfeiffer F, 2002, J APPL CRYSTALLOGR, V35, P163, DOI 10.1107/S0021889801021628; Riekel C, 2000, REP PROG PHYS, V63, P233, DOI 10.1088/0034-4885/63/3/201; SUTTON M, 1991, NATURE, V352, P608, DOI 10.1038/352608a0; Suzuki Y, 1997, J SYNCHROTRON RADIAT, V4, P60, DOI 10.1107/S0909049596014720; Weiss D, 1998, APPL PHYS LETT, V72, P1805, DOI 10.1063/1.121190; Zwanenburg MJ, 2000, PHYS REV LETT, V85, P5154, DOI 10.1103/PhysRevLett.85.5154	14	136	139	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 12	2002	297	5579					230	234		10.1126/science.1071994	http://dx.doi.org/10.1126/science.1071994			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571UT	12114620				2022-12-28	WOS:000176738100035
J	Jung, A; Maier, R; Vartanian, JP; Bocharov, G; Jung, V; Fischer, U; Meese, E; Wain-Hobson, S; Meyerhans, A				Jung, A; Maier, R; Vartanian, JP; Bocharov, G; Jung, V; Fischer, U; Meese, E; Wain-Hobson, S; Meyerhans, A			Recombination - Multiply infected spleen cells in HIV patients	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1		Univ Saarland, Dept Virol, D-66421 Homburg, Germany; Univ Saarland, Dept Human Genet, D-66421 Homburg, Germany; Inst Pasteur, Unite Retrovirol Mol, F-75724 Paris 15, France; Russian Acad Sci, Inst Numer Math, Moscow, Russia	Saarland University; Saarland University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Russian Academy of Sciences	Meyerhans, A (corresponding author), Univ Saarland, Dept Virol, D-66421 Homburg, Germany.	andreas.meyerhans@uniklinik-saarland.de	Bocharov, Gennady/T-1322-2017; Meyerhans, Andreas/D-3382-2014; Bocharov, Gennady/H-1832-2016; Maier, Reinhard/AAH-5159-2020; Meese, Eckart Ulrich/ABD-1983-2021; Meyerhans, Andreas/S-2559-2019; Bocharov, Gennady/AGA-7312-2022; Bocharov, Gennady/AAN-7508-2020; Bocharov, Gennady/GSN-1705-2022	Bocharov, Gennady/0000-0002-5049-0656; Meyerhans, Andreas/0000-0003-0620-5317; Meyerhans, Andreas/0000-0003-0620-5317; Bocharov, Gennady/0000-0002-5049-0656; Bocharov, Gennady/0000-0002-5049-0656; Bocharov, Gennady/0000-0002-5049-0656; Vartanian, Jean-Pierre/0000-0001-8079-8814				Carr JK, 1998, VIROLOGY, V247, P22, DOI 10.1006/viro.1998.9211; Gratton S, 2000, P NATL ACAD SCI USA, V97, P14566, DOI 10.1073/pnas.97.26.14566; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Hoelscher M, 2001, AIDS, V15, P1461, DOI 10.1097/00002030-200108170-00002; Jetzt AE, 2000, J VIROL, V74, P1234, DOI 10.1128/JVI.74.3.1234-1240.2000; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; McCutchan FE, 2000, AIDS, V14, pS31; ROBERTSON DL, 1995, NATURE, V374, P124, DOI 10.1038/374124b0; Schierup MH, 2000, GENETICS, V156, P879; WAINHOBSON S, 1993, NATURE, V366, P22, DOI 10.1038/366022b0; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	11	321	330	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 11	2002	418	6894					144	144		10.1038/418144a	http://dx.doi.org/10.1038/418144a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571GV	12110879				2022-12-28	WOS:000176710400029
J	Cahill, DJ; Wardle, PG				Cahill, DJ; Wardle, PG			Management of infertility	BMJ-BRITISH MEDICAL JOURNAL			English	Review							POLYCYSTIC-OVARY-SYNDROME; PREGNANCY RATES; WOMEN; OVULATION; GONADOTROPIN; POPULATION; METFORMIN; PROGNOSIS; COUPLES; POWER		Southmead Gen Hosp, Cotswold Ctr, Dept Womens Hlth, Bristol BS10 5NB, Avon, England; Univ Bristol, St Michaels Hosp, Div Obstet & Gynaecol, Bristol BS2 8EG, Avon, England	Southmead Hospital; University of Bristol	Wardle, PG (corresponding author), Southmead Gen Hosp, Cotswold Ctr, Dept Womens Hlth, Bristol BS10 5NB, Avon, England.	peter@flaxb.freeserve.co.uk	Cahill, David/AAE-9893-2019					Akande VA, 2001, BRIT C OBST GYN BIRM; BROOK PF, 1994, FERTIL STERIL, V61, P308; CAHILL DJ, 1994, BRIT J OBSTET GYNAEC, V101, P999, DOI 10.1111/j.1471-0528.1994.tb13047.x; COLLINS JA, 1995, FERTIL STERIL, V64, P22, DOI 10.1016/s0015-0282(16)57650-x; FOX R, 1991, CLIN ENDOCRINOL, V34, P127, DOI 10.1111/j.1365-2265.1991.tb00282.x; Glazener CMA, 2000, HUM REPROD, V15, P1953, DOI 10.1093/humrep/15.9.1953; Haddow JE, 1999, NEW ENGL J MED, V341, P549, DOI 10.1056/NEJM199908193410801; HAMILTONFAIRLEY D, 1992, BRIT J OBSTET GYNAEC, V99, P128, DOI 10.1111/j.1471-0528.1992.tb14470.x; Hughes EG, 1996, FERTIL STERIL, V66, P679; HULL MGR, 1985, BRIT MED J, V291, P1693, DOI 10.1136/bmj.291.6510.1693; Hull MGR, 1997, SERONO SYMP, P287; HULL MGR, 1997, GYNAECOLOGY, P201; JOELS LA, 1997, J REPROD FERTIL 19, P35; Nestler JE, 1998, NEW ENGL J MED, V338, P1876, DOI 10.1056/NEJM199806253382603; *OFF NAT STAT, 1987, SER FMI, V16, P73; *OFF NAT STAT, 1997, SER FMI, V26, P59; Pirwany IR, 1999, HUM REPROD, V14, P2963, DOI 10.1093/humrep/14.12.2963; POLSON DW, 1989, FERTIL STERIL, V51, P30; ROSSING MA, 1994, NEW ENGL J MED, V331, P771, DOI 10.1056/NEJM199409223311204; SCOTT RT, 1995, HUM REPROD, V10, P1706, DOI 10.1093/oxfordjournals.humrep.a136159; Snick HKA, 1997, HUM REPROD, V12, P1582, DOI 10.1093/humrep/12.7.1582; TEMPLETON A, 1990, BRIT MED J, V301, P148, DOI 10.1136/bmj.301.6744.148; Templeton A, 1996, LANCET, V348, P1402, DOI 10.1016/S0140-6736(96)05291-9; Wang JX, 2000, BRIT MED J, V321, P1320, DOI 10.1136/bmj.321.7272.1320; Wang JX, 2001, HUM REPROD, V16, P2606, DOI 10.1093/humrep/16.12.2606; World Health Organization (WHO), 1999, WHO LAB MANUAL EXAMI, V4th	26	67	69	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 6	2002	325	7354					28	32		10.1136/bmj.325.7354.28	http://dx.doi.org/10.1136/bmj.325.7354.28			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573BC	12098728	Green Published			2022-12-28	WOS:000176808600022
J	Little, P; Gould, C; Moore, M; Warner, G; Dunleavey, J; Williamson, I				Little, P; Gould, C; Moore, M; Warner, G; Dunleavey, J; Williamson, I			Predictors of poor outcome and benefits from antibiotics in children with acute otitis media: pragmatic randomised trial	BRITISH MEDICAL JOURNAL			English	Article							PRESCRIBING STRATEGIES; GENERAL-PRACTICE; CHILDHOOD OTALGIA; SORE THROAT; ANTIMICROBIALS; QUESTIONNAIRE; DECISION	Objectives To identify which children with acute otitis media are at risk of poor outcome and to assess benefit from antibiotics in these children. Design Secondary analysis of randomised controlled trial cohort. Setting Primary care. Participants 315 children aged 6 months to 10 years. Intervention Immediate or delayed (taken after 72 hours if necessary) antibiotics. Main outcome measure Predictors of short term outcome: an episode of distress or night disturbance three days after child saw doctor. Results Distress by day three was more likely in children with high temperature (adjusted odds ratio 4.5, 95% confidence interval 2.3 to 9.0), vomiting (2.6,1.3 to 5.0), and cough (2.0, 1.1 to 3.8) on day one. Night disturbance by day three was more likely with high temperature 2.4 (1.2 to 4.8), vomiting (2.1,1.1 to 4.0), cough (2.3,1.3 to 4.2), and ear discharge (2.1, 1.2 to 3.9). Among the children with high temperature or vomiting, distress by day three was less likely with immediate antibiotics (32% for immediate v 53% for delayed, chi(2) = 4.0; P = 0.045, number needed to teat 5) as was night disturbance (26% v 59%, chi(2) = 9.3; P = 0.002; number needed to teat 3). In children without higher temperature or vomiting, immediate antibiotics made little difference to distress by day three (15% v 19%, chi(2) = 0.74; P = 0.39) or night disturbance (20% v 27%, chi(2) = 1.6; P = 0.20). Addition of cough did riot significantly improve prediction of benefit. Conclusion In children with otitis media but without fever and vomiting antibiotic treatment has little benefit and a poor outcome is unlikely.	Univ Southampton, Aldermoor Hlth Ctr, Community Clin Sci Primary Med Care Grp, Southampton SO15 6ST, Hants, England; Three Swans Surg, Salisbury SP1 1DX, Wilts, England; Nightingale Surg, Romsey SO51 7QN, Hants, England	University of Southampton	Little, P (corresponding author), Univ Southampton, Aldermoor Hlth Ctr, Community Clin Sci Primary Med Care Grp, Southampton SO15 6ST, Hants, England.		Moore, Michael/C-3447-2011; Doust, Jenny/AGI-8773-2022	Moore, Michael/0000-0002-5127-4509; Doust, Jenny/0000-0002-4024-9308; Little, Paul/0000-0003-3664-1873				Arason VA, 1996, BMJ-BRIT MED J, V313, P387; BAIN J, 1990, BMJ-BRIT MED J, V300, P1006, DOI 10.1136/bmj.300.6730.1006; Britten N, 1997, BRIT MED J, V315, P1506, DOI 10.1136/bmj.315.7121.1506; BROWNING GG, 1990, BRIT MED J, V300, P1005, DOI 10.1136/bmj.300.6730.1005; BURKE P, 1991, BRIT MED J, V303, P558, DOI 10.1136/bmj.303.6802.558; Froom J, 1997, BRIT MED J, V315, P98, DOI 10.1136/bmj.315.7100.98; GLASZIOU P, 2002, COCHRANE DATABASE SY, DOI UNSP CD000219; Little P, 2001, BMJ-BRIT MED J, V322, P336, DOI 10.1136/bmj.322.7282.336; Little P, 1997, BRIT MED J, V315, P350; Little P, 1997, BMJ-BRIT MED J, V314, P722, DOI 10.1136/bmj.314.7082.722; Macfarlane J, 1997, BMJ-BRIT MED J, V315, P1211, DOI 10.1136/bmj.315.7117.1211; PITTS J, 1987, PRACTITIONER, V231, P1232; ROGERS M, 1992, PAEDIATRIC NURSING, V4, P8; VANBUCHEM FL, 1985, BRIT MED J, V290, P1033, DOI 10.1136/bmj.290.6474.1033	14	44	45	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 6	2002	325	7354					22	24		10.1136/bmj.325.7354.22	http://dx.doi.org/10.1136/bmj.325.7354.22			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573BC	12098725	Bronze, Green Published			2022-12-28	WOS:000176808600018
J	Rao, JN; Cassia, LJS				Rao, JN; Cassia, LJS			Ethics of undisclosed payments to doctors recruiting patients in clinical trials	BRITISH MEDICAL JOURNAL			English	Article							POSTMARKETING RESEARCH; INFORMED CONSENT; FINANCIAL TIES; PRIMARY-CARE; SCOPE; PART		W Midlands Multictr Res Eth Comm, Birmingham B15 3DP, W Midlands, England; Univ Hosp Coventry NHS, Coventry Res Eth Comm, Coventry CV2 2DX, W Midlands, England		Rao, JN (corresponding author), W Midlands Multictr Res Eth Comm, 27 Highfield Rd, Birmingham B15 3DP, W Midlands, England.							Chalmers I, 1998, BMJ-BRIT MED J, V317, P1167, DOI 10.1136/bmj.317.7167.1167; Foy R, 1998, BRIT MED J, V317, P1168, DOI 10.1136/bmj.317.7167.1168; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; GILLON R, 1994, BRIT MED J, V309, P184, DOI 10.1136/bmj.309.6948.184; LAPUMA J, 1995, BRIT MED J, V310, P1660, DOI 10.1136/bmj.310.6995.1660; NEUBERGER J, 1995, BRIT MED J, V310, P1661, DOI 10.1136/bmj.310.6995.1661a; Rao JN, 2000, BRIT MED J, V321, P1530; Royal College of Physicians, 1990, RES INV PAT; Wilson S, 1999, BRIT MED J, V318, P1484, DOI 10.1136/bmj.318.7196.1484a; 1996, MEDECONOMICS     AUG, P44; 2001, LANCET, V357, P1141; 2001, LANCET, V357, P1721	12	21	21	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 6	2002	325	7354					36	37		10.1136/bmj.325.7354.36	http://dx.doi.org/10.1136/bmj.325.7354.36			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573BC	12098730	Green Published			2022-12-28	WOS:000176808600024
J	Yusuf, S				Yusuf, S			Two decades of progress in preventing vascular disease	LANCET			English	Editorial Material									McMaster Univ, Populat Hlth Res Inst, Hamilton, ON L8L 2X2, Canada	McMaster University; Population Health Research Institute	Yusuf, S (corresponding author), McMaster Univ, Populat Hlth Res Inst, Hamilton, ON L8L 2X2, Canada.	yusufs@mcmaster.ca		Yusuf, Salim/0000-0003-4776-5601				Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Law M., 1998, EVIDENCE BASED CARDI, P191; PECHACEK TF, 1998, EVIDENCE BASED CARDI, P165; PEDERSEN TR, 1994, LANCET, V344, P1383; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Yusuf S, 2001, CIRCULATION, V104, P2746, DOI 10.1161/hc4601.099487; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302; Yusuf S, 2000, NEW ENGL J MED, V342, P145	10	272	287	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 6	2002	360	9326					2	3		10.1016/S0140-6736(02)09358-3	http://dx.doi.org/10.1016/S0140-6736(02)09358-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569JR	12114031				2022-12-28	WOS:000176599700002
J	Mikkola, I; Heavey, B; Horcher, M; Busslinger, M				Mikkola, I; Heavey, B; Horcher, M; Busslinger, M			Reversion of B cell commitment upon loss of Pax5 expression	SCIENCE			English	Article							LINEAGE COMMITMENT; BONE-MARROW; BSAP; DIFFERENTIATION; LYMPHOPOIESIS; PROGENITORS; MICE; IDENTIFICATION; PAX5/BSAP; LACKING	The transcription factor Pax5 is essential for initiating B cell lineage commitment, but its role in maintaining commitment is unknown. Using conditional Pax5 inactivation in committed pro-B cells, we demonstrate that Pax5 is required not only to initiate its B lymphoid transcription program, but also to maintain it in early B cell development. As a consequence of Pax5 inactivation, previously committed pro-B cells regained the capacity to differentiate into macrophages in vitro and to reconstitute T cell development in vivo in RAG2(-/-) mice. Hence, Pax5 expression is continuously required to maintain B cell lineage commitment, because its loss converts committed pro-B cells into hematopoietic progenitors with multilineage potential.	Res Inst Mol Pathol, Vienna Bioctr, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Busslinger, M (corresponding author), Res Inst Mol Pathol, Vienna Bioctr, Dr Bohr Gasse 7, A-1030 Vienna, Austria.		Busslinger, Meinrad J./J-1249-2016	Busslinger, Meinrad J./0000-0002-9111-9351; Mikkola, Ingvild/0000-0001-6442-7626				ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Bjorck P, 1998, J IMMUNOL, V161, P5795; Busslinger M, 2000, CURR OPIN IMMUNOL, V12, P151, DOI 10.1016/S0952-7915(99)00065-5; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; Fischer A, 1997, ANNU REV IMMUNOL, V15, P93, DOI 10.1146/annurev.immunol.15.1.93; Horcher M, 2001, IMMUNITY, V14, P779, DOI 10.1016/S1074-7613(01)00153-4; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; LeBien TW, 2000, BLOOD, V96, P9, DOI 10.1182/blood.V96.1.9; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; Manabe N, 2001, J IMMUNOL, V167, P2625, DOI 10.4049/jimmunol.167.5.2625; MIKKOLA I, UNPUB; Montecino-Rodriguez E, 2001, NAT IMMUNOL, V2, P83, DOI 10.1038/83210; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; Nutt SL, 1999, NAT GENET, V21, P390, DOI 10.1038/7720; Nutt SL, 1999, COLD SPRING HARB SYM, V64, P51, DOI 10.1101/sqb.1999.64.51; Rinkenberger JL, 1996, IMMUNITY, V5, P377, DOI 10.1016/S1074-7613(00)80263-0; Rolink AG, 1999, NATURE, V401, P603, DOI 10.1038/44164; Schwenk F, 1998, NUCLEIC ACIDS RES, V26, P1427, DOI 10.1093/nar/26.6.1427; Sigvardsson M, 1997, IMMUNITY, V7, P25, DOI 10.1016/S1074-7613(00)80507-5; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5	25	219	232	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 5	2002	297	5578					110	113		10.1126/science.1067518	http://dx.doi.org/10.1126/science.1067518			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571HB	12098702				2022-12-28	WOS:000176711000046
J	Miquel, C; Paz, JP; Saraceno, M; Knill, E; Laflamme, R; Negrevergne, C				Miquel, C; Paz, JP; Saraceno, M; Knill, E; Laflamme, R; Negrevergne, C			Interpretation of tomography and spectroscopy as dual forms of quantum computation	NATURE			English	Article							WIGNER-FUNCTION; ALGORITHMS; STATES	It is important to be able to determine the state of a quantum system and to measure properties of its evolution. State determination can be achieved using tomography(1), in which the system is subjected to a series of experiments, whereas spectroscopy can be used to probe the energy spectrum associated with the system's evolution. Here we show that, for a quantum system whose state or evolution can be modelled on a quantum computer, tomography and spectroscopy can be interpreted as dual forms of quantum computation(2). Specifically, we find that the phase estimation algorithm(3) (which underlies a quantum computer's ability to perform efficient simulations(4) and to factorize large numbers(5)) can be adapted for tomography or spectroscopy. This is analogous to the situation encountered in scattering experiments, in which it is possible to obtain information about both the state of the scatterer and its interactions. We provide an experimental demonstration of the tomographic application by performing a measurement of the Wigner function (a phase space distribution) of a quantum system. For this purpose, we use three qubits formed from spin-1/2 nuclei in a quantum computation involving liquid-state nuclear magnetic resonance.	Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Fis, RA-1428 Buenos Aires, DF, Argentina; CNEA Buenos Aires, Unidad Act Fis, Buenos Aires, DF, Argentina; Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Univ Waterloo, Dept Phys, Waterloo, ON N2L 3G1, Canada; Perimeter Inst Theoret Phys, Waterloo, ON N2J 2W9, Canada	University of Buenos Aires; Comision Nacional de Energia Atomica (CNEA); United States Department of Energy (DOE); Los Alamos National Laboratory; University of Waterloo; Perimeter Institute for Theoretical Physics	Paz, JP (corresponding author), Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Fis, Pabellon 1,Ciudad Univ, RA-1428 Buenos Aires, DF, Argentina.	paz@df.uba.ar	Paz, Juan Pablo/C-5947-2008	Miquel, Cesar/0000-0002-3038-1823; Saraceno, Marcos/0000-0003-2569-7927				Abrams DS, 1999, PHYS REV LETT, V83, P5162, DOI 10.1103/PhysRevLett.83.5162; BARENCO A, 1995, PHYS REV A, V52, P3457, DOI 10.1103/PhysRevA.52.3457; Cory DG, 1998, PHYS REV LETT, V81, P2152, DOI 10.1103/PhysRevLett.81.2152; FEYNMAN RP, 1982, INT J THEOR PHYS, V21, P467, DOI 10.1007/BF02650179; HILLERY M, 1984, PHYS REP, V106, P121, DOI 10.1016/0370-1573(84)90160-1; Kitaev A., 1995, QUANTUM MEASUREMENTS; Knill E, 1998, PHYS REV LETT, V81, P5672, DOI 10.1103/PhysRevLett.81.5672; Knill E, 1998, PHYS REV A, V57, P3348, DOI 10.1103/PhysRevA.57.3348; Leonhardt U, 1996, PHYS REV A, V53, P2998, DOI 10.1103/PhysRevA.53.2998; Lloyd S, 1996, SCIENCE, V273, P1073, DOI 10.1126/science.273.5278.1073; Lutterbach LG, 1997, PHYS REV LETT, V78, P2547, DOI 10.1103/PhysRevLett.78.2547; Lvovsky AI, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.050402; Miquel C, 1996, PHYS REV A, V54, P2605, DOI 10.1103/PhysRevA.54.2605; MIQUEL C, 2002, IN PRESS PHYS REV A; NIELSEN M, 2000, QUANTUM INFORMATION; Nogues G, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.054101; Paz JP, 2001, LES HOUCH S, V72, P535; Shor PW, 1997, SIAM J COMPUT, V26, P1484, DOI [10.1137/S0097539795293172, 10.1137/S0036144598347011]; SMITHEY DT, 1993, PHYS REV LETT, V70, P1244, DOI 10.1103/PhysRevLett.70.1244; WOOTTERS WK, 1987, ANN PHYS-NEW YORK, V176, P1, DOI 10.1016/0003-4916(87)90176-X; Zurek WH, 2001, NATURE, V412, P712, DOI 10.1038/35089017	22	79	79	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 4	2002	418	6893					59	62		10.1038/nature00801	http://dx.doi.org/10.1038/nature00801			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	569JL	12097904				2022-12-28	WOS:000176599200036
J	Pandha, HS; Kirby, RS				Pandha, HS; Kirby, RS			PC-SPES: phytotherapy for prostate cancer	LANCET			English	Editorial Material							CHINESE HERBAL PREPARATION; IN-VITRO; ETHANOLIC EXTRACTS; CELLS; SUPPLEMENT; EXPRESSION; APOPTOSIS; THERAPY; TRIAL		St George Hosp, Sch Med, Dept Oncol, London SW17 0RE, England; St George Hosp, Sch Med, Dept Urol, London SW17 0RE, England	St Georges University London; St Georges University London	Pandha, HS (corresponding author), St George Hosp, Sch Med, Dept Oncol, London SW17 0RE, England.							Carraro JC, 1996, PROSTATE, V29, P231, DOI 10.1002/(SICI)1097-0045(199610)29:4&lt;231::AID-PROS4&gt;3.0.CO;2-E; Chen S, 2001, UROLOGY, V58, P28, DOI 10.1016/S0090-4295(01)01239-0; De la Taille A, 2000, J UROLOGY, V164, P1229, DOI 10.1097/00005392-200010000-00021; Di Silverio F, 1993, Minerva Urol Nefrol, V45, P143; DiPaola RS, 1998, NEW ENGL J MED, V339, P785, DOI 10.1056/NEJM199809173391201; Duda RB, 1996, ANN SURG ONCOL, V3, P515, DOI 10.1007/BF02306082; Halicka HD, 1997, INT J ONCOL, V11, P437; Hsieh TC, 1998, INT J ONCOL, V13, P1199; Hsieh TC, 1997, BIOCHEM MOL BIOL INT, V42, P535; IKEZOE T, 2002, ANN M AM ASS CANC RE; Kubota T, 2000, PROSTATE, V42, P163; Pfeifer BL, 2000, BJU INT, V85, P481, DOI 10.1046/j.1464-410x.2000.00476.x; Small EJ, 2000, J CLIN ONCOL, V18, P3595, DOI 10.1200/JCO.2000.18.21.3595; Small EJ, 1997, J CLIN ONCOL, V15, P382, DOI 10.1200/JCO.1997.15.1.382; Smith DC, 1998, UROLOGY, V52, P257, DOI 10.1016/S0090-4295(98)00173-3; SOVAK M, 2002, ANN M AM ASS CANC RE; Tiwari RK, 1999, INT J ONCOL, V14, P713; Wang SY, 1997, INT J CANCER, V70, P699, DOI 10.1002/(SICI)1097-0215(19970317)70:6&lt;699::AID-IJC12&gt;3.0.CO;2-5; Weinrobe MC, 2001, NEW ENGL J MED, V345, P1213, DOI 10.1056/NEJM200110183451616; Zhu BT, 1997, CANCER RES, V57, P2419	20	10	11	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 29	2002	359	9325					2213	2215		10.1016/S0140-6736(02)09313-3	http://dx.doi.org/10.1016/S0140-6736(02)09313-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567YJ	12103281				2022-12-28	WOS:000176514500003
J	Walsh, K; King, M; Jones, L; Tookman, A; Blizard, R				Walsh, K; King, M; Jones, L; Tookman, A; Blizard, R			Spiritual beliefs may affect outcome of bereavement: prospective study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ROYAL FREE INTERVIEW; ADJUSTMENT; DEPRESSION; SCALE	Objective To explore the relation between spiritual beliefs and resolution of bereavement. Design Prospective cohort study of people about to be bereaved with follow up continuing for 14 months after the death. Setting A Marie Curie centre for specialist palliative care in London. Participants 135 relatives and close friends of patients admitted to the centre with terminal illness. Main outcome measure Core bereavement items, a standardised measure of grief, measured 1, 9, and 14 months after the patients' death. Results People reporting no spiritual belief had not resolved their grief by 14 months after the death. Participants with strong spiritual beliefs resolved their grief progressively over the same period. People with low levels of belief showed little change in die first nine months but thereafter resolved their grief. These differences approached significance in a repeated measures analysis of variance (F=2.42, P=0.058). Strength of spiritual belief remained an important predictor after the explanatory power of relevant confounding variables was controlled for. At 14 months the difference between the group with no beliefs and the combined low and high belief groups was 7.30 (95% confidence interval 0.86 to 13.73) points on the core bereavement items scale. Adjusting for confounders in the final model reduced this difference to 4.64 (1.04 to 10.32) points. Conclusion People who profess stronger spiritual beliefs seem to resolve their grief more rapidly and completely after the death of a close person dian do people with no spiritual beliefs.	UCL Royal Free & Univ Coll Med Sch, Dept Psychiat & Behav Sci, London NW3 2PF, England; Edenhall Marie Curie Ctr, London NW3 5NS, England	University of London; University College London; UCL Medical School	King, M (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Psychiat & Behav Sci, Royal Free Campus, London NW3 2PF, England.	m.king@rfc.ucl.ac.uk	King, Michael B/D-7477-2011	King, Michael B/0000-0003-4715-7171				Burnett P, 1997, PSYCHOL MED, V27, P49, DOI 10.1017/S0033291796004151; CLAYTON PJ, 1990, J CLIN PSYCHIAT, V51, P34; CRAIG AR, 1984, BRIT J MED PSYCHOL, V57, P173, DOI 10.1111/j.2044-8341.1984.tb01597.x; Huber R, 1990, Hosp J, V6, P49; KING M, 1995, PSYCHOL MED, V25, P1125, DOI 10.1017/S0033291700033109; King M, 1999, SOC SCI MED, V48, P1291, DOI 10.1016/S0277-9536(98)00452-3; King M, 2001, PSYCHOL MED, V31, P1015, DOI 10.1017/S0033291701004160; LAUER ME, 1989, CANCER, V63, P988, DOI 10.1002/1097-0142(19890301)63:5<988::AID-CNCR2820630534>3.0.CO;2-Y; MCINTOSH DN, 1993, J PERS SOC PSYCHOL, V65, P812, DOI 10.1037/0022-3514.65.4.812; ROSIK CH, 1989, INT J AGING HUM DEV, V28, P251, DOI 10.2190/37H9-UDP5-UQRC-QHTT; STANSFELD S, 1992, SOC SCI MED, V35, P1027, DOI 10.1016/0277-9536(92)90242-I; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	12	83	85	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 29	2002	324	7353					1551	1554		10.1136/bmj.324.7353.1551	http://dx.doi.org/10.1136/bmj.324.7353.1551			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	570WP	12089091	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000176683000017
J	Gil, D; Schamel, WWA; Montoya, M; Sanchez-Madrid, F; Alarcon, B				Gil, D; Schamel, WWA; Montoya, M; Sanchez-Madrid, F; Alarcon, B			Recruitment of Nck by CD3 epsilon reveals a Ligand-Induced conformational change essential for T cell receptor signaling and synapse formation	CELL			English	Article							ANTIGEN RECEPTOR; ACTIVATION; TRANSDUCTION; CHAIN; PHOSPHORYLATION; INHIBITOR; SELECTION; REGION; ZETA; CD4	How membrane receptors initiate signal transduction upon ligand binding is a matter of intense scrutiny. The T cell receptor complex (TCR-CD3) is composed of TCRalpha/beta ligand binding subunits bound to the CD3 subunits responsible for signal transduction. Although it has long been speculated that TCR-CD3 may undergo a conformational change, confirmation is still lacking. We present strong evidence that ligand engagement of TCR-CD3 induces a conformational change that exposes a proline-rich sequence in CD3epsilon and results in recruitment of the adaptor protein Nck. This occurs earlier than and independently of tyrosine kinase activation. Finally, by interfering with Nck-CD3epsilon association in vivo, we demonstrate that TCR-CD3 recruitment of Nck is critical for maturation of the immune synapse and for T cell activation.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; Univ Autonoma Madrid, Hosp Princesa, Serv Inmunol, Madrid 28006, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Autonomous University of Madrid; Hospital de La Princesa	Alarcon, B (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.	balarcon@cbm.uam.es	Sanchez-Madrid, Francisco/M-7889-2016; Montoya, María/N-1558-2014; Alarcon, Balbino/N-9648-2016	Sanchez-Madrid, Francisco/0000-0001-5303-0762; Montoya, María/0000-0001-8878-7028; Alarcon, Balbino/0000-0001-7820-1070				Aivazian D, 2000, NAT STRUCT BIOL, V7, P1023; ALARCON B, 1991, EMBO J, V10, P903, DOI 10.1002/j.1460-2075.1991.tb08023.x; ARONHEIM A, 2000, METH MOL B, V177, P319; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; Borroto A, 1998, J BIOL CHEM, V273, P12807, DOI 10.1074/jbc.273.21.12807; Borroto A, 1999, J IMMUNOL, V163, P25; Borroto A, 1997, BIOPOLYMERS, V42, P75; Borroto A, 2000, EUR J IMMUNOL, V30, P3403, DOI 10.1002/1521-4141(2000012)30:12<3403::AID-IMMU3403>3.0.CO;2-H; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; Bunnell SC, 2001, IMMUNITY, V14, P315, DOI 10.1016/S1074-7613(01)00112-1; Cochran JR, 2000, IMMUNITY, V12, P241, DOI 10.1016/S1074-7613(00)80177-6; Cochran JR, 2001, TRENDS BIOCHEM SCI, V26, P304, DOI 10.1016/S0968-0004(01)01815-1; Delon J, 1998, EUR J IMMUNOL, V28, P716, DOI 10.1002/(SICI)1521-4141(199802)28:02<716::AID-IMMU716>3.0.CO;2-E; DIANZANI U, 1992, J IMMUNOL, V148, P678; Ding YH, 1999, IMMUNITY, V11, P45, DOI 10.1016/S1074-7613(00)80080-1; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; Fernandez-Miguel G, 1999, P NATL ACAD SCI USA, V96, P1547, DOI 10.1073/pnas.96.4.1547; Gil D, 2001, J BIOL CHEM, V276, P11174, DOI 10.1074/jbc.M010114200; Gobel TWF, 2000, CURR TOP MICROBIOL, V248, P303; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; JACOBS RR, 1997, INT J OCCUP ENV HL S, V3, P3; JANEWAY CA, 1995, IMMUNOL TODAY, V16, P223, DOI 10.1016/0167-5699(95)80163-4; Jiang GQ, 1999, CURR BIOL, V9, pR568, DOI 10.1016/S0960-9822(99)80357-1; Jose ES, 1998, EUR J IMMUNOL, V28, P12; KAYE J, 1992, J IMMUNOL, V148, P3342; Krummel MF, 2000, SCIENCE, V289, P1349, DOI 10.1126/science.289.5483.1349; Laczko I, 1998, BIOCHEM BIOPH RES CO, V242, P474, DOI 10.1006/bbrc.1997.7989; Lin J, 2001, J CELL SCI, V114, P243; MALLABIABARRENA A, 1992, NATURE, V357, P593, DOI 10.1038/357593a0; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Montoya MC, 2002, NAT IMMUNOL, V3, P159, DOI 10.1038/ni753; Niedergang F, 1997, J IMMUNOL, V159, P1703; Ottemann KM, 1999, SCIENCE, V285, P1751, DOI 10.1126/science.285.5434.1751; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Reth M, 2001, TRENDS IMMUNOL, V22, P356, DOI 10.1016/S1471-4906(01)01964-0; Schamel WWA, 2000, IMMUNITY, V13, P5, DOI 10.1016/S1074-7613(00)00003-0; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; Sun ZYJ, 2001, CELL, V105, P913, DOI 10.1016/S0092-8674(01)00395-6; Villalba M, 2000, IMMUNITY, V12, P151, DOI 10.1016/S1074-7613(00)80168-5; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647; YOON ST, 1994, IMMUNITY, V1, P563	42	341	359	3	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	2002	109	7					901	912		10.1016/S0092-8674(02)00799-7	http://dx.doi.org/10.1016/S0092-8674(02)00799-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	570KJ	12110186	Bronze			2022-12-28	WOS:000176657200012
J	Hollingsworth, RG; Armstrong, JW; Campbell, E				Hollingsworth, RG; Armstrong, JW; Campbell, E			Pest control: Caffeine as a repellent for slugs and snails	NATURE			English	Article							CALCIUM; NEURONS		ARS, US Pacific Basin Agr Res Ctr, USDA, Hilo, HI 96720 USA; USDA, APHIS, WS, Natl Wildlife Res Ctr, Hilo, HI 96721 USA	United States Department of Agriculture (USDA); United States Department of Agriculture (USDA)	Hollingsworth, RG (corresponding author), ARS, US Pacific Basin Agr Res Ctr, USDA, POB 4459, Hilo, HI 96720 USA.							Ahmed IA, 1997, GEN PHARMACOL, V28, P245, DOI 10.1016/S0306-3623(96)00233-9; AHMED IA, 1993, COMP BIOCHEM PHYS C, V105, P363, DOI 10.1016/0742-8413(93)90072-S; COOK BJ, 1980, COMP BIOCHEM PHYS C, V67, P115, DOI 10.1016/0306-4492(80)90005-2; FAHIM MA, 1983, J NEUROBIOL, V14, P391, DOI 10.1002/neu.480140507; MARTIN A, 1991, OUTLOOK AGR, V20, P167, DOI 10.1177/003072709102000307; MOFFETT DF, 1983, COMP BIOCHEM PHYS C, V75, P305, DOI 10.1016/0742-8413(83)90196-2; NATHANSON JA, 1984, SCIENCE, V226, P184, DOI 10.1126/science.6207592; *SAS I, 1988, SAS STAT US GUID 6 0; Steel RGD, 1980, PRINCIPLES PROCEDURE; WILKINS RM, 1995, PESTIC SCI, V43, P321, DOI 10.1002/ps.2780430412; WINDHOLZ M, 1976, MERCK INDEX	11	91	102	2	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 27	2002	417	6892					915	916		10.1038/417915a	http://dx.doi.org/10.1038/417915a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	566RC	12087394	Green Published			2022-12-28	WOS:000176441200028
J	Dawson, E; Abecasis, GR; Bumpstead, S; Chen, Y; Hunt, S; Beare, DM; Pabial, J; Dibling, T; Tinsley, E; Kirby, S; Carter, D; Papaspyridonos, M; Livingstone, S; Ganske, R; Lohmmussaar, E; Zernant, J; Tonisson, N; Remm, M; Magi, R; Puurand, T; Vilo, J; Kurg, A; Rice, K; Deloukas, P; Mott, R; Metspalu, A; Bentley, DR; Cardon, LR; Dunham, I				Dawson, E; Abecasis, GR; Bumpstead, S; Chen, Y; Hunt, S; Beare, DM; Pabial, J; Dibling, T; Tinsley, E; Kirby, S; Carter, D; Papaspyridonos, M; Livingstone, S; Ganske, R; Lohmmussaar, E; Zernant, J; Tonisson, N; Remm, M; Magi, R; Puurand, T; Vilo, J; Kurg, A; Rice, K; Deloukas, P; Mott, R; Metspalu, A; Bentley, DR; Cardon, LR; Dunham, I			A first-generation linkage disequilibrium map of human chromosome 22	NATURE			English	Article							MEIOTIC RECOMBINATION; SEQUENCE; FINLAND; REGION; SCAN	DNA sequence variants in specific genes or regions of the human genome are responsible for a variety of phenotypes such as disease risk or variable drug response(1). These variants can be investigated directly, or through their non-random associations with neighbouring markers (called linkage disequilibrium (LD))(2-8). Here we report measurement of LD along the complete sequence of human chromosome 22. Duplicate genotyping and analysis of 1,504 markers in Centre d'Etude du Polymorphisme Humain (CEPH) reference families at a median spacing of 15 kilobases (kb) reveals a highly variable pattern of LD along the chromosome, in which extensive regions of nearly complete LD up to 804 kb in length are interspersed with regions of little or no detectable LD. The LD patterns are replicated in a panel of unrelated UK Caucasians. There is a strong correlation between high LD and low recombination frequency in the extant genetic map, suggesting that historical and contemporary recombination rates are similar. This study demonstrates the feasibility of developing genome-wide maps of LD.	Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA; Third Wave Technol Inc, Madison, WI 53719 USA; Univ Tartu, IMCB, EE-51010 Tartu, Estonia; Univ Tartu, Estonian Bioctr, EE-51010 Tartu, Estonia; Asper Ltd, EE-51014 Tartu, Estonia; European Bioinformat Inst, Cambridge CB10 1SD, England	Wellcome Trust Sanger Institute; University of Oxford; Wellcome Centre for Human Genetics; University of Michigan System; University of Michigan; University of Tartu; Estonian Biocentre; University of Tartu; European Molecular Biology Laboratory (EMBL)	Dunham, I (corresponding author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Cambridge CB10 1SA, England.	lon.cardon@well.ox.ac.uk; id1@sanger.ac.uk	Remm, Maido/L-9072-2019; Deloukas, Panos/B-2922-2013; Org, Elin/AAJ-9631-2021; Vilo, Jaak/A-7183-2008; Vilo, Jaak/AAK-2228-2020; Tonisson, Neeme/H-2783-2015; Kurg, Ants/J-2616-2015; Mägi, Reedik/AAJ-9679-2021; Abecasis, Goncalo R/B-7840-2010; Kurg, Ants/AAM-1292-2020	Remm, Maido/0000-0003-3966-8422; Deloukas, Panos/0000-0001-9251-070X; Vilo, Jaak/0000-0001-5604-4107; Vilo, Jaak/0000-0001-5604-4107; Kurg, Ants/0000-0002-0829-1987; Carter, Emma/0000-0002-0825-2793; Abecasis, Goncalo/0000-0003-1509-1825; Magi, Reedik/0000-0002-2964-6011; Hunt, Sarah/0000-0002-8350-1235; Mott, Richard/0000-0002-1022-9330; Dunham, Ian/0000-0003-2525-5598; Org, Elin/0000-0001-8688-9717				Abecasis GR, 2001, AM J HUM GENET, V68, P191, DOI 10.1086/316944; Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786; Abecasis GR, 2001, BIOINFORMATICS, V17, P742, DOI 10.1093/bioinformatics/17.8.742; Abecasis GR, 2000, BIOINFORMATICS, V16, P182, DOI 10.1093/bioinformatics/16.2.182; Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229; Dawson E, 2001, GENOME RES, V11, P170, DOI 10.1101/gr.156901; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Eaves IA, 2000, NAT GENET, V25, P320; Eisenbarth I, 2001, HUM MOL GENET, V10, P2833, DOI 10.1093/hmg/10.24.2833; Ghosh S, 2000, AM J HUM GENET, V67, P1174, DOI 10.1016/S0002-9297(07)62948-6; Huttley GA, 1999, GENETICS, V152, P1711; Jeffreys AJ, 2001, NAT GENET, V29, P217, DOI 10.1038/ng1001-217; KARLIN S, 1990, P NATL ACAD SCI USA, V87, P2264, DOI 10.1073/pnas.87.6.2264; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; Kurg A, 2000, GENET TEST, V4, P1, DOI 10.1089/109065700316408; Mein CA, 2000, GENOME RES, V10, P330, DOI 10.1101/gr.10.3.330; Mullikin JC, 2000, NATURE, V407, P516, DOI 10.1038/35035089; Patil N, 2001, SCIENCE, V294, P1719, DOI 10.1126/science.1065573; Payseur BA, 2000, GENETICS, V156, P1285; Petes TD, 2001, NAT REV GENET, V2, P360, DOI 10.1038/35072078; PULVER AE, 1994, AM J MED GENET, V54, P36, DOI 10.1002/ajmg.1320540108; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Taillon-Miller P, 2000, NAT GENET, V25, P324, DOI 10.1038/77100; THOMPSON EA, 1988, AM J HUM GENET, V42, P113; Weir B.S., 1996, GENETIC DATA ANAL; WEIR BS, 1979, HEREDITY, V42, P105, DOI 10.1038/hdy.1979.10; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; Yu A, 2001, NATURE, V409, P951, DOI 10.1038/35057185	30	293	331	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 1	2002	418	6897					544	548		10.1038/nature00864	http://dx.doi.org/10.1038/nature00864			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	579EE	12110843	Green Published, Bronze			2022-12-28	WOS:000177162800043
J	Andre-Schmutz, I; Le Deist, F; Hacein-Bey-Abina, S; Vitetta, E; Schindler, J; Chedeville, G; Vilmer, E; Fischer, A; Cavazzana-Calvo, M				Andre-Schmutz, I; Le Deist, F; Hacein-Bey-Abina, S; Vitetta, E; Schindler, J; Chedeville, G; Vilmer, E; Fischer, A; Cavazzana-Calvo, M			Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study	LANCET			English	Article							BONE-MARROW-TRANSPLANTATION; SEVERE COMBINED IMMUNODEFICIENCY; ALLOREACTIVE T-CELLS; MONOCLONAL-ANTIBODY; DEPLETION; LEUKEMIA; DONORS; CYTOMEGALOVIRUS; IMMUNOTHERAPY; IMMUNOTOXIN	Background Allogeneic haemopoietic stem-cell transplantation (HSCT) is the treatment of choice for many haemological malignancies and inherited disorders. When stem cells for transplantation come from a human leucocyte antigen matched unrelated donor, or from a partly mismatched related donor, ex-vivo T-cell depletion of the graft can prevent development of graft-versus-host disease, but lead in turn to a delay in immune reconstitution and a concordant increase in incidence of opportunistic infections and leukaemic relapses. We aimed to infuse T cells selectively depleted in allogeneic T cells that cause graft-versus-host disease using an ex-vivo procedure designed to eliminate alloactivated donor T cells, with an immunotoxin that reacts with a cell surface activation antigen, CD25. Methods We did a phase 1/2 study, in which 1-8x10(5) allodepleted T cells/kg were infused between days 15 and 47 into 15 paediatric patients who had acquired or congenital haemopoietic disorders and who received HSCT on day 0. Occurrence of graft-versus-host disease and time to immune reconstitution were assessed. No treatment for graft-versus-host disease was given. Findings Less than 1% residual anti-host alloreactivity was recorded in 12 of 16 procedures. Other immune responses were preserved by the allodepletion procedure in 12 cases. No cases of severe (greater than grade II) graft-versus-host disease arose. Evidence for early T-cell expansion was shown in three patients with continuing viral infections. Specific antiviral responses, such as strong cytolytic activity, were noted. Interpretation Our results show that ex-vivo selective depletion of T cells that cause graft-versus-host disease is efficient and feasible, even in haploidentical settings.	Assistance Publ Hop Paris, Hop Necker Enfants Malad, Lab Therapie Cellulaire & Genet, INSERM,U429, F-75743 Paris 15, France; Hop Bichat Claude Bernard, Lab Immunol Pediat, F-75877 Paris 18, France; Hop Bichat Claude Bernard, Serv Immunol & Hematol Pediat, F-75877 Paris 18, France; Hop Robert Debre, Serv Immunohematol, Paris, France; Univ Texas, SW Med Ctr, Ctr Canc Immunobiol, Dallas, TX 75235 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cavazzana-Calvo, M (corresponding author), Assistance Publ Hop Paris, Hop Necker Enfants Malad, Lab Therapie Cellulaire & Genet, INSERM,U429, 149 Rue Sevres, F-75743 Paris 15, France.	cavazzan@necker.fr	Andre, Isabelle/F-6263-2013; Andre-Schmutz, Isabelle/M-1279-2016	Andre, Isabelle/0000-0002-3905-9910; Cavazzana, Marina/0000-0002-0264-0891				Andre-Schmutz I, 2001, BLOOD, V98, p390A; Aversa F, 1998, NEW ENGL J MED, V339, P1186, DOI 10.1056/NEJM199810223391702; BLAISE D, 1989, LANCET, V1, P1333; Bodmer JG, 1999, HUM IMMUNOL, V60, P361; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Cavazzana-Calvo M, 2002, SEMIN HEMATOL, V39, P32, DOI 10.1053/shem.2002.29251; CAVAZZANACALVO M, 1990, TRANSPLANTATION, V50, P1, DOI 10.1097/00007890-199007000-00001; de Vries E, 2000, BONE MARROW TRANSPL, V25, P267, DOI 10.1038/sj.bmt.1702141; FERRARA JLM, 1991, NEW ENGL J MED, V324, P667; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; Goker H, 2001, EXP HEMATOL, V29, P259, DOI 10.1016/S0301-472X(00)00677-9; Haddad E, 1998, BLOOD, V91, P3646; Hansen JA, 1997, IMMUNOL REV, V157, P141, DOI 10.1111/j.1600-065X.1997.tb00979.x; HensleeDowney PJ, 1997, BLOOD, V89, P3864, DOI 10.1182/blood.V89.10.3864.3864_3864_3872; HERVE P, 1988, LANCET, V2, P1072; HESLOP HE, 1994, NEW ENGL J MED, V331, P679; Ho VT, 2001, BLOOD, V98, P3192, DOI 10.1182/blood.V98.12.3192; Jabado N, 1996, PEDIATRICS, V98, P420; Koh MBC, 1999, BONE MARROW TRANSPL, V23, P1071, DOI 10.1038/sj.bmt.1701749; LI CR, 1994, BLOOD, V83, P1971, DOI 10.1182/blood.V83.7.1971.1971; Lucas KG, 1996, BLOOD, V87, P2594, DOI 10.1182/blood.V87.6.2594.bloodjournal8762594; MACKINNON S, 1995, BLOOD, V86, P1261, DOI 10.1182/blood.V86.4.1261.bloodjournal8641261; Madrigal JA, 1997, IMMUNOL REV, V157, P153, DOI 10.1111/j.1600-065X.1997.tb00980.x; Montagna D, 1999, BLOOD, V93, P3550, DOI 10.1182/blood.V93.10.3550.410k24_3550_3557; Mutis T, 1999, BLOOD, V93, P2336, DOI 10.1182/blood.V93.7.2336.407k26_2336_2341; REUSSER P, 1991, BLOOD, V78, P1373; Schnell R, 2000, LEUKEMIA, V14, P129, DOI 10.1038/sj.leu.2401626; Small TN, 1999, BLOOD, V93, P467, DOI 10.1182/blood.V93.2.467.402k22_467_480; VIA CS, 1991, J IMMUNOL, V146, P2603	30	169	180	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 13	2002	360	9327					130	137		10.1016/S0140-6736(02)09413-8	http://dx.doi.org/10.1016/S0140-6736(02)09413-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573PB	12126823				2022-12-28	WOS:000176839100012
J	Parmar, MS				Parmar, MS			Chronic renal disease	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RECOMBINANT-HUMAN-ERYTHROPOIETIN; REPLACEMENT THERAPY; SERUM CREATININE; NEPHROPATHY; PROGRESSION; FAILURE; PATHOPHYSIOLOGY; INHIBITION; PREDICTION; MANAGEMENT		Timmins & Dist Hosp, Timmons, ON, Canada		Parmar, MS (corresponding author), 707 Ross Ave E,Suite 108, Timmins, ON P4N 8R1, Canada.	atbeat@ntl.sympatico.ca	Fouque, Denis/C-5338-2014; Parmar, Malvinder S/Q-1532-2019	Fouque, Denis/0000-0002-9707-7199; Parmar, Malvinder S/0000-0003-3182-0530				BINIK YM, 1993, J NERV MENT DIS, V181, P371, DOI 10.1097/00005053-199306000-00006; BRENNER BM, 1982, NEW ENGL J MED, V307, P652, DOI 10.1056/NEJM198209093071104; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; *CAN ORG REPL REG, 2000, DIAL REN TRANSPL, V1; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Coen G, 1996, NEPHROL DIAL TRANSPL, V11, P813, DOI 10.1093/oxfordjournals.ndt.a027404; *DIAB CONTR COMPL, 1996, KIDNEY INT, V47, P1703; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; ESCHBACH JW, 1992, CLIN NEPHROL, V38, pS98; ESCHBACH JW, 1989, KIDNEY INT, V35, P134, DOI 10.1038/ki.1989.18; Foley R N, 1997, Adv Ren Replace Ther, V4, P234; Foley RN, 1996, AM J KIDNEY DIS, V28, P53, DOI 10.1016/S0272-6386(96)90130-4; Fried LF, 2001, KIDNEY INT, V59, P260, DOI 10.1046/j.1523-1755.2001.00487.x; Ifudu O, 1998, NEW ENGL J MED, V339, P1054, DOI 10.1056/NEJM199810083391507; Jones CA, 1998, AM J KIDNEY DIS, V32, P992, DOI 10.1016/S0272-6386(98)70074-5; Klahr S, 1996, Curr Opin Nephrol Hypertens, V5, P384, DOI 10.1097/00041552-199607000-00017; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; Levey AS, 1996, J AM SOC NEPHROL, V7, P556; Levey AS, 1996, AM J KIDNEY DIS, V27, P652, DOI 10.1016/S0272-6386(96)90099-2; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; Martinez I, 1997, AM J KIDNEY DIS, V29, P496, DOI 10.1016/S0272-6386(97)90330-9; MASON PD, 1994, BRIT MED J, V309, P1557, DOI 10.1136/bmj.309.6968.1557; Mogensen CE, 2000, BRIT MED J, V321, P1440, DOI 10.1136/bmj.321.7274.1440; Muntner P, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133745; Obrador GT, 1998, AM J KIDNEY DIS, V31, P398, DOI 10.1053/ajkd.1998.v31.pm9506677; Orth SR, 1998, KIDNEY INT, V54, P926, DOI 10.1046/j.1523-1755.1998.00067.x; Parving HH, 2001, NEW ENGL J MED, V345, P870, DOI 10.1056/NEJMoa011489; PARVING HH, 1996, KIDNEY, P1864; Portoles J, 1997, AM J KIDNEY DIS, V29, P541, DOI 10.1016/S0272-6386(97)90335-8; Remuzzi G, 1998, NEW ENGL J MED, V339, P1448, DOI 10.1056/NEJM199811123392007; Remuzzi G, 2002, NEW ENGL J MED, V346, P1145, DOI 10.1056/NEJMcp011773; Ritz E, 2000, DIABETES METAB, V26, P54; RUGGENENTI, 1997, KIDNEY INT S63, V52, pS54; Ruggenenti P, 1997, CURR OPIN NEPHROL HY, V6, P489, DOI 10.1097/00041552-199709000-00014; Ruggenenti P, 1997, LANCET, V349, P1857; Ruggenenti P, 1999, LANCET, V354, P359, DOI 10.1016/S0140-6736(98)10363-X; Ruggenenti P, 1998, LANCET, V352, P1252, DOI 10.1016/S0140-6736(98)04433-X; Schwab S, 1997, AM J KIDNEY DIS, V30, pS150; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Tomson CRV, 2000, BRIT MED J, V320, P98, DOI 10.1136/bmj.320.7227.98; *UK PROSP DIAB STU, 1998, KIDNEY INT, V317, P703; Walker R, 1997, BMJ-BRIT MED J, V315, P1429, DOI 10.1136/bmj.315.7120.1429; Walser M, 1998, AM J KIDNEY DIS, V32, P23, DOI 10.1053/ajkd.1998.v32.pm9669420; WANG PH, 1993, LANCET, V341, P1306, DOI 10.1016/0140-6736(93)90816-Y; 1997, ARCH INTERN MED, V157, P2413; 1999, NEPHROL DIAL TRAN S5, V14, P21	48	71	77	1	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 13	2002	325	7355					85	90		10.1136/bmj.325.7355.85	http://dx.doi.org/10.1136/bmj.325.7355.85			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575CU	12114240	Green Published			2022-12-28	WOS:000176929400022
J	Bull, JJ; Parrish, CR				Bull, JJ; Parrish, CR			Microbiology: A binding contract for anthrax	SCIENCE			English	Editorial Material									Univ Texas, Sect Integrat Biol, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Cornell Univ, Coll Vet Med, James A Baker Inst, Ithaca, NY 14853 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Cornell University	Bull, JJ (corresponding author), Univ Texas, Sect Integrat Biol, Austin, TX 78712 USA.							Enserink M, 2002, SCIENCE, V295, P777; Enserink M, 2002, SCIENCE, V296, P639; Maynard JA, 2002, NAT BIOTECHNOL, V20, P597, DOI 10.1038/nbt0602-597	3	6	11	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 12	2002	297	5579					201	202		10.1126/science.1074590	http://dx.doi.org/10.1126/science.1074590			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571UT	12114612				2022-12-28	WOS:000176738100025
J	Robinson, GE				Robinson, GE			Development: Sociogenomics takes flight	SCIENCE			English	Editorial Material							EVOLUTION; BEHAVIOR; BRAIN		Univ Illinois, Dept Entomol, Urbana, IL 61801 USA; Univ Illinois, Program Neurosci, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Robinson, GE (corresponding author), Univ Illinois, Dept Entomol, 320 Morrill Hall, Urbana, IL 61801 USA.	generobi@uiuc.edu						Abouheif E, 2002, SCIENCE, V297, P249, DOI 10.1126/science.1071468; Ben-Shahar Y, 2002, SCIENCE, V296, P741, DOI 10.1126/science.1069911; Carroll S. B., 2001, DNA DIVERSITY MOL GE; Evans JD, 2001, GENOME BIOL, V2; Fernald RD, 2002, NOVART FDN SYMP, V244, P169; FOUNTAIN H, 2002, NY TIMES WEEK R 0421, P5; Giraud T, 2002, P NATL ACAD SCI USA, V99, P6075, DOI 10.1073/pnas.092694199; Holldobler B., 1990, pi; Holldobler B, 1994, JOURNEY ANTS; Julian GE, 2002, P NATL ACAD SCI USA, V99, P8157, DOI 10.1073/pnas.112222099; Krieger MJB, 2002, SCIENCE, V295, P328, DOI 10.1126/science.1065247; Kucharski R, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-2-research0007; Nijhout H.F., 1994, INSECT HORMONES; Page RE, 2002, GENETICS, V160, P375; Robinson GE, 1997, BIOESSAYS, V19, P1099, DOI 10.1002/bies.950191209; Robinson GE, 1999, TRENDS ECOL EVOL, V14, P202, DOI 10.1016/S0169-5347(98)01536-5; Volny VP, 2002, P NATL ACAD SCI USA, V99, P6108, DOI 10.1073/pnas.092066699; Whitfield CW, 2002, GENOME RES, V12, P555, DOI 10.1101/gr.5302; Wilson E.O., 1975, P1	19	22	25	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 12	2002	297	5579					204	205		10.1126/science.1074493	http://dx.doi.org/10.1126/science.1074493			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571UT	12114614				2022-12-28	WOS:000176738100027
J	Brundtland, GH				Brundtland, GH			Health: A pathway to sustainable development	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									WHO, CH-1211 Geneva, Switzerland	World Health Organization	Brundtland, GH (corresponding author), WHO, CH-1211 Geneva, Switzerland.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	2002	288	2					156	156		10.1001/jama.288.2.156	http://dx.doi.org/10.1001/jama.288.2.156			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	571HC	12095374				2022-12-28	WOS:000176711100008
J	Hammer, SM; Vaida, F; Bennett, KK; Holohan, MK; Sheiner, L; Eron, JJ; Wheat, LJ; Mitsuyasu, RT; Gulick, RM; Valentine, FT; Aberg, JA; Rogers, MD; Karol, CN; Saah, AJ; Lewis, RH; Bessen, LJ; Brosgart, C; DeGruttola, V; Mellors, JW				Hammer, SM; Vaida, F; Bennett, KK; Holohan, MK; Sheiner, L; Eron, JJ; Wheat, LJ; Mitsuyasu, RT; Gulick, RM; Valentine, FT; Aberg, JA; Rogers, MD; Karol, CN; Saah, AJ; Lewis, RH; Bessen, LJ; Brosgart, C; DeGruttola, V; Mellors, JW		AIDS Clin Trials Grp 398 Study Team	Dual vs single protease inhibitor therapy following antiretroviral treatment failure - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HIV-INFECTED ADULTS; SOCIETY-USA PANEL; HIV-1-INFECTED PATIENTS; COMBINATION THERAPY; VIROLOGICAL FAILURE; DRUG-INTERACTIONS; CLINICAL PHARMACOKINETICS; PLUS INDINAVIR; RESISTANCE	Context Management of antiretroviral treatment failure in patients receiving protease inhibitor (Pi)-containing regimens is a therapeutic challenge. Objective To assess whether adding a second PI improves antiviral efficacy of a 4-drug combination in patients with virologic failure while taking a PI-containing regimen. Design Multicenter, randomized, 4-arm trial, double-blind and placebo-controlled for second PI, conducted between October 1998 and April 2000, for which there was a 24-week primary analysis with extension to 48 weeks. Setting Thirty-one participating AIDS (acquired immunodeficiency syndrome) Clinical Trials Units in the United States. Participants A total of 481 human immunodeficiency virus (HIV)-infected persons with prior exposure to a maximum of 3 Pis and viral load above 1000 copies/mL. Intervention Selectively randomized assignment (per prior PI exposure) to saquina.. vir (n=116); indinavir (n=69); nelfinavir (n=139); or placebo twice per day (n=157); in combination with amprenavir, abacavir, efavirenz, and adefovir dipivoxii,., Main Outcome Measures Primary efficacy analysis involved the proportion with viral load below 200 copies/mL at 24 weeks. Other measures were changes in viral load and CD4 cell count from baseline, adverse events, and HIV drug susceptibility. Results Of 481 patients, 148 (31%) had a Viral load below 200 copies/mL at week 24. The proportions of patients with a viral load below 200 copies/mL in, the saquinavir, indinavir, nelfinavir, and placebo arms were 34% (40/116), 36% (25/69), 34% (47/139), and 23% (36/157), respectively. The proportion in the combined dual-PI arms was higher than in the amprenavir-plus-placebo arm (35% [112/324] vs 23% [36/157], respectively; P=.002). Overall, a higher proportion of nonnucleoside reverse transcriptase inhibitor (NNRTI)-naive patients had a viral load below 200 copies/mL compared with NNRTI-experienced patients (43% [116/270] vs 16% [33/ 211], respectively; P<.001), Baseline HIV-1 hypersusceptibility to efavirenz (&LE;0.4-fold difference in susceptibility compared with reference virus) was associated with suppression of viral load at 24 weeks to below 200 copies/mL (odds ratio [OR], 3.49; 95% confidence interval [CI], 1.62-7.33; P=.001), and more than 10-fold reduction in efavirenz susceptibility, with less likelihood of suppression at 24 weeks (OR, 0.28; 95% Cl, 0.09-0.87; P=.03). Conclusions In this study of anti retroviral-experienced patients with advanced immunodeficiency, viral load suppression to below 200 copies/mL was achieved in 31% of patients with regimens containing 4 or 5 new drugs. Use of 2 Pis, being naive to NNRTIs, and baseline hypersusceptibility to efavirenz were associated with a favorable outcome.	Columbia Univ Coll Phys & Surg, Dept Med, Div Infect Dis, New York, NY 10032 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Stat & Data Anal Ctr, Boston, MA 02115 USA; AIDS Clin Trial Grp Operat Ctr, Silver Spring, MD USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ N Carolina, Dept Med, Chapel Hill, NC USA; Indiana Univ, Dept Med, Bloomington, IN USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA; Cornell Univ, Weill Med Coll, Dept Med, New York, NY USA; NYU, Dept Med, New York, NY 10016 USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA; GlaxoSmithKline, Res Triangle Pk, NC USA; Hoffman LaRoche, Nutley, NJ USA; Merck Res Labs, Blue Bell, PA USA; Agouron Pharmaceut, La Jolla, CA USA; Dupont Merck Pharmaceut Co, Wilmington, DE 19880 USA; Gilead Sci Inc, Foster City, CA 94404 USA	Columbia University; Harvard University; Harvard T.H. Chan School of Public Health; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of North Carolina; University of North Carolina Chapel Hill; Indiana University System; Indiana University Bloomington; University of California System; University of California Los Angeles; Cornell University; New York University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; GlaxoSmithKline; Roche Holding; Merck & Company; Pfizer; DuPont; Gilead Sciences	Hammer, SM (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, Div Infect Dis, 630 W 168th St, New York, NY 10032 USA.			Valentine, Fred/0000-0002-6046-5913	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000865] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI038855, P30AI027742, U01AI048013, P30AI042848, U01AI046386, U01AI027665, U01AI027660] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00865, RR00083] Funding Source: Medline; NIAID NIH HHS [AI46386, AI48013, AI27665, AI27660, AI27742, AI42848, AI38855] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adkins JC, 1998, DRUGS, V55, P837, DOI 10.2165/00003495-199855060-00015; Bacheler L, 2001, J VIROL, V75, P4999, DOI 10.1128/JVI.75.11.4999-5008.2001; Barry M, 1999, CLIN PHARMACOKINET, V36, P289, DOI 10.2165/00003088-199936040-00004; Baxter JD, 2000, AIDS, V14, pF83, DOI 10.1097/00002030-200006160-00001; BECKER S, 2000, 40 INT C ANT AG CHEM; Benson CA, 2002, J INFECT DIS, V185, P599, DOI 10.1086/339014; BRIONES C, 2000, 40 INT C ANT AG CHEM; BUCKLEY J, 1979, BIOMETRIKA, V66, P429; Cameron DW, 1999, AIDS, V13, P213, DOI 10.1097/00002030-199902040-00009; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; Cingolani A, 2002, AIDS, V16, P369, DOI 10.1097/00002030-200202150-00008; Cohen CJ, 2002, AIDS, V16, P579, DOI 10.1097/00002030-200203080-00009; Condra JH, 1996, J VIROL, V70, P8270, DOI 10.1128/JVI.70.12.8270-8276.1996; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; Coull JJ, 2001, J ACQ IMMUN DEF SYND, V26, P423, DOI 10.1097/00126334-200104150-00004; Cundy KC, 1999, CLIN PHARMACOKINET, V36, P127, DOI 10.2165/00003088-199936020-00004; Decker CJ, 1998, J PHARM SCI, V87, P803, DOI 10.1021/js980029p; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; Deeks SG, 1998, ANTIMICROB AGENTS CH, V42, P2380, DOI 10.1128/AAC.42.9.2380; Deeks SG, 1999, AIDS, V13, pF35, DOI 10.1097/00002030-199904160-00001; DeGruttola V, 2000, ANTIVIR THER, V5, P41; Demeter LM, 2001, ANN INTERN MED, V135, P954, DOI 10.7326/0003-4819-135-11-200112040-00007; Durant J, 1999, LANCET, V353, P2195, DOI 10.1016/S0140-6736(98)12291-2; Eron JJ, 2001, J ACQ IMMUN DEF SYND, V26, P458, DOI 10.1097/00126334-200104150-00008; Falloon J, 2000, CLIN INFECT DIS, V30, P313, DOI 10.1086/313667; FALLOON J, 1908, AIDS, V16, P387; Fletcher CV, 2000, AIDS, V14, P2495, DOI 10.1097/00002030-200011100-00011; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; Fung HB, 2000, CLIN THER, V22, P549, DOI 10.1016/S0149-2918(00)80044-2; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gulick RM, 2000, J INFECT DIS, V182, P1375, DOI 10.1086/315867; HAMMER S, 1999, 3 INT WORKSH HIV DRU; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Harrigan PR, 2001, AIDS, V15, P1671, DOI 10.1097/00002030-200109070-00010; HAUBRICH R, 2000, ANTIVIR THER S, V5, pS68; Havlir DV, 2001, JAMA-J AM MED ASSOC, V286, P171, DOI 10.1001/jama.286.2.171; Hirsch MS, 2000, JAMA-J AM MED ASSOC, V283, P2417, DOI 10.1001/jama.283.18.2417; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; Hsu A, 1998, CLIN PHARMACOKINET, V35, P275, DOI 10.2165/00003088-199835040-00002; Hugen PWH, 2000, J ACQ IMMUN DEF SYND, V25, P236, DOI 10.1097/00126334-200011010-00005; Jackson KA, 2000, ANTIMICROB AGENTS CH, V44, P1832, DOI 10.1128/AAC.44.7.1832-1837.2000; Kahn J, 1999, JAMA-J AM MED ASSOC, V282, P2305, DOI 10.1001/jama.282.24.2305; Katlama C, 2000, AIDS, V14, P781, DOI 10.1097/00002030-200005050-00003; Kempf DJ, 1998, AIDS, V12, pF9, DOI 10.1097/00002030-199805000-00001; Kempf DJ, 1997, ANTIMICROB AGENTS CH, V41, P654, DOI 10.1128/AAC.41.3.654; LANIER ER, 2001, 8 C RETR OPP INF FEB; Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002; Marschner IC, 1998, J INFECT DIS, V177, P40, DOI 10.1086/513823; Martinez E, 2001, LANCET, V357, P592, DOI 10.1016/S0140-6736(00)04056-3; Mellors JW, 1999, JAMA-J AM MED ASSOC, V282, P2355, DOI 10.1001/jama.282.24.2355; Miller V, 2000, AIDS, V14, P2857, DOI 10.1097/00002030-200012220-00007; Mocroft A, 2000, LANCET, V356, P291, DOI 10.1016/S0140-6736(00)02504-6; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; Montaner JSG, 2001, AIDS, V15, P61, DOI 10.1097/00002030-200101050-00010; Montaner JSG, 2001, NEW ENGL J MED, V345, P452, DOI 10.1056/NEJM200108093450610; *NAT I ALL INF DIS, 1992, DIV AIDS TABL GRAD S; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Petropoulos CJ, 2000, ANTIMICROB AGENTS CH, V44, P920, DOI 10.1128/AAC.44.4.920-928.2000; Polis MA, 2001, LANCET, V358, P1760, DOI 10.1016/S0140-6736(01)06802-7; Raboud JM, 1998, AIDS, V12, P1619, DOI 10.1097/00002030-199813000-00008; Raines CP, 2000, J ACQ IMMUN DEF SYND, V25, P322, DOI 10.1097/00126334-200012010-00005; Rutschmann OT, 2000, AIDS, V14, P2145, DOI 10.1097/00002030-200009290-00011; Saag MS, 1998, AIDS, V12, pF203, DOI 10.1097/00002030-199816000-00002; Sadler BM, 2001, ANTIMICROB AGENTS CH, V45, P3663, DOI 10.1128/AAC.45.12.3663-3668.2001; Schmidt B, 2000, ANTIMICROB AGENTS CH, V44, P3213, DOI 10.1128/AAC.44.11.3213-3216.2000; Schooley R, 2000, 40 INT C ANT AG CHEM; Sham HL, 1998, ANTIMICROB AGENTS CH, V42, P3218, DOI 10.1128/AAC.42.12.3218; Shulman N, 2001, AIDS, V15, P1125, DOI 10.1097/00002030-200106150-00007; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; Staszewski S, 2001, JAMA-J AM MED ASSOC, V285, P1155, DOI 10.1001/jama.285.9.1155; Tebas P, 1999, AIDS, V13, pF23, DOI 10.1097/00002030-199902040-00002; Tural C, 2002, AIDS, V16, P209, DOI 10.1097/00002030-200201250-00010; *USPHS, 2002, GUID US ANT AG HIV I; Vanhove GF, 1997, ANTIMICROB AGENTS CH, V41, P2433, DOI 10.1128/AAC.41.11.2433; Villani P, 1999, BRIT J CLIN PHARMACO, V48, P712; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; Zhou XJ, 2000, AIDS, V14, P2869, DOI 10.1097/00002030-200012220-00008	78	151	153	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	2002	288	2					169	180		10.1001/jama.288.2.169	http://dx.doi.org/10.1001/jama.288.2.169			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	571HC	12095381	Bronze			2022-12-28	WOS:000176711100017
J	Hulley, S; Furberg, C; Barrett-Connor, E; Cauley, J; Grady, D; Haskell, W; Knopp, R; Lowery, M; Satterfield, S; Schrott, H; Vittinghoff, E; Hunninghake, D				Hulley, S; Furberg, C; Barrett-Connor, E; Cauley, J; Grady, D; Haskell, W; Knopp, R; Lowery, M; Satterfield, S; Schrott, H; Vittinghoff, E; Hunninghake, D		HERS Res Grp	Noncardiovascular disease outcomes during 6.8 years of hormone therapy - Heart and Estrogen/progestin Replacement Study follow-up (HERS II)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESTROGEN PLUS PROGESTIN; POSTMENOPAUSAL WOMEN; BREAST-CANCER; VENOUS THROMBOEMBOLISM; RANDOMIZED TRIAL; ELDERLY WOMEN; RISK; PREVENTION; FRACTURES; METAANALYSIS	Context The Heart and Estrogen/progestin Replacement Study (HERS) was a randomized trial of estrogen plus progestin therapy after menopause. Objective To examine the effect of long-term postmenopausal hormone therapy on common noncardiovascular disease outcomes. Design and Setting Randomized, blinded, placebo-controlled trial of 4.1 years' duration (HERS) and subsequent open-label observational follow-up for 2.7 years (HERS II), carried out between 1993 and 2000 in outpatient and community settings at 20 US clinical centers. Participants A total of 2763 postmenopausal women with coronary disease and average age of 67 years at enrollment in HERS; 2321 women (93% of those surviving) consented to follow-up in HERS II. Intervention Participants were randomly assigned to receive 0.625 mg/d of conjugated estrogens plus 2.5 mg of medroxyprogesterone acetate (n = 1380) or placebo (n = 1383) during HERS; open-label hormone therapy was prescribed at personal physicians' discretion during HERS II. The proportions with at least 80% adherence to hormones declined from 81% (year 1) to 45% (year 6) in the hormone group and increased from 0% (year 1) to 8% (year 6) in the placebo group. Main Outcome Measures Thromboembolic events, biliary tract surgery, cancer, fracture, and total mortality. Results Comparing women assigned to hormone therapy with those assigned to placebo, the unadjusted intention-to-treat relative hazard (RH) for venous thromboembolism declined from 2.66 (95% confidence interval [CI], 1.41-5.04) during HERS to 1.40 (95% CI, 0.64-3.05) during HERS II (P for time trend=.08); it was 2.08 overall for the 6.8 years (95% CI, 1.28-3.40), and 3 of the 73 women with thromboembolism died within 30 days due to pulmonary embolism. The overall RH for biliary tract surgery was 1.48 (95% CI, 1.12-1.95); for any cancer, 1.19 (95% CI, 0.95-1.50); and for any fracture, 1.04 (95% CI, 0.87-1.25). There were 261 deaths among those assigned to hormone therapy and 239 among those assigned to placebo (RH, 1.10; 95% CI, 0.92-1.31). Adjusted and as-treated analyses did not alter our conclusions. Conclusions Treatment for 6.8 years with estrogen plus progestin in older women with coronary disease increased the rates of venous thromboembolism and biliary tract surgery. Trends in other disease outcomes were not favorable and should be assessed in larger trials and in broader populations.	Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27103 USA; Univ Calif San Diego, Dept Family & Prevent Med, Div Epidemiol, San Diego, CA 92103 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA; Stanford Univ, Dept Med, Stanford, CA 94305 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; Univ Miami, Sch Med, Miami, FL USA; Univ Tennessee, Dept Prevent Med, Memphis, TN USA; Univ Iowa, Coll Publ Hlth & Med, Iowa City, IA USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	University of California System; University of California San Francisco; Wake Forest University; Wake Forest Baptist Medical Center; University of California System; University of California San Diego; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Stanford University; University of Washington; University of Washington Seattle; University of Miami; University of Tennessee System; University of Tennessee Health Science Center; University of Iowa; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Hulley, S (corresponding author), Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.		lowery, maeve/AAG-2575-2019; Cauley, Jane A/N-4836-2015	lowery, maeve/0000-0003-1354-7606; Cauley, Jane A/0000-0003-0752-4408				Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BURKMAN RT, 2001, BRIT J HAEMATOL, V115, P415; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; Cauley JA, 2001, AM J MED, V110, P442, DOI 10.1016/S0002-9343(01)00647-7; *CDC RES GROUP, 1977, NEW ENGL J MED, V296, P1185; *CDP RES GROUP, 1973, JAMA-J AM MED ASSOC, V226, P652; Clemons M, 2001, NEW ENGL J MED, V344, P276, DOI 10.1056/NEJM200101253440407; Colditz GA, 1997, ANN NY ACAD SCI, V833, P129, DOI 10.1111/j.1749-6632.1997.tb48598.x; *COLL GROUP, 1997, LANCET, V350, P985; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Grady D, 2000, ANN INTERN MED, V132, P689, DOI 10.7326/0003-4819-132-9-200005020-00002; Grady D, 1997, JAMA-J AM MED ASSOC, V278, P477, DOI 10.1001/jama.1997.03550060053030; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grady D, 1998, CONTROL CLIN TRIALS, V19, P314, DOI 10.1016/S0197-2456(98)00010-5; Grady D, 2001, JAMA-J AM MED ASSOC, V285, P2909, DOI 10.1001/jama.285.22.2909; Grady D, 2000, ANN INTERN MED, V133, P999, DOI 10.7326/0003-4819-133-12-200012190-00016; Greendale GA, 1998, OBSTET GYNECOL, V92, P982, DOI 10.1016/S0029-7844(98)00305-6; Grodstein F, 1999, AM J MED, V106, P574, DOI 10.1016/S0002-9343(99)00063-7; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Gutthann SP, 1997, BMJ-BRIT MED J, V314, P796, DOI 10.1136/bmj.314.7083.796; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; JOHNSTON DE, 1993, NEW ENGL J MED, V328, P412, DOI 10.1056/NEJM199302113280608; MacLennan A, 2001, Climacteric, V4, P58, DOI 10.1080/713605036; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; Petitti Diana B., 1994, Annals of Epidemiology, V4, P115; Psaty BM, 2001, JAMA-J AM MED ASSOC, V285, P906, DOI 10.1001/jama.285.7.906; Siegfried JM, 2001, LANCET ONCOL, V2, P506, DOI 10.1016/S1470-2045(01)00457-0; Simon JA, 2001, ANN INTERN MED, V135, P493, DOI 10.7326/0003-4819-135-7-200110020-00008; Torgerson DJ, 2001, JAMA-J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891; Vandenbroucke JP, 2001, NEW ENGL J MED, V344, P1527, DOI 10.1056/NEJM200105173442007; Villareal DT, 2001, JAMA-J AM MED ASSOC, V286, P815, DOI 10.1001/jama.286.7.815	43	523	561	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	2002	288	1					58	66		10.1001/jama.288.1.58	http://dx.doi.org/10.1001/jama.288.1.58			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	568YW	12090863	Bronze			2022-12-28	WOS:000176573400020
J	Tamas, I; Klasson, L; Canback, B; Naslund, AK; Eriksson, AS; Wernegreen, JJ; Sandstrom, JP; Moran, NA; Andersson, SGE				Tamas, I; Klasson, L; Canback, B; Naslund, AK; Eriksson, AS; Wernegreen, JJ; Sandstrom, JP; Moran, NA; Andersson, SGE			50 million years of genomic stasis in endosymbiotic bacteria	SCIENCE			English	Article							ESCHERICHIA-COLI; EVOLUTION; SEQUENCE; SYMBIONTS; GENES; RATES	Comparison of two fully sequenced genomes of Buchnera aphidicola, the obligate endosymbionts of aphids, reveals the most extreme genome stability to date: no chromosome rearrangements or gene acquisitions have occurred in the past 50 to 70 million years, despite substantial sequence evolution and the inactivation and loss of individual genes. In contrast, the genomes of their closest free-living relatives, Escherichia coli and Salmonella spp., are more than 2000-fold more labile in content and gene order. The genomic stasis of B. aphidicola, likely attributable to the loss of phages, repeated sequences, and recA, indicates that B. aphidicola is no longer a source of ecological innovation for its hosts.	Uppsala Univ, Evolutionary Biol Ctr, Dept Mol Evolut, Uppsala, Sweden; Univ Arizona, Dept Ecol & Evolutionary Biol, Tucson, AZ 85721 USA	Uppsala University; University of Arizona	Andersson, SGE (corresponding author), Uppsala Univ, Evolutionary Biol Ctr, Dept Mol Evolut, Uppsala, Sweden.	Siv.Andersson@ebc.uu.se	Moran, Nancy A/G-1591-2010	Klasson, Lisa/0000-0002-5874-7153; Tamas, Ivica/0000-0001-8397-4561				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andersson B, 1996, ANAL BIOCHEM, V236, P107, DOI 10.1006/abio.1996.0138; Andersson SGE, 1998, TRENDS MICROBIOL, V6, P263, DOI 10.1016/S0966-842X(98)01312-2; BAUMANN P, 1999, PROKARYOTES; BERG OG, 1995, J MOL EVOL, V41, P449, DOI 10.1007/BF00160316; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Boye E, 2000, EMBO REP, V1, P479, DOI 10.1093/embo-reports/kvd116; Brochier C, 2002, TRENDS GENET, V18, P1, DOI 10.1016/S0168-9525(01)02522-7; Brynnel EU, 1998, MOL BIOL EVOL, V15, P574, DOI 10.1093/oxfordjournals.molbev.a025958; Clark MA, 1999, MOL BIOL EVOL, V16, P1586, DOI 10.1093/oxfordjournals.molbev.a026071; Courcelle J, 2001, BIOESSAYS, V23, P463, DOI 10.1002/bies.1065; DALEVI D, 2002, IN PRESS J MOL EVOL; Dalevi DA, 2002, J MOL EVOL, V55, P24, DOI 10.1007/s00239-001-0087-9; DELCHER AL, 1999, NUCLEIC ACIDS RES, V27; Frank AC, 2002, GENETICA, V115, P1; GIROUSSE C, 1991, PLANT PHYSIOL BIOCH, V29, P41; Gordon D, 2001, GENOME RES, V11, P614, DOI 10.1101/gr.171401; Komaki K, 1999, J MOL EVOL, V48, P717, DOI 10.1007/PL00006516; Kurtz S, 1999, BIOINFORMATICS, V15, P426, DOI 10.1093/bioinformatics/15.5.426; LI WH, 1993, J MOL EVOL, V36, P96, DOI 10.1007/BF02407308; Moran NA, 1996, P NATL ACAD SCI USA, V93, P2873, DOI 10.1073/pnas.93.7.2873; MORAN NA, 2001, GENOME BIOL, V54, P1; MUNSON MA, 1991, J BACTERIOL, V173, P6321, DOI 10.1128/jb.173.20.6321-6324.1991; Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29; Ogata H, 2001, SCIENCE, V293, P2093, DOI 10.1126/science.1061471; Sandstrom J, 2000, J INSECT PHYSIOL, V46, P33, DOI 10.1016/S0022-1910(99)00098-0; Sandstrom JP, 2001, MOL ECOL, V10, P217, DOI 10.1046/j.1365-294X.2001.01189.x; Shigenobu S, 2000, NATURE, V407, P81, DOI 10.1038/35024074; Suyama M, 2001, TRENDS GENET, V17, P10, DOI 10.1016/S0168-9525(00)02159-4; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	30	450	1023	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 28	2002	296	5577					2376	2379		10.1126/science.1071278	http://dx.doi.org/10.1126/science.1071278			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	567CE	12089438				2022-12-28	WOS:000176467200036
J	Fischer, KM				Fischer, KM			Waning buoyancy in the crustal roots of old mountains	NATURE			English	Article							CONTINENTAL-CRUST; SOUTHERN URALS; SEISMIC IMAGES; EVOLUTION; MANTLE; REFLECTION; MODEL; CONSTRAINTS; LITHOSPHERE; SUBDUCTION	When mountains form through the collision of lithospheric plates, uplift of the Earth's surface is accompanied by thickening of the crust, and the buoyancy of these deep crustal roots (relative to the surrounding mantle) is thought to contribute to the support of mountain topography. Once active tectonism ceases, continuing erosion will progressively wear away surface relief. Here I provide new constraints on how crustal roots respond to erosional unloading over very long timescales. In old collisional mountain belts, ratios of surface relief to the thickness of the underlying crustal root are observed to be smaller than in young mountains. On the basis of gravity data, this trend is best explained by a decrease in the buoyancy of the crustal root with greater age since the most recent mountain-building episode-which is consistent with metamorphic reactions(1,2) produced by long-term cooling. An approximate balance between mountain and root mass anomalies suggests that the continental lithosphere remains weak enough to permit exhumation of crustal roots in response to surface erosion for hundreds of millions of years. The amount of such uplift, however, appears to be significantly reduced by progressive loss of root buoyancy.	Brown Univ, Dept Geol Sci, Providence, RI 02912 USA	Brown University	Fischer, KM (corresponding author), Brown Univ, Dept Geol Sci, Providence, RI 02912 USA.							Baird DJ, 1996, TECTONICS, V15, P416, DOI 10.1029/95TC02425; BELOUSOV VV, 1992, INT GEOL REV, V34, P345; Bousquet R, 1997, TECTONOPHYSICS, V273, P105, DOI 10.1016/S0040-1951(96)00290-9; Carbonell R, 2000, J GEOPHYS RES-SOL EA, V105, P13755, DOI 10.1029/2000JB900048; Chalot-Prat F, 2000, TECTONOPHYSICS, V327, P83, DOI 10.1016/S0040-1951(00)00155-4; CHRISTENSEN NI, 1995, J GEOPHYS RES-SOL EA, V100, P9761, DOI 10.1029/95JB00259; Clitheroe G, 2000, J GEOPHYS RES-SOL EA, V105, P13697, DOI 10.1029/1999JB900317; Djomani YHP, 1999, EARTH PLANET SC LETT, V174, P139, DOI 10.1016/S0012-821X(99)00260-5; Doring J, 1999, GEOL RUNDSCH, V87, P500, DOI 10.1007/s005310050226; Fernandez-Viejo G, 1998, GEOPHYS RES LETT, V25, P4249, DOI 10.1029/1998GL900149; FORSYTH DW, 1985, J GEOPHYS RES-SOLID, V90, P2623, DOI 10.1029/JB090iB14p12623; Hacker BR, 2000, SCIENCE, V287, P2463, DOI 10.1126/science.287.5462.2463; HACKER BR, 1996, GEOPHYS MONOGR SER, V96, P337, DOI DOI 10.1029/GM096P0337; HITTELMAN AM, 1990, GEOPHYSICS N AM CD R; James D.E., 1999, SOC EC GEOL SPEC PUB, V7, P1, DOI DOI 10.5382/SP.07.01; Jull M, 2001, J GEOPHYS RES-SOL EA, V106, P6423, DOI 10.1029/2000JB900357; Knapp JH, 1998, TECTONOPHYSICS, V288, P115, DOI 10.1016/S0040-1951(97)00288-6; Korsman K, 1999, INT GEOL REV, V41, P287, DOI 10.1080/00206819909465144; LI A, 2002, J GEOPHYS RES, V107; Mahdi H, 1998, J GEOPHYS RES-SOL EA, V103, P2693, DOI 10.1029/97JB03250; Marchant RH, 1997, TECTONOPHYSICS, V269, P217, DOI 10.1016/S0040-1951(96)00170-9; McKenzie D, 1997, J GEOPHYS RES-SOL EA, V102, P27523, DOI 10.1029/97JB02481; MUSACCHIO G, 1988, TECTONOPHYSICS, V294, P75; Nguuri TK, 2001, GEOPHYS RES LETT, V28, P2501, DOI 10.1029/2000GL012587; Owens TJ, 1997, NATURE, V387, P37, DOI 10.1038/387037a0; Rondenay S, 2000, J GEOPHYS RES-SOL EA, V105, P13735, DOI 10.1029/2000JB900022; RUDNICK RL, 1995, REV GEOPHYS, V33, P267, DOI 10.1029/95RG01302; Schueller W, 1997, B SEISMOL SOC AM, V87, P414; Stewart J, 1997, J GEOPHYS RES-SOL EA, V102, P5327, DOI 10.1029/96JB03664; TAYLOR SR, 1989, MEM GEOL SOC AM, V172, P317; Vacher P, 2001, GEOPHYS J INT, V145, P460, DOI 10.1046/j.0956-540x.2001.01393.x; Wissinger ES, 1997, J GEOPHYS RES-SOL EA, V102, P20847, DOI 10.1029/96JB03662	32	98	100	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 27	2002	417	6892					933	936		10.1038/nature00855	http://dx.doi.org/10.1038/nature00855			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	566RC	12087400				2022-12-28	WOS:000176441200034
J	Lai, KC; Lam, SK; Chu, KM; Wong, BCY; Hui, WM; Hu, WHC; Lau, GKK; Wong, WM; Yuen, MF; Chan, AOO; Lai, CL; Wong, J				Lai, KC; Lam, SK; Chu, KM; Wong, BCY; Hui, WM; Hu, WHC; Lau, GKK; Wong, WM; Yuen, MF; Chan, AOO; Lai, CL; Wong, J			Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HELICOBACTER-PYLORI; RISK; ERADICATION; OMEPRAZOLE	Background: The role of gastric acid suppression in preventing the recurrence of ulcer complications after the eradication of Helicobacter pylori infection in patients taking long-term low-dose aspirin is uncertain. Methods: We enrolled 123 patients who had ulcer complications after using low-dose aspirin continuously for more than one month and who had H. pylori infection. After the ulcers had healed and the H. pylori infection was eradicated, the patients were randomly assigned to treatment with 30 mg of lansoprazole daily or placebo, in addition to 100 mg of aspirin daily, for 12 months. The primary end point was the recurrence of ulcer complications. Results: During a median follow-up of 12 months, 9 of the 61 patients in the placebo group (14.8 percent), as compared with 1 of the 62 patients in the lansoprazole group (1.6 percent), had a recurrence of ulcer complications (adjusted hazard ratio, 9.6; 95 percent confidence interval, 1.2 to 76.1). Of these 10 patients, 4 had evidence of a recurrence of H. pylori infection and 2 had taken nonsteroidal antiinflammatory drugs before the onset of complications. Patients in the lansoprazole group were significantly less likely to have a recurrence of ulcer complications than patients in the placebo group (P=0.008). There was no significant difference in mortality between the two groups. Conclusions: In patients who had ulcer complications related to the long-term use of low-dose aspirin, treatment with lansoprazole in addition to the eradication of H. pylori infection significantly reduced the rate of recurrence of ulcer complications.	Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Lai, CL (corresponding author), Queen Mary Hosp, Dept Med, Pokfulam, Hong Kong, Peoples R China.	kclai@hku.hk	Lai, Ching Lung/C-4298-2009; Yuen, Man-Fung/C-4466-2009; Wong, Benjamin Chun Yu/C-4436-2009; Chu, Kent/C-4251-2009; Wong, Benjamin Chun Yu/ABB-1962-2020	Yuen, Man-Fung/0000-0001-7985-7725; Lai, Ching-Lung/0000-0002-5927-2436				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; *ANT TRIAL COLL, 1981, BMJ-BRIT MED J, V308, P1540; COLE AT, 1992, ALIMENT PHARM THERAP, V6, P707; Cryer B, 1999, GASTROENTEROLOGY, V117, P17, DOI 10.1016/S0016-5085(99)70545-7; Hawkey CJ, 1998, NEW ENGL J MED, V338, P727, DOI 10.1056/NEJM199803123381105; Henry D, 1996, BRIT MED J, V312, P1563, DOI 10.1136/bmj.312.7046.1563; HUI WM, 1991, DIGEST DIS SCI, V36, P577, DOI 10.1007/BF01297022; Lai KC, 2000, GASTROENTEROLOGY, V118, pA251, DOI 10.1016/S0016-5085(00)83078-4; Lai KC, 2001, GASTROENTEROLOGY, V120, pA104, DOI 10.1016/S0016-5085(08)80512-4; Lam SJ, 1998, J GASTROEN HEPATOL, V13, P1, DOI 10.1111/j.1440-1746.1998.tb00537.x; Lanas A, 2000, NEW ENGL J MED, V343, P834, DOI 10.1056/NEJM200009213431202; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; WEIL J, 1995, BMJ-BRIT MED J, V310, P827, DOI 10.1136/bmj.310.6983.827; Wong BCY, 2001, ALIMENT PHARM THERAP, V15, P505, DOI 10.1046/j.1365-2036.2001.00947.x	14	468	495	0	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 27	2002	346	26					2033	2038		10.1056/NEJMoa012877	http://dx.doi.org/10.1056/NEJMoa012877			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566DN	12087138	Green Published			2022-12-28	WOS:000176411900003
J	Plug, LJ; Werner, BT				Plug, LJ; Werner, BT			Nonlinear dynamics of ice-wedge networks and resulting sensitivity to severe cooling events	NATURE			English	Article							WESTERN ARCTIC COAST; PERMAFROST; CASTS; CRACKING; GROWTH; CANADA	Patterns of subsurface wedges of ice that form along cooling-induced tension fractures, expressed at the ground surface by ridges or troughs spaced 10-30 m apart, are ubiquitous in polar lowlands(1). Fossilized ice wedges, which are widespread at lower latitudes, have been used to infer the duration(2-4) and mean temperature(5,6) of cold periods within Proterozoic(2) and Quaternary climates(3-13), and recent climate trends have been inferred from fracture frequency in active ice wedges(14). Here we present simulations from a numerical model for the evolution of ice-wedge networks over a range of climate scenarios, based on the interactions between thermal tensile stress, fracture and ice wedges. We find that short-lived periods of severe cooling permanently alter the spacing between ice wedges as well as their fracture frequency. This affects the rate at which the widths of ice wedges increase as well as the network's response to subsequent climate change. We conclude that wedge spacing and width in ice-wedge networks mainly reflect infrequent episodes of rapidly falling ground temperatures rather than mean conditions.	Univ Calif San Diego, Cecil & Ida Green Inst Geophys & Planetary Phys, Complex Syst Lab, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Plug, LJ (corresponding author), Dalhousie Univ, Dept Earth Sci, Halifax, NS B3H 4R2, Canada.							BLACK RF, 1976, QUATERNARY RES, V6, P3, DOI 10.1016/0033-5894(76)90037-5; Black RF., 1974, GLACIAL GEOMORPHOLOG, P247; BORNS HW, 1965, SCIENCE, V148, P1223, DOI 10.1126/science.148.3674.1223; FRENCH HM, 1996, PERIGLACIAL ENV, V2nd; Gold L. W, 1977, J GLACIOL, V19, P197, DOI DOI 10.3189/S0022143000215608; Goodman D.J., 1978, J GLACIOL, V21, P651, DOI [10.3189/S0022143000033761, DOI 10.1017/S0022143000033761]; GROSSO SA, 1989, GEOGR ANN A, V71, P125, DOI 10.2307/521384; HANKS TC, 1984, J GEOPHYS RES, V89, P5771, DOI 10.1029/JB089iB07p05771; HOPKINS DM, 1949, J GEOL, V57, P119, DOI 10.1086/625591; Isarin RFB, 1997, PERMAFROST PERIGLAC, V8, P313, DOI 10.1002/(SICI)1099-1530(199709)8:3<313::AID-PPP255>3.0.CO;2-E; JOHNSON WH, 1990, QUATERNARY RES, V33, P51, DOI 10.1016/0033-5894(90)90084-X; Kasper JN, 2001, HOLOCENE, V11, P563, DOI 10.1191/095968301680223512; Lachenbruch A.H, 1962, SPEC PAP GEOL SOC AM, V70; MACKAY JR, 1993, CAN J EARTH SCI, V30, P1720, DOI 10.1139/e93-151; MACKAY JR, 1986, CAN J EARTH SCI, V23, P1782, DOI 10.1139/e86-164; MACKAY JR, 1992, CAN J EARTH SCI, V29, P236, DOI 10.1139/e92-022; Maizels J. K, 1986, B PERYGLACJALNY, V30, P67; Nicolis G, 1977, SELF ORG NONEQUILIBR; Owen LA, 1998, J QUATERNARY SCI, V13, P539; PEWE TL, 1966, PUBLICATION NATL ACA, V1287, P76; Plug LJ, 2001, J GEOPHYS RES-SOL EA, V106, P8599, DOI 10.1029/2000JB900320; Renssen H, 2001, GLOBAL PLANET CHANGE, V30, P117, DOI 10.1016/S0921-8181(01)00082-0; WALTERS JC, 1994, PERMAFROST PERIGLAC, V5, P269, DOI 10.1002/ppp.3430050406; Werner BT, 1999, SCIENCE, V284, P102, DOI 10.1126/science.284.5411.102; WILLIAMS GE, 1994, EARTHS GLACIAL RECOR, P146; ZHU Y, 1987, 8714 ARM COLD REG RE	26	39	39	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 27	2002	417	6892					929	933		10.1038/nature00796	http://dx.doi.org/10.1038/nature00796			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	566RC	12087399				2022-12-28	WOS:000176441200033
J	Kienberger, R; Hentschel, M; Uiberacker, M; Spielmann, C; Kitzler, M; Scrinzi, A; Wieland, M; Westerwalbesloh, T; Kleineberg, U; Heinzmann, U; Drescher, M; Krausz, F				Kienberger, R; Hentschel, M; Uiberacker, M; Spielmann, C; Kitzler, M; Scrinzi, A; Wieland, M; Westerwalbesloh, T; Kleineberg, U; Heinzmann, U; Drescher, M; Krausz, F			Steering attosecond electron wave packets with light	SCIENCE			English	Article							ABOVE-THRESHOLD IONIZATION; ORDER HARMONIC-GENERATION; X-RAY PULSES; LASER-PULSES	Photoelectrons excited by extreme ultraviolet or x-ray photons in the presence of a strong laser field generally suffer a spread of their energies due to the absorption and emission of laser photons. We demonstrate that if the emitted electron wave packet is temporally confined to a small fraction of the oscillation period of the interacting light wave, its energy spectrum can be up- or down-shifted by many times the laser photon energy without substantial broadening. The light wave can accelerate or decelerate the electrons drift velocity, i.e., steer the electron wave packet like a classical particle. This capability strictly relies on a sub-femtosecond duration of the ionizing x-ray pulse and on its timing to the phase of the light wave with a similar accuracy, offering a simple and potentially single-shot diagnostic tool for attosecond pump-probe spectroscopy.	Vienna Tech Univ, Inst Photon, A-1040 Vienna, Austria; Univ Wurzburg, Phys Inst EP1, D-97074 Wurzburg, Germany; Fachhsch Koblenz, D-53424 Remagen, Germany; Univ Bielefeld, Fak Phys, D-33615 Bielefeld, Germany	Technische Universitat Wien; University of Wurzburg; University of Bielefeld	Krausz, F (corresponding author), Vienna Tech Univ, Inst Photon, Gusshausstr 27, A-1040 Vienna, Austria.		Spielmann, Christian/G-9476-2013; Kitzler, Markus/D-8185-2012; Heinzmann, Ulrich/A-6248-2012	Spielmann, Christian/0000-0002-5223-4170; Kitzler, Markus/0000-0002-4835-3548; Kienberger, Reinhard/0000-0001-8781-3685				Brabec T, 2000, REV MOD PHYS, V72, P545, DOI 10.1103/RevModPhys.72.545; BUCKSBAUM PH, 1987, PHYS REV LETT, V58, P439; Christov IP, 1997, PHYS REV LETT, V78, P1251, DOI 10.1103/PhysRevLett.78.1251; de Bohan A, 1998, PHYS REV LETT, V81, P1837, DOI 10.1103/PhysRevLett.81.1837; Drescher M, 2001, SCIENCE, V291, P1923, DOI 10.1126/science.1058561; FREEMAN RR, 1991, J PHYS B-AT MOL OPT, V24, P325, DOI 10.1088/0953-4075/24/2/004; Glover TE, 1996, PHYS REV LETT, V76, P2468, DOI 10.1103/PhysRevLett.76.2468; Hentschel M, 2001, NATURE, V414, P509, DOI 10.1038/35107000; Huillier A. L., 1993, PHYS REV LETT, V70, P774; Itatani J, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.173903; Kan C, 1997, PHYS REV LETT, V79, P2971, DOI 10.1103/PhysRevLett.79.2971; Kitzler M, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.173904; Kobayashi Y, 1998, OPT LETT, V23, P64, DOI 10.1364/OL.23.000064; Krausz F, 2002, OPT PHOTONICS NEWS, V13, P62, DOI 10.1364/OPN.13.5.000062; MACKLIN JJ, 1993, PHYS REV LETT, V70, P766, DOI 10.1103/PhysRevLett.70.766; Papadogiannis NA, 1999, PHYS REV LETT, V83, P4289, DOI 10.1103/PhysRevLett.83.4289; Paul PM, 2001, SCIENCE, V292, P1689, DOI 10.1126/science.1059413; Paulus GG, 2001, NATURE, V414, P182, DOI 10.1038/35102520; SCHINS JM, 1994, PHYS REV LETT, V73, P2180, DOI 10.1103/PhysRevLett.73.2180; Schnurer M, 1999, PHYS REV LETT, V83, P722, DOI 10.1103/PhysRevLett.83.722; TATE DA, 1990, PHYS REV A, V42, P5703, DOI 10.1103/PhysRevA.42.5703; Toma ES, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.061801; WEINGARTSHOFER A, 1977, PHYS REV LETT, V39, P269, DOI 10.1103/PhysRevLett.39.269; YABLONOVITCH E, 1988, PHYS REV LETT, V60, P795, DOI 10.1103/PhysRevLett.60.795	24	316	319	1	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 16	2002	297	5584					1144	1148		10.1126/science.1073866	http://dx.doi.org/10.1126/science.1073866			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	584BP	12114530				2022-12-28	WOS:000177447600038
J	Fairbrother, WG; Yeh, RF; Sharp, PA; Burge, CB				Fairbrother, WG; Yeh, RF; Sharp, PA; Burge, CB			Predictive identification of exonic splicing enhancers in human genes	SCIENCE			English	Article							PRE-MESSENGER-RNA; T ALTERNATIVE EXON; SR-PROTEINS; SITE SELECTION; SEQUENCES; BINDING; MUTATIONS; RECOGNITION; ELEMENTS; INVITRO	Specific short oligonucleotide sequences that enhance pre-mRNA splicing when present in exons, termed exonic splicing enhancers (ESEs), play important roles in constitutive and alternative splicing. A computational method, RESCUE-ESE, was developed that predicts which sequences have ESE activity by statistical analysis of exon-intron and splice site composition. When large data sets of human gene sequences were used, this method identified 10 predicted ESE motifs. Representatives of all 10 motifs were found to display enhancer activity in vivo, whereas point mutants of these sequences exhibited sharply reduced activity. The motifs identified enable prediction of the splicing phenotypes of exonic mutations in human genes.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Burge, CB (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		Burge, Christopher B./AAH-2177-2020	Fairbrother, William/0000-0002-6312-5615	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002439] Funding Source: NIH RePORTER; NHGRI NIH HHS [1 R01 HG02439-01] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BLACK DL, 1991, GENE DEV, V5, P389, DOI 10.1101/gad.5.3.389; BLACK DL, 1995, RNA, V1, P763; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Bourgeois CF, 1999, MOL CELL BIOL, V19, P7347; Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Cavaloc Y, 1999, RNA, V5, P468, DOI 10.1017/S1355838299981967; COOPER TA, 1992, J BIOL CHEM, V267, P5330; Coulter LR, 1997, MOL CELL BIOL, V17, P2143, DOI 10.1128/MCB.17.4.2143; DIRKSEN WP, 1994, J BIOL CHEM, V269, P6431; DOMINSKI Z, 1992, MOL CELL BIOL, V12, P2108, DOI 10.1128/MCB.12.5.2108; DOMINSKI Z, 1991, MOL CELL BIOL, V11, P6075, DOI 10.1128/MCB.11.12.6075; FU XD, 1991, GENE DEV, V5, P211, DOI 10.1101/gad.5.2.211; Gersappe A, 1999, MOL CELL BIOL, V19, P1640; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; HELFMAN DM, 1988, GENE DEV, V2, P1627, DOI 10.1101/gad.2.12a.1627; Kanopka A, 1996, NATURE, V381, P535, DOI 10.1038/381535a0; KATZ RA, 1990, MOL CELL BIOL, V10, P696, DOI 10.1128/MCB.10.2.696; LAVIGUEUR A, 1993, GENE DEV, V7, P2405, DOI 10.1101/gad.7.12a.2405; Lim LP, 2001, P NATL ACAD SCI USA, V98, P11193, DOI 10.1073/pnas.201407298; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; Liu HX, 2000, MOL CELL BIOL, V20, P1063, DOI 10.1128/MCB.20.3.1063-1071.2000; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; MARDON HJ, 1987, NUCLEIC ACIDS RES, V15, P7725, DOI 10.1093/nar/15.19.7725; McNally LM, 1998, MOL CELL BIOL, V18, P3103, DOI 10.1128/MCB.18.6.3103; NELSON KK, 1988, GENE DEV, V2, P319, DOI 10.1101/gad.2.3.319; RAMCHATESINGH J, 1995, MOL CELL BIOL, V15, P4898; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; Schaal TD, 1999, MOL CELL BIOL, V19, P1705; Schaal TD, 1999, MOL CELL BIOL, V19, P261; Selvakumar M, 1999, RNA, V5, P378, DOI 10.1017/S1355838299981050; Staffa A, 1997, J BIOL CHEM, V272, P33394, DOI 10.1074/jbc.272.52.33394; STEINGRIMSDOTTIR H, 1992, NUCLEIC ACIDS RES, V20, P1201, DOI 10.1093/nar/20.6.1201; Stickeler E, 2001, EMBO J, V20, P3821, DOI 10.1093/emboj/20.14.3821; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; Tacke R, 1997, P NATL ACAD SCI USA, V94, P1148, DOI 10.1073/pnas.94.4.1148; Tacke R, 1998, CELL, V93, P139, DOI 10.1016/S0092-8674(00)81153-8; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TIAN HC, 1995, MOL CELL BIOL, V15, P6291; Tu M, 2000, MUTAT RES-GENOMICS, V432, P15, DOI 10.1016/S1383-5726(99)00011-4; Valentine CR, 1998, MUTAT RES-REV MUTAT, V411, P87, DOI 10.1016/S1383-5742(98)00010-6; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660	45	824	861	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 9	2002	297	5583					1007	1013		10.1126/science.1073774	http://dx.doi.org/10.1126/science.1073774			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	581ZN	12114529				2022-12-28	WOS:000177325400043
J	Maurer, BT				Maurer, BT			A perfect match	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 24	2002	288	4					420	420		10.1001/jama.288.4.420	http://dx.doi.org/10.1001/jama.288.4.420			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575NZ	12132951				2022-12-28	WOS:000176955400001
J	Sattar, N; Greer, IA				Sattar, N; Greer, IA			Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TYPE-2 DIABETES-MELLITUS; ISCHEMIC-HEART-DISEASE; LIFE-STYLE; WOMEN; HYPERTENSION; LIPOPROTEIN; PREVENTION; HISTORY		Glasgow Royal Infirm Univ NHS Trust, Glasgow G31 2ER, Lanark, Scotland		Sattar, N (corresponding author), Glasgow Royal Infirm Univ NHS Trust, Glasgow G31 2ER, Lanark, Scotland.	nsattar@clinmed.gla.ac.uk						Bryans C I Jr, 1966, Clin Obstet Gynecol, V9, P973, DOI 10.1097/00003081-196612000-00011; Chambers JC, 2001, JAMA-J AM MED ASSOC, V285, P1607, DOI 10.1001/jama.285.12.1607; CHESLEY LC, 1976, AM J OBSTET GYNECOL, V124, P446, DOI 10.1016/0002-9378(76)90168-X; Clapp JF, 2000, AM J OBSTET GYNECOL, V183, P1484, DOI 10.1067/mob.2000.107096; Dornhorst A, 1998, DIABETES CARE, V21, pB43; FISHER KA, 1981, MEDICINE, V60, P267, DOI 10.1097/00005792-198107000-00002; Godfrey KM, 2000, AM J CLIN NUTR, V71, p1344S, DOI 10.1093/ajcn/71.5.1344s; Greer IA, 1999, LANCET, V353, P1258, DOI 10.1016/S0140-6736(98)10265-9; Haffner SM, 2001, CIRCULATION, V103, P346; Hannaford P, 1997, HEART, V77, P154, DOI 10.1136/hrt.77.2.154; He S, 1999, THROMB HAEMOSTASIS, V81, P538; Hu FB, 2001, NEW ENGL J MED, V345, P790, DOI 10.1056/NEJMoa010492; Hu J, 1998, BRIT J OBSTET GYNAEC, V105, P1279, DOI 10.1111/j.1471-0528.1998.tb10006.x; Jonsdottir LS, 1995, ACTA OBSTET GYN SCAN, V74, P772; KAUFMANN RC, 1995, AM J OBSTET GYNECOL, V172, P621, DOI 10.1016/0002-9378(95)90582-0; Laivuori H, 1996, J CLIN ENDOCR METAB, V81, P2908, DOI 10.1210/jc.81.8.2908; Martin U, 1999, CLIN SCI, V96, P421, DOI 10.1042/CS19980326; MeyersSeifer CH, 1996, DIABETES CARE, V19, P1351, DOI 10.2337/diacare.19.12.1351; Peters RK, 1996, LANCET, V347, P227, DOI 10.1016/S0140-6736(96)90405-5; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; Sacks GP, 1998, AM J OBSTET GYNECOL, V179, P80, DOI 10.1016/S0002-9378(98)70254-6; Sattar N, 1996, BRIT J OBSTET GYNAEC, V103, P614, DOI 10.1111/j.1471-0528.1996.tb09827.x; SIBAI BM, 1986, AM J OBSTET GYNECOL, V155, P1011, DOI 10.1016/0002-9378(86)90336-4; Smith GCS, 2001, LANCET, V357, P2002, DOI 10.1016/S0140-6736(00)05112-6; Smith GD, 2000, BRIT MED J, V320, P839, DOI 10.1136/bmj.320.7238.839; Smith GD, 2000, LANCET, V356, P2066, DOI 10.1016/S0140-6736(00)03406-1; Thomson AJ, 1999, HUM REPROD, V14, P229, DOI 10.1093/humrep/14.1.229; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801	28	555	570	0	22	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 20	2002	325	7356					157	160		10.1136/bmj.325.7356.157	http://dx.doi.org/10.1136/bmj.325.7356.157			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	577PG	12130616	Green Published, Green Accepted			2022-12-28	WOS:000177069900029
J	Faigman, DL				Faigman, DL			Science and the law: Is science different for lawyers?	SCIENCE			English	Editorial Material									Univ Calif San Francisco, Hastings Coll Law, San Francisco, CA 94102 USA	University of California System; University of California San Francisco	Faigman, DL (corresponding author), Univ Calif San Francisco, Hastings Coll Law, San Francisco, CA 94102 USA.								0	35	35	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 19	2002	297	5580					339	340		10.1126/science.1072515	http://dx.doi.org/10.1126/science.1072515			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574LV	12130766				2022-12-28	WOS:000176892600028
J	Burns, A; Byrne, EJ; Maurer, K				Burns, A; Byrne, EJ; Maurer, K			Alzheimer's disease	LANCET			English	Editorial Material							CONTROLLED TRIAL; AUGUSTE-D		Univ Manchester, Wythenshawe Hosp, Dept Old Age Psychiat, Educ & Res Ctr, Manchester M23 9LT, Lancs, England; Goethe Univ Frankfurt, Dept Psychiat & Psychotherapy 1, D-6000 Frankfurt, Germany	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Goethe University Frankfurt	Burns, A (corresponding author), Univ Manchester, Wythenshawe Hosp, Dept Old Age Psychiat, Educ & Res Ctr, Manchester M23 9LT, Lancs, England.	a_burns@fs1.with.man.ac.uk		Burns, Alistair/0000-0002-9837-0645				Alzheimer A, 1911, Z GESAMTE NEUROL PSY, V4, P356, DOI 10.1007/BF02866241; Alzheimer A., 1907, ALLGEMEINE Z PSYCHIA, V64, P146, DOI DOI 10.1002/CA.980080612; Alzheimer A, 1906, NEUROLOGISCHES CENTR, V23, P1129; BERRIOS G, 2000, DEMENTIA, P3; BONFIGLIO F, 1908, RIV SPERIMENTALE FRE, V34, P196; Burns A, 1999, DEMENT GERIATR COGN, V10, P237, DOI 10.1159/000017126; Fischer O, 1907, MON PSYCHIATR NEUROL, V22, P361; FORSTL H, 1991, INT J GERIATR PSYCH, V6, P529, DOI 10.1002/gps.930060710; Fuller SC, 1907, AM J INSANITY, V63, P415, DOI 10.1176/ajp.63.4.415; Graeber MB, 1997, NEUROGENETICS, V1, P73, DOI 10.1007/s100480050011; Graeber MB, 1998, NEUROGENETICS, V1, P223, DOI 10.1007/s100480050033; HOFF P, 1991, ALZHEIMER DEMENTIAS, P29; KRAEPELIN E, 1910, PSYCHIAT LEHRBUCH ST, P593; Maurer K, 1997, LANCET, V349, P1546, DOI 10.1016/S0140-6736(96)10203-8; Perusini G., 1909, HISTOLOGISCHE HISTOP, P297; Rosler M, 1999, BMJ-BRIT MED J, V318, P633, DOI 10.1136/bmj.318.7184.633; St George-Hyslop P, 2001, LANCET, pS1; Tariot PN, 2000, NEUROLOGY, V54, P2269, DOI 10.1212/WNL.54.12.2269; Whittaker P, 2000, CONCEPTS ALZHEIMERS, P1	19	68	72	1	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 13	2002	360	9327					163	165		10.1016/S0140-6736(02)09420-5	http://dx.doi.org/10.1016/S0140-6736(02)09420-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573PB	12126840				2022-12-28	WOS:000176839100028
J	Helfgott, SM; Smith, RN				Helfgott, SM; Smith, RN			A 21-year-old man with arthritis during treatment for hyperthyroidism - Propylthiouracil-induced, ANCA-positive vasculitis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; CHURG-STRAUSS-SYNDROME; SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTIMYELOPEROXIDASE ANTIBODIES; MICROSCOPIC POLYANGIITIS; GLOMERULONEPHRITIS; MYELOPEROXIDASE; AUTOANTIBODIES; GRANULOMATOSIS; NEUTROPHILS		Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Helfgott, SM (corresponding author), Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA.							BAYER AS, 1993, CLIN INFECT DIS, V17, P313, DOI 10.1093/clinids/17.3.313; CARRASCO MD, 1987, ARCH INTERN MED, V147, P1677, DOI 10.1001/archinte.147.9.1677; CHAJEK T, 1975, MEDICINE, V54, P179, DOI 10.1097/00005792-197505000-00001; Choi HK, 2000, ARTHRITIS RHEUM, V43, P405, DOI 10.1002/1529-0131(200002)43:2<405::AID-ANR22>3.0.CO;2-5; Choi HK, 2000, ARTHRITIS RHEUM, V43, P226, DOI 10.1002/1529-0131(200001)43:1<226::AID-ANR27>3.0.CO;2-Q; DAVIES DJ, 1982, BMJ-BRIT MED J, V285, P606, DOI 10.1136/bmj.285.6342.606; DILLON MJ, 1995, RHEUM DIS CLIN N AM, V21, P1115; Dimitrakopoulos AN, 1999, ANN INTERN MED, V130, P226, DOI 10.7326/0003-4819-130-3-199902020-00027; DOLMAN KM, 1993, LANCET, V342, P651, DOI 10.1016/0140-6736(93)91761-A; FALK RJ, 1988, NEW ENGL J MED, V318, P1651, DOI 10.1056/NEJM198806233182504; Franssen CFM, 2000, KIDNEY INT, V57, P2195, DOI 10.1046/j.1523-1755.2000.00080.x; GROSS WL, 1993, CLIN EXP IMMUNOL, V91, P1; Guillevin L, 1999, MEDICINE, V78, P26, DOI 10.1097/00005792-199901000-00003; Gunton JE, 2000, EUR J ENDOCRINOL, V142, P587, DOI 10.1530/eje.0.1420587; HALL JB, 1984, AUST NZ J MED, V14, P277, DOI 10.1111/j.1445-5994.1984.tb03769.x; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; Hoffman GS, 1998, ARTHRITIS RHEUM-US, V41, P1521, DOI 10.1002/1529-0131(199809)41:9<1521::AID-ART2>3.0.CO;2-A; Irvine AD, 1997, ARCH DERMATOL, V133, P474, DOI 10.1001/archderm.133.4.474; Jennette JC, 1997, NEW ENGL J MED, V337, P1512, DOI 10.1056/NEJM199711203372106; JIANG XX, 1994, SCIENCE, V266, P810, DOI 10.1126/science.7973636; KAMMER GM, 1980, CLIN IMMUNOL IMMUNOP, V15, P658, DOI 10.1016/0090-1229(80)90011-2; Kaye V N, 1990, Adv Dermatol, V5, P215; KEMMETT D, 1991, J AM ACAD DERMATOL, V24, P967, DOI 10.1016/0190-9622(91)70154-T; KERR GS, 1994, ANN INTERN MED, V120, P919, DOI 10.7326/0003-4819-120-11-199406010-00004; Langford CA, 2001, ARTHRITIS RHEUM-US, V44, P508, DOI 10.1002/1529-0131(200103)44:3<508::AID-ANR96>3.3.CO;2-2; LEE E, 1990, BIOCHEM PHARMACOL, V39, P1467, DOI 10.1016/0006-2952(90)90428-N; LIE JT, 1995, SEMIN ARTHRITIS RHEU, V24, P422, DOI 10.1016/S0049-0172(95)80010-7; MADDISON PJ, 1981, MEDICINE, V60, P87, DOI 10.1097/00005792-198103000-00002; MASI AT, 1990, ARTHRITIS RHEUM, V33, P1094, DOI 10.1002/art.1780330806; NILES JL, 1991, J AM SOC NEPHROL, V2, P27; Otsuka S, 2000, BRIT J DERMATOL, V142, P828, DOI 10.1046/j.1365-2133.2000.03445.x; PETRI M, 1991, J RHEUMATOL, V18, P1529; SCHNABEL A, 1995, ARTHRITIS RHEUM-US, V38, P633, DOI 10.1002/art.1780380509; SCHUR PH, 2001, UPTODATE; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; TERVAERT JWC, 1993, J NEUROL, V240, P449, DOI 10.1007/BF00867361; VANDERWOUDE FJ, 1985, LANCET, V1, P425; VONSCHMIEDEBERG S, 1995, SCIENCE, V268, P585, DOI 10.1126/science.7725110	38	16	18	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 11	2002	347	2					122	130		10.1056/NEJMcpc020104	http://dx.doi.org/10.1056/NEJMcpc020104			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	572HC	12110741				2022-12-28	WOS:000176767300008
J	Amornwichet, P; Teeraratkul, A; Simonds, RJ; Naiwatanakul, T; Chantharojwong, N; Culnane, M; Tappero, JW; Kanshana, S				Amornwichet, P; Teeraratkul, A; Simonds, RJ; Naiwatanakul, T; Chantharojwong, N; Culnane, M; Tappero, JW; Kanshana, S			Preventing mother-to-child HIV transmission - The first year of Thailand's national program	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SHORT-COURSE ZIDOVUDINE; TRIAL; REGIMENS	Context Each year in Thailand, about 10000 children are born at risk for mother-to-child human immunodeficiency virus (HIV) transmission. In 2000, Thailand implemented a national program to prevent mother-to-child HIV transmission. Objective To describe the results of implementation of the program. Design Monthly collection of summary data from hospitals. Setting Public health hospitals (n=822) in all 12 regions of Thailand, representing .75 provinces, excluding Bangkok. Participants Women giving birth from October 2000 through September 2001, including HIV-seropositive women and their neonates. Main Outcome Measures Percentages of women giving birth who were tested for HIV, HIV-seropositive women giving birth who received antenatal prophylactic antiretroviral drugs, and HIV-exposed neonates who received prophylactic antiretroviral drugs and infant formula. Results Among 573 655 women (range, 27344-77806 by region) giving birth, 554 912 (96.7%) received antenatal care (range, 91.9%-98.8% by region). Of 554912 women giving birth who had antenatal care, 517488 (93.3%) were tested for HIV (range, 87.7%-99.4% by region) before giving birth; of 18743 women giving birth who did not have antenatal care, 13314 (71.0%) were tested for HIV (range, 21.7%-92.9% by region). Of 6646 HIV-seropositive women giving birth, 4659 (70.1%) received prophylactic antiretroviral drugs before delivery (range, 55.3%-81.2% by region). Of 6475 neonates of HIV-seropositive women, 5741 (88.7%) received prophylactic antireiroviral, drugs (range, 67.4%-96.9% by region) and 5386 (83.2%) received infant formula (range, 65.3%-100% by-region). Conclusions Major program components of Thailand's national program for preventing mother-to-child HIV transmission were implemented. Thailand's experience may encourage other developing countries to implement or expand similar national programs.	Minist Publ Hlth, Dept Hlth, Nonthaburi 11000, Thailand; Thailand Minist Publ Hlth US Ctr Dis Control & Pr, Nonthaburi, Thailand; Ctr Dis Control & Prevent, Global AIDS Program, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA	Ministry of Public Health - Thailand; Ministry of Public Health - Thailand; Centers for Disease Control & Prevention - USA	Amornwichet, P (corresponding author), Minist Publ Hlth, Dept Hlth, Tivanon Rd, Nonthaburi 11000, Thailand.			Culnane, Mary/0000-0003-2070-4454				[Anonymous], PROJ HIV AIDS THAIL; *CDCP, 2001, MMWR-MORBID MORTAL W, V50, P599; Dean AG, 1995, EPI INFO VERSION 6; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Kanshana S, 2000, AIDS, V14, P1617, DOI 10.1097/00002030-200007280-00018; Kanshana S, 2002, AIDS, V16, P953, DOI 10.1097/00002030-200205030-00001; Lallemant M, 2000, NEW ENGL J MED, V343, P982, DOI 10.1056/NEJM200010053431401; *MIN PUBL HLTH THA, 2000, NAT GUID CLIN MAN HI; NOLAN M, 2001, 3 C GLOB STRAT PREV; ROONGPISUTHIPON.A, 2001, 3 C GLOB STRAT PREV; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; TANGCHAROENSATH.V, 2001, 8 NAT AIDS SEM JUL 1; THAINEUA V, 2000, 13 INT AIDS C JUL 9; Thaineua Vallop, 1998, Southeast Asian Journal of Tropical Medicine and Public Health, V29, P429; Wade NA, 1998, NEW ENGL J MED, V339, P1409, DOI 10.1056/NEJM199811123392001; *WHO MIN PUBL HLTH, 2001, EV VOL COUNS TEST NA	16	34	42	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	2002	288	2					245	248		10.1001/jama.288.2.245	http://dx.doi.org/10.1001/jama.288.2.245			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	571HC	12095391				2022-12-28	WOS:000176711100027
J	Price, J; Leaver, L				Price, J; Leaver, L			ABC of psychological medicine - Beginning treatment	BMJ-BRITISH MEDICAL JOURNAL			English	Review									Univ Oxford, Dept Psychiat, Oxford OX1 2JD, England; Jericho Hlth Ctr, Oxford, England	University of Oxford	Price, J (corresponding author), Univ Oxford, Dept Psychiat, Oxford OX1 2JD, England.							Balint M., 1957, DOCTOR; Campling F, 2000, CHRONIC FATIGUE SYND; Coulter A, 1999, BRIT MED J, V318, P318, DOI 10.1136/bmj.318.7179.318; *DEP HLTH, 2000, NHS PLAN PLAN INVEST; Department of Health, 2001, EXP PAT NEW APPR CHR; Di Blasi Z, 2001, LANCET, V357, P757, DOI 10.1016/S0140-6736(00)04169-6; STEWART MA, 1995, CAN MED ASSOC J, V152, P1423; THOMAS KB, 1997, BRIT MED J, V294, P1200	8	17	17	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 6	2002	325	7354					33	35		10.1136/bmj.325.7354.33	http://dx.doi.org/10.1136/bmj.325.7354.33			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	573BC	12098729	Green Published			2022-12-28	WOS:000176808600023
J	Hossfeld, U; Olsson, L				Hossfeld, U; Olsson, L			Portraits of science: From the modern synthesis to Lysenkoism, and back?	SCIENCE			English	Editorial Material									Univ Jena, Dept Hist Med Sci & Technol, D-07745 Jena, Germany; Univ Jena, Dept Systemat Zool & Evolutionary Biol, D-07743 Jena, Germany	Friedrich Schiller University of Jena; Friedrich Schiller University of Jena	Hossfeld, U (corresponding author), Univ Jena, Dept Hist Med Sci & Technol, Ernst Haeckel House, D-07745 Jena, Germany.		Hossfeld, Uwe/AAC-1757-2022; Olsson, Lennart/D-3859-2011	Hossfeld, Uwe/0000-0001-8238-9774; Olsson, Lennart/0000-0002-2696-6423				AROSEVSKIJ MG, 1994, REPRESSIROVANNAJA NA; HOSSFELD U, 2001, DARWINISMUS IDEOLOGI; Hoxtermann Ekkerhard, 2000, ACTA HISTORICA LEOP, V36, P273; Krau<ss>e E, 1999, VERHANDLUNGEN GESCH, V3, P203; Schaxel J, 1939, CR ACAD SCI URSS, V23, P962; Schmalhausen II, 1949, FACTORS EVOLUTION TH; Schneider G, 1940, CR ACAD SCI URSS, V29, P640; SCHNEIDER G, 1947, URANIA, V10, P41; SCHNEIDER G, 1950, EVOLUTIONSTHEORIE GR, P113; Siemens Johannes, 1997, BIOL UNSERER ZEIT, V27, P255; 2001, AXOLOTL NEWS     FAL	11	21	22	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 5	2002	297	5578					55	56		10.1126/science.1068355	http://dx.doi.org/10.1126/science.1068355			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571HB	12098687				2022-12-28	WOS:000176711000023
J	Sriraman, S; Agarwal, S; Aydil, ES; Maroudas, D				Sriraman, S; Agarwal, S; Aydil, ES; Maroudas, D			Mechanism of hydrogen-induced crystallization of amorphous silicon	NATURE			English	Article							CHEMICAL-VAPOR-DEPOSITION; MICROCRYSTALLINE SILICON; SIH3; ENERGETICS; DYNAMICS; GROWTH; ADSORPTION; RADICALS; SURFACES; FILMS	Hydrogenated amorphous and nanocrystalline silicon films manufactured by plasma deposition techniques are used widely in electronic and optoelectronic devices(1,2). The crystalline fraction and grain size of these films determines electronic and optical properties; the nanocrystal nucleation mechanism, which dictates the final film structure, is governed by the interactions between the hydrogen atoms of the plasma and the solid silicon matrix. Fundamental understanding of these interactions is important for optimizing the film structure and properties. Here we report the mechanism of hydrogen-induced crystallization of hydrogenated amorphous silicon films during post-deposition treatment with an H-2 (or D-2) plasma. Using molecular-dynamics simulations(3,4) and infrared spectroscopy(5), we show that crystallization is mediated by the insertion of H atoms into strained Si-Si bonds as the atoms diffuse through the film. This chemically driven mechanism may be operative in other covalently bonded materials, where the presence of hydrogen leads to disorder-to-order transitions.	Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Aydil, ES (corresponding author), Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA.	aydil@engineering.ucsb.edu; maroudas@engineering.ucsb.edu	Aydil, Eray/M-5503-2019; Agarwal, Sumit/D-8950-2011; Maroudas, Dimitrios/AHE-3213-2022	Aydil, Eray/0000-0002-8377-9480				ABELSON JR, 1993, APPL PHYS A-MATER, V56, P493, DOI 10.1007/BF00331400; BOLAND JJ, 1992, SCIENCE, V256, P1304, DOI 10.1126/science.256.5061.1304; Cabarrocas PRI, 2000, J NON-CRYST SOLIDS, V266, P31, DOI 10.1016/S0022-3093(99)00714-0; CHABAL YJ, 1988, SURF SCI REP, V8, P211, DOI 10.1016/0167-5729(88)90011-8; Edelberg E, 1997, J APPL PHYS, V81, P2410, DOI 10.1063/1.364247; JUN X, 1996, J NONCRYST SOLIDS, V200, P582; Kaiser I, 1998, PHYS REV B, V58, pR1718, DOI 10.1103/PhysRevB.58.R1718; Katiyar M, 2001, MAT SCI ENG A-STRUCT, V304, P349, DOI 10.1016/S0921-5093(00)01528-8; LAYADI N, 1995, PHYS REV B, V52, P5136, DOI 10.1103/PhysRevB.52.5136; MAROUDAS D, 2001, ADV CHEM ENG, V28, P251; Marra DC, 1998, J VAC SCI TECHNOL A, V16, P3199, DOI 10.1116/1.581520; Morral AFI, 2000, MAT SCI ENG B-SOLID, V69, P559, DOI 10.1016/S0921-5107(99)00324-4; NICKEL NH, 1995, PHYS REV B, V51, P4872, DOI 10.1103/PhysRevB.51.4872; NOMOTO K, 1990, JPN J APPL PHYS 2, V29, pL1372, DOI 10.1143/JJAP.29.L1372; OHIRA T, 1995, PHYS REV B, V52, P8283, DOI 10.1103/PhysRevB.52.8283; Ramalingam S, 1999, J APPL PHYS, V86, P2872, DOI 10.1063/1.371136; Ramalingam S, 1998, J APPL PHYS, V84, P3895, DOI 10.1063/1.368569; Ramalingam S, 1998, SURF SCI, V418, pL8, DOI 10.1016/S0039-6028(98)00703-1; Ramalingam S, 2001, APPL PHYS LETT, V78, P2685, DOI 10.1063/1.1367298; Saitoh K, 1997, APPL PHYS LETT, V71, P3403, DOI 10.1063/1.120324; Shah A, 1999, SCIENCE, V285, P692, DOI 10.1126/science.285.5428.692; SHIRAI H, 1991, JPN J APPL PHYS 2, V30, pL679, DOI 10.1143/JJAP.30.L679; Street RA, 1998, PHYS STATUS SOLIDI A, V166, P695, DOI 10.1002/(SICI)1521-396X(199804)166:2<695::AID-PSSA695>3.0.CO;2-U; Summonte C, 2000, PHILOS MAG B, V80, P459, DOI 10.1080/13642810008209754; TERSOFF J, 1988, PHYS REV B, V37, P6991, DOI 10.1103/PhysRevB.37.6991; TSAI CC, 1989, J NON-CRYST SOLIDS, V114, P151, DOI 10.1016/0022-3093(89)90096-3; Tuttle B, 1998, PHYS REV B, V57, P12859, DOI 10.1103/PhysRevB.57.12859; VAN DE WALLE CG, 1989, PHYS REV B, V39, P10791, DOI 10.1103/PhysRevB.39.10791; Walch SP, 2000, CHEM PHYS LETT, V329, P304, DOI 10.1016/S0009-2614(00)01007-1; Walch SP, 2001, CHEM PHYS LETT, V344, P249, DOI 10.1016/S0009-2614(01)00777-1	30	363	369	9	156	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 4	2002	418	6893					62	65		10.1038/nature00866	http://dx.doi.org/10.1038/nature00866			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	569JL	12097905				2022-12-28	WOS:000176599200037
J	Flores, G; Fuentes-Afflick, E; Barbot, O; Carter-Pokras, O; Claudio, L; Lara, M; McLaurin, JA; Pachter, L; Gomez, FR; Mendoza, F; Valdez, RB; Villarruel, AM; Zambrana, RE; Greenberg, R; Weitzman, M				Flores, G; Fuentes-Afflick, E; Barbot, O; Carter-Pokras, O; Claudio, L; Lara, M; McLaurin, JA; Pachter, L; Gomez, FR; Mendoza, F; Valdez, RB; Villarruel, AM; Zambrana, RE; Greenberg, R; Weitzman, M			The health of Latino children - Urgent priorities, unanswered questions, and a research agenda	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							MEXICAN-AMERICAN CHILDREN; AIDS CLINICAL-TRIALS; PUERTO-RICAN; ENVIRONMENTAL-HEALTH; HISPANIC CHILDREN; DRUG-USE; CRITERION VALIDITY; PRESCHOOL-CHILDREN; ETHNIC-DIFFERENCES; ENGLISH-SPEAKING	Latinos recently became the largest racial/ethnic minority group of US children. The Latino Consortium of the American Academy of Pediatrics Center for Child Health Research, consisting of 13 expert panelists, identified the most important urgent priorities and unanswered questions in Latino child health. Conclusions were drawn when consensus was reached among members, with refinement through multiple iterations. A consensus statement with supporting references was drafted and revised. This article summarizes the key issues, including lack of validated research instruments, frequent unjustified exclusion from studies, and failure to analyze data by pertinent subgroups. Latino children are at high risk for behavioral and developmental disorders, and there are many unanswered questions about their mental health needs and use of services. The prevalence of dental caries is disproportionately higher for Latino children, but the reasons for this disparity are unclear. Culture and language can profoundly affect Latino children's health, but not enough cultural competency training of health care professionals and provision of linguistically appropriate care occur. Latinos are underrepresented at every level of the health care professions. Latino children are at high risk for school dropout, environmental hazards, obesity, diabetes mellitus, asthma, lack of health insurance, nonfinancial barriers to health care access, and impaired quality of care, but many key questions in these areas remain unanswered. This article suggests areas in which more research is needed and ways to improve research and care of Latino children.	Boston Univ, Sch Med, Boston Med Ctr, Dept Pediat,Div Gen Pediat, Boston, MA 02118 USA; Boston Univ, Sch Publ Hlth, Boston Med Ctr, Dept Pediat, Boston, MA 02118 USA; Med Coll Wisconsin, Dept Pediat, Ctr Advancement Urban Children, Milwaukee, WI 53226 USA; Univ Calif San Francisco, Sch Med, Dept Pediat, San Francisco, CA 94143 USA; Natl Hispan Med Assoc, Washington, DC USA; US Dept HHS, Off Minor Hlth, Rockville, MD USA; Mt Sinai Sch Med, Dept Community Med, New York, NY USA; Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA 90024 USA; Migrant Clinicians Network, Austin, TX USA; Univ Connecticut, Sch Med, St Francis Hosp & Med Ctr, Dept Pediat, Hartford, CT 06112 USA; Univ Connecticut, Sch Med, St Francis Hosp & Med Ctr, Dept Anthropol, Hartford, CT 06112 USA; Univ Calif San Francisco, Sch Dent, Dept Hlth Serv Res, San Francisco, CA 94143 USA; Stanford Univ, Sch Med, Dept Pediat, Palo Alto, CA 94304 USA; MCP Hahnemann Univ, Sch Publ Hlth, Philadelphia, PA USA; RAND Corp, Hlth Sci Program, Santa Monica, CA USA; Univ Michigan, Sch Nursing, Div Hlth Promot, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Nursing, Risk Reduct Programs, Ann Arbor, MI 48109 USA; Univ Maryland, Dept Womens Studies, College Pk, MD 20742 USA; Univ New Mexico, Sch Med, Dept Pediat, Albuquerque, NM 87131 USA; Univ Rochester, Sch Med, Rochester, NY USA; Ctr Child Hlth Res, Rochester, NY USA	Boston Medical Center; Boston University; Boston Medical Center; Boston University; Medical College of Wisconsin; University of California System; University of California San Francisco; Icahn School of Medicine at Mount Sinai; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Saint Francis Hospital & Medical Center; University of Connecticut; Saint Francis Hospital & Medical Center; University of Connecticut; University of California System; University of California San Francisco; Stanford University; Drexel University; RAND Corporation; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University System of Maryland; University of Maryland College Park; University of New Mexico; University of Rochester	Flores, G (corresponding author), Boston Univ, Sch Med, Boston Med Ctr, Dept Pediat,Div Gen Pediat, 91 E Concord St,Matern 419, Boston, MA 02118 USA.	glenn.flores@bmc.org	Ramos-Gomez, Francisco/ABF-4255-2021; Zambrana, Ruth Enid/ABD-5509-2020; Carter-Pokras, Olivia D/B-1652-2012	Ramos-Gomez, Francisco/0000-0002-4961-2150; Carter-Pokras, Olivia D/0000-0002-6310-6932; Mendoza, Fernando/0000-0001-5516-4588; Pachter, Lee/0000-0002-5766-0953	PHS HHS [K02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Agran P F, 1998, Inj Prev, V4, P188; AGUIRREMOLINA M, 1994, LATINO HLTH US GROWI, P3; Anderson LM, 1997, AM J PUBLIC HEALTH, V87, P2018, DOI 10.2105/AJPH.87.12.2018; [Anonymous], 1991, MANUAL CHILD BEHAV C; ARCIA E, 1994, J DEV BEHAV PEDIATR, V15, P27, DOI 10.1097/00004703-199402000-00005; *ASS AM MED COLL F, 2000, US MED SCH FAC; Baker DW, 1996, JAMA-J AM MED ASSOC, V275, P783, DOI 10.1001/jama.275.10.783; Ballew C, 1999, J PEDIATR-US, V134, P623, DOI 10.1016/S0022-3476(99)70250-7; BURGOS AE, 1999, AMB PED ASS 39 ANN M; CANINO IA, 1986, J AM ACAD CHILD PSY, V25, P254, DOI 10.1016/S0002-7138(09)60234-X; Carlisle DM, 1998, AM J PUBLIC HEALTH, V88, P1314, DOI 10.2105/AJPH.88.9.1314; CARTERPOKRAS OD, 1993, AM J PUBLIC HEALTH, V83, P580, DOI 10.2105/AJPH.83.4.580; *CDCP, 2002, YOUTH RISK BEH SURV; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P198; Chabra A, 1999, WESTERN J MED, V170, P28; Chaloupka FJ, 1999, TOB CONTROL, V8, P373, DOI 10.1136/tc.8.4.373; Claudio L, 1998, ENVIRON HEALTH PERSP, V106, P849, DOI 10.2307/3434200; Conners CK, 1998, J ABNORM CHILD PSYCH, V26, P257, DOI 10.1023/A:1022602400621; Conners CK, 1998, J ABNORM CHILD PSYCH, V26, P279, DOI 10.1023/A:1022606501530; Cooper WO, 2001, ARCH PEDIAT ADOL MED, V155, P1111, DOI 10.1001/archpedi.155.10.1111; *CTR MED STAT OP, 1999, ANN EPSDT PART REP F; *DIV HUM SUBJ PROT, 2002, OBT DOC INF CONS SUB; DUSENBERY L, 1994, PUBLIC HEALTH REP, V109, P421; *ERIC CLEAR URB ED, 2002, LAT SCH; Escobar JI, 2000, J NERV MENT DIS, V188, P736, DOI 10.1097/00005053-200011000-00003; FarreRiba A, 1997, REV NEUROLOGIA, V25, P200; FINKELSTEIN JA, 1995, PEDIATRICS, V95, P389; Flores G, 2000, ACAD MED, V75, P451, DOI 10.1097/00001888-200005000-00015; Flores G, 2000, J PEDIATR-US, V137, P842, DOI 10.1067/mpd.2000.109150; Flores G, 1998, Fam Med, V30, P196; Flores G, 2000, J PEDIATR-US, V136, P14, DOI 10.1016/S0022-3476(00)90043-X; Flores G, 1998, ARCH PEDIAT ADOL MED, V152, P1119; Flores G, 1999, AM J PUBLIC HEALTH, V89, P1066, DOI 10.2105/AJPH.89.7.1066; Flores G, 2001, HLTH ISSUES LATINO C, P77; FLORES G, 1999, AMB PED ASS 39 ANN M; Frayne SM, 1996, J GEN INTERN MED, V11, P39, DOI 10.1007/BF02603484; FuentesAfflick E, 1997, ARCH PEDIAT ADOL MED, V151, P665, DOI 10.1001/archpedi.1997.02170440027005; GARCIAGODOY F, 1994, J DENT RES, V73, P144; GINSBERG C, 1995, INTERPRETATION TRANS; Glazer ER, 1999, CANCER, V86, P1070, DOI 10.1002/(SICI)1097-0142(19990915)86:6<1070::AID-CNCR25>3.3.CO;2-0; GOLDMAN BA, 1994, TOXIC WASTES RACE RE, P1; Golova N, 1999, PEDIATRICS, V103, P993, DOI 10.1542/peds.103.5.993; GUENDELMAN S, 1986, MED CARE, V24, P925, DOI 10.1097/00005650-198610000-00006; HAHN BA, 1995, PEDIATRICS, V95, P727; Hayes RP, 1998, MED CARE, V36, P230, DOI 10.1097/00005650-199802000-00011; Herrera GA, 2001, AM J PREV MED, V20, P69, DOI 10.1016/S0749-3797(01)00277-X; *HLTH RES SERV ADM, 2001, NAT SAMPL SURV REG N; Kaste LM, 1999, J PUBLIC HEALTH DENT, V59, P198, DOI 10.1111/j.1752-7325.1999.tb03269.x; Keenan, 2000, Ann Epidemiol, V10, P459, DOI 10.1016/S1047-2797(00)00091-0; Komaromy M, 1996, NEW ENGL J MED, V334, P1305, DOI 10.1056/NEJM199605163342006; LANDERS SJ, 2002, DOCTORS RESENT BEING; Lara M, 2000, MED CARE, V38, P342, DOI 10.1097/00005650-200003000-00011; Lara M, 1999, WESTERN J MED, V170, P75; Ledogar RJ, 2000, AM J PUBLIC HEALTH, V90, P929, DOI 10.2105/AJPH.90.6.929; Libby DL, 1997, HEALTH AFFAIR, V16, P205, DOI 10.1377/hlthaff.16.4.205; London RF, 1999, JAMA-J AM MED ASSOC, V282, P875, DOI 10.1001/jama.282.9.875; MCLAURIN JA, 1999, AMBULATORY PEDIAT, P524; Mendoza FS, 1999, WESTERN J MED, V170, P85; MENDOZA FS, 1991, JAMA-J AM MED ASSOC, V265, P227, DOI 10.1001/jama.265.2.227; METZGER R, 1995, ENVIRON HEALTH PERSP, V103, P25, DOI 10.2307/3432340; MINES R, 1993, 4 US DEP LAB OFF PRO; MOTT L, 1995, ENVIRON HEALTH PERSP, V103, P33, DOI 10.2307/3432341; *NAT CTR ED STAT, 2002, DROP RAT US 1999; *NAT I DENT RES, 1989, US DHHS PUBL; National Museum of Gwangju, 2000, SCI FRONT DEV TOX RI, P1; Neufeld ND, 1998, DIABETES CARE, V21, P80, DOI 10.2337/diacare.21.1.80; Ng B, 1996, PSYCHOSOM MED, V58, P125, DOI 10.1097/00006842-199603000-00005; *OFF MAN BUDG, 2002, REP C ASS TOT BEN CO; PASKO T, 2001, PHYSICIAN CHARACTERI, P36; Perry M, 2000, MEDICAID CHILDREN OV; Pineda D A, 2000, Appl Neuropsychol, V7, P40, DOI 10.1207/S15324826AN0701_6; Prislin R, 1998, SOC SCI MED, V47, P1947, DOI 10.1016/S0277-9536(98)00336-0; Quintana JM, 1997, INT J QUAL HEALTH C, V9, P419, DOI 10.1093/intqhc/9.6.419; Ramos-Gomez Francisco J, 2002, J Clin Pediatr Dent, V26, P165; REYNOSO TC, 1993, J ADOLESCENT HEALTH, V14, P257, DOI 10.1016/1054-139X(93)90171-K; ROBERSON NL, 1994, CANCER, V74, P2687, DOI 10.1002/1097-0142(19941101)74:9+<2687::AID-CNCR2820741817>3.0.CO;2-B; RUBIOSTIPEC M, 1990, J ABNORM CHILD PSYCH, V18, P393, DOI 10.1007/BF00917642; RUMBERGER RW, 1987, REV EDUC RES, V57, P101, DOI 10.2307/1170232; Saha S, 1999, ARCH INTERN MED, V159, P997, DOI 10.1001/archinte.159.9.997; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; SOKOLKATZ JS, 1992, INT J ADDICT, V27, P1197, DOI 10.3109/10826089209047344; *STAT CAL DEP FIN, 2002, COUNT POP PROJ AG SE; Stoddard JJ, 2000, PEDIATRICS, V105, P27, DOI 10.1542/peds.105.1.27; Stone VE, 1997, J GEN INTERN MED, V12, P150, DOI 10.1046/j.1525-1497.1997.012003150.x; Stone VE, 1998, J ACQ IMMUN DEF SYND, V19, P245, DOI 10.1097/00042560-199811010-00006; Suminski RR, 1999, INT J OBESITY, V23, P823, DOI 10.1038/sj.ijo.0800933; SWANSON JW, 1992, J AM ACAD CHILD PSY, V31, P669, DOI 10.1097/00004583-199207000-00014; Trevino RP, 1999, DIABETES CARE, V22, P202, DOI 10.2337/diacare.22.2.202; *US CENS BUR, 2000, CURR POP SURV POP SE; *US CENS BUR, 2002, HLTH INS DET TABL 19; *US CENS BUR, 2002, POV STAT POP 1999 SE; *US CENS BUR, 2002, POV 1999 TABL A PEOP; *US CENS BUR, 2002, QT PL RAC HISP LAT A; *US DEP ED, 1998, NO MOR EXC FIN REP H; *US DHHS, 2002, MENT HLTH REP SURG G; *US DHHS, 1996, US DHHS PUBL; *US DHHS NAT I DEN, 2000, OR HLTH AM REP SURG; Ussery XT, 1996, PEDIATR INFECT DIS J, V15, P697, DOI 10.1097/00006454-199608000-00013; VELEZ CN, 1989, SOC SCI MED, V29, P779, DOI 10.1016/0277-9536(89)90158-5; VILLARRUEL AM, 1991, ADV NURS SCI, V14, P32, DOI 10.1097/00012272-199112000-00005; WASSERMAN RC, 1992, PEDIATRICS, V89, P834; Weidmer B, 1999, MED CARE, V37, pMS89, DOI 10.1097/00005650-199903001-00010; WENDROFF AP, 1990, NATURE, V347, P623, DOI 10.1038/347623a0; Wernette D.R., 1992, EPA J, V18, P16; *WK KELL FDN, 2002, BIG CAV DECR ENR MIN; WOOLFOLK M, 1984, J PUBLIC HEALTH DENT, V44, P101, DOI 10.1111/j.1752-7325.1984.tb03059.x; Zambrana R E, 1996, J Am Med Womens Assoc (1972), V51, P147; Zambrana RE, 2001, J HEALTH CARE POOR U, V12, P20; Zambrana RE, 2000, AM J PUBLIC HEALTH, V90, P1827, DOI 10.2105/AJPH.90.12.1827; 2002, EXECUTIVE ORDER IMPR	110	356	356	0	42	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	2002	288	1					82	90		10.1001/jama.288.1.82	http://dx.doi.org/10.1001/jama.288.1.82			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	568YW	12090866				2022-12-28	WOS:000176573400023
J	Miller, KD; Masur, H; Jones, EC; Joe, GO; Rick, ME; Kelly, GG; Mican, JM; Liu, SY; Gerber, LH; Blackwelder, WC; Falloon, J; Davey, RT; Polis, MA; Walker, RE; Lane, HC; Kovacs, JA				Miller, KD; Masur, H; Jones, EC; Joe, GO; Rick, ME; Kelly, GG; Mican, JM; Liu, SY; Gerber, LH; Blackwelder, WC; Falloon, J; Davey, RT; Polis, MA; Walker, RE; Lane, HC; Kovacs, JA			High prevalence of osteonecrosis of the femoral head in HIV-infected adults	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; SYSTEMIC-LUPUS-ERYTHEMATOSUS; AVASCULAR NECROSIS; VENOUS THROMBOSIS; ANTIPHOSPHOLIPID ANTIBODIES; RENAL-TRANSPLANTATION; ARTERIAL-DISEASE; RISK-FACTORS; BONE	Background: osteonecrosis has been reported to occur occasionally among HIV-infected patients. The diagnosis of symptomatic osteonecrosis of the hip in two of the authors' patients, together with reports from community physicians, raised a concern that the prevalence of osteonecrosis is increasing. Objective: To determine the prevalence of osteonecrosis of the hip in asymptomatic HIV-infected patients and to identify potential risk factors associated with osteonecrosis. Design: Survey and comparison study. Setting: The Clinical Center of the U.S. National Institutes of Health. Participants: 339 asymptomatic HIV-infected adults (of 364 asked to participate) and 118 age- and sex-matched HIV-negative volunteers enrolled between 1 June and 15 December 1999. Measurements: Osteonecrosis of the hip, as documented by magnetic resonance imaging. Data from clinic records and a patient questionnaire administered before magnetic resonance imaging were used in an analysis of risk factors. A subset of patients was evaluated for hypercoagulable state. Results: Fifteen (4.4% [95% Cl, 2.5% to 7.2%]) of 339 HIV-infected participants had osteonecrosis lesions on magnetic resonance imaging, and no HIV-negative participants had similar lesions. Among HIV-infected participants, osteonecrosis occurred more frequently in those who used systemic corticosteroids, lipid-lowering agents, or testosterone; those who exercised routinely by bodybuilding; and those who had detectable levels of anticardiolipin antibodies. Conclusions: Patients infected with HIV have an unexpectedly high occurrence of osteonecrosis of the hip. Although screening a-symptomatic patients is not warranted, HIV-infected patients with persistent groin or hip pain should be evaluated for this debilitating complication.	NIH, Ctr Clin, Bethesda, MD 20892 USA; NIAID, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kovacs, JA (corresponding author), NIH, Ctr Clin, Bldg 10,room 7D43,MSC1662, Bethesda, MD 20892 USA.	jkovacs@niaid.nih.gov	Kovacs, Joseph/AAU-6105-2021	Kovacs, Joseph/0000-0002-5191-9880; Polis, Michael/0000-0002-9151-2268; Gerber, Lynn/0000-0001-7525-680X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000865, ZIAAI000390, Z01AI000636, Z01AI000866, ZIAAI000636, ZIAAI000865, Z01AI000390] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL001159, Z01CL001159] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CLINICAL CENTER		Arruda VR, 1997, THROMB HAEMOSTASIS, V78, P1430; Arruda VR, 1997, THROMB HAEMOSTASIS, V77, P818; BELMONTE MA, 1993, J RHEUMATOL, V20, P1425; Blacksin MF, 1999, CLIN IMAG, V23, P314, DOI 10.1016/S0899-7071(99)00151-5; Blangy H, 2000, AIDS, V14, P2214, DOI 10.1097/00002030-200009290-00025; Bonfanti P, 2001, ORTHOPEDICS, V24, P271; Carr A, 2000, LANCET, V356, P1423, DOI 10.1016/S0140-6736(00)02854-3; CHANG CC, 1993, SEMIN ARTHRITIS RHEU, V23, P47, DOI 10.1016/S0049-0172(05)80026-5; CHEVALIER X, 1993, J BONE JOINT SURG BR, V75, P160, DOI 10.1302/0301-620X.75B1.8421018; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; Colwell CW, 1996, ORTHOPEDICS, V19, P941; CONE LA, 1996, 3 C RETR OPP INF 28; DETRUCHIS P, 1996, 11 INT C AIDS VANC B; Finazzi G, 1996, AM J MED, V100, P530, DOI 10.1016/S0002-9343(96)00060-5; Fink B, 1997, ARCH ORTHOP TRAUM SU, V116, P151, DOI 10.1007/BF00426064; FORDYCE MJF, 1993, J BONE JOINT SURG BR, V75, P365, DOI 10.1302/0301-620X.75B3.8496201; GALLANT JE, 1999, AIDS READ, V9, P602; GART JJ, 1988, BIOMETRICS, V44, P323, DOI 10.2307/2531848; GERSTER JC, 1991, J RHEUMATOL, V18, P300; Glueck CJ, 1997, CLIN ORTHOP RELAT R, P43; GONZALEZ LM, 1994, AN MED INTERNA, V11, P601; GOORNEY BP, 1990, GENITOURIN MED, V66, P451; GUERRA JJ, 1995, J BONE JOINT SURG AM, V77A, P616, DOI 10.2106/00004623-199504000-00017; Johns DG, 1999, AIDS, V13, P1997, DOI 10.1097/00002030-199910010-00036; Koeger AC, 1999, J RHEUMATOL, V26, P752; Koeger Anne Claude, 1995, Arthritis and Rheumatism, V38, pS199; Koller E, 2000, AIDS PATIENT CARE ST, V14, P405, DOI 10.1089/108729100416614; LAFFORGUE P, 1993, RADIOLOGY, V187, P199, DOI 10.1148/radiology.187.1.8451413; Llauger J, 1998, AM J ROENTGENOL, V171, P987, DOI 10.2214/ajr.171.4.9762981; MANKIN HJ, 1992, NEW ENGL J MED, V326, P1473; MARTINCRESPO R, 1992, 8 INT AIDS C AMST NE; MEHTA C, 1999, STATXACT 4 WINDOWS U; Meyer D, 1999, AIDS, V13, P1147, DOI 10.1097/00002030-199906180-00025; Mirzai R, 1999, J ASTHMA, V36, P77, DOI 10.3109/02770909909065152; Mirzai Ray, 1998, Comprehensive Therapy, V24, P251; MITCHELL DG, 1987, RADIOLOGY, V162, P709, DOI 10.1148/radiology.162.3.3809484; Monier P, 2000, CLIN INFECT DIS, V31, P1488, DOI 10.1086/317503; MONT MA, 1995, J BONE JOINT SURG AM, V77A, P459, DOI 10.2106/00004623-199503000-00018; Mont MA, 1997, J RHEUMATOL, V24, P654; Olive A, 1998, J RHEUMATOL, V25, P1243; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PATTON PR, 1988, SURGERY, V103, P63; Rademaker J, 1997, J RHEUMATOL, V24, P601; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; ROBINS J, 1986, BIOMETRICS, V42, P311, DOI 10.2307/2531052; Roudiere L, 2000, AIDS, V14, P2056, DOI 10.1097/00002030-200009080-00026; Sakamoto M, 1997, J BONE JOINT SURG BR, V79B, P213, DOI 10.1302/0301-620X.79B2.7179; Scribner AN, 2000, J ACQ IMMUN DEF SYND, V25, P19, DOI 10.1097/00126334-200009010-00003; Sighinolfi L, 2000, INFECTION, V28, P254, DOI 10.1007/s150100070049; SOLOMON G, 1991, RHEUM DIS CLIN N AM, V17, P43; Stovall D Jr, 1995, Am J Orthop (Belle Mead NJ), V24, P71; SUGANO N, 1994, CLIN ORTHOP RELAT R, P190; Sugano N, 1999, J BONE JOINT SURG BR, V81B, P590, DOI 10.1302/0301-620X.81B4.9393; TERVONEN O, 1992, RADIOLOGY, V182, P845, DOI 10.1148/radiology.182.3.1535906; TIMPONE J, 1999, 6 C RETR OPP INF CHI; Vande Berg B C, 1997, J Belge Radiol, V80, P243; Varis T, 2000, CLIN PHARMACOL THER, V68, P487, DOI 10.1067/mcp.2000.110772; YOUNG JL, 1996, PHYSICAL MED REHABIL, P783	58	138	151	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 2	2002	137	1					17	24		10.7326/0003-4819-137-1-200207020-00008	http://dx.doi.org/10.7326/0003-4819-137-1-200207020-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569VA	12093241				2022-12-28	WOS:000176622000003
J	Lorsch, JR				Lorsch, JR			RNA chaperones exist and DEAD box proteins get a life	CELL			English	Review							RIBOZYME; INTRON; MOTORS; CORE	The RNA chaperone hypothesis suggests the existence of proteins that resolve misfolded RNA structures in vivo. A recent study (Mohr et al., 2002) has found an RNA-dependent ATPase that functions in this manner.	Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Lorsch, JR (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.			Lorsch, Jon/0000-0002-4521-4999				Clodi E, 1999, EMBO J, V18, P3776, DOI 10.1093/emboj/18.13.3776; COETZEE T, 1994, GENE DEV, V8, P1575, DOI 10.1101/gad.8.13.1575; GRALLA J, 1974, NATURE, V248, P330, DOI 10.1038/248330a0; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; HERSCHLAG D, 1994, EMBO J, V13, P2913, DOI 10.1002/j.1460-2075.1994.tb06586.x; KARPEL RL, 1982, BIOCHEMISTRY-US, V21, P2102, DOI 10.1021/bi00538a019; Lambowitz AM., 1999, GROUP GROUP 2 RIBOZY, P451; MOHR G, 1992, CELL, V69, P483, DOI 10.1016/0092-8674(92)90449-M; MOHR G, 1994, NATURE, V370, P147, DOI 10.1038/370147a0; Mohr S, 2002, CELL, V109, P769, DOI 10.1016/S0092-8674(02)00771-7; PONTIUS BW, 1992, J BIOL CHEM, V267, P13815; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; Treiber DK, 2001, CURR OPIN STRUC BIOL, V11, P309, DOI 10.1016/S0959-440X(00)00206-2; Webb AE, 2001, J MOL BIOL, V309, P1087, DOI 10.1006/jmbi.2001.4714; Weeks KM, 1997, CURR OPIN STRUC BIOL, V7, P336, DOI 10.1016/S0959-440X(97)80048-6; WEEKS KM, 1995, CELL, V82, P221, DOI 10.1016/0092-8674(95)90309-7; Woodson SA, 2000, CELL MOL LIFE SCI, V57, P796, DOI 10.1007/s000180050042	19	123	129	0	3	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 28	2002	109	7					797	800		10.1016/S0092-8674(02)00804-8	http://dx.doi.org/10.1016/S0092-8674(02)00804-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	570KJ	12110176	Bronze			2022-12-28	WOS:000176657200002
J	Pratt, DW				Pratt, DW			Molecular dynamics: Biomolecules see the light	SCIENCE			English	Editorial Material							SPECTROSCOPY; CONFORMATION; CLUSTERS		Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Pratt, DW (corresponding author), Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA.							BALDESCHWIELER JD, 1960, J CHEM PHYS, V33, P1008, DOI 10.1063/1.1731324; BALDWIN RL, 1995, J BIOMOL NMR, V5, P103; Betancourt MR, 2002, J PHYS CHEM B, V106, P599, DOI 10.1021/jp012014c; COVELESKIE RA, 1985, J PHYS CHEM-US, V89, P645, DOI 10.1021/j100250a019; Dian BC, 2002, SCIENCE, V296, P2369, DOI 10.1126/science.1071563; DILL KA, 1997, NAT STRUCT BIOL, V4, P11; Dobson CM, 1998, ANGEW CHEM INT EDIT, V37, P868, DOI 10.1002/(SICI)1521-3773(19980420)37:7<868::AID-ANIE868>3.0.CO;2-H; EVANS DJF, COMMUNICATION; FLORIO GM, IN PRESS J AM CHEM S; Godfrey PD, 1996, J MOL STRUCT, V376, P65, DOI 10.1016/0022-2860(95)09065-7; Lednev IK, 2001, J AM CHEM SOC, V123, P2388, DOI 10.1021/ja003381p; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Robertson EG, 2001, PHYS CHEM CHEM PHYS, V3, P1, DOI 10.1039/b008225m; Sun LP, 2002, SCIENCE, V296, P875, DOI 10.1126/science.1068053; WINKLER JR, 1998, ACC CHEM RES, V31; Zwier TS, 2001, J PHYS CHEM A, V105, P8827, DOI 10.1021/jp011659+	16	14	14	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 28	2002	296	5577					2347	2348		10.1126/science.1073589	http://dx.doi.org/10.1126/science.1073589			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	567CE	12089431				2022-12-28	WOS:000176467200027
J	Constancia, M; Hemberger, M; Hughes, J; Dean, W; Ferguson-Smith, A; Fundele, R; Stewart, F; Kelsey, G; Fowden, A; Sibley, C; Reik, W				Constancia, M; Hemberger, M; Hughes, J; Dean, W; Ferguson-Smith, A; Fundele, R; Stewart, F; Kelsey, G; Fowden, A; Sibley, C; Reik, W			Placental-specific IGF-II is a major modulator of placental and fetal growth	NATURE			English	Article							MAMMALIAN DEVELOPMENT; MATERNAL-BEHAVIOR; POSTNATAL-GROWTH; MOUSE; GENE; H19; TRANSLATION; GESTATION; DELETION; REGION	Imprinted genes in mammals are expressed from only one of the parental chromosomes, and are crucial for placental development and fetal growth(1-4). The insulin-like growth factor II gene (Igf2) is paternally expressed in the fetus and placenta(5). Here we show that deletion from the Igf2 gene of a transcript (P0)(6,7) specifically expressed in the labyrinthine trophoblast of the placenta leads to reduced growth of the placenta, followed several days later by fetal growth restriction. The fetal to placental weight ratio is thus increased in the absence of the P0 transcript. We show that passive permeability for nutrients of the mutant placenta is decreased, but that secondary active placental amino acid transport is initially upregulated, compensating for the decrease in passive permeability. Later the compensation fails and fetal growth restriction ensues. Our study provides experimental evidence for imprinted gene action in the placenta that directly controls the supply of maternal nutrients to the fetus, and supports the genetic conflict theory of imprinting(8). We propose that the Igf2 gene, and perhaps other imprinted genes, control both the placental supply of, and the genetic demand for, maternal nutrients to the mammalian fetus.	Babraham Inst, Dev Genet Programme, Lab Dev Genet & Imprinting, Cambridge CB2 4AT, England; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England; Max Planck Inst Mol Genet, D-14195 Berlin, Germany	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Calgary; University of Cambridge; Max Planck Society	Constancia, M (corresponding author), Babraham Inst, Dev Genet Programme, Lab Dev Genet & Imprinting, Cambridge CB2 4AT, England.		Reik, Wolf/I-6794-2012; Ferguson-Smith, Anne C/G-7534-2011; Constancia, Miguel/F-6654-2013	Hemberger, Myriam/0000-0003-3332-6958; Constancia, Miguel/0000-0002-8976-1679; Dean, Wendy/0000-0001-9441-5044; Ferguson-Smith, Anne/0000-0002-7608-5894; Reik, Wolf/0000-0003-0216-9881; Kelsey, Gavin/0000-0002-9762-5634				Adam GIR, 1996, DEVELOPMENT, V122, P839; ATKINSON DE, 1991, AM J PHYSIOL, V261, pR1461, DOI 10.1152/ajpregu.1991.261.6.R1461; Burns JL, 2001, DEVELOPMENT, V128, P3819; Constancia M, 2000, NAT GENET, V26, P203, DOI 10.1038/79930; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; Duvillie B, 1997, P NATL ACAD SCI USA, V94, P5137, DOI 10.1073/pnas.94.10.5137; Ferguson-Smith AC, 2001, SCIENCE, V293, P1086, DOI 10.1126/science.1064020; Gardner RL, 1999, BIOL REPROD, V60, P190, DOI 10.1095/biolreprod60.1.190; Georgiades P, 2001, P NATL ACAD SCI USA, V98, P4522, DOI 10.1073/pnas.081540898; Godfrey K M, 2001, Public Health Nutr, V4, P611; GUILLEMOT F, 1995, NAT GENET, V9, P235, DOI 10.1038/ng0395-235; HILL DJ, 1990, EARLY HUM DEV, V21, P49, DOI 10.1016/0378-3782(90)90110-5; JOHNSON LW, 1988, AM J PHYSIOL, V254, pC773, DOI 10.1152/ajpcell.1988.254.6.C773; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; Lefebvre L, 1998, NAT GENET, V20, P163, DOI 10.1038/2464; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; Li LL, 1999, SCIENCE, V284, P330, DOI 10.1126/science.284.5412.330; MOORE T, 1991, TRENDS GENET, V7, P45, DOI 10.1016/0168-9525(91)90230-N; Moore T, 1997, P NATL ACAD SCI USA, V94, P12509, DOI 10.1073/pnas.94.23.12509; NEWELL S, 1994, MOL REPROD DEV, V39, P249, DOI 10.1002/mrd.1080390302; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; Ozanne SE, 1999, P NUTR SOC, V58, P615, DOI 10.1017/S0029665199000804; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Reik W, 2001, NOVART FDN SYMP, V237, P19, DOI 10.1002/0470846666.ch3; Sleutels F, 2000, CURR OPIN GENET DEV, V10, P229, DOI 10.1016/S0959-437X(00)00062-9; Sun FL, 1997, NATURE, V389, P809, DOI 10.1038/39797; Tilghman SM, 1999, CELL, V96, P185, DOI 10.1016/S0092-8674(00)80559-0; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0	30	756	796	2	97	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 27	2002	417	6892					945	948		10.1038/nature00819	http://dx.doi.org/10.1038/nature00819			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	566RC	12087403				2022-12-28	WOS:000176441200038
J	He, QY; Cheng, P; Yang, YH; Wang, LX; Gardner, KH; Liu, Y				He, QY; Cheng, P; Yang, YH; Wang, LX; Gardner, KH; Liu, Y			White collar-1, a DNA binding transcription factor and a light sensor	SCIENCE			English	Article							SIGNAL-TRANSDUCTION; NEUROSPORA-CRASSA; CIRCADIAN CLOCK; ESCHERICHIA-COLI; PAS PROTEIN; PHOTORECEPTOR; DOMAIN; ARABIDOPSIS; FREQUENCY; PHOSPHORYLATION	Blue light regulates many physiological processes in fungi, but their photoreceptors are not known. In Neurospora crassa, all light responses depend on the Per-Arnt-Sim (PAS) domain-containing transcription factor white collar-1 (wc-1). By removing the WC-1 light, oxygen, or voltage domain, a specialized PAS domain that binds flavin mononucleotide in plant phototropins, we show that light responses are abolished, including light entrainment of the circadian clock. However, the WC-1-mediated dark activation of frq remains normal in this mutant, and the circadian clock can be entrained by temperature. Furthermore, we demonstrate that the purified Neurospora WC-1-WC-2 protein complex is associated with stoichiometric amounts of the chromophore flavin-adenine dinucleotide. Together, these observations suggest that WC-1 is the blue-light photoreceptor for the circadian clock and other light responses in Neurospora.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Liu, Y (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		He, qiyang/GQA-4070-2022; Yang, Yuhong/A-6033-2013; Gardner, Kevin H./K-7802-2012; Gardner, Kevin/K-5493-2019; He, qiyang/AAT-5826-2021	Gardner, Kevin H./0000-0002-8671-2556; he, qiyang/0000-0003-3694-6036				ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; Ballario P, 1996, EMBO J, V15, P1650, DOI 10.1002/j.1460-2075.1996.tb00510.x; Bibikov SI, 2000, P NATL ACAD SCI USA, V97, P5830, DOI 10.1073/pnas.100118697; Briggs WR, 1999, ANNU REV CELL DEV BI, V15, P33, DOI 10.1146/annurev.cellbio.15.1.33; Cheng P, 2002, MOL CELL BIOL, V22, P517, DOI 10.1128/MCB.22.2.517-524.2002; Cheng P, 2001, P NATL ACAD SCI USA, V98, P7408, DOI 10.1073/pnas.121170298; Cheng P, 2001, EMBO J, V20, P101, DOI 10.1093/emboj/20.1.101; Christie JM, 1999, P NATL ACAD SCI USA, V96, P8779, DOI 10.1073/pnas.96.15.8779; Christie JM, 1998, SCIENCE, V282, P1698, DOI 10.1126/science.282.5394.1698; Collett MA, 2002, GENETICS, V160, P149; Crosson S, 2001, P NATL ACAD SCI USA, V98, P2995, DOI 10.1073/pnas.051520298; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Denault DL, 2001, EMBO J, V20, P109, DOI 10.1093/emboj/20.1.109; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; Froehlich AC, 2002, SCIENCE, V297, P815, DOI 10.1126/science.1073681; Garceau NY, 1997, CELL, V89, P469, DOI 10.1016/S0092-8674(00)80227-5; HE Q, UNPUB; Heintzen C, 2001, CELL, V104, P453, DOI 10.1016/S0092-8674(01)00232-X; HUENNEKENS FM, 1957, METHOD ENZYMOL, V3, P950, DOI 10.1016/S0076-6879(57)03484-9; Iseki M, 2002, NATURE, V415, P1047, DOI 10.1038/4151047a; LAKINTHOMAS PL, 1990, CRIT REV MICROBIOL, V17, P365, DOI 10.3109/10408419009114762; Linden H, 1997, EMBO J, V16, P98, DOI 10.1093/emboj/16.1.98; Liu Y, 1998, SCIENCE, V281, P825, DOI 10.1126/science.281.5378.825; Nelson DC, 2000, CELL, V101, P331, DOI 10.1016/S0092-8674(00)80842-9; Repik A, 2000, MOL MICROBIOL, V36, P806, DOI 10.1046/j.1365-2958.2000.01910.x; Salomon M, 2000, BIOCHEMISTRY-US, V39, P9401, DOI 10.1021/bi000585+; Sancar A, 2000, ANNU REV BIOCHEM, V69, P31, DOI 10.1146/annurev.biochem.69.1.31; Schwerdtfeger C, 2000, EUR J BIOCHEM, V267, P414, DOI 10.1046/j.1432-1327.2000.01016.x; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; Somers DE, 2000, CELL, V101, P319, DOI 10.1016/S0092-8674(00)80841-7; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Talora C, 1999, EMBO J, V18, P4961, DOI 10.1093/emboj/18.18.4961	34	332	351	3	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 2	2002	297	5582					840	843		10.1126/science.1072795	http://dx.doi.org/10.1126/science.1072795			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	579RZ	12098705				2022-12-28	WOS:000177192800052
J	Mezard, M; Parisi, G; Zecchina, R				Mezard, M; Parisi, G; Zecchina, R			Analytic and algorithmic solution of random satisfiability problems	SCIENCE			English	Article							OPTIMIZATION; COMPLEXITY	We study the satisfiability of random Boolean expressions built from many clauses with K variables per clause (K-satisfiability). Expressions with a ratio alpha of clauses to variables less than a threshold alpha(c) are almost always satisfiable, whereas those with a ratio above this threshold are almost always unsatisfiable. We show the existence of an intermediate phase below alpha(c), where the proliferation of metastable states is responsible for the onset of complexity in search algorithms. We introduce a class of optimization algorithms that can deal with these metastable states; one such algorithm has been tested successfully on the largest existing benchmark of K-satisfiability.	Lab Phys Theor & Modeles Stat, CNRS, F-91405 Orsay, France; Univ Paris 11, F-91405 Orsay, France; Univ Roma La Sapienza, Sez INFN, SMC, I-00185 Rome, Italy; Univ Roma La Sapienza, INFM, UdRM1, I-00185 Rome, Italy; Abdus Salaam Int Ctr Theoret Phys, I-34100 Trieste, Italy	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Gran Sasso Science Institute (GSSI); Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); Sapienza University Rome; Abdus Salam International Centre for Theoretical Physics (ICTP)	Zecchina, R (corresponding author), Lab Phys Theor & Modeles Stat, CNRS, Bat 100, F-91405 Orsay, France.	zecchina@ictp.trieste.it		ZECCHINA, Riccardo/0000-0002-1221-5207				ASPVALL B, 1979, INFORM PROCESS LETT, V8, P121, DOI 10.1016/0020-0190(79)90002-4; BENDAVID S, 1992, J COMPUT SYST SCI, V44, P193, DOI 10.1016/0022-0000(92)90019-F; Biroli G, 2000, EUR PHYS J B, V14, P551, DOI 10.1007/s100510051065; Bollobas B, 2001, RANDOM STRUCT ALGOR, V18, P201, DOI 10.1002/rsa.1006; Bouchaud JP, 1997, SPIN GLASSES RANDOM, P161; Chvatal V., 1992, Proceedings 33rd Annual Symposium on Foundations of Computer Science (Cat. No.92CH3188-0), P620, DOI 10.1109/SFCS.1992.267789; Cook SA, 1971, P 3 ANN ACM S THEOR, P151, DOI DOI 10.1145/800157.805047; Crawford JM, 1996, ARTIF INTELL, V81, P31, DOI 10.1016/0004-3702(95)00046-1; DUBOIS O, 2000, P 11 ACM SIAM S DISC, P124; DUBOIS O, 2001, THEORET COMP SCI, V265; Franz S, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.127209; Friedgut E, 1999, J AM MATH SOC, V12, P1017, DOI 10.1090/S0894-0347-99-00305-7; FU YT, 1986, J PHYS A-MATH GEN, V19, P1605, DOI 10.1088/0305-4470/19/9/033; Garey M.R., 1979, COMPUTERS INTRACTABI; GOERDT A, 1992, P 7 INT S MATH FDN C, P264; GUREVICH Y, 1991, J COMPUT SYST SCI, V42, P346, DOI 10.1016/0022-0000(91)90007-R; HOGG T, 1996, ARTIF INTELL, V81; KAPORIS A, IN PRESS P 10 EUR S; Kschischang FR, 2001, IEEE T INFORM THEORY, V47, P498, DOI 10.1109/18.910572; LEVIN LA, 1986, SIAM J COMPUT, V15, P285, DOI 10.1137/0215020; Martin OC, 2001, THEOR COMPUT SCI, V265, P3, DOI 10.1016/S0304-3975(01)00149-9; Mezard M, 2001, EUR PHYS J B, V20, P217, DOI 10.1007/PL00011099; Mezard M., 1987, WORLD SCI LECT NOT P, V9; MONASSON R, 1995, PHYS REV LETT, V75, P2847, DOI 10.1103/PhysRevLett.75.2847; SELMAN B, 1993, P DIMACS, P661; Talagrand M, 2000, PROBAB THEORY REL, V117, P303, DOI 10.1007/s004400050009	27	656	680	0	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 2	2002	297	5582					812	815		10.1126/science.1073287	http://dx.doi.org/10.1126/science.1073287			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	579RZ	12089451				2022-12-28	WOS:000177192800043
J	Bartels, RA; Paul, A; Green, H; Kapteyn, HC; Murnane, MM; Backus, S; Christov, IP; Liu, YW; Attwood, D; Jacobsen, C				Bartels, RA; Paul, A; Green, H; Kapteyn, HC; Murnane, MM; Backus, S; Christov, IP; Liu, YW; Attwood, D; Jacobsen, C			Generation of spatially coherent light at extreme ultraviolet wavelengths	SCIENCE			English	Article							HIGH-ORDER HARMONICS; SOFT X-RAYS; LASER; PHASE; INTERFEROMETRY; RADIATION; AMPLIFIER; EMISSION; DYNAMICS; PULSES	We present spatial coherence measurements of extreme ultraviolet (EUV) light generated through the process of high-harmonic up-conversion of a femtosecond laser. With a phase-matched hollow-fiber geometry, the generated beam was found to exhibit essentially full spatial coherence. The coherence of this laser-like EUV source was shown by recording Gabor holograms of small objects. This work demonstrates the capability to perform EUV holography with a tabletop experimental setup. Such an EUV source, with low divergence and high spatial coherence, can be used for experiments involving high-precision metrology, inspection of optical components for EUV lithography, and microscopy and holography with nanometer resolution. Furthermore, the short time duration of the EUV radiation ( a few femtoseconds) will enable EUV microscopy and holography to be performed with ultrahigh time resolution.	Univ Colorado, Dept Phys, Boulder, CO 80309 USA; Univ Colorado, Joint Inst Lab Astrophys, Boulder, CO 80309 USA; Natl Inst Stand & Technol, Boulder, CO 80309 USA; Univ Sofia, Dept Phys, BU-1126 Sofia, Bulgaria; Univ Calif Berkeley, Lawrence Berkeley Lab, Ctr Xray Opt, Berkeley, CA 94720 USA; SUNY Stony Brook, Dept Phys & Astron, Stony Brook, NY 11794 USA	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; National Institute of Standards & Technology (NIST) - USA; Bulgarian Academy of Sciences; University of Sofia; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Murnane, MM (corresponding author), Univ Colorado, Dept Phys, Boulder, CO 80309 USA.		Jacobsen, Chris Johnson/E-2827-2015; Kapteyn, Henry C/H-6559-2011; Backus, Sterling/C-2506-2008; Christov, Ivan P/D-4446-2014; Bartels, Randy/A-1217-2011	Jacobsen, Chris Johnson/0000-0001-8562-0353; Kapteyn, Henry C/0000-0001-8386-6317; Christov, Ivan P/0000-0002-9146-6708; Bartels, Randy/0000-0003-0530-0435				Andruszkow J, 2000, PHYS REV LETT, V85, P3825, DOI 10.1103/PhysRevLett.85.3825; Attwood D., 1999, SOFT X RAYS EXTREME; Backus S, 2001, OPT LETT, V26, P465, DOI 10.1364/OL.26.000465; Bartels R, 2000, NATURE, V406, P164, DOI 10.1038/35018029; Bartels RA, 2002, OPT LETT, V27, P707, DOI 10.1364/OL.27.000707; Chang ZH, 1997, PHYS REV LETT, V79, P2967, DOI 10.1103/PhysRevLett.79.2967; DASILVA LB, 1995, REV SCI INSTRUM, V66, P574, DOI 10.1063/1.1146289; Descamps D, 2000, OPT LETT, V25, P135, DOI 10.1364/OL.25.000135; Ditmire T, 1996, PHYS REV LETT, V77, P4756, DOI 10.1103/PhysRevLett.77.4756; Drescher M, 2001, SCIENCE, V291, P1923, DOI 10.1126/science.1058561; Durfee CG, 1999, PHYS REV LETT, V83, P2187, DOI 10.1103/PhysRevLett.83.2187; FRIBERG AT, 1995, OPT LETT, V20, P623, DOI 10.1364/OL.20.000623; GABOR D, 1948, NATURE, V161, P777, DOI 10.1038/161777a0; Goldberg KA, 1998, J VAC SCI TECHNOL B, V16, P3435, DOI 10.1116/1.590498; KULANDER KC, 1993, NATO ADV SCI INST SE, V316, P95, DOI 10.1007/978-1-4615-7963-2_10; Lee SH, 2001, APPL OPTICS, V40, P2655, DOI 10.1364/AO.40.002655; LEITH E, 1977, APPL OPTICS, V16, P2565, DOI 10.1364/AO.16.002565; LEWENSTEIN M, 1995, PHYS REV A, V52, P4747, DOI 10.1103/PhysRevA.52.4747; LEWENSTEIN M, 1994, PHYS REV A, V49, P2117, DOI 10.1103/PhysRevA.49.2117; LHUILLIER A, 1991, PHYS REV LETT, V66, P2200, DOI 10.1103/PhysRevLett.66.2200; Lindaas S, 1996, J OPT SOC AM A, V13, P1788, DOI 10.1364/JOSAA.13.001788; Macchietto CD, 1999, OPT LETT, V24, P1115, DOI 10.1364/OL.24.001115; Marconi MC, 2000, PHYS REV E, V62, P7209, DOI 10.1103/PhysRevE.62.7209; MATTHEWS DL, 1985, PHYS REV LETT, V54, P110, DOI 10.1103/PhysRevLett.54.110; MCPHERSON A, 1987, J OPT SOC AM B, V4, P595, DOI 10.1364/JOSAB.4.000595; Rundquist A, 1998, SCIENCE, V280, P1412, DOI 10.1126/science.280.5368.1412; Salieres P, 1996, J PHYS B-AT MOL OPT, V29, P4771, DOI 10.1088/0953-4075/29/20/027; SALIERES P, 1995, PHYS REV LETT, V74, P3776, DOI 10.1103/PhysRevLett.74.3776; SCHNARS U, 1994, APPL OPTICS, V33, P4373, DOI 10.1364/AO.33.004373; THOMPSON B, 1957, J OPT SOC AM, V46, P895	30	318	325	5	109	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 19	2002	297	5580					376	378		10.1126/science.1071718	http://dx.doi.org/10.1126/science.1071718			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574LV	12130779	Green Submitted			2022-12-28	WOS:000176892600044
J	Chenn, A; Walsh, CA				Chenn, A; Walsh, CA			Regulation of cerebral cortical size by control of cell cycle exit in neural precursors	SCIENCE			English	Article							BETA-CATENIN; MICE LACKING; EXPRESSION; BRAIN; MORPHOGENESIS; HYPERPLASIA; EVOLUTION; EXPANSION; DELETION; POLARITY	Transgenic mice expressing a stabilized beta-catenin in neural precursors develop enlarged brains with increased cerebral cortical surface area and folds resembling sulci and gyri of higher mammals. Brains from transgenic animals have enlarged lateral ventricles lined with neuroepithelial precursor cells, reflecting an expansion of the precursor population. Compared with wild-type precursors, a greater proportion of transgenic precursors reenter the cell cycle after mitosis. These results show that beta-catenin can function in the decision of precursors to proliferate or differentiate during mammalian neuronal development and suggest that beta-catenin can regulate cerebral cortical size by controlling the generation of neural precursor cells.	Beth Israel Deaconess Med Ctr, Dept Neurol, Div Neurogenet, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital	Walsh, CA (corresponding author), Beth Israel Deaconess Med Ctr, Dept Neurol, Div Neurogenet, Boston, MA 02115 USA.	cwalsh@caregroup.harvard.edu		Walsh, Christopher/0000-0002-0156-2238	NINDS NIH HHS [R01NS32457] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032457] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson SA, 2001, DEVELOPMENT, V128, P353; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; Barton RA, 2000, NATURE, V405, P1055, DOI 10.1038/35016580; Berger UV, 2001, J COMP NEUROL, V433, P101, DOI 10.1002/cne.1128; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Brault V, 2001, DEVELOPMENT, V128, P1253; BULFONE A, 1995, NEURON, V15, P63, DOI 10.1016/0896-6273(95)90065-9; Butz S, 1995, CELL ADHES COMMUN, V3, P337, DOI 10.3109/15419069509081018; CAVINESS VS, 1995, TRENDS NEUROSCI, V18, P379, DOI 10.1016/0166-2236(95)93933-O; Cho EA, 1998, MECH DEVELOP, V77, P9; Clark DA, 2001, NATURE, V411, P189, DOI 10.1038/35075564; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; Cox RT, 1996, J CELL BIOL, V134, P133, DOI 10.1083/jcb.134.1.133; DISALVO CV, 1995, CELL PROLIFERAT, V28, P511, DOI 10.1111/j.1365-2184.1995.tb00089.x; ELIAS H, 1969, SCIENCE, V166, P111, DOI 10.1126/science.166.3901.111; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FINLAY BL, 1995, SCIENCE, V268, P1578, DOI 10.1126/science.7777856; Galceran J, 2000, DEVELOPMENT, V127, P469; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HAUG H, 1987, AM J ANAT, V180, P126, DOI 10.1002/aja.1001800203; Huang HT, 2000, AM J PATHOL, V156, P433, DOI 10.1016/S0002-9440(10)64747-5; Kee N, 2002, J NEUROSCI METH, V115, P97, DOI 10.1016/S0165-0270(02)00007-9; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kuan CY, 2000, TRENDS NEUROSCI, V23, P291, DOI 10.1016/S0166-2236(00)01581-2; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Lee SMK, 2000, DEVELOPMENT, V127, P457; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Mountcastle VB, 1997, BRAIN, V120, P701, DOI 10.1093/brain/120.4.701; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Ohtsuka T, 2001, J BIOL CHEM, V276, P30467, DOI 10.1074/jbc.M102420200; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; OOSTERWEGEL M, 1993, DEVELOPMENT, V118, P439; PARR BA, 1993, DEVELOPMENT, V119, P247; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1995, TRENDS NEUROSCI, V18, P383, DOI 10.1016/0166-2236(95)93934-P; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Takahashi T, 1996, J NEUROSCI, V16, P6183; van de Water S, 2001, DEVELOPMENT, V128, P3877; VanEssen DC, 1997, NATURE, V385, P313, DOI 10.1038/385313a0; Yaworsky PJ, 1999, DEV BIOL, V205, P309, DOI 10.1006/dbio.1998.9035	43	1105	1159	1	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 19	2002	297	5580					365	369		10.1126/science.1074192	http://dx.doi.org/10.1126/science.1074192			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	574LV	12130776				2022-12-28	WOS:000176892600041
J	Cohen, P; Miyazaki, M; Socci, ND; Hagge-Greenberg, A; Liedtke, W; Soukas, AA; Sharma, R; Hudgins, LC; Ntambi, JM; Friedman, JM				Cohen, P; Miyazaki, M; Socci, ND; Hagge-Greenberg, A; Liedtke, W; Soukas, AA; Sharma, R; Hudgins, LC; Ntambi, JM; Friedman, JM			Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss	SCIENCE			English	Article							FATTY-ACID OXIDATION; GENE-EXPRESSION; OBESE GENE; OB PROTEIN; MICE; MOUSE; BIOSYNTHESIS; CHOLESTEROL; DEFICIENCY; METABOLISM	Leptin elicits a metabolic response that cannot be explained by its anorectic effects alone. To examine the mechanism underlying leptin's metabolic actions, we used transcription pro ling to identify leptin-regulated genes in ob/ob liver. Leptin was found to specifically repress RNA levels and enzymatic activity of hepatic stearoyl-CoA desaturase-1 (SCD-1), which catalyzes the biosynthesis of monounsaturated fatty acids. Mice lacking SCD-1 were lean and hypermetabolic. ob/ob mice with mutations in SCD-1 were significantly less obese than ob/ob controls and had markedly increased energy expenditure. ob/ob mice with mutations in SCD-1 had histologically normal livers with significantly reduced triglyceride storage and VLDL ( very low density lipoprotein) production. These findings suggest that down-regulation of SCD-1 is an important component of leptin's metabolic actions.	Rockefeller Univ, Mol Genet Lab, New York, NY 10021 USA; Rockefeller Univ, Ctr Studies Phys & Biol, New York, NY 10021 USA; Rockefeller Univ, Rogosin Inst, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA	Rockefeller University; Rockefeller University; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Friedman, JM (corresponding author), Rockefeller Univ, Mol Genet Lab, 1230 York Ave, New York, NY 10021 USA.		Liedtke, Wolfgang/GNH-1878-2022; Liedtke, Wolfgang B/G-4633-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041096] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK41096] Funding Source: Medline; NIGMS NIH HHS [GM07739] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; ASILMAZ E, UNPUB; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Cohen P, 2001, J CLIN INVEST, V108, P1113, DOI 10.1172/JCI200113914; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; Ferrante AW, 2001, DIABETES, V50, P2268, DOI 10.2337/diabetes.50.10.2268; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; GATES AH, 1965, SCIENCE, V148, P1471, DOI 10.1126/science.148.3676.1471; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Kamohara S, 1997, NATURE, V389, P374, DOI 10.1038/38717; Levin N, 1996, P NATL ACAD SCI USA, V93, P1726, DOI 10.1073/pnas.93.4.1726; Liang CP, 2001, J BIOL CHEM, V276, P49066, DOI 10.1074/jbc.M107250200; LUNZER MA, 1977, J BIOL CHEM, V252, P5483; MCGARRY JD, 1977, J CLIN INVEST, V60, P265, DOI 10.1172/JCI108764; Merkel M, 1998, J CLIN INVEST, V102, P893, DOI 10.1172/JCI2912; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Miyazaki M, 2001, J NUTR, V131, P2260, DOI 10.1093/jn/131.9.2260; Miyazaki M, 2000, J BIOL CHEM, V275, P30132, DOI 10.1074/jbc.M005488200; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; Ntambi JM, 1999, J LIPID RES, V40, P1549; Oral EA, 2002, NEW ENGL J MED, V346, P570, DOI 10.1056/NEJMoa012437; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Soukas A, 2000, GENE DEV, V14, P963; VOLPE JJ, 1976, PHYSIOL REV, V56, P339, DOI 10.1152/physrev.1976.56.2.339; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zheng Y, 1999, NAT GENET, V23, P268, DOI 10.1038/15446	27	603	653	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 12	2002	297	5579					240	243		10.1126/science.1071527	http://dx.doi.org/10.1126/science.1071527			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571UT	12114623				2022-12-28	WOS:000176738100038
J	Brunet, M; Guy, F; Pilbeam, D; Mackaye, HT; Likius, A; Ahounta, D; Beauvilain, A; Blondel, C; Bocherens, H; Boisserie, JR; De Bonis, L; Coppens, Y; Dejax, J; Denys, C; Duringer, P; Eisenmann, VR; Fanone, G; Fronty, P; Geraads, D; Lehmann, T; Lihoreau, F; Louchart, A; Mahamat, A; Merceron, G; Mouchelin, G; Otero, O; Campomanes, PP; De Leon, MP; Rage, JC; Sapanet, M; Schuster, M; Sudre, J; Tassy, P; Valentin, X; Vignaud, P; Viriot, L; Zazzo, A; Zollikofer, C				Brunet, M; Guy, F; Pilbeam, D; Mackaye, HT; Likius, A; Ahounta, D; Beauvilain, A; Blondel, C; Bocherens, H; Boisserie, JR; De Bonis, L; Coppens, Y; Dejax, J; Denys, C; Duringer, P; Eisenmann, VR; Fanone, G; Fronty, P; Geraads, D; Lehmann, T; Lihoreau, F; Louchart, A; Mahamat, A; Merceron, G; Mouchelin, G; Otero, O; Campomanes, PP; De Leon, MP; Rage, JC; Sapanet, M; Schuster, M; Sudre, J; Tassy, P; Valentin, X; Vignaud, P; Viriot, L; Zazzo, A; Zollikofer, C			A new hominid from the Upper Miocene of Chad, central Africa	NATURE			English	Article							AUSTRALOPITHECUS-AFARENSIS; LUKEINO; HADAR; SKULL	The search for the earliest fossil evidence of the human lineage has been concentrated in East Africa. Here we report the discovery of six hominid specimens from Chad, central Africa, 2,500 km from the East African Rift Valley. The fossils include a nearly complete cranium and fragmentary lower jaws. The associated fauna suggest the fossils are between 6 and 7 million years old. The fossils display a unique mosaic of primitive and derived characters, and constitute a new genus and species of hominid. The distance from the Rift Valley, and the great antiquity of the fossils, suggest that the earliest members of the hominid clade were more widely distributed than has been thought, and that the divergence between the human and chimpanzee lineages was earlier than indicated by most molecular studies.	Univ Poitiers, Fac Sci, 40 Ave Recteur Pineau, F-86022 Poitiers, France; Univ Poitiers, CNRS, UMR 6046, F-86022 Poitiers, France; Harvard Univ, Peabody Museum, Cambridge, MA 02138 USA; Univ NDjamena, Ndjamena, Chad; Ctr Natl Appui Rech, Ndjamena, Chad; Univ Montpellier 2, Inst Sci Evolut, CNRS, UMR 5554, F-34095 Montpellier 5, France; Coll France, F-75005 Paris, France; Museum Natl Hist Nat, F-75005 Paris, France; CNRS, UMR 8569, F-75005 Paris, France; Univ Strasbourg, Ctr Geochem Surface, CNRS, UMR 7517, F-67084 Strasbourg, France; CNRS, UPR 2147, F-75014 Paris, France; Univ Lyon 1, Ctr Sci Terre, CNRS, UMR 5125, F-69622 Villeurbanne, France; CSIC, Museo Nacl Ciencias Nat, E-28006 Madrid, Spain; Univ Zurich Irchel, Inst Anthropol, Multimedia Lab, CH-8057 Zurich, Switzerland; Ctr Hosp Univ Poitiers, F-86021 Poitiers, France; Univ Paris 06, CNRS, UMR 162, F-75252 Paris 05, France; Univ Paris 06, Inst Natl Rech Agron, F-75252 Paris 05, France	Universite de Poitiers; Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers; Harvard University; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Institut de Recherche pour le Developpement (IRD); Universite de Montpellier; UDICE-French Research Universities; PSL Research University Paris; College de France; Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Museo Nacional de Ciencias Naturales (MNCN); University of Zurich; CHU Poitiers; Universite de Poitiers; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; INRAE; UDICE-French Research Universities; Sorbonne Universite	Brunet, M (corresponding author), Univ Poitiers, Fac Sci, 40 Ave Recteur Pineau, F-86022 Poitiers, France.	michel.brunet@univ-poitiers.fr	Merceron, Gildas/C-8648-2012; Blondel, cecile/AAH-2618-2022; Otero, Olga/T-5467-2018; zazzo, Antoine/H-1697-2011; BOCHERENS, Hervé/F-3580-2011; Peláez-Campomanes, Pablo/G-4561-2010; Lund, Laura/H-7335-2012; Blondel, cecile/AEY-9166-2022; Lihoreau, Fabrice/C-6671-2015; Geraads, Denis/AAY-6051-2020; Denys, Christiane/K-8144-2019; GERAADS, Denis/AAC-7241-2021	Merceron, Gildas/0000-0001-5777-7126; Otero, Olga/0000-0002-8129-2054; zazzo, Antoine/0000-0001-7608-2207; BOCHERENS, Hervé/0000-0002-0494-0126; Peláez-Campomanes, Pablo/0000-0002-6551-1026; Blondel, cecile/0000-0002-7022-6959; Lihoreau, Fabrice/0000-0002-4327-5341; Denys, Christiane/0000-0002-1519-1546; GERAADS, Denis/0000-0003-2475-8011; Schuster, Mathieu/0000-0002-4412-8685; Louchart, Antoine/0000-0003-3847-6007; Viriot, Laurent/0000-0003-2092-588X; GUY, Franck/0000-0001-7032-7963				[Anonymous], [No title captured]; Brunet M, 1996, CR ACAD SCI II A, V322, P907; Dart RA, 1925, NATURE, V115, P195, DOI 10.1038/115195a0; DEBONIS L, 1993, J HUM EVOL, V24, P469, DOI 10.1006/jhev.1993.1032; Deino AL, 2002, J HUM EVOL, V42, P117, DOI 10.1006/jhev.2001.0521; Haile-Selassie Y, 2001, NATURE, V412, P178, DOI 10.1038/35084063; Ishida H, 1997, CR ACAD SCI II A, V325, P823, DOI 10.1016/S1251-8050(97)82762-0; KIMBEL WH, 1994, NATURE, V368, P449, DOI 10.1038/368449a0; KIMBEL WH, 1984, AM J PHYS ANTHROPOL, V64, P337, DOI 10.1002/ajpa.1330640403; Kimbel WH, 1997, AM J PHYS ANTHROPOL, V103, P235, DOI 10.1002/(SICI)1096-8644(199706)103:2<235::AID-AJPA8>3.3.CO;2-V; Kordos L, 2001, J HUM EVOL, V41, P689, DOI 10.1006/jhev.2001.0523; KORTLANDT A, 1972, NEW PERSPECTIVES APE, P9; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; LEAKEY MG, 1995, NATURE, V376, P565, DOI 10.1038/376565a0; Leakey MG, 2001, NATURE, V410, P433, DOI 10.1038/35068500; Lockwood CA, 1999, AM J PHYS ANTHROPOL, V108, P97, DOI 10.1002/(SICI)1096-8644(199901)108:1<97::AID-AJPA6>3.0.CO;2-O; Lockwood CA, 2000, J HUM EVOL, V39, P23, DOI 10.1006/jhev.2000.0401; McDougall I, 1999, J GEOL SOC LONDON, V156, P731, DOI 10.1144/gsjgs.156.4.0731; PILBEAM D, 1982, NATURE, V295, P232, DOI 10.1038/295232a0; Pilbeam DR, 2002, CAM S BIO EVOL ANTHR, V33, P303; Senut B, 2001, CR ACAD SCI II A, V332, P137, DOI 10.1016/S1251-8050(01)01529-4; Tobias P. V., 1967, CRANIUM MAXILLARY DE; Uchida A., 1992, THESIS HARVARD U; Vignaud P, 2002, NATURE, V418, P152, DOI 10.1038/nature00880; Ward CV, 2001, J HUM EVOL, V41, P255, DOI 10.1006/jhev.2001.0507; WHITE TD, 1994, NATURE, V371, P306, DOI 10.1038/371306a0; Wood B., 1991, HOMINID CRANIAL REMA, V4	28	633	667	3	125	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 11	2002	418	6894					145	151		10.1038/nature00879	http://dx.doi.org/10.1038/nature00879			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	571GV	12110880	Green Published			2022-12-28	WOS:000176710400030
J	Carr, A; Workman, C; Smith, DE; Hoy, J; Hudson, J; Doong, N; Martin, A; Amin, J; Freund, J; Law, M; Cooper, DA				Carr, A; Workman, C; Smith, DE; Hoy, J; Hudson, J; Doong, N; Martin, A; Amin, J; Freund, J; Law, M; Cooper, DA		MITOX Study Grp	Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROTEASE INHIBITOR INDINAVIR; ANTIRETROVIRAL THERAPY; INSULIN-RESISTANCE; OPEN-LABEL; LIPODYSTROPHY; INFECTION; FAT; COHORT; DIFFERENTIATION; HYPERLIPIDEMIA	Context Peripheral lipoatrophy may complicate antiretroviral therapy of human immunodeficiency virus (HIV) infection, often related to duration and type of nucleoside analog therapy, and may have a mitochondrial pathogenesis. No proven therapy exists for lipoatrophy, but abacavir is a nucleoside analog that may be less toxic to mitochondria. Objective To determine if substitution of stavudine orzidovudine with abacavir improves HIV lipoatrophy without affecting control of HIV replication. Design Randomized, open-label 24-week study. Setting Seventeen hospital HIV outpatient clinics and primary care centers in Australia and England, with randomization from June 2000 through January 2001. Participants A total of 111 adults (109 men) with moderate or severe lipoatrophy who were receiving stavudine (n=85) or zidovudine (n=26) and had stable plasma HIV RNA levels below 400 copies/mL and no prior abacavir therapy. Intervention Patients were randomly assigned to switch from stavudine orzidovudine to abacavir, 300 mg twice per day, while continuing all other antiretroviral therapy (n=54) or to continue all antiretroviral therapy (n=57). Main Outcome Measures The primary end point was limb fat mass, measured by dual-energy x-ray absorptiometry; key secondary end points were plasma HIV RNA levels, adverse events, physician-assessed (via subjective measures) lipodystrophy severity, total and central fat mass, and fasting metabolic (lipid, glycemic, and lactate) levels. Results There was a significant increase in limb fat in the abacavir group relative to the stavudine/zidovudine group (0.39 vs 0.08 kg; mean difference, 0.31; 95% confidence interval [CI], 0.06-0.57 kg), as well as significant relative increases in subcutaneous thigh (P=.01), arm (P<.001), and abdominal (P=.001) fat areas on computed tomography. Switching had no significant effect on secondary end points, including plasma HIV RNA (for unadjusted comparison between groups,at week 24, odds ratio, 1.38; 95% Cl, 0.48-3.96). Change in limb fat mass at week 24 did not correlate with change in subjectively determined perceived lipoatrophy Severity (r=-0.06; P=.53 by Spearman correlation). Hypersensitivity to abacavir was seen in 5 patients (10%). Conclusions In this sample of lipoatrophic HIV-infected adults, switching from stavudine or zidovudine to abacavir for 24 weeks led to significant, albeit modest, objectively measured increases in limb fat. Clinical lipoatrophy, as assessed subjectively, did not resolve, however, and at the rate of increase observed may take years to resolve with use of this strategy. Longer-term follow-up is needed.	St Vincents Hosp, HIV Immunol & Infect Dis Clin Serv Unit, Sydney, NSW 2010, Australia; Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, AIDS Res Initiat, Sydney, NSW, Australia; Burwood Rd Med Ctr, Sydney, NSW, Australia; Alfred Hosp, Melbourne, Vic, Australia; Monash Univ, Melbourne, Vic 3004, Australia	St Vincents Hospital Sydney; University of New South Wales Sydney; Kirby Institute; Florey Institute of Neuroscience & Mental Health; Monash University	Carr, A (corresponding author), St Vincents Hosp, HIV Immunol & Infect Dis Clin Serv Unit, Sydney, NSW 2010, Australia.		Hoy, Jennifer/AAK-7968-2020	Hoy, Jennifer/0000-0002-6948-7086; Law, Matthew/0000-0002-3540-8837; Amin, Janaki/0000-0003-2161-9366; Martin, Allison/0000-0001-6065-1188				Arioglu E, 2000, ANN INTERN MED, V133, P263, DOI 10.7326/0003-4819-133-4-200008150-00009; Caron M, 2001, DIABETES, V50, P1378, DOI 10.2337/diabetes.50.6.1378; Carr A, 2000, AIDS, V14, P1171, DOI 10.1097/00002030-200006160-00014; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Carr A, 2000, AIDS, V14, pF25, DOI 10.1097/00002030-200002180-00001; Carr A, 2001, AIDS, V15, P1811, DOI 10.1097/00002030-200109280-00010; Carr A, 2000, LANCET, V356, P1423, DOI 10.1016/S0140-6736(00)02854-3; Cooper D, 1999, LANCET, V353, P2061, DOI 10.1016/S0140-6736(98)10391-4; Duran S, 2001, AIDS, V15, P2441, DOI 10.1097/00002030-200112070-00012; Gervasoni C, 1999, AIDS, V13, P465, DOI 10.1097/00002030-199903110-00004; Hetherington S, 2001, CLIN THER, V23, P1603, DOI 10.1016/S0149-2918(01)80132-6; Johnson AA, 2001, J BIOL CHEM, V276, P40847, DOI 10.1074/jbc.M106743200; Kind P, 1998, BMJ-BRIT MED J, V316, P736, DOI 10.1136/bmj.316.7133.736; Kotler DP, 1999, J ACQ IMMUN DEF SYND, V20, P228, DOI 10.1097/00042560-199903010-00003; Lenhard JM, 2000, BIOCHEM PHARMACOL, V59, P1063, DOI 10.1016/S0006-2952(00)00246-X; Lichtenstein KA, 2001, AIDS, V15, P1389, DOI 10.1097/00002030-200107270-00008; Lo JC, 1998, LANCET, V351, P867, DOI 10.1016/S0140-6736(97)11443-X; Madge S, 1999, AIDS, V13, P735, DOI 10.1097/00002030-199904160-00020; Mallal SA, 2000, AIDS, V14, P1309, DOI 10.1097/00002030-200007070-00002; Martinez E, 2001, LANCET, V357, P592, DOI 10.1016/S0140-6736(00)04056-3; Miller KD, 1998, LANCET, V351, P871, DOI 10.1016/S0140-6736(97)11518-5; PARKER RA, 2000, 2 INT WORKSH ADV DRU; Saint-Marc T, 1999, AIDS, V13, P1659, DOI 10.1097/00002030-199909100-00009; Saint-Marc T, 1999, AIDS, V13, P2188, DOI 10.1097/00002030-199910220-00035; SHUKURNA CM, 2001, AIDS, V15, P1801; Smith D, 2000, AIDS CARE, V12, P41, DOI 10.1080/09540120047459; SMITH D, 2001, 1 INT C AIDS PATH TR; Thiebaut R, 2000, CLIN INFECT DIS, V31, P1482, DOI 10.1086/317477; *US DEP HHS, 2002, GUID US ANT AG HIV I; WHITE A, 2000, 2 INT WORKSH ADV DRU; Zhang B, 1999, J CLIN ENDOCR METAB, V84, P4274, DOI 10.1210/jc.84.11.4274	32	243	245	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	2002	288	2					207	215		10.1001/jama.288.2.207	http://dx.doi.org/10.1001/jama.288.2.207			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	571HC	12095385	Bronze			2022-12-28	WOS:000176711100021
J	Stover, J; Walker, N; Garnett, GP; Salomon, JA; Stanecki, KA; Ghys, PD; Grassly, NC; Anderson, RM; Schwartlander, B				Stover, J; Walker, N; Garnett, GP; Salomon, JA; Stanecki, KA; Ghys, PD; Grassly, NC; Anderson, RM; Schwartlander, B			Can we reverse the HIV/AIDS pandemic with an expanded response?	LANCET			English	Article							INJECTING DRUG-USERS; HIV RISK BEHAVIOR; EXCHANGE PROGRAMS; IMPACT; SEROCONVERSION	HIV/AIDS has reached pandemic proportions, and is one of the leading causes of death worldwide. In 2001, the Declaration of Commitment on HIV/AIDS set out several alms with respect to reducing the effect and spread of HIV/AIDS, and an expanded response In low-income and middle-income countries was initiated. Here we examine the potential effect of the expanded global response based on analyses of epidemiological data, of mathematical models of HIV-1 transmission, and a review of the impact of prevention interventions on risk behaviours. Analyses suggest that If the successes achieved in some countries in prevention of transmission can be expanded to a global scale by 2005, about 29 million new Infections could be prevented by 2010.	Futures Grp Int, Glastonbury, CT 06033 USA; UNAIDS, Joint UN Programme HIV AIDS, Geneva, Switzerland; Univ London Imperial Coll Sci Technol & Med, London, England; WHO, CH-1211 Geneva, Switzerland; US Bur Census, Washington, DC 20233 USA	UNAIDS; Imperial College London; World Health Organization	Stover, J (corresponding author), Futures Grp Int, Glastonbury, CT 06033 USA.		Garnett, Geoffrey P/A-9312-2008; Grassly, Nicholas C/C-6381-2008; Salomon, Joshua A/D-3898-2009; Salomon, Joshua/S-1929-2019	Grassly, Nicholas C/0000-0001-6067-4507; Salomon, Joshua A/0000-0003-3929-5515; Salomon, Joshua/0000-0003-3929-5515; Anderson, Roy/0000-0002-9528-3175				Artzrouni M, 2002, AIDS, V16, pW1; BERKMAN A, 2001, AM J PUBLIC HEALTH, V91, P9; BLUMENTHAL RN, 2000, AIDS, V14, P605; BOLLINGER L, 2002, GOALS IMPACT MATRIX; FERGUSON NM, NIMH AIDS STRATEGIC; Gibson DR, 1999, AIDS, V13, P1807, DOI 10.1097/00002030-199910010-00002; Gibson DR, 2001, AIDS, V15, P1329, DOI 10.1097/00002030-200107270-00002; Grassly NC, 2001, B WORLD HEALTH ORGAN, V79, P1121; Jenkins C, 2001, AIDS EDUC PREV, V13, P452, DOI 10.1521/aeap.13.5.452.24141; Rehle TM, 1998, AIDS, V12, pS27; ROWLEY JT, 1994, AIDS, V8, P539, DOI 10.1097/00002030-199404000-00019; Schwartlander B, 2001, SCIENCE, V292, P2434, DOI 10.1126/science.1062876; STOVER J, 2001, GOALS MODEL ESTIMATI; *UNAIDS WHO, 2002, AIDS EP UPD DEC 2001; United Nations, 2001, DECL COMM HIV AIDS G; van Ameijden EJC, 1998, AIDS, V12, P625, DOI 10.1097/00002030-199806000-00012; WEINSTEIN MC, 1989, CONFRONTING AIDS SEX, P471; 2001, HIV AIDS SURVEILLANC	18	119	121	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 6	2002	360	9326					73	77		10.1016/S0140-6736(02)09339-X	http://dx.doi.org/10.1016/S0140-6736(02)09339-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569JR	12114060				2022-12-28	WOS:000176599700029
J	Brittain, SD; Rettig, TW				Brittain, SD; Rettig, TW			CO and H-3(+) in the protoplanetary disk around the star HD141569	NATURE			English	Article							HERBIG AE/BE STARS; CIRCUMSTELLAR DISK; PLANET FORMATION; HIGH-RESOLUTION; YOUNG STARS; HD-141569; JUPITER; H-3+; EMISSION; GAS	Massive planets have now been found orbiting about 80 stars. A long outstanding question critical to theories of planet formation has been the timescale on which gas-giant planets form; in particular, stars more massive than the Sun may blow away the surrounding gas associated with their formation more quickly than it can be accumulated by the protoplanetary cores(1). Evidence for a protoplanet around a Herbig AeBe star (such stars are 2-3 times more massive than the Sun) would constrain the timescale of planet formation. Here we report the detection of CO and H-3(+) emission from the 5-10-million-year-old Herbig AeBe star HD141569. We interpret the CO data as indicating that the inner disk surrounding the star is past the early phase of accretion and planetesimal formation, and that most of the gas has been cleared out to a distance of more than 17 astronomical units. CO effectively destroys H-3(+) (ref. 2), so their presence in the same source is surprising. Moreover, H-3(+) line emission has previously been detected only from the atmospheres of the giant planets in the Solar System(3,4). The H-3(+) and CO may therefore be distributed in the disk at different circumstellar distances, or, alternatively, H-3(+) may be located in the extended envelope of a protoplanet.	Univ Notre Dame, Ctr Astrophys, Notre Dame, IN 46556 USA	University of Notre Dame	Rettig, TW (corresponding author), Univ Notre Dame, Ctr Astrophys, Notre Dame, IN 46556 USA.		Brittain, Sean D/K-9001-2012	Brittain, Sean D/0000-0001-5638-1330				Boss AP, 1998, EARTH MOON PLANETS, V81, P19, DOI 10.1023/A:1006370021545; BOSS AP, 2000, INT ASTRONOMICAL UNI, V202, P202; DROSSART P, 1989, NATURE, V340, P539, DOI 10.1038/340539a0; Dunkin SK, 1997, MON NOT R ASTRON SOC, V286, P604, DOI 10.1093/mnras/286.3.604; Fisher RS, 2000, ASTROPHYS J, V532, pL141, DOI 10.1086/312575; FRISCH PC, 1987, ASTROPHYS J SUPPL S, V65, P313, DOI 10.1086/191227; KUNDE VG, 1974, J QUANT SPECTROSC RA, V14, P803, DOI 10.1016/0022-4073(74)90124-1; LISSAUER JJ, 1993, ANNU REV ASTRON ASTR, V31, P129, DOI 10.1146/annurev.aa.31.090193.001021; MAILLARD JP, 1990, ASTROPHYS J, V363, pL37, DOI 10.1086/185859; Malfait K, 1998, ASTRON ASTROPHYS, V331, P211; McCall BJ, 1998, FARADAY DISCUSS, V109, P267, DOI 10.1039/a800655e; McCall BJ, 1999, ASTROPHYS J, V522, P338, DOI 10.1086/307637; MILLER S, 1990, ASTROPHYS J, V360, pL55, DOI 10.1086/185811; Natta A., 2000, Protostars and planets 4, P559; OKA T, 1981, PHILOS T R SOC A, V303, P543, DOI 10.1098/rsta.1981.0223; OKA T, 1990, ASTROPHYS J, V351, pLK3; Podolak M., 1993, PROTOSTARS PLANETS, P1109; ROTHMAN LS, 1992, J QUANT SPECTROSC RA, V48, P469, DOI 10.1016/0022-4073(92)90115-K; RUDEN SP, 1991, ASTROPHYS J, V375, P740, DOI 10.1086/170239; Thi WF, 2001, ASTROPHYS J, V561, P1074, DOI 10.1086/323361; TOKUNAGA AT, 1990, P INSTRUMENTATION AS, V7, P131; TRAFTON LM, 1993, ASTROPHYS J, V405, P761, DOI 10.1086/172404; van den Ancker ME, 1998, ASTRON ASTROPHYS, V330, P145; Weinberger AJ, 1999, ASTROPHYS J, V525, pL53, DOI 10.1086/312334; Weinberger AJ, 2000, ASTROPHYS J, V544, P937, DOI 10.1086/317243; Wuchterl G., 2000, Protostars and planets 4, P1081; ZUCKERMAN B, 1995, NATURE, V373, P494, DOI 10.1038/373494a0	27	48	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 4	2002	418	6893					57	59		10.1038/nature00800	http://dx.doi.org/10.1038/nature00800			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	569JL	12097903				2022-12-28	WOS:000176599200035
J	Naoumova, RP; Betteridge, DJ				Naoumova, RP; Betteridge, DJ			A new drug target for treatment of dyslipidaemia associated with type 2 diabetes and the metabolic syndrome?	LANCET			English	Editorial Material									Middlesex Hosp, Royal Free & Univ Coll Med Sch, Dept Med, London W1N 8AA, England; Hammersmith Hosp, MRC, Clin Sci Ctr, London, England	University of London; University College London; Imperial College London	Betteridge, DJ (corresponding author), Middlesex Hosp, Royal Free & Univ Coll Med Sch, Dept Med, London W1N 8AA, England.	j.betteridge@ucl.ac.uk						Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Conklin D, 1999, GENOMICS, V62, P477, DOI 10.1006/geno.1999.6041; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; Koishi R, 2002, NAT GENET, V30, P151, DOI 10.1038/ng814; Krssak M, 1999, DIABETOLOGIA, V42, P113, DOI 10.1007/s001250051123; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; Moller DE, 2001, NATURE, V414, P821, DOI 10.1038/414821a; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863	9	11	21	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 29	2002	359	9325					2215	2216		10.1016/S0140-6736(02)09315-7	http://dx.doi.org/10.1016/S0140-6736(02)09315-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567YJ	12103282				2022-12-28	WOS:000176514500004
J	Weidle, PJ; Mastro, TD; Grant, AD; Nkengasong, J; Macharia, D				Weidle, PJ; Mastro, TD; Grant, AD; Nkengasong, J; Macharia, D			HIV/AIDS treatment and HIV vaccines for Africa	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ACTIVE ANTIRETROVIRAL THERAPY; PROTEASE INHIBITOR THERAPY; REVERSE-TRANSCRIPTASE; DRUG SUSCEPTIBILITY; TRIMETHOPRIM-SULFAMETHOXAZOLE; HIV-1-INFECTED ADULTS; GENETIC DIVERSITY; COTE-DIVOIRE; AIDS	Increased support from the global HIV/AIDS community is driving advances in HIV treatment and vaccine development in the developing world. Care of patients with AIDS includes many biomedical, nutritional, psychosocial, and behavioural interventions. In resource-poor settings, antiretroviral drugs should be given with use of standardised treatment regimens and streamlined algorithms for monitoring use. A safe and effective HIV vaccine will supplement prevention efforts to protect uninfected people against infection, or might possibly be able to modify the course of HIV infection. Advances have been made in understanding the immune response and immunisation to HIV, and new ideas for candidate vaccines have been developed, including several based on HIV-1 strains prevalent in Africa. HIV vaccine efficacy trials are needed in Africa to determine whether these advances can be translated into clinical and public health benefits. In this review, we discuss the prospects for use of treatment and vaccines in resource-poor settings.	Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA; London Sch Hyg & Trop Med, Climat Res Unit, London WC1, England; Projet RETROCI, Abidjan, Cote Ivoire; CDC Kenya, Nairobi, Kenya	Centers for Disease Control & Prevention - USA; University of London; London School of Hygiene & Tropical Medicine	Weidle, PJ (corresponding author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Mailstop E-45,1600 Clifton Rd, Atlanta, GA 30333 USA.	pweidle@cdc.gov						Ainsworth M, 2001, AIDS, V15, pW27; Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1; Apetrei C, 1998, J VIROL, V72, P3534, DOI 10.1128/JVI.72.5.3534-3538.1998; Badri M, 2001, AIDS, V15, P1143, DOI 10.1097/00002030-200106150-00009; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; Berman PW, 1998, AIDS RES HUM RETROV, V14, pS277; Binswanger HP, 2001, SCIENCE, V292, P221, DOI 10.1126/science.1057504; BIRX D, 2001, P AIDS VACC 2001 C S; Brindeiro R, 1999, ANTIMICROB AGENTS CH, V43, P1674, DOI 10.1128/AAC.43.7.1674; BUCHBINDER S, 2001, P AIDS VACC 2001 C S; Bucher HC, 1999, AIDS, V13, P501, DOI 10.1097/00002030-199903110-00009; CAO H, 2002, P 13 INT AIDS C JUL; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; Carr A, 2000, LANCET, V356, P1423, DOI 10.1016/S0140-6736(00)02854-3; Cohen J, 2000, SCIENCE, V289, P368, DOI 10.1126/science.289.5478.368; Cohen J, 2002, SCIENCE, V295, P1616, DOI 10.1126/science.295.5560.1616; Curtis H, 1998, LANCET, V352, P1379; Deeks SG, 1999, AIDS, V13, pF35, DOI 10.1097/00002030-199904160-00001; Descamps D, 1998, AIDS, V12, P1109; Descamps D, 1997, J VIROL, V71, P8893, DOI 10.1128/JVI.71.11.8893-8898.1997; Dilley JW, 1997, NEW ENGL J MED, V337, P501, DOI 10.1056/NEJM199708143370715; DIMANDE F, 2001, 12 INT C AIDS STDS A; Eshleman SH, 2001, J INFECT DIS, V184, P914, DOI 10.1086/323153; Eshleman SH, 2001, AIDS, V15, P1951, DOI 10.1097/00002030-200110190-00006; Esparza J, 2000, LANCET, V355, P2061, DOI 10.1016/S0140-6736(00)02360-6; Excler JL, 2000, J HUMAN VIROL, V3, P193; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; FRANCIS D, 2001, P AIDS VACC 2001 C S; Frater AJ, 2001, AIDS, V15, P1493, DOI 10.1097/00002030-200108170-00006; French N, 2000, LANCET, V355, P2106, DOI 10.1016/S0140-6736(00)02377-1; Gilks C F, 1997, AIDS, V11 Suppl B, pS99; *GLOB FUND FIGHT A, 2002, GEN GLOB FIND FIGHT; Grant AD, 2001, AM J TROP MED HYG, V65, P810, DOI 10.4269/ajtmh.2001.65.810; Hanke T, 2000, NAT MED, V6, P951, DOI 10.1038/79626; Hanke T, 1999, J VIROL, V73, P7524, DOI 10.1128/JVI.73.9.7524-7532.1999; Hanke T, 1999, IMMUNOL LETT, V66, P177, DOI 10.1016/S0165-2478(98)00164-3; Harries AD, 2001, LANCET, V358, P410, DOI 10.1016/S0140-6736(01)05551-9; Harrigan PR, 2001, AIDS, V15, P1671, DOI 10.1097/00002030-200109070-00010; *HIV VACC TRIALS N, 2002, GLOB TRIALS SIT; *IAVI DAT PREV AID, 2002, IAVI DAT PREV AIDS V; *INT AIDS VACC IN, DAT PREV PREV AIDS V; Iyer JK, 2001, LANCET, V358, P1066, DOI 10.1016/S0140-6736(01)06201-8; Johnson JL, 2001, AIDS, V15, P2137, DOI 10.1097/00002030-200111090-00009; Kumar S, 2001, LANCET, V357, P616, DOI 10.1016/S0140-6736(05)71411-2; Lamptey PR, 2002, BMJ-BRIT MED J, V324, P207, DOI 10.1136/bmj.324.7331.207; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; MacNeil JM, 1998, AIDS, V12, pS19; Makgoba MW, 2002, BRIT MED J, V324, P211, DOI 10.1136/bmj.324.7331.211; McCutchan FE, 2000, AIDS, V14, pS31; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; MUGWERA RD, 2002, BMJ-BRIT MED J, V324, P226; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Palmer S, 1998, AIDS RES HUM RETROV, V14, P157, DOI 10.1089/aid.1998.14.157; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Peeters M, 2000, AIDS, V14, pS129; PITISUTHITHUM P, 2001, P AIDS VACC 2001 C S; Quigley MA, 2001, AIDS, V15, P215, DOI 10.1097/00002030-200101260-00011; Rani S, 2022, SPAT INF RES, V30, P417, DOI 10.1007/s41324-022-00442-9; RICHMAN DD, 2001, 41 INT C ANT AG CHEM; Robinson HL, 2002, NAT REV IMMUNOL, V2, P239, DOI 10.1038/nri776; Romano L, 2002, J MED VIROL, V66, P143, DOI 10.1002/jmv.2123; Schultz AM, 2001, AIDS, V15, pS147, DOI 10.1097/00002030-200100005-00018; Shafer RW, 1999, AIDS RES HUM RETROV, V15, P65, DOI 10.1089/088922299311727; Shafer RW, 1997, J VIROL, V71, P5441, DOI 10.1128/JVI.71.7.5441-5448.1997; Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a; Tanuri A, 1999, ANTIMICROB AGENTS CH, V43, P253, DOI 10.1093/jac/43.2.253; *UN GEN ASS SPEC S, 2001, S262 UN GEN ASS SPEC; *UNAIDS, 2001, ACC ACC HIV CAR SUPP; *UNAIDS, 2001, MED HDB HIV VACC TRI; UNAIDS and WHO, 2000, ETH CONS HIV PREV VA; Wainberg MA, 1998, JAMA-J AM MED ASSOC, V279, P1977, DOI 10.1001/jama.279.24.1977; Wee EGT, 2002, J GEN VIROL, V83, P75, DOI 10.1099/0022-1317-83-1-75; Weidle PJ, 2001, J ACQ IMMUN DEF SYND, V26, P495, DOI 10.1097/00126334-200104150-00017; WEIDLE PJ, IN PRESS LANCET; *WHO GLOB TUB PROG, 1998, WHOTB98255; *WHO UNAIDS HIV VA, 2002, MISS WHO UNAIDS HIV; Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0; Witvrouw M, 1999, AIDS, V13, P1477, DOI 10.1097/00002030-199908200-00006; World Health Organization, 2002, SCAL ANT THER RES LT; 2000, MMWR, V49, P185	81	30	32	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 29	2002	359	9325					2261	2267		10.1016/S0140-6736(02)09297-8	http://dx.doi.org/10.1016/S0140-6736(02)09297-8			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	567YJ	12103304				2022-12-28	WOS:000176514500026
J	Mitchell-Olds, T; Knight, CA				Mitchell-Olds, T; Knight, CA			Evolution: Chaperones as buffering agents?	SCIENCE			English	Editorial Material							HEAT-SHOCK; HSP90; CAPACITOR		Max Planck Inst Chem Ecol, D-07745 Jena, Germany	Max Planck Society	Mitchell-Olds, T (corresponding author), Max Planck Inst Chem Ecol, Winzerlaer Str 10, D-07745 Jena, Germany.	tmo@ice.mpg.de	Mitchell-Olds, Thomas/K-8121-2012	Mitchell-Olds, Thomas/0000-0003-3439-9921				BETTENCOURT BR, IN PRESS EVOLUTION; Heckathorn SA, 1998, PLANT PHYSIOL, V116, P439, DOI 10.1104/pp.116.1.439; Knight CA, 2001, AM J BOT, V88, P411, DOI 10.2307/2657105; Lauter N, 2002, GENETICS, V160, P333; NECKERS L, 2002, TRENDS MOL MED S, V8, P56; Park SY, 1997, PLANT PHYSIOL, V115, P229, DOI 10.1104/pp.115.1.229; Queitsch C, 2002, NATURE, V417, P618, DOI 10.1038/nature749; Queitsch C, 2000, PLANT CELL, V12, P479, DOI 10.1105/tpc.12.4.479; Roberts SP, 2000, FUNCT ECOL, V14, P353, DOI 10.1046/j.1365-2435.2000.00429.x; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Waddington CH, 1942, NATURE, V150, P563, DOI 10.1038/150563a0; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	12	33	34	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 28	2002	296	5577					2348	2349		10.1126/science.1073846	http://dx.doi.org/10.1126/science.1073846			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	567CE	12089432	Green Submitted			2022-12-28	WOS:000176467200028
J	Endre, G; Kereszt, A; Kevei, Z; Mihacea, S; Kalo, P; Kiss, GB				Endre, G; Kereszt, A; Kevei, Z; Mihacea, S; Kalo, P; Kiss, GB			A receptor kinase gene regulating symbiotic nodule development	NATURE			English	Article							MEDICAGO-TRUNCATULA; CALCIUM SPIKING; NODULATION SIGNALS; ALFALFA NODULATION; RHIZOBIUM-MELILOTI; ROOT HAIRS; TRANSDUCTION; RESPONSES; MUTANTS	Leguminous plants are able to establish a nitrogen-fixing symbiosis with soil bacteria generally known as rhizobia. Metabolites exuded by the plant root activate the production of a rhizobial signal molecule, the Nod factor, which is essential for symbiotic nodule development(1,2). This lipo-chitooligosaccharide signal is active at femtomolar concentrations, and its structure is correlated with host specificity of symbiosis(3), suggesting the involvement of a cognate perception system in the plant host. Here we describe the cloning of a gene from Medicago sativa that is essential for Nod-factor perception in alfalfa, and by genetic analogy, in the related legumes Medicago truncatula and Pisum sativum. The identified 'nodulation receptor kinase', NORK, is predicted to function in the Nod-factor perception/transduction system (the NORK system) that initiates a signal cascade leading to nodulation. The family of 'NORK extracellular-sequence-like' (NSL) genes is broadly distributed in the plant kingdom, although their biological function has not been previously ascribed. We suggest that during the evolution of symbiosis an ancestral NSL system was co-opted for transduction of an external ligand, the rhizobial Nod factor, leading to development of the symbiotic root nodule.	Hungarian Acad Sci, Biol Res Ctr, Inst Genet, H-6701 Szeged, Hungary	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center	Kiss, GB (corresponding author), Hungarian Acad Sci, Biol Res Ctr, Inst Genet, POB 521, H-6701 Szeged, Hungary.	kgb@nucleus.szbk.u-szeged.hu	Kevei, Zoltan/AAF-5054-2021; Kalo, Peter/A-3919-2012; poinssot, benoit/B-2569-2009; Mihacea, Sorina/K-4167-2019	Kevei, Zoltan/0000-0002-3065-3198; Kalo, Peter/0000-0002-0404-8904; poinssot, benoit/0000-0001-5890-4318; Kereszt, Attila/0000-0002-4421-6554				Boisson-Dernier A, 2001, MOL PLANT MICROBE IN, V14, P695, DOI 10.1094/MPMI.2001.14.6.695; BRADBURY SM, 1991, NEW PHYTOL, V119, P115, DOI 10.1111/j.1469-8137.1991.tb01014.x; CAETANOANOLLES G, 1993, CURR PLANT SCI BIOT, V17, P297; Catoira R, 2000, PLANT CELL, V12, P1647, DOI 10.1105/tpc.12.9.1647; Deeken R, 1997, PLANTA, V202, P479, DOI 10.1007/s004250050152; Doyle JJ, 1998, TRENDS PLANT SCI, V3, P473, DOI 10.1016/S1360-1385(98)01340-5; DUDLEY ME, 1989, PLANT CELL, V1, P65, DOI 10.1105/tpc.1.1.65; Ehrhardt DW, 1996, CELL, V85, P673, DOI 10.1016/S0092-8674(00)81234-9; Endre G, 2002, MOL GENET GENOMICS, V266, P1012, DOI 10.1007/s00438-001-0628-3; Felle HH, 1996, PLANT J, V10, P295, DOI 10.1046/j.1365-313X.1996.10020295.x; GianinazziPearson V, 1996, PLANT CELL, V8, P1871, DOI 10.1105/tpc.8.10.1871; Hajouj T, 2000, PLANT PHYSIOL, V124, P1305, DOI 10.1104/pp.124.3.1305; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; Nam YW, 1999, THEOR APPL GENET, V98, P638, DOI 10.1007/s001220051115; PETERSON MA, 1981, CROP SCI, V21, P611, DOI 10.2135/cropsci1981.0011183X002100040033x; Pingret JL, 1998, PLANT CELL, V10, P659; Schenk PW, 1999, BBA-MOL CELL RES, V1449, P1, DOI 10.1016/S0167-4889(98)00178-5; Schneider A, 1999, MOL GEN GENET, V262, P1, DOI 10.1007/s004380051053; SCHULTZE M, 1995, TRENDS MICROBIOL, V3, P370, DOI 10.1016/S0966-842X(00)88980-5; Schultze M, 1998, ANNU REV GENET, V32, P33, DOI 10.1146/annurev.genet.32.1.33; Shiu SH, 2001, P NATL ACAD SCI USA, V98, P10763, DOI 10.1073/pnas.181141598; Stougaard J, 2001, CURR OPIN PLANT BIOL, V4, P328, DOI 10.1016/S1369-5266(00)00181-3; SZABADOS L, 1995, MOL BREEDING, V1, P419, DOI 10.1007/BF01248419; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRUCHET G, 1989, MOL GEN GENET, V219, P65, DOI 10.1007/BF00261158; Wais RJ, 2000, P NATL ACAD SCI USA, V97, P13407, DOI 10.1073/pnas.230439797; Walker SA, 2000, P NATL ACAD SCI USA, V97, P13413, DOI 10.1073/pnas.230440097	30	543	618	1	135	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 27	2002	417	6892					962	966		10.1038/nature00842	http://dx.doi.org/10.1038/nature00842			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	566RC	12087406				2022-12-28	WOS:000176441200042
J	Norhammar, A; Tenerz, A; Nilsson, G; Hamsten, A; Efendic, S; Ryden, L; Malmberg, K				Norhammar, A; Tenerz, A; Nilsson, G; Hamsten, A; Efendic, S; Ryden, L; Malmberg, K			Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study	LANCET			English	Article							CORONARY-HEART-DISEASE; STRESS HYPERGLYCEMIA; INSULIN-TREATMENT; RISK; TOLERANCE; TERM; PROGNOSIS; MORTALITY; ADMISSION; SURVIVAL	Background Glycometabolic state at hospital admission is an important risk marker for long-term mortality in patients with acute myocardial infarction, whether or not they have known diabetes mellitus. Our aim was to ascertain the prevalence of impaired glucose metabolism in patients without diagnosed diabetes but with myocardial infarction, and to assess whether such abnormalities can be identified in the early course of a myocardial infarction. Methods We did a prospective study, in which we enrolled 181 consecutive patients admitted to the coronary care units of two hospitals in Sweden with acute myocardial infarction, no diagnosis of diabetes, and a blood glucose concentration of less than 11.1 mmol/L. We recorded glucose concentrations during the hospital stay, and did standardised oral glucose tolerance tests with 75 g of glucose at discharge and again 3 months later. Findings The mean age of our cohort was 63.5 years (SD 9) and the mean blood glucose concentration at admission was 6.5 mmol/L (1.4). The mean 2-h postload blood glucose concentration was 9.2 mmol/L (2.9) at hospital discharge, and 9.0 mmol/L (3.0) 3 months later. 58 of 164 (35%, 95% CI 28-43) and 58 of 144 (40%, 32-48) individuals had impaired glucose tolerance at discharge and after 3 months, respectively, and 51 of 164 (31%, 24-38) and 36 of 144 (25%, 18-32) had previously undiagnosed diabetes mellitus. Independent predictors of abnormal glucose tolerance at 3 months were concentrations of HbA(1c) at admission (p=0.024) and fasting blood glucose concentrations on day 4 (p=0.044). Interpretation Previously undiagnosed diabetes and impaired glucose tolerance are common in patients with an acute myocardial infarction. These abnormalities can be detected early in the postinfarction period. Our results suggest that fasting and postchallenge hyperglycaemia in the early phase of an acute myocardial infarction could be used as early markers of high-risk individuals.	Karolinska Hosp, Dept Cardiol, S-17176 Stockholm, Sweden; Karolinska Hosp, Dept Endocrinol, S-17176 Stockholm, Sweden; Cent Hosp Vasteras, Dept Med, Vasteras, Sweden; Cent Hosp Vasteras, Clin Res Ctr, Vasteras, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Vasteras Central Hospital; Vasteras Central Hospital	Norhammar, A (corresponding author), Karolinska Hosp, Dept Cardiol, S-17176 Stockholm, Sweden.	anna.norhammar@ks.se		Norhammar, Anna/0000-0002-4467-0132				ABBOTT RD, 1988, JAMA-J AM MED ASSOC, V260, P3456, DOI 10.1001/jama.260.23.3456; ABBUD ZA, 1995, AM HEART J, V130, P51, DOI 10.1016/0002-8703(95)90235-X; Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; Alpert JS, 2000, J AM COLL CARDIOL, V36, P959, DOI 10.1016/S0735-1097(00)00804-4; Barrett-Connor E, 1998, DIABETES CARE, V21, P1236, DOI 10.2337/diacare.21.8.1236; BELLODI G, 1989, AM J CARDIOL, V64, P885, DOI 10.1016/0002-9149(89)90836-9; Borch-Johnsen K, 1999, LANCET, V354, P617; Capes SE, 2000, LANCET, V355, P773, DOI 10.1016/S0140-6736(99)08415-9; Coutinho M, 1999, DIABETES CARE, V22, P233, DOI 10.2337/diacare.22.2.233; Fava S, 1996, DIABETIC MED, V13, P80, DOI 10.1002/(SICI)1096-9136(199601)13:1<80::AID-DIA10>3.3.CO;2-N; FULLER JH, 1980, LANCET, V1, P1373; Gavin JR, 1997, DIABETES CARE, V20, P1183; Jeppsson JO, 1996, DIABETES CARE, V19, P142, DOI 10.2337/diacare.19.2.142; Lindahl B, 1999, DIABETES CARE, V22, P1988, DOI 10.2337/diacare.22.12.1988; Mak K. H., 1993, Annals Academy of Medicine Singapore, V22, P291; Malmberg K, 1999, CIRCULATION, V99, P2626, DOI 10.1161/01.CIR.99.20.2626; Malmberg K, 1997, BRIT MED J, V314, P1512, DOI 10.1136/bmj.314.7093.1512; MALMBERG K, 1995, J AM COLL CARDIOL, V26, P57, DOI 10.1016/0735-1097(95)00126-K; MALMBERG K, 1988, EUR HEART J, V9, P259, DOI 10.1093/oxfordjournals.eurheartj.a062494; McKeigue PM, 1998, DIABETOLOGIA, V41, P1133, DOI 10.1007/s001250051042; Norhammar AM, 1999, DIABETES CARE, V22, P1827, DOI 10.2337/diacare.22.11.1827; ORLANDER PR, 1994, DIABETES, V43, P897, DOI 10.2337/diabetes.43.7.897; OSULLIVAN JJ, 1991, DIABETES CARE, V14, P758, DOI 10.2337/diacare.14.8.758; OSWALD GA, 1986, BMJ-BRIT MED J, V293, P917, DOI 10.1136/bmj.293.6552.917; PYORALA K, 1979, J CHRON DIS, V32, P729, DOI 10.1016/0021-9681(79)90052-3; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Tuomilehto Jaakko, 2001, New England Journal of Medicine, V344, P1343, DOI 10.1056/NEJM200105033441801; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Woodfield SL, 1996, J AM COLL CARDIOL, V28, P1661, DOI 10.1016/S0735-1097(96)00397-X; 2000, EUR HEART J, V21, P1502, DOI 10.1053/eurj.2000.2305	30	791	832	0	28	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 22	2002	359	9324					2140	2144		10.1016/S0140-6736(02)09089-X	http://dx.doi.org/10.1016/S0140-6736(02)09089-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	566RJ	12090978				2022-12-28	WOS:000176441800007
J	Okkenhaug, K; Bilancio, A; Farjot, G; Priddle, H; Sancho, S; Peskett, E; Pearce, W; Meek, SE; Salpekar, A; Waterfield, MD; Smith, AJH; Vanhaesebroeck, B				Okkenhaug, K; Bilancio, A; Farjot, G; Priddle, H; Sancho, S; Peskett, E; Pearce, W; Meek, SE; Salpekar, A; Waterfield, MD; Smith, AJH; Vanhaesebroeck, B			Impaired B and T cell antigen receptor signaling in p110 delta PI 3-kinase mutant mice	SCIENCE			English	Article							PHOSPHOINOSITIDE 3-KINASE P85-ALPHA; P110 DELTA; SUBUNIT; THYMOCYTES; LEUKOCYTES; DELETION; IMMUNITY; KINASES; ABSENCE	Class IA phosphoinositide 3-kinases (PI3Ks) are a family of p85/p110 heterodimeric lipid kinases that generate second messenger signals downstream of tyrosine kinases, thereby controlling cell metabolism, growth, proliferation, differentiation, motility, and survival. Mammals express three class IA catalytic subunits: p110alpha, p110beta, and p110delta. It is unclear to what extent these p110 isoforms have overlapping or distinct biological roles. Mice expressing a catalytically inactive form of p110delta (p110delta(D910A)) were generated by gene targeting. Antigen receptor signaling in B and T cells was impaired and immune responses in vivo were attenuated in p110delta mutant mice. They also developed inflammatory bowel disease. These results reveal a selective role for p110delta in immunity.	Ludwig Inst Canc Res, London W1W 7BS, England; Univ Edinburgh, Ctr Genome Res, Gene Targeting Lab, Edinburgh EH9 3JQ, Midlothian, Scotland; Frimorfo, CH-1705 Fribourg, Switzerland; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	Ludwig Institute for Cancer Research; University of Edinburgh; University of London; University College London	Vanhaesebroeck, B (corresponding author), Ludwig Inst Canc Res, 91 Riding House St, London W1W 7BS, England.	bartvanh@ludwig.ucl.ac.uk	Okkenhaug, Klaus/H-3154-2019; Okkenhaug, Klaus/D-5149-2012	Okkenhaug, Klaus/0000-0002-9432-4051; Okkenhaug, Klaus/0000-0002-9432-4051; Pearce, Wayne/0000-0001-5407-4767; Peskett, Emma/0000-0002-0978-5401; BILANCIO, Antonio/0000-0002-5118-3359				Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; Cho JH, 2000, HUM MOL GENET, V9, P1425, DOI 10.1093/hmg/9.9.1425; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; Ebert PJR, 2000, J IMMUNOL, V165, P5435, DOI 10.4049/jimmunol.165.10.5435; Fruman DA, 2002, SEMIN IMMUNOL, V14, P7, DOI 10.1006/smim.2001.0337; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Lu-Kuo JM, 2000, J BIOL CHEM, V275, P6022, DOI 10.1074/jbc.275.8.6022; Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Okkenhaug K, 2001, NAT IMMUNOL, V2, P325, DOI 10.1038/86327; OKKENHAUG K, 2001, SCI STKE; Sasaki T, 2002, J BIOCHEM, V131, P495, DOI 10.1093/oxfordjournals.jbchem.a003126; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Seki N, 1997, DNA Res, V4, P355, DOI 10.1093/dnares/4.5.355; Sprent J, 2002, ANNU REV IMMUNOL, V20, P551, DOI 10.1146/annurev.immunol.20.100101.151926; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Vanhaesebroeck B, 1999, EMBO J, V18, P1292, DOI 10.1093/emboj/18.5.1292; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680	25	768	856	2	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	2002	297	5583					1031	1034						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	581ZN	12130661				2022-12-28	WOS:000177325400049
J	Schillinger, D; Grumbach, K; Piette, J; Wang, F; Osmond, D; Daher, C; Palacios, J; Sullivan, GD; Bindman, AB				Schillinger, D; Grumbach, K; Piette, J; Wang, F; Osmond, D; Daher, C; Palacios, J; Sullivan, GD; Bindman, AB			Association of health literacy with diabetes outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NON-HISPANIC WHITES; MEXICAN-AMERICANS; GLYCEMIC CONTROL; CARE; KNOWLEDGE; RETINOPATHY; SKILLS; DEPRESSION; MANAGEMENT; ADHERENCE	Context Health literacy is a measure of patients' ability to read, comprehend, and act on medical instructions. Poor health literacy is common among racial and ethnic minorities, elderly persons, and patients with chronic conditions, particularly in public-sector settings. Little is known about the extent to which health literacy affects clinical health outcomes. Objectives To examine the association between health literacy and diabetes outcomes among patients with type 2 diabetes. Design, Setting, and Participants Cross-sectional observational study of 408 English- and Spanish-speaking patients who were older than 30 years and had type 2 diabetes identified from the clinical database of 2 primary care clinics of a University-affiliated public hospital in San Francisco, Calif. Participants were enrolled and completed questionnaires between June and December 2000. We assessed patients' health literacy by using the short-form Test of Functional Health Literacy in Adults (s-TOFHLA) in English or Spanish Main Outcome Measures Most recent hemoglobin A(1c) (HbA(1c)) level. Patients were classified as having tight glycemic control if their HbA(1c) was in the lowest quartile and poor control if it was in the highest quartile. We also measured the presence of self-reported diabetes complications. Results After adjusting for patients' sociodemographic characteristics, depressive symptoms, social support, treatment regimen, and years with diabetes, for each 1-point decrement in s-TOFHLA score, the HbA(1c), value increased by 0.02 (P=.02). Patients with inadequate health literacy were less likely than patients with adequate health literacy to achieve tight glycemic control (HbA(1c) less than or equal to 7.2%; adjusted odds ratio [OR], 0.57; 95% confidence interval [CI], 0.32-1.00; P=.05) and were more likely to have poor glycemic control (HbA(1c) greater than or equal to9.5%; adjusted OR, 2.03; 95% Cl, 1.11-3.73; P=.02) and to report having retinopathy (adjusted OR, 2.33; 95% Cl, 1.19-4.57; P=.01). Conclusions Among primary care patients with type 2 diabetes, inadequate health literacy is independently associated with worse glycemic control and higher rates of retinopathy. Inadequate health literacy may contribute to the disproportionate burden of diabetes-related problems among disadvantaged populations. Efforts should focus on developing and evaluating interventions to improve diabetes outcomes among patients with inadequate health literacy.	Univ Calif San Francisco, San Francisco Gen Hosp, Primary Care Res Ctr, Dept Med, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA; VA Ann Arbor Hlth Care Syst, Ctr Practice Management & Outcomes Res, Ann Arbor, MI USA; Univ Michigan, Sch Med, Ann Arbor, MI USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan	Schillinger, D (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Primary Care Res Ctr, Dept Med, San Francisco, CA 94110 USA.		Grumbach, Kevin/L-9222-2016		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P01HS010856] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000084] Funding Source: NIH RePORTER; AHRQ HHS [P01HS/10856] Funding Source: Medline; NCRR NIH HHS [M01-RR00084-30] Funding Source: Medline; PHS HHS [DII 99187-1] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Anderson RM, 2000, DIABETES EDUCATOR, V26, P597, DOI 10.1177/014572170002600405; ANDRESEN EM, 1994, AM J PREV MED, V10, P77, DOI 10.1016/S0749-3797(18)30622-6; Baker DW, 1998, J GEN INTERN MED, V13, P791, DOI 10.1046/j.1525-1497.1998.00242.x; Baker DW, 1999, PATIENT EDUC COUNS, V38, P33, DOI 10.1016/S0738-3991(98)00116-5; Baker DW, 1997, AM J PUBLIC HEALTH, V87, P1027, DOI 10.2105/AJPH.87.6.1027; BILD DE, 1989, DIABETES CARE, V12, P24, DOI 10.2337/diacare.12.1.24; Burton P, 1998, STAT MED, V17, P1261, DOI 10.1002/(SICI)1097-0258(19980615)17:11<1261::AID-SIM846>3.0.CO;2-Z; *CDCP, 2000, NAT DIAB FACT SHEET; Centers for Disease Control and Prevention, 2001, MMWR MORB MORTAL WKL, V50, P1; COWIE CC, 1989, NEW ENGL J MED, V321, P1074, DOI 10.1056/NEJM198910193211603; COWIE CC, 1995, PUBLICATION, P85; Doak CC, 1998, CA-CANCER J CLIN, V48, P151, DOI 10.3322/canjclin.48.3.151; Doak CC, 1996, TEACHING PATIENTS LO; El-Kebbi IM, 2001, ARCH INTERN MED, V161, P1295, DOI 10.1001/archinte.161.10.1295; Elasy TA, 2001, PATIENT EDUC COUNS, V43, P121, DOI 10.1016/S0738-3991(00)00150-6; Fisher L, 1998, DIABETES EDUCATOR, V24, P599, DOI 10.1177/014572179802400504; Fitzgerald JT, 1996, EVAL HEALTH PROF, V19, P208, DOI 10.1177/016327879601900205; FLEGAL KM, 1991, DIABETES CARE, V14, P628, DOI 10.2337/diacare.14.7.628; Fleming BB, 2001, DIABETES CARE, V24, P1815, DOI 10.2337/diacare.24.10.1815; Gazmararian JA, 1999, JAMA-J AM MED ASSOC, V281, P545, DOI 10.1001/jama.281.6.545; Glasgow RE, 1997, DIABETES CARE, V20, P556, DOI 10.2337/diacare.20.4.556; Gunning Robert, 1968, TECHNIQUE CLEAR WRIT; Hadden W C, 1987, Vital Health Stat 11, P1; HAFFNER SM, 1988, DIABETES, V37, P878, DOI 10.2337/diabetes.37.7.878; Harris MI, 1998, DIABETES CARE, V21, P1230, DOI 10.2337/diacare.21.8.1230; Harris MI, 2000, DIABETES CARE, V23, P754, DOI 10.2337/diacare.23.6.754; HARRIS MI, 1995, PUBLICATION; Kalichman SC, 1999, J GEN INTERN MED, V14, P267, DOI 10.1046/j.1525-1497.1999.00334.x; Kalichman SC, 2000, AM J PREV MED, V18, P325, DOI 10.1016/S0749-3797(00)00121-5; Kalichman SC, 2000, J ACQ IMMUN DEF SYND, V25, P337, DOI 10.1097/00126334-200012010-00007; KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P1217, DOI 10.1001/archopht.1994.01090210105023; Lavery LA, 1996, DIABETES CARE, V19, P48, DOI 10.2337/diacare.19.1.48; LEAHY JL, 2000, MED MANAGEMENT DIABE; Lustman PJ, 2000, DIABETES CARE, V23, P934, DOI 10.2337/diacare.23.7.934; Mayeaux EJ, 1996, AM FAM PHYSICIAN, V53, P205; McCulloch DK, 2000, DIS MANAG, V3, P75; *MI DIAB RES TRAIN, 2002, SURV INSTR; PARKER RM, 1995, J GEN INTERN MED, V10, P537, DOI 10.1007/BF02640361; Parker RM, 1999, JAMA-J AM MED ASSOC, V281, P552; Schillinger D, 2001, DIS MANAGE, V4, P103; SCHILLINGER D, IN PRESS ARCH INTERN; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Taylor WL, 1953, JOURNALISM QUART, V30, P415, DOI 10.1177/107769905303000401; TULL ES, 1995, PUB NIH, P613; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; U.S. Department of Health and Human Services, 2002, HLTH PEOPL 2010; *US DEP HHS, 2001, HLTH PEOPL 2010 UND; Von Korff M, 1997, ANN INTERN MED, V127, P1097, DOI 10.7326/0003-4819-127-12-199712150-00008; Wagner EH, 2001, JAMA-J AM MED ASSOC, V285, P182, DOI 10.1001/jama.285.2.182; Weiss B D, 1992, J Am Board Fam Pract, V5, P257; Williams M, 1995, ACAD EMERG MED, V2, P386; WILLIAMS MV, 1995, JAMA-J AM MED ASSOC, V274, P1677; Williams MV, 1998, CHEST, V114, P1008, DOI 10.1378/chest.114.4.1008; Williams MV, 1998, ARCH INTERN MED, V158, P166, DOI 10.1001/archinte.158.2.166	54	1137	1157	4	143	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 24	2002	288	4					475	482		10.1001/jama.288.4.475	http://dx.doi.org/10.1001/jama.288.4.475			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575NZ	12132978	Bronze			2022-12-28	WOS:000176955400030
J	Zitter, JN; Mazonson, PD; Miller, DP; Hulley, SB; Balmes, JR				Zitter, JN; Mazonson, PD; Miller, DP; Hulley, SB; Balmes, JR			Aircraft cabin air recirculation and symptoms of the common cold	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LONG AIRPLANE FLIGHT; MYCOBACTERIUM-TUBERCULOSIS; TRANSMISSION; RISK	Context In recent years, new commercial aircraft have been designed to recirculate approximately 50% of the cabin air to increase fuel efficiency. Some older aircraft use only fresh air. Whether air recirculation increases the transmission of infectious disease is unknown; some studies have demonstrated higher rates of the common cold among persons working in buildings that recirculate air. Objective To evaluate the role of air recirculation as a predictor of postflight upper respiratory tract infections (URIs). Design, Setting, and Participants A natural experiment conducted among 1100 passengers departing the San Francisco Bay area in California and traveling to Denver, Colo, during January through early April 1999, and who completed a questionnaire in the boarding area and a follow-up telephone interview 5 to 7 days later. Forty-seven percent traveled aboard airplanes using 100% fresh air for ventilation, and 53% traveled aboard aircraft that recirculated cabin air. Main Outcome Measure Incidence of reporting new URI symptoms within 1 week of the flight. Results Passengers on airplanes that did and did not recirculate air had similar rates of postflight respiratory symptoms. The rates of reporting a cold were 19% vs 21% (P=34); a runny nose and a cold, 10% vs 11%, (P=70); and an aggregation of 8 URI symptoms 3% in both groups (P>.99). Results were similar after statistical adjustment for potential confounders. Conclusion We found no evidence that aircraft cabin air recirculation increases the risk for URI symptoms in passengers traveling aboard commercial jets.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Lewin Grp, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Zitter, JN (corresponding author), Univ Calif San Francisco, Dept Med, Box 0843, San Francisco, CA 94143 USA.	nutik@itsa.ucsf.edu	Balmes, John/L-6281-2019	Miller, Dave/0000-0003-2947-152X	NHLBI NIH HHS [HL07185] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1995, MMWR-MORBID MORTAL W, V44, P137; BRUNDAGE JF, 1988, JAMA-J AM MED ASSOC, V259, P2108, DOI 10.1001/jama.259.14.2108; DRIVER CR, 1994, JAMA-J AM MED ASSOC, V272, P1031, DOI 10.1001/jama.272.13.1031; HALFPENNY P, 1990, FLIGHT ATT OCC HLTH; HENDLEY JO, 1988, EPIDEMIOL REV, V10, P242, DOI 10.1093/oxfordjournals.epirev.a036024; HIGGINS M, 2000, WALL STREET J   0609; Hueston WJ, 1998, J FAM PRACTICE, V46, P487; JAAKKOLA JJK, 1995, EUR J EPIDEMIOL, V11, P213, DOI 10.1007/BF01719490; JACKSON GG, 1958, ARCH INTERN MED, V101, P267, DOI 10.1001/archinte.1958.00260140099015; Kenyon TA, 1996, NEW ENGL J MED, V334, P933, DOI 10.1056/NEJM199604113341501; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Lina B, 1996, J CLIN MICROBIOL, V34, P3007, DOI 10.1128/JCM.34.12.3007-3011.1996; MARINI RA, 2000, FREQUENT FLYER   MAR, P20; MOSER MR, 1979, AM J EPIDEMIOL, V110, P1; NEEDELMAN WM, 1997, PALL CORP SEPT 5 POR; ODONNELL A, 1991, ASHRAE J, V33, P42; REID DD, 1953, LANCET, V265, P1303; Tracy MJ, 1996, NEW ENGL J MED, V335, P675; 1994, CONSUMER REPORTS AUG, P501	19	52	53	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 24	2002	288	4					483	486		10.1001/jama.288.4.483	http://dx.doi.org/10.1001/jama.288.4.483			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575NZ	12132979	Bronze			2022-12-28	WOS:000176955400031
J	Pignone, M; Saha, S; Hoerger, T; Mandelblatt, J				Pignone, M; Saha, S; Hoerger, T; Mandelblatt, J			Cost-effectiveness analyses of colorectal cancer screening: A systematic review for the US preventive services task force	ANNALS OF INTERNAL MEDICINE			English	Review							CONTRAST BARIUM ENEMA; FECAL OCCULT-BLOOD; AVERAGE-RISK; COLONOSCOPY; ADULTS; COLON; SURVEILLANCE; MODEL	Purpose: To perform a systematic review of the cost-effectiveness of colorectal cancer screening for the U.S. Preventive Services Task Force. Data Sources: MEDLINE and the British National Health Service Economic Evaluation Database, January 1993 through September 2001. Study Selection: original economic evaluations of colorectal cancer screening in average-risk patients were reviewed. The authors sought studies addressing the incremental cost-effectiveness of different screening strategies compared with no screening, of different screening strategies compared with one another, and of different ages of screening initiation and cessation. Two investigators independently reviewed each abstract, and potentially eligible articles were retrieved. A four-member working group reached consensus regarding final inclusion or exclusion of articles. Data Extraction: One reviewer extracted data into evidence tables. The results were checked by other members and discrepancies resolved by consensus. Data Synthesis: Among 180 potential articles identified, 7 were retained in the final analysis. Compared with no screening, cost-effectiveness ratios for screening with any of the commonly considered methods were generally between $10 000 and $25 000 per life-year saved. No one strategy was consistently found to be the most effective or to have the best incremental cost-effectiveness ratio. Currently available models provided insufficient evidence to determine optimal starting and stopping ages for screening. Conclusions: screening for colorectal cancer appears cost-effective compared with no screening, but a single optimal strategy cannot be determined from the currently available data. Additional data regarding adherence with screening over time, complication rates in real-world settings, and colorectal cancer biology are needed. Additional analyses are necessary to determine optimal ages of initiation and cessation.	Univ N Carolina, Chapel Hill & Res Triangle Inst, Evidence Based Practice Ctr, Chapel Hill, NC 27514 USA; Res Triangle Inst, Res Triangle Pk, NC 27709 USA; Oregon Hlth & Sci Univ, Evidence Based Practice Ctr, Portland, OR USA; Georgetown Univ, Ctr Med, Washington, DC USA	University of North Carolina; University of North Carolina Chapel Hill; Research Triangle Institute; Oregon Health & Science University; Georgetown University	Pignone, M (corresponding author), Univ N Carolina, Chapel Hill & Res Triangle Inst, Evidence Based Practice Ctr, Chapel Hill, NC 27514 USA.			Saha, Shampa/0000-0002-8305-3495; Hoerger, Thomas/0000-0003-4154-7806; Pignone, Michael/0000-0002-6657-7342	NATIONAL CANCER INSTITUTE [U01CA088283, R01CA072908] Funding Source: NIH RePORTER; NCI NIH HHS [CA 74187, U01CA88283A, CA 72908] Funding Source: Medline; PHS HHS [290-97-0011] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		American Cancer Society, 2002, CANC FACTS FIG; BROWN ML, 1999, PRIM CARE CANC, V19, P15; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; Frazier AL, 2000, JAMA-J AM MED ASSOC, V284, P1954, DOI 10.1001/jama.284.15.1954; Glick S, 1998, AM J ROENTGENOL, V170, P629, DOI 10.2214/ajr.170.3.9490943; Hankey, 1973, SEER CANC STAT REV; Khandker RK, 2000, INT J TECHNOL ASSESS, V16, P799, DOI 10.1017/S0266462300102077; Lieberman DA, 2000, NEW ENGL J MED, V343, P162, DOI 10.1056/NEJM200007203430301; LIEBERMAN DA, 1995, GASTROENTEROLOGY, V109, P1781, DOI 10.1016/0016-5085(95)90744-0; Lieberman DA, 2001, NEW ENGL J MED, V345, P555, DOI 10.1056/NEJMoa010328; Loeve F, 2000, J NATL CANCER I, V92, P557, DOI 10.1093/jnci/92.7.557; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; Mandelblatt JS, 1997, J GEN INTERN MED, V12, P551, DOI 10.1046/j.1525-1497.1997.07107.x; McMahon PM, 2001, RADIOLOGY, V219, P44, DOI 10.1148/radiology.219.1.r01ap3144; Ness RM, 2000, AM J GASTROENTEROL, V95, P1800; Pignone M, 2002, ANN INTERN MED, V137, P132, DOI 10.7326/0003-4819-137-2-200207160-00015; Podolsky DK, 2000, NEW ENGL J MED, V343, P207, DOI 10.1056/NEJM200007203430309; Rich J S, 2000, Eff Clin Pract, V3, P78; Saha S, 2001, AM J PREV MED, V20, P36, DOI 10.1016/S0749-3797(01)00260-4; Sonnenberg A, 2000, ANN INTERN MED, V133, P573, DOI 10.7326/0003-4819-133-8-200010170-00007; Vijan S, 2001, AM J MED, V111, P593, DOI 10.1016/S0002-9343(01)00977-9; Wagner JL, 1996, PREVENTION EARLY DET, P321; Walter LC, 2001, JAMA-J AM MED ASSOC, V285, P2750, DOI 10.1001/jama.285.21.2750; Winawer SJ, 2000, NEW ENGL J MED, V342, P1766, DOI 10.1056/NEJM200006153422401; Woolf SH, 2000, NEW ENGL J MED, V343, P1641, DOI 10.1056/NEJM200011303432211	25	448	453	1	23	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 16	2002	137	2					96	104		10.7326/0003-4819-137-2-200207160-00007	http://dx.doi.org/10.7326/0003-4819-137-2-200207160-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575VN	12118964				2022-12-28	WOS:000176969300003
J	Mehta, NM; Thomas, RM				Mehta, NM; Thomas, RM			Lesson of the week - Antenatal screening for rubella - infection or immunity?	BMJ-BRITISH MEDICAL JOURNAL			English	Review									Northwick Pk Hosp & Clin Res Ctr, Neonatal Intens Care Unit, Harrow HA1 3UJ, Middx, England	Imperial College London	Thomas, RM (corresponding author), Northwick Pk Hosp & Clin Res Ctr, Neonatal Intens Care Unit, Harrow HA1 3UJ, Middx, England.	ros.thomas@nwlh.nhs.uk	Mehta, Nilesh M./G-7073-2016					MATTER L, 1995, EUR J EPIDEMIOL, V11, P305, DOI 10.1007/BF01719435; Miller E, 1997, Commun Dis Rep CDR Rev, V7, pR26; MORGANCAPNER P, 2000, GUIDANCE MANAGEMENT; ROWEN M, 1972, AM J ROENTGENOL, V115, P86, DOI 10.2214/ajr.115.1.86; Sullivan E M, 1999, Commun Dis Intell, V23, P209; Tookey PA, 1999, BRIT MED J, V318, P769, DOI 10.1136/bmj.318.7186.769; TOOKEY PA, 1998, PUBLIC HLTH, V102, P57	7	8	9	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 13	2002	325	7355					90	91		10.1136/bmj.325.7355.90	http://dx.doi.org/10.1136/bmj.325.7355.90			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	575CU	12114241	Green Published			2022-12-28	WOS:000176929400023
J	van Es, RF; Jonker, JJC; Verheugt, FWA; Deckers, JW; Grobbee, DE				van Es, RF; Jonker, JJC; Verheugt, FWA; Deckers, JW; Grobbee, DE		ASPECT-2 Res Grp	Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial	LANCET			English	Article							INFARCTION; WARFARIN; THERAPY; ANGINA	Background Antiplatelet treatment with aspirin and oral anticoagulants reduces reocurrence of ischaemic events after myocardial infarction. We aimed to investigate which of these drugs is more effective in the long term after acute coronary events, and whether the combination of aspirin and oral anticoagulants offers greater benefit than either of these agents alone, without excessive risk of bleeding. Methods In a randomised open-label trial in 53 sites, we randomly assigned 999 patients to low-dose aspirin, high-intensity oral anticoagulation, or combined low-dose aspirin and moderate intensity oral anticoagulation. Patients were followed up for a maximum of 26 months. The primary composite endpoint was first occurrence of myocardial infarction, stroke, or death. Findings The primary endpoint was reached in 31 (9%) of 336 patients on aspirin, in 17 (5%) of 325 on anticoagulants (hazard ratio 0.55 [95% CI 0.30-1.00], p=0.0479), and in 16 (5%) of 332 on combination therapy (0.50 [0.27-0.92], p=0.03). Major bleeding was recorded in three (1%) patients on aspirin, three (1%) on anticoagulants (1.03 [0.21-5.08], p=1.0), and seven (2%) on combination therapy (2.35 [0.61-9.10], p=0.2). Frequency of minor bleeding was 5%, 8% (1.68 [0.92-3.07], p=0.20), and 15% (3.13 [1.82-5.37], p=<0.0001), in the three groups, respectively. 164 patients permanently discontinued the study drug. Analyses were done by intention to treat. Interpretation In patients recently admitted with acute coronary events, treatment with high-intensity oral anticoagulants or aspirin with medium-intensity oral anticoagulants was more effective than aspirin on its own in reduction of subsequent cardiovascular events and death.	Univ Med Ctr Utrecht, Julius Ctr Gen Practice & Patient Oriented Res, NL-3508 GA Utrecht, Netherlands; Andro Med Res, Rotterdam, Netherlands; Univ Med Ctr, Dept Cardiol, Nijmegen, Netherlands; Erasmus MC, Thoraxctr, Dept Cardiol, Rotterdam, Netherlands	Utrecht University; Utrecht University Medical Center; Radboud University Nijmegen; Erasmus University Rotterdam; Erasmus MC	Grobbee, DE (corresponding author), Univ Med Ctr Utrecht, Julius Ctr Gen Practice & Patient Oriented Res, POB 85500, NL-3508 GA Utrecht, Netherlands.	d.e.grobbee@jc.azu.nl	Grobbee, Diederick/C-7651-2014; Verheugt, F.W.A./H-8105-2014	Grobbee, Diederick/0000-0003-4472-4468; 				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Anand SS, 1999, JAMA-J AM MED ASSOC, V282, P2058, DOI 10.1001/jama.282.21.2058; ARNESEN H, 2001, 23 EUR C CARD STOCKH; BOISSEL JP, 1982, NEW ENGL J MED, V307, P701; BREDDIN K, 1980, CIRCULATION, V62, P63; COHEN M, 1994, CIRCULATION, V89, P81, DOI 10.1161/01.CIR.89.1.81; Fiore LD, 2002, CIRCULATION, V105, P557, DOI 10.1161/hc0502.103329; Fuster V, 1997, LANCET, V350, P389; JONKER JJC, 1994, LANCET, V343, P499; MERLINI PA, 1994, CIRCULATION, V90, P61, DOI 10.1161/01.CIR.90.1.61; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; Wallentin L, 1999, LANCET, V354, P701; Yusuf S, 2001, NEW ENGL J MED, V345, P494; Yusuf S, 2001, J AM COLL CARDIOL, V37, P475	14	325	332	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 13	2002	360	9327					109	113		10.1016/S0140-6736(02)09409-6	http://dx.doi.org/10.1016/S0140-6736(02)09409-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573PB	12126819				2022-12-28	WOS:000176839100008
J	Pilcher, CD; McPherson, JT; Leone, PA; Smurzynski, M; Owen-O'Dowd, J; Peace-Brewer, AL; Harris, J; Hicks, CB; Eron, JJ; Fiscus, SA				Pilcher, CD; McPherson, JT; Leone, PA; Smurzynski, M; Owen-O'Dowd, J; Peace-Brewer, AL; Harris, J; Hicks, CB; Eron, JJ; Fiscus, SA			Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PUBLIC-HEALTH; TRANSMISSION; DIAGNOSIS; ANTIBODIES; SERA; RNA	Context Acute human immunodeficiency virus (HIV) infection cannot be diagnosed by routine antibody tests and is rarely diagnosed in clinical practice. However, HIV nucleic acid-based testing is widely used to screen for anti body-negative acute infection among low-risk blood donors. Objective To assess the feasibility of screening in high-volume laboratories for acute and long-term HIV infection in a routine HIV testing population, in which HIV infection prevalence is low, using specimen pooling and HIV RNA reverse transcriptase-polymerase chain reaction (RT-PCR) tests. Design and Setting Clinical diagnostic performance evaluation at a state-funded public health virology and serology laboratory. Participants A total of 8505 consecutive individuals presenting for routine HIV counseling and testing during a total of 20 business days to simulate a month of testing in August and December 2001 at 110 publicly funded testing sites in North Carolina. Main Outcome Measures Prevalence of acute and long-term HIV infection. Serum specimens negative by HIV enzyme immunoassay (EIA) were screened in pools by an ultrasensitive HIV RNA RT-PCR test. Results for individual HIV RNA-positive specimens were reclassified as true or false according to results of confirmatory testing. Results Of the 8505 individuals screened, 8194 had not previously tested HIV positive and had sufficient serum to complete the testing protocol. Of those, 39 had long-term HIV infection (prevalence, 47.6 per 10000 at-risk persons [95% confidence interval, 33.8-65.0 per 100001). Of the 8155 at-risk individuals whose antibody tests were negative, 5 were HIV RNA positive. Four of those had true-positive acute infection (prevalence, 4.9 per 10000 [95% confidence interval, 1.3-12.5 per 100001). All 4 were women; 2 developed symptoms consistent with an acute retroviral syndrome in the week after testing. Screening all specimens required 147 HIV RNA tests. Overall specificity of the strategy was 0.9999. Conclusions These findings suggest the widespread diagnosis of acute HIV infections in a routine testing population is not only possible but feasible using specimen pooling and nucleic acid testing. These additional procedures may increase diagnostic yield by approximately 10% compared with conventional HIV antibody testing.	Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA; N Carolina State Ral Publ Hlth, Serol Virol Lab, Raleigh, NC USA; N Carolina Dept Hlth & Human Serv, HIV STD Prevent & Care Branch, Raleigh, NC USA; Duke Univ, Dept Med, Durham, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Duke University	Pilcher, CD (corresponding author), Univ N Carolina, Dept Med, CB No 7030,547 Burnett Womack Bldg, Chapel Hill, NC 27599 USA.	cpilcher@med.unc.edu			NIAID NIH HHS [K23AI01781-01, 9-P30-AI50410-04, K24 AI01608-O1, AI-07001] Funding Source: Medline; NIDDK NIH HHS [DK-R0149381] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI001608, K23AI001781, P30AI050410] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049381] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cates W, 1997, AM J PUBLIC HEALTH, V87, P1928, DOI 10.2105/AJPH.87.12.1928; *CDCP, 2001, HIV AIDS SURV REP, P13; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; Daar ES, 2001, ANN INTERN MED, V134, P25, DOI 10.7326/0003-4819-134-1-200101020-00010; ERB P, 2001, 8 C RETR OPP INF FEB; JACQUEZ JA, 1994, J ACQ IMMUN DEF SYND, V7, P1169; Janssen RS, 2001, AM J PUBLIC HEALTH, V91, P1019, DOI 10.2105/AJPH.91.7.1019; Janssen RS, 1998, JAMA-J AM MED ASSOC, V280, P42, DOI 10.1001/jama.280.1.42; Leynaert B, 1998, AM J EPIDEMIOL, V148, P88, DOI 10.1093/oxfordjournals.aje.a009564; Lindback S, 2000, AIDS, V14, P2333, DOI 10.1097/00002030-200010200-00014; Ly TD, 2000, J CLIN MICROBIOL, V38, P2459; MAY RM, 1987, NATURE, V326, P137, DOI 10.1038/326137a0; Morandi PA, 1998, J CLIN MICROBIOL, V36, P1534, DOI 10.1128/JCM.36.6.1534-1538.1998; *NC DEP HLTH HUM S, 2000, 2000 HIV PREV COMM P; Oxenius A, 2000, P NATL ACAD SCI USA, V97, P3382, DOI 10.1073/pnas.97.7.3382; PILCHER C, 9 C RETR OPP INF FEB; Pilcher CD, 2001, AIDS, V15, P837, DOI 10.1097/00002030-200105040-00004; Pilcher CD, 2001, JAMA-J AM MED ASSOC, V286, P1713, DOI 10.1001/jama.286.14.1713; Pullium JK, 2001, J INFECT DIS, V183, P1023, DOI 10.1086/319293; Quinn TC, 2000, AIDS, V14, P2751, DOI 10.1097/00002030-200012010-00015; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; *US DEP HHS, 1992, HIV COUNS TEST SIT S; WEINTROB A, 9 C RETR OPP INF FEB; Yerly S, 2001, AIDS, V15, P2287, DOI 10.1097/00002030-200111230-00010	26	119	123	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	2002	288	2					216	221		10.1001/jama.288.2.216	http://dx.doi.org/10.1001/jama.288.2.216			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	571HC	12095386				2022-12-28	WOS:000176711100022
J	Weidle, PJ; Malamba, S; Mwebaze, R; Sozi, C; Rukundo, G; Downing, R; Hanson, D; Ochola, D; Mugyenyi, P; Mermin, J; Samb, B; Lackritz, E				Weidle, PJ; Malamba, S; Mwebaze, R; Sozi, C; Rukundo, G; Downing, R; Hanson, D; Ochola, D; Mugyenyi, P; Mermin, J; Samb, B; Lackritz, E			Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance	LANCET			English	Article							HIV-INFECTED PATIENTS; CONTROLLED-TRIAL; REVERSE-TRANSCRIPTASE; VIROLOGICAL FAILURE; ADULTS; ZIDOVUDINE; INHIBITORS; INDINAVIR; PROTEASE	Background Little is known about how to implement antiretroviral treatment programmes in resource-limited countries. We assessed the UNAIDS/Uganda Ministry of Health HIV Drug Access Initiative-one of the first pilot antiretroviral programmes in Africa-in which patients paid for their medications at negotiated reduced prices. Methods We assessed patients' clinical and laboratory information from August, 1998, to July, 2000, from three of the five accredited treatment centres in Uganda, and tested a subset of specimens for phenotypic drug resistance. Findings 912 patients presented for care at five treatment centres. We assessed the care of 476 patients at three centres, of whom 399 started antiretroviral therapy. 204 (51%) received highly active antiretroviral therapy (HAART), 189 (47%) dual nucleoside reverse transcriptase inhibitors (2NRTI), and six (2%) NRTI monotherapy. Median baseline CD4 cell counts were 73 cells/muL (IQR 15-187); viral load was 193 817 copies/mL (37 013-651 716). The probability of remaining alive and in care was 0.63 (95% Cl 0.58-0.67) at 6 months and 0.49 (0.43-0.55) at 1 year. Patients receiving HAART had greater virological responses than those receiving 2NRTI. Cox's proportional hazards models adjusted for viral load and regimen showed that a CD4 cell count of less than 50 cells/muL (vs 50 cells/muL or more) was strongly associated with death (hazard ratio 2.93 [1.51-5.68], p=0.001). Among 82 patients with a viral load of more than 1000 copies/mL more than 90 days into therapy, phenotypic resistance to NRTIs was found for 47 (57%): 29 of 37 (78%) who never received HAART versus 18 of 45 (40%) who received HAART (p=0.0005). Interpretation This pilot programme successfully expanded access to antiretroviral drugs in Uganda. Identification and treatment of patients earlier in the course of their illness and increased use of HAART could improve probability of survival and decrease drug resistance.	CDCP, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA; Uganda Virus Res Inst, CDC Uganda, Entebbe, Uganda; Nsambya Hosp, Kampala, Uganda; Mildmay HIV Care & Rehabil Ctr, Kampala, Uganda; Mulago Hosp, Kampala, Uganda; Uganda Minist Hlth, Kampala, Uganda; UN AIDS Program, Kampala, Uganda; Joint Clin Res Ctr, Kampala, Uganda; UNAIDS, Geneva, Switzerland; CDC, Flobal AIDS Program, NCHSTP, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA; Uganda Virus Research Institute; Mulago National Referral Hospital; Joint Clinic Research Center - United Arab Emirates; UNAIDS; Centers for Disease Control & Prevention - USA	Weidle, PJ (corresponding author), CDCP, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Mailstop E-45,1600 Clifton Rd, Atlanta, GA 30333 USA.	pweidle@cdc.gov	Mermin, Jonathan/J-9847-2012	Lackritz, Eve/0000-0002-5397-7291				Adler MW, 1998, LANCET, V351, P232, DOI 10.1016/S0140-6736(05)78276-3; Binswanger HP, 2001, SCIENCE, V292, P221, DOI 10.1126/science.1057504; Cameron DW, 1998, LANCET, V351, P543, DOI 10.1016/S0140-6736(97)04161-5; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; Cohen J, 2000, SCIENCE, V289, P368, DOI 10.1126/science.289.5478.368; Colebunders R, 1997, AIDS, V11 Suppl B, pS107; Descamps D, 2000, JAMA-J AM MED ASSOC, V283, P205, DOI 10.1001/jama.283.2.205; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; Gartland M, 2000, AIDS, V14, P367, DOI 10.1097/00002030-200003100-00009; Gilks C F, 1997, AIDS, V11 Suppl B, pS99; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Henry K, 1998, J ACQ IMMUN DEF SYND, V19, P339, DOI 10.1097/00042560-199812010-00004; Hertogs K, 1998, ANTIMICROB AGENTS CH, V42, P269, DOI 10.1093/jac/42.2.269; Hirsch M, 1999, J INFECT DIS, V180, P659, DOI 10.1086/314948; Larder BA, 2000, AIDS, V14, pS111; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; Rani S, 2022, SPAT INF RES, V30, P417, DOI 10.1007/s41324-022-00442-9; *REP UG, 2000, NATL STRAT FRAM HIV; Romano L, 2002, J MED VIROL, V66, P143, DOI 10.1002/jmv.2123; Rubin DB, 1987, MULTIPLE IMPUTATIONS; SCHOOFS M, 2001, WALL STREET J   0626, pA1; SCHOOPS M, 2001, WALL STREET J   0307, pA14; *UNAIDS, 2001, ACC ACC HIV CAR SUPP; *UNAIDS, 1998, ACC DRUGS UNAIDS TEC; World Health Organization, 2002, SCAL ANT THER RES LT	27	229	235	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 6	2002	360	9326					34	40		10.1016/S0140-6736(02)09330-3	http://dx.doi.org/10.1016/S0140-6736(02)09330-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569JR	12114039				2022-12-28	WOS:000176599700009
J	Gorbunova, YV; Spitzer, NC				Gorbunova, YV; Spitzer, NC			Dynamic interactions of cyclic AMP transients and spontaneous Ca2+ spikes	NATURE			English	Article							APLYSIA SENSORY NEURONS; GENE-EXPRESSION; CALCIUM OSCILLATIONS; PROTEIN-KINASE; ADENYLYL CYCLASES; IN-SITU; CAMP; ACTIVATION; RECEPTOR; CELLS	Transient increases of intracellular Ca2+ drive many cellular processes, ranging from membrane channel kinetics to transcriptional regulation(1-5), and links of Ca2+ to other second messengers should activate signalling networks(6-11). However, real-time kinetic interactions have been difficult to investigate. Here we report observations of spontaneous increases in concentration of cyclic AMP (cAMP) in embryonic spinal neurons, and their dynamic interactions with Ca2+ oscillations. Blocking the production of these cAMP transients decreases the intrinsic frequency of spontaneous Ca2+ spikes, whereas inducing cAMP increases causes spike frequency to increase. Transients of cAMP in turn are absent when Ca2+ spikes are blocked, and are generated only in response to specific patterns of stimulated spikes that mimic endogenous Ca2+ kinetics. We present a mathematical model of Ca2+-cAMP reciprocity that generates the slow cAMP oscillations and reproduces the dynamics of Ca2+-cAMP interactions observed experimentally. The model predicts that this module of coupled second messengers is tuned to optimize production of cAMP transients, and that simultaneous stimulation of Ca2+ and cAMP systems produces distinct temporal patterns of oscillations of both messengers. Our findings may prove useful in the investigation of the regulation of gene expression by second-messenger transients.	Univ Calif San Diego, Neurobiol Sect, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Phys, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Spitzer, NC (corresponding author), Univ Calif San Diego, Neurobiol Sect, La Jolla, CA 92093 USA.			Spitzer, Nicholas/0000-0002-3523-1103				BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; Beck F, 2001, P ROY SOC B-BIOL SCI, V268, P1307, DOI 10.1098/rspb.2001.1655; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; Carey MB, 1999, DEV BIOL, V215, P298, DOI 10.1006/dbio.1999.9433; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; CUTHBERTSON KSR, 1985, NATURE, V316, P541, DOI 10.1038/316541a0; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; ELIOT LS, 1989, P NATL ACAD SCI USA, V86, P9564, DOI 10.1073/pnas.86.23.9564; FEWTRELL C, 1993, ANNU REV PHYSIOL, V55, P427, DOI 10.1146/annurev.physiol.55.1.427; Fields RD, 1997, J NEUROSCI, V17, P7252; Goldbeter A, 2000, Novartis Found Symp, V227, P19; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; Haisenleder DJ, 1997, ENDOCRINOLOGY, V138, P5227, DOI 10.1210/en.138.12.5227; HAISENLEDER DJ, 1992, ENDOCRINOLOGY, V131, P3027, DOI 10.1210/en.131.6.3027; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Haug LS, 1999, J BIOL CHEM, V274, P7467, DOI 10.1074/jbc.274.11.7467; Islam MS, 1998, P NATL ACAD SCI USA, V95, P6145, DOI 10.1073/pnas.95.11.6145; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; KLINE D, 1992, DEV BIOL, V149, P80, DOI 10.1016/0012-1606(92)90265-I; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Mons N, 1998, LIFE SCI, V62, P1647, DOI 10.1016/S0024-3205(98)00122-2; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; RASMUSSEN H, 1981, CALCIUM CAMP SYNARCH; SETTE C, 1994, J BIOL CHEM, V269, P18271; TANG YH, 1995, P NATL ACAD SCI USA, V92, P7869, DOI 10.1073/pnas.92.17.7869; Villalobos C, 1998, MOL ENDOCRINOL, V12, P87, DOI 10.1210/mend.12.1.0055; WAYMAN GA, 1995, J BIOL CHEM, V270, P24108, DOI 10.1074/jbc.270.41.24108; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	30	142	145	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 4	2002	418	6893					93	96		10.1038/nature00835	http://dx.doi.org/10.1038/nature00835			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	569JL	12097913				2022-12-28	WOS:000176599200045
J	Crawford, LM				Crawford, LM			Commercial speech and public health: Request for comment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Crawford, LM (corresponding author), US FDA, Rockville, MD 20857 USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	2002	288	1					36	36		10.1001/jama.288.1.36	http://dx.doi.org/10.1001/jama.288.1.36			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	568YW	12090852				2022-12-28	WOS:000176573400005
J	Crawford, LM				Crawford, LM			Drugs-herbals workshop	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Crawford, LM (corresponding author), US FDA, Rockville, MD 20857 USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	2002	288	1					36	36		10.1001/jama.288.1.36	http://dx.doi.org/10.1001/jama.288.1.36			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	568YW	12090852				2022-12-28	WOS:000176573400006
J	Crawford, LM				Crawford, LM			Pulmonary hypertension	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Crawford, LM (corresponding author), US FDA, Rockville, MD 20857 USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	2002	288	1					36	36		10.1001/jama.288.1.36	http://dx.doi.org/10.1001/jama.288.1.36			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	568YW	12090852				2022-12-28	WOS:000176573400007
J	O'Leary, DR; Nasci, RS; Campbell, GL; Marfin, AA				O'Leary, DR; Nasci, RS; Campbell, GL; Marfin, AA		CDC	West Nile virus activity - United States, 2001 (Reprinted from MMWR, vol 51, pg 497-501, 2002)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Reprint							NEW-YORK; MOSQUITOS; INFECTION; HORSES; BIRDS		CDC, Div Vector Borne Infect Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	O'Leary, DR (corresponding author), CDC, Div Vector Borne Infect Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA.							Bunning ML, 2002, EMERG INFECT DIS, V8, P380; *CDC, 2001, UPD EP EP W NIL VIR; *HLTH CAN, 2002, W NIL VIR SURV 2002; Komar N, 2001, ANN NY ACAD SCI, V951, P58; Kulasekera VL, 2001, EMERG INFECT DIS, V7, P722, DOI 10.3201/eid0704.010421; Marfin AA, 2001, EMERG INFECT DIS, V7, P730; Nasci RS, 2001, EMERG INFECT DIS, V7, P626; O'Leary DR, 2002, JAMA-J AM MED ASSOC, V288, P158; Rappole JH, 2000, EMERG INFECT DIS, V6, P319, DOI 10.3201/eid0604.000401; Sardelis MR, 2001, EMERG INFECT DIS, V7, P1018, DOI 10.3201/eid0706.010617; Turell MJ, 2001, J MED ENTOMOL, V38, P130, DOI 10.1603/0022-2585-38.2.130	11	57	64	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	2002	288	2					158	160						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	571HC	12113262				2022-12-28	WOS:000176711100010
